<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d436">
    <sentence id="DDI-DrugBank.d436.s0" text="No drug, nutritional supplement, food or herb interactions have yet been reported."/>
    <sentence id="DDI-DrugBank.d519.s0" text="No formal drug/drug interaction studies with Plenaxis were performed.">
        <entity id="DDI-DrugBank.d519.s0.e0" charOffset="45-52"
            type="brand" text="Plenaxis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s1" text="Cytochrome P-450 is not known to be involved in the metabolism of Plenaxis.">
        <entity id="DDI-DrugBank.d519.s1.e0" charOffset="66-73"
            type="brand" text="Plenaxis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s2" text="Plenaxis is highly bound to plasma proteins (96 to 99%).">
        <entity id="DDI-DrugBank.d519.s2.e0" charOffset="0-7"
            type="brand" text="Plenaxis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s3" text="Laboratory Tests Response to Plenaxis should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.">
        <entity id="DDI-DrugBank.d519.s3.e0" charOffset="29-36"
            type="brand" text="Plenaxis"/>
        <entity id="DDI-DrugBank.d519.s3.e1" charOffset="83-94"
            type="drug" text="testosterone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s4" text="Serum transaminase levels should be obtained before starting treatment with Plenaxis and periodically during treatment.">
        <entity id="DDI-DrugBank.d519.s4.e0" charOffset="76-83"
            type="brand" text="Plenaxis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s5" text="Periodic measurement of serum PSA levels may also be considered."/>
    <sentence id="DDI-DrugBank.d297.s0" text="Formal drug interaction studies have not been conducted with ORENCIA.">
        <entity id="DDI-DrugBank.d297.s0.e0" charOffset="61-67"
            type="brand" text="ORENCIA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d297.s1" text="Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.">
        <entity id="DDI-DrugBank.d297.s1.e0" charOffset="50-52"
            type="drug" text="MTX"/>
        <entity id="DDI-DrugBank.d297.s1.e1" charOffset="55-60"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d297.s1.e2" charOffset="63-77"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d297.s1.e3" charOffset="84-102"
            type="group" text="TNF blocking agents"/>
        <entity id="DDI-DrugBank.d297.s1.e4" charOffset="122-130"
            type="drug" text="abatacept"/>
    </sentence>
    <sentence id="DDI-DrugBank.d297.s2" text="The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.">
        <entity id="DDI-DrugBank.d297.s2.e0" charOffset="115-121"
            type="brand" text="ORENCIA"/>
        <entity id="DDI-DrugBank.d297.s2.e1" charOffset="124-126"
            type="drug" text="MTX"/>
        <entity id="DDI-DrugBank.d297.s2.e2" charOffset="129-134"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d297.s2.e3" charOffset="137-151"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d297.s2.e4" charOffset="154-172"
            type="group" text="TNF blocking agents"/>
        <entity id="DDI-DrugBank.d297.s2.e5" charOffset="175-186"
            type="drug" text="azathioprine"/>
        <entity id="DDI-DrugBank.d297.s2.e6" charOffset="189-199"
            type="drug" text="chloroquine"/>
        <entity id="DDI-DrugBank.d297.s2.e7" charOffset="202-205"
            type="drug" text="gold"/>
        <entity id="DDI-DrugBank.d297.s2.e8" charOffset="208-225"
            type="drug" text="hydroxychloroquine"/>
        <entity id="DDI-DrugBank.d297.s2.e9" charOffset="228-238"
            type="drug" text="leflunomide"/>
        <entity id="DDI-DrugBank.d297.s2.e10" charOffset="241-253"
            type="drug" text="sulfasalazine"/>
        <entity id="DDI-DrugBank.d297.s2.e11" charOffset="260-267"
            type="drug" text="anakinra"/>
    </sentence>
    <sentence id="DDI-DrugBank.d297.s3" text="Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.">
        <entity id="DDI-DrugBank.d297.s3.e0" charOffset="31-44"
            type="group" text="TNF antagonist"/>
        <entity id="DDI-DrugBank.d297.s3.e1" charOffset="51-57"
            type="brand" text="ORENCIA"/>
        <entity id="DDI-DrugBank.d297.s3.e2" charOffset="179-193"
            type="group" text="TNF antagonists"/>
        <ddi id="DDI-DrugBank.d297.s3.d0" e1="DDI-DrugBank.d297.s3.e0"
            e2="DDI-DrugBank.d297.s3.e1"/>
    </sentence>
    <sentence id="DDI-DrugBank.d297.s4" text="Concurrent therapy with ORENCIA and TNF antagonists is not recommended.">
        <entity id="DDI-DrugBank.d297.s4.e0" charOffset="24-30"
            type="brand" text="ORENCIA"/>
        <entity id="DDI-DrugBank.d297.s4.e1" charOffset="36-50"
            type="group" text="TNF antagonists"/>
        <ddi id="DDI-DrugBank.d297.s4.d0" e1="DDI-DrugBank.d297.s4.e0"
            e2="DDI-DrugBank.d297.s4.e1"/>
    </sentence>
    <sentence id="DDI-DrugBank.d297.s5" text="There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.">
        <entity id="DDI-DrugBank.d297.s5.e0" charOffset="70-76"
            type="brand" text="ORENCIA"/>
        <entity id="DDI-DrugBank.d297.s5.e1" charOffset="109-116"
            type="drug" text="anakinra"/>
        <ddi id="DDI-DrugBank.d297.s5.d0" e1="DDI-DrugBank.d297.s5.e0"
            e2="DDI-DrugBank.d297.s5.e1"/>
    </sentence>
    <sentence id="DDI-DrugBank.d532.s0" text="Formal drug interaction studies with Abciximab have not been conducted.">
        <entity id="DDI-DrugBank.d532.s0.e0" charOffset="37-45"
            type="drug" text="Abciximab"/>
    </sentence>
    <sentence id="DDI-DrugBank.d532.s1" text="Abciximab has been administered to patients with ischemic heart disease treated concomitantly with a broad range of medications used in the treatment of angina myocardial infarction and hypertension.">
        <entity id="DDI-DrugBank.d532.s1.e0" charOffset="0-8"
            type="drug" text="Abciximab"/>
    </sentence>
    <sentence id="DDI-DrugBank.d532.s2" text="These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.">
        <entity id="DDI-DrugBank.d532.s2.e0" charOffset="32-38"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d532.s2.e1" charOffset="41-48"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d532.s2.e2" charOffset="51-83"
            type="group" text="beta-adrenergic receptor blockers"/>
        <entity id="DDI-DrugBank.d532.s2.e3" charOffset="86-112"
            type="group" text="calcium channel antagonists"/>
        <entity id="DDI-DrugBank.d532.s2.e4" charOffset="115-154"
            type="group" text="angiotensin converting enzyme inhibitors"/>
        <entity id="DDI-DrugBank.d532.s2.e5" charOffset="178-185"
            type="group" text="nitrates"/>
        <entity id="DDI-DrugBank.d532.s2.e6" charOffset="188-198"
            type="drug" text="ticlopidine"/>
        <entity id="DDI-DrugBank.d532.s2.e7" charOffset="205-211"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d532.s3" text="Heparin, other anticoagulants, thrombolytics, and anti platelet agents are associated with an increase in bleeding.">
        <entity id="DDI-DrugBank.d532.s3.e0" charOffset="0-6"
            type="drug" text="Heparin"/>
        <entity id="DDI-DrugBank.d532.s3.e1" charOffset="15-28"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d532.s3.e2" charOffset="31-43"
            type="group" text="thrombolytics"/>
        <entity id="DDI-DrugBank.d532.s3.e3" charOffset="50-69"
            type="group" text="anti platelet agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d532.s4" text="Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.">
        <entity id="DDI-DrugBank.d532.s4.e0" charOffset="98-107;124-144"
            type="group" text="diagnostic monoclonal antibodies"/>
        <entity id="DDI-DrugBank.d532.s4.e1" charOffset="112-144"
            type="group" text="therapeutic monoclonal antibodies"/>
    </sentence>
    <sentence id="DDI-DrugBank.d0.s0" text="The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.">
        <entity id="DDI-DrugBank.d0.s0.e0" charOffset="26-32"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d0.s0.e1" charOffset="38-48"
            type="drug" text="Acamprosate"/>
        <entity id="DDI-DrugBank.d0.s0.e2" charOffset="97-103"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d0.s0.e3" charOffset="108-118"
            type="drug" text="acamprosate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d0.s1" text="Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate.">
        <entity id="DDI-DrugBank.d0.s1.e0" charOffset="56-65"
            type="drug" text="disulfiram"/>
        <entity id="DDI-DrugBank.d0.s1.e1" charOffset="70-77"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d0.s1.e2" charOffset="119-129"
            type="drug" text="acamprosate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d0.s2" text="Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.">
        <entity id="DDI-DrugBank.d0.s2.e0" charOffset="21-30"
            type="drug" text="naltrexone"/>
        <entity id="DDI-DrugBank.d0.s2.e1" charOffset="37-47"
            type="drug" text="Acamprosate"/>
        <entity id="DDI-DrugBank.d0.s2.e2" charOffset="114-124"
            type="drug" text="acamprosate"/>
        <ddi id="DDI-DrugBank.d0.s2.d0" e1="DDI-DrugBank.d0.s2.e0"
            e2="DDI-DrugBank.d0.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d0.s3" text="No adjustment of dosage is recommended in such patients."/>
    <sentence id="DDI-DrugBank.d0.s4" text="The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate.">
        <entity id="DDI-DrugBank.d0.s4.e0" charOffset="24-33"
            type="drug" text="naltrexone"/>
        <entity id="DDI-DrugBank.d0.s4.e1" charOffset="60-75"
            type="drug_n" text="6-beta-naltrexol"/>
        <entity id="DDI-DrugBank.d0.s4.e2" charOffset="126-136"
            type="drug" text="Acamprosate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d0.s5" text="Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.">
        <entity id="DDI-DrugBank.d0.s5.e0" charOffset="93-103"
            type="drug" text="Acamprosate"/>
        <entity id="DDI-DrugBank.d0.s5.e1" charOffset="124-134"
            type="group" text="anxiolytics"/>
        <entity id="DDI-DrugBank.d0.s5.e2" charOffset="137-145"
            type="group" text="hypnotics"/>
        <entity id="DDI-DrugBank.d0.s5.e3" charOffset="151-159"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d0.s5.e4" charOffset="172-186"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d0.s5.e5" charOffset="193-213"
            type="group" text="non-opioid analgesics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d0.s6" text="Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.">
        <entity id="DDI-DrugBank.d0.s6.e0" charOffset="16-26"
            type="drug" text="Acamprosate"/>
        <entity id="DDI-DrugBank.d0.s6.e1" charOffset="47-61"
            type="group" text="antidepressants"/>
        <ddi id="DDI-DrugBank.d0.s6.d0" e1="DDI-DrugBank.d0.s6.e0"
            e2="DDI-DrugBank.d0.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d536.s0" text="Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control."/>
    <sentence id="DDI-DrugBank.d536.s1" text="These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.">
        <entity id="DDI-DrugBank.d536.s1.e0" charOffset="24-32"
            type="group" text="thiazides"/>
        <entity id="DDI-DrugBank.d536.s1.e1" charOffset="44-52"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d536.s1.e2" charOffset="55-69"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d536.s1.e3" charOffset="72-85"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d536.s1.e4" charOffset="88-103"
            type="group" text="thyroid products"/>
        <entity id="DDI-DrugBank.d536.s1.e5" charOffset="106-114"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d536.s1.e6" charOffset="122-135"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d536.s1.e7" charOffset="138-146"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d536.s1.e8" charOffset="149-162"
            type="drug" text="nicotinic acid"/>
        <entity id="DDI-DrugBank.d536.s1.e9" charOffset="165-180"
            type="group" text="sympathomimetics"/>
        <entity id="DDI-DrugBank.d536.s1.e10" charOffset="183-212"
            type="group" text="calcium channel-blocking drugs"/>
        <entity id="DDI-DrugBank.d536.s1.e11" charOffset="219-227"
            type="drug" text="isoniazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d536.s2" text="When such drugs are administered to a patient receiving Acarbose, the patient should be closely observed for loss of blood glucose control.">
        <entity id="DDI-DrugBank.d536.s2.e0" charOffset="56-63"
            type="drug" text="Acarbose"/>
    </sentence>
    <sentence id="DDI-DrugBank.d536.s3" text="When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.">
        <entity id="DDI-DrugBank.d536.s3.e0" charOffset="54-61"
            type="drug" text="Acarbose"/>
        <entity id="DDI-DrugBank.d536.s3.e1" charOffset="83-95"
            type="group" text="sulfonylureas"/>
        <entity id="DDI-DrugBank.d536.s3.e2" charOffset="100-106"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d536.s4" text="Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.">
        <entity id="DDI-DrugBank.d536.s4.e0" charOffset="0-20"
            type="group" text="Intestinal adsorbents"/>
        <entity id="DDI-DrugBank.d536.s4.e1" charOffset="30-37"
            type="drug" text="charcoal"/>
        <entity id="DDI-DrugBank.d536.s4.e2" charOffset="44-72"
            type="group" text="digestive enzyme preparations"/>
        <entity id="DDI-DrugBank.d536.s4.e3" charOffset="124-130"
            type="drug" text="amylase"/>
        <entity id="DDI-DrugBank.d536.s4.e4" charOffset="133-142"
            type="drug" text="pancreatin"/>
        <entity id="DDI-DrugBank.d536.s4.e5" charOffset="170-177"
            type="drug" text="Acarbose"/>
        <ddi id="DDI-DrugBank.d536.s4.d0" e1="DDI-DrugBank.d536.s4.e0"
            e2="DDI-DrugBank.d536.s4.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d536.s4.d1" e1="DDI-DrugBank.d536.s4.e1"
            e2="DDI-DrugBank.d536.s4.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d536.s4.d2" e1="DDI-DrugBank.d536.s4.e3"
            e2="DDI-DrugBank.d536.s4.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d536.s4.d3" e1="DDI-DrugBank.d536.s4.e4"
            e2="DDI-DrugBank.d536.s4.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d536.s5" text="Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.">
        <entity id="DDI-DrugBank.d536.s5.e0" charOffset="0-7"
            type="drug" text="Acarbose"/>
        <entity id="DDI-DrugBank.d536.s5.e1" charOffset="54-60"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d536.s5.e2" charOffset="111-117"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d536.s5.d0" e1="DDI-DrugBank.d536.s5.e0"
            e2="DDI-DrugBank.d536.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d536.s6" text="Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.">
        <entity id="DDI-DrugBank.d536.s6.e0" charOffset="46-53"
            type="drug" text="Acarbose"/>
        <entity id="DDI-DrugBank.d536.s6.e1" charOffset="123-129"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d536.s6.e2" charOffset="132-141"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d536.s6.e3" charOffset="144-154"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d536.s6.e4" charOffset="160-169"
            type="drug" text="ranitidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d536.s7" text="Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.">
        <entity id="DDI-DrugBank.d536.s7.e0" charOffset="0-7"
            type="drug" text="Acarbose"/>
        <entity id="DDI-DrugBank.d536.s7.e1" charOffset="69-80"
            type="drug" text="sulfonylurea"/>
        <entity id="DDI-DrugBank.d536.s7.e2" charOffset="82-90"
            type="drug" text="glyburide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d536.s8" text="Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).">
        <entity id="DDI-DrugBank.d536.s8.e0" charOffset="0-7"
            type="drug" text="Acarbose"/>
        <entity id="DDI-DrugBank.d536.s8.e1" charOffset="20-26"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d536.s8.e2" charOffset="79-85"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d536.s8.e3" charOffset="148-154"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d536.s8.e4" charOffset="240-246"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d536.s9" text="The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.">
        <entity id="DDI-DrugBank.d536.s9.e0" charOffset="14-22"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d536.s9.e1" charOffset="46-53"
            type="drug" text="Acarbose"/>
    </sentence>
    <sentence id="DDI-DrugBank.d536.s10" text="However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.">
        <entity id="DDI-DrugBank.d536.s10.e0" charOffset="34-42"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d536.s10.e1" charOffset="89-96"
            type="drug" text="Acarbose"/>
        <entity id="DDI-DrugBank.d536.s10.e2" charOffset="141-149"
            type="drug" text="metformin"/>
        <ddi id="DDI-DrugBank.d536.s10.d0" e1="DDI-DrugBank.d536.s10.e0"
            e2="DDI-DrugBank.d536.s10.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d536.s10.d1" e1="DDI-DrugBank.d536.s10.e1"
            e2="DDI-DrugBank.d536.s10.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d536.s11" text="There is little if any clinically significant interaction between Acarbose and metformin.">
        <entity id="DDI-DrugBank.d536.s11.e0" charOffset="66-73"
            type="drug" text="Acarbose"/>
        <entity id="DDI-DrugBank.d536.s11.e1" charOffset="79-87"
            type="drug" text="metformin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d388.s0" text="Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.">
        <entity id="DDI-DrugBank.d388.s0.e0" charOffset="0-28"
            type="group" text="Catecholamine-depleting drugs"/>
        <entity id="DDI-DrugBank.d388.s0.e1" charOffset="39-47"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d388.s0.e2" charOffset="94-113"
            type="group" text="beta-blocking agents"/>
        <ddi id="DDI-DrugBank.d388.s0.d0" e1="DDI-DrugBank.d388.s0.e0"
            e2="DDI-DrugBank.d388.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d388.s0.d1" e1="DDI-DrugBank.d388.s0.e1"
            e2="DDI-DrugBank.d388.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d388.s1" text="Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.">
        <entity id="DDI-DrugBank.d388.s1.e0" charOffset="22-31"
            type="drug" text="acebutolol"/>
        <entity id="DDI-DrugBank.d388.s1.e1" charOffset="38-60"
            type="group" text="catecholamine depletors"/>
        <ddi id="DDI-DrugBank.d388.s1.d0" e1="DDI-DrugBank.d388.s1.e0"
            e2="DDI-DrugBank.d388.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d388.s2" text="Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.">
        <entity id="DDI-DrugBank.d388.s2.e0" charOffset="79-105"
            type="group" text="beta-adrenergic antagonists"/>
        <entity id="DDI-DrugBank.d388.s2.e1" charOffset="111-137"
            type="group" text="alpha-adrenergic stimulants"/>
        <ddi id="DDI-DrugBank.d388.s2.d0" e1="DDI-DrugBank.d388.s2.e0"
            e2="DDI-DrugBank.d388.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d388.s3" text="Patients receiving beta-blockers should be warned of this potential hazard.">
        <entity id="DDI-DrugBank.d388.s3.e0" charOffset="19-31"
            type="group" text="beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d388.s4" text="Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.">
        <entity id="DDI-DrugBank.d388.s4.e0" charOffset="43-75"
            type="group" text="beta-adrenoceptor blocking agents"/>
        <entity id="DDI-DrugBank.d388.s4.e1" charOffset="80-115"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
        <ddi id="DDI-DrugBank.d388.s4.d0" e1="DDI-DrugBank.d388.s4.e0"
            e2="DDI-DrugBank.d388.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d388.s5" text="No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.">
        <entity id="DDI-DrugBank.d388.s5.e0" charOffset="33-39"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d388.s5.e1" charOffset="42-60"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d388.s5.e2" charOffset="63-73"
            type="drug" text="hydralazine"/>
        <entity id="DDI-DrugBank.d388.s5.e3" charOffset="76-89"
            type="drug" text="sulfinpyrazone"/>
        <entity id="DDI-DrugBank.d388.s5.e4" charOffset="97-110"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d388.s5.e5" charOffset="113-123"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d388.s5.e6" charOffset="129-136"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s0" text="DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.">
        <entity id="DDI-DrugBank.d368.s0.e0" charOffset="0-5"
            type="brand" text="DIAMOX"/>
        <entity id="DDI-DrugBank.d368.s0.e1" charOffset="16-24"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d368.s0.e2" charOffset="68-76"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d368.s0.d0" e1="DDI-DrugBank.d368.s0.e0"
            e2="DDI-DrugBank.d368.s0.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d368.s0.d1" e1="DDI-DrugBank.d368.s0.e0"
            e2="DDI-DrugBank.d368.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s1" text="This may increase or enhance the occurrence of osteomalacia in some patients receiving chronic phenytoin therapy.">
        <entity id="DDI-DrugBank.d368.s1.e0" charOffset="95-103"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s2" text="Caution is advised in patients receiving chronic concomitant therapy."/>
    <sentence id="DDI-DrugBank.d368.s3" text="By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.">
        <entity id="DDI-DrugBank.d368.s3.e0" charOffset="49-57"
            type="drug" text="primidone"/>
        <entity id="DDI-DrugBank.d368.s3.e1" charOffset="60-65"
            type="brand" text="DIAMOX"/>
        <entity id="DDI-DrugBank.d368.s3.e2" charOffset="104-112"
            type="drug" text="primidone"/>
        <ddi id="DDI-DrugBank.d368.s3.d0" e1="DDI-DrugBank.d368.s3.e1"
            e2="DDI-DrugBank.d368.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s4" text="Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.">
        <entity id="DDI-DrugBank.d368.s4.e0" charOffset="74-79"
            type="brand" text="DIAMOX"/>
        <entity id="DDI-DrugBank.d368.s4.e1" charOffset="103-111"
            type="drug" text="primidone"/>
        <ddi id="DDI-DrugBank.d368.s4.d0" e1="DDI-DrugBank.d368.s4.e0"
            e2="DDI-DrugBank.d368.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s5" text="Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable.">
        <entity id="DDI-DrugBank.d368.s5.e0" charOffset="48-76"
            type="group" text="carbonic anhydrase inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s6" text="Acetazolamide may increase the effects of other folic acid antagonists.">
        <entity id="DDI-DrugBank.d368.s6.e0" charOffset="0-12"
            type="drug" text="Acetazolamide"/>
        <entity id="DDI-DrugBank.d368.s6.e1" charOffset="48-69"
            type="group" text="folic acid antagonists"/>
        <ddi id="DDI-DrugBank.d368.s6.d0" e1="DDI-DrugBank.d368.s6.e0"
            e2="DDI-DrugBank.d368.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s7" text="Acetazolamide may increase or decrease blood glucose levels.">
        <entity id="DDI-DrugBank.d368.s7.e0" charOffset="0-12"
            type="drug" text="Acetazolamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s8" text="Consideration should be taken in patients being treated with antidiabetic agents.">
        <entity id="DDI-DrugBank.d368.s8.e0" charOffset="61-72"
            type="drug" text="antidiabetic"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s9" text="Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.">
        <entity id="DDI-DrugBank.d368.s9.e0" charOffset="0-12"
            type="drug" text="Acetazolamide"/>
        <entity id="DDI-DrugBank.d368.s9.e1" charOffset="45-55"
            type="drug" text="amphetamine"/>
        <ddi id="DDI-DrugBank.d368.s9.d0" e1="DDI-DrugBank.d368.s9.e0"
            e2="DDI-DrugBank.d368.s9.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s10" text="Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.">
        <entity id="DDI-DrugBank.d368.s10.e0" charOffset="0-12"
            type="drug" text="Acetazolamide"/>
        <entity id="DDI-DrugBank.d368.s10.e1" charOffset="43-51"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d368.s10.d0" e1="DDI-DrugBank.d368.s10.e0"
            e2="DDI-DrugBank.d368.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s11" text="Acetazolamide may prevent the urinary antiseptic effect of methenamine.">
        <entity id="DDI-DrugBank.d368.s11.e0" charOffset="0-12"
            type="drug" text="Acetazolamide"/>
        <entity id="DDI-DrugBank.d368.s11.e1" charOffset="59-69"
            type="drug" text="methenamine"/>
        <ddi id="DDI-DrugBank.d368.s11.d0" e1="DDI-DrugBank.d368.s11.e0"
            e2="DDI-DrugBank.d368.s11.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s12" text="Acetazolamide increases lithium excretion and the lithium may be decreased.">
        <entity id="DDI-DrugBank.d368.s12.e0" charOffset="0-12"
            type="drug" text="Acetazolamide"/>
        <entity id="DDI-DrugBank.d368.s12.e1" charOffset="24-30"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d368.s12.e2" charOffset="50-56"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d368.s12.d0" e1="DDI-DrugBank.d368.s12.e0"
            e2="DDI-DrugBank.d368.s12.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s13" text="Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.">
        <entity id="DDI-DrugBank.d368.s13.e0" charOffset="0-12"
            type="drug" text="Acetazolamide"/>
        <entity id="DDI-DrugBank.d368.s13.e1" charOffset="18-35"
            type="drug" text="sodium bicarbonate"/>
        <ddi id="DDI-DrugBank.d368.s13.d0" e1="DDI-DrugBank.d368.s13.e0"
            e2="DDI-DrugBank.d368.s13.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d368.s14" text="Acetazolamide may elevate cyclosporine levels.">
        <entity id="DDI-DrugBank.d368.s14.e0" charOffset="0-12"
            type="drug" text="Acetazolamide"/>
        <entity id="DDI-DrugBank.d368.s14.e1" charOffset="26-37"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d368.s14.d0" e1="DDI-DrugBank.d368.s14.e0"
            e2="DDI-DrugBank.d368.s14.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d117.s0" text="Concomitant use with iron supplements may result in the reduced absorption of iron.">
        <entity id="DDI-DrugBank.d117.s0.e0" charOffset="21-35"
            type="group" text="iron supplement"/>
        <entity id="DDI-DrugBank.d117.s0.e1" charOffset="78-81"
            type="drug" text="iron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d200.s0" text="Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.">
        <entity id="DDI-DrugBank.d200.s0.e0" charOffset="21-30"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d200.s0.e1" charOffset="37-45"
            type="drug" text="acyclovir"/>
        <ddi id="DDI-DrugBank.d200.s0.d0" e1="DDI-DrugBank.d200.s0.e0"
            e2="DDI-DrugBank.d200.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d200.s1" text="Urinary excretion and renal clearance were correspondingly reduced."/>
    <sentence id="DDI-DrugBank.d200.s2" text="The clinical effects of this combination have not been studied."/>
    <sentence id="DDI-DrugBank.d353.s0" text="Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.">
        <entity id="DDI-DrugBank.d353.s0.e0" charOffset="0-6"
            type="drug" text="Ethanol"/>
        <entity id="DDI-DrugBank.d353.s0.e1" charOffset="41-50"
            type="drug" text="etretinate"/>
        <entity id="DDI-DrugBank.d353.s0.e2" charOffset="95-103"
            type="drug" text="acitretin"/>
        <entity id="DDI-DrugBank.d353.s0.e3" charOffset="109-115"
            type="drug" text="ethanol"/>
        <ddi id="DDI-DrugBank.d353.s0.d0" e1="DDI-DrugBank.d353.s0.e2"
            e2="DDI-DrugBank.d353.s0.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s1" text="Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.">
        <entity id="DDI-DrugBank.d353.s1.e0" charOffset="0-12"
            type="drug" text="Glibenclamide"/>
        <entity id="DDI-DrugBank.d353.s1.e1" charOffset="56-64"
            type="drug" text="acitretin"/>
        <entity id="DDI-DrugBank.d353.s1.e2" charOffset="125-137"
            type="drug" text="glibenclamide"/>
        <entity id="DDI-DrugBank.d353.s1.e3" charOffset="142-153"
            type="group" text="sulfonylurea"/>
        <entity id="DDI-DrugBank.d353.s1.e4" charOffset="166-179"
            type="drug" text="chlorpropamide"/>
        <ddi id="DDI-DrugBank.d353.s1.d0" e1="DDI-DrugBank.d353.s1.e1"
            e2="DDI-DrugBank.d353.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s2" text="Repeating the study with 6 healthy male volunteers in the absence of glibenclamide did not detect an effect of acitretin on glucose tolerance.">
        <entity id="DDI-DrugBank.d353.s2.e0" charOffset="69-81"
            type="drug" text="glibenclamide"/>
        <entity id="DDI-DrugBank.d353.s2.e1" charOffset="111-119"
            type="drug" text="acitretin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s3" text="Careful supervision of diabetic patients under treatment with Soriatane is recommended.">
        <entity id="DDI-DrugBank.d353.s3.e0" charOffset="62-70"
            type="brand" text="Soriatane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s4" text="Hormonal Contraceptives: It has not been established if there is a pharmacokinetic interaction between acitretin and combined oral contraceptives.">
        <entity id="DDI-DrugBank.d353.s4.e0" charOffset="0-22"
            type="group" text="Hormonal Contraceptives"/>
        <entity id="DDI-DrugBank.d353.s4.e1" charOffset="103-111"
            type="drug" text="acitretin"/>
        <entity id="DDI-DrugBank.d353.s4.e2" charOffset="117-144"
            type="group" text="combined oral contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s5" text="However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.">
        <entity id="DDI-DrugBank.d353.s5.e0" charOffset="38-46"
            type="drug" text="acitretin"/>
        <entity id="DDI-DrugBank.d353.s5.e1" charOffset="103-111"
            type="drug" text="progestin"/>
        <ddi id="DDI-DrugBank.d353.s5.d0" e1="DDI-DrugBank.d353.s5.e0"
            e2="DDI-DrugBank.d353.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s6" text="Microdosed minipill progestin preparations are not recommended for use with Soriatane.">
        <entity id="DDI-DrugBank.d353.s6.e0" charOffset="20-28"
            type="drug" text="progestin"/>
        <entity id="DDI-DrugBank.d353.s6.e1" charOffset="76-84"
            type="drug" text="Soriatane"/>
        <ddi id="DDI-DrugBank.d353.s6.d0" e1="DDI-DrugBank.d353.s6.e0"
            e2="DDI-DrugBank.d353.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s7" text="It is not known whether other progestational contraceptives, such as implants and injectables, are adequate methods of contraception during acitretin therapy.">
        <entity id="DDI-DrugBank.d353.s7.e0" charOffset="30-58"
            type="group" text="progestational contraceptives"/>
        <entity id="DDI-DrugBank.d353.s7.e1" charOffset="140-148"
            type="drug" text="acitretin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s8" text="Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.">
        <entity id="DDI-DrugBank.d353.s8.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d353.s8.e1" charOffset="94-105"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d353.s8.e2" charOffset="111-120"
            type="drug" text="etretinate"/>
        <ddi id="DDI-DrugBank.d353.s8.d0" e1="DDI-DrugBank.d353.s8.e1"
            e2="DDI-DrugBank.d353.s8.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s9" text="Consequently, the combination of methotrexate with acitretin is also contraindicated.">
        <entity id="DDI-DrugBank.d353.s9.e0" charOffset="33-44"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d353.s9.e1" charOffset="51-59"
            type="drug" text="acitretin"/>
        <ddi id="DDI-DrugBank.d353.s9.d0" e1="DDI-DrugBank.d353.s9.e0"
            e2="DDI-DrugBank.d353.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s10" text="Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.">
        <entity id="DDI-DrugBank.d353.s10.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d353.s10.e1" charOffset="14-22"
            type="drug" text="acitretin"/>
        <entity id="DDI-DrugBank.d353.s10.e2" charOffset="51-59"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d353.s10.e3" charOffset="85-93"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d353.s10.d0" e1="DDI-DrugBank.d353.s10.e1"
            e2="DDI-DrugBank.d353.s10.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s11" text="Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.">
        <entity id="DDI-DrugBank.d353.s11.e0" charOffset="0-12"
            type="group" text="Tetracyclines"/>
        <entity id="DDI-DrugBank.d353.s11.e1" charOffset="26-34"
            type="drug" text="acitretin"/>
        <entity id="DDI-DrugBank.d353.s11.e2" charOffset="40-52"
            type="group" text="tetracyclines"/>
        <ddi id="DDI-DrugBank.d353.s11.d0" e1="DDI-DrugBank.d353.s11.e1"
            e2="DDI-DrugBank.d353.s11.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s12" text="Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.">
        <entity id="DDI-DrugBank.d353.s12.e0" charOffset="0-8"
            type="group" text="Vitamin A"/>
        <entity id="DDI-DrugBank.d353.s12.e1" charOffset="19-27"
            type="group" text="retinoids"/>
        <entity id="DDI-DrugBank.d353.s12.e2" charOffset="60-68"
            type="group" text="vitamin A"/>
        <entity id="DDI-DrugBank.d353.s12.e3" charOffset="88-96"
            type="group" text="retinoids"/>
        <entity id="DDI-DrugBank.d353.s12.e4" charOffset="103-111"
            type="drug" text="acitretin"/>
        <ddi id="DDI-DrugBank.d353.s12.d0" e1="DDI-DrugBank.d353.s12.e2"
            e2="DDI-DrugBank.d353.s12.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d353.s12.d1" e1="DDI-DrugBank.d353.s12.e3"
            e2="DDI-DrugBank.d353.s12.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s13" text="Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide.">
        <entity id="DDI-DrugBank.d353.s13.e0" charOffset="66-74"
            type="drug" text="acitretin"/>
        <entity id="DDI-DrugBank.d353.s13.e1" charOffset="80-89"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d353.s13.e2" charOffset="92-98"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d353.s13.e3" charOffset="104-112"
            type="drug" text="glyburide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s14" text="Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.">
        <entity id="DDI-DrugBank.d353.s14.e0" charOffset="34-42"
            type="drug" text="acitretin"/>
        <entity id="DDI-DrugBank.d353.s14.e1" charOffset="70-104"
            type="group" text="anticoagulants of the coumarin type"/>
        <entity id="DDI-DrugBank.d353.s14.e2" charOffset="107-114"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s15" text="Laboratory Tests If significant abnormal laboratory results are obtained, either dosage reduction with careful monitoring or treatment discontinuation is recommended, depending on clinical judgement."/>
    <sentence id="DDI-DrugBank.d353.s16" text="Blood Sugar: Some patients receiving retinoids have experienced problems with blood sugar control.">
        <entity id="DDI-DrugBank.d353.s16.e0" charOffset="37-45"
            type="group" text="retinoids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s17" text="In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.">
        <entity id="DDI-DrugBank.d353.s17.e0" charOffset="62-69"
            type="group" text="retinoid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s18" text="In diabetics, blood-sugar levels should be monitored very carefully."/>
    <sentence id="DDI-DrugBank.d353.s19" text="Lipids: In clinical studies, the incidence of hypertriglyceridemia was 66%, hypercholesterolemia was 33% and that of decreased HDL was 40%."/>
    <sentence id="DDI-DrugBank.d353.s20" text="Pretreatment and follow-up measurements should be obtained under fasting conditions."/>
    <sentence id="DDI-DrugBank.d353.s21" text="It is recommended that these tests be performed weekly or every other week until the lipid response to Soriatane has stabilized.">
        <entity id="DDI-DrugBank.d353.s21.e0" charOffset="103-111"
            type="brand" text="Soriatane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s22" text="Liver Function Tests: Elevations of AST (SGOT), ALT (SGPT) or LDH were experienced by approximately 1 in 3 patients treated with Soriatane.">
        <entity id="DDI-DrugBank.d353.s22.e0" charOffset="129-137"
            type="brand" text="Soriatane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d353.s23" text="It is recommended that these tests be performed prior to initiation of Soriatane therapy, at 1- to 2-week intervals until stable and thereafter at intervals as clinically indicated.">
        <entity id="DDI-DrugBank.d353.s23.e0" charOffset="71-79"
            type="brand" text="Soriatane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d493.s0" text="Methotrexate: HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX.">
        <entity id="DDI-DrugBank.d493.s0.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d493.s0.e1" charOffset="14-19"
            type="brand" text="HUMIRA"/>
        <entity id="DDI-DrugBank.d493.s0.e2" charOffset="90-92"
            type="drug" text="MTX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d493.s1" text="The data do not suggest the need for dose adjustment of either HUMIRA or MTX.">
        <entity id="DDI-DrugBank.d493.s1.e0" charOffset="63-68"
            type="brand" text="HUMIRA"/>
        <entity id="DDI-DrugBank.d493.s1.e1" charOffset="73-75"
            type="drug" text="MTX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d493.s2" text="Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.">
        <entity id="DDI-DrugBank.d493.s2.e0" charOffset="0-7"
            type="drug" text="Anakinra"/>
        <entity id="DDI-DrugBank.d493.s2.e1" charOffset="39-46"
            type="drug" text="anakinra"/>
        <entity id="DDI-DrugBank.d493.s2.e2" charOffset="52-75"
            type="group" text="interleukin-1 antagonist"/>
        <entity id="DDI-DrugBank.d493.s2.e3" charOffset="90-107"
            type="group" text="TNF-blocking agent"/>
        <ddi id="DDI-DrugBank.d493.s2.d0" e1="DDI-DrugBank.d493.s2.e1"
            e2="DDI-DrugBank.d493.s2.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d493.s2.d1" e1="DDI-DrugBank.d493.s2.e2"
            e2="DDI-DrugBank.d493.s2.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d493.s3" text="The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.">
        <entity id="DDI-DrugBank.d493.s3.e0" charOffset="27-34"
            type="drug" text="anakinra"/>
        <entity id="DDI-DrugBank.d493.s3.e1" charOffset="61-66"
            type="brand" text="HUMIRA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d493.s4" text="Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.">
        <entity id="DDI-DrugBank.d493.s4.e0" charOffset="30-37"
            type="drug" text="anakinra"/>
        <entity id="DDI-DrugBank.d493.s4.e1" charOffset="50-68"
            type="group" text="TNF-blocking agents"/>
        <entity id="DDI-DrugBank.d493.s4.e2" charOffset="81-86"
            type="brand" text="HUMIRA"/>
        <ddi id="DDI-DrugBank.d493.s4.d0" e1="DDI-DrugBank.d493.s4.e0"
            e2="DDI-DrugBank.d493.s4.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d493.s4.d1" e1="DDI-DrugBank.d493.s4.e0"
            e2="DDI-DrugBank.d493.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d370.s0" text="As DIFFERIN Gel has the potential to produce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime) should be approached with caution.">
        <entity id="DDI-DrugBank.d370.s0.e0" charOffset="3-10"
            type="brand" text="DIFFERIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d370.s1" text="Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Gel.">
        <entity id="DDI-DrugBank.d370.s1.e0" charOffset="72-77"
            type="drug" text="sulfur"/>
        <entity id="DDI-DrugBank.d370.s1.e1" charOffset="80-89"
            type="drug" text="resorcinol"/>
        <entity id="DDI-DrugBank.d370.s1.e2" charOffset="95-108"
            type="drug" text="salicylic acid"/>
        <entity id="DDI-DrugBank.d370.s1.e3" charOffset="130-137"
            type="brand" text="DIFFERIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d370.s2" text="If these preparations have been used it is advisable not to start therapy with DIFFERIN Gel until the effects of such preparations in the skin have subsided.">
        <entity id="DDI-DrugBank.d370.s2.e0" charOffset="79-86"
            type="brand" text="DIFFERIN"/>
    </sentence>
	    <sentence id="DDI-DrugBank.d64.s4" text="Chloral hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.">
        <entity id="DDI-DrugBank.d64.s4.e0" charOffset="0-14"
            type="drug" text="Chloral hydrate"/>
        <entity id="DDI-DrugBank.d64.s4.e1" charOffset="78-90"
            type="group" text="anticoagulant"/>
        <ddi id="DDI-DrugBank.d64.s4.d0" e1="DDI-DrugBank.d64.s4.e0"
            e2="DDI-DrugBank.d64.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s5" text="An interacting drug which leads to a decrease in prothrombin time necessitating an increased dose of oral anticoagulant to maintain an adequate degree of anticoagulation may, if abruptly discontinued, increase the risk of subsequent bleeding.">
        <entity id="DDI-DrugBank.d64.s5.e0" charOffset="106-118"
            type="group" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s6" text="Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;">
        <entity id="DDI-DrugBank.d64.s6.e0" charOffset="47-59"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d64.s6.e1" charOffset="143-165"
            type="group" text="adrenocortical steroids"/>
        <ddi id="DDI-DrugBank.d64.s6.d0" e1="DDI-DrugBank.d64.s6.e0"
            e2="DDI-DrugBank.d64.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s7" text="alcohol*;">
        <entity id="DDI-DrugBank.d64.s7.e0" charOffset="0-6" type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s8" text="antacids;">
        <entity id="DDI-DrugBank.d64.s8.e0" charOffset="0-7"
            type="group" text="antacids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s9" text="antihistamines;">
        <entity id="DDI-DrugBank.d64.s9.e0" charOffset="0-13"
            type="group" text="antihistamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s10" text="barbiturates;">
        <entity id="DDI-DrugBank.d64.s10.e0" charOffset="0-11"
            type="group" text="barbiturates"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s11" text="carbamazepine;">
        <entity id="DDI-DrugBank.d64.s11.e0" charOffset="0-12"
            type="drug" text="carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s12" text="chloral hydrate*;">
        <entity id="DDI-DrugBank.d64.s12.e0" charOffset="0-14"
            type="drug" text="chloral hydrate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s13" text="chlordiazepoxide;">
        <entity id="DDI-DrugBank.d64.s13.e0" charOffset="0-15"
            type="drug" text="chlordiazepoxide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s14" text="cholestyramine;">
        <entity id="DDI-DrugBank.d64.s14.e0" charOffset="0-13"
            type="drug" text="cholestyramine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s15" text="diet high in vitamin K;">
        <entity id="DDI-DrugBank.d64.s15.e0" charOffset="13-21"
            type="group" text="vitamin K"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s16" text="diuretics*;">
        <entity id="DDI-DrugBank.d64.s16.e0" charOffset="0-8"
            type="group" text="diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s17" text="ethchlorvynol;">
        <entity id="DDI-DrugBank.d64.s17.e0" charOffset="0-12"
            type="drug" text="ethchlorvynol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s18" text="glutethimide;">
        <entity id="DDI-DrugBank.d64.s18.e0" charOffset="0-11"
            type="drug" text="glutethimide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s19" text="griseofulvin;">
        <entity id="DDI-DrugBank.d64.s19.e0" charOffset="0-11"
            type="drug" text="griseofulvin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s20" text="haloperidol;">
        <entity id="DDI-DrugBank.d64.s20.e0" charOffset="0-10"
            type="drug" text="haloperidol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s21" text="meprobamate;">
        <entity id="DDI-DrugBank.d64.s21.e0" charOffset="0-10"
            type="drug" text="meprobamate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s22" text="oral contraceptives;">
        <entity id="DDI-DrugBank.d64.s22.e0" charOffset="5-18"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s23" text="paraldehyde;">
        <entity id="DDI-DrugBank.d64.s23.e0" charOffset="0-10"
            type="drug" text="paraldehyde"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s24" text="primidone;">
        <entity id="DDI-DrugBank.d64.s24.e0" charOffset="0-8"
            type="drug" text="primidone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s25" text="ranitidine*;">
        <entity id="DDI-DrugBank.d64.s25.e0" charOffset="0-9"
            type="drug" text="ranitidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s26" text="rifampin;">
        <entity id="DDI-DrugBank.d64.s26.e0" charOffset="0-7"
            type="drug" text="rifampin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s27" text="unreliable prothrombin time determinations;"/>
    <sentence id="DDI-DrugBank.d64.s28" text="vitamin C;">
        <entity id="DDI-DrugBank.d64.s28.e0" charOffset="0-8"
            type="drug" text="vitamin C"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s29" text="Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.">
        <entity id="DDI-DrugBank.d64.s29.e0" charOffset="47-59"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d64.s29.e1" charOffset="143-165"
            type="group" text="adrenocortical steroids"/>
        <entity id="DDI-DrugBank.d64.s29.e2" charOffset="167-173"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d64.s29.e3" charOffset="176-183"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d64.s29.e4" charOffset="185-198"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d64.s29.e5" charOffset="200-211"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d64.s29.e6" charOffset="213-225"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d64.s29.e7" charOffset="227-241"
            type="drug" text="chloral hydrate"/>
        <entity id="DDI-DrugBank.d64.s29.e8" charOffset="244-259"
            type="drug" text="chlordiazepoxide"/>
        <entity id="DDI-DrugBank.d64.s29.e9" charOffset="261-274"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d64.s29.e10" charOffset="289-297"
            type="group" text="vitamin K"/>
        <entity id="DDI-DrugBank.d64.s29.e11" charOffset="299-307"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d64.s29.e12" charOffset="310-322"
            type="drug" text="ethchlorvynol"/>
        <entity id="DDI-DrugBank.d64.s29.e13" charOffset="324-335"
            type="drug" text="glutethimide"/>
        <entity id="DDI-DrugBank.d64.s29.e14" charOffset="337-348"
            type="drug" text="griseofulvin"/>
        <entity id="DDI-DrugBank.d64.s29.e15" charOffset="350-360"
            type="drug" text="haloperidol"/>
        <entity id="DDI-DrugBank.d64.s29.e16" charOffset="362-372"
            type="drug" text="meprobamate"/>
        <entity id="DDI-DrugBank.d64.s29.e17" charOffset="379-392"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d64.s29.e18" charOffset="394-404"
            type="drug" text="paraldehyde"/>
        <entity id="DDI-DrugBank.d64.s29.e19" charOffset="406-414"
            type="drug" text="primidone"/>
        <entity id="DDI-DrugBank.d64.s29.e20" charOffset="416-425"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d64.s29.e21" charOffset="428-435"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d64.s29.e22" charOffset="480-488"
            type="drug" text="vitamin C"/>
        <entity id="DDI-DrugBank.d64.s29.e23" charOffset="490-504"
            type="drug" text="warfarin sodium"/>
        <ddi id="DDI-DrugBank.d64.s29.d0" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d1" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d2" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d3" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d4" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d5" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d6" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d7" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d8" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d9" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e10" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d10" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e11" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d11" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e12" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d12" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e13" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d13" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e14" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d14" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e15" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d15" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e16" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d16" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e17" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d17" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e18" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d18" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e19" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d19" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e20" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d20" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e21" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d21" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e22" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s29.d22" e1="DDI-DrugBank.d64.s29.e0"
            e2="DDI-DrugBank.d64.s29.e23" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s30" text="Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;">
        <entity id="DDI-DrugBank.d64.s30.e0" charOffset="40-52"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d64.s30.e1" charOffset="115-121"
            type="drug" text="alcohol"/>
        <ddi id="DDI-DrugBank.d64.s30.d0" e1="DDI-DrugBank.d64.s30.e0"
            e2="DDI-DrugBank.d64.s30.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s31" text="allopurinol;">
        <entity id="DDI-DrugBank.d64.s31.e0" charOffset="0-10"
            type="drug" text="allopurinol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s32" text="aminosalicylic acid;">
        <entity id="DDI-DrugBank.d64.s32.e0" charOffset="0-18"
            type="drug" text="aminosalicylic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s33" text="amiodarone;">
        <entity id="DDI-DrugBank.d64.s33.e0" charOffset="0-9"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s34" text="anabolic steroids;">
        <entity id="DDI-DrugBank.d64.s34.e0" charOffset="0-16"
            type="group" text="anabolic steroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s35" text="antibiotics;">
        <entity id="DDI-DrugBank.d64.s35.e0" charOffset="0-10"
            type="group" text="antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s36" text="bromelains;">
        <entity id="DDI-DrugBank.d64.s36.e0" charOffset="0-9"
            type="drug" text="bromelains"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s37" text="chloral hydrate*;">
        <entity id="DDI-DrugBank.d64.s37.e0" charOffset="0-14"
            type="drug" text="chloral hydrate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s38" text="chlorpropamide;">
        <entity id="DDI-DrugBank.d64.s38.e0" charOffset="0-13"
            type="drug" text="chlorpropamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s39" text="chymotrypsin;">
        <entity id="DDI-DrugBank.d64.s39.e0" charOffset="0-11"
            type="drug" text="chymotrypsin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s40" text="cimetidine;">
        <entity id="DDI-DrugBank.d64.s40.e0" charOffset="0-9"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s41" text="cinchophen;">
        <entity id="DDI-DrugBank.d64.s41.e0" charOffset="0-9"
            type="drug" text="cinchophen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s42" text="clofibrate;">
        <entity id="DDI-DrugBank.d64.s42.e0" charOffset="0-9"
            type="drug" text="clofibrate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s43" text="dextran;">
        <entity id="DDI-DrugBank.d64.s43.e0" charOffset="0-6"
            type="drug" text="dextran"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s44" text="dextrothyroxine;">
        <entity id="DDI-DrugBank.d64.s44.e0" charOffset="0-14"
            type="drug" text="dextrothyroxine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s45" text="diazoxide;">
        <entity id="DDI-DrugBank.d64.s45.e0" charOffset="0-8"
            type="drug" text="diazoxide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s46" text="dietary deficiencies;"/>
    <sentence id="DDI-DrugBank.d64.s47" text="diflunisal;">
        <entity id="DDI-DrugBank.d64.s47.e0" charOffset="0-9"
            type="drug" text="diflunisal"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s48" text="diuretics*;">
        <entity id="DDI-DrugBank.d64.s48.e0" charOffset="0-8"
            type="group" text="diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s49" text="disulfiram;">
        <entity id="DDI-DrugBank.d64.s49.e0" charOffset="0-9"
            type="drug" text="disulfiram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s50" text="drugs affecting blood elements;"/>
    <sentence id="DDI-DrugBank.d64.s51" text="ethacrynic acid;">
        <entity id="DDI-DrugBank.d64.s51.e0" charOffset="0-14"
            type="drug" text="ethacrynic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s52" text="fenoprofen;">
        <entity id="DDI-DrugBank.d64.s52.e0" charOffset="0-9"
            type="drug" text="fenoprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s53" text="glucagon;">
        <entity id="DDI-DrugBank.d64.s53.e0" charOffset="0-7"
            type="drug" text="glucagon"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s54" text="hepatotoxic drugs;"/>
    <sentence id="DDI-DrugBank.d64.s55" text="ibuprofen;">
        <entity id="DDI-DrugBank.d64.s55.e0" charOffset="0-8"
            type="drug" text="ibuprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s56" text="indomethacin;">
        <entity id="DDI-DrugBank.d64.s56.e0" charOffset="0-11"
            type="drug" text="indomethacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s57" text="influenza virus vaccine;">
        <entity id="DDI-DrugBank.d64.s57.e0" charOffset="0-22"
            type="group" text="influenza virus vaccine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s58" text="inhalation anesthetics;">
        <entity id="DDI-DrugBank.d64.s58.e0" charOffset="11-21"
            type="group" text="anesthetics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s59" text="mefenamic acid;">
        <entity id="DDI-DrugBank.d64.s59.e0" charOffset="0-13"
            type="drug" text="mefenamic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s60" text="methyldopa;">
        <entity id="DDI-DrugBank.d64.s60.e0" charOffset="0-9"
            type="drug" text="methyldopa"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s61" text="methylphenidate;">
        <entity id="DDI-DrugBank.d64.s61.e0" charOffset="0-14"
            type="drug" text="methylphenidate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s62" text="metronidazole;">
        <entity id="DDI-DrugBank.d64.s62.e0" charOffset="0-12"
            type="drug" text="metronidazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s63" text="miconazole;">
        <entity id="DDI-DrugBank.d64.s63.e0" charOffset="0-9"
            type="drug" text="miconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s64" text="monoamine oxidase inhibitors;">
        <entity id="DDI-DrugBank.d64.s64.e0" charOffset="0-27"
            type="group" text="monoamine oxidase inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s65" text="nalidixic acid;">
        <entity id="DDI-DrugBank.d64.s65.e0" charOffset="0-13"
            type="drug" text="nalidixic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s66" text="naproxen;">
        <entity id="DDI-DrugBank.d64.s66.e0" charOffset="0-7"
            type="drug" text="naproxen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s67" text="oxolinic acid;">
        <entity id="DDI-DrugBank.d64.s67.e0" charOffset="0-12"
            type="drug" text="oxolinic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s68" text="oxyphenbutazone;">
        <entity id="DDI-DrugBank.d64.s68.e0" charOffset="0-14"
            type="drug" text="oxyphenbutazone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s69" text="pentoxifylline;">
        <entity id="DDI-DrugBank.d64.s69.e0" charOffset="0-13"
            type="drug" text="pentoxifylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s70" text="phenylbutazone;">
        <entity id="DDI-DrugBank.d64.s70.e0" charOffset="0-13"
            type="drug" text="phenylbutazone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s71" text="phenyramidol;">
        <entity id="DDI-DrugBank.d64.s71.e0" charOffset="0-11"
            type="drug_n" text="phenyramidol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s72" text="phenytoin;">
        <entity id="DDI-DrugBank.d64.s72.e0" charOffset="0-8"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s73" text="prolonged hot weather;"/>
    <sentence id="DDI-DrugBank.d64.s74" text="prolonged narcotics;">
        <entity id="DDI-DrugBank.d64.s74.e0" charOffset="0-18"
            type="group" text="prolonged narcotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s75" text="pyrazolones;">
        <entity id="DDI-DrugBank.d64.s75.e0" charOffset="0-10"
            type="group" text="pyrazolones"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s76" text="quinidine;">
        <entity id="DDI-DrugBank.d64.s76.e0" charOffset="0-8"
            type="drug" text="quinidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s77" text="quinine;">
        <entity id="DDI-DrugBank.d64.s77.e0" charOffset="0-6"
            type="drug" text="quinine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s78" text="ranitidine*;">
        <entity id="DDI-DrugBank.d64.s78.e0" charOffset="0-9"
            type="drug" text="ranitidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s79" text="salicylates;sulfinpyrazone;">
        <entity id="DDI-DrugBank.d64.s79.e0" charOffset="0-10"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d64.s79.e1" charOffset="12-25"
            type="drug" text="sulfinpyrazone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s80" text="sulfonamides, long acting;">
        <entity id="DDI-DrugBank.d64.s80.e0" charOffset="0-11"
            type="group" text="sulfonamides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s81" text="sulindac;">
        <entity id="DDI-DrugBank.d64.s81.e0" charOffset="0-7"
            type="drug" text="sulindac"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s82" text="thyroid drugs;">
        <entity id="DDI-DrugBank.d64.s82.e0" charOffset="0-12"
            type="group" text="thyroid drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s83" text="tolbutamide;">
        <entity id="DDI-DrugBank.d64.s83.e0" charOffset="0-10"
            type="drug" text="tolbutamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s84" text="triclofos sodium;">
        <entity id="DDI-DrugBank.d64.s84.e0" charOffset="0-15"
            type="drug" text="triclofos sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s85" text="trimethoprim/sulfamethoxazole;">
        <entity id="DDI-DrugBank.d64.s85.e0" charOffset="0-11"
            type="drug" text="trimethoprim"/>
        <entity id="DDI-DrugBank.d64.s85.e1" charOffset="13-28"
            type="drug" text="sulfamethoxazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s86" text="unreliable prothrombin time determinations;"/>
    <sentence id="DDI-DrugBank.d64.s87" text="Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.">
        <entity id="DDI-DrugBank.d64.s87.e0" charOffset="40-52"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d64.s87.e1" charOffset="115-121"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d64.s87.e2" charOffset="124-134"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d64.s87.e3" charOffset="136-154"
            type="drug" text="aminosalicylic acid"/>
        <entity id="DDI-DrugBank.d64.s87.e4" charOffset="156-165"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d64.s87.e5" charOffset="167-183"
            type="group" text="anabolic steroids"/>
        <entity id="DDI-DrugBank.d64.s87.e6" charOffset="185-195"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d64.s87.e7" charOffset="197-206"
            type="drug" text="bromelains"/>
        <entity id="DDI-DrugBank.d64.s87.e8" charOffset="208-222"
            type="drug" text="chloral hydrate"/>
        <entity id="DDI-DrugBank.d64.s87.e9" charOffset="225-238"
            type="drug" text="chlorpropamide"/>
        <entity id="DDI-DrugBank.d64.s87.e10" charOffset="240-251"
            type="drug" text="chymotrypsin"/>
        <entity id="DDI-DrugBank.d64.s87.e11" charOffset="253-262"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d64.s87.e12" charOffset="264-273"
            type="drug" text="cinchophen"/>
        <entity id="DDI-DrugBank.d64.s87.e13" charOffset="275-284"
            type="drug" text="clofibrate"/>
        <entity id="DDI-DrugBank.d64.s87.e14" charOffset="286-292"
            type="drug" text="dextran"/>
        <entity id="DDI-DrugBank.d64.s87.e15" charOffset="294-308"
            type="drug" text="dextrothyroxine"/>
        <entity id="DDI-DrugBank.d64.s87.e16" charOffset="310-318"
            type="drug" text="diazoxide"/>
        <entity id="DDI-DrugBank.d64.s87.e17" charOffset="341-350"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d64.s87.e18" charOffset="352-361"
            type="drug" text="disulfiram"/>
        <entity id="DDI-DrugBank.d64.s87.e19" charOffset="394-408"
            type="drug" text="ethacrynic acid"/>
        <entity id="DDI-DrugBank.d64.s87.e20" charOffset="410-419"
            type="drug" text="fenoprofen"/>
        <entity id="DDI-DrugBank.d64.s87.e21" charOffset="421-428"
            type="drug" text="glucagon"/>
        <entity id="DDI-DrugBank.d64.s87.e22" charOffset="448-456"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d64.s87.e23" charOffset="458-469"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d64.s87.e24" charOffset="471-493"
            type="group" text="influenza virus vaccine"/>
        <entity id="DDI-DrugBank.d64.s87.e25" charOffset="506-516"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d64.s87.e26" charOffset="518-531"
            type="drug" text="mefenamic acid"/>
        <entity id="DDI-DrugBank.d64.s87.e27" charOffset="533-542"
            type="drug" text="methyldopa"/>
        <entity id="DDI-DrugBank.d64.s87.e28" charOffset="544-558"
            type="drug" text="methylphenidate"/>
        <entity id="DDI-DrugBank.d64.s87.e29" charOffset="560-572"
            type="drug" text="metronidazole"/>
        <entity id="DDI-DrugBank.d64.s87.e30" charOffset="574-583"
            type="drug" text="miconazole"/>
        <entity id="DDI-DrugBank.d64.s87.e31" charOffset="585-612"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d64.s87.e32" charOffset="614-627"
            type="drug" text="nalidixic acid"/>
        <entity id="DDI-DrugBank.d64.s87.e33" charOffset="629-636"
            type="drug" text="naproxen"/>
        <entity id="DDI-DrugBank.d64.s87.e34" charOffset="638-650"
            type="drug" text="oxolinic acid"/>
        <entity id="DDI-DrugBank.d64.s87.e35" charOffset="652-666"
            type="drug" text="oxyphenbutazone"/>
        <entity id="DDI-DrugBank.d64.s87.e36" charOffset="668-681"
            type="drug" text="pentoxifylline"/>
        <entity id="DDI-DrugBank.d64.s87.e37" charOffset="683-696"
            type="drug" text="phenylbutazone"/>
        <entity id="DDI-DrugBank.d64.s87.e38" charOffset="698-709"
            type="drug_n" text="phenyramidol"/>
        <entity id="DDI-DrugBank.d64.s87.e39" charOffset="711-719"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d64.s87.e40" charOffset="743-761"
            type="group" text="prolonged narcotics"/>
        <entity id="DDI-DrugBank.d64.s87.e41" charOffset="763-773"
            type="group" text="pyrazolones"/>
        <entity id="DDI-DrugBank.d64.s87.e42" charOffset="775-783"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d64.s87.e43" charOffset="785-791"
            type="drug" text="quinine"/>
        <entity id="DDI-DrugBank.d64.s87.e44" charOffset="793-802"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d64.s87.e45" charOffset="805-815"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d64.s87.e46" charOffset="817-830"
            type="drug" text="sulfinpyrazone"/>
        <entity id="DDI-DrugBank.d64.s87.e47" charOffset="832-843"
            type="group" text="sulfonamides"/>
        <entity id="DDI-DrugBank.d64.s87.e48" charOffset="858-865"
            type="drug" text="sulindac"/>
        <entity id="DDI-DrugBank.d64.s87.e49" charOffset="867-879"
            type="group" text="thyroid drugs"/>
        <entity id="DDI-DrugBank.d64.s87.e50" charOffset="881-891"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d64.s87.e51" charOffset="893-908"
            type="drug" text="triclofos sodium"/>
        <entity id="DDI-DrugBank.d64.s87.e52" charOffset="910-921"
            type="drug" text="trimethoprim"/>
        <entity id="DDI-DrugBank.d64.s87.e53" charOffset="923-938"
            type="drug" text="sulfamethoxazole"/>
        <entity id="DDI-DrugBank.d64.s87.e54" charOffset="983-997"
            type="drug" text="warfarin sodium"/>
        <ddi id="DDI-DrugBank.d64.s87.d0" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d1" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d2" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d3" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d4" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d5" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d6" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d7" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d8" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d9" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e10" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d10" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e11" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d11" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e12" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d12" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e13" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d13" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e14" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d14" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e15" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d15" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e16" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d16" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e17" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d17" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e18" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d18" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e19" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d19" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e20" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d20" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e21" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d21" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e22" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d22" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e23" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d23" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e24" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d24" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e25" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d25" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e26" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d26" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e27" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d27" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e28" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d28" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e29" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d29" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e30" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d30" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e31" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d31" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e32" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d32" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e33" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d33" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e34" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d34" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e35" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d35" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e36" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d36" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e37" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d37" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e38" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d38" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e39" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d39" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e40" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d40" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e41" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d41" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e42" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d42" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e43" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d43" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e44" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d44" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e45" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d45" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e46" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d46" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e47" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d47" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e48" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d48" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e49" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d49" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e50" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d50" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e51" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d51" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e52" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d52" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e53" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s87.d53" e1="DDI-DrugBank.d64.s87.e0"
            e2="DDI-DrugBank.d64.s87.e54" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s88" text="Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.">
        <entity id="DDI-DrugBank.d64.s88.e0" charOffset="5-18"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d64.s88.e1" charOffset="62-80"
            type="group" text="hypoglycemic agents"/>
        <entity id="DDI-DrugBank.d64.s88.e2" charOffset="87-97"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d64.s88.e3" charOffset="103-116"
            type="drug" text="chlorpropamide"/>
        <ddi id="DDI-DrugBank.d64.s88.d0" e1="DDI-DrugBank.d64.s88.e0"
            e2="DDI-DrugBank.d64.s88.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d64.s88.d1" e1="DDI-DrugBank.d64.s88.e0"
            e2="DDI-DrugBank.d64.s88.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d64.s88.d2" e1="DDI-DrugBank.d64.s88.e0"
            e2="DDI-DrugBank.d64.s88.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s89" text="Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.">
        <entity id="DDI-DrugBank.d64.s89.e0" charOffset="13-26"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d64.s89.e1" charOffset="73-81"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d64.s89.e2" charOffset="104-117"
            type="group" text="anticonvulsant"/>
        <entity id="DDI-DrugBank.d64.s89.e3" charOffset="142-154"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d64.s89.e4" charOffset="160-168"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d64.s89.d0" e1="DDI-DrugBank.d64.s89.e0"
            e2="DDI-DrugBank.d64.s89.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d64.s89.d1" e1="DDI-DrugBank.d64.s89.e3"
            e2="DDI-DrugBank.d64.s89.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s90" text="Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.">
        <entity id="DDI-DrugBank.d64.s90.e0" charOffset="91-111"
            type="group" text="antineoplastic agents"/>
        <entity id="DDI-DrugBank.d64.s90.e1" charOffset="160-166"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d64.s90.e2" charOffset="178-214"
            type="group" text="non-steroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d64.s90.e3" charOffset="217-228"
            type="drug" text="dipyridamole"/>
        <entity id="DDI-DrugBank.d64.s90.e4" charOffset="231-246"
            type="drug" text="hydrochloroquine"/>
        <entity id="DDI-DrugBank.d64.s90.e5" charOffset="249-258"
            type="drug" text="clofibrate"/>
        <entity id="DDI-DrugBank.d64.s90.e6" charOffset="261-267"
            type="drug" text="dextran"/>
        <entity id="DDI-DrugBank.d64.s90.e7" charOffset="317-330"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d64.s90.d0" e1="DDI-DrugBank.d64.s90.e0"
            e2="DDI-DrugBank.d64.s90.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s90.d1" e1="DDI-DrugBank.d64.s90.e1"
            e2="DDI-DrugBank.d64.s90.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s90.d2" e1="DDI-DrugBank.d64.s90.e2"
            e2="DDI-DrugBank.d64.s90.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s90.d3" e1="DDI-DrugBank.d64.s90.e3"
            e2="DDI-DrugBank.d64.s90.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s90.d4" e1="DDI-DrugBank.d64.s90.e4"
            e2="DDI-DrugBank.d64.s90.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s90.d5" e1="DDI-DrugBank.d64.s90.e5"
            e2="DDI-DrugBank.d64.s90.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d64.s90.d6" e1="DDI-DrugBank.d64.s90.e6"
            e2="DDI-DrugBank.d64.s90.e7" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s91" text="The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet and anticoagulant medication must be weighed against an increased risk of inducing hemorrhage.">
        <entity id="DDI-DrugBank.d64.s91.e0" charOffset="81-92;112-121"
            type="group" text="antiplatelet medication"/>
        <entity id="DDI-DrugBank.d64.s91.e1" charOffset="98-121"
            type="group" text="anticoagulant medication"/>
        <ddi id="DDI-DrugBank.d64.s91.d0" e1="DDI-DrugBank.d64.s91.e0"
            e2="DDI-DrugBank.d64.s91.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s92" text="*Increased and decreased prothrombin time responses have been reported."/>
    <sentence id="DDI-DrugBank.d64.s93" text="Drug/Laboratory Test Interferences: Dicumarol and indanedione anticoagulants, including anisindione, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.">
        <entity id="DDI-DrugBank.d64.s93.e0" charOffset="36-44"
            type="drug" text="Dicumarol"/>
        <entity id="DDI-DrugBank.d64.s93.e1" charOffset="50-75"
            type="group" text="indanedione anticoagulants"/>
        <entity id="DDI-DrugBank.d64.s93.e2" charOffset="88-98"
            type="drug" text="anisindione"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s94" text="The color reverses when the test sample is acidified in vitro to a pH below 4."/>
    <sentence id="DDI-DrugBank.d357.s0" text="5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .">
        <entity id="DDI-DrugBank.d357.s0.e0" charOffset="0-15"
            type="group" text="5HT3 Antagonists"/>
        <entity id="DDI-DrugBank.d357.s0.e1" charOffset="90-100"
            type="drug" text="apomorphine"/>
        <entity id="DDI-DrugBank.d357.s0.e2" charOffset="124-134"
            type="drug" text="ondansetron"/>
        <entity id="DDI-DrugBank.d357.s0.e3" charOffset="160-170"
            type="drug" text="apomorphine"/>
        <entity id="DDI-DrugBank.d357.s0.e4" charOffset="190-210"
            type="group" text="5HT3 antagonist class"/>
        <entity id="DDI-DrugBank.d357.s0.e5" charOffset="237-247"
            type="drug" text="ondansetron"/>
        <entity id="DDI-DrugBank.d357.s0.e6" charOffset="250-260"
            type="drug" text="granisetron"/>
        <entity id="DDI-DrugBank.d357.s0.e7" charOffset="263-272"
            type="drug" text="dolasetron"/>
        <entity id="DDI-DrugBank.d357.s0.e8" charOffset="275-286"
            type="drug" text="palonosetron"/>
        <entity id="DDI-DrugBank.d357.s0.e9" charOffset="293-301"
            type="drug" text="alosetron"/>
        <ddi id="DDI-DrugBank.d357.s0.d0" e1="DDI-DrugBank.d357.s0.e1"
            e2="DDI-DrugBank.d357.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d357.s0.d1" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d357.s0.d2" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d357.s0.d3" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d357.s0.d4" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d357.s0.d5" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d357.s0.d6" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e9" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d357.s1" text="Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.">
        <entity id="DDI-DrugBank.d357.s1.e0" charOffset="0-26"
            type="group" text="Antihypertensive Medication"/>
        <entity id="DDI-DrugBank.d357.s1.e1" charOffset="33-44"
            type="group" text="Vasodilators"/>
        <entity id="DDI-DrugBank.d357.s1.e2" charOffset="141-168"
            type="group" text="antihypertensive medications"/>
        <entity id="DDI-DrugBank.d357.s1.e3" charOffset="173-184"
            type="group" text="vasodilators"/>
        <ddi id="DDI-DrugBank.d357.s1.d0" e1="DDI-DrugBank.d357.s1.e2"
            e2="DDI-DrugBank.d357.s1.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d357.s2" text="The mechanism underlying many of these events is unknown, but may represent increased hypotension ."/>
    <sentence id="DDI-DrugBank.d357.s3" text="Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.">
        <entity id="DDI-DrugBank.d357.s3.e0" charOffset="0-19"
            type="group" text="Dopamine Antagonists"/>
        <entity id="DDI-DrugBank.d357.s3.e1" charOffset="28-38"
            type="drug" text="apomorphine"/>
        <entity id="DDI-DrugBank.d357.s3.e2" charOffset="45-60"
            type="group" text="dopamine agonist"/>
        <entity id="DDI-DrugBank.d357.s3.e3" charOffset="83-102"
            type="group" text="dopamine antagonists"/>
        <entity id="DDI-DrugBank.d357.s3.e4" charOffset="117-128"
            type="group" text="neuroleptics"/>
        <entity id="DDI-DrugBank.d357.s3.e5" charOffset="131-144"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d357.s3.e6" charOffset="147-160"
            type="group" text="butyrophenones"/>
        <entity id="DDI-DrugBank.d357.s3.e7" charOffset="163-175"
            type="group" text="thioxanthenes"/>
        <entity id="DDI-DrugBank.d357.s3.e8" charOffset="181-194"
            type="drug" text="metoclopramide"/>
        <entity id="DDI-DrugBank.d357.s3.e9" charOffset="231-236"
            type="brand" text="APOKYN"/>
        <ddi id="DDI-DrugBank.d357.s3.d0" e1="DDI-DrugBank.d357.s3.e3"
            e2="DDI-DrugBank.d357.s3.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d357.s3.d1" e1="DDI-DrugBank.d357.s3.e5"
            e2="DDI-DrugBank.d357.s3.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d357.s3.d2" e1="DDI-DrugBank.d357.s3.e6"
            e2="DDI-DrugBank.d357.s3.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d357.s3.d3" e1="DDI-DrugBank.d357.s3.e7"
            e2="DDI-DrugBank.d357.s3.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d357.s3.d4" e1="DDI-DrugBank.d357.s3.e8"
            e2="DDI-DrugBank.d357.s3.e9" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d357.s4" text="Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.">
        <entity id="DDI-DrugBank.d357.s4.e0" charOffset="54-65"
            type="group" text="neuroleptics"/>
        <entity id="DDI-DrugBank.d357.s4.e1" charOffset="91-107"
            type="group" text="dopamine agonists"/>
        <ddi id="DDI-DrugBank.d357.s4.d0" e1="DDI-DrugBank.d357.s4.e0"
            e2="DDI-DrugBank.d357.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d357.s5" text="Drugs Prolonging the QT/QTc Interval Caution should be exercised when prescribing apomorphine concomitantly with drugs that prolong the QT/QTc interval.">
        <entity id="DDI-DrugBank.d357.s5.e0" charOffset="82-92"
            type="drug" text="apomorphine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d357.s6" text="Drug/Laboratory Test Interactions There are no known interactions between APOKYN and laboratory tests.">
        <entity id="DDI-DrugBank.d357.s6.e0" charOffset="74-79"
            type="brand" text="APOKYN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s0" text="Apraclonidine should not be used in patients receiving MAO inhibitors..">
        <entity id="DDI-DrugBank.d224.s0.e0" charOffset="0-12"
            type="drug" text="Apraclonidine"/>
        <entity id="DDI-DrugBank.d224.s0.e1" charOffset="55-68"
            type="group" text="MAO inhibitors"/>
        <ddi id="DDI-DrugBank.d224.s0.d0" e1="DDI-DrugBank.d224.s0.e0"
            e2="DDI-DrugBank.d224.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s1" text="Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.">
        <entity id="DDI-DrugBank.d224.s1.e0" charOffset="130-137"
            type="brand" text="IOPIDINE"/>
        <entity id="DDI-DrugBank.d224.s1.e1" charOffset="224-238"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d224.s1.e2" charOffset="241-247"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d224.s1.e3" charOffset="250-261"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d224.s1.e4" charOffset="264-270"
            type="group" text="opiates"/>
        <entity id="DDI-DrugBank.d224.s1.e5" charOffset="273-281"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d224.s1.e6" charOffset="284-294"
            type="group" text="anesthetics"/>
        <ddi id="DDI-DrugBank.d224.s1.d0" e1="DDI-DrugBank.d224.s1.e0"
            e2="DDI-DrugBank.d224.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d224.s1.d1" e1="DDI-DrugBank.d224.s1.e0"
            e2="DDI-DrugBank.d224.s1.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d224.s1.d2" e1="DDI-DrugBank.d224.s1.e0"
            e2="DDI-DrugBank.d224.s1.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d224.s1.d3" e1="DDI-DrugBank.d224.s1.e0"
            e2="DDI-DrugBank.d224.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d224.s1.d4" e1="DDI-DrugBank.d224.s1.e0"
            e2="DDI-DrugBank.d224.s1.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d224.s1.d5" e1="DDI-DrugBank.d224.s1.e0"
            e2="DDI-DrugBank.d224.s1.e6" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s2" text="Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.">
        <entity id="DDI-DrugBank.d224.s2.e0" charOffset="0-24"
            type="group" text="Tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d224.s2.e1" charOffset="89-97"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d224.s2.d0" e1="DDI-DrugBank.d224.s2.e0"
            e2="DDI-DrugBank.d224.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s3" text="It is not known whether the concurrent use of these agents with apraclonidine can lead to a reduction in IOP lowering effect.">
        <entity id="DDI-DrugBank.d224.s3.e0" charOffset="64-76"
            type="drug" text="apraclonidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s4" text="No data on the level of circulating catecholamines after apraclonidine withdrawal are available.">
        <entity id="DDI-DrugBank.d224.s4.e0" charOffset="57-69"
            type="drug" text="apraclonidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s5" text="Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.">
        <entity id="DDI-DrugBank.d224.s5.e0" charOffset="48-72"
            type="group" text="tricyclic antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s6" text="An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.">
        <entity id="DDI-DrugBank.d224.s6.e0" charOffset="82-90"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d224.s6.e1" charOffset="96-106"
            type="group" text="neuroleptic"/>
        <ddi id="DDI-DrugBank.d224.s6.d0" e1="DDI-DrugBank.d224.s6.e0"
            e2="DDI-DrugBank.d224.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s7" text="Systemic clonidine may inhibit the production of catecholamines in response to insulin-induced hypoglycemia and mask the signs and symptoms of hypoglycemia.">
        <entity id="DDI-DrugBank.d224.s7.e0" charOffset="9-17"
            type="drug" text="clonidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s8" text="Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.">
        <entity id="DDI-DrugBank.d224.s8.e0" charOffset="6-18"
            type="drug" text="apraclonidine"/>
        <entity id="DDI-DrugBank.d224.s8.e1" charOffset="88-100"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d224.s8.e2" charOffset="129-145"
            type="group" text="antihypertensives"/>
        <entity id="DDI-DrugBank.d224.s8.e3" charOffset="152-169"
            type="group" text="cardiac glycosides"/>
        <ddi id="DDI-DrugBank.d224.s8.d0" e1="DDI-DrugBank.d224.s8.e0"
            e2="DDI-DrugBank.d224.s8.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d224.s8.d1" e1="DDI-DrugBank.d224.s8.e0"
            e2="DDI-DrugBank.d224.s8.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d224.s8.d2" e1="DDI-DrugBank.d224.s8.e0"
            e2="DDI-DrugBank.d224.s8.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s9" text="Patients using cardiovascular drugs concurrently with IOPIDINE 0.5% Ophthalmic Solution should have pulse and blood pressures frequently monitored.">
        <entity id="DDI-DrugBank.d224.s9.e0" charOffset="54-61"
            type="brand" text="IOPIDINE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s10" text="Caution should be exercised with simultaneous use of clonidine and other similar pharmacologic agents">
        <entity id="DDI-DrugBank.d224.s10.e0" charOffset="53-61"
            type="drug" text="clonidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d224.s11" text="."/>
    <sentence id="DDI-DrugBank.d224.s12" text=""/>
    <sentence id="DDI-DrugBank.d382.s0" text="Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4.">
        <entity id="DDI-DrugBank.d382.s0.e0" charOffset="0-9"
            type="drug" text="Aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s1" text="Aprepitant is also an inducer of CYP2C9.">
        <entity id="DDI-DrugBank.d382.s1.e0" charOffset="0-9"
            type="drug" text="Aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s2" text="Effect of aprepitant on the pharmacokinetics of other agents">
        <entity id="DDI-DrugBank.d382.s2.e0" charOffset="10-19"
            type="drug" text="aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s3" text="As a moderate inhibitor of CYP3A4, aprepitant can increase plasma concentrations of coadministered medicinal products that are metabolized through CYP3A4.">
        <entity id="DDI-DrugBank.d382.s3.e0" charOffset="35-44"
            type="drug" text="aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s4" text="Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.">
        <entity id="DDI-DrugBank.d382.s4.e0" charOffset="0-9"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s4.e1" charOffset="54-66"
            type="drug" text="S(-) warfarin"/>
        <entity id="DDI-DrugBank.d382.s4.e2" charOffset="72-82"
            type="drug" text="tolbutamide"/>
        <ddi id="DDI-DrugBank.d382.s4.d0" e1="DDI-DrugBank.d382.s4.e0"
            e2="DDI-DrugBank.d382.s4.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d382.s4.d1" e1="DDI-DrugBank.d382.s4.e0"
            e2="DDI-DrugBank.d382.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s5" text="Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.">
        <entity id="DDI-DrugBank.d382.s5.e0" charOffset="20-29"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s5.e1" charOffset="115-123"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d382.s5.d0" e1="DDI-DrugBank.d382.s5.e0"
            e2="DDI-DrugBank.d382.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s6" text="Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study.">
        <entity id="DDI-DrugBank.d382.s6.e0" charOffset="0-9"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s6.e1" charOffset="148-157"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s6.e2" charOffset="164-170"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s7" text="5-HT3 antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron.">
        <entity id="DDI-DrugBank.d382.s7.e0" charOffset="0-16"
            type="group" text="5-HT3 antagonists"/>
        <entity id="DDI-DrugBank.d382.s7.e1" charOffset="57-66"
            type="drug" text="aprepitant"/>
        <entity id="DDI-DrugBank.d382.s7.e2" charOffset="137-147"
            type="drug" text="ondansetron"/>
        <entity id="DDI-DrugBank.d382.s7.e3" charOffset="152-162"
            type="drug" text="granisetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s8" text="No clinical or drug interaction study was conducted with dolasetron.">
        <entity id="DDI-DrugBank.d382.s8.e0" charOffset="57-66"
            type="drug" text="dolasetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s9" text="Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.">
        <entity id="DDI-DrugBank.d382.s9.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d382.s9.e1" charOffset="17-29"
            type="drug" text="Dexamethasone"/>
        <entity id="DDI-DrugBank.d382.s9.e2" charOffset="32-41"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s9.e3" charOffset="82-94"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d382.s9.e4" charOffset="141-150"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s9.e5" charOffset="181-193"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d382.s9.e6" charOffset="267-279"
            type="drug" text="dexamethasone"/>
        <ddi id="DDI-DrugBank.d382.s9.d0" e1="DDI-DrugBank.d382.s9.e2"
            e2="DDI-DrugBank.d382.s9.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d382.s9.d1" e1="DDI-DrugBank.d382.s9.e4"
            e2="DDI-DrugBank.d382.s9.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s10" text="The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.">
        <entity id="DDI-DrugBank.d382.s10.e0" charOffset="9-21"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d382.s10.e1" charOffset="93-102"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s10.e2" charOffset="129-141"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d382.s10.e3" charOffset="194-203"
            type="drug" text="Aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s10.d0" e1="DDI-DrugBank.d382.s10.e0"
            e2="DDI-DrugBank.d382.s10.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s11" text="The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.">
        <entity id="DDI-DrugBank.d382.s11.e0" charOffset="18-30"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d382.s11.e1" charOffset="70-79"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s11.e2" charOffset="134-146"
            type="drug" text="dexamethasone"/>
        <ddi id="DDI-DrugBank.d382.s11.d0" e1="DDI-DrugBank.d382.s11.e0"
            e2="DDI-DrugBank.d382.s11.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s12" text="Methylprednisolone">
        <entity id="DDI-DrugBank.d382.s12.e0" charOffset="0-17"
            type="drug" text="Methylprednisolone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s13" text="Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.">
        <entity id="DDI-DrugBank.d382.s13.e0" charOffset="0-9"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s13.e1" charOffset="107-124"
            type="drug" text="methylprednisolone"/>
        <entity id="DDI-DrugBank.d382.s13.e2" charOffset="200-217"
            type="drug" text="methylprednisolone"/>
        <ddi id="DDI-DrugBank.d382.s13.d0" e1="DDI-DrugBank.d382.s13.e0"
            e2="DDI-DrugBank.d382.s13.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s14" text="The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.">
        <entity id="DDI-DrugBank.d382.s14.e0" charOffset="7-24"
            type="drug" text="methylprednisolone"/>
        <entity id="DDI-DrugBank.d382.s14.e1" charOffset="84-101"
            type="drug" text="methylprednisolone"/>
        <entity id="DDI-DrugBank.d382.s14.e2" charOffset="172-181"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s14.e3" charOffset="207-224"
            type="drug" text="methylprednisolone"/>
        <entity id="DDI-DrugBank.d382.s14.e4" charOffset="277-286"
            type="drug" text="Aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s14.d0" e1="DDI-DrugBank.d382.s14.e0"
            e2="DDI-DrugBank.d382.s14.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d382.s14.d1" e1="DDI-DrugBank.d382.s14.e1"
            e2="DDI-DrugBank.d382.s14.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s15" text="Warfarin: A single 125-mg dose of Aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy.">
        <entity id="DDI-DrugBank.d382.s15.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d382.s15.e1" charOffset="34-43"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s15.e2" charOffset="152-159"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s16" text="Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.">
        <entity id="DDI-DrugBank.d382.s16.e0" charOffset="32-41"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s16.e1" charOffset="64-67;77-84"
            type="drug" text="R(+) warfarin"/>
        <entity id="DDI-DrugBank.d382.s16.e2" charOffset="72-84"
            type="drug" text="S(-) warfarin"/>
        <entity id="DDI-DrugBank.d382.s16.e3" charOffset="135-146"
            type="drug" text="S(-)warfarin"/>
        <entity id="DDI-DrugBank.d382.s16.e4" charOffset="335-344"
            type="drug" text="Aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s16.d0" e1="DDI-DrugBank.d382.s16.e3"
            e2="DDI-DrugBank.d382.s16.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s17" text="In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.">
        <entity id="DDI-DrugBank.d382.s17.e0" charOffset="23-30"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d382.s17.e1" charOffset="193-202"
            type="drug" text="Aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s17.d0" e1="DDI-DrugBank.d382.s17.e0"
            e2="DDI-DrugBank.d382.s17.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s18" text="Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.">
        <entity id="DDI-DrugBank.d382.s18.e0" charOffset="0-10"
            type="drug" text="Tolbutamide"/>
        <entity id="DDI-DrugBank.d382.s18.e1" charOffset="13-22"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s18.e2" charOffset="107-117"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d382.s18.e3" charOffset="212-222"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d382.s18.e4" charOffset="308-317"
            type="drug" text="Aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s18.d0" e1="DDI-DrugBank.d382.s18.e3"
            e2="DDI-DrugBank.d382.s18.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s19" text="Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;">
        <entity id="DDI-DrugBank.d382.s19.e0" charOffset="5-18"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d382.s19.e1" charOffset="21-30"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s19.e2" charOffset="100-112"
            type="group" text="contraceptive"/>
        <entity id="DDI-DrugBank.d382.s19.e3" charOffset="135-151"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d382.s19.e4" charOffset="165-177"
            type="drug" text="norethindrone"/>
        <entity id="DDI-DrugBank.d382.s19.e5" charOffset="201-217"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d382.s19.e6" charOffset="252-264"
            type="drug" text="norethindrone"/>
        <ddi id="DDI-DrugBank.d382.s19.d0" e1="DDI-DrugBank.d382.s19.e1"
            e2="DDI-DrugBank.d382.s19.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d382.s19.d1" e1="DDI-DrugBank.d382.s19.e1"
            e2="DDI-DrugBank.d382.s19.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s20" text="therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.">
        <entity id="DDI-DrugBank.d382.s20.e0" charOffset="32-45"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d382.s20.e1" charOffset="72-81"
            type="drug" text="Aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s20.d0" e1="DDI-DrugBank.d382.s20.e0"
            e2="DDI-DrugBank.d382.s20.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s21" text="Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.">
        <entity id="DDI-DrugBank.d382.s21.e0" charOffset="28-37"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s21.e1" charOffset="69-82"
            type="group" text="contraceptives"/>
        <ddi id="DDI-DrugBank.d382.s21.d0" e1="DDI-DrugBank.d382.s21.e0"
            e2="DDI-DrugBank.d382.s21.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s22" text="Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.">
        <entity id="DDI-DrugBank.d382.s22.e0" charOffset="0-8"
            type="drug" text="Midazolam"/>
        <entity id="DDI-DrugBank.d382.s22.e1" charOffset="11-20"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s22.e2" charOffset="43-51"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d382.s22.e3" charOffset="155-163"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d382.s22.e4" charOffset="224-233"
            type="drug" text="Aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s22.d0" e1="DDI-DrugBank.d382.s22.e1"
            e2="DDI-DrugBank.d382.s22.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s23" text="The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.">
        <entity id="DDI-DrugBank.d382.s23.e0" charOffset="60-68"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d382.s23.e1" charOffset="79-93"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d382.s23.e2" charOffset="119-128"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d382.s23.e3" charOffset="131-139"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d382.s23.e4" charOffset="202-211"
            type="drug" text="Aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s23.d0" e1="DDI-DrugBank.d382.s23.e0"
            e2="DDI-DrugBank.d382.s23.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d382.s23.d1" e1="DDI-DrugBank.d382.s23.e1"
            e2="DDI-DrugBank.d382.s23.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d382.s23.d2" e1="DDI-DrugBank.d382.s23.e2"
            e2="DDI-DrugBank.d382.s23.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d382.s23.d3" e1="DDI-DrugBank.d382.s23.e3"
            e2="DDI-DrugBank.d382.s23.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s24" text="In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.">
        <entity id="DDI-DrugBank.d382.s24.e0" charOffset="52-60"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d382.s24.e1" charOffset="63-72"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s24.e2" charOffset="138-146"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d382.s24.e3" charOffset="218-227"
            type="drug" text="Aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s25" text="Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.">
        <entity id="DDI-DrugBank.d382.s25.e0" charOffset="0-9"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s25.e1" charOffset="32-40"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d382.s25.e2" charOffset="83-91"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d382.s25.e3" charOffset="135-144"
            type="drug" text="Aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s25.d0" e1="DDI-DrugBank.d382.s25.e0"
            e2="DDI-DrugBank.d382.s25.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d382.s25.d1" e1="DDI-DrugBank.d382.s25.e0"
            e2="DDI-DrugBank.d382.s25.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s26" text="These effects were not considered clinically important."/>
    <sentence id="DDI-DrugBank.d382.s27" text="The AUC of midazolam on Day 15 was similar to that observed at baseline.">
        <entity id="DDI-DrugBank.d382.s27.e0" charOffset="11-19"
            type="drug" text="midazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s28" text="Effect of other agents on the pharmacokinefics of aprepitant">
        <entity id="DDI-DrugBank.d382.s28.e0" charOffset="50-59"
            type="drug" text="aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s29" text="Aprepitant is a substrate for CYP3A4;">
        <entity id="DDI-DrugBank.d382.s29.e0" charOffset="0-9"
            type="drug" text="Aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s30" text="therefore, coadministration of Aprepitant with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of aprepitant.">
        <entity id="DDI-DrugBank.d382.s30.e0" charOffset="31-40"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s30.e1" charOffset="131-140"
            type="drug" text="aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s31" text="Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.">
        <entity id="DDI-DrugBank.d382.s31.e0" charOffset="44-53"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s31.e1" charOffset="92-103"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d382.s31.e2" charOffset="106-117"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d382.s31.e3" charOffset="120-129"
            type="drug" text="nefazodone"/>
        <entity id="DDI-DrugBank.d382.s31.e4" charOffset="132-145"
            type="drug" text="troleandomycin"/>
        <entity id="DDI-DrugBank.d382.s31.e5" charOffset="148-161"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d382.s31.e6" charOffset="164-172"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d382.s31.e7" charOffset="175-184"
            type="drug" text="nelfinavir"/>
        <ddi id="DDI-DrugBank.d382.s31.d0" e1="DDI-DrugBank.d382.s31.e0"
            e2="DDI-DrugBank.d382.s31.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d382.s31.d1" e1="DDI-DrugBank.d382.s31.e0"
            e2="DDI-DrugBank.d382.s31.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d382.s31.d2" e1="DDI-DrugBank.d382.s31.e0"
            e2="DDI-DrugBank.d382.s31.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d382.s31.d3" e1="DDI-DrugBank.d382.s31.e0"
            e2="DDI-DrugBank.d382.s31.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d382.s31.d4" e1="DDI-DrugBank.d382.s31.e0"
            e2="DDI-DrugBank.d382.s31.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d382.s31.d5" e1="DDI-DrugBank.d382.s31.e0"
            e2="DDI-DrugBank.d382.s31.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d382.s31.d6" e1="DDI-DrugBank.d382.s31.e0"
            e2="DDI-DrugBank.d382.s31.e7" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s32" text="Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.">
        <entity id="DDI-DrugBank.d382.s32.e0" charOffset="42-50"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d382.s32.e1" charOffset="107-116"
            type="drug" text="aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s32.d0" e1="DDI-DrugBank.d382.s32.e0"
            e2="DDI-DrugBank.d382.s32.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s33" text="Aprepitant is a substrate for CYP3A4;">
        <entity id="DDI-DrugBank.d382.s33.e0" charOffset="0-9"
            type="drug" text="Aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s34" text="therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.">
        <entity id="DDI-DrugBank.d382.s34.e0" charOffset="31-40"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s34.e1" charOffset="97-104"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d382.s34.e2" charOffset="107-119"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d382.s34.e3" charOffset="122-130"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d382.s34.e4" charOffset="180-189"
            type="drug" text="aprepitant"/>
        <entity id="DDI-DrugBank.d382.s34.e5" charOffset="232-241"
            type="drug" text="Aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s34.d0" e1="DDI-DrugBank.d382.s34.e0"
            e2="DDI-DrugBank.d382.s34.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d382.s34.d1" e1="DDI-DrugBank.d382.s34.e0"
            e2="DDI-DrugBank.d382.s34.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d382.s34.d2" e1="DDI-DrugBank.d382.s34.e0"
            e2="DDI-DrugBank.d382.s34.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s35" text="Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a">
        <entity id="DDI-DrugBank.d382.s35.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d382.s35.e1" charOffset="43-52"
            type="drug" text="Aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s36" text="Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.">
        <entity id="DDI-DrugBank.d382.s36.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d382.s36.e1" charOffset="43-52"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s36.e2" charOffset="116-127"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d382.s36.e3" charOffset="168-177"
            type="drug" text="aprepitant"/>
        <entity id="DDI-DrugBank.d382.s36.e4" charOffset="245-254"
            type="drug" text="aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s36.d0" e1="DDI-DrugBank.d382.s36.e1"
            e2="DDI-DrugBank.d382.s36.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s37" text="Concomitant administration of Aprepitant with strong CYP3A4 inhibitors should be approached cautiously.">
        <entity id="DDI-DrugBank.d382.s37.e0" charOffset="30-39"
            type="drug" text="Aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s38" text="Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.">
        <entity id="DDI-DrugBank.d382.s38.e0" charOffset="0-7"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d382.s38.e1" charOffset="39-48"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s38.e2" charOffset="112-119"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d382.s38.e3" charOffset="158-167"
            type="drug" text="aprepitant"/>
        <ddi id="DDI-DrugBank.d382.s38.d0" e1="DDI-DrugBank.d382.s38.e1"
            e2="DDI-DrugBank.d382.s38.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s39" text="Coadministration of Aprepitant with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of Aprepitant.">
        <entity id="DDI-DrugBank.d382.s39.e0" charOffset="20-29"
            type="drug" text="Aprepitant"/>
        <entity id="DDI-DrugBank.d382.s39.e1" charOffset="140-149"
            type="drug" text="Aprepitant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s40" text="Additional interactions"/>
    <sentence id="DDI-DrugBank.d382.s41" text="Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.">
        <entity id="DDI-DrugBank.d382.s41.e0" charOffset="0-8"
            type="drug" text="Diltiazem"/>
        <entity id="DDI-DrugBank.d382.s41.e1" charOffset="77-86"
            type="drug" text="aprepitant"/>
        <entity id="DDI-DrugBank.d382.s41.e2" charOffset="178-186"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d382.s41.e3" charOffset="254-263"
            type="drug" text="aprepitant"/>
        <entity id="DDI-DrugBank.d382.s41.e4" charOffset="309-317"
            type="drug" text="diltiazem"/>
        <ddi id="DDI-DrugBank.d382.s41.d0" e1="DDI-DrugBank.d382.s41.e1"
            e2="DDI-DrugBank.d382.s41.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s42" text="These pharmacokinetic effects did not result in clinically meaningful changes in ECG, heart rate or blood pressure beyond those changes induced by diltiazem alone.">
        <entity id="DDI-DrugBank.d382.s42.e0" charOffset="147-155"
            type="drug" text="diltiazem"/>
    </sentence>
    <sentence id="DDI-DrugBank.d382.s43" text="Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.">
        <entity id="DDI-DrugBank.d382.s43.e0" charOffset="0-9"
            type="drug" text="Paroxetine"/>
        <entity id="DDI-DrugBank.d382.s43.e1" charOffset="52-61"
            type="drug" text="aprepitant"/>
        <entity id="DDI-DrugBank.d382.s43.e2" charOffset="151-160"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d382.s43.e3" charOffset="270-279"
            type="drug" text="aprepitant"/>
        <entity id="DDI-DrugBank.d382.s43.e4" charOffset="285-294"
            type="drug" text="paroxetine"/>
        <ddi id="DDI-DrugBank.d382.s43.d0" e1="DDI-DrugBank.d382.s43.e1"
            e2="DDI-DrugBank.d382.s43.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d253.s0" text="Beta-adrenergic blocking agents: concurrent use may blunt the response to arbutamine.">
        <entity id="DDI-DrugBank.d253.s0.e0" charOffset="0-30"
            type="group" text="Beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d253.s0.e1" charOffset="74-83"
            type="drug" text="arbutamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d253.s1" text="Beta-adrenergic blocking agents should be withdrawn at least 48 hours before conducting an arbutamine-mediated stress test.">
        <entity id="DDI-DrugBank.d253.s1.e0" charOffset="0-30"
            type="group" text="Beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d253.s1.e1" charOffset="91-100"
            type="drug" text="arbutamine"/>
        <ddi id="DDI-DrugBank.d253.s1.d0" e1="DDI-DrugBank.d253.s1.e0"
            e2="DDI-DrugBank.d253.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d253.s2" text="Antiarrhythmic agents, class I (such as flecainide, lidocaine, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.">
        <entity id="DDI-DrugBank.d253.s2.e0" charOffset="0-29"
            type="drug" text="Antiarrhythmic agents, class I"/>
        <entity id="DDI-DrugBank.d253.s2.e1" charOffset="40-49"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d253.s2.e2" charOffset="52-60"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d253.s2.e3" charOffset="66-74"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d253.s2.e4" charOffset="98-107"
            type="drug" text="arbutamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d253.s3" text="Antidepressants (tricyclic), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.">
        <entity id="DDI-DrugBank.d253.s3.e0" charOffset="0-14"
            type="group" text="Antidepressants"/>
        <entity id="DDI-DrugBank.d253.s3.e1" charOffset="17-25"
            type="group" text="tricyclic"/>
        <entity id="DDI-DrugBank.d253.s3.e2" charOffset="29-36"
            type="drug" text="atropine"/>
        <entity id="DDI-DrugBank.d253.s3.e3" charOffset="47-68"
            type="group" text="anticholinergic agents"/>
        <entity id="DDI-DrugBank.d253.s3.e4" charOffset="74-93"
            type="group" text="digitalis glycosides"/>
        <entity id="DDI-DrugBank.d253.s3.e5" charOffset="116-125"
            type="drug" text="arbutamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d105.s0" text="Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.">
        <entity id="DDI-DrugBank.d105.s0.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d105.s0.e1" charOffset="75-105"
            type="group" text="platelet aggregation inhibitors"/>
        <entity id="DDI-DrugBank.d105.s0.e2" charOffset="115-150"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d105.s0.e3" charOffset="153-158"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d105.s0.e4" charOffset="166-172"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d105.s0.e5" charOffset="245-253"
            type="drug" text="ardeparin"/>
        <ddi id="DDI-DrugBank.d105.s0.d0" e1="DDI-DrugBank.d105.s0.e0"
            e2="DDI-DrugBank.d105.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d105.s0.d1" e1="DDI-DrugBank.d105.s0.e1"
            e2="DDI-DrugBank.d105.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d105.s0.d2" e1="DDI-DrugBank.d105.s0.e2"
            e2="DDI-DrugBank.d105.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d105.s0.d3" e1="DDI-DrugBank.d105.s0.e3"
            e2="DDI-DrugBank.d105.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d105.s0.d4" e1="DDI-DrugBank.d105.s0.e4"
            e2="DDI-DrugBank.d105.s0.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s0" text="If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated.">
        <entity id="DDI-DrugBank.d284.s0.e0" charOffset="14-29"
            type="group" text="adrenergic drugs"/>
        <entity id="DDI-DrugBank.d284.s0.e1" charOffset="166-172"
            type="brand" text="BROVANA"/>
        <ddi id="DDI-DrugBank.d284.s0.d0" e1="DDI-DrugBank.d284.s0.e0"
            e2="DDI-DrugBank.d284.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s1" text="When paroxetine, a potent inhibitor of CYP2D6, was co-administered with BROVANA at steady-state, exposure to either drug was not altered.">
        <entity id="DDI-DrugBank.d284.s1.e0" charOffset="5-14"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d284.s1.e1" charOffset="72-78"
            type="brand" text="BROVANA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s2" text="Dosage adjustments of BROVANA are not necessary when the drug is given concomitantly with potent CYP2D6 inhibitors.">
        <entity id="DDI-DrugBank.d284.s2.e0" charOffset="22-28"
            type="brand" text="BROVANA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s3" text="Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.">
        <entity id="DDI-DrugBank.d284.s3.e0" charOffset="27-41"
            type="group" text="methylxanthines"/>
        <entity id="DDI-DrugBank.d284.s3.e1" charOffset="44-56"
            type="drug" text="aminophylline"/>
        <entity id="DDI-DrugBank.d284.s3.e2" charOffset="59-70"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d284.s3.e3" charOffset="74-81"
            type="group" text="steroids"/>
        <entity id="DDI-DrugBank.d284.s3.e4" charOffset="87-95"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d284.s3.e5" charOffset="138-156"
            type="group" text="adrenergic agonists"/>
        <ddi id="DDI-DrugBank.d284.s3.d0" e1="DDI-DrugBank.d284.s3.e0"
            e2="DDI-DrugBank.d284.s3.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d284.s3.d1" e1="DDI-DrugBank.d284.s3.e1"
            e2="DDI-DrugBank.d284.s3.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d284.s3.d2" e1="DDI-DrugBank.d284.s3.e2"
            e2="DDI-DrugBank.d284.s3.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d284.s3.d3" e1="DDI-DrugBank.d284.s3.e3"
            e2="DDI-DrugBank.d284.s3.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d284.s3.d4" e1="DDI-DrugBank.d284.s3.e4"
            e2="DDI-DrugBank.d284.s3.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s4" text="The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.">
        <entity id="DDI-DrugBank.d284.s4.e0" charOffset="78-108"
            type="group" text="non-potassium sparing diuretics"/>
        <entity id="DDI-DrugBank.d284.s4.e1"
            charOffset="119-122;136-144" type="group" text="loop diuretics"/>
        <entity id="DDI-DrugBank.d284.s4.e2" charOffset="127-144"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d284.s4.e3" charOffset="174-186"
            type="group" text="beta-agonists"/>
        <entity id="DDI-DrugBank.d284.s4.e4" charOffset="233-244"
            type="group" text="beta-agonist"/>
        <ddi id="DDI-DrugBank.d284.s4.d0" e1="DDI-DrugBank.d284.s4.e0"
            e2="DDI-DrugBank.d284.s4.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d284.s4.d1" e1="DDI-DrugBank.d284.s4.e1"
            e2="DDI-DrugBank.d284.s4.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d284.s4.d2" e1="DDI-DrugBank.d284.s4.e2"
            e2="DDI-DrugBank.d284.s4.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s5" text="Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.">
        <entity id="DDI-DrugBank.d284.s5.e0" charOffset="113-125"
            type="group" text="beta-agonists"/>
        <entity id="DDI-DrugBank.d284.s5.e1" charOffset="132-162"
            type="group" text="non-potassium sparing diuretics"/>
        <ddi id="DDI-DrugBank.d284.s5.d0" e1="DDI-DrugBank.d284.s5.e0"
            e2="DDI-DrugBank.d284.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s6" text="BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.">
        <entity id="DDI-DrugBank.d284.s6.e0" charOffset="0-6"
            type="brand" text="BROVANA"/>
        <entity id="DDI-DrugBank.d284.s6.e1" charOffset="23-36"
            type="group" text="beta2-agonists"/>
        <entity id="DDI-DrugBank.d284.s6.e2" charOffset="114-141"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d284.s6.e3" charOffset="144-168"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d284.s6.e4" charOffset="236-254"
            type="group" text="adrenergic agonists"/>
        <ddi id="DDI-DrugBank.d284.s6.d0" e1="DDI-DrugBank.d284.s6.e0"
            e2="DDI-DrugBank.d284.s6.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d284.s6.d1" e1="DDI-DrugBank.d284.s6.e0"
            e2="DDI-DrugBank.d284.s6.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d284.s6.d2" e1="DDI-DrugBank.d284.s6.e1"
            e2="DDI-DrugBank.d284.s6.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d284.s6.d3" e1="DDI-DrugBank.d284.s6.e1"
            e2="DDI-DrugBank.d284.s6.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d284.s6.d4" e1="DDI-DrugBank.d284.s6.e4"
            e2="DDI-DrugBank.d284.s6.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d284.s6.d5" e1="DDI-DrugBank.d284.s6.e4"
            e2="DDI-DrugBank.d284.s6.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s7" text="Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias."/>
    <sentence id="DDI-DrugBank.d284.s8" text="The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by patients receiving BROVANA has not been completely evaluated.">
        <entity id="DDI-DrugBank.d284.s8.e0" charOffset="59-73"
            type="group" text="methylxanthines"/>
        <entity id="DDI-DrugBank.d284.s8.e1" charOffset="82-94"
            type="drug" text="aminophylline"/>
        <entity id="DDI-DrugBank.d284.s8.e2" charOffset="97-108"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d284.s8.e3" charOffset="133-139"
            type="brand" text="BROVANA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s9" text="In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant theophylline at study entry.">
        <entity id="DDI-DrugBank.d284.s9.e0" charOffset="64-70"
            type="brand" text="BROVANA"/>
        <entity id="DDI-DrugBank.d284.s9.e1" charOffset="154-160"
            type="brand" text="BROVANA"/>
        <entity id="DDI-DrugBank.d284.s9.e2" charOffset="201-212"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s10" text="In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 BROVANA -treated subjects received concomitant theophylline at study entry.">
        <entity id="DDI-DrugBank.d284.s10.e0" charOffset="65-71"
            type="brand" text="BROVANA"/>
        <entity id="DDI-DrugBank.d284.s10.e1" charOffset="93-99"
            type="brand" text="BROVANA"/>
        <entity id="DDI-DrugBank.d284.s10.e2" charOffset="140-151"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s11" text="In these trials, heart rate and systolic blood pressure were approximately 2-3 bpm and 6-8 mm Hg higher, respectively, in subjects on concomitant theophylline compared with the overall population.">
        <entity id="DDI-DrugBank.d284.s11.e0" charOffset="146-157"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s12" text="Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.">
        <entity id="DDI-DrugBank.d284.s12.e0" charOffset="0-35"
            type="group" text="Beta-adrenergic receptor antagonists"/>
        <entity id="DDI-DrugBank.d284.s12.e1" charOffset="38-50"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d284.s12.e2" charOffset="57-63"
            type="brand" text="BROVANA"/>
        <ddi id="DDI-DrugBank.d284.s12.d0" e1="DDI-DrugBank.d284.s12.e0"
            e2="DDI-DrugBank.d284.s12.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d284.s12.d1" e1="DDI-DrugBank.d284.s12.e1"
            e2="DDI-DrugBank.d284.s12.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s13" text="Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients.">
        <entity id="DDI-DrugBank.d284.s13.e0" charOffset="0-12"
            type="group" text="Beta-blockers"/>
        <entity id="DDI-DrugBank.d284.s13.e1" charOffset="56-68"
            type="group" text="beta-agonists"/>
        <ddi id="DDI-DrugBank.d284.s13.d0" e1="DDI-DrugBank.d284.s13.e0"
            e2="DDI-DrugBank.d284.s13.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s14" text="Therefore, patients with COPD should not normally be treated with beta-blockers.">
        <entity id="DDI-DrugBank.d284.s14.e0" charOffset="66-78"
            type="group" text="beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s15" text="However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD.">
        <entity id="DDI-DrugBank.d284.s15.e0" charOffset="142-154"
            type="group" text="beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d284.s16" text="In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.">
        <entity id="DDI-DrugBank.d284.s16.e0" charOffset="17-45"
            type="group" text="cardioselective beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d148.s0" text="Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.">
        <entity id="DDI-DrugBank.d148.s0.e0" charOffset="0-6"
            type="drug" text="Heparin"/>
        <entity id="DDI-DrugBank.d148.s0.e1" charOffset="15-21"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d148.s0.e2" charOffset="59-65"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d148.s0.e3" charOffset="118-127"
            type="drug" text="Argatroban"/>
        <entity id="DDI-DrugBank.d148.s0.e4" charOffset="133-139"
            type="drug" text="heparin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d148.s1" text="However, if Argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.">
        <entity id="DDI-DrugBank.d148.s1.e0" charOffset="12-21"
            type="drug" text="Argatroban"/>
        <entity id="DDI-DrugBank.d148.s1.e1" charOffset="61-67"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d148.s1.e2" charOffset="167-176"
            type="drug" text="Argatroban"/>
    </sentence>
    <sentence id="DDI-DrugBank.d148.s2" text="Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).">
        <entity id="DDI-DrugBank.d148.s2.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d148.s2.e1" charOffset="8-20"
            type="drug" text="Acetaminophen"/>
        <entity id="DDI-DrugBank.d148.s2.e2" charOffset="116-125"
            type="drug" text="Argatroban"/>
        <entity id="DDI-DrugBank.d148.s2.e3" charOffset="158-164"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d148.s2.e4" charOffset="227-236"
            type="drug" text="Argatroban"/>
        <entity id="DDI-DrugBank.d148.s2.e5" charOffset="268-280"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d148.s2.e6" charOffset="380-389"
            type="drug" text="Argatroban"/>
    </sentence>
    <sentence id="DDI-DrugBank.d148.s3" text="Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between Argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated.">
        <entity id="DDI-DrugBank.d148.s3.e0" charOffset="5-24"
            type="group" text="anticoagulant agents"/>
        <entity id="DDI-DrugBank.d148.s3.e1" charOffset="74-83"
            type="drug" text="Argatroban"/>
        <entity id="DDI-DrugBank.d148.s3.e2" charOffset="89-96"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d148.s4" text="However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).">
        <entity id="DDI-DrugBank.d148.s4.e0" charOffset="32-41"
            type="drug" text="Argatroban"/>
        <entity id="DDI-DrugBank.d148.s4.e1" charOffset="47-54"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d148.s4.d0" e1="DDI-DrugBank.d148.s4.e0"
            e2="DDI-DrugBank.d148.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d148.s5" text="Thrombolytic agents: The safety and effectiveness of Argatroban with thrombolytic agents have not been established.">
        <entity id="DDI-DrugBank.d148.s5.e0" charOffset="0-18"
            type="group" text="Thrombolytic agents"/>
        <entity id="DDI-DrugBank.d148.s5.e1" charOffset="53-62"
            type="drug" text="Argatroban"/>
        <entity id="DDI-DrugBank.d148.s5.e2" charOffset="69-87"
            type="group" text="thrombolytic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d148.s6" text="Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.">
        <entity id="DDI-DrugBank.d148.s6.e0" charOffset="38-47"
            type="drug" text="Argatroban"/>
        <entity id="DDI-DrugBank.d148.s6.e1" charOffset="54-72"
            type="group" text="antiplatelet agents"/>
        <entity id="DDI-DrugBank.d148.s6.e2" charOffset="75-87"
            type="group" text="thrombolytics"/>
        <entity id="DDI-DrugBank.d148.s6.e3" charOffset="100-113"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d148.s6.d0" e1="DDI-DrugBank.d148.s6.e0"
            e2="DDI-DrugBank.d148.s6.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d148.s6.d1" e1="DDI-DrugBank.d148.s6.e0"
            e2="DDI-DrugBank.d148.s6.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d148.s6.d2" e1="DDI-DrugBank.d148.s6.e0"
            e2="DDI-DrugBank.d148.s6.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d148.s7" text="Drug-drug interactions have not been observed between Argatroban and digoxin or erythromycin.">
        <entity id="DDI-DrugBank.d148.s7.e0" charOffset="54-63"
            type="drug" text="Argatroban"/>
        <entity id="DDI-DrugBank.d148.s7.e1" charOffset="69-75"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d148.s7.e2" charOffset="80-91"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s0" text="Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.">
        <entity id="DDI-DrugBank.d509.s0.e0" charOffset="56-67"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s0.e1" charOffset="98-104"
            type="brand" text="ABILIFY"/>
        <entity id="DDI-DrugBank.d509.s0.e2" charOffset="141-162"
            type="group" text="centrally acting drugs"/>
        <entity id="DDI-DrugBank.d509.s0.e3" charOffset="168-174"
            type="drug" text="alcohol"/>
        <ddi id="DDI-DrugBank.d509.s0.d0" e1="DDI-DrugBank.d509.s0.e1"
            e2="DDI-DrugBank.d509.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d509.s0.d1" e1="DDI-DrugBank.d509.s0.e1"
            e2="DDI-DrugBank.d509.s0.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s1" text="Due to its"/>
    <sentence id="DDI-DrugBank.d509.s2" text="1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.">
        <entity id="DDI-DrugBank.d509.s2.e0" charOffset="35-46"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s2.e1" charOffset="99-121"
            type="group" text="antihypertensive agents"/>
        <ddi id="DDI-DrugBank.d509.s2.d0" e1="DDI-DrugBank.d509.s2.e0"
            e2="DDI-DrugBank.d509.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s3" text="Potential for Other Drugs to Affect ABILIFY Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.">
        <entity id="DDI-DrugBank.d509.s3.e0" charOffset="36-42"
            type="brand" text="ABILIFY"/>
        <entity id="DDI-DrugBank.d509.s3.e1" charOffset="44-55"
            type="brand" text="Aripiprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s4" text="Aripiprazole also does not undergo direct glucuronidation.">
        <entity id="DDI-DrugBank.d509.s4.e0" charOffset="0-11"
            type="drug" text="Aripiprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s5" text="This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.">
        <entity id="DDI-DrugBank.d509.s5.e0" charOffset="37-48"
            type="drug" text="aripiprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s6" text="Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism.">
        <entity id="DDI-DrugBank.d509.s6.e0" charOffset="43-54"
            type="drug" text="aripiprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s7" text="Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.">
        <entity id="DDI-DrugBank.d509.s7.e0" charOffset="31-43"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d509.s7.e1" charOffset="73-84"
            type="drug" text="aripiprazole"/>
        <ddi id="DDI-DrugBank.d509.s7.d0" e1="DDI-DrugBank.d509.s7.e0"
            e2="DDI-DrugBank.d509.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s8" text="Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.">
        <entity id="DDI-DrugBank.d509.s8.e0" charOffset="26-37"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d509.s8.e1" charOffset="55-63"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d509.s8.e2" charOffset="66-75"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d509.s8.e3" charOffset="81-90"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d509.s8.e4" charOffset="105-116"
            type="drug" text="aripiprazole"/>
        <ddi id="DDI-DrugBank.d509.s8.d0" e1="DDI-DrugBank.d509.s8.e0"
            e2="DDI-DrugBank.d509.s8.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d509.s8.d1" e1="DDI-DrugBank.d509.s8.e1"
            e2="DDI-DrugBank.d509.s8.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d509.s8.d2" e1="DDI-DrugBank.d509.s8.e2"
            e2="DDI-DrugBank.d509.s8.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d509.s8.d3" e1="DDI-DrugBank.d509.s8.e3"
            e2="DDI-DrugBank.d509.s8.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s9" text="Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.">
        <entity id="DDI-DrugBank.d509.s9.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d509.s9.e1" charOffset="34-45"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d509.s9.e2" charOffset="100-111"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s9.e3" charOffset="134-145"
            type="drug" text="aripiprazole"/>
        <ddi id="DDI-DrugBank.d509.s9.d0" e1="DDI-DrugBank.d509.s9.e1"
            e2="DDI-DrugBank.d509.s9.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s10" text="The effect of a higher ketoconazole dose (400 mg/day) has not been studied.">
        <entity id="DDI-DrugBank.d509.s10.e0" charOffset="23-34"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s11" text="When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.">
        <entity id="DDI-DrugBank.d509.s11.e0" charOffset="35-46"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d509.s11.e1" charOffset="53-64"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s11.e2" charOffset="74-85"
            type="drug" text="aripiprazole"/>
        <ddi id="DDI-DrugBank.d509.s11.d0" e1="DDI-DrugBank.d509.s11.e0"
            e2="DDI-DrugBank.d509.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s12" text="Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions;">
        <entity id="DDI-DrugBank.d509.s12.e0" charOffset="35-46"
            type="drug" text="itraconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s13" text="weaker inhibitors (erythromycin, grapefruit juice) have not been studied.">
        <entity id="DDI-DrugBank.d509.s13.e0" charOffset="19-30"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s14" text="When the CYP3A4 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased.">
        <entity id="DDI-DrugBank.d509.s14.e0" charOffset="69-80"
            type="drug" text="aripiprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s15" text="Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.">
        <entity id="DDI-DrugBank.d509.s15.e0" charOffset="0-8"
            type="drug" text="Quinidine"/>
        <entity id="DDI-DrugBank.d509.s15.e1" charOffset="54-65"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s15.e2" charOffset="72-80"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d509.s15.e3" charOffset="159-170"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s15.e4" charOffset="228-246"
            type="drug_n" text="dehydroaripiprazole"/>
        <ddi id="DDI-DrugBank.d509.s15.d0" e1="DDI-DrugBank.d509.s15.e1"
            e2="DDI-DrugBank.d509.s15.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s16" text="Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.">
        <entity id="DDI-DrugBank.d509.s16.e0" charOffset="0-11"
            type="drug" text="Aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s16.e1" charOffset="102-110"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d509.s16.e2" charOffset="117-128"
            type="drug" text="aripiprazole"/>
        <ddi id="DDI-DrugBank.d509.s16.d0" e1="DDI-DrugBank.d509.s16.e1"
            e2="DDI-DrugBank.d509.s16.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s17" text="Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions.">
        <entity id="DDI-DrugBank.d509.s17.e0" charOffset="48-57"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d509.s17.e1" charOffset="62-71"
            type="drug" text="paroxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s18" text="When the CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased.">
        <entity id="DDI-DrugBank.d509.s18.e0" charOffset="69-80"
            type="drug" text="aripiprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s19" text="Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.">
        <entity id="DDI-DrugBank.d509.s19.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d509.s19.e1" charOffset="35-47"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d509.s19.e2" charOffset="93-104"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s19.e3" charOffset="188-199"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s19.e4" charOffset="228-247"
            type="drug_n" text="dehydro-aripiprazole"/>
        <ddi id="DDI-DrugBank.d509.s19.d0" e1="DDI-DrugBank.d509.s19.e1"
            e2="DDI-DrugBank.d509.s19.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s20" text="When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.">
        <entity id="DDI-DrugBank.d509.s20.e0" charOffset="5-17"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d509.s20.e1" charOffset="31-42"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s20.e2" charOffset="53-64"
            type="drug" text="aripiprazole"/>
        <ddi id="DDI-DrugBank.d509.s20.d0" e1="DDI-DrugBank.d509.s20.e0"
            e2="DDI-DrugBank.d509.s20.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s21" text="Additional dose increases should be based on clinical evaluation."/>
    <sentence id="DDI-DrugBank.d509.s22" text="When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.">
        <entity id="DDI-DrugBank.d509.s22.e0" charOffset="5-17"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d509.s22.e1" charOffset="62-73"
            type="drug" text="aripiprazole"/>
        <ddi id="DDI-DrugBank.d509.s22.d0" e1="DDI-DrugBank.d509.s22.e0"
            e2="DDI-DrugBank.d509.s22.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s23" text="No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions).">
        <entity id="DDI-DrugBank.d509.s23.e0" charOffset="36-45"
            type="drug" text="famotidine"/>
        <entity id="DDI-DrugBank.d509.s23.e1" charOffset="48-56"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d509.s23.e2" charOffset="62-68"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d509.s23.e3" charOffset="106-117"
            type="drug" text="aripiprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s24" text="Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.">
        <entity id="DDI-DrugBank.d509.s24.e0" charOffset="14-20"
            type="brand" text="ABILIFY"/>
        <entity id="DDI-DrugBank.d509.s24.e1" charOffset="44-55"
            type="drug" text="Aripiprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s25" text="In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.">
        <entity id="DDI-DrugBank.d509.s25.e0" charOffset="46-57"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s25.e1" charOffset="110-125"
            type="drug" text="dextromethorphan"/>
        <entity id="DDI-DrugBank.d509.s25.e2" charOffset="137-144"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d509.s25.e3" charOffset="157-166"
            type="drug" text="omeprazole"/>
        <entity id="DDI-DrugBank.d509.s25.e4" charOffset="169-176"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d509.s25.e5" charOffset="192-207"
            type="drug" text="dextromethorphan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s26" text="Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.">
        <entity id="DDI-DrugBank.d509.s26.e0" charOffset="14-25"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s26.e1" charOffset="31-49"
            type="drug_n" text="dehydroaripiprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s27" text="Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.">
        <entity id="DDI-DrugBank.d509.s27.e0" charOffset="0-6"
            type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d509.s27.e1" charOffset="53-64"
            type="drug" text="aripiprazole"/>
        <entity id="DDI-DrugBank.d509.s27.e2" charOffset="86-92"
            type="drug" text="ethanol"/>
        <entity id="DDI-DrugBank.d509.s27.e3" charOffset="126-132"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s28" text="As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY">
        <entity id="DDI-DrugBank.d509.s28.e0" charOffset="75-81"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d509.s28.e1" charOffset="96-102"
            type="brand" text="ABILIFY"/>
        <ddi id="DDI-DrugBank.d509.s28.d0" e1="DDI-DrugBank.d509.s28.e0"
            e2="DDI-DrugBank.d509.s28.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d509.s29" text="."/>
    <sentence id="DDI-DrugBank.d509.s30" text=""/>
    <sentence id="DDI-DrugBank.d470.s0" text="No formal assessments of pharmacokinetic drug-drug interactions between TRISENOX and other agents have been conducted.">
        <entity id="DDI-DrugBank.d470.s0.e0" charOffset="72-79"
            type="brand" text="TRISENOX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d470.s1" text="Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).">
        <entity id="DDI-DrugBank.d470.s1.e0" charOffset="24-31"
            type="brand" text="TRISENOX"/>
        <entity id="DDI-DrugBank.d470.s1.e1" charOffset="121-135"
            type="group" text="antiarrhythmics"/>
        <entity id="DDI-DrugBank.d470.s1.e2" charOffset="140-151"
            type="drug" text="thioridazine"/>
        <entity id="DDI-DrugBank.d470.s1.e3" charOffset="200-208"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d470.s1.e4" charOffset="213-226"
            type="drug" text="amphotericin B"/>
        <ddi id="DDI-DrugBank.d470.s1.d0" e1="DDI-DrugBank.d470.s1.e0"
            e2="DDI-DrugBank.d470.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d470.s1.d1" e1="DDI-DrugBank.d470.s1.e0"
            e2="DDI-DrugBank.d470.s1.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d470.s1.d2" e1="DDI-DrugBank.d470.s1.e0"
            e2="DDI-DrugBank.d470.s1.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d470.s1.d3" e1="DDI-DrugBank.d470.s1.e0"
            e2="DDI-DrugBank.d470.s1.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d21.s0" text="Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.">
        <entity id="DDI-DrugBank.d21.s0.e0" charOffset="48-53"
            type="brand" text="ELSPAR"/>
        <entity id="DDI-DrugBank.d21.s0.e1" charOffset="93-104"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d21.s0.e2" charOffset="143-154"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d21.s0.d0" e1="DDI-DrugBank.d21.s0.e0"
            e2="DDI-DrugBank.d21.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d21.s1" text="These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.">
        <entity id="DDI-DrugBank.d21.s1.e0" charOffset="64-75"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d21.s1.e1" charOffset="82-87"
            type="brand" text="ELSPAR"/>
        <entity id="DDI-DrugBank.d21.s1.e2" charOffset="121-126"
            type="brand" text="ELSPAR"/>
        <ddi id="DDI-DrugBank.d21.s1.d0" e1="DDI-DrugBank.d21.s1.e0"
            e2="DDI-DrugBank.d21.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d443.s0" text="Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.">
        <entity id="DDI-DrugBank.d443.s0.e0" charOffset="0-16"
            type="group" text="Uricosuric Agents"/>
        <entity id="DDI-DrugBank.d443.s0.e1" charOffset="19-25"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d443.s0.e2" charOffset="55-64"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d443.s0.e3" charOffset="67-80"
            type="drug" text="sulfinpyrazone"/>
        <entity id="DDI-DrugBank.d443.s0.e4" charOffset="87-100"
            type="drug" text="phenylbutazone"/>
        <ddi id="DDI-DrugBank.d443.s0.d0" e1="DDI-DrugBank.d443.s0.e1"
            e2="DDI-DrugBank.d443.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d443.s0.d1" e1="DDI-DrugBank.d443.s0.e1"
            e2="DDI-DrugBank.d443.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d443.s0.d2" e1="DDI-DrugBank.d443.s0.e1"
            e2="DDI-DrugBank.d443.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d443.s1" text="Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.">
        <entity id="DDI-DrugBank.d443.s1.e0" charOffset="0-6"
            type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d443.s1.e1" charOffset="39-45"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d443.s1.d0" e1="DDI-DrugBank.d443.s1.e0"
            e2="DDI-DrugBank.d443.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d443.s2" text="Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.">
        <entity id="DDI-DrugBank.d443.s2.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d443.s2.e1" charOffset="49-55"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d443.s2.d0" e1="DDI-DrugBank.d443.s2.e0"
            e2="DDI-DrugBank.d443.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d443.s3" text="Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.">
        <entity id="DDI-DrugBank.d443.s3.e0" charOffset="0-21"
            type="group" text="Pyrazolone Derivatives"/>
        <entity id="DDI-DrugBank.d443.s3.e1" charOffset="24-37"
            type="drug" text="phenylbutazone"/>
        <entity id="DDI-DrugBank.d443.s3.e2" charOffset="40-54"
            type="drug" text="oxyphenbutazone"/>
        <entity id="DDI-DrugBank.d443.s3.e3" charOffset="70-77"
            type="drug" text="dipyrone"/>
        <entity id="DDI-DrugBank.d443.s3.e4" charOffset="113-119"
            type="drug" text="aspirin"/>
        <ddi id="DDI-DrugBank.d443.s3.d0" e1="DDI-DrugBank.d443.s3.e0"
            e2="DDI-DrugBank.d443.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d443.s3.d1" e1="DDI-DrugBank.d443.s3.e1"
            e2="DDI-DrugBank.d443.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d443.s3.d2" e1="DDI-DrugBank.d443.s3.e2"
            e2="DDI-DrugBank.d443.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d443.s3.d3" e1="DDI-DrugBank.d443.s3.e3"
            e2="DDI-DrugBank.d443.s3.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d443.s4" text="Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.">
        <entity id="DDI-DrugBank.d443.s4.e0" charOffset="0-28"
            type="drug" text="Nonsteroidal Antiinflammatory"/>
        <entity id="DDI-DrugBank.d443.s4.e1" charOffset="38-44"
            type="drug" text="Aspirin"/>
        <entity id="DDI-DrugBank.d443.s4.e2" charOffset="103-132"
            type="drug" text="nonsteroidal anti-inflammatory"/>
        <ddi id="DDI-DrugBank.d443.s4.d0" e1="DDI-DrugBank.d443.s4.e1"
            e2="DDI-DrugBank.d443.s4.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d443.s5" text="Urinary Alkalinizers: Decrease aspirin effectiveness by increasing the rate of salicylate renal excretion.">
        <entity id="DDI-DrugBank.d443.s5.e0" charOffset="31-37"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d443.s5.e1" charOffset="79-88"
            type="group" text="salicylate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d443.s6" text="Phenobarbital: Decreases aspirin effectiveness by enzyme induction.">
        <entity id="DDI-DrugBank.d443.s6.e0" charOffset="0-12"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d443.s6.e1" charOffset="25-31"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d443.s6.d0" e1="DDI-DrugBank.d443.s6.e0"
            e2="DDI-DrugBank.d443.s6.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d443.s7" text="Phenytoin: Serum phenytoin levels may be increased by aspirin.">
        <entity id="DDI-DrugBank.d443.s7.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d443.s7.e1" charOffset="17-25"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d443.s7.e2" charOffset="54-60"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d443.s7.d0" e1="DDI-DrugBank.d443.s7.e1"
            e2="DDI-DrugBank.d443.s7.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d443.s8" text="Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.">
        <entity id="DDI-DrugBank.d443.s8.e0" charOffset="0-10"
            type="drug" text="Propranolol"/>
        <entity id="DDI-DrugBank.d443.s8.e1" charOffset="26-33"
            type="brand" text="aspirins"/>
        <ddi id="DDI-DrugBank.d443.s8.d0" e1="DDI-DrugBank.d443.s8.e0"
            e2="DDI-DrugBank.d443.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d443.s9" text="Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.">
        <entity id="DDI-DrugBank.d443.s9.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d443.s9.e1" charOffset="25-31"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d443.s9.e2" charOffset="71-78"
            type="group" text="antacids"/>
        <ddi id="DDI-DrugBank.d443.s9.d0" e1="DDI-DrugBank.d443.s9.e1"
            e2="DDI-DrugBank.d443.s9.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d109.s0" text="Ketoconazole/Itraconazole, Macrolides, Including Erythromycin">
        <entity id="DDI-DrugBank.d109.s0.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d109.s0.e1" charOffset="13-24"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d109.s0.e2" charOffset="27-36"
            type="group" text="Macrolides"/>
        <entity id="DDI-DrugBank.d109.s0.e3" charOffset="49-60"
            type="drug" text="Erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d73.s0" text="Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.">
        <entity id="DDI-DrugBank.d73.s0.e0" charOffset="35-43"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d73.s0.e1" charOffset="90-108"
            type="group" text="beta-blocking agent"/>
        <ddi id="DDI-DrugBank.d73.s0.d0" e1="DDI-DrugBank.d73.s0.e0"
            e2="DDI-DrugBank.d73.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d73.s1" text="Patients treated with TENORMIN plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.">
        <entity id="DDI-DrugBank.d73.s1.e0" charOffset="22-29"
            type="brand" text="TENORMIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d73.s2" text="Calcium channel blockers may also have an additive effect when given with TENORMIN .">
        <entity id="DDI-DrugBank.d73.s2.e0" charOffset="0-23"
            type="group" text="Calcium channel blockers"/>
        <entity id="DDI-DrugBank.d73.s2.e1" charOffset="74-81"
            type="brand" text="TENORMIN"/>
        <ddi id="DDI-DrugBank.d73.s2.d0" e1="DDI-DrugBank.d73.s2.e0"
            e2="DDI-DrugBank.d73.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d73.s3" text="Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.">
        <entity id="DDI-DrugBank.d73.s3.e0" charOffset="0-12"
            type="group" text="Beta blockers"/>
        <entity id="DDI-DrugBank.d73.s3.e1" charOffset="89-97"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d73.s3.d0" e1="DDI-DrugBank.d73.s3.e0"
            e2="DDI-DrugBank.d73.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d73.s4" text="If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.">
        <entity id="DDI-DrugBank.d73.s4.e0" charOffset="41-52"
            type="group" text="beta blocker"/>
        <entity id="DDI-DrugBank.d73.s4.e1" charOffset="120-128"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d73.s4.d0" e1="DDI-DrugBank.d73.s4.e0"
            e2="DDI-DrugBank.d73.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d73.s5" text="If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.">
        <entity id="DDI-DrugBank.d73.s5.e0" charOffset="13-21"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d73.s5.e1" charOffset="26-37"
            type="group" text="beta-blocker"/>
        <entity id="DDI-DrugBank.d73.s5.e2" charOffset="68-80"
            type="group" text="beta blockers"/>
        <entity id="DDI-DrugBank.d73.s5.e3" charOffset="123-131"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d73.s5.d0" e1="DDI-DrugBank.d73.s5.e2"
            e2="DDI-DrugBank.d73.s5.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d73.s6" text="Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.">
        <entity id="DDI-DrugBank.d73.s6.e0" charOffset="64-75"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d73.s6.e1" charOffset="118-130"
            type="group" text="beta blockers"/>
        <ddi id="DDI-DrugBank.d73.s6.d0" e1="DDI-DrugBank.d73.s6.e0"
            e2="DDI-DrugBank.d73.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d73.s7" text="Information on concurrent usage of atenolol and aspirin is limited.">
        <entity id="DDI-DrugBank.d73.s7.e0" charOffset="35-42"
            type="drug" text="atenolol"/>
        <entity id="DDI-DrugBank.d73.s7.e1" charOffset="48-54"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d73.s8" text="Data from several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting.">
        <entity id="DDI-DrugBank.d73.s8.e0" charOffset="106-112"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d73.s8.e1" charOffset="118-130"
            type="group" text="beta blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d73.s9" text="While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic.">
        <entity id="DDI-DrugBank.d73.s9.e0" charOffset="13-25"
            type="group" text="beta blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d73.s10" text="Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.">
        <entity id="DDI-DrugBank.d73.s10.e0" charOffset="56-66"
            type="drug" text="epinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d11.s0" text="Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.">
        <entity id="DDI-DrugBank.d11.s0.e0" charOffset="23-31"
            type="drug" text="Albuterol"/>
        <entity id="DDI-DrugBank.d11.s0.e1" charOffset="35-43"
            type="brand" text="STRATTERA"/>
        <entity id="DDI-DrugBank.d11.s0.e2" charOffset="160-168"
            type="drug" text="albuterol"/>
        <entity id="DDI-DrugBank.d11.s0.e3" charOffset="180-193"
            type="group" text="beta2 agonists"/>
        <entity id="DDI-DrugBank.d11.s0.e4" charOffset="218-226"
            type="drug" text="albuterol"/>
        <ddi id="DDI-DrugBank.d11.s0.d0" e1="DDI-DrugBank.d11.s0.e1"
            e2="DDI-DrugBank.d11.s0.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d11.s1" text="CYP2D6 inhibitors - Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine.">
        <entity id="DDI-DrugBank.d11.s1.e0" charOffset="20-30"
            type="drug" text="Atomoxetine"/>
        <entity id="DDI-DrugBank.d11.s1.e1" charOffset="82-101"
            type="drug_n" text="4-hydroxyatomoxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d11.s2" text="In EMs, selective inhibitors of CYP2D6 increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in PMs.">
        <entity id="DDI-DrugBank.d11.s2.e0" charOffset="48-58"
            type="drug" text="atomoxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d11.s3" text="Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.">
        <entity id="DDI-DrugBank.d11.s3.e0" charOffset="21-29"
            type="brand" text="STRATTERA"/>
        <entity id="DDI-DrugBank.d11.s3.e1" charOffset="98-107"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d11.s3.e2" charOffset="110-119"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d11.s3.e3" charOffset="126-134"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d11.s3.d0" e1="DDI-DrugBank.d11.s3.e0"
            e2="DDI-DrugBank.d11.s3.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d11.s3.d1" e1="DDI-DrugBank.d11.s3.e0"
            e2="DDI-DrugBank.d11.s3.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d11.s3.d2" e1="DDI-DrugBank.d11.s3.e0"
            e2="DDI-DrugBank.d11.s3.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d11.s4" text="In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.">
        <entity id="DDI-DrugBank.d11.s4.e0" charOffset="31-40"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d11.s4.e1" charOffset="45-54"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d11.s4.e2" charOffset="68-78"
            type="drug" text="atomoxetine"/>
        <entity id="DDI-DrugBank.d11.s4.e3" charOffset="157-167"
            type="drug" text="atomoxetine"/>
        <ddi id="DDI-DrugBank.d11.s4.d0" e1="DDI-DrugBank.d11.s4.e0"
            e2="DDI-DrugBank.d11.s4.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d11.s4.d1" e1="DDI-DrugBank.d11.s4.e1"
            e2="DDI-DrugBank.d11.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d11.s5" text="In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.">
        <entity id="DDI-DrugBank.d11.s5.e0" charOffset="131-141"
            type="drug" text="atomoxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d11.s6" text="Pressor agents - Because of possible effects on blood pressure, STRATTERA should be used cautiously with pressor agents.">
        <entity id="DDI-DrugBank.d11.s6.e0" charOffset="64-72"
            type="brand" text="STRATTERA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s0" text="The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid), erythromycin, azole antifungals.">
        <entity id="DDI-DrugBank.d140.s0.e0" charOffset="110-121"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d140.s0.e1" charOffset="124-146"
            type="group" text="fibric acid derivatives"/>
        <entity id="DDI-DrugBank.d140.s0.e2" charOffset="149-154"
            type="drug" text="niacin"/>
        <entity id="DDI-DrugBank.d140.s0.e3" charOffset="157-170"
            type="drug" text="nicotinic acid"/>
        <entity id="DDI-DrugBank.d140.s0.e4" charOffset="174-185"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d140.s0.e5" charOffset="188-204"
            type="group" text="azole antifungals"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s1" text="Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.">
        <entity id="DDI-DrugBank.d140.s1.e0" charOffset="0-6"
            type="group" text="Antacid"/>
        <entity id="DDI-DrugBank.d140.s1.e1" charOffset="14-25"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d140.s1.e2" charOffset="31-39"
            type="brand" text="Maalox TC"/>
        <entity id="DDI-DrugBank.d140.s1.e3" charOffset="98-109"
            type="drug" text="atorvastatin"/>
        <ddi id="DDI-DrugBank.d140.s1.d0" e1="DDI-DrugBank.d140.s1.e1"
            e2="DDI-DrugBank.d140.s1.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s2" text="However, LDL-C reduction was not altered."/>
    <sentence id="DDI-DrugBank.d140.s3" text="Antipyrine: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.">
        <entity id="DDI-DrugBank.d140.s3.e0" charOffset="0-9"
            type="drug" text="Antipyrine"/>
        <entity id="DDI-DrugBank.d140.s3.e1" charOffset="20-31"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d140.s3.e2" charOffset="73-82"
            type="drug" text="antipyrine"/>
        <entity id="DDI-DrugBank.d140.s3.e3" charOffset="109-113"
            type="drug" text="drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s4" text="Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.">
        <entity id="DDI-DrugBank.d140.s4.e0" charOffset="0-9"
            type="drug" text="Colestipol"/>
        <entity id="DDI-DrugBank.d140.s4.e1" charOffset="37-48"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d140.s4.e2" charOffset="83-92"
            type="drug" text="colestipol"/>
        <entity id="DDI-DrugBank.d140.s4.e3" charOffset="98-109"
            type="drug" text="atorvastatin"/>
        <ddi id="DDI-DrugBank.d140.s4.d0" e1="DDI-DrugBank.d140.s4.e2"
            e2="DDI-DrugBank.d140.s4.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s5" text="However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.">
        <entity id="DDI-DrugBank.d140.s5.e0" charOffset="42-53"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d140.s5.e1" charOffset="59-68"
            type="drug" text="colestipol"/>
        <ddi id="DDI-DrugBank.d140.s5.d0" e1="DDI-DrugBank.d140.s5.e0"
            e2="DDI-DrugBank.d140.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s6" text="Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.">
        <entity id="DDI-DrugBank.d140.s6.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d140.s6.e1" charOffset="12-23"
            type="drug" text="Atorvastatin"/>
        <entity id="DDI-DrugBank.d140.s6.e2" charOffset="107-116"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s7" text="Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.">
        <entity id="DDI-DrugBank.d140.s7.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d140.s7.e1" charOffset="32-43"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d140.s7.e2" charOffset="49-55"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d140.s7.e3" charOffset="98-104"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d140.s7.d0" e1="DDI-DrugBank.d140.s7.e1"
            e2="DDI-DrugBank.d140.s7.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s8" text="Patients taking digoxin should be monitored appropriately.">
        <entity id="DDI-DrugBank.d140.s8.e0" charOffset="16-22"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s9" text="Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.">
        <entity id="DDI-DrugBank.d140.s9.e0" charOffset="0-11"
            type="drug" text="Erythromycin"/>
        <entity id="DDI-DrugBank.d140.s9.e1" charOffset="63-74"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d140.s9.e2" charOffset="129-140"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d140.s9.e3" charOffset="146-157"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d140.s9.d0" e1="DDI-DrugBank.d140.s9.e2"
            e2="DDI-DrugBank.d140.s9.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s10" text="Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.">
        <entity id="DDI-DrugBank.d140.s10.e0" charOffset="5-18"
            type="group" text="Contraceptives"/>
        <entity id="DDI-DrugBank.d140.s10.e1" charOffset="41-52"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d140.s10.e2" charOffset="66-78"
            type="group" text="contraceptive"/>
        <entity id="DDI-DrugBank.d140.s10.e3" charOffset="105-117"
            type="drug" text="norethindrone"/>
        <entity id="DDI-DrugBank.d140.s10.e4" charOffset="123-139"
            type="drug" text="ethinyl estradiol"/>
        <ddi id="DDI-DrugBank.d140.s10.d0" e1="DDI-DrugBank.d140.s10.e1"
            e2="DDI-DrugBank.d140.s10.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d140.s10.d1" e1="DDI-DrugBank.d140.s10.e1"
            e2="DDI-DrugBank.d140.s10.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d140.s10.d2" e1="DDI-DrugBank.d140.s10.e1"
            e2="DDI-DrugBank.d140.s10.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s11" text="These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.">
        <entity id="DDI-DrugBank.d140.s11.e0" charOffset="60-72"
            type="group" text="contraceptive"/>
        <entity id="DDI-DrugBank.d140.s11.e1" charOffset="93-104"
            type="drug" text="atorvastatin"/>
        <ddi id="DDI-DrugBank.d140.s11.d0" e1="DDI-DrugBank.d140.s11.e0"
            e2="DDI-DrugBank.d140.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s12" text="Warfarin: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.">
        <entity id="DDI-DrugBank.d140.s12.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d140.s12.e1" charOffset="10-21"
            type="drug" text="Atorvastatin"/>
        <entity id="DDI-DrugBank.d140.s12.e2" charOffset="128-135"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s13" text="Endocrine Function HMG-CoA reductase inhibitors interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production.">
        <entity id="DDI-DrugBank.d140.s13.e0" charOffset="19-46"
            type="group" text="HMG-CoA reductase inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s14" text="Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve.">
        <entity id="DDI-DrugBank.d140.s14.e0" charOffset="33-44"
            type="drug" text="atorvastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s15" text="The effects of HMG-CoA reductase inhibitors on male fertility have not been studied in adequate numbers of patients.">
        <entity id="DDI-DrugBank.d140.s15.e0" charOffset="15-42"
            type="group" text="HMG-CoA reductase inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s16" text="The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown."/>
    <sentence id="DDI-DrugBank.d140.s17" text="Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.">
        <entity id="DDI-DrugBank.d140.s17.e0" charOffset="34-60"
            type="group" text="HMG-CoA reductase inhibitor"/>
        <entity id="DDI-DrugBank.d140.s17.e1" charOffset="184-195"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d140.s17.e2" charOffset="198-211"
            type="drug" text="spironolactone"/>
        <entity id="DDI-DrugBank.d140.s17.e3" charOffset="218-227"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d140.s17.d0" e1="DDI-DrugBank.d140.s17.e0"
            e2="DDI-DrugBank.d140.s17.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d140.s17.d1" e1="DDI-DrugBank.d140.s17.e0"
            e2="DDI-DrugBank.d140.s17.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d140.s17.d2" e1="DDI-DrugBank.d140.s17.e0"
            e2="DDI-DrugBank.d140.s17.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d140.s18" text="CNS Toxicity Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day."/>
    <sentence id="DDI-DrugBank.d140.s19" text="Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day."/>
    <sentence id="DDI-DrugBank.d140.s20" text="The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day."/>
    <sentence id="DDI-DrugBank.d140.s21" text="A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study."/>
    <sentence id="DDI-DrugBank.d140.s22" text="No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day."/>
    <sentence id="DDI-DrugBank.d140.s23" text="These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0-24) based on the maximum recommended human dose of 80 mg/day."/>
    <sentence id="DDI-DrugBank.d140.s24" text="CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class."/>
    <sentence id="DDI-DrugBank.d140.s25" text="A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose."/>
    <sentence id="DDI-DrugBank.d424.s0" text="Atovaquone is highly bound to plasma protein (99.9%).">
        <entity id="DDI-DrugBank.d424.s0.e0" charOffset="0-9"
            type="drug" text="Atovaquone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d424.s1" text="Therefore, caution should be used when administering MEPRON concurrently with other highly plasma protein- bound drugs with narrow therapeutic indices, as competition for binding sites may occur.">
        <entity id="DDI-DrugBank.d424.s1.e0" charOffset="53-58"
            type="brand" text="MEPRON"/>
    </sentence>
    <sentence id="DDI-DrugBank.d424.s2" text="The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone.">
        <entity id="DDI-DrugBank.d424.s2.e0" charOffset="40-49"
            type="drug" text="atovaquone"/>
        <entity id="DDI-DrugBank.d424.s2.e1" charOffset="132-140"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d424.s2.e2" charOffset="178-186"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d424.s2.e3" charOffset="216-225"
            type="drug" text="atovaquone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d424.s3" text="Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.">
        <entity id="DDI-DrugBank.d424.s3.e0" charOffset="0-7"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d424.s3.e1" charOffset="30-37"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d424.s3.e2" charOffset="43-48"
            type="brand" text="MEPRON"/>
        <entity id="DDI-DrugBank.d424.s3.e3" charOffset="127-136"
            type="drug" text="atovaquone"/>
        <ddi id="DDI-DrugBank.d424.s3.d0" e1="DDI-DrugBank.d424.s3.e1"
            e2="DDI-DrugBank.d424.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d424.s4" text="Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON.">
        <entity id="DDI-DrugBank.d424.s4.e0" charOffset="16-23"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d424.s4.e1" charOffset="86-91"
            type="brand" text="MEPRON"/>
        <ddi id="DDI-DrugBank.d424.s4.d0" e1="DDI-DrugBank.d424.s4.e0"
            e2="DDI-DrugBank.d424.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d424.s5" text="Rifabutin, another rifamycin, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin.">
        <entity id="DDI-DrugBank.d424.s5.e0" charOffset="0-8"
            type="drug" text="Rifabutin"/>
        <entity id="DDI-DrugBank.d424.s5.e1" charOffset="19-27"
            type="drug" text="rifamycin"/>
        <entity id="DDI-DrugBank.d424.s5.e2" charOffset="57-64"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d424.s5.e3" charOffset="126-133"
            type="drug" text="rifampin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d424.s6" text="No interaction trials have been conducted with MEPRON and rifabutin.">
        <entity id="DDI-DrugBank.d424.s6.e0" charOffset="47-52"
            type="brand" text="MEPRON"/>
        <entity id="DDI-DrugBank.d424.s6.e1" charOffset="58-66"
            type="drug" text="rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d424.s7" text="Drug/ Laboratory Test Interactions: It is not known if MEPRON interferes with clinical laboratory test or assay results.">
        <entity id="DDI-DrugBank.d424.s7.e0" charOffset="55-60"
            type="brand" text="MEPRON"/>
    </sentence>
    <sentence id="DDI-DrugBank.d469.s0" text="Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;">
        <entity id="DDI-DrugBank.d469.s0.e0" charOffset="61-68"
            type="brand" text="TRACRIUM"/>
        <entity id="DDI-DrugBank.d469.s0.e1" charOffset="79-87"
            type="drug" text="enflurane"/>
        <ddi id="DDI-DrugBank.d469.s0.d0" e1="DDI-DrugBank.d469.s0.e0"
            e2="DDI-DrugBank.d469.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d469.s1" text="isoflurane;">
        <entity id="DDI-DrugBank.d469.s1.e0" charOffset="0-9"
            type="drug" text="isoflurane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d469.s2" text="halothane;">
        <entity id="DDI-DrugBank.d469.s2.e0" charOffset="0-8"
            type="drug" text="halothane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d469.s3" text="certain antibiotics, especially the aminoglycosides and polymyxins;">
        <entity id="DDI-DrugBank.d469.s3.e0" charOffset="8-18"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d469.s3.e1" charOffset="36-50"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d469.s3.e2" charOffset="56-65"
            type="group" text="polymyxins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d469.s4" text="lithium;">
        <entity id="DDI-DrugBank.d469.s4.e0" charOffset="0-6"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d469.s5" text="magnesium salts;">
        <entity id="DDI-DrugBank.d469.s5.e0" charOffset="0-8"
            type="drug" text="magnesium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d469.s6" text="procainamide;">
        <entity id="DDI-DrugBank.d469.s6.e0" charOffset="0-11"
            type="drug" text="procainamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d469.s7" text="Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.">
        <entity id="DDI-DrugBank.d469.s7.e0" charOffset="61-68"
            type="brand" text="TRACRIUM"/>
        <entity id="DDI-DrugBank.d469.s7.e1" charOffset="79-87"
            type="drug" text="enflurane"/>
        <entity id="DDI-DrugBank.d469.s7.e2" charOffset="89-98"
            type="drug" text="isoflurane"/>
        <entity id="DDI-DrugBank.d469.s7.e3" charOffset="100-108"
            type="drug" text="halothane"/>
        <entity id="DDI-DrugBank.d469.s7.e4" charOffset="118-128"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d469.s7.e5" charOffset="146-160"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d469.s7.e6" charOffset="166-175"
            type="group" text="polymyxins"/>
        <entity id="DDI-DrugBank.d469.s7.e7" charOffset="177-183"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d469.s7.e8" charOffset="185-193"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d469.s7.e9" charOffset="201-212"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d469.s7.e10" charOffset="218-226"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d469.s7.d0" e1="DDI-DrugBank.d469.s7.e0"
            e2="DDI-DrugBank.d469.s7.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d469.s7.d1" e1="DDI-DrugBank.d469.s7.e0"
            e2="DDI-DrugBank.d469.s7.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d469.s7.d2" e1="DDI-DrugBank.d469.s7.e0"
            e2="DDI-DrugBank.d469.s7.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d469.s7.d3" e1="DDI-DrugBank.d469.s7.e0"
            e2="DDI-DrugBank.d469.s7.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d469.s7.d4" e1="DDI-DrugBank.d469.s7.e0"
            e2="DDI-DrugBank.d469.s7.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d469.s7.d5" e1="DDI-DrugBank.d469.s7.e0"
            e2="DDI-DrugBank.d469.s7.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d469.s7.d6" e1="DDI-DrugBank.d469.s7.e0"
            e2="DDI-DrugBank.d469.s7.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d469.s7.d7" e1="DDI-DrugBank.d469.s7.e0"
            e2="DDI-DrugBank.d469.s7.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d469.s7.d8" e1="DDI-DrugBank.d469.s7.e0"
            e2="DDI-DrugBank.d469.s7.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d469.s7.d9" e1="DDI-DrugBank.d469.s7.e0"
            e2="DDI-DrugBank.d469.s7.e10" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d469.s8" text="If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.">
        <entity id="DDI-DrugBank.d469.s8.e0" charOffset="9-24"
            type="group" text="muscle relaxants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d469.s9" text="The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM.">
        <entity id="DDI-DrugBank.d469.s9.e0" charOffset="28-42"
            type="drug" text="succinylcholine"/>
        <entity id="DDI-DrugBank.d469.s9.e1" charOffset="160-167"
            type="brand" text="TRACRIUM"/>
        <ddi id="DDI-DrugBank.d469.s9.d0" e1="DDI-DrugBank.d469.s9.e0"
            e2="DDI-DrugBank.d469.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d469.s10" text="TRACRIUM should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.">
        <entity id="DDI-DrugBank.d469.s10.e0" charOffset="0-7"
            type="brand" text="TRACRIUM"/>
        <entity id="DDI-DrugBank.d469.s10.e1" charOffset="71-85"
            type="drug" text="succinylcholine"/>
        <ddi id="DDI-DrugBank.d469.s10.d0" e1="DDI-DrugBank.d469.s10.e0"
            e2="DDI-DrugBank.d469.s10.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d222.s0" text="When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.">
        <entity id="DDI-DrugBank.d222.s0.e0" charOffset="5-12"
            type="drug" text="atropine"/>
        <entity id="DDI-DrugBank.d222.s0.e1" charOffset="18-28"
            type="drug" text="pralidoxime"/>
        <entity id="DDI-DrugBank.d222.s0.e2" charOffset="194-201"
            type="drug" text="atropine"/>
        <entity id="DDI-DrugBank.d222.s0.e3" charOffset="225-235"
            type="drug" text="pralidoxime"/>
        <entity id="DDI-DrugBank.d222.s0.e4" charOffset="266-273"
            type="drug" text="atropine"/>
        <ddi id="DDI-DrugBank.d222.s0.d0" e1="DDI-DrugBank.d222.s0.e0"
            e2="DDI-DrugBank.d222.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d222.s0.d1" e1="DDI-DrugBank.d222.s0.e3"
            e2="DDI-DrugBank.d222.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d222.s1" text="The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.">
        <entity id="DDI-DrugBank.d222.s1.e0" charOffset="147-154"
            type="drug" text="atropine"/>
        <entity id="DDI-DrugBank.d222.s1.e1" charOffset="160-170"
            type="drug" text="pralidoxime"/>
        <ddi id="DDI-DrugBank.d222.s1.d0" e1="DDI-DrugBank.d222.s1.e0"
            e2="DDI-DrugBank.d222.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d222.s2" text="Since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions.">
        <entity id="DDI-DrugBank.d222.s2.e0" charOffset="6-17"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d222.s2.e1" charOffset="42-60"
            type="group" text="anticholinesterases"/>
        <ddi id="DDI-DrugBank.d222.s2.d0" e1="DDI-DrugBank.d222.s2.e0"
            e2="DDI-DrugBank.d222.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d374.s0" text="Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.">
        <entity id="DDI-DrugBank.d374.s0.e0" charOffset="0-8"
            type="drug" text="Auranofin"/>
        <entity id="DDI-DrugBank.d374.s0.e1" charOffset="82-96"
            type="group" text="gold medication"/>
        <entity id="DDI-DrugBank.d374.s0.e2" charOffset="109-116"
            type="brand" text="Solganal"/>
        <entity id="DDI-DrugBank.d374.s0.e3" charOffset="122-132"
            type="brand" text="Myochrysine"/>
        <ddi id="DDI-DrugBank.d374.s0.d0" e1="DDI-DrugBank.d374.s0.e0"
            e2="DDI-DrugBank.d374.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d374.s0.d1" e1="DDI-DrugBank.d374.s0.e0"
            e2="DDI-DrugBank.d374.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d374.s0.d2" e1="DDI-DrugBank.d374.s0.e0"
            e2="DDI-DrugBank.d374.s0.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d374.s1" text="Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.">
        <entity id="DDI-DrugBank.d374.s1.e0" charOffset="0-8"
            type="drug" text="Auranofin"/>
        <entity id="DDI-DrugBank.d374.s1.e1" charOffset="43-55"
            type="drug" text="penicillamine"/>
        <entity id="DDI-DrugBank.d374.s1.e2" charOffset="58-62"
            type="brand" text="Depen"/>
        <entity id="DDI-DrugBank.d374.s1.e3" charOffset="65-73"
            type="brand" text="Cuprimine"/>
        <ddi id="DDI-DrugBank.d374.s1.d0" e1="DDI-DrugBank.d374.s1.e0"
            e2="DDI-DrugBank.d374.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d374.s1.d1" e1="DDI-DrugBank.d374.s1.e0"
            e2="DDI-DrugBank.d374.s1.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d374.s1.d2" e1="DDI-DrugBank.d374.s1.e0"
            e2="DDI-DrugBank.d374.s1.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d374.s2" text="It should also be avoided in patients with blood, liver or kidney diseases, recent radiation treatment, or uncontrolled diabetes."/>
    <sentence id="DDI-DrugBank.d374.s3" text="Patients should report to their practitioners any new rashes, itching, mouth sores, or unusual taste while taking auranofin.">
        <entity id="DDI-DrugBank.d374.s3.e0" charOffset="114-122"
            type="drug" text="auranofin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d374.s4" text="Gold is excreted slowly from the body.">
        <entity id="DDI-DrugBank.d374.s4.e0" charOffset="0-3"
            type="group" text="Gold"/>
    </sentence>
    <sentence id="DDI-DrugBank.d374.s5" text="Safety and effectiveness in children has not been established."/>
    <sentence id="DDI-DrugBank.d147.s0" text="No formal assessments of drug-drug interactions between Vidaza and other agents have been conducted">
        <entity id="DDI-DrugBank.d147.s0.e0" charOffset="56-61"
            type="brand" text="Vidaza"/>
    </sentence>
    <sentence id="DDI-DrugBank.d147.s1" text="."/>
    <sentence id="DDI-DrugBank.d147.s2" text=""/>
    <sentence id="DDI-DrugBank.d448.s0" text="MAO inhibitors prolong and intensify the effects of antihistamines.">
        <entity id="DDI-DrugBank.d448.s0.e0" charOffset="0-13"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d448.s0.e1" charOffset="52-65"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d448.s0.d0" e1="DDI-DrugBank.d448.s0.e0"
            e2="DDI-DrugBank.d448.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d448.s1" text="Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.">
        <entity id="DDI-DrugBank.d448.s1.e0" charOffset="19-32"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d448.s1.e1" charOffset="39-45"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d448.s1.e2" charOffset="48-72"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d448.s1.e3" charOffset="75-86"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d448.s1.e4" charOffset="98-131"
            type="group" text="central nervous system depressants"/>
        <ddi id="DDI-DrugBank.d448.s1.d0" e1="DDI-DrugBank.d448.s1.e0"
            e2="DDI-DrugBank.d448.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d448.s1.d1" e1="DDI-DrugBank.d448.s1.e0"
            e2="DDI-DrugBank.d448.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d448.s1.d2" e1="DDI-DrugBank.d448.s1.e0"
            e2="DDI-DrugBank.d448.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d448.s1.d3" e1="DDI-DrugBank.d448.s1.e0"
            e2="DDI-DrugBank.d448.s1.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d448.s2" text="When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.">
        <entity id="DDI-DrugBank.d448.s2.e0" charOffset="5-25"
            type="group" text="sympathomimetic drugs"/>
        <entity id="DDI-DrugBank.d448.s2.e1" charOffset="59-86"
            type="group" text="monoamine oxidase inhibitors"/>
        <ddi id="DDI-DrugBank.d448.s2.d0" e1="DDI-DrugBank.d448.s2.e0"
            e2="DDI-DrugBank.d448.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d448.s3" text="The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.">
        <entity id="DDI-DrugBank.d448.s3.e0" charOffset="32-41"
            type="drug" text="methyldopa"/>
        <entity id="DDI-DrugBank.d448.s3.e1" charOffset="44-55"
            type="drug" text="mecamylamine"/>
        <entity id="DDI-DrugBank.d448.s3.e2" charOffset="58-66"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d448.s3.e3" charOffset="73-90"
            type="drug" text="veratrum alkaloids"/>
        <entity id="DDI-DrugBank.d448.s3.e4" charOffset="110-125"
            type="group" text="sympathomimetics"/>
        <ddi id="DDI-DrugBank.d448.s3.d0" e1="DDI-DrugBank.d448.s3.e0"
            e2="DDI-DrugBank.d448.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d448.s3.d1" e1="DDI-DrugBank.d448.s3.e1"
            e2="DDI-DrugBank.d448.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d448.s3.d2" e1="DDI-DrugBank.d448.s3.e2"
            e2="DDI-DrugBank.d448.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d448.s3.d3" e1="DDI-DrugBank.d448.s3.e3"
            e2="DDI-DrugBank.d448.s3.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d448.s4" text="Beta-adrenergic blocking agents may also interact with sympathomimetics.">
        <entity id="DDI-DrugBank.d448.s4.e0" charOffset="0-30"
            type="group" text="Beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d448.s4.e1" charOffset="55-70"
            type="group" text="sympathomimetics"/>
        <ddi id="DDI-DrugBank.d448.s4.d0" e1="DDI-DrugBank.d448.s4.e0"
            e2="DDI-DrugBank.d448.s4.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d448.s5" text="Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.">
        <entity id="DDI-DrugBank.d448.s5.e0" charOffset="52-66"
            type="drug" text="pseudoephedrine"/>
        <entity id="DDI-DrugBank.d448.s5.e1" charOffset="95-103"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d448.s5.d0" e1="DDI-DrugBank.d448.s5.e0"
            e2="DDI-DrugBank.d448.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d448.s6" text="Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.">
        <entity id="DDI-DrugBank.d448.s6.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d448.s6.e1" charOffset="44-58"
            type="drug" text="pseudoephedrine"/>
        <entity id="DDI-DrugBank.d448.s6.e2" charOffset="67-72"
            type="drug" text="kaolin"/>
        <ddi id="DDI-DrugBank.d448.s6.d0" e1="DDI-DrugBank.d448.s6.e0"
            e2="DDI-DrugBank.d448.s6.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d448.s6.d1" e1="DDI-DrugBank.d448.s6.e1"
            e2="DDI-DrugBank.d448.s6.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d233.s0" text="Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.">
        <entity id="DDI-DrugBank.d233.s0.e0" charOffset="9-19"
            type="drug" text="Allopurinol"/>
        <entity id="DDI-DrugBank.d233.s0.e1" charOffset="66-77"
            type="drug" text="azathioprine"/>
        <entity id="DDI-DrugBank.d233.s0.e2" charOffset="95-105"
            type="drug" text="allopurinol"/>
        <ddi id="DDI-DrugBank.d233.s0.d0" e1="DDI-DrugBank.d233.s0.e1"
            e2="DDI-DrugBank.d233.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d233.s1" text="Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.">
        <entity id="DDI-DrugBank.d233.s1.e0" charOffset="19-30"
            type="drug" text="azathioprine"/>
        <entity id="DDI-DrugBank.d233.s1.e1" charOffset="36-46"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d233.s1.e2" charOffset="94-105"
            type="drug" text="azathioprine"/>
        <ddi id="DDI-DrugBank.d233.s1.d0" e1="DDI-DrugBank.d233.s1.e0"
            e2="DDI-DrugBank.d233.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d233.s2" text="Use with Other Agents Affecting Myelopoesis: Drugs which may affect leukocyte production, including co-trimoxazole, may lead to exaggerated leukopenia, especially in renal transplant recipients.">
        <entity id="DDI-DrugBank.d233.s2.e0" charOffset="100-113"
            type="brand" text="co-trimoxazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d233.s3" text="Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.">
        <entity id="DDI-DrugBank.d233.s3.e0" charOffset="9-48"
            type="group" text="Angiotensln Converting Enzyme Inhibitors"/>
        <entity id="DDI-DrugBank.d233.s3.e1" charOffset="62-101"
            type="group" text="angiotensin converting enzyme inhibitors"/>
        <entity id="DDI-DrugBank.d233.s3.e2" charOffset="142-153"
            type="drug" text="azathioprine"/>
        <ddi id="DDI-DrugBank.d233.s3.d0" e1="DDI-DrugBank.d233.s3.e1"
            e2="DDI-DrugBank.d233.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d383.s0" text="No information provided"/>
    <sentence id="DDI-DrugBank.d53.s0" text="Co-administration of nelfinavir at steady-state with a single dose of azithromycin.">
        <entity id="DDI-DrugBank.d53.s0.e0" charOffset="21-30"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d53.s0.e1" charOffset="70-81"
            type="drug" text="azithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s1" text="Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.">
        <entity id="DDI-DrugBank.d53.s1.e0" charOffset="21-30"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d53.s1.e1" charOffset="70-81"
            type="drug" text="azithromycin"/>
        <entity id="DDI-DrugBank.d53.s1.e2" charOffset="125-136"
            type="drug" text="azithromycin"/>
        <ddi id="DDI-DrugBank.d53.s1.d0" e1="DDI-DrugBank.d53.s1.e0"
            e2="DDI-DrugBank.d53.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s2" text="Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.">
        <entity id="DDI-DrugBank.d53.s2.e0" charOffset="30-41"
            type="drug" text="azithromycin"/>
        <entity id="DDI-DrugBank.d53.s2.e1" charOffset="100-109"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d53.s2.e2" charOffset="155-166"
            type="drug" text="azithromycin"/>
        <ddi id="DDI-DrugBank.d53.s2.d0" e1="DDI-DrugBank.d53.s2.e0"
            e2="DDI-DrugBank.d53.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s3" text="Azithromycin did not affect the prothrombin time response to a single dose of warfarin.">
        <entity id="DDI-DrugBank.d53.s3.e0" charOffset="0-11"
            type="drug" text="Azithromycin"/>
        <entity id="DDI-DrugBank.d53.s3.e1" charOffset="78-85"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s4" text="However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.">
        <entity id="DDI-DrugBank.d53.s4.e0" charOffset="111-122"
            type="drug" text="azithromycin"/>
        <entity id="DDI-DrugBank.d53.s4.e1" charOffset="128-135"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d53.s4.d0" e1="DDI-DrugBank.d53.s4.e0"
            e2="DDI-DrugBank.d53.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s5" text="Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.">
        <entity id="DDI-DrugBank.d53.s5.e0" charOffset="18-27"
            type="group" text="macrolides"/>
        <entity id="DDI-DrugBank.d53.s5.e1" charOffset="33-40"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d53.s5.d0" e1="DDI-DrugBank.d53.s5.e0"
            e2="DDI-DrugBank.d53.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s6" text="Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered.">
        <entity id="DDI-DrugBank.d53.s6.e0" charOffset="45-56"
            type="drug" text="azithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s7" text="When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.">
        <entity id="DDI-DrugBank.d53.s7.e0" charOffset="32-43"
            type="drug" text="azithromycin"/>
        <entity id="DDI-DrugBank.d53.s7.e1" charOffset="92-103"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d53.s7.e2" charOffset="106-118"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d53.s7.e3" charOffset="121-130"
            type="drug" text="cetirizine"/>
        <entity id="DDI-DrugBank.d53.s7.e4" charOffset="133-142"
            type="drug" text="didanosine"/>
        <entity id="DDI-DrugBank.d53.s7.e5" charOffset="145-153"
            type="drug" text="efavirenz"/>
        <entity id="DDI-DrugBank.d53.s7.e6" charOffset="156-166"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d53.s7.e7" charOffset="169-177"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d53.s7.e8" charOffset="180-188"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d53.s7.e9" charOffset="191-199"
            type="drug" text="rifabutin"/>
        <entity id="DDI-DrugBank.d53.s7.e10" charOffset="202-211"
            type="drug" text="sildenafil"/>
        <entity id="DDI-DrugBank.d53.s7.e11" charOffset="214-225"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d53.s7.e12" charOffset="251-259"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d53.s7.e13" charOffset="262-273"
            type="drug" text="trimethoprim"/>
        <entity id="DDI-DrugBank.d53.s7.e14" charOffset="275-290"
            type="drug" text="sulfamethoxazole"/>
        <entity id="DDI-DrugBank.d53.s7.e15" charOffset="295-304"
            type="drug" text="zidovudine"/>
        <ddi id="DDI-DrugBank.d53.s7.d0" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d1" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d2" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d3" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d4" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d5" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d6" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d7" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d8" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d9" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e10" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d10" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e11" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d11" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e12" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d12" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e13" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d13" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e14" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s7.d14" e1="DDI-DrugBank.d53.s7.e0"
            e2="DDI-DrugBank.d53.s7.e15" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s8" text="Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.">
        <entity id="DDI-DrugBank.d53.s8.e0" charOffset="23-31"
            type="drug" text="efavirenz"/>
        <entity id="DDI-DrugBank.d53.s8.e1" charOffset="36-46"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d53.s8.e2" charOffset="95-106"
            type="drug" text="azithromycin"/>
        <ddi id="DDI-DrugBank.d53.s8.d0" e1="DDI-DrugBank.d53.s8.e0"
            e2="DDI-DrugBank.d53.s8.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d53.s8.d1" e1="DDI-DrugBank.d53.s8.e1"
            e2="DDI-DrugBank.d53.s8.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s9" text="No dosage adjustment of either drug is recommended when azithromycin is co administered with any of the above agents.">
        <entity id="DDI-DrugBank.d53.s9.e0" charOffset="56-67"
            type="drug" text="azithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s10" text="Interactions with the drugs listed below have not been reported in clinical trials with azithromycin;">
        <entity id="DDI-DrugBank.d53.s10.e0" charOffset="88-99"
            type="drug" text="azithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s11" text="however, no specific drug interaction studies have been performed to evaluate potential drug-drug interaction."/>
    <sentence id="DDI-DrugBank.d53.s12" text="Nonetheless, they have been observed with macrolide products.">
        <entity id="DDI-DrugBank.d53.s12.e0" charOffset="42-59"
            type="group" text="macrolide products"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s13" text="Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations.">
        <entity id="DDI-DrugBank.d53.s13.e0" charOffset="66-77"
            type="drug" text="azithromycin"/>
        <entity id="DDI-DrugBank.d53.s13.e1" charOffset="162-168"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d53.s13.e2" charOffset="179-185"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s14" text="Ergotamine or dihydroergotamine acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.">
        <entity id="DDI-DrugBank.d53.s14.e0" charOffset="0-9"
            type="drug" text="Ergotamine"/>
        <entity id="DDI-DrugBank.d53.s14.e1" charOffset="14-30"
            type="drug" text="dihydroergotamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s15" text="Cyclosporine, hexobarbital and phenytoin concentrations.">
        <entity id="DDI-DrugBank.d53.s15.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d53.s15.e1" charOffset="14-25"
            type="drug" text="hexobarbital"/>
        <entity id="DDI-DrugBank.d53.s15.e2" charOffset="31-39"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d53.s16" text="Laboratory Test Interactions There are no reported laboratory test interactions."/>
    <sentence id="DDI-DrugBank.d53.s17" text="Repeat Treatment Studies evaluating the use of repeated courses of Zmax have not been conducted.">
        <entity id="DDI-DrugBank.d53.s17.e0" charOffset="67-70"
            type="brand" text="Zmax"/>
    </sentence>
    <sentence id="DDI-DrugBank.d9.s0" text="Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.">
        <entity id="DDI-DrugBank.d9.s0.e0" charOffset="0-9" type="drug" text="Azlocillin"/>
        <entity id="DDI-DrugBank.d9.s0.e1" charOffset="57-64"
            type="drug" text="amikacin"/>
        <entity id="DDI-DrugBank.d9.s0.e2" charOffset="67-79"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d9.s0.e3" charOffset="82-91"
            type="drug" text="gentamicin"/>
        <entity id="DDI-DrugBank.d9.s0.e4" charOffset="94-103"
            type="drug" text="netilmicin"/>
        <entity id="DDI-DrugBank.d9.s0.e5" charOffset="109-118"
            type="drug" text="tobramycin"/>
        <ddi id="DDI-DrugBank.d9.s0.d0" e1="DDI-DrugBank.d9.s0.e0"
            e2="DDI-DrugBank.d9.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d9.s0.d1" e1="DDI-DrugBank.d9.s0.e0"
            e2="DDI-DrugBank.d9.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d9.s0.d2" e1="DDI-DrugBank.d9.s0.e0"
            e2="DDI-DrugBank.d9.s0.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d9.s0.d3" e1="DDI-DrugBank.d9.s0.e0"
            e2="DDI-DrugBank.d9.s0.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d9.s0.d4" e1="DDI-DrugBank.d9.s0.e0"
            e2="DDI-DrugBank.d9.s0.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d523.s0" text="Injection There is inadequate systematic experience with the use of baclofen injection in combination with other medications to predict specific drug-drug interactions.">
        <entity id="DDI-DrugBank.d523.s0.e0" charOffset="68-75"
            type="drug" text="baclofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d523.s1" text="Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.">
        <entity id="DDI-DrugBank.d523.s1.e0" charOffset="47-54"
            type="drug" text="baclofen"/>
        <entity id="DDI-DrugBank.d523.s1.e1" charOffset="79-86"
            type="drug" text="morphine"/>
        <ddi id="DDI-DrugBank.d523.s1.d0" e1="DDI-DrugBank.d523.s1.e0"
            e2="DDI-DrugBank.d523.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d523.s2" text="SIDE EFFECTS (KEMSTRO) The most common adverse reaction during treatment with baclofen is transient drowsiness (10-63%).">
        <entity id="DDI-DrugBank.d523.s2.e0" charOffset="14-20"
            type="brand" text="KEMSTRO"/>
        <entity id="DDI-DrugBank.d523.s2.e1" charOffset="78-85"
            type="drug" text="baclofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d523.s3" text="In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen tablets compared to 36% of those in the placebo group.">
        <entity id="DDI-DrugBank.d523.s3.e0" charOffset="101-108"
            type="drug" text="baclofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d523.s4" text="Other common adverse reactions are dizziness (5-15%), weakness (5-15%) and fatigue (2-4%)."/>
    <sentence id="DDI-DrugBank.d523.s5" text="Others reported: Neuropsychiatric: Confusion (1-11%), headache (4-8%), insomnia (2-7%);"/>
    <sentence id="DDI-DrugBank.d523.s6" text="and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure."/>
    <sentence id="DDI-DrugBank.d523.s7" text="Cardiovascular: Hypotension (0-9%)."/>
    <sentence id="DDI-DrugBank.d523.s8" text="Rare instances of dyspnea, palpitation, chest pain, syncope."/>
    <sentence id="DDI-DrugBank.d523.s9" text="Gastrointestinal: Nausea (4-12%), constipation (2-6%);"/>
    <sentence id="DDI-DrugBank.d523.s10" text="and, rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool."/>
    <sentence id="DDI-DrugBank.d523.s11" text="Genitourinary: Urinary frequency (2-6%);"/>
    <sentence id="DDI-DrugBank.d523.s12" text="and, rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria."/>
    <sentence id="DDI-DrugBank.d523.s13" text="Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion."/>
    <sentence id="DDI-DrugBank.d523.s14" text="Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy."/>
    <sentence id="DDI-DrugBank.d523.s15" text="The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.">
        <entity id="DDI-DrugBank.d523.s15.e0" charOffset="90-97"
            type="drug" text="baclofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d523.s16" text="The adverse experience profile seen with KEMSTROTM was similar to that seen with baclofen tablets.">
        <entity id="DDI-DrugBank.d523.s16.e0" charOffset="41-49"
            type="brand" text="KEMSTROTM"/>
        <entity id="DDI-DrugBank.d523.s16.e1" charOffset="81-88"
            type="drug" text="baclofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d486.s0" text="No drug interaction studies have been conducted for COLAZAL, however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.">
        <entity id="DDI-DrugBank.d486.s0.e0" charOffset="52-58"
            type="brand" text="COLAZAL"/>
        <entity id="DDI-DrugBank.d486.s0.e1" charOffset="100-110"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d486.s0.e2" charOffset="164-173"
            type="drug" text="mesalamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d544.s0" text="No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil.">
        <entity id="DDI-DrugBank.d544.s0.e0" charOffset="37-44"
            type="brand" text="Simulect"/>
        <entity id="DDI-DrugBank.d544.s0.e1" charOffset="102-113"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d544.s0.e2" charOffset="116-130"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d544.s0.e3" charOffset="144-155"
            type="drug" text="azathioprine"/>
        <entity id="DDI-DrugBank.d544.s0.e4" charOffset="160-180"
            type="drug" text="mycophenolate mofetil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d544.s1" text="Three clinical trials have investigated Simulect use in combination with triple-therapy regimens.">
        <entity id="DDI-DrugBank.d544.s1.e0" charOffset="40-47"
            type="brand" text="Simulect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d544.s2" text="Pharmacokinetics were assessed in two of these trials."/>
    <sentence id="DDI-DrugBank.d544.s3" text="Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.">
        <entity id="DDI-DrugBank.d544.s3.e0" charOffset="24-31"
            type="brand" text="Simulect"/>
        <entity id="DDI-DrugBank.d544.s3.e1" charOffset="76-87"
            type="drug" text="azathioprine"/>
        <entity id="DDI-DrugBank.d544.s3.e2" charOffset="93-113"
            type="drug" text="mycophenolate mofetil"/>
        <entity id="DDI-DrugBank.d544.s3.e3" charOffset="168-179"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d544.s3.e4" charOffset="201-215"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d544.s3.d0" e1="DDI-DrugBank.d544.s3.e0"
            e2="DDI-DrugBank.d544.s3.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d544.s3.d1" e1="DDI-DrugBank.d544.s3.e0"
            e2="DDI-DrugBank.d544.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d544.s4" text="Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).">
        <entity id="DDI-DrugBank.d544.s4.e0" charOffset="37-44"
            type="brand" text="Simulect"/>
        <entity id="DDI-DrugBank.d544.s4.e1" charOffset="82-93"
            type="drug" text="azathioprine"/>
        <entity id="DDI-DrugBank.d544.s4.e2" charOffset="111-131"
            type="drug" text="mycophenolate mofetil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d544.s5" text="The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromonab-CD3.">
        <entity id="DDI-DrugBank.d544.s5.e0" charOffset="73-80"
            type="brand" text="Simulect"/>
        <entity id="DDI-DrugBank.d544.s5.e1" charOffset="130-141"
            type="drug" text="azathioprine"/>
        <entity id="DDI-DrugBank.d544.s5.e2" charOffset="144-158"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d544.s5.e3" charOffset="161-172"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d544.s5.e4" charOffset="175-195"
            type="drug" text="mycophenolate mofetil"/>
        <entity id="DDI-DrugBank.d544.s5.e5" charOffset="202-214"
            type="drug" text="muromonab-CD3"/>
    </sentence>
    <sentence id="DDI-DrugBank.d385.s0" text="It is not known if REGRANEX Gel interacts with other topical medications applied to the ulcer site.">
        <entity id="DDI-DrugBank.d385.s0.e0" charOffset="19-26"
            type="brand" text="REGRANEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d385.s1" text="The use of REGRANEX Gel with other topical drugs has not been studied.">
        <entity id="DDI-DrugBank.d385.s1.e0" charOffset="11-18"
            type="brand" text="REGRANEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d524.s0" text="Albuterol, Antihistamines, antidiabetic drugs, diuretics, digitalis.">
        <entity id="DDI-DrugBank.d524.s0.e0" charOffset="0-8"
            type="drug" text="Albuterol"/>
        <entity id="DDI-DrugBank.d524.s0.e1" charOffset="11-24"
            type="group" text="Antihistamines"/>
        <entity id="DDI-DrugBank.d524.s0.e2" charOffset="27-44"
            type="group" text="antidiabetic drugs"/>
        <entity id="DDI-DrugBank.d524.s0.e3" charOffset="47-55"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d524.s0.e4" charOffset="58-66"
            type="group" text="digitalis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s0" text="Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.">
        <entity id="DDI-DrugBank.d561.s0.e0" charOffset="0-8"
            type="group" text="Diuretics"/>
        <entity id="DDI-DrugBank.d561.s0.e1" charOffset="23-31"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d561.s0.e2" charOffset="203-210"
            type="brand" text="Lotensin"/>
        <ddi id="DDI-DrugBank.d561.s0.d0" e1="DDI-DrugBank.d561.s0.e1"
            e2="DDI-DrugBank.d561.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s1" text="The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.">
        <entity id="DDI-DrugBank.d561.s1.e0" charOffset="44-51"
            type="brand" text="Lotensin"/>
        <entity id="DDI-DrugBank.d561.s1.e1" charOffset="98-105"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d561.s1.e2" charOffset="175-182"
            type="brand" text="Lotensin"/>
        <ddi id="DDI-DrugBank.d561.s1.d0" e1="DDI-DrugBank.d561.s1.e1"
            e2="DDI-DrugBank.d561.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s2" text="If this is not possible, the starting dose should be reduced."/>
    <sentence id="DDI-DrugBank.d561.s3" text="Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.">
        <entity id="DDI-DrugBank.d561.s3.e0" charOffset="0-8"
            type="drug" text="Potassium"/>
        <entity id="DDI-DrugBank.d561.s3.e1" charOffset="26-52"
            type="group" text="Potassium-Sparing Diuretics"/>
        <entity id="DDI-DrugBank.d561.s3.e2" charOffset="102-119"
            type="group" text="thiazide diuretics"/>
        <ddi id="DDI-DrugBank.d561.s3.d0" e1="DDI-DrugBank.d561.s3.e1"
            e2="DDI-DrugBank.d561.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s4" text="Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.">
        <entity id="DDI-DrugBank.d561.s4.e0" charOffset="0-26"
            type="group" text="Potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d561.s4.e1" charOffset="29-42"
            type="drug" text="spironolactone"/>
        <entity id="DDI-DrugBank.d561.s4.e2" charOffset="45-53"
            type="drug" text="amiloride"/>
        <entity id="DDI-DrugBank.d561.s4.e3" charOffset="56-66"
            type="drug" text="triamterene"/>
        <entity id="DDI-DrugBank.d561.s4.e4" charOffset="84-92"
            type="drug" text="potassium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s5" text="Therefore, if concomitant use of such agents is indicated, they should be given with caution, and the patient's serum potassium should be monitored frequently."/>
    <sentence id="DDI-DrugBank.d561.s6" text="Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.">
        <entity id="DDI-DrugBank.d561.s6.e0" charOffset="5-18"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d561.s6.e1" charOffset="45-52"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d561.s6.e2" charOffset="58-70"
            type="drug" text="acenocoumarol"/>
        <entity id="DDI-DrugBank.d561.s6.e3" charOffset="181-194"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s7" text="Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.">
        <entity id="DDI-DrugBank.d561.s7.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d561.s7.e1" charOffset="25-31"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d561.s7.e2" charOffset="56-62"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d561.s7.e3" charOffset="114-127"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d561.s7.e4" charOffset="149-155"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d561.s7.d0" e1="DDI-DrugBank.d561.s7.e3"
            e2="DDI-DrugBank.d561.s7.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s8" text="These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.">
        <entity id="DDI-DrugBank.d561.s8.e0" charOffset="84-90"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s9" text="If a diuretic is also used, the risk of lithium toxicity may be increased.">
        <entity id="DDI-DrugBank.d561.s9.e0" charOffset="5-12"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d561.s9.e1" charOffset="40-46"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d561.s9.d0" e1="DDI-DrugBank.d561.s9.e0"
            e2="DDI-DrugBank.d561.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s10" text="Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, furosemide, digoxin, propranolol, atenolol, naproxen, or cimetidine.">
        <entity id="DDI-DrugBank.d561.s10.e0" charOffset="73-80"
            type="brand" text="Lotensin"/>
        <entity id="DDI-DrugBank.d561.s10.e1" charOffset="118-136"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d561.s10.e2" charOffset="139-152"
            type="drug" text="chlorthalidone"/>
        <entity id="DDI-DrugBank.d561.s10.e3" charOffset="155-164"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d561.s10.e4" charOffset="167-173"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d561.s10.e5" charOffset="176-186"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d561.s10.e6" charOffset="189-196"
            type="drug" text="atenolol"/>
        <entity id="DDI-DrugBank.d561.s10.e7" charOffset="199-206"
            type="drug" text="naproxen"/>
        <entity id="DDI-DrugBank.d561.s10.e8" charOffset="212-221"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s11" text="Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.">
        <entity id="DDI-DrugBank.d561.s11.e0" charOffset="0-7"
            type="brand" text="Lotensin"/>
        <entity id="DDI-DrugBank.d561.s11.e1" charOffset="42-72"
            type="group" text="beta-adrenergic-blocking agents"/>
        <entity id="DDI-DrugBank.d561.s11.e2" charOffset="75-105"
            type="group" text="calcium-channel-blocking agents"/>
        <entity id="DDI-DrugBank.d561.s11.e3" charOffset="108-116"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d561.s11.e4" charOffset="119-125"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d561.s11.e5" charOffset="132-142"
            type="drug" text="hydralazine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s12" text="Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system">
        <entity id="DDI-DrugBank.d561.s12.e0" charOffset="0-9"
            type="drug" text="Benazepril"/>
        <entity id="DDI-DrugBank.d561.s12.e1" charOffset="23-36"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d561.s12.e2" charOffset="79-102"
            type="group" text="beta-adrenergic blockers"/>
        <ddi id="DDI-DrugBank.d561.s12.d0" e1="DDI-DrugBank.d561.s12.e0"
            e2="DDI-DrugBank.d561.s12.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d561.s12.d1" e1="DDI-DrugBank.d561.s12.e1"
            e2="DDI-DrugBank.d561.s12.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s13" text="."/>
    <sentence id="DDI-DrugBank.d561.s14" text=""/>
    <sentence id="DDI-DrugBank.d304.s0" text="May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;">
        <entity id="DDI-DrugBank.d304.s0.e0" charOffset="33-46"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d304.s0.e1" charOffset="49-58"
            type="drug" text="colestipol"/>
        <entity id="DDI-DrugBank.d304.s0.e2" charOffset="70-87"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d304.s0.e3" charOffset="105-112"
            type="group" text="diuretic"/>
        <ddi id="DDI-DrugBank.d304.s0.d0" e1="DDI-DrugBank.d304.s0.e0"
            e2="DDI-DrugBank.d304.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d304.s0.d1" e1="DDI-DrugBank.d304.s0.e1"
            e2="DDI-DrugBank.d304.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d537.s0" text="Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).">
        <entity id="DDI-DrugBank.d537.s0.e0" charOffset="0-10"
            type="drug" text="Bentiromide"/>
        <entity id="DDI-DrugBank.d537.s0.e1" charOffset="30-42"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d537.s0.e2" charOffset="51-57"
            type="brand" text="Tylenol"/>
        <entity id="DDI-DrugBank.d537.s0.e3" charOffset="61-75"
            type="drug" text="chloramphenicol"/>
        <entity id="DDI-DrugBank.d537.s0.e4" charOffset="84-96"
            type="brand" text="Chloromycetin"/>
        <entity id="DDI-DrugBank.d537.s0.e5" charOffset="106-116"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d537.s0.e6" charOffset="125-134"
            type="drug" text="benzocaine"/>
        <entity id="DDI-DrugBank.d537.s0.e7" charOffset="140-148"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d537.s0.e8" charOffset="152-173"
            type="drug_n" text="para-aminobenzoic acid"/>
        <entity id="DDI-DrugBank.d537.s0.e9" charOffset="176-179"
            type="drug_n" text="PABA"/>
        <entity id="DDI-DrugBank.d537.s0.e10" charOffset="233-245"
            type="group" text="multivitamins"/>
        <entity id="DDI-DrugBank.d537.s0.e11" charOffset="249-260"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d537.s0.e12" charOffset="269-277"
            type="brand" text="Pronestyl"/>
        <entity id="DDI-DrugBank.d537.s0.e13" charOffset="281-292"
            type="group" text="sulfonamides"/>
        <entity id="DDI-DrugBank.d537.s0.e14" charOffset="313-330"
            type="group" text="thiazide diuretics"/>
        <ddi id="DDI-DrugBank.d537.s0.d0" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e1" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d1" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e2" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d2" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e3" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d3" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e4" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d4" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e5" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d5" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e6" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d6" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e7" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d7" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e8" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d8" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e9" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d9" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e10" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d10" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e11" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d11" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e12" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d12" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e13" type="int"/>
        <ddi id="DDI-DrugBank.d537.s0.d13" e1="DDI-DrugBank.d537.s0.e0"
            e2="DDI-DrugBank.d537.s0.e14" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d173.s0" text="May interact with other creams, lotions, or skin medicines when placed on the same areas of your skin that you are using bentoquatam.">
        <entity id="DDI-DrugBank.d173.s0.e0" charOffset="121-131"
            type="drug_n" text="bentoquatam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d24.s0" text="No information is available."/>
    <sentence id="DDI-DrugBank.d477.s0" text="Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.">
        <entity id="DDI-DrugBank.d477.s0.e0" charOffset="39-60"
            type="group" text="sympathomimetic amines"/>
        <entity id="DDI-DrugBank.d477.s0.e1" charOffset="122-149"
            type="group" text="monoamine oxidase inhibitors"/>
        <ddi id="DDI-DrugBank.d477.s0.d0" e1="DDI-DrugBank.d477.s0.e0"
            e2="DDI-DrugBank.d477.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d477.s1" text="DIDREX should not be used concomitantly with other CNS stimulants.">
        <entity id="DDI-DrugBank.d477.s1.e0" charOffset="0-5"
            type="brand" text="DIDREX"/>
        <entity id="DDI-DrugBank.d477.s1.e1" charOffset="51-64"
            type="group" text="CNS stimulants"/>
        <ddi id="DDI-DrugBank.d477.s1.d0" e1="DDI-DrugBank.d477.s1.e0"
            e2="DDI-DrugBank.d477.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d477.s2" text="Amphetamines may decrease the hypotensive effect of antihypertensives.">
        <entity id="DDI-DrugBank.d477.s2.e0" charOffset="0-11"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d477.s2.e1" charOffset="52-68"
            type="group" text="antihypertensives"/>
        <ddi id="DDI-DrugBank.d477.s2.d0" e1="DDI-DrugBank.d477.s2.e0"
            e2="DDI-DrugBank.d477.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d477.s3" text="Amphetamines may enhance the effects of tricyclic antidepressants.">
        <entity id="DDI-DrugBank.d477.s3.e0" charOffset="0-11"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d477.s3.e1" charOffset="40-64"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d477.s3.d0" e1="DDI-DrugBank.d477.s3.e0"
            e2="DDI-DrugBank.d477.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d477.s4" text="Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines.">
        <entity id="DDI-DrugBank.d477.s4.e0" charOffset="76-87"
            type="group" text="amphetamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d477.s5" text="Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.">
        <entity id="DDI-DrugBank.d477.s5.e0" charOffset="0-17"
            type="drug" text="Urinary acidifying"/>
        <entity id="DDI-DrugBank.d477.s5.e1" charOffset="74-85"
            type="group" text="amphetamines"/>
        <ddi id="DDI-DrugBank.d477.s5.d0" e1="DDI-DrugBank.d477.s5.e0"
            e2="DDI-DrugBank.d477.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d208.s0" text="Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.">
        <entity id="DDI-DrugBank.d208.s0.e0" charOffset="0-11"
            type="drug" text="Benzthiazide"/>
        <entity id="DDI-DrugBank.d208.s0.e1" charOffset="31-37"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d208.s0.e2" charOffset="40-52"
            type="group" text="blood thinner"/>
        <entity id="DDI-DrugBank.d208.s0.e3" charOffset="56-73"
            type="group" text="decongestant drugs"/>
        <entity id="DDI-DrugBank.d208.s0.e4" charOffset="129-135"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d208.s0.e5" charOffset="138-151"
            type="drug" text="norepinephrine"/>
        <entity id="DDI-DrugBank.d208.s0.e6" charOffset="154-159"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d208.s0.e7" charOffset="166-170"
            type="brand" text="Aleve"/>
        <entity id="DDI-DrugBank.d208.s0.e8" charOffset="175-183"
            type="drug" text="Ibuprofen"/>
        <ddi id="DDI-DrugBank.d208.s0.d0" e1="DDI-DrugBank.d208.s0.e0"
            e2="DDI-DrugBank.d208.s0.e1" type="int"/>
        <ddi id="DDI-DrugBank.d208.s0.d1" e1="DDI-DrugBank.d208.s0.e0"
            e2="DDI-DrugBank.d208.s0.e2" type="int"/>
        <ddi id="DDI-DrugBank.d208.s0.d2" e1="DDI-DrugBank.d208.s0.e0"
            e2="DDI-DrugBank.d208.s0.e3" type="int"/>
        <ddi id="DDI-DrugBank.d208.s0.d3" e1="DDI-DrugBank.d208.s0.e0"
            e2="DDI-DrugBank.d208.s0.e4" type="int"/>
        <ddi id="DDI-DrugBank.d208.s0.d4" e1="DDI-DrugBank.d208.s0.e0"
            e2="DDI-DrugBank.d208.s0.e5" type="int"/>
        <ddi id="DDI-DrugBank.d208.s0.d5" e1="DDI-DrugBank.d208.s0.e0"
            e2="DDI-DrugBank.d208.s0.e6" type="int"/>
        <ddi id="DDI-DrugBank.d208.s0.d6" e1="DDI-DrugBank.d208.s0.e0"
            e2="DDI-DrugBank.d208.s0.e7" type="int"/>
        <ddi id="DDI-DrugBank.d208.s0.d7" e1="DDI-DrugBank.d208.s0.e0"
            e2="DDI-DrugBank.d208.s0.e8" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d390.s0" text="Antipsychotic drugs such as phenothiazines or haloperidol;">
        <entity id="DDI-DrugBank.d390.s0.e0" charOffset="0-18"
            type="group" text="Antipsychotic drugs"/>
        <entity id="DDI-DrugBank.d390.s0.e1" charOffset="28-41"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d390.s0.e2" charOffset="46-56"
            type="drug" text="haloperidol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d390.s1" text="tricyclic antidepressants.">
        <entity id="DDI-DrugBank.d390.s1.e0" charOffset="0-24"
            type="group" text="tricyclic antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d137.s0" text="Nitrates: The concomitant use of Bepridil with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.">
        <entity id="DDI-DrugBank.d137.s0.e0" charOffset="0-7"
            type="group" text="Nitrates"/>
        <entity id="DDI-DrugBank.d137.s0.e1" charOffset="33-40"
            type="drug" text="Bepridil"/>
        <entity id="DDI-DrugBank.d137.s0.e2" charOffset="70-77"
            type="group" text="nitrates"/>
    </sentence>
    <sentence id="DDI-DrugBank.d137.s1" text="Sublingual nitroglycerin may be taken if necessary for the control of acute angina attacks during Bepridil therapy.">
        <entity id="DDI-DrugBank.d137.s1.e0" charOffset="11-23"
            type="drug" text="nitroglycerin"/>
        <entity id="DDI-DrugBank.d137.s1.e1" charOffset="98-105"
            type="drug" text="Bepridil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d137.s2" text="Beta-blocking Agents: The concomitant use of Bepridil and beta-blocking agents has been well tolerated in patients with stable angina.">
        <entity id="DDI-DrugBank.d137.s2.e0" charOffset="0-19"
            type="group" text="Beta-blocking Agents"/>
        <entity id="DDI-DrugBank.d137.s2.e1" charOffset="45-52"
            type="drug" text="Bepridil"/>
        <entity id="DDI-DrugBank.d137.s2.e2" charOffset="58-77"
            type="group" text="beta-blocking agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d137.s3" text="Available data are not sufficient, however, to predict the effects of concomitant medication on patients with impaired ventricular function or cardiac conduction abnormalities."/>
    <sentence id="DDI-DrugBank.d137.s4" text="Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.">
        <entity id="DDI-DrugBank.d137.s4.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d137.s4.e1" charOffset="54-75"
            type="drug" text="bepridil hydrochloride"/>
        <entity id="DDI-DrugBank.d137.s4.e2" charOffset="197-203"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d137.s4.d0" e1="DDI-DrugBank.d137.s4.e1"
            e2="DDI-DrugBank.d137.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d137.s5" text="Limited clinical data in angina patients receiving concomitant bepridil hydrochloride and digoxin therapy indicate no discernible changes in serum digoxin levels.">
        <entity id="DDI-DrugBank.d137.s5.e0" charOffset="63-84"
            type="drug" text="bepridil hydrochloride"/>
        <entity id="DDI-DrugBank.d137.s5.e1" charOffset="90-96"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d137.s6" text="Available data are neither sufficient to rule out possible increases in serum digoxin with concomitant treatment in some patients, nor other possible interactions, particularly in patients with cardiac conduction abnormalities (Also see WARNINGS Congestive Heart Failure).">
        <entity id="DDI-DrugBank.d137.s6.e0" charOffset="78-84"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d137.s7" text="Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.">
        <entity id="DDI-DrugBank.d137.s7.e0" charOffset="5-17"
            type="group" text="Hypoglycemics"/>
        <entity id="DDI-DrugBank.d137.s7.e1" charOffset="20-27"
            type="drug" text="Bepridil"/>
        <entity id="DDI-DrugBank.d137.s7.e2" charOffset="156-162"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d137.s7.e3" charOffset="172-190"
            type="group" text="hypoglycemic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d137.s8" text="General Interactions: Certain drugs could increase the likelihood of potentially serious adverse effects with bepridil hydrochloride.">
        <entity id="DDI-DrugBank.d137.s8.e0" charOffset="110-131"
            type="drug" text="bepridil hydrochloride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d137.s9" text="In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.">
        <entity id="DDI-DrugBank.d137.s9.e0" charOffset="86-107"
            type="drug" text="bepridil hydrochloride"/>
        <entity id="DDI-DrugBank.d137.s9.e1" charOffset="120-141"
            type="group" text="anti-arrhythmic agents"/>
        <entity id="DDI-DrugBank.d137.s9.e2" charOffset="151-159"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d137.s9.e3" charOffset="165-176"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d137.s9.e4" charOffset="179-196"
            type="group" text="cardiac glycosides"/>
        <entity id="DDI-DrugBank.d137.s9.e5" charOffset="202-227"
            type="group" text="tricyclic anti-depressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d137.s10" text="Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.">
        <entity id="DDI-DrugBank.d137.s10.e0" charOffset="0-15"
            type="group" text="Anti-arrhythmics"/>
        <entity id="DDI-DrugBank.d137.s10.e1" charOffset="21-46"
            type="group" text="tricyclic anti-depressants"/>
        <entity id="DDI-DrugBank.d137.s10.e2" charOffset="115-136"
            type="drug" text="bepridil hydrochloride"/>
        <ddi id="DDI-DrugBank.d137.s10.d0" e1="DDI-DrugBank.d137.s10.e0"
            e2="DDI-DrugBank.d137.s10.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d137.s10.d1" e1="DDI-DrugBank.d137.s10.e1"
            e2="DDI-DrugBank.d137.s10.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d137.s11" text="Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.">
        <entity id="DDI-DrugBank.d137.s11.e0" charOffset="0-17"
            type="group" text="Cardiac glycosides"/>
        <entity id="DDI-DrugBank.d137.s11.e1" charOffset="88-109"
            type="drug" text="bepridil hydrochloride"/>
        <ddi id="DDI-DrugBank.d137.s11.d0" e1="DDI-DrugBank.d137.s11.e0"
            e2="DDI-DrugBank.d137.s11.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d432.s0" text="APRD00513_IN,txt"/>
    <sentence id="DDI-DrugBank.d489.s0" text="The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine, nifedipine, chlorthalidone, and hydrochlorothiazide.">
        <entity id="DDI-DrugBank.d489.s0.e0" charOffset="50-56"
            type="brand" text="Kerlone"/>
        <entity id="DDI-DrugBank.d489.s0.e1" charOffset="101-110"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d489.s0.e2" charOffset="113-122"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d489.s0.e3" charOffset="125-138"
            type="drug" text="chlorthalidone"/>
        <entity id="DDI-DrugBank.d489.s0.e4" charOffset="145-163"
            type="drug" text="hydrochlorothiazide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d489.s1" text="Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.">
        <entity id="DDI-DrugBank.d489.s1.e0" charOffset="30-36"
            type="brand" text="Kerlone"/>
        <entity id="DDI-DrugBank.d489.s1.e1" charOffset="52-64"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d489.s1.e2" charOffset="66-73"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d489.s1.e3" charOffset="136-143"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d489.s2" text="Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.">
        <entity id="DDI-DrugBank.d489.s2.e0" charOffset="37-45"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d489.s2.e1" charOffset="92-104"
            type="drug" text="beta-blocking"/>
        <ddi id="DDI-DrugBank.d489.s2.d0" e1="DDI-DrugBank.d489.s2.e0"
            e2="DDI-DrugBank.d489.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d489.s3" text="Patients treated with a beta-adrenergic receptor blocking agent plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.">
        <entity id="DDI-DrugBank.d489.s3.e0" charOffset="24-62"
            type="group" text="beta-adrenergic receptor blocking agent"/>
    </sentence>
    <sentence id="DDI-DrugBank.d489.s4" text="Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.">
        <entity id="DDI-DrugBank.d489.s4.e0" charOffset="66-78"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d489.s4.e1" charOffset="84-92"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d489.s4.e2" charOffset="112-123"
            type="group" text="beta-blocker"/>
        <entity id="DDI-DrugBank.d489.s4.e3" charOffset="206-214"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d489.s4.d0" e1="DDI-DrugBank.d489.s4.e0"
            e2="DDI-DrugBank.d489.s4.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d489.s4.d1" e1="DDI-DrugBank.d489.s4.e2"
            e2="DDI-DrugBank.d489.s4.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d489.s5" text="Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.">
        <entity id="DDI-DrugBank.d489.s5.e0" charOffset="37-55"
            type="group" text="calcium antagonists"/>
        <entity id="DDI-DrugBank.d489.s5.e1" charOffset="89-119"
            type="group" text="beta-adrenergic blocking agents"/>
        <ddi id="DDI-DrugBank.d489.s5.d0" e1="DDI-DrugBank.d489.s5.e0"
            e2="DDI-DrugBank.d489.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d489.s6" text="Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.">
        <entity id="DDI-DrugBank.d489.s6.e0" charOffset="116-146"
            type="group" text="beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d489.s6.e1" charOffset="161-178"
            type="group" text="calcium antagonist"/>
        <ddi id="DDI-DrugBank.d489.s6.d0" e1="DDI-DrugBank.d489.s6.e0"
            e2="DDI-DrugBank.d489.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d489.s7" text="Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.">
        <entity id="DDI-DrugBank.d489.s7.e0" charOffset="44-61"
            type="group" text="calcium antagonist"/>
        <entity id="DDI-DrugBank.d489.s7.e1" charOffset="70-95"
            type="group" text="dihydropyridine derivative"/>
        <entity id="DDI-DrugBank.d489.s7.e2" charOffset="104-113"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d489.s7.e3" charOffset="249-257"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d489.s7.e4" charOffset="262-270"
            type="drug" text="diltiazem"/>
    </sentence>
    <sentence id="DDI-DrugBank.d489.s8" text="Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.">
        <entity id="DDI-DrugBank.d489.s8.e0" charOffset="69-81"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d489.s8.e1" charOffset="104-114"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d489.s8.e2" charOffset="156-168"
            type="group" text="beta-blockers"/>
        <ddi id="DDI-DrugBank.d489.s8.d0" e1="DDI-DrugBank.d489.s8.e0"
            e2="DDI-DrugBank.d489.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d489.s9" text="Severe allergic reactions including anaphylaxis have been reported in patients exposed to a variety of allergens either by repeated challenge, or accidental contact, and with diagnostic or therapeutic agents while receiving beta-blockers.">
        <entity id="DDI-DrugBank.d489.s9.e0" charOffset="224-236"
            type="group" text="beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d489.s10" text="Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.">
        <entity id="DDI-DrugBank.d489.s10.e0" charOffset="56-66"
            type="drug" text="epinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d513.s0" text="Special care is required if this drug is given to patients receiving ganglion blocking compounds because a critical fall in blood pressure may occur.">
        <entity id="DDI-DrugBank.d513.s0.e0" charOffset="69-95"
            type="group" text="ganglion blocking compounds"/>
    </sentence>
    <sentence id="DDI-DrugBank.d513.s1" text="Usually, severe abdominal symptoms appear before there is such a fall in the blood pressure."/>
    <sentence id="DDI-DrugBank.d312.s0" text="No formal drug interaction studies with anti-neoplastic agents have been conducted.">
        <entity id="DDI-DrugBank.d312.s0.e0" charOffset="40-61"
            type="group" text="anti-neoplastic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d312.s1" text="In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or without AVASTIN.">
        <entity id="DDI-DrugBank.d312.s1.e0" charOffset="55-64"
            type="drug" text="irinotecan"/>
        <entity id="DDI-DrugBank.d312.s1.e1" charOffset="66-69"
            type="drug" text="5-FU"/>
        <entity id="DDI-DrugBank.d312.s1.e2" charOffset="71-80"
            type="drug" text="leucovorin"/>
        <entity id="DDI-DrugBank.d312.s1.e3" charOffset="110-116"
            type="brand" text="AVASTIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d312.s2" text="Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN.">
        <entity id="DDI-DrugBank.d312.s2.e0" charOffset="0-9"
            type="drug" text="Irinotecan"/>
        <entity id="DDI-DrugBank.d312.s2.e1" charOffset="101-107"
            type="brand" text="AVASTIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d312.s3" text="The concentrations of SN38, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone.">
        <entity id="DDI-DrugBank.d312.s3.e0" charOffset="22-25"
            type="drug_n" text="SN38"/>
        <entity id="DDI-DrugBank.d312.s3.e1" charOffset="53-62"
            type="drug" text="irinotecan"/>
        <entity id="DDI-DrugBank.d312.s3.e2" charOffset="144-150"
            type="brand" text="AVASTIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d312.s4" text="In Study 1, patients receiving bolus-IFL plus AVASTIN had a higher incidence of Grade 3-4 diarrhea and neutropenia.">
        <entity id="DDI-DrugBank.d312.s4.e0" charOffset="46-52"
            type="brand" text="AVASTIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d312.s5" text="Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.">
        <entity id="DDI-DrugBank.d312.s5.e0" charOffset="90-93"
            type="drug_n" text="SN38"/>
        <entity id="DDI-DrugBank.d312.s5.e1" charOffset="135-144"
            type="drug" text="irinotecan"/>
        <entity id="DDI-DrugBank.d312.s5.e2" charOffset="150-156"
            type="brand" text="AVASTIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d467.s0" text="No formal studies to evaluate drug interactions with bexarotene have been conducted.">
        <entity id="DDI-DrugBank.d467.s0.e0" charOffset="53-62"
            type="drug" text="bexarotene"/>
    </sentence>
    <sentence id="DDI-DrugBank.d467.s1" text="Bexarotene oxidative metabolites appear to be formed by cytochrome P450 3A4.">
        <entity id="DDI-DrugBank.d467.s1.e0" charOffset="0-9"
            type="drug" text="Bexarotene"/>
    </sentence>
    <sentence id="DDI-DrugBank.d467.s2" text="On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.">
        <entity id="DDI-DrugBank.d467.s2.e0" charOffset="34-43"
            type="drug" text="bexarotene"/>
        <entity id="DDI-DrugBank.d467.s2.e1" charOffset="69-80"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d467.s2.e2" charOffset="83-94"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d467.s2.e3" charOffset="97-108"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d467.s2.e4" charOffset="111-121"
            type="drug" text="gemfibrozil"/>
        <entity id="DDI-DrugBank.d467.s2.e5" charOffset="237-246"
            type="drug" text="bexarotene"/>
        <ddi id="DDI-DrugBank.d467.s2.d0" e1="DDI-DrugBank.d467.s2.e1"
            e2="DDI-DrugBank.d467.s2.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d467.s2.d1" e1="DDI-DrugBank.d467.s2.e2"
            e2="DDI-DrugBank.d467.s2.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d467.s2.d2" e1="DDI-DrugBank.d467.s2.e3"
            e2="DDI-DrugBank.d467.s2.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d467.s2.d3" e1="DDI-DrugBank.d467.s2.e4"
            e2="DDI-DrugBank.d467.s2.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d467.s3" text="Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.">
        <entity id="DDI-DrugBank.d467.s3.e0" charOffset="13-20"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d467.s3.e1" charOffset="23-31"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d467.s3.e2" charOffset="34-46"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d467.s3.e3" charOffset="123-132"
            type="drug" text="bexarotene"/>
        <ddi id="DDI-DrugBank.d467.s3.d0" e1="DDI-DrugBank.d467.s3.e0"
            e2="DDI-DrugBank.d467.s3.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d467.s3.d1" e1="DDI-DrugBank.d467.s3.e1"
            e2="DDI-DrugBank.d467.s3.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d467.s3.d2" e1="DDI-DrugBank.d467.s3.e2"
            e2="DDI-DrugBank.d467.s3.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d467.s4" text="Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.">
        <entity id="DDI-DrugBank.d467.s4.e0" charOffset="30-38"
            type="brand" text="Targretin"/>
        <entity id="DDI-DrugBank.d467.s4.e1" charOffset="53-63"
            type="drug" text="gemfibrozil"/>
        <entity id="DDI-DrugBank.d467.s4.e2" charOffset="127-136"
            type="drug" text="bexarotene"/>
        <entity id="DDI-DrugBank.d467.s4.e3" charOffset="212-222"
            type="drug" text="gemfibrozil"/>
        <ddi id="DDI-DrugBank.d467.s4.d0" e1="DDI-DrugBank.d467.s4.e0"
            e2="DDI-DrugBank.d467.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d467.s5" text="Under similar conditions, bexarotene concentrations were not affected by concomitant atorvastatin administration.">
        <entity id="DDI-DrugBank.d467.s5.e0" charOffset="26-35"
            type="drug" text="bexarotene"/>
        <entity id="DDI-DrugBank.d467.s5.e1" charOffset="85-96"
            type="drug" text="atorvastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d467.s6" text="Concomitant administration of gemfibrozil with Targretin capsules is not recommended.">
        <entity id="DDI-DrugBank.d467.s6.e0" charOffset="30-40"
            type="drug" text="gemfibrozil"/>
        <entity id="DDI-DrugBank.d467.s6.e1" charOffset="47-55"
            type="brand" text="Targretin"/>
        <ddi id="DDI-DrugBank.d467.s6.d0" e1="DDI-DrugBank.d467.s6.e0"
            e2="DDI-DrugBank.d467.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s0" text="When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.">
        <entity id="DDI-DrugBank.d291.s0.e0" charOffset="5-11"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s0.e1" charOffset="16-29"
            type="brand" text="Bezalip retard"/>
        <entity id="DDI-DrugBank.d291.s0.e2" charOffset="146-152"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s0.e3" charOffset="158-171"
            type="brand" text="Bezalip retard"/>
        <entity id="DDI-DrugBank.d291.s0.e4" charOffset="199-233"
            type="group" text="anticoagulants of the coumarin type"/>
        <ddi id="DDI-DrugBank.d291.s0.d0" e1="DDI-DrugBank.d291.s0.e2"
            e2="DDI-DrugBank.d291.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d291.s0.d1" e1="DDI-DrugBank.d291.s0.e3"
            e2="DDI-DrugBank.d291.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s1" text="For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters">
        <entity id="DDI-DrugBank.d291.s1.e0" charOffset="33-45"
            type="drug" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d291.s1.e1" charOffset="108-114"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s1.e2" charOffset="119-125"
            type="brand" text="Bezalip"/>
        <ddi id="DDI-DrugBank.d291.s1.d0" e1="DDI-DrugBank.d291.s1.e0"
            e2="DDI-DrugBank.d291.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s1.d1" e1="DDI-DrugBank.d291.s1.e0"
            e2="DDI-DrugBank.d291.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s2" text="."/>
    <sentence id="DDI-DrugBank.d291.s3" text="- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.">
        <entity id="DDI-DrugBank.d291.s3.e0" charOffset="16-29"
            type="group" text="sulphonylureas"/>
        <entity id="DDI-DrugBank.d291.s3.e1" charOffset="35-41"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d291.s3.e2" charOffset="62-68"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s3.e3" charOffset="73-86"
            type="brand" text="Bezalip retard"/>
        <ddi id="DDI-DrugBank.d291.s3.d0" e1="DDI-DrugBank.d291.s3.e0"
            e2="DDI-DrugBank.d291.s3.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d291.s3.d1" e1="DDI-DrugBank.d291.s3.e0"
            e2="DDI-DrugBank.d291.s3.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d291.s3.d2" e1="DDI-DrugBank.d291.s3.e1"
            e2="DDI-DrugBank.d291.s3.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d291.s3.d3" e1="DDI-DrugBank.d291.s3.e1"
            e2="DDI-DrugBank.d291.s3.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s4" text="This may be due to an improved glucose utilization with simultaneous reduction in insulin requirement">
        <entity id="DDI-DrugBank.d291.s4.e0" charOffset="82-88"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s5" text="."/>
    <sentence id="DDI-DrugBank.d291.s6" text="- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.">
        <entity id="DDI-DrugBank.d291.s6.e0" charOffset="211-228"
            type="group" text="immuno-suppressant"/>
        <entity id="DDI-DrugBank.d291.s6.e1" charOffset="254-264"
            type="drug" text="bezafibrate"/>
        <ddi id="DDI-DrugBank.d291.s6.d0" e1="DDI-DrugBank.d291.s6.e0"
            e2="DDI-DrugBank.d291.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s7" text="Accordingly, renal function should be closely monitored in these patients and, in the event of relevant significant changes in laboratory parameters, bezafibrate should, if necessary, be discontinued">
        <entity id="DDI-DrugBank.d291.s7.e0" charOffset="150-160"
            type="drug" text="bezafibrate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s8" text="."/>
    <sentence id="DDI-DrugBank.d291.s9" text="- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired">
        <entity id="DDI-DrugBank.d291.s9.e0" charOffset="7-13"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s9.e1" charOffset="18-31"
            type="brand" text="Bezalip retard"/>
        <entity id="DDI-DrugBank.d291.s9.e2" charOffset="59-79"
            type="group" text="anion-exchange resins"/>
        <entity id="DDI-DrugBank.d291.s9.e3" charOffset="87-101"
            type="drug" text="cholestryramine"/>
        <entity id="DDI-DrugBank.d291.s9.e4" charOffset="209-215"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s9.e5" charOffset="220-233"
            type="brand" text="Bezalip retard"/>
        <ddi id="DDI-DrugBank.d291.s9.d0" e1="DDI-DrugBank.d291.s9.e0"
            e2="DDI-DrugBank.d291.s9.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s9.d1" e1="DDI-DrugBank.d291.s9.e0"
            e2="DDI-DrugBank.d291.s9.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s9.d2" e1="DDI-DrugBank.d291.s9.e1"
            e2="DDI-DrugBank.d291.s9.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s9.d3" e1="DDI-DrugBank.d291.s9.e1"
            e2="DDI-DrugBank.d291.s9.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s10" text="."/>
    <sentence id="DDI-DrugBank.d291.s11" text="- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.">
        <entity id="DDI-DrugBank.d291.s11.e0" charOffset="2-29"
            type="drug" text="Perhexiline hydrogen maleate"/>
        <entity id="DDI-DrugBank.d291.s11.e1" charOffset="34-47"
            type="group" text="MAO-inhibitors"/>
        <entity id="DDI-DrugBank.d291.s11.e2" charOffset="117-123"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s11.e3" charOffset="128-141"
            type="brand" text="Bezalip retard"/>
        <ddi id="DDI-DrugBank.d291.s11.d0" e1="DDI-DrugBank.d291.s11.e0"
            e2="DDI-DrugBank.d291.s11.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s11.d1" e1="DDI-DrugBank.d291.s11.e0"
            e2="DDI-DrugBank.d291.s11.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s11.d2" e1="DDI-DrugBank.d291.s11.e1"
            e2="DDI-DrugBank.d291.s11.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s11.d3" e1="DDI-DrugBank.d291.s11.e1"
            e2="DDI-DrugBank.d291.s11.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d266.s0" text="In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.">
        <entity id="DDI-DrugBank.d266.s0.e0" charOffset="28-34"
            type="brand" text="CASODEX"/>
        <entity id="DDI-DrugBank.d266.s0.e1" charOffset="49-70"
            type="group" text="coumarin anticoagulant"/>
        <entity id="DDI-DrugBank.d266.s0.e2" charOffset="82-89"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d266.s0.d0" e1="DDI-DrugBank.d266.s0.e0"
            e2="DDI-DrugBank.d266.s0.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d266.s0.d1" e1="DDI-DrugBank.d266.s0.e1"
            e2="DDI-DrugBank.d266.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d266.s1" text="It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.">
        <entity id="DDI-DrugBank.d266.s1.e0" charOffset="26-32"
            type="brand" text="CASODEX"/>
        <entity id="DDI-DrugBank.d266.s1.e1" charOffset="75-97"
            type="group" text="coumarin anticoagulants"/>
        <entity id="DDI-DrugBank.d266.s1.e2" charOffset="168-180"
            type="group" text="anticoagulant"/>
        <ddi id="DDI-DrugBank.d266.s1.d0" e1="DDI-DrugBank.d266.s1.e0"
            e2="DDI-DrugBank.d266.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d266.s1.d1" e1="DDI-DrugBank.d266.s1.e0"
            e2="DDI-DrugBank.d266.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d264.s0" text="No Information Provided"/>
    <sentence id="DDI-DrugBank.d401.s0" text="Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.">
        <entity id="DDI-DrugBank.d401.s0.e0" charOffset="31-45"
            type="group" text="anticholinergic"/>
        <entity id="DDI-DrugBank.d401.s0.e1" charOffset="102-109"
            type="brand" text="AKINETON"/>
        <entity id="DDI-DrugBank.d401.s0.e2" charOffset="212-230"
            type="group" text="narcotic analgesics"/>
        <entity id="DDI-DrugBank.d401.s0.e3" charOffset="240-249"
            type="drug" text="meperidine"/>
        <entity id="DDI-DrugBank.d401.s0.e4" charOffset="256-269"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d401.s0.e5" charOffset="281-294"
            type="group" text="antipsychotics"/>
        <entity id="DDI-DrugBank.d401.s0.e6" charOffset="297-321"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d401.s0.e7" charOffset="332-346"
            type="group" text="antiarrhythmics"/>
        <entity id="DDI-DrugBank.d401.s0.e8" charOffset="360-368"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d401.s0.e9" charOffset="381-394"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d401.s0.d0" e1="DDI-DrugBank.d401.s0.e0"
            e2="DDI-DrugBank.d401.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d1" e1="DDI-DrugBank.d401.s0.e0"
            e2="DDI-DrugBank.d401.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d2" e1="DDI-DrugBank.d401.s0.e0"
            e2="DDI-DrugBank.d401.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d3" e1="DDI-DrugBank.d401.s0.e0"
            e2="DDI-DrugBank.d401.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d4" e1="DDI-DrugBank.d401.s0.e0"
            e2="DDI-DrugBank.d401.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d5" e1="DDI-DrugBank.d401.s0.e0"
            e2="DDI-DrugBank.d401.s0.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d6" e1="DDI-DrugBank.d401.s0.e0"
            e2="DDI-DrugBank.d401.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d7" e1="DDI-DrugBank.d401.s0.e0"
            e2="DDI-DrugBank.d401.s0.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d8" e1="DDI-DrugBank.d401.s0.e1"
            e2="DDI-DrugBank.d401.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d9" e1="DDI-DrugBank.d401.s0.e1"
            e2="DDI-DrugBank.d401.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d10" e1="DDI-DrugBank.d401.s0.e1"
            e2="DDI-DrugBank.d401.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d11" e1="DDI-DrugBank.d401.s0.e1"
            e2="DDI-DrugBank.d401.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d12" e1="DDI-DrugBank.d401.s0.e1"
            e2="DDI-DrugBank.d401.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d13" e1="DDI-DrugBank.d401.s0.e1"
            e2="DDI-DrugBank.d401.s0.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d14" e1="DDI-DrugBank.d401.s0.e1"
            e2="DDI-DrugBank.d401.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d401.s0.d15" e1="DDI-DrugBank.d401.s0.e1"
            e2="DDI-DrugBank.d401.s0.e9" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s0" text="ZEBETA should not be combined with other beta-blocking agents.">
        <entity id="DDI-DrugBank.d476.s0.e0" charOffset="0-5"
            type="brand" text="ZEBETA"/>
        <entity id="DDI-DrugBank.d476.s0.e1" charOffset="41-60"
            type="group" text="beta-blocking agents"/>
        <ddi id="DDI-DrugBank.d476.s0.d0" e1="DDI-DrugBank.d476.s0.e0"
            e2="DDI-DrugBank.d476.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s1" text="Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.">
        <entity id="DDI-DrugBank.d476.s1.e0" charOffset="58-66"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d476.s1.e1" charOffset="71-82"
            type="drug" text="guanethidine"/>
        <entity id="DDI-DrugBank.d476.s1.e2" charOffset="167-172"
            type="brand" text="ZEBETA"/>
        <ddi id="DDI-DrugBank.d476.s1.d0" e1="DDI-DrugBank.d476.s1.e0"
            e2="DDI-DrugBank.d476.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d476.s1.d1" e1="DDI-DrugBank.d476.s1.e1"
            e2="DDI-DrugBank.d476.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s2" text="In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.">
        <entity id="DDI-DrugBank.d476.s2.e0" charOffset="46-54"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d476.s2.e1" charOffset="112-117"
            type="brand" text="ZEBETA"/>
        <entity id="DDI-DrugBank.d476.s2.e2" charOffset="177-185"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d476.s2.d0" e1="DDI-DrugBank.d476.s2.e1"
            e2="DDI-DrugBank.d476.s2.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s3" text="ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.">
        <entity id="DDI-DrugBank.d476.s3.e0" charOffset="0-5"
            type="brand" text="ZEBETA"/>
        <entity id="DDI-DrugBank.d476.s3.e1" charOffset="37-58"
            type="group" text="myocardial depressants"/>
        <entity id="DDI-DrugBank.d476.s3.e2" charOffset="108-126"
            type="group" text="calcium antagonists"/>
        <entity id="DDI-DrugBank.d476.s3.e3" charOffset="149-164"
            type="group" text="phenylalkylamine"/>
        <entity id="DDI-DrugBank.d476.s3.e4" charOffset="167-175"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d476.s3.e5" charOffset="182-196"
            type="group" text="benzothiazepine"/>
        <entity id="DDI-DrugBank.d476.s3.e6" charOffset="199-207"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d476.s3.e7" charOffset="223-243"
            type="group" text="antiarrhythmic agents"/>
        <entity id="DDI-DrugBank.d476.s3.e8" charOffset="254-265"
            type="drug" text="disopyramide"/>
        <ddi id="DDI-DrugBank.d476.s3.d0" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d1" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d2" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d3" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d4" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d5" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d6" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d7" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e8" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s4" text="Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.">
        <entity id="DDI-DrugBank.d476.s4.e0" charOffset="18-25"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d476.s4.e1" charOffset="64-69"
            type="brand" text="ZEBETA"/>
        <entity id="DDI-DrugBank.d476.s4.e2" charOffset="122-127"
            type="brand" text="ZEBETA"/>
        <ddi id="DDI-DrugBank.d476.s4.d0" e1="DDI-DrugBank.d476.s4.e0"
            e2="DDI-DrugBank.d476.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s5" text="However, initial dose modification is generally not necessary."/>
    <sentence id="DDI-DrugBank.d476.s6" text="Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics, digoxin, and cimetidine.">
        <entity id="DDI-DrugBank.d476.s6.e0" charOffset="118-135"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d476.s6.e1" charOffset="138-144"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d476.s6.e2" charOffset="151-160"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s7" text="There was no effect of ZEBETA on prothrombin time in patients on stable doses of warfarin.">
        <entity id="DDI-DrugBank.d476.s7.e0" charOffset="23-28"
            type="brand" text="ZEBETA"/>
        <entity id="DDI-DrugBank.d476.s7.e1" charOffset="81-88"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s8" text="Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.">
        <entity id="DDI-DrugBank.d476.s8.e0" charOffset="44-56"
            type="group" text="beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s9" text="Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.">
        <entity id="DDI-DrugBank.d476.s9.e0" charOffset="56-66"
            type="drug" text="epinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d560.s0" text="Use of MAO inhibitors may cause an excessive increase in blood pressure and heart stimulation.">
        <entity id="DDI-DrugBank.d560.s0.e0" charOffset="7-20"
            type="group" text="MAO inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d560.s1" text="If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.">
        <entity id="DDI-DrugBank.d560.s1.e0" charOffset="24-30"
            type="group" text="steroid"/>
        <entity id="DDI-DrugBank.d560.s1.e1" charOffset="46-55"
            type="drug" text="bitolterol"/>
        <entity id="DDI-DrugBank.d560.s1.e2" charOffset="111-117"
            type="group" text="steroid"/>
        <ddi id="DDI-DrugBank.d560.s1.d0" e1="DDI-DrugBank.d560.s1.e0"
            e2="DDI-DrugBank.d560.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d560.s1.d1" e1="DDI-DrugBank.d560.s1.e1"
            e2="DDI-DrugBank.d560.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d560.s2" text="This allows bitolterol to open air passages, increasing the effectiveness of the steroid.">
        <entity id="DDI-DrugBank.d560.s2.e0" charOffset="12-21"
            type="drug" text="bitolterol"/>
        <entity id="DDI-DrugBank.d560.s2.e1" charOffset="81-87"
            type="group" text="steroid"/>
        <ddi id="DDI-DrugBank.d560.s2.d0" e1="DDI-DrugBank.d560.s2.e0"
            e2="DDI-DrugBank.d560.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s0" text="Angiomax does not exhibit binding to plasma proteins (other than thrombin) or red blood cells.">
        <entity id="DDI-DrugBank.d569.s0.e0" charOffset="0-7"
            type="brand" text="Angiomax"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s1" text="In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.">
        <entity id="DDI-DrugBank.d569.s1.e0" charOffset="73-80"
            type="brand" text="Angiomax"/>
        <entity id="DDI-DrugBank.d569.s1.e1" charOffset="87-93"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d569.s1.e2" charOffset="96-103"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d569.s1.e3" charOffset="106-118"
            type="group" text="thrombolytics"/>
        <ddi id="DDI-DrugBank.d569.s1.d0" e1="DDI-DrugBank.d569.s1.e0"
            e2="DDI-DrugBank.d569.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d569.s1.d1" e1="DDI-DrugBank.d569.s1.e0"
            e2="DDI-DrugBank.d569.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d569.s1.d2" e1="DDI-DrugBank.d569.s1.e0"
            e2="DDI-DrugBank.d569.s1.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s2" text="There is no experience with co-administration of Angiomax and plasma expanders such as dextran.">
        <entity id="DDI-DrugBank.d569.s2.e0" charOffset="49-56"
            type="brand" text="Angiomax"/>
        <entity id="DDI-DrugBank.d569.s2.e1" charOffset="87-93"
            type="drug" text="dextran"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s3" text="Angiomax should be used with caution in patients with disease states associated with an increased risk of bleeding.">
        <entity id="DDI-DrugBank.d569.s3.e0" charOffset="0-7"
            type="brand" text="Angiomax"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s4" text="Immunogenicity/Re-exposure: In in vitro studies, Angiomax exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS.">
        <entity id="DDI-DrugBank.d569.s4.e0" charOffset="49-56"
            type="brand" text="Angiomax"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s5" text="Among 494 subjects who received Angiomax in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests.">
        <entity id="DDI-DrugBank.d569.s5.e0" charOffset="32-39"
            type="brand" text="Angiomax"/>
        <entity id="DDI-DrugBank.d569.s5.e1" charOffset="135-145"
            type="drug" text="bivalirudin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s6" text="Neither subject demonstrated clinical evidence of allergic or anaphylactic reactions and repeat testing was not performed."/>
    <sentence id="DDI-DrugBank.d569.s7" text="Nine additional patients who had initial positive tests were negative on repeat testing."/>
    <sentence id="DDI-DrugBank.d554.s0" text="Certain antibiotic, cisplatin, cyclosporine, diuretic, foscarnet, and vaccines.">
        <entity id="DDI-DrugBank.d554.s0.e0" charOffset="8-17"
            type="group" text="antibiotic"/>
        <entity id="DDI-DrugBank.d554.s0.e1" charOffset="20-28"
            type="drug" text="cisplatin"/>
        <entity id="DDI-DrugBank.d554.s0.e2" charOffset="31-42"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d554.s0.e3" charOffset="45-52"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d554.s0.e4" charOffset="55-63"
            type="drug" text="foscarnet"/>
        <entity id="DDI-DrugBank.d554.s0.e5" charOffset="70-77"
            type="group" text="vaccines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d571.s0" text="No formal drug interaction studies have been conducted with VELCADE.">
        <entity id="DDI-DrugBank.d571.s0.e0" charOffset="60-66"
            type="brand" text="VELCADE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d571.s1" text="In vitro studies with human liver microsomes indicate that bortezomib is primarily a substrate for cytochrome P450 3A4, 2C19, and 1A2.">
        <entity id="DDI-DrugBank.d571.s1.e0" charOffset="59-68"
            type="drug" text="bortezomib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d571.s2" text="Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy .">
        <entity id="DDI-DrugBank.d571.s2.e0" charOffset="41-47"
            type="brand" text="VELCADE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d571.s3" text="During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics.">
        <entity id="DDI-DrugBank.d571.s3.e0" charOffset="105-117"
            type="group" text="hypoglycemics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d571.s4" text="Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.">
        <entity id="DDI-DrugBank.d571.s4.e0" charOffset="17-35"
            type="group" text="antidiabetic agents"/>
        <entity id="DDI-DrugBank.d571.s4.e1" charOffset="47-53"
            type="brand" text="VELCADE"/>
        <entity id="DDI-DrugBank.d571.s4.e2" charOffset="160-182"
            type="group" text="antidiabetic medication"/>
        <ddi id="DDI-DrugBank.d571.s4.d0" e1="DDI-DrugBank.d571.s4.e0"
            e2="DDI-DrugBank.d571.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d571.s5" text="Drug Laboratory Test Interactions None known."/>
    <sentence id="DDI-DrugBank.d289.s0" text="Bosentan is metabolized by CYP2C9 and CYP3A4.">
        <entity id="DDI-DrugBank.d289.s0.e0" charOffset="0-7"
            type="drug" text="Bosentan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s1" text="Inhibition of these isoenzymes may increase the plasma concentration of bosentan.">
        <entity id="DDI-DrugBank.d289.s1.e0" charOffset="72-79"
            type="drug" text="bosentan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s2" text="Bosentan is an inducer of CYP3A4 and CYP2C9.">
        <entity id="DDI-DrugBank.d289.s2.e0" charOffset="0-7"
            type="drug" text="Bosentan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s3" text="Consequently, plasma concentrations of drugs metabolized by these two isoenzymes will be decreased when TRACLEER is co-administered.">
        <entity id="DDI-DrugBank.d289.s3.e0" charOffset="104-111"
            type="brand" text="TRACLEER"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s4" text="Bosentan had no relevant inhibitory effect on any CYP isoenzymes tested (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4).">
        <entity id="DDI-DrugBank.d289.s4.e0" charOffset="0-7"
            type="drug" text="Bosentan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s5" text="Consequently, TRACLEER is not expected to increase the plasma concentrations of drugs metabolized by these enzymes.">
        <entity id="DDI-DrugBank.d289.s5.e0" charOffset="14-21"
            type="brand" text="TRACLEER"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s6" text="Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.">
        <entity id="DDI-DrugBank.d289.s6.e0" charOffset="0-22"
            type="group" text="Hormonal Contraceptives"/>
        <entity id="DDI-DrugBank.d289.s6.e1" charOffset="82-95"
            type="group" text="Contraceptives"/>
        <entity id="DDI-DrugBank.d289.s6.e2" charOffset="158-165"
            type="drug" text="bosentan"/>
        <entity id="DDI-DrugBank.d289.s6.e3" charOffset="180-201"
            type="group" text="hormonal contraceptive"/>
        <entity id="DDI-DrugBank.d289.s6.e4" charOffset="203-213"
            type="brand" text="Ortho-Novum"/>
        <entity id="DDI-DrugBank.d289.s6.e5" charOffset="245-257"
            type="drug" text="norethindrone"/>
        <entity id="DDI-DrugBank.d289.s6.e6" charOffset="263-279"
            type="drug" text="ethinyl estradiol"/>
        <ddi id="DDI-DrugBank.d289.s6.d0" e1="DDI-DrugBank.d289.s6.e2"
            e2="DDI-DrugBank.d289.s6.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s7" text="However, decreases in exposure were as much as 56% and 66%, respectively, in individual subjects."/>
    <sentence id="DDI-DrugBank.d289.s8" text="Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.">
        <entity id="DDI-DrugBank.d289.s8.e0" charOffset="11-33"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d289.s8.e1" charOffset="125-132"
            type="brand" text="TRACLEER"/>
        <ddi id="DDI-DrugBank.d289.s8.d0" e1="DDI-DrugBank.d289.s8.e0"
            e2="DDI-DrugBank.d289.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s9" text="Women should practice additional methods of contraception and not rely on hormonal contraception alone when taking TRACLEER.">
        <entity id="DDI-DrugBank.d289.s9.e0" charOffset="115-122"
            type="brand" text="TRACLEER"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s10" text="Specific interaction studies have demonstrated the following: Cyclosporine A: During the first day of concomitant administration, trough concentrations of bosentan were increased by about 30-fold.">
        <entity id="DDI-DrugBank.d289.s10.e0" charOffset="62-75"
            type="drug" text="Cyclosporine A"/>
        <entity id="DDI-DrugBank.d289.s10.e1" charOffset="155-162"
            type="drug" text="bosentan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s11" text="Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.">
        <entity id="DDI-DrugBank.d289.s11.e0" charOffset="13-20"
            type="drug" text="bosentan"/>
        <entity id="DDI-DrugBank.d289.s11.e1" charOffset="92-105"
            type="drug" text="cyclosporine A"/>
        <ddi id="DDI-DrugBank.d289.s11.d0" e1="DDI-DrugBank.d289.s11.e0"
            e2="DDI-DrugBank.d289.s11.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s12" text="The concomitant administration of bosentan and cyclosporine A is contraindicated.">
        <entity id="DDI-DrugBank.d289.s12.e0" charOffset="34-41"
            type="drug" text="bosentan"/>
        <entity id="DDI-DrugBank.d289.s12.e1" charOffset="47-60"
            type="drug" text="cyclosporine A"/>
        <ddi id="DDI-DrugBank.d289.s12.d0" e1="DDI-DrugBank.d289.s12.e0"
            e2="DDI-DrugBank.d289.s12.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s13" text="Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.">
        <entity id="DDI-DrugBank.d289.s13.e0" charOffset="21-28"
            type="drug" text="bosentan"/>
        <entity id="DDI-DrugBank.d289.s13.e1" charOffset="69-82"
            type="drug" text="cyclosporine A"/>
        <ddi id="DDI-DrugBank.d289.s13.d0" e1="DDI-DrugBank.d289.s13.e0"
            e2="DDI-DrugBank.d289.s13.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s14" text="Tacrolimus: Co-administration of tacrolimus and bosentan has not been studied in man.">
        <entity id="DDI-DrugBank.d289.s14.e0" charOffset="0-9"
            type="drug" text="Tacrolimus"/>
        <entity id="DDI-DrugBank.d289.s14.e1" charOffset="33-42"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d289.s14.e2" charOffset="48-55"
            type="drug" text="bosentan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s15" text="Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.">
        <entity id="DDI-DrugBank.d289.s15.e0" charOffset="21-30"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d289.s15.e1" charOffset="36-43"
            type="drug" text="bosentan"/>
        <entity id="DDI-DrugBank.d289.s15.e2" charOffset="101-108"
            type="drug" text="bosentan"/>
        <ddi id="DDI-DrugBank.d289.s15.d0" e1="DDI-DrugBank.d289.s15.e0"
            e2="DDI-DrugBank.d289.s15.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s16" text="Caution should be exercised if tacrolimus and bosentan are used together.">
        <entity id="DDI-DrugBank.d289.s16.e0" charOffset="31-40"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d289.s16.e1" charOffset="46-53"
            type="drug" text="bosentan"/>
        <ddi id="DDI-DrugBank.d289.s16.d0" e1="DDI-DrugBank.d289.s16.e0"
            e2="DDI-DrugBank.d289.s16.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s17" text="Glyburide: An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with glyburide.">
        <entity id="DDI-DrugBank.d289.s17.e0" charOffset="0-8"
            type="drug" text="Glyburide"/>
        <entity id="DDI-DrugBank.d289.s17.e1" charOffset="125-133"
            type="drug" text="glyburide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s18" text="Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.">
        <entity id="DDI-DrugBank.d289.s18.e0" charOffset="45-52"
            type="brand" text="TRACLEER"/>
        <entity id="DDI-DrugBank.d289.s18.e1" charOffset="58-66"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d289.s18.e2" charOffset="104-122"
            type="group" text="hypoglycemic agents"/>
        <ddi id="DDI-DrugBank.d289.s18.d0" e1="DDI-DrugBank.d289.s18.e0"
            e2="DDI-DrugBank.d289.s18.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s19" text="Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.">
        <entity id="DDI-DrugBank.d289.s19.e0" charOffset="21-28"
            type="drug" text="bosentan"/>
        <entity id="DDI-DrugBank.d289.s19.e1" charOffset="69-77"
            type="drug" text="glyburide"/>
        <ddi id="DDI-DrugBank.d289.s19.d0" e1="DDI-DrugBank.d289.s19.e0"
            e2="DDI-DrugBank.d289.s19.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s20" text="The plasma concentrations of bosentan were also decreased by approximately 30%.">
        <entity id="DDI-DrugBank.d289.s20.e0" charOffset="29-36"
            type="drug" text="bosentan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s21" text="Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.">
        <entity id="DDI-DrugBank.d289.s21.e0" charOffset="0-7"
            type="drug" text="Bosentan"/>
        <entity id="DDI-DrugBank.d289.s21.e1" charOffset="72-90"
            type="group" text="hypoglycemic agents"/>
        <ddi id="DDI-DrugBank.d289.s21.d0" e1="DDI-DrugBank.d289.s21.e0"
            e2="DDI-DrugBank.d289.s21.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s22" text="The possibility of worsened glucose control in patients using these agents should be considered."/>
    <sentence id="DDI-DrugBank.d289.s23" text="Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.">
        <entity id="DDI-DrugBank.d289.s23.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d289.s23.e1" charOffset="35-42"
            type="drug" text="bosentan"/>
        <entity id="DDI-DrugBank.d289.s23.e2" charOffset="62-73"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d289.s23.e3" charOffset="142-149"
            type="drug" text="bosentan"/>
        <ddi id="DDI-DrugBank.d289.s23.d0" e1="DDI-DrugBank.d289.s23.e1"
            e2="DDI-DrugBank.d289.s23.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s24" text="No dose adjustment of bosentan is necessary, but increased effects of bosentan should be considered.">
        <entity id="DDI-DrugBank.d289.s24.e0" charOffset="22-29"
            type="drug" text="bosentan"/>
        <entity id="DDI-DrugBank.d289.s24.e1" charOffset="70-77"
            type="drug" text="bosentan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s25" text="Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.">
        <entity id="DDI-DrugBank.d289.s25.e0" charOffset="0-10"
            type="drug" text="Simvastatin"/>
        <entity id="DDI-DrugBank.d289.s25.e1" charOffset="22-28"
            type="group" text="Statins"/>
        <entity id="DDI-DrugBank.d289.s25.e2" charOffset="52-59"
            type="drug" text="bosentan"/>
        <entity id="DDI-DrugBank.d289.s25.e3" charOffset="100-110"
            type="drug" text="simvastatin"/>
        <ddi id="DDI-DrugBank.d289.s25.d0" e1="DDI-DrugBank.d289.s25.e2"
            e2="DDI-DrugBank.d289.s25.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s26" text="The plasma concentrations of bosentan were not affected.">
        <entity id="DDI-DrugBank.d289.s26.e0" charOffset="29-36"
            type="drug" text="bosentan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s27" text="Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.">
        <entity id="DDI-DrugBank.d289.s27.e0" charOffset="0-7"
            type="drug" text="Bosentan"/>
        <entity id="DDI-DrugBank.d289.s27.e1" charOffset="67-73"
            type="group" text="statins"/>
        <entity id="DDI-DrugBank.d289.s27.e2" charOffset="127-136"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d289.s27.e3" charOffset="142-153"
            type="drug" text="atorvastatin"/>
        <ddi id="DDI-DrugBank.d289.s27.d0" e1="DDI-DrugBank.d289.s27.e0"
            e2="DDI-DrugBank.d289.s27.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d289.s27.d1" e1="DDI-DrugBank.d289.s27.e0"
            e2="DDI-DrugBank.d289.s27.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d289.s27.d2" e1="DDI-DrugBank.d289.s27.e0"
            e2="DDI-DrugBank.d289.s27.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s28" text="The possibility of reduced statin efficacy should be considered.">
        <entity id="DDI-DrugBank.d289.s28.e0" charOffset="27-32"
            type="group" text="statin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s29" text="Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.">
        <entity id="DDI-DrugBank.d289.s29.e0" charOffset="34-40"
            type="group" text="statins"/>
        <entity id="DDI-DrugBank.d289.s29.e1" charOffset="89-96"
            type="brand" text="TRACLEER"/>
        <entity id="DDI-DrugBank.d289.s29.e2" charOffset="130-135"
            type="group" text="statin"/>
        <ddi id="DDI-DrugBank.d289.s29.d0" e1="DDI-DrugBank.d289.s29.e0"
            e2="DDI-DrugBank.d289.s29.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s30" text="Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.">
        <entity id="DDI-DrugBank.d289.s30.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d289.s30.e1" charOffset="31-38"
            type="drug" text="bosentan"/>
        <entity id="DDI-DrugBank.d289.s30.e2" charOffset="109-118"
            type="drug" text="S-warfarin"/>
        <entity id="DDI-DrugBank.d289.s30.e3" charOffset="145-154"
            type="drug" text="R-warfarin"/>
        <ddi id="DDI-DrugBank.d289.s30.d0" e1="DDI-DrugBank.d289.s30.e1"
            e2="DDI-DrugBank.d289.s30.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d289.s30.d1" e1="DDI-DrugBank.d289.s30.e1"
            e2="DDI-DrugBank.d289.s30.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s31" text="Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.">
        <entity id="DDI-DrugBank.d289.s31.e0" charOffset="55-62"
            type="drug" text="bosentan"/>
        <entity id="DDI-DrugBank.d289.s31.e1" charOffset="68-75"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d289.s31.e2" charOffset="177-184"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d289.s31.e3" charOffset="262-269"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d289.s31.e4" charOffset="359-366"
            type="drug" text="bosentan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d289.s32" text="Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.">
        <entity id="DDI-DrugBank.d289.s32.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d289.s32.e1" charOffset="9-18"
            type="drug" text="Nimodipine"/>
        <entity id="DDI-DrugBank.d289.s32.e2" charOffset="24-31"
            type="drug" text="Losartan"/>
        <entity id="DDI-DrugBank.d289.s32.e3" charOffset="34-41"
            type="drug" text="Bosentan"/>
        <entity id="DDI-DrugBank.d289.s32.e4" charOffset="96-102"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d289.s32.e5" charOffset="108-117"
            type="drug" text="nimodipine"/>
        <entity id="DDI-DrugBank.d289.s32.e6" charOffset="124-131"
            type="drug" text="losartan"/>
        <entity id="DDI-DrugBank.d289.s32.e7" charOffset="179-186"
            type="drug" text="bosentan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d133.s0" text="Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.">
        <entity id="DDI-DrugBank.d133.s0.e0" charOffset="21-25"
            type="brand" text="BOTOX"/>
        <entity id="DDI-DrugBank.d133.s0.e1" charOffset="31-45"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d133.s0.e2" charOffset="114-134"
            type="group" text="curare-like compounds"/>
        <entity id="DDI-DrugBank.d133.s0.e3" charOffset="196-200"
            type="drug" text="toxin"/>
        <ddi id="DDI-DrugBank.d133.s0.d0" e1="DDI-DrugBank.d133.s0.e0"
            e2="DDI-DrugBank.d133.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d133.s0.d1" e1="DDI-DrugBank.d133.s0.e0"
            e2="DDI-DrugBank.d133.s0.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d133.s1" text="The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown.">
        <entity id="DDI-DrugBank.d133.s1.e0" charOffset="38-57"
            type="group" text="botulinum neurotoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d133.s2" text="Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.">
        <entity id="DDI-DrugBank.d133.s2.e0" charOffset="81-95"
            type="group" text="botulinum toxin"/>
        <entity id="DDI-DrugBank.d133.s2.e1" charOffset="165-179"
            type="group" text="botulinum toxin"/>
        <ddi id="DDI-DrugBank.d133.s2.d0" e1="DDI-DrugBank.d133.s2.e0"
            e2="DDI-DrugBank.d133.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d323.s0" text="Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.">
        <entity id="DDI-DrugBank.d323.s0.e0" charOffset="21-27"
            type="brand" text="MYOBLOC"/>
        <entity id="DDI-DrugBank.d323.s0.e1" charOffset="33-47"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d323.s0.e2" charOffset="116-136"
            type="group" text="curare-like compounds"/>
        <entity id="DDI-DrugBank.d323.s0.e3" charOffset="198-202"
            type="drug" text="toxin"/>
        <ddi id="DDI-DrugBank.d323.s0.d0" e1="DDI-DrugBank.d323.s0.e0"
            e2="DDI-DrugBank.d323.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d323.s0.d1" e1="DDI-DrugBank.d323.s0.e0"
            e2="DDI-DrugBank.d323.s0.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d323.s1" text="The effect of administering different botulinum neurotoxin serotypes at the same time or within less than 4 months of each other is unknown.">
        <entity id="DDI-DrugBank.d323.s1.e0" charOffset="38-57"
            type="group" text="botulinum neurotoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d323.s2" text="However, neuromuscular paralysis may be potentiated by co-administration or overlapping administration of different botulinum toxin serotypes.">
        <entity id="DDI-DrugBank.d323.s2.e0" charOffset="116-130"
            type="group" text="botulinum toxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d180.s0" text="Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.">
        <entity id="DDI-DrugBank.d180.s0.e0" charOffset="0-8"
            type="group" text="Digitalis"/>
        <entity id="DDI-DrugBank.d180.s0.e1" charOffset="88-105"
            type="drug" text="Bretylium Tosylate"/>
        <ddi id="DDI-DrugBank.d180.s0.d0" e1="DDI-DrugBank.d180.s0.e0"
            e2="DDI-DrugBank.d180.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d180.s1" text="The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.">
        <entity id="DDI-DrugBank.d180.s1.e0" charOffset="23-36"
            type="group" text="catecholamines"/>
        <entity id="DDI-DrugBank.d180.s1.e1" charOffset="46-53"
            type="drug" text="dopamine"/>
        <entity id="DDI-DrugBank.d180.s1.e2" charOffset="58-71"
            type="drug" text="norepinephrine"/>
        <entity id="DDI-DrugBank.d180.s1.e3" charOffset="89-106"
            type="drug" text="Bretylium Tosylate"/>
        <ddi id="DDI-DrugBank.d180.s1.d0" e1="DDI-DrugBank.d180.s1.e0"
            e2="DDI-DrugBank.d180.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d180.s1.d1" e1="DDI-DrugBank.d180.s1.e1"
            e2="DDI-DrugBank.d180.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d180.s1.d2" e1="DDI-DrugBank.d180.s1.e2"
            e2="DDI-DrugBank.d180.s1.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d180.s2" text="When catecholamines are administered, dilute solutions should be used and blood pressure should be monitored closely.">
        <entity id="DDI-DrugBank.d180.s2.e0" charOffset="5-18"
            type="group" text="catecholamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d180.s3" text="Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.">
        <entity id="DDI-DrugBank.d180.s3.e0" charOffset="80-88"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d180.s3.e1" charOffset="94-111"
            type="drug" text="Bretylium Tosylate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d138.s0" text="Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.">
        <entity id="DDI-DrugBank.d138.s0.e0" charOffset="72-81"
            type="brand" text="ALPHAGAN P"/>
        <entity id="DDI-DrugBank.d138.s0.e1" charOffset="143-157"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d138.s0.e2" charOffset="160-166"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d138.s0.e3" charOffset="169-180"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d138.s0.e4" charOffset="183-189"
            type="group" text="opiates"/>
        <entity id="DDI-DrugBank.d138.s0.e5" charOffset="192-200"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d138.s0.e6" charOffset="206-216"
            type="group" text="anesthetics"/>
        <ddi id="DDI-DrugBank.d138.s0.d0" e1="DDI-DrugBank.d138.s0.e0"
            e2="DDI-DrugBank.d138.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d138.s0.d1" e1="DDI-DrugBank.d138.s0.e0"
            e2="DDI-DrugBank.d138.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d138.s0.d2" e1="DDI-DrugBank.d138.s0.e0"
            e2="DDI-DrugBank.d138.s0.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d138.s0.d3" e1="DDI-DrugBank.d138.s0.e0"
            e2="DDI-DrugBank.d138.s0.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d138.s0.d4" e1="DDI-DrugBank.d138.s0.e0"
            e2="DDI-DrugBank.d138.s0.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d138.s0.d5" e1="DDI-DrugBank.d138.s0.e0"
            e2="DDI-DrugBank.d138.s0.e6" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d138.s1" text="Alpha-agonists, as a class, may reduce pulse and blood pressure.">
        <entity id="DDI-DrugBank.d138.s1.e0" charOffset="0-13"
            type="group" text="Alpha-agonists"/>
    </sentence>
    <sentence id="DDI-DrugBank.d138.s2" text="Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.">
        <entity id="DDI-DrugBank.d138.s2.e0" charOffset="43-55"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d138.s2.e1" charOffset="84-101"
            type="group" text="anti-hypertensives"/>
        <entity id="DDI-DrugBank.d138.s2.e2" charOffset="110-127"
            type="group" text="cardiac glycosides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d138.s3" text="Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.">
        <entity id="DDI-DrugBank.d138.s3.e0" charOffset="0-24"
            type="group" text="Tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d138.s3.e1" charOffset="89-97"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d138.s3.e2" charOffset="163-172"
            type="brand" text="ALPHAGAN P"/>
        <ddi id="DDI-DrugBank.d138.s3.d0" e1="DDI-DrugBank.d138.s3.e0"
            e2="DDI-DrugBank.d138.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d138.s4" text="No data on the level of circulating catecholamines after ALPHAGAN P administration are available.">
        <entity id="DDI-DrugBank.d138.s4.e0" charOffset="57-66"
            type="brand" text="ALPHAGAN P"/>
    </sentence>
    <sentence id="DDI-DrugBank.d138.s5" text="Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.">
        <entity id="DDI-DrugBank.d138.s5.e0" charOffset="48-72"
            type="group" text="tricyclic antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d497.s0" text="AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.">
        <entity id="DDI-DrugBank.d497.s0.e0" charOffset="0-4"
            type="brand" text="AZOPT"/>
        <entity id="DDI-DrugBank.d497.s0.e1" charOffset="7-18"
            type="drug" text="brinzolamide"/>
        <entity id="DDI-DrugBank.d497.s0.e2" charOffset="57-84"
            type="group" text="carbonic anhydrase inhibitor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d497.s1" text="Acid-base and electrolyte alterations were not reported in the clinical trials with brinzolamide.">
        <entity id="DDI-DrugBank.d497.s1.e0" charOffset="84-95"
            type="drug" text="brinzolamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d497.s2" text="However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.">
        <entity id="DDI-DrugBank.d497.s2.e0" charOffset="39-67"
            type="group" text="carbonic anhydrase inhibitors"/>
        <entity id="DDI-DrugBank.d497.s2.e1" charOffset="135-144"
            type="drug" text="salicylate"/>
        <ddi id="DDI-DrugBank.d497.s2.d0" e1="DDI-DrugBank.d497.s2.e0"
            e2="DDI-DrugBank.d497.s2.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d497.s3" text="Therefore, the potential for such drug interaction should be considered in patients receiving AZOPT (brinzolamide ophthalmic suspension) 1%.">
        <entity id="DDI-DrugBank.d497.s3.e0" charOffset="94-98"
            type="brand" text="AZOPT"/>
        <entity id="DDI-DrugBank.d497.s3.e1" charOffset="101-112"
            type="drug" text="brinzolamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d272.s0" text="The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.">
        <entity id="DDI-DrugBank.d272.s0.e0" charOffset="18-39"
            type="drug" text="bromocriptine mesylate"/>
        <entity id="DDI-DrugBank.d272.s0.e1" charOffset="116-122"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d272.s0.e2" charOffset="159-180"
            type="drug" text="bromocriptine mesylate"/>
        <ddi id="DDI-DrugBank.d272.s0.d0" e1="DDI-DrugBank.d272.s0.e1"
            e2="DDI-DrugBank.d272.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d272.s1" text="Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.">
        <entity id="DDI-DrugBank.d272.s1.e0" charOffset="0-21"
            type="drug" text="Bromocriptine mesylate"/>
        <entity id="DDI-DrugBank.d272.s1.e1" charOffset="41-60"
            type="group" text="dopamine antagonists"/>
        <entity id="DDI-DrugBank.d272.s1.e2" charOffset="63-76"
            type="group" text="butyrophenones"/>
        <ddi id="DDI-DrugBank.d272.s1.d0" e1="DDI-DrugBank.d272.s1.e0"
            e2="DDI-DrugBank.d272.s1.e1" type="int"/>
        <ddi id="DDI-DrugBank.d272.s1.d1" e1="DDI-DrugBank.d272.s1.e0"
            e2="DDI-DrugBank.d272.s1.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d272.s2" text="Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.">
        <entity id="DDI-DrugBank.d272.s2.e0" charOffset="64-85"
            type="drug" text="bromocriptine mesylate"/>
        <entity id="DDI-DrugBank.d272.s2.e1" charOffset="88-101"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d272.s2.e2" charOffset="104-114"
            type="drug" text="haloperidol"/>
        <entity id="DDI-DrugBank.d272.s2.e3" charOffset="117-130"
            type="drug" text="metoclopramide"/>
        <entity id="DDI-DrugBank.d272.s2.e4" charOffset="133-140"
            type="drug" text="pimozide"/>
        <ddi id="DDI-DrugBank.d272.s2.d0" e1="DDI-DrugBank.d272.s2.e0"
            e2="DDI-DrugBank.d272.s2.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d272.s2.d1" e1="DDI-DrugBank.d272.s2.e0"
            e2="DDI-DrugBank.d272.s2.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d272.s2.d2" e1="DDI-DrugBank.d272.s2.e0"
            e2="DDI-DrugBank.d272.s2.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d272.s2.d3" e1="DDI-DrugBank.d272.s2.e0"
            e2="DDI-DrugBank.d272.s2.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d272.s3" text="Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.">
        <entity id="DDI-DrugBank.d272.s3.e0" charOffset="19-40"
            type="drug" text="bromocriptine mesylate"/>
        <entity id="DDI-DrugBank.d272.s3.e1" charOffset="53-67"
            type="group" text="ergot alkaloids"/>
        <ddi id="DDI-DrugBank.d272.s3.d0" e1="DDI-DrugBank.d272.s3.e0"
            e2="DDI-DrugBank.d272.s3.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d192.s0" text="Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).">
        <entity id="DDI-DrugBank.d192.s0.e0" charOffset="0-17"
            type="drug" text="Dexbrompheniramine"/>
        <entity id="DDI-DrugBank.d192.s0.e1" charOffset="37-43"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d192.s0.e2" charOffset="54-68"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d192.s0.e3" charOffset="144-157"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d192.s0.e4" charOffset="161-176"
            type="group" text="anticholinergics"/>
        <entity id="DDI-DrugBank.d192.s0.e5" charOffset="323-336"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d192.s0.e6" charOffset="344-377"
            type="group" text="monoamine oxidase (MAO) inhibitors"/>
        <entity id="DDI-DrugBank.d192.s0.e7" charOffset="400-413"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d192.s0.e8" charOffset="491-504"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d192.s0.d0" e1="DDI-DrugBank.d192.s0.e0"
            e2="DDI-DrugBank.d192.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d192.s0.d1" e1="DDI-DrugBank.d192.s0.e0"
            e2="DDI-DrugBank.d192.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d192.s0.d2" e1="DDI-DrugBank.d192.s0.e0"
            e2="DDI-DrugBank.d192.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d192.s0.d3" e1="DDI-DrugBank.d192.s0.e0"
            e2="DDI-DrugBank.d192.s0.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d342.s0" text="This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).">
        <entity id="DDI-DrugBank.d342.s0.e0" charOffset="28-34"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d342.s0.e1" charOffset="45-59"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d342.s0.e2" charOffset="135-148"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d342.s0.e3" charOffset="152-167"
            type="group" text="anticholinergics"/>
        <entity id="DDI-DrugBank.d342.s0.e4" charOffset="314-327"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d342.s0.e5" charOffset="335-368"
            type="group" text="monoamine oxidase (MAO) inhibitors"/>
        <entity id="DDI-DrugBank.d342.s0.e6" charOffset="391-404"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d342.s0.e7" charOffset="482-495"
            type="group" text="antihistamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d144.s0" text="Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.">
        <entity id="DDI-DrugBank.d144.s0.e0" charOffset="35-46"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d144.s0.e1" charOffset="192-201"
            type="drug" text="budesonide"/>
        <ddi id="DDI-DrugBank.d144.s0.d0" e1="DDI-DrugBank.d144.s0.e0"
            e2="DDI-DrugBank.d144.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d144.s1" text="If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.">
        <entity id="DDI-DrugBank.d144.s1.e0" charOffset="57-68"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d144.s1.e1" charOffset="71-83"
            type="drug" text="intraconazole"/>
        <entity id="DDI-DrugBank.d144.s1.e2" charOffset="86-94"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d144.s1.e3" charOffset="97-105"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d144.s1.e4" charOffset="108-117"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d144.s1.e5" charOffset="120-131"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d144.s1.e6" charOffset="171-180"
            type="drug" text="budesonide"/>
        <ddi id="DDI-DrugBank.d144.s1.d0" e1="DDI-DrugBank.d144.s1.e0"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d144.s1.d1" e1="DDI-DrugBank.d144.s1.e1"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d144.s1.d2" e1="DDI-DrugBank.d144.s1.e2"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d144.s1.d3" e1="DDI-DrugBank.d144.s1.e3"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d144.s1.d4" e1="DDI-DrugBank.d144.s1.e4"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d144.s1.d5" e1="DDI-DrugBank.d144.s1.e5"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d144.s2" text="After extensive intake of grapefruit juice (which inhibits CYP3A4 activity predominantly in the intestinal mucosa), the systemic exposure for oral budesonide increased about two times.">
        <entity id="DDI-DrugBank.d144.s2.e0" charOffset="147-156"
            type="drug" text="budesonide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d144.s3" text="As with other drugs primarily being metabolized through CYP3A4, ingestion of grapefruit or grapefruit juice should be avoided in connection with budesonide administration.">
        <entity id="DDI-DrugBank.d144.s3.e0" charOffset="145-154"
            type="drug" text="budesonide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d331.s0" text="- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.">
        <entity id="DDI-DrugBank.d331.s0.e0" charOffset="125-134"
            type="drug" text="bumetanide"/>
        <entity id="DDI-DrugBank.d331.s0.e1" charOffset="156-181"
            type="group" text="aminoglycoside antibiotics"/>
        <ddi id="DDI-DrugBank.d331.s0.d0" e1="DDI-DrugBank.d331.s0.e0"
            e2="DDI-DrugBank.d331.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d331.s1" text="- Drugs with nephrotoxic potential: There has been no experience on the concurrent use of bumetanide with drugs known to have a nephrotoxic potential.">
        <entity id="DDI-DrugBank.d331.s1.e0" charOffset="90-99"
            type="drug" text="bumetanide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d331.s2" text="Therefore, the simultaneous administration of these drugs should be avoided."/>
    <sentence id="DDI-DrugBank.d331.s3" text="- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.">
        <entity id="DDI-DrugBank.d331.s3.e0" charOffset="2-8"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d331.s3.e1" charOffset="11-17"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d331.s3.e2" charOffset="54-62"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d331.s3.e3" charOffset="73-82"
            type="drug" text="bumetanide"/>
        <entity id="DDI-DrugBank.d331.s3.e4" charOffset="148-154"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d331.s3.d0" e1="DDI-DrugBank.d331.s3.e1"
            e2="DDI-DrugBank.d331.s3.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d331.s3.d1" e1="DDI-DrugBank.d331.s3.e1"
            e2="DDI-DrugBank.d331.s3.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d331.s4" text="- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.">
        <entity id="DDI-DrugBank.d331.s4.e0" charOffset="2-11"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d331.s4.e1" charOffset="32-41"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d331.s4.e2" charOffset="103-112"
            type="drug" text="bumetanide"/>
        <ddi id="DDI-DrugBank.d331.s4.d0" e1="DDI-DrugBank.d331.s4.e1"
            e2="DDI-DrugBank.d331.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d331.s5" text="This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.">
        <entity id="DDI-DrugBank.d331.s5.e0" charOffset="28-37"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d331.s5.e1" charOffset="42-51"
            type="drug" text="bumetanide"/>
        <entity id="DDI-DrugBank.d331.s5.e2" charOffset="196-205"
            type="drug" text="bumetanide"/>
        <ddi id="DDI-DrugBank.d331.s5.d0" e1="DDI-DrugBank.d331.s5.e0"
            e2="DDI-DrugBank.d331.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d331.s6" text="Thus, probenecid should not be administered concurrently with bumetanide.">
        <entity id="DDI-DrugBank.d331.s6.e0" charOffset="6-15"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d331.s6.e1" charOffset="62-71"
            type="drug" text="bumetanide"/>
        <ddi id="DDI-DrugBank.d331.s6.d0" e1="DDI-DrugBank.d331.s6.e0"
            e2="DDI-DrugBank.d331.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d331.s7" text="- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.">
        <entity id="DDI-DrugBank.d331.s7.e0" charOffset="2-13"
            type="drug" text="Indomethacin"/>
        <entity id="DDI-DrugBank.d331.s7.e1" charOffset="16-27"
            type="drug" text="Indomethacin"/>
        <entity id="DDI-DrugBank.d331.s7.e2" charOffset="99-108"
            type="drug" text="bumetanide"/>
        <entity id="DDI-DrugBank.d331.s7.e3" charOffset="137-146"
            type="drug" text="bumetanide"/>
        <ddi id="DDI-DrugBank.d331.s7.d0" e1="DDI-DrugBank.d331.s7.e1"
            e2="DDI-DrugBank.d331.s7.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d331.s7.d1" e1="DDI-DrugBank.d331.s7.e1"
            e2="DDI-DrugBank.d331.s7.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d331.s8" text="Concurrent therapy with bumetanide is thus not recommended.">
        <entity id="DDI-DrugBank.d331.s8.e0" charOffset="24-33"
            type="drug" text="bumetanide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d331.s9" text="- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.">
        <entity id="DDI-DrugBank.d331.s9.e0" charOffset="2-18"
            type="group" text="Antihypertensives"/>
        <entity id="DDI-DrugBank.d331.s9.e1" charOffset="21-30"
            type="drug" text="Bumetanide"/>
        <entity id="DDI-DrugBank.d331.s9.e2" charOffset="69-90"
            type="group" text="antihypertensive drugs"/>
        <ddi id="DDI-DrugBank.d331.s9.d0" e1="DDI-DrugBank.d331.s9.e1"
            e2="DDI-DrugBank.d331.s9.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d331.s10" text="- Digoxin: Interaction studies in humans have shown no effect on digoxin blood levels.">
        <entity id="DDI-DrugBank.d331.s10.e0" charOffset="2-8"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d331.s10.e1" charOffset="65-71"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d331.s11" text="- Anticoagulants: Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity.">
        <entity id="DDI-DrugBank.d331.s11.e0" charOffset="2-15"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d331.s11.e1" charOffset="59-68"
            type="drug" text="bumetanide"/>
        <entity id="DDI-DrugBank.d331.s11.e2" charOffset="91-98"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d153.s0" text="The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.">
        <entity id="DDI-DrugBank.d153.s0.e0" charOffset="28-47"
            type="group" text="anesthetic solutions"/>
        <entity id="DDI-DrugBank.d153.s0.e1" charOffset="60-70"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d153.s0.e2" charOffset="75-88"
            type="drug" text="norepinephrine"/>
        <entity id="DDI-DrugBank.d153.s0.e3" charOffset="112-139"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d153.s0.e4" charOffset="144-168"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d153.s0.d0" e1="DDI-DrugBank.d153.s0.e1"
            e2="DDI-DrugBank.d153.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d153.s0.d1" e1="DDI-DrugBank.d153.s0.e1"
            e2="DDI-DrugBank.d153.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d153.s0.d2" e1="DDI-DrugBank.d153.s0.e2"
            e2="DDI-DrugBank.d153.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d153.s0.d3" e1="DDI-DrugBank.d153.s0.e2"
            e2="DDI-DrugBank.d153.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d153.s1" text="Concurrent use of these agents should generally be avoided."/>
    <sentence id="DDI-DrugBank.d153.s2" text="In situations in which concurrent therapy is necessary, careful patient monitoring is essential."/>
    <sentence id="DDI-DrugBank.d153.s3" text="Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.">
        <entity id="DDI-DrugBank.d153.s3.e0" charOffset="29-45"
            type="group" text="vasopressor drugs"/>
        <entity id="DDI-DrugBank.d153.s3.e1" charOffset="54-78"
            type="group" text="ergot-type oxytocic drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d153.s4" text="Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.">
        <entity id="DDI-DrugBank.d153.s4.e0" charOffset="0-13"
            type="group" text="Phenothiazines"/>
        <entity id="DDI-DrugBank.d153.s4.e1" charOffset="19-32"
            type="group" text="butyrophenones"/>
        <entity id="DDI-DrugBank.d153.s4.e2" charOffset="78-88"
            type="drug" text="epinephrine"/>
        <ddi id="DDI-DrugBank.d153.s4.d0" e1="DDI-DrugBank.d153.s4.e0"
            e2="DDI-DrugBank.d153.s4.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d153.s4.d1" e1="DDI-DrugBank.d153.s4.e1"
            e2="DDI-DrugBank.d153.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d380.s0" text="Buprenorphine is metabolized to norbuprenorphine by cytochrome CYP 3A4.">
        <entity id="DDI-DrugBank.d380.s0.e0" charOffset="0-12"
            type="drug" text="Buprenorphine"/>
        <entity id="DDI-DrugBank.d380.s0.e1" charOffset="32-47"
            type="drug_n" text="norbuprenorphine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d380.s1" text="Because CYP 3A4 inhibitors may increase plasma concentrations of buprenorphine, patients already on CYP 3A4 inhibitors such as azole antifungals (e.g.">
        <entity id="DDI-DrugBank.d380.s1.e0" charOffset="65-77"
            type="drug" text="buprenorphine"/>
        <entity id="DDI-DrugBank.d380.s1.e1" charOffset="127-143"
            type="group" text="azole antifungals"/>
    </sentence>
    <sentence id="DDI-DrugBank.d380.s2" text="ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.">
        <entity id="DDI-DrugBank.d380.s2.e0" charOffset="0-11"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d380.s2.e1" charOffset="15-35"
            type="group" text="macrolide antibiotics"/>
        <entity id="DDI-DrugBank.d380.s2.e2" charOffset="43-54"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d380.s2.e3" charOffset="62-84"
            type="group" text="HIV protease inhibitors"/>
        <entity id="DDI-DrugBank.d380.s2.e4" charOffset="92-100"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d380.s2.e5" charOffset="103-111"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d380.s2.e6" charOffset="117-126"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d380.s2.e7" charOffset="155-161"
            type="brand" text="SUBUTEX"/>
        <entity id="DDI-DrugBank.d380.s2.e8" charOffset="166-173"
            type="brand" text="SUBOXONE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d380.s3" text="Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.">
        <entity id="DDI-DrugBank.d380.s3.e0" charOffset="64-76"
            type="drug" text="buprenorphine"/>
        <entity id="DDI-DrugBank.d380.s3.e1" charOffset="82-96"
            type="group" text="benzodiazepines"/>
        <ddi id="DDI-DrugBank.d380.s3.d0" e1="DDI-DrugBank.d380.s3.e0"
            e2="DDI-DrugBank.d380.s3.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d380.s4" text="There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.">
        <entity id="DDI-DrugBank.d380.s4.e0" charOffset="141-153"
            type="drug" text="buprenorphine"/>
        <entity id="DDI-DrugBank.d380.s4.e1" charOffset="159-173"
            type="drug" text="benzodiazepines"/>
        <ddi id="DDI-DrugBank.d380.s4.d0" e1="DDI-DrugBank.d380.s4.e0"
            e2="DDI-DrugBank.d380.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d380.s5" text="In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.">
        <entity id="DDI-DrugBank.d380.s5.e0" charOffset="24-36"
            type="drug" text="buprenorphine"/>
        <entity id="DDI-DrugBank.d380.s5.e1" charOffset="79-85"
            type="brand" text="SUBUTEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d380.s6" text="SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.">
        <entity id="DDI-DrugBank.d380.s6.e0" charOffset="0-6"
            type="brand" text="SUBUTEX"/>
        <entity id="DDI-DrugBank.d380.s6.e1" charOffset="12-19"
            type="brand" text="SUBOXONE"/>
        <entity id="DDI-DrugBank.d380.s6.e2" charOffset="70-84"
            type="group" text="benzodiazepines"/>
        <ddi id="DDI-DrugBank.d380.s6.d0" e1="DDI-DrugBank.d380.s6.e0"
            e2="DDI-DrugBank.d380.s6.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d380.s6.d1" e1="DDI-DrugBank.d380.s6.e1"
            e2="DDI-DrugBank.d380.s6.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d380.s7" text="Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.">
        <entity id="DDI-DrugBank.d380.s7.e0" charOffset="92-106"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d380.s7.e1" charOffset="135-142"
            type="brand" text="SUBOXONE"/>
        <entity id="DDI-DrugBank.d380.s7.e2" charOffset="147-153"
            type="brand" text="SUBUTEX"/>
        <ddi id="DDI-DrugBank.d380.s7.d0" e1="DDI-DrugBank.d380.s7.e0"
            e2="DDI-DrugBank.d380.s7.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d380.s7.d1" e1="DDI-DrugBank.d380.s7.e0"
            e2="DDI-DrugBank.d380.s7.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s0" text="Few systemic data have been collected on the metabolism of WELLBUTRIN following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of WELLBUTRIN on the metabolism of other drugs.">
        <entity id="DDI-DrugBank.d5.s0.e0" charOffset="59-68"
            type="brand" text="WELLBUTRIN"/>
        <entity id="DDI-DrugBank.d5.s0.e1" charOffset="187-196"
            type="brand" text="WELLBUTRIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s1" text="Because bupropion is extensively metabolized, the coadministration of other drugs may affect its clinical activity.">
        <entity id="DDI-DrugBank.d5.s1.e0" charOffset="8-16" type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s2" text="In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme.">
        <entity id="DDI-DrugBank.d5.s2.e0" charOffset="31-39"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s2.e1" charOffset="69-84"
            type="drug_n" text="hydroxybupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s3" text="Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).">
        <entity id="DDI-DrugBank.d5.s3.e0" charOffset="63-72"
            type="brand" text="WELLBUTRIN"/>
        <entity id="DDI-DrugBank.d5.s3.e1" charOffset="124-135"
            type="drug" text="orphenadrine"/>
        <entity id="DDI-DrugBank.d5.s3.e2" charOffset="141-156"
            type="drug" text="cyclophosphamide"/>
        <ddi id="DDI-DrugBank.d5.s3.d0" e1="DDI-DrugBank.d5.s3.e0"
            e2="DDI-DrugBank.d5.s3.e1" type="int"/>
        <ddi id="DDI-DrugBank.d5.s3.d1" e1="DDI-DrugBank.d5.s3.e0"
            e2="DDI-DrugBank.d5.s3.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s4" text="The threohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes.">
        <entity id="DDI-DrugBank.d5.s4.e0" charOffset="4-22"
            type="drug_n" text="threohydrobupropion"/>
        <entity id="DDI-DrugBank.d5.s4.e1" charOffset="38-46"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s5" text="The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers.">
        <entity id="DDI-DrugBank.d5.s5.e0" charOffset="45-54"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d5.s5.e1" charOffset="83-91"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s6" text="Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected.">
        <entity id="DDI-DrugBank.d5.s6.e0" charOffset="97-106"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d5.s6.e1" charOffset="133-141"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s6.e2" charOffset="147-162"
            type="drug_n" text="hydroxybupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s7" text="However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.">
        <entity id="DDI-DrugBank.d5.s7.e0" charOffset="105-123"
            type="drug_n" text="threohydrobupropion"/>
        <entity id="DDI-DrugBank.d5.s7.e1" charOffset="129-149"
            type="drug_n" text="erythrohydrobupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s8" text="While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).">
        <entity id="DDI-DrugBank.d5.s8.e0" charOffset="77-85"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s8.e1" charOffset="94-106"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d5.s8.e2" charOffset="109-121"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d5.s8.e3" charOffset="124-132"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d5.s8.d0" e1="DDI-DrugBank.d5.s8.e0"
            e2="DDI-DrugBank.d5.s8.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d5.s8.d1" e1="DDI-DrugBank.d5.s8.e0"
            e2="DDI-DrugBank.d5.s8.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d5.s8.d2" e1="DDI-DrugBank.d5.s8.e0"
            e2="DDI-DrugBank.d5.s8.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s9" text="Animal data indicated that bupropion may be an inducer of drug-metabolizing enzymes in humans.">
        <entity id="DDI-DrugBank.d5.s9.e0" charOffset="27-35"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s10" text="In one study, following chronic administration of bupropion, 100 mg 3 times daily to 8 healthy male volunteers for 14 days, there was no evidence of induction of its own metabolism.">
        <entity id="DDI-DrugBank.d5.s10.e0" charOffset="50-58"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s11" text="Nevertheless, there may be the potential for clinically important alterations of blood levels of coadministered drugs."/>
    <sentence id="DDI-DrugBank.d5.s12" text="Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.">
        <entity id="DDI-DrugBank.d5.s12.e0" charOffset="78-92"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d5.s12.e1" charOffset="107-116"
            type="group" text="tricyclics"/>
        <entity id="DDI-DrugBank.d5.s12.e2" charOffset="120-132"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d5.s12.e3" charOffset="135-149"
            type="drug" text="antiarrhythmics"/>
        <entity id="DDI-DrugBank.d5.s12.e4" charOffset="156-169"
            type="group" text="antipsychotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s13" text="Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.">
        <entity id="DDI-DrugBank.d5.s13.e0" charOffset="9-17"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s13.e1" charOffset="57-65"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s13.e2" charOffset="71-86"
            type="drug_n" text="hydroxybupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s14" text="In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.">
        <entity id="DDI-DrugBank.d5.s14.e0" charOffset="125-133"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s14.e1" charOffset="198-208"
            type="drug" text="desipramine"/>
        <entity id="DDI-DrugBank.d5.s14.e2" charOffset="247-257"
            type="drug" text="desipramine"/>
        <ddi id="DDI-DrugBank.d5.s14.d0" e1="DDI-DrugBank.d5.s14.e0"
            e2="DDI-DrugBank.d5.s14.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s15" text="The effect was present for at least 7 days after the last dose of bupropion.">
        <entity id="DDI-DrugBank.d5.s15.e0" charOffset="66-74"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s16" text="Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.">
        <entity id="DDI-DrugBank.d5.s16.e0" charOffset="19-27"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s17" text="Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.">
        <entity id="DDI-DrugBank.d5.s17.e0" charOffset="32-40"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s17.e1" charOffset="112-126"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d5.s17.e2" charOffset="135-147"
            type="drug" text="nortriptyline"/>
        <entity id="DDI-DrugBank.d5.s17.e3" charOffset="150-159"
            type="drug" text="imipramine"/>
        <entity id="DDI-DrugBank.d5.s17.e4" charOffset="162-172"
            type="drug" text="desipramine"/>
        <entity id="DDI-DrugBank.d5.s17.e5" charOffset="175-184"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d5.s17.e6" charOffset="187-196"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d5.s17.e7" charOffset="199-208"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d5.s17.e8" charOffset="212-225"
            type="group" text="antipsychotics"/>
        <entity id="DDI-DrugBank.d5.s17.e9" charOffset="234-244"
            type="drug" text="haloperidol"/>
        <entity id="DDI-DrugBank.d5.s17.e10" charOffset="247-257"
            type="drug" text="risperidone"/>
        <entity id="DDI-DrugBank.d5.s17.e11" charOffset="260-271"
            type="drug" text="thioridazine"/>
        <entity id="DDI-DrugBank.d5.s17.e12" charOffset="275-287"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d5.s17.e13" charOffset="296-305"
            type="drug" text="metoprolol"/>
        <entity id="DDI-DrugBank.d5.s17.e14" charOffset="313-335"
            type="group" text="Type 1C antiarrhythmics"/>
        <entity id="DDI-DrugBank.d5.s17.e15" charOffset="344-354"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d5.s17.e16" charOffset="357-366"
            type="drug" text="flecainide"/>
        <ddi id="DDI-DrugBank.d5.s17.d0" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d1" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d2" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d3" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d4" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d5" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d6" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d7" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d8" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d9" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e10" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d10" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d11" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e12" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d12" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d13" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e14" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d14" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e15" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d15" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e16" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s18" text="If bupropion is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need to decrease the dose of the original medication should be considered, particularly for those concomitant medications with a narrow therapeutic index.">
        <entity id="DDI-DrugBank.d5.s18.e0" charOffset="3-11"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s19" text="MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .">
        <entity id="DDI-DrugBank.d5.s19.e0" charOffset="0-13"
            type="group" text="MAO Inhibitors"/>
        <entity id="DDI-DrugBank.d5.s19.e1" charOffset="74-82"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s19.e2" charOffset="103-115"
            type="group" text="MAO inhibitor"/>
        <entity id="DDI-DrugBank.d5.s19.e3" charOffset="117-126"
            type="drug" text="phenelzine"/>
        <ddi id="DDI-DrugBank.d5.s19.d0" e1="DDI-DrugBank.d5.s19.e1"
            e2="DDI-DrugBank.d5.s19.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s20" text="Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.">
        <entity id="DDI-DrugBank.d5.s20.e0" charOffset="0-7" type="drug" text="Levodopa"/>
        <entity id="DDI-DrugBank.d5.s20.e1" charOffset="13-22"
            type="drug" text="Amantadine"/>
        <entity id="DDI-DrugBank.d5.s20.e2" charOffset="119-127"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s20.e3" charOffset="154-161"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d5.s20.e4" charOffset="166-175"
            type="drug" text="amantadine"/>
        <ddi id="DDI-DrugBank.d5.s20.d0" e1="DDI-DrugBank.d5.s20.e2"
            e2="DDI-DrugBank.d5.s20.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d5.s20.d1" e1="DDI-DrugBank.d5.s20.e2"
            e2="DDI-DrugBank.d5.s20.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s21" text="Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.">
        <entity id="DDI-DrugBank.d5.s21.e0" charOffset="18-27"
            type="brand" text="WELLBUTRIN"/>
        <entity id="DDI-DrugBank.d5.s21.e1" charOffset="66-73"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d5.s21.e2" charOffset="78-87"
            type="drug" text="amantadine"/>
        <ddi id="DDI-DrugBank.d5.s21.d0" e1="DDI-DrugBank.d5.s21.e0"
            e2="DDI-DrugBank.d5.s21.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s21.d1" e1="DDI-DrugBank.d5.s21.e0"
            e2="DDI-DrugBank.d5.s21.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s22" text="Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.">
        <entity id="DDI-DrugBank.d5.s22.e0" charOffset="65-74"
            type="brand" text="WELLBUTRIN"/>
        <entity id="DDI-DrugBank.d5.s22.e1" charOffset="94-107"
            type="group" text="antipsychotics"/>
        <entity id="DDI-DrugBank.d5.s22.e2" charOffset="116-130"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d5.s22.e3" charOffset="133-144"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d5.s22.e4" charOffset="156-163"
            type="group" text="steroids"/>
        <ddi id="DDI-DrugBank.d5.s22.d0" e1="DDI-DrugBank.d5.s22.e0"
            e2="DDI-DrugBank.d5.s22.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s22.d1" e1="DDI-DrugBank.d5.s22.e0"
            e2="DDI-DrugBank.d5.s22.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s22.d2" e1="DDI-DrugBank.d5.s22.e0"
            e2="DDI-DrugBank.d5.s22.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s22.d3" e1="DDI-DrugBank.d5.s22.e0"
            e2="DDI-DrugBank.d5.s22.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s23" text="Low initial dosing and small gradual dose increases should be employed."/>
    <sentence id="DDI-DrugBank.d5.s24" text="Nicotine Transdermal System: .">
        <entity id="DDI-DrugBank.d5.s24.e0" charOffset="0-7" type="drug" text="Nicotine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s25" text="Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.">
        <entity id="DDI-DrugBank.d5.s25.e0" charOffset="0-6" type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d5.s25.e1" charOffset="114-120"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d5.s25.e2" charOffset="162-168"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d5.s25.e3" charOffset="192-201"
            type="brand" text="WELLBUTRIN"/>
        <ddi id="DDI-DrugBank.d5.s25.d0" e1="DDI-DrugBank.d5.s25.e2"
            e2="DDI-DrugBank.d5.s25.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s26" text="The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)">
        <entity id="DDI-DrugBank.d5.s26.e0" charOffset="19-25"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d5.s26.e1" charOffset="49-58"
            type="brand" text="WELLBUTRIN"/>
        <ddi id="DDI-DrugBank.d5.s26.d0" e1="DDI-DrugBank.d5.s26.e0"
            e2="DDI-DrugBank.d5.s26.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s27" text="."/>
    <sentence id="DDI-DrugBank.d5.s28" text=""/>
    <sentence id="DDI-DrugBank.d463.s0" text="It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.">
        <entity id="DDI-DrugBank.d463.s0.e0" charOffset="23-45"
            type="drug" text="buspirone hydrochloride"/>
        <entity id="DDI-DrugBank.d463.s0.e1" charOffset="78-91"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d463.s0.e2" charOffset="146-158"
            type="drug" text="buspirone HCl"/>
        <entity id="DDI-DrugBank.d463.s0.e3" charOffset="176-193"
            type="group" text="psychotropic drugs"/>
        <entity id="DDI-DrugBank.d463.s0.e4" charOffset="241-253"
            type="drug" text="buspirone HCl"/>
        <ddi id="DDI-DrugBank.d463.s0.d0" e1="DDI-DrugBank.d463.s0.e0"
            e2="DDI-DrugBank.d463.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d463.s1" text="There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.">
        <entity id="DDI-DrugBank.d463.s1.e0" charOffset="59-81"
            type="drug" text="trazodone hydrochloride"/>
        <entity id="DDI-DrugBank.d463.s1.e1" charOffset="84-90"
            type="brand" text="Desyrel"/>
        <entity id="DDI-DrugBank.d463.s1.e2" charOffset="97-109"
            type="drug" text="buspirone HCl"/>
        <ddi id="DDI-DrugBank.d463.s1.d0" e1="DDI-DrugBank.d463.s1.e0"
            e2="DDI-DrugBank.d463.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d463.s1.d1" e1="DDI-DrugBank.d463.s1.e1"
            e2="DDI-DrugBank.d463.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d463.s2" text="In a similar study, attempting to replicate this finding, no interactive effect on hepatic transaminases was identified."/>
    <sentence id="DDI-DrugBank.d463.s3" text="In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.">
        <entity id="DDI-DrugBank.d463.s3.e0" charOffset="63-75"
            type="drug" text="buspirone HCl"/>
        <entity id="DDI-DrugBank.d463.s3.e1" charOffset="81-91"
            type="drug" text="haloperidol"/>
        <entity id="DDI-DrugBank.d463.s3.e2" charOffset="121-131"
            type="drug" text="haloperidol"/>
        <ddi id="DDI-DrugBank.d463.s3.d0" e1="DDI-DrugBank.d463.s3.e0"
            e2="DDI-DrugBank.d463.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d463.s4" text="The clinical significance of this finding is not clear."/>
    <sentence id="DDI-DrugBank.d463.s5" text="In vitro, buspirone does not displace tightly bound drugs like phenytoin, propranolol, and warfarin from serum proteins.">
        <entity id="DDI-DrugBank.d463.s5.e0" charOffset="10-18"
            type="drug" text="buspirone"/>
        <entity id="DDI-DrugBank.d463.s5.e1" charOffset="63-71"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d463.s5.e2" charOffset="74-84"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d463.s5.e3" charOffset="91-98"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d463.s6" text="However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.">
        <entity id="DDI-DrugBank.d463.s6.e0" charOffset="70-78"
            type="drug" text="buspirone"/>
        <entity id="DDI-DrugBank.d463.s6.e1" charOffset="131-138"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d463.s6.d0" e1="DDI-DrugBank.d463.s6.e0"
            e2="DDI-DrugBank.d463.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d463.s7" text="The patient was also chronically receiving phenytoin, phenobarbital, digoxin, and levothyroxine sodium.">
        <entity id="DDI-DrugBank.d463.s7.e0" charOffset="43-51"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d463.s7.e1" charOffset="54-66"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d463.s7.e2" charOffset="69-75"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d463.s7.e3" charOffset="82-101"
            type="drug" text="levothyroxine sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d463.s8" text="In vitro, buspirone may displace less firmly bound drugs like digoxin.">
        <entity id="DDI-DrugBank.d463.s8.e0" charOffset="10-18"
            type="drug" text="buspirone"/>
        <entity id="DDI-DrugBank.d463.s8.e1" charOffset="62-68"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d463.s8.d0" e1="DDI-DrugBank.d463.s8.e0"
            e2="DDI-DrugBank.d463.s8.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d463.s9" text="The clinical significance of this property is unknown."/>
    <sentence id="DDI-DrugBank.d72.s0" text="Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.">
        <entity id="DDI-DrugBank.d72.s0.e0" charOffset="0-11"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d72.s0.e1" charOffset="23-30"
            type="drug" text="busulfan"/>
        <ddi id="DDI-DrugBank.d72.s0.d0" e1="DDI-DrugBank.d72.s0.e0"
            e2="DDI-DrugBank.d72.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d72.s1" text="Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.">
        <entity id="DDI-DrugBank.d72.s1.e0" charOffset="0-10"
            type="drug" text="Fluconazole"/>
        <entity id="DDI-DrugBank.d72.s1.e1" charOffset="21-37"
            type="group" text="5-HT3 antiemetics"/>
        <entity id="DDI-DrugBank.d72.s1.e2" charOffset="39-49"
            type="drug" text="ondansetron"/>
        <entity id="DDI-DrugBank.d72.s1.e3" charOffset="52-57"
            type="brand" text="Zofran"/>
        <entity id="DDI-DrugBank.d72.s1.e4" charOffset="64-74"
            type="drug" text="granisetron"/>
        <entity id="DDI-DrugBank.d72.s1.e5" charOffset="77-82"
            type="brand" text="Kytril"/>
        <entity id="DDI-DrugBank.d72.s1.e6" charOffset="109-116"
            type="brand" text="BUSULFEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d72.s2" text="Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.">
        <entity id="DDI-DrugBank.d72.s2.e0" charOffset="0-8" type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d72.s2.e1" charOffset="37-44"
            type="drug" text="busulfan"/>
        <ddi id="DDI-DrugBank.d72.s2.d0" e1="DDI-DrugBank.d72.s2.e0"
            e2="DDI-DrugBank.d72.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d72.s3" text="Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.">
        <entity id="DDI-DrugBank.d72.s3.e0" charOffset="30-37"
            type="brand" text="BUSULFEX"/>
        <entity id="DDI-DrugBank.d72.s3.e1" charOffset="77-85"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d72.s3.e2" charOffset="105-112"
            type="brand" text="BUSULFEX"/>
        <entity id="DDI-DrugBank.d72.s3.e3" charOffset="206-214"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d72.s3.d0" e1="DDI-DrugBank.d72.s3.e0"
            e2="DDI-DrugBank.d72.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d72.s4" text="Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.">
        <entity id="DDI-DrugBank.d72.s4.e0" charOffset="8-15"
            type="drug" text="busulfan"/>
        <entity id="DDI-DrugBank.d72.s4.e1" charOffset="86-98"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d72.s4.e2" charOffset="140-147"
            type="brand" text="BUSULFEX"/>
        <entity id="DDI-DrugBank.d72.s4.e3" charOffset="171-178"
            type="drug" text="busulfan"/>
        <entity id="DDI-DrugBank.d72.s4.e4" charOffset="223-235"
            type="drug" text="acetaminophen"/>
        <ddi id="DDI-DrugBank.d72.s4.d0" e1="DDI-DrugBank.d72.s4.e1"
            e2="DDI-DrugBank.d72.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d184.s0" text="Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).">
        <entity id="DDI-DrugBank.d184.s0.e0" charOffset="87-100"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d184.s0.e1" charOffset="103-115"
            type="group" text="blood thinner"/>
        <entity id="DDI-DrugBank.d184.s0.e2" charOffset="120-132"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d184.s0.e3" charOffset="135-147"
            type="drug" text="corticotropin"/>
        <entity id="DDI-DrugBank.d184.s0.e4" charOffset="150-161"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d184.s0.e5" charOffset="209-248"
            type="group" text="central nervous system (CNS) depressants"/>
        <entity id="DDI-DrugBank.d184.s0.e6" charOffset="278-289"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d184.s0.e7" charOffset="340-356"
            type="drug" text="divalproex sodium"/>
        <entity id="DDI-DrugBank.d184.s0.e8" charOffset="359-371"
            type="drug" text="valproic acid"/>
        <entity id="DDI-DrugBank.d184.s0.e9" charOffset="401-412"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d184.s0.e10" charOffset="488-501"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d184.s0.e11" charOffset="514-522"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d184.s0.e12" charOffset="525-536"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d184.s0.e13" charOffset="583-596"
            type="group" text="contraceptives"/>
        <ddi id="DDI-DrugBank.d184.s0.d0" e1="DDI-DrugBank.d184.s0.e12"
            e2="DDI-DrugBank.d184.s0.e13" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d559.s0" text="The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.">
        <entity id="DDI-DrugBank.d559.s0.e0" charOffset="19-28"
            type="drug" text="butalbital"/>
        <entity id="DDI-DrugBank.d559.s0.e1" charOffset="49-82"
            type="group" text="monoamine oxidase (MAO) inhibitors"/>
        <ddi id="DDI-DrugBank.d559.s0.d0" e1="DDI-DrugBank.d559.s0.e0"
            e2="DDI-DrugBank.d559.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d559.s1" text="Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.">
        <entity id="DDI-DrugBank.d559.s1.e0" charOffset="0-9"
            type="drug" text="Butalbital"/>
        <entity id="DDI-DrugBank.d559.s1.e1" charOffset="12-24"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d559.s1.e2" charOffset="30-37"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d559.s1.e3" charOffset="73-90"
            type="group" text="narcotic analgesic"/>
        <entity id="DDI-DrugBank.d559.s1.e4" charOffset="94-100"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d559.s1.e5" charOffset="111-121"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d559.s1.e6" charOffset="124-136"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d559.s1.e7" charOffset="146-161"
            type="drug" text="chlordiazepoxide"/>
        <entity id="DDI-DrugBank.d559.s1.e8" charOffset="164-181"
            type="group" text="sedative-hypnotics"/>
        <entity id="DDI-DrugBank.d559.s1.e9" charOffset="193-207"
            type="group" text="CNS depressants"/>
        <ddi id="DDI-DrugBank.d559.s1.d0" e1="DDI-DrugBank.d559.s1.e0"
            e2="DDI-DrugBank.d559.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d1" e1="DDI-DrugBank.d559.s1.e0"
            e2="DDI-DrugBank.d559.s1.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d2" e1="DDI-DrugBank.d559.s1.e0"
            e2="DDI-DrugBank.d559.s1.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d3" e1="DDI-DrugBank.d559.s1.e0"
            e2="DDI-DrugBank.d559.s1.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d4" e1="DDI-DrugBank.d559.s1.e0"
            e2="DDI-DrugBank.d559.s1.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d5" e1="DDI-DrugBank.d559.s1.e0"
            e2="DDI-DrugBank.d559.s1.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d6" e1="DDI-DrugBank.d559.s1.e0"
            e2="DDI-DrugBank.d559.s1.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d7" e1="DDI-DrugBank.d559.s1.e1"
            e2="DDI-DrugBank.d559.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d8" e1="DDI-DrugBank.d559.s1.e1"
            e2="DDI-DrugBank.d559.s1.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d9" e1="DDI-DrugBank.d559.s1.e1"
            e2="DDI-DrugBank.d559.s1.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d10" e1="DDI-DrugBank.d559.s1.e1"
            e2="DDI-DrugBank.d559.s1.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d11" e1="DDI-DrugBank.d559.s1.e1"
            e2="DDI-DrugBank.d559.s1.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d12" e1="DDI-DrugBank.d559.s1.e1"
            e2="DDI-DrugBank.d559.s1.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d13" e1="DDI-DrugBank.d559.s1.e1"
            e2="DDI-DrugBank.d559.s1.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d14" e1="DDI-DrugBank.d559.s1.e2"
            e2="DDI-DrugBank.d559.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d15" e1="DDI-DrugBank.d559.s1.e2"
            e2="DDI-DrugBank.d559.s1.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d16" e1="DDI-DrugBank.d559.s1.e2"
            e2="DDI-DrugBank.d559.s1.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d17" e1="DDI-DrugBank.d559.s1.e2"
            e2="DDI-DrugBank.d559.s1.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d18" e1="DDI-DrugBank.d559.s1.e2"
            e2="DDI-DrugBank.d559.s1.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d19" e1="DDI-DrugBank.d559.s1.e2"
            e2="DDI-DrugBank.d559.s1.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d559.s1.d20" e1="DDI-DrugBank.d559.s1.e2"
            e2="DDI-DrugBank.d559.s1.e9" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d559.s2" text="Drug/Laboratory Test Interactions Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.">
        <entity id="DDI-DrugBank.d559.s2.e0" charOffset="34-46"
            type="drug" text="Acetaminophen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d80.s0" text="Potential drug interactions between Mentax (butenafine HCl cream) Cream, 1%, and other drugs have not been systematically evaluated.">
        <entity id="DDI-DrugBank.d80.s0.e0" charOffset="36-41"
            type="brand" text="Mentax"/>
        <entity id="DDI-DrugBank.d80.s0.e1" charOffset="44-57"
            type="drug" text="butenafine HCl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s0" text="Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.">
        <entity id="DDI-DrugBank.d246.s0.e0" charOffset="18-28"
            type="drug" text="butorphanol"/>
        <entity id="DDI-DrugBank.d246.s0.e1" charOffset="35-68"
            type="group" text="central nervous system depressants"/>
        <entity id="DDI-DrugBank.d246.s0.e2" charOffset="77-83"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d246.s0.e3" charOffset="86-97"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d246.s0.e4" charOffset="100-112"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d246.s0.e5" charOffset="119-132"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d246.s0.e6" charOffset="159-191"
            type="group" text="central nervous system depressant"/>
        <ddi id="DDI-DrugBank.d246.s0.d0" e1="DDI-DrugBank.d246.s0.e0"
            e2="DDI-DrugBank.d246.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d246.s0.d1" e1="DDI-DrugBank.d246.s0.e0"
            e2="DDI-DrugBank.d246.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d246.s0.d2" e1="DDI-DrugBank.d246.s0.e0"
            e2="DDI-DrugBank.d246.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d246.s0.d3" e1="DDI-DrugBank.d246.s0.e0"
            e2="DDI-DrugBank.d246.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d246.s0.d4" e1="DDI-DrugBank.d246.s0.e0"
            e2="DDI-DrugBank.d246.s0.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s1" text="When used concurrently with such drugs, the dose of butorphanol should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of opioids.">
        <entity id="DDI-DrugBank.d246.s1.e0" charOffset="52-62"
            type="drug" text="butorphanol"/>
        <entity id="DDI-DrugBank.d246.s1.e1" charOffset="231-237"
            type="group" text="opioids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s2" text="In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan.">
        <entity id="DDI-DrugBank.d246.s2.e0" charOffset="62-72"
            type="drug" text="butorphanol"/>
        <entity id="DDI-DrugBank.d246.s2.e1" charOffset="90-98"
            type="brand" text="STADOL NS"/>
        <entity id="DDI-DrugBank.d246.s2.e2" charOffset="180-190"
            type="drug" text="sumatriptan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s3" text="However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.">
        <entity id="DDI-DrugBank.d246.s3.e0" charOffset="73-83"
            type="drug" text="butorphanol"/>
        <entity id="DDI-DrugBank.d246.s3.e1" charOffset="179-187"
            type="brand" text="STADOL NS"/>
        <entity id="DDI-DrugBank.d246.s3.e2" charOffset="237-247"
            type="drug" text="sumatriptan"/>
        <ddi id="DDI-DrugBank.d246.s3.d0" e1="DDI-DrugBank.d246.s3.e1"
            e2="DDI-DrugBank.d246.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s4" text="(The two drugs were administered in opposite nostrils.)"/>
    <sentence id="DDI-DrugBank.d246.s5" text="When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.">
        <entity id="DDI-DrugBank.d246.s5.e0" charOffset="9-17"
            type="brand" text="STADOL NS"/>
        <entity id="DDI-DrugBank.d246.s5.e1" charOffset="57-67"
            type="drug" text="sumatriptan"/>
        <entity id="DDI-DrugBank.d246.s5.e2" charOffset="93-103"
            type="drug" text="butorphanol"/>
        <ddi id="DDI-DrugBank.d246.s5.d0" e1="DDI-DrugBank.d246.s5.e0"
            e2="DDI-DrugBank.d246.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s6" text="In neither case were the pharmacokinetics of sumatriptan affected by coadministration with STADOL NS.">
        <entity id="DDI-DrugBank.d246.s6.e0" charOffset="45-55"
            type="drug" text="sumatriptan"/>
        <entity id="DDI-DrugBank.d246.s6.e1" charOffset="91-99"
            type="brand" text="STADOL NS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s7" text="These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.">
        <entity id="DDI-DrugBank.d246.s7.e0" charOffset="51-59"
            type="brand" text="STADOL NS"/>
        <entity id="DDI-DrugBank.d246.s7.e1" charOffset="117-127"
            type="drug" text="sumatriptan"/>
        <ddi id="DDI-DrugBank.d246.s7.d0" e1="DDI-DrugBank.d246.s7.e0"
            e2="DDI-DrugBank.d246.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s8" text="The safety of using STADOL NS and IMITREX (sumatriptan) Nasal Spray during the same episode of migraine has not been established.">
        <entity id="DDI-DrugBank.d246.s8.e0" charOffset="20-28"
            type="brand" text="STADOL NS"/>
        <entity id="DDI-DrugBank.d246.s8.e1" charOffset="34-40"
            type="brand" text="IMITREX"/>
        <entity id="DDI-DrugBank.d246.s8.e2" charOffset="43-53"
            type="drug" text="sumatriptan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s9" text="However, it should be noted that both products are capable of producing transient increases in blood pressure."/>
    <sentence id="DDI-DrugBank.d246.s10" text="The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of cimetidine (300 mg QID).">
        <entity id="DDI-DrugBank.d246.s10.e0" charOffset="39-49"
            type="drug" text="butorphanol"/>
        <entity id="DDI-DrugBank.d246.s10.e1" charOffset="67-75"
            type="brand" text="STADOL NS"/>
        <entity id="DDI-DrugBank.d246.s10.e2" charOffset="122-131"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s11" text="Conversely, the administration of STADOL NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.">
        <entity id="DDI-DrugBank.d246.s11.e0" charOffset="34-42"
            type="brand" text="STADOL NS"/>
        <entity id="DDI-DrugBank.d246.s11.e1" charOffset="50-60"
            type="drug" text="butorphanol"/>
        <entity id="DDI-DrugBank.d246.s11.e2" charOffset="122-131"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s12" text="It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.">
        <entity id="DDI-DrugBank.d246.s12.e0" charOffset="34-44"
            type="drug" text="butorphanol"/>
        <entity id="DDI-DrugBank.d246.s12.e1" charOffset="126-137"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d246.s12.d0" e1="DDI-DrugBank.d246.s12.e0"
            e2="DDI-DrugBank.d246.s12.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s13" text="The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor (oxymetazoline), but the rate of absorption is decreased.">
        <entity id="DDI-DrugBank.d246.s13.e0" charOffset="16-24"
            type="brand" text="STADOL NS"/>
        <entity id="DDI-DrugBank.d246.s13.e1" charOffset="88-108"
            type="group" text="nasal vasoconstrictor"/>
        <entity id="DDI-DrugBank.d246.s13.e2" charOffset="111-123"
            type="drug" text="oxymetazoline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s14" text="Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.">
        <entity id="DDI-DrugBank.d246.s14.e0" charOffset="48-56"
            type="brand" text="STADOL NS"/>
        <entity id="DDI-DrugBank.d246.s14.e1" charOffset="122-142"
            type="group" text="nasal vasoconstrictor"/>
        <ddi id="DDI-DrugBank.d246.s14.d0" e1="DDI-DrugBank.d246.s14.e0"
            e2="DDI-DrugBank.d246.s14.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d246.s15" text="No information is available about the use of butorphanol concurrently with MAO inhibitors.">
        <entity id="DDI-DrugBank.d246.s15.e0" charOffset="45-55"
            type="drug" text="butorphanol"/>
        <entity id="DDI-DrugBank.d246.s15.e1" charOffset="75-88"
            type="group" text="MAO inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d282.s0" text="DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.">
        <entity id="DDI-DrugBank.d282.s0.e0" charOffset="0-7"
            type="brand" text="DOSTINEX"/>
        <entity id="DDI-DrugBank.d282.s0.e1" charOffset="78-91"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d282.s0.e2" charOffset="94-107"
            type="group" text="butyrophenones"/>
        <entity id="DDI-DrugBank.d282.s0.e3" charOffset="110-122"
            type="group" text="thioxanthines"/>
        <entity id="DDI-DrugBank.d282.s0.e4" charOffset="128-141"
            type="drug" text="metoclopramide"/>
        <ddi id="DDI-DrugBank.d282.s0.d0" e1="DDI-DrugBank.d282.s0.e0"
            e2="DDI-DrugBank.d282.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d282.s0.d1" e1="DDI-DrugBank.d282.s0.e0"
            e2="DDI-DrugBank.d282.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d282.s0.d2" e1="DDI-DrugBank.d282.s0.e0"
            e2="DDI-DrugBank.d282.s0.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d282.s0.d3" e1="DDI-DrugBank.d282.s0.e0"
            e2="DDI-DrugBank.d282.s0.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d89.s0" text="Cytochrome P450 1A2 (CYP1A2) is known to be the major enzyme involved in the metabolism of caffeine.">
        <entity id="DDI-DrugBank.d89.s0.e0" charOffset="91-98"
            type="drug" text="caffeine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d89.s1" text="Therefore, caffeine has the potential to interact with drugs that are substrates for CYP1A2, inhibit CYP1A2, or induce CYP1A2.">
        <entity id="DDI-DrugBank.d89.s1.e0" charOffset="11-18"
            type="drug" text="caffeine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d89.s2" text="Few data exist on drug interactions with caffeine in preterm neonates.">
        <entity id="DDI-DrugBank.d89.s2.e0" charOffset="41-48"
            type="drug" text="caffeine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d89.s3" text="Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).">
        <entity id="DDI-DrugBank.d89.s3.e0" charOffset="36-43"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d89.s3.e1" charOffset="126-133"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d89.s3.e2" charOffset="154-163"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d89.s3.e3" charOffset="169-180"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d89.s3.e4" charOffset="194-201"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d89.s3.e5" charOffset="273-280"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d89.s3.e6" charOffset="301-313"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d89.s3.e7" charOffset="319-327"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d89.s3.d0" e1="DDI-DrugBank.d89.s3.e0"
            e2="DDI-DrugBank.d89.s3.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d89.s3.d1" e1="DDI-DrugBank.d89.s3.e0"
            e2="DDI-DrugBank.d89.s3.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d89.s3.d2" e1="DDI-DrugBank.d89.s3.e4"
            e2="DDI-DrugBank.d89.s3.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d89.s3.d3" e1="DDI-DrugBank.d89.s3.e4"
            e2="DDI-DrugBank.d89.s3.e7" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d89.s4" text="Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.">
        <entity id="DDI-DrugBank.d89.s4.e0" charOffset="0-7" type="drug" text="Caffeine"/>
        <entity id="DDI-DrugBank.d89.s4.e1" charOffset="40-49"
            type="drug" text="ketoprofen"/>
        <ddi id="DDI-DrugBank.d89.s4.d0" e1="DDI-DrugBank.d89.s4.e0"
            e2="DDI-DrugBank.d89.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d89.s5" text="The clinical significance of this interaction in preterm neonates is not known."/>
    <sentence id="DDI-DrugBank.d89.s6" text="Interconversion between caffeine and theophylline has been reported in preterm neonates.">
        <entity id="DDI-DrugBank.d89.s6.e0" charOffset="24-31"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d89.s6.e1" charOffset="37-48"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d89.s7" text="The concurrent use of these drugs is not recommended."/>
    <sentence id="DDI-DrugBank.d98.s0" text="Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;">
        <entity id="DDI-DrugBank.d98.s0.e0" charOffset="17-35"
            type="group" text="vitamin D analogues"/>
        <entity id="DDI-DrugBank.d98.s0.e1" charOffset="38-47"
            type="drug" text="Vitamin D2"/>
        <entity id="DDI-DrugBank.d98.s0.e2" charOffset="50-59"
            type="drug" text="Vitamin D3"/>
        <entity id="DDI-DrugBank.d98.s0.e3" charOffset="62-71"
            type="drug" text="Calcitriol"/>
        <entity id="DDI-DrugBank.d98.s0.e4" charOffset="78-86"
            type="drug" text="Calcidiol"/>
        <entity id="DDI-DrugBank.d98.s0.e5" charOffset="90-103"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d98.s0.e6" charOffset="106-119"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d98.s0.e7" charOffset="174-193"
            type="group" text="fat soluble vitamins"/>
        <ddi id="DDI-DrugBank.d98.s0.d0" e1="DDI-DrugBank.d98.s0.e6"
            e2="DDI-DrugBank.d98.s0.e7" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s1" text="as such it may impair intestinal absorption of any of vitamin D.">
        <entity id="DDI-DrugBank.d98.s1.e0" charOffset="54-62"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s2" text="Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.">
        <entity id="DDI-DrugBank.d98.s2.e0" charOffset="0-8" type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d98.s2.e1" charOffset="10-22"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d98.s2.e2" charOffset="49-57"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d98.s2.e3" charOffset="62-74"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d98.s2.e4" charOffset="117-125"
            type="group" text="vitamin D"/>
        <entity id="DDI-DrugBank.d98.s2.e5" charOffset="171-180"
            type="drug" text="calcitriol"/>
        <ddi id="DDI-DrugBank.d98.s2.d0" e1="DDI-DrugBank.d98.s2.e2"
            e2="DDI-DrugBank.d98.s2.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d98.s2.d1" e1="DDI-DrugBank.d98.s2.e3"
            e2="DDI-DrugBank.d98.s2.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s3" text="Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.">
        <entity id="DDI-DrugBank.d98.s3.e0" charOffset="21-30"
            type="drug" text="calcitriol"/>
        <entity id="DDI-DrugBank.d98.s3.e1" charOffset="80-88"
            type="brand" text="Rocaltrol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s4" text="Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.">
        <entity id="DDI-DrugBank.d98.s4.e0" charOffset="0-8"
            type="group" text="Thiazides"/>
        <entity id="DDI-DrugBank.d98.s4.e1" charOffset="11-19"
            type="group" text="Thiazides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s5" text="Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.">
        <entity id="DDI-DrugBank.d98.s5.e0" charOffset="63-71"
            type="group" text="thiazides"/>
        <entity id="DDI-DrugBank.d98.s5.e1" charOffset="78-86"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d98.s5.d0" e1="DDI-DrugBank.d98.s5.e0"
            e2="DDI-DrugBank.d98.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s6" text="Therefore, precaution should be taken when coadministration is necessary."/>
    <sentence id="DDI-DrugBank.d98.s7" text="Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.">
        <entity id="DDI-DrugBank.d98.s7.e0" charOffset="0-8"
            type="group" text="Digitalis"/>
        <entity id="DDI-DrugBank.d98.s7.e1" charOffset="11-19"
            type="group" text="Vitamin D"/>
        <entity id="DDI-DrugBank.d98.s7.e2" charOffset="95-103"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d98.s7.d0" e1="DDI-DrugBank.d98.s7.e1"
            e2="DDI-DrugBank.d98.s7.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s8" text="Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.">
        <entity id="DDI-DrugBank.d98.s8.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d98.s8.e1" charOffset="14-25"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d98.s8.e2" charOffset="79-87"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d98.s8.d0" e1="DDI-DrugBank.d98.s8.e1"
            e2="DDI-DrugBank.d98.s8.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s9" text="Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.">
        <entity id="DDI-DrugBank.d98.s9.e0" charOffset="133-144"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s10" text="However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.">
        <entity id="DDI-DrugBank.d98.s10.e0" charOffset="45-56"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d98.s10.e1" charOffset="63-71"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s11" text="Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.">
        <entity id="DDI-DrugBank.d98.s11.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d98.s11.e1" charOffset="72-90"
            type="group" text="vitamin D analogues"/>
        <entity id="DDI-DrugBank.d98.s11.e2" charOffset="131-145"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d98.s11.d0" e1="DDI-DrugBank.d98.s11.e1"
            e2="DDI-DrugBank.d98.s11.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s12" text="Phosphate-Binding Agents: Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.">
        <entity id="DDI-DrugBank.d98.s12.e0" charOffset="32-40"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s13" text="Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.">
        <entity id="DDI-DrugBank.d98.s13.e0" charOffset="0-8"
            type="group" text="Vitamin D"/>
        <entity id="DDI-DrugBank.d98.s13.e1" charOffset="46-64"
            type="group" text="vitamin D analogues"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s14" text="Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.">
        <entity id="DDI-DrugBank.d98.s14.e0" charOffset="0-6"
            type="drug" text="Calcium"/>
        <entity id="DDI-DrugBank.d98.s14.e1" charOffset="55-61"
            type="drug" text="calcium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s15" text="Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.">
        <entity id="DDI-DrugBank.d98.s15.e0" charOffset="0-8"
            type="drug" text="Magnesium"/>
        <entity id="DDI-DrugBank.d98.s15.e1" charOffset="11-19"
            type="drug" text="Magnesium"/>
        <entity id="DDI-DrugBank.d98.s15.e2" charOffset="50-57"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d98.s15.e3" charOffset="140-148"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d98.s15.d0" e1="DDI-DrugBank.d98.s15.e1"
            e2="DDI-DrugBank.d98.s15.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d98.s15.d1" e1="DDI-DrugBank.d98.s15.e2"
            e2="DDI-DrugBank.d98.s15.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s0" text="Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;">
        <entity id="DDI-DrugBank.d384.s0.e0" charOffset="17-35"
            type="group" text="vitamin D analogues"/>
        <entity id="DDI-DrugBank.d384.s0.e1" charOffset="38-47"
            type="drug" text="Vitamin D2"/>
        <entity id="DDI-DrugBank.d384.s0.e2" charOffset="50-59"
            type="drug" text="Vitamin D3"/>
        <entity id="DDI-DrugBank.d384.s0.e3" charOffset="62-71"
            type="drug" text="Calcitriol"/>
        <entity id="DDI-DrugBank.d384.s0.e4" charOffset="78-86"
            type="drug" text="Calcidiol"/>
        <entity id="DDI-DrugBank.d384.s0.e5" charOffset="90-103"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d384.s0.e6" charOffset="106-119"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d384.s0.e7" charOffset="174-193"
            type="group" text="fat soluble vitamins"/>
        <ddi id="DDI-DrugBank.d384.s0.d0" e1="DDI-DrugBank.d384.s0.e6"
            e2="DDI-DrugBank.d384.s0.e7" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s1" text="as such it may impair intestinal absorption of any of vitamin D.">
        <entity id="DDI-DrugBank.d384.s1.e0" charOffset="54-62"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s2" text="Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.">
        <entity id="DDI-DrugBank.d384.s2.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d384.s2.e1" charOffset="10-22"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d384.s2.e2" charOffset="49-57"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d384.s2.e3" charOffset="62-74"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d384.s2.e4" charOffset="117-125"
            type="group" text="vitamin D"/>
        <entity id="DDI-DrugBank.d384.s2.e5" charOffset="171-180"
            type="drug" text="calcitriol"/>
        <ddi id="DDI-DrugBank.d384.s2.d0" e1="DDI-DrugBank.d384.s2.e2"
            e2="DDI-DrugBank.d384.s2.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d384.s2.d1" e1="DDI-DrugBank.d384.s2.e3"
            e2="DDI-DrugBank.d384.s2.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s3" text="Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.">
        <entity id="DDI-DrugBank.d384.s3.e0" charOffset="21-30"
            type="drug" text="calcitriol"/>
        <entity id="DDI-DrugBank.d384.s3.e1" charOffset="80-88"
            type="brand" text="Rocaltrol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s4" text="Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.">
        <entity id="DDI-DrugBank.d384.s4.e0" charOffset="0-8"
            type="group" text="Thiazides"/>
        <entity id="DDI-DrugBank.d384.s4.e1" charOffset="11-19"
            type="group" text="Thiazides"/>
        <entity id="DDI-DrugBank.d384.s4.e2" charOffset="75-81"
            type="drug" text="calcium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s5" text="Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.">
        <entity id="DDI-DrugBank.d384.s5.e0" charOffset="63-71"
            type="group" text="thiazides"/>
        <entity id="DDI-DrugBank.d384.s5.e1" charOffset="78-86"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d384.s5.d0" e1="DDI-DrugBank.d384.s5.e0"
            e2="DDI-DrugBank.d384.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s6" text="Therefore, precaution should be taken when coadministration is necessary."/>
    <sentence id="DDI-DrugBank.d384.s7" text="Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.">
        <entity id="DDI-DrugBank.d384.s7.e0" charOffset="0-8"
            type="group" text="Digitalis"/>
        <entity id="DDI-DrugBank.d384.s7.e1" charOffset="11-19"
            type="group" text="Vitamin D"/>
        <entity id="DDI-DrugBank.d384.s7.e2" charOffset="95-103"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d384.s7.d0" e1="DDI-DrugBank.d384.s7.e1"
            e2="DDI-DrugBank.d384.s7.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s8" text="Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.">
        <entity id="DDI-DrugBank.d384.s8.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d384.s8.e1" charOffset="14-25"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d384.s8.e2" charOffset="79-87"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d384.s8.d0" e1="DDI-DrugBank.d384.s8.e1"
            e2="DDI-DrugBank.d384.s8.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s9" text="Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.">
        <entity id="DDI-DrugBank.d384.s9.e0" charOffset="133-144"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s10" text="However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.">
        <entity id="DDI-DrugBank.d384.s10.e0" charOffset="45-56"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d384.s10.e1" charOffset="63-71"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s11" text="Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.">
        <entity id="DDI-DrugBank.d384.s11.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d384.s11.e1" charOffset="72-90"
            type="group" text="vitamin D analogues"/>
        <entity id="DDI-DrugBank.d384.s11.e2" charOffset="131-145"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d384.s11.d0" e1="DDI-DrugBank.d384.s11.e1"
            e2="DDI-DrugBank.d384.s11.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s12" text="Phosphate-Binding Agents: Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.">
        <entity id="DDI-DrugBank.d384.s12.e0" charOffset="32-40"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s13" text="Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.">
        <entity id="DDI-DrugBank.d384.s13.e0" charOffset="0-8"
            type="group" text="Vitamin D"/>
        <entity id="DDI-DrugBank.d384.s13.e1" charOffset="46-64"
            type="group" text="vitamin D analogues"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s14" text="Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.">
        <entity id="DDI-DrugBank.d384.s14.e0" charOffset="0-6"
            type="drug" text="Calcium"/>
        <entity id="DDI-DrugBank.d384.s14.e1" charOffset="55-61"
            type="drug" text="calcium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d384.s15" text="Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.">
        <entity id="DDI-DrugBank.d384.s15.e0" charOffset="0-8"
            type="drug" text="Magnesium"/>
        <entity id="DDI-DrugBank.d384.s15.e1" charOffset="11-19"
            type="drug" text="Magnesium"/>
        <entity id="DDI-DrugBank.d384.s15.e2" charOffset="50-57"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d384.s15.e3" charOffset="140-148"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d384.s15.d0" e1="DDI-DrugBank.d384.s15.e1"
            e2="DDI-DrugBank.d384.s15.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d384.s15.d1" e1="DDI-DrugBank.d384.s15.e2"
            e2="DDI-DrugBank.d384.s15.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d494.s0" text="Concomitant use with other calcium-containing medicines (including antacids) may cause too much calcium in the blood or urine, which may increase the chance of side effects.">
        <entity id="DDI-DrugBank.d494.s0.e0" charOffset="27-33"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d494.s0.e1" charOffset="67-74"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d494.s0.e2" charOffset="96-102"
            type="drug" text="calcium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d494.s1" text="Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.">
        <entity id="DDI-DrugBank.d494.s1.e0" charOffset="6-20"
            type="drug" text="calcium acetate"/>
        <entity id="DDI-DrugBank.d494.s1.e1" charOffset="27-46"
            type="group" text="digitalis glycosides"/>
        <entity id="DDI-DrugBank.d494.s1.e2" charOffset="99-105"
            type="drug" text="calcium"/>
        <ddi id="DDI-DrugBank.d494.s1.d0" e1="DDI-DrugBank.d494.s1.e0"
            e2="DDI-DrugBank.d494.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d406.s0" text="May interact with cefamandole naftate, cephalothin sodium, magnesium sulfate, prednisolone sodium succinate, and prochlorperazine edisylate.">
        <entity id="DDI-DrugBank.d406.s0.e0" charOffset="18-36"
            type="drug" text="cefamandole naftate"/>
        <entity id="DDI-DrugBank.d406.s0.e1" charOffset="39-56"
            type="drug" text="cephalothin sodium"/>
        <entity id="DDI-DrugBank.d406.s0.e2" charOffset="59-75"
            type="drug" text="magnesium sulfate"/>
        <entity id="DDI-DrugBank.d406.s0.e3" charOffset="78-106"
            type="drug" text="prednisolone sodium succinate"/>
        <entity id="DDI-DrugBank.d406.s0.e4" charOffset="113-138"
            type="drug" text="prochlorperazine edisylate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d547.s0" text="No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).">
        <entity id="DDI-DrugBank.d547.s0.e0" charOffset="66-86"
            type="drug" text="candesartan cilexetil"/>
        <entity id="DDI-DrugBank.d547.s0.e1" charOffset="119-127"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d547.s0.e2" charOffset="130-139"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d547.s0.e3" charOffset="142-148"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d547.s0.e4" charOffset="151-158"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d547.s0.e5" charOffset="161-179"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d547.s0.e6" charOffset="191-204"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d547.s0.e7" charOffset="243-251"
            type="drug" text="enalapril"/>
    </sentence>
    <sentence id="DDI-DrugBank.d547.s1" text="Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.">
        <entity id="DDI-DrugBank.d547.s1.e0" charOffset="8-18"
            type="drug" text="candesartan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d547.s2" text="Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.">
        <entity id="DDI-DrugBank.d547.s2.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d547.s2.e1" charOffset="38-44"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d547.s2.e2" charOffset="130-136"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d547.s2.e3" charOffset="143-156"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d547.s2.e4" charOffset="173-207"
            type="group" text="angiotensin II receptor antagonists"/>
        <ddi id="DDI-DrugBank.d547.s2.d0" e1="DDI-DrugBank.d547.s2.e2"
            e2="DDI-DrugBank.d547.s2.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d547.s2.d1" e1="DDI-DrugBank.d547.s2.e2"
            e2="DDI-DrugBank.d547.s2.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d547.s3" text="An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.">
        <entity id="DDI-DrugBank.d547.s3.e0" charOffset="21-27"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d547.s3.e1" charOffset="98-104"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d547.s3.e2" charOffset="111-117"
            type="brand" text="ATACAND"/>
        <entity id="DDI-DrugBank.d547.s3.e3" charOffset="151-157"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d547.s3.d0" e1="DDI-DrugBank.d547.s3.e1"
            e2="DDI-DrugBank.d547.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d88.s0" text="Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.">
        <entity id="DDI-DrugBank.d88.s0.e0" charOffset="0-6"
            type="group" text="Antacid"/>
        <entity id="DDI-DrugBank.d88.s0.e1" charOffset="26-43"
            type="drug" text="aluminum hydroxide"/>
        <entity id="DDI-DrugBank.d88.s0.e2" charOffset="50-68"
            type="drug" text="magnesium hydroxide"/>
        <entity id="DDI-DrugBank.d88.s0.e3" charOffset="81-87"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d88.s0.e4" charOffset="90-95"
            type="brand" text="Maalox"/>
        <entity id="DDI-DrugBank.d88.s0.e5" charOffset="126-137"
            type="drug" text="capecitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d88.s1" text="There was a small increase in plasma concentrations of capecitabine and one metabolite (5-DFCR);">
        <entity id="DDI-DrugBank.d88.s1.e0" charOffset="55-66"
            type="drug" text="capecitabine"/>
        <entity id="DDI-DrugBank.d88.s1.e1" charOffset="88-93"
            type="drug_n" text="5-DFCR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d88.s2" text="there was no effect on the 3 major metabolites (5-DFUR, 5-FU and FBAL).">
        <entity id="DDI-DrugBank.d88.s2.e0" charOffset="48-53"
            type="drug_n" text="5-DFUR"/>
        <entity id="DDI-DrugBank.d88.s2.e1" charOffset="56-59"
            type="drug_n" text="5-FU"/>
        <entity id="DDI-DrugBank.d88.s2.e2" charOffset="65-68"
            type="drug_n" text="FBAL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d88.s3" text="Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.">
        <entity id="DDI-DrugBank.d88.s3.e0" charOffset="0-22"
            type="group" text="Coumarin Anticoagulants"/>
        <entity id="DDI-DrugBank.d88.s3.e1" charOffset="109-120"
            type="drug" text="capecitabine"/>
        <entity id="DDI-DrugBank.d88.s3.e2" charOffset="141-174"
            type="group" text="coumarin-derivative anticoagulants"/>
        <entity id="DDI-DrugBank.d88.s3.e3" charOffset="184-191"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d88.s3.e4" charOffset="197-209"
            type="drug" text="phenprocoumon"/>
        <ddi id="DDI-DrugBank.d88.s3.d0" e1="DDI-DrugBank.d88.s3.e1"
            e2="DDI-DrugBank.d88.s3.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d88.s3.d1" e1="DDI-DrugBank.d88.s3.e1"
            e2="DDI-DrugBank.d88.s3.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d88.s4" text="Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).">
        <entity id="DDI-DrugBank.d88.s4.e0" charOffset="16-49"
            type="group" text="coumarin-derivative anticoagulants"/>
        <entity id="DDI-DrugBank.d88.s4.e1" charOffset="70-81"
            type="drug" text="capecitabine"/>
        <ddi id="DDI-DrugBank.d88.s4.d0" e1="DDI-DrugBank.d88.s4.e0"
            e2="DDI-DrugBank.d88.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d88.s5" text="Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.">
        <entity id="DDI-DrugBank.d88.s5.e0" charOffset="0-9" type="drug" text="Leucovorin"/>
        <entity id="DDI-DrugBank.d88.s5.e1" charOffset="33-46"
            type="drug" text="5-fluorouracil"/>
        <entity id="DDI-DrugBank.d88.s5.e2" charOffset="97-106"
            type="drug" text="leucovorin"/>
        <ddi id="DDI-DrugBank.d88.s5.d0" e1="DDI-DrugBank.d88.s5.e1"
            e2="DDI-DrugBank.d88.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d88.s6" text="Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.">
        <entity id="DDI-DrugBank.d88.s6.e0" charOffset="116-125"
            type="drug" text="leucovorin"/>
        <entity id="DDI-DrugBank.d88.s6.e1" charOffset="131-142"
            type="drug" text="fluorouracil"/>
        <ddi id="DDI-DrugBank.d88.s6.d0" e1="DDI-DrugBank.d88.s6.e0"
            e2="DDI-DrugBank.d88.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s0" text="Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.">
        <entity id="DDI-DrugBank.d175.s0.e0" charOffset="26-33"
            type="group" text="Diuretic"/>
        <entity id="DDI-DrugBank.d175.s0.e1" charOffset="56-64"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d175.s0.e2" charOffset="95-102"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d175.s0.e3" charOffset="338-346"
            type="drug" text="captopril"/>
        <ddi id="DDI-DrugBank.d175.s0.d0" e1="DDI-DrugBank.d175.s0.e1"
            e2="DDI-DrugBank.d175.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s1" text="The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).">
        <entity id="DDI-DrugBank.d175.s1.e0" charOffset="44-52"
            type="drug" text="captopril"/>
        <entity id="DDI-DrugBank.d175.s1.e1" charOffset="99-106"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d175.s1.e2" charOffset="199-207"
            type="drug" text="captopril"/>
        <entity id="DDI-DrugBank.d175.s1.e3" charOffset="210-218"
            type="drug" text="captopril"/>
        <ddi id="DDI-DrugBank.d175.s1.d0" e1="DDI-DrugBank.d175.s1.e0"
            e2="DDI-DrugBank.d175.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s2" text="Alternatively, provide medical supervision for at least one hour after the initial dose."/>
    <sentence id="DDI-DrugBank.d175.s3" text="If hypotension occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline."/>
    <sentence id="DDI-DrugBank.d175.s4" text="This transient hypotensive response is not a contraindication to further doses which can be given without difficulty once the blood pressure has increased after volume expansion."/>
    <sentence id="DDI-DrugBank.d175.s5" text="Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for heart failure are not available;">
        <entity id="DDI-DrugBank.d175.s5.e0" charOffset="83-94"
            type="group" text="vasodilators"/>
        <entity id="DDI-DrugBank.d175.s5.e1" charOffset="118-126"
            type="drug" text="captopril"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s6" text="therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.">
        <entity id="DDI-DrugBank.d175.s6.e0" charOffset="11-23"
            type="drug" text="nitroglycerin"/>
        <entity id="DDI-DrugBank.d175.s6.e1" charOffset="34-41"
            type="group" text="nitrates"/>
        <entity id="DDI-DrugBank.d175.s6.e2" charOffset="174-182"
            type="drug" text="captopril"/>
        <ddi id="DDI-DrugBank.d175.s6.d0" e1="DDI-DrugBank.d175.s6.e0"
            e2="DDI-DrugBank.d175.s6.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d175.s6.d1" e1="DDI-DrugBank.d175.s6.e1"
            e2="DDI-DrugBank.d175.s6.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s7" text="If resumed during captopril therapy, such agents should be administered cautiously, and perhaps at lower dosage.">
        <entity id="DDI-DrugBank.d175.s7.e0" charOffset="18-26"
            type="drug" text="captopril"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s8" text="Agents Causing Renin Release Captopril's effect will be augmented by antihypertensive agents that cause renin release.">
        <entity id="DDI-DrugBank.d175.s8.e0" charOffset="29-37"
            type="drug" text="Captopril"/>
        <entity id="DDI-DrugBank.d175.s8.e1" charOffset="69-91"
            type="group" text="antihypertensive agents"/>
        <ddi id="DDI-DrugBank.d175.s8.d0" e1="DDI-DrugBank.d175.s8.e0"
            e2="DDI-DrugBank.d175.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s9" text="For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system.">
        <entity id="DDI-DrugBank.d175.s9.e0" charOffset="13-21"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d175.s9.e1" charOffset="30-38"
            type="group" text="thiazides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s10" text="Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics.">
        <entity id="DDI-DrugBank.d175.s10.e0" charOffset="148-156"
            type="drug" text="captopril"/>
        <entity id="DDI-DrugBank.d175.s10.e1" charOffset="172-180"
            type="group" text="diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s11" text="Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution.">
        <entity id="DDI-DrugBank.d175.s11.e0" charOffset="56-81"
            type="group" text="ganglionic blocking agents"/>
        <entity id="DDI-DrugBank.d175.s11.e1" charOffset="86-118"
            type="group" text="adrenergic neuron blocking agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s12" text="Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.">
        <entity id="DDI-DrugBank.d175.s12.e0" charOffset="0-29"
            type="group" text="Beta-adrenergic blocking drugs"/>
        <entity id="DDI-DrugBank.d175.s12.e1" charOffset="75-83"
            type="drug" text="captopril"/>
        <ddi id="DDI-DrugBank.d175.s12.d0" e1="DDI-DrugBank.d175.s12.e0"
            e2="DDI-DrugBank.d175.s12.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s13" text="Agents Increasing Serum Potassium Since captopril decreases aldosterone production, elevation of serum potassium may occur.">
        <entity id="DDI-DrugBank.d175.s13.e0" charOffset="40-48"
            type="drug" text="captopril"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s14" text="Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.">
        <entity id="DDI-DrugBank.d175.s14.e0" charOffset="0-26"
            type="group" text="Potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d175.s14.e1" charOffset="36-49"
            type="drug" text="spironolactone"/>
        <entity id="DDI-DrugBank.d175.s14.e2" charOffset="52-62"
            type="drug" text="triamterene"/>
        <entity id="DDI-DrugBank.d175.s14.e3" charOffset="68-76"
            type="drug" text="amiloride"/>
        <entity id="DDI-DrugBank.d175.s14.e4" charOffset="82-90"
            type="drug" text="potassium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s15" text="Salt substitutes containing potassium should also be used with caution.">
        <entity id="DDI-DrugBank.d175.s15.e0" charOffset="28-36"
            type="drug" text="potassium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s16" text="Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.">
        <entity id="DDI-DrugBank.d175.s16.e0" charOffset="75-86"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d175.s16.e1" charOffset="130-138"
            type="drug" text="captopril"/>
        <ddi id="DDI-DrugBank.d175.s16.d0" e1="DDI-DrugBank.d175.s16.e0"
            e2="DDI-DrugBank.d175.s16.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s17" text="Other nonsteroidal anti-inflammatory agents (e.g., aspirin) may also have this effect.">
        <entity id="DDI-DrugBank.d175.s17.e0" charOffset="6-42"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d175.s17.e1" charOffset="51-57"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s18" text="Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.">
        <entity id="DDI-DrugBank.d175.s18.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d175.s18.e1" charOffset="25-31"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d175.s18.e2" charOffset="56-62"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d175.s18.e3" charOffset="126-132"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d175.s18.e4" charOffset="138-150"
            type="group" text="ACE inhibitor"/>
        <ddi id="DDI-DrugBank.d175.s18.d0" e1="DDI-DrugBank.d175.s18.e3"
            e2="DDI-DrugBank.d175.s18.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s19" text="These drugs should be coad-ministered with caution and frequent monitoring of serum lithium levels is recommended.">
        <entity id="DDI-DrugBank.d175.s19.e0" charOffset="84-90"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s20" text="If a diuretic is also used, it may increase the risk of lithium toxicity.">
        <entity id="DDI-DrugBank.d175.s20.e0" charOffset="5-12"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d175.s20.e1" charOffset="56-62"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d175.s20.d0" e1="DDI-DrugBank.d175.s20.e0"
            e2="DDI-DrugBank.d175.s20.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s21" text="Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found.">
        <entity id="DDI-DrugBank.d175.s21.e0" charOffset="0-17"
            type="group" text="Cardiac Glycosides"/>
        <entity id="DDI-DrugBank.d175.s21.e1" charOffset="102-110"
            type="drug" text="captopril"/>
        <entity id="DDI-DrugBank.d175.s21.e2" charOffset="112-118"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s22" text="Loop Diuretics: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.">
        <entity id="DDI-DrugBank.d175.s22.e0" charOffset="0-13"
            type="group" text="Loop Diuretics"/>
        <entity id="DDI-DrugBank.d175.s22.e1" charOffset="16-25"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d175.s22.e2" charOffset="58-66"
            type="drug" text="captopril"/>
        <entity id="DDI-DrugBank.d175.s22.e3" charOffset="107-115"
            type="drug" text="captopril"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s23" text="Allopurinol: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allopurinol were administered concomitantly for 6 days.">
        <entity id="DDI-DrugBank.d175.s23.e0" charOffset="0-10"
            type="drug" text="Allopurinol"/>
        <entity id="DDI-DrugBank.d175.s23.e1" charOffset="108-116"
            type="drug" text="captopril"/>
        <entity id="DDI-DrugBank.d175.s23.e2" charOffset="122-132"
            type="drug" text="allopurinol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d175.s24" text="Drug/Laboratory Test Interaction Captopril may cause a false-positive urine test for acetone.">
        <entity id="DDI-DrugBank.d175.s24.e0" charOffset="33-41"
            type="drug" text="Captopril"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s0" text="Clinically meaningful drug interactions have occurred with concomitant medications and include, but are not limited to the following: Agents Highly Bound to Plasma Protein Carbamazepine is not highly bound to plasma proteins;">
        <entity id="DDI-DrugBank.d94.s0.e0" charOffset="172-184"
            type="drug" text="Carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s1" text="therefore, administration of EQUETROTM to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.">
        <entity id="DDI-DrugBank.d94.s1.e0" charOffset="29-37"
            type="brand" text="EQUETROTM"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s2" text="Agents that Inhibit Cytochrome P450 Isoenzymes and/or Epoxide Hydrolase Carbamazepine is metabolized mainly by cytochrome P450 (CYP) 3A4 to the active carbamazepine 10,11-epoxide, which is further metabolized to the trans-diol by epoxide hydrolase.">
        <entity id="DDI-DrugBank.d94.s2.e0" charOffset="72-84"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d94.s2.e1" charOffset="151-177"
            type="drug" text="carbamazepine 10,11-epoxide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s3" text="Therefore, the potential exists for interaction between carbamazepine and any agent that inhibits CYP3A4 and/or epoxide hydrolase.">
        <entity id="DDI-DrugBank.d94.s3.e0" charOffset="56-68"
            type="drug" text="carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s4" text="Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.">
        <entity id="DDI-DrugBank.d94.s4.e0" charOffset="102-110"
            type="brand" text="EQUETROTM"/>
        <entity id="DDI-DrugBank.d94.s4.e1" charOffset="131-143"
            type="drug" text="Acetazolamide"/>
        <entity id="DDI-DrugBank.d94.s4.e2" charOffset="146-162"
            type="group" text="azole antifungals"/>
        <entity id="DDI-DrugBank.d94.s4.e3" charOffset="165-174"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d94.s4.e4" charOffset="177-190"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d94.s4.e5" charOffset="196-207"
            type="drug" text="dalfopristin"/>
        <entity id="DDI-DrugBank.d94.s4.e6" charOffset="210-216"
            type="drug" text="danazol"/>
        <entity id="DDI-DrugBank.d94.s4.e7" charOffset="219-229"
            type="drug" text="delavirdine"/>
        <entity id="DDI-DrugBank.d94.s4.e8" charOffset="232-240"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d94.s4.e9" charOffset="243-254"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d94.s4.e10" charOffset="260-269"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d94.s4.e11" charOffset="272-282"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d94.s4.e12" charOffset="303-311"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d94.s4.e13" charOffset="314-325"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d94.s4.e14" charOffset="328-339"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d94.s4.e15" charOffset="342-351"
            type="drug" text="loratadine"/>
        <entity id="DDI-DrugBank.d94.s4.e16" charOffset="354-363"
            type="drug" text="nefazodone"/>
        <entity id="DDI-DrugBank.d94.s4.e17" charOffset="366-376"
            type="drug" text="niacinamide"/>
        <entity id="DDI-DrugBank.d94.s4.e18" charOffset="379-390"
            type="drug" text="nicotinamide"/>
        <entity id="DDI-DrugBank.d94.s4.e19" charOffset="393-411"
            type="group" text="protease inhibitors"/>
        <entity id="DDI-DrugBank.d94.s4.e20" charOffset="414-425"
            type="drug" text="propoxyphene"/>
        <entity id="DDI-DrugBank.d94.s4.e21" charOffset="428-434"
            type="drug" text="quinine"/>
        <entity id="DDI-DrugBank.d94.s4.e22" charOffset="437-448"
            type="drug" text="quinupristin"/>
        <entity id="DDI-DrugBank.d94.s4.e23" charOffset="451-464"
            type="drug" text="troleandomycin"/>
        <entity id="DDI-DrugBank.d94.s4.e24" charOffset="467-475"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d94.s4.e25" charOffset="481-489"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d94.s4.e26" charOffset="492-499"
            type="drug" text="zileuton"/>
        <ddi id="DDI-DrugBank.d94.s4.d0" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d1" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d2" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d3" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d4" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d5" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d6" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d7" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d8" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d9" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e10" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d10" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e11" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d11" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e12" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d12" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e13" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d13" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e14" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d14" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e15" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d15" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d16" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e17" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d17" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e18" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d18" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e19" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d19" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e20" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d20" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e21" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d21" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e22" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d22" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e23" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d23" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e24" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d24" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e25" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s4.d25" e1="DDI-DrugBank.d94.s4.e0"
            e2="DDI-DrugBank.d94.s4.e26" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s5" text="Thus, if a patient has been titrated to a stable dosage of EQUETROTM, and then begins a course of treatment with one of these CYP3A4 or epoxide hydrolase inhibitors, it is reasonable to expect that a dose reduction for EQUETROTM may be necessary.">
        <entity id="DDI-DrugBank.d94.s5.e0" charOffset="59-67"
            type="brand" text="EQUETROTM"/>
        <entity id="DDI-DrugBank.d94.s5.e1" charOffset="219-227"
            type="brand" text="EQUETROTM"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s6" text="Agents that Induce Cytochrome P450 Isoenzymes Carbamazepine is metabolized by CYP3A4.">
        <entity id="DDI-DrugBank.d94.s6.e0" charOffset="46-58"
            type="drug" text="Carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s7" text="Therefore, the potential exists for interaction between carbamazepine and any agent that induces CYP3A4.">
        <entity id="DDI-DrugBank.d94.s7.e0" charOffset="56-68"
            type="drug" text="carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s8" text="Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.">
        <entity id="DDI-DrugBank.d94.s8.e0" charOffset="97-105"
            type="brand" text="EQUETROTM"/>
        <entity id="DDI-DrugBank.d94.s8.e1" charOffset="126-134"
            type="drug" text="Cisplatin"/>
        <entity id="DDI-DrugBank.d94.s8.e2" charOffset="137-151"
            type="drug" text="doxorubicin HCL"/>
        <entity id="DDI-DrugBank.d94.s8.e3" charOffset="154-162"
            type="drug" text="felbamate"/>
        <entity id="DDI-DrugBank.d94.s8.e4" charOffset="165-172"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d94.s8.e5" charOffset="175-187"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d94.s8.e6" charOffset="190-198"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d94.s8.e7" charOffset="204-212"
            type="drug" text="primidone"/>
        <entity id="DDI-DrugBank.d94.s8.e8" charOffset="215-226"
            type="drug" text="methsuximide"/>
        <entity id="DDI-DrugBank.d94.s8.e9" charOffset="233-244"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d94.s8.e10" charOffset="305-313"
            type="brand" text="EQUETROTM"/>
        <entity id="DDI-DrugBank.d94.s8.e11" charOffset="441-449"
            type="brand" text="EQUETROTM"/>
        <ddi id="DDI-DrugBank.d94.s8.d0" e1="DDI-DrugBank.d94.s8.e0"
            e2="DDI-DrugBank.d94.s8.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s8.d1" e1="DDI-DrugBank.d94.s8.e0"
            e2="DDI-DrugBank.d94.s8.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s8.d2" e1="DDI-DrugBank.d94.s8.e0"
            e2="DDI-DrugBank.d94.s8.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s8.d3" e1="DDI-DrugBank.d94.s8.e0"
            e2="DDI-DrugBank.d94.s8.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s8.d4" e1="DDI-DrugBank.d94.s8.e0"
            e2="DDI-DrugBank.d94.s8.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s8.d5" e1="DDI-DrugBank.d94.s8.e0"
            e2="DDI-DrugBank.d94.s8.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s8.d6" e1="DDI-DrugBank.d94.s8.e0"
            e2="DDI-DrugBank.d94.s8.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s8.d7" e1="DDI-DrugBank.d94.s8.e0"
            e2="DDI-DrugBank.d94.s8.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s8.d8" e1="DDI-DrugBank.d94.s8.e0"
            e2="DDI-DrugBank.d94.s8.e9" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s9" text="Agents with Decreased Levels in the Presence of Carbamazepine due to Induction of Cytochrome P450 Enzymes Carbamazepine is known to induce CYP1A2 and CYP3A4.">
        <entity id="DDI-DrugBank.d94.s9.e0" charOffset="48-60"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d94.s9.e1" charOffset="106-118"
            type="drug" text="Carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d551.s4" text="In clinical studies, coadministration of WelChol  with atorvastatin, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.">
        <entity id="DDI-DrugBank.d551.s4.e0" charOffset="41-47"
            type="brand" text="WelChol"/>
        <entity id="DDI-DrugBank.d551.s4.e1" charOffset="55-66"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d551.s4.e2" charOffset="69-78"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d551.s4.e3" charOffset="84-94"
            type="drug" text="simvastatin"/>
        <entity id="DDI-DrugBank.d551.s4.e4" charOffset="154-180"
            type="group" text="HMG-CoA reductase inhibitor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d551.s5" text="Other drugs have not been studied."/>
    <sentence id="DDI-DrugBank.d551.s6" text="When administering other drugs for which alterations in blood levels could have a clinically significant effect on safety or efficacy, physicians should consider monitoring drug levels or effects."/>
    <sentence id="DDI-DrugBank.d345.s0" text="Since colestipol hydrochloride is an anion exchange resin, it may have a strong affinity for anions other than the bile acids.">
        <entity id="DDI-DrugBank.d345.s0.e0" charOffset="6-29"
            type="drug" text="colestipol hydrochloride"/>
        <entity id="DDI-DrugBank.d345.s0.e1" charOffset="37-56"
            type="group" text="anion exchange resin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s1" text="In vitro studies have indicated that colestipol hydrochloride binds a number of drugs.">
        <entity id="DDI-DrugBank.d345.s1.e0" charOffset="37-60"
            type="drug" text="colestipol hydrochloride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s2" text="Therefore, COLESTlD Tablets may delay or reduce the absorption of concomitant oral medication.">
        <entity id="DDI-DrugBank.d345.s2.e0" charOffset="11-18"
            type="brand" text="COLESTlD"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s3" text="The interval between the administration of COLESTID Tablets and any other medication should be as long as possible.">
        <entity id="DDI-DrugBank.d345.s3.e0" charOffset="43-50"
            type="brand" text="COLESTID"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s4" text="Patients should take other drugs at least one hour before or four hours after COLESTID Tablets to avoid impeding their absorption.">
        <entity id="DDI-DrugBank.d345.s4.e0" charOffset="78-85"
            type="brand" text="COLESTID"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s5" text="Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.">
        <entity id="DDI-DrugBank.d345.s5.e0" charOffset="18-41"
            type="drug" text="colestipol hydrochloride"/>
        <entity id="DDI-DrugBank.d345.s5.e1" charOffset="75-85"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d345.s5.e2" charOffset="134-144"
            type="drug" text="propranolol"/>
        <ddi id="DDI-DrugBank.d345.s5.d0" e1="DDI-DrugBank.d345.s5.e0"
            e2="DDI-DrugBank.d345.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s6" text="However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;">
        <entity id="DDI-DrugBank.d345.s6.e0" charOffset="80-103"
            type="drug" text="colestipol hydrochloride"/>
        <entity id="DDI-DrugBank.d345.s6.e1" charOffset="109-119"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d345.s6.e2" charOffset="207-217"
            type="drug" text="propranolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s7" text="the time to reach maximum concentration was delayed approximately 30 minutes."/>
    <sentence id="DDI-DrugBank.d345.s8" text="Effects on the absorption of other beta-blockers have not been determined.">
        <entity id="DDI-DrugBank.d345.s8.e0" charOffset="35-47"
            type="group" text="beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s9" text="Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.">
        <entity id="DDI-DrugBank.d345.s9.e0" charOffset="23-33"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d345.s9.e1" charOffset="59-66"
            type="brand" text="COLESTID"/>
        <ddi id="DDI-DrugBank.d345.s9.d0" e1="DDI-DrugBank.d345.s9.e0"
            e2="DDI-DrugBank.d345.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s10" text="Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride.">
        <entity id="DDI-DrugBank.d345.s10.e0" charOffset="46-59"
            type="drug" text="chlorothiazide"/>
        <entity id="DDI-DrugBank.d345.s10.e1" charOffset="156-179"
            type="drug" text="colestipol hydrochloride"/>
        <ddi id="DDI-DrugBank.d345.s10.d0" e1="DDI-DrugBank.d345.s10.e0"
            e2="DDI-DrugBank.d345.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s11" text="The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;">
        <entity id="DDI-DrugBank.d345.s11.e0" charOffset="18-29"
            type="drug" text="tetracycline"/>
        <entity id="DDI-DrugBank.d345.s11.e1" charOffset="32-41"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d345.s11.e2" charOffset="44-55"
            type="drug" text="penicillin G"/>
        <entity id="DDI-DrugBank.d345.s11.e3" charOffset="58-76"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d345.s11.e4" charOffset="83-93"
            type="drug" text="gemfibrozil"/>
        <entity id="DDI-DrugBank.d345.s11.e5" charOffset="154-177"
            type="drug" text="colestipol hydrochloride"/>
        <ddi id="DDI-DrugBank.d345.s11.d0" e1="DDI-DrugBank.d345.s11.e0"
            e2="DDI-DrugBank.d345.s11.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d345.s11.d1" e1="DDI-DrugBank.d345.s11.e1"
            e2="DDI-DrugBank.d345.s11.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d345.s11.d2" e1="DDI-DrugBank.d345.s11.e2"
            e2="DDI-DrugBank.d345.s11.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d345.s11.d3" e1="DDI-DrugBank.d345.s11.e3"
            e2="DDI-DrugBank.d345.s11.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d345.s11.d4" e1="DDI-DrugBank.d345.s11.e4"
            e2="DDI-DrugBank.d345.s11.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s12" text="these drugs were not tested to determine the effect of administration one hour before colestipol hydrochloride.">
        <entity id="DDI-DrugBank.d345.s12.e0" charOffset="86-109"
            type="drug" text="colestipol hydrochloride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s13" text="No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.">
        <entity id="DDI-DrugBank.d345.s13.e0" charOffset="62-85"
            type="drug" text="colestipol hydrochloride"/>
        <entity id="DDI-DrugBank.d345.s13.e1" charOffset="137-143"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d345.s13.e2" charOffset="146-156"
            type="brand" text="clindamycin"/>
        <entity id="DDI-DrugBank.d345.s13.e3" charOffset="159-168"
            type="drug" text="clofibrate"/>
        <entity id="DDI-DrugBank.d345.s13.e4" charOffset="171-180"
            type="drug" text="methyldopa"/>
        <entity id="DDI-DrugBank.d345.s13.e5" charOffset="183-196"
            type="drug" text="nicotinic acid"/>
        <entity id="DDI-DrugBank.d345.s13.e6" charOffset="199-204"
            type="drug" text="niacin"/>
        <entity id="DDI-DrugBank.d345.s13.e7" charOffset="208-218"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d345.s13.e8" charOffset="221-229"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d345.s13.e9" charOffset="234-241"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s14" text="Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.">
        <entity id="DDI-DrugBank.d345.s14.e0" charOffset="43-64"
            type="group" text="digitalis preparations"/>
        <entity id="DDI-DrugBank.d345.s14.e1" charOffset="120-143"
            type="drug" text="colestipol hydrochloride"/>
        <entity id="DDI-DrugBank.d345.s14.e2" charOffset="168-174"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d345.s14.e3" charOffset="180-188"
            type="drug" text="digitoxin"/>
        <ddi id="DDI-DrugBank.d345.s14.d0" e1="DDI-DrugBank.d345.s14.e0"
            e2="DDI-DrugBank.d345.s14.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d345.s14.d1" e1="DDI-DrugBank.d345.s14.e1"
            e2="DDI-DrugBank.d345.s14.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d345.s14.d2" e1="DDI-DrugBank.d345.s14.e1"
            e2="DDI-DrugBank.d345.s14.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s15" text="The potential for binding of these drugs if given concomitantly is present."/>
    <sentence id="DDI-DrugBank.d345.s16" text="Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.">
        <entity id="DDI-DrugBank.d345.s16.e0" charOffset="14-37"
            type="drug" text="colestipol hydrochloride"/>
        <entity id="DDI-DrugBank.d345.s16.e1" charOffset="132-136"
            type="group" text="resin"/>
        <entity id="DDI-DrugBank.d345.s16.e2" charOffset="208-231"
            type="drug" text="colestipol hydrochloride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d345.s17" text="Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.">
        <entity id="DDI-DrugBank.d345.s17.e0" charOffset="0-23"
            type="group" text="Bile acid binding resins"/>
        <entity id="DDI-DrugBank.d345.s17.e1" charOffset="72-80"
            type="drug" text="phosphate"/>
        <entity id="DDI-DrugBank.d345.s17.e2" charOffset="98-111"
            type="drug" text="hydrocortisone"/>
        <ddi id="DDI-DrugBank.d345.s17.d0" e1="DDI-DrugBank.d345.s17.e0"
            e2="DDI-DrugBank.d345.s17.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d345.s17.d1" e1="DDI-DrugBank.d345.s17.e0"
            e2="DDI-DrugBank.d345.s17.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d250.s0" text="Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction.">
        <entity id="DDI-DrugBank.d250.s0.e0" charOffset="14-24"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d250.s0.e1" charOffset="27-41"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d250.s0.e2" charOffset="47-55"
            type="group" text="polymyxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d250.s1" text="Based on this reported activity, they should not be given concomitantly with Coly-Mycin M Parenteral except with the greatest caution.">
        <entity id="DDI-DrugBank.d250.s1.e0" charOffset="77-88"
            type="brand" text="Coly-Mycin M"/>
    </sentence>
    <sentence id="DDI-DrugBank.d250.s2" text="Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.">
        <entity id="DDI-DrugBank.d250.s2.e0" charOffset="0-26"
            type="brand" text="Curariform muscle relaxants"/>
        <entity id="DDI-DrugBank.d250.s2.e1" charOffset="33-44"
            type="drug" text="tubocurarine"/>
        <entity id="DDI-DrugBank.d250.s2.e2" charOffset="81-95"
            type="drug" text="succinylcholine"/>
        <entity id="DDI-DrugBank.d250.s2.e3" charOffset="98-106"
            type="drug" text="gallamine"/>
        <entity id="DDI-DrugBank.d250.s2.e4" charOffset="109-121"
            type="drug" text="decamethonium"/>
        <entity id="DDI-DrugBank.d250.s2.e5" charOffset="127-140"
            type="drug" text="sodium citrate"/>
        <entity id="DDI-DrugBank.d250.s2.e6" charOffset="259-270"
            type="brand" text="Coly-Mycin M"/>
        <ddi id="DDI-DrugBank.d250.s2.d0" e1="DDI-DrugBank.d250.s2.e0"
            e2="DDI-DrugBank.d250.s2.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d250.s2.d1" e1="DDI-DrugBank.d250.s2.e1"
            e2="DDI-DrugBank.d250.s2.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d250.s2.d2" e1="DDI-DrugBank.d250.s2.e2"
            e2="DDI-DrugBank.d250.s2.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d250.s2.d3" e1="DDI-DrugBank.d250.s2.e3"
            e2="DDI-DrugBank.d250.s2.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d250.s2.d4" e1="DDI-DrugBank.d250.s2.e4"
            e2="DDI-DrugBank.d250.s2.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d250.s2.d5" e1="DDI-DrugBank.d250.s2.e5"
            e2="DDI-DrugBank.d250.s2.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d250.s3" text="Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.">
        <entity id="DDI-DrugBank.d250.s3.e0" charOffset="0-17"
            type="drug" text="Sodium cephalothin"/>
        <entity id="DDI-DrugBank.d250.s3.e1" charOffset="53-64"
            type="brand" text="Coly-Mycin M"/>
        <ddi id="DDI-DrugBank.d250.s3.d0" e1="DDI-DrugBank.d250.s3.e0"
            e2="DDI-DrugBank.d250.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d250.s4" text="The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.">
        <entity id="DDI-DrugBank.d250.s4.e0" charOffset="23-40"
            type="drug" text="sodium cephalothin"/>
        <entity id="DDI-DrugBank.d250.s4.e1" charOffset="46-57"
            type="brand" text="Coly-Mycin M"/>
        <ddi id="DDI-DrugBank.d250.s4.d0" e1="DDI-DrugBank.d250.s4.e0"
            e2="DDI-DrugBank.d250.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d315.s0" text="Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.">
        <entity id="DDI-DrugBank.d315.s0.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d315.s0.e1" charOffset="29-35"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d315.s0.e2" charOffset="76-85"
            type="drug" text="conivaptan"/>
        <entity id="DDI-DrugBank.d315.s0.e3" charOffset="143-149"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d315.s0.d0" e1="DDI-DrugBank.d315.s0.e1"
            e2="DDI-DrugBank.d315.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d315.s1" text="Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.">
        <entity id="DDI-DrugBank.d315.s1.e0" charOffset="14-20"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d315.s1.e1" charOffset="43-50"
            type="brand" text="VAPRISOL"/>
        <entity id="DDI-DrugBank.d315.s1.e2" charOffset="118-124"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d315.s1.d0" e1="DDI-DrugBank.d315.s1.e0"
            e2="DDI-DrugBank.d315.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d317.s0" text="DRUG/LABORATORY TEST INTERACTIONS 1."/>
    <sentence id="DDI-DrugBank.d317.s1" text="Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time;"/>
    <sentence id="DDI-DrugBank.d317.s2" text="increased platelet count;"/>
    <sentence id="DDI-DrugBank.d317.s3" text="increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin;"/>
    <sentence id="DDI-DrugBank.d317.s4" text="decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity;">
        <entity id="DDI-DrugBank.d317.s4.e0" charOffset="39-54"
            type="drug" text="antithrombin III"/>
        <entity id="DDI-DrugBank.d317.s4.e1" charOffset="67-82"
            type="drug" text="antithrombin III"/>
    </sentence>
    <sentence id="DDI-DrugBank.d317.s5" text="increased levels of fibrinogen and fibrinogen activity;">
        <entity id="DDI-DrugBank.d317.s5.e0" charOffset="20-29"
            type="drug" text="fibrinogen"/>
        <entity id="DDI-DrugBank.d317.s5.e1" charOffset="35-44"
            type="drug" text="fibrinogen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d317.s6" text="increased plasminogen antigen and activity."/>
    <sentence id="DDI-DrugBank.d317.s7" text="2."/>
    <sentence id="DDI-DrugBank.d317.s8" text="Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay.">
        <entity id="DDI-DrugBank.d317.s8.e0" charOffset="139-144"
            type="drug" text="iodine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d317.s9" text="T3 resin uptake is decreased, reflecting the elevated TBG."/>
    <sentence id="DDI-DrugBank.d317.s10" text="Free T4 and free T3 concentrations are unaltered."/>
    <sentence id="DDI-DrugBank.d317.s11" text="Patients on thyroid replacement therapy may require higher doses of thyroid hormone.">
        <entity id="DDI-DrugBank.d317.s11.e0" charOffset="68-82"
            type="group" text="thyroid hormone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d317.s12" text="3."/>
    <sentence id="DDI-DrugBank.d317.s13" text="Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively.">
        <entity id="DDI-DrugBank.d317.s13.e0" charOffset="171-185"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d317.s13.e1" charOffset="191-202"
            type="group" text="sex steroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d317.s14" text="Free hormone concentrations may be decreased."/>
    <sentence id="DDI-DrugBank.d317.s15" text="Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin)."/>
    <sentence id="DDI-DrugBank.d317.s16" text="4."/>
    <sentence id="DDI-DrugBank.d317.s17" text="Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels."/>
    <sentence id="DDI-DrugBank.d317.s18" text="5."/>
    <sentence id="DDI-DrugBank.d317.s19" text="Impaired glucose tolerance."/>
    <sentence id="DDI-DrugBank.d317.s20" text="6."/>
    <sentence id="DDI-DrugBank.d317.s21" text="Reduced response to metyrapone test."/>
    <sentence id="DDI-DrugBank.d25.s0" text="Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.">
        <entity id="DDI-DrugBank.d25.s0.e0" charOffset="0-12"
            type="drug" text="Corticotropin"/>
        <entity id="DDI-DrugBank.d25.s0.e1" charOffset="66-73"
            type="drug" text="diuretic"/>
        <ddi id="DDI-DrugBank.d25.s0.d0" e1="DDI-DrugBank.d25.s0.e0"
            e2="DDI-DrugBank.d25.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d487.s0" text="The pharmacokinetic interactions listed below are potentially clinically important."/>
    <sentence id="DDI-DrugBank.d487.s1" text="Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.">
        <entity id="DDI-DrugBank.d487.s1.e0" charOffset="42-54"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d487.s1.e1" charOffset="57-65"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d487.s1.e2" charOffset="71-78"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d487.s1.e3" charOffset="110-124"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d487.s1.e4" charOffset="155-168"
            type="group" text="corticosteroid"/>
        <ddi id="DDI-DrugBank.d487.s1.d0" e1="DDI-DrugBank.d487.s1.e0"
            e2="DDI-DrugBank.d487.s1.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d487.s1.d1" e1="DDI-DrugBank.d487.s1.e1"
            e2="DDI-DrugBank.d487.s1.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d487.s1.d2" e1="DDI-DrugBank.d487.s1.e2"
            e2="DDI-DrugBank.d487.s1.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d487.s1.d3" e1="DDI-DrugBank.d487.s1.e0"
            e2="DDI-DrugBank.d487.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d487.s1.d4" e1="DDI-DrugBank.d487.s1.e1"
            e2="DDI-DrugBank.d487.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d487.s1.d5" e1="DDI-DrugBank.d487.s1.e2"
            e2="DDI-DrugBank.d487.s1.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d487.s2" text="Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.">
        <entity id="DDI-DrugBank.d487.s2.e0" charOffset="14-27"
            type="drug" text="troleandomycin"/>
        <entity id="DDI-DrugBank.d487.s2.e1" charOffset="33-44"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d487.s2.e2" charOffset="76-90"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d487.s2.d0" e1="DDI-DrugBank.d487.s2.e0"
            e2="DDI-DrugBank.d487.s2.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d487.s2.d1" e1="DDI-DrugBank.d487.s2.e1"
            e2="DDI-DrugBank.d487.s2.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d487.s3" text="Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity.">
        <entity id="DDI-DrugBank.d487.s3.e0" charOffset="23-36"
            type="group" text="corticosteroid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d487.s4" text="Corticosteroids may increase the clearance of chronic high dose aspirin.">
        <entity id="DDI-DrugBank.d487.s4.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d487.s4.e1" charOffset="64-70"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d487.s4.d0" e1="DDI-DrugBank.d487.s4.e0"
            e2="DDI-DrugBank.d487.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d487.s5" text="This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.">
        <entity id="DDI-DrugBank.d487.s5.e0" charOffset="29-38"
            type="group" text="salicylate"/>
        <entity id="DDI-DrugBank.d487.s5.e1" charOffset="77-86"
            type="group" text="salicylate"/>
        <entity id="DDI-DrugBank.d487.s5.e2" charOffset="102-115"
            type="drug" text="corticosteroid"/>
        <ddi id="DDI-DrugBank.d487.s5.d0" e1="DDI-DrugBank.d487.s5.e1"
            e2="DDI-DrugBank.d487.s5.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d487.s6" text="Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.">
        <entity id="DDI-DrugBank.d487.s6.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d487.s6.e1" charOffset="54-69"
            type="group" text="cortico-steroids"/>
        <ddi id="DDI-DrugBank.d487.s6.d0" e1="DDI-DrugBank.d487.s6.e0"
            e2="DDI-DrugBank.d487.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d487.s7" text="The effect of corticosteroids on oral anticoagulants is variable.">
        <entity id="DDI-DrugBank.d487.s7.e0" charOffset="14-28"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d487.s7.e1" charOffset="38-51"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d487.s7.d0" e1="DDI-DrugBank.d487.s7.e0"
            e2="DDI-DrugBank.d487.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d487.s8" text="There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.">
        <entity id="DDI-DrugBank.d487.s8.e0" charOffset="63-76"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d487.s8.e1" charOffset="107-121"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d487.s8.d0" e1="DDI-DrugBank.d487.s8.e0"
            e2="DDI-DrugBank.d487.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d487.s9" text="Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect."/>
    <sentence id="DDI-DrugBank.d439.s0" text="Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.">
        <entity id="DDI-DrugBank.d439.s0.e0" charOffset="0-12"
            type="drug" text="Corticotropin"/>
        <entity id="DDI-DrugBank.d439.s0.e1" charOffset="66-73"
            type="group" text="diuretic"/>
        <ddi id="DDI-DrugBank.d439.s0.d0" e1="DDI-DrugBank.d439.s0.e0"
            e2="DDI-DrugBank.d439.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d229.s0" text="Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.">
        <entity id="DDI-DrugBank.d229.s0.e0" charOffset="35-49"
            type="drug" text="Cromolyn sodium"/>
        <entity id="DDI-DrugBank.d229.s0.e1" charOffset="55-67"
            type="drug" text="isoproterenol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d229.s1" text="Cromolyn sodium alone in doses up to 540 mg/kg/day (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) did not cause significant increases in resorptions or major malformations.">
        <entity id="DDI-DrugBank.d229.s1.e0" charOffset="0-14"
            type="drug" text="Cromolyn sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d229.s2" text="Isoproterenol alone at a dose of 2.7 mg/kg/day (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) increased both resorptions and malformations.">
        <entity id="DDI-DrugBank.d229.s2.e0" charOffset="0-12"
            type="drug" text="Isoproterenol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d229.s3" text="The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.">
        <entity id="DDI-DrugBank.d229.s3.e0" charOffset="33-47"
            type="drug" text="cromolyn sodium"/>
        <entity id="DDI-DrugBank.d229.s3.e1" charOffset="168-180"
            type="drug" text="isoproterenol"/>
        <ddi id="DDI-DrugBank.d229.s3.d0" e1="DDI-DrugBank.d229.s3.e0"
            e2="DDI-DrugBank.d229.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d349.s0" text="None known."/>
    <sentence id="DDI-DrugBank.d39.s0" text="Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.">
        <entity id="DDI-DrugBank.d39.s0.e0" charOffset="20-30"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d39.s0.e1" charOffset="33-44"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d39.s0.e2" charOffset="50-62"
            type="drug" text="pyrimethamine"/>
        <entity id="DDI-DrugBank.d39.s0.e3" charOffset="75-84"
            type="drug" text="folic acid"/>
        <entity id="DDI-DrugBank.d39.s0.e4" charOffset="90-100"
            type="drug" text="vitamin B12"/>
    </sentence>
    <sentence id="DDI-DrugBank.d39.s1" text="Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.">
        <entity id="DDI-DrugBank.d39.s1.e0" charOffset="0-9" type="drug" text="Colchicine"/>
        <entity id="DDI-DrugBank.d39.s1.e1" charOffset="11-34"
            type="drug" text="para-aminosalicylic acid"/>
        <entity id="DDI-DrugBank.d39.s1.e2" charOffset="46-52"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d39.s1.e3" charOffset="114-124"
            type="drug" text="vitamin B12"/>
        <ddi id="DDI-DrugBank.d39.s1.d0" e1="DDI-DrugBank.d39.s1.e0"
            e2="DDI-DrugBank.d39.s1.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d39.s1.d1" e1="DDI-DrugBank.d39.s1.e1"
            e2="DDI-DrugBank.d39.s1.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d39.s1.d2" e1="DDI-DrugBank.d39.s1.e2"
            e2="DDI-DrugBank.d39.s1.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d150.s0" text="FLEXERIL may have life-threatening interactions with MAO inhibitors.">
        <entity id="DDI-DrugBank.d150.s0.e0" charOffset="0-7"
            type="brand" text="FLEXERIL"/>
        <entity id="DDI-DrugBank.d150.s0.e1" charOffset="53-66"
            type="group" text="MAO inhibitors"/>
        <ddi id="DDI-DrugBank.d150.s0.d0" e1="DDI-DrugBank.d150.s0.e0"
            e2="DDI-DrugBank.d150.s0.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d150.s1" text="FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.">
        <entity id="DDI-DrugBank.d150.s1.e0" charOffset="0-7"
            type="brand" text="FLEXERIL"/>
        <entity id="DDI-DrugBank.d150.s1.e1" charOffset="36-42"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d150.s1.e2" charOffset="45-56"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d150.s1.e3" charOffset="69-83"
            type="group" text="CNS depressants"/>
        <ddi id="DDI-DrugBank.d150.s1.d0" e1="DDI-DrugBank.d150.s1.e0"
            e2="DDI-DrugBank.d150.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d150.s1.d1" e1="DDI-DrugBank.d150.s1.e0"
            e2="DDI-DrugBank.d150.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d150.s1.d2" e1="DDI-DrugBank.d150.s1.e0"
            e2="DDI-DrugBank.d150.s1.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d150.s2" text="Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.">
        <entity id="DDI-DrugBank.d150.s2.e0" charOffset="0-24"
            type="group" text="Tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d150.s2.e1" charOffset="67-78"
            type="drug" text="guanethidine"/>
        <ddi id="DDI-DrugBank.d150.s2.d0" e1="DDI-DrugBank.d150.s2.e0"
            e2="DDI-DrugBank.d150.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d150.s3" text="Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol">
        <entity id="DDI-DrugBank.d150.s3.e0" charOffset="0-24"
            type="group" text="Tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d150.s3.e1" charOffset="74-81"
            type="drug" text="tramadol"/>
        <ddi id="DDI-DrugBank.d150.s3.d0" e1="DDI-DrugBank.d150.s3.e0"
            e2="DDI-DrugBank.d150.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d150.s4" text="."/>
    <sentence id="DDI-DrugBank.d150.s5" text=""/>
    <sentence id="DDI-DrugBank.d298.s0" text="Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;">
        <entity id="DDI-DrugBank.d298.s0.e0" charOffset="0-13"
            type="drug" text="Cyclopentolate"/>
        <entity id="DDI-DrugBank.d298.s0.e1" charOffset="62-70"
            type="drug" text="carbachol"/>
        <entity id="DDI-DrugBank.d298.s0.e2" charOffset="75-85"
            type="drug" text="pilocarpine"/>
        <ddi id="DDI-DrugBank.d298.s0.d0" e1="DDI-DrugBank.d298.s0.e0"
            e2="DDI-DrugBank.d298.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d298.s0.d1" e1="DDI-DrugBank.d298.s0.e0"
            e2="DDI-DrugBank.d298.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d298.s1" text="also, concurrent use of this medication may antagonise the anti-glaucoma and miotic actions of ophthalmic cholinesterase inhibitors.">
        <entity id="DDI-DrugBank.d298.s1.e0" charOffset="106-130"
            type="group" text="cholinesterase inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d7.s0" text="The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.">
        <entity id="DDI-DrugBank.d7.s0.e0" charOffset="54-69"
            type="drug" text="cyclophosphamide"/>
        <entity id="DDI-DrugBank.d7.s0.e1" charOffset="139-151"
            type="drug" text="phenobarbital"/>
        <ddi id="DDI-DrugBank.d7.s0.d0" e1="DDI-DrugBank.d7.s0.e0"
            e2="DDI-DrugBank.d7.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d7.s1" text="The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.">
        <entity id="DDI-DrugBank.d7.s1.e0" charOffset="102-117"
            type="drug" text="cyclophosphamide"/>
        <entity id="DDI-DrugBank.d7.s1.e1" charOffset="131-146"
            type="drug" text="cyclophosphamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d7.s2" text="Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.">
        <entity id="DDI-DrugBank.d7.s2.e0" charOffset="0-15" type="drug" text="Cyclophosphamide"/>
        <entity id="DDI-DrugBank.d7.s2.e1" charOffset="130-153"
            type="drug" text="succinylcholine chloride"/>
        <ddi id="DDI-DrugBank.d7.s2.d0" e1="DDI-DrugBank.d7.s2.e0"
            e2="DDI-DrugBank.d7.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d7.s3" text="If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.">
        <entity id="DDI-DrugBank.d7.s3.e0" charOffset="35-50"
            type="drug" text="cyclophosphamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d128.s0" text="May interact with wthionamide (Trecator-SC) and isoniazid (Nydrazid).">
        <entity id="DDI-DrugBank.d128.s0.e0" charOffset="31-41"
            type="brand" text="Trecator-SC"/>
        <entity id="DDI-DrugBank.d128.s0.e1" charOffset="48-56"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d128.s0.e2" charOffset="59-66"
            type="brand" text="Nydrazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d492.s0" text="MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.">
        <entity id="DDI-DrugBank.d492.s0.e0" charOffset="0-13"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d492.s0.e1" charOffset="68-81"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d492.s0.d0" e1="DDI-DrugBank.d492.s0.e0"
            e2="DDI-DrugBank.d492.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d492.s1" text="Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.">
        <entity id="DDI-DrugBank.d492.s1.e0" charOffset="0-13"
            type="group" text="Antihistamines"/>
        <entity id="DDI-DrugBank.d492.s1.e1" charOffset="46-52"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d492.s1.e2" charOffset="64-78"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d492.s1.e3" charOffset="87-95"
            type="group" text="hypnotics"/>
        <entity id="DDI-DrugBank.d492.s1.e4" charOffset="98-106"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d492.s1.e5" charOffset="109-121"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d492.s1.e6" charOffset="124-141"
            type="group" text="antianxiety agents"/>
        <ddi id="DDI-DrugBank.d492.s1.d0" e1="DDI-DrugBank.d492.s1.e0"
            e2="DDI-DrugBank.d492.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d492.s1.d1" e1="DDI-DrugBank.d492.s1.e0"
            e2="DDI-DrugBank.d492.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d492.s1.d2" e1="DDI-DrugBank.d492.s1.e0"
            e2="DDI-DrugBank.d492.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d492.s1.d3" e1="DDI-DrugBank.d492.s1.e0"
            e2="DDI-DrugBank.d492.s1.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d492.s1.d4" e1="DDI-DrugBank.d492.s1.e0"
            e2="DDI-DrugBank.d492.s1.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d492.s1.d5" e1="DDI-DrugBank.d492.s1.e0"
            e2="DDI-DrugBank.d492.s1.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d259.s0" text="No drug interactions have been reported."/>
    <sentence id="DDI-DrugBank.d101.s0" text="Steady state plasma digitoxin concentrations did not appear to change.">
        <entity id="DDI-DrugBank.d101.s0.e0" charOffset="20-28"
            type="drug" text="digitoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d101.s1" text="Therefore, monitoring of plasma digoxin levels may be indicated in patients receiving similar combination chemotherapy regimens.">
        <entity id="DDI-DrugBank.d101.s1.e0" charOffset="32-38"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d101.s2" text="The utilization of digitoxin for such patients may be considered as an alternative.">
        <entity id="DDI-DrugBank.d101.s2.e0" charOffset="19-27"
            type="drug" text="digitoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d101.s3" text="Also flucytosine.">
        <entity id="DDI-DrugBank.d101.s3.e0" charOffset="5-15"
            type="drug" text="flucytosine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d294.s0" text="Drug/LaboratoryTest Interactions Dactinomycin may interfere with bioassay procedures for the determination of antibacterial drug levels.">
        <entity id="DDI-DrugBank.d294.s0.e0" charOffset="33-44"
            type="drug" text="Dactinomycin"/>
        <entity id="DDI-DrugBank.d294.s0.e1" charOffset="110-127"
            type="group" text="antibacterial drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d305.s0" text="Dantrium is metabolized by the liver, and it is theoretically possible that its metabolism may be enhanced by drugs known to induce hepatic microsomal enzymes.">
        <entity id="DDI-DrugBank.d305.s0.e0" charOffset="0-7"
            type="brand" text="Dantrium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d305.s1" text="However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism.">
        <entity id="DDI-DrugBank.d305.s1.e0" charOffset="17-29"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d305.s1.e1" charOffset="35-42"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d305.s1.e2" charOffset="62-69"
            type="brand" text="Dantrium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d305.s2" text="Binding to plasma protein is not significantly altered by diazepam, diphenylhydantoin, or phenylbutazone.">
        <entity id="DDI-DrugBank.d305.s2.e0" charOffset="58-65"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d305.s2.e1" charOffset="68-84"
            type="drug" text="diphenylhydantoin"/>
        <entity id="DDI-DrugBank.d305.s2.e2" charOffset="90-103"
            type="drug" text="phenylbutazone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d305.s3" text="Binding to plasma proteins is reduced by warfarin and clotibrate and increased by tolbutamide.">
        <entity id="DDI-DrugBank.d305.s3.e0" charOffset="41-48"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d305.s3.e1" charOffset="82-92"
            type="drug" text="tolbutamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d305.s4" text="Cardiovascular collapse in patients treated simultaneously with varapamil and dantrolene sodium is rare.">
        <entity id="DDI-DrugBank.d305.s4.e0" charOffset="78-94"
            type="drug" text="dantrolene sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d305.s5" text="The combination of therapeutic doses of intravenous dantrolene sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.">
        <entity id="DDI-DrugBank.d305.s5.e0" charOffset="52-68"
            type="drug" text="dantrolene sodium"/>
        <entity id="DDI-DrugBank.d305.s5.e1" charOffset="74-82"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d305.s5.e2" charOffset="87-95"
            type="drug" text="halothane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d305.s6" text="It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.">
        <entity id="DDI-DrugBank.d305.s6.e0" charOffset="54-70"
            type="drug" text="dantrolene sodium"/>
        <entity id="DDI-DrugBank.d305.s6.e1" charOffset="76-99"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d305.s6.e2" charOffset="110-118"
            type="drug" text="verapamil"/>
        <ddi id="DDI-DrugBank.d305.s6.d0" e1="DDI-DrugBank.d305.s6.e0"
            e2="DDI-DrugBank.d305.s6.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d305.s6.d1" e1="DDI-DrugBank.d305.s6.e0"
            e2="DDI-DrugBank.d305.s6.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d305.s7" text="Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.">
        <entity id="DDI-DrugBank.d305.s7.e0" charOffset="18-27"
            type="drug" text="dantrolene"/>
        <entity id="DDI-DrugBank.d305.s7.e1" charOffset="44-53"
            type="drug" text="vecuronium"/>
        <ddi id="DDI-DrugBank.d305.s7.d0" e1="DDI-DrugBank.d305.s7.e0"
            e2="DDI-DrugBank.d305.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d185.s0" text="A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/SMX).">
        <entity id="DDI-DrugBank.d185.s0.e0" charOffset="65-70"
            type="brand" text="ACZONE"/>
        <entity id="DDI-DrugBank.d185.s0.e1" charOffset="133-144"
            type="drug" text="trimethoprim"/>
        <entity id="DDI-DrugBank.d185.s0.e2" charOffset="146-161"
            type="drug" text="sulfamethoxazole"/>
        <entity id="DDI-DrugBank.d185.s0.e3" charOffset="164-166"
            type="drug" text="TMP"/>
        <entity id="DDI-DrugBank.d185.s0.e4" charOffset="168-170"
            type="drug" text="SMX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d185.s1" text="During co-administration, systemic levels of TMP and SMX were essentially unchanged.">
        <entity id="DDI-DrugBank.d185.s1.e0" charOffset="45-47"
            type="drug" text="TMP"/>
        <entity id="DDI-DrugBank.d185.s1.e1" charOffset="53-55"
            type="drug" text="SMX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d185.s2" text="Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of TMP/SMX.">
        <entity id="DDI-DrugBank.d185.s2.e0" charOffset="40-60"
            type="drug_n" text="dapsone hydroxylamine"/>
        <entity id="DDI-DrugBank.d185.s2.e1" charOffset="63-65"
            type="drug_n" text="DHA"/>
        <entity id="DDI-DrugBank.d185.s2.e2" charOffset="109-111"
            type="drug" text="TMP"/>
        <entity id="DDI-DrugBank.d185.s2.e3" charOffset="113-115"
            type="drug" text="SMX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d185.s3" text="Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX.">
        <entity id="DDI-DrugBank.d185.s3.e0" charOffset="118-120"
            type="drug" text="TMP"/>
        <entity id="DDI-DrugBank.d185.s3.e1" charOffset="122-124"
            type="drug" text="SMX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d185.s4" text="Certain concomitant medications (such as rifampin, anticonvulsants, St.">
        <entity id="DDI-DrugBank.d185.s4.e0" charOffset="41-48"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d185.s4.e1" charOffset="51-65"
            type="group" text="anticonvulsants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d185.s5" text="John s wort) may increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with hemolysis.">
        <entity id="DDI-DrugBank.d185.s5.e0" charOffset="43-63"
            type="drug_n" text="dapsone hydroxylamine"/>
        <entity id="DDI-DrugBank.d185.s5.e1" charOffset="82-88"
            type="drug" text="dapsone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d185.s6" text="With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions">
        <entity id="DDI-DrugBank.d185.s6.e0" charOffset="10-16"
            type="drug" text="dapsone"/>
        <entity id="DDI-DrugBank.d185.s6.e1" charOffset="29-50"
            type="group" text="folic acid antagonists"/>
        <entity id="DDI-DrugBank.d185.s6.e2" charOffset="60-72"
            type="drug" text="pyrimethamine"/>
        <ddi id="DDI-DrugBank.d185.s6.d0" e1="DDI-DrugBank.d185.s6.e0"
            e2="DDI-DrugBank.d185.s6.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d185.s6.d1" e1="DDI-DrugBank.d185.s6.e0"
            e2="DDI-DrugBank.d185.s6.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d185.s7" text="."/>
    <sentence id="DDI-DrugBank.d185.s8" text=""/>
    <sentence id="DDI-DrugBank.d337.s0" text="Warfarin: Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.">
        <entity id="DDI-DrugBank.d337.s0.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d337.s0.e1" charOffset="40-49"
            type="drug" text="daptomycin"/>
        <entity id="DDI-DrugBank.d337.s0.e2" charOffset="96-103"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d337.s1" text="HMG-CoA Reductase Inhibitors: Inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.">
        <entity id="DDI-DrugBank.d337.s1.e0" charOffset="0-27"
            type="group" text="HMG-CoA Reductase Inhibitors"/>
        <entity id="DDI-DrugBank.d337.s1.e1" charOffset="30-60"
            type="group" text="Inhibitors of HMG-CoA reductase"/>
    </sentence>
    <sentence id="DDI-DrugBank.d337.s2" text="There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable simvastatin therapy were treated concurrently with daptomycin (4 mg/kg once every 24 hours) for 14 days.">
        <entity id="DDI-DrugBank.d337.s2.e0" charOffset="120-130"
            type="drug" text="simvastatin"/>
        <entity id="DDI-DrugBank.d337.s2.e1" charOffset="171-180"
            type="drug" text="daptomycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d337.s3" text="Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.">
        <entity id="DDI-DrugBank.d337.s3.e0" charOffset="37-64"
            type="group" text="HMG-CoA reductase inhibitors"/>
        <entity id="DDI-DrugBank.d337.s3.e1" charOffset="70-77"
            type="drug" text="Fentanyl"/>
        <entity id="DDI-DrugBank.d337.s3.e2" charOffset="175-202"
            type="group" text="HMG-CoA reductase inhibitors"/>
        <entity id="DDI-DrugBank.d337.s3.e3" charOffset="226-233"
            type="drug" text="Fentanyl"/>
        <ddi id="DDI-DrugBank.d337.s3.d0" e1="DDI-DrugBank.d337.s3.e2"
            e2="DDI-DrugBank.d337.s3.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d337.s4" text="Drug-Laboratory Test Interactions: There are no reported drug-laboratory test interactions."/>
    <sentence id="DDI-DrugBank.d534.s0" text="No formal drug interaction studies of Aranesp  have been performed.">
        <entity id="DDI-DrugBank.d534.s0.e0" charOffset="38-44"
            type="brand" text="Aranesp"/>
    </sentence>
    <sentence id="DDI-DrugBank.d459.s0" text="The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .">
        <entity id="DDI-DrugBank.d459.s0.e0" charOffset="18-24"
            type="brand" text="ENABLEX"/>
        <entity id="DDI-DrugBank.d459.s0.e1" charOffset="108-119"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d459.s0.e2" charOffset="122-133"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d459.s0.e3" charOffset="136-144"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d459.s0.e4" charOffset="147-156"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d459.s0.e5" charOffset="159-172"
            type="drug" text="clarithromycin"/>
        <ddi id="DDI-DrugBank.d459.s0.d0" e1="DDI-DrugBank.d459.s0.e0"
            e2="DDI-DrugBank.d459.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s0.d1" e1="DDI-DrugBank.d459.s0.e0"
            e2="DDI-DrugBank.d459.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s0.d2" e1="DDI-DrugBank.d459.s0.e0"
            e2="DDI-DrugBank.d459.s0.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s0.d3" e1="DDI-DrugBank.d459.s0.e0"
            e2="DDI-DrugBank.d459.s0.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s0.d4" e1="DDI-DrugBank.d459.s0.e0"
            e2="DDI-DrugBank.d459.s0.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d459.s1" text="Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).">
        <entity id="DDI-DrugBank.d459.s1.e0" charOffset="29-35"
            type="brand" text="ENABLEX"/>
        <entity id="DDI-DrugBank.d459.s1.e1" charOffset="173-182"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d459.s1.e2" charOffset="185-196"
            type="drug" text="thioridazine"/>
        <entity id="DDI-DrugBank.d459.s1.e3" charOffset="202-226"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d459.s1.d0" e1="DDI-DrugBank.d459.s1.e0"
            e2="DDI-DrugBank.d459.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s1.d1" e1="DDI-DrugBank.d459.s1.e0"
            e2="DDI-DrugBank.d459.s1.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s1.d2" e1="DDI-DrugBank.d459.s1.e0"
            e2="DDI-DrugBank.d459.s1.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d459.s2" text="The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.">
        <entity id="DDI-DrugBank.d459.s2.e0" charOffset="23-29"
            type="brand" text="ENABLEX"/>
        <entity id="DDI-DrugBank.d459.s2.e1" charOffset="42-63"
            type="group" text="anticholinergic agents"/>
        <ddi id="DDI-DrugBank.d459.s2.d0" e1="DDI-DrugBank.d459.s2.e0"
            e2="DDI-DrugBank.d459.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d459.s3" text="Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to effects on gastrointestinal motility.">
        <entity id="DDI-DrugBank.d459.s3.e0" charOffset="0-21"
            type="group" text="Anticholinergic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d459.s4" text="Drug Laboratory Test Interactions Interactions between darifenacin and laboratory tests have not been studied.">
        <entity id="DDI-DrugBank.d459.s4.e0" charOffset="55-65"
            type="drug" text="darifenacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s0" text="Drugs that may increase dasatinib plasma concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate.">
        <entity id="DDI-DrugBank.d48.s0.e0" charOffset="24-32"
            type="drug" text="dasatinib"/>
        <entity id="DDI-DrugBank.d48.s0.e1" charOffset="75-83"
            type="drug" text="Dasatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s1" text="Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.">
        <entity id="DDI-DrugBank.d48.s1.e0" charOffset="19-25"
            type="brand" text="SPRYCEL"/>
        <entity id="DDI-DrugBank.d48.s1.e1" charOffset="62-73"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d48.s1.e2" charOffset="76-87"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d48.s1.e3" charOffset="90-101"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d48.s1.e4" charOffset="104-117"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d48.s1.e5" charOffset="120-128"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d48.s1.e6" charOffset="131-140"
            type="drug" text="atazanavir"/>
        <entity id="DDI-DrugBank.d48.s1.e7" charOffset="143-151"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d48.s1.e8" charOffset="154-163"
            type="drug" text="nefazodone"/>
        <entity id="DDI-DrugBank.d48.s1.e9" charOffset="166-175"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d48.s1.e10" charOffset="178-187"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d48.s1.e11" charOffset="190-202"
            type="drug" text="telithromycin"/>
        <entity id="DDI-DrugBank.d48.s1.e12" charOffset="230-238"
            type="drug" text="dasatinib"/>
        <ddi id="DDI-DrugBank.d48.s1.d0" e1="DDI-DrugBank.d48.s1.e0"
            e2="DDI-DrugBank.d48.s1.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d48.s1.d1" e1="DDI-DrugBank.d48.s1.e0"
            e2="DDI-DrugBank.d48.s1.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d48.s1.d2" e1="DDI-DrugBank.d48.s1.e0"
            e2="DDI-DrugBank.d48.s1.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d48.s1.d3" e1="DDI-DrugBank.d48.s1.e0"
            e2="DDI-DrugBank.d48.s1.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d48.s1.d4" e1="DDI-DrugBank.d48.s1.e0"
            e2="DDI-DrugBank.d48.s1.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d48.s1.d5" e1="DDI-DrugBank.d48.s1.e0"
            e2="DDI-DrugBank.d48.s1.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d48.s1.d6" e1="DDI-DrugBank.d48.s1.e0"
            e2="DDI-DrugBank.d48.s1.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d48.s1.d7" e1="DDI-DrugBank.d48.s1.e0"
            e2="DDI-DrugBank.d48.s1.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d48.s1.d8" e1="DDI-DrugBank.d48.s1.e0"
            e2="DDI-DrugBank.d48.s1.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d48.s1.d9" e1="DDI-DrugBank.d48.s1.e0"
            e2="DDI-DrugBank.d48.s1.e10" type="mechanism"/>
        <ddi id="DDI-DrugBank.d48.s1.d10" e1="DDI-DrugBank.d48.s1.e0"
            e2="DDI-DrugBank.d48.s1.e11" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s2" text="In patients receiving treatment with SPRYCEL, close monitoring for toxicity and a SPRYCEL dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.">
        <entity id="DDI-DrugBank.d48.s2.e0" charOffset="37-43"
            type="brand" text="SPRYCEL"/>
        <entity id="DDI-DrugBank.d48.s2.e1" charOffset="82-88"
            type="brand" text="SPRYCEL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s3" text="Drugs that may decrease dasatinib plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease dasatinib plasma concentrations.">
        <entity id="DDI-DrugBank.d48.s3.e0" charOffset="24-32"
            type="drug" text="dasatinib"/>
        <entity id="DDI-DrugBank.d48.s3.e1" charOffset="120-128"
            type="drug" text="dasatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s4" text="In patients in whom CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital) are indicated, alternative agents with less enzyme induction potential should be used.">
        <entity id="DDI-DrugBank.d48.s4.e0" charOffset="41-53"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d48.s4.e1" charOffset="56-64"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d48.s4.e2" charOffset="67-79"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d48.s4.e3" charOffset="82-91"
            type="drug" text="rifampicin"/>
        <entity id="DDI-DrugBank.d48.s4.e4" charOffset="94-106"
            type="drug" text="phenobarbital"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s5" text="If SPRYCEL must be administered with a CYP3A4 inducer, a dose increase in SPRYCEL should be considered.">
        <entity id="DDI-DrugBank.d48.s5.e0" charOffset="3-9"
            type="brand" text="SPRYCEL"/>
        <entity id="DDI-DrugBank.d48.s5.e1" charOffset="74-80"
            type="brand" text="SPRYCEL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s6" text="St. Johns wort (Hypericum perforatum) may decrease SPRYCEL plasma concentrations unpredictably.">
        <entity id="DDI-DrugBank.d48.s6.e0" charOffset="51-57"
            type="brand" text="SPRYCEL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s7" text="Patients receiving SPRYCEL should not take St. Johns wort.">
        <entity id="DDI-DrugBank.d48.s7.e0" charOffset="19-25"
            type="brand" text="SPRYCEL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s8" text="Antacids: Nonclinical data demonstrate that the solubility of dasatinib is pH dependent.">
        <entity id="DDI-DrugBank.d48.s8.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d48.s8.e1" charOffset="62-70"
            type="drug" text="dasatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s9" text="Simultaneous administration of SPRYCEL with antacids should be avoided.">
        <entity id="DDI-DrugBank.d48.s9.e0" charOffset="31-37"
            type="brand" text="SPRYCEL"/>
        <entity id="DDI-DrugBank.d48.s9.e1" charOffset="44-51"
            type="group" text="antacids"/>
        <ddi id="DDI-DrugBank.d48.s9.d0" e1="DDI-DrugBank.d48.s9.e0"
            e2="DDI-DrugBank.d48.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s10" text="If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.">
        <entity id="DDI-DrugBank.d48.s10.e0" charOffset="3-9"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d48.s10.e1" charOffset="125-131"
            type="brand" text="SPRYCEL"/>
        <ddi id="DDI-DrugBank.d48.s10.d0" e1="DDI-DrugBank.d48.s10.e0"
            e2="DDI-DrugBank.d48.s10.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s11" text="H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.">
        <entity id="DDI-DrugBank.d48.s11.e0" charOffset="0-10"
            type="group" text="H2 Blockers"/>
        <entity id="DDI-DrugBank.d48.s11.e1" charOffset="12-33"
            type="group" text="Proton Pump Inhibitors"/>
        <entity id="DDI-DrugBank.d48.s11.e2" charOffset="87-97"
            type="group" text="H2 blockers"/>
        <entity id="DDI-DrugBank.d48.s11.e3" charOffset="102-123"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-DrugBank.d48.s11.e4" charOffset="130-139"
            type="drug" text="famotidine"/>
        <entity id="DDI-DrugBank.d48.s11.e5" charOffset="145-154"
            type="drug" text="omeprazole"/>
        <entity id="DDI-DrugBank.d48.s11.e6" charOffset="177-185"
            type="drug" text="dasatinib"/>
        <ddi id="DDI-DrugBank.d48.s11.d0" e1="DDI-DrugBank.d48.s11.e2"
            e2="DDI-DrugBank.d48.s11.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d48.s11.d1" e1="DDI-DrugBank.d48.s11.e3"
            e2="DDI-DrugBank.d48.s11.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d48.s11.d2" e1="DDI-DrugBank.d48.s11.e4"
            e2="DDI-DrugBank.d48.s11.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d48.s11.d3" e1="DDI-DrugBank.d48.s11.e5"
            e2="DDI-DrugBank.d48.s11.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s12" text="The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.">
        <entity id="DDI-DrugBank.d48.s12.e0" charOffset="23-33"
            type="group" text="H2 blockers"/>
        <entity id="DDI-DrugBank.d48.s12.e1" charOffset="38-59"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-DrugBank.d48.s12.e2" charOffset="66-72"
            type="brand" text="SPRYCEL"/>
        <ddi id="DDI-DrugBank.d48.s12.d0" e1="DDI-DrugBank.d48.s12.e0"
            e2="DDI-DrugBank.d48.s12.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s12.d1" e1="DDI-DrugBank.d48.s12.e1"
            e2="DDI-DrugBank.d48.s12.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s13" text="The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.">
        <entity id="DDI-DrugBank.d48.s13.e0" charOffset="11-18"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d48.s13.e1" charOffset="53-63"
            type="group" text="H2 blockers"/>
        <entity id="DDI-DrugBank.d48.s13.e2" charOffset="68-89"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-DrugBank.d48.s13.e3" charOffset="113-119"
            type="brand" text="SPRYCEL"/>
        <ddi id="DDI-DrugBank.d48.s13.d0" e1="DDI-DrugBank.d48.s13.e1"
            e2="DDI-DrugBank.d48.s13.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s13.d1" e1="DDI-DrugBank.d48.s13.e2"
            e2="DDI-DrugBank.d48.s13.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s14" text="Drugs that may have their plasma concentration altered by dasatinib CYP3A4 Substrates: Dasatinib is a time-dependent inhibitor of CYP3A4.">
        <entity id="DDI-DrugBank.d48.s14.e0" charOffset="58-66"
            type="drug" text="dasatinib"/>
        <entity id="DDI-DrugBank.d48.s14.e1" charOffset="87-95"
            type="drug" text="Dasatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s15" text="Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.">
        <entity id="DDI-DrugBank.d48.s15.e0" charOffset="78-87"
            type="drug" text="alfentanil"/>
        <entity id="DDI-DrugBank.d48.s15.e1" charOffset="90-99"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d48.s15.e2" charOffset="102-112"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d48.s15.e3" charOffset="115-123"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d48.s15.e4" charOffset="126-137"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d48.s15.e5" charOffset="140-147"
            type="drug" text="fentanyl"/>
        <entity id="DDI-DrugBank.d48.s15.e6" charOffset="150-157"
            type="drug" text="pimozide"/>
        <entity id="DDI-DrugBank.d48.s15.e7" charOffset="160-168"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d48.s15.e8" charOffset="171-179"
            type="drug" text="sirolimus"/>
        <entity id="DDI-DrugBank.d48.s15.e9" charOffset="182-191"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d48.s15.e10" charOffset="197-211"
            type="group" text="ergot alkaloids"/>
        <entity id="DDI-DrugBank.d48.s15.e11" charOffset="214-223"
            type="drug" text="ergotamine"/>
        <entity id="DDI-DrugBank.d48.s15.e12" charOffset="226-242"
            type="drug" text="dihydroergotamine"/>
        <entity id="DDI-DrugBank.d48.s15.e13" charOffset="303-309"
            type="brand" text="SPRYCEL"/>
        <ddi id="DDI-DrugBank.d48.s15.d0" e1="DDI-DrugBank.d48.s15.e0"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d1" e1="DDI-DrugBank.d48.s15.e1"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d2" e1="DDI-DrugBank.d48.s15.e2"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d3" e1="DDI-DrugBank.d48.s15.e3"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d4" e1="DDI-DrugBank.d48.s15.e4"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d5" e1="DDI-DrugBank.d48.s15.e5"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d6" e1="DDI-DrugBank.d48.s15.e6"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d7" e1="DDI-DrugBank.d48.s15.e7"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d8" e1="DDI-DrugBank.d48.s15.e8"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d9" e1="DDI-DrugBank.d48.s15.e9"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d10" e1="DDI-DrugBank.d48.s15.e10"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d11" e1="DDI-DrugBank.d48.s15.e11"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d48.s15.d12" e1="DDI-DrugBank.d48.s15.e12"
            e2="DDI-DrugBank.d48.s15.e13" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s16" text="Hepatic Impairment There are currently no clinical studies with SPRYCEL in patients with impaired liver function (clinical studies have excluded patients with ALT and/or AST  2.5 times the upper limit of the normal range and/or total bilirubin  2 times the upper limit of the normal range).">
        <entity id="DDI-DrugBank.d48.s16.e0" charOffset="64-70"
            type="brand" text="SPRYCEL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s17" text="Metabolism of dasatinib is mainly hepatic.">
        <entity id="DDI-DrugBank.d48.s17.e0" charOffset="14-22"
            type="drug" text="dasatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s18" text="Caution is recommended in patients with hepatic impairment."/>
    <sentence id="DDI-DrugBank.d48.s19" text="Renal Impairment There are currently no clinical studies with SPRYCEL in patients with impaired renal function (clinical studies have excluded patients with serum creatinine concentration  1.5 times the upper limit of the normal range).">
        <entity id="DDI-DrugBank.d48.s19.e0" charOffset="62-68"
            type="brand" text="SPRYCEL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s20" text="Dasatinib and its metabolites are minimally excreted via the kidney.">
        <entity id="DDI-DrugBank.d48.s20.e0" charOffset="0-8"
            type="drug" text="Dasatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d48.s21" text="Since the renal excretion of unchanged dasatinib and its metabolites is  4%, a decrease in total body clearance is not expected in patients with renal insufficiency.">
        <entity id="DDI-DrugBank.d48.s21.e0" charOffset="39-47"
            type="drug" text="dasatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d69.s0" text="Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.">
        <entity id="DDI-DrugBank.d69.s0.e0" charOffset="7-16"
            type="brand" text="Cerubidine"/>
        <entity id="DDI-DrugBank.d69.s0.e1" charOffset="59-69"
            type="drug" text="doxorubicin"/>
        <ddi id="DDI-DrugBank.d69.s0.d0" e1="DDI-DrugBank.d69.s0.e0"
            e2="DDI-DrugBank.d69.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d69.s1" text="Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.">
        <entity id="DDI-DrugBank.d69.s1.e0" charOffset="0-9"
            type="brand" text="Cerubidine"/>
        <entity id="DDI-DrugBank.d69.s1.e1" charOffset="115-125"
            type="drug" text="doxorubicin"/>
        <entity id="DDI-DrugBank.d69.s1.e2" charOffset="130-139"
            type="brand" text="Cerubidine"/>
        <ddi id="DDI-DrugBank.d69.s1.d0" e1="DDI-DrugBank.d69.s1.e0"
            e2="DDI-DrugBank.d69.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d69.s2" text="Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.">
        <entity id="DDI-DrugBank.d69.s2.e0" charOffset="0-15"
            type="drug" text="Cyclophosphamide"/>
        <entity id="DDI-DrugBank.d69.s2.e1" charOffset="40-49"
            type="brand" text="Cerubidine"/>
        <ddi id="DDI-DrugBank.d69.s2.d0" e1="DDI-DrugBank.d69.s2.e0"
            e2="DDI-DrugBank.d69.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d69.s3" text="Dosage reduction of Cerubidine may be required when used concurrently with other myelosuppressive agents.">
        <entity id="DDI-DrugBank.d69.s3.e0" charOffset="20-29"
            type="brand" text="Cerubidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d69.s4" text="Hepatotoxic medications, such as high-dose methotrexate, may impair liver function and increase the risk of toxicity.">
        <entity id="DDI-DrugBank.d69.s4.e0" charOffset="43-54"
            type="drug" text="methotrexate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d167.s0" text="Potentially fatal drug interactions may occur when coadministered with digoxin, as this may enhance cardiovascular depression and bradyarrhythmias may occur.">
        <entity id="DDI-DrugBank.d167.s0.e0" charOffset="71-77"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d167.s1" text="Anticholinesterases (neostgmine, physostigmine), lignocaine, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.">
        <entity id="DDI-DrugBank.d167.s1.e0" charOffset="0-18"
            type="group" text="Anticholinesterases"/>
        <entity id="DDI-DrugBank.d167.s1.e1" charOffset="33-45"
            type="drug" text="physostigmine"/>
        <entity id="DDI-DrugBank.d167.s1.e2" charOffset="49-58"
            type="drug" text="lignocaine"/>
        <entity id="DDI-DrugBank.d167.s1.e3" charOffset="61-67"
            type="drug" text="quinine"/>
        <entity id="DDI-DrugBank.d167.s1.e4" charOffset="70-81"
            type="drug" text="procainamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d167.s2" text="In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.">
        <entity id="DDI-DrugBank.d167.s2.e0" charOffset="66-76"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d167.s2.e1" charOffset="85-95"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d167.s2.e2" charOffset="102-110"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d167.s2.e3" charOffset="113-120"
            type="drug" text="procaine"/>
        <entity id="DDI-DrugBank.d167.s2.e4" charOffset="123-135"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d167.s2.e5" charOffset="138-151"
            type="drug" text="metaclopramide"/>
        <entity id="DDI-DrugBank.d167.s2.e6" charOffset="154-170"
            type="drug" text="lithium carbonate"/>
        <entity id="DDI-DrugBank.d167.s2.e7" charOffset="177-187"
            type="drug" text="terbutaline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d126.s0" text="Drug interaction studies with decitabine have not been conducted.">
        <entity id="DDI-DrugBank.d126.s0.e0" charOffset="30-39"
            type="drug" text="decitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d126.s1" text="In vitro studies in human liver microsomes suggest that decitabine is unlikely to inhibit or induce cytochrome P450 enzymes.">
        <entity id="DDI-DrugBank.d126.s1.e0" charOffset="56-65"
            type="drug" text="decitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d126.s2" text="In vitro metabolism studies have suggested that decitabine is not a substrate for the human liver cytochrome P450 enzymes.">
        <entity id="DDI-DrugBank.d126.s2.e0" charOffset="48-57"
            type="drug" text="decitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d126.s3" text="As plasma protein binding of decitabine is negligible ( 1%), interactions due to displacement of more highly protein bound drugs from plasma proteins are not expected.">
        <entity id="DDI-DrugBank.d126.s3.e0" charOffset="29-38"
            type="drug" text="decitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s0" text="The concomitant administration of Exjade and aluminum-containing antacid preparations has not been formally studied.">
        <entity id="DDI-DrugBank.d84.s0.e0" charOffset="34-39"
            type="brand" text="Exjade"/>
        <entity id="DDI-DrugBank.d84.s0.e1" charOffset="45-52"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d84.s0.e2" charOffset="65-84"
            type="group" text="antacid preparations"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s1" text="Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.">
        <entity id="DDI-DrugBank.d84.s1.e0" charOffset="9-19"
            type="drug" text="deferasirox"/>
        <entity id="DDI-DrugBank.d84.s1.e1" charOffset="46-53"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d84.s1.e2" charOffset="64-67"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d84.s1.e3" charOffset="70-75"
            type="brand" text="Exjade"/>
        <entity id="DDI-DrugBank.d84.s1.e4" charOffset="102-109"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d84.s1.e5" charOffset="122-141"
            type="group" text="antacid preparations"/>
        <ddi id="DDI-DrugBank.d84.s1.d0" e1="DDI-DrugBank.d84.s1.e3"
            e2="DDI-DrugBank.d84.s1.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s2" text="In healthy volunteers, Exjade had no effect on the pharmacokinetics of digoxin.">
        <entity id="DDI-DrugBank.d84.s2.e0" charOffset="23-28"
            type="brand" text="Exjade"/>
        <entity id="DDI-DrugBank.d84.s2.e1" charOffset="71-77"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s3" text="The effect of digoxin on Exjade pharmacokinetics has not been studied.">
        <entity id="DDI-DrugBank.d84.s3.e0" charOffset="14-20"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d84.s3.e1" charOffset="25-30"
            type="brand" text="Exjade"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s4" text="The concomitant administration of Exjade and vitamin C has not been formally studied.">
        <entity id="DDI-DrugBank.d84.s4.e0" charOffset="34-39"
            type="brand" text="Exjade"/>
        <entity id="DDI-DrugBank.d84.s4.e1" charOffset="45-53"
            type="drug" text="vitamin C"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s5" text="Doses of vitamin C up to 200 mg were allowed in clinical studies without negative consequences.">
        <entity id="DDI-DrugBank.d84.s5.e0" charOffset="9-17"
            type="drug" text="vitamin C"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s6" text="The interaction of Exjade with hydroxyurea has not been formally studied.">
        <entity id="DDI-DrugBank.d84.s6.e0" charOffset="19-24"
            type="brand" text="Exjade"/>
        <entity id="DDI-DrugBank.d84.s6.e1" charOffset="31-41"
            type="drug" text="hydroxyurea"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s7" text="No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study.">
        <entity id="DDI-DrugBank.d84.s7.e0" charOffset="17-27"
            type="drug" text="deferasirox"/>
        <entity id="DDI-DrugBank.d84.s7.e1" charOffset="43-53"
            type="drug" text="hydroxyurea"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s8" text="Exjade should not be combined with other iron chelator therapies, as safety of such combinations has not been established.">
        <entity id="DDI-DrugBank.d84.s8.e0" charOffset="0-5"
            type="brand" text="Exjade"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s9" text="Drug/Food Interactions The bioavailability (AUC) of deferasirox was variably increased when taken with a meal.">
        <entity id="DDI-DrugBank.d84.s9.e0" charOffset="52-62"
            type="drug" text="deferasirox"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s10" text="Deferasirox should be taken on an empty stomach 30 minutes before eating.">
        <entity id="DDI-DrugBank.d84.s10.e0" charOffset="0-10"
            type="drug" text="Deferasirox"/>
    </sentence>
    <sentence id="DDI-DrugBank.d84.s11" text="Exjade tablets for oral suspension can be dispersed in water, orange juice, or apple juice.">
        <entity id="DDI-DrugBank.d84.s11.e0" charOffset="0-5"
            type="brand" text="Exjade"/>
    </sentence>
    <sentence id="DDI-DrugBank.d251.s0" text="Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.">
        <entity id="DDI-DrugBank.d251.s0.e0" charOffset="10-23"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d251.s0.e1" charOffset="26-35"
            type="drug" text="Didanosine"/>
        <entity id="DDI-DrugBank.d251.s0.e2" charOffset="38-48"
            type="drug" text="Fluconazole"/>
        <entity id="DDI-DrugBank.d251.s0.e3" charOffset="51-60"
            type="drug" text="Fluoxetine"/>
        <entity id="DDI-DrugBank.d251.s0.e4" charOffset="74-85"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d251.s0.e5" charOffset="88-96"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d251.s0.e6" charOffset="114-126"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d251.s0.e7" charOffset="129-137"
            type="drug" text="Rifabutin"/>
        <entity id="DDI-DrugBank.d251.s0.e8" charOffset="140-147"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d251.s0.e9" charOffset="161-170"
            type="drug" text="Saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d149.s0" text="Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.">
        <entity id="DDI-DrugBank.d149.s0.e0" charOffset="30-37"
            type="brand" text="HUMORSOL"/>
        <entity id="DDI-DrugBank.d149.s0.e1" charOffset="44-58"
            type="drug" text="succinylcholine"/>
        <entity id="DDI-DrugBank.d149.s0.e2" charOffset="74-98"
            type="group" text="anticholinesterase agents"/>
        <ddi id="DDI-DrugBank.d149.s0.d0" e1="DDI-DrugBank.d149.s0.e0"
            e2="DDI-DrugBank.d149.s0.e1" type="int"/>
        <ddi id="DDI-DrugBank.d149.s0.d1" e1="DDI-DrugBank.d149.s0.e0"
            e2="DDI-DrugBank.d149.s0.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d409.s0" text="Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.">
        <entity id="DDI-DrugBank.d409.s0.e0" charOffset="12-24"
            type="group" text="tetracyclines"/>
        <entity id="DDI-DrugBank.d409.s0.e1" charOffset="102-114"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d409.s0.e2" charOffset="165-177"
            type="group" text="anticoagulant"/>
        <ddi id="DDI-DrugBank.d409.s0.d0" e1="DDI-DrugBank.d409.s0.e0"
            e2="DDI-DrugBank.d409.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d409.s1" text="Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.">
        <entity id="DDI-DrugBank.d409.s1.e0" charOffset="40-57"
            type="group" text="tetracycline class"/>
        <entity id="DDI-DrugBank.d409.s1.e1" charOffset="62-72"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d409.s1.e2" charOffset="121-131"
            type="group" text="penicillins"/>
        <ddi id="DDI-DrugBank.d409.s1.d0" e1="DDI-DrugBank.d409.s1.e0"
            e2="DDI-DrugBank.d409.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d409.s2" text="Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.">
        <entity id="DDI-DrugBank.d409.s2.e0" charOffset="18-30"
            type="group" text="tetracyclines"/>
        <entity id="DDI-DrugBank.d409.s2.e1" charOffset="42-55"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d409.s2.e2" charOffset="73-86"
            type="group" text="contraceptives"/>
        <ddi id="DDI-DrugBank.d409.s2.d0" e1="DDI-DrugBank.d409.s2.e0"
            e2="DDI-DrugBank.d409.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d409.s3" text="Breakthrough bleeding has been reported"/>
    <sentence id="DDI-DrugBank.d182.s0" text="No clinical drug interaction studies have been conducted."/>
    <sentence id="DDI-DrugBank.d182.s1" text="However, in a single in vivo rodent study denileukin diftitox had no effect on P450 levels.">
        <entity id="DDI-DrugBank.d182.s1.e0" charOffset="42-60"
            type="drug" text="denileukin diftitox"/>
    </sentence>
    <sentence id="DDI-DrugBank.d311.s0" text="Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.">
        <entity id="DDI-DrugBank.d311.s0.e0" charOffset="9-26"
            type="group" text="rauwolfia alkaloid"/>
        <entity id="DDI-DrugBank.d311.s0.e1" charOffset="77-90"
            type="group" text="MAO inhibitors"/>
        <ddi id="DDI-DrugBank.d311.s0.d0" e1="DDI-DrugBank.d311.s0.e0"
            e2="DDI-DrugBank.d311.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d363.s0" text="No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials.">
        <entity id="DDI-DrugBank.d363.s0.e0" charOffset="120-135"
            type="group" text="muscle relaxants"/>
        <entity id="DDI-DrugBank.d363.s0.e1" charOffset="168-184"
            type="group" text="anesthetic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d363.s1" text="The effect of desflurane on the disposition of other drugs has not been determined.">
        <entity id="DDI-DrugBank.d363.s1.e0" charOffset="14-23"
            type="drug" text="desflurane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d363.s2" text="Like isoflurane, desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine.">
        <entity id="DDI-DrugBank.d363.s2.e0" charOffset="5-14"
            type="drug" text="isoflurane"/>
        <entity id="DDI-DrugBank.d363.s2.e1" charOffset="17-26"
            type="drug" text="desflurane"/>
        <entity id="DDI-DrugBank.d363.s2.e2" charOffset="124-134"
            type="drug" text="epinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s0" text="1."/>
    <sentence id="DDI-DrugBank.d386.s1" text="Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers);"/>
    <sentence id="DDI-DrugBank.d386.s2" text="reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available."/>
    <sentence id="DDI-DrugBank.d386.s3" text="Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.">
        <entity id="DDI-DrugBank.d386.s3.e0" charOffset="69-93"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d386.s3.e1" charOffset="96-99"
            type="group" text="TCAs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s4" text="Depending on the traction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).">
        <entity id="DDI-DrugBank.d386.s4.e0" charOffset="163-165"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s5" text="In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o."/>
    <sentence id="DDI-DrugBank.d386.s6" text="metabolizers."/>
    <sentence id="DDI-DrugBank.d386.s7" text="An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.">
        <entity id="DDI-DrugBank.d386.s7.e0" charOffset="47-49"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s8" text="The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;">
        <entity id="DDI-DrugBank.d386.s8.e0" charOffset="96-104"
            type="drug" text="quinidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s9" text="cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).">
        <entity id="DDI-DrugBank.d386.s9.e0" charOffset="0-9"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d386.s9.e1" charOffset="66-80"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d386.s9.e2" charOffset="83-96"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d386.s9.e3" charOffset="148-157"
            type="drug" text="flecainide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s10" text="While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.">
        <entity id="DDI-DrugBank.d386.s10.e0" charOffset="14-52"
            type="group" text="selective serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d386.s10.e1" charOffset="55-59"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d386.s10.e2" charOffset="69-78"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d386.s10.e3" charOffset="97-106"
            type="drug" text="paroxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s11" text="The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.">
        <entity id="DDI-DrugBank.d386.s11.e0" charOffset="20-23"
            type="group" text="SSRI"/>
        <entity id="DDI-DrugBank.d386.s11.e1" charOffset="25-27"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d386.s11.e2" charOffset="141-144"
            type="group" text="SSRI"/>
        <ddi id="DDI-DrugBank.d386.s11.d0" e1="DDI-DrugBank.d386.s11.e0"
            e2="DDI-DrugBank.d386.s11.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s12" text="Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.">
        <entity id="DDI-DrugBank.d386.s12.e0" charOffset="63-66"
            type="group" text="T.A."/>
        <entity id="DDI-DrugBank.d386.s12.e1" charOffset="84-88"
            type="group" text="SSRIs"/>
        <ddi id="DDI-DrugBank.d386.s12.d0" e1="DDI-DrugBank.d386.s12.e0"
            e2="DDI-DrugBank.d386.s12.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s13" text="Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).">
        <entity id="DDI-DrugBank.d386.s13.e0" charOffset="120-129"
            type="drug" text="fluoxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s14" text="Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.">
        <entity id="DDI-DrugBank.d386.s14.e0" charOffset="19-43"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d386.s14.e1" charOffset="156-179"
            type="group" text="tricyclic antidepressant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s15" text="Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.">
        <entity id="DDI-DrugBank.d386.s15.e0" charOffset="98-121"
            type="group" text="tricyclic antidepressant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s16" text="It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.">
        <entity id="DDI-DrugBank.d386.s16.e0" charOffset="27-29"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d386.s16.e1" charOffset="56-58"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s17" text="2."/>
    <sentence id="DDI-DrugBank.d386.s18" text="Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs.">
        <entity id="DDI-DrugBank.d386.s18.e0" charOffset="107-121"
            type="group" text="anticholinergic"/>
        <entity id="DDI-DrugBank.d386.s18.e1" charOffset="126-146"
            type="group" text="sympathomimetic drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s19" text="3."/>
    <sentence id="DDI-DrugBank.d386.s20" text="Clinical experience in the concurrent administration of ECT and antidepressant drugs is limited.">
        <entity id="DDI-DrugBank.d386.s20.e0" charOffset="64-83"
            type="group" text="antidepressant drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s21" text="Thus, if such treatment is essential, the possibility of increased risk relative to benefits should be considered."/>
    <sentence id="DDI-DrugBank.d386.s22" text="4."/>
    <sentence id="DDI-DrugBank.d386.s23" text="If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.">
        <entity id="DDI-DrugBank.d386.s23.e0" charOffset="3-27"
            type="drug" text="desipramine hydrochloride"/>
        <entity id="DDI-DrugBank.d386.s23.e1" charOffset="58-76"
            type="group" text="psychotropic agents"/>
        <entity id="DDI-DrugBank.d386.s23.e2" charOffset="86-98"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d386.s23.e3" charOffset="103-110"
            type="group" text="sedative"/>
        <entity id="DDI-DrugBank.d386.s23.e4" charOffset="112-120"
            type="group" text="hypnotics"/>
        <entity id="DDI-DrugBank.d386.s23.e5" charOffset="234-244"
            type="drug" text="desipramine"/>
        <entity id="DDI-DrugBank.d386.s23.e6" charOffset="250-264"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d386.s23.e7" charOffset="273-288"
            type="drug" text="chlordiazepoxide"/>
        <entity id="DDI-DrugBank.d386.s23.e8" charOffset="293-300"
            type="drug" text="diazepam"/>
        <ddi id="DDI-DrugBank.d386.s23.d0" e1="DDI-DrugBank.d386.s23.e0"
            e2="DDI-DrugBank.d386.s23.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d386.s23.d1" e1="DDI-DrugBank.d386.s23.e0"
            e2="DDI-DrugBank.d386.s23.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d386.s23.d2" e1="DDI-DrugBank.d386.s23.e0"
            e2="DDI-DrugBank.d386.s23.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d386.s23.d3" e1="DDI-DrugBank.d386.s23.e0"
            e2="DDI-DrugBank.d386.s23.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d386.s23.d4" e1="DDI-DrugBank.d386.s23.e5"
            e2="DDI-DrugBank.d386.s23.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d386.s23.d5" e1="DDI-DrugBank.d386.s23.e5"
            e2="DDI-DrugBank.d386.s23.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d386.s23.d6" e1="DDI-DrugBank.d386.s23.e5"
            e2="DDI-DrugBank.d386.s23.e8" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s24" text="Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.">
        <entity id="DDI-DrugBank.d386.s24.e0" charOffset="53-71"
            type="group" text="major tranquilizers"/>
        <entity id="DDI-DrugBank.d386.s24.e1" charOffset="103-113"
            type="drug" text="desipramine"/>
        <ddi id="DDI-DrugBank.d386.s24.d0" e1="DDI-DrugBank.d386.s24.e0"
            e2="DDI-DrugBank.d386.s24.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s25" text="5."/>
    <sentence id="DDI-DrugBank.d386.s26" text="Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.">
        <entity id="DDI-DrugBank.d386.s26.e0" charOffset="29-38"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d386.s26.e1" charOffset="44-68"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d386.s26.e2" charOffset="143-167"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d386.s26.d0" e1="DDI-DrugBank.d386.s26.e0"
            e2="DDI-DrugBank.d386.s26.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s27" text="Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.">
        <entity id="DDI-DrugBank.d386.s27.e0" charOffset="46-70"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d386.s27.e1" charOffset="115-124"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d386.s27.e2" charOffset="190-213"
            type="group" text="tricyclic antidepressant"/>
        <ddi id="DDI-DrugBank.d386.s27.d0" e1="DDI-DrugBank.d386.s27.e0"
            e2="DDI-DrugBank.d386.s27.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d386.s28" text="There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.">
        <entity id="DDI-DrugBank.d386.s28.e0" charOffset="86-110"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d386.s28.e1" charOffset="117-126"
            type="drug" text="fluoxetine"/>
        <ddi id="DDI-DrugBank.d386.s28.d0" e1="DDI-DrugBank.d386.s28.e0"
            e2="DDI-DrugBank.d386.s28.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d67.s0" text="In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.">
        <entity id="DDI-DrugBank.d67.s0.e0" charOffset="140-152"
            type="drug" text="desloratadine"/>
        <entity id="DDI-DrugBank.d67.s0.e1" charOffset="223-234"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d67.s0.e2" charOffset="260-271"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d67.s1" text="In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.">
        <entity id="DDI-DrugBank.d67.s1.e0" charOffset="76-88"
            type="drug" text="desloratadine"/>
        <entity id="DDI-DrugBank.d67.s1.e1" charOffset="148-159"
            type="drug" text="azithromycin"/>
        <entity id="DDI-DrugBank.d67.s1.e2" charOffset="224-233"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d67.s1.e3" charOffset="303-312"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d67.s1.e4" charOffset="329-338"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d67.s2" text="Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.">
        <entity id="DDI-DrugBank.d67.s2.e0" charOffset="69-81"
            type="drug" text="desloratadine"/>
        <entity id="DDI-DrugBank.d67.s2.e1" charOffset="87-108"
            type="drug_n" text="3-hydroxydesloratadine"/>
        <entity id="DDI-DrugBank.d67.s2.e2" charOffset="193-205"
            type="drug" text="desloratadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d67.s3" text="Table 1 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers">
        <entity id="DDI-DrugBank.d67.s3.e0" charOffset="19-31"
            type="drug" text="Desloratadine"/>
        <entity id="DDI-DrugBank.d67.s3.e1" charOffset="37-58"
            type="drug_n" text="3-Hydroxydesloratadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d67.s4" text=""/>
    <sentence id="DDI-DrugBank.d67.s5" text="Desloratadine 3-Hydroxydesloratadine">
        <entity id="DDI-DrugBank.d67.s5.e0" charOffset="0-12"
            type="drug" text="Desloratadine"/>
        <entity id="DDI-DrugBank.d67.s5.e1" charOffset="14-35"
            type="drug_n" text="3-Hydroxydesloratadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d67.s6" text=""/>
    <sentence id="DDI-DrugBank.d67.s7" text="C max AUC 0-24 hrs C max AUC 0-24 hrs"/>
    <sentence id="DDI-DrugBank.d67.s8" text="Erythromycin">
        <entity id="DDI-DrugBank.d67.s8.e0" charOffset="0-11"
            type="drug" text="Erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d67.s9" text="(500 mg Q8h)"/>
    <sentence id="DDI-DrugBank.d67.s10" text="+24% +14% +43% +40%"/>
    <sentence id="DDI-DrugBank.d67.s11" text="Ketoconazole">
        <entity id="DDI-DrugBank.d67.s11.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d67.s12" text="(200 mg Q12h)"/>
    <sentence id="DDI-DrugBank.d67.s13" text="+45% +39% +43% +72%"/>
    <sentence id="DDI-DrugBank.d67.s14" text="Azithromycin">
        <entity id="DDI-DrugBank.d67.s14.e0" charOffset="0-11"
            type="drug" text="Azithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d67.s15" text="(500 mg day 1, 250 mg QD   4 days)"/>
    <sentence id="DDI-DrugBank.d67.s16" text="+15% +5% +15% +4%"/>
    <sentence id="DDI-DrugBank.d67.s17" text="Fluoxetine">
        <entity id="DDI-DrugBank.d67.s17.e0" charOffset="0-9"
            type="drug" text="Fluoxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d67.s18" text="(20 mg QD)"/>
    <sentence id="DDI-DrugBank.d67.s19" text="+15% +0% +17% +13%"/>
    <sentence id="DDI-DrugBank.d67.s20" text="Cimetidine">
        <entity id="DDI-DrugBank.d67.s20.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d67.s21" text="(600 mg Q12h)"/>
    <sentence id="DDI-DrugBank.d67.s22" text="+12% +19% -11%  -3%"/>
    <sentence id="DDI-DrugBank.d348.s0" text="Although the pressor activity of Desmopressin is very low compared to its antidiuretic activity, large doses of Desmopressin Tablets should be used with other pressor agents only with careful patient monitoring.">
        <entity id="DDI-DrugBank.d348.s0.e0" charOffset="33-44"
            type="drug" text="Desmopressin"/>
        <entity id="DDI-DrugBank.d348.s0.e1" charOffset="112-123"
            type="drug" text="Desmopressin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d285.s0" text="Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin.">
        <entity id="DDI-DrugBank.d285.s0.e0" charOffset="140-147"
            type="drug" text="rifampin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d285.s1" text="A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)">
        <entity id="DDI-DrugBank.d285.s1.e0" charOffset="67-78"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d285.s1.e1" charOffset="98-113"
            type="drug" text="phenytoin sodium"/>
        <entity id="DDI-DrugBank.d285.s1.e2" charOffset="116-128"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d285.s1.e3" charOffset="148-159"
            type="drug" text="griseofulvin"/>
        <entity id="DDI-DrugBank.d285.s1.e4" charOffset="162-171"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d285.s1.e5" charOffset="178-190"
            type="group" text="tetracyclines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d285.s2" text="."/>
    <sentence id="DDI-DrugBank.d285.s3" text=""/>
    <sentence id="DDI-DrugBank.d285.s4" text=""/>
    <sentence id="DDI-DrugBank.d280.s0" text="No specific information available"/>
    <sentence id="DDI-DrugBank.d280.s1" text="."/>
    <sentence id="DDI-DrugBank.d280.s2" text=""/>
    <sentence id="DDI-DrugBank.d314.s0" text="Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.">
        <entity id="DDI-DrugBank.d314.s0.e0" charOffset="0-16"
            type="drug" text="Aminoglutethimide"/>
        <entity id="DDI-DrugBank.d314.s0.e1" charOffset="19-35"
            type="drug" text="Aminoglutethimide"/>
        <entity id="DDI-DrugBank.d314.s0.e2" charOffset="73-87"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d314.s0.d0" e1="DDI-DrugBank.d314.s0.e1"
            e2="DDI-DrugBank.d314.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s1" text="Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.">
        <entity id="DDI-DrugBank.d314.s1.e0" charOffset="0-13"
            type="drug" text="Amphotericin B"/>
        <entity id="DDI-DrugBank.d314.s1.e1" charOffset="62-76"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d314.s1.e2" charOffset="148-161"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d314.s1.e3" charOffset="164-172"
            type="group" text="diuretics"/>
        <ddi id="DDI-DrugBank.d314.s1.d0" e1="DDI-DrugBank.d314.s1.e1"
            e2="DDI-DrugBank.d314.s1.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d314.s1.d1" e1="DDI-DrugBank.d314.s1.e1"
            e2="DDI-DrugBank.d314.s1.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s2" text="In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.">
        <entity id="DDI-DrugBank.d314.s2.e0" charOffset="72-85"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d314.s2.e1" charOffset="91-104"
            type="drug" text="hydrocortisone"/>
        <ddi id="DDI-DrugBank.d314.s2.d0" e1="DDI-DrugBank.d314.s2.e0"
            e2="DDI-DrugBank.d314.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s3" text="Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.">
        <entity id="DDI-DrugBank.d314.s3.e0" charOffset="0-10"
            type="group" text="Antibiotics"/>
        <entity id="DDI-DrugBank.d314.s3.e1" charOffset="13-33"
            type="group" text="Macrolide antibiotics"/>
        <entity id="DDI-DrugBank.d314.s3.e2" charOffset="89-102"
            type="group" text="corticosteroid"/>
        <ddi id="DDI-DrugBank.d314.s3.d0" e1="DDI-DrugBank.d314.s3.e1"
            e2="DDI-DrugBank.d314.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s4" text="Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.">
        <entity id="DDI-DrugBank.d314.s4.e0" charOffset="0-18"
            type="group" text="Anticholinesterases"/>
        <entity id="DDI-DrugBank.d314.s4.e1" charOffset="40-64"
            type="group" text="anticholinesterase agents"/>
        <entity id="DDI-DrugBank.d314.s4.e2" charOffset="70-84"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d314.s4.d0" e1="DDI-DrugBank.d314.s4.e1"
            e2="DDI-DrugBank.d314.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s5" text="If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.">
        <entity id="DDI-DrugBank.d314.s5.e0" charOffset="13-37"
            type="group" text="anticholinesterase agents"/>
        <entity id="DDI-DrugBank.d314.s5.e1" charOffset="95-108"
            type="group" text="corticosteroid"/>
        <ddi id="DDI-DrugBank.d314.s5.d0" e1="DDI-DrugBank.d314.s5.e0"
            e2="DDI-DrugBank.d314.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s6" text="Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.">
        <entity id="DDI-DrugBank.d314.s6.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d314.s6.e1" charOffset="43-57"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d314.s6.e2" charOffset="63-70"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d314.s6.e3" charOffset="117-124"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d314.s6.d0" e1="DDI-DrugBank.d314.s6.e1"
            e2="DDI-DrugBank.d314.s6.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s7" text="Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."/>
    <sentence id="DDI-DrugBank.d314.s8" text="Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.">
        <entity id="DDI-DrugBank.d314.s8.e0" charOffset="0-12"
            type="group" text="Antidiabetics"/>
        <entity id="DDI-DrugBank.d314.s8.e1" charOffset="23-37"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d314.s8.e2" charOffset="104-122"
            type="group" text="antidiabetic agents"/>
        <ddi id="DDI-DrugBank.d314.s8.d0" e1="DDI-DrugBank.d314.s8.e1"
            e2="DDI-DrugBank.d314.s8.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s9" text="Antitubercular drugs: Serum concentrations of isoniazid may be decreased.">
        <entity id="DDI-DrugBank.d314.s9.e0" charOffset="46-54"
            type="drug" text="isoniazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s10" text="Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.">
        <entity id="DDI-DrugBank.d314.s10.e0" charOffset="0-13"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d314.s10.e1" charOffset="16-29"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d314.s10.e2" charOffset="61-75"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d314.s10.d0" e1="DDI-DrugBank.d314.s10.e1"
            e2="DDI-DrugBank.d314.s10.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s11" text="Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.">
        <entity id="DDI-DrugBank.d314.s11.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d314.s11.e1" charOffset="41-52"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d314.s11.e2" charOffset="58-72"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d314.s11.d0" e1="DDI-DrugBank.d314.s11.e1"
            e2="DDI-DrugBank.d314.s11.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s12" text="Convulsions have been reported with this concurrent use."/>
    <sentence id="DDI-DrugBank.d314.s13" text="Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported.">
        <entity id="DDI-DrugBank.d314.s13.e0" charOffset="136-147"
            type="drug" text="indomethacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s14" text="Thus, results of the DST should be interpreted with caution in these patients."/>
    <sentence id="DDI-DrugBank.d314.s15" text="Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.">
        <entity id="DDI-DrugBank.d314.s15.e0" charOffset="0-19"
            type="group" text="Digitalis glycosides"/>
        <entity id="DDI-DrugBank.d314.s15.e1" charOffset="34-53"
            type="group" text="digitalis glycosides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s16" text="Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.">
        <entity id="DDI-DrugBank.d314.s16.e0" charOffset="0-8"
            type="drug" text="Ephedrine"/>
        <entity id="DDI-DrugBank.d314.s16.e1" charOffset="11-19"
            type="drug" text="Ephedrine"/>
        <entity id="DDI-DrugBank.d314.s16.e2" charOffset="60-74"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d314.s16.e3" charOffset="178-191"
            type="group" text="corticosteroid"/>
        <ddi id="DDI-DrugBank.d314.s16.d0" e1="DDI-DrugBank.d314.s16.e1"
            e2="DDI-DrugBank.d314.s16.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s17" text="Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.">
        <entity id="DDI-DrugBank.d314.s17.e0" charOffset="0-8"
            type="group" text="Estrogens"/>
        <entity id="DDI-DrugBank.d314.s17.e1" charOffset="26-39"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d314.s17.e2" charOffset="42-50"
            type="group" text="Estrogens"/>
        <entity id="DDI-DrugBank.d314.s17.e3" charOffset="99-113"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d314.s17.d0" e1="DDI-DrugBank.d314.s17.e2"
            e2="DDI-DrugBank.d314.s17.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s18" text="Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.">
        <entity id="DDI-DrugBank.d314.s18.e0" charOffset="124-135"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d314.s18.e1" charOffset="138-146"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d314.s18.e2" charOffset="149-161"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d314.s18.e3" charOffset="164-171"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d314.s18.e4" charOffset="204-218"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d314.s18.e5" charOffset="255-268"
            type="group" text="corticosteroid"/>
        <ddi id="DDI-DrugBank.d314.s18.d0" e1="DDI-DrugBank.d314.s18.e0"
            e2="DDI-DrugBank.d314.s18.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d314.s18.d1" e1="DDI-DrugBank.d314.s18.e1"
            e2="DDI-DrugBank.d314.s18.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d314.s18.d2" e1="DDI-DrugBank.d314.s18.e2"
            e2="DDI-DrugBank.d314.s18.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d314.s18.d3" e1="DDI-DrugBank.d314.s18.e3"
            e2="DDI-DrugBank.d314.s18.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s19" text="Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.">
        <entity id="DDI-DrugBank.d314.s19.e0" charOffset="35-46"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d314.s19.e1" charOffset="49-69"
            type="group" text="macrolide antibiotics"/>
        <entity id="DDI-DrugBank.d314.s19.e2" charOffset="79-90"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d314.s19.e3" charOffset="160-174"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d314.s19.d0" e1="DDI-DrugBank.d314.s19.e0"
            e2="DDI-DrugBank.d314.s19.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d314.s19.d1" e1="DDI-DrugBank.d314.s19.e1"
            e2="DDI-DrugBank.d314.s19.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d314.s19.d2" e1="DDI-DrugBank.d314.s19.e2"
            e2="DDI-DrugBank.d314.s19.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s20" text="Dexamethasone is a moderate inducer of CYP 3A4.">
        <entity id="DDI-DrugBank.d314.s20.e0" charOffset="0-12"
            type="drug" text="Dexamethasone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s21" text="Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration.">
        <entity id="DDI-DrugBank.d314.s21.e0" charOffset="74-82"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d314.s21.e1" charOffset="85-96"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s22" text="Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.">
        <entity id="DDI-DrugBank.d314.s22.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d314.s22.e1" charOffset="14-25"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d314.s22.e2" charOffset="83-97"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d314.s22.e3" charOffset="142-155"
            type="group" text="corticosteroid"/>
        <ddi id="DDI-DrugBank.d314.s22.d0" e1="DDI-DrugBank.d314.s22.e1"
            e2="DDI-DrugBank.d314.s22.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s23" text="In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.">
        <entity id="DDI-DrugBank.d314.s23.e0" charOffset="13-24"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d314.s23.e1" charOffset="52-65"
            type="drug" text="corticosteroid"/>
        <ddi id="DDI-DrugBank.d314.s23.d0" e1="DDI-DrugBank.d314.s23.e0"
            e2="DDI-DrugBank.d314.s23.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s24" text="Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.">
        <entity id="DDI-DrugBank.d314.s24.e0" charOffset="0-36"
            type="group" text="Nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d314.s24.e1" charOffset="39-44"
            type="group" text="NSAIDS"/>
        <entity id="DDI-DrugBank.d314.s24.e2" charOffset="67-73"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d314.s24.e3" charOffset="85-120"
            type="group" text="nonsteroidal antiinflammatory agents"/>
        <entity id="DDI-DrugBank.d314.s24.e4" charOffset="127-141"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d314.s24.d0" e1="DDI-DrugBank.d314.s24.e2"
            e2="DDI-DrugBank.d314.s24.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d314.s24.d1" e1="DDI-DrugBank.d314.s24.e3"
            e2="DDI-DrugBank.d314.s24.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s25" text="Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.">
        <entity id="DDI-DrugBank.d314.s25.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d314.s25.e1" charOffset="54-68"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d314.s25.d0" e1="DDI-DrugBank.d314.s25.e0"
            e2="DDI-DrugBank.d314.s25.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s26" text="The clearance of salicylates may be increased with concurrent use of corticosteroids.">
        <entity id="DDI-DrugBank.d314.s26.e0" charOffset="17-27"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d314.s26.e1" charOffset="69-83"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d314.s26.d0" e1="DDI-DrugBank.d314.s26.e0"
            e2="DDI-DrugBank.d314.s26.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s27" text="Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.">
        <entity id="DDI-DrugBank.d314.s27.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d314.s27.e1" charOffset="100-108"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d314.s27.e2" charOffset="122-134"
            type="drug" text="dexamethasone"/>
        <ddi id="DDI-DrugBank.d314.s27.d0" e1="DDI-DrugBank.d314.s27.e2"
            e2="DDI-DrugBank.d314.s27.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s28" text="Skin tests: Corticosteroids may suppress reactions to skin tests.">
        <entity id="DDI-DrugBank.d314.s28.e0" charOffset="12-26"
            type="group" text="Corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s29" text="Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.">
        <entity id="DDI-DrugBank.d314.s29.e0" charOffset="0-10"
            type="drug" text="Thalidomide"/>
        <entity id="DDI-DrugBank.d314.s29.e1" charOffset="36-46"
            type="drug" text="thalidomide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s30" text="Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.">
        <entity id="DDI-DrugBank.d314.s30.e0" charOffset="0-7"
            type="group" text="Vaccines"/>
        <entity id="DDI-DrugBank.d314.s30.e1" charOffset="22-35"
            type="group" text="corticosteroid"/>
        <entity id="DDI-DrugBank.d314.s30.e2" charOffset="94-97;114-121"
            type="group" text="live vaccines"/>
        <entity id="DDI-DrugBank.d314.s30.e3" charOffset="102-121"
            type="group" text="inactivated vaccines"/>
        <ddi id="DDI-DrugBank.d314.s30.d0" e1="DDI-DrugBank.d314.s30.e1"
            e2="DDI-DrugBank.d314.s30.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d314.s30.d1" e1="DDI-DrugBank.d314.s30.e1"
            e2="DDI-DrugBank.d314.s30.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s31" text="Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.">
        <entity id="DDI-DrugBank.d314.s31.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d314.s31.e1" charOffset="83-106"
            type="group" text="live attenuated vaccines"/>
        <ddi id="DDI-DrugBank.d314.s31.d0" e1="DDI-DrugBank.d314.s31.e0"
            e2="DDI-DrugBank.d314.s31.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d314.s32" text="Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.">
        <entity id="DDI-DrugBank.d314.s32.e0" charOffset="26-33"
            type="group" text="vaccines"/>
        <entity id="DDI-DrugBank.d314.s32.e1" charOffset="71-84"
            type="group" text="corticosteroid"/>
        <ddi id="DDI-DrugBank.d314.s32.d0" e1="DDI-DrugBank.d314.s32.e0"
            e2="DDI-DrugBank.d314.s32.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d62.s0" text="Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).">
        <entity id="DDI-DrugBank.d62.s0.e0" charOffset="0-17"
            type="drug" text="Dexbrompheniramine"/>
        <entity id="DDI-DrugBank.d62.s0.e1" charOffset="37-43"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d62.s0.e2" charOffset="54-68"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d62.s0.e3" charOffset="144-157"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d62.s0.e4" charOffset="161-176"
            type="group" text="anticholinergics"/>
        <entity id="DDI-DrugBank.d62.s0.e5" charOffset="323-336"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d62.s0.e6" charOffset="344-377"
            type="group" text="monoamine oxidase (MAO) inhibitors"/>
        <entity id="DDI-DrugBank.d62.s0.e7" charOffset="400-413"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d62.s0.e8" charOffset="491-504"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d62.s0.d0" e1="DDI-DrugBank.d62.s0.e0"
            e2="DDI-DrugBank.d62.s0.e1" type="int"/>
        <ddi id="DDI-DrugBank.d62.s0.d1" e1="DDI-DrugBank.d62.s0.e0"
            e2="DDI-DrugBank.d62.s0.e2" type="int"/>
        <ddi id="DDI-DrugBank.d62.s0.d2" e1="DDI-DrugBank.d62.s0.e0"
            e2="DDI-DrugBank.d62.s0.e4" type="int"/>
        <ddi id="DDI-DrugBank.d62.s0.d3" e1="DDI-DrugBank.d62.s0.e0"
            e2="DDI-DrugBank.d62.s0.e6" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d423.s0" text="In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.">
        <entity id="DDI-DrugBank.d423.s0.e0" charOffset="35-62"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d423.s0.e1" charOffset="65-69"
            type="group" text="MAOIs"/>
        <entity id="DDI-DrugBank.d423.s0.e2" charOffset="79-102"
            type="drug" text="selegiline hydrochloride"/>
        <entity id="DDI-DrugBank.d423.s0.e3" charOffset="125-145"
            type="group" text="serotoninergic agents"/>
        <entity id="DDI-DrugBank.d423.s0.e4" charOffset="154-163"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d423.s0.e5" charOffset="166-176"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d423.s0.e6" charOffset="179-188"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d423.s0.e7" charOffset="191-200"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d423.s0.e8" charOffset="203-213"
            type="drug" text="venlafaxine"/>
        <ddi id="DDI-DrugBank.d423.s0.d0" e1="DDI-DrugBank.d423.s0.e0"
            e2="DDI-DrugBank.d423.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d1" e1="DDI-DrugBank.d423.s0.e0"
            e2="DDI-DrugBank.d423.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d2" e1="DDI-DrugBank.d423.s0.e0"
            e2="DDI-DrugBank.d423.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d3" e1="DDI-DrugBank.d423.s0.e0"
            e2="DDI-DrugBank.d423.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d4" e1="DDI-DrugBank.d423.s0.e0"
            e2="DDI-DrugBank.d423.s0.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d5" e1="DDI-DrugBank.d423.s0.e0"
            e2="DDI-DrugBank.d423.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d6" e1="DDI-DrugBank.d423.s0.e1"
            e2="DDI-DrugBank.d423.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d7" e1="DDI-DrugBank.d423.s0.e1"
            e2="DDI-DrugBank.d423.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d8" e1="DDI-DrugBank.d423.s0.e1"
            e2="DDI-DrugBank.d423.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d9" e1="DDI-DrugBank.d423.s0.e1"
            e2="DDI-DrugBank.d423.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d10" e1="DDI-DrugBank.d423.s0.e1"
            e2="DDI-DrugBank.d423.s0.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d11" e1="DDI-DrugBank.d423.s0.e1"
            e2="DDI-DrugBank.d423.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d12" e1="DDI-DrugBank.d423.s0.e2"
            e2="DDI-DrugBank.d423.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d13" e1="DDI-DrugBank.d423.s0.e2"
            e2="DDI-DrugBank.d423.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d14" e1="DDI-DrugBank.d423.s0.e2"
            e2="DDI-DrugBank.d423.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d15" e1="DDI-DrugBank.d423.s0.e2"
            e2="DDI-DrugBank.d423.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d16" e1="DDI-DrugBank.d423.s0.e2"
            e2="DDI-DrugBank.d423.s0.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s0.d17" e1="DDI-DrugBank.d423.s0.e2"
            e2="DDI-DrugBank.d423.s0.e8" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d423.s1" text="Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.">
        <entity id="DDI-DrugBank.d423.s1.e0" charOffset="8-22"
            type="drug" text="dexfenfluramine"/>
        <entity id="DDI-DrugBank.d423.s1.e1" charOffset="72-86"
            type="drug" text="dexfenfluramine"/>
        <entity id="DDI-DrugBank.d423.s1.e2" charOffset="128-140"
            type="group" text="MAO inhibitor"/>
        <ddi id="DDI-DrugBank.d423.s1.d0" e1="DDI-DrugBank.d423.s1.e1"
            e2="DDI-DrugBank.d423.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d423.s2" text="At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.">
        <entity id="DDI-DrugBank.d423.s2.e0" charOffset="60-72"
            type="group" text="MAO inhibitor"/>
        <entity id="DDI-DrugBank.d423.s2.e1" charOffset="107-121"
            type="drug" text="dexfenfluramine"/>
        <ddi id="DDI-DrugBank.d423.s2.d0" e1="DDI-DrugBank.d423.s2.e0"
            e2="DDI-DrugBank.d423.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d423.s3" text="At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.">
        <entity id="DDI-DrugBank.d423.s3.e0" charOffset="58-72"
            type="drug" text="dexfenfluramine"/>
        <entity id="DDI-DrugBank.d423.s3.e1" charOffset="109-121"
            type="group" text="MAO inhibitor"/>
        <ddi id="DDI-DrugBank.d423.s3.d0" e1="DDI-DrugBank.d423.s3.e0"
            e2="DDI-DrugBank.d423.s3.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d423.s4" text="A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.">
        <entity id="DDI-DrugBank.d423.s4.e0" charOffset="121-159"
            type="group" text="selective serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d423.s4.e1" charOffset="162-166"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d423.s4.e2" charOffset="210-216"
            type="brand" text="Imitrex"/>
        <entity id="DDI-DrugBank.d423.s4.e3" charOffset="219-239"
            type="drug" text="sumatriptan succinate"/>
        <entity id="DDI-DrugBank.d423.s4.e4" charOffset="246-262"
            type="drug" text="dihydroergotamine"/>
        <ddi id="DDI-DrugBank.d423.s4.d0" e1="DDI-DrugBank.d423.s4.e0"
            e2="DDI-DrugBank.d423.s4.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s4.d1" e1="DDI-DrugBank.d423.s4.e0"
            e2="DDI-DrugBank.d423.s4.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s4.d2" e1="DDI-DrugBank.d423.s4.e0"
            e2="DDI-DrugBank.d423.s4.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s4.d3" e1="DDI-DrugBank.d423.s4.e1"
            e2="DDI-DrugBank.d423.s4.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s4.d4" e1="DDI-DrugBank.d423.s4.e1"
            e2="DDI-DrugBank.d423.s4.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d423.s4.d5" e1="DDI-DrugBank.d423.s4.e1"
            e2="DDI-DrugBank.d423.s4.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d423.s5" text="The syndrome requires immediate medical attention and may include one or more of the following symptoms: excitement, hypomania, restlessness, loss of consciousness, confusion, disorientation, anxiety, agitation, motor weakness, myoclonus, tremor, hemiballismus, hyperreflexia, ataxia, dysarthria, incoordination, hyperthermia, shivering, pupillary dilation, diaphoresis, emesis, and tachycardia."/>
    <sentence id="DDI-DrugBank.d423.s6" text="Dexfenfluramine should not be administered with other serotoninergic agents.">
        <entity id="DDI-DrugBank.d423.s6.e0" charOffset="0-14"
            type="drug" text="Dexfenfluramine"/>
        <entity id="DDI-DrugBank.d423.s6.e1" charOffset="54-74"
            type="group" text="serotoninergic agents"/>
        <ddi id="DDI-DrugBank.d423.s6.d0" e1="DDI-DrugBank.d423.s6.e0"
            e2="DDI-DrugBank.d423.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d423.s7" text="The appropriate interval between administration of these agents and dexfenfluramine has not been established.">
        <entity id="DDI-DrugBank.d423.s7.e0" charOffset="68-82"
            type="drug" text="dexfenfluramine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d423.s8" text="The use of dexfenfluramine with other CNS-active drugs has not been systematically evaluated;">
        <entity id="DDI-DrugBank.d423.s8.e0" charOffset="11-25"
            type="drug" text="dexfenfluramine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d423.s9" text="consequently, caution is advised if dexfenfluramine and such drugs are prescribed concurrently.">
        <entity id="DDI-DrugBank.d423.s9.e0" charOffset="36-50"
            type="drug" text="dexfenfluramine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d197.s0" text="General In vitro studies in human liver microsomes demonstrated no evidence of cytochrome P450-mediated drug interactions that are likely to be of clinical relevance."/>
    <sentence id="DDI-DrugBank.d197.s1" text="Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.">
        <entity id="DDI-DrugBank.d197.s1.e0" charOffset="0-10"
            type="group" text="Anesthetics"/>
        <entity id="DDI-DrugBank.d197.s1.e1" charOffset="12-20"
            type="group" text="Sedatives"/>
        <entity id="DDI-DrugBank.d197.s1.e2" charOffset="22-30"
            type="group" text="Hypnotics"/>
        <entity id="DDI-DrugBank.d197.s1.e3" charOffset="32-38"
            type="group" text="Opioids"/>
        <entity id="DDI-DrugBank.d197.s1.e4" charOffset="62-69"
            type="brand" text="PRECEDEX"/>
        <entity id="DDI-DrugBank.d197.s1.e5" charOffset="76-86"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d197.s1.e6" charOffset="89-97"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d197.s1.e7" charOffset="100-108"
            type="group" text="hypnotics"/>
        <entity id="DDI-DrugBank.d197.s1.e8" charOffset="115-121"
            type="group" text="opioids"/>
        <ddi id="DDI-DrugBank.d197.s1.d0" e1="DDI-DrugBank.d197.s1.e4"
            e2="DDI-DrugBank.d197.s1.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d197.s1.d1" e1="DDI-DrugBank.d197.s1.e4"
            e2="DDI-DrugBank.d197.s1.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d197.s1.d2" e1="DDI-DrugBank.d197.s1.e4"
            e2="DDI-DrugBank.d197.s1.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d197.s1.d3" e1="DDI-DrugBank.d197.s1.e4"
            e2="DDI-DrugBank.d197.s1.e8" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d197.s2" text="Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.">
        <entity id="DDI-DrugBank.d197.s2.e0" charOffset="51-61"
            type="drug" text="sevoflurane"/>
        <entity id="DDI-DrugBank.d197.s2.e1" charOffset="64-73"
            type="drug" text="isoflurane"/>
        <entity id="DDI-DrugBank.d197.s2.e2" charOffset="76-83"
            type="drug" text="propofol"/>
        <entity id="DDI-DrugBank.d197.s2.e3" charOffset="86-95"
            type="drug" text="alfentanil"/>
        <entity id="DDI-DrugBank.d197.s2.e4" charOffset="102-110"
            type="drug" text="midazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d197.s3" text="No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.">
        <entity id="DDI-DrugBank.d197.s3.e0" charOffset="40-54"
            type="drug" text="dexmedetomidine"/>
        <entity id="DDI-DrugBank.d197.s3.e1" charOffset="60-69"
            type="drug" text="isoflurane"/>
        <entity id="DDI-DrugBank.d197.s3.e2" charOffset="72-79"
            type="drug" text="propofol"/>
        <entity id="DDI-DrugBank.d197.s3.e3" charOffset="82-91"
            type="drug" text="alfentanil"/>
        <entity id="DDI-DrugBank.d197.s3.e4" charOffset="98-106"
            type="drug" text="midazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d197.s4" text="However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.">
        <entity id="DDI-DrugBank.d197.s4.e0" charOffset="81-88"
            type="brand" text="PRECEDEX"/>
        <entity id="DDI-DrugBank.d197.s4.e1" charOffset="116-123"
            type="brand" text="PRECEDEX"/>
        <entity id="DDI-DrugBank.d197.s4.e2" charOffset="144-153"
            type="group" text="anesthetic"/>
        <entity id="DDI-DrugBank.d197.s4.e3" charOffset="156-163"
            type="group" text="sedative"/>
        <entity id="DDI-DrugBank.d197.s4.e4" charOffset="166-173"
            type="group" text="hypnotic"/>
        <entity id="DDI-DrugBank.d197.s4.e5" charOffset="178-183"
            type="group" text="opioid"/>
        <ddi id="DDI-DrugBank.d197.s4.d0" e1="DDI-DrugBank.d197.s4.e1"
            e2="DDI-DrugBank.d197.s4.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d197.s4.d1" e1="DDI-DrugBank.d197.s4.e1"
            e2="DDI-DrugBank.d197.s4.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d197.s4.d2" e1="DDI-DrugBank.d197.s4.e1"
            e2="DDI-DrugBank.d197.s4.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d197.s4.d3" e1="DDI-DrugBank.d197.s4.e1"
            e2="DDI-DrugBank.d197.s4.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d197.s5" text="Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.">
        <entity id="DDI-DrugBank.d197.s5.e0" charOffset="0-21"
            type="group" text="Neuromuscular Blockers"/>
        <entity id="DDI-DrugBank.d197.s5.e1" charOffset="81-88"
            type="brand" text="PRECEDEX"/>
        <entity id="DDI-DrugBank.d197.s5.e2" charOffset="254-263"
            type="drug" text="rocuronium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d38.s0" text="ZINECARD does not influence the pharmacokinetics of doxorubicin.">
        <entity id="DDI-DrugBank.d38.s0.e0" charOffset="0-7"
            type="brand" text="ZINECARD"/>
        <entity id="DDI-DrugBank.d38.s0.e1" charOffset="52-62"
            type="drug" text="doxorubicin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d38.s1" text="Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term carcinogenicity studies have been carried out with dexrazoxane in animals.">
        <entity id="DDI-DrugBank.d38.s1.e0" charOffset="117-127"
            type="drug" text="dexrazoxane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d38.s2" text="Dexrazoxane was not mutagenic in the Ames test but was found to be clastogenic to human lymphocytes in vitro and to mouse bone marrow erythrocytes in vivo (micronucleus test).">
        <entity id="DDI-DrugBank.d38.s2.e0" charOffset="0-10"
            type="drug" text="Dexrazoxane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d38.s3" text="The possible adverse effects of ZINECARD on the fertility of humans and experimental animals, male or female, have not been adequately studied.">
        <entity id="DDI-DrugBank.d38.s3.e0" charOffset="32-39"
            type="brand" text="ZINECARD"/>
    </sentence>
    <sentence id="DDI-DrugBank.d38.s4" text="Testicular atrophy was seen with dexrazoxane administration at doses as low as 30 mg/kg weekly for 6 weeks in rats (1/3 the human dose on a mg/m 2 basis) and as low as 20 mg/kg weekly for 13 weeks in dogs (approximately equal to the human dose on a mg/m 2 basis).">
        <entity id="DDI-DrugBank.d38.s4.e0" charOffset="33-43"
            type="drug" text="dexrazoxane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s0" text="Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.">
        <entity id="DDI-DrugBank.d236.s0.e0" charOffset="0-16"
            type="group" text="Acidifying agents"/>
        <entity id="DDI-DrugBank.d236.s0.e1" charOffset="19-52"
            type="group" text="Gastrointestinal acidifying agents"/>
        <entity id="DDI-DrugBank.d236.s0.e2" charOffset="55-66"
            type="drug" text="guanethidine"/>
        <entity id="DDI-DrugBank.d236.s0.e3" charOffset="69-77"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d236.s0.e4" charOffset="80-96"
            type="drug" text="glutamic acid HCl"/>
        <entity id="DDI-DrugBank.d236.s0.e5" charOffset="99-111"
            type="drug" text="ascorbic acid"/>
        <entity id="DDI-DrugBank.d236.s0.e6" charOffset="154-165"
            type="group" text="amphetamines"/>
        <ddi id="DDI-DrugBank.d236.s0.d0" e1="DDI-DrugBank.d236.s0.e1"
            e2="DDI-DrugBank.d236.s0.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d236.s0.d1" e1="DDI-DrugBank.d236.s0.e2"
            e2="DDI-DrugBank.d236.s0.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d236.s0.d2" e1="DDI-DrugBank.d236.s0.e3"
            e2="DDI-DrugBank.d236.s0.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d236.s0.d3" e1="DDI-DrugBank.d236.s0.e4"
            e2="DDI-DrugBank.d236.s0.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d236.s0.d4" e1="DDI-DrugBank.d236.s0.e5"
            e2="DDI-DrugBank.d236.s0.e6" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s1" text="Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.">
        <entity id="DDI-DrugBank.d236.s1.e0" charOffset="0-24"
            type="group" text="Urinary acidifying agents"/>
        <entity id="DDI-DrugBank.d236.s1.e1" charOffset="27-43"
            type="drug" text="ammonium chloride"/>
        <entity id="DDI-DrugBank.d236.s1.e2" charOffset="46-66"
            type="drug" text="sodium acid phosphate"/>
        <entity id="DDI-DrugBank.d236.s1.e3" charOffset="132-142"
            type="drug" text="amphetamine"/>
        <ddi id="DDI-DrugBank.d236.s1.d0" e1="DDI-DrugBank.d236.s1.e0"
            e2="DDI-DrugBank.d236.s1.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d236.s1.d1" e1="DDI-DrugBank.d236.s1.e1"
            e2="DDI-DrugBank.d236.s1.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d236.s1.d2" e1="DDI-DrugBank.d236.s1.e2"
            e2="DDI-DrugBank.d236.s1.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s2" text="Both groups of agents lower blood levels and efficacy of amphetamines.">
        <entity id="DDI-DrugBank.d236.s2.e0" charOffset="57-68"
            type="group" text="amphetamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s3" text="Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.">
        <entity id="DDI-DrugBank.d236.s3.e0" charOffset="0-18"
            type="group" text="Adrenergic blockers"/>
        <entity id="DDI-DrugBank.d236.s3.e1" charOffset="21-39"
            type="group" text="Adrenergic blockers"/>
        <entity id="DDI-DrugBank.d236.s3.e2" charOffset="58-69"
            type="group" text="amphetamines"/>
        <ddi id="DDI-DrugBank.d236.s3.d0" e1="DDI-DrugBank.d236.s3.e1"
            e2="DDI-DrugBank.d236.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s4" text="Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.">
        <entity id="DDI-DrugBank.d236.s4.e0" charOffset="59-76"
            type="drug" text="sodium bicarbonate"/>
        <entity id="DDI-DrugBank.d236.s4.e1" charOffset="108-119"
            type="drug" text="amphetamines"/>
        <ddi id="DDI-DrugBank.d236.s4.d0" e1="DDI-DrugBank.d236.s4.e0"
            e2="DDI-DrugBank.d236.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s5" text="Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.">
        <entity id="DDI-DrugBank.d236.s5.e0" charOffset="29-41"
            type="drug" text="acetazolamide"/>
        <entity id="DDI-DrugBank.d236.s5.e1" charOffset="49-57"
            type="group" text="thiazides"/>
        <entity id="DDI-DrugBank.d236.s5.e2" charOffset="121-131"
            type="drug" text="amphetamine"/>
        <ddi id="DDI-DrugBank.d236.s5.d0" e1="DDI-DrugBank.d236.s5.e0"
            e2="DDI-DrugBank.d236.s5.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d236.s5.d1" e1="DDI-DrugBank.d236.s5.e1"
            e2="DDI-DrugBank.d236.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s6" text="Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.">
        <entity id="DDI-DrugBank.d236.s6.e0" charOffset="84-95"
            type="group" text="amphetamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s7" text="Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;">
        <entity id="DDI-DrugBank.d236.s7.e0" charOffset="0-14"
            type="group" text="Antidepressants"/>
        <entity id="DDI-DrugBank.d236.s7.e1" charOffset="17-25"
            type="group" text="tricyclic"/>
        <entity id="DDI-DrugBank.d236.s7.e2" charOffset="28-39"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d236.s7.e3" charOffset="69-77"
            type="group" text="tricyclic"/>
        <entity id="DDI-DrugBank.d236.s7.e4" charOffset="82-103"
            type="group" text="sympathomimetic agents"/>
        <ddi id="DDI-DrugBank.d236.s7.d0" e1="DDI-DrugBank.d236.s7.e2"
            e2="DDI-DrugBank.d236.s7.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d236.s7.d1" e1="DDI-DrugBank.d236.s7.e2"
            e2="DDI-DrugBank.d236.s7.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s8" text="d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;">
        <entity id="DDI-DrugBank.d236.s8.e0" charOffset="0-12"
            type="drug" text="d-amphetamine"/>
        <entity id="DDI-DrugBank.d236.s8.e1" charOffset="19-29"
            type="drug" text="desipramine"/>
        <entity id="DDI-DrugBank.d236.s8.e2" charOffset="34-46"
            type="drug" text="protriptyline"/>
        <entity id="DDI-DrugBank.d236.s8.e3" charOffset="67-76"
            type="group" text="tricyclics"/>
        <entity id="DDI-DrugBank.d236.s8.e4" charOffset="141-153"
            type="drug" text="d-amphetamine"/>
        <ddi id="DDI-DrugBank.d236.s8.d0" e1="DDI-DrugBank.d236.s8.e0"
            e2="DDI-DrugBank.d236.s8.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d236.s8.d1" e1="DDI-DrugBank.d236.s8.e0"
            e2="DDI-DrugBank.d236.s8.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d236.s8.d2" e1="DDI-DrugBank.d236.s8.e0"
            e2="DDI-DrugBank.d236.s8.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s9" text="cardiovascular effects can be potentiated."/>
    <sentence id="DDI-DrugBank.d236.s10" text="MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.">
        <entity id="DDI-DrugBank.d236.s10.e0" charOffset="0-13"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d236.s10.e1" charOffset="16-35"
            type="group" text="MAOI antidepressants"/>
        <entity id="DDI-DrugBank.d236.s10.e2" charOffset="65-76"
            type="drug" text="furazolidone"/>
        <entity id="DDI-DrugBank.d236.s10.e3" charOffset="84-94"
            type="group" text="amphetamine"/>
        <ddi id="DDI-DrugBank.d236.s10.d0" e1="DDI-DrugBank.d236.s10.e1"
            e2="DDI-DrugBank.d236.s10.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d236.s10.d1" e1="DDI-DrugBank.d236.s10.e2"
            e2="DDI-DrugBank.d236.s10.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s11" text="This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings;">
        <entity id="DDI-DrugBank.d236.s11.e0" charOffset="25-36"
            type="group" text="amphetamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s12" text="this can cause headaches and other signs of hypertensive crisis."/>
    <sentence id="DDI-DrugBank.d236.s13" text="A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results."/>
    <sentence id="DDI-DrugBank.d236.s14" text="Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.">
        <entity id="DDI-DrugBank.d236.s14.e0" charOffset="0-13"
            type="group" text="Antihistamines"/>
        <entity id="DDI-DrugBank.d236.s14.e1" charOffset="16-27"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d236.s14.e2" charOffset="67-80"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d236.s14.d0" e1="DDI-DrugBank.d236.s14.e1"
            e2="DDI-DrugBank.d236.s14.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s15" text="Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.">
        <entity id="DDI-DrugBank.d236.s15.e0" charOffset="0-16"
            type="group" text="Antihypertensives"/>
        <entity id="DDI-DrugBank.d236.s15.e1" charOffset="19-30"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d236.s15.e2" charOffset="74-90"
            type="group" text="antihypertensives"/>
        <ddi id="DDI-DrugBank.d236.s15.d0" e1="DDI-DrugBank.d236.s15.e1"
            e2="DDI-DrugBank.d236.s15.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s16" text="Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.">
        <entity id="DDI-DrugBank.d236.s16.e0" charOffset="0-13"
            type="drug" text="Chlorpromazine"/>
        <entity id="DDI-DrugBank.d236.s16.e1" charOffset="16-29"
            type="drug" text="Chlorpromazine"/>
        <entity id="DDI-DrugBank.d236.s16.e2" charOffset="125-136"
            type="group" text="amphetamines"/>
        <entity id="DDI-DrugBank.d236.s16.e3" charOffset="164-174"
            type="group" text="amphetamine"/>
        <ddi id="DDI-DrugBank.d236.s16.d0" e1="DDI-DrugBank.d236.s16.e1"
            e2="DDI-DrugBank.d236.s16.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s17" text="Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.">
        <entity id="DDI-DrugBank.d236.s17.e0" charOffset="0-11"
            type="drug" text="Ethosuximide"/>
        <entity id="DDI-DrugBank.d236.s17.e1" charOffset="14-25"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d236.s17.e2" charOffset="62-73"
            type="drug" text="ethosuximide"/>
        <ddi id="DDI-DrugBank.d236.s17.d0" e1="DDI-DrugBank.d236.s17.e1"
            e2="DDI-DrugBank.d236.s17.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s18" text="Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.">
        <entity id="DDI-DrugBank.d236.s18.e0" charOffset="0-10"
            type="drug" text="Haloperidol"/>
        <entity id="DDI-DrugBank.d236.s18.e1" charOffset="13-23"
            type="drug" text="Haloperidol"/>
        <entity id="DDI-DrugBank.d236.s18.e2" charOffset="119-130"
            type="group" text="amphetamines"/>
        <ddi id="DDI-DrugBank.d236.s18.d0" e1="DDI-DrugBank.d236.s18.e1"
            e2="DDI-DrugBank.d236.s18.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s19" text="Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.">
        <entity id="DDI-DrugBank.d236.s19.e0" charOffset="0-16"
            type="drug" text="Lithium carbonate"/>
        <entity id="DDI-DrugBank.d236.s19.e1" charOffset="46-57"
            type="group" text="amphetamines"/>
        <entity id="DDI-DrugBank.d236.s19.e2" charOffset="79-95"
            type="drug" text="lithium carbonate"/>
        <ddi id="DDI-DrugBank.d236.s19.d0" e1="DDI-DrugBank.d236.s19.e1"
            e2="DDI-DrugBank.d236.s19.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s20" text="Meperidine: Amphetamines potentiate the analgesic effect of meperidine.">
        <entity id="DDI-DrugBank.d236.s20.e0" charOffset="0-9"
            type="drug" text="Meperidine"/>
        <entity id="DDI-DrugBank.d236.s20.e1" charOffset="12-23"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d236.s20.e2" charOffset="60-69"
            type="drug" text="meperidine"/>
        <ddi id="DDI-DrugBank.d236.s20.d0" e1="DDI-DrugBank.d236.s20.e1"
            e2="DDI-DrugBank.d236.s20.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s21" text="Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.">
        <entity id="DDI-DrugBank.d236.s21.e0" charOffset="0-10"
            type="drug" text="Methenamine"/>
        <entity id="DDI-DrugBank.d236.s21.e1" charOffset="42-53"
            type="group" text="amphetamines"/>
        <entity id="DDI-DrugBank.d236.s21.e2" charOffset="97-113"
            type="group" text="acidifying agents"/>
        <entity id="DDI-DrugBank.d236.s21.e3" charOffset="123-133"
            type="drug" text="methenamine"/>
        <ddi id="DDI-DrugBank.d236.s21.d0" e1="DDI-DrugBank.d236.s21.e1"
            e2="DDI-DrugBank.d236.s21.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s22" text="Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.">
        <entity id="DDI-DrugBank.d236.s22.e0" charOffset="0-13"
            type="drug" text="Norepinephrine"/>
        <entity id="DDI-DrugBank.d236.s22.e1" charOffset="16-27"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d236.s22.e2" charOffset="62-75"
            type="drug" text="norepinephrine"/>
        <ddi id="DDI-DrugBank.d236.s22.d0" e1="DDI-DrugBank.d236.s22.e1"
            e2="DDI-DrugBank.d236.s22.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s23" text="Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;">
        <entity id="DDI-DrugBank.d236.s23.e0" charOffset="0-12"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d236.s23.e1" charOffset="15-26"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d236.s23.e2" charOffset="63-75"
            type="drug" text="phenobarbital"/>
        <ddi id="DDI-DrugBank.d236.s23.d0" e1="DDI-DrugBank.d236.s23.e1"
            e2="DDI-DrugBank.d236.s23.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s24" text="co-administration of phenobarbital may produce a synergistic anticonvulsant action.">
        <entity id="DDI-DrugBank.d236.s24.e0" charOffset="21-33"
            type="drug" text="phenobarbital"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s25" text="Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;">
        <entity id="DDI-DrugBank.d236.s25.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d236.s25.e1" charOffset="11-22"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d236.s25.e2" charOffset="59-67"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d236.s25.d0" e1="DDI-DrugBank.d236.s25.e1"
            e2="DDI-DrugBank.d236.s25.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s26" text="co-administration of phenytoin may produce a synergistic anticonvulsant action.">
        <entity id="DDI-DrugBank.d236.s26.e0" charOffset="21-29"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s27" text="Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.">
        <entity id="DDI-DrugBank.d236.s27.e0" charOffset="0-11"
            type="drug" text="Propoxyphene"/>
        <entity id="DDI-DrugBank.d236.s27.e1" charOffset="26-37"
            type="drug" text="propoxyphene"/>
        <entity id="DDI-DrugBank.d236.s27.e2" charOffset="51-61"
            type="group" text="amphetamine"/>
        <ddi id="DDI-DrugBank.d236.s27.d0" e1="DDI-DrugBank.d236.s27.e1"
            e2="DDI-DrugBank.d236.s27.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s28" text="Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.">
        <entity id="DDI-DrugBank.d236.s28.e0" charOffset="0-17"
            type="group" text="Veratrum alkaloids"/>
        <entity id="DDI-DrugBank.d236.s28.e1" charOffset="20-31"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d236.s28.e2" charOffset="67-84"
            type="group" text="veratrum alkaloids"/>
        <ddi id="DDI-DrugBank.d236.s28.d0" e1="DDI-DrugBank.d236.s28.e1"
            e2="DDI-DrugBank.d236.s28.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s29" text="Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.">
        <entity id="DDI-DrugBank.d236.s29.e0" charOffset="35-46"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d236.s29.e1" charOffset="92-105"
            type="group" text="corticosteroid"/>
        <ddi id="DDI-DrugBank.d236.s29.d0" e1="DDI-DrugBank.d236.s29.e1"
            e2="DDI-DrugBank.d236.s29.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d236.s30" text="This increase is greatest in the evening."/>
    <sentence id="DDI-DrugBank.d236.s31" text="Amphetamines may interfere with urinary steroid determinations.">
        <entity id="DDI-DrugBank.d236.s31.e0" charOffset="0-11"
            type="group" text="Amphetamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d461.s0" text="Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, hypnotics, alcohol, and other opiate analgesics.">
        <entity id="DDI-DrugBank.d461.s0.e0" charOffset="50-60"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d461.s0.e1" charOffset="63-71"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d461.s0.e2" charOffset="74-90"
            type="group" text="antianxiety drugs"/>
        <entity id="DDI-DrugBank.d461.s0.e3" charOffset="93-101"
            type="group" text="hypnotics"/>
        <entity id="DDI-DrugBank.d461.s0.e4" charOffset="104-110"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d461.s0.e5" charOffset="123-139"
            type="group" text="opiate analgesics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d293.s0" text="May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).">
        <entity id="DDI-DrugBank.d293.s0.e0" charOffset="44-56"
            type="drug" text="levothyroxine"/>
        <entity id="DDI-DrugBank.d293.s0.e1" charOffset="60-65"
            type="drug" text="iodine"/>
        <entity id="DDI-DrugBank.d293.s0.e2" charOffset="88-95"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d293.s0.e3" charOffset="98-111"
            type="group" text="H2-antagonists"/>
        <entity id="DDI-DrugBank.d293.s0.e4" charOffset="120-129"
            type="drug" text="famotidine"/>
        <entity id="DDI-DrugBank.d293.s0.e5" charOffset="132-141"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d293.s0.e6" charOffset="149-170"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-DrugBank.d293.s0.e7" charOffset="179-190"
            type="drug" text="lansoprazole"/>
        <entity id="DDI-DrugBank.d293.s0.e8" charOffset="193-202"
            type="drug" text="omeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d293.s1" text="This product can affect the results of certain lab tests."/>
    <sentence id="DDI-DrugBank.d36.s0" text="Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.">
        <entity id="DDI-DrugBank.d36.s0.e0" charOffset="63-69"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d36.s0.e1" charOffset="75-103"
            type="group" text="carbonic anhydrase inhibitors"/>
        <ddi id="DDI-DrugBank.d36.s0.d0" e1="DDI-DrugBank.d36.s0.e0"
            e2="DDI-DrugBank.d36.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s0" text="Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.">
        <entity id="DDI-DrugBank.d249.s0.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d249.s0.e1" charOffset="39-48"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d249.s0.e2" charOffset="54-60"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d249.s0.e3" charOffset="89-98"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d249.s0.e4" charOffset="177-183"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d249.s0.d0" e1="DDI-DrugBank.d249.s0.e1"
            e2="DDI-DrugBank.d249.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d249.s0.d1" e1="DDI-DrugBank.d249.s0.e3"
            e2="DDI-DrugBank.d249.s0.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s1" text="Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.">
        <entity id="DDI-DrugBank.d249.s1.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d249.s1.e1" charOffset="45-54"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d249.s1.e2" charOffset="73-107"
            type="group" text="anticoagulants of the warfarin type"/>
        <entity id="DDI-DrugBank.d249.s1.e3" charOffset="197-202"
            type="group" text="NSAIDs"/>
        <ddi id="DDI-DrugBank.d249.s1.d0" e1="DDI-DrugBank.d249.s1.e1"
            e2="DDI-DrugBank.d249.s1.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s2" text="Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.">
        <entity id="DDI-DrugBank.d249.s2.e0" charOffset="65-70"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d249.s2.e1" charOffset="134-139"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d249.s2.e2" charOffset="152-161"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d249.s2.e3" charOffset="168-175"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d249.s2.e4" charOffset="253-265"
            type="group" text="anticoagulant"/>
        <ddi id="DDI-DrugBank.d249.s2.d0" e1="DDI-DrugBank.d249.s2.e1"
            e2="DDI-DrugBank.d249.s2.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d249.s2.d1" e1="DDI-DrugBank.d249.s2.e2"
            e2="DDI-DrugBank.d249.s2.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s3" text="Digoxin, Methotrexate, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.">
        <entity id="DDI-DrugBank.d249.s3.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d249.s3.e1" charOffset="9-20"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d249.s3.e2" charOffset="23-34"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d249.s3.e3" charOffset="37-46"
            type="drug" text="Diclofenac"/>
        <entity id="DDI-DrugBank.d249.s3.e4" charOffset="60-65"
            type="group" text="NSAIDs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s4" text="Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.">
        <entity id="DDI-DrugBank.d249.s4.e0" charOffset="13-22"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d249.s4.e1" charOffset="61-67"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d249.s4.e2" charOffset="73-84"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d249.s4.e3" charOffset="99-110"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d249.s4.d0" e1="DDI-DrugBank.d249.s4.e0"
            e2="DDI-DrugBank.d249.s4.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d249.s4.d1" e1="DDI-DrugBank.d249.s4.e0"
            e2="DDI-DrugBank.d249.s4.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d249.s4.d2" e1="DDI-DrugBank.d249.s4.e0"
            e2="DDI-DrugBank.d249.s4.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s5" text="Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.">
        <entity id="DDI-DrugBank.d249.s5.e0" charOffset="26-35"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d249.s5.e1" charOffset="59-68"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d249.s5.e2" charOffset="88-92"
            type="group" text="NSAID"/>
        <entity id="DDI-DrugBank.d249.s5.e3" charOffset="107-113"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d249.s5.e4" charOffset="116-127"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d249.s5.e5" charOffset="133-144"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d249.s5.d0" e1="DDI-DrugBank.d249.s5.e0"
            e2="DDI-DrugBank.d249.s5.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d249.s5.d1" e1="DDI-DrugBank.d249.s5.e0"
            e2="DDI-DrugBank.d249.s5.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d249.s5.d2" e1="DDI-DrugBank.d249.s5.e0"
            e2="DDI-DrugBank.d249.s5.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d249.s5.d3" e1="DDI-DrugBank.d249.s5.e2"
            e2="DDI-DrugBank.d249.s5.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d249.s5.d4" e1="DDI-DrugBank.d249.s5.e2"
            e2="DDI-DrugBank.d249.s5.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d249.s5.d5" e1="DDI-DrugBank.d249.s5.e2"
            e2="DDI-DrugBank.d249.s5.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s6" text="They should be observed closely, particularly if renal function is impaired."/>
    <sentence id="DDI-DrugBank.d249.s7" text="In the case of digoxin, serum levels should be monitored.">
        <entity id="DDI-DrugBank.d249.s7.e0" charOffset="15-21"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s8" text="Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.">
        <entity id="DDI-DrugBank.d249.s8.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d249.s8.e1" charOffset="9-18"
            type="drug" text="Diclofenac"/>
        <entity id="DDI-DrugBank.d249.s8.e2" charOffset="30-36"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d249.s8.e3" charOffset="68-74"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d249.s8.d0" e1="DDI-DrugBank.d249.s8.e1"
            e2="DDI-DrugBank.d249.s8.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d249.s8.d1" e1="DDI-DrugBank.d249.s8.e1"
            e2="DDI-DrugBank.d249.s8.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s9" text="In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.">
        <entity id="DDI-DrugBank.d249.s9.e0" charOffset="19-28"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d249.s9.e1" charOffset="34-40"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d249.s9.e2" charOffset="57-63"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d249.s9.d0" e1="DDI-DrugBank.d249.s9.e0"
            e2="DDI-DrugBank.d249.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s10" text="Oral Hypoglycemics: Diclofenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents.">
        <entity id="DDI-DrugBank.d249.s10.e0" charOffset="5-17"
            type="group" text="Hypoglycemics"/>
        <entity id="DDI-DrugBank.d249.s10.e1" charOffset="20-29"
            type="drug" text="Diclofenac"/>
        <entity id="DDI-DrugBank.d249.s10.e2" charOffset="122-140"
            type="group" text="hypoglycemic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s11" text="There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.">
        <entity id="DDI-DrugBank.d249.s11.e0" charOffset="86-92"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d249.s11.e1" charOffset="102-120"
            type="group" text="hypoglycemic agents"/>
        <entity id="DDI-DrugBank.d249.s11.e2" charOffset="141-150"
            type="drug" text="diclofenac"/>
        <ddi id="DDI-DrugBank.d249.s11.d0" e1="DDI-DrugBank.d249.s11.e0"
            e2="DDI-DrugBank.d249.s11.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d249.s11.d1" e1="DDI-DrugBank.d249.s11.e1"
            e2="DDI-DrugBank.d249.s11.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s12" text="Both hypo- and hyperglycemic effects have been reported."/>
    <sentence id="DDI-DrugBank.d249.s13" text="A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.">
        <entity id="DDI-DrugBank.d249.s13.e0" charOffset="107-116"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d249.s13.e1" charOffset="161-167"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d249.s13.e2" charOffset="177-195"
            type="group" text="hypoglycemic agents"/>
        <ddi id="DDI-DrugBank.d249.s13.d0" e1="DDI-DrugBank.d249.s13.e0"
            e2="DDI-DrugBank.d249.s13.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d249.s13.d1" e1="DDI-DrugBank.d249.s13.e0"
            e2="DDI-DrugBank.d249.s13.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s14" text="Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.">
        <entity id="DDI-DrugBank.d249.s14.e0" charOffset="0-8"
            type="group" text="Diuretics"/>
        <entity id="DDI-DrugBank.d249.s14.e1" charOffset="11-20"
            type="drug" text="Diclofenac"/>
        <entity id="DDI-DrugBank.d249.s14.e2" charOffset="32-37"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d249.s14.e3" charOffset="67-75"
            type="group" text="diuretics"/>
        <ddi id="DDI-DrugBank.d249.s14.d0" e1="DDI-DrugBank.d249.s14.e1"
            e2="DDI-DrugBank.d249.s14.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d249.s14.d1" e1="DDI-DrugBank.d249.s14.e2"
            e2="DDI-DrugBank.d249.s14.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s15" text="Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium levels.">
        <entity id="DDI-DrugBank.d249.s15.e0" charOffset="27-53"
            type="group" text="potassium-sparing diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s16" text="Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.">
        <entity id="DDI-DrugBank.d249.s16.e0" charOffset="101-112"
            type="drug" text="azathioprine"/>
        <entity id="DDI-DrugBank.d249.s16.e1" charOffset="115-118"
            type="group" text="gold"/>
        <entity id="DDI-DrugBank.d249.s16.e2" charOffset="121-131"
            type="drug" text="chloroquine"/>
        <entity id="DDI-DrugBank.d249.s16.e3" charOffset="134-148"
            type="drug" text="D-penicillamine"/>
        <entity id="DDI-DrugBank.d249.s16.e4" charOffset="151-162"
            type="drug" text="prednisolone"/>
        <entity id="DDI-DrugBank.d249.s16.e5" charOffset="165-175"
            type="drug" text="doxycycline"/>
        <entity id="DDI-DrugBank.d249.s16.e6" charOffset="181-189"
            type="drug" text="digitoxin"/>
        <entity id="DDI-DrugBank.d249.s16.e7" charOffset="254-263"
            type="drug" text="diclofenac"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s17" text="Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.">
        <entity id="DDI-DrugBank.d249.s17.e0" charOffset="0-12"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d249.s17.e1" charOffset="82-94"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d249.s17.e2" charOffset="134-143"
            type="drug" text="diclofenac"/>
        <ddi id="DDI-DrugBank.d249.s17.d0" e1="DDI-DrugBank.d249.s17.e1"
            e2="DDI-DrugBank.d249.s17.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s18" text="Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.">
        <entity id="DDI-DrugBank.d249.s18.e0" charOffset="26-35"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d249.s18.e1" charOffset="100-113"
            type="drug" text="salicylic acid"/>
        <entity id="DDI-DrugBank.d249.s18.e2" charOffset="142-152"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d249.s18.e3" charOffset="155-166"
            type="drug" text="prednisolone"/>
        <entity id="DDI-DrugBank.d249.s18.e4" charOffset="198-205"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d249.s18.d0" e1="DDI-DrugBank.d249.s18.e0"
            e2="DDI-DrugBank.d249.s18.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d249.s18.d1" e1="DDI-DrugBank.d249.s18.e0"
            e2="DDI-DrugBank.d249.s18.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d249.s18.d2" e1="DDI-DrugBank.d249.s18.e0"
            e2="DDI-DrugBank.d249.s18.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d249.s18.d3" e1="DDI-DrugBank.d249.s18.e0"
            e2="DDI-DrugBank.d249.s18.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s19" text="Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.">
        <entity id="DDI-DrugBank.d249.s19.e0" charOffset="0-15"
            type="drug" text="Benzylpenicillin"/>
        <entity id="DDI-DrugBank.d249.s19.e1" charOffset="18-27"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d249.s19.e2" charOffset="30-38"
            type="drug" text="oxacillin"/>
        <entity id="DDI-DrugBank.d249.s19.e3" charOffset="41-57"
            type="drug" text="chlortetracycline"/>
        <entity id="DDI-DrugBank.d249.s19.e4" charOffset="60-70"
            type="drug" text="doxycycline"/>
        <entity id="DDI-DrugBank.d249.s19.e5" charOffset="73-83"
            type="drug" text="cephalothin"/>
        <entity id="DDI-DrugBank.d249.s19.e6" charOffset="86-97"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d249.s19.e7" charOffset="104-119"
            type="drug" text="sulfamethoxazole"/>
        <entity id="DDI-DrugBank.d249.s19.e8" charOffset="174-183"
            type="drug" text="diclofenac"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s20" text="Drug/Laboratory Test Interactions Effect on Blood Coagulation: Diclofenac increases platelet aggregation time but does not affect bleeding time, plasma thrombin clotting time, plasma fibrinogen, or factors V and VII to XII.">
        <entity id="DDI-DrugBank.d249.s20.e0" charOffset="63-72"
            type="drug" text="Diclofenac"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s21" text="Statistically significant changes in prothrombin and partial thromboplastin times have been reported in normal volunteers."/>
    <sentence id="DDI-DrugBank.d249.s22" text="The mean changes were observed to be less than 1 second in both instances, however, and are unlikely to be clinically important."/>
    <sentence id="DDI-DrugBank.d249.s23" text="Diclofenac is a prostaglandin synthetase inhibitor, however, and all drugs that inhibit prostaglandin synthesis interfere with platelet function to some degree;">
        <entity id="DDI-DrugBank.d249.s23.e0" charOffset="0-9"
            type="drug" text="Diclofenac"/>
    </sentence>
    <sentence id="DDI-DrugBank.d249.s24" text="therefore, patients who may be adversely affected by such an action should be carefully observed."/>
    <sentence id="DDI-DrugBank.d517.s0" text="Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.">
        <entity id="DDI-DrugBank.d517.s0.e0" charOffset="0-11"
            type="drug" text="Tetracycline"/>
        <entity id="DDI-DrugBank.d517.s0.e1" charOffset="16-40"
            type="group" text="bacteriostatic antibiotic"/>
        <entity id="DDI-DrugBank.d517.s0.e2" charOffset="84-93"
            type="drug" text="penicillin"/>
        <ddi id="DDI-DrugBank.d517.s0.d0" e1="DDI-DrugBank.d517.s0.e0"
            e2="DDI-DrugBank.d517.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d543.s0" text="The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.">
        <entity id="DDI-DrugBank.d543.s0.e0" charOffset="69-89"
            type="group" text="anticholinergic drugs"/>
        <entity id="DDI-DrugBank.d543.s0.e1" charOffset="92-101"
            type="drug" text="amantadine"/>
        <entity id="DDI-DrugBank.d543.s0.e2" charOffset="103-123"
            type="group" text="antiarrhythmic agents"/>
        <entity id="DDI-DrugBank.d543.s0.e3" charOffset="140-148"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d543.s0.e4" charOffset="152-165"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d543.s0.e5" charOffset="167-186"
            type="group" text="antipsychotic agents"/>
        <entity id="DDI-DrugBank.d543.s0.e6" charOffset="194-207"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d543.s0.e7" charOffset="211-225"
            type="group" text="benzodiazepines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d543.s1" text="MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.">
        <entity id="DDI-DrugBank.d543.s1.e0" charOffset="0-13"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d543.s1.e1" charOffset="16-34"
            type="group" text="narcotic analgesics"/>
        <entity id="DDI-DrugBank.d543.s1.e2" charOffset="43-52"
            type="drug" text="meperidine"/>
        <entity id="DDI-DrugBank.d543.s1.e3" charOffset="56-63"
            type="group" text="nitrates"/>
        <entity id="DDI-DrugBank.d543.s1.e4" charOffset="69-76"
            type="group" text="nitrites"/>
        <entity id="DDI-DrugBank.d543.s1.e5" charOffset="79-100"
            type="group" text="sympathomimetic agents"/>
        <entity id="DDI-DrugBank.d543.s1.e6" charOffset="103-127"
            type="group" text="tricyclic antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d543.s2" text="Anticholinergics antagonize the effects of antiglaucoma agents.">
        <entity id="DDI-DrugBank.d543.s2.e0" charOffset="0-15"
            type="group" text="Anticholinergics"/>
        <entity id="DDI-DrugBank.d543.s2.e1" charOffset="43-61"
            type="group" text="antiglaucoma agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d543.s3" text="Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corti costeroids..">
        <entity id="DDI-DrugBank.d543.s3.e0" charOffset="0-20"
            type="group" text="Anticholinergic drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d543.s4" text="Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;">
        <entity id="DDI-DrugBank.d543.s4.e0" charOffset="0-21"
            type="group" text="Anticholinergic agents"/>
        <entity id="DDI-DrugBank.d543.s4.e1" charOffset="122-128"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d543.s4.d0" e1="DDI-DrugBank.d543.s4.e0"
            e2="DDI-DrugBank.d543.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d543.s5" text="increased serum digoxin concentrations may result.">
        <entity id="DDI-DrugBank.d543.s5.e0" charOffset="16-22"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d543.s6" text="Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.">
        <entity id="DDI-DrugBank.d543.s6.e0" charOffset="0-20"
            type="group" text="Anticholinergic drugs"/>
        <entity id="DDI-DrugBank.d543.s6.e1" charOffset="108-121"
            type="drug" text="metoclopramide"/>
        <ddi id="DDI-DrugBank.d543.s6.d0" e1="DDI-DrugBank.d543.s6.e0"
            e2="DDI-DrugBank.d543.s6.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d543.s7" text="Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.">
        <entity id="DDI-DrugBank.d543.s7.e0" charOffset="8-15"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d543.s7.e1" charOffset="54-75"
            type="group" text="anticholinergic agents"/>
        <ddi id="DDI-DrugBank.d543.s7.d0" e1="DDI-DrugBank.d543.s7.e0"
            e2="DDI-DrugBank.d543.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d543.s8" text="The inhibiting effects of anticholinergic drugs on gastric hydrochloric acid secretion are antagonized by agents used to treat achlorhydria and those used to test gastric secretion.">
        <entity id="DDI-DrugBank.d543.s8.e0" charOffset="26-46"
            type="group" text="anticholinergic drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s0" text="Coadministration of VIDEX with drugs that are known to cause pancreatitis may increase the risk of this toxicity (see WARNINGS) and should be done with extreme caution, only if other alternatives are not available, and only if clearly indicated.">
        <entity id="DDI-DrugBank.d43.s0.e0" charOffset="20-24"
            type="brand" text="VIDEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s1" text="Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including stavudine, and these patients may be at increased risk of neuropathy during VIDEX therapy (see ADVERSE REACTIONS).">
        <entity id="DDI-DrugBank.d43.s1.e0" charOffset="119-127"
            type="drug" text="stavudine"/>
        <entity id="DDI-DrugBank.d43.s1.e1" charOffset="195-199"
            type="brand" text="VIDEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s2" text="Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).">
        <entity id="DDI-DrugBank.d43.s2.e0" charOffset="0-10"
            type="drug" text="Allopurinol"/>
        <entity id="DDI-DrugBank.d43.s2.e1" charOffset="24-33"
            type="drug" text="didanosine"/>
        <entity id="DDI-DrugBank.d43.s2.e2" charOffset="67-77"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d43.s2.e3" charOffset="141-145"
            type="brand" text="VIDEX"/>
        <ddi id="DDI-DrugBank.d43.s2.d0" e1="DDI-DrugBank.d43.s2.e2"
            e2="DDI-DrugBank.d43.s2.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s3" text="The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known.">
        <entity id="DDI-DrugBank.d43.s3.e0" charOffset="15-25"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d43.s3.e1" charOffset="30-39"
            type="drug" text="didanosine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s4" text="Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.">
        <entity id="DDI-DrugBank.d43.s4.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d43.s4.e1" charOffset="40-47"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d43.s4.e2" charOffset="60-68"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d43.s4.e3" charOffset="73-80"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d43.s4.e4" charOffset="87-91"
            type="brand" text="VIDEX"/>
        <entity id="DDI-DrugBank.d43.s4.e5" charOffset="219-225"
            type="group" text="antacid"/>
        <ddi id="DDI-DrugBank.d43.s4.d0" e1="DDI-DrugBank.d43.s4.e1"
            e2="DDI-DrugBank.d43.s4.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d43.s4.d1" e1="DDI-DrugBank.d43.s4.e2"
            e2="DDI-DrugBank.d43.s4.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d43.s4.d2" e1="DDI-DrugBank.d43.s4.e3"
            e2="DDI-DrugBank.d43.s4.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s5" text="Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.">
        <entity id="DDI-DrugBank.d43.s5.e0" charOffset="93-104"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d43.s5.e1" charOffset="110-121"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d43.s5.e2" charOffset="184-188"
            type="brand" text="VIDEX"/>
        <ddi id="DDI-DrugBank.d43.s5.d0" e1="DDI-DrugBank.d43.s5.e0"
            e2="DDI-DrugBank.d43.s5.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d43.s5.d1" e1="DDI-DrugBank.d43.s5.e1"
            e2="DDI-DrugBank.d43.s5.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s6" text="Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).">
        <entity id="DDI-DrugBank.d43.s6.e0" charOffset="0-10"
            type="drug" text="Ganciclovir"/>
        <entity id="DDI-DrugBank.d43.s6.e1" charOffset="31-35"
            type="brand" text="VIDEX"/>
        <entity id="DDI-DrugBank.d43.s6.e2" charOffset="78-88"
            type="drug" text="ganciclovir"/>
        <entity id="DDI-DrugBank.d43.s6.e3" charOffset="159-168"
            type="drug" text="didanosine"/>
        <ddi id="DDI-DrugBank.d43.s6.d0" e1="DDI-DrugBank.d43.s6.e1"
            e2="DDI-DrugBank.d43.s6.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s7" text="A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).">
        <entity id="DDI-DrugBank.d43.s7.e0" charOffset="47-57"
            type="drug" text="ganciclovir"/>
        <entity id="DDI-DrugBank.d43.s7.e1" charOffset="77-81"
            type="brand" text="VIDEX"/>
        <entity id="DDI-DrugBank.d43.s7.e2" charOffset="117-127"
            type="drug" text="ganciclovir"/>
        <ddi id="DDI-DrugBank.d43.s7.d0" e1="DDI-DrugBank.d43.s7.e1"
            e2="DDI-DrugBank.d43.s7.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s8" text="Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.">
        <entity id="DDI-DrugBank.d43.s8.e0" charOffset="0-19"
            type="group" text="Quinolone Antibiotic"/>
        <entity id="DDI-DrugBank.d43.s8.e1" charOffset="23-27"
            type="brand" text="VIDEX"/>
        <entity id="DDI-DrugBank.d43.s8.e2" charOffset="105-117"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d43.s8.e3" charOffset="152-164"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d43.s8.e4" charOffset="203-210"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d43.s8.e5" charOffset="223-231"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d43.s8.e6" charOffset="234-240"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d43.s8.e7" charOffset="246-253"
            type="drug" text="aluminum"/>
        <ddi id="DDI-DrugBank.d43.s8.d0" e1="DDI-DrugBank.d43.s8.e1"
            e2="DDI-DrugBank.d43.s8.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d43.s8.d1" e1="DDI-DrugBank.d43.s8.e3"
            e2="DDI-DrugBank.d43.s8.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d43.s8.d2" e1="DDI-DrugBank.d43.s8.e3"
            e2="DDI-DrugBank.d43.s8.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d43.s8.d3" e1="DDI-DrugBank.d43.s8.e3"
            e2="DDI-DrugBank.d43.s8.e7" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s9" text="In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.">
        <entity id="DDI-DrugBank.d43.s9.e0" charOffset="56-68"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d43.s9.e1" charOffset="127-139"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d43.s9.e2" charOffset="229-233"
            type="brand" text="VIDEX"/>
        <ddi id="DDI-DrugBank.d43.s9.d0" e1="DDI-DrugBank.d43.s9.e1"
            e2="DDI-DrugBank.d43.s9.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s10" text="The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.">
        <entity id="DDI-DrugBank.d43.s10.e0" charOffset="11-23"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d43.s10.e1" charOffset="90-102"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d43.s10.e2" charOffset="108-117"
            type="drug" text="didanosine"/>
        <ddi id="DDI-DrugBank.d43.s10.d0" e1="DDI-DrugBank.d43.s10.e1"
            e2="DDI-DrugBank.d43.s10.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s11" text="In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.">
        <entity id="DDI-DrugBank.d43.s11.e0" charOffset="38-50"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d43.s11.e1" charOffset="76-85"
            type="drug" text="didanosine"/>
        <entity id="DDI-DrugBank.d43.s11.e2" charOffset="147-159"
            type="drug" text="ciprofloxacin"/>
        <ddi id="DDI-DrugBank.d43.s11.d0" e1="DDI-DrugBank.d43.s11.e0"
            e2="DDI-DrugBank.d43.s11.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s12" text="Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.">
        <entity id="DDI-DrugBank.d43.s12.e0" charOffset="25-45"
            type="group" text="quinolone antibiotics"/>
        <entity id="DDI-DrugBank.d43.s12.e1" charOffset="84-91"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d43.s12.e2" charOffset="104-112"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d43.s12.e3" charOffset="115-121"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d43.s12.e4" charOffset="127-134"
            type="drug" text="aluminum"/>
        <ddi id="DDI-DrugBank.d43.s12.d0" e1="DDI-DrugBank.d43.s12.e0"
            e2="DDI-DrugBank.d43.s12.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d43.s12.d1" e1="DDI-DrugBank.d43.s12.e0"
            e2="DDI-DrugBank.d43.s12.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d43.s12.d2" e1="DDI-DrugBank.d43.s12.e0"
            e2="DDI-DrugBank.d43.s12.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s13" text="The optimal dosing interval for coadministration with VIDEX should be determined by consulting the appropriate quinolone package insert.">
        <entity id="DDI-DrugBank.d43.s13.e0" charOffset="54-58"
            type="brand" text="VIDEX"/>
        <entity id="DDI-DrugBank.d43.s13.e1" charOffset="111-119"
            type="group" text="quinolone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s14" text="Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.">
        <entity id="DDI-DrugBank.d43.s14.e0" charOffset="24-43"
            type="group" text="Antiretroviral Drugs"/>
        <entity id="DDI-DrugBank.d43.s14.e1" charOffset="82-92"
            type="drug" text="delavirdine"/>
        <entity id="DDI-DrugBank.d43.s14.e2" charOffset="104-112"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d43.s14.e3" charOffset="188-192"
            type="brand" text="VIDEX"/>
        <ddi id="DDI-DrugBank.d43.s14.d0" e1="DDI-DrugBank.d43.s14.e1"
            e2="DDI-DrugBank.d43.s14.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d43.s14.d1" e1="DDI-DrugBank.d43.s14.e2"
            e2="DDI-DrugBank.d43.s14.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s15" text="To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.">
        <entity id="DDI-DrugBank.d43.s15.e0" charOffset="27-37"
            type="drug" text="delavirdine"/>
        <entity id="DDI-DrugBank.d43.s15.e1" charOffset="42-50"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d43.s15.e2" charOffset="96-100"
            type="brand" text="VIDEX"/>
        <ddi id="DDI-DrugBank.d43.s15.d0" e1="DDI-DrugBank.d43.s15.e0"
            e2="DDI-DrugBank.d43.s15.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d43.s15.d1" e1="DDI-DrugBank.d43.s15.e1"
            e2="DDI-DrugBank.d43.s15.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d43.s16" text="The pharmacokinetics of nelfinavir are not altered to a clinically significant degree when it is administered with a light meal 1 hour after VIDEX.">
        <entity id="DDI-DrugBank.d43.s16.e0" charOffset="24-33"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d43.s16.e1" charOffset="141-145"
            type="brand" text="VIDEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d570.s0" text="Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.">
        <entity id="DDI-DrugBank.d570.s0.e0" charOffset="97-104"
            type="group" text="estrogen"/>
        <entity id="DDI-DrugBank.d570.s0.e1" charOffset="122-135"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d570.s1" text="The following similar changes may be expected with larger doses of estrogen: - Increased sulfobromophthalein retention">
        <entity id="DDI-DrugBank.d570.s1.e0" charOffset="67-74"
            type="group" text="estrogen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d570.s2" text="."/>
    <sentence id="DDI-DrugBank.d570.s3" text="- Increased prothrombin and factors VII, VIII, IX, and X;"/>
    <sentence id="DDI-DrugBank.d570.s4" text="decreased antithrombin 3;">
        <entity id="DDI-DrugBank.d570.s4.e0" charOffset="10-23"
            type="drug" text="antithrombin 3"/>
    </sentence>
    <sentence id="DDI-DrugBank.d570.s5" text="increased norepinephrine-induced platelet aggregability"/>
    <sentence id="DDI-DrugBank.d570.s6" text="."/>
    <sentence id="DDI-DrugBank.d570.s7" text="- Increased thyroid-binding globulin (TBG) leading to in-creased circulating total thyroid hormone;"/>
    <sentence id="DDI-DrugBank.d570.s8" text="as measured by PBI, T4 by column, or T4 by radioimmunoassay."/>
    <sentence id="DDI-DrugBank.d570.s9" text="Free T3 resin uptake is decreased, reflecting the elevated TBG;"/>
    <sentence id="DDI-DrugBank.d570.s10" text="free T4 concentration is unaltered"/>
    <sentence id="DDI-DrugBank.d570.s11" text="."/>
    <sentence id="DDI-DrugBank.d570.s12" text="- Impaired glucose tolerance"/>
    <sentence id="DDI-DrugBank.d570.s13" text="."/>
    <sentence id="DDI-DrugBank.d570.s14" text="- Decreased pregnanediol excretion"/>
    <sentence id="DDI-DrugBank.d570.s15" text="."/>
    <sentence id="DDI-DrugBank.d570.s16" text="- Reduced response to metyrapone test"/>
    <sentence id="DDI-DrugBank.d570.s17" text="."/>
    <sentence id="DDI-DrugBank.d570.s18" text="- Reduced serum folate concentration"/>
    <sentence id="DDI-DrugBank.d570.s19" text="."/>
    <sentence id="DDI-DrugBank.d570.s20" text="- Increased serum triglyceride and phospholipid concentration."/>
    <sentence id="DDI-DrugBank.d352.s0" text="Antidiabetic drug requirements (i.e., insulin) may be altered.">
        <entity id="DDI-DrugBank.d352.s0.e0" charOffset="0-16"
            type="group" text="Antidiabetic drug"/>
        <entity id="DDI-DrugBank.d352.s0.e1" charOffset="38-44"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d352.s1" text="Concurrent use with general anesthetics may result in arrhythmias.">
        <entity id="DDI-DrugBank.d352.s1.e0" charOffset="28-38"
            type="group" text="anesthetics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d352.s2" text="The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly;">
        <entity id="DDI-DrugBank.d352.s2.e0" charOffset="23-36"
            type="drug" text="diethylpropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d352.s3" text="conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).">
        <entity id="DDI-DrugBank.d352.s3.e0" charOffset="12-25"
            type="drug" text="diethylpropion"/>
        <entity id="DDI-DrugBank.d352.s3.e1" charOffset="46-67"
            type="group" text="antihypertensive drugs"/>
        <entity id="DDI-DrugBank.d352.s3.e2" charOffset="76-87"
            type="drug" text="guanethidine"/>
        <entity id="DDI-DrugBank.d352.s3.e3" charOffset="90-101"
            type="drug" text="a-methyldopa"/>
        <ddi id="DDI-DrugBank.d352.s3.d0" e1="DDI-DrugBank.d352.s3.e0"
            e2="DDI-DrugBank.d352.s3.e1" type="int"/>
        <ddi id="DDI-DrugBank.d352.s3.d1" e1="DDI-DrugBank.d352.s3.e0"
            e2="DDI-DrugBank.d352.s3.e2" type="int"/>
        <ddi id="DDI-DrugBank.d352.s3.d2" e1="DDI-DrugBank.d352.s3.e0"
            e2="DDI-DrugBank.d352.s3.e3" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d352.s4" text="Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.">
        <entity id="DDI-DrugBank.d352.s4.e0" charOffset="18-31"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d352.s4.e1" charOffset="72-85"
            type="drug" text="diethylpropion"/>
        <ddi id="DDI-DrugBank.d352.s4.d0" e1="DDI-DrugBank.d352.s4.e0"
            e2="DDI-DrugBank.d352.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d248.s0" text="May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).">
        <entity id="DDI-DrugBank.d248.s0.e0" charOffset="13-26"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d248.s0.e1" charOffset="67-78"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d248.s0.e2" charOffset="81-88"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d248.s0.e3" charOffset="176-193"
            type="drug" text="diethylstilbestrol"/>
        <entity id="DDI-DrugBank.d248.s0.e4" charOffset="197-211"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d248.s0.e5" charOffset="234-248"
            type="group" text="corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s0" text="Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.">
        <entity id="DDI-DrugBank.d132.s0.e0" charOffset="5-18"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d132.s0.e1" charOffset="82-91"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s0.e2" charOffset="97-104"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d132.s0.e3" charOffset="107-119"
            type="drug" text="acenocoumarol"/>
        <entity id="DDI-DrugBank.d132.s0.e4" charOffset="125-137"
            type="drug" text="phenprocoumon"/>
        <ddi id="DDI-DrugBank.d132.s0.d0" e1="DDI-DrugBank.d132.s0.e1"
            e2="DDI-DrugBank.d132.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d132.s0.d1" e1="DDI-DrugBank.d132.s0.e1"
            e2="DDI-DrugBank.d132.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d132.s0.d2" e1="DDI-DrugBank.d132.s0.e1"
            e2="DDI-DrugBank.d132.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s1" text="This may occur because diflunisal competitively displaces coumarins from protein binding sites.">
        <entity id="DDI-DrugBank.d132.s1.e0" charOffset="23-32"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s1.e1" charOffset="58-66"
            type="group" text="coumarins"/>
        <ddi id="DDI-DrugBank.d132.s1.d0" e1="DDI-DrugBank.d132.s1.e0"
            e2="DDI-DrugBank.d132.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s2" text="Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.">
        <entity id="DDI-DrugBank.d132.s2.e0" charOffset="18-27"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s2.e1" charOffset="55-68"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d132.s2.d0" e1="DDI-DrugBank.d132.s2.e0"
            e2="DDI-DrugBank.d132.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s3" text="Adjustment of dosage of oral anticoagulants may be required.">
        <entity id="DDI-DrugBank.d132.s3.e0" charOffset="29-42"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s4" text="Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.">
        <entity id="DDI-DrugBank.d132.s4.e0" charOffset="0-10"
            type="drug" text="Tolbutamide"/>
        <entity id="DDI-DrugBank.d132.s4.e1" charOffset="44-53"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s4.e2" charOffset="59-69"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d132.s4.e3" charOffset="108-118"
            type="drug" text="tolbutamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s5" text="Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.">
        <entity id="DDI-DrugBank.d132.s5.e0" charOffset="0-18"
            type="drug" text="Hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d132.s5.e1" charOffset="73-82"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s5.e2" charOffset="88-106"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d132.s5.e3" charOffset="161-179"
            type="drug" text="hydrochlorothiazide"/>
        <ddi id="DDI-DrugBank.d132.s5.d0" e1="DDI-DrugBank.d132.s5.e1"
            e2="DDI-DrugBank.d132.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s6" text="Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.">
        <entity id="DDI-DrugBank.d132.s6.e0" charOffset="0-9"
            type="drug" text="Diflunisal"/>
        <entity id="DDI-DrugBank.d132.s6.e1" charOffset="49-67"
            type="drug" text="hydrochlorothiazide"/>
        <ddi id="DDI-DrugBank.d132.s6.d0" e1="DDI-DrugBank.d132.s6.e0"
            e2="DDI-DrugBank.d132.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s7" text="Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.">
        <entity id="DDI-DrugBank.d132.s7.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d132.s7.e1" charOffset="68-77"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s7.e2" charOffset="83-92"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d132.s7.e3" charOffset="136-145"
            type="drug" text="furosemide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s8" text="Diflunisal decreased the hyperuricemic effect of furosemide.">
        <entity id="DDI-DrugBank.d132.s8.e0" charOffset="0-9"
            type="drug" text="Diflunisal"/>
        <entity id="DDI-DrugBank.d132.s8.e1" charOffset="49-58"
            type="drug" text="furosemide"/>
        <ddi id="DDI-DrugBank.d132.s8.d0" e1="DDI-DrugBank.d132.s8.e0"
            e2="DDI-DrugBank.d132.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s9" text="Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.">
        <entity id="DDI-DrugBank.d132.s9.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d132.s9.e1" charOffset="40-47"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d132.s9.e2" charOffset="77-86"
            type="drug" text="diflunisal"/>
        <ddi id="DDI-DrugBank.d132.s9.d0" e1="DDI-DrugBank.d132.s9.e1"
            e2="DDI-DrugBank.d132.s9.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s10" text="This effect is small with occasional doses of antacids, but may be clinically significant when antacids are used on a continuous schedule.">
        <entity id="DDI-DrugBank.d132.s10.e0" charOffset="46-53"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d132.s10.e1" charOffset="95-102"
            type="group" text="antacids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s11" text="Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.">
        <entity id="DDI-DrugBank.d132.s11.e0" charOffset="0-12"
            type="drug" text="Acetaminophen"/>
        <entity id="DDI-DrugBank.d132.s11.e1" charOffset="67-76"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s11.e2" charOffset="82-94"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d132.s11.e3" charOffset="156-168"
            type="drug" text="acetaminophen"/>
        <ddi id="DDI-DrugBank.d132.s11.d0" e1="DDI-DrugBank.d132.s11.e1"
            e2="DDI-DrugBank.d132.s11.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s12" text="Acetaminophen had no effect on plasma levels of diflunisal.">
        <entity id="DDI-DrugBank.d132.s12.e0" charOffset="0-12"
            type="drug" text="Acetaminophen"/>
        <entity id="DDI-DrugBank.d132.s12.e1" charOffset="48-57"
            type="drug" text="diflunisal"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s13" text="Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.">
        <entity id="DDI-DrugBank.d132.s13.e0" charOffset="6-18"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d132.s13.e1" charOffset="105-114"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s13.e2" charOffset="120-132"
            type="drug" text="acetaminophen"/>
        <ddi id="DDI-DrugBank.d132.s13.d0" e1="DDI-DrugBank.d132.s13.e1"
            e2="DDI-DrugBank.d132.s13.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s14" text="Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.">
        <entity id="DDI-DrugBank.d132.s14.e0" charOffset="30-39"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s14.e1" charOffset="45-57"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d132.s14.e2" charOffset="188-197"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s14.e3" charOffset="199-211"
            type="drug" text="acetaminophen"/>
        <ddi id="DDI-DrugBank.d132.s14.d0" e1="DDI-DrugBank.d132.s14.e0"
            e2="DDI-DrugBank.d132.s14.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s15" text="The clinical significance of these findings has not been established."/>
    <sentence id="DDI-DrugBank.d132.s16" text="Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.">
        <entity id="DDI-DrugBank.d132.s16.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d132.s16.e1" charOffset="40-49"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s16.e2" charOffset="86-97"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d132.s16.d0" e1="DDI-DrugBank.d132.s16.e1"
            e2="DDI-DrugBank.d132.s16.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s17" text="Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.">
        <entity id="DDI-DrugBank.d132.s17.e0" charOffset="0-35"
            type="group" text="Nonsteroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d132.s17.e1" charOffset="93-104"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d132.s17.d0" e1="DDI-DrugBank.d132.s17.e0"
            e2="DDI-DrugBank.d132.s17.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s18" text="Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.">
        <entity id="DDI-DrugBank.d132.s18.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d132.s18.e1" charOffset="32-66"
            type="group" text="nonsteroial anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d132.s18.e2" charOffset="87-98"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d132.s18.e3" charOffset="140-151"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d132.s18.d0" e1="DDI-DrugBank.d132.s18.e1"
            e2="DDI-DrugBank.d132.s18.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s19" text="NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.">
        <entity id="DDI-DrugBank.d132.s19.e0" charOffset="0-5"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d132.s19.e1" charOffset="54-65"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d132.s19.d0" e1="DDI-DrugBank.d132.s19.e0"
            e2="DDI-DrugBank.d132.s19.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s20" text="Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.">
        <entity id="DDI-DrugBank.d132.s20.e0" charOffset="0-35"
            type="group" text="Nonsteroidal Anti-Inflammatory Drugs"/>
        <entity id="DDI-DrugBank.d132.s20.e1" charOffset="60-69"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s20.e2" charOffset="102-113"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d132.s20.e3" charOffset="194-205"
            type="drug" text="indomethacin"/>
        <ddi id="DDI-DrugBank.d132.s20.d0" e1="DDI-DrugBank.d132.s20.e1"
            e2="DDI-DrugBank.d132.s20.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s21" text="In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.">
        <entity id="DDI-DrugBank.d132.s21.e0" charOffset="37-48"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d132.s21.e1" charOffset="54-63"
            type="drug" text="diflunisal"/>
        <ddi id="DDI-DrugBank.d132.s21.d0" e1="DDI-DrugBank.d132.s21.e0"
            e2="DDI-DrugBank.d132.s21.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s22" text="Therefore, indomethacin and diflunisal should not be used concomitantly.">
        <entity id="DDI-DrugBank.d132.s22.e0" charOffset="11-22"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d132.s22.e1" charOffset="28-37"
            type="drug" text="diflunisal"/>
        <ddi id="DDI-DrugBank.d132.s22.d0" e1="DDI-DrugBank.d132.s22.e0"
            e2="DDI-DrugBank.d132.s22.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s23" text="The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.">
        <entity id="DDI-DrugBank.d132.s23.e0" charOffset="23-32"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s23.e1" charOffset="52-57"
            type="group" text="NSAIDs"/>
        <ddi id="DDI-DrugBank.d132.s23.d0" e1="DDI-DrugBank.d132.s23.e0"
            e2="DDI-DrugBank.d132.s23.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s24" text="The following information was obtained from studies in normal volunteers."/>
    <sentence id="DDI-DrugBank.d132.s25" text="Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.">
        <entity id="DDI-DrugBank.d132.s25.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d132.s25.e1" charOffset="51-60"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s25.e2" charOffset="105-114"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s25.e3" charOffset="120-126"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d132.s25.d0" e1="DDI-DrugBank.d132.s25.e2"
            e2="DDI-DrugBank.d132.s25.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s26" text="Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.">
        <entity id="DDI-DrugBank.d132.s26.e0" charOffset="0-7"
            type="drug" text="Sulindac"/>
        <entity id="DDI-DrugBank.d132.s26.e1" charOffset="44-53"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s26.e2" charOffset="59-66"
            type="drug" text="sulindac"/>
        <ddi id="DDI-DrugBank.d132.s26.d0" e1="DDI-DrugBank.d132.s26.e1"
            e2="DDI-DrugBank.d132.s26.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s27" text="Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.">
        <entity id="DDI-DrugBank.d132.s27.e0" charOffset="0-7"
            type="drug" text="Naproxen"/>
        <entity id="DDI-DrugBank.d132.s27.e1" charOffset="44-53"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d132.s27.e2" charOffset="59-66"
            type="drug" text="naproxen"/>
        <entity id="DDI-DrugBank.d132.s27.e3" charOffset="127-134"
            type="drug" text="naproxen"/>
        <entity id="DDI-DrugBank.d132.s27.e4" charOffset="190-197"
            type="drug" text="naproxen"/>
        <ddi id="DDI-DrugBank.d132.s27.d0" e1="DDI-DrugBank.d132.s27.e1"
            e2="DDI-DrugBank.d132.s27.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s28" text="Naproxen had no effect on plasma levels of diflunisal.">
        <entity id="DDI-DrugBank.d132.s28.e0" charOffset="0-7"
            type="drug" text="Naproxen"/>
        <entity id="DDI-DrugBank.d132.s28.e1" charOffset="43-52"
            type="drug" text="diflunisal"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s29" text="Drug laboratory Test Interactions Serum Salicylate Assays: Caution should be used in interpreting the results of serum salicylate assays when diflunisal is present.">
        <entity id="DDI-DrugBank.d132.s29.e0" charOffset="142-151"
            type="drug" text="diflunisal"/>
    </sentence>
    <sentence id="DDI-DrugBank.d132.s30" text="Salicylate levels have been found to be falsely elevated with some assay methods.">
        <entity id="DDI-DrugBank.d132.s30.e0" charOffset="0-9"
            type="group" text="Salicylate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s0" text="Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.">
        <entity id="DDI-DrugBank.d450.s0.e0" charOffset="0-28"
            type="group" text="Potassium-depleting diuretics"/>
        <entity id="DDI-DrugBank.d450.s0.e1" charOffset="65-73"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d450.s0.d0" e1="DDI-DrugBank.d450.s0.e0"
            e2="DDI-DrugBank.d450.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s1" text="Calcium, particularly if administered rapidly by the intravenous route, may produce serious arrhythmias in digitalized patients.">
        <entity id="DDI-DrugBank.d450.s1.e0" charOffset="0-6"
            type="drug" text="Calcium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s2" text="Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.">
        <entity id="DDI-DrugBank.d450.s2.e0" charOffset="0-8"
            type="drug" text="Quinidine"/>
        <entity id="DDI-DrugBank.d450.s2.e1" charOffset="11-19"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d450.s2.e2" charOffset="22-31"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d450.s2.e3" charOffset="34-44"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d450.s2.e4" charOffset="47-58"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d450.s2.e5" charOffset="61-72"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d450.s2.e6" charOffset="75-84"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d450.s2.e7" charOffset="91-104"
            type="drug" text="spironolactone"/>
        <entity id="DDI-DrugBank.d450.s2.e8" charOffset="122-128"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d450.s2.e9" charOffset="248-256"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d450.s2.d0" e1="DDI-DrugBank.d450.s2.e0"
            e2="DDI-DrugBank.d450.s2.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s2.d1" e1="DDI-DrugBank.d450.s2.e1"
            e2="DDI-DrugBank.d450.s2.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s2.d2" e1="DDI-DrugBank.d450.s2.e2"
            e2="DDI-DrugBank.d450.s2.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s2.d3" e1="DDI-DrugBank.d450.s2.e3"
            e2="DDI-DrugBank.d450.s2.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s2.d4" e1="DDI-DrugBank.d450.s2.e4"
            e2="DDI-DrugBank.d450.s2.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s2.d5" e1="DDI-DrugBank.d450.s2.e5"
            e2="DDI-DrugBank.d450.s2.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s2.d6" e1="DDI-DrugBank.d450.s2.e6"
            e2="DDI-DrugBank.d450.s2.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s2.d7" e1="DDI-DrugBank.d450.s2.e7"
            e2="DDI-DrugBank.d450.s2.e8" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s3" text="Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.">
        <entity id="DDI-DrugBank.d450.s3.e0" charOffset="0-11"
            type="drug" text="Erythromycin"/>
        <entity id="DDI-DrugBank.d450.s3.e1" charOffset="17-30"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d450.s3.e2" charOffset="52-72"
            type="group" text="macrolide antibiotics"/>
        <entity id="DDI-DrugBank.d450.s3.e3" charOffset="79-90"
            type="drug" text="tetracycline"/>
        <entity id="DDI-DrugBank.d450.s3.e4" charOffset="105-111"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d450.s3.e5" charOffset="151-157"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d450.s3.e6" charOffset="215-223"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d450.s3.d0" e1="DDI-DrugBank.d450.s3.e0"
            e2="DDI-DrugBank.d450.s3.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s3.d1" e1="DDI-DrugBank.d450.s3.e1"
            e2="DDI-DrugBank.d450.s3.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s3.d2" e1="DDI-DrugBank.d450.s3.e2"
            e2="DDI-DrugBank.d450.s3.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s3.d3" e1="DDI-DrugBank.d450.s3.e3"
            e2="DDI-DrugBank.d450.s3.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s4" text="The risk of this interaction may be reduced if digoxin is given as capsules.">
        <entity id="DDI-DrugBank.d450.s4.e0" charOffset="47-53"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s5" text="Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.">
        <entity id="DDI-DrugBank.d450.s5.e0" charOffset="0-12"
            type="drug" text="Propantheline"/>
        <entity id="DDI-DrugBank.d450.s5.e1" charOffset="18-30"
            type="drug" text="diphenoxylate"/>
        <entity id="DDI-DrugBank.d450.s5.e2" charOffset="74-80"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d450.s5.d0" e1="DDI-DrugBank.d450.s5.e0"
            e2="DDI-DrugBank.d450.s5.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s5.d1" e1="DDI-DrugBank.d450.s5.e1"
            e2="DDI-DrugBank.d450.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s6" text="Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.">
        <entity id="DDI-DrugBank.d450.s6.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d450.s6.e1" charOffset="10-15"
            type="drug" text="kaolin"/>
        <entity id="DDI-DrugBank.d450.s6.e2" charOffset="25-37"
            type="drug" text="sulfasalazine"/>
        <entity id="DDI-DrugBank.d450.s6.e3" charOffset="40-47"
            type="drug" text="neomycin"/>
        <entity id="DDI-DrugBank.d450.s6.e4" charOffset="50-63"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d450.s6.e5" charOffset="96-109"
            type="drug" text="metoclopramide"/>
        <entity id="DDI-DrugBank.d450.s6.e6" charOffset="141-147"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d450.s6.d0" e1="DDI-DrugBank.d450.s6.e0"
            e2="DDI-DrugBank.d450.s6.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s6.d1" e1="DDI-DrugBank.d450.s6.e1"
            e2="DDI-DrugBank.d450.s6.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s6.d2" e1="DDI-DrugBank.d450.s6.e2"
            e2="DDI-DrugBank.d450.s6.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s6.d3" e1="DDI-DrugBank.d450.s6.e3"
            e2="DDI-DrugBank.d450.s6.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s6.d4" e1="DDI-DrugBank.d450.s6.e4"
            e2="DDI-DrugBank.d450.s6.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d450.s6.d5" e1="DDI-DrugBank.d450.s6.e5"
            e2="DDI-DrugBank.d450.s6.e6" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s7" text="Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.">
        <entity id="DDI-DrugBank.d450.s7.e0" charOffset="0-7"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d450.s7.e1" charOffset="28-34"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d450.s7.e2" charOffset="139-145"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d450.s7.d0" e1="DDI-DrugBank.d450.s7.e0"
            e2="DDI-DrugBank.d450.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s8" text="There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, penicillamine) on serum digoxin concentration.">
        <entity id="DDI-DrugBank.d450.s8.e0" charOffset="81-87"
            type="drug" text="quinine"/>
        <entity id="DDI-DrugBank.d450.s8.e1" charOffset="90-102"
            type="drug" text="penicillamine"/>
        <entity id="DDI-DrugBank.d450.s8.e2" charOffset="114-120"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s9" text="Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.">
        <entity id="DDI-DrugBank.d450.s9.e0" charOffset="0-6"
            type="group" text="Thyroid"/>
        <entity id="DDI-DrugBank.d450.s9.e1" charOffset="98-104"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d450.s9.d0" e1="DDI-DrugBank.d450.s9.e0"
            e2="DDI-DrugBank.d450.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s10" text="Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.">
        <entity id="DDI-DrugBank.d450.s10.e0" charOffset="19-25"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d450.s10.e1" charOffset="31-46"
            type="group" text="sympathomimetics"/>
        <ddi id="DDI-DrugBank.d450.s10.d0" e1="DDI-DrugBank.d450.s10.e0"
            e2="DDI-DrugBank.d450.s10.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s11" text="Succinylcholine may cause a sudden extrusion of potassium from muscle cells, and may thereby cause arrhythmias in digitalized patients.">
        <entity id="DDI-DrugBank.d450.s11.e0" charOffset="0-14"
            type="drug" text="Succinylcholine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s12" text="Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.">
        <entity id="DDI-DrugBank.d450.s12.e0" charOffset="9-32"
            type="group" text="beta-adrenergic blockers"/>
        <entity id="DDI-DrugBank.d450.s12.e1" charOffset="37-60"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d450.s12.e2" charOffset="66-72"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d450.s12.d0" e1="DDI-DrugBank.d450.s12.e0"
            e2="DDI-DrugBank.d450.s12.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d450.s12.d1" e1="DDI-DrugBank.d450.s12.e1"
            e2="DDI-DrugBank.d450.s12.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s13" text="Due to the considerable variability of these interactions, the dosage of digoxin should be individualized when patients receive these medications concurrently.">
        <entity id="DDI-DrugBank.d450.s13.e0" charOffset="73-79"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d450.s14" text="Furthermore, caution should be exercised when combining digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.">
        <entity id="DDI-DrugBank.d450.s14.e0" charOffset="56-62"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d450.s14.e1" charOffset="230-236"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d410.s0" text="Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.">
        <entity id="DDI-DrugBank.d410.s0.e0" charOffset="0-15"
            type="group" text="Vasoconstrictors"/>
        <entity id="DDI-DrugBank.d410.s0.e1" charOffset="18-26"
            type="brand" text="D.H.E. 45"/>
        <entity id="DDI-DrugBank.d410.s0.e2" charOffset="30-55"
            type="drug" text="dihydroergotamine mesylate"/>
        <entity id="DDI-DrugBank.d410.s0.e3" charOffset="97-123"
            type="group" text="peripheral vasoconstrictors"/>
        <ddi id="DDI-DrugBank.d410.s0.d0" e1="DDI-DrugBank.d410.s0.e1"
            e2="DDI-DrugBank.d410.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d410.s0.d1" e1="DDI-DrugBank.d410.s0.e2"
            e2="DDI-DrugBank.d410.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d410.s1" text="Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.">
        <entity id="DDI-DrugBank.d410.s1.e0" charOffset="0-10"
            type="drug" text="Sumatriptan"/>
        <entity id="DDI-DrugBank.d410.s1.e1" charOffset="13-23"
            type="drug" text="Sumatriptan"/>
        <entity id="DDI-DrugBank.d410.s1.e2" charOffset="117-125"
            type="brand" text="D.H.E. 45"/>
        <entity id="DDI-DrugBank.d410.s1.e3" charOffset="129-154"
            type="drug" text="dihydroergotamine mesylate"/>
        <ddi id="DDI-DrugBank.d410.s1.d0" e1="DDI-DrugBank.d410.s1.e1"
            e2="DDI-DrugBank.d410.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d410.s1.d1" e1="DDI-DrugBank.d410.s1.e1"
            e2="DDI-DrugBank.d410.s1.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d410.s2" text="Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..">
        <entity id="DDI-DrugBank.d410.s2.e0" charOffset="0-10"
            type="drug" text="Sumatriptan"/>
        <entity id="DDI-DrugBank.d410.s2.e1" charOffset="16-24"
            type="brand" text="D.H.E. 45"/>
        <entity id="DDI-DrugBank.d410.s2.e2" charOffset="28-53"
            type="drug" text="dihydroergotamine mesylate"/>
        <ddi id="DDI-DrugBank.d410.s2.d0" e1="DDI-DrugBank.d410.s2.e0"
            e2="DDI-DrugBank.d410.s2.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d410.s2.d1" e1="DDI-DrugBank.d410.s2.e0"
            e2="DDI-DrugBank.d410.s2.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d410.s3" text="Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.">
        <entity id="DDI-DrugBank.d410.s3.e0" charOffset="0-12"
            type="group" text="Beta Blockers"/>
        <entity id="DDI-DrugBank.d410.s3.e1" charOffset="126-134"
            type="brand" text="D.H.E. 45"/>
        <entity id="DDI-DrugBank.d410.s3.e2" charOffset="138-163"
            type="drug" text="dihydroergotamine mesylate"/>
        <entity id="DDI-DrugBank.d410.s3.e3" charOffset="211-221"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d410.s3.e4" charOffset="253-263"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d410.s3.e5" charOffset="311-320"
            type="drug" text="ergotamine"/>
        <ddi id="DDI-DrugBank.d410.s3.d0" e1="DDI-DrugBank.d410.s3.e4"
            e2="DDI-DrugBank.d410.s3.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d410.s4" text="Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.">
        <entity id="DDI-DrugBank.d410.s4.e0" charOffset="0-7"
            type="drug" text="Nicotine"/>
        <entity id="DDI-DrugBank.d410.s4.e1" charOffset="10-17"
            type="drug" text="Nicotine"/>
        <entity id="DDI-DrugBank.d410.s4.e2" charOffset="113-117"
            type="drug" text="ergot"/>
        <ddi id="DDI-DrugBank.d410.s4.d0" e1="DDI-DrugBank.d410.s4.e1"
            e2="DDI-DrugBank.d410.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d410.s5" text="Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.">
        <entity id="DDI-DrugBank.d410.s5.e0" charOffset="0-20"
            type="group" text="Macrolide Antibiotics"/>
        <entity id="DDI-DrugBank.d410.s5.e1" charOffset="29-40"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d410.s5.e2" charOffset="46-59"
            type="drug" text="troleandomycin"/>
        <entity id="DDI-DrugBank.d410.s5.e3" charOffset="77-96"
            type="group" text="ergot alkaloid class"/>
        <entity id="DDI-DrugBank.d410.s5.e4" charOffset="108-116"
            type="brand" text="D.H.E. 45"/>
        <entity id="DDI-DrugBank.d410.s5.e5" charOffset="120-145"
            type="drug" text="dihydroergotamine mesylate"/>
        <entity id="DDI-DrugBank.d410.s5.e6" charOffset="209-219"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d410.s5.e7" charOffset="228-242"
            type="group" text="macrolide class"/>
        <ddi id="DDI-DrugBank.d410.s5.d0" e1="DDI-DrugBank.d410.s5.e3"
            e2="DDI-DrugBank.d410.s5.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d410.s5.d1" e1="DDI-DrugBank.d410.s5.e4"
            e2="DDI-DrugBank.d410.s5.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d410.s5.d2" e1="DDI-DrugBank.d410.s5.e5"
            e2="DDI-DrugBank.d410.s5.e7" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d410.s6" text="Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.">
        <entity id="DDI-DrugBank.d410.s6.e0" charOffset="67-76"
            type="drug" text="ergotamine"/>
        <entity id="DDI-DrugBank.d410.s6.e1" charOffset="127-137"
            type="group" text="antibiotics"/>
        <ddi id="DDI-DrugBank.d410.s6.d0" e1="DDI-DrugBank.d410.s6.e0"
            e2="DDI-DrugBank.d410.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d410.s7" text="SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.">
        <entity id="DDI-DrugBank.d410.s7.e0" charOffset="0-4"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d410.s7.e1" charOffset="81-94"
            type="group" text="5-HT1 agonists"/>
        <entity id="DDI-DrugBank.d410.s7.e2" charOffset="127-131"
            type="group" text="SSRIs"/>
        <ddi id="DDI-DrugBank.d410.s7.d0" e1="DDI-DrugBank.d410.s7.e1"
            e2="DDI-DrugBank.d410.s7.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d410.s8" text="fluoxetine, fluvoxamine, paroxetine, sertraline).">
        <entity id="DDI-DrugBank.d410.s8.e0" charOffset="0-9"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d410.s8.e1" charOffset="12-22"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d410.s8.e2" charOffset="25-34"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d410.s8.e3" charOffset="37-46"
            type="drug" text="sertraline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d410.s9" text="There have been no reported cases from spontaneous reports of drug interaction between SSRIs and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.">
        <entity id="DDI-DrugBank.d410.s9.e0" charOffset="87-91"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d410.s9.e1" charOffset="97-105"
            type="brand" text="D.H.E. 45"/>
        <entity id="DDI-DrugBank.d410.s9.e2" charOffset="109-134"
            type="drug" text="dihydroergotamine mesylate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d410.s10" text="Oral Contraceptives: The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP has not been studied.">
        <entity id="DDI-DrugBank.d410.s10.e0" charOffset="5-18"
            type="group" text="Contraceptives"/>
        <entity id="DDI-DrugBank.d410.s10.e1" charOffset="40-53"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d410.s10.e2" charOffset="82-90"
            type="brand" text="D.H.E. 45"/>
        <entity id="DDI-DrugBank.d410.s10.e3" charOffset="94-119"
            type="drug" text="dihydroergotamine mesylate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d452.s0" text="Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.">
        <entity id="DDI-DrugBank.d452.s0.e0" charOffset="18-35"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d452.s0.e1" charOffset="105-122"
            type="drug" text="dihydrotachysterol"/>
        <ddi id="DDI-DrugBank.d452.s0.d0" e1="DDI-DrugBank.d452.s0.e0"
            e2="DDI-DrugBank.d452.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s0" text="Due to the potential for additive effects, caution and careful titration are warranted in patients receiving diltiazem hydrochloride concomitantly with other agents known to affect cardiac contractility and/or conduction.">
        <entity id="DDI-DrugBank.d565.s0.e0" charOffset="109-131"
            type="drug" text="diltiazem hydrochloride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s1" text="Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.">
        <entity id="DDI-DrugBank.d565.s1.e0" charOffset="105-117"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d565.s1.e1" charOffset="122-130"
            type="group" text="digitalis"/>
        <entity id="DDI-DrugBank.d565.s1.e2" charOffset="151-156"
            type="brand" text="Tiazac"/>
        <ddi id="DDI-DrugBank.d565.s1.d0" e1="DDI-DrugBank.d565.s1.e0"
            e2="DDI-DrugBank.d565.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d565.s1.d1" e1="DDI-DrugBank.d565.s1.e1"
            e2="DDI-DrugBank.d565.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s2" text="As with all drugs, care should be exercised when treating patients with multiple medications."/>
    <sentence id="DDI-DrugBank.d565.s3" text="Diltiazem is both a substrate and an inhibitor of the cytochrome P-450 3A4 enzyme system.">
        <entity id="DDI-DrugBank.d565.s3.e0" charOffset="0-8"
            type="drug" text="Diltiazem"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s4" text="Other drugs that are specific substrates, inhibitors, or inducers of the enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem.">
        <entity id="DDI-DrugBank.d565.s4.e0" charOffset="160-168"
            type="drug" text="diltiazem"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s5" text="Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels.">
        <entity id="DDI-DrugBank.d565.s5.e0" charOffset="204-212"
            type="drug" text="diltiazem"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s6" text="Beta Blockers">
        <entity id="DDI-DrugBank.d565.s6.e0" charOffset="0-12"
            type="group" text="Beta Blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s7" text="Controlled and uncontrolled domestic studies suggest that concomitant use of diltiazem hydrochloride and beta-blockers is usually well tolerated, but available data are not sufficient to predict the effects of concomitant treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities.">
        <entity id="DDI-DrugBank.d565.s7.e0" charOffset="77-99"
            type="drug" text="diltiazem hydrochloride"/>
        <entity id="DDI-DrugBank.d565.s7.e1" charOffset="105-117"
            type="group" text="beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s8" text="Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.">
        <entity id="DDI-DrugBank.d565.s8.e0" charOffset="18-40"
            type="drug" text="diltiazem hydrochloride"/>
        <entity id="DDI-DrugBank.d565.s8.e1" charOffset="61-71"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d565.s8.e2" charOffset="121-131"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d565.s8.e3" charOffset="179-189"
            type="drug" text="propranolol"/>
        <ddi id="DDI-DrugBank.d565.s8.d0" e1="DDI-DrugBank.d565.s8.e0"
            e2="DDI-DrugBank.d565.s8.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s9" text="In vitro, propranolol appears to be displaced from its binding sites by diltiazem.">
        <entity id="DDI-DrugBank.d565.s9.e0" charOffset="10-20"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d565.s9.e1" charOffset="72-80"
            type="drug" text="diltiazem"/>
        <ddi id="DDI-DrugBank.d565.s9.d0" e1="DDI-DrugBank.d565.s9.e0"
            e2="DDI-DrugBank.d565.s9.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s10" text="If combination therapy is initiated or withdrawn in conjunction with propranolol, an adjustment in the propranolol dose may be warranted.">
        <entity id="DDI-DrugBank.d565.s10.e0" charOffset="69-79"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d565.s10.e1" charOffset="103-113"
            type="drug" text="propranolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s11" text="Cimetidine">
        <entity id="DDI-DrugBank.d565.s11.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s12" text="A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.">
        <entity id="DDI-DrugBank.d565.s12.e0" charOffset="75-83"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d565.s12.e1" charOffset="144-153"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d565.s12.e2" charOffset="188-196"
            type="drug" text="diltiazem"/>
        <ddi id="DDI-DrugBank.d565.s12.d0" e1="DDI-DrugBank.d565.s12.e1"
            e2="DDI-DrugBank.d565.s12.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s13" text="Ranitidine produced smaller, nonsignificant increases.">
        <entity id="DDI-DrugBank.d565.s13.e0" charOffset="0-9"
            type="drug" text="Ranitidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s14" text="The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.">
        <entity id="DDI-DrugBank.d565.s14.e0" charOffset="30-39"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d565.s14.e1" charOffset="151-159"
            type="drug" text="diltiazem"/>
        <ddi id="DDI-DrugBank.d565.s14.d0" e1="DDI-DrugBank.d565.s14.e0"
            e2="DDI-DrugBank.d565.s14.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s15" text="Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.">
        <entity id="DDI-DrugBank.d565.s15.e0" charOffset="29-37"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d565.s15.e1" charOffset="163-172"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d565.s15.d0" e1="DDI-DrugBank.d565.s15.e0"
            e2="DDI-DrugBank.d565.s15.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s16" text="An adjustment in the diltiazem dose may be warranted.">
        <entity id="DDI-DrugBank.d565.s16.e0" charOffset="21-29"
            type="drug" text="diltiazem"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s17" text="Digitalis">
        <entity id="DDI-DrugBank.d565.s17.e0" charOffset="0-8"
            type="group" text="Digitalis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s18" text="Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.">
        <entity id="DDI-DrugBank.d565.s18.e0" charOffset="18-40"
            type="drug" text="diltiazem hydrochloride"/>
        <entity id="DDI-DrugBank.d565.s18.e1" charOffset="47-53"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d565.s18.e2" charOffset="100-106"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d565.s18.d0" e1="DDI-DrugBank.d565.s18.e0"
            e2="DDI-DrugBank.d565.s18.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s19" text="Another investigator found no increase in digoxin levels in 12 patients with coronary artery disease.">
        <entity id="DDI-DrugBank.d565.s19.e0" charOffset="42-48"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s20" text="Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.">
        <entity id="DDI-DrugBank.d565.s20.e0" charOffset="66-72"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d565.s20.e1" charOffset="105-111"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d565.s20.e2" charOffset="179-201"
            type="drug" text="diltiazem hydrochloride"/>
        <ddi id="DDI-DrugBank.d565.s20.d0" e1="DDI-DrugBank.d565.s20.e1"
            e2="DDI-DrugBank.d565.s20.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s21" text="Anesthetics">
        <entity id="DDI-DrugBank.d565.s21.e0" charOffset="0-10"
            type="group" text="Anesthetics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s22" text="The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.">
        <entity id="DDI-DrugBank.d565.s22.e0" charOffset="121-131"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d565.s22.e1" charOffset="155-178"
            type="group" text="calcium channel blockers"/>
        <ddi id="DDI-DrugBank.d565.s22.d0" e1="DDI-DrugBank.d565.s22.e0"
            e2="DDI-DrugBank.d565.s22.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s23" text="When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.">
        <entity id="DDI-DrugBank.d565.s23.e0" charOffset="25-35"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d565.s23.e1" charOffset="41-64"
            type="group" text="calcium channel blockers"/>
        <ddi id="DDI-DrugBank.d565.s23.d0" e1="DDI-DrugBank.d565.s23.e0"
            e2="DDI-DrugBank.d565.s23.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s24" text="Cyclosporine">
        <entity id="DDI-DrugBank.d565.s24.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s25" text="A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.">
        <entity id="DDI-DrugBank.d565.s25.e0" charOffset="38-46"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d565.s25.e1" charOffset="52-63"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d565.s25.d0" e1="DDI-DrugBank.d565.s25.e0"
            e2="DDI-DrugBank.d565.s25.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s26" text="In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.">
        <entity id="DDI-DrugBank.d565.s26.e0" charOffset="59-70"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d565.s26.e1" charOffset="127-138"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d565.s26.e2" charOffset="209-217"
            type="drug" text="diltiazem"/>
        <ddi id="DDI-DrugBank.d565.s26.d0" e1="DDI-DrugBank.d565.s26.e0"
            e2="DDI-DrugBank.d565.s26.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s27" text="If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.">
        <entity id="DDI-DrugBank.d565.s27.e0" charOffset="53-64"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d565.s27.e1" charOffset="118-126"
            type="drug" text="diltiazem"/>
        <ddi id="DDI-DrugBank.d565.s27.d0" e1="DDI-DrugBank.d565.s27.e0"
            e2="DDI-DrugBank.d565.s27.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s28" text="The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated.">
        <entity id="DDI-DrugBank.d565.s28.e0" charOffset="14-25"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d565.s28.e1" charOffset="30-38"
            type="drug" text="diltiazem"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s29" text="Carbamazepine">
        <entity id="DDI-DrugBank.d565.s29.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s30" text="Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.">
        <entity id="DDI-DrugBank.d565.s30.e0" charOffset="30-38"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d565.s30.e1" charOffset="45-57"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d565.s30.e2" charOffset="115-127"
            type="drug" text="carbamazepine"/>
        <ddi id="DDI-DrugBank.d565.s30.d0" e1="DDI-DrugBank.d565.s30.e0"
            e2="DDI-DrugBank.d565.s30.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s31" text="Patients receiving these drugs concurrently should be monitored for a potential drug interaction."/>
    <sentence id="DDI-DrugBank.d565.s32" text="Benzodiazepines">
        <entity id="DDI-DrugBank.d565.s32.e0" charOffset="0-14"
            type="group" text="Benzodiazepines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s33" text="Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.">
        <entity id="DDI-DrugBank.d565.s33.e0" charOffset="20-28"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d565.s33.e1" charOffset="51-59"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d565.s33.e2" charOffset="65-73"
            type="drug" text="triazolam"/>
        <ddi id="DDI-DrugBank.d565.s33.d0" e1="DDI-DrugBank.d565.s33.e0"
            e2="DDI-DrugBank.d565.s33.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d565.s33.d1" e1="DDI-DrugBank.d565.s33.e0"
            e2="DDI-DrugBank.d565.s33.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s34" text="The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.">
        <entity id="DDI-DrugBank.d565.s34.e0" charOffset="29-37"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d565.s34.e1" charOffset="43-51"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d565.s34.e2" charOffset="112-120"
            type="drug" text="diltiazem"/>
        <ddi id="DDI-DrugBank.d565.s34.d0" e1="DDI-DrugBank.d565.s34.e0"
            e2="DDI-DrugBank.d565.s34.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d565.s34.d1" e1="DDI-DrugBank.d565.s34.e1"
            e2="DDI-DrugBank.d565.s34.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s35" text="These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.">
        <entity id="DDI-DrugBank.d565.s35.e0" charOffset="42-50"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d565.s35.e1" charOffset="144-152"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d565.s35.e2" charOffset="158-166"
            type="drug" text="triazolam"/>
        <ddi id="DDI-DrugBank.d565.s35.d0" e1="DDI-DrugBank.d565.s35.e0"
            e2="DDI-DrugBank.d565.s35.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d565.s35.d1" e1="DDI-DrugBank.d565.s35.e0"
            e2="DDI-DrugBank.d565.s35.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s36" text="Lovastatin">
        <entity id="DDI-DrugBank.d565.s36.e0" charOffset="0-9"
            type="drug" text="Lovastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s37" text="In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;">
        <entity id="DDI-DrugBank.d565.s37.e0" charOffset="44-52"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d565.s37.e1" charOffset="72-81"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d565.s37.e2" charOffset="124-133"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d565.s37.e3" charOffset="152-161"
            type="drug" text="lovastatin"/>
        <ddi id="DDI-DrugBank.d565.s37.d0" e1="DDI-DrugBank.d565.s37.e0"
            e2="DDI-DrugBank.d565.s37.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s38" text="no change in pravastatin AUC and Cmax was observed during diltiazem coadministration.">
        <entity id="DDI-DrugBank.d565.s38.e0" charOffset="13-23"
            type="drug" text="pravastatin"/>
        <entity id="DDI-DrugBank.d565.s38.e1" charOffset="58-66"
            type="drug" text="diltiazem"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s39" text="Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.">
        <entity id="DDI-DrugBank.d565.s39.e0" charOffset="0-8"
            type="drug" text="Diltiazem"/>
        <entity id="DDI-DrugBank.d565.s39.e1" charOffset="59-68"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d565.s39.e2" charOffset="73-83"
            type="drug" text="pravastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s40" text="Rifampin">
        <entity id="DDI-DrugBank.d565.s40.e0" charOffset="0-7"
            type="drug" text="Rifampin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s41" text="Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.">
        <entity id="DDI-DrugBank.d565.s41.e0" charOffset="20-27"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d565.s41.e1" charOffset="34-42"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d565.s41.e2" charOffset="56-64"
            type="drug" text="diltiazem"/>
        <ddi id="DDI-DrugBank.d565.s41.d0" e1="DDI-DrugBank.d565.s41.e0"
            e2="DDI-DrugBank.d565.s41.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d565.s42" text="Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.">
        <entity id="DDI-DrugBank.d565.s42.e0" charOffset="20-28"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d565.s42.e1" charOffset="35-42"
            type="drug" text="rifampin"/>
        <ddi id="DDI-DrugBank.d565.s42.d0" e1="DDI-DrugBank.d565.s42.e0"
            e2="DDI-DrugBank.d565.s42.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d96.s0" text="Dimenhydrinate may decrease emetic response to apomorphine.">
        <entity id="DDI-DrugBank.d96.s0.e0" charOffset="0-13"
            type="drug" text="Dimenhydrinate"/>
        <entity id="DDI-DrugBank.d96.s0.e1" charOffset="28-33"
            type="group" text="emetic"/>
        <entity id="DDI-DrugBank.d96.s0.e2" charOffset="47-57"
            type="drug" text="apomorphine"/>
        <ddi id="DDI-DrugBank.d96.s0.d0" e1="DDI-DrugBank.d96.s0.e0"
            e2="DDI-DrugBank.d96.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d181.s0" text="Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;">
        <entity id="DDI-DrugBank.d181.s0.e0" charOffset="0-7"
            type="drug" text="Oxytocin"/>
        <entity id="DDI-DrugBank.d181.s0.e1" charOffset="18-26"
            type="group" text="oxytocics"/>
        <entity id="DDI-DrugBank.d181.s0.e2" charOffset="49-57"
            type="drug" text="dinoprost"/>
        <ddi id="DDI-DrugBank.d181.s0.d0" e1="DDI-DrugBank.d181.s0.e0"
            e2="DDI-DrugBank.d181.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d181.s0.d1" e1="DDI-DrugBank.d181.s0.e1"
            e2="DDI-DrugBank.d181.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d181.s1" text="although combinations are sometimes used for therapeutic advantage, when used concurrently, patient should be closely monitored."/>
    <sentence id="DDI-DrugBank.d2.s0" text="PROSTIN E2 may augment the activity of other oxytocic drugs.">
        <entity id="DDI-DrugBank.d2.s0.e0" charOffset="0-9" type="brand" text="PROSTIN E2"/>
        <entity id="DDI-DrugBank.d2.s0.e1" charOffset="45-58"
            type="group" text="oxytocic drugs"/>
        <ddi id="DDI-DrugBank.d2.s0.d0" e1="DDI-DrugBank.d2.s0.e0"
            e2="DDI-DrugBank.d2.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d2.s1" text="Concomitant use with other oxytocic agents is not recommended.">
        <entity id="DDI-DrugBank.d2.s1.e0" charOffset="27-41"
            type="group" text="oxytocic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d296.s0" text="Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).">
        <entity id="DDI-DrugBank.d296.s0.e0" charOffset="0-28"
            type="drug" text="Diphenhydramine hydrochloride"/>
        <entity id="DDI-DrugBank.d296.s0.e1" charOffset="56-62"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d296.s0.e2" charOffset="74-88"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d296.s0.e3" charOffset="91-99"
            type="group" text="hypnotics"/>
        <entity id="DDI-DrugBank.d296.s0.e4" charOffset="102-110"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d296.s0.e5" charOffset="113-125"
            type="group" text="tranquilizers"/>
        <ddi id="DDI-DrugBank.d296.s0.d0" e1="DDI-DrugBank.d296.s0.e0"
            e2="DDI-DrugBank.d296.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d296.s0.d1" e1="DDI-DrugBank.d296.s0.e0"
            e2="DDI-DrugBank.d296.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d296.s0.d2" e1="DDI-DrugBank.d296.s0.e0"
            e2="DDI-DrugBank.d296.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d296.s0.d3" e1="DDI-DrugBank.d296.s0.e0"
            e2="DDI-DrugBank.d296.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d296.s0.d4" e1="DDI-DrugBank.d296.s0.e0"
            e2="DDI-DrugBank.d296.s0.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d296.s1" text="MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.">
        <entity id="DDI-DrugBank.d296.s1.e0" charOffset="0-13"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d296.s1.e1" charOffset="77-90"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d296.s1.d0" e1="DDI-DrugBank.d296.s1.e0"
            e2="DDI-DrugBank.d296.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d120.s0" text="CNS depression producing medications - concurrent use may potentiate the effects of either these medications or diphenidol;">
        <entity id="DDI-DrugBank.d120.s0.e0" charOffset="112-121"
            type="drug" text="diphenidol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d120.s1" text="anticholinergics or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with diphenidol;">
        <entity id="DDI-DrugBank.d120.s1.e0" charOffset="0-15"
            type="group" text="anticholinergics"/>
        <entity id="DDI-DrugBank.d120.s1.e1" charOffset="163-172"
            type="drug" text="diphenidol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d120.s2" text="apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.">
        <entity id="DDI-DrugBank.d120.s2.e0" charOffset="0-10"
            type="drug" text="apomorphine"/>
        <entity id="DDI-DrugBank.d120.s2.e1" charOffset="33-42"
            type="drug" text="diphenidol"/>
        <entity id="DDI-DrugBank.d120.s2.e2" charOffset="61-66"
            type="group" text="emetic"/>
        <entity id="DDI-DrugBank.d120.s2.e3" charOffset="80-90"
            type="drug" text="apomorphine"/>
        <ddi id="DDI-DrugBank.d120.s2.d0" e1="DDI-DrugBank.d120.s2.e1"
            e2="DDI-DrugBank.d120.s2.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d538.s0" text="Known drug interactions include barbiturates, tranquilizers, and alcohol.">
        <entity id="DDI-DrugBank.d538.s0.e0" charOffset="32-43"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d538.s0.e1" charOffset="46-58"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d538.s0.e2" charOffset="65-71"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d538.s1" text="Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.">
        <entity id="DDI-DrugBank.d538.s1.e0" charOffset="0-16"
            type="drug" text="Diphenoxylate HCl"/>
        <entity id="DDI-DrugBank.d538.s1.e1" charOffset="22-37"
            type="drug" text="atropine sulfate"/>
        <entity id="DDI-DrugBank.d538.s1.e2" charOffset="57-70"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d538.s1.e3" charOffset="99-125"
            type="drug" text="diphenoxylate hydrochloride"/>
        <ddi id="DDI-DrugBank.d538.s1.d0" e1="DDI-DrugBank.d538.s1.e0"
            e2="DDI-DrugBank.d538.s1.e2" type="int"/>
        <ddi id="DDI-DrugBank.d538.s1.d1" e1="DDI-DrugBank.d538.s1.e1"
            e2="DDI-DrugBank.d538.s1.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d538.s2" text="Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.">
        <entity id="DDI-DrugBank.d538.s2.e0" charOffset="11-23"
            type="drug" text="diphenoxylate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d168.s0" text="This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).">
        <entity id="DDI-DrugBank.d168.s0.e0" charOffset="28-34"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d168.s0.e1" charOffset="45-59"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d168.s0.e2" charOffset="135-148"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d168.s0.e3" charOffset="152-167"
            type="group" text="anticholinergics"/>
        <entity id="DDI-DrugBank.d168.s0.e4" charOffset="314-327"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d168.s0.e5" charOffset="335-368"
            type="group" text="monoamine oxidase (MAO) inhibitors"/>
        <entity id="DDI-DrugBank.d168.s0.e6" charOffset="391-404"
            type="drug" text="antihistamines"/>
        <entity id="DDI-DrugBank.d168.s0.e7" charOffset="482-495"
            type="drug" text="antihistamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d505.s0" text="No pharmacokinetic drug-drug interaction studies were conducted with PERSANTINE  (dipyridamole USP) Tablets.">
        <entity id="DDI-DrugBank.d505.s0.e0" charOffset="69-78"
            type="brand" text="PERSANTINE"/>
        <entity id="DDI-DrugBank.d505.s0.e1" charOffset="82-93"
            type="drug" text="dipyridamole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d505.s1" text="The following information was obtained from the literature."/>
    <sentence id="DDI-DrugBank.d505.s2" text="Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.">
        <entity id="DDI-DrugBank.d505.s2.e0" charOffset="0-8"
            type="drug" text="Adenosine"/>
        <entity id="DDI-DrugBank.d505.s2.e1" charOffset="11-22"
            type="drug" text="Dipyridamole"/>
        <entity id="DDI-DrugBank.d505.s2.e2" charOffset="102-110"
            type="drug" text="adenosine"/>
        <ddi id="DDI-DrugBank.d505.s2.d0" e1="DDI-DrugBank.d505.s2.e1"
            e2="DDI-DrugBank.d505.s2.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d505.s3" text="Adjustment of adenosine dosage may be necessary.">
        <entity id="DDI-DrugBank.d505.s3.e0" charOffset="14-22"
            type="drug" text="adenosine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d505.s4" text="Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.">
        <entity id="DDI-DrugBank.d505.s4.e0" charOffset="0-24"
            type="group" text="Cholinesterase Inhibitors"/>
        <entity id="DDI-DrugBank.d505.s4.e1" charOffset="27-38"
            type="drug" text="Dipyridamole"/>
        <entity id="DDI-DrugBank.d505.s4.e2" charOffset="88-112"
            type="group" text="cholinesterase inhibitors"/>
        <ddi id="DDI-DrugBank.d505.s4.d0" e1="DDI-DrugBank.d505.s4.e1"
            e2="DDI-DrugBank.d505.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s0" text="Terfenadine: In a prospective study involving six-healthy-male volunteers, dirithromycin did not affect the metabolism of terfenadine.">
        <entity id="DDI-DrugBank.d522.s0.e0" charOffset="0-10"
            type="drug" text="Terfenadine"/>
        <entity id="DDI-DrugBank.d522.s0.e1" charOffset="75-87"
            type="drug" text="dirithromycin"/>
        <entity id="DDI-DrugBank.d522.s0.e2" charOffset="122-132"
            type="drug" text="terfenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s1" text="These six volunteers received terfenadine alone (60 mg twice daily) for 8 days, followed by terfenadine in combination with dirithromycin (500 mg once daily) for 10 days.">
        <entity id="DDI-DrugBank.d522.s1.e0" charOffset="30-40"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s1.e1" charOffset="92-102"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s1.e2" charOffset="124-136"
            type="drug" text="dirithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s2" text="(Both drugs were thus dosed to steady state.)"/>
    <sentence id="DDI-DrugBank.d522.s3" text="The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with terfenadine alone, and with terfenadine plus dirithromycin.">
        <entity id="DDI-DrugBank.d522.s3.e0" charOffset="24-34"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s3.e1" charOffset="143-153"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s3.e2" charOffset="171-181"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s3.e3" charOffset="188-200"
            type="drug" text="dirithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s4" text="In five men, terfenadine levels were undetectable ( 5 ng/mL) throughout the study;">
        <entity id="DDI-DrugBank.d522.s4.e0" charOffset="13-23"
            type="drug" text="terfenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s5" text="in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.">
        <entity id="DDI-DrugBank.d522.s5.e0" charOffset="25-35"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s5.e1" charOffset="56-66"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s5.e2" charOffset="93-103"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s5.e3" charOffset="110-122"
            type="drug" text="dirithromycin"/>
        <ddi id="DDI-DrugBank.d522.s5.d0" e1="DDI-DrugBank.d522.s5.e2"
            e2="DDI-DrugBank.d522.s5.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s6" text="The mean C max , T max , and AUC of the acid metabolite of terfenadine were not significantly changed.">
        <entity id="DDI-DrugBank.d522.s6.e0" charOffset="59-69"
            type="drug" text="terfenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s7" text="The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.">
        <entity id="DDI-DrugBank.d522.s7.e0" charOffset="43-53"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s7.e1" charOffset="74-84"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s7.e2" charOffset="91-103"
            type="drug" text="dirithromycin"/>
        <ddi id="DDI-DrugBank.d522.s7.d0" e1="DDI-DrugBank.d522.s7.e1"
            e2="DDI-DrugBank.d522.s7.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s8" text="Also, in vitro experiments demonstrated a lack of interaction between dirithromycin and terfenadine.">
        <entity id="DDI-DrugBank.d522.s8.e0" charOffset="70-82"
            type="drug" text="dirithromycin"/>
        <entity id="DDI-DrugBank.d522.s8.e1" charOffset="88-98"
            type="drug" text="terfenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s9" text="Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.">
        <entity id="DDI-DrugBank.d522.s9.e0" charOffset="39-50"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d522.s9.e1" charOffset="56-66"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s9.e2" charOffset="88-100"
            type="drug" text="dirithromycin"/>
        <ddi id="DDI-DrugBank.d522.s9.d0" e1="DDI-DrugBank.d522.s9.e0"
            e2="DDI-DrugBank.d522.s9.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s10" text="Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.">
        <entity id="DDI-DrugBank.d522.s10.e0" charOffset="91-101"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d522.s10.e1" charOffset="128-148"
            type="group" text="macrolide antibiotics"/>
        <ddi id="DDI-DrugBank.d522.s10.d0" e1="DDI-DrugBank.d522.s10.e0"
            e2="DDI-DrugBank.d522.s10.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s11" text="In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.">
        <entity id="DDI-DrugBank.d522.s11.e0" charOffset="18-27"
            type="group" text="macrolides"/>
        <entity id="DDI-DrugBank.d522.s11.e1" charOffset="71-81"
            type="drug" text="terfenadine"/>
        <ddi id="DDI-DrugBank.d522.s11.d0" e1="DDI-DrugBank.d522.s11.e0"
            e2="DDI-DrugBank.d522.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s12" text="Theophylline: Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.">
        <entity id="DDI-DrugBank.d522.s12.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d522.s12.e1" charOffset="56-68"
            type="drug" text="dirithromycin"/>
        <entity id="DDI-DrugBank.d522.s12.e2" charOffset="114-125"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d522.s12.e3" charOffset="237-248"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s13" text="In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.">
        <entity id="DDI-DrugBank.d522.s13.e0" charOffset="39-51"
            type="drug" text="dirithromycin"/>
        <entity id="DDI-DrugBank.d522.s13.e1" charOffset="83-94"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d522.s13.e2" charOffset="142-153"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d522.s13.e3" charOffset="179-190"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s14" text="However, theophylline plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given theophylline plasma concentration for optimal pulmonary function or in patients with theophylline concentrations at the higher end of the therapeutic range.">
        <entity id="DDI-DrugBank.d522.s14.e0" charOffset="9-20"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d522.s14.e1" charOffset="169-180"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d522.s14.e2" charOffset="254-265"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s15" text="Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.">
        <entity id="DDI-DrugBank.d522.s15.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d522.s15.e1" charOffset="12-35"
            type="group" text="H 2 receptor antagonists"/>
        <entity id="DDI-DrugBank.d522.s15.e2" charOffset="43-55"
            type="drug" text="dirithromycin"/>
        <entity id="DDI-DrugBank.d522.s15.e3" charOffset="95-102"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d522.s15.e4" charOffset="107-131"
            type="group" text="H 2 -receptor antagonists"/>
        <entity id="DDI-DrugBank.d522.s15.e5" charOffset="152-164"
            type="drug" text="dirithromycin"/>
        <ddi id="DDI-DrugBank.d522.s15.d0" e1="DDI-DrugBank.d522.s15.e2"
            e2="DDI-DrugBank.d522.s15.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d522.s15.d1" e1="DDI-DrugBank.d522.s15.e2"
            e2="DDI-DrugBank.d522.s15.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s16" text="The following drug interactions have been reported with erythromycin products.">
        <entity id="DDI-DrugBank.d522.s16.e0" charOffset="56-67"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s17" text="It is presently not known whether these same drug interactions occur with dirithromycin.">
        <entity id="DDI-DrugBank.d522.s17.e0" charOffset="74-86"
            type="drug" text="dirithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s18" text="Until further data are available regarding the potential interaction of dirithromycin with these compounds, caution should be used during coadministration.">
        <entity id="DDI-DrugBank.d522.s18.e0" charOffset="72-84"
            type="drug" text="dirithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s19" text="Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.">
        <entity id="DDI-DrugBank.d522.s19.e0" charOffset="0-8"
            type="drug" text="Triazolam"/>
        <entity id="DDI-DrugBank.d522.s19.e1" charOffset="11-22"
            type="drug" text="Erythromycin"/>
        <entity id="DDI-DrugBank.d522.s19.e2" charOffset="71-79"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d522.s19.e3" charOffset="133-141"
            type="drug" text="triazolam"/>
        <ddi id="DDI-DrugBank.d522.s19.d0" e1="DDI-DrugBank.d522.s19.e1"
            e2="DDI-DrugBank.d522.s19.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d522.s19.d1" e1="DDI-DrugBank.d522.s19.e1"
            e2="DDI-DrugBank.d522.s19.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s20" text="Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.">
        <entity id="DDI-DrugBank.d522.s20.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d522.s20.e1" charOffset="39-50"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d522.s20.e2" charOffset="56-62"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d522.s20.e3" charOffset="104-110"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d522.s20.d0" e1="DDI-DrugBank.d522.s20.e1"
            e2="DDI-DrugBank.d522.s20.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s21" text="Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.">
        <entity id="DDI-DrugBank.d522.s21.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d522.s21.e1" charOffset="80-91"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d522.s21.e2" charOffset="102-115"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d522.s21.d0" e1="DDI-DrugBank.d522.s21.e1"
            e2="DDI-DrugBank.d522.s21.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s22" text="Increased anticoagulation effects due to a drug interaction with erythromycin may be more pronounced in the elderly.">
        <entity id="DDI-DrugBank.d522.s22.e0" charOffset="65-76"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s23" text="Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.">
        <entity id="DDI-DrugBank.d522.s23.e0" charOffset="0-9"
            type="drug" text="Ergotamine"/>
        <entity id="DDI-DrugBank.d522.s23.e1" charOffset="30-41"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d522.s23.e2" charOffset="47-56"
            type="drug" text="ergotamine"/>
        <entity id="DDI-DrugBank.d522.s23.e3" charOffset="61-77"
            type="drug" text="dihydroergotamine"/>
        <ddi id="DDI-DrugBank.d522.s23.d0" e1="DDI-DrugBank.d522.s23.e1"
            e2="DDI-DrugBank.d522.s23.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d522.s23.d1" e1="DDI-DrugBank.d522.s23.e1"
            e2="DDI-DrugBank.d522.s23.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d522.s24" text="Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.">
        <entity id="DDI-DrugBank.d522.s24.e0" charOffset="84-95"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d522.s24.e1" charOffset="130-141"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d522.s24.e2" charOffset="144-155"
            type="drug" text="hexobarbital"/>
        <entity id="DDI-DrugBank.d522.s24.e3" charOffset="158-170"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d522.s24.e4" charOffset="173-182"
            type="drug" text="alfentanil"/>
        <entity id="DDI-DrugBank.d522.s24.e5" charOffset="185-196"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d522.s24.e6" charOffset="199-207"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d522.s24.e7" charOffset="210-222"
            type="drug" text="bromocriptine"/>
        <entity id="DDI-DrugBank.d522.s24.e8" charOffset="225-233"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d522.s24.e9" charOffset="236-245"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d522.s24.e10" charOffset="252-261"
            type="drug" text="lovastatin"/>
        <ddi id="DDI-DrugBank.d522.s24.d0" e1="DDI-DrugBank.d522.s24.e0"
            e2="DDI-DrugBank.d522.s24.e1" type="int"/>
        <ddi id="DDI-DrugBank.d522.s24.d1" e1="DDI-DrugBank.d522.s24.e0"
            e2="DDI-DrugBank.d522.s24.e2" type="int"/>
        <ddi id="DDI-DrugBank.d522.s24.d2" e1="DDI-DrugBank.d522.s24.e0"
            e2="DDI-DrugBank.d522.s24.e3" type="int"/>
        <ddi id="DDI-DrugBank.d522.s24.d3" e1="DDI-DrugBank.d522.s24.e0"
            e2="DDI-DrugBank.d522.s24.e4" type="int"/>
        <ddi id="DDI-DrugBank.d522.s24.d4" e1="DDI-DrugBank.d522.s24.e0"
            e2="DDI-DrugBank.d522.s24.e5" type="int"/>
        <ddi id="DDI-DrugBank.d522.s24.d5" e1="DDI-DrugBank.d522.s24.e0"
            e2="DDI-DrugBank.d522.s24.e6" type="int"/>
        <ddi id="DDI-DrugBank.d522.s24.d6" e1="DDI-DrugBank.d522.s24.e0"
            e2="DDI-DrugBank.d522.s24.e7" type="int"/>
        <ddi id="DDI-DrugBank.d522.s24.d7" e1="DDI-DrugBank.d522.s24.e0"
            e2="DDI-DrugBank.d522.s24.e8" type="int"/>
        <ddi id="DDI-DrugBank.d522.s24.d8" e1="DDI-DrugBank.d522.s24.e0"
            e2="DDI-DrugBank.d522.s24.e9" type="int"/>
        <ddi id="DDI-DrugBank.d522.s24.d9" e1="DDI-DrugBank.d522.s24.e0"
            e2="DDI-DrugBank.d522.s24.e10" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d506.s0" text="If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.">
        <entity id="DDI-DrugBank.d506.s0.e0" charOffset="3-11"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d506.s0.e1" charOffset="74-80"
            type="brand" text="Norpace"/>
        <entity id="DDI-DrugBank.d506.s0.e2" charOffset="85-94"
            type="brand" text="Norpace CR"/>
        <entity id="DDI-DrugBank.d506.s0.e3" charOffset="120-131"
            type="drug" text="disopyramide"/>
        <ddi id="DDI-DrugBank.d506.s0.d0" e1="DDI-DrugBank.d506.s0.e0"
            e2="DDI-DrugBank.d506.s0.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d506.s0.d1" e1="DDI-DrugBank.d506.s0.e0"
            e2="DDI-DrugBank.d506.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d506.s1" text="Monitoring of disopyramide plasma levels is recommended in such concurrent use to avoid ineffective therapy.">
        <entity id="DDI-DrugBank.d506.s1.e0" charOffset="14-25"
            type="drug" text="disopyramide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d506.s2" text="Other antiarrhythmic drugs (eg, quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace.">
        <entity id="DDI-DrugBank.d506.s2.e0" charOffset="6-25"
            type="group" text="antiarrhythmic drugs"/>
        <entity id="DDI-DrugBank.d506.s2.e1" charOffset="32-40"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d506.s2.e2" charOffset="43-54"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d506.s2.e3" charOffset="57-65"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d506.s2.e4" charOffset="68-78"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d506.s2.e5" charOffset="127-133"
            type="brand" text="Norpace"/>
    </sentence>
    <sentence id="DDI-DrugBank.d506.s3" text="Excessive widening of the QRS complex and/or prolongation of the Q-T interval may occur in these situations."/>
    <sentence id="DDI-DrugBank.d506.s4" text="In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam.">
        <entity id="DDI-DrugBank.d506.s4.e0" charOffset="76-82"
            type="brand" text="Norpace"/>
        <entity id="DDI-DrugBank.d506.s4.e1" charOffset="115-125"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d506.s4.e2" charOffset="130-137"
            type="drug" text="diazepam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d506.s5" text="Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.">
        <entity id="DDI-DrugBank.d506.s5.e0" charOffset="30-36"
            type="brand" text="Norpace"/>
        <entity id="DDI-DrugBank.d506.s5.e1" charOffset="42-50"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d506.s5.e2" charOffset="91-102"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d506.s5.e3" charOffset="142-150"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d506.s5.d0" e1="DDI-DrugBank.d506.s5.e0"
            e2="DDI-DrugBank.d506.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d506.s6" text="Norpace does not increase serum digoxin levels.">
        <entity id="DDI-DrugBank.d506.s6.e0" charOffset="0-6"
            type="brand" text="Norpace"/>
        <entity id="DDI-DrugBank.d506.s6.e1" charOffset="32-38"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d506.s7" text="Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.">
        <entity id="DDI-DrugBank.d506.s7.e0" charOffset="16-37"
            type="drug" text="disopyramide phosphate"/>
        <entity id="DDI-DrugBank.d506.s7.e1" charOffset="43-54"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d506.s7.e2" charOffset="116-127"
            type="drug" text="disopyramide"/>
        <ddi id="DDI-DrugBank.d506.s7.d0" e1="DDI-DrugBank.d506.s7.e0"
            e2="DDI-DrugBank.d506.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d506.s8" text="Patients taking disopyramide phosphate and hepatic enzyme inhibitors concomitantly should be closely monitored.">
        <entity id="DDI-DrugBank.d506.s8.e0" charOffset="16-37"
            type="drug" text="disopyramide phosphate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d506.s9" text="Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.">
        <entity id="DDI-DrugBank.d506.s9.e0" charOffset="44-52"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d506.s9.e1" charOffset="58-79"
            type="drug" text="disopyramide phosphate"/>
        <entity id="DDI-DrugBank.d506.s9.e2" charOffset="95-106"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d506.s9.e3" charOffset="176-184"
            type="drug" text="verapamil"/>
        <ddi id="DDI-DrugBank.d506.s9.d0" e1="DDI-DrugBank.d506.s9.e2"
            e2="DDI-DrugBank.d506.s9.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s0" text="Disulfiram appears to decrease the rate at which certain drugs are metabolized and therefore may increase the blood levels and the possibility of clinical toxicity of drugs given concomitantly.">
        <entity id="DDI-DrugBank.d19.s0.e0" charOffset="0-9" type="drug" text="Disulfiram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s1" text="DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.">
        <entity id="DDI-DrugBank.d19.s1.e0" charOffset="0-9" type="drug" text="DISULFIRAM"/>
        <entity id="DDI-DrugBank.d19.s1.e1" charOffset="67-75"
            type="drug" text="PHENYTOIN"/>
        <ddi id="DDI-DrugBank.d19.s1.d0" e1="DDI-DrugBank.d19.s1.e0"
            e2="DDI-DrugBank.d19.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s2" text="SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.">
        <entity id="DDI-DrugBank.d19.s2.e0" charOffset="68-76"
            type="drug" text="PHENYTOIN"/>
        <entity id="DDI-DrugBank.d19.s2.e1" charOffset="115-124"
            type="drug" text="DISULFIRAM"/>
        <entity id="DDI-DrugBank.d19.s2.e2" charOffset="142-150"
            type="drug" text="PHENYTOIN"/>
        <entity id="DDI-DrugBank.d19.s2.e3" charOffset="172-180"
            type="drug" text="PHENYTOIN"/>
        <ddi id="DDI-DrugBank.d19.s2.d0" e1="DDI-DrugBank.d19.s2.e1"
            e2="DDI-DrugBank.d19.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s3" text="SUBSEQUENT TO INITIATION OF DISULFIRAM THERAPY.">
        <entity id="DDI-DrugBank.d19.s3.e0" charOffset="28-37"
            type="drug" text="DISULFIRAM"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s4" text="SERUM LEVELS OF PHENYTOIN SHOULD BE DETERMINED ON DIFFERENT DAYS FOR EVIDENCE OF AN INCREASE OR FOR A CONTINUING RISE IN LEVELS.">
        <entity id="DDI-DrugBank.d19.s4.e0" charOffset="16-24"
            type="drug" text="PHENYTOIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s3" text="As with other agents which prolong ECG intervals, caution should be exercised in patients taking drugs which prolong ECG intervals, particularly QTc."/>
    <sentence id="DDI-DrugBank.d42.s4" text="In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.">
        <entity id="DDI-DrugBank.d42.s4.e0" charOffset="19-28"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d42.s4.e1" charOffset="31-40"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d42.s4.e2" charOffset="43-51"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d42.s4.e3" charOffset="54-67"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d42.s4.e4" charOffset="70-78"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d42.s4.e5" charOffset="81-89"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d42.s4.e6" charOffset="92-102"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d42.s4.e7" charOffset="178-192"
            type="drug_n" text="hydrodolasetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s5" text="Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.">
        <entity id="DDI-DrugBank.d42.s5.e0" charOffset="13-27"
            type="drug_n" text="hydrodolasetron"/>
        <entity id="DDI-DrugBank.d42.s5.e1" charOffset="57-75"
            type="drug" text="dolasetron mesylate"/>
        <entity id="DDI-DrugBank.d42.s5.e2" charOffset="127-134"
            type="drug" text="atenolol"/>
        <ddi id="DDI-DrugBank.d42.s5.d0" e1="DDI-DrugBank.d42.s5.e1"
            e2="DDI-DrugBank.d42.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s6" text="Dolasetron does not influence anesthesia recovery time in patients.">
        <entity id="DDI-DrugBank.d42.s6.e0" charOffset="0-9" type="drug" text="Dolasetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s7" text="Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.">
        <entity id="DDI-DrugBank.d42.s7.e0" charOffset="0-18"
            type="drug" text="Dolasetron mesylate"/>
        <entity id="DDI-DrugBank.d42.s7.e1" charOffset="67-89"
            type="group" text="chemotherapeutic agents"/>
        <entity id="DDI-DrugBank.d42.s7.e2" charOffset="92-100"
            type="drug" text="cisplatin"/>
        <entity id="DDI-DrugBank.d42.s7.e3" charOffset="103-116"
            type="drug" text="5-fluorouracil"/>
        <entity id="DDI-DrugBank.d42.s7.e4" charOffset="119-129"
            type="drug" text="doxorubicin"/>
        <entity id="DDI-DrugBank.d42.s7.e5" charOffset="132-147"
            type="drug" text="cyclophosphamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d319.s0" text="Drugs that inhibit or Induce CYP 2D6 and CYP 3A4 may affect the concentration on Aricept.">
        <entity id="DDI-DrugBank.d319.s0.e0" charOffset="81-87"
            type="brand" text="Aricept"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s0" text="Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine.">
        <entity id="DDI-DrugBank.d325.s0.e0" charOffset="8-15"
            type="drug" text="dopamine"/>
        <entity id="DDI-DrugBank.d325.s0.e1" charOffset="125-132"
            type="drug" text="dopamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s1" text="Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.">
        <entity id="DDI-DrugBank.d325.s1.e0" charOffset="36-49"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d325.s1.e1" charOffset="108-119"
            type="drug" text="dopamine HCl"/>
        <entity id="DDI-DrugBank.d325.s1.e2" charOffset="153-164"
            type="drug" text="dopamine HCl"/>
        <ddi id="DDI-DrugBank.d325.s1.d0" e1="DDI-DrugBank.d325.s1.e0"
            e2="DDI-DrugBank.d325.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s2" text="Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.">
        <entity id="DDI-DrugBank.d325.s2.e0" charOffset="38-49"
            type="drug" text="dopamine HCl"/>
        <entity id="DDI-DrugBank.d325.s2.e1" charOffset="55-69"
            type="group" text="diuretic agents"/>
        <ddi id="DDI-DrugBank.d325.s2.d0" e1="DDI-DrugBank.d325.s2.e0"
            e2="DDI-DrugBank.d325.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s3" text="Tricyclic antidepressants may potentiate the cardiovascular effects of adreneric agents.">
        <entity id="DDI-DrugBank.d325.s3.e0" charOffset="0-24"
            type="group" text="Tricyclic antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s4" text="Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.">
        <entity id="DDI-DrugBank.d325.s4.e0" charOffset="19-26"
            type="drug" text="dopamine"/>
        <entity id="DDI-DrugBank.d325.s4.e1" charOffset="47-77"
            type="group" text="beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d325.s4.e2" charOffset="88-98"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d325.s4.e3" charOffset="104-113"
            type="drug" text="metoprolol"/>
        <ddi id="DDI-DrugBank.d325.s4.d0" e1="DDI-DrugBank.d325.s4.e0"
            e2="DDI-DrugBank.d325.s4.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d325.s4.d1" e1="DDI-DrugBank.d325.s4.e0"
            e2="DDI-DrugBank.d325.s4.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d325.s4.d2" e1="DDI-DrugBank.d325.s4.e0"
            e2="DDI-DrugBank.d325.s4.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s5" text="The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.">
        <entity id="DDI-DrugBank.d325.s5.e0" charOffset="56-67"
            type="drug" text="dopamine HCl"/>
        <entity id="DDI-DrugBank.d325.s5.e1" charOffset="87-118"
            type="group" text="alpha-adrenergic blocking agents"/>
        <ddi id="DDI-DrugBank.d325.s5.d0" e1="DDI-DrugBank.d325.s5.e0"
            e2="DDI-DrugBank.d325.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s6" text="Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or beta-adrenergic blocking agents.">
        <entity id="DDI-DrugBank.d325.s6.e0" charOffset="0-7"
            type="drug" text="Dopamine"/>
        <entity id="DDI-DrugBank.d325.s6.e1" charOffset="80-85;95-120"
            type="group" text="alpha-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d325.s6.e2" charOffset="90-120"
            type="drug" text="beta-adrenergic blocking agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s7" text="Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.">
        <entity id="DDI-DrugBank.d325.s7.e0" charOffset="0-13"
            type="group" text="Butyrophenones"/>
        <entity id="DDI-DrugBank.d325.s7.e1" charOffset="24-34"
            type="drug" text="haloperidol"/>
        <entity id="DDI-DrugBank.d325.s7.e2" charOffset="41-54"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d325.s7.e3" charOffset="73-80"
            type="drug" text="dopamine"/>
        <ddi id="DDI-DrugBank.d325.s7.d0" e1="DDI-DrugBank.d325.s7.e0"
            e2="DDI-DrugBank.d325.s7.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d325.s7.d1" e1="DDI-DrugBank.d325.s7.e1"
            e2="DDI-DrugBank.d325.s7.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d325.s7.d2" e1="DDI-DrugBank.d325.s7.e2"
            e2="DDI-DrugBank.d325.s7.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s8" text="Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.">
        <entity id="DDI-DrugBank.d325.s8.e0" charOffset="0-11"
            type="drug" text="Cyclopropane"/>
        <entity id="DDI-DrugBank.d325.s8.e1" charOffset="16-50"
            type="group" text="halogenated hydrocarbon anesthetics"/>
        <entity id="DDI-DrugBank.d325.s8.e2" charOffset="177-190"
            type="group" text="catecholamines"/>
        <entity id="DDI-DrugBank.d325.s8.e3" charOffset="201-208"
            type="drug" text="dopamine"/>
        <ddi id="DDI-DrugBank.d325.s8.d0" e1="DDI-DrugBank.d325.s8.e0"
            e2="DDI-DrugBank.d325.s8.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d325.s8.d1" e1="DDI-DrugBank.d325.s8.e0"
            e2="DDI-DrugBank.d325.s8.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d325.s8.d2" e1="DDI-DrugBank.d325.s8.e1"
            e2="DDI-DrugBank.d325.s8.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d325.s8.d3" e1="DDI-DrugBank.d325.s8.e1"
            e2="DDI-DrugBank.d325.s8.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s9" text="This interaction appears to be related both to pressor activity and to beta-adrenergic stimulating properties of these catecholamines and may produce ventricular arrhythmias and hypertension.">
        <entity id="DDI-DrugBank.d325.s9.e0" charOffset="119-132"
            type="group" text="catecholamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s10" text="Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.">
        <entity id="DDI-DrugBank.d325.s10.e0" charOffset="66-77"
            type="drug" text="dopamine HCl"/>
        <entity id="DDI-DrugBank.d325.s10.e1" charOffset="101-112"
            type="drug" text="cyclopropane"/>
        <entity id="DDI-DrugBank.d325.s10.e2" charOffset="117-151"
            type="group" text="halogenated hydrocarbon anesthetics"/>
        <ddi id="DDI-DrugBank.d325.s10.d0" e1="DDI-DrugBank.d325.s10.e0"
            e2="DDI-DrugBank.d325.s10.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d325.s10.d1" e1="DDI-DrugBank.d325.s10.e0"
            e2="DDI-DrugBank.d325.s10.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s11" text="It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.">
        <entity id="DDI-DrugBank.d325.s11.e0" charOffset="70-77"
            type="drug" text="dopamine"/>
        <entity id="DDI-DrugBank.d325.s11.e1" charOffset="148-158"
            type="drug" text="propranolol"/>
        <ddi id="DDI-DrugBank.d325.s11.d0" e1="DDI-DrugBank.d325.s11.e0"
            e2="DDI-DrugBank.d325.s11.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s12" text="The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.">
        <entity id="DDI-DrugBank.d325.s12.e0" charOffset="23-33"
            type="group" text="vasopressor"/>
        <entity id="DDI-DrugBank.d325.s12.e1" charOffset="70-79"
            type="drug" text="ergonovine"/>
        <entity id="DDI-DrugBank.d325.s12.e2" charOffset="91-104"
            type="group" text="oxytocic drugs"/>
        <ddi id="DDI-DrugBank.d325.s12.d0" e1="DDI-DrugBank.d325.s12.e0"
            e2="DDI-DrugBank.d325.s12.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d325.s12.d1" e1="DDI-DrugBank.d325.s12.e1"
            e2="DDI-DrugBank.d325.s12.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s13" text="Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.">
        <entity id="DDI-DrugBank.d325.s13.e0" charOffset="18-26"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d325.s13.e1" charOffset="50-61"
            type="drug" text="dopamine HCl"/>
        <ddi id="DDI-DrugBank.d325.s13.d0" e1="DDI-DrugBank.d325.s13.e0"
            e2="DDI-DrugBank.d325.s13.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d325.s14" text="It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.">
        <entity id="DDI-DrugBank.d325.s14.e0" charOffset="43-54"
            type="drug" text="dopamine HCl"/>
        <entity id="DDI-DrugBank.d325.s14.e1" charOffset="73-81"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d325.s14.e2" charOffset="101-114"
            type="group" text="anticonvulsant"/>
        <ddi id="DDI-DrugBank.d325.s14.d0" e1="DDI-DrugBank.d325.s14.e0"
            e2="DDI-DrugBank.d325.s14.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d93.s0" text="Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.">
        <entity id="DDI-DrugBank.d93.s0.e0" charOffset="36-44"
            type="brand" text="Pulmozyme"/>
        <entity id="DDI-DrugBank.d93.s0.e1" charOffset="178-188"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d93.s0.e2" charOffset="191-205"
            type="group" text="bronchodilators"/>
        <entity id="DDI-DrugBank.d93.s0.e3" charOffset="228-235"
            type="group" text="vitamins"/>
        <entity id="DDI-DrugBank.d93.s0.e4" charOffset="254-268"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d93.s0.e5" charOffset="275-284"
            type="group" text="analgesics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d93.s1" text="No formal drug interaction studies have been performed."/>
    <sentence id="DDI-DrugBank.d34.s0" text="Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).">
        <entity id="DDI-DrugBank.d34.s0.e0" charOffset="94-104"
            type="drug" text="dorzolamide"/>
        <entity id="DDI-DrugBank.d34.s0.e1" charOffset="155-183"
            type="group" text="carbonic anhydrase inhibitors"/>
        <entity id="DDI-DrugBank.d34.s0.e2" charOffset="286-295"
            type="group" text="salicylate"/>
        <ddi id="DDI-DrugBank.d34.s0.d0" e1="DDI-DrugBank.d34.s0.e0"
            e2="DDI-DrugBank.d34.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d34.s1" text="Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide.">
        <entity id="DDI-DrugBank.d34.s1.e0" charOffset="95-105"
            type="drug" text="dorzolamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d267.s0" text="Prior administration of succinylcholine has no clinically important effect on the neuromuscular blocking action of NUROMAX.">
        <entity id="DDI-DrugBank.d267.s0.e0" charOffset="24-38"
            type="drug" text="succinylcholine"/>
        <entity id="DDI-DrugBank.d267.s0.e1" charOffset="115-121"
            type="brand" text="NUROMAX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d267.s1" text="The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.">
        <entity id="DDI-DrugBank.d267.s1.e0" charOffset="11-17"
            type="brand" text="NUROMAX"/>
        <entity id="DDI-DrugBank.d267.s1.e1" charOffset="26-40"
            type="drug" text="succinylcholine"/>
        <entity id="DDI-DrugBank.d267.s1.e2" charOffset="83-97"
            type="drug" text="succinylcholine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d267.s2" text="There are no clinical data on concomitant use of NUROMAX and other nondepolarizing neuromuscular blocking agents.">
        <entity id="DDI-DrugBank.d267.s2.e0" charOffset="49-55"
            type="brand" text="NUROMAX"/>
        <entity id="DDI-DrugBank.d267.s2.e1" charOffset="83-111"
            type="group" text="neuromuscular blocking agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d267.s3" text="Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.">
        <entity id="DDI-DrugBank.d267.s3.e0" charOffset="0-9"
            type="drug" text="Isoflurane"/>
        <entity id="DDI-DrugBank.d267.s3.e1" charOffset="12-20"
            type="drug" text="enflurane"/>
        <entity id="DDI-DrugBank.d267.s3.e2" charOffset="27-35"
            type="drug" text="halothane"/>
        <entity id="DDI-DrugBank.d267.s3.e3" charOffset="58-64"
            type="brand" text="NUROMAX"/>
        <ddi id="DDI-DrugBank.d267.s3.d0" e1="DDI-DrugBank.d267.s3.e0"
            e2="DDI-DrugBank.d267.s3.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d267.s3.d1" e1="DDI-DrugBank.d267.s3.e1"
            e2="DDI-DrugBank.d267.s3.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d267.s3.d2" e1="DDI-DrugBank.d267.s3.e2"
            e2="DDI-DrugBank.d267.s3.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d267.s4" text="These agents may also prolong the clinically effective duration of action by up to 25%."/>
    <sentence id="DDI-DrugBank.d267.s5" text="Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.">
        <entity id="DDI-DrugBank.d267.s5.e0" charOffset="98-104"
            type="brand" text="NUROMAX"/>
        <entity id="DDI-DrugBank.d267.s5.e1" charOffset="122-132"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d267.s5.e2" charOffset="142-156"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d267.s5.e3" charOffset="159-171"
            type="group" text="tetracyclines"/>
        <entity id="DDI-DrugBank.d267.s5.e4" charOffset="174-183"
            type="group" text="bacitracin"/>
        <entity id="DDI-DrugBank.d267.s5.e5" charOffset="186-195"
            type="group" text="polymyxins"/>
        <entity id="DDI-DrugBank.d267.s5.e6" charOffset="198-207"
            type="drug" text="lincomycin"/>
        <entity id="DDI-DrugBank.d267.s5.e7" charOffset="210-220"
            type="drug" text="clindamycin"/>
        <entity id="DDI-DrugBank.d267.s5.e8" charOffset="223-230"
            type="drug" text="colistin"/>
        <entity id="DDI-DrugBank.d267.s5.e9" charOffset="237-257"
            type="drug" text="sodium colistimethate"/>
        <entity id="DDI-DrugBank.d267.s5.e10" charOffset="261-269"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d267.s5.e11" charOffset="278-284"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d267.s5.e12" charOffset="293-303"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d267.s5.e13" charOffset="306-317"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d267.s5.e14" charOffset="324-332"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d267.s5.d0" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d1" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d2" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d3" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d4" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d5" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d6" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d7" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d8" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d9" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e10" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d10" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e11" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d11" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e12" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d12" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e13" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s5.d13" e1="DDI-DrugBank.d267.s5.e0"
            e2="DDI-DrugBank.d267.s5.e14" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d267.s6" text="As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.">
        <entity id="DDI-DrugBank.d267.s6.e0" charOffset="19-63"
            type="group" text="nondepolarizing neuromuscular blocking agents"/>
        <entity id="DDI-DrugBank.d267.s6.e1" charOffset="118-124"
            type="brand" text="NUROMAX"/>
        <entity id="DDI-DrugBank.d267.s6.e2" charOffset="201-209"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d267.s6.e3" charOffset="214-226"
            type="drug" text="carbamazepine"/>
        <ddi id="DDI-DrugBank.d267.s6.d0" e1="DDI-DrugBank.d267.s6.e0"
            e2="DDI-DrugBank.d267.s6.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s6.d1" e1="DDI-DrugBank.d267.s6.e0"
            e2="DDI-DrugBank.d267.s6.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s6.d2" e1="DDI-DrugBank.d267.s6.e1"
            e2="DDI-DrugBank.d267.s6.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d267.s6.d3" e1="DDI-DrugBank.d267.s6.e1"
            e2="DDI-DrugBank.d267.s6.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d332.s0" text="Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .">
        <entity id="DDI-DrugBank.d332.s0.e0" charOffset="18-25"
            type="drug" text="doxapram"/>
        <entity id="DDI-DrugBank.d332.s0.e1" charOffset="57-71"
            type="group" text="sympathomimetic"/>
        <entity id="DDI-DrugBank.d332.s0.e2" charOffset="76-109"
            type="group" text="monoamine oxidase inhibiting drugs"/>
        <ddi id="DDI-DrugBank.d332.s0.d0" e1="DDI-DrugBank.d332.s0.e0"
            e2="DDI-DrugBank.d332.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d332.s0.d1" e1="DDI-DrugBank.d332.s0.e0"
            e2="DDI-DrugBank.d332.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d332.s1" text="In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.">
        <entity id="DDI-DrugBank.d332.s1.e0" charOffset="30-45"
            type="group" text="muscle relaxants"/>
        <entity id="DDI-DrugBank.d332.s1.e1" charOffset="48-55"
            type="drug" text="doxapram"/>
        <entity id="DDI-DrugBank.d332.s1.e2" charOffset="102-122"
            type="group" text="muscle relaxant drugs"/>
        <ddi id="DDI-DrugBank.d332.s1.d0" e1="DDI-DrugBank.d332.s1.e1"
            e2="DDI-DrugBank.d332.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d332.s2" text="In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for arrhythmias, including ventricular tachycardia and ventricular fibrillation.">
        <entity id="DDI-DrugBank.d332.s2.e0" charOffset="147-154"
            type="drug" text="doxapram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s0" text="Most (98%) of plasma doxazosin is protein bound.">
        <entity id="DDI-DrugBank.d367.s0.e0" charOffset="21-29"
            type="drug" text="doxazosin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s1" text="In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin.">
        <entity id="DDI-DrugBank.d367.s1.e0" charOffset="44-61"
            type="drug" text="doxazosin mesylate"/>
        <entity id="DDI-DrugBank.d367.s1.e1" charOffset="99-105"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d367.s1.e2" charOffset="108-115"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d367.s1.e3" charOffset="118-126"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d367.s1.e4" charOffset="131-142"
            type="drug" text="indomethacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s2" text="There is no information on the effect of other highly plasma protein bound drugs on doxazosin binding.">
        <entity id="DDI-DrugBank.d367.s2.e0" charOffset="84-92"
            type="drug" text="doxazosin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s3" text="Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs.">
        <entity id="DDI-DrugBank.d367.s3.e0" charOffset="0-17"
            type="drug" text="Doxazosin mesylate"/>
        <entity id="DDI-DrugBank.d367.s3.e1" charOffset="115-132"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d367.s3.e2" charOffset="135-153"
            type="group" text="beta-blocking agent"/>
        <entity id="DDI-DrugBank.d367.s3.e3" charOffset="161-196"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s4" text="In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.">
        <entity id="DDI-DrugBank.d367.s4.e0" charOffset="96-104"
            type="drug" text="doxazosin"/>
        <entity id="DDI-DrugBank.d367.s4.e1" charOffset="145-154"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d367.s4.e2" charOffset="219-227"
            type="drug" text="doxazosin"/>
        <entity id="DDI-DrugBank.d367.s4.e3" charOffset="331-339"
            type="drug" text="doxazosin"/>
        <ddi id="DDI-DrugBank.d367.s4.d0" e1="DDI-DrugBank.d367.s4.e0"
            e2="DDI-DrugBank.d367.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s5" text="The clinical significance of this increase in doxazosin AUC is unknown.">
        <entity id="DDI-DrugBank.d367.s5.e0" charOffset="46-54"
            type="drug" text="doxazosin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s6" text="In clinical trials, doxazosin mesylate tablets have been administered to patients on a variety of concomitant medications;">
        <entity id="DDI-DrugBank.d367.s6.e0" charOffset="20-37"
            type="drug" text="doxazosin mesylate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s7" text="while no formal interaction studies have been conducted, no interactions were observed."/>
    <sentence id="DDI-DrugBank.d367.s8" text="Doxazosin mesylate tablets have been used with the following drugs or drug classes: 1.">
        <entity id="DDI-DrugBank.d367.s8.e0" charOffset="0-17"
            type="drug" text="Doxazosin mesylate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s9" text="Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).">
        <entity id="DDI-DrugBank.d367.s9.e0" charOffset="0-8"
            type="group" text="Analgesic"/>
        <entity id="DDI-DrugBank.d367.s9.e1" charOffset="10-26"
            type="group" text="anti-inflammatory"/>
        <entity id="DDI-DrugBank.d367.s9.e2" charOffset="35-47"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d367.s9.e3" charOffset="50-56"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d367.s9.e4" charOffset="59-65"
            type="drug" text="codeine"/>
        <entity id="DDI-DrugBank.d367.s9.e5" charOffset="71-77"
            type="drug" text="codeine"/>
        <entity id="DDI-DrugBank.d367.s9.e6" charOffset="93-101"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d367.s9.e7" charOffset="104-115"
            type="drug" text="indomethacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s10" text="2."/>
    <sentence id="DDI-DrugBank.d367.s11" text="Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin).">
        <entity id="DDI-DrugBank.d367.s11.e0" charOffset="0-10"
            type="group" text="Antibiotics"/>
        <entity id="DDI-DrugBank.d367.s11.e1" charOffset="19-30"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d367.s11.e2" charOffset="33-44"
            type="drug" text="trimethoprim"/>
        <entity id="DDI-DrugBank.d367.s11.e3" charOffset="50-65"
            type="drug" text="sulfamethoxazole"/>
        <entity id="DDI-DrugBank.d367.s11.e4" charOffset="68-78"
            type="drug" text="amoxicillin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s12" text="3."/>
    <sentence id="DDI-DrugBank.d367.s13" text="Antihistamines (e.g., chlorpheniramine).">
        <entity id="DDI-DrugBank.d367.s13.e0" charOffset="0-13"
            type="group" text="Antihistamines"/>
        <entity id="DDI-DrugBank.d367.s13.e1" charOffset="22-37"
            type="group" text="chlorpheniramine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s14" text="4."/>
    <sentence id="DDI-DrugBank.d367.s15" text="Cardiovascular agents (e.g., atenolol, hydrochlorothiazide, propranolol).">
        <entity id="DDI-DrugBank.d367.s15.e0" charOffset="29-36"
            type="drug" text="atenolol"/>
        <entity id="DDI-DrugBank.d367.s15.e1" charOffset="39-57"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d367.s15.e2" charOffset="60-70"
            type="drug" text="propranolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s16" text="5."/>
    <sentence id="DDI-DrugBank.d367.s17" text="Corticosteroids.">
        <entity id="DDI-DrugBank.d367.s17.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s18" text="6."/>
    <sentence id="DDI-DrugBank.d367.s19" text="Gastrointestinal agents (e.g., antacids).">
        <entity id="DDI-DrugBank.d367.s19.e0" charOffset="31-38"
            type="group" text="antacids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s20" text="7."/>
    <sentence id="DDI-DrugBank.d367.s21" text="Hypoglycemics and endocrine drugs.">
        <entity id="DDI-DrugBank.d367.s21.e0" charOffset="0-12"
            type="group" text="Hypoglycemics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s22" text="8."/>
    <sentence id="DDI-DrugBank.d367.s23" text="Sedatives and tranquilizers (e.g., diazepam).">
        <entity id="DDI-DrugBank.d367.s23.e0" charOffset="0-8"
            type="group" text="Sedatives"/>
        <entity id="DDI-DrugBank.d367.s23.e1" charOffset="14-26"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d367.s23.e2" charOffset="35-42"
            type="drug" text="diazepam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d367.s24" text="9."/>
    <sentence id="DDI-DrugBank.d367.s25" text="Cold and flu remedies."/>
    <sentence id="DDI-DrugBank.d223.s0" text="Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called poor metabolizers);"/>
    <sentence id="DDI-DrugBank.d223.s1" text="reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available."/>
    <sentence id="DDI-DrugBank.d223.s2" text="Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.">
        <entity id="DDI-DrugBank.d223.s2.e0" charOffset="69-93"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d223.s2.e1" charOffset="96-99"
            type="group" text="TCAs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s3" text="Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA)."/>
    <sentence id="DDI-DrugBank.d223.s4" text="In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers."/>
    <sentence id="DDI-DrugBank.d223.s5" text="An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.">
        <entity id="DDI-DrugBank.d223.s5.e0" charOffset="47-49"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s6" text="The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;">
        <entity id="DDI-DrugBank.d223.s6.e0" charOffset="96-104"
            type="drug" text="quinidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s7" text="cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).">
        <entity id="DDI-DrugBank.d223.s7.e0" charOffset="0-9"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d223.s7.e1" charOffset="66-80"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d223.s7.e2" charOffset="83-96"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d223.s7.e3" charOffset="107-129"
            type="group" text="Type 1C antiarrhythmics"/>
        <entity id="DDI-DrugBank.d223.s7.e4" charOffset="131-141"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d223.s7.e5" charOffset="147-156"
            type="drug" text="flecainide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s8" text="While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.">
        <entity id="DDI-DrugBank.d223.s8.e0" charOffset="14-52"
            type="group" text="selective serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d223.s8.e1" charOffset="55-59"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d223.s8.e2" charOffset="69-78"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d223.s8.e3" charOffset="81-92"
            type="drug" text="escitalopram"/>
        <entity id="DDI-DrugBank.d223.s8.e4" charOffset="95-104"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d223.s8.e5" charOffset="107-116"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d223.s8.e6" charOffset="123-132"
            type="drug" text="paroxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s9" text="The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.">
        <entity id="DDI-DrugBank.d223.s9.e0" charOffset="20-23"
            type="group" text="SSRI"/>
        <entity id="DDI-DrugBank.d223.s9.e1" charOffset="25-27"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d223.s9.e2" charOffset="141-144"
            type="group" text="SSRI"/>
        <ddi id="DDI-DrugBank.d223.s9.d0" e1="DDI-DrugBank.d223.s9.e0"
            e2="DDI-DrugBank.d223.s9.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s10" text="Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.">
        <entity id="DDI-DrugBank.d223.s10.e0" charOffset="63-66"
            type="group" text="TCAs"/>
        <entity id="DDI-DrugBank.d223.s10.e1" charOffset="84-88"
            type="group" text="SSRIs"/>
        <ddi id="DDI-DrugBank.d223.s10.d0" e1="DDI-DrugBank.d223.s10.e0"
            e2="DDI-DrugBank.d223.s10.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s11" text="Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).">
        <entity id="DDI-DrugBank.d223.s11.e0" charOffset="120-129"
            type="drug" text="fluoxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s12" text="Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.">
        <entity id="DDI-DrugBank.d223.s12.e0" charOffset="19-43"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d223.s12.e1" charOffset="156-179"
            type="group" text="tricyclic antidepressant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s13" text="Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.">
        <entity id="DDI-DrugBank.d223.s13.e0" charOffset="98-121"
            type="group" text="tricyclic antidepressant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s14" text="It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.">
        <entity id="DDI-DrugBank.d223.s14.e0" charOffset="27-29"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d223.s14.e1" charOffset="56-58"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s15" text="Doxepin is primarily metabolized by CYP2D6 (with CYP1A2  and  CYP3A4 as minor pathways).">
        <entity id="DDI-DrugBank.d223.s15.e0" charOffset="0-6"
            type="drug" text="Doxepin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s16" text="Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.">
        <entity id="DDI-DrugBank.d223.s16.e0" charOffset="42-50"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d223.s16.e1" charOffset="53-91"
            type="group" text="selective serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d223.s16.e2" charOffset="94-98"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d223.s16.e3" charOffset="143-149"
            type="drug" text="doxepin"/>
        <ddi id="DDI-DrugBank.d223.s16.d0" e1="DDI-DrugBank.d223.s16.e0"
            e2="DDI-DrugBank.d223.s16.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d223.s16.d1" e1="DDI-DrugBank.d223.s16.e1"
            e2="DDI-DrugBank.d223.s16.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d223.s16.d2" e1="DDI-DrugBank.d223.s16.e2"
            e2="DDI-DrugBank.d223.s16.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s17" text="The extent of interaction depends on the variability of effect on CYP2D6."/>
    <sentence id="DDI-DrugBank.d223.s18" text="The clinical significance of this interaction with doxepin has not been systematically evaluated.">
        <entity id="DDI-DrugBank.d223.s18.e0" charOffset="51-57"
            type="drug" text="doxepin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s19" text="MAO Inhibitors: Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors.">
        <entity id="DDI-DrugBank.d223.s19.e0" charOffset="0-13"
            type="group" text="MAO Inhibitors"/>
        <entity id="DDI-DrugBank.d223.s19.e1" charOffset="123-136"
            type="group" text="MAO inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s20" text="Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN.">
        <entity id="DDI-DrugBank.d223.s20.e0" charOffset="11-24"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d223.s20.e1" charOffset="117-124"
            type="brand" text="SINEQUAN"/>
        <ddi id="DDI-DrugBank.d223.s20.d0" e1="DDI-DrugBank.d223.s20.e0"
            e2="DDI-DrugBank.d223.s20.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s21" text="The exact length of time may vary and is dependent upon the particular MAO inhibitor being used, the length of time it has been administered, and the dosage involved.">
        <entity id="DDI-DrugBank.d223.s21.e0" charOffset="71-83"
            type="group" text="MAO inhibitor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s22" text="Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.">
        <entity id="DDI-DrugBank.d223.s22.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d223.s22.e1" charOffset="12-21"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d223.s22.e2" charOffset="136-160"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d223.s22.d0" e1="DDI-DrugBank.d223.s22.e1"
            e2="DDI-DrugBank.d223.s22.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s23" text="Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.">
        <entity id="DDI-DrugBank.d223.s23.e0" charOffset="156-179"
            type="group" text="tricyclic antidepressant"/>
        <entity id="DDI-DrugBank.d223.s23.e1" charOffset="186-195"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d223.s23.d0" e1="DDI-DrugBank.d223.s23.e0"
            e2="DDI-DrugBank.d223.s23.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s24" text="Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.">
        <entity id="DDI-DrugBank.d223.s24.e0" charOffset="35-58"
            type="group" text="tricyclic antidepressant"/>
        <entity id="DDI-DrugBank.d223.s24.e1" charOffset="133-142"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d223.s24.d0" e1="DDI-DrugBank.d223.s24.e0"
            e2="DDI-DrugBank.d223.s24.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s25" text="In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.">
        <entity id="DDI-DrugBank.d223.s25.e0" charOffset="60-84"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d223.s25.e1" charOffset="107-116"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d223.s25.e2" charOffset="146-155"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d223.s25.e3" charOffset="218-241"
            type="group" text="tricyclic antidepressant"/>
        <ddi id="DDI-DrugBank.d223.s25.d0" e1="DDI-DrugBank.d223.s25.e2"
            e2="DDI-DrugBank.d223.s25.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s26" text="Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.">
        <entity id="DDI-DrugBank.d223.s26.e0" charOffset="0-6"
            type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d223.s26.e1" charOffset="41-47"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d223.s26.e2" charOffset="128-135"
            type="brand" text="SINEQUAN"/>
        <ddi id="DDI-DrugBank.d223.s26.d0" e1="DDI-DrugBank.d223.s26.e1"
            e2="DDI-DrugBank.d223.s26.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s27" text="This is especially important in patients who may use alcohol excessively.">
        <entity id="DDI-DrugBank.d223.s27.e0" charOffset="53-59"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d223.s28" text="Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).">
        <entity id="DDI-DrugBank.d223.s28.e0" charOffset="0-9"
            type="drug" text="Tolazamide"/>
        <entity id="DDI-DrugBank.d223.s28.e1" charOffset="104-113"
            type="drug" text="tolazamide"/>
        <entity id="DDI-DrugBank.d223.s28.e2" charOffset="156-162"
            type="drug" text="doxepin"/>
        <ddi id="DDI-DrugBank.d223.s28.d0" e1="DDI-DrugBank.d223.s28.e1"
            e2="DDI-DrugBank.d223.s28.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d127.s0" text="No formal drug interaction studies have been conducted with DOXIL  .">
        <entity id="DDI-DrugBank.d127.s0.e0" charOffset="60-64"
            type="brand" text="DOXIL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d127.s1" text="Until specific compatibility data are available, it is not recommended that DOXIL  be mixed with other drugs.">
        <entity id="DDI-DrugBank.d127.s1.e0" charOffset="76-80"
            type="brand" text="DOXIL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d127.s2" text="DOXIL  may interact with drugs known to interact with the conventional formulation of doxorubicin HCl.">
        <entity id="DDI-DrugBank.d127.s2.e0" charOffset="0-4"
            type="brand" text="DOXIL"/>
        <entity id="DDI-DrugBank.d127.s2.e1" charOffset="86-100"
            type="drug" text="doxorubicin HCl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d500.s0" text="Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.">
        <entity id="DDI-DrugBank.d500.s0.e0" charOffset="8-20"
            type="group" text="tetracyclines"/>
        <entity id="DDI-DrugBank.d500.s0.e1" charOffset="98-110"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d500.s0.e2" charOffset="161-173"
            type="group" text="anticoagulant"/>
        <ddi id="DDI-DrugBank.d500.s0.d0" e1="DDI-DrugBank.d500.s0.e0"
            e2="DDI-DrugBank.d500.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d500.s1" text="Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.">
        <entity id="DDI-DrugBank.d500.s1.e0" charOffset="73-82"
            type="drug" text="penicillin"/>
        <entity id="DDI-DrugBank.d500.s1.e1" charOffset="117-129"
            type="group" text="tetracyclines"/>
        <entity id="DDI-DrugBank.d500.s1.e2" charOffset="151-160"
            type="group" text="penicillin"/>
        <ddi id="DDI-DrugBank.d500.s1.d0" e1="DDI-DrugBank.d500.s1.e1"
            e2="DDI-DrugBank.d500.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d500.s2" text="Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.">
        <entity id="DDI-DrugBank.d500.s2.e0" charOffset="14-26"
            type="group" text="tetracyclines"/>
        <entity id="DDI-DrugBank.d500.s2.e1" charOffset="43-50"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d500.s2.e2" charOffset="63-70"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d500.s2.e3" charOffset="73-79"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d500.s2.e4" charOffset="85-93"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d500.s2.e5" charOffset="100-103"
            type="drug" text="iron"/>
        <ddi id="DDI-DrugBank.d500.s2.d0" e1="DDI-DrugBank.d500.s2.e0"
            e2="DDI-DrugBank.d500.s2.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d500.s2.d1" e1="DDI-DrugBank.d500.s2.e0"
            e2="DDI-DrugBank.d500.s2.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d500.s2.d2" e1="DDI-DrugBank.d500.s2.e0"
            e2="DDI-DrugBank.d500.s2.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d500.s2.d3" e1="DDI-DrugBank.d500.s2.e0"
            e2="DDI-DrugBank.d500.s2.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d500.s3" text="Absorption of tetracycline is impaired by bismuth subsalicylate.">
        <entity id="DDI-DrugBank.d500.s3.e0" charOffset="14-25"
            type="drug" text="tetracycline"/>
        <entity id="DDI-DrugBank.d500.s3.e1" charOffset="42-62"
            type="drug" text="bismuth subsalicylate"/>
        <ddi id="DDI-DrugBank.d500.s3.d0" e1="DDI-DrugBank.d500.s3.e0"
            e2="DDI-DrugBank.d500.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d500.s4" text="Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.">
        <entity id="DDI-DrugBank.d500.s4.e0" charOffset="0-11"
            type="group" text="Barbiturates"/>
        <entity id="DDI-DrugBank.d500.s4.e1" charOffset="14-26"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d500.s4.e2" charOffset="33-41"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d500.s4.e3" charOffset="69-79"
            type="drug" text="doxycycline"/>
        <ddi id="DDI-DrugBank.d500.s4.d0" e1="DDI-DrugBank.d500.s4.e0"
            e2="DDI-DrugBank.d500.s4.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d500.s4.d1" e1="DDI-DrugBank.d500.s4.e1"
            e2="DDI-DrugBank.d500.s4.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d500.s4.d2" e1="DDI-DrugBank.d500.s4.e2"
            e2="DDI-DrugBank.d500.s4.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d500.s5" text="The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.">
        <entity id="DDI-DrugBank.d500.s5.e0" charOffset="22-33"
            type="drug" text="tetracycline"/>
        <entity id="DDI-DrugBank.d500.s5.e1" charOffset="39-47"
            type="brand" text="Penthrane"/>
        <entity id="DDI-DrugBank.d500.s5.e2" charOffset="50-63"
            type="drug" text="methoxyflurane"/>
        <ddi id="DDI-DrugBank.d500.s5.d0" e1="DDI-DrugBank.d500.s5.e0"
            e2="DDI-DrugBank.d500.s5.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d500.s5.d1" e1="DDI-DrugBank.d500.s5.e0"
            e2="DDI-DrugBank.d500.s5.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d500.s6" text="Concurrent use of tetracycline may render oral contraceptives less effective.">
        <entity id="DDI-DrugBank.d500.s6.e0" charOffset="18-29"
            type="drug" text="tetracycline"/>
        <entity id="DDI-DrugBank.d500.s6.e1" charOffset="47-60"
            type="group" text="contraceptives"/>
        <ddi id="DDI-DrugBank.d500.s6.d0" e1="DDI-DrugBank.d500.s6.e0"
            e2="DDI-DrugBank.d500.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d500.s7" text="Drug/Laboratory Test Interactions False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test."/>
    <sentence id="DDI-DrugBank.d387.s0" text="Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.">
        <entity id="DDI-DrugBank.d387.s0.e0" charOffset="32-41"
            type="drug" text="doxylamine"/>
        <entity id="DDI-DrugBank.d387.s0.e1" charOffset="74-83"
            type="drug" text="doxylamine"/>
        <entity id="DDI-DrugBank.d387.s0.e2" charOffset="108-127"
            type="group" text="CNS depressant drugs"/>
        <ddi id="DDI-DrugBank.d387.s0.d0" e1="DDI-DrugBank.d387.s0.e1"
            e2="DDI-DrugBank.d387.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d387.s1" text="Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.">
        <entity id="DDI-DrugBank.d387.s1.e0" charOffset="0-13"
            type="group" text="Antihistamines"/>
        <entity id="DDI-DrugBank.d387.s1.e1" charOffset="71-77"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d387.s1.e2" charOffset="82-89"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d387.s1.d0" e1="DDI-DrugBank.d387.s1.e0"
            e2="DDI-DrugBank.d387.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d387.s1.d1" e1="DDI-DrugBank.d387.s1.e0"
            e2="DDI-DrugBank.d387.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d387.s2" text="Doxylamine may enhance the effects of epinephrine.">
        <entity id="DDI-DrugBank.d387.s2.e0" charOffset="0-9"
            type="drug" text="Doxylamine"/>
        <entity id="DDI-DrugBank.d387.s2.e1" charOffset="38-48"
            type="drug" text="epinephrine"/>
        <ddi id="DDI-DrugBank.d387.s2.d0" e1="DDI-DrugBank.d387.s2.e0"
            e2="DDI-DrugBank.d387.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d129.s0" text="Androgens may increase sensitivity to oral anticoagulahts.">
        <entity id="DDI-DrugBank.d129.s0.e0" charOffset="0-8"
            type="group" text="Androgens"/>
    </sentence>
    <sentence id="DDI-DrugBank.d129.s1" text="Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.">
        <entity id="DDI-DrugBank.d129.s1.e0" charOffset="14-26"
            type="group" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d129.s2" text="Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.">
        <entity id="DDI-DrugBank.d129.s2.e0" charOffset="29-43"
            type="drug" text="oxyphenbutazone"/>
        <entity id="DDI-DrugBank.d129.s2.e1" charOffset="49-57"
            type="group" text="androgens"/>
        <entity id="DDI-DrugBank.d129.s2.e2" charOffset="98-112"
            type="drug" text="oxyphenbutazone"/>
        <ddi id="DDI-DrugBank.d129.s2.d0" e1="DDI-DrugBank.d129.s2.e0"
            e2="DDI-DrugBank.d129.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d129.s3" text="In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.">
        <entity id="DDI-DrugBank.d129.s3.e0" charOffset="47-55"
            type="group" text="androgens"/>
        <entity id="DDI-DrugBank.d129.s3.e1" charOffset="99-105"
            type="drug" text="insulin"/>
        <ddi id="DDI-DrugBank.d129.s3.d0" e1="DDI-DrugBank.d129.s3.e0"
            e2="DDI-DrugBank.d129.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d254.s0" text="Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.">
        <entity id="DDI-DrugBank.d254.s0.e0" charOffset="6-25"
            type="group" text="CNS depressant drugs"/>
        <entity id="DDI-DrugBank.d254.s0.e1" charOffset="33-44"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d254.s0.e2" charOffset="47-59"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d254.s0.e3" charOffset="62-68"
            type="group" text="opioids"/>
        <entity id="DDI-DrugBank.d254.s0.e4" charOffset="82-92"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d254.s0.e5" charOffset="138-145"
            type="brand" text="INAPSINE"/>
        <ddi id="DDI-DrugBank.d254.s0.d0" e1="DDI-DrugBank.d254.s0.e0"
            e2="DDI-DrugBank.d254.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d254.s0.d1" e1="DDI-DrugBank.d254.s0.e1"
            e2="DDI-DrugBank.d254.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d254.s0.d2" e1="DDI-DrugBank.d254.s0.e2"
            e2="DDI-DrugBank.d254.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d254.s0.d3" e1="DDI-DrugBank.d254.s0.e3"
            e2="DDI-DrugBank.d254.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d254.s0.d4" e1="DDI-DrugBank.d254.s0.e4"
            e2="DDI-DrugBank.d254.s0.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d254.s1" text="When patients have received such drugs, the dose of INAPSINE required will be less than usual.">
        <entity id="DDI-DrugBank.d254.s1.e0" charOffset="52-59"
            type="brand" text="INAPSINE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d254.s2" text="Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.">
        <entity id="DDI-DrugBank.d254.s2.e0" charOffset="32-39"
            type="brand" text="INAPSINE"/>
        <entity id="DDI-DrugBank.d254.s2.e1" charOffset="60-79"
            type="group" text="CNS depressant drugs"/>
        <ddi id="DDI-DrugBank.d254.s2.d0" e1="DDI-DrugBank.d254.s2.e0"
            e2="DDI-DrugBank.d254.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d190.s0" text="Drug interaction studies with Xigris have not been performed in patients with severe sepsis.">
        <entity id="DDI-DrugBank.d190.s0.e0" charOffset="30-35"
            type="brand" text="Xigris"/>
    </sentence>
    <sentence id="DDI-DrugBank.d190.s1" text="However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis.">
        <entity id="DDI-DrugBank.d190.s1.e0" charOffset="59-64"
            type="brand" text="Xigris"/>
        <entity id="DDI-DrugBank.d190.s1.e1" charOffset="99-104"
            type="brand" text="Xigris"/>
    </sentence>
    <sentence id="DDI-DrugBank.d190.s2" text="Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.">
        <entity id="DDI-DrugBank.d190.s2.e0" charOffset="93-99"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d190.s2.e1" charOffset="102-123"
            type="drug" text="unfractionated heparin"/>
        <entity id="DDI-DrugBank.d190.s2.e2" charOffset="174-202"
            type="group" text="low molecular weight heparins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d190.s3" text="Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial.">
        <entity id="DDI-DrugBank.d190.s3.e0" charOffset="41-47"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d190.s3.e1" charOffset="122-127"
            type="brand" text="Xigris"/>
    </sentence>
    <sentence id="DDI-DrugBank.d190.s4" text="Drug/Laboratory Test Interaction Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays).">
        <entity id="DDI-DrugBank.d190.s4.e0" charOffset="41-46"
            type="brand" text="Xigris"/>
        <entity id="DDI-DrugBank.d190.s4.e1" charOffset="75-80"
            type="brand" text="Xigris"/>
    </sentence>
    <sentence id="DDI-DrugBank.d190.s5" text="This interference may result in an apparent factor concentration that is lower than the true concentration."/>
    <sentence id="DDI-DrugBank.d190.s6" text="Xigris present in plasma samples does not interfere with one-stage factor assays based on the PT (such as factor II, V, VII, and X assays).">
        <entity id="DDI-DrugBank.d190.s6.e0" charOffset="0-5"
            type="brand" text="Xigris"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s0" text="Potential for Other Drugs to Affect Duloxetine: Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.">
        <entity id="DDI-DrugBank.d548.s0.e0" charOffset="36-45"
            type="drug" text="Duloxetine"/>
        <entity id="DDI-DrugBank.d548.s0.e1" charOffset="91-100"
            type="drug" text="duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s1" text="Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.">
        <entity id="DDI-DrugBank.d548.s1.e0" charOffset="41-50"
            type="drug" text="duloxetine"/>
        <entity id="DDI-DrugBank.d548.s1.e1" charOffset="57-67"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d548.s1.e2" charOffset="185-194"
            type="drug" text="duloxetine"/>
        <ddi id="DDI-DrugBank.d548.s1.d0" e1="DDI-DrugBank.d548.s1.e0"
            e2="DDI-DrugBank.d548.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s2" text="Some quinolone antibiotics would be expected to have similar effects and these combinations should be avoided.">
        <entity id="DDI-DrugBank.d548.s2.e0" charOffset="5-25"
            type="group" text="quinolone antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s3" text="Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.">
        <entity id="DDI-DrugBank.d548.s3.e0" charOffset="52-61"
            type="drug" text="duloxetine"/>
        <entity id="DDI-DrugBank.d548.s3.e1" charOffset="94-103"
            type="drug" text="duloxetine"/>
        <entity id="DDI-DrugBank.d548.s3.e2" charOffset="177-186"
            type="drug" text="duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s4" text="Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.">
        <entity id="DDI-DrugBank.d548.s4.e0" charOffset="0-9"
            type="drug" text="Paroxetine"/>
        <entity id="DDI-DrugBank.d548.s4.e1" charOffset="53-62"
            type="drug" text="duloxetine"/>
        <entity id="DDI-DrugBank.d548.s4.e2" charOffset="157-166"
            type="drug" text="paroxetine"/>
        <ddi id="DDI-DrugBank.d548.s4.d0" e1="DDI-DrugBank.d548.s4.e0"
            e2="DDI-DrugBank.d548.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s5" text="Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine).">
        <entity id="DDI-DrugBank.d548.s5.e0" charOffset="77-86"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d548.s5.e1" charOffset="89-97"
            type="drug" text="quinidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s6" text="Potential for Duloxetine to Affect Other Drugs: Drugs Metabolized by CYP1A2: In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity, and it is unlikely to have a clinically significant effect on the metabolism of CYP1A2 substrates.">
        <entity id="DDI-DrugBank.d548.s6.e0" charOffset="14-23"
            type="drug" text="Duloxetine"/>
        <entity id="DDI-DrugBank.d548.s6.e1" charOffset="128-137"
            type="drug" text="duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s7" text="Drugs Metabolized by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6.">
        <entity id="DDI-DrugBank.d548.s7.e0" charOffset="29-38"
            type="drug" text="Duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s8" text="When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.">
        <entity id="DDI-DrugBank.d548.s8.e0" charOffset="5-14"
            type="drug" text="duloxetine"/>
        <entity id="DDI-DrugBank.d548.s8.e1" charOffset="101-111"
            type="drug" text="desipramine"/>
        <entity id="DDI-DrugBank.d548.s8.e2" charOffset="145-155"
            type="drug" text="desipramine"/>
        <ddi id="DDI-DrugBank.d548.s8.d0" e1="DDI-DrugBank.d548.s8.e0"
            e2="DDI-DrugBank.d548.s8.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s9" text="Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.">
        <entity id="DDI-DrugBank.d548.s9.e0" charOffset="32-41"
            type="drug" text="Duloxetine"/>
        <entity id="DDI-DrugBank.d548.s9.e1" charOffset="170-184"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d548.s9.e2" charOffset="187-211"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d548.s9.e3" charOffset="214-217"
            type="group" text="TCAs"/>
        <entity id="DDI-DrugBank.d548.s9.e4" charOffset="229-241"
            type="drug" text="nortriptyline"/>
        <entity id="DDI-DrugBank.d548.s9.e5" charOffset="244-256"
            type="drug" text="amitriptyline"/>
        <entity id="DDI-DrugBank.d548.s9.e6" charOffset="263-272"
            type="drug" text="imipramine"/>
        <entity id="DDI-DrugBank.d548.s9.e7" charOffset="276-289"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d548.s9.e8" charOffset="295-317"
            type="group" text="Type 1C antiarrhythmics"/>
        <entity id="DDI-DrugBank.d548.s9.e9" charOffset="326-336"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d548.s9.e10" charOffset="339-348"
            type="drug" text="flecainide"/>
        <ddi id="DDI-DrugBank.d548.s9.d0" e1="DDI-DrugBank.d548.s9.e0"
            e2="DDI-DrugBank.d548.s9.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d548.s9.d1" e1="DDI-DrugBank.d548.s9.e0"
            e2="DDI-DrugBank.d548.s9.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d548.s9.d2" e1="DDI-DrugBank.d548.s9.e0"
            e2="DDI-DrugBank.d548.s9.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d548.s9.d3" e1="DDI-DrugBank.d548.s9.e0"
            e2="DDI-DrugBank.d548.s9.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d548.s9.d4" e1="DDI-DrugBank.d548.s9.e0"
            e2="DDI-DrugBank.d548.s9.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d548.s9.d5" e1="DDI-DrugBank.d548.s9.e0"
            e2="DDI-DrugBank.d548.s9.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d548.s9.d6" e1="DDI-DrugBank.d548.s9.e0"
            e2="DDI-DrugBank.d548.s9.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d548.s9.d7" e1="DDI-DrugBank.d548.s9.e0"
            e2="DDI-DrugBank.d548.s9.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d548.s9.d8" e1="DDI-DrugBank.d548.s9.e0"
            e2="DDI-DrugBank.d548.s9.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d548.s9.d9" e1="DDI-DrugBank.d548.s9.e0"
            e2="DDI-DrugBank.d548.s9.e10" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s10" text="Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.">
        <entity id="DDI-DrugBank.d548.s10.e0" charOffset="7-9"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d548.s10.e1" charOffset="71-73"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d548.s10.e2" charOffset="103-105"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d548.s10.e3" charOffset="131-140"
            type="drug" text="Duloxetine"/>
        <ddi id="DDI-DrugBank.d548.s10.d0" e1="DDI-DrugBank.d548.s10.e2"
            e2="DDI-DrugBank.d548.s10.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s11" text="Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.">
        <entity id="DDI-DrugBank.d548.s11.e0" charOffset="126-137"
            type="drug" text="thioridazine"/>
        <entity id="DDI-DrugBank.d548.s11.e1" charOffset="140-149"
            type="drug" text="Duloxetine"/>
        <entity id="DDI-DrugBank.d548.s11.e2" charOffset="155-166"
            type="drug" text="thioridazine"/>
        <ddi id="DDI-DrugBank.d548.s11.d0" e1="DDI-DrugBank.d548.s11.e1"
            e2="DDI-DrugBank.d548.s11.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s12" text="Drugs Metabolized by CYP3A: Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity.">
        <entity id="DDI-DrugBank.d548.s12.e0" charOffset="73-82"
            type="drug" text="duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s13" text="Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.">
        <entity id="DDI-DrugBank.d548.s13.e0" charOffset="0-9"
            type="drug" text="Duloxetine"/>
        <entity id="DDI-DrugBank.d548.s13.e1" charOffset="87-93"
            type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d548.s13.e2" charOffset="101-110"
            type="drug" text="Duloxetine"/>
        <entity id="DDI-DrugBank.d548.s13.e3" charOffset="116-122"
            type="drug" text="ethanol"/>
        <entity id="DDI-DrugBank.d548.s13.e4" charOffset="214-223"
            type="drug" text="Duloxetine"/>
        <entity id="DDI-DrugBank.d548.s13.e5" charOffset="294-300"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s14" text="In the Duloxetine clinical trials database, three Duloxetine-treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction.">
        <entity id="DDI-DrugBank.d548.s14.e0" charOffset="7-16"
            type="drug" text="Duloxetine"/>
        <entity id="DDI-DrugBank.d548.s14.e1" charOffset="50-59"
            type="drug" text="Duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s15" text="Substantial intercurrent ethanol use was present in each of these cases, and this may have contributed to the abnormalities seen.">
        <entity id="DDI-DrugBank.d548.s15.e0" charOffset="25-31"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s16" text="CNS Acting Drugs: Given the primary CNS effects of Duloxetine, it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action.">
        <entity id="DDI-DrugBank.d548.s16.e0" charOffset="51-60"
            type="drug" text="Duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s17" text="Potential for Interaction with Drugs that Affect Gastric Acidity: Duloxetine has an enteric coating that resists dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5.">
        <entity id="DDI-DrugBank.d548.s17.e0" charOffset="66-75"
            type="drug" text="Duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s18" text="In extremely acidic conditions, Duloxetine, unprotected by the enteric coating, may undergo hydrolysis to form naphthol.">
        <entity id="DDI-DrugBank.d548.s18.e0" charOffset="32-41"
            type="drug" text="Duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s19" text="Caution is advised in using Duloxetine in patients with conditions that may slow gastric emptying (e.g., some diabetics).">
        <entity id="DDI-DrugBank.d548.s19.e0" charOffset="28-37"
            type="drug" text="Duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s20" text="Drugs that raise the gastrointestinal pH may lead to an earlier release of duloxetine.">
        <entity id="DDI-DrugBank.d548.s20.e0" charOffset="75-84"
            type="drug" text="duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s21" text="However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.">
        <entity id="DDI-DrugBank.d548.s21.e0" charOffset="30-39"
            type="drug" text="Duloxetine"/>
        <entity id="DDI-DrugBank.d548.s21.e1" charOffset="46-53"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d548.s21.e2" charOffset="60-68"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d548.s21.e3" charOffset="81-88"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d548.s21.e4" charOffset="102-111"
            type="drug" text="Duloxetine"/>
        <entity id="DDI-DrugBank.d548.s21.e5" charOffset="118-127"
            type="drug" text="famotidine"/>
        <entity id="DDI-DrugBank.d548.s21.e6" charOffset="181-190"
            type="drug" text="duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d548.s22" text="It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption.">
        <entity id="DDI-DrugBank.d548.s22.e0" charOffset="56-77"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-DrugBank.d548.s22.e1" charOffset="87-96"
            type="drug" text="duloxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d4.s0" text="Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.">
        <entity id="DDI-DrugBank.d4.s0.e0" charOffset="18-41"
            type="group" text="xanthine bronchodilators"/>
        <entity id="DDI-DrugBank.d4.s0.e1" charOffset="50-61"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d4.s0.e2" charOffset="65-73"
            type="drug" text="ephedrine"/>
        <entity id="DDI-DrugBank.d4.s0.e3" charOffset="86-116"
            type="group" text="sympathomimetic bronchodilators"/>
        <ddi id="DDI-DrugBank.d4.s0.d0" e1="DDI-DrugBank.d4.s0.e0"
            e2="DDI-DrugBank.d4.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d4.s0.d1" e1="DDI-DrugBank.d4.s0.e1"
            e2="DDI-DrugBank.d4.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d4.s0.d2" e1="DDI-DrugBank.d4.s0.e2"
            e2="DDI-DrugBank.d4.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d4.s1" text="This should be considered whenever these agents are prescribed concomitantly."/>
    <sentence id="DDI-DrugBank.d4.s2" text="Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .">
        <entity id="DDI-DrugBank.d4.s2.e0" charOffset="29-38"
            type="drug" text="dyphylline"/>
        <entity id="DDI-DrugBank.d4.s2.e1" charOffset="44-53"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d4.s2.e2" charOffset="145-154"
            type="drug" text="dyphylline"/>
        <ddi id="DDI-DrugBank.d4.s2.d0" e1="DDI-DrugBank.d4.s2.e0"
            e2="DDI-DrugBank.d4.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d377.s0" text="Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.">
        <entity id="DDI-DrugBank.d377.s0.e0" charOffset="0-17"
            type="drug" text="Phospholine Iodide"/>
        <entity id="DDI-DrugBank.d377.s0.e1" charOffset="37-61"
            type="group" text="cholinesterase inhibitors"/>
        <entity id="DDI-DrugBank.d377.s0.e2" charOffset="71-85"
            type="drug" text="succinylcholine"/>
        <entity id="DDI-DrugBank.d377.s0.e3" charOffset="90-104;120-130"
            type="drug_n" text="organophosphate insecticide"/>
        <entity id="DDI-DrugBank.d377.s0.e4" charOffset="110-130"
            type="drug_n" text="carbamate insecticide"/>
        <ddi id="DDI-DrugBank.d377.s0.d0" e1="DDI-DrugBank.d377.s0.e0"
            e2="DDI-DrugBank.d377.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d377.s0.d1" e1="DDI-DrugBank.d377.s0.e0"
            e2="DDI-DrugBank.d377.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d377.s0.d2" e1="DDI-DrugBank.d377.s0.e0"
            e2="DDI-DrugBank.d377.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d377.s0.d3" e1="DDI-DrugBank.d377.s0.e0"
            e2="DDI-DrugBank.d377.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d377.s1" text="Patients undergoing systemic anticholinesterase treatment should be warned of the possible additive effects of Phospholine Iodide.">
        <entity id="DDI-DrugBank.d377.s1.e0" charOffset="111-128"
            type="drug" text="Phospholine Iodide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d49.s0" text="Drug interaction studies have not been performed with Soliris.">
        <entity id="DDI-DrugBank.d49.s0.e0" charOffset="54-60"
            type="brand" text="Soliris"/>
    </sentence>
    <sentence id="DDI-DrugBank.d191.s0" text="There is no known drug interference with standard clinical laboratory tests."/>
    <sentence id="DDI-DrugBank.d191.s1" text="Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7">
        <entity id="DDI-DrugBank.d191.s1.e0" charOffset="0-7"
            type="group" text="Steroids"/>
        <entity id="DDI-DrugBank.d191.s1.e1" charOffset="39-62"
            type="drug" text="edetate calcium disodium"/>
        <entity id="DDI-DrugBank.d191.s1.e2" charOffset="78-101"
            type="drug" text="Edetate calcium disodium"/>
        <entity id="DDI-DrugBank.d191.s1.e3" charOffset="133-144"
            type="drug" text="zinc insulin"/>
        <entity id="DDI-DrugBank.d191.s1.e4" charOffset="176-179"
            type="drug" text="zinc"/>
        <ddi id="DDI-DrugBank.d191.s1.d0" e1="DDI-DrugBank.d191.s1.e0"
            e2="DDI-DrugBank.d191.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d191.s1.d1" e1="DDI-DrugBank.d191.s1.e2"
            e2="DDI-DrugBank.d191.s1.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d292.s0" text="Care should be given when administering this drug to patients with symptoms of myasthenic weakness who are also on anticholinesterase drugs.">
        <entity id="DDI-DrugBank.d292.s0.e0" charOffset="115-138"
            type="group" text="anticholinesterase drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d292.s1" text="Since symptoms of anticholinesterase overdose (cholinergic crisis) may mimic underdosage (myasthenic weakness), their condition may be worsened by the use of this drug."/>
    <sentence id="DDI-DrugBank.d44.s0" text="No formal drug interaction studies have been performed with RAPTIVA.">
        <entity id="DDI-DrugBank.d44.s0.e0" charOffset="60-66"
            type="brand" text="RAPTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d44.s1" text="RAPTIVA should not be used with other immunosuppressive drugs.">
        <entity id="DDI-DrugBank.d44.s1.e0" charOffset="0-6"
            type="brand" text="RAPTIVA"/>
        <entity id="DDI-DrugBank.d44.s1.e1" charOffset="38-60"
            type="group" text="immunosuppressive drugs"/>
        <ddi id="DDI-DrugBank.d44.s1.d0" e1="DDI-DrugBank.d44.s1.e0"
            e2="DDI-DrugBank.d44.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d44.s2" text="Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.">
        <entity id="DDI-DrugBank.d44.s2.e0" charOffset="0-8;36-43"
            type="group" text="Acellular vaccines"/>
        <entity id="DDI-DrugBank.d44.s2.e1" charOffset="11-14;36-43"
            type="group" text="live vaccines"/>
        <entity id="DDI-DrugBank.d44.s2.e2" charOffset="20-43"
            type="group" text="live-attenuated vaccines"/>
        <entity id="DDI-DrugBank.d44.s2.e3" charOffset="79-85"
            type="brand" text="RAPTIVA"/>
        <ddi id="DDI-DrugBank.d44.s2.d0" e1="DDI-DrugBank.d44.s2.e0"
            e2="DDI-DrugBank.d44.s2.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d44.s2.d1" e1="DDI-DrugBank.d44.s2.e1"
            e2="DDI-DrugBank.d44.s2.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d44.s2.d2" e1="DDI-DrugBank.d44.s2.e2"
            e2="DDI-DrugBank.d44.s2.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d44.s3" text="Drug/Laboratory Test Interactions Increases in lymphocyte counts related to the pharmacologic mechanism of action are frequently observed during RAPTIVA treatment.">
        <entity id="DDI-DrugBank.d44.s3.e0" charOffset="145-151"
            type="brand" text="RAPTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s0" text="Efavirenz has been shown in vivo to induce CYP3A4.">
        <entity id="DDI-DrugBank.d531.s0.e0" charOffset="0-8"
            type="drug" text="Efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s1" text="Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with SUSTIVA (efavirenz).">
        <entity id="DDI-DrugBank.d531.s1.e0" charOffset="112-118"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s1.e1" charOffset="121-129"
            type="drug" text="efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s2" text="In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations.">
        <entity id="DDI-DrugBank.d531.s2.e0" charOffset="40-48"
            type="drug" text="efavirenz"/>
        <entity id="DDI-DrugBank.d531.s2.e1" charOffset="112-120"
            type="drug" text="efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s3" text="Coadministration of efavirenz with drugs primarily metabolized by these isozymes may result in altered plasma concentrations of the coadministered drug.">
        <entity id="DDI-DrugBank.d531.s3.e0" charOffset="20-28"
            type="drug" text="efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s4" text="Therefore, appropriate dose adjustments may be necessary for these drugs."/>
    <sentence id="DDI-DrugBank.d531.s5" text="Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.">
        <entity id="DDI-DrugBank.d531.s5.e0" charOffset="40-52"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d531.s5.e1" charOffset="55-62"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d531.s5.e2" charOffset="65-73"
            type="drug" text="rifabutin"/>
        <entity id="DDI-DrugBank.d531.s5.e3" charOffset="123-131"
            type="drug" text="efavirenz"/>
        <ddi id="DDI-DrugBank.d531.s5.d0" e1="DDI-DrugBank.d531.s5.e0"
            e2="DDI-DrugBank.d531.s5.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d531.s5.d1" e1="DDI-DrugBank.d531.s5.e1"
            e2="DDI-DrugBank.d531.s5.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d531.s5.d2" e1="DDI-DrugBank.d531.s5.e2"
            e2="DDI-DrugBank.d531.s5.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s6" text="Drug interactions with SUSTIVA are summarized in Table 5.">
        <entity id="DDI-DrugBank.d531.s6.e0" charOffset="23-29"
            type="brand" text="SUSTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s7" text="Table 5a: Drugs That Should Not Be Coadministered With SUSTIVA">
        <entity id="DDI-DrugBank.d531.s7.e0" charOffset="55-61"
            type="brand" text="SUSTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s8" text="Drug Class"/>
    <sentence id="DDI-DrugBank.d531.s9" text="Drugs Within Class Not To Be Coadministered With SUSTIVA">
        <entity id="DDI-DrugBank.d531.s9.e0" charOffset="49-55"
            type="brand" text="SUSTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s10" text="Antihistamines: Benzodiazepines GI Motility Agents Anti-Migraine Antifungal">
        <entity id="DDI-DrugBank.d531.s10.e0" charOffset="0-13"
            type="group" text="Antihistamines"/>
        <entity id="DDI-DrugBank.d531.s10.e1" charOffset="16-30"
            type="group" text="Benzodiazepines"/>
        <entity id="DDI-DrugBank.d531.s10.e2" charOffset="51-63"
            type="group" text="Anti-Migraine"/>
        <entity id="DDI-DrugBank.d531.s10.e3" charOffset="65-74"
            type="group" text="Antifungal"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s11" text="astemizole midazolam, triazolam cisapride ergot derivatives voriconazole">
        <entity id="DDI-DrugBank.d531.s11.e0" charOffset="0-9"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d531.s11.e1" charOffset="11-19"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d531.s11.e2" charOffset="22-30"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d531.s11.e3" charOffset="32-40"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d531.s11.e4" charOffset="60-71"
            type="drug" text="voriconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s12" text="Established Drug Interactions"/>
    <sentence id="DDI-DrugBank.d531.s13" text=""/>
    <sentence id="DDI-DrugBank.d531.s14" text="Drug Name"/>
    <sentence id="DDI-DrugBank.d531.s15" text="Effect"/>
    <sentence id="DDI-DrugBank.d531.s16" text="Clinical Comment"/>
    <sentence id="DDI-DrugBank.d531.s17" text="Atazanavir">
        <entity id="DDI-DrugBank.d531.s17.e0" charOffset="0-9"
            type="drug" text="Atazanavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s18" text="atazanavir">
        <entity id="DDI-DrugBank.d531.s18.e0" charOffset="0-9"
            type="drug" text="atazanavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s19" text="When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).">
        <entity id="DDI-DrugBank.d531.s19.e0" charOffset="25-31"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s19.e1" charOffset="86-95"
            type="drug" text="atazanavir"/>
        <entity id="DDI-DrugBank.d531.s19.e2" charOffset="112-120"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d531.s19.e3" charOffset="133-139"
            type="brand" text="SUSTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s20" text="Dosing recommendations for SUSTIVA and atazanavir in treatment-experienced patients have not been established.">
        <entity id="DDI-DrugBank.d531.s20.e0" charOffset="27-33"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s20.e1" charOffset="39-48"
            type="drug" text="atazanavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s21" text="Established Drug Interactions (continued)"/>
    <sentence id="DDI-DrugBank.d531.s22" text="Drug Name"/>
    <sentence id="DDI-DrugBank.d531.s23" text="Effect"/>
    <sentence id="DDI-DrugBank.d531.s24" text="Clinical Comment"/>
    <sentence id="DDI-DrugBank.d531.s25" text="Clarithromycin">
        <entity id="DDI-DrugBank.d531.s25.e0" charOffset="0-13"
            type="drug" text="Clarithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s26" text="clarithromycin concentration">
        <entity id="DDI-DrugBank.d531.s26.e0" charOffset="0-13"
            type="drug" text="clarithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s27" text="Plasma concentrations decreased by SUSTIVA;">
        <entity id="DDI-DrugBank.d531.s27.e0" charOffset="35-41"
            type="brand" text="SUSTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s28" text="clinical significance unknown."/>
    <sentence id="DDI-DrugBank.d531.s29" text="In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.">
        <entity id="DDI-DrugBank.d531.s29.e0" charOffset="61-67"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s29.e1" charOffset="73-86"
            type="drug" text="clarithromycin"/>
        <ddi id="DDI-DrugBank.d531.s29.d0" e1="DDI-DrugBank.d531.s29.e0"
            e2="DDI-DrugBank.d531.s29.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s30" text="No dose adjustment of SUSTIVA is recommended when given with clarithromycin.">
        <entity id="DDI-DrugBank.d531.s30.e0" charOffset="22-28"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s30.e1" charOffset="61-74"
            type="drug" text="clarithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s31" text="Alternatives to clarithromycin, such as azithromycin, should be considered.">
        <entity id="DDI-DrugBank.d531.s31.e0" charOffset="16-29"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d531.s31.e1" charOffset="40-51"
            type="drug" text="azithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s32" text="Other macrolide antibiotics, such as erythromycin, have not been studied in combination with SUSTIVA.">
        <entity id="DDI-DrugBank.d531.s32.e0" charOffset="6-26"
            type="group" text="macrolide antibiotics"/>
        <entity id="DDI-DrugBank.d531.s32.e1" charOffset="37-48"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d531.s32.e2" charOffset="93-99"
            type="brand" text="SUSTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s33" text=""/>
    <sentence id="DDI-DrugBank.d531.s34" text="14-OH metabolite concentration"/>
    <sentence id="DDI-DrugBank.d531.s35" text="Indinavir">
        <entity id="DDI-DrugBank.d531.s35.e0" charOffset="0-8"
            type="drug" text="Indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s36" text="indinavir concentration">
        <entity id="DDI-DrugBank.d531.s36.e0" charOffset="0-8"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s37" text="The optimal dose of indinavir, when given in combination with SUSTIVA, is not known.">
        <entity id="DDI-DrugBank.d531.s37.e0" charOffset="20-28"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d531.s37.e1" charOffset="62-68"
            type="brand" text="SUSTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s38" text="Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.">
        <entity id="DDI-DrugBank.d531.s38.e0" charOffset="15-23"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d531.s38.e1" charOffset="93-101"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d531.s38.e2" charOffset="121-127"
            type="brand" text="SUSTIVA"/>
        <ddi id="DDI-DrugBank.d531.s38.d0" e1="DDI-DrugBank.d531.s38.e1"
            e2="DDI-DrugBank.d531.s38.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s39" text="When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.">
        <entity id="DDI-DrugBank.d531.s39.e0" charOffset="5-13"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d531.s39.e1" charOffset="75-81"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s39.e2" charOffset="108-116"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d531.s39.e3" charOffset="210-218"
            type="drug" text="indinavir"/>
        <ddi id="DDI-DrugBank.d531.s39.d0" e1="DDI-DrugBank.d531.s39.e0"
            e2="DDI-DrugBank.d531.s39.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s40" text="Lopinavir/ritonavir">
        <entity id="DDI-DrugBank.d531.s40.e0" charOffset="0-8"
            type="drug" text="Lopinavir"/>
        <entity id="DDI-DrugBank.d531.s40.e1" charOffset="10-18"
            type="drug" text="ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s41" text="lopinavir concentration">
        <entity id="DDI-DrugBank.d531.s41.e0" charOffset="0-8"
            type="drug" text="lopinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s42" text="A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.">
        <entity id="DDI-DrugBank.d531.s42.e0" charOffset="19-27"
            type="drug" text="lopinavir"/>
        <entity id="DDI-DrugBank.d531.s42.e1" charOffset="29-37"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d531.s42.e2" charOffset="149-155"
            type="brand" text="SUSTIVA"/>
        <ddi id="DDI-DrugBank.d531.s42.d0" e1="DDI-DrugBank.d531.s42.e0"
            e2="DDI-DrugBank.d531.s42.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d531.s42.d1" e1="DDI-DrugBank.d531.s42.e1"
            e2="DDI-DrugBank.d531.s42.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s43" text="Methadone">
        <entity id="DDI-DrugBank.d531.s43.e0" charOffset="0-8"
            type="drug" text="Methadone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s44" text="methadone concentration">
        <entity id="DDI-DrugBank.d531.s44.e0" charOffset="0-8"
            type="drug" text="methadone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s45" text="Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of methadone and signs of opiate withdrawal.">
        <entity id="DDI-DrugBank.d531.s45.e0" charOffset="121-129"
            type="drug" text="methadone"/>
        <entity id="DDI-DrugBank.d531.s45.e1" charOffset="144-149"
            type="group" text="opiate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s46" text="Methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms.">
        <entity id="DDI-DrugBank.d531.s46.e0" charOffset="0-8"
            type="drug" text="Methadone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s47" text="Patients should be monitored for signs of withdrawal and their methadone dose increased as required to alleviate withdrawal symptoms.">
        <entity id="DDI-DrugBank.d531.s47.e0" charOffset="63-71"
            type="drug" text="methadone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s48" text="Ethinyl estradiol">
        <entity id="DDI-DrugBank.d531.s48.e0" charOffset="0-16"
            type="drug" text="Ethinyl estradiol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s49" text="ethinyl estradiol concentration">
        <entity id="DDI-DrugBank.d531.s49.e0" charOffset="0-16"
            type="drug" text="ethinyl estradiol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s50" text="Plasma concentrations increased by SUSTIVA (efavirenz);">
        <entity id="DDI-DrugBank.d531.s50.e0" charOffset="35-41"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s50.e1" charOffset="44-52"
            type="drug" text="efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s51" text="clinical significance unknown."/>
    <sentence id="DDI-DrugBank.d531.s52" text="Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.">
        <entity id="DDI-DrugBank.d531.s52.e0" charOffset="37-45"
            type="drug" text="efavirenz"/>
        <entity id="DDI-DrugBank.d531.s52.e1" charOffset="57-70"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d531.s52.e2" charOffset="184-197"
            type="group" text="contraceptives"/>
        <ddi id="DDI-DrugBank.d531.s52.d0" e1="DDI-DrugBank.d531.s52.e0"
            e2="DDI-DrugBank.d531.s52.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s53" text="Rifabutin">
        <entity id="DDI-DrugBank.d531.s53.e0" charOffset="0-8"
            type="drug" text="Rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s54" text="rifabutin concentration">
        <entity id="DDI-DrugBank.d531.s54.e0" charOffset="0-8"
            type="drug" text="rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s55" text="Increase daily dose of rifabutin by 50%.">
        <entity id="DDI-DrugBank.d531.s55.e0" charOffset="23-31"
            type="drug" text="rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s56" text="Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.">
        <entity id="DDI-DrugBank.d531.s56.e0" charOffset="22-30"
            type="drug" text="rifabutin"/>
        <entity id="DDI-DrugBank.d531.s56.e1" charOffset="55-63"
            type="drug" text="rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s57" text="Rifampin">
        <entity id="DDI-DrugBank.d531.s57.e0" charOffset="0-7"
            type="drug" text="Rifampin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s58" text="efavirenz concentration">
        <entity id="DDI-DrugBank.d531.s58.e0" charOffset="0-8"
            type="drug" text="efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s59" text="Clinical significance of reduced efavirenz concentrations unknown.">
        <entity id="DDI-DrugBank.d531.s59.e0" charOffset="33-41"
            type="drug" text="efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s60" text="Ritonavir">
        <entity id="DDI-DrugBank.d531.s60.e0" charOffset="0-8"
            type="drug" text="Ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s61" text="ritonavir concentration">
        <entity id="DDI-DrugBank.d531.s61.e0" charOffset="0-8"
            type="drug" text="ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s62" text="Combination was associated with a higher frequency of adverse clinical experiences (eg, dizziness, nausea, paresthesia) and laboratory abnormalities (elevated liver enzymes)."/>
    <sentence id="DDI-DrugBank.d531.s63" text="Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.">
        <entity id="DDI-DrugBank.d531.s63.e0" charOffset="48-54"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s63.e1" charOffset="84-92"
            type="drug" text="ritonavir"/>
        <ddi id="DDI-DrugBank.d531.s63.d0" e1="DDI-DrugBank.d531.s63.e0"
            e2="DDI-DrugBank.d531.s63.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s64" text="efavirenz concentration">
        <entity id="DDI-DrugBank.d531.s64.e0" charOffset="0-8"
            type="drug" text="efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s65" text="Saquinavir">
        <entity id="DDI-DrugBank.d531.s65.e0" charOffset="0-9"
            type="drug" text="Saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s66" text="saquinavir concentration">
        <entity id="DDI-DrugBank.d531.s66.e0" charOffset="0-9"
            type="drug" text="saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s67" text="Should not be used as sole protease inhibitor in combination with SUSTIVA.">
        <entity id="DDI-DrugBank.d531.s67.e0" charOffset="27-44"
            type="group" text="protease inhibitor"/>
        <entity id="DDI-DrugBank.d531.s67.e1" charOffset="66-72"
            type="brand" text="SUSTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s68" text="Sertraline">
        <entity id="DDI-DrugBank.d531.s68.e0" charOffset="0-9"
            type="drug" text="Sertraline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s69" text="sertraline concentration">
        <entity id="DDI-DrugBank.d531.s69.e0" charOffset="0-9"
            type="drug" text="sertraline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s70" text="Increases in sertraline dose should be guided by clinical response.">
        <entity id="DDI-DrugBank.d531.s70.e0" charOffset="13-22"
            type="drug" text="sertraline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s71" text="Other Potentially Clinically Significant Drug or Herbal Product Interactions With SUSTIVAb"/>
    <sentence id="DDI-DrugBank.d531.s72" text="Anticoagulants: Warfarin">
        <entity id="DDI-DrugBank.d531.s72.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d531.s72.e1" charOffset="16-23"
            type="drug" text="Warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s73" text="Plasma concentrations and effects potentially increased or decreased by SUSTIVA.">
        <entity id="DDI-DrugBank.d531.s73.e0" charOffset="72-78"
            type="brand" text="SUSTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s74" text="Anticonvulsants: Phenytoin Phenobarbital Carbamazepine">
        <entity id="DDI-DrugBank.d531.s74.e0" charOffset="0-14"
            type="group" text="Anticonvulsants"/>
        <entity id="DDI-DrugBank.d531.s74.e1" charOffset="17-25"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d531.s74.e2" charOffset="27-39"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d531.s74.e3" charOffset="41-53"
            type="drug" text="Carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s75" text="Potential for reduction in anticonvulsant and/or efavirenz plasma levels;">
        <entity id="DDI-DrugBank.d531.s75.e0" charOffset="27-40"
            type="group" text="anticonvulsant"/>
        <entity id="DDI-DrugBank.d531.s75.e1" charOffset="49-57"
            type="drug" text="efavirenz"/>
        <ddi id="DDI-DrugBank.d531.s75.d0" e1="DDI-DrugBank.d531.s75.e0"
            e2="DDI-DrugBank.d531.s75.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s76" text="periodic monitoring of anticonvulsant plasma levels should be conducted.">
        <entity id="DDI-DrugBank.d531.s76.e0" charOffset="23-36"
            type="group" text="anticonvulsant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s77" text="Antifungals: Itraconazole Ketoconazole">
        <entity id="DDI-DrugBank.d531.s77.e0" charOffset="0-10"
            type="group" text="Antifungals"/>
        <entity id="DDI-DrugBank.d531.s77.e1" charOffset="13-24"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d531.s77.e2" charOffset="26-37"
            type="drug" text="Ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s78" text="Drug interaction studies with SUSTIVA and these imidazole and triazole antifungals have not been conducted.">
        <entity id="DDI-DrugBank.d531.s78.e0" charOffset="30-36"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s78.e1" charOffset="48-56;71-81"
            type="group" text="imidazole antifungals"/>
        <entity id="DDI-DrugBank.d531.s78.e2" charOffset="62-81"
            type="group" text="triazole antifungals"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s79" text="SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.">
        <entity id="DDI-DrugBank.d531.s79.e0" charOffset="0-6"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s79.e1" charOffset="63-74"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d531.s79.e2" charOffset="80-91"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d531.s79.d0" e1="DDI-DrugBank.d531.s79.e0"
            e2="DDI-DrugBank.d531.s79.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d531.s79.d1" e1="DDI-DrugBank.d531.s79.e0"
            e2="DDI-DrugBank.d531.s79.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s80" text="Anti-HIV protease inhibitors: Saquinavir/ritonavir combination">
        <entity id="DDI-DrugBank.d531.s80.e0" charOffset="0-27"
            type="group" text="Anti-HIV protease inhibitors"/>
        <entity id="DDI-DrugBank.d531.s80.e1" charOffset="30-39"
            type="drug" text="Saquinavir"/>
        <entity id="DDI-DrugBank.d531.s80.e2" charOffset="41-49"
            type="drug" text="ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s81" text="No pharmacokinetic data are available."/>
    <sentence id="DDI-DrugBank.d531.s82" text="Amprenavir">
        <entity id="DDI-DrugBank.d531.s82.e0" charOffset="0-9"
            type="drug" text="Amprenavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s83" text="SUSTIVAhas the potential to decrease serum concentrations of amprenavir.">
        <entity id="DDI-DrugBank.d531.s83.e0" charOffset="61-70"
            type="drug" text="amprenavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s84" text="Non-nucleoside reverse transcriptase inhibitors">
        <entity id="DDI-DrugBank.d531.s84.e0" charOffset="0-46"
            type="group" text="Non-nucleoside reverse transcriptase inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s85" text="No studies have been performed with other NNRTIs.">
        <entity id="DDI-DrugBank.d531.s85.e0" charOffset="42-47"
            type="group" text="NNRTIs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s86" text="St. John s wort (Hypericum perforatum)"/>
    <sentence id="DDI-DrugBank.d531.s87" text="Expected to substantially decrease plasma levels of efavirenz;has not been studied in combination with SUSTIVA.">
        <entity id="DDI-DrugBank.d531.s87.e0" charOffset="52-60"
            type="drug" text="efavirenz"/>
        <entity id="DDI-DrugBank.d531.s87.e1" charOffset="103-109"
            type="brand" text="SUSTIVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s88" text="a See Tables 1 and 2."/>
    <sentence id="DDI-DrugBank.d531.s89" text="b This table is not all-inclusive."/>
    <sentence id="DDI-DrugBank.d531.s90" text="Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.">
        <entity id="DDI-DrugBank.d531.s90.e0" charOffset="104-110"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s90.e1" charOffset="113-121"
            type="drug" text="efavirenz"/>
        <entity id="DDI-DrugBank.d531.s90.e2" charOffset="153-189"
            type="group" text="aluminum/magnesium hydroxide antacids"/>
        <entity id="DDI-DrugBank.d531.s90.e3" charOffset="192-203"
            type="drug" text="azithromycin"/>
        <entity id="DDI-DrugBank.d531.s90.e4" charOffset="206-215"
            type="drug" text="cetirizine"/>
        <entity id="DDI-DrugBank.d531.s90.e5" charOffset="218-227"
            type="drug" text="famotidine"/>
        <entity id="DDI-DrugBank.d531.s90.e6" charOffset="230-240"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d531.s90.e7" charOffset="243-252"
            type="drug" text="lamivudine"/>
        <entity id="DDI-DrugBank.d531.s90.e8" charOffset="255-263"
            type="drug" text="lorazepam"/>
        <entity id="DDI-DrugBank.d531.s90.e9" charOffset="266-275"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d531.s90.e10" charOffset="278-287"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d531.s90.e11" charOffset="294-303"
            type="drug" text="zidovudine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s91" text="Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.">
        <entity id="DDI-DrugBank.d531.s91.e0" charOffset="63-69"
            type="brand" text="SUSTIVA"/>
        <entity id="DDI-DrugBank.d531.s91.e1" charOffset="75-79"
            type="group" text="NRTIs"/>
        <entity id="DDI-DrugBank.d531.s91.e2" charOffset="92-101"
            type="drug" text="lamivudine"/>
        <entity id="DDI-DrugBank.d531.s91.e3" charOffset="107-116"
            type="drug" text="zidovudine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d531.s92" text="Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.">
        <entity id="DDI-DrugBank.d531.s92.e0" charOffset="68-72"
            type="group" text="NRTIs"/>
        <entity id="DDI-DrugBank.d531.s92.e1" charOffset="117-125"
            type="drug" text="efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d375.s0" text="The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.">
        <entity id="DDI-DrugBank.d375.s0.e0" charOffset="41-47"
            type="brand" text="EMTRIVA"/>
        <entity id="DDI-DrugBank.d375.s0.e1" charOffset="86-94"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d375.s0.e2" charOffset="97-105"
            type="drug" text="stavudine"/>
        <entity id="DDI-DrugBank.d375.s0.e3" charOffset="108-118"
            type="drug" text="famciclovir"/>
        <entity id="DDI-DrugBank.d375.s0.e4" charOffset="125-153"
            type="drug" text="tenofovir disoproxil fumarate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d375.s1" text="There were no clinically significant drug interactions for any of these drugs"/>
    <sentence id="DDI-DrugBank.d375.s2" text="."/>
    <sentence id="DDI-DrugBank.d375.s3" text=""/>
    <sentence id="DDI-DrugBank.d107.s0" text="Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.">
        <entity id="DDI-DrugBank.d107.s0.e0" charOffset="55-63"
            type="drug" text="diuretics"/>
        <entity id="DDI-DrugBank.d107.s0.e1" charOffset="238-246"
            type="drug" text="enalapril"/>
        <entity id="DDI-DrugBank.d107.s0.e2" charOffset="251-261"
            type="drug" text="enalaprilat"/>
        <ddi id="DDI-DrugBank.d107.s0.d0" e1="DDI-DrugBank.d107.s0.e0"
            e2="DDI-DrugBank.d107.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d107.s0.d1" e1="DDI-DrugBank.d107.s0.e0"
            e2="DDI-DrugBank.d107.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s1" text="The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.">
        <entity id="DDI-DrugBank.d107.s1.e0" charOffset="44-52"
            type="drug" text="enalapril"/>
        <entity id="DDI-DrugBank.d107.s1.e1" charOffset="57-67"
            type="drug" text="enalaprilat"/>
        <entity id="DDI-DrugBank.d107.s1.e2" charOffset="114-121"
            type="drug" text="diuretic"/>
        <entity id="DDI-DrugBank.d107.s1.e3" charOffset="191-199"
            type="drug" text="enalapril"/>
        <entity id="DDI-DrugBank.d107.s1.e4" charOffset="204-214"
            type="drug" text="enalaprilat"/>
        <ddi id="DDI-DrugBank.d107.s1.d0" e1="DDI-DrugBank.d107.s1.e0"
            e2="DDI-DrugBank.d107.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d107.s1.d1" e1="DDI-DrugBank.d107.s1.e1"
            e2="DDI-DrugBank.d107.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s2" text="If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour..">
        <entity id="DDI-DrugBank.d107.s2.e0" charOffset="35-42"
            type="group" text="diuretic"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s3" text="Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).">
        <entity id="DDI-DrugBank.d107.s3.e0" charOffset="61-69"
            type="drug" text="enalapril"/>
        <entity id="DDI-DrugBank.d107.s3.e1" charOffset="75-83"
            type="drug" text="enalapril"/>
        <entity id="DDI-DrugBank.d107.s3.e2" charOffset="104-126"
            type="group" text="antihypertensive agents"/>
        <entity id="DDI-DrugBank.d107.s3.e3" charOffset="160-168"
            type="group" text="diuretics"/>
        <ddi id="DDI-DrugBank.d107.s3.d0" e1="DDI-DrugBank.d107.s3.e0"
            e2="DDI-DrugBank.d107.s3.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d107.s3.d1" e1="DDI-DrugBank.d107.s3.e0"
            e2="DDI-DrugBank.d107.s3.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d107.s3.d2" e1="DDI-DrugBank.d107.s3.e1"
            e2="DDI-DrugBank.d107.s3.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d107.s3.d3" e1="DDI-DrugBank.d107.s3.e1"
            e2="DDI-DrugBank.d107.s3.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s4" text="Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.">
        <entity id="DDI-DrugBank.d107.s4.e0" charOffset="0-37"
            type="group" text="Non-steroidal Anti-inflammatory Agents"/>
        <entity id="DDI-DrugBank.d107.s4.e1" charOffset="116-151"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d107.s4.e2" charOffset="179-187"
            type="drug" text="enalapril"/>
        <ddi id="DDI-DrugBank.d107.s4.d0" e1="DDI-DrugBank.d107.s4.e1"
            e2="DDI-DrugBank.d107.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s5" text="These effects are usually reversible."/>
    <sentence id="DDI-DrugBank.d107.s6" text="In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC.">
        <entity id="DDI-DrugBank.d107.s6.e0" charOffset="34-45"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d107.s6.e1" charOffset="50-57"
            type="drug" text="sulindac"/>
        <entity id="DDI-DrugBank.d107.s6.e2" charOffset="111-117"
            type="brand" text="VASOTEC"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s7" text="In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC.">
        <entity id="DDI-DrugBank.d107.s7.e0" charOffset="84-90"
            type="brand" text="VASOTEC"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s8" text="However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.">
        <entity id="DDI-DrugBank.d107.s8.e0" charOffset="30-35"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d107.s8.e1" charOffset="81-94"
            type="group" text="ACE inhibitors"/>
        <ddi id="DDI-DrugBank.d107.s8.d0" e1="DDI-DrugBank.d107.s8.e0"
            e2="DDI-DrugBank.d107.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s9" text="This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.">
        <entity id="DDI-DrugBank.d107.s9.e0" charOffset="66-71"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d107.s9.e1" charOffset="92-105"
            type="group" text="ACE inhibitors"/>
        <ddi id="DDI-DrugBank.d107.s9.d0" e1="DDI-DrugBank.d107.s9.e0"
            e2="DDI-DrugBank.d107.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s10" text="Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.">
        <entity id="DDI-DrugBank.d107.s10.e0" charOffset="29-37"
            type="drug" text="Enalapril"/>
        <entity id="DDI-DrugBank.d107.s10.e1" charOffset="43-51"
            type="drug" text="enalapril"/>
        <entity id="DDI-DrugBank.d107.s10.e2" charOffset="90-120"
            type="group" text="beta adrenergic-blocking agents"/>
        <entity id="DDI-DrugBank.d107.s10.e3" charOffset="123-132"
            type="drug" text="methyldopa"/>
        <entity id="DDI-DrugBank.d107.s10.e4" charOffset="135-142"
            type="group" text="nitrates"/>
        <entity id="DDI-DrugBank.d107.s10.e5" charOffset="145-167"
            type="group" text="calcium-blocking agents"/>
        <entity id="DDI-DrugBank.d107.s10.e6" charOffset="170-180"
            type="drug" text="hydralazine"/>
        <entity id="DDI-DrugBank.d107.s10.e7" charOffset="183-190"
            type="drug" text="prazosin"/>
        <entity id="DDI-DrugBank.d107.s10.e8" charOffset="196-202"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s11" text="Enalapril IV has been used concomitantly with digitalis without evidence of clinically significant adverse reactions.">
        <entity id="DDI-DrugBank.d107.s11.e0" charOffset="0-8"
            type="drug" text="Enalapril"/>
        <entity id="DDI-DrugBank.d107.s11.e1" charOffset="46-54"
            type="group" text="digitalis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s12" text="Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.">
        <entity id="DDI-DrugBank.d107.s12.e0" charOffset="35-43"
            type="drug" text="Enalapril"/>
        <entity id="DDI-DrugBank.d107.s12.e1" charOffset="49-57"
            type="drug" text="enalapril"/>
        <entity id="DDI-DrugBank.d107.s12.e2" charOffset="97-119"
            type="group" text="thiazide-type diuretics"/>
        <ddi id="DDI-DrugBank.d107.s12.d0" e1="DDI-DrugBank.d107.s12.e0"
            e2="DDI-DrugBank.d107.s12.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d107.s12.d1" e1="DDI-DrugBank.d107.s12.e1"
            e2="DDI-DrugBank.d107.s12.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s13" text="Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.">
        <entity id="DDI-DrugBank.d107.s13.e0" charOffset="0-26"
            type="group" text="Potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d107.s13.e1" charOffset="35-48"
            type="drug" text="spironolactone"/>
        <entity id="DDI-DrugBank.d107.s13.e2" charOffset="51-61"
            type="drug" text="triamterene"/>
        <entity id="DDI-DrugBank.d107.s13.e3" charOffset="67-75"
            type="drug" text="amiloride"/>
        <entity id="DDI-DrugBank.d107.s13.e4" charOffset="79-87"
            type="drug" text="potassium"/>
        <entity id="DDI-DrugBank.d107.s13.e5" charOffset="105-113"
            type="drug" text="potassium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s14" text="Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium."/>
    <sentence id="DDI-DrugBank.d107.s15" text="Potassium sparing agents should generally not be used in patients with heart failure receiving enalapril.">
        <entity id="DDI-DrugBank.d107.s15.e0" charOffset="95-103"
            type="drug" text="enalapril"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s16" text="Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.">
        <entity id="DDI-DrugBank.d107.s16.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d107.s16.e1" charOffset="9-15"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d107.s16.e2" charOffset="66-72"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d107.s16.e3" charOffset="144-157"
            type="group" text="ACE inhibitors"/>
        <ddi id="DDI-DrugBank.d107.s16.d0" e1="DDI-DrugBank.d107.s16.e2"
            e2="DDI-DrugBank.d107.s16.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d107.s17" text="It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.">
        <entity id="DDI-DrugBank.d107.s17.e0" charOffset="29-35"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d107.s17.e1" charOffset="71-79"
            type="drug" text="enalapril"/>
        <entity id="DDI-DrugBank.d107.s17.e2" charOffset="116-122"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d107.s17.d0" e1="DDI-DrugBank.d107.s17.e1"
            e2="DDI-DrugBank.d107.s17.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d6.s0" text="The action of nondepolarizing relaxants is augmented by Enflurane.">
        <entity id="DDI-DrugBank.d6.s0.e0" charOffset="56-64"
            type="drug" text="Enflurane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d6.s1" text="Less than the usual amounts of these medicines should be used."/>
    <sentence id="DDI-DrugBank.d6.s2" text="If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.">
        <entity id="DDI-DrugBank.d6.s2.e0" charOffset="145-153"
            type="drug" text="Enflurane"/>
        <entity id="DDI-DrugBank.d6.s2.e1" charOffset="165-173"
            type="drug" text="halothane"/>
        <entity id="DDI-DrugBank.d6.s2.e2" charOffset="178-190"
            type="drug" text="nitrous oxide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d535.s0" text="CYP450 Metabolized Drugs Results from in vitro and in vivo studies suggest that enfuvirtide is unlikely to have significant drug interactions with concomitantly administered drugs metabolized by CYP450 enzymes.">
        <entity id="DDI-DrugBank.d535.s0.e0" charOffset="80-90"
            type="drug" text="enfuvirtide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d535.s1" text="Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.">
        <entity id="DDI-DrugBank.d535.s1.e0" charOffset="0-20"
            type="group" text="Antiretroviral Agents"/>
        <entity id="DDI-DrugBank.d535.s1.e1" charOffset="55-80"
            type="group" text="antiretroviral medications"/>
        <entity id="DDI-DrugBank.d535.s1.e2" charOffset="147-157"
            type="drug" text="enfuvirtide"/>
        <entity id="DDI-DrugBank.d535.s1.e3" charOffset="189-213"
            type="group" text="antiretroviral medication"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s0" text="Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.">
        <entity id="DDI-DrugBank.d395.s0.e0" charOffset="0-6"
            type="drug" text="Bismuth"/>
        <entity id="DDI-DrugBank.d395.s0.e1" charOffset="9-29"
            type="drug" text="Bismuth subsalicylate"/>
        <entity id="DDI-DrugBank.d395.s0.e2" charOffset="57-64"
            type="drug" text="enoxacin"/>
        <entity id="DDI-DrugBank.d395.s0.e3" charOffset="90-97"
            type="drug" text="enoxacin"/>
        <entity id="DDI-DrugBank.d395.s0.e4" charOffset="125-132"
            type="drug" text="enoxacin"/>
        <ddi id="DDI-DrugBank.d395.s0.d0" e1="DDI-DrugBank.d395.s0.e1"
            e2="DDI-DrugBank.d395.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s1" text="Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.">
        <entity id="DDI-DrugBank.d395.s1.e0" charOffset="36-43"
            type="drug" text="enoxacin"/>
        <entity id="DDI-DrugBank.d395.s1.e1" charOffset="49-69"
            type="drug" text="bismuth subsalicylate"/>
        <ddi id="DDI-DrugBank.d395.s1.d0" e1="DDI-DrugBank.d395.s1.e0"
            e2="DDI-DrugBank.d395.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s2" text="Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.">
        <entity id="DDI-DrugBank.d395.s2.e0" charOffset="0-7"
            type="drug" text="Caffeine"/>
        <entity id="DDI-DrugBank.d395.s2.e1" charOffset="10-17"
            type="drug" text="Enoxacin"/>
        <entity id="DDI-DrugBank.d395.s2.e2" charOffset="108-122"
            type="group" text="methylxanthines"/>
        <ddi id="DDI-DrugBank.d395.s2.d0" e1="DDI-DrugBank.d395.s2.e1"
            e2="DDI-DrugBank.d395.s2.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s3" text="In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.">
        <entity id="DDI-DrugBank.d395.s3.e0" charOffset="26-33"
            type="drug" text="enoxacin"/>
        <entity id="DDI-DrugBank.d395.s3.e1" charOffset="103-110"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d395.s3.e2" charOffset="149-156"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d395.s3.e3" charOffset="239-246"
            type="drug" text="caffeine"/>
        <ddi id="DDI-DrugBank.d395.s3.d0" e1="DDI-DrugBank.d395.s3.e0"
            e2="DDI-DrugBank.d395.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s4" text="Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.">
        <entity id="DDI-DrugBank.d395.s4.e0" charOffset="14-21"
            type="drug" text="enoxacin"/>
        <entity id="DDI-DrugBank.d395.s4.e1" charOffset="56-63"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d395.s4.e2" charOffset="69-76"
            type="drug" text="enoxacin"/>
        <ddi id="DDI-DrugBank.d395.s4.d0" e1="DDI-DrugBank.d395.s4.e1"
            e2="DDI-DrugBank.d395.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s5" text="Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.">
        <entity id="DDI-DrugBank.d395.s5.e0" charOffset="0-7"
            type="drug" text="Caffeine"/>
        <entity id="DDI-DrugBank.d395.s5.e1" charOffset="69-76"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d395.s5.e2" charOffset="100-107"
            type="drug" text="enoxacin"/>
        <ddi id="DDI-DrugBank.d395.s5.d0" e1="DDI-DrugBank.d395.s5.e1"
            e2="DDI-DrugBank.d395.s5.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s6" text="Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.">
        <entity id="DDI-DrugBank.d395.s6.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d395.s6.e1" charOffset="39-50"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d395.s6.e2" charOffset="95-106"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d395.s6.e3" charOffset="134-148"
            type="group" text="quinolone class"/>
        <ddi id="DDI-DrugBank.d395.s6.d0" e1="DDI-DrugBank.d395.s6.e2"
            e2="DDI-DrugBank.d395.s6.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s7" text="Digoxin: Enoxacin may raise serum digoxin levels in some individuals.">
        <entity id="DDI-DrugBank.d395.s7.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d395.s7.e1" charOffset="9-16"
            type="drug" text="Enoxacin"/>
        <entity id="DDI-DrugBank.d395.s7.e2" charOffset="34-40"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d395.s7.d0" e1="DDI-DrugBank.d395.s7.e1"
            e2="DDI-DrugBank.d395.s7.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s8" text="If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.">
        <entity id="DDI-DrugBank.d395.s8.e0" charOffset="36-42"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d395.s8.e1" charOffset="64-71"
            type="drug" text="enoxacin"/>
        <entity id="DDI-DrugBank.d395.s8.e2" charOffset="77-83"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d395.s8.e3" charOffset="149-155"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d395.s8.e4" charOffset="175-181"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d395.s8.d0" e1="DDI-DrugBank.d395.s8.e1"
            e2="DDI-DrugBank.d395.s8.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s9" text="Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.">
        <entity id="DDI-DrugBank.d395.s9.e0" charOffset="0-37"
            type="group" text="Non-steroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d395.s9.e1" charOffset="87-94"
            type="drug" text="enoxacin"/>
        <entity id="DDI-DrugBank.d395.s9.e2" charOffset="119-153"
            type="group" text="nonsteroidal anti-inflammatory drug"/>
        <entity id="DDI-DrugBank.d395.s9.e3" charOffset="155-162"
            type="drug" text="fenbufen"/>
        <ddi id="DDI-DrugBank.d395.s9.d0" e1="DDI-DrugBank.d395.s9.e1"
            e2="DDI-DrugBank.d395.s9.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s10" text="Animal studies also suggest an increased potential for seizures when these two drugs are given concomitantly."/>
    <sentence id="DDI-DrugBank.d395.s11" text="Fenbufen is not approved in the United States at this time.">
        <entity id="DDI-DrugBank.d395.s11.e0" charOffset="0-7"
            type="drug" text="Fenbufen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s12" text="Sucralfate and antacids: Quinolones form chelates with metal cations.">
        <entity id="DDI-DrugBank.d395.s12.e0" charOffset="0-9"
            type="drug" text="Sucralfate"/>
        <entity id="DDI-DrugBank.d395.s12.e1" charOffset="15-22"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d395.s12.e2" charOffset="25-34"
            type="group" text="Quinolones"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s13" text="Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;">
        <entity id="DDI-DrugBank.d395.s13.e0" charOffset="29-38"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d395.s13.e1" charOffset="45-52"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d395.s13.e2" charOffset="65-71"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d395.s13.e3" charOffset="74-82"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d395.s13.e4" charOffset="88-95"
            type="drug" text="aluminum"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s14" text="with sucralfate;">
        <entity id="DDI-DrugBank.d395.s14.e0" charOffset="5-14"
            type="drug" text="sucralfate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s15" text="with divalent or trivalent cations such as iron;">
        <entity id="DDI-DrugBank.d395.s15.e0" charOffset="43-46"
            type="drug" text="iron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s16" text="or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.">
        <entity id="DDI-DrugBank.d395.s16.e0" charOffset="8-20"
            type="group" text="multivitamins"/>
        <entity id="DDI-DrugBank.d395.s16.e1" charOffset="33-36"
            type="drug" text="zinc"/>
        <entity id="DDI-DrugBank.d395.s16.e2" charOffset="132-140"
            type="group" text="quinolone"/>
        <ddi id="DDI-DrugBank.d395.s16.d0" e1="DDI-DrugBank.d395.s16.e1"
            e2="DDI-DrugBank.d395.s16.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s17" text="Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.">
        <entity id="DDI-DrugBank.d395.s17.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d395.s17.e1" charOffset="20-37"
            type="drug" text="aluminum hydroxide"/>
        <entity id="DDI-DrugBank.d395.s17.e2" charOffset="43-61"
            type="drug" text="magnesium hydroxide"/>
        <entity id="DDI-DrugBank.d395.s17.e3" charOffset="93-100"
            type="drug" text="enoxacin"/>
        <ddi id="DDI-DrugBank.d395.s17.d0" e1="DDI-DrugBank.d395.s17.e1"
            e2="DDI-DrugBank.d395.s17.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d395.s17.d1" e1="DDI-DrugBank.d395.s17.e2"
            e2="DDI-DrugBank.d395.s17.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s18" text="The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.">
        <entity id="DDI-DrugBank.d395.s18.e0" charOffset="28-35"
            type="drug" text="enoxacin"/>
        <entity id="DDI-DrugBank.d395.s18.e1" charOffset="80-89"
            type="drug" text="ranitidine"/>
        <ddi id="DDI-DrugBank.d395.s18.d0" e1="DDI-DrugBank.d395.s18.e0"
            e2="DDI-DrugBank.d395.s18.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s19" text="These agents should not be taken for 8 hours before or for 2 hours after enoxacin administration.">
        <entity id="DDI-DrugBank.d395.s19.e0" charOffset="73-80"
            type="drug" text="enoxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s20" text="Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.">
        <entity id="DDI-DrugBank.d395.s20.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d395.s20.e1" charOffset="14-21"
            type="drug" text="Enoxacin"/>
        <entity id="DDI-DrugBank.d395.s20.e2" charOffset="112-126"
            type="group" text="methylxanthines"/>
        <ddi id="DDI-DrugBank.d395.s20.d0" e1="DDI-DrugBank.d395.s20.e1"
            e2="DDI-DrugBank.d395.s20.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s21" text="Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.">
        <entity id="DDI-DrugBank.d395.s21.e0" charOffset="0-7"
            type="drug" text="Enoxacin"/>
        <entity id="DDI-DrugBank.d395.s21.e1" charOffset="43-54"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d395.s21.e2" charOffset="107-118"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d395.s21.d0" e1="DDI-DrugBank.d395.s21.e0"
            e2="DDI-DrugBank.d395.s21.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s22" text="Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.">
        <entity id="DDI-DrugBank.d395.s22.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d395.s22.e1" charOffset="68-79"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d395.s22.e2" charOffset="85-92"
            type="drug" text="enoxacin"/>
        <ddi id="DDI-DrugBank.d395.s22.d0" e1="DDI-DrugBank.d395.s22.e1"
            e2="DDI-DrugBank.d395.s22.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s23" text="Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.">
        <entity id="DDI-DrugBank.d395.s23.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d395.s23.e1" charOffset="10-19"
            type="group" text="Quinolones"/>
        <entity id="DDI-DrugBank.d395.s23.e2" charOffset="32-39"
            type="drug" text="enoxacin"/>
        <entity id="DDI-DrugBank.d395.s23.e3" charOffset="68-77"
            type="drug" text="R-warfarin"/>
        <entity id="DDI-DrugBank.d395.s23.e4" charOffset="114-121"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d395.s23.d0" e1="DDI-DrugBank.d395.s23.e1"
            e2="DDI-DrugBank.d395.s23.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d395.s23.d1" e1="DDI-DrugBank.d395.s23.e2"
            e2="DDI-DrugBank.d395.s23.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s24" text="Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.">
        <entity id="DDI-DrugBank.d395.s24.e0" charOffset="0-7"
            type="drug" text="Enoxacin"/>
        <entity id="DDI-DrugBank.d395.s24.e1" charOffset="120-127"
            type="drug" text="enoxacin"/>
        <entity id="DDI-DrugBank.d395.s24.e2" charOffset="133-140"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d395.s25" text="Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.">
        <entity id="DDI-DrugBank.d395.s25.e0" charOffset="95-102"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d395.s25.e1" charOffset="127-134"
            type="drug" text="enoxacin"/>
        <ddi id="DDI-DrugBank.d395.s25.d0" e1="DDI-DrugBank.d395.s25.e0"
            e2="DDI-DrugBank.d395.s25.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d474.s0" text="Unless really needed, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of Lovenox Injection therapy.">
        <entity id="DDI-DrugBank.d474.s0.e0" charOffset="116-122"
            type="brand" text="Lovenox"/>
    </sentence>
    <sentence id="DDI-DrugBank.d474.s1" text="These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.">
        <entity id="DDI-DrugBank.d474.s1.e0" charOffset="42-55"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d474.s1.e1" charOffset="58-76"
            type="group" text="platelet inhibitors"/>
        <entity id="DDI-DrugBank.d474.s1.e2" charOffset="88-107"
            type="drug" text="acetylsalicylic acid"/>
        <entity id="DDI-DrugBank.d474.s1.e3" charOffset="124-129"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d474.s1.e4" charOffset="142-163"
            type="drug" text="ketorolac tromethamine"/>
        <entity id="DDI-DrugBank.d474.s1.e5" charOffset="167-178"
            type="drug" text="dipyridamole"/>
        <entity id="DDI-DrugBank.d474.s1.e6" charOffset="184-197"
            type="drug" text="sulfinpyrazone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d474.s2" text="If co-administration is essential, conduct close clinical and laboratory monitoring"/>
    <sentence id="DDI-DrugBank.d474.s3" text="."/>
    <sentence id="DDI-DrugBank.d474.s4" text=""/>
    <sentence id="DDI-DrugBank.d455.s0" text="In vitro studies of human CYP enzymes showed that entacapone inhibited the CYP enzymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A only at very high concentrations (IC50 from 200 to over 1000 uM;">
        <entity id="DDI-DrugBank.d455.s0.e0" charOffset="50-59"
            type="drug" text="entacapone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d455.s1" text="an oral 200 mg dose achieves a highest level of approximately 5 uM in people);"/>
    <sentence id="DDI-DrugBank.d455.s2" text="these enzymes would therefore not be expected to be inhibited in clinical use."/>
    <sentence id="DDI-DrugBank.d455.s3" text="Protein Binding: Entacapone is highly protein bound (98%).">
        <entity id="DDI-DrugBank.d455.s3.e0" charOffset="17-26"
            type="drug" text="Entacapone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d455.s4" text="In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam.">
        <entity id="DDI-DrugBank.d455.s4.e0" charOffset="60-69"
            type="drug" text="entacapone"/>
        <entity id="DDI-DrugBank.d455.s4.e1" charOffset="109-116"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d455.s4.e2" charOffset="119-132"
            type="drug" text="salicylic acid"/>
        <entity id="DDI-DrugBank.d455.s4.e3" charOffset="135-148"
            type="drug" text="phenylbutazone"/>
        <entity id="DDI-DrugBank.d455.s4.e4" charOffset="155-162"
            type="drug" text="diazepam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d455.s5" text="Drugs Metabolized by Catechol-O-methyltransferase (COMT): Hormone levels: Levodopa is known to depress prolactin secretion and increase growth hormone levels.">
        <entity id="DDI-DrugBank.d455.s5.e0" charOffset="74-81"
            type="drug" text="Levodopa"/>
    </sentence>
    <sentence id="DDI-DrugBank.d455.s6" text="Treatment with entacapone coadministered with levodopa/dopa decarboxylase inhibitor does not change these effects.">
        <entity id="DDI-DrugBank.d455.s6.e0" charOffset="15-24"
            type="drug" text="entacapone"/>
        <entity id="DDI-DrugBank.d455.s6.e1" charOffset="46-53"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d455.s6.e2" charOffset="55-82"
            type="group" text="dopa decarboxylase inhibitor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d455.s7" text="No interaction was noted with the MAO-B inhibitor selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/dopa decarboxylase inhibitor (n=29).">
        <entity id="DDI-DrugBank.d455.s7.e0" charOffset="34-48"
            type="group" text="MAO-B inhibitor"/>
        <entity id="DDI-DrugBank.d455.s7.e1" charOffset="50-59"
            type="drug" text="selegiline"/>
        <entity id="DDI-DrugBank.d455.s7.e2" charOffset="107-116"
            type="drug" text="entacapone"/>
        <entity id="DDI-DrugBank.d455.s7.e3" charOffset="144-151"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d455.s7.e4" charOffset="153-180"
            type="group" text="dopa decarboxylase inhibitor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d455.s8" text="More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with entacapone and levodopa/dopa decarboxylase inhibitor.">
        <entity id="DDI-DrugBank.d455.s8.e0" charOffset="71-80"
            type="drug" text="selegiline"/>
        <entity id="DDI-DrugBank.d455.s8.e1" charOffset="102-111"
            type="drug" text="entacapone"/>
        <entity id="DDI-DrugBank.d455.s8.e2" charOffset="117-124"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d455.s8.e3" charOffset="126-153"
            type="group" text="dopa decarboxylase inhibitor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d455.s9" text="As most entacapone excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase are given concurrently with entacapone.">
        <entity id="DDI-DrugBank.d455.s9.e0" charOffset="8-17"
            type="drug" text="entacapone"/>
        <entity id="DDI-DrugBank.d455.s9.e1" charOffset="207-216"
            type="drug" text="entacapone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d455.s10" text="These include probenecid, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).">
        <entity id="DDI-DrugBank.d455.s10.e0" charOffset="14-23"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d455.s10.e1" charOffset="26-39"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d455.s10.e2" charOffset="51-61"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d455.s10.e3" charOffset="69-80"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d455.s10.e4" charOffset="96-105"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d455.s10.e5" charOffset="111-125"
            type="drug" text="chloramphenicol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d455.s11" text="No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.">
        <entity id="DDI-DrugBank.d455.s11.e0" charOffset="24-47"
            type="group" text="tricyclic antidepressant"/>
        <entity id="DDI-DrugBank.d455.s11.e1" charOffset="49-58"
            type="drug" text="imipramine"/>
        <entity id="DDI-DrugBank.d455.s11.e2" charOffset="98-107"
            type="drug" text="entacapone"/>
        <entity id="DDI-DrugBank.d455.s11.e3" charOffset="132-139"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d455.s11.e4" charOffset="141-168"
            type="group" text="dopa-decarboxylase inhibitor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d295.s0" text="Since entecavir is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.">
        <entity id="DDI-DrugBank.d295.s0.e0" charOffset="6-14"
            type="drug" text="entecavir"/>
        <entity id="DDI-DrugBank.d295.s0.e1" charOffset="76-84"
            type="brand" text="BARACLUDE"/>
        <entity id="DDI-DrugBank.d295.s0.e2" charOffset="208-216"
            type="drug" text="entecavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d295.s1" text="Coadministration of entecavir with lamivudine, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.">
        <entity id="DDI-DrugBank.d295.s1.e0" charOffset="20-28"
            type="drug" text="entecavir"/>
        <entity id="DDI-DrugBank.d295.s1.e1" charOffset="35-44"
            type="drug" text="lamivudine"/>
        <entity id="DDI-DrugBank.d295.s1.e2" charOffset="47-64"
            type="drug" text="adefovir dipivoxil"/>
        <entity id="DDI-DrugBank.d295.s1.e3" charOffset="69-97"
            type="drug" text="tenofovir disoproxil fumarate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d295.s2" text="The effects of coadministration of BARACLUDE with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when BARACLUDE is coadministered with such drugs.">
        <entity id="DDI-DrugBank.d295.s2.e0" charOffset="35-43"
            type="brand" text="BARACLUDE"/>
        <entity id="DDI-DrugBank.d295.s2.e1" charOffset="218-226"
            type="brand" text="BARACLUDE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d156.s0" text="None Reported"/>
    <sentence id="DDI-DrugBank.d247.s0" text="Epinephrine should be used cautiously in patients with hyperthyroidism, hypertension and cardiac arrhythmias.">
        <entity id="DDI-DrugBank.d247.s0.e0" charOffset="0-10"
            type="drug" text="Epinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d247.s1" text="All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.">
        <entity id="DDI-DrugBank.d247.s1.e0" charOffset="4-15"
            type="group" text="vasopressors"/>
        <entity id="DDI-DrugBank.d247.s1.e1" charOffset="62-95"
            type="group" text="monoamine oxidase (MAO) inhibitors"/>
        <ddi id="DDI-DrugBank.d247.s1.d0" e1="DDI-DrugBank.d247.s1.e0"
            e2="DDI-DrugBank.d247.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d247.s2" text="Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.">
        <entity id="DDI-DrugBank.d247.s2.e0" charOffset="0-10"
            type="drug" text="Epinephrine"/>
        <entity id="DDI-DrugBank.d247.s2.e1" charOffset="64-84"
            type="group" text="sympathomimetic drugs"/>
        <entity id="DDI-DrugBank.d247.s2.e2" charOffset="95-107"
            type="drug" text="isoproterenol"/>
        <ddi id="DDI-DrugBank.d247.s2.d0" e1="DDI-DrugBank.d247.s2.e0"
            e2="DDI-DrugBank.d247.s2.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d247.s2.d1" e1="DDI-DrugBank.d247.s2.e0"
            e2="DDI-DrugBank.d247.s2.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d247.s3" text="Combined effects may induce serious cardiac arrhythmias."/>
    <sentence id="DDI-DrugBank.d247.s4" text="They may be administered alternately when the preceding effect of other such drug has subsided."/>
    <sentence id="DDI-DrugBank.d247.s5" text="Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..">
        <entity id="DDI-DrugBank.d247.s5.e0" charOffset="18-28"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d247.s5.e1" charOffset="52-63"
            type="drug" text="cyclopropane"/>
        <entity id="DDI-DrugBank.d247.s5.e2" charOffset="68-110"
            type="group" text="halogenated hydrocarbon general anesthetics"/>
        <entity id="DDI-DrugBank.d247.s5.e3" charOffset="120-128"
            type="drug" text="halothane"/>
        <ddi id="DDI-DrugBank.d247.s5.d0" e1="DDI-DrugBank.d247.s5.e0"
            e2="DDI-DrugBank.d247.s5.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d247.s5.d1" e1="DDI-DrugBank.d247.s5.e0"
            e2="DDI-DrugBank.d247.s5.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d247.s5.d2" e1="DDI-DrugBank.d247.s5.e0"
            e2="DDI-DrugBank.d247.s5.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d247.s6" text="When encountered, such arrhythmias may respond to administration of a beta-adrenergic blocking drug.">
        <entity id="DDI-DrugBank.d247.s6.e0" charOffset="70-98"
            type="group" text="beta-adrenergic blocking drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d247.s7" text="Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.">
        <entity id="DDI-DrugBank.d247.s7.e0" charOffset="0-10"
            type="drug" text="Epinephrine"/>
        <entity id="DDI-DrugBank.d247.s7.e1" charOffset="67-75"
            type="group" text="digitalis"/>
        <entity id="DDI-DrugBank.d247.s7.e2" charOffset="78-87"
            type="group" text="glycosides"/>
        <entity id="DDI-DrugBank.d247.s7.e3" charOffset="138-158"
            type="group" text="sympathomimetic drugs"/>
        <ddi id="DDI-DrugBank.d247.s7.d0" e1="DDI-DrugBank.d247.s7.e0"
            e2="DDI-DrugBank.d247.s7.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d247.s7.d1" e1="DDI-DrugBank.d247.s7.e0"
            e2="DDI-DrugBank.d247.s7.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d247.s8" text="Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.">
        <entity id="DDI-DrugBank.d247.s8.e0" charOffset="0-14"
            type="group" text="Diuretic agents"/>
        <entity id="DDI-DrugBank.d247.s8.e1" charOffset="72-82"
            type="drug" text="epinephrine"/>
        <ddi id="DDI-DrugBank.d247.s8.d0" e1="DDI-DrugBank.d247.s8.e0"
            e2="DDI-DrugBank.d247.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d247.s9" text="Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.">
        <entity id="DDI-DrugBank.d247.s9.e0" charOffset="0-10"
            type="drug" text="Epinephrine"/>
        <entity id="DDI-DrugBank.d247.s9.e1" charOffset="59-70"
            type="drug" text="guanethidine"/>
        <ddi id="DDI-DrugBank.d247.s9.d0" e1="DDI-DrugBank.d247.s9.e0"
            e2="DDI-DrugBank.d247.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s0" text="ELLENCE when used in combination with other cytotoxic drugs may show on-treatment additive toxicity, especially hematologic and gastrointestinal effects.">
        <entity id="DDI-DrugBank.d428.s0.e0" charOffset="0-6"
            type="brand" text="ELLENCE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s1" text="Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.">
        <entity id="DDI-DrugBank.d428.s1.e0" charOffset="19-25"
            type="brand" text="ELLENCE"/>
        <entity id="DDI-DrugBank.d428.s1.e1" charOffset="99-122"
            type="group" text="calcium channel blockers"/>
        <ddi id="DDI-DrugBank.d428.s1.d0" e1="DDI-DrugBank.d428.s1.e0"
            e2="DDI-DrugBank.d428.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s2" text="There are few data regarding the coadministration of radiation therapy and epirubicin.">
        <entity id="DDI-DrugBank.d428.s2.e0" charOffset="75-84"
            type="drug" text="epirubicin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s3" text="In adjuvant trials of epirubicin-containing CEF-120 or FEC-100 chemotherapies, breast irradiation was delayed until after chemotherapy was completed.">
        <entity id="DDI-DrugBank.d428.s3.e0" charOffset="22-31"
            type="drug" text="epirubicin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s4" text="This practice resulted in no apparent increase in local breast cancer recurrence relative to published accounts in the literature."/>
    <sentence id="DDI-DrugBank.d428.s5" text="A small number of patients received epirubicin-based chemotherapy concomitantly with radiation therapy but had chemotherapy interrupted in order to avoid potential overlapping toxicities.">
        <entity id="DDI-DrugBank.d428.s5.e0" charOffset="36-45"
            type="drug" text="epirubicin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s6" text="It is likely that use of epirubicin with radiotherapy may sensitize tissues to the cytotoxic actions of irradiation.">
        <entity id="DDI-DrugBank.d428.s6.e0" charOffset="25-34"
            type="drug" text="epirubicin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s7" text="Administration of ELLENCE after previous radiation therapy may induce an inflammatory recall reaction at the site of the irradiation.">
        <entity id="DDI-DrugBank.d428.s7.e0" charOffset="18-24"
            type="brand" text="ELLENCE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s8" text="Epirubicin is extensively metabolized by the liver.">
        <entity id="DDI-DrugBank.d428.s8.e0" charOffset="0-9"
            type="drug" text="Epirubicin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s9" text="Changes in hepatic function induced by concomitant therapies may affect epirubicin metabolism, pharmacokinetics, therapeutic efficacy, and/or toxicity.">
        <entity id="DDI-DrugBank.d428.s9.e0" charOffset="72-81"
            type="drug" text="epirubicin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s10" text="Cimetidine increased the AUC of epirubicin by 50%.">
        <entity id="DDI-DrugBank.d428.s10.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d428.s10.e1" charOffset="32-41"
            type="drug" text="epirubicin"/>
        <ddi id="DDI-DrugBank.d428.s10.d0" e1="DDI-DrugBank.d428.s10.e0"
            e2="DDI-DrugBank.d428.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s11" text="Cimetidine treatment should be stopped during treatment with ELLENCE.">
        <entity id="DDI-DrugBank.d428.s11.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d428.s11.e1" charOffset="61-67"
            type="brand" text="ELLENCE"/>
        <ddi id="DDI-DrugBank.d428.s11.d0" e1="DDI-DrugBank.d428.s11.e0"
            e2="DDI-DrugBank.d428.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d428.s12" text="Drug-Laboratory Test Interactions There are no known interactions between ELLENCE and laboratory tests.">
        <entity id="DDI-DrugBank.d428.s12.e0" charOffset="74-80"
            type="brand" text="ELLENCE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s0" text="Inhibitors of CYP3A4-Eplerenone metabolism is predominantly mediated via CYP3A4.">
        <entity id="DDI-DrugBank.d20.s0.e0" charOffset="21-30"
            type="drug" text="Eplerenone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s1" text="A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.">
        <entity id="DDI-DrugBank.d20.s1.e0" charOffset="74-79"
            type="brand" text="INSPRA"/>
        <entity id="DDI-DrugBank.d20.s1.e1" charOffset="93-104"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d20.s1.e2" charOffset="198-207"
            type="drug" text="eplerenone"/>
        <entity id="DDI-DrugBank.d20.s1.e3" charOffset="243-252"
            type="drug" text="eplerenone"/>
        <ddi id="DDI-DrugBank.d20.s1.d0" e1="DDI-DrugBank.d20.s1.e0"
            e2="DDI-DrugBank.d20.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s2" text="INSPRA should not be used with drugs described as strong inhibitors of CYP3A4 in their labeling.">
        <entity id="DDI-DrugBank.d20.s2.e0" charOffset="0-5"
            type="brand" text="INSPRA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s3" text="Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.">
        <entity id="DDI-DrugBank.d20.s3.e0" charOffset="18-27"
            type="drug" text="eplerenone"/>
        <entity id="DDI-DrugBank.d20.s3.e1" charOffset="65-76"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d20.s3.e2" charOffset="90-98"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d20.s3.e3" charOffset="111-120"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d20.s3.e4" charOffset="135-145"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d20.s3.e5" charOffset="191-200"
            type="drug" text="eplerenone"/>
        <ddi id="DDI-DrugBank.d20.s3.d0" e1="DDI-DrugBank.d20.s3.e0"
            e2="DDI-DrugBank.d20.s3.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d20.s3.d1" e1="DDI-DrugBank.d20.s3.e0"
            e2="DDI-DrugBank.d20.s3.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d20.s3.d2" e1="DDI-DrugBank.d20.s3.e0"
            e2="DDI-DrugBank.d20.s3.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d20.s3.d3" e1="DDI-DrugBank.d20.s3.e0"
            e2="DDI-DrugBank.d20.s3.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s4" text="ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).">
        <entity id="DDI-DrugBank.d20.s4.e0" charOffset="0-13"
            type="group" text="ACE Inhibitors"/>
        <entity id="DDI-DrugBank.d20.s4.e1" charOffset="19-53"
            type="group" text="Angiotensin II Receptor Antagonists"/>
        <entity id="DDI-DrugBank.d20.s4.e2" charOffset="152-157"
            type="brand" text="INSPRA"/>
        <entity id="DDI-DrugBank.d20.s4.e3" charOffset="185-198"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d20.s4.e4" charOffset="203-237"
            type="group" text="angiotensin II receptor antagonists"/>
        <entity id="DDI-DrugBank.d20.s4.e5" charOffset="240-243"
            type="group" text="ACEI"/>
        <entity id="DDI-DrugBank.d20.s4.e6" charOffset="245-247"
            type="group" text="ARB"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s5" text="Rates of patients with maximum potassium levels  5.5 mEq/L were similar regardless of the use of ACEI/ARB.">
        <entity id="DDI-DrugBank.d20.s5.e0" charOffset="97-100"
            type="group" text="ACEI"/>
        <entity id="DDI-DrugBank.d20.s5.e1" charOffset="102-104"
            type="group" text="ARB"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s6" text="ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).">
        <entity id="DDI-DrugBank.d20.s6.e0" charOffset="0-13"
            type="group" text="ACE Inhibitors"/>
        <entity id="DDI-DrugBank.d20.s6.e1" charOffset="19-53"
            type="group" text="Angiotensin II Receptor Antagonists"/>
        <entity id="DDI-DrugBank.d20.s6.e2" charOffset="138-143"
            type="brand" text="INSPRA"/>
        <entity id="DDI-DrugBank.d20.s6.e3" charOffset="161-174"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d20.s6.e4" charOffset="180-214"
            type="group" text="angiotensin II receptor antagonists"/>
        <ddi id="DDI-DrugBank.d20.s6.d0" e1="DDI-DrugBank.d20.s6.e2"
            e2="DDI-DrugBank.d20.s6.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d20.s6.d1" e1="DDI-DrugBank.d20.s6.e2"
            e2="DDI-DrugBank.d20.s6.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s7" text="In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.">
        <entity id="DDI-DrugBank.d20.s7.e0" charOffset="46-51"
            type="brand" text="INSPRA"/>
        <entity id="DDI-DrugBank.d20.s7.e1" charOffset="78-90"
            type="group" text="ACE inhibitor"/>
        <entity id="DDI-DrugBank.d20.s7.e2" charOffset="92-100"
            type="drug" text="enalapril"/>
        <entity id="DDI-DrugBank.d20.s7.e3" charOffset="189-197"
            type="drug" text="enalapril"/>
        <ddi id="DDI-DrugBank.d20.s7.d0" e1="DDI-DrugBank.d20.s7.e0"
            e2="DDI-DrugBank.d20.s7.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s8" text="Lithium-A drug interaction study of eplerenone with lithium has not been conducted.">
        <entity id="DDI-DrugBank.d20.s8.e0" charOffset="0-6" type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d20.s8.e1" charOffset="36-45"
            type="drug" text="eplerenone"/>
        <entity id="DDI-DrugBank.d20.s8.e2" charOffset="52-58"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s9" text="Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.">
        <entity id="DDI-DrugBank.d20.s9.e0" charOffset="6-12"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d20.s9.e1" charOffset="55-60"
            type="brand" text="INSPRA"/>
        <entity id="DDI-DrugBank.d20.s9.e2" charOffset="97-103"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d20.s9.d0" e1="DDI-DrugBank.d20.s9.e1"
            e2="DDI-DrugBank.d20.s9.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s10" text="Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of eplerenone with an NSAID has not been conducted.">
        <entity id="DDI-DrugBank.d20.s10.e0" charOffset="0-35"
            type="group" text="Nonsteroidal Anti-Inflammatory Drugs"/>
        <entity id="DDI-DrugBank.d20.s10.e1" charOffset="38-43"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d20.s10.e2" charOffset="74-83"
            type="drug" text="eplerenone"/>
        <entity id="DDI-DrugBank.d20.s10.e3" charOffset="93-97"
            type="group" text="NSAID"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s11" text="The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.">
        <entity id="DDI-DrugBank.d20.s11.e0" charOffset="28-62"
            type="group" text="potassium-sparing antihypertensives"/>
        <entity id="DDI-DrugBank.d20.s11.e1" charOffset="69-74"
            type="group" text="NSAIDs"/>
        <ddi id="DDI-DrugBank.d20.s11.d0" e1="DDI-DrugBank.d20.s11.e0"
            e2="DDI-DrugBank.d20.s11.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d20.s12" text="Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.">
        <entity id="DDI-DrugBank.d20.s12.e0" charOffset="16-21"
            type="brand" text="INSPRA"/>
        <entity id="DDI-DrugBank.d20.s12.e1" charOffset="27-32"
            type="group" text="NSAIDs"/>
        <ddi id="DDI-DrugBank.d20.s12.d0" e1="DDI-DrugBank.d20.s12.e0"
            e2="DDI-DrugBank.d20.s12.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d496.s0" text="No evidence of interaction of PROCRIT with other drugs was observed in the course of clinical trials.">
        <entity id="DDI-DrugBank.d496.s0.e0" charOffset="30-36"
            type="brand" text="PROCRIT"/>
    </sentence>
    <sentence id="DDI-DrugBank.d241.s0" text="Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.">
        <entity id="DDI-DrugBank.d241.s0.e0" charOffset="55-60"
            type="brand" text="FLOLAN"/>
        <entity id="DDI-DrugBank.d241.s0.e1" charOffset="83-91"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d241.s0.e2" charOffset="94-116"
            type="group" text="antihypertensive agents"/>
        <entity id="DDI-DrugBank.d241.s0.e3" charOffset="128-139"
            type="group" text="vasodilators"/>
        <ddi id="DDI-DrugBank.d241.s0.d0" e1="DDI-DrugBank.d241.s0.e0"
            e2="DDI-DrugBank.d241.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d241.s0.d1" e1="DDI-DrugBank.d241.s0.e0"
            e2="DDI-DrugBank.d241.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d241.s0.d2" e1="DDI-DrugBank.d241.s0.e0"
            e2="DDI-DrugBank.d241.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d241.s1" text="When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.">
        <entity id="DDI-DrugBank.d241.s1.e0" charOffset="11-29"
            type="group" text="antiplatelet agents"/>
        <entity id="DDI-DrugBank.d241.s1.e1" charOffset="34-47"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d241.s1.e2" charOffset="100-105"
            type="brand" text="FLOLAN"/>
        <ddi id="DDI-DrugBank.d241.s1.d0" e1="DDI-DrugBank.d241.s1.e0"
            e2="DDI-DrugBank.d241.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d241.s1.d1" e1="DDI-DrugBank.d241.s1.e1"
            e2="DDI-DrugBank.d241.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d241.s2" text="However, patients receiving infusions of FLOLAN in clinical trials were maintained on anticoagulants without evidence of increased bleeding.">
        <entity id="DDI-DrugBank.d241.s2.e0" charOffset="41-46"
            type="brand" text="FLOLAN"/>
        <entity id="DDI-DrugBank.d241.s2.e1" charOffset="86-99"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d241.s3" text="In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.">
        <entity id="DDI-DrugBank.d241.s3.e0" charOffset="20-25"
            type="brand" text="FLOLAN"/>
        <entity id="DDI-DrugBank.d241.s3.e1" charOffset="41-47"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d241.s3.e2" charOffset="50-58"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d241.s3.e3" charOffset="61-74"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d241.s3.e4" charOffset="82-93"
            type="group" text="vasodilators"/>
        <entity id="DDI-DrugBank.d241.s3.e5" charOffset="113-118"
            type="drug" text="oxygen"/>
        <entity id="DDI-DrugBank.d241.s3.e6" charOffset="202-211"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d241.s3.e7" charOffset="216-222"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d241.s3.e8" charOffset="245-250"
            type="brand" text="FLOLAN"/>
        <entity id="DDI-DrugBank.d241.s3.e9" charOffset="302-311"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d241.s3.e10" charOffset="326-332"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d241.s3.d0" e1="DDI-DrugBank.d241.s3.e6"
            e2="DDI-DrugBank.d241.s3.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d241.s3.d1" e1="DDI-DrugBank.d241.s3.e7"
            e2="DDI-DrugBank.d241.s3.e8" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d241.s4" text="The change in furosemide clearance value is not likely to be clinically significant.">
        <entity id="DDI-DrugBank.d241.s4.e0" charOffset="14-23"
            type="drug" text="furosemide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d241.s5" text="However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.">
        <entity id="DDI-DrugBank.d241.s5.e0" charOffset="21-27"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d241.s5.e1" charOffset="52-58"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d241.s5.e2" charOffset="108-113"
            type="brand" text="FLOLAN"/>
        <entity id="DDI-DrugBank.d241.s5.e3" charOffset="173-179"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d241.s5.d0" e1="DDI-DrugBank.d241.s5.e0"
            e2="DDI-DrugBank.d241.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d525.s0" text="Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide.">
        <entity id="DDI-DrugBank.d525.s0.e0" charOffset="0-9"
            type="drug" text="Eprosartan"/>
        <entity id="DDI-DrugBank.d525.s0.e1" charOffset="71-77"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d525.s0.e2" charOffset="107-114"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d525.s0.e3" charOffset="120-128"
            type="drug" text="glyburide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d525.s1" text="Thus no dosing adjustments are necessary during concomitant use with these agents."/>
    <sentence id="DDI-DrugBank.d525.s2" text="Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.">
        <entity id="DDI-DrugBank.d525.s2.e0" charOffset="8-17"
            type="drug" text="eprosartan"/>
        <entity id="DDI-DrugBank.d525.s2.e1" charOffset="149-160"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d525.s2.e2" charOffset="166-176"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d525.s2.e3" charOffset="266-275"
            type="drug" text="eprosartan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d525.s3" text="Ranitidine also has no effect on eprosartan pharmacokinetics.">
        <entity id="DDI-DrugBank.d525.s3.e0" charOffset="0-9"
            type="drug" text="Ranitidine"/>
        <entity id="DDI-DrugBank.d525.s3.e1" charOffset="33-42"
            type="drug" text="eprosartan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d525.s4" text="Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide).">
        <entity id="DDI-DrugBank.d525.s4.e0" charOffset="0-9"
            type="drug" text="Eprosartan"/>
        <entity id="DDI-DrugBank.d525.s4.e1" charOffset="97-113"
            type="group" text="thiazide diuretic"/>
        <entity id="DDI-DrugBank.d525.s4.e2" charOffset="116-134"
            type="drug" text="hydrochlorothiazide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d525.s5" text="Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions.">
        <entity id="DDI-DrugBank.d525.s5.e0" charOffset="0-9"
            type="drug" text="Eprosartan"/>
        <entity id="DDI-DrugBank.d525.s5.e1" charOffset="99-122"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d525.s5.e2" charOffset="143-152"
            type="drug" text="nifedipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d278.s0" text="Enoxaparin dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of eptifibatide or the level of platelet aggregation in healthy adults.">
        <entity id="DDI-DrugBank.d278.s0.e0" charOffset="0-9"
            type="drug" text="Enoxaparin"/>
        <entity id="DDI-DrugBank.d278.s0.e1" charOffset="113-124"
            type="drug" text="eptifibatide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d471.s0" text="Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.">
        <entity id="DDI-DrugBank.d471.s0.e0" charOffset="0-10"
            type="drug" text="Mineral oil"/>
        <entity id="DDI-DrugBank.d471.s0.e1" charOffset="46-65"
            type="group" text="fat-soluble vitamins"/>
        <entity id="DDI-DrugBank.d471.s0.e2" charOffset="78-99"
            type="group" text="vitamin D preparations"/>
        <ddi id="DDI-DrugBank.d471.s0.d0" e1="DDI-DrugBank.d471.s0.e0"
            e2="DDI-DrugBank.d471.s0.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d471.s0.d1" e1="DDI-DrugBank.d471.s0.e0"
            e2="DDI-DrugBank.d471.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d471.s1" text="Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.">
        <entity id="DDI-DrugBank.d471.s1.e0" charOffset="18-35"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d471.s1.e1" charOffset="105-118"
            type="drug" text="ergocalciferol"/>
        <ddi id="DDI-DrugBank.d471.s1.d0" e1="DDI-DrugBank.d471.s1.e0"
            e2="DDI-DrugBank.d471.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d201.s0" text="No reported interactions."/>
    <sentence id="DDI-DrugBank.d59.s0" text="The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.">
        <entity id="DDI-DrugBank.d59.s0.e0" charOffset="15-21"
            type="brand" text="ERGOMAR"/>
        <entity id="DDI-DrugBank.d59.s0.e1" charOffset="45-65"
            type="drug" text="triacetyloleandomycin"/>
        <entity id="DDI-DrugBank.d59.s0.e2" charOffset="100-109"
            type="drug" text="ergotamine"/>
        <ddi id="DDI-DrugBank.d59.s0.d0" e1="DDI-DrugBank.d59.s0.e0"
            e2="DDI-DrugBank.d59.s0.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d59.s0.d1" e1="DDI-DrugBank.d59.s0.e1"
            e2="DDI-DrugBank.d59.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d59.s1" text="The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.">
        <entity id="DDI-DrugBank.d59.s1.e0" charOffset="23-29"
            type="brand" text="ERGOMAR"/>
        <entity id="DDI-DrugBank.d59.s1.e1" charOffset="41-61"
            type="group" text="vasoconstrictor drugs"/>
        <ddi id="DDI-DrugBank.d59.s1.d0" e1="DDI-DrugBank.d59.s1.e0"
            e2="DDI-DrugBank.d59.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s0" text="Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.">
        <entity id="DDI-DrugBank.d456.s0.e0" charOffset="46-57"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d456.s0.e1" charOffset="69-77"
            type="drug" text="erlotinib"/>
        <ddi id="DDI-DrugBank.d456.s0.d0" e1="DDI-DrugBank.d456.s0.e0"
            e2="DDI-DrugBank.d456.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s1" text="Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .">
        <entity id="DDI-DrugBank.d456.s1.e0" charOffset="52-58"
            type="brand" text="TARCEVA"/>
        <entity id="DDI-DrugBank.d456.s1.e1" charOffset="65-76"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d456.s1.e2" charOffset="142-151"
            type="drug" text="atazanavir"/>
        <entity id="DDI-DrugBank.d456.s1.e3" charOffset="154-167"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d456.s1.e4" charOffset="170-178"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d456.s1.e5" charOffset="181-192"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d456.s1.e6" charOffset="195-204"
            type="drug" text="nefazodone"/>
        <entity id="DDI-DrugBank.d456.s1.e7" charOffset="207-216"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d456.s1.e8" charOffset="219-227"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d456.s1.e9" charOffset="230-239"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d456.s1.e10" charOffset="242-254"
            type="drug" text="telithromycin"/>
        <entity id="DDI-DrugBank.d456.s1.e11" charOffset="257-270"
            type="drug" text="troleandomycin"/>
        <entity id="DDI-DrugBank.d456.s1.e12" charOffset="273-275"
            type="drug" text="TAO"/>
        <entity id="DDI-DrugBank.d456.s1.e13" charOffset="283-294"
            type="drug" text="voriconazole"/>
        <ddi id="DDI-DrugBank.d456.s1.d0" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d1" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d2" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d3" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d4" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d5" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d6" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d7" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d8" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d9" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e10" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d10" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d11" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e12" type="advise"/>
        <ddi id="DDI-DrugBank.d456.s1.d12" e1="DDI-DrugBank.d456.s1.e0"
            e2="DDI-DrugBank.d456.s1.e13" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s2" text="Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.">
        <entity id="DDI-DrugBank.d456.s2.e0" charOffset="38-47"
            type="drug" text="rifampicin"/>
        <entity id="DDI-DrugBank.d456.s2.e1" charOffset="59-67"
            type="drug" text="erlotinib"/>
        <ddi id="DDI-DrugBank.d456.s2.d0" e1="DDI-DrugBank.d456.s2.e0"
            e2="DDI-DrugBank.d456.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s3" text="Alternate treatments lacking CYP3A4 inducing activity should be considered."/>
    <sentence id="DDI-DrugBank.d456.s4" text="If an alternative treatment is unavailable, a TARCEVA dose greater than 150 mg should be considered for NSCLC patients, and greater than 100 mg considered for pancreatic cancer patients.">
        <entity id="DDI-DrugBank.d456.s4.e0" charOffset="46-52"
            type="brand" text="TARCEVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s5" text="If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.">
        <entity id="DDI-DrugBank.d456.s5.e0" charOffset="7-13"
            type="brand" text="TARCEVA"/>
        <entity id="DDI-DrugBank.d456.s5.e1" charOffset="97-106"
            type="drug" text="rifampicin"/>
        <ddi id="DDI-DrugBank.d456.s5.d0" e1="DDI-DrugBank.d456.s5.e0"
            e2="DDI-DrugBank.d456.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s6" text="Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and St. Johns Wort.">
        <entity id="DDI-DrugBank.d456.s6.e0" charOffset="55-63"
            type="drug" text="rifabutin"/>
        <entity id="DDI-DrugBank.d456.s6.e1" charOffset="66-76"
            type="drug" text="rifapentine"/>
        <entity id="DDI-DrugBank.d456.s6.e2" charOffset="79-87"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d456.s6.e3" charOffset="90-102"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d456.s6.e4" charOffset="105-117"
            type="drug" text="phenobarbital"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s7" text="Hepatotoxicity Asymptomatic increases in liver transaminases have been observed in TARCEVA treated patients;">
        <entity id="DDI-DrugBank.d456.s7.e0" charOffset="83-89"
            type="brand" text="TARCEVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s8" text="therefore, periodic liver function testing (transaminases, bilirubin, and alkaline phosphatase) should be considered."/>
    <sentence id="DDI-DrugBank.d456.s9" text="Dose reduction or interruption of TARCEVA should be considered if changes in liver function are severe.">
        <entity id="DDI-DrugBank.d456.s9.e0" charOffset="34-40"
            type="brand" text="TARCEVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s10" text="Patients with Hepatic Impairment In vitro and in vivo evidence suggest that erlotinib is cleared primarily by the liver.">
        <entity id="DDI-DrugBank.d456.s10.e0" charOffset="76-84"
            type="drug" text="erlotinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s11" text="Therefore, erlotinib exposure may be increased in patients with hepatic dysfunction.">
        <entity id="DDI-DrugBank.d456.s11.e0" charOffset="11-19"
            type="drug" text="erlotinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s12" text="Elevated International Normalized Ratio and Potential Bleeding International Normalized Ratio (INR) elevations and infrequent reports of bleeding events including gastrointestinal and non-gastrointestinal bleedings have been reported in clinical studies, some associated with concomitant warfarin administration.">
        <entity id="DDI-DrugBank.d456.s12.e0" charOffset="288-295"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s13" text="Patients taking warfarin or other coumarin-derivative anticoagulants should be monitored regularly for changes in prothrombin time or INR">
        <entity id="DDI-DrugBank.d456.s13.e0" charOffset="16-23"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d456.s13.e1" charOffset="34-67"
            type="group" text="coumarin-derivative anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d456.s14" text="."/>
    <sentence id="DDI-DrugBank.d456.s15" text=""/>
    <sentence id="DDI-DrugBank.d329.s0" text="When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.">
        <entity id="DDI-DrugBank.d329.s0.e0" charOffset="5-13"
            type="drug" text="ertapenem"/>
        <entity id="DDI-DrugBank.d329.s0.e1" charOffset="39-48"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d329.s0.e2" charOffset="79-88"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d329.s0.e3" charOffset="163-171"
            type="drug" text="ertapenem"/>
        <ddi id="DDI-DrugBank.d329.s0.d0" e1="DDI-DrugBank.d329.s0.e2"
            e2="DDI-DrugBank.d329.s0.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d329.s1" text="Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.">
        <entity id="DDI-DrugBank.d329.s1.e0" charOffset="15-23"
            type="drug" text="ertapenem"/>
        <entity id="DDI-DrugBank.d329.s1.e1" charOffset="41-50"
            type="drug" text="probenecid"/>
        <ddi id="DDI-DrugBank.d329.s1.d0" e1="DDI-DrugBank.d329.s1.e0"
            e2="DDI-DrugBank.d329.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d329.s2" text="The half-life increased from 4.0 to 4.8 hours."/>
    <sentence id="DDI-DrugBank.d329.s3" text="Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.">
        <entity id="DDI-DrugBank.d329.s3.e0" charOffset="68-77"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d329.s3.e1" charOffset="106-114"
            type="drug" text="ertapenem"/>
        <ddi id="DDI-DrugBank.d329.s3.d0" e1="DDI-DrugBank.d329.s3.e0"
            e2="DDI-DrugBank.d329.s3.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d329.s4" text="In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.">
        <entity id="DDI-DrugBank.d329.s4.e0" charOffset="31-39"
            type="drug" text="ertapenem"/>
        <entity id="DDI-DrugBank.d329.s4.e1" charOffset="95-101"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d329.s4.e2" charOffset="106-116"
            type="drug" text="vinblastine"/>
        <entity id="DDI-DrugBank.d329.s4.e3" charOffset="127-135"
            type="drug" text="ertapenem"/>
    </sentence>
    <sentence id="DDI-DrugBank.d329.s5" text="In vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the following six cytochrome p450 (CYP) isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.">
        <entity id="DDI-DrugBank.d329.s5.e0" charOffset="57-65"
            type="drug" text="ertapenem"/>
    </sentence>
    <sentence id="DDI-DrugBank.d329.s6" text="Drug interactions caused by inhibition of P-glycoprotein-mediated drug clearance or CYP-mediated drug clearance with the listed isoforms are unlikely."/>
    <sentence id="DDI-DrugBank.d329.s7" text="Other than with probenecid, no specific clinical drug interaction studies have been conducted">
        <entity id="DDI-DrugBank.d329.s7.e0" charOffset="16-25"
            type="drug" text="probenecid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d329.s8" text="."/>
    <sentence id="DDI-DrugBank.d329.s9" text=""/>
    <sentence id="DDI-DrugBank.d397.s0" text="Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.">
        <entity id="DDI-DrugBank.d397.s0.e0" charOffset="0-11"
            type="drug" text="Erythromycin"/>
        <entity id="DDI-DrugBank.d397.s0.e1" charOffset="61-72"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d397.s0.e2" charOffset="118-129"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d397.s0.e3" charOffset="152-163"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d397.s0.d0" e1="DDI-DrugBank.d397.s0.e0"
            e2="DDI-DrugBank.d397.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s1" text="In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.">
        <entity id="DDI-DrugBank.d397.s1.e0" charOffset="11-22"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d397.s1.e1" charOffset="55-66"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d397.s1.e2" charOffset="88-99"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d397.s1.e3" charOffset="162-173"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d397.s1.d0" e1="DDI-DrugBank.d397.s1.e2"
            e2="DDI-DrugBank.d397.s1.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s2" text="Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.">
        <entity id="DDI-DrugBank.d397.s2.e0" charOffset="30-41"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d397.s2.e1" charOffset="47-53"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d397.s2.e2" charOffset="95-101"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d397.s2.d0" e1="DDI-DrugBank.d397.s2.e0"
            e2="DDI-DrugBank.d397.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s3" text="There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.">
        <entity id="DDI-DrugBank.d397.s3.e0" charOffset="64-75"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d397.s3.e1" charOffset="86-99"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d397.s3.d0" e1="DDI-DrugBank.d397.s3.e0"
            e2="DDI-DrugBank.d397.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s4" text="Increased anticoagulation effects due to interactions of erythromycin with various oral anticoagulents may be more pronounced in the elderly.">
        <entity id="DDI-DrugBank.d397.s4.e0" charOffset="57-68"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s5" text="Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.">
        <entity id="DDI-DrugBank.d397.s5.e0" charOffset="18-29"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d397.s5.e1" charOffset="35-44"
            type="drug" text="ergotamine"/>
        <entity id="DDI-DrugBank.d397.s5.e2" charOffset="49-65"
            type="drug" text="dihydroergotamine"/>
        <ddi id="DDI-DrugBank.d397.s5.d0" e1="DDI-DrugBank.d397.s5.e0"
            e2="DDI-DrugBank.d397.s5.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d397.s5.d1" e1="DDI-DrugBank.d397.s5.e0"
            e2="DDI-DrugBank.d397.s5.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s6" text="Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.">
        <entity id="DDI-DrugBank.d397.s6.e0" charOffset="0-11"
            type="drug" text="Erythromycin"/>
        <entity id="DDI-DrugBank.d397.s6.e1" charOffset="60-68"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d397.s6.e2" charOffset="74-82"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d397.s6.e3" charOffset="140-154"
            type="group" text="benzodiazepines"/>
        <ddi id="DDI-DrugBank.d397.s6.d0" e1="DDI-DrugBank.d397.s6.e0"
            e2="DDI-DrugBank.d397.s6.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d397.s6.d1" e1="DDI-DrugBank.d397.s6.e0"
            e2="DDI-DrugBank.d397.s6.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d397.s6.d2" e1="DDI-DrugBank.d397.s6.e0"
            e2="DDI-DrugBank.d397.s6.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s7" text="The use of erythromycin in patients concurrently taking drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these other drugs.">
        <entity id="DDI-DrugBank.d397.s7.e0" charOffset="11-22"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s8" text="There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.">
        <entity id="DDI-DrugBank.d397.s8.e0" charOffset="43-54"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d397.s8.e1" charOffset="61-73"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d397.s8.e2" charOffset="76-87"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d397.s8.e3" charOffset="90-99"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d397.s8.e4" charOffset="102-113"
            type="drug" text="hexobarbital"/>
        <entity id="DDI-DrugBank.d397.s8.e5" charOffset="116-124"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d397.s8.e6" charOffset="127-136"
            type="drug" text="alfentanil"/>
        <entity id="DDI-DrugBank.d397.s8.e7" charOffset="139-147"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d397.s8.e8" charOffset="150-161"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d397.s8.e9" charOffset="164-173"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d397.s8.e10" charOffset="176-188"
            type="drug" text="bromocriptine"/>
        <entity id="DDI-DrugBank.d397.s8.e11" charOffset="191-199"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d397.s8.e12" charOffset="202-212"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d397.s8.e13" charOffset="219-228"
            type="drug" text="astemizole"/>
        <ddi id="DDI-DrugBank.d397.s8.d0" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e1" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d1" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e2" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d2" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e3" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d3" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e4" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d4" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e5" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d5" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e6" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d6" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e7" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d7" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e8" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d8" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e9" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d9" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e10" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d10" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e11" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d11" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e12" type="int"/>
        <ddi id="DDI-DrugBank.d397.s8.d12" e1="DDI-DrugBank.d397.s8.e0"
            e2="DDI-DrugBank.d397.s8.e13" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s9" text="Serum concentrations of drugs metabolized by the cytochrome P450 system should be monitored closely in patients concurrently receiving erythromycin.">
        <entity id="DDI-DrugBank.d397.s9.e0" charOffset="135-146"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s10" text="Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.">
        <entity id="DDI-DrugBank.d397.s10.e0" charOffset="0-11"
            type="drug" text="Erythromycin"/>
        <entity id="DDI-DrugBank.d397.s10.e1" charOffset="84-97"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d397.s10.e2" charOffset="99-109"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d397.s10.e3" charOffset="115-124"
            type="drug" text="astemizole"/>
        <ddi id="DDI-DrugBank.d397.s10.d0" e1="DDI-DrugBank.d397.s10.e0"
            e2="DDI-DrugBank.d397.s10.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d397.s10.d1" e1="DDI-DrugBank.d397.s10.e0"
            e2="DDI-DrugBank.d397.s10.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s11" text="Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QTc interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias have been observed."/>
    <sentence id="DDI-DrugBank.d397.s12" text="In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.">
        <entity id="DDI-DrugBank.d397.s12.e0" charOffset="81-91"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d397.s12.e1" charOffset="97-108"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d397.s12.d0" e1="DDI-DrugBank.d397.s12.e0"
            e2="DDI-DrugBank.d397.s12.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s13" text="There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.">
        <entity id="DDI-DrugBank.d397.s13.e0" charOffset="64-75"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d397.s13.e1" charOffset="100-108"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d397.s13.e2" charOffset="289-297"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d397.s13.e3" charOffset="302-313"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d397.s13.d0" e1="DDI-DrugBank.d397.s13.e0"
            e2="DDI-DrugBank.d397.s13.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d397.s13.d1" e1="DDI-DrugBank.d397.s13.e2"
            e2="DDI-DrugBank.d397.s13.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s14" text="Fatalities have been reported."/>
    <sentence id="DDI-DrugBank.d397.s15" text="Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;">
        <entity id="DDI-DrugBank.d397.s15.e0" charOffset="31-40"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d397.s15.e1" charOffset="46-57"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d397.s15.d0" e1="DDI-DrugBank.d397.s15.e0"
            e2="DDI-DrugBank.d397.s15.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d397.s16" text="cases of rhabdomyolysis have been reported in seriously ill patients."/>
    <sentence id="DDI-DrugBank.d568.s0" text="CNS Drugs - Given the primary CNS effects of escitalopram, caution should be used when it is taken in combination with other centrally acting drugs.">
        <entity id="DDI-DrugBank.d568.s0.e0" charOffset="45-56"
            type="drug" text="escitalopram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s1" text="Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.">
        <entity id="DDI-DrugBank.d568.s1.e0" charOffset="0-6"
            type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d568.s1.e1" charOffset="19-25"
            type="brand" text="LEXAPRO"/>
        <entity id="DDI-DrugBank.d568.s1.e2" charOffset="81-87"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d568.s1.e3" charOffset="124-147"
            type="group" text="psychotropic medications"/>
        <entity id="DDI-DrugBank.d568.s1.e4" charOffset="161-167"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d568.s1.e5" charOffset="188-194"
            type="brand" text="LEXAPRO"/>
        <ddi id="DDI-DrugBank.d568.s1.d0" e1="DDI-DrugBank.d568.s1.e3"
            e2="DDI-DrugBank.d568.s1.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d568.s1.d1" e1="DDI-DrugBank.d568.s1.e4"
            e2="DDI-DrugBank.d568.s1.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s2" text="Monoamine Oxidase Inhibitors (MAOIs)">
        <entity id="DDI-DrugBank.d568.s2.e0" charOffset="0-27"
            type="group" text="Monoamine Oxidase Inhibitors"/>
        <entity id="DDI-DrugBank.d568.s2.e1" charOffset="30-34"
            type="group" text="MAOIs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s3" text="Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)">
        <entity id="DDI-DrugBank.d568.s3.e0" charOffset="38-43"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d568.s3.e1" charOffset="46-52"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d568.s3.e2" charOffset="55-62"
            type="drug" text="Warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s4" text="Serotonin release by platelets plays an important role in hemostasis."/>
    <sentence id="DDI-DrugBank.d568.s5" text="Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.">
        <entity id="DDI-DrugBank.d568.s5.e0" charOffset="115-132"
            type="group" text="psychotropic drugs"/>
        <entity id="DDI-DrugBank.d568.s5.e1" charOffset="269-273"
            type="group" text="NSAID"/>
        <entity id="DDI-DrugBank.d568.s5.e2" charOffset="278-284"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d568.s5.d0" e1="DDI-DrugBank.d568.s5.e0"
            e2="DDI-DrugBank.d568.s5.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d568.s5.d1" e1="DDI-DrugBank.d568.s5.e0"
            e2="DDI-DrugBank.d568.s5.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s6" text="Thus, patients should be cautioned about the use of such drugs concurrently with LEXAPRO.">
        <entity id="DDI-DrugBank.d568.s6.e0" charOffset="81-87"
            type="brand" text="LEXAPRO"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s7" text="Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.">
        <entity id="DDI-DrugBank.d568.s7.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d568.s7.e1" charOffset="71-80"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s7.e2" charOffset="121-130"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d568.s7.e3" charOffset="170-179"
            type="drug" text="citalopram"/>
        <ddi id="DDI-DrugBank.d568.s7.d0" e1="DDI-DrugBank.d568.s7.e1"
            e2="DDI-DrugBank.d568.s7.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s8" text="The clinical significance of these findings is unknown."/>
    <sentence id="DDI-DrugBank.d568.s9" text="Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.">
        <entity id="DDI-DrugBank.d568.s9.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d568.s9.e1" charOffset="68-77"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s9.e2" charOffset="107-116"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s9.e3" charOffset="122-128"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d568.s9.e4" charOffset="212-221"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s9.e5" charOffset="226-232"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s10" text="Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.">
        <entity id="DDI-DrugBank.d568.s10.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d568.s10.e1" charOffset="38-47"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s10.e2" charOffset="77-83"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d568.s10.e3" charOffset="163-172"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s10.e4" charOffset="177-183"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s11" text="Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.">
        <entity id="DDI-DrugBank.d568.s11.e0" charOffset="21-27"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d568.s11.e1" charOffset="91-97"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s12" text="Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.">
        <entity id="DDI-DrugBank.d568.s12.e0" charOffset="8-14"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d568.s12.e1" charOffset="56-67"
            type="drug" text="escitalopram"/>
        <entity id="DDI-DrugBank.d568.s12.e2" charOffset="103-109"
            type="brand" text="LEXAPRO"/>
        <entity id="DDI-DrugBank.d568.s12.e3" charOffset="115-121"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d568.s12.d0" e1="DDI-DrugBank.d568.s12.e0"
            e2="DDI-DrugBank.d568.s12.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d568.s12.d1" e1="DDI-DrugBank.d568.s12.e2"
            e2="DDI-DrugBank.d568.s12.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s13" text="Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.">
        <entity id="DDI-DrugBank.d568.s13.e0" charOffset="0-7"
            type="drug" text="Pimozide"/>
        <entity id="DDI-DrugBank.d568.s13.e1" charOffset="13-18"
            type="brand" text="Celexa"/>
        <entity id="DDI-DrugBank.d568.s13.e2" charOffset="62-69"
            type="drug" text="pimozide"/>
        <entity id="DDI-DrugBank.d568.s13.e3" charOffset="105-114"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s13.e4" charOffset="238-245"
            type="drug" text="pimozide"/>
        <ddi id="DDI-DrugBank.d568.s13.d0" e1="DDI-DrugBank.d568.s13.e2"
            e2="DDI-DrugBank.d568.s13.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s14" text="Racemic citalopram did not alter the mean AUC or Cmax of pimozide.">
        <entity id="DDI-DrugBank.d568.s14.e0" charOffset="8-17"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s14.e1" charOffset="57-64"
            type="drug" text="pimozide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s15" text="The mechanism of this pharmacodynamic interaction is not known."/>
    <sentence id="DDI-DrugBank.d568.s16" text="Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.">
        <entity id="DDI-DrugBank.d568.s16.e0" charOffset="0-10"
            type="drug" text="Sumatriptan"/>
        <entity id="DDI-DrugBank.d568.s16.e1" charOffset="149-186"
            type="group" text="selective serotonin reuptake inhibitor"/>
        <entity id="DDI-DrugBank.d568.s16.e2" charOffset="189-192"
            type="group" text="SSRI"/>
        <entity id="DDI-DrugBank.d568.s16.e3" charOffset="199-209"
            type="drug" text="sumatriptan"/>
        <ddi id="DDI-DrugBank.d568.s16.d0" e1="DDI-DrugBank.d568.s16.e1"
            e2="DDI-DrugBank.d568.s16.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d568.s16.d1" e1="DDI-DrugBank.d568.s16.e2"
            e2="DDI-DrugBank.d568.s16.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s17" text="If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.">
        <entity id="DDI-DrugBank.d568.s17.e0" charOffset="30-40"
            type="drug" text="sumatriptan"/>
        <entity id="DDI-DrugBank.d568.s17.e1" charOffset="49-52"
            type="group" text="SSRI"/>
        <entity id="DDI-DrugBank.d568.s17.e2" charOffset="61-70"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d568.s17.e3" charOffset="73-83"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d568.s17.e4" charOffset="86-95"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d568.s17.e5" charOffset="98-107"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d568.s17.e6" charOffset="110-119"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s17.e7" charOffset="122-133"
            type="drug" text="escitalopram"/>
        <ddi id="DDI-DrugBank.d568.s17.d0" e1="DDI-DrugBank.d568.s17.e0"
            e2="DDI-DrugBank.d568.s17.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d568.s17.d1" e1="DDI-DrugBank.d568.s17.e0"
            e2="DDI-DrugBank.d568.s17.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d568.s17.d2" e1="DDI-DrugBank.d568.s17.e0"
            e2="DDI-DrugBank.d568.s17.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d568.s17.d3" e1="DDI-DrugBank.d568.s17.e0"
            e2="DDI-DrugBank.d568.s17.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d568.s17.d4" e1="DDI-DrugBank.d568.s17.e0"
            e2="DDI-DrugBank.d568.s17.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d568.s17.d5" e1="DDI-DrugBank.d568.s17.e0"
            e2="DDI-DrugBank.d568.s17.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d568.s17.d6" e1="DDI-DrugBank.d568.s17.e0"
            e2="DDI-DrugBank.d568.s17.e7" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s18" text="Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.">
        <entity id="DDI-DrugBank.d568.s18.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d568.s18.e1" charOffset="50-59"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s18.e2" charOffset="110-121"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d568.s18.e3" charOffset="186-197"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s19" text="The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.">
        <entity id="DDI-DrugBank.d568.s19.e0" charOffset="14-25"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d568.s19.e1" charOffset="54-63"
            type="drug" text="citalopram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s20" text="Warfarin - Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.">
        <entity id="DDI-DrugBank.d568.s20.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d568.s20.e1" charOffset="47-56"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s20.e2" charOffset="109-116"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s21" text="Prothrombin time was increased by 5%, the clinical significance of which is unknown."/>
    <sentence id="DDI-DrugBank.d568.s22" text="Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.">
        <entity id="DDI-DrugBank.d568.s22.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d568.s22.e1" charOffset="51-60"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s22.e2" charOffset="90-102"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d568.s22.e3" charOffset="194-206"
            type="drug" text="carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s23" text="Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.">
        <entity id="DDI-DrugBank.d568.s23.e0" charOffset="16-25"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s23.e1" charOffset="98-110"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d568.s23.e2" charOffset="134-146"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d568.s23.e3" charOffset="180-191"
            type="drug" text="escitalopram"/>
        <ddi id="DDI-DrugBank.d568.s23.d0" e1="DDI-DrugBank.d568.s23.e2"
            e2="DDI-DrugBank.d568.s23.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s24" text="Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.">
        <entity id="DDI-DrugBank.d568.s24.e0" charOffset="0-8"
            type="drug" text="Triazolam"/>
        <entity id="DDI-DrugBank.d568.s24.e1" charOffset="47-56"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s24.e2" charOffset="119-127"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d568.s24.e3" charOffset="214-223"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s24.e4" charOffset="228-236"
            type="drug" text="triazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s25" text="Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.">
        <entity id="DDI-DrugBank.d568.s25.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d568.s25.e1" charOffset="50-59"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s25.e2" charOffset="73-84"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d568.s25.e3" charOffset="125-136"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d568.s25.e4" charOffset="225-234"
            type="drug" text="citalopram"/>
        <ddi id="DDI-DrugBank.d568.s25.d0" e1="DDI-DrugBank.d568.s25.e1"
            e2="DDI-DrugBank.d568.s25.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s26" text="Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.">
        <entity id="DDI-DrugBank.d568.s26.e0" charOffset="0-8"
            type="drug" text="Ritonavir"/>
        <entity id="DDI-DrugBank.d568.s26.e1" charOffset="56-64"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d568.s26.e2" charOffset="138-149"
            type="drug" text="escitalopram"/>
        <entity id="DDI-DrugBank.d568.s26.e3" charOffset="205-213"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d568.s26.e4" charOffset="218-229"
            type="drug" text="escitalopram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s27" text="CYP3A4 and -2C19 Inhibitors - In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram.">
        <entity id="DDI-DrugBank.d568.s27.e0" charOffset="133-144"
            type="drug" text="escitalopram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s28" text="However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram.">
        <entity id="DDI-DrugBank.d568.s28.e0" charOffset="29-40"
            type="drug" text="escitalopram"/>
        <entity id="DDI-DrugBank.d568.s28.e1" charOffset="54-62"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d568.s28.e2" charOffset="157-168"
            type="drug" text="escitalopram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s29" text="Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.">
        <entity id="DDI-DrugBank.d568.s29.e0" charOffset="8-19"
            type="drug" text="escitalopram"/>
        <entity id="DDI-DrugBank.d568.s29.e1" charOffset="123-134"
            type="drug" text="escitalopram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s30" text="Drugs Metabolized by Cytochrome P4502D6 - In vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6.">
        <entity id="DDI-DrugBank.d568.s30.e0" charOffset="98-109"
            type="drug" text="escitalopram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s31" text="In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.">
        <entity id="DDI-DrugBank.d568.s31.e0" charOffset="44-53"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s31.e1" charOffset="181-190"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s31.e2" charOffset="232-243"
            type="drug" text="escitalopram"/>
        <entity id="DDI-DrugBank.d568.s31.e3" charOffset="332-343"
            type="drug" text="escitalopram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s32" text="However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.">
        <entity id="DDI-DrugBank.d568.s32.e0" charOffset="89-100"
            type="drug" text="escitalopram"/>
        <entity id="DDI-DrugBank.d568.s32.e1" charOffset="129-140"
            type="drug" text="escitalopram"/>
        <entity id="DDI-DrugBank.d568.s32.e2" charOffset="175-198"
            type="group" text="tricyclic antidepressant"/>
        <entity id="DDI-DrugBank.d568.s32.e3" charOffset="200-210"
            type="drug" text="desipramine"/>
        <entity id="DDI-DrugBank.d568.s32.e4" charOffset="325-335"
            type="drug" text="desipramine"/>
        <ddi id="DDI-DrugBank.d568.s32.d0" e1="DDI-DrugBank.d568.s32.e1"
            e2="DDI-DrugBank.d568.s32.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s33" text="The clinical significance of this finding is unknown."/>
    <sentence id="DDI-DrugBank.d568.s34" text="Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6.">
        <entity id="DDI-DrugBank.d568.s34.e0" charOffset="62-73"
            type="drug" text="escitalopram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s35" text="Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).">
        <entity id="DDI-DrugBank.d568.s35.e0" charOffset="0-9"
            type="drug" text="Metoprolol"/>
        <entity id="DDI-DrugBank.d568.s35.e1" charOffset="41-47"
            type="brand" text="LEXAPRO"/>
        <entity id="DDI-DrugBank.d568.s35.e2" charOffset="149-171"
            type="group" text="beta-adrenergic blocker"/>
        <entity id="DDI-DrugBank.d568.s35.e3" charOffset="173-182"
            type="drug" text="metoprolol"/>
        <ddi id="DDI-DrugBank.d568.s35.d0" e1="DDI-DrugBank.d568.s35.e1"
            e2="DDI-DrugBank.d568.s35.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s36" text="Increased metoprolol plasma levels have been associated with decreased cardioselectivity.">
        <entity id="DDI-DrugBank.d568.s36.e0" charOffset="10-19"
            type="drug" text="metoprolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s37" text="Coadministration of LEXAPRO and metoprolol had no clinically significant effects on blood pressure or heart rate.">
        <entity id="DDI-DrugBank.d568.s37.e0" charOffset="20-26"
            type="brand" text="LEXAPRO"/>
        <entity id="DDI-DrugBank.d568.s37.e1" charOffset="32-41"
            type="drug" text="metoprolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s38" text="Electroconvulsive Therapy (ECT) - There are no clinical studies of the combined use of ECT and escitalopram.">
        <entity id="DDI-DrugBank.d568.s38.e0" charOffset="95-106"
            type="drug" text="escitalopram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d568.s39" text="Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.">
        <entity id="DDI-DrugBank.d568.s39.e0" charOffset="40-49"
            type="drug" text="Citalopram"/>
        <entity id="DDI-DrugBank.d568.s39.e1" charOffset="51-60"
            type="drug" text="Citalopram"/>
        <entity id="DDI-DrugBank.d568.s39.e2" charOffset="70-81"
            type="drug" text="escitalopram"/>
        <entity id="DDI-DrugBank.d568.s39.e3" charOffset="115-124"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d568.s39.e4" charOffset="127-132"
            type="brand" text="Celexa"/>
        <ddi id="DDI-DrugBank.d568.s39.d0" e1="DDI-DrugBank.d568.s39.e2"
            e2="DDI-DrugBank.d568.s39.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d568.s39.d1" e1="DDI-DrugBank.d568.s39.e2"
            e2="DDI-DrugBank.d568.s39.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s0" text="Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.">
        <entity id="DDI-DrugBank.d422.s0.e0" charOffset="37-45"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d422.s0.e1" charOffset="92-111"
            type="group" text="beta blocking agents"/>
        <ddi id="DDI-DrugBank.d422.s0.d0" e1="DDI-DrugBank.d422.s0.e0"
            e2="DDI-DrugBank.d422.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s1" text="Patients treated concurrently with BREVIBLOC (esmolol HCl) and a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.">
        <entity id="DDI-DrugBank.d422.s1.e0" charOffset="35-43"
            type="brand" text="BREVIBLOC"/>
        <entity id="DDI-DrugBank.d422.s1.e1" charOffset="46-56"
            type="drug" text="esmolol HCl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s2" text="A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.">
        <entity id="DDI-DrugBank.d422.s2.e0" charOffset="31-39"
            type="brand" text="BREVIBLOC"/>
        <entity id="DDI-DrugBank.d422.s2.e1" charOffset="45-52"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d422.s2.e2" charOffset="96-104"
            type="brand" text="BREVIBLOC"/>
        <entity id="DDI-DrugBank.d422.s2.e3" charOffset="110-117"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d422.s2.e4" charOffset="134-141"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s3" text="BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.">
        <entity id="DDI-DrugBank.d422.s3.e0" charOffset="0-8"
            type="brand" text="BREVIBLOC"/>
        <entity id="DDI-DrugBank.d422.s3.e1" charOffset="65-72"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d422.s3.d0" e1="DDI-DrugBank.d422.s3.e0"
            e2="DDI-DrugBank.d422.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s4" text="When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.">
        <entity id="DDI-DrugBank.d422.s4.e0" charOffset="5-11"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d422.s4.e1" charOffset="17-25"
            type="brand" text="BREVIBLOC"/>
        <entity id="DDI-DrugBank.d422.s4.e2" charOffset="126-132"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d422.s4.d0" e1="DDI-DrugBank.d422.s4.e0"
            e2="DDI-DrugBank.d422.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s5" text="Digoxin did not affect BREVIBLOC pharmacokinetics.">
        <entity id="DDI-DrugBank.d422.s5.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d422.s5.e1" charOffset="23-31"
            type="brand" text="BREVIBLOC"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s6" text="When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.">
        <entity id="DDI-DrugBank.d422.s6.e0" charOffset="17-24"
            type="drug" text="morphine"/>
        <entity id="DDI-DrugBank.d422.s6.e1" charOffset="30-38"
            type="brand" text="BREVIBLOC"/>
        <entity id="DDI-DrugBank.d422.s6.e2" charOffset="105-112"
            type="drug" text="morphine"/>
        <entity id="DDI-DrugBank.d422.s6.e3" charOffset="141-149"
            type="brand" text="BREVIBLOC"/>
        <entity id="DDI-DrugBank.d422.s6.e4" charOffset="218-225"
            type="drug" text="morphine"/>
        <ddi id="DDI-DrugBank.d422.s6.d0" e1="DDI-DrugBank.d422.s6.e3"
            e2="DDI-DrugBank.d422.s6.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s7" text="No other pharmacokinetic parameters were changed."/>
    <sentence id="DDI-DrugBank.d422.s8" text="The effect of BREVIBLOC on the duration of succinylcholine-induced neuromuscular blockade was studied in patients undergoing surgery.">
        <entity id="DDI-DrugBank.d422.s8.e0" charOffset="14-22"
            type="drug" text="BREVIBLOC"/>
        <entity id="DDI-DrugBank.d422.s8.e1" charOffset="43-57"
            type="drug" text="succinylcholine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s9" text="The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.">
        <entity id="DDI-DrugBank.d422.s9.e0" charOffset="39-53"
            type="drug" text="succinylcholine"/>
        <entity id="DDI-DrugBank.d422.s9.e1" charOffset="73-81"
            type="brand" text="BREVIBLOC"/>
        <ddi id="DDI-DrugBank.d422.s9.d0" e1="DDI-DrugBank.d422.s9.e0"
            e2="DDI-DrugBank.d422.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s10" text="Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.">
        <entity id="DDI-DrugBank.d422.s10.e0" charOffset="102-110"
            type="brand" text="BREVIBLOC"/>
        <entity id="DDI-DrugBank.d422.s10.e1" charOffset="188-194"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d422.s10.e2" charOffset="197-204"
            type="drug" text="morphine"/>
        <entity id="DDI-DrugBank.d422.s10.e3" charOffset="207-221"
            type="drug" text="succinylcholine"/>
        <entity id="DDI-DrugBank.d422.s10.e4" charOffset="226-233"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d422.s10.d0" e1="DDI-DrugBank.d422.s10.e0"
            e2="DDI-DrugBank.d422.s10.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d422.s10.d1" e1="DDI-DrugBank.d422.s10.e0"
            e2="DDI-DrugBank.d422.s10.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d422.s10.d2" e1="DDI-DrugBank.d422.s10.e0"
            e2="DDI-DrugBank.d422.s10.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d422.s10.d3" e1="DDI-DrugBank.d422.s10.e0"
            e2="DDI-DrugBank.d422.s10.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s11" text="While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.">
        <entity id="DDI-DrugBank.d422.s11.e0" charOffset="13-25"
            type="group" text="beta blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s12" text="Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.">
        <entity id="DDI-DrugBank.d422.s12.e0" charOffset="56-66"
            type="drug" text="epinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s13" text="Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.">
        <entity id="DDI-DrugBank.d422.s13.e0" charOffset="56-64"
            type="brand" text="BREVIBLOC"/>
        <entity id="DDI-DrugBank.d422.s13.e1" charOffset="70-78"
            type="drug" text="verapamil"/>
        <ddi id="DDI-DrugBank.d422.s13.d0" e1="DDI-DrugBank.d422.s13.e0"
            e2="DDI-DrugBank.d422.s13.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d422.s14" text="Fatal cardiac arrests have occurred in patients receiving both drugs."/>
    <sentence id="DDI-DrugBank.d422.s15" text="Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.">
        <entity id="DDI-DrugBank.d422.s15.e0" charOffset="14-22"
            type="brand" text="BREVIBLOC"/>
        <entity id="DDI-DrugBank.d422.s15.e1" charOffset="158-165"
            type="drug" text="dopamine"/>
        <entity id="DDI-DrugBank.d422.s15.e2" charOffset="168-178"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d422.s15.e3" charOffset="185-198"
            type="drug" text="norepinephrine"/>
        <ddi id="DDI-DrugBank.d422.s15.d0" e1="DDI-DrugBank.d422.s15.e0"
            e2="DDI-DrugBank.d422.s15.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d422.s15.d1" e1="DDI-DrugBank.d422.s15.e0"
            e2="DDI-DrugBank.d422.s15.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d422.s15.d2" e1="DDI-DrugBank.d422.s15.e0"
            e2="DDI-DrugBank.d422.s15.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s0" text="Esomeprazole is extensively metabolized in the liver by CYP2C19 and CYP3A4.">
        <entity id="DDI-DrugBank.d29.s0.e0" charOffset="0-11"
            type="drug" text="Esomeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s1" text="In vitro and in vivo studies have shown that esomeprazole is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1 and 3A4.">
        <entity id="DDI-DrugBank.d29.s1.e0" charOffset="45-56"
            type="drug" text="esomeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s2" text="No clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected."/>
    <sentence id="DDI-DrugBank.d29.s3" text="Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.">
        <entity id="DDI-DrugBank.d29.s3.e0" charOffset="41-52"
            type="drug" text="esomeprazole"/>
        <entity id="DDI-DrugBank.d29.s3.e1" charOffset="113-121"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d29.s3.e2" charOffset="124-131"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d29.s3.e3" charOffset="134-142"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d29.s3.e4" charOffset="145-158"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d29.s3.e5" charOffset="163-173"
            type="drug" text="amoxicillin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s4" text="Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy.">
        <entity id="DDI-DrugBank.d29.s4.e0" charOffset="107-114"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d29.s4.e1" charOffset="120-131"
            type="drug" text="esomeprazole"/>
        <ddi id="DDI-DrugBank.d29.s4.d0" e1="DDI-DrugBank.d29.s4.e1"
            e2="DDI-DrugBank.d29.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s5" text="Increases in INR and prothrombin time may lead to abnormal bleeding and even death."/>
    <sentence id="DDI-DrugBank.d29.s6" text="Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.">
        <entity id="DDI-DrugBank.d29.s6.e0" charOffset="22-43"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-DrugBank.d29.s6.e1" charOffset="49-56"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d29.s6.d0" e1="DDI-DrugBank.d29.s6.e0"
            e2="DDI-DrugBank.d29.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s7" text="Esomeprazole may potentially interfere with CYP2C19, the major esomeprazole metabolizing enzyme.">
        <entity id="DDI-DrugBank.d29.s7.e0" charOffset="0-11"
            type="drug" text="Esomeprazole"/>
        <entity id="DDI-DrugBank.d29.s7.e1" charOffset="63-74"
            type="drug" text="esomeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s8" text="Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.">
        <entity id="DDI-DrugBank.d29.s8.e0" charOffset="20-31"
            type="drug" text="esomeprazole"/>
        <entity id="DDI-DrugBank.d29.s8.e1" charOffset="43-50"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d29.s8.e2" charOffset="117-124"
            type="drug" text="diazepam"/>
        <ddi id="DDI-DrugBank.d29.s8.d0" e1="DDI-DrugBank.d29.s8.e0"
            e2="DDI-DrugBank.d29.s8.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s9" text="Increased plasma levels of diazepam were observed 12 hours after dosing and onwards.">
        <entity id="DDI-DrugBank.d29.s9.e0" charOffset="27-34"
            type="drug" text="diazepam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s10" text="However, at that time, the plasma levels of diazepam were below the therapeutic interval, and thus this interaction is unlikely to be of clinical relevance.">
        <entity id="DDI-DrugBank.d29.s10.e0" charOffset="44-51"
            type="drug" text="diazepam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s11" text="Esomeprazole inhibits gastric acid secretion.">
        <entity id="DDI-DrugBank.d29.s11.e0" charOffset="0-11"
            type="drug" text="Esomeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s12" text="Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).">
        <entity id="DDI-DrugBank.d29.s12.e0" charOffset="11-22"
            type="drug" text="esomeprazole"/>
        <entity id="DDI-DrugBank.d29.s12.e1" charOffset="136-147"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d29.s12.e2" charOffset="150-153"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d29.s12.e3" charOffset="165-171"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d29.s12.d0" e1="DDI-DrugBank.d29.s12.e0"
            e2="DDI-DrugBank.d29.s12.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d29.s12.d1" e1="DDI-DrugBank.d29.s12.e0"
            e2="DDI-DrugBank.d29.s12.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d29.s12.d2" e1="DDI-DrugBank.d29.s12.e0"
            e2="DDI-DrugBank.d29.s12.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s13" text="Coadministration of oral contraceptives, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.">
        <entity id="DDI-DrugBank.d29.s13.e0" charOffset="25-38"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d29.s13.e1" charOffset="41-48"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d29.s13.e2" charOffset="51-59"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d29.s13.e3" charOffset="65-73"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d29.s13.e4" charOffset="129-140"
            type="drug" text="esomeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d29.s14" text="Concomitant administration of clarithromycin with pimozide is contraindicated.">
        <entity id="DDI-DrugBank.d29.s14.e0" charOffset="30-43"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d29.s14.e1" charOffset="50-57"
            type="drug" text="pimozide"/>
        <ddi id="DDI-DrugBank.d29.s14.d0" e1="DDI-DrugBank.d29.s14.e0"
            e2="DDI-DrugBank.d29.s14.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s0" text="If ProSom is given concomitantly with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of all agents.">
        <entity id="DDI-DrugBank.d338.s0.e0" charOffset="3-8"
            type="brand" text="ProSom"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s1" text="The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.">
        <entity id="DDI-DrugBank.d338.s1.e0" charOffset="18-32"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d338.s1.e1" charOffset="56-70"
            type="group" text="anticonvulsants"/>
        <entity id="DDI-DrugBank.d338.s1.e2" charOffset="73-86"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d338.s1.e3" charOffset="89-95"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d338.s1.e4" charOffset="98-109"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d338.s1.e5" charOffset="112-139"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d338.s1.e6" charOffset="142-150"
            type="group" text="narcotics"/>
        <entity id="DDI-DrugBank.d338.s1.e7" charOffset="153-166"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d338.s1.e8" charOffset="169-192"
            type="group" text="psychotropic medications"/>
        <ddi id="DDI-DrugBank.d338.s1.d0" e1="DDI-DrugBank.d338.s1.e0"
            e2="DDI-DrugBank.d338.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d338.s1.d1" e1="DDI-DrugBank.d338.s1.e0"
            e2="DDI-DrugBank.d338.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d338.s1.d2" e1="DDI-DrugBank.d338.s1.e0"
            e2="DDI-DrugBank.d338.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d338.s1.d3" e1="DDI-DrugBank.d338.s1.e0"
            e2="DDI-DrugBank.d338.s1.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d338.s1.d4" e1="DDI-DrugBank.d338.s1.e0"
            e2="DDI-DrugBank.d338.s1.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d338.s1.d5" e1="DDI-DrugBank.d338.s1.e0"
            e2="DDI-DrugBank.d338.s1.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d338.s1.d6" e1="DDI-DrugBank.d338.s1.e0"
            e2="DDI-DrugBank.d338.s1.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d338.s1.d7" e1="DDI-DrugBank.d338.s1.e0"
            e2="DDI-DrugBank.d338.s1.e8" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s2" text="Smokers have an increased clearance of benzodiazepines as compared to nonsmokers;">
        <entity id="DDI-DrugBank.d338.s2.e0" charOffset="39-53"
            type="group" text="benzodiazepines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s3" text="this was seen in studies with estazolam.">
        <entity id="DDI-DrugBank.d338.s3.e0" charOffset="30-38"
            type="drug" text="estazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s4" text="While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.">
        <entity id="DDI-DrugBank.d338.s4.e0" charOffset="70-78"
            type="drug" text="estazolam"/>
        <entity id="DDI-DrugBank.d338.s4.e1" charOffset="153-165"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d338.s4.e2" charOffset="168-176"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d338.s4.e3" charOffset="179-186"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d338.s4.e4" charOffset="193-204"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d338.s4.e5" charOffset="237-245"
            type="drug" text="estazolam"/>
        <ddi id="DDI-DrugBank.d338.s4.d0" e1="DDI-DrugBank.d338.s4.e0"
            e2="DDI-DrugBank.d338.s4.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d338.s4.d1" e1="DDI-DrugBank.d338.s4.e0"
            e2="DDI-DrugBank.d338.s4.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d338.s4.d2" e1="DDI-DrugBank.d338.s4.e0"
            e2="DDI-DrugBank.d338.s4.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d338.s4.d3" e1="DDI-DrugBank.d338.s4.e0"
            e2="DDI-DrugBank.d338.s4.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d338.s4.d4" e1="DDI-DrugBank.d338.s4.e0"
            e2="DDI-DrugBank.d338.s4.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s5" text="Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.">
        <entity id="DDI-DrugBank.d338.s5.e0" charOffset="0-8"
            type="drug" text="Estazolam"/>
        <entity id="DDI-DrugBank.d338.s5.e1" charOffset="108-116"
            type="drug" text="estazolam"/>
        <entity id="DDI-DrugBank.d338.s5.e2" charOffset="154-172"
            type="drug_n" text="4-hydroxy-estazolam"/>
        <entity id="DDI-DrugBank.d338.s5.e3" charOffset="202-224"
            type="group" text="triazolobenzodiazepines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s6" text="Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.">
        <entity id="DDI-DrugBank.d338.s6.e0" charOffset="14-22"
            type="drug" text="estazolam"/>
        <entity id="DDI-DrugBank.d338.s6.e1" charOffset="64-75"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d338.s6.e2" charOffset="81-92"
            type="drug" text="itraconazole"/>
        <ddi id="DDI-DrugBank.d338.s6.d0" e1="DDI-DrugBank.d338.s6.e0"
            e2="DDI-DrugBank.d338.s6.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d338.s6.d1" e1="DDI-DrugBank.d338.s6.e0"
            e2="DDI-DrugBank.d338.s6.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s7" text="With drugs inhibiting CYP3A to a lesser, but still significant degree, estazolam should be used only with caution and consideration of appropriate dosage reduction.">
        <entity id="DDI-DrugBank.d338.s7.e0" charOffset="71-79"
            type="drug" text="estazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s8" text="The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.">
        <entity id="DDI-DrugBank.d338.s8.e0" charOffset="85-99"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d338.s8.e1" charOffset="142-151"
            type="drug" text="nefazodone"/>
        <entity id="DDI-DrugBank.d338.s8.e2" charOffset="154-164"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d338.s8.e3" charOffset="167-176"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d338.s8.e4" charOffset="179-187"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d338.s8.e5" charOffset="190-199"
            type="drug" text="isoniazide"/>
        <entity id="DDI-DrugBank.d338.s8.e6" charOffset="211-231"
            type="group" text="macrolide antibiotics"/>
        <ddi id="DDI-DrugBank.d338.s8.d0" e1="DDI-DrugBank.d338.s8.e0"
            e2="DDI-DrugBank.d338.s8.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d338.s8.d1" e1="DDI-DrugBank.d338.s8.e0"
            e2="DDI-DrugBank.d338.s8.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d338.s8.d2" e1="DDI-DrugBank.d338.s8.e0"
            e2="DDI-DrugBank.d338.s8.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d338.s8.d3" e1="DDI-DrugBank.d338.s8.e0"
            e2="DDI-DrugBank.d338.s8.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d338.s8.d4" e1="DDI-DrugBank.d338.s8.e0"
            e2="DDI-DrugBank.d338.s8.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d338.s8.d5" e1="DDI-DrugBank.d338.s8.e0"
            e2="DDI-DrugBank.d338.s8.e6" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s9" text="Drug Interaction with Fluoxetine: A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days.">
        <entity id="DDI-DrugBank.d338.s9.e0" charOffset="22-31"
            type="drug" text="Fluoxetine"/>
        <entity id="DDI-DrugBank.d338.s9.e1" charOffset="94-103"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d338.s9.e2" charOffset="142-150"
            type="drug" text="estazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s10" text="The pharmacokinetics of estazolam (Cmax and AUC) were not affected during multiple-dose fluoxetine, suggesting no clinically significant pharmacokinetic interaction.">
        <entity id="DDI-DrugBank.d338.s10.e0" charOffset="24-32"
            type="drug" text="estazolam"/>
        <entity id="DDI-DrugBank.d338.s10.e1" charOffset="88-97"
            type="drug" text="fluoxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s11" text="Estazolam: Interaction with Other Drugs that are Metabolized by Cytochrome P450 (CYP): At clinically relevant concentrations, in vitro studies indicate that estazolam (0.6 M) was not inhibitory towards the major cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A.">
        <entity id="DDI-DrugBank.d338.s11.e0" charOffset="0-8"
            type="drug" text="Estazolam"/>
        <entity id="DDI-DrugBank.d338.s11.e1" charOffset="157-165"
            type="drug" text="estazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s12" text="Therefore, based on these in vitro data, estazolam is very unlikely to inhibit the biotransformation of other drugs metabolized by these CYP isoforms">
        <entity id="DDI-DrugBank.d338.s12.e0" charOffset="41-49"
            type="drug" text="estazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d338.s13" text="."/>
    <sentence id="DDI-DrugBank.d338.s14" text=""/>
    <sentence id="DDI-DrugBank.d301.s0" text="D."/>
    <sentence id="DDI-DrugBank.d301.s1" text="Drug and Laboratory Test Interactions 1."/>
    <sentence id="DDI-DrugBank.d301.s2" text="Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time;"/>
    <sentence id="DDI-DrugBank.d301.s3" text="increased platelet count;"/>
    <sentence id="DDI-DrugBank.d301.s4" text="increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin;"/>
    <sentence id="DDI-DrugBank.d301.s5" text="decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity;"/>
    <sentence id="DDI-DrugBank.d301.s6" text="increased levels of fibrinogen and fibrinogen activity;"/>
    <sentence id="DDI-DrugBank.d301.s7" text="increased plasminogen antigen and activity."/>
    <sentence id="DDI-DrugBank.d301.s8" text="2."/>
    <sentence id="DDI-DrugBank.d301.s9" text="Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone levels, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay."/>
    <sentence id="DDI-DrugBank.d301.s10" text="T3 resin uptake is decreased, reflecting the elevated TBG."/>
    <sentence id="DDI-DrugBank.d301.s11" text="Free T4 and T3 concentrations are unaltered."/>
    <sentence id="DDI-DrugBank.d301.s12" text="Patients on thyroid replacement therapy may require higher doses of thyroid hormone.">
        <entity id="DDI-DrugBank.d301.s12.e0" charOffset="68-82"
            type="group" text="thyroid hormone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d301.s13" text="3."/>
    <sentence id="DDI-DrugBank.d301.s14" text="Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.">
        <entity id="DDI-DrugBank.d301.s14.e0" charOffset="170-184"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d301.s14.e1" charOffset="190-201"
            type="group" text="sex steroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d301.s15" text="Free hormone concentrations may be decreased."/>
    <sentence id="DDI-DrugBank.d301.s16" text="Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin)."/>
    <sentence id="DDI-DrugBank.d301.s17" text="4."/>
    <sentence id="DDI-DrugBank.d301.s18" text="Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels."/>
    <sentence id="DDI-DrugBank.d301.s19" text="5."/>
    <sentence id="DDI-DrugBank.d301.s20" text="Impaired glucose tolerance."/>
    <sentence id="DDI-DrugBank.d301.s21" text="6."/>
    <sentence id="DDI-DrugBank.d301.s22" text="Reduced response to metyrapone test."/>
    <sentence id="DDI-DrugBank.d481.s0" text="Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.">
        <entity id="DDI-DrugBank.d481.s0.e0" charOffset="25-31"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d481.s0.e1" charOffset="82-86"
            type="brand" text="EMCYT"/>
        <ddi id="DDI-DrugBank.d481.s0.d0" e1="DDI-DrugBank.d481.s0.e0"
            e2="DDI-DrugBank.d481.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s0" text="CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.">
        <entity id="DDI-DrugBank.d216.s0.e0" charOffset="17-23"
            type="drug" text="Ethanol"/>
        <entity id="DDI-DrugBank.d216.s0.e1" charOffset="105-115"
            type="drug" text="eszopiclone"/>
        <entity id="DDI-DrugBank.d216.s0.e2" charOffset="121-127"
            type="drug" text="ethanol"/>
        <entity id="DDI-DrugBank.d216.s0.e3" charOffset="163-169"
            type="drug" text="ethanol"/>
        <ddi id="DDI-DrugBank.d216.s0.d0" e1="DDI-DrugBank.d216.s0.e1"
            e2="DDI-DrugBank.d216.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s1" text="Paroxetine: Coadministration of single doses of eszopiclone 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.">
        <entity id="DDI-DrugBank.d216.s1.e0" charOffset="0-9"
            type="drug" text="Paroxetine"/>
        <entity id="DDI-DrugBank.d216.s1.e1" charOffset="48-58"
            type="drug" text="eszopiclone"/>
        <entity id="DDI-DrugBank.d216.s1.e2" charOffset="69-78"
            type="drug" text="paroxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s2" text="Lorazepam: Coadministration of single doses of eszopiclone 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.">
        <entity id="DDI-DrugBank.d216.s2.e0" charOffset="0-8"
            type="drug" text="Lorazepam"/>
        <entity id="DDI-DrugBank.d216.s2.e1" charOffset="47-57"
            type="drug" text="eszopiclone"/>
        <entity id="DDI-DrugBank.d216.s2.e2" charOffset="68-76"
            type="drug" text="lorazepam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s3" text="Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.">
        <entity id="DDI-DrugBank.d216.s3.e0" charOffset="0-9"
            type="drug" text="Olanzapine"/>
        <entity id="DDI-DrugBank.d216.s3.e1" charOffset="32-42"
            type="drug" text="eszopiclone"/>
        <entity id="DDI-DrugBank.d216.s3.e2" charOffset="53-62"
            type="drug" text="olanzapine"/>
        <ddi id="DDI-DrugBank.d216.s3.d0" e1="DDI-DrugBank.d216.s3.e1"
            e2="DDI-DrugBank.d216.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s4" text="The interaction was pharmacodynamic;"/>
    <sentence id="DDI-DrugBank.d216.s5" text="there was no alteration in the pharmacokinetics of either drug."/>
    <sentence id="DDI-DrugBank.d216.s6" text="Drugs That Inhibit CYP3A4 (Ketoconazole) CYP3A4 is a major metabolic pathway for elimination of eszopiclone.">
        <entity id="DDI-DrugBank.d216.s6.e0" charOffset="27-38"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d216.s6.e1" charOffset="96-106"
            type="drug" text="eszopiclone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s7" text="The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.">
        <entity id="DDI-DrugBank.d216.s7.e0" charOffset="11-21"
            type="drug" text="eszopiclone"/>
        <entity id="DDI-DrugBank.d216.s7.e1" charOffset="69-80"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d216.s7.d0" e1="DDI-DrugBank.d216.s7.e0"
            e2="DDI-DrugBank.d216.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s8" text="Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively."/>
    <sentence id="DDI-DrugBank.d216.s9" text="Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.">
        <entity id="DDI-DrugBank.d216.s9.e0" charOffset="41-52"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d216.s9.e1" charOffset="55-68"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d216.s9.e2" charOffset="71-80"
            type="drug" text="nefazodone"/>
        <entity id="DDI-DrugBank.d216.s9.e3" charOffset="83-96"
            type="drug" text="troleandomycin"/>
        <entity id="DDI-DrugBank.d216.s9.e4" charOffset="99-107"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d216.s9.e5" charOffset="110-119"
            type="drug" text="nelfinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s10" text="Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.">
        <entity id="DDI-DrugBank.d216.s10.e0" charOffset="26-35"
            type="drug" text="Rifampicin"/>
        <entity id="DDI-DrugBank.d216.s10.e1" charOffset="46-54"
            type="drug" text="zopiclone"/>
        <entity id="DDI-DrugBank.d216.s10.e2" charOffset="104-113"
            type="drug" text="rifampicin"/>
        <ddi id="DDI-DrugBank.d216.s10.d0" e1="DDI-DrugBank.d216.s10.e1"
            e2="DDI-DrugBank.d216.s10.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s11" text="A similar effect would be expected with eszopiclone.">
        <entity id="DDI-DrugBank.d216.s11.e0" charOffset="40-50"
            type="drug" text="eszopiclone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s12" text="Drugs Highly Bound To Plasma Protein Eszopiclone is not highly bound to plasma proteins (52-59% bound);">
        <entity id="DDI-DrugBank.d216.s12.e0" charOffset="37-47"
            type="drug" text="Eszopiclone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s13" text="therefore, the disposition of eszopiclone is not expected to be sensitive to alterations in protein binding.">
        <entity id="DDI-DrugBank.d216.s13.e0" charOffset="30-40"
            type="drug" text="eszopiclone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s14" text="Administration of eszopiclone 3 mg to a patient taking another drug that is highly protein-bound would not be expected to cause an alteration in the free concentration of either drug.">
        <entity id="DDI-DrugBank.d216.s14.e0" charOffset="18-28"
            type="drug" text="eszopiclone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s15" text="Drugs With A Narrow Therapeutic Index Digoxin A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.">
        <entity id="DDI-DrugBank.d216.s15.e0" charOffset="38-44"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d216.s15.e1" charOffset="63-73"
            type="drug" text="eszopiclone"/>
        <entity id="DDI-DrugBank.d216.s15.e2" charOffset="119-125"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s16" text="Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin">
        <entity id="DDI-DrugBank.d216.s16.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d216.s16.e1" charOffset="10-20"
            type="drug" text="Eszopiclone"/>
        <entity id="DDI-DrugBank.d216.s16.e2" charOffset="95-98;107-114"
            type="drug" text="(R)-warfarin"/>
        <entity id="DDI-DrugBank.d216.s16.e3" charOffset="104-115"
            type="drug" text="(S)-warfarin"/>
        <entity id="DDI-DrugBank.d216.s16.e4" charOffset="233-240"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d216.s17" text="."/>
    <sentence id="DDI-DrugBank.d216.s18" text=""/>
    <sentence id="DDI-DrugBank.d341.s0" text="Specific drug interaction studies have not been conducted with ENBREL .">
        <entity id="DDI-DrugBank.d341.s0.e0" charOffset="63-68"
            type="brand" text="ENBREL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d341.s1" text="However, it was observed that the pharmacokinetics of ENBREL  was unaltered by concomitant methotrexate in rheumatoid arthritis patients.">
        <entity id="DDI-DrugBank.d341.s1.e0" charOffset="54-59"
            type="brand" text="ENBREL"/>
        <entity id="DDI-DrugBank.d341.s1.e1" charOffset="91-102"
            type="drug" text="methotrexate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d341.s2" text="In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).">
        <entity id="DDI-DrugBank.d341.s2.e0" charOffset="92-97"
            type="brand" text="ENBREL"/>
        <entity id="DDI-DrugBank.d341.s2.e1" charOffset="104-111"
            type="drug" text="anakinra"/>
        <entity id="DDI-DrugBank.d341.s2.e2" charOffset="209-214"
            type="brand" text="ENBREL"/>
        <ddi id="DDI-DrugBank.d341.s2.d0" e1="DDI-DrugBank.d341.s2.e0"
            e2="DDI-DrugBank.d341.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d341.s3" text="Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).">
        <entity id="DDI-DrugBank.d341.s3.e0" charOffset="50-55"
            type="brand" text="ENBREL"/>
        <entity id="DDI-DrugBank.d341.s3.e1" charOffset="62-69"
            type="drug" text="anakinra"/>
        <ddi id="DDI-DrugBank.d341.s3.d0" e1="DDI-DrugBank.d341.s3.e0"
            e2="DDI-DrugBank.d341.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d341.s4" text="Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.">
        <entity id="DDI-DrugBank.d341.s4.e0" charOffset="66-78"
            type="drug" text="sulfasalazine"/>
        <entity id="DDI-DrugBank.d341.s4.e1" charOffset="90-95"
            type="brand" text="ENBREL"/>
        <entity id="DDI-DrugBank.d341.s4.e2" charOffset="216-221"
            type="brand" text="ENBREL"/>
        <entity id="DDI-DrugBank.d341.s4.e3" charOffset="229-241"
            type="drug" text="sulfasalazine"/>
        <ddi id="DDI-DrugBank.d341.s4.d0" e1="DDI-DrugBank.d341.s4.e0"
            e2="DDI-DrugBank.d341.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d341.s5" text="The clinical significance of this observation is unknown."/>
    <sentence id="DDI-DrugBank.d414.s0" text="Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.">
        <entity id="DDI-DrugBank.d414.s0.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d414.s0.e1" charOffset="43-51"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d414.s0.e2" charOffset="116-122"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d414.s0.d0" e1="DDI-DrugBank.d414.s0.e0"
            e2="DDI-DrugBank.d414.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d414.s1" text="Read circulars for lithium preparations before use of such concomitant therapy.">
        <entity id="DDI-DrugBank.d414.s1.e0" charOffset="19-25"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d414.s2" text="EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.">
        <entity id="DDI-DrugBank.d414.s2.e0" charOffset="0-6"
            type="brand" text="EDECRIN"/>
        <entity id="DDI-DrugBank.d414.s2.e1" charOffset="67-80"
            type="group" text="aminoglycoside"/>
        <entity id="DDI-DrugBank.d414.s2.e2" charOffset="91-115"
            type="group" text="cephalosporin antibiotics"/>
        <ddi id="DDI-DrugBank.d414.s2.d0" e1="DDI-DrugBank.d414.s2.e0"
            e2="DDI-DrugBank.d414.s2.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d414.s2.d1" e1="DDI-DrugBank.d414.s2.e0"
            e2="DDI-DrugBank.d414.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d414.s3" text="Their concurrent use should be avoided."/>
    <sentence id="DDI-DrugBank.d414.s4" text="A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;">
        <entity id="DDI-DrugBank.d414.s4.e0" charOffset="29-43"
            type="drug" text="ethacrynic acid"/>
        <entity id="DDI-DrugBank.d414.s4.e1" charOffset="74-81"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d414.s4.d0" e1="DDI-DrugBank.d414.s4.e0"
            e2="DDI-DrugBank.d414.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d414.s5" text="a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs.">
        <entity id="DDI-DrugBank.d414.s5.e0" charOffset="25-37"
            type="group" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d414.s6" text="In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.">
        <entity id="DDI-DrugBank.d414.s6.e0" charOffset="42-78"
            type="group" text="non- steroidal antiinflammatory agent"/>
        <entity id="DDI-DrugBank.d414.s6.e1"
            charOffset="150-153;188-196" type="group" text="loop diuretics"/>
        <entity id="DDI-DrugBank.d414.s6.e2"
            charOffset="156-173;188-196" type="group" text="potassium- sparing diuretics"/>
        <entity id="DDI-DrugBank.d414.s6.e3" charOffset="179-196"
            type="group" text="thiazide diuretics"/>
        <ddi id="DDI-DrugBank.d414.s6.d0" e1="DDI-DrugBank.d414.s6.e0"
            e2="DDI-DrugBank.d414.s6.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d414.s6.d1" e1="DDI-DrugBank.d414.s6.e0"
            e2="DDI-DrugBank.d414.s6.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d414.s6.d2" e1="DDI-DrugBank.d414.s6.e0"
            e2="DDI-DrugBank.d414.s6.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d414.s7" text="Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.">
        <entity id="DDI-DrugBank.d414.s7.e0" charOffset="16-22"
            type="brand" text="EDECRIN"/>
        <entity id="DDI-DrugBank.d414.s7.e1" charOffset="28-67"
            type="group" text="non- steroidal anti- inflammatory agents"/>
        <entity id="DDI-DrugBank.d414.s7.e2" charOffset="174-181"
            type="group" text="diuretic"/>
        <ddi id="DDI-DrugBank.d414.s7.d0" e1="DDI-DrugBank.d414.s7.e0"
            e2="DDI-DrugBank.d414.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d160.s0" text="The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.">
        <entity id="DDI-DrugBank.d160.s0.e0" charOffset="46-55"
            type="drug" text="ethambutol"/>
        <entity id="DDI-DrugBank.d160.s0.e1" charOffset="76-93"
            type="drug" text="aluminum hydroxide"/>
        <entity id="DDI-DrugBank.d160.s0.e2" charOffset="106-112"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d160.s0.e3" charOffset="220-229"
            type="drug" text="ethambutol"/>
        <entity id="DDI-DrugBank.d160.s0.e4" charOffset="314-323"
            type="drug" text="ethambutol"/>
        <entity id="DDI-DrugBank.d160.s0.e5" charOffset="349-364"
            type="group" text="antacid products"/>
        <ddi id="DDI-DrugBank.d160.s0.d0" e1="DDI-DrugBank.d160.s0.e0"
            e2="DDI-DrugBank.d160.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d160.s1" text="It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.">
        <entity id="DDI-DrugBank.d160.s1.e0" charOffset="56-65"
            type="drug" text="ethambutol"/>
        <entity id="DDI-DrugBank.d160.s1.e1" charOffset="72-89"
            type="drug" text="aluminum hydroxide"/>
        <entity id="DDI-DrugBank.d160.s1.e2" charOffset="102-109"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d160.s1.e3" charOffset="142-151"
            type="drug" text="ethambutol"/>
        <ddi id="DDI-DrugBank.d160.s1.d0" e1="DDI-DrugBank.d160.s1.e0"
            e2="DDI-DrugBank.d160.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d405.s0" text="Dicumarol and warfarin may decrease hypoprothrombinemic effect.">
        <entity id="DDI-DrugBank.d405.s0.e0" charOffset="0-8"
            type="drug" text="Dicumarol"/>
        <entity id="DDI-DrugBank.d405.s0.e1" charOffset="14-21"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d405.s1" text="Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.">
        <entity id="DDI-DrugBank.d405.s1.e0" charOffset="27-33"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d405.s1.e1" charOffset="36-47"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d405.s1.e2" charOffset="54-58"
            type="group" text="MAOIs"/>
        <entity id="DDI-DrugBank.d405.s1.e3" charOffset="110-122"
            type="drug" text="ethchlorvynol"/>
        <ddi id="DDI-DrugBank.d405.s1.d0" e1="DDI-DrugBank.d405.s1.e0"
            e2="DDI-DrugBank.d405.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d405.s1.d1" e1="DDI-DrugBank.d405.s1.e1"
            e2="DDI-DrugBank.d405.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d405.s1.d2" e1="DDI-DrugBank.d405.s1.e2"
            e2="DDI-DrugBank.d405.s1.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d376.s0" text="May interact with addictive medications, especially central nervous system (CNS) depressants with habituating potential (prolonged concurrent use may increase the risk of habituation), alcohol or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or ethinamate).">
        <entity id="DDI-DrugBank.d376.s0.e0" charOffset="52-91"
            type="group" text="central nervous system (CNS) depressants"/>
        <entity id="DDI-DrugBank.d376.s0.e1" charOffset="185-191"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d376.s0.e2" charOffset="320-329"
            type="drug" text="ethinamate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d152.s0" text="Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.">
        <entity id="DDI-DrugBank.d152.s0.e0" charOffset="62-69"
            type="group" text="estrogen"/>
        <entity id="DDI-DrugBank.d152.s0.e1" charOffset="87-100"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d152.s1" text="The following similar changes may be expected with larger doses of estrogen: Increased sulfobromophthalein retention;">
        <entity id="DDI-DrugBank.d152.s1.e0" charOffset="67-74"
            type="group" text="estrogen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d152.s2" text="increased prothrombin and factors VII, VIII, IX, and X;"/>
    <sentence id="DDI-DrugBank.d152.s3" text="decreased antithrombin 3;"/>
    <sentence id="DDI-DrugBank.d152.s4" text="increased norepinephrine-induced platel et aggregation;"/>
    <sentence id="DDI-DrugBank.d152.s5" text="increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by PBI, T4 by column, or T4 by radioimmunoassay."/>
    <sentence id="DDI-DrugBank.d152.s6" text="Free T3 resin uptake is decreased, reflecting the elevated TBG;"/>
    <sentence id="DDI-DrugBank.d152.s7" text="free T4 concentration is unaltered: impaired glucose tolerance;"/>
    <sentence id="DDI-DrugBank.d152.s8" text="decreased pregnanediol excretion;"/>
    <sentence id="DDI-DrugBank.d152.s9" text="reduced response to metyrapone test;"/>
    <sentence id="DDI-DrugBank.d152.s10" text="reduced serum folate concentration;"/>
    <sentence id="DDI-DrugBank.d152.s11" text="increased serum triglyceride and phospholipid concentration."/>
    <sentence id="DDI-DrugBank.d166.s0" text="Trecator has been found to temporarily raise serum concentrations of isoniazid.">
        <entity id="DDI-DrugBank.d166.s0.e0" charOffset="0-7"
            type="brand" text="Trecator"/>
        <entity id="DDI-DrugBank.d166.s0.e1" charOffset="69-77"
            type="drug" text="isoniazid"/>
        <ddi id="DDI-DrugBank.d166.s0.d0" e1="DDI-DrugBank.d166.s0.e0"
            e2="DDI-DrugBank.d166.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d166.s1" text="Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.">
        <entity id="DDI-DrugBank.d166.s1.e0" charOffset="0-7"
            type="brand" text="Trecator"/>
        <entity id="DDI-DrugBank.d166.s1.e1" charOffset="53-73"
            type="group" text="antituberculous drugs"/>
        <ddi id="DDI-DrugBank.d166.s1.d0" e1="DDI-DrugBank.d166.s1.e0"
            e2="DDI-DrugBank.d166.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d166.s2" text="In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.">
        <entity id="DDI-DrugBank.d166.s2.e0" charOffset="51-61"
            type="drug" text="ethionamide"/>
        <entity id="DDI-DrugBank.d166.s2.e1" charOffset="84-94"
            type="drug" text="cycloserine"/>
        <ddi id="DDI-DrugBank.d166.s2.d0" e1="DDI-DrugBank.d166.s2.e0"
            e2="DDI-DrugBank.d166.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d166.s3" text="Excessive ethanol ingestion should be avoided because a psychotic reaction has been reported.">
        <entity id="DDI-DrugBank.d166.s3.e0" charOffset="10-16"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d240.s0" text="Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.">
        <entity id="DDI-DrugBank.d240.s0.e0" charOffset="0-12"
            type="drug" text="Ethopropazine"/>
        <entity id="DDI-DrugBank.d240.s0.e1" charOffset="32-38"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d240.s0.e2" charOffset="49-63"
            type="group" text="CNS depressants"/>
        <ddi id="DDI-DrugBank.d240.s0.d0" e1="DDI-DrugBank.d240.s0.e0"
            e2="DDI-DrugBank.d240.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d240.s0.d1" e1="DDI-DrugBank.d240.s0.e0"
            e2="DDI-DrugBank.d240.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d240.s1" text="It may also interact with amantadine or other anticholinergic drugs or MAOIs, which may intensify the anticholinergic action.">
        <entity id="DDI-DrugBank.d240.s1.e0" charOffset="26-35"
            type="drug" text="amantadine"/>
        <entity id="DDI-DrugBank.d240.s1.e1" charOffset="46-66"
            type="group" text="anticholinergic drugs"/>
        <entity id="DDI-DrugBank.d240.s1.e2" charOffset="71-75"
            type="group" text="MAOIs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d240.s2" text="Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.">
        <entity id="DDI-DrugBank.d240.s2.e0" charOffset="0-12"
            type="drug" text="Ethopropazine"/>
        <entity id="DDI-DrugBank.d240.s2.e1" charOffset="32-45"
            type="drug" text="chlorpromazine"/>
        <entity id="DDI-DrugBank.d240.s2.e2" charOffset="77-90"
            type="drug" text="chlorpromazine"/>
        <ddi id="DDI-DrugBank.d240.s2.d0" e1="DDI-DrugBank.d240.s2.e0"
            e2="DDI-DrugBank.d240.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d205.s0" text="Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).">
        <entity id="DDI-DrugBank.d205.s0.e0" charOffset="6-13"
            type="brand" text="Zarontin"/>
        <entity id="DDI-DrugBank.d205.s0.e1" charOffset="16-27"
            type="drug" text="ethosuximide"/>
        <entity id="DDI-DrugBank.d205.s0.e2" charOffset="74-92"
            type="group" text="antiepileptic drugs"/>
        <entity id="DDI-DrugBank.d205.s0.e3" charOffset="168-179"
            type="drug" text="ethosuximide"/>
        <entity id="DDI-DrugBank.d205.s0.e4" charOffset="193-201"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d205.s0.e5" charOffset="220-232"
            type="drug" text="valproic acid"/>
        <entity id="DDI-DrugBank.d205.s0.e6" charOffset="282-293"
            type="drug" text="ethosuximide"/>
        <ddi id="DDI-DrugBank.d205.s0.d0" e1="DDI-DrugBank.d205.s0.e0"
            e2="DDI-DrugBank.d205.s0.e2" type="int"/>
        <ddi id="DDI-DrugBank.d205.s0.d1" e1="DDI-DrugBank.d205.s0.e1"
            e2="DDI-DrugBank.d205.s0.e2" type="int"/>
        <ddi id="DDI-DrugBank.d205.s0.d2" e1="DDI-DrugBank.d205.s0.e3"
            e2="DDI-DrugBank.d205.s0.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d205.s0.d3" e1="DDI-DrugBank.d205.s0.e5"
            e2="DDI-DrugBank.d205.s0.e6" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d359.s0" text="PEGANONE used in combination with other drugs known to adversely affect the hematopoietic system should be avoided if possible.">
        <entity id="DDI-DrugBank.d359.s0.e0" charOffset="0-7"
            type="brand" text="PEGANONE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d359.s1" text="Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.">
        <entity id="DDI-DrugBank.d359.s1.e0" charOffset="44-51"
            type="brand" text="PEGANONE"/>
        <entity id="DDI-DrugBank.d359.s1.e1" charOffset="87-95"
            type="brand" text="Phenurone"/>
        <entity id="DDI-DrugBank.d359.s1.e2" charOffset="98-108"
            type="drug" text="phenacemide"/>
        <ddi id="DDI-DrugBank.d359.s1.d0" e1="DDI-DrugBank.d359.s1.e0"
            e2="DDI-DrugBank.d359.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d359.s1.d1" e1="DDI-DrugBank.d359.s1.e0"
            e2="DDI-DrugBank.d359.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d359.s2" text="A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.">
        <entity id="DDI-DrugBank.d359.s2.e0" charOffset="34-56"
            type="group" text="hydantoin antiepileptic"/>
        <entity id="DDI-DrugBank.d359.s2.e1" charOffset="59-67"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d359.s2.e2" charOffset="78-99"
            type="group" text="coumarin anticoagulant"/>
        <ddi id="DDI-DrugBank.d359.s2.d0" e1="DDI-DrugBank.d359.s2.e0"
            e2="DDI-DrugBank.d359.s2.e1" type="int"/>
        <ddi id="DDI-DrugBank.d359.s2.d1" e1="DDI-DrugBank.d359.s2.e0"
            e2="DDI-DrugBank.d359.s2.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d359.s3" text="Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.">
        <entity id="DDI-DrugBank.d359.s3.e0" charOffset="12-20"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d359.s3.e1" charOffset="46-53"
            type="group" text="coumarin"/>
        <entity id="DDI-DrugBank.d359.s3.e2" charOffset="127-149"
            type="group" text="coumarin anticoagulants"/>
        <ddi id="DDI-DrugBank.d359.s3.d0" e1="DDI-DrugBank.d359.s3.e0"
            e2="DDI-DrugBank.d359.s3.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d359.s3.d1" e1="DDI-DrugBank.d359.s3.e0"
            e2="DDI-DrugBank.d359.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d359.s4" text="Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.">
        <entity id="DDI-DrugBank.d359.s4.e0" charOffset="16-38"
            type="group" text="coumarin anticoagulants"/>
        <entity id="DDI-DrugBank.d359.s4.e1" charOffset="123-131"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d359.s4.d0" e1="DDI-DrugBank.d359.s4.e0"
            e2="DDI-DrugBank.d359.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d359.s5" text="Although there is no documentation of such, a similar interaction between ethotoin and the coumarin anticoagulants may occur.">
        <entity id="DDI-DrugBank.d359.s5.e0" charOffset="74-81"
            type="drug" text="ethotoin"/>
        <entity id="DDI-DrugBank.d359.s5.e1" charOffset="91-113"
            type="group" text="coumarin anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d359.s6" text="Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.">
        <entity id="DDI-DrugBank.d359.s6.e0" charOffset="48-55"
            type="brand" text="PEGANONE"/>
        <entity id="DDI-DrugBank.d359.s6.e1" charOffset="79-101"
            type="group" text="coumarin anticoagulants"/>
        <ddi id="DDI-DrugBank.d359.s6.d0" e1="DDI-DrugBank.d359.s6.e0"
            e2="DDI-DrugBank.d359.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d286.s0" text="Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.">
        <entity id="DDI-DrugBank.d286.s0.e0" charOffset="0-12"
            type="drug" text="Ethoxzolamide"/>
        <entity id="DDI-DrugBank.d286.s0.e1" charOffset="41-50"
            type="group" text="tricyclics"/>
        <entity id="DDI-DrugBank.d286.s0.e2" charOffset="53-64"
            type="group" text="amphetamines"/>
        <entity id="DDI-DrugBank.d286.s0.e3" charOffset="67-78"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d286.s0.e4" charOffset="85-93"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d286.s0.d0" e1="DDI-DrugBank.d286.s0.e0"
            e2="DDI-DrugBank.d286.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d286.s0.d1" e1="DDI-DrugBank.d286.s0.e0"
            e2="DDI-DrugBank.d286.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d286.s0.d2" e1="DDI-DrugBank.d286.s0.e0"
            e2="DDI-DrugBank.d286.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d286.s0.d3" e1="DDI-DrugBank.d286.s0.e0"
            e2="DDI-DrugBank.d286.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d286.s1" text="It may increase excretion of barbiturates, lithium, and ASA and may also increase the toxicity of salicylates.">
        <entity id="DDI-DrugBank.d286.s1.e0" charOffset="29-40"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d286.s1.e1" charOffset="43-49"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d286.s1.e2" charOffset="56-58"
            type="drug" text="ASA"/>
        <entity id="DDI-DrugBank.d286.s1.e3" charOffset="98-108"
            type="group" text="salicylates"/>
    </sentence>
    <sentence id="DDI-DrugBank.d286.s2" text="Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.">
        <entity id="DDI-DrugBank.d286.s2.e0" charOffset="20-32"
            type="drug" text="ethoxzolamide"/>
        <entity id="DDI-DrugBank.d286.s2.e1" charOffset="45-53"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d286.s2.e2" charOffset="56-69"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d286.s2.e3" charOffset="76-90"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d286.s2.d0" e1="DDI-DrugBank.d286.s2.e0"
            e2="DDI-DrugBank.d286.s2.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d286.s2.d1" e1="DDI-DrugBank.d286.s2.e0"
            e2="DDI-DrugBank.d286.s2.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d286.s2.d2" e1="DDI-DrugBank.d286.s2.e0"
            e2="DDI-DrugBank.d286.s2.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s0" text="Ethinyl estradiol: Substrate of CYP3A4 (major), 3A5-7 (minor);">
        <entity id="DDI-DrugBank.d485.s0.e0" charOffset="0-16"
            type="drug" text="Ethinyl estradiol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s1" text="Inhibits CYP1A2 (weak), 2B6 (weak), 2C19 (weak), 3A4 (weak)."/>
    <sentence id="DDI-DrugBank.d485.s2" text="Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.">
        <entity id="DDI-DrugBank.d485.s2.e0" charOffset="0-12"
            type="drug" text="Acetaminophen"/>
        <entity id="DDI-DrugBank.d485.s2.e1" charOffset="52-70"
            type="group" text="synthetic estrogens"/>
        <ddi id="DDI-DrugBank.d485.s2.d0" e1="DDI-DrugBank.d485.s2.e0"
            e2="DDI-DrugBank.d485.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s3" text="Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.">
        <entity id="DDI-DrugBank.d485.s3.e0" charOffset="12-34"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d485.s3.e1" charOffset="82-94"
            type="drug" text="acetaminophen"/>
        <ddi id="DDI-DrugBank.d485.s3.d0" e1="DDI-DrugBank.d485.s3.e0"
            e2="DDI-DrugBank.d485.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s4" text="Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.">
        <entity id="DDI-DrugBank.d485.s4.e0" charOffset="0-8"
            type="drug" text="Acitretin"/>
        <entity id="DDI-DrugBank.d485.s4.e1" charOffset="66-74"
            type="group" text="progestin"/>
        <ddi id="DDI-DrugBank.d485.s4.d0" e1="DDI-DrugBank.d485.s4.e0"
            e2="DDI-DrugBank.d485.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s5" text="The effect on other progestational contraceptives (eg, implants, injectables) is unknown.">
        <entity id="DDI-DrugBank.d485.s5.e0" charOffset="20-48"
            type="group" text="progestational contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s6" text="Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.">
        <entity id="DDI-DrugBank.d485.s6.e0" charOffset="0-16"
            type="drug" text="Aminoglutethimide"/>
        <entity id="DDI-DrugBank.d485.s6.e1" charOffset="50-59"
            type="group" text="progestins"/>
        <ddi id="DDI-DrugBank.d485.s6.d0" e1="DDI-DrugBank.d485.s6.e0"
            e2="DDI-DrugBank.d485.s6.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s7" text="Use of a nonhormonal contraceptive product is recommended.">
        <entity id="DDI-DrugBank.d485.s7.e0" charOffset="9-41"
            type="group" text="nonhormonal contraceptive product"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s8" text="Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.">
        <entity id="DDI-DrugBank.d485.s8.e0" charOffset="0-10"
            type="group" text="Antibiotics"/>
        <entity id="DDI-DrugBank.d485.s8.e1" charOffset="13-22"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d485.s8.e2" charOffset="25-36"
            type="drug" text="tetracycline"/>
        <entity id="DDI-DrugBank.d485.s8.e3" charOffset="173-183"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d485.s8.e4" charOffset="213-230"
            type="group" text="synthetic steroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s9" text="Use of a nonhormonal contraceptive product is recommended.">
        <entity id="DDI-DrugBank.d485.s9.e0" charOffset="9-41"
            type="group" text="nonhormonal contraceptive product"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s10" text="Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.">
        <entity id="DDI-DrugBank.d485.s10.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d485.s10.e1" charOffset="28-50"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d485.s10.e2" charOffset="92-111"
            type="group" text="coumarin derivatives"/>
        <ddi id="DDI-DrugBank.d485.s10.d0" e1="DDI-DrugBank.d485.s10.e1"
            e2="DDI-DrugBank.d485.s10.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s11" text="Combination hormonal contraceptives may also increase risk of thromboembolic disorders.">
        <entity id="DDI-DrugBank.d485.s11.e0" charOffset="12-34"
            type="group" text="hormonal contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s12" text="Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.">
        <entity id="DDI-DrugBank.d485.s12.e0" charOffset="0-14"
            type="group" text="Anticonvulsants"/>
        <entity id="DDI-DrugBank.d485.s12.e1" charOffset="17-29"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d485.s12.e2" charOffset="32-40"
            type="drug" text="felbamate"/>
        <entity id="DDI-DrugBank.d485.s12.e3" charOffset="43-55"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d485.s12.e4" charOffset="58-66"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d485.s12.e5" charOffset="69-78"
            type="drug" text="topiramate"/>
        <entity id="DDI-DrugBank.d485.s12.e6" charOffset="109-125"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d485.s12.e7" charOffset="139-148"
            type="group" text="progestins"/>
        <ddi id="DDI-DrugBank.d485.s12.d0" e1="DDI-DrugBank.d485.s12.e0"
            e2="DDI-DrugBank.d485.s12.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s12.d1" e1="DDI-DrugBank.d485.s12.e1"
            e2="DDI-DrugBank.d485.s12.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s12.d2" e1="DDI-DrugBank.d485.s12.e2"
            e2="DDI-DrugBank.d485.s12.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s12.d3" e1="DDI-DrugBank.d485.s12.e3"
            e2="DDI-DrugBank.d485.s12.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s12.d4" e1="DDI-DrugBank.d485.s12.e4"
            e2="DDI-DrugBank.d485.s12.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s12.d5" e1="DDI-DrugBank.d485.s12.e5"
            e2="DDI-DrugBank.d485.s12.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s12.d6" e1="DDI-DrugBank.d485.s12.e0"
            e2="DDI-DrugBank.d485.s12.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s12.d7" e1="DDI-DrugBank.d485.s12.e1"
            e2="DDI-DrugBank.d485.s12.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s12.d8" e1="DDI-DrugBank.d485.s12.e2"
            e2="DDI-DrugBank.d485.s12.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s12.d9" e1="DDI-DrugBank.d485.s12.e3"
            e2="DDI-DrugBank.d485.s12.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s12.d10"
            e1="DDI-DrugBank.d485.s12.e4" e2="DDI-DrugBank.d485.s12.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s12.d11"
            e1="DDI-DrugBank.d485.s12.e5" e2="DDI-DrugBank.d485.s12.e7" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s13" text="Use of a nonhormonal contraceptive product is recommended.">
        <entity id="DDI-DrugBank.d485.s13.e0" charOffset="9-41"
            type="group" text="nonhormonal contraceptive product"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s14" text="Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;">
        <entity id="DDI-DrugBank.d485.s14.e0" charOffset="0-12"
            type="drug" text="Ascorbic acid"/>
        <entity id="DDI-DrugBank.d485.s14.e1" charOffset="24-36"
            type="drug" text="ascorbic acid"/>
        <entity id="DDI-DrugBank.d485.s14.e2" charOffset="39-47"
            type="drug" text="vitamin C"/>
        <entity id="DDI-DrugBank.d485.s14.e3" charOffset="113-131"
            type="group" text="synthetic estrogens"/>
        <ddi id="DDI-DrugBank.d485.s14.d0" e1="DDI-DrugBank.d485.s14.e1"
            e2="DDI-DrugBank.d485.s14.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s14.d1" e1="DDI-DrugBank.d485.s14.e2"
            e2="DDI-DrugBank.d485.s14.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s15" text="clinical implications are unclear."/>
    <sentence id="DDI-DrugBank.d485.s16" text="Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.">
        <entity id="DDI-DrugBank.d485.s16.e0" charOffset="0-11"
            type="drug" text="Atorvastatin"/>
        <entity id="DDI-DrugBank.d485.s16.e1" charOffset="14-25"
            type="drug" text="Atorvastatin"/>
        <entity id="DDI-DrugBank.d485.s16.e2" charOffset="49-61"
            type="drug" text="norethindrone"/>
        <entity id="DDI-DrugBank.d485.s16.e3" charOffset="67-83"
            type="drug" text="ethinyl estradiol"/>
        <ddi id="DDI-DrugBank.d485.s16.d0" e1="DDI-DrugBank.d485.s16.e1"
            e2="DDI-DrugBank.d485.s16.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s16.d1" e1="DDI-DrugBank.d485.s16.e1"
            e2="DDI-DrugBank.d485.s16.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s17" text="Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).">
        <entity id="DDI-DrugBank.d485.s17.e0" charOffset="0-14"
            type="group" text="Benzodiazepines"/>
        <entity id="DDI-DrugBank.d485.s17.e1" charOffset="29-51"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d485.s17.e2" charOffset="88-102"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d485.s17.e3" charOffset="105-114"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d485.s17.e4" charOffset="117-132"
            type="drug" text="chlordiazepoxide"/>
        <entity id="DDI-DrugBank.d485.s17.e5" charOffset="135-142"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d485.s17.e6" charOffset="183-191"
            type="drug" text="lorazepam"/>
        <entity id="DDI-DrugBank.d485.s17.e7" charOffset="194-201"
            type="drug" text="oxazepam"/>
        <entity id="DDI-DrugBank.d485.s17.e8" charOffset="204-212"
            type="drug" text="temazepam"/>
        <ddi id="DDI-DrugBank.d485.s17.d0" e1="DDI-DrugBank.d485.s17.e1"
            e2="DDI-DrugBank.d485.s17.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s17.d1" e1="DDI-DrugBank.d485.s17.e1"
            e2="DDI-DrugBank.d485.s17.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s17.d2" e1="DDI-DrugBank.d485.s17.e1"
            e2="DDI-DrugBank.d485.s17.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s17.d3" e1="DDI-DrugBank.d485.s17.e1"
            e2="DDI-DrugBank.d485.s17.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s17.d4" e1="DDI-DrugBank.d485.s17.e1"
            e2="DDI-DrugBank.d485.s17.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s17.d5" e1="DDI-DrugBank.d485.s17.e1"
            e2="DDI-DrugBank.d485.s17.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s17.d6" e1="DDI-DrugBank.d485.s17.e1"
            e2="DDI-DrugBank.d485.s17.e8" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s18" text="Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.">
        <entity id="DDI-DrugBank.d485.s18.e0" charOffset="0-13"
            type="drug_n" text="Clofibric acid"/>
        <entity id="DDI-DrugBank.d485.s18.e1" charOffset="28-50"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d485.s18.e2" charOffset="82-95"
            type="drug_n" text="clofibric acid"/>
        <ddi id="DDI-DrugBank.d485.s18.d0" e1="DDI-DrugBank.d485.s18.e1"
            e2="DDI-DrugBank.d485.s18.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s19" text="Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;">
        <entity id="DDI-DrugBank.d485.s19.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d485.s19.e1" charOffset="26-48"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d485.s19.e2" charOffset="80-91"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d485.s19.d0" e1="DDI-DrugBank.d485.s19.e1"
            e2="DDI-DrugBank.d485.s19.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s20" text="monitor cyclosporine levels.">
        <entity id="DDI-DrugBank.d485.s20.e0" charOffset="8-19"
            type="drug" text="cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s21" text="CYP3A4 inducers: CYP3A4 inducers may decrease the levels/effects of ethinyl estradiol.">
        <entity id="DDI-DrugBank.d485.s21.e0" charOffset="68-84"
            type="drug" text="ethinyl estradiol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s22" text="Example inducers include aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins.">
        <entity id="DDI-DrugBank.d485.s22.e0" charOffset="25-41"
            type="drug" text="aminoglutethimide"/>
        <entity id="DDI-DrugBank.d485.s22.e1" charOffset="44-56"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d485.s22.e2" charOffset="59-67"
            type="drug" text="nafcillin"/>
        <entity id="DDI-DrugBank.d485.s22.e3" charOffset="70-79"
            type="drug" text="nevirapine"/>
        <entity id="DDI-DrugBank.d485.s22.e4" charOffset="82-94"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d485.s22.e5" charOffset="97-105"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d485.s22.e6" charOffset="112-121"
            type="group" text="rifamycins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s23" text="Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;">
        <entity id="DDI-DrugBank.d485.s23.e0" charOffset="0-11"
            type="drug" text="Griseofulvin"/>
        <entity id="DDI-DrugBank.d485.s23.e1" charOffset="14-25"
            type="drug" text="Griseofulvin"/>
        <entity id="DDI-DrugBank.d485.s23.e2" charOffset="56-90"
            type="group" text="combination hormonal contraceptives"/>
        <ddi id="DDI-DrugBank.d485.s23.d0" e1="DDI-DrugBank.d485.s23.e1"
            e2="DDI-DrugBank.d485.s23.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s24" text="pregnancies have been reported."/>
    <sentence id="DDI-DrugBank.d485.s25" text="Use of barrier form of contraception is suggested while on griseofulvin therapy.">
        <entity id="DDI-DrugBank.d485.s25.e0" charOffset="59-70"
            type="drug" text="griseofulvin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s26" text="Morphine: Combination hormonal contraceptives may increase the clearance of morphine.">
        <entity id="DDI-DrugBank.d485.s26.e0" charOffset="0-7"
            type="drug" text="Morphine"/>
        <entity id="DDI-DrugBank.d485.s26.e1" charOffset="22-44"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d485.s26.e2" charOffset="76-83"
            type="drug" text="morphine"/>
        <ddi id="DDI-DrugBank.d485.s26.d0" e1="DDI-DrugBank.d485.s26.e1"
            e2="DDI-DrugBank.d485.s26.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s27" text="Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;">
        <entity id="DDI-DrugBank.d485.s27.e0" charOffset="0-46"
            type="group" text="Non-nucleoside reverse transcriptase inhibitors"/>
        <entity id="DDI-DrugBank.d485.s27.e1" charOffset="49-54"
            type="group" text="NNRTIs"/>
        <entity id="DDI-DrugBank.d485.s27.e2" charOffset="58-67"
            type="drug" text="Nevirapine"/>
        <entity id="DDI-DrugBank.d485.s27.e3" charOffset="99-133"
            type="group" text="combination hormonal contraceptives"/>
        <ddi id="DDI-DrugBank.d485.s27.d0" e1="DDI-DrugBank.d485.s27.e2"
            e2="DDI-DrugBank.d485.s27.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s28" text="use of a nonhormonal contraceptive product is recommended.">
        <entity id="DDI-DrugBank.d485.s28.e0" charOffset="9-41"
            type="group" text="nonhormonal contraceptive product"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s29" text="No data for delavirdine;">
        <entity id="DDI-DrugBank.d485.s29.e0" charOffset="12-22"
            type="drug" text="delavirdine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s30" text="incomplete data for efavirenz.">
        <entity id="DDI-DrugBank.d485.s30.e0" charOffset="20-28"
            type="drug" text="efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s31" text="Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.">
        <entity id="DDI-DrugBank.d485.s31.e0" charOffset="0-11"
            type="drug" text="Prednisolone"/>
        <entity id="DDI-DrugBank.d485.s31.e1" charOffset="14-30"
            type="drug" text="Ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d485.s31.e2" charOffset="62-73"
            type="drug" text="prednisolone"/>
        <ddi id="DDI-DrugBank.d485.s31.d0" e1="DDI-DrugBank.d485.s31.e1"
            e2="DDI-DrugBank.d485.s31.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s32" text="Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;">
        <entity id="DDI-DrugBank.d485.s32.e0" charOffset="0-18"
            type="group" text="Protease inhibitors"/>
        <entity id="DDI-DrugBank.d485.s32.e1" charOffset="21-30"
            type="drug" text="Amprenavir"/>
        <entity id="DDI-DrugBank.d485.s32.e2" charOffset="33-41"
            type="drug" text="lopinavir"/>
        <entity id="DDI-DrugBank.d485.s32.e3" charOffset="44-53"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d485.s32.e4" charOffset="60-68"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d485.s32.e5" charOffset="115-149"
            type="group" text="combination hormonal contraceptives"/>
        <ddi id="DDI-DrugBank.d485.s32.d0" e1="DDI-DrugBank.d485.s32.e1"
            e2="DDI-DrugBank.d485.s32.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s32.d1" e1="DDI-DrugBank.d485.s32.e2"
            e2="DDI-DrugBank.d485.s32.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s32.d2" e1="DDI-DrugBank.d485.s32.e3"
            e2="DDI-DrugBank.d485.s32.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s32.d3" e1="DDI-DrugBank.d485.s32.e4"
            e2="DDI-DrugBank.d485.s32.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s33" text="use of a nonhormonal contraceptive product is recommended.">
        <entity id="DDI-DrugBank.d485.s33.e0" charOffset="9-41"
            type="group" text="nonhormonal contraceptive product"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s34" text="Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.">
        <entity id="DDI-DrugBank.d485.s34.e0" charOffset="0-8"
            type="drug" text="Indinavir"/>
        <entity id="DDI-DrugBank.d485.s34.e1" charOffset="54-88"
            type="group" text="combination hormonal contraceptives"/>
        <ddi id="DDI-DrugBank.d485.s34.d0" e1="DDI-DrugBank.d485.s34.e0"
            e2="DDI-DrugBank.d485.s34.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s35" text="No data for saquinavir.">
        <entity id="DDI-DrugBank.d485.s35.e0" charOffset="12-21"
            type="drug" text="saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s36" text="Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.">
        <entity id="DDI-DrugBank.d485.s36.e0" charOffset="0-7"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d485.s36.e1" charOffset="10-17"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d485.s36.e2" charOffset="47-63"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d485.s36.e3" charOffset="74-83"
            type="group" text="progestins"/>
        <entity id="DDI-DrugBank.d485.s36.e4" charOffset="86-98"
            type="drug" text="norethindrone"/>
        <ddi id="DDI-DrugBank.d485.s36.d0" e1="DDI-DrugBank.d485.s36.e1"
            e2="DDI-DrugBank.d485.s36.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s36.d1" e1="DDI-DrugBank.d485.s36.e1"
            e2="DDI-DrugBank.d485.s36.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s36.d2" e1="DDI-DrugBank.d485.s36.e1"
            e2="DDI-DrugBank.d485.s36.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s37" text="Use of a nonhormonal contraceptive product is recommended.">
        <entity id="DDI-DrugBank.d485.s37.e0" charOffset="9-41"
            type="group" text="nonhormonal contraceptive product"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s38" text="Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.">
        <entity id="DDI-DrugBank.d485.s38.e0" charOffset="0-13"
            type="drug" text="Salicylic acid"/>
        <entity id="DDI-DrugBank.d485.s38.e1" charOffset="28-50"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d485.s38.e2" charOffset="82-95"
            type="drug" text="salicylic acid"/>
        <ddi id="DDI-DrugBank.d485.s38.d0" e1="DDI-DrugBank.d485.s38.e1"
            e2="DDI-DrugBank.d485.s38.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s39" text="Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.">
        <entity id="DDI-DrugBank.d485.s39.e0" charOffset="0-9"
            type="drug" text="Selegiline"/>
        <entity id="DDI-DrugBank.d485.s39.e1" charOffset="12-46"
            type="group" text="Combination hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d485.s39.e2" charOffset="88-97"
            type="drug" text="selegiline"/>
        <ddi id="DDI-DrugBank.d485.s39.d0" e1="DDI-DrugBank.d485.s39.e1"
            e2="DDI-DrugBank.d485.s39.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s40" text="Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.">
        <entity id="DDI-DrugBank.d485.s40.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d485.s40.e1" charOffset="14-30"
            type="drug" text="Ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d485.s40.e2" charOffset="62-73"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d485.s40.d0" e1="DDI-DrugBank.d485.s40.e1"
            e2="DDI-DrugBank.d485.s40.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s41" text="Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;">
        <entity id="DDI-DrugBank.d485.s41.e0" charOffset="0-24"
            type="group" text="Tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d485.s41.e1" charOffset="27-39"
            type="drug" text="amitriptyline"/>
        <entity id="DDI-DrugBank.d485.s41.e2" charOffset="42-51"
            type="drug" text="imipramine"/>
        <entity id="DDI-DrugBank.d485.s41.e3" charOffset="54-66"
            type="drug" text="nortriptyline"/>
        <entity id="DDI-DrugBank.d485.s41.e4" charOffset="101-135"
            type="group" text="combination hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d485.s41.e5" charOffset="166-179"
            type="group" text="antidepressant"/>
        <ddi id="DDI-DrugBank.d485.s41.d0" e1="DDI-DrugBank.d485.s41.e0"
            e2="DDI-DrugBank.d485.s41.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s41.d1" e1="DDI-DrugBank.d485.s41.e1"
            e2="DDI-DrugBank.d485.s41.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s41.d2" e1="DDI-DrugBank.d485.s41.e2"
            e2="DDI-DrugBank.d485.s41.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d485.s41.d3" e1="DDI-DrugBank.d485.s41.e3"
            e2="DDI-DrugBank.d485.s41.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s42" text="use caution."/>
    <sentence id="DDI-DrugBank.d485.s43" text="ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.">
        <entity id="DDI-DrugBank.d485.s43.e0" charOffset="0-6"
            type="drug" text="ETHANOL"/>
        <entity id="DDI-DrugBank.d485.s43.e1" charOffset="62-69"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d485.s43.e2" charOffset="90-124"
            type="group" text="combination hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d485.s43.e3" charOffset="153-160"
            type="drug" text="caffeine"/>
        <ddi id="DDI-DrugBank.d485.s43.d0" e1="DDI-DrugBank.d485.s43.e2"
            e2="DDI-DrugBank.d485.s43.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s44" text="Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well;">
        <entity id="DDI-DrugBank.d485.s44.e0" charOffset="27-43"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d485.s44.e1" charOffset="94-105"
            type="drug" text="progesterone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s45" text="clinical implications are unclear."/>
    <sentence id="DDI-DrugBank.d485.s46" text="Herb/Nutraceutical: St Johns wort may decrease the effectiveness of combination hormonal contraceptives by inducing hepatic enzymes.">
        <entity id="DDI-DrugBank.d485.s46.e0" charOffset="68-102"
            type="group" text="combination hormonal contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d485.s47" text="Avoid dong quai and black cohosh (have estrogen activity)."/>
    <sentence id="DDI-DrugBank.d485.s48" text="Avoid saw palmetto, red clover, ginseng."/>
    <sentence id="DDI-DrugBank.d327.s0" text="There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.">
        <entity id="DDI-DrugBank.d327.s0.e0" charOffset="100-109"
            type="drug" text="etidronate"/>
        <entity id="DDI-DrugBank.d327.s0.e1" charOffset="124-131"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d327.s0.d0" e1="DDI-DrugBank.d327.s0.e0"
            e2="DDI-DrugBank.d327.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d327.s1" text="The majority of these reports concerned variable elevations in prothrombin times without clinically significant sequelae."/>
    <sentence id="DDI-DrugBank.d327.s2" text="Although the relevance of these reports and any mechanism of coagulation alterations is unclear, patients on warfarin should have their prothrombin time monitored.">
        <entity id="DDI-DrugBank.d327.s2.e0" charOffset="109-116"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s0" text="ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.">
        <entity id="DDI-DrugBank.d219.s0.e0" charOffset="0-13"
            type="group" text="ACE-inhibitors"/>
        <entity id="DDI-DrugBank.d219.s0.e1" charOffset="36-41"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d219.s0.e2" charOffset="87-100"
            type="group" text="ACE-inhibitors"/>
        <ddi id="DDI-DrugBank.d219.s0.d0" e1="DDI-DrugBank.d219.s0.e1"
            e2="DDI-DrugBank.d219.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s1" text="This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.">
        <entity id="DDI-DrugBank.d219.s1.e0" charOffset="66-71"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d219.s1.e1" charOffset="92-105"
            type="group" text="ACE-inhibitors"/>
        <ddi id="DDI-DrugBank.d219.s1.d0" e1="DDI-DrugBank.d219.s1.e0"
            e2="DDI-DrugBank.d219.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s2" text="Antacids: The concomitant administration of antacids has no apparent effect on the extent of absorption of Lodine.">
        <entity id="DDI-DrugBank.d219.s2.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d219.s2.e1" charOffset="44-51"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d219.s2.e2" charOffset="107-112"
            type="brand" text="Lodine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s3" text="However, antacids can decrease the peak concentration reached by 15% to 20% but have no detectable effect on the time-to-peak.">
        <entity id="DDI-DrugBank.d219.s3.e0" charOffset="9-16"
            type="group" text="antacids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s4" text="Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.">
        <entity id="DDI-DrugBank.d219.s4.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d219.s4.e1" charOffset="14-19"
            type="brand" text="Lodine"/>
        <entity id="DDI-DrugBank.d219.s4.e2" charOffset="42-48"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d219.s4.e3" charOffset="114-121"
            type="drug" text="etodolac"/>
        <ddi id="DDI-DrugBank.d219.s4.d0" e1="DDI-DrugBank.d219.s4.e1"
            e2="DDI-DrugBank.d219.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s5" text="The clinical significance of this interaction is not known;"/>
    <sentence id="DDI-DrugBank.d219.s6" text="however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.">
        <entity id="DDI-DrugBank.d219.s6.e0" charOffset="23-28"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d219.s6.e1" charOffset="61-66"
            type="brand" text="Lodine"/>
        <entity id="DDI-DrugBank.d219.s6.e2" charOffset="72-78"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d219.s6.d0" e1="DDI-DrugBank.d219.s6.e1"
            e2="DDI-DrugBank.d219.s6.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s7" text="Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.">
        <entity id="DDI-DrugBank.d219.s7.e0" charOffset="36-41"
            type="brand" text="Lodine"/>
        <entity id="DDI-DrugBank.d219.s7.e1" charOffset="55-60"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d219.s7.e2" charOffset="192-203"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d219.s7.e3" charOffset="206-212"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d219.s7.e4" charOffset="215-226"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d219.s7.d0" e1="DDI-DrugBank.d219.s7.e0"
            e2="DDI-DrugBank.d219.s7.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d219.s7.d1" e1="DDI-DrugBank.d219.s7.e0"
            e2="DDI-DrugBank.d219.s7.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d219.s7.d2" e1="DDI-DrugBank.d219.s7.e0"
            e2="DDI-DrugBank.d219.s7.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d219.s7.d3" e1="DDI-DrugBank.d219.s7.e1"
            e2="DDI-DrugBank.d219.s7.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d219.s7.d4" e1="DDI-DrugBank.d219.s7.e1"
            e2="DDI-DrugBank.d219.s7.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d219.s7.d5" e1="DDI-DrugBank.d219.s7.e1"
            e2="DDI-DrugBank.d219.s7.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s8" text="Nephrotoxicity associated with cyclosporine may also be enhanced.">
        <entity id="DDI-DrugBank.d219.s8.e0" charOffset="31-42"
            type="drug" text="cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s9" text="Patients receiving these drugs who are given Lodine, or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs.">
        <entity id="DDI-DrugBank.d219.s9.e0" charOffset="45-50"
            type="brand" text="Lodine"/>
        <entity id="DDI-DrugBank.d219.s9.e1" charOffset="66-70"
            type="group" text="NSAID"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s10" text="Diuretics: Etodolac has no apparent pharmacokinetic interaction when administered with furosemide or hydrochlorothiazide.">
        <entity id="DDI-DrugBank.d219.s10.e0" charOffset="0-8"
            type="group" text="Diuretics"/>
        <entity id="DDI-DrugBank.d219.s10.e1" charOffset="87-96"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d219.s10.e2" charOffset="101-119"
            type="drug" text="hydrochlorothiazide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s11" text="Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.">
        <entity id="DDI-DrugBank.d219.s11.e0" charOffset="86-91"
            type="brand" text="Lodine"/>
        <entity id="DDI-DrugBank.d219.s11.e1" charOffset="130-139"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d219.s11.e2" charOffset="145-153"
            type="group" text="thiazides"/>
        <ddi id="DDI-DrugBank.d219.s11.d0" e1="DDI-DrugBank.d219.s11.e0"
            e2="DDI-DrugBank.d219.s11.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d219.s11.d1" e1="DDI-DrugBank.d219.s11.e0"
            e2="DDI-DrugBank.d219.s11.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s12" text="This response has been attributed to inhibition of renal prostaglandin synthesis."/>
    <sentence id="DDI-DrugBank.d219.s13" text="During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.">
        <entity id="DDI-DrugBank.d219.s13.e0" charOffset="32-37"
            type="group" text="NSAIDs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s14" text="Glyburide: Etodolac has no apparent pharmacokinetic interaction when administered with glyburide.">
        <entity id="DDI-DrugBank.d219.s14.e0" charOffset="0-8"
            type="drug" text="Glyburide"/>
        <entity id="DDI-DrugBank.d219.s14.e1" charOffset="11-18"
            type="drug" text="Etodolac"/>
        <entity id="DDI-DrugBank.d219.s14.e2" charOffset="87-95"
            type="drug" text="glyburide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s15" text="Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.">
        <entity id="DDI-DrugBank.d219.s15.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d219.s15.e1" charOffset="9-14"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d219.s15.e2" charOffset="53-59"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d219.s15.e3" charOffset="93-99"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d219.s15.d0" e1="DDI-DrugBank.d219.s15.e1"
            e2="DDI-DrugBank.d219.s15.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s16" text="The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%.">
        <entity id="DDI-DrugBank.d219.s16.e0" charOffset="17-23"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s17" text="These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID.">
        <entity id="DDI-DrugBank.d219.s17.e0" charOffset="89-93"
            type="group" text="NSAID"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s18" text="Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.">
        <entity id="DDI-DrugBank.d219.s18.e0" charOffset="11-16"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d219.s18.e1" charOffset="22-28"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d219.s18.e2" charOffset="112-118"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d219.s18.d0" e1="DDI-DrugBank.d219.s18.e0"
            e2="DDI-DrugBank.d219.s18.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s19" text="Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.">
        <entity id="DDI-DrugBank.d219.s19.e0" charOffset="0-13"
            type="drug" text="Phenylbutazone"/>
        <entity id="DDI-DrugBank.d219.s19.e1" charOffset="16-29"
            type="drug" text="Phenylbutazone"/>
        <entity id="DDI-DrugBank.d219.s19.e2" charOffset="86-93"
            type="drug" text="etodolac"/>
        <ddi id="DDI-DrugBank.d219.s19.d0" e1="DDI-DrugBank.d219.s19.e1"
            e2="DDI-DrugBank.d219.s19.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s20" text="Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.">
        <entity id="DDI-DrugBank.d219.s20.e0" charOffset="54-61"
            type="drug" text="etodolac"/>
        <entity id="DDI-DrugBank.d219.s20.e1" charOffset="107-120"
            type="drug" text="phenylbutazone"/>
        <ddi id="DDI-DrugBank.d219.s20.d0" e1="DDI-DrugBank.d219.s20.e0"
            e2="DDI-DrugBank.d219.s20.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s21" text="Phenytoin: Etodolac has no apparent pharmacokinetic interaction when administered with phenytoin.">
        <entity id="DDI-DrugBank.d219.s21.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d219.s21.e1" charOffset="11-18"
            type="drug" text="Etodolac"/>
        <entity id="DDI-DrugBank.d219.s21.e2" charOffset="87-95"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s22" text="Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.">
        <entity id="DDI-DrugBank.d219.s22.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d219.s22.e1" charOffset="25-32"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d219.s22.e2" charOffset="38-43"
            type="group" text="NSAIDs"/>
        <ddi id="DDI-DrugBank.d219.s22.d0" e1="DDI-DrugBank.d219.s22.e1"
            e2="DDI-DrugBank.d219.s22.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s23" text="Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.">
        <entity id="DDI-DrugBank.d219.s23.e0" charOffset="88-95"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d219.s23.e1" charOffset="101-106"
            type="brand" text="Lodine"/>
        <entity id="DDI-DrugBank.d219.s23.e2" charOffset="110-117"
            type="drug" text="etodolac"/>
        <entity id="DDI-DrugBank.d219.s23.e3" charOffset="179-186"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d219.s23.e4" charOffset="238-245"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d219.s23.d0" e1="DDI-DrugBank.d219.s23.e0"
            e2="DDI-DrugBank.d219.s23.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d219.s23.d1" e1="DDI-DrugBank.d219.s23.e0"
            e2="DDI-DrugBank.d219.s23.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s24" text="There was no significant difference in the pharmacodynamic effect of warfarin administered alone and warfarin administered with Lodine as measured by prothrombin time.">
        <entity id="DDI-DrugBank.d219.s24.e0" charOffset="69-76"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d219.s24.e1" charOffset="101-108"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d219.s24.e2" charOffset="128-133"
            type="brand" text="Lodine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s25" text="Thus, concomitant therapy with warfarin and Lodine should not require dosage adjustment of either drug.">
        <entity id="DDI-DrugBank.d219.s25.e0" charOffset="31-38"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d219.s25.e1" charOffset="44-49"
            type="brand" text="Lodine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s26" text="However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.">
        <entity id="DDI-DrugBank.d219.s26.e0" charOffset="148-155"
            type="drug" text="etodolac"/>
        <entity id="DDI-DrugBank.d219.s26.e1" charOffset="196-203"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d219.s26.d0" e1="DDI-DrugBank.d219.s26.e0"
            e2="DDI-DrugBank.d219.s26.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s27" text="Drug/Laboratory Test Interactions The urine of patients who take Lodine can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of etodolac.">
        <entity id="DDI-DrugBank.d219.s27.e0" charOffset="65-70"
            type="brand" text="Lodine"/>
        <entity id="DDI-DrugBank.d219.s27.e1" charOffset="187-194"
            type="drug" text="etodolac"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s28" text="Diagnostic dip-stick methodology, used to detect ketone bodies in urine, has resulted in false-positive findings in some patients treated with Lodine.">
        <entity id="DDI-DrugBank.d219.s28.e0" charOffset="143-148"
            type="brand" text="Lodine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s29" text="Generally, this phenomenon has not been associated with other clinically significant events."/>
    <sentence id="DDI-DrugBank.d219.s30" text="No dose relationship has been observed."/>
    <sentence id="DDI-DrugBank.d219.s31" text="Lodine treatment is associated with a small decrease in serum uric acid levels.">
        <entity id="DDI-DrugBank.d219.s31.e0" charOffset="0-5"
            type="brand" text="Lodine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s32" text="In clinical trials, mean decreases of 1 to 2 mg/dL were observed in arthritic patients receiving etodolac (600 mg to 1000 mg/day) after 4 weeks of therapy.">
        <entity id="DDI-DrugBank.d219.s32.e0" charOffset="97-104"
            type="drug" text="etodolac"/>
    </sentence>
    <sentence id="DDI-DrugBank.d219.s33" text="These levels then remained stable for up to 1 year of therapy."/>
    <sentence id="DDI-DrugBank.d219.s34" text=""/>
    <sentence id="DDI-DrugBank.d119.s0" text="The following drug interactions have been reported with etomidate.">
        <entity id="DDI-DrugBank.d119.s0.e0" charOffset="56-64"
            type="drug" text="etomidate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d119.s1" text="Drug Effect"/>
    <sentence id="DDI-DrugBank.d119.s2" text="Probenecid    Prolonged action of etomidate">
        <entity id="DDI-DrugBank.d119.s2.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d119.s2.e1" charOffset="34-42"
            type="drug" text="etomidate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d119.s3" text="Diazoxide    Hypotension">
        <entity id="DDI-DrugBank.d119.s3.e0" charOffset="0-8"
            type="drug" text="Diazoxide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d119.s4" text="Zimelidine    etomidate antagonism">
        <entity id="DDI-DrugBank.d119.s4.e0" charOffset="0-9"
            type="drug_n" text="Zimelidine"/>
        <entity id="DDI-DrugBank.d119.s4.e1" charOffset="14-22"
            type="drug" text="etomidate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d119.s5" text="Opioid analgesics    Decreased antinociceptive action">
        <entity id="DDI-DrugBank.d119.s5.e0" charOffset="0-16"
            type="group" text="Opioid analgesics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d119.s6" text="Aminophylline     Etomidate antagonism">
        <entity id="DDI-DrugBank.d119.s6.e0" charOffset="0-12"
            type="drug" text="Aminophylline"/>
        <entity id="DDI-DrugBank.d119.s6.e1" charOffset="18-26"
            type="drug" text="Etomidate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d119.s7" text="Midazolam    Synergism">
        <entity id="DDI-DrugBank.d119.s7.e0" charOffset="0-8"
            type="drug" text="Midazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d484.s0" text="Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.">
        <entity id="DDI-DrugBank.d484.s0.e0" charOffset="0-11"
            type="drug" text="Etonogestrel"/>
        <entity id="DDI-DrugBank.d484.s0.e1" charOffset="58-70"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d484.s0.e2" charOffset="73-79"
            type="brand" text="Tylenol"/>
        <entity id="DDI-DrugBank.d484.s0.e3" charOffset="83-93"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d484.s0.e4" charOffset="103-112"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d484.s0.e5" charOffset="118-129"
            type="drug" text="tetracycline"/>
        <entity id="DDI-DrugBank.d484.s0.e6" charOffset="132-146"
            type="group" text="anticonvulsants"/>
        <entity id="DDI-DrugBank.d484.s0.e7" charOffset="149-156"
            type="brand" text="Dilantin"/>
        <entity id="DDI-DrugBank.d484.s0.e8" charOffset="159-171"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d484.s0.e9" charOffset="174-181"
            type="brand" text="Tegretol"/>
        <entity id="DDI-DrugBank.d484.s0.e10" charOffset="184-192"
            type="brand" text="Trileptal"/>
        <entity id="DDI-DrugBank.d484.s0.e11" charOffset="195-201"
            type="brand" text="Topamax"/>
        <entity id="DDI-DrugBank.d484.s0.e12" charOffset="204-211"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d484.s0.e13" charOffset="215-225"
            type="group" text="antifungals"/>
        <entity id="DDI-DrugBank.d484.s0.e14" charOffset="228-235"
            type="brand" text="Gris-PEG"/>
        <entity id="DDI-DrugBank.d484.s0.e15" charOffset="238-244"
            type="brand" text="Nizoral"/>
        <entity id="DDI-DrugBank.d484.s0.e16" charOffset="247-254"
            type="brand" text="Sporanox"/>
        <entity id="DDI-DrugBank.d484.s0.e17" charOffset="258-269"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d484.s0.e18" charOffset="272-278"
            type="brand" text="Lipitor"/>
        <entity id="DDI-DrugBank.d484.s0.e19" charOffset="282-291"
            type="drug" text="clofibrate"/>
        <entity id="DDI-DrugBank.d484.s0.e20" charOffset="294-302"
            type="brand" text="Atromid-S"/>
        <entity id="DDI-DrugBank.d484.s0.e21" charOffset="306-317"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d484.s0.e22" charOffset="320-325"
            type="brand" text="Neoral"/>
        <entity id="DDI-DrugBank.d484.s0.e23" charOffset="328-337"
            type="brand" text="Sandimmune"/>
        <entity id="DDI-DrugBank.d484.s0.e24" charOffset="365-383"
            type="group" text="protease inhibitors"/>
        <entity id="DDI-DrugBank.d484.s0.e25" charOffset="386-394"
            type="brand" text="Agenerase"/>
        <entity id="DDI-DrugBank.d484.s0.e26" charOffset="397-404"
            type="brand" text="Crixivan"/>
        <entity id="DDI-DrugBank.d484.s0.e27" charOffset="407-415"
            type="brand" text="Fortovase"/>
        <entity id="DDI-DrugBank.d484.s0.e28" charOffset="418-425"
            type="brand" text="Invirase"/>
        <entity id="DDI-DrugBank.d484.s0.e29" charOffset="428-434"
            type="brand" text="Kaletra"/>
        <entity id="DDI-DrugBank.d484.s0.e30" charOffset="437-442"
            type="brand" text="Norvir"/>
        <entity id="DDI-DrugBank.d484.s0.e31" charOffset="445-452"
            type="brand" text="Viracept"/>
        <entity id="DDI-DrugBank.d484.s0.e32" charOffset="456-463"
            type="drug" text="morphine"/>
        <entity id="DDI-DrugBank.d484.s0.e33" charOffset="466-475"
            type="brand" text="Astramorph"/>
        <entity id="DDI-DrugBank.d484.s0.e34" charOffset="478-483"
            type="brand" text="Kadian"/>
        <entity id="DDI-DrugBank.d484.s0.e35" charOffset="486-494"
            type="brand" text="MS Contin"/>
        <entity id="DDI-DrugBank.d484.s0.e36" charOffset="498-511"
            type="drug" text="phenylbutazone"/>
        <entity id="DDI-DrugBank.d484.s0.e37" charOffset="514-525"
            type="drug" text="prednisolone"/>
        <entity id="DDI-DrugBank.d484.s0.e38" charOffset="528-534"
            type="brand" text="Prelone"/>
        <entity id="DDI-DrugBank.d484.s0.e39" charOffset="538-544"
            type="brand" text="rifadin"/>
        <entity id="DDI-DrugBank.d484.s0.e40" charOffset="547-554"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d484.s0.e41" charOffset="574-582"
            type="drug" text="temazepam"/>
        <entity id="DDI-DrugBank.d484.s0.e42" charOffset="585-596"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d484.s0.e43" charOffset="599-606"
            type="brand" text="Theo-Dur"/>
        <entity id="DDI-DrugBank.d484.s0.e44" charOffset="614-622"
            type="drug" text="vitamin C"/>
        <ddi id="DDI-DrugBank.d484.s0.d0" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e1" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d1" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e2" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d2" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e3" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d3" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e4" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d4" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e5" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d5" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e6" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d6" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e7" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d7" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e8" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d8" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e9" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d9" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e10" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d10" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e11" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d11" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e12" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d12" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e13" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d13" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e14" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d14" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e15" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d15" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e16" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d16" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e17" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d17" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e18" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d18" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e19" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d19" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e20" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d20" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e21" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d21" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e22" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d22" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e23" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d23" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e24" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d24" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e25" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d25" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e26" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d26" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e27" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d27" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e28" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d28" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e29" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d29" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e30" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d30" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e31" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d31" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e32" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d32" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e33" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d33" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e34" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d34" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e35" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d35" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e36" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d36" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e37" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d37" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e38" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d38" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e39" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d39" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e40" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d40" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e41" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d41" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e42" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d42" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e43" type="int"/>
        <ddi id="DDI-DrugBank.d484.s0.d43" e1="DDI-DrugBank.d484.s0.e0"
            e2="DDI-DrugBank.d484.s0.e44" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d194.s0" text="Caution should be exercised when administering ETOPOPHOS with drugs that are known to inhibit phosphatase activities (e.g., levamisole hydrochloride).">
        <entity id="DDI-DrugBank.d194.s0.e0" charOffset="47-55"
            type="brand" text="ETOPOPHOS"/>
        <entity id="DDI-DrugBank.d194.s0.e1" charOffset="124-147"
            type="drug" text="levamisole hydrochloride"/>
        <ddi id="DDI-DrugBank.d194.s0.d0" e1="DDI-DrugBank.d194.s0.e0"
            e2="DDI-DrugBank.d194.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d194.s1" text="High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.">
        <entity id="DDI-DrugBank.d194.s1.e0" charOffset="10-22"
            type="drug" text="cyclosporin A"/>
        <entity id="DDI-DrugBank.d194.s1.e1" charOffset="92-100"
            type="drug" text="etoposide"/>
        <entity id="DDI-DrugBank.d194.s1.e2" charOffset="132-140"
            type="drug" text="etoposide"/>
        <entity id="DDI-DrugBank.d194.s1.e3" charOffset="198-206"
            type="drug" text="etoposide"/>
        <entity id="DDI-DrugBank.d194.s1.e4" charOffset="220-228"
            type="drug" text="etoposide"/>
        <ddi id="DDI-DrugBank.d194.s1.d0" e1="DDI-DrugBank.d194.s1.e0"
            e2="DDI-DrugBank.d194.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d435.s0" text="Exemestane is extensively metabolized by CYP 3A4, but coadministration of ketoconazole, a potent inhibitor of CYP 3A4, has no significant effect on exemestane pharmacokinetics.">
        <entity id="DDI-DrugBank.d435.s0.e0" charOffset="0-9"
            type="drug" text="Exemestane"/>
        <entity id="DDI-DrugBank.d435.s0.e1" charOffset="74-85"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d435.s0.e2" charOffset="148-157"
            type="drug" text="exemestane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d435.s1" text="Significant pharmacokinetic interactions mediated by inhibition of CYP isoenzymes therefore appear unlikely."/>
    <sentence id="DDI-DrugBank.d435.s2" text="Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.">
        <entity id="DDI-DrugBank.d435.s2.e0" charOffset="42-51"
            type="drug" text="rifampicin"/>
        <entity id="DDI-DrugBank.d435.s2.e1" charOffset="54-62"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d435.s2.e2" charOffset="65-77"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d435.s2.e3" charOffset="80-92"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d435.s2.e4" charOffset="154-163"
            type="drug" text="exemestane"/>
        <ddi id="DDI-DrugBank.d435.s2.d0" e1="DDI-DrugBank.d435.s2.e0"
            e2="DDI-DrugBank.d435.s2.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d435.s2.d1" e1="DDI-DrugBank.d435.s2.e1"
            e2="DDI-DrugBank.d435.s2.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d435.s2.d2" e1="DDI-DrugBank.d435.s2.e2"
            e2="DDI-DrugBank.d435.s2.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d435.s2.d3" e1="DDI-DrugBank.d435.s2.e3"
            e2="DDI-DrugBank.d435.s2.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d435.s3" text="Dose modification is recommended for patients who are also receiving a potent CYP 3A4 inducer."/>
    <sentence id="DDI-DrugBank.d435.s4" text="Drug/Laboratory Tests Interactions No clinically relevant changes in the results of clinical laboratory tests have been observed."/>
    <sentence id="DDI-DrugBank.d112.s0" text="Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.">
        <entity id="DDI-DrugBank.d112.s0.e0" charOffset="20-29"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d112.s0.e1" charOffset="154-164"
            type="drug" text="penciclovir"/>
        <ddi id="DDI-DrugBank.d112.s0.d0" e1="DDI-DrugBank.d112.s0.e0"
            e2="DDI-DrugBank.d112.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d112.s1" text="The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase.">
        <entity id="DDI-DrugBank.d112.s1.e0" charOffset="18-36"
            type="drug_n" text="6-deoxy penciclovir"/>
        <entity id="DDI-DrugBank.d112.s1.e1" charOffset="41-51"
            type="drug" text="penciclovir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d112.s2" text="Interactions with other drugs metabolized by this enzyme could potentially occur."/>
    <sentence id="DDI-DrugBank.d203.s0" text="No drug interactions have been identified."/>
    <sentence id="DDI-DrugBank.d203.s1" text="Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system.">
        <entity id="DDI-DrugBank.d203.s1.e0" charOffset="13-22"
            type="drug" text="famotidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d203.s2" text="Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine.">
        <entity id="DDI-DrugBank.d203.s2.e0" charOffset="32-39"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d203.s2.e1" charOffset="42-53"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d203.s2.e2" charOffset="56-64"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d203.s2.e3" charOffset="67-74"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d203.s2.e4" charOffset="77-87"
            type="drug" text="aminopyrine"/>
        <entity id="DDI-DrugBank.d203.s2.e5" charOffset="93-102"
            type="drug" text="antipyrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d203.s3" text="Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.">
        <entity id="DDI-DrugBank.d203.s3.e0" charOffset="0-16"
            type="drug_n" text="Indocyanine green"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s0" text="The drug interaction data described in this section were obtained from controlled clinical trials and studies involving otherwise healthy adults with epilepsy."/>
    <sentence id="DDI-DrugBank.d434.s1" text="Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.">
        <entity id="DDI-DrugBank.d434.s1.e0" charOffset="30-48"
            type="group" text="Antiepileptic Drugs"/>
        <entity id="DDI-DrugBank.d434.s1.e1" charOffset="67-74"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s1.e2" charOffset="80-98"
            type="group" text="antiepileptic drugs"/>
        <entity id="DDI-DrugBank.d434.s1.e3" charOffset="101-104"
            type="group" text="AEDs"/>
        <entity id="DDI-DrugBank.d434.s1.e4" charOffset="157-160"
            type="group" text="AEDs"/>
        <ddi id="DDI-DrugBank.d434.s1.d0" e1="DDI-DrugBank.d434.s1.e1"
            e2="DDI-DrugBank.d434.s1.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d434.s1.d1" e1="DDI-DrugBank.d434.s1.e1"
            e2="DDI-DrugBank.d434.s1.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s2" text="The net effect of these interactions is summarized in the following table: AED AED Felbatol">
        <entity id="DDI-DrugBank.d434.s2.e0" charOffset="75-77"
            type="group" text="AED"/>
        <entity id="DDI-DrugBank.d434.s2.e1" charOffset="79-81"
            type="group" text="AED"/>
        <entity id="DDI-DrugBank.d434.s2.e2" charOffset="83-90"
            type="brand" text="Felbatol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s3" text="Coadministered Concentration Concentration"/>
    <sentence id="DDI-DrugBank.d434.s4" text="Phenytoin">
        <entity id="DDI-DrugBank.d434.s4.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s5" text="Valproate    **">
        <entity id="DDI-DrugBank.d434.s5.e0" charOffset="0-8"
            type="drug" text="Valproate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s6" text="Carbamazepine (CBZ)">
        <entity id="DDI-DrugBank.d434.s6.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d434.s6.e1" charOffset="15-17"
            type="drug" text="CBZ"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s7" text="*CBZ epoxide"/>
    <sentence id="DDI-DrugBank.d434.s8" text="Phenobarbital">
        <entity id="DDI-DrugBank.d434.s8.e0" charOffset="0-12"
            type="drug" text="Phenobarbital"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s9" text="*Not administered, but an active metabolite of carbamazepine.">
        <entity id="DDI-DrugBank.d434.s9.e0" charOffset="47-59"
            type="drug" text="carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s10" text="**No significant effect."/>
    <sentence id="DDI-DrugBank.d434.s11" text="Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.">
        <entity id="DDI-DrugBank.d434.s11.e0" charOffset="20-27"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s11.e1" charOffset="39-57"
            type="group" text="Antiepileptic Drugs"/>
        <entity id="DDI-DrugBank.d434.s11.e2" charOffset="59-67"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d434.s11.e3" charOffset="70-77"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s11.e4" charOffset="115-123"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d434.s11.d0" e1="DDI-DrugBank.d434.s11.e3"
            e2="DDI-DrugBank.d434.s11.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s12" text="In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steadystate trough (Cmin) phenytoin plasma concentration was 17 5 micrograms/mL.">
        <entity id="DDI-DrugBank.d434.s12.e0" charOffset="57-65"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d434.s12.e1" charOffset="98-106"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s13" text="The steady-state Cmin increased to 21 5 micrograms/mL when 1200 mg/day of felbamate was coadministered.">
        <entity id="DDI-DrugBank.d434.s13.e0" charOffset="74-82"
            type="drug" text="felbamate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s14" text="Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.">
        <entity id="DDI-DrugBank.d434.s14.e0" charOffset="15-23"
            type="drug" text="felbamate"/>
        <entity id="DDI-DrugBank.d434.s14.e1" charOffset="97-105"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d434.s14.d0" e1="DDI-DrugBank.d434.s14.e0"
            e2="DDI-DrugBank.d434.s14.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s15" text="In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.">
        <entity id="DDI-DrugBank.d434.s15.e0" charOffset="21-29"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d434.s15.e1" charOffset="82-90"
            type="drug" text="felbamate"/>
        <entity id="DDI-DrugBank.d434.s15.e2" charOffset="115-123"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d434.s15.d0" e1="DDI-DrugBank.d434.s15.e1"
            e2="DDI-DrugBank.d434.s15.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s16" text="In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.">
        <entity id="DDI-DrugBank.d434.s16.e0" charOffset="55-63"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d434.s16.e1" charOffset="91-98"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s16.e2" charOffset="121-129"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d434.s16.e3" charOffset="167-174"
            type="brand" text="Felbatol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s17" text="Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.">
        <entity id="DDI-DrugBank.d434.s17.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d434.s17.e1" charOffset="15-22"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s17.e2" charOffset="63-75"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d434.s17.e3" charOffset="135-155"
            type="drug_n" text="carbamazepine epoxide"/>
        <ddi id="DDI-DrugBank.d434.s17.d0" e1="DDI-DrugBank.d434.s17.e1"
            e2="DDI-DrugBank.d434.s17.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s18" text="In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8 2 micrograms/mL.">
        <entity id="DDI-DrugBank.d434.s18.e0" charOffset="59-71"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d434.s18.e1" charOffset="105-117"
            type="drug" text="carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s19" text="The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.">
        <entity id="DDI-DrugBank.d434.s19.e0" charOffset="4-16"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d434.s19.e1" charOffset="76-84"
            type="drug" text="felbamate"/>
        <ddi id="DDI-DrugBank.d434.s19.d0" e1="DDI-DrugBank.d434.s19.e0"
            e2="DDI-DrugBank.d434.s19.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s20" text="Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.0 0.3 to 1.6 0.4 micrograms/mL with the addition of felbamate.">
        <entity id="DDI-DrugBank.d434.s20.e0" charOffset="0-20"
            type="drug_n" text="Carbamazepine epoxide"/>
        <entity id="DDI-DrugBank.d434.s20.e1" charOffset="128-136"
            type="drug" text="felbamate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s21" text="In clinical trials, similar changes in carbamazepine and carbamazepine epoxide were seen.">
        <entity id="DDI-DrugBank.d434.s21.e0" charOffset="39-51"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d434.s21.e1" charOffset="57-77"
            type="drug_n" text="carbamazepine epoxide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s22" text="Valproate: Felbatol  causes an increase in steady-state valproate concentrations.">
        <entity id="DDI-DrugBank.d434.s22.e0" charOffset="0-8"
            type="drug" text="Valproate"/>
        <entity id="DDI-DrugBank.d434.s22.e1" charOffset="11-18"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s22.e2" charOffset="56-64"
            type="drug" text="valproate"/>
        <ddi id="DDI-DrugBank.d434.s22.d0" e1="DDI-DrugBank.d434.s22.e1"
            e2="DDI-DrugBank.d434.s22.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s23" text="In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63 16 micrograms/mL.">
        <entity id="DDI-DrugBank.d434.s23.e0" charOffset="41-49"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d434.s23.e1" charOffset="83-91"
            type="drug" text="valproate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s24" text="The steady-state Cmin increased to 78 14 micrograms/mL when 1200 mg/day of felbamate was coadministered.">
        <entity id="DDI-DrugBank.d434.s24.e0" charOffset="75-83"
            type="drug" text="felbamate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s25" text="Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.">
        <entity id="DDI-DrugBank.d434.s25.e0" charOffset="15-23"
            type="drug" text="felbamate"/>
        <entity id="DDI-DrugBank.d434.s25.e1" charOffset="71-79"
            type="drug" text="valproate"/>
        <ddi id="DDI-DrugBank.d434.s25.d0" e1="DDI-DrugBank.d434.s25.e0"
            e2="DDI-DrugBank.d434.s25.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s26" text="Corresponding values for free valproate Cmin concentrations were 7 3, 9 4, and 11 6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol , respectively.">
        <entity id="DDI-DrugBank.d434.s26.e0" charOffset="30-38"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d434.s26.e1" charOffset="127-134"
            type="brand" text="Felbatol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s27" text="The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol , respectively.">
        <entity id="DDI-DrugBank.d434.s27.e0" charOffset="34-42"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d434.s27.e1" charOffset="69-77"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d434.s27.e2" charOffset="163-170"
            type="brand" text="Felbatol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s28" text="Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.">
        <entity id="DDI-DrugBank.d434.s28.e0" charOffset="0-12"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d434.s28.e1" charOffset="35-43"
            type="drug" text="felbamate"/>
        <entity id="DDI-DrugBank.d434.s28.e2" charOffset="50-62"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d434.s28.e3" charOffset="86-98"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d434.s28.e4" charOffset="173-185"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d434.s28.e5" charOffset="219-231"
            type="drug" text="phenobarbital"/>
        <ddi id="DDI-DrugBank.d434.s28.d0" e1="DDI-DrugBank.d434.s28.e1"
            e2="DDI-DrugBank.d434.s28.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s29" text="The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week.">
        <entity id="DDI-DrugBank.d434.s29.e0" charOffset="88-96"
            type="drug" text="felbamate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s30" text="Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.">
        <entity id="DDI-DrugBank.d434.s30.e0" charOffset="17-35"
            type="group" text="Antiepileptic Drugs"/>
        <entity id="DDI-DrugBank.d434.s30.e1" charOffset="40-47"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s30.e2" charOffset="50-58"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d434.s30.e3" charOffset="61-69"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d434.s30.e4" charOffset="122-129"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s30.e5" charOffset="133-141"
            type="drug" text="felbamate"/>
        <entity id="DDI-DrugBank.d434.s30.e6" charOffset="192-200"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d434.s30.e7" charOffset="282-289"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s30.e8" charOffset="324-331"
            type="brand" text="Felbatol"/>
        <ddi id="DDI-DrugBank.d434.s30.d0" e1="DDI-DrugBank.d434.s30.e3"
            e2="DDI-DrugBank.d434.s30.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d434.s30.d1" e1="DDI-DrugBank.d434.s30.e3"
            e2="DDI-DrugBank.d434.s30.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d434.s30.d2" e1="DDI-DrugBank.d434.s30.e6"
            e2="DDI-DrugBank.d434.s30.e7" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s31" text="Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.">
        <entity id="DDI-DrugBank.d434.s31.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d434.s31.e1" charOffset="15-27"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d434.s31.e2" charOffset="84-91"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s31.e3" charOffset="142-154"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d434.s31.e4" charOffset="240-247"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s31.e5" charOffset="282-289"
            type="brand" text="Felbatol"/>
        <ddi id="DDI-DrugBank.d434.s31.d0" e1="DDI-DrugBank.d434.s31.e1"
            e2="DDI-DrugBank.d434.s31.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d434.s31.d1" e1="DDI-DrugBank.d434.s31.e3"
            e2="DDI-DrugBank.d434.s31.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s32" text="Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.">
        <entity id="DDI-DrugBank.d434.s32.e0" charOffset="0-8"
            type="drug" text="Valproate"/>
        <entity id="DDI-DrugBank.d434.s32.e1" charOffset="73-81"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d434.s32.e2" charOffset="103-110"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s32.e3" charOffset="157-165"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d434.s32.e4" charOffset="225-232"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s32.e5" charOffset="236-244"
            type="drug" text="felbamate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s33" text="Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.">
        <entity id="DDI-DrugBank.d434.s33.e0" charOffset="0-12"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d434.s33.e1" charOffset="31-43"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d434.s33.e2" charOffset="63-71"
            type="drug" text="felbamate"/>
        <ddi id="DDI-DrugBank.d434.s33.d0" e1="DDI-DrugBank.d434.s33.e1"
            e2="DDI-DrugBank.d434.s33.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s34" text="Steady-state plasma felbamate concentrations were found to be 29% lower than the mean concentrations of a group of newly diagnosed subjects with epilepsy also receiving 2400 mg of felbamate a day.">
        <entity id="DDI-DrugBank.d434.s34.e0" charOffset="20-28"
            type="drug" text="felbamate"/>
        <entity id="DDI-DrugBank.d434.s34.e1" charOffset="180-188"
            type="drug" text="felbamate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s35" text="Effects of Antacids on Felbatol  The rate and extent of absorption of a 2400 mg dose of Felbatol  as monotherapy given as tablets was not affected when coadministered with antacids.">
        <entity id="DDI-DrugBank.d434.s35.e0" charOffset="11-18"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d434.s35.e1" charOffset="23-30"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s35.e2" charOffset="88-95"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s35.e3" charOffset="172-179"
            type="group" text="antacids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s36" text="Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.">
        <entity id="DDI-DrugBank.d434.s36.e0" charOffset="11-22"
            type="drug" text="Erythromycin"/>
        <entity id="DDI-DrugBank.d434.s36.e1" charOffset="27-34"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s36.e2" charOffset="61-72"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d434.s36.e3" charOffset="182-190"
            type="drug" text="felbamate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s37" text="Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.">
        <entity id="DDI-DrugBank.d434.s37.e0" charOffset="11-18"
            type="brand" text="Felbatol"/>
        <entity id="DDI-DrugBank.d434.s37.e1" charOffset="33-63"
            type="group" text="Combination Oral Contraceptives"/>
        <entity id="DDI-DrugBank.d434.s37.e2" charOffset="146-158"
            type="group" text="contraceptive"/>
        <entity id="DDI-DrugBank.d434.s37.e3" charOffset="185-201"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d434.s37.e4" charOffset="213-221"
            type="drug" text="gestodene"/>
        <entity id="DDI-DrugBank.d434.s37.e5" charOffset="269-277"
            type="drug" text="felbamate"/>
        <entity id="DDI-DrugBank.d434.s37.e6" charOffset="347-359"
            type="group" text="contraceptive"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s38" text="Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.">
        <entity id="DDI-DrugBank.d434.s38.e0" charOffset="0-8"
            type="drug" text="Felbamate"/>
        <entity id="DDI-DrugBank.d434.s38.e1" charOffset="54-62"
            type="drug" text="gestodene"/>
        <entity id="DDI-DrugBank.d434.s38.e2" charOffset="158-174"
            type="drug" text="ethinyl estradiol"/>
        <ddi id="DDI-DrugBank.d434.s38.d0" e1="DDI-DrugBank.d434.s38.e0"
            e2="DDI-DrugBank.d434.s38.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d434.s39" text="No volunteer showed hormonal evidence of ovulation, but one volunteer reported intermenstrual bleeding during felbamate treatment.">
        <entity id="DDI-DrugBank.d434.s39.e0" charOffset="110-118"
            type="drug" text="felbamate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s0" text="CYP3A4 Inhibitors Felodipine is metabolized by CYP3A4.">
        <entity id="DDI-DrugBank.d316.s0.e0" charOffset="0-5"
            type="drug" text="CYP3A4"/>
        <entity id="DDI-DrugBank.d316.s0.e1" charOffset="47-52"
            type="drug" text="CYP3A4"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s1" text="Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.">
        <entity id="DDI-DrugBank.d316.s1.e0" charOffset="44-55"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d316.s1.e1" charOffset="58-69"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d316.s1.e2" charOffset="72-83"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d316.s1.e3" charOffset="104-113"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d316.s1.e4" charOffset="121-130"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d316.s1.e5" charOffset="192-201"
            type="drug" text="felodipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s2" text="These increases in concentration may lead to increased effects, (lower blood pressure and increased heart rate)."/>
    <sentence id="DDI-DrugBank.d316.s3" text="These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor).">
        <entity id="DDI-DrugBank.d316.s3.e0" charOffset="59-70"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d316.s3.e1" charOffset="82-87"
            type="drug" text="CYP3A4"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s4" text="Caution should be used when CYP3A4 inhibitors are co-administered with felodipine.">
        <entity id="DDI-DrugBank.d316.s4.e0" charOffset="28-33"
            type="drug" text="CYP3A4"/>
        <entity id="DDI-DrugBank.d316.s4.e1" charOffset="71-80"
            type="drug" text="felodipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s5" text="A conservative approach to dosing felodipine should be taken.">
        <entity id="DDI-DrugBank.d316.s5.e0" charOffset="34-43"
            type="drug" text="felodipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s6" text="The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.">
        <entity id="DDI-DrugBank.d316.s6.e0" charOffset="130-139"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d316.s6.e1" charOffset="146-157"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d316.s6.e2" charOffset="298-307"
            type="drug" text="felodipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s7" text="Erythromycin Co-administration of felodipine (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.">
        <entity id="DDI-DrugBank.d316.s7.e0" charOffset="34-43"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d316.s7.e1" charOffset="46-52"
            type="drug" text="PLENDIL"/>
        <entity id="DDI-DrugBank.d316.s7.e2" charOffset="60-71"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d316.s7.e3" charOffset="191-200"
            type="drug" text="felodipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s8" text="Grapefruit juice Co-administration of felodipine with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of felodipine.">
        <entity id="DDI-DrugBank.d316.s8.e0" charOffset="38-47"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d316.s8.e1" charOffset="171-180"
            type="drug" text="felodipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s9" text="Cimetidine Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine.">
        <entity id="DDI-DrugBank.d316.s9.e0" charOffset="32-41"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d316.s9.e1" charOffset="48-57"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d316.s9.e2" charOffset="167-176"
            type="drug" text="felodipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s10" text="Beta-Blocking Agents  A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine.">
        <entity id="DDI-DrugBank.d316.s10.e0" charOffset="49-58"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d316.s10.e1" charOffset="80-89"
            type="drug" text="metoprolol"/>
        <entity id="DDI-DrugBank.d316.s10.e2" charOffset="154-163"
            type="drug" text="felodipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s11" text="The AUC and Cmax of metoprolol, however, were increased approximately 31 and 38%, respectively.">
        <entity id="DDI-DrugBank.d316.s11.e0" charOffset="20-29"
            type="drug" text="metoprolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s12" text="In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.">
        <entity id="DDI-DrugBank.d316.s12.e0" charOffset="40-52"
            type="drug" text="beta blockers"/>
        <entity id="DDI-DrugBank.d316.s12.e1" charOffset="64-73"
            type="drug" text="metoprolol"/>
        <entity id="DDI-DrugBank.d316.s12.e2" charOffset="111-120"
            type="drug" text="felodipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s13" text="Digoxin  When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered.">
        <entity id="DDI-DrugBank.d316.s13.e0" charOffset="39-45"
            type="drug" text="PLENDIL"/>
        <entity id="DDI-DrugBank.d316.s13.e1" charOffset="71-77"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s14" text="Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.">
        <entity id="DDI-DrugBank.d316.s14.e0" charOffset="0-14"
            type="group" text="Anticonvulsants"/>
        <entity id="DDI-DrugBank.d316.s14.e1" charOffset="78-87"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d316.s14.e2" charOffset="148-161"
            type="group" text="anticonvulsant"/>
        <entity id="DDI-DrugBank.d316.s14.e3" charOffset="176-184"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d316.s14.e4" charOffset="187-199"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d316.s14.e5" charOffset="205-217"
            type="drug" text="phenobarbital"/>
        <ddi id="DDI-DrugBank.d316.s14.d0" e1="DDI-DrugBank.d316.s14.e1"
            e2="DDI-DrugBank.d316.s14.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d316.s14.d1" e1="DDI-DrugBank.d316.s14.e1"
            e2="DDI-DrugBank.d316.s14.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d316.s14.d2" e1="DDI-DrugBank.d316.s14.e1"
            e2="DDI-DrugBank.d316.s14.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d316.s14.d3" e1="DDI-DrugBank.d316.s14.e1"
            e2="DDI-DrugBank.d316.s14.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s15" text="In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately 6% of that observed in healthy volunteers.">
        <entity id="DDI-DrugBank.d316.s15.e0" charOffset="42-51"
            type="drug" text="felodipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s16" text="Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.">
        <entity id="DDI-DrugBank.d316.s16.e0" charOffset="75-90"
            type="drug" text="antihypertensive"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s17" text="Tacrolimus  Felodipine may increase the blood concentration of tacrolimus.">
        <entity id="DDI-DrugBank.d316.s17.e0" charOffset="12-21"
            type="drug" text="Felodipine"/>
        <entity id="DDI-DrugBank.d316.s17.e1" charOffset="63-72"
            type="drug" text="tacrolimus"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s18" text="When given concomitantly with felodipine, the tacrolimus blood concentration should be followed and the tacrolimus dose may need to be adjusted.">
        <entity id="DDI-DrugBank.d316.s18.e0" charOffset="30-39"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d316.s18.e1" charOffset="46-55"
            type="drug" text="tacrolimus"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s19" text="Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.">
        <entity id="DDI-DrugBank.d316.s19.e0" charOffset="102-111"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d316.s19.e1" charOffset="142-153"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d316.s19.e2" charOffset="158-171"
            type="drug" text="spironolactone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d316.s20" text="Interaction with Food  See CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism."/>
    <sentence id="DDI-DrugBank.d104.s0" text="Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.">
        <entity id="DDI-DrugBank.d104.s0.e0" charOffset="0-11"
            type="drug" text="Fenfluramine"/>
        <entity id="DDI-DrugBank.d104.s0.e1" charOffset="49-70"
            type="group" text="antihypertensive drugs"/>
        <entity id="DDI-DrugBank.d104.s0.e2" charOffset="79-90"
            type="drug" text="guanethidine"/>
        <entity id="DDI-DrugBank.d104.s0.e3" charOffset="93-102"
            type="drug" text="methyldopa"/>
        <entity id="DDI-DrugBank.d104.s0.e4" charOffset="105-113"
            type="drug" text="reserpine"/>
        <ddi id="DDI-DrugBank.d104.s0.d0" e1="DDI-DrugBank.d104.s0.e0"
            e2="DDI-DrugBank.d104.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d104.s0.d1" e1="DDI-DrugBank.d104.s0.e0"
            e2="DDI-DrugBank.d104.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d104.s0.d2" e1="DDI-DrugBank.d104.s0.e0"
            e2="DDI-DrugBank.d104.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d104.s0.d3" e1="DDI-DrugBank.d104.s0.e0"
            e2="DDI-DrugBank.d104.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d104.s1" text="Other CNS depressant drugs should be used with caution in patients taking fenfluramine, since the effects may be additive.">
        <entity id="DDI-DrugBank.d104.s1.e0" charOffset="6-25"
            type="group" text="CNS depressant drugs"/>
        <entity id="DDI-DrugBank.d104.s1.e1" charOffset="74-85"
            type="drug" text="fenfluramine"/>
        <ddi id="DDI-DrugBank.d104.s1.d0" e1="DDI-DrugBank.d104.s1.e0"
            e2="DDI-DrugBank.d104.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s0" text="Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR.">
        <entity id="DDI-DrugBank.d283.s0.e0" charOffset="5-18"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d283.s0.e1" charOffset="53-75"
            type="group" text="COUMARIN ANTICOAGULANTS"/>
        <entity id="DDI-DrugBank.d283.s0.e2" charOffset="107-112"
            type="brand" text="TRICOR"/>
        <ddi id="DDI-DrugBank.d283.s0.d0" e1="DDI-DrugBank.d283.s0.e1"
            e2="DDI-DrugBank.d283.s0.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s1" text="THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS.">
        <entity id="DDI-DrugBank.d283.s1.e0" charOffset="18-31"
            type="group" text="ANTICOAGULANTS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s2" text="FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED."/>
    <sentence id="DDI-DrugBank.d283.s3" text="HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.">
        <entity id="DDI-DrugBank.d283.s3.e0" charOffset="0-27"
            type="group" text="HMG-CoA reductase inhibitors"/>
        <entity id="DDI-DrugBank.d283.s3.e1" charOffset="50-55"
            type="brand" text="TRICOR"/>
        <entity id="DDI-DrugBank.d283.s3.e2" charOffset="61-88"
            type="group" text="HMG-CoA reductase inhibitors"/>
        <ddi id="DDI-DrugBank.d283.s3.d0" e1="DDI-DrugBank.d283.s3.e1"
            e2="DDI-DrugBank.d283.s3.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s4" text="Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.">
        <entity id="DDI-DrugBank.d283.s4.e0" charOffset="0-5"
            type="group" text="Resins"/>
        <entity id="DDI-DrugBank.d283.s4.e1" charOffset="14-35"
            type="group" text="bile acid sequestrants"/>
        <entity id="DDI-DrugBank.d283.s4.e2" charOffset="99-104"
            type="brand" text="TRICOR"/>
        <entity id="DDI-DrugBank.d283.s4.e3" charOffset="150-172"
            type="group" text="bile acid binding resin"/>
        <ddi id="DDI-DrugBank.d283.s4.d0" e1="DDI-DrugBank.d283.s4.e2"
            e2="DDI-DrugBank.d283.s4.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s5" text="Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.">
        <entity id="DDI-DrugBank.d283.s5.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d283.s5.e1" charOffset="22-33"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d283.s5.e2" charOffset="196-208"
            type="group" text="fibrate drugs"/>
        <entity id="DDI-DrugBank.d283.s5.e3" charOffset="220-225"
            type="brand" text="TRICOR"/>
        <ddi id="DDI-DrugBank.d283.s5.d0" e1="DDI-DrugBank.d283.s5.e1"
            e2="DDI-DrugBank.d283.s5.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d283.s5.d1" e1="DDI-DrugBank.d283.s5.e1"
            e2="DDI-DrugBank.d283.s5.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s6" text="The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed">
        <entity id="DDI-DrugBank.d283.s6.e0" charOffset="32-37"
            type="brand" text="TRICOR"/>
        <entity id="DDI-DrugBank.d283.s6.e1" charOffset="44-61"
            type="group" text="immunosuppressants"/>
        <ddi id="DDI-DrugBank.d283.s6.d0" e1="DDI-DrugBank.d283.s6.e0"
            e2="DDI-DrugBank.d283.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s7" text="."/>
    <sentence id="DDI-DrugBank.d283.s8" text="Drug-drug interactions In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.">
        <entity id="DDI-DrugBank.d283.s8.e0" charOffset="83-93"
            type="drug" text="fenofibrate"/>
        <entity id="DDI-DrugBank.d283.s8.e1" charOffset="99-113"
            type="drug_n" text="fenofibric acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s9" text="They are weak inhibitors of CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations."/>
    <sentence id="DDI-DrugBank.d283.s10" text="Potentiation of coumarin-type anticoagulants has been observed with prolongation of the prothrombin time/INR.">
        <entity id="DDI-DrugBank.d283.s10.e0" charOffset="16-43"
            type="group" text="coumarin-type anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s11" text="Bile acid sequestrants have been shown to bind other drugs given concurrently.">
        <entity id="DDI-DrugBank.d283.s11.e0" charOffset="0-21"
            type="group" text="Bile acid sequestrants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s12" text="Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .">
        <entity id="DDI-DrugBank.d283.s12.e0" charOffset="11-21"
            type="drug" text="fenofibrate"/>
        <entity id="DDI-DrugBank.d283.s12.e1" charOffset="83-105"
            type="group" text="bile acid binding resin"/>
        <ddi id="DDI-DrugBank.d283.s12.d0" e1="DDI-DrugBank.d283.s12.e0"
            e2="DDI-DrugBank.d283.s12.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s13" text="Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.">
        <entity id="DDI-DrugBank.d283.s13.e0" charOffset="30-40"
            type="drug" text="fenofibrate"/>
        <entity id="DDI-DrugBank.d283.s13.e1" charOffset="63-68"
            type="brand" text="TRICOR"/>
        <entity id="DDI-DrugBank.d283.s13.e2" charOffset="76-86"
            type="drug" text="pravastatin"/>
        <entity id="DDI-DrugBank.d283.s13.e3" charOffset="179-189"
            type="drug" text="pravastatin"/>
        <ddi id="DDI-DrugBank.d283.s13.d0" e1="DDI-DrugBank.d283.s13.e0"
            e2="DDI-DrugBank.d283.s13.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d283.s13.d1" e1="DDI-DrugBank.d283.s13.e1"
            e2="DDI-DrugBank.d283.s13.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s14" text="A single dose of pravastatin had no clinically important effect on the pharmacokinetics of fenofibric acid.">
        <entity id="DDI-DrugBank.d283.s14.e0" charOffset="17-27"
            type="drug" text="pravastatin"/>
        <entity id="DDI-DrugBank.d283.s14.e1" charOffset="91-105"
            type="drug_n" text="fenofibric acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s15" text="Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.">
        <entity id="DDI-DrugBank.d283.s15.e0" charOffset="30-40"
            type="drug" text="fenofibrate"/>
        <entity id="DDI-DrugBank.d283.s15.e1" charOffset="64-69"
            type="brand" text="TRICOR"/>
        <entity id="DDI-DrugBank.d283.s15.e2" charOffset="77-88"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d283.s15.e3" charOffset="205-216"
            type="drug" text="atorvastatin"/>
        <ddi id="DDI-DrugBank.d283.s15.d0" e1="DDI-DrugBank.d283.s15.e0"
            e2="DDI-DrugBank.d283.s15.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d283.s15.d1" e1="DDI-DrugBank.d283.s15.e1"
            e2="DDI-DrugBank.d283.s15.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s16" text="The atorvastatin Cmax values were not significantly affected by fenofibrate.">
        <entity id="DDI-DrugBank.d283.s16.e0" charOffset="4-15"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d283.s16.e1" charOffset="64-74"
            type="drug" text="fenofibrate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s17" text="The pharmacokinetics of fenofibric acid were not significantly affected by atorvastatin">
        <entity id="DDI-DrugBank.d283.s17.e0" charOffset="24-38"
            type="drug_n" text="fenofibric acid"/>
        <entity id="DDI-DrugBank.d283.s17.e1" charOffset="75-86"
            type="drug" text="atorvastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d283.s18" text="."/>
    <sentence id="DDI-DrugBank.d283.s19" text=""/>
    <sentence id="DDI-DrugBank.d546.s0" text="Drug Interactions with Beta-Blockers: Concomitant use of fenoldopam with beta-blockers should be avoided.">
        <entity id="DDI-DrugBank.d546.s0.e0" charOffset="23-35"
            type="group" text="Beta-Blockers"/>
        <entity id="DDI-DrugBank.d546.s0.e1" charOffset="57-66"
            type="drug" text="fenoldopam"/>
        <entity id="DDI-DrugBank.d546.s0.e2" charOffset="73-85"
            type="group" text="beta-blockers"/>
        <ddi id="DDI-DrugBank.d546.s0.d0" e1="DDI-DrugBank.d546.s0.e1"
            e2="DDI-DrugBank.d546.s0.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d546.s1" text="If the drugs are used together, caution should be exercised because unexpected hypotension could result from beta-blocker inhibition of the sympathetic reflex response to fenoldopam.">
        <entity id="DDI-DrugBank.d546.s1.e0" charOffset="171-180"
            type="drug" text="fenoldopam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d546.s2" text="Drug Interactions, General: Although there have been no formal interaction studies, intravenous fenoldopam has been administered safely with drugs such as digitalis and sublingual nitroglycerin.">
        <entity id="DDI-DrugBank.d546.s2.e0" charOffset="96-105"
            type="drug" text="fenoldopam"/>
        <entity id="DDI-DrugBank.d546.s2.e1" charOffset="155-163"
            type="group" text="digitalis"/>
        <entity id="DDI-DrugBank.d546.s2.e2" charOffset="180-192"
            type="drug" text="nitroglycerin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d546.s3" text="There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers, ACE inhibitors, and diuretics (both thiazide-like and loop).">
        <entity id="DDI-DrugBank.d546.s3.e0" charOffset="45-67"
            type="group" text="antihypertensive agents"/>
        <entity id="DDI-DrugBank.d546.s3.e1" charOffset="77-90"
            type="group" text="alpha-blockers"/>
        <entity id="DDI-DrugBank.d546.s3.e2" charOffset="93-116"
            type="group" text="calcium channel-blockers"/>
        <entity id="DDI-DrugBank.d546.s3.e3" charOffset="119-132"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d546.s3.e4" charOffset="139-147"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d546.s3.e5" charOffset="155-162"
            type="group" text="thiazide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d154.s0" text="The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.">
        <entity id="DDI-DrugBank.d154.s0.e0" charOffset="24-30"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d154.s0.e1" charOffset="68-77"
            type="drug" text="fenoprofen"/>
        <entity id="DDI-DrugBank.d154.s0.e2" charOffset="161-183"
            type="drug_n" text="hydroxylated fenoprofen"/>
        <ddi id="DDI-DrugBank.d154.s0.d0" e1="DDI-DrugBank.d154.s0.e0"
            e2="DDI-DrugBank.d154.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d154.s1" text="Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.">
        <entity id="DDI-DrugBank.d154.s1.e0" charOffset="46-55"
            type="drug" text="fenoprofen"/>
        <entity id="DDI-DrugBank.d154.s1.e1" charOffset="61-67"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d154.s1.e2" charOffset="128-137"
            type="drug" text="fenoprofen"/>
        <ddi id="DDI-DrugBank.d154.s1.d0" e1="DDI-DrugBank.d154.s1.e0"
            e2="DDI-DrugBank.d154.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d154.s2" text="Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.">
        <entity id="DDI-DrugBank.d154.s2.e0" charOffset="8-13"
            type="brand" text="Nalfon"/>
        <entity id="DDI-DrugBank.d154.s2.e1" charOffset="93-99"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d154.s2.e2" charOffset="119-125"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d154.s2.e3" charOffset="162-167"
            type="brand" text="Nalfon"/>
        <entity id="DDI-DrugBank.d154.s2.e4" charOffset="193-198"
            type="brand" text="Nalfon"/>
        <entity id="DDI-DrugBank.d154.s2.e5" charOffset="204-214"
            type="group" text="salicylates"/>
        <ddi id="DDI-DrugBank.d154.s2.d0" e1="DDI-DrugBank.d154.s2.e2"
            e2="DDI-DrugBank.d154.s2.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d154.s2.d1" e1="DDI-DrugBank.d154.s2.e4"
            e2="DDI-DrugBank.d154.s2.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d154.s3" text="Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.">
        <entity id="DDI-DrugBank.d154.s3.e0" charOffset="26-38"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d154.s3.e1" charOffset="126-135"
            type="drug" text="fenoprofen"/>
        <ddi id="DDI-DrugBank.d154.s3.d0" e1="DDI-DrugBank.d154.s3.e0"
            e2="DDI-DrugBank.d154.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d154.s4" text="When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.">
        <entity id="DDI-DrugBank.d154.s4.e0" charOffset="5-17"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d154.s4.e1" charOffset="81-86"
            type="brand" text="Nalfon"/>
        <ddi id="DDI-DrugBank.d154.s4.d0" e1="DDI-DrugBank.d154.s4.e0"
            e2="DDI-DrugBank.d154.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d154.s5" text="In vitro studies have shown that fenoprofen, because of its affinity for albumin, may displace from their binding sites other drugs that are also albumin bound, and this may lead to drug interaction.">
        <entity id="DDI-DrugBank.d154.s5.e0" charOffset="33-42"
            type="drug" text="fenoprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d154.s6" text="Theoretically, fenoprofen could likewise be displaced.">
        <entity id="DDI-DrugBank.d154.s6.e0" charOffset="15-24"
            type="drug" text="fenoprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d154.s7" text="Patients receiving hydantoins, sulfonamides, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.">
        <entity id="DDI-DrugBank.d154.s7.e0" charOffset="19-28"
            type="group" text="hydantoins"/>
        <entity id="DDI-DrugBank.d154.s7.e1" charOffset="31-42"
            type="group" text="sulfonamides"/>
        <entity id="DDI-DrugBank.d154.s7.e2" charOffset="48-60"
            type="group" text="sulfonylureas"/>
    </sentence>
    <sentence id="DDI-DrugBank.d154.s8" text="In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.">
        <entity id="DDI-DrugBank.d154.s8.e0" charOffset="22-49"
            type="group" text="coumarin-type anticoagulants"/>
        <entity id="DDI-DrugBank.d154.s8.e1" charOffset="68-73"
            type="brand" text="Nalfon"/>
        <ddi id="DDI-DrugBank.d154.s8.d0" e1="DDI-DrugBank.d154.s8.e0"
            e2="DDI-DrugBank.d154.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d154.s9" text="Patients receiving both drugs should be under careful observation."/>
    <sentence id="DDI-DrugBank.d154.s10" text="Patients treated with Nalfon may be resistant to the effects of loop diuretics.">
        <entity id="DDI-DrugBank.d154.s10.e0" charOffset="22-27"
            type="brand" text="Nalfon"/>
        <entity id="DDI-DrugBank.d154.s10.e1" charOffset="64-77"
            type="group" text="loop diuretics"/>
        <ddi id="DDI-DrugBank.d154.s10.d0" e1="DDI-DrugBank.d154.s10.e0"
            e2="DDI-DrugBank.d154.s10.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d154.s11" text="In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.">
        <entity id="DDI-DrugBank.d154.s11.e0" charOffset="22-27"
            type="brand" text="Nalfon"/>
        <entity id="DDI-DrugBank.d154.s11.e1" charOffset="35-41"
            type="group" text="steroid"/>
        <entity id="DDI-DrugBank.d154.s11.e2" charOffset="75-81"
            type="group" text="steroid"/>
        <entity id="DDI-DrugBank.d154.s11.e3" charOffset="163-169"
            type="group" text="steroid"/>
        <ddi id="DDI-DrugBank.d154.s11.d0" e1="DDI-DrugBank.d154.s11.e0"
            e2="DDI-DrugBank.d154.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d170.s0" text="Agents Affecting Cytochrome P450 3A4 Isoenzyme System Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when DURAGESIC  is given concurrently with agents that affect CYP3A4 activity.">
        <entity id="DDI-DrugBank.d170.s0.e0" charOffset="54-61"
            type="drug" text="Fentanyl"/>
        <entity id="DDI-DrugBank.d170.s0.e1" charOffset="194-202"
            type="brand" text="DURAGESIC"/>
    </sentence>
    <sentence id="DDI-DrugBank.d170.s1" text="Coadminstration with agents that induce 3A4 activity may reduce the efficacy of DURAGESIC .">
        <entity id="DDI-DrugBank.d170.s1.e0" charOffset="80-88"
            type="brand" text="DURAGESIC"/>
    </sentence>
    <sentence id="DDI-DrugBank.d170.s2" text="The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.">
        <entity id="DDI-DrugBank.d170.s2.e0" charOffset="35-42"
            type="drug" text="fentanyl"/>
        <entity id="DDI-DrugBank.d170.s2.e1" charOffset="49-57"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d170.s2.e2" charOffset="98-109"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d170.s2.e3" charOffset="112-123"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d170.s2.e4" charOffset="126-139"
            type="drug" text="troleandomycin"/>
        <entity id="DDI-DrugBank.d170.s2.e5" charOffset="142-155"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d170.s2.e6" charOffset="158-167"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d170.s2.e7" charOffset="214-221"
            type="drug" text="fentanyl"/>
        <ddi id="DDI-DrugBank.d170.s2.d0" e1="DDI-DrugBank.d170.s2.e0"
            e2="DDI-DrugBank.d170.s2.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d170.s2.d1" e1="DDI-DrugBank.d170.s2.e0"
            e2="DDI-DrugBank.d170.s2.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d170.s2.d2" e1="DDI-DrugBank.d170.s2.e0"
            e2="DDI-DrugBank.d170.s2.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d170.s2.d3" e1="DDI-DrugBank.d170.s2.e0"
            e2="DDI-DrugBank.d170.s2.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d170.s2.d4" e1="DDI-DrugBank.d170.s2.e0"
            e2="DDI-DrugBank.d170.s2.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d170.s2.d5" e1="DDI-DrugBank.d170.s2.e0"
            e2="DDI-DrugBank.d170.s2.e6" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d170.s3" text="The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.">
        <entity id="DDI-DrugBank.d170.s3.e0" charOffset="55-63"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d170.s3.e1" charOffset="69-80"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d170.s3.e2" charOffset="99-106"
            type="drug" text="fentanyl"/>
        <entity id="DDI-DrugBank.d170.s3.e3" charOffset="142-149"
            type="drug" text="fentanyl"/>
        <ddi id="DDI-DrugBank.d170.s3.d0" e1="DDI-DrugBank.d170.s3.e0"
            e2="DDI-DrugBank.d170.s3.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d170.s3.d1" e1="DDI-DrugBank.d170.s3.e1"
            e2="DDI-DrugBank.d170.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d170.s4" text="In this situation, special patient care and observation are appropriate."/>
    <sentence id="DDI-DrugBank.d170.s5" text="Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.">
        <entity id="DDI-DrugBank.d170.s5.e0" charOffset="0-33"
            type="group" text="Central Nervous System Depressants"/>
        <entity id="DDI-DrugBank.d170.s5.e1" charOffset="59-67"
            type="brand" text="DURAGESIC"/>
        <entity id="DDI-DrugBank.d170.s5.e2" charOffset="71-78"
            type="drug" text="fentanyl"/>
        <entity id="DDI-DrugBank.d170.s5.e3" charOffset="111-144"
            type="group" text="central nervous system depressants"/>
        <entity id="DDI-DrugBank.d170.s5.e4" charOffset="182-188"
            type="group" text="opioids"/>
        <entity id="DDI-DrugBank.d170.s5.e5" charOffset="191-199"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d170.s5.e6" charOffset="202-210"
            type="group" text="hypnotics"/>
        <entity id="DDI-DrugBank.d170.s5.e7" charOffset="213-225"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d170.s5.e8" charOffset="234-248"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d170.s5.e9" charOffset="260-270"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d170.s5.e10" charOffset="273-286"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d170.s5.e11" charOffset="289-313"
            type="group" text="skeletal muscle relaxants"/>
        <entity id="DDI-DrugBank.d170.s5.e12" charOffset="320-326"
            type="drug" text="alcohol"/>
        <ddi id="DDI-DrugBank.d170.s5.d0" e1="DDI-DrugBank.d170.s5.e1"
            e2="DDI-DrugBank.d170.s5.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d1" e1="DDI-DrugBank.d170.s5.e1"
            e2="DDI-DrugBank.d170.s5.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d2" e1="DDI-DrugBank.d170.s5.e1"
            e2="DDI-DrugBank.d170.s5.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d3" e1="DDI-DrugBank.d170.s5.e1"
            e2="DDI-DrugBank.d170.s5.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d4" e1="DDI-DrugBank.d170.s5.e1"
            e2="DDI-DrugBank.d170.s5.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d5" e1="DDI-DrugBank.d170.s5.e1"
            e2="DDI-DrugBank.d170.s5.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d6" e1="DDI-DrugBank.d170.s5.e1"
            e2="DDI-DrugBank.d170.s5.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d7" e1="DDI-DrugBank.d170.s5.e1"
            e2="DDI-DrugBank.d170.s5.e10" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d8" e1="DDI-DrugBank.d170.s5.e1"
            e2="DDI-DrugBank.d170.s5.e11" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d9" e1="DDI-DrugBank.d170.s5.e1"
            e2="DDI-DrugBank.d170.s5.e12" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d10" e1="DDI-DrugBank.d170.s5.e2"
            e2="DDI-DrugBank.d170.s5.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d11" e1="DDI-DrugBank.d170.s5.e2"
            e2="DDI-DrugBank.d170.s5.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d12" e1="DDI-DrugBank.d170.s5.e2"
            e2="DDI-DrugBank.d170.s5.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d13" e1="DDI-DrugBank.d170.s5.e2"
            e2="DDI-DrugBank.d170.s5.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d14" e1="DDI-DrugBank.d170.s5.e2"
            e2="DDI-DrugBank.d170.s5.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d15" e1="DDI-DrugBank.d170.s5.e2"
            e2="DDI-DrugBank.d170.s5.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d16" e1="DDI-DrugBank.d170.s5.e2"
            e2="DDI-DrugBank.d170.s5.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d17" e1="DDI-DrugBank.d170.s5.e2"
            e2="DDI-DrugBank.d170.s5.e10" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d18" e1="DDI-DrugBank.d170.s5.e2"
            e2="DDI-DrugBank.d170.s5.e11" type="effect"/>
        <ddi id="DDI-DrugBank.d170.s5.d19" e1="DDI-DrugBank.d170.s5.e2"
            e2="DDI-DrugBank.d170.s5.e12" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d170.s6" text="When such combined therapy is contemplated, the dose of one or both agents should be significantly reduced."/>
    <sentence id="DDI-DrugBank.d170.s7" text="MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics">
        <entity id="DDI-DrugBank.d170.s7.e0" charOffset="0-13"
            type="group" text="MAO Inhibitors"/>
        <entity id="DDI-DrugBank.d170.s7.e1" charOffset="16-24"
            type="brand" text="DURAGESIC"/>
        <entity id="DDI-DrugBank.d170.s7.e2" charOffset="84-87"
            type="group" text="MAOI"/>
        <entity id="DDI-DrugBank.d170.s7.e3" charOffset="153-166"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d170.s7.e4" charOffset="191-207"
            type="group" text="opioid analgesics"/>
        <ddi id="DDI-DrugBank.d170.s7.d0" e1="DDI-DrugBank.d170.s7.e1"
            e2="DDI-DrugBank.d170.s7.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d170.s7.d1" e1="DDI-DrugBank.d170.s7.e3"
            e2="DDI-DrugBank.d170.s7.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d170.s8" text="."/>
    <sentence id="DDI-DrugBank.d170.s9" text=""/>
    <sentence id="DDI-DrugBank.d466.s0" text="Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.">
        <entity id="DDI-DrugBank.d466.s0.e0" charOffset="22-33"
            type="drug" text="Erythromycin"/>
        <entity id="DDI-DrugBank.d466.s0.e1" charOffset="39-50"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d466.s0.e2" charOffset="52-63"
            type="drug" text="Fexofenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s1" text="However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.">
        <entity id="DDI-DrugBank.d466.s1.e0" charOffset="31-56"
            type="drug" text="fexofenadine hydrochloride"/>
        <entity id="DDI-DrugBank.d466.s1.e1" charOffset="70-81"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d466.s1.e2" charOffset="86-97"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d466.s1.e3" charOffset="141-152"
            type="drug" text="fexofenadine"/>
        <ddi id="DDI-DrugBank.d466.s1.d0" e1="DDI-DrugBank.d466.s1.e0"
            e2="DDI-DrugBank.d466.s1.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d466.s1.d1" e1="DDI-DrugBank.d466.s1.e0"
            e2="DDI-DrugBank.d466.s1.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s2" text="Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.">
        <entity id="DDI-DrugBank.d466.s2.e0" charOffset="0-11"
            type="drug" text="Fexofenadine"/>
        <entity id="DDI-DrugBank.d466.s2.e1" charOffset="61-72"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d466.s2.e2" charOffset="77-88"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s3" text="In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).">
        <entity id="DDI-DrugBank.d466.s3.e0" charOffset="23-48"
            type="drug" text="fexofenadine hydrochloride"/>
        <entity id="DDI-DrugBank.d466.s3.e1" charOffset="127-138"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d466.s3.e2" charOffset="164-175"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s4" text="No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.">
        <entity id="DDI-DrugBank.d466.s4.e0" charOffset="95-120"
            type="drug" text="fexofenadine hydrochloride"/>
        <entity id="DDI-DrugBank.d466.s4.e1" charOffset="158-169"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d466.s4.e2" charOffset="174-185"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s5" text="The findings of these studies are summarized in the following table: Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24)">
        <entity id="DDI-DrugBank.d466.s5.e0" charOffset="93-104"
            type="drug" text="fexofenadine"/>
        <entity id="DDI-DrugBank.d466.s5.e1" charOffset="162-187"
            type="drug" text="fexofenadine hydrochloride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s6" text="Concomitant Drug"/>
    <sentence id="DDI-DrugBank.d466.s7" text="cmaxSS (Peak plasma concentration)"/>
    <sentence id="DDI-DrugBank.d466.s8" text="AUCss(0-12h) (Extent of systemic exposure)"/>
    <sentence id="DDI-DrugBank.d466.s9" text="Erythromycin (500 mg every 8 hrs)">
        <entity id="DDI-DrugBank.d466.s9.e0" charOffset="0-11"
            type="drug" text="Erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s10" text="+82%"/>
    <sentence id="DDI-DrugBank.d466.s11" text="+109%"/>
    <sentence id="DDI-DrugBank.d466.s12" text="Ketoconazole (400 mg once daily)">
        <entity id="DDI-DrugBank.d466.s12.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s13" text="+135%"/>
    <sentence id="DDI-DrugBank.d466.s14" text="+164%"/>
    <sentence id="DDI-DrugBank.d466.s15" text="The changes in plasma levels were within the range of plasma levels achieved in adequate and well-controlled clinical trials."/>
    <sentence id="DDI-DrugBank.d466.s16" text="The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models."/>
    <sentence id="DDI-DrugBank.d466.s17" text="These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.">
        <entity id="DDI-DrugBank.d466.s17.e0" charOffset="28-39"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d466.s17.e1" charOffset="44-55"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d466.s17.e2" charOffset="84-95"
            type="drug" text="fexofenadine"/>
        <ddi id="DDI-DrugBank.d466.s17.d0" e1="DDI-DrugBank.d466.s17.e0"
            e2="DDI-DrugBank.d466.s17.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d466.s17.d1" e1="DDI-DrugBank.d466.s17.e1"
            e2="DDI-DrugBank.d466.s17.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s11" text="If you are taking medications for migraines such as Imitrex, talk to your doctor before starting this medicine.">
        <entity id="DDI-DrugBank.d482.s11.e0" charOffset="52-58"
            type="brand" text="Imitrex"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s12" text="If you are taking a tricyclic antidepressant, talk to your doctor before taking this medicine.">
        <entity id="DDI-DrugBank.d482.s12.e0" charOffset="20-43"
            type="group" text="tricyclic antidepressant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s13" text="St. John  s Wort should be avoided while taking this medicine due to the additive effects of serotonin."/>
    <sentence id="DDI-DrugBank.d482.s14" text="Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications">
        <entity id="DDI-DrugBank.d482.s14.e0" charOffset="63-75"
            type="group" text="blood thinner"/>
        <entity id="DDI-DrugBank.d482.s14.e1" charOffset="79-86"
            type="brand" text="Coumadin"/>
        <entity id="DDI-DrugBank.d482.s14.e2" charOffset="95-109"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d482.s14.e3" charOffset="111-120"
            type="drug" text="metoprolol"/>
        <entity id="DDI-DrugBank.d482.s14.e4" charOffset="122-135"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d482.s14.e5" charOffset="137-149"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d482.s14.e6" charOffset="152-159"
            type="brand" text="Tegretol"/>
        <entity id="DDI-DrugBank.d482.s14.e7" charOffset="162-171"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d482.s14.e8" charOffset="174-180"
            type="brand" text="Tagamet"/>
        <entity id="DDI-DrugBank.d482.s14.e9" charOffset="183-191"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d482.s14.e10" charOffset="193-202"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d482.s14.e11" charOffset="205-210"
            type="brand" text="Prozac"/>
        <entity id="DDI-DrugBank.d482.s14.e12" charOffset="228-235"
            type="brand" text="Sporanox"/>
        <entity id="DDI-DrugBank.d482.s14.e13" charOffset="238-249"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d482.s14.e14" charOffset="252-258"
            type="brand" text="Nizoral"/>
        <entity id="DDI-DrugBank.d482.s14.e15" charOffset="261-268"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d482.s14.e16" charOffset="270-276"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d482.s14.e17" charOffset="278-293"
            type="group" text="muscle relaxants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d355.s0" text="Androgens may increase sensitivity to oral anticoagulahts.">
        <entity id="DDI-DrugBank.d355.s0.e0" charOffset="0-8"
            type="group" text="Androgens"/>
    </sentence>
    <sentence id="DDI-DrugBank.d355.s1" text="Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.">
        <entity id="DDI-DrugBank.d355.s1.e0" charOffset="14-26"
            type="group" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d355.s2" text="Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.">
        <entity id="DDI-DrugBank.d355.s2.e0" charOffset="29-43"
            type="drug" text="oxyphenbutazone"/>
        <entity id="DDI-DrugBank.d355.s2.e1" charOffset="49-57"
            type="group" text="androgens"/>
        <entity id="DDI-DrugBank.d355.s2.e2" charOffset="98-112"
            type="drug" text="oxyphenbutazone"/>
        <ddi id="DDI-DrugBank.d355.s2.d0" e1="DDI-DrugBank.d355.s2.e0"
            e2="DDI-DrugBank.d355.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d355.s3" text="In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.">
        <entity id="DDI-DrugBank.d355.s3.e0" charOffset="47-55"
            type="group" text="androgens"/>
        <entity id="DDI-DrugBank.d355.s3.e1" charOffset="99-105"
            type="drug" text="insulin"/>
        <ddi id="DDI-DrugBank.d355.s3.d0" e1="DDI-DrugBank.d355.s3.e0"
            e2="DDI-DrugBank.d355.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d13.s0" text="Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants">
        <entity id="DDI-DrugBank.d13.s0.e0" charOffset="19-30"
            type="drug" text="Flupenthixol"/>
        <entity id="DDI-DrugBank.d13.s0.e1" charOffset="67-94"
            type="group" text="Monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d13.s0.e2" charOffset="97-100"
            type="group" text="MAOI"/>
        <entity id="DDI-DrugBank.d13.s0.e3" charOffset="104-107"
            type="group" text="MAOI"/>
        <entity id="DDI-DrugBank.d13.s0.e4" charOffset="136-147"
            type="drug" text="flupenthixol"/>
        <entity id="DDI-DrugBank.d13.s0.e5" charOffset="168-176"
            type="drug_n" text="Arecoline"/>
        <entity id="DDI-DrugBank.d13.s0.e6" charOffset="194-200"
            type="drug" text="Ethanol"/>
        <entity id="DDI-DrugBank.d13.s0.e7" charOffset="203-214"
            type="drug" text="Flupenthixol"/>
        <entity id="DDI-DrugBank.d13.s0.e8" charOffset="220-226"
            type="drug" text="Ethanol"/>
        <entity id="DDI-DrugBank.d13.s0.e9" charOffset="260-284"
            type="group" text="Tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d13.s0.e10" charOffset="287-298"
            type="drug" text="Flupenthixol"/>
        <entity id="DDI-DrugBank.d13.s0.e11" charOffset="324-348"
            type="group" text="Tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d13.s0.d0" e1="DDI-DrugBank.d13.s0.e0"
            e2="DDI-DrugBank.d13.s0.e1" type="int"/>
        <ddi id="DDI-DrugBank.d13.s0.d1" e1="DDI-DrugBank.d13.s0.e0"
            e2="DDI-DrugBank.d13.s0.e2" type="int"/>
        <ddi id="DDI-DrugBank.d13.s0.d2" e1="DDI-DrugBank.d13.s0.e3"
            e2="DDI-DrugBank.d13.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d13.s0.d3" e1="DDI-DrugBank.d13.s0.e7"
            e2="DDI-DrugBank.d13.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d13.s0.d4" e1="DDI-DrugBank.d13.s0.e10"
            e2="DDI-DrugBank.d13.s0.e11" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s0" text="Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).">
        <entity id="DDI-DrugBank.d529.s0.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d529.s0.e1" charOffset="28-39"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s0.e2" charOffset="89-95"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d529.s0.e3" charOffset="130-141"
            type="drug" text="flurbiprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s1" text="In geriatric subjects (n=7) there was a reduction in the rate but not the extent of flurbiprofen absorption.">
        <entity id="DDI-DrugBank.d529.s1.e0" charOffset="84-95"
            type="drug" text="flurbiprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s2" text="Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.">
        <entity id="DDI-DrugBank.d529.s2.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d529.s2.e1" charOffset="16-27"
            type="drug" text="Flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s2.e2" charOffset="40-75"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d529.s2.e3" charOffset="145-159"
            type="group" text="anti-coagulants"/>
        <ddi id="DDI-DrugBank.d529.s2.d0" e1="DDI-DrugBank.d529.s2.e1"
            e2="DDI-DrugBank.d529.s2.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d529.s2.d1" e1="DDI-DrugBank.d529.s2.e2"
            e2="DDI-DrugBank.d529.s2.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s3" text="The physician should be cautious when administering flurbiprofen to patients taking anticoagulants.">
        <entity id="DDI-DrugBank.d529.s3.e0" charOffset="52-63"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s3.e1" charOffset="84-97"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d529.s3.d0" e1="DDI-DrugBank.d529.s3.e0"
            e2="DDI-DrugBank.d529.s3.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s4" text="Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.">
        <entity id="DDI-DrugBank.d529.s4.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d529.s4.e1" charOffset="38-44"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d529.s4.e2" charOffset="50-61"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s4.e3" charOffset="91-102"
            type="drug" text="flurbiprofen"/>
        <ddi id="DDI-DrugBank.d529.s4.d0" e1="DDI-DrugBank.d529.s4.e1"
            e2="DDI-DrugBank.d529.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s5" text="This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).">
        <entity id="DDI-DrugBank.d529.s5.e0" charOffset="15-21"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d529.s5.e1" charOffset="72-107"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s6" text="Concurrent use of flurbiprofen and aspirin is therefore not recommended.">
        <entity id="DDI-DrugBank.d529.s6.e0" charOffset="18-29"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s6.e1" charOffset="35-41"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d529.s6.d0" e1="DDI-DrugBank.d529.s6.e0"
            e2="DDI-DrugBank.d529.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s7" text="Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).">
        <entity id="DDI-DrugBank.d529.s7.e0" charOffset="0-30"
            type="group" text="Beta-adrenergic Blocking Agents"/>
        <entity id="DDI-DrugBank.d529.s7.e1" charOffset="47-58"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s7.e2" charOffset="90-100"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d529.s7.e3" charOffset="106-113"
            type="drug" text="atenolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s8" text="Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol.">
        <entity id="DDI-DrugBank.d529.s8.e0" charOffset="0-11"
            type="drug" text="Flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s8.e1" charOffset="80-90"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d529.s8.e2" charOffset="100-107"
            type="drug" text="atenolol"/>
        <ddi id="DDI-DrugBank.d529.s8.d0" e1="DDI-DrugBank.d529.s8.e0"
            e2="DDI-DrugBank.d529.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s9" text="Flurbiprofen did not appear to affect the beta-blocker-mediated reduction in heart rate.">
        <entity id="DDI-DrugBank.d529.s9.e0" charOffset="0-11"
            type="drug" text="Flurbiprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s10" text="Flurbiprofen did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with propranolols hypotensive effect is unknown.">
        <entity id="DDI-DrugBank.d529.s10.e0" charOffset="0-11"
            type="drug" text="Flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s10.e1" charOffset="124-134"
            type="drug" text="propranolol"/>
        <ddi id="DDI-DrugBank.d529.s10.d0" e1="DDI-DrugBank.d529.s10.e0"
            e2="DDI-DrugBank.d529.s10.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s11" text="Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.">
        <entity id="DDI-DrugBank.d529.s11.e0" charOffset="21-32"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s11.e1" charOffset="40-51"
            type="group" text="beta-blocker"/>
        <ddi id="DDI-DrugBank.d529.s11.d0" e1="DDI-DrugBank.d529.s11.e0"
            e2="DDI-DrugBank.d529.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s12" text="Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.">
        <entity id="DDI-DrugBank.d529.s12.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d529.s12.e1" charOffset="12-21"
            type="drug" text="Ranitidine"/>
        <entity id="DDI-DrugBank.d529.s12.e2" charOffset="70-79"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d529.s12.e3" charOffset="84-93"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d529.s12.e4" charOffset="110-121"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s12.e5" charOffset="257-268"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s12.e6" charOffset="284-293"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d529.s12.d0" e1="DDI-DrugBank.d529.s12.e5"
            e2="DDI-DrugBank.d529.s12.e6" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s13" text="Digoxin: Studies of concomitant administration of flurbiprofen and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.">
        <entity id="DDI-DrugBank.d529.s13.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d529.s13.e1" charOffset="50-61"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s13.e2" charOffset="67-73"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s14" text="Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.">
        <entity id="DDI-DrugBank.d529.s14.e0" charOffset="0-8"
            type="group" text="Diuretics"/>
        <entity id="DDI-DrugBank.d529.s14.e1" charOffset="56-67"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s14.e2" charOffset="80-115"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d529.s14.e3" charOffset="152-161"
            type="drug" text="furosemide"/>
        <ddi id="DDI-DrugBank.d529.s14.d0" e1="DDI-DrugBank.d529.s14.e1"
            e2="DDI-DrugBank.d529.s14.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d529.s14.d1" e1="DDI-DrugBank.d529.s14.e2"
            e2="DDI-DrugBank.d529.s14.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s15" text="Although results have varied from study to study, effects have been shown on furosemide-stimulated diuresis, natriuresis, and kaliuresis.">
        <entity id="DDI-DrugBank.d529.s15.e0" charOffset="77-86"
            type="drug" text="furosemide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s16" text="Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.">
        <entity id="DDI-DrugBank.d529.s16.e0" charOffset="6-41"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d529.s16.e1" charOffset="114-131"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d529.s16.e2" charOffset="158-184"
            type="group" text="potassium-sparing diuretics"/>
        <ddi id="DDI-DrugBank.d529.s16.d0" e1="DDI-DrugBank.d529.s16.e0"
            e2="DDI-DrugBank.d529.s16.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d529.s16.d1" e1="DDI-DrugBank.d529.s16.e0"
            e2="DDI-DrugBank.d529.s16.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s17" text="Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.">
        <entity id="DDI-DrugBank.d529.s17.e0" charOffset="19-30"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s17.e1" charOffset="36-45"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d529.s17.e2" charOffset="56-64"
            type="group" text="diuretics"/>
        <ddi id="DDI-DrugBank.d529.s17.d0" e1="DDI-DrugBank.d529.s17.e0"
            e2="DDI-DrugBank.d529.s17.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d529.s17.d1" e1="DDI-DrugBank.d529.s17.e0"
            e2="DDI-DrugBank.d529.s17.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s18" text="Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).">
        <entity id="DDI-DrugBank.d529.s18.e0" charOffset="5-23"
            type="group" text="Hypoglycemic Agents"/>
        <entity id="DDI-DrugBank.d529.s18.e1" charOffset="40-51"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s18.e2" charOffset="109-117"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d529.s18.e3" charOffset="126-134"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d529.s18.e4" charOffset="142-155"
            type="drug" text="chlorpropamide"/>
        <entity id="DDI-DrugBank.d529.s18.e5" charOffset="162-171"
            type="drug" text="phenformin"/>
        <entity id="DDI-DrugBank.d529.s18.e6" charOffset="183-191"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d529.s18.e7" charOffset="198-207"
            type="drug" text="phenformin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d529.s19" text="Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of hypoglycemia.">
        <entity id="DDI-DrugBank.d529.s19.e0" charOffset="105-116"
            type="drug" text="flurbiprofen"/>
        <entity id="DDI-DrugBank.d529.s19.e1" charOffset="122-140"
            type="group" text="hypoglycemic agents"/>
        <ddi id="DDI-DrugBank.d529.s19.d0" e1="DDI-DrugBank.d529.s19.e0"
            e2="DDI-DrugBank.d529.s19.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d442.s0" text="Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.">
        <entity id="DDI-DrugBank.d442.s0.e0" charOffset="79-86"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d442.s0.e1" charOffset="102-110"
            type="drug" text="flutamide"/>
        <ddi id="DDI-DrugBank.d442.s0.d0" e1="DDI-DrugBank.d442.s0.e0"
            e2="DDI-DrugBank.d442.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d442.s1" text="Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.">
        <entity id="DDI-DrugBank.d442.s1.e0" charOffset="85-97"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d442.s1.e1" charOffset="126-132"
            type="brand" text="EULEXIN"/>
        <entity id="DDI-DrugBank.d442.s1.e2" charOffset="179-186"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d442.s1.d0" e1="DDI-DrugBank.d442.s1.e1"
            e2="DDI-DrugBank.d442.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s0" text="Potential for Interaction with Monoamine Oxidase Inhibitors">
        <entity id="DDI-DrugBank.d76.s0.e0" charOffset="31-58"
            type="group" text="Monoamine Oxidase Inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s1" text="In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.">
        <entity id="DDI-DrugBank.d76.s1.e0" charOffset="30-62"
            type="group" text="serotonin reuptake inhibitor drug"/>
        <entity id="DDI-DrugBank.d76.s1.e1" charOffset="84-111"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d76.s1.e2" charOffset="114-117"
            type="group" text="MAOI"/>
        <ddi id="DDI-DrugBank.d76.s1.d0" e1="DDI-DrugBank.d76.s1.e0"
            e2="DDI-DrugBank.d76.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d76.s1.d1" e1="DDI-DrugBank.d76.s1.e0"
            e2="DDI-DrugBank.d76.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s2" text="These reactions have also been reported in patients who have discontinued that drug and have been started on a MAOI.">
        <entity id="DDI-DrugBank.d76.s2.e0" charOffset="111-114"
            type="group" text="MAOI"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s3" text="Some cases presented with features resembling neuroleptic malignant syndrome."/>
    <sentence id="DDI-DrugBank.d76.s4" text="Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.">
        <entity id="DDI-DrugBank.d76.s4.e0" charOffset="34-44"
            type="drug" text="Fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s4.e1" charOffset="86-90"
            type="group" text="MAOIs"/>
        <entity id="DDI-DrugBank.d76.s4.e2" charOffset="145-148"
            type="group" text="MAOI"/>
        <ddi id="DDI-DrugBank.d76.s4.d0" e1="DDI-DrugBank.d76.s4.e0"
            e2="DDI-DrugBank.d76.s4.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d76.s4.d1" e1="DDI-DrugBank.d76.s4.e0"
            e2="DDI-DrugBank.d76.s4.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s5" text="After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.">
        <entity id="DDI-DrugBank.d76.s5.e0" charOffset="15-25"
            type="drug" text="Fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s5.e1" charOffset="89-92"
            type="group" text="MAOI"/>
        <ddi id="DDI-DrugBank.d76.s5.d0" e1="DDI-DrugBank.d76.s5.e0"
            e2="DDI-DrugBank.d76.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s6" text="Potential Terfenadine, Astemizole, and Cisapride Interactions">
        <entity id="DDI-DrugBank.d76.s6.e0" charOffset="10-20"
            type="drug" text="Terfenadine"/>
        <entity id="DDI-DrugBank.d76.s6.e1" charOffset="23-32"
            type="drug" text="Astemizole"/>
        <entity id="DDI-DrugBank.d76.s6.e2" charOffset="39-47"
            type="drug" text="Cisapride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s7" text="Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.">
        <entity id="DDI-DrugBank.d76.s7.e0" charOffset="0-10"
            type="drug" text="Terfenadine"/>
        <entity id="DDI-DrugBank.d76.s7.e1" charOffset="13-22"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d76.s7.e2" charOffset="28-36"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d76.s7.e3" charOffset="129-140"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d76.s7.d0" e1="DDI-DrugBank.d76.s7.e0"
            e2="DDI-DrugBank.d76.s7.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d76.s7.d1" e1="DDI-DrugBank.d76.s7.e1"
            e2="DDI-DrugBank.d76.s7.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d76.s7.d2" e1="DDI-DrugBank.d76.s7.e2"
            e2="DDI-DrugBank.d76.s7.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s8" text="Increased plasma concentrations of terfenadine, astemizole, and cisapride cause QT prolongation and have been associated with torsades de pointes-type ventricular tachycardia, sometimes fatal.">
        <entity id="DDI-DrugBank.d76.s8.e0" charOffset="35-45"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d76.s8.e1" charOffset="48-57"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d76.s8.e2" charOffset="64-72"
            type="drug" text="cisapride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s9" text="As noted below, a sub- for fluvoxamine in combination with alprazolam, a drug that is known to be metabolized by the IIIA4 isozyme.">
        <entity id="DDI-DrugBank.d76.s9.e0" charOffset="27-37"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s9.e1" charOffset="59-68"
            type="drug" text="alprazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s10" text="Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.">
        <entity id="DDI-DrugBank.d76.s10.e0" charOffset="56-66"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s10.e1" charOffset="154-164"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s10.e2" charOffset="171-180"
            type="drug" text="alprazolam"/>
        <ddi id="DDI-DrugBank.d76.s10.d0" e1="DDI-DrugBank.d76.s10.e1"
            e2="DDI-DrugBank.d76.s10.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s11" text="Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.">
        <entity id="DDI-DrugBank.d76.s11.e0" charOffset="37-47"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s11.e1" charOffset="88-98"
            type="drug" text="terbinafine"/>
        <entity id="DDI-DrugBank.d76.s11.e2" charOffset="101-110"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d76.s11.e3" charOffset="116-124"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d76.s11.d0" e1="DDI-DrugBank.d76.s11.e0"
            e2="DDI-DrugBank.d76.s11.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d76.s11.d1" e1="DDI-DrugBank.d76.s11.e0"
            e2="DDI-DrugBank.d76.s11.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d76.s11.d2" e1="DDI-DrugBank.d76.s11.e0"
            e2="DDI-DrugBank.d76.s11.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s12" text="Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.">
        <entity id="DDI-DrugBank.d76.s12.e0" charOffset="47-61"
            type="group" text="Benzodiazepines"/>
        <entity id="DDI-DrugBank.d76.s12.e1" charOffset="64-78"
            type="group" text="Benzodiazepines"/>
        <entity id="DDI-DrugBank.d76.s12.e2" charOffset="120-129"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d76.s12.e3" charOffset="132-140"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d76.s12.e4" charOffset="143-151"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d76.s12.e5" charOffset="251-261"
            type="drug" text="fluvoxamine"/>
        <ddi id="DDI-DrugBank.d76.s12.d0" e1="DDI-DrugBank.d76.s12.e1"
            e2="DDI-DrugBank.d76.s12.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d76.s12.d1" e1="DDI-DrugBank.d76.s12.e2"
            e2="DDI-DrugBank.d76.s12.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d76.s12.d2" e1="DDI-DrugBank.d76.s12.e3"
            e2="DDI-DrugBank.d76.s12.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d76.s12.d3" e1="DDI-DrugBank.d76.s12.e4"
            e2="DDI-DrugBank.d76.s12.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s13" text="The clearance of benzodiazepines metabolized by glucuronidation (e. g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine.">
        <entity id="DDI-DrugBank.d76.s13.e0" charOffset="17-31"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d76.s13.e1" charOffset="72-80"
            type="drug" text="lorazepam"/>
        <entity id="DDI-DrugBank.d76.s13.e2" charOffset="83-90"
            type="drug" text="oxazepam"/>
        <entity id="DDI-DrugBank.d76.s13.e3" charOffset="93-101"
            type="drug" text="temazepam"/>
        <entity id="DDI-DrugBank.d76.s13.e4" charOffset="134-144"
            type="drug" text="fluvoxamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s14" text="Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;">
        <entity id="DDI-DrugBank.d76.s14.e0" charOffset="0-9"
            type="drug" text="Alprazolam"/>
        <entity id="DDI-DrugBank.d76.s14.e1" charOffset="17-35"
            type="drug" text="fluvoxamine maleate"/>
        <entity id="DDI-DrugBank.d76.s14.e2" charOffset="53-62"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d76.s14.e3" charOffset="194-203"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d76.s14.e4" charOffset="250-259"
            type="drug" text="alprazolam"/>
        <ddi id="DDI-DrugBank.d76.s14.d0" e1="DDI-DrugBank.d76.s14.e1"
            e2="DDI-DrugBank.d76.s14.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s15" text="oral clearance was reduced by about 50%."/>
    <sentence id="DDI-DrugBank.d76.s16" text="The elevated plasma alprazolam concentrations resulted in decreased psychomotor performance and memory.">
        <entity id="DDI-DrugBank.d76.s16.e0" charOffset="20-29"
            type="drug" text="alprazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s17" text="This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.">
        <entity id="DDI-DrugBank.d76.s17.e0" charOffset="72-82"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s17.e1" charOffset="170-180"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s17.e2" charOffset="256-265"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d76.s17.e3" charOffset="291-301"
            type="drug" text="Fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s17.e4" charOffset="324-333"
            type="drug" text="alprazolam"/>
        <ddi id="DDI-DrugBank.d76.s17.d0" e1="DDI-DrugBank.d76.s17.e2"
            e2="DDI-DrugBank.d76.s17.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s18" text="No dosage adjustment is required for Fluvoxamine Tablets.">
        <entity id="DDI-DrugBank.d76.s18.e0" charOffset="37-47"
            type="drug" text="Fluvoxamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s19" text="Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.">
        <entity id="DDI-DrugBank.d76.s19.e0" charOffset="0-7"
            type="drug" text="Diazepam"/>
        <entity id="DDI-DrugBank.d76.s19.e1" charOffset="35-45"
            type="drug" text="Fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s19.e2" charOffset="59-66"
            type="drug" text="diazepam"/>
        <ddi id="DDI-DrugBank.d76.s19.d0" e1="DDI-DrugBank.d76.s19.e1"
            e2="DDI-DrugBank.d76.s19.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s20" text="Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.">
        <entity id="DDI-DrugBank.d76.s20.e0" charOffset="8-18"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s20.e1" charOffset="50-57"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d76.s20.e2" charOffset="86-104"
            type="drug_n" text="N-desmethyldiazepam"/>
        <ddi id="DDI-DrugBank.d76.s20.d0" e1="DDI-DrugBank.d76.s20.e0"
            e2="DDI-DrugBank.d76.s20.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d76.s20.d1" e1="DDI-DrugBank.d76.s20.e0"
            e2="DDI-DrugBank.d76.s20.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s21" text="Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.">
        <entity id="DDI-DrugBank.d76.s21.e0" charOffset="75-85"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s21.e1" charOffset="91-98"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d76.s21.e2" charOffset="173-183"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s21.e3" charOffset="234-241"
            type="drug" text="diazepam"/>
        <ddi id="DDI-DrugBank.d76.s21.d0" e1="DDI-DrugBank.d76.s21.e0"
            e2="DDI-DrugBank.d76.s21.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s22" text="In these subjects (R= B), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study.">
        <entity id="DDI-DrugBank.d76.s22.e0" charOffset="43-50"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d76.s22.e1" charOffset="83-101"
            type="drug_n" text="N-desmethyldiazepam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s23" text="It is likely that experience significantly underestimates the degree of accumulation that might occur with repealed diazepam administration.">
        <entity id="DDI-DrugBank.d76.s23.e0" charOffset="116-123"
            type="drug" text="diazepam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s24" text="Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.">
        <entity id="DDI-DrugBank.d76.s24.e0" charOffset="24-33"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d76.s24.e1" charOffset="50-60"
            type="drug" text="fluvoxamine"/>
        <ddi id="DDI-DrugBank.d76.s24.d0" e1="DDI-DrugBank.d76.s24.e0"
            e2="DDI-DrugBank.d76.s24.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s25" text="Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.">
        <entity id="DDI-DrugBank.d76.s25.e0" charOffset="13-20"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d76.s25.e1" charOffset="26-36"
            type="drug" text="fluvoxamine"/>
        <ddi id="DDI-DrugBank.d76.s25.d0" e1="DDI-DrugBank.d76.s25.e0"
            e2="DDI-DrugBank.d76.s25.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s26" text="Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.">
        <entity id="DDI-DrugBank.d76.s26.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d76.s26.e1" charOffset="41-51"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s26.e2" charOffset="108-119"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d76.s26.e3" charOffset="140-152"
            type="drug" text="aminophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s27" text="The clearance of theophylline was decreased approximately 3-fold.">
        <entity id="DDI-DrugBank.d76.s27.e0" charOffset="17-28"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s28" text="Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.">
        <entity id="DDI-DrugBank.d76.s28.e0" charOffset="14-25"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d76.s28.e1" charOffset="51-69"
            type="drug" text="fluvoxamine maleate"/>
        <entity id="DDI-DrugBank.d76.s28.e2" charOffset="177-188"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d76.s28.d0" e1="DDI-DrugBank.d76.s28.e0"
            e2="DDI-DrugBank.d76.s28.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s29" text="No dosage adjustment is required for Fluvoxamine Tablets.">
        <entity id="DDI-DrugBank.d76.s29.e0" charOffset="37-47"
            type="drug" text="Fluvoxamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s30" text="Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.">
        <entity id="DDI-DrugBank.d76.s30.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d76.s30.e1" charOffset="15-33"
            type="drug" text="fluvoxamine maleate"/>
        <entity id="DDI-DrugBank.d76.s30.e2" charOffset="83-90"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d76.s30.e3" charOffset="107-114"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d76.s30.d0" e1="DDI-DrugBank.d76.s30.e1"
            e2="DDI-DrugBank.d76.s30.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s31" text="Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.">
        <entity id="DDI-DrugBank.d76.s31.e0" charOffset="29-42"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d76.s31.e1" charOffset="48-58"
            type="drug" text="Fluvoxamine"/>
        <entity id="DDI-DrugBank.d76.s31.e2" charOffset="123-135"
            type="group" text="anticoagulant"/>
        <ddi id="DDI-DrugBank.d76.s31.d0" e1="DDI-DrugBank.d76.s31.e0"
            e2="DDI-DrugBank.d76.s31.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d76.s32" text="No dosage adjustment is required for Fluvoxamine Tablets.">
        <entity id="DDI-DrugBank.d76.s32.e0" charOffset="37-47"
            type="drug" text="Fluvoxamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d425.s0" text="Medications that interfere with your bodys ability to use folate may also increase the need for this vitamin.">
        <entity id="DDI-DrugBank.d425.s0.e0" charOffset="101-107"
            type="group" text="vitamin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d425.s1" text="Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.">
        <entity id="DDI-DrugBank.d425.s1.e0" charOffset="62-87"
            type="group" text="anticonvulsant medications"/>
        <entity id="DDI-DrugBank.d425.s1.e1" charOffset="98-106"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d425.s1.e2" charOffset="113-121"
            type="drug" text="primidone"/>
        <entity id="DDI-DrugBank.d425.s1.e3" charOffset="124-132"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d425.s1.e4" charOffset="199-211"
            type="drug" text="sulfasalazine"/>
        <entity id="DDI-DrugBank.d425.s1.e5" charOffset="298-308"
            type="drug" text="triamterene"/>
        <entity id="DDI-DrugBank.d425.s1.e6" charOffset="313-320"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d425.s1.e7" charOffset="323-334"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d425.s1.e8" charOffset="389-399"
            type="drug" text="vitamin B12"/>
        <entity id="DDI-DrugBank.d425.s1.e9" charOffset="405-414"
            type="drug" text="folic acid"/>
        <ddi id="DDI-DrugBank.d425.s1.d0" e1="DDI-DrugBank.d425.s1.e8"
            e2="DDI-DrugBank.d425.s1.e9" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d425.s2" text="Folic acid supplements can correct the anemia associated with vitamin B12 deficiency.">
        <entity id="DDI-DrugBank.d425.s2.e0" charOffset="0-9"
            type="drug" text="Folic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d425.s3" text="Unfortunately, folic acid will not correct changes in the nervous system that result from vitamin B12 deficiency.">
        <entity id="DDI-DrugBank.d425.s3.e0" charOffset="15-24"
            type="drug" text="folic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d425.s4" text="Permanent nerve damage could theoretically occur if vitamin B12 deficiency is not treated."/>
    <sentence id="DDI-DrugBank.d425.s5" text="Therefore, intake of supplemental folic acid should not exceed 1000 micrograms ( g, sometimes mcg) per day to prevent folic acid from masking symptoms of vitamin B12 deficiency.">
        <entity id="DDI-DrugBank.d425.s5.e0" charOffset="34-43"
            type="drug" text="folic acid"/>
        <entity id="DDI-DrugBank.d425.s5.e1" charOffset="118-127"
            type="drug" text="folic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d425.s6" text="It is important for older adults to be aware of the relationship between folic acid and vitamin B12 because they are at greater risk of having a vitamin B12 deficiency.">
        <entity id="DDI-DrugBank.d425.s6.e0" charOffset="73-82"
            type="drug" text="folic acid"/>
        <entity id="DDI-DrugBank.d425.s6.e1" charOffset="88-98"
            type="drug" text="vitamin B12"/>
    </sentence>
    <sentence id="DDI-DrugBank.d425.s7" text="If you are 50 years of age or older, ask your physician to check your B12 status before you take a supplement that contains folic acid.">
        <entity id="DDI-DrugBank.d425.s7.e0" charOffset="124-133"
            type="drug" text="folic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d402.s0" text="No drug/drug interaction studies have been performed."/>
    <sentence id="DDI-DrugBank.d228.s0" text="Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.">
        <entity id="DDI-DrugBank.d228.s0.e0" charOffset="14-20"
            type="brand" text="Antizol"/>
        <entity id="DDI-DrugBank.d228.s0.e1" charOffset="124-130"
            type="drug" text="ethanol"/>
        <ddi id="DDI-DrugBank.d228.s0.d0" e1="DDI-DrugBank.d228.s0.e0"
            e2="DDI-DrugBank.d228.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d228.s1" text="Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.">
        <entity id="DDI-DrugBank.d228.s1.e0" charOffset="11-17"
            type="drug" text="ethanol"/>
        <entity id="DDI-DrugBank.d228.s1.e1" charOffset="56-62"
            type="brand" text="Antizol"/>
        <ddi id="DDI-DrugBank.d228.s1.d0" e1="DDI-DrugBank.d228.s1.e0"
            e2="DDI-DrugBank.d228.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d228.s2" text="Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied">
        <entity id="DDI-DrugBank.d228.s2.e0" charOffset="58-64"
            type="brand" text="Antizol"/>
        <entity id="DDI-DrugBank.d228.s2.e1" charOffset="135-143"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d228.s2.e2" charOffset="146-158"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d228.s2.e3" charOffset="161-170"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d228.s2.e4" charOffset="173-184"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d228.s2.d0" e1="DDI-DrugBank.d228.s2.e0"
            e2="DDI-DrugBank.d228.s2.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d228.s2.d1" e1="DDI-DrugBank.d228.s2.e0"
            e2="DDI-DrugBank.d228.s2.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d228.s2.d2" e1="DDI-DrugBank.d228.s2.e0"
            e2="DDI-DrugBank.d228.s2.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d228.s2.d3" e1="DDI-DrugBank.d228.s2.e0"
            e2="DDI-DrugBank.d228.s2.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d228.s3" text="."/>
    <sentence id="DDI-DrugBank.d228.s4" text=""/>
    <sentence id="DDI-DrugBank.d15.s0" text="In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.">
        <entity id="DDI-DrugBank.d15.s0.e0" charOffset="35-46"
            type="drug" text="Fondaparinux"/>
        <entity id="DDI-DrugBank.d15.s0.e1" charOffset="77-90"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d15.s0.e2" charOffset="93-100"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d15.s0.e3" charOffset="104-122"
            type="group" text="platelet inhibitors"/>
        <entity id="DDI-DrugBank.d15.s0.e4" charOffset="125-144"
            type="drug" text="acetylsalicylic acid"/>
        <entity id="DDI-DrugBank.d15.s0.e5" charOffset="148-153"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d15.s0.e6" charOffset="156-164"
            type="drug" text="piroxicam"/>
        <entity id="DDI-DrugBank.d15.s0.e7" charOffset="172-178"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d15.s0.e8" charOffset="250-268"
            type="drug" text="fondaparinux sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d15.s1" text="In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.">
        <entity id="DDI-DrugBank.d15.s1.e0" charOffset="13-24"
            type="drug" text="Fondaparinux"/>
        <entity id="DDI-DrugBank.d15.s1.e1" charOffset="69-76"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d15.s1.e2" charOffset="79-98"
            type="drug" text="acetylsalicylic acid"/>
        <entity id="DDI-DrugBank.d15.s1.e3" charOffset="101-109"
            type="drug" text="piroxicam"/>
        <entity id="DDI-DrugBank.d15.s1.e4" charOffset="116-122"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d15.s1.e5" charOffset="153-159"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d15.s2" text="Agents that may enhance the risk of hemorrhage should be discontinued prior to initiation of Fondaparinux therapy.">
        <entity id="DDI-DrugBank.d15.s2.e0" charOffset="93-104"
            type="drug" text="Fondaparinux"/>
    </sentence>
    <sentence id="DDI-DrugBank.d15.s3" text="If co-administration is essential, close monitoring may be appropriate."/>
    <sentence id="DDI-DrugBank.d15.s4" text="In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 m m M i.e., 350 mg/L) was 17-28%.">
        <entity id="DDI-DrugBank.d15.s4.e0" charOffset="86-93"
            type="group" text="coumarin"/>
        <entity id="DDI-DrugBank.d15.s4.e1" charOffset="98-109"
            type="drug" text="fondaparinux"/>
        <ddi id="DDI-DrugBank.d15.s4.d0" e1="DDI-DrugBank.d15.s4.e0"
            e2="DDI-DrugBank.d15.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d15.s5" text="Inhibition of the other isozymes evaluated (CYPs 2A1, 2C9, 2C19, 2D6, 3A4, and 3E1) was 0-16%."/>
    <sentence id="DDI-DrugBank.d15.s6" text="Since fondaparinux does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, fondaparinux sodium is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.">
        <entity id="DDI-DrugBank.d15.s6.e0" charOffset="6-17"
            type="drug" text="fondaparinux"/>
        <entity id="DDI-DrugBank.d15.s6.e1" charOffset="124-142"
            type="drug" text="fondaparinux sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d15.s7" text="Since fondaparinux sodium does not bind significantly to plasma proteins other than ATIII, no drug interactions by protein-binding displacement are expected.">
        <entity id="DDI-DrugBank.d15.s7.e0" charOffset="6-24"
            type="drug" text="fondaparinux sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s0" text="Short-Acting beta2-agonists: Aerosol bronchodilators of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using formoterol.">
        <entity id="DDI-DrugBank.d103.s0.e0" charOffset="0-26"
            type="group" text="Short-Acting beta2-agonists"/>
        <entity id="DDI-DrugBank.d103.s0.e1" charOffset="37-51"
            type="group" text="bronchodilators"/>
        <entity id="DDI-DrugBank.d103.s0.e2" charOffset="159-168"
            type="drug" text="formoterol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s1" text="However, increasing use of such preparations to control symptoms indicates deterioration of asthma control and the need to reassess the patient s therapy."/>
    <sentence id="DDI-DrugBank.d103.s2" text="Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.">
        <entity id="DDI-DrugBank.d103.s2.e0" charOffset="36-57"
            type="group" text="sympathomimetic agents"/>
        <entity id="DDI-DrugBank.d103.s2.e1" charOffset="101-107"
            type="brand" text="FORADIL"/>
        <ddi id="DDI-DrugBank.d103.s2.d0" e1="DDI-DrugBank.d103.s2.e0"
            e2="DDI-DrugBank.d103.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s3" text="Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.">
        <entity id="DDI-DrugBank.d103.s3.e0" charOffset="0-27"
            type="group" text="Monoamine Oxidase Inhibitors"/>
        <entity id="DDI-DrugBank.d103.s3.e1" charOffset="33-57"
            type="group" text="Tricyclic Antidepressants"/>
        <entity id="DDI-DrugBank.d103.s3.e2" charOffset="60-66"
            type="brand" text="FORADIL"/>
        <entity id="DDI-DrugBank.d103.s3.e3" charOffset="143-170"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d103.s3.e4" charOffset="175-199"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d103.s3.e5" charOffset="223-232"
            type="drug" text="formoterol"/>
        <ddi id="DDI-DrugBank.d103.s3.d0" e1="DDI-DrugBank.d103.s3.e2"
            e2="DDI-DrugBank.d103.s3.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d103.s3.d1" e1="DDI-DrugBank.d103.s3.e2"
            e2="DDI-DrugBank.d103.s3.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s4" text="Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.">
        <entity id="DDI-DrugBank.d103.s4.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d103.s4.e1" charOffset="17-31"
            type="group" text="Methylxanthines"/>
        <entity id="DDI-DrugBank.d103.s4.e2" charOffset="37-45"
            type="group" text="Diuretics"/>
        <entity id="DDI-DrugBank.d103.s4.e3" charOffset="75-94"
            type="group" text="xanthine derivatives"/>
        <entity id="DDI-DrugBank.d103.s4.e4" charOffset="97-104"
            type="group" text="steroids"/>
        <entity id="DDI-DrugBank.d103.s4.e5" charOffset="110-118"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d103.s4.e6" charOffset="169-183"
            type="group" text="beta2-agonists."/>
        <ddi id="DDI-DrugBank.d103.s4.d0" e1="DDI-DrugBank.d103.s4.e3"
            e2="DDI-DrugBank.d103.s4.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d103.s4.d1" e1="DDI-DrugBank.d103.s4.e4"
            e2="DDI-DrugBank.d103.s4.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d103.s4.d2" e1="DDI-DrugBank.d103.s4.e5"
            e2="DDI-DrugBank.d103.s4.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s5" text="Hypokalemia may increase susceptibility to cardiac arrhythmias in patients treated with digitalis.">
        <entity id="DDI-DrugBank.d103.s5.e0" charOffset="88-96"
            type="group" text="digitalis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s6" text="-adrenergic Blockers:  -adrenergic blockers may weaken or antagonise the effect of FORADIL.">
        <entity id="DDI-DrugBank.d103.s6.e0" charOffset="83-89"
            type="brand" text="FORADIL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s7" text="Therefore FORADIL should not be given together with  -adrenergic blockers (including eye drops) unless there are compelling reasons for their use.">
        <entity id="DDI-DrugBank.d103.s7.e0" charOffset="10-16"
            type="brand" text="FORADIL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s8" text="Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.">
        <entity id="DDI-DrugBank.d103.s8.e0" charOffset="26-34"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d103.s8.e1" charOffset="37-48"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d103.s8.e2" charOffset="51-62"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d103.s8.e3" charOffset="65-78"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d103.s8.e4" charOffset="81-94"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d103.s8.e5" charOffset="101-125"
            type="group" text="tricyclic antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s9" text="INFORMATION TO BE PROVIDED TO THE PATIENT OR GUARDIAN See illustrated Information For The Patient or Guardian section."/>
    <sentence id="DDI-DrugBank.d103.s10" text="It is important that patients understand how to use FORADIL  (formoterol fumarate) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.">
        <entity id="DDI-DrugBank.d103.s10.e0" charOffset="52-58"
            type="brand" text="FORADIL"/>
        <entity id="DDI-DrugBank.d103.s10.e1" charOffset="62-80"
            type="drug" text="formoterol fumarate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s11" text="Patients/Guardians should be given the following information: i."/>
    <sentence id="DDI-DrugBank.d103.s12" text="The recommended dosage (one or two capsules twice daily, morning and evening) should not be exceeded."/>
    <sentence id="DDI-DrugBank.d103.s13" text="ii."/>
    <sentence id="DDI-DrugBank.d103.s14" text="FORADIL is not meant to relieve acute asthma or COPD symptoms and extra doses should not be used for that purpose.">
        <entity id="DDI-DrugBank.d103.s14.e0" charOffset="0-6"
            type="brand" text="FORADIL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s15" text="Acute symptoms should be treated with a short-acting, inhaled  beta2-agonist such as salbutamol (the physician should provide the patient with such medication and instruct the patient in how it should be used).">
        <entity id="DDI-DrugBank.d103.s15.e0" charOffset="63-75"
            type="group" text="beta2-agonist"/>
        <entity id="DDI-DrugBank.d103.s15.e1" charOffset="85-94"
            type="drug" text="salbutamol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s16" text="iii."/>
    <sentence id="DDI-DrugBank.d103.s17" text="The physician should be notified immediately if any of the following situations occur, which may be a sign of seriously worsening asthma:   Decreased effectiveness of short-acting, inhaled beta2-agonists;">
        <entity id="DDI-DrugBank.d103.s17.e0" charOffset="167-202"
            type="group" text="short-acting, inhaled beta2-agonists"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s18" text="Need for more inhalations than usual of short-acting, inhaled beta2-agonists.">
        <entity id="DDI-DrugBank.d103.s18.e0" charOffset="40-75"
            type="group" text="short-acting, inhaled beta2-agonists"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s19" text="iv."/>
    <sentence id="DDI-DrugBank.d103.s20" text="FORADIL should not be used as a substitute for oral or inhaled corticosteroids.">
        <entity id="DDI-DrugBank.d103.s20.e0" charOffset="0-6"
            type="brand" text="FORADIL"/>
        <entity id="DDI-DrugBank.d103.s20.e1" charOffset="63-77"
            type="group" text="corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s21" text="The dosage of these medications should not be changed and they should not be stopped without consulting the physician, even if the patient feels better after initiating treatment with FORADIL.">
        <entity id="DDI-DrugBank.d103.s21.e0" charOffset="184-190"
            type="brand" text="FORADIL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s22" text="v. Patients should be cautioned regarding potential adverse cardiovascular effects, such as palpitations or chest pain."/>
    <sentence id="DDI-DrugBank.d103.s23" text="vi."/>
    <sentence id="DDI-DrugBank.d103.s24" text="In patients receiving FORADIL, other inhaled medications should be used only as directed by the physician.">
        <entity id="DDI-DrugBank.d103.s24.e0" charOffset="22-28"
            type="brand" text="FORADIL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d103.s25" text="vii."/>
    <sentence id="DDI-DrugBank.d103.s26" text="Guardians of children who have been prescribed FORADIL should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of short-acting  beta2-agonists.">
        <entity id="DDI-DrugBank.d103.s26.e0" charOffset="47-53"
            type="brand" text="FORADIL"/>
        <entity id="DDI-DrugBank.d103.s26.e1" charOffset="196-223"
            type="group" text="short-acting  beta2-agonists"/>
    </sentence>
    <sentence id="DDI-DrugBank.d511.s0" text="A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.">
        <entity id="DDI-DrugBank.d511.s0.e0" charOffset="31-38"
            type="brand" text="FOSCAVIR"/>
        <entity id="DDI-DrugBank.d511.s0.e1" charOffset="56-66"
            type="drug" text="pentamidine"/>
        <ddi id="DDI-DrugBank.d511.s0.d0" e1="DDI-DrugBank.d511.s0.e0"
            e2="DDI-DrugBank.d511.s0.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d511.s1" text="Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;">
        <entity id="DDI-DrugBank.d511.s1.e0" charOffset="66-73"
            type="brand" text="FOSCAVIR"/>
        <entity id="DDI-DrugBank.d511.s1.e1" charOffset="91-101"
            type="drug" text="pentamidine"/>
        <ddi id="DDI-DrugBank.d511.s1.d0" e1="DDI-DrugBank.d511.s1.e0"
            e2="DDI-DrugBank.d511.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d511.s2" text="one patient died with severe hypocalcemia."/>
    <sentence id="DDI-DrugBank.d511.s3" text="Toxicity associated with concomitant use of aerosolized pentamidine has not been reported.">
        <entity id="DDI-DrugBank.d511.s3.e0" charOffset="56-66"
            type="drug" text="pentamidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d511.s4" text="Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.">
        <entity id="DDI-DrugBank.d511.s4.e0" charOffset="11-19"
            type="drug" text="foscarnet"/>
        <entity id="DDI-DrugBank.d511.s4.e1" charOffset="69-76"
            type="brand" text="FOSCAVIR"/>
        <entity id="DDI-DrugBank.d511.s4.e2" charOffset="154-168"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d511.s4.e3" charOffset="171-184"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d511.s4.e4" charOffset="202-212"
            type="drug" text="pentamidine"/>
        <ddi id="DDI-DrugBank.d511.s4.d0" e1="DDI-DrugBank.d511.s4.e1"
            e2="DDI-DrugBank.d511.s4.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d511.s4.d1" e1="DDI-DrugBank.d511.s4.e1"
            e2="DDI-DrugBank.d511.s4.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d511.s4.d2" e1="DDI-DrugBank.d511.s4.e1"
            e2="DDI-DrugBank.d511.s4.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d511.s5" text="Since FOSCAVIR decreases serum concentrations of ionized calcium, concurrent treatment with other drugs known to influence serum calcium concentrations should be used with particular caution.">
        <entity id="DDI-DrugBank.d511.s5.e0" charOffset="6-13"
            type="brand" text="FOSCAVIR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d511.s6" text="Ganciclovir: The pharmacokinetics of foscarnet and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.">
        <entity id="DDI-DrugBank.d511.s6.e0" charOffset="0-10"
            type="drug" text="Ganciclovir"/>
        <entity id="DDI-DrugBank.d511.s6.e1" charOffset="37-45"
            type="drug" text="foscarnet"/>
        <entity id="DDI-DrugBank.d511.s6.e2" charOffset="51-61"
            type="drug" text="ganciclovir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d199.s0" text="Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.">
        <entity id="DDI-DrugBank.d199.s0.e0" charOffset="0-13"
            type="drug" text="Metoclopramide"/>
        <entity id="DDI-DrugBank.d199.s0.e1" charOffset="41-47"
            type="brand" text="MONUROL"/>
        <entity id="DDI-DrugBank.d199.s0.e2" charOffset="50-63"
            type="drug" text="metoclopramide"/>
        <entity id="DDI-DrugBank.d199.s0.e3" charOffset="172-181"
            type="drug" text="fosfomycin"/>
        <ddi id="DDI-DrugBank.d199.s0.d0" e1="DDI-DrugBank.d199.s0.e1"
            e2="DDI-DrugBank.d199.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d199.s1" text="Other drugs that increase gastrointestinal motility may produce similar effects."/>
    <sentence id="DDI-DrugBank.d199.s2" text="Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.">
        <entity id="DDI-DrugBank.d199.s2.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d199.s2.e1" charOffset="12-21"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d199.s2.e2" charOffset="63-72"
            type="drug" text="fosfomycin"/>
        <entity id="DDI-DrugBank.d199.s2.e3" charOffset="99-105"
            type="brand" text="MONUROL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s0" text="Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.">
        <entity id="DDI-DrugBank.d176.s0.e0" charOffset="0-8"
            type="group" text="Diuretics"/>
        <entity id="DDI-DrugBank.d176.s0.e1" charOffset="23-31"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d176.s0.e2" charOffset="190-206"
            type="drug" text="fosinopril sodium"/>
        <ddi id="DDI-DrugBank.d176.s0.d0" e1="DDI-DrugBank.d176.s0.e1"
            e2="DDI-DrugBank.d176.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s1" text="The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium.">
        <entity id="DDI-DrugBank.d176.s1.e0" charOffset="84-91"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d176.s1.e1" charOffset="157-173"
            type="drug" text="fosinopril sodium"/>
        <ddi id="DDI-DrugBank.d176.s1.d0" e1="DDI-DrugBank.d176.s1.e0"
            e2="DDI-DrugBank.d176.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s2" text="If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION.)"/>
    <sentence id="DDI-DrugBank.d176.s3" text="Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.">
        <entity id="DDI-DrugBank.d176.s3.e0" charOffset="0-8"
            type="drug" text="Potassium"/>
        <entity id="DDI-DrugBank.d176.s3.e1" charOffset="26-52"
            type="group" text="Potassium-Sparing Diuretics"/>
        <entity id="DDI-DrugBank.d176.s3.e2" charOffset="55-71"
            type="drug" text="Fosinopril sodium"/>
        <entity id="DDI-DrugBank.d176.s3.e3" charOffset="112-129"
            type="group" text="thiazide diuretics"/>
        <ddi id="DDI-DrugBank.d176.s3.d0" e1="DDI-DrugBank.d176.s3.e2"
            e2="DDI-DrugBank.d176.s3.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s4" text="Potassium-sparing diuretics (spironolactone, amiloride,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.">
        <entity id="DDI-DrugBank.d176.s4.e0" charOffset="0-26"
            type="group" text="Potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d176.s4.e1" charOffset="29-42"
            type="drug" text="spironolactone"/>
        <entity id="DDI-DrugBank.d176.s4.e2" charOffset="45-53"
            type="drug" text="amiloride"/>
        <entity id="DDI-DrugBank.d176.s4.e3" charOffset="55-65"
            type="drug" text="triamterene"/>
        <entity id="DDI-DrugBank.d176.s4.e4" charOffset="83-91"
            type="drug" text="potassium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s5" text="Therefore, if concomitant use of such agents is indicated, they should be given with caution, and the patients serum potassium should be monitored frequently."/>
    <sentence id="DDI-DrugBank.d176.s6" text="Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.">
        <entity id="DDI-DrugBank.d176.s6.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d176.s6.e1" charOffset="25-31"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d176.s6.e2" charOffset="56-62"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d176.s6.e3" charOffset="114-127"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d176.s6.e4" charOffset="149-155"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d176.s6.d0" e1="DDI-DrugBank.d176.s6.e3"
            e2="DDI-DrugBank.d176.s6.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s7" text="These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.">
        <entity id="DDI-DrugBank.d176.s7.e0" charOffset="84-90"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s8" text="If a diuretic is also used, the risk of lithium toxicity may be increased.">
        <entity id="DDI-DrugBank.d176.s8.e0" charOffset="5-12"
            type="group" text="diuretic"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s9" text="Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.">
        <entity id="DDI-DrugBank.d176.s9.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d176.s9.e1" charOffset="67-73"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d176.s9.e2" charOffset="76-93"
            type="drug" text="aluminum hydroxide"/>
        <entity id="DDI-DrugBank.d176.s9.e3" charOffset="96-114"
            type="drug" text="magnesium hydroxide"/>
        <entity id="DDI-DrugBank.d176.s9.e4" charOffset="121-131"
            type="drug" text="simethicone"/>
        <entity id="DDI-DrugBank.d176.s9.e5" charOffset="139-148"
            type="drug" text="fosinopril"/>
        <entity id="DDI-DrugBank.d176.s9.e6" charOffset="196-207"
            type="drug_n" text="fosinoprilat"/>
        <entity id="DDI-DrugBank.d176.s9.e7" charOffset="226-235"
            type="drug" text="fosinopril"/>
        <entity id="DDI-DrugBank.d176.s9.e8" charOffset="273-280"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d176.s9.e9" charOffset="307-316"
            type="drug" text="fosinopril"/>
        <ddi id="DDI-DrugBank.d176.s9.d0" e1="DDI-DrugBank.d176.s9.e1"
            e2="DDI-DrugBank.d176.s9.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d176.s9.d1" e1="DDI-DrugBank.d176.s9.e2"
            e2="DDI-DrugBank.d176.s9.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d176.s9.d2" e1="DDI-DrugBank.d176.s9.e3"
            e2="DDI-DrugBank.d176.s9.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d176.s9.d3" e1="DDI-DrugBank.d176.s9.e4"
            e2="DDI-DrugBank.d176.s9.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d176.s9.d4" e1="DDI-DrugBank.d176.s9.e8"
            e2="DDI-DrugBank.d176.s9.e9" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s10" text="Therefore, if concomitant administration of these agents is indicated, dosing should be separated by 2 hours."/>
    <sentence id="DDI-DrugBank.d176.s11" text="Other: Neither fosinopril sodium nor its metabolites have been found to interact with food.">
        <entity id="DDI-DrugBank.d176.s11.e0" charOffset="15-31"
            type="drug" text="fosinopril sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s12" text="In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.">
        <entity id="DDI-DrugBank.d176.s12.e0" charOffset="77-90"
            type="drug" text="chlorthalidone"/>
        <entity id="DDI-DrugBank.d176.s12.e1" charOffset="93-102"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d176.s12.e2" charOffset="105-114"
            type="drug" text="propanolol"/>
        <entity id="DDI-DrugBank.d176.s12.e3" charOffset="117-135"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d176.s12.e4" charOffset="138-147"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d176.s12.e5" charOffset="150-163"
            type="drug" text="metoclopramide"/>
        <entity id="DDI-DrugBank.d176.s12.e6" charOffset="166-178"
            type="drug" text="propantheline"/>
        <entity id="DDI-DrugBank.d176.s12.e7" charOffset="181-187"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d176.s12.e8" charOffset="194-201"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d176.s12.e9" charOffset="227-238"
            type="drug_n" text="fosinoprilat"/>
        <entity id="DDI-DrugBank.d176.s12.e10" charOffset="279-288"
            type="drug" text="fosinopril"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s13" text="In a study with concomitant administration of aspirin and fosinopril sodium, the bioavailability of unbound fosinoprilat was not altered.">
        <entity id="DDI-DrugBank.d176.s13.e0" charOffset="46-52"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d176.s13.e1" charOffset="58-74"
            type="drug" text="fosinopril sodium"/>
        <entity id="DDI-DrugBank.d176.s13.e2" charOffset="108-119"
            type="drug_n" text="fosinoprilat"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s14" text="In a pharmacokinetic interaction study with warfarin, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of warfarin were not significantly changed.">
        <entity id="DDI-DrugBank.d176.s14.e0" charOffset="44-51"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d176.s14.e1" charOffset="176-183"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s15" text="Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab  RIA Kit for Digoxin.">
        <entity id="DDI-DrugBank.d176.s15.e0" charOffset="33-42"
            type="drug" text="Fosinopril"/>
        <entity id="DDI-DrugBank.d176.s15.e1" charOffset="87-93"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d176.s15.e2" charOffset="134-140"
            type="drug" text="Digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d176.s16" text="Other kits, such as the Coat-A-Count  RIA Kit, may be used."/>
    <sentence id="DDI-DrugBank.d40.s0" text="No drugs are known to interfere with the conversion of fosphenytoin to phenytoin.">
        <entity id="DDI-DrugBank.d40.s0.e0" charOffset="55-66"
            type="drug" text="fosphenytoin"/>
        <entity id="DDI-DrugBank.d40.s0.e1" charOffset="71-79"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s1" text="Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of fosphenytoin to phenytoin.">
        <entity id="DDI-DrugBank.d40.s1.e0" charOffset="240-251"
            type="drug" text="fosphenytoin"/>
        <entity id="DDI-DrugBank.d40.s1.e1" charOffset="256-264"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s2" text="Drugs highly bound to albumin could increase the unbound fraction of fosphenytoin.">
        <entity id="DDI-DrugBank.d40.s2.e0" charOffset="69-80"
            type="drug" text="fosphenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s3" text="Although, it is unknown whether this could result in clinically significant effects, caution is advised when administering Cerebyx with other drugs that significantly bind to serum albumin.">
        <entity id="DDI-DrugBank.d40.s3.e0" charOffset="123-129"
            type="brand" text="Cerebyx"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s4" text="The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.">
        <entity id="DDI-DrugBank.d40.s4.e0" charOffset="44-55"
            type="drug" text="fosphenytoin"/>
        <entity id="DDI-DrugBank.d40.s4.e1" charOffset="58-66"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d40.s4.e2" charOffset="73-80"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d40.s4.e3" charOffset="104-111"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d40.s4.e4" charOffset="117-123"
            type="brand" text="Cerebyx"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s5" text="The most significant drug interactions following administration of Cerebyx are expected to occur with drugs that interact with phenytoin.">
        <entity id="DDI-DrugBank.d40.s5.e0" charOffset="67-73"
            type="brand" text="Cerebyx"/>
        <entity id="DDI-DrugBank.d40.s5.e1" charOffset="127-135"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s6" text="Phenytoin is extensively bound to serum plasma proteins and is prone to competitive displacement.">
        <entity id="DDI-DrugBank.d40.s6.e0" charOffset="0-8" type="drug" text="Phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s7" text="Phenytoin is metabolized by hepatic cytochrome P450 enzymes and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism.">
        <entity id="DDI-DrugBank.d40.s7.e0" charOffset="0-8" type="drug" text="Phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s8" text="Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity.">
        <entity id="DDI-DrugBank.d40.s8.e0" charOffset="74-82"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s9" text="Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes.">
        <entity id="DDI-DrugBank.d40.s9.e0" charOffset="0-8" type="drug" text="Phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s10" text="The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone">
        <entity id="DDI-DrugBank.d40.s10.e0" charOffset="97-105"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d40.s10.e1" charOffset="137-143"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d40.s10.e2" charOffset="153-162"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d40.s10.e3" charOffset="182-197"
            type="drug" text="chlordiazepoxide"/>
        <entity id="DDI-DrugBank.d40.s10.e4" charOffset="200-209"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d40.s10.e5" charOffset="212-219"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d40.s10.e6" charOffset="222-230"
            type="drug" text="dicumarol"/>
        <entity id="DDI-DrugBank.d40.s10.e7" charOffset="233-242"
            type="drug" text="disulfiram"/>
        <entity id="DDI-DrugBank.d40.s10.e8" charOffset="245-253"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d40.s10.e9" charOffset="256-267"
            type="drug" text="ethosuximide"/>
        <entity id="DDI-DrugBank.d40.s10.e10" charOffset="270-279"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d40.s10.e11" charOffset="282-295"
            type="group" text="H2-antagonists"/>
        <entity id="DDI-DrugBank.d40.s10.e12" charOffset="298-306"
            type="drug" text="halothane"/>
        <entity id="DDI-DrugBank.d40.s10.e13" charOffset="309-317"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d40.s10.e14" charOffset="320-334"
            type="drug" text="methylphenidate"/>
        <entity id="DDI-DrugBank.d40.s10.e15" charOffset="337-350"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d40.s10.e16" charOffset="353-366"
            type="drug" text="phenylbutazone"/>
        <entity id="DDI-DrugBank.d40.s10.e17" charOffset="369-379"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d40.s10.e18" charOffset="382-393"
            type="group" text="succinimides"/>
        <entity id="DDI-DrugBank.d40.s10.e19" charOffset="396-407"
            type="group" text="sulfonamides"/>
        <entity id="DDI-DrugBank.d40.s10.e20" charOffset="410-420"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d40.s10.e21" charOffset="423-431"
            type="drug" text="trazodone"/>
        <ddi id="DDI-DrugBank.d40.s10.d0" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d1" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d2" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d3" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d4" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d5" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d6" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d7" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d8" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d9" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e10" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d10" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e11" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d11" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e12" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d12" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e13" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d13" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e14" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d14" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e15" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d15" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d16" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e17" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d17" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e18" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d18" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e19" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d19" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e20" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s10.d20" e1="DDI-DrugBank.d40.s10.e0"
            e2="DDI-DrugBank.d40.s10.e21" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s11" text="."/>
    <sentence id="DDI-DrugBank.d40.s12" text="- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine">
        <entity id="DDI-DrugBank.d40.s12.e0" charOffset="33-41"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d40.s12.e1" charOffset="67-79"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d40.s12.e2" charOffset="90-96"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d40.s12.e3" charOffset="105-113"
            type="drug" text="reserpine"/>
        <ddi id="DDI-DrugBank.d40.s12.d0" e1="DDI-DrugBank.d40.s12.e0"
            e2="DDI-DrugBank.d40.s12.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s12.d1" e1="DDI-DrugBank.d40.s12.e0"
            e2="DDI-DrugBank.d40.s12.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s12.d2" e1="DDI-DrugBank.d40.s12.e0"
            e2="DDI-DrugBank.d40.s12.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s13" text="."/>
    <sentence id="DDI-DrugBank.d40.s14" text="- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.">
        <entity id="DDI-DrugBank.d40.s14.e0" charOffset="52-60"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d40.s14.e1" charOffset="86-98"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d40.s14.e2" charOffset="120-135"
            type="drug" text="sodium valproate"/>
        <ddi id="DDI-DrugBank.d40.s14.d0" e1="DDI-DrugBank.d40.s14.e0"
            e2="DDI-DrugBank.d40.s14.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d40.s14.d1" e1="DDI-DrugBank.d40.s14.e0"
            e2="DDI-DrugBank.d40.s14.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s15" text="Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable">
        <entity id="DDI-DrugBank.d40.s15.e0" charOffset="26-34"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d40.s15.e1" charOffset="39-51"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d40.s15.e2" charOffset="54-66"
            type="drug" text="valproic acid"/>
        <entity id="DDI-DrugBank.d40.s15.e3" charOffset="86-94"
            type="drug" text="valproate"/>
        <ddi id="DDI-DrugBank.d40.s15.d0" e1="DDI-DrugBank.d40.s15.e0"
            e2="DDI-DrugBank.d40.s15.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s15.d1" e1="DDI-DrugBank.d40.s15.e0"
            e2="DDI-DrugBank.d40.s15.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s15.d2" e1="DDI-DrugBank.d40.s15.e0"
            e2="DDI-DrugBank.d40.s15.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s16" text="."/>
    <sentence id="DDI-DrugBank.d40.s17" text="- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted">
        <entity id="DDI-DrugBank.d40.s17.e0" charOffset="40-64"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d40.s17.e1" charOffset="119-125"
            type="brand" text="Cerebyx"/>
        <ddi id="DDI-DrugBank.d40.s17.d0" e1="DDI-DrugBank.d40.s17.e0"
            e2="DDI-DrugBank.d40.s17.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s18" text="."/>
    <sentence id="DDI-DrugBank.d40.s19" text="- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.">
        <entity id="DDI-DrugBank.d40.s19.e0" charOffset="38-46"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d40.s19.e1" charOffset="57-70"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d40.s19.e2" charOffset="73-87"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d40.s19.e3" charOffset="90-97"
            type="group" text="coumarin"/>
        <entity id="DDI-DrugBank.d40.s19.e4" charOffset="100-108"
            type="drug" text="digitoxin"/>
        <entity id="DDI-DrugBank.d40.s19.e5" charOffset="111-121"
            type="drug" text="doxycycline"/>
        <entity id="DDI-DrugBank.d40.s19.e6" charOffset="124-132"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d40.s19.e7" charOffset="135-144"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d40.s19.e8" charOffset="152-165"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d40.s19.e9" charOffset="168-175"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d40.s19.e10" charOffset="178-186"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d40.s19.e11" charOffset="189-200"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d40.s19.e12" charOffset="203-211"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d40.s19.d0" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s19.d1" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s19.d2" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s19.d3" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s19.d4" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s19.d5" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s19.d6" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s19.d7" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s19.d8" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s19.d9" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e10" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s19.d10" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e11" type="effect"/>
        <ddi id="DDI-DrugBank.d40.s19.d11" e1="DDI-DrugBank.d40.s19.e0"
            e2="DDI-DrugBank.d40.s19.e12" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s20" text="Monitoring of plasma phenytoin concentrations may be helpful when possible drug interactions are suspected.">
        <entity id="DDI-DrugBank.d40.s20.e0" charOffset="21-29"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s21" text="Drug/Laboratory Test Interactions Phenytoin may decrease serum concentrations of 14.">
        <entity id="DDI-DrugBank.d40.s21.e0" charOffset="34-42"
            type="drug" text="Phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s22" text="It may also produce artifactually low results in dexamethasone or metyrapone tests."/>
    <sentence id="DDI-DrugBank.d40.s23" text="Phenytoin may also cause increased serum concentrations of glucose, alkaline phosphatase, and gamma glutamyl transpeptidase (GGT).">
        <entity id="DDI-DrugBank.d40.s23.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d40.s24" text="Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations following Cerebyx administration.">
        <entity id="DDI-DrugBank.d40.s24.e0" charOffset="75-83"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d40.s24.e1" charOffset="110-116"
            type="brand" text="Cerebyx"/>
    </sentence>
    <sentence id="DDI-DrugBank.d426.s0" text="Ergot-containing drugs have been reported to cause prolonged vasospastic reactions."/>
    <sentence id="DDI-DrugBank.d426.s1" text="Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).">
        <entity id="DDI-DrugBank.d426.s1.e0" charOffset="67-76"
            type="drug" text="ergotamine"/>
        <entity id="DDI-DrugBank.d426.s1.e1" charOffset="92-113"
            type="group" text="ergot-type medications"/>
        <entity id="DDI-DrugBank.d426.s1.e2" charOffset="121-137"
            type="drug" text="dihydroergotamine"/>
        <entity id="DDI-DrugBank.d426.s1.e3" charOffset="142-153"
            type="drug" text="methysergide"/>
        <entity id="DDI-DrugBank.d426.s1.e4" charOffset="160-164"
            type="brand" text="FROVA"/>
        <ddi id="DDI-DrugBank.d426.s1.d0" e1="DDI-DrugBank.d426.s1.e0"
            e2="DDI-DrugBank.d426.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d426.s1.d1" e1="DDI-DrugBank.d426.s1.e1"
            e2="DDI-DrugBank.d426.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d426.s1.d2" e1="DDI-DrugBank.d426.s1.e2"
            e2="DDI-DrugBank.d426.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d426.s1.d3" e1="DDI-DrugBank.d426.s1.e3"
            e2="DDI-DrugBank.d426.s1.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d426.s2" text="Concomitant use of other 5-HT1B/1D agonists within 24 hours of FROVA treatment is not recommended.">
        <entity id="DDI-DrugBank.d426.s2.e0" charOffset="63-67"
            type="brand" text="FROVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d426.s3" text="Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.">
        <entity id="DDI-DrugBank.d426.s3.e0" charOffset="0-38"
            type="group" text="Selective serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d426.s3.e1" charOffset="41-45"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d426.s3.e2" charOffset="55-64"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d426.s3.e3" charOffset="67-77"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d426.s3.e4" charOffset="80-89"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d426.s3.e5" charOffset="92-101"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d426.s3.e6" charOffset="210-223"
            type="group" text="5-HT1 agonists"/>
        <ddi id="DDI-DrugBank.d426.s3.d0" e1="DDI-DrugBank.d426.s3.e0"
            e2="DDI-DrugBank.d426.s3.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d426.s3.d1" e1="DDI-DrugBank.d426.s3.e1"
            e2="DDI-DrugBank.d426.s3.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d426.s3.d2" e1="DDI-DrugBank.d426.s3.e2"
            e2="DDI-DrugBank.d426.s3.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d426.s3.d3" e1="DDI-DrugBank.d426.s3.e3"
            e2="DDI-DrugBank.d426.s3.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d426.s3.d4" e1="DDI-DrugBank.d426.s3.e4"
            e2="DDI-DrugBank.d426.s3.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d426.s3.d5" e1="DDI-DrugBank.d426.s3.e5"
            e2="DDI-DrugBank.d426.s3.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d426.s4" text="If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.">
        <entity id="DDI-DrugBank.d426.s4.e0" charOffset="30-41"
            type="drug" text="frovatriptan"/>
        <entity id="DDI-DrugBank.d426.s4.e1" charOffset="50-53"
            type="group" text="SSRI"/>
        <ddi id="DDI-DrugBank.d426.s4.d0" e1="DDI-DrugBank.d426.s4.e0"
            e2="DDI-DrugBank.d426.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d426.s5" text="Drug/Laboratory Test Interactions FROVA is not known to interfere with commonly employed clinical laboratory tests.">
        <entity id="DDI-DrugBank.d426.s5.e0" charOffset="34-38"
            type="brand" text="FROVA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s0" text="Fulvestrant is metabolized by CYP 3A4 in vitro.">
        <entity id="DDI-DrugBank.d70.s0.e0" charOffset="0-10"
            type="drug" text="Fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s1" text="Clinical studies of the effect of strong CYP 3A4 inhibitors on the pharmacokinetics of fulvestrant have not been performed.">
        <entity id="DDI-DrugBank.d70.s1.e0" charOffset="87-97"
            type="drug" text="fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s2" text="Carcinogenesis, Mutagenesis and Impairment of Fertility A two-year carcinogenesis study was conducted in female and male rats, at intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days and 10 mg/rat/15 days."/>
    <sentence id="DDI-DrugBank.d70.s3" text="These doses correspond to approximately 1-, 3-, and 5-fold (in females) and 1.3-, 1.3-, and 1.6-fold (in males) the systemic exposure [AUC0-30 days]] achieved in women receiving the recommended dose of 250 mg/month."/>
    <sentence id="DDI-DrugBank.d70.s4" text="An increased incidence of benign ovarian granulosa cell tumors and testicular Leydig cell tumors was evident, in females dosed at 10 mg/rat/15 days and males dosed at 15 mg/rat/30 days, respectively."/>
    <sentence id="DDI-DrugBank.d70.s5" text="Induction of such tumors is consistent with the pharmacology-related endocrine feedback alterations in gonadotropin levels caused by an antiestrogen.">
        <entity id="DDI-DrugBank.d70.s5.e0" charOffset="136-147"
            type="group" text="antiestrogen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s6" text="Fulvestrant was not mutagenic or clastogenic in multiple in vitro tests with and without the addition of a mammalian liver metabolic activation factor (bacterial mutation assay in strains of Salmonella typhimurium and Escherichia coli, in vitro cytogenetics study in human lymphocytes, mammalian cell mutation assay in mouse lymphoma cells and in vivo micronucleus test in rat.">
        <entity id="DDI-DrugBank.d70.s6.e0" charOffset="0-10"
            type="drug" text="Fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s7" text="In female rats, fulvestrant administered at doses   0.01 mg/kg/day (approximately one-hundredth of the human recommended dose based on body surface area [BSA], for 2 weeks prior to and for 1 week following mating, caused a reduction in fertility and embryonic survival.">
        <entity id="DDI-DrugBank.d70.s7.e0" charOffset="16-26"
            type="drug" text="fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s8" text="No adverse effects on female fertility and embryonic survival were evident in female animals dosed at 0.001 mg/kg/day (approximately one-thousandth of the human dose based on BSA)."/>
    <sentence id="DDI-DrugBank.d70.s9" text="Restoration of female fertility to values similar to controls was evident following a 29-day withdrawal period after dosing at 2 mg/kg/day (twice the human dose based on BSA)."/>
    <sentence id="DDI-DrugBank.d70.s10" text="The effects of fulvestrant on the fertility of female rats appear to be consistent with its anti-estrogenic activity.">
        <entity id="DDI-DrugBank.d70.s10.e0" charOffset="15-25"
            type="drug" text="fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s11" text="The potential effects of fulvestrant on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days fulvestrant showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides.">
        <entity id="DDI-DrugBank.d70.s11.e0" charOffset="25-35"
            type="drug" text="fulvestrant"/>
        <entity id="DDI-DrugBank.d70.s11.e1" charOffset="226-236"
            type="drug" text="fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s12" text="Changes in the testes and epididymides had not recovered 20 weeks after cessation of dosing."/>
    <sentence id="DDI-DrugBank.d70.s13" text="These fulvestrant doses correspond to approximately 2-, 3-, and 3-fold the systemic exposure [AUC0-30 days] achieved in women.">
        <entity id="DDI-DrugBank.d70.s13.e0" charOffset="6-16"
            type="drug" text="fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s14" text="Pregnancy Pregnancy Category D: ."/>
    <sentence id="DDI-DrugBank.d70.s15" text="In studies in female rats at doses   0.01 mg/kg/day (IM;"/>
    <sentence id="DDI-DrugBank.d70.s16" text="approximately one-hundredth of the human recommended dose based on body surface area [BSA]), fulvestrant caused a reversible reduction in female fertility, as well as effects on embryo/fetal development consistent with its anti-estrogenic activity.">
        <entity id="DDI-DrugBank.d70.s16.e0" charOffset="93-103"
            type="drug" text="fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s17" text="Fulvestrant caused an increased incidence of fetal abnormalities in rats (tarsal flexure of the hind paw at 2 mg/kg/day IM;">
        <entity id="DDI-DrugBank.d70.s17.e0" charOffset="0-10"
            type="drug" text="Fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s18" text="twice the human dose on BSA) and non-ossification of the odontoid and ventral tubercle of the first cervical vertebra at doses   0.1 mg/kg/day IM (approximately one-tenth of the human dose on BSA) when administered during the period of organogenesis."/>
    <sentence id="DDI-DrugBank.d70.s19" text="Rabbits failed to maintain pregnancy when dosed with 1 mg/kg/day fulvestrant IM (twice the human dose on BSA) during the period of organogenesis.">
        <entity id="DDI-DrugBank.d70.s19.e0" charOffset="65-75"
            type="drug" text="fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s20" text="Further, in rabbits dosed at 0.25 mg/kg/day (about one-half the human dose on BSA), increases in placental weight and post-implantation loss were observed but, there were no observed effects on fetal development."/>
    <sentence id="DDI-DrugBank.d70.s21" text="Fulvestrant was associated with an increased incidence of fetal variations in rabbits (backwards displacement of the pelvic girdle, and 27 pre-sacral vertebrae at 0.25 mg/kg/day IM;">
        <entity id="DDI-DrugBank.d70.s21.e0" charOffset="0-10"
            type="drug" text="Fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s22" text="one-half the human dose on BSA) when administered during the period of organogenesis."/>
    <sentence id="DDI-DrugBank.d70.s23" text="Because pregnancy could not be maintained in the rabbit following doses of fulvestrant of 1 mg/kg/day and above, this study was inadequate to fully define the possible adverse effects on fetal development at clinically relevant exposures.">
        <entity id="DDI-DrugBank.d70.s23.e0" charOffset="75-85"
            type="drug" text="fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s24" text="Nursing Mothers Fulvestrant is found in rat milk at levels significantly higher (approximately 12-fold) than plasma after administration of 2 mg/kg.">
        <entity id="DDI-DrugBank.d70.s24.e0" charOffset="16-26"
            type="drug" text="Fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s25" text="Drug exposure in rodent pups from fulvestrant-treated lactating dams was estimated as 10% of the administered dose.">
        <entity id="DDI-DrugBank.d70.s25.e0" charOffset="34-44"
            type="drug" text="fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s26" text="It is not known if fulvestrant is excreted in human milk.">
        <entity id="DDI-DrugBank.d70.s26.e0" charOffset="19-29"
            type="drug" text="fulvestrant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s27" text="Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions from FASLODEX in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.">
        <entity id="DDI-DrugBank.d70.s27.e0" charOffset="111-118"
            type="brand" text="FASLODEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s28" text="Pediatric Use The safety and efficacy of FASLODEX in pediatric patients have not been established.">
        <entity id="DDI-DrugBank.d70.s28.e0" charOffset="41-48"
            type="brand" text="FASLODEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d70.s29" text="Geriatric Use When tumor response was considered by age, objective responses were seen in 24% and 22% of patients under 65 years of age and in 16% and 11% of patients 65 years of age and older, who were treated with FASLODEX in the European and North American trials, respectively.">
        <entity id="DDI-DrugBank.d70.s29.e0" charOffset="216-223"
            type="brand" text="FASLODEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s0" text="Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.">
        <entity id="DDI-DrugBank.d231.s0.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d231.s0.e1" charOffset="50-75"
            type="group" text="aminoglycoside antibiotics"/>
        <ddi id="DDI-DrugBank.d231.s0.d0" e1="DDI-DrugBank.d231.s0.e0"
            e2="DDI-DrugBank.d231.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s1" text="Except in life-threatening situations, avoid this combination."/>
    <sentence id="DDI-DrugBank.d231.s2" text="Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.">
        <entity id="DDI-DrugBank.d231.s2.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d231.s2.e1" charOffset="49-63"
            type="drug" text="ethacrynic acid"/>
        <ddi id="DDI-DrugBank.d231.s2.d0" e1="DDI-DrugBank.d231.s2.e0"
            e2="DDI-DrugBank.d231.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s3" text="Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.">
        <entity id="DDI-DrugBank.d231.s3.e0" charOffset="33-43"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d231.s3.e1" charOffset="64-73"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s3.e2" charOffset="116-125"
            type="group" text="salicylate"/>
        <ddi id="DDI-DrugBank.d231.s3.d0" e1="DDI-DrugBank.d231.s3.e0"
            e2="DDI-DrugBank.d231.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s4" text="Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.">
        <entity id="DDI-DrugBank.d231.s4.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d231.s4.e1" charOffset="79-90"
            type="drug" text="tubocurarine"/>
        <entity id="DDI-DrugBank.d231.s4.e2" charOffset="125-139"
            type="drug" text="succinylcholine"/>
        <ddi id="DDI-DrugBank.d231.s4.d0" e1="DDI-DrugBank.d231.s4.e0"
            e2="DDI-DrugBank.d231.s4.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d231.s4.d1" e1="DDI-DrugBank.d231.s4.e0"
            e2="DDI-DrugBank.d231.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s5" text="Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.">
        <entity id="DDI-DrugBank.d231.s5.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d231.s5.e1" charOffset="43-51"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d231.s5.e2" charOffset="73-79"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d231.s5.e3" charOffset="121-127"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d231.s5.d0" e1="DDI-DrugBank.d231.s5.e0"
            e2="DDI-DrugBank.d231.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s6" text="Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.">
        <entity id="DDI-DrugBank.d231.s6.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d231.s6.e1" charOffset="68-89"
            type="group" text="antihypertensive drugs"/>
        <ddi id="DDI-DrugBank.d231.s6.d0" e1="DDI-DrugBank.d231.s6.e0"
            e2="DDI-DrugBank.d231.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s7" text="Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.">
        <entity id="DDI-DrugBank.d231.s7.e0" charOffset="25-34;50-74"
            type="group" text="ganglionic adrenergic blocking drugs"/>
        <entity id="DDI-DrugBank.d231.s7.e1" charOffset="39-74"
            type="group" text="peripheral adrenergic blocking drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s8" text="Furosemide may decrease arterial responsiveness to norepinephrine.">
        <entity id="DDI-DrugBank.d231.s8.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d231.s8.e1" charOffset="51-64"
            type="drug" text="norepinephrine"/>
        <ddi id="DDI-DrugBank.d231.s8.d0" e1="DDI-DrugBank.d231.s8.e0"
            e2="DDI-DrugBank.d231.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s9" text="However, norepinephrine may still be used effectively.">
        <entity id="DDI-DrugBank.d231.s9.e0" charOffset="9-22"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s10" text="Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.">
        <entity id="DDI-DrugBank.d231.s10.e0" charOffset="39-48"
            type="drug" text="sucralfate"/>
        <entity id="DDI-DrugBank.d231.s10.e1" charOffset="54-63"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s10.e2" charOffset="132-141"
            type="drug" text="furosemide"/>
        <ddi id="DDI-DrugBank.d231.s10.d0" e1="DDI-DrugBank.d231.s10.e0"
            e2="DDI-DrugBank.d231.s10.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s11" text="Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.">
        <entity id="DDI-DrugBank.d231.s11.e0" charOffset="128-137"
            type="drug" text="furosemide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s12" text="The intake of furosemide and sucralfate should be separated by at least two hours.">
        <entity id="DDI-DrugBank.d231.s12.e0" charOffset="14-23"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s12.e1" charOffset="29-38"
            type="drug" text="sucralfate"/>
        <ddi id="DDI-DrugBank.d231.s12.d0" e1="DDI-DrugBank.d231.s12.e0"
            e2="DDI-DrugBank.d231.s12.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s13" text="Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.">
        <entity id="DDI-DrugBank.d231.s13.e0" charOffset="101-110"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s13.e1" charOffset="116-135"
            type="drug" text="acetylsalicylic acid"/>
        <ddi id="DDI-DrugBank.d231.s13.d0" e1="DDI-DrugBank.d231.s13.e0"
            e2="DDI-DrugBank.d231.s13.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s14" text="There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.">
        <entity id="DDI-DrugBank.d231.s14.e0" charOffset="130-139"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s14.e1" charOffset="170-175"
            type="group" text="NSAIDs"/>
        <ddi id="DDI-DrugBank.d231.s14.d0" e1="DDI-DrugBank.d231.s14.e0"
            e2="DDI-DrugBank.d231.s14.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s15" text="Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.">
        <entity id="DDI-DrugBank.d231.s15.e0" charOffset="53-64"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d231.s15.e1" charOffset="125-134"
            type="drug" text="furosemide"/>
        <ddi id="DDI-DrugBank.d231.s15.d0" e1="DDI-DrugBank.d231.s15.e0"
            e2="DDI-DrugBank.d231.s15.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s16" text="Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.">
        <entity id="DDI-DrugBank.d231.s16.e0" charOffset="0-11"
            type="drug" text="Indomethacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s17" text="Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.">
        <entity id="DDI-DrugBank.d231.s17.e0" charOffset="24-35"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d231.s17.e1" charOffset="41-50"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s17.e2" charOffset="150-159"
            type="drug" text="furosemide"/>
        <ddi id="DDI-DrugBank.d231.s17.d0" e1="DDI-DrugBank.d231.s17.e0"
            e2="DDI-DrugBank.d231.s17.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s0" text="In vitro studies were conducted to investigate the potential of gabapentin to inhibit the major cytochrome P450 enzymes (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) that mediate drug and xenobiotic metabolism using isoform selective marker substrates and human liver microsomal preparations.">
        <entity id="DDI-DrugBank.d438.s0.e0" charOffset="64-73"
            type="drug" text="gabapentin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s1" text="Only at the highest concentration tested (171"/>
    <sentence id="DDI-DrugBank.d438.s2" text="g/mL;"/>
    <sentence id="DDI-DrugBank.d438.s3" text="1 mM) was a slight degree of inhibition (14%-30%) of isoform CYP2A6 observed."/>
    <sentence id="DDI-DrugBank.d438.s4" text="No inhibition of any of the other isoforms tested was observed at gabapentin concentrations up to 171 mg/mL (approximately 15 times the Cmax at 3600 mg/day).">
        <entity id="DDI-DrugBank.d438.s4.e0" charOffset="66-75"
            type="drug" text="gabapentin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s5" text="Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs.">
        <entity id="DDI-DrugBank.d438.s5.e0" charOffset="0-9"
            type="drug" text="Gabapentin"/>
        <entity id="DDI-DrugBank.d438.s5.e1" charOffset="111-129"
            type="group" text="antiepileptic drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s6" text="The drug interaction data described in this section were obtained from studies involving healthy adults and adult patients with epilepsy."/>
    <sentence id="DDI-DrugBank.d438.s7" text="Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.">
        <entity id="DDI-DrugBank.d438.s7.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d438.s7.e1" charOffset="72-80"
            type="brand" text="Neurontin"/>
        <entity id="DDI-DrugBank.d438.s7.e2" charOffset="124-132"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d438.s7.e3" charOffset="169-178"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d438.s7.e4" charOffset="246-254"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d438.s7.e5" charOffset="260-268"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d438.s7.e6" charOffset="287-296"
            type="drug" text="gabapentin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s8" text="Carbamazepine: Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;">
        <entity id="DDI-DrugBank.d438.s8.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d438.s8.e1" charOffset="42-54"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d438.s8.e2" charOffset="60-87"
            type="drug_n" text="carbamazepine 10, 11 epoxide"/>
        <entity id="DDI-DrugBank.d438.s8.e3" charOffset="137-146"
            type="drug" text="gabapentin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s9" text="N=12) administration."/>
    <sentence id="DDI-DrugBank.d438.s10" text="Likewise, gabapentin pharmacokinetics were unaltered by carbamazepine administration.">
        <entity id="DDI-DrugBank.d438.s10.e0" charOffset="10-19"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d438.s10.e1" charOffset="56-68"
            type="drug" text="carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s11" text="Valproic Acid: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg TID;">
        <entity id="DDI-DrugBank.d438.s11.e0" charOffset="0-12"
            type="drug" text="Valproic Acid"/>
        <entity id="DDI-DrugBank.d438.s11.e1" charOffset="50-62"
            type="drug" text="valproic acid"/>
        <entity id="DDI-DrugBank.d438.s11.e2" charOffset="111-120"
            type="drug" text="gabapentin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s12" text="N=17) were not different and neither were gabapentin pharmacokinetic parameters affected by valproic acid.">
        <entity id="DDI-DrugBank.d438.s12.e0" charOffset="42-51"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d438.s12.e1" charOffset="92-104"
            type="drug" text="valproic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s13" text="Phenobarbital: Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg TID;">
        <entity id="DDI-DrugBank.d438.s13.e0" charOffset="0-12"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d438.s13.e1" charOffset="72-84"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d438.s13.e2" charOffset="89-98"
            type="drug" text="gabapentin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s14" text="N=12) are identical whether the drugs are administered alone or together."/>
    <sentence id="DDI-DrugBank.d438.s15" text="Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.">
        <entity id="DDI-DrugBank.d438.s15.e0" charOffset="0-7"
            type="drug" text="Naproxen"/>
        <entity id="DDI-DrugBank.d438.s15.e1" charOffset="37-51"
            type="drug" text="naproxen sodium"/>
        <entity id="DDI-DrugBank.d438.s15.e2" charOffset="76-84"
            type="brand" text="Neurontin"/>
        <entity id="DDI-DrugBank.d438.s15.e3" charOffset="129-138"
            type="drug" text="gabapentin"/>
        <ddi id="DDI-DrugBank.d438.s15.d0" e1="DDI-DrugBank.d438.s15.e1"
            e2="DDI-DrugBank.d438.s15.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s16" text="Gabapentin had no effect on naproxen pharmacokinetic parameters.">
        <entity id="DDI-DrugBank.d438.s16.e0" charOffset="0-9"
            type="drug" text="Gabapentin"/>
        <entity id="DDI-DrugBank.d438.s16.e1" charOffset="28-35"
            type="drug" text="naproxen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s17" text="These doses are lower than the therapeutic doses for both drugs."/>
    <sentence id="DDI-DrugBank.d438.s18" text="The magnitude of interaction within the recommended dose ranges of either drug is not known."/>
    <sentence id="DDI-DrugBank.d438.s19" text="Hydrocodone: Coadministration of Neurontin  (125 to 500 mg;">
        <entity id="DDI-DrugBank.d438.s19.e0" charOffset="0-10"
            type="drug" text="Hydrocodone"/>
        <entity id="DDI-DrugBank.d438.s19.e1" charOffset="33-41"
            type="brand" text="Neurontin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s20" text="N=48) decreases hydrocodone (10 mg;">
        <entity id="DDI-DrugBank.d438.s20.e0" charOffset="16-26"
            type="drug" text="hydrocodone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s21" text="N=50) Cmax and AUC values in a dose-dependent manner relative to administration of hydrocodone alone;">
        <entity id="DDI-DrugBank.d438.s21.e0" charOffset="83-93"
            type="drug" text="hydrocodone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s22" text="Cmax and AUC values are 3% to 4% lower, respectively, after administration of 125 mg Neurontin  and 21% to 22% lower, respectively, after administration of 500 mg Neurontin .">
        <entity id="DDI-DrugBank.d438.s22.e0" charOffset="85-93"
            type="brand" text="Neurontin"/>
        <entity id="DDI-DrugBank.d438.s22.e1" charOffset="163-171"
            type="brand" text="Neurontin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s23" text="The mechanism for this interaction is unknown."/>
    <sentence id="DDI-DrugBank.d438.s24" text="Hydrocodone increases gabapentin AUC values by 14%.">
        <entity id="DDI-DrugBank.d438.s24.e0" charOffset="0-10"
            type="drug" text="Hydrocodone"/>
        <entity id="DDI-DrugBank.d438.s24.e1" charOffset="22-31"
            type="drug" text="gabapentin"/>
        <ddi id="DDI-DrugBank.d438.s24.d0" e1="DDI-DrugBank.d438.s24.e0"
            e2="DDI-DrugBank.d438.s24.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s25" text="The magnitude of interaction at other doses is not known."/>
    <sentence id="DDI-DrugBank.d438.s26" text="Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.">
        <entity id="DDI-DrugBank.d438.s26.e0" charOffset="0-7"
            type="drug" text="Morphine"/>
        <entity id="DDI-DrugBank.d438.s26.e1" charOffset="77-84"
            type="drug" text="morphine"/>
        <entity id="DDI-DrugBank.d438.s26.e2" charOffset="137-145"
            type="brand" text="Neurontin"/>
        <entity id="DDI-DrugBank.d438.s26.e3" charOffset="169-178"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d438.s26.e4" charOffset="213-222"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d438.s26.e5" charOffset="245-252"
            type="drug" text="morphine"/>
        <ddi id="DDI-DrugBank.d438.s26.d0" e1="DDI-DrugBank.d438.s26.e1"
            e2="DDI-DrugBank.d438.s26.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s27" text="Morphine pharmacokinetic parameter values were not affected by administration of Neurontin  2 hours after morphine.">
        <entity id="DDI-DrugBank.d438.s27.e0" charOffset="0-7"
            type="drug" text="Morphine"/>
        <entity id="DDI-DrugBank.d438.s27.e1" charOffset="81-89"
            type="brand" text="Neurontin"/>
        <entity id="DDI-DrugBank.d438.s27.e2" charOffset="106-113"
            type="drug" text="morphine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s28" text="The magnitude of interaction at other doses is not known."/>
    <sentence id="DDI-DrugBank.d438.s29" text="Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.">
        <entity id="DDI-DrugBank.d438.s29.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d438.s29.e1" charOffset="31-40"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d438.s29.e2" charOffset="99-108"
            type="drug" text="gabapentin"/>
        <ddi id="DDI-DrugBank.d438.s29.d0" e1="DDI-DrugBank.d438.s29.e1"
            e2="DDI-DrugBank.d438.s29.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s30" text="Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.">
        <entity id="DDI-DrugBank.d438.s30.e0" charOffset="5-14"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d438.s30.e1" charOffset="62-71"
            type="drug" text="gabapentin"/>
        <ddi id="DDI-DrugBank.d438.s30.d0" e1="DDI-DrugBank.d438.s30.e0"
            e2="DDI-DrugBank.d438.s30.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s31" text="This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.">
        <entity id="DDI-DrugBank.d438.s31.e0" charOffset="36-45"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d438.s31.e1" charOffset="50-59"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d438.s31.d0" e1="DDI-DrugBank.d438.s31.e0"
            e2="DDI-DrugBank.d438.s31.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s32" text="The effect of gabapentin on cimetidine was not evaluated.">
        <entity id="DDI-DrugBank.d438.s32.e0" charOffset="14-23"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d438.s32.e1" charOffset="28-37"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s33" text="Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;">
        <entity id="DDI-DrugBank.d438.s33.e0" charOffset="5-17"
            type="group" text="Contraceptive"/>
        <entity id="DDI-DrugBank.d438.s33.e1" charOffset="90-102"
            type="drug" text="norethindrone"/>
        <entity id="DDI-DrugBank.d438.s33.e2" charOffset="108-124"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d438.s33.e3" charOffset="183-203"
            type="drug" text="norethindrone acetate"/>
        <entity id="DDI-DrugBank.d438.s33.e4" charOffset="219-235"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d438.s33.e5" charOffset="287-296"
            type="drug" text="gabapentin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s34" text="N=13)."/>
    <sentence id="DDI-DrugBank.d438.s35" text="The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;">
        <entity id="DDI-DrugBank.d438.s35.e0" charOffset="12-24"
            type="drug" text="norethindrone"/>
        <entity id="DDI-DrugBank.d438.s35.e1" charOffset="73-82"
            type="drug" text="gabapentin"/>
        <ddi id="DDI-DrugBank.d438.s35.d0" e1="DDI-DrugBank.d438.s35.e0"
            e2="DDI-DrugBank.d438.s35.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s36" text="this interaction is not expected to be of clinical importance."/>
    <sentence id="DDI-DrugBank.d438.s37" text="Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.">
        <entity id="DDI-DrugBank.d438.s37.e0" charOffset="0-6"
            type="group" text="Antacid"/>
        <entity id="DDI-DrugBank.d438.s37.e1" charOffset="9-14"
            type="brand" text="Maalox"/>
        <entity id="DDI-DrugBank.d438.s37.e2" charOffset="19-24"
            type="brand" text="Maalox"/>
        <entity id="DDI-DrugBank.d438.s37.e3" charOffset="57-66"
            type="drug" text="gabapentin"/>
        <ddi id="DDI-DrugBank.d438.s37.d0" e1="DDI-DrugBank.d438.s37.e2"
            e2="DDI-DrugBank.d438.s37.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s38" text="This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.">
        <entity id="DDI-DrugBank.d438.s38.e0" charOffset="51-60"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d438.s38.e1" charOffset="93-98"
            type="brand" text="Maalox"/>
        <ddi id="DDI-DrugBank.d438.s38.d0" e1="DDI-DrugBank.d438.s38.e0"
            e2="DDI-DrugBank.d438.s38.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s39" text="It is recommended that gabapentin be taken at least 2 hours following Maalox administration.">
        <entity id="DDI-DrugBank.d438.s39.e0" charOffset="23-32"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d438.s39.e1" charOffset="70-75"
            type="brand" text="Maalox"/>
        <ddi id="DDI-DrugBank.d438.s39.d0" e1="DDI-DrugBank.d438.s39.e0"
            e2="DDI-DrugBank.d438.s39.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s40" text="Effect of Probenecid: Probenecid is a blocker of renal tubular secretion.">
        <entity id="DDI-DrugBank.d438.s40.e0" charOffset="10-19"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d438.s40.e1" charOffset="22-31"
            type="drug" text="Probenecid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s41" text="Gabapentin pharmacokinetic parameters without and with probenecid were comparable.">
        <entity id="DDI-DrugBank.d438.s41.e0" charOffset="0-9"
            type="drug" text="Gabapentin"/>
        <entity id="DDI-DrugBank.d438.s41.e1" charOffset="55-64"
            type="drug" text="probenecid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s42" text="This indicates that gabapentin does not undergo renal tubular secretion by the pathway that is blocked by probenecid.">
        <entity id="DDI-DrugBank.d438.s42.e0" charOffset="20-29"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d438.s42.e1" charOffset="106-115"
            type="drug" text="probenecid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s43" text="Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when gabapentin was added to other antiepileptic drugs, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein">
        <entity id="DDI-DrugBank.d438.s43.e0" charOffset="149-158"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d438.s43.e1" charOffset="179-197"
            type="group" text="antiepileptic drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d438.s44" text="."/>
    <sentence id="DDI-DrugBank.d438.s45" text=""/>
    <sentence id="DDI-DrugBank.d230.s0" text="LABORATORY TEST FINDINGS Asymptomatic, transitory changes in serum iron have been observed."/>
    <sentence id="DDI-DrugBank.d230.s1" text="The clinical significance is unknown."/>
    <sentence id="DDI-DrugBank.d230.s2" text="Omniscan interferes with serum calcium measurements with some colorimetric (complexometric) methods commonly used in hospitals, resulting in serum calcium concentrations lower than the true values.">
        <entity id="DDI-DrugBank.d230.s2.e0" charOffset="0-7"
            type="brand" text="Omniscan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d230.s3" text="Thus, it is recommended not to use such methods for 12-24 hours after administration of Omniscan.">
        <entity id="DDI-DrugBank.d230.s3.e0" charOffset="88-95"
            type="brand" text="Omniscan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d230.s4" text="If such measurements are necessary, the use of other methods is recommended."/>
    <sentence id="DDI-DrugBank.d230.s5" text="All patients in whom this effect was observed remained asymptomatic."/>
    <sentence id="DDI-DrugBank.d58.s0" text="No formal drug interaction studies have been conducted."/>
    <sentence id="DDI-DrugBank.d159.s0" text="No drug interactions have been observed with the Vitrasert Implant.">
        <entity id="DDI-DrugBank.d159.s0.e0" charOffset="49-57"
            type="brand" text="Vitrasert"/>
    </sentence>
    <sentence id="DDI-DrugBank.d159.s1" text="There is limited experience with use of retinal tamponades in conjunction with the Vitrasert Implant.">
        <entity id="DDI-DrugBank.d159.s1.e0" charOffset="83-91"
            type="brand" text="Vitrasert"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s0" text="Substances that are inducers of CYP3A4 activity increase the metabolism of gefitinib and decrease its plasma concentrations.">
        <entity id="DDI-DrugBank.d207.s0.e0" charOffset="75-83"
            type="drug" text="gefitinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s1" text="In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).">
        <entity id="DDI-DrugBank.d207.s1.e0" charOffset="54-63"
            type="drug" text="rifampicin"/>
        <entity id="DDI-DrugBank.d207.s1.e1" charOffset="68-76"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s2" text="International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.">
        <entity id="DDI-DrugBank.d207.s2.e0" charOffset="114-121"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d207.s2.e1" charOffset="132-137"
            type="brand" text="IRESSA"/>
        <ddi id="DDI-DrugBank.d207.s2.d0" e1="DDI-DrugBank.d207.s2.e0"
            e2="DDI-DrugBank.d207.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s3" text="Patients taking warfarin should be monitored regularly for changes in prothrombin time or INR.">
        <entity id="DDI-DrugBank.d207.s3.e0" charOffset="16-23"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s4" text="Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.">
        <entity id="DDI-DrugBank.d207.s4.e0" charOffset="62-73"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d207.s4.e1" charOffset="79-90"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d207.s4.e2" charOffset="102-110"
            type="drug" text="gefitinib"/>
        <entity id="DDI-DrugBank.d207.s4.e3" charOffset="136-144"
            type="drug" text="gefitinib"/>
        <ddi id="DDI-DrugBank.d207.s4.d0" e1="DDI-DrugBank.d207.s4.e0"
            e2="DDI-DrugBank.d207.s4.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d207.s4.d1" e1="DDI-DrugBank.d207.s4.e1"
            e2="DDI-DrugBank.d207.s4.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d207.s4.d2" e1="DDI-DrugBank.d207.s4.e0"
            e2="DDI-DrugBank.d207.s4.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d207.s4.d3" e1="DDI-DrugBank.d207.s4.e1"
            e2="DDI-DrugBank.d207.s4.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s5" text="This increase may be clinically relevant as adverse experiences are related to dose and exposure;"/>
    <sentence id="DDI-DrugBank.d207.s6" text="therefore, caution should be used when administering CYP3A4 inhibitors with IRESSA.">
        <entity id="DDI-DrugBank.d207.s6.e0" charOffset="76-81"
            type="brand" text="IRESSA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s7" text="Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.">
        <entity id="DDI-DrugBank.d207.s7.e0" charOffset="64-96"
            type="group" text="histamine H2-receptor antagonists"/>
        <entity id="DDI-DrugBank.d207.s7.e1" charOffset="106-115"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d207.s7.e2" charOffset="120-129"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d207.s7.e3" charOffset="168-173"
            type="brand" text="IRESSA"/>
        <ddi id="DDI-DrugBank.d207.s7.d0" e1="DDI-DrugBank.d207.s7.e0"
            e2="DDI-DrugBank.d207.s7.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d207.s7.d1" e1="DDI-DrugBank.d207.s7.e1"
            e2="DDI-DrugBank.d207.s7.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d207.s7.d2" e1="DDI-DrugBank.d207.s7.e2"
            e2="DDI-DrugBank.d207.s7.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d207.s8" text="Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.">
        <entity id="DDI-DrugBank.d207.s8.e0" charOffset="36-41"
            type="brand" text="IRESSA"/>
        <entity id="DDI-DrugBank.d207.s8.e1" charOffset="47-57"
            type="drug" text="vinorelbine"/>
        <entity id="DDI-DrugBank.d207.s8.e2" charOffset="103-108"
            type="brand" text="IRESSA"/>
        <entity id="DDI-DrugBank.d207.s8.e3" charOffset="151-161"
            type="drug" text="vinorelbine"/>
        <ddi id="DDI-DrugBank.d207.s8.d0" e1="DDI-DrugBank.d207.s8.e2"
            e2="DDI-DrugBank.d207.s8.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d161.s0" text="No specific drug interaction studies have been conducted."/>
    <sentence id="DDI-DrugBank.d161.s1" text="For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.">
        <entity id="DDI-DrugBank.d161.s1.e0" charOffset="43-48"
            type="brand" text="Gemzar"/>
        <entity id="DDI-DrugBank.d161.s1.e1" charOffset="54-62"
            type="drug" text="cisplatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d490.s0" text=")"/>
    <sentence id="DDI-DrugBank.d490.s1" text=""/>
    <sentence id="DDI-DrugBank.d490.s2" text="Clinical Laboratory"/>
    <sentence id="DDI-DrugBank.d490.s3" text=""/>
    <sentence id="DDI-DrugBank.d490.s4" text="increased creatine"/>
    <sentence id="DDI-DrugBank.d490.s5" text="positive antinuclear"/>
    <sentence id="DDI-DrugBank.d490.s6" text=""/>
    <sentence id="DDI-DrugBank.d490.s7" text="phosphokinase"/>
    <sentence id="DDI-DrugBank.d490.s8" text="antibody"/>
    <sentence id="DDI-DrugBank.d490.s9" text=""/>
    <sentence id="DDI-DrugBank.d490.s10" text="increased bilirubin"/>
    <sentence id="DDI-DrugBank.d490.s11" text=""/>
    <sentence id="DDI-DrugBank.d490.s12" text=""/>
    <sentence id="DDI-DrugBank.d490.s13" text="increased liver"/>
    <sentence id="DDI-DrugBank.d490.s14" text=""/>
    <sentence id="DDI-DrugBank.d490.s15" text=""/>
    <sentence id="DDI-DrugBank.d490.s16" text="transaminases (AST"/>
    <sentence id="DDI-DrugBank.d490.s17" text=""/>
    <sentence id="DDI-DrugBank.d490.s18" text=""/>
    <sentence id="DDI-DrugBank.d490.s19" text="(SGOT), ALT (SGPT)"/>
    <sentence id="DDI-DrugBank.d490.s20" text=""/>
    <sentence id="DDI-DrugBank.d490.s21" text=""/>
    <sentence id="DDI-DrugBank.d490.s22" text="increased alkaline"/>
    <sentence id="DDI-DrugBank.d490.s23" text=""/>
    <sentence id="DDI-DrugBank.d490.s24" text=""/>
    <sentence id="DDI-DrugBank.d490.s25" text="phophatase"/>
    <sentence id="DDI-DrugBank.d490.s26" text=""/>
    <sentence id="DDI-DrugBank.d490.s27" text="Hematopoietic"/>
    <sentence id="DDI-DrugBank.d490.s28" text="anemia"/>
    <sentence id="DDI-DrugBank.d490.s29" text="thrombocytopenia"/>
    <sentence id="DDI-DrugBank.d490.s30" text=""/>
    <sentence id="DDI-DrugBank.d490.s31" text="leukopenia"/>
    <sentence id="DDI-DrugBank.d490.s32" text=""/>
    <sentence id="DDI-DrugBank.d490.s33" text=""/>
    <sentence id="DDI-DrugBank.d490.s34" text="bone marrow hypoplasia"/>
    <sentence id="DDI-DrugBank.d490.s35" text=""/>
    <sentence id="DDI-DrugBank.d490.s36" text=""/>
    <sentence id="DDI-DrugBank.d490.s37" text="eosinophilia"/>
    <sentence id="DDI-DrugBank.d490.s38" text=""/>
    <sentence id="DDI-DrugBank.d490.s39" text="Immunologic"/>
    <sentence id="DDI-DrugBank.d490.s40" text="angioedema"/>
    <sentence id="DDI-DrugBank.d490.s41" text="anaphylaxis"/>
    <sentence id="DDI-DrugBank.d490.s42" text=""/>
    <sentence id="DDI-DrugBank.d490.s43" text="laryngeal edema"/>
    <sentence id="DDI-DrugBank.d490.s44" text="Lupus-like syndrome"/>
    <sentence id="DDI-DrugBank.d490.s45" text=""/>
    <sentence id="DDI-DrugBank.d490.s46" text="urticaria"/>
    <sentence id="DDI-DrugBank.d490.s47" text="vasculitis"/>
    <sentence id="DDI-DrugBank.d490.s48" text="Integumentary"/>
    <sentence id="DDI-DrugBank.d490.s49" text="exfoliative dermatitis"/>
    <sentence id="DDI-DrugBank.d490.s50" text="alopecia"/>
    <sentence id="DDI-DrugBank.d490.s51" text=""/>
    <sentence id="DDI-DrugBank.d490.s52" text="rash"/>
    <sentence id="DDI-DrugBank.d490.s53" text=""/>
    <sentence id="DDI-DrugBank.d490.s54" text=""/>
    <sentence id="DDI-DrugBank.d490.s55" text="dermatitis"/>
    <sentence id="DDI-DrugBank.d490.s56" text=""/>
    <sentence id="DDI-DrugBank.d490.s57" text=""/>
    <sentence id="DDI-DrugBank.d490.s58" text="pruritus"/>
    <sentence id="DDI-DrugBank.d490.s59" text=""/>
    <sentence id="DDI-DrugBank.d347.s0" text="Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.">
        <entity id="DDI-DrugBank.d347.s0.e0" charOffset="34-40"
            type="brand" text="FACTIVE"/>
        <entity id="DDI-DrugBank.d347.s0.e1" charOffset="95-106"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d347.s0.e2" charOffset="109-115"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d347.s0.e3" charOffset="123-138"
            type="drug" text="ethinylestradiol"/>
        <entity id="DDI-DrugBank.d347.s0.e4" charOffset="160-180"
            type="group" text="contraceptive product"/>
    </sentence>
    <sentence id="DDI-DrugBank.d347.s1" text="Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.">
        <entity id="DDI-DrugBank.d347.s1.e0" charOffset="30-36"
            type="brand" text="FACTIVE"/>
        <entity id="DDI-DrugBank.d347.s1.e1" charOffset="42-58"
            type="drug" text="calcium carbonate"/>
        <entity id="DDI-DrugBank.d347.s1.e2" charOffset="61-70"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d347.s1.e3" charOffset="73-82"
            type="drug" text="omeprazole"/>
        <entity id="DDI-DrugBank.d347.s1.e4" charOffset="91-98"
            type="group" text="estrogen"/>
        <entity id="DDI-DrugBank.d347.s1.e5" charOffset="100-111"
            type="drug" text="progesterone"/>
        <entity id="DDI-DrugBank.d347.s1.e6" charOffset="118-130"
            type="group" text="contraceptive"/>
        <entity id="DDI-DrugBank.d347.s1.e7" charOffset="182-193"
            type="drug" text="gemifloxacin"/>
        <ddi id="DDI-DrugBank.d347.s1.d0" e1="DDI-DrugBank.d347.s1.e0"
            e2="DDI-DrugBank.d347.s1.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d347.s1.d1" e1="DDI-DrugBank.d347.s1.e0"
            e2="DDI-DrugBank.d347.s1.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d347.s1.d2" e1="DDI-DrugBank.d347.s1.e0"
            e2="DDI-DrugBank.d347.s1.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d347.s1.d3" e1="DDI-DrugBank.d347.s1.e0"
            e2="DDI-DrugBank.d347.s1.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d347.s1.d4" e1="DDI-DrugBank.d347.s1.e0"
            e2="DDI-DrugBank.d347.s1.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d347.s1.d5" e1="DDI-DrugBank.d347.s1.e0"
            e2="DDI-DrugBank.d347.s1.e6" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d347.s2" text="Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.">
        <entity id="DDI-DrugBank.d347.s2.e0" charOffset="30-36"
            type="brand" text="FACTIVE"/>
        <entity id="DDI-DrugBank.d347.s2.e1" charOffset="43-52"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d347.s2.e2" charOffset="105-116"
            type="drug" text="gemifloxacin"/>
        <ddi id="DDI-DrugBank.d347.s2.d0" e1="DDI-DrugBank.d347.s2.e0"
            e2="DDI-DrugBank.d347.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d347.s3" text="FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy.">
        <entity id="DDI-DrugBank.d347.s3.e0" charOffset="0-6"
            type="brand" text="FACTIVE"/>
        <entity id="DDI-DrugBank.d347.s3.e1" charOffset="65-72"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d347.s3.e2" charOffset="104-111"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d347.s4" text="However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.">
        <entity id="DDI-DrugBank.d347.s4.e0" charOffset="22-31"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d347.s4.e1" charOffset="92-99"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d347.s4.e2" charOffset="222-244"
            type="group" text="quinolone antimicrobial"/>
        <entity id="DDI-DrugBank.d347.s4.e3" charOffset="281-288"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d347.s4.d0" e1="DDI-DrugBank.d347.s4.e0"
            e2="DDI-DrugBank.d347.s4.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d347.s4.d1" e1="DDI-DrugBank.d347.s4.e2"
            e2="DDI-DrugBank.d347.s4.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d347.s5" text="Quinolones form chelates with alkaline earth and transition metals.">
        <entity id="DDI-DrugBank.d347.s5.e0" charOffset="0-9"
            type="group" text="Quinolones"/>
    </sentence>
    <sentence id="DDI-DrugBank.d347.s6" text="The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.">
        <entity id="DDI-DrugBank.d347.s6.e0" charOffset="23-34"
            type="drug" text="gemifloxacin"/>
        <entity id="DDI-DrugBank.d347.s6.e1" charOffset="101-107"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d347.s6.e2" charOffset="120-127"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d347.s6.e3" charOffset="133-141"
            type="drug" text="magnesium"/>
        <ddi id="DDI-DrugBank.d347.s6.d0" e1="DDI-DrugBank.d347.s6.e0"
            e2="DDI-DrugBank.d347.s6.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d347.s6.d1" e1="DDI-DrugBank.d347.s6.e0"
            e2="DDI-DrugBank.d347.s6.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d347.s7" text="Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.">
        <entity id="DDI-DrugBank.d347.s7.e0" charOffset="0-8"
            type="drug" text="Magnesium"/>
        <entity id="DDI-DrugBank.d347.s7.e1" charOffset="18-25"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d347.s7.e2" charOffset="38-45"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d347.s7.e3" charOffset="68-82"
            type="drug" text="ferrous sulfate"/>
        <entity id="DDI-DrugBank.d347.s7.e4" charOffset="85-88"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d347.s7.e5" charOffset="92-116"
            type="group" text="multivitamin preparations"/>
        <entity id="DDI-DrugBank.d347.s7.e6" charOffset="129-132"
            type="drug" text="zinc"/>
        <entity id="DDI-DrugBank.d347.s7.e7" charOffset="161-165"
            type="brand" text="Videx"/>
        <entity id="DDI-DrugBank.d347.s7.e8" charOffset="168-177"
            type="drug" text="didanosine"/>
        <entity id="DDI-DrugBank.d347.s7.e9" charOffset="307-313"
            type="brand" text="FACTIVE"/>
        <ddi id="DDI-DrugBank.d347.s7.d0" e1="DDI-DrugBank.d347.s7.e0"
            e2="DDI-DrugBank.d347.s7.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d347.s7.d1" e1="DDI-DrugBank.d347.s7.e1"
            e2="DDI-DrugBank.d347.s7.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d347.s7.d2" e1="DDI-DrugBank.d347.s7.e3"
            e2="DDI-DrugBank.d347.s7.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d347.s7.d3" e1="DDI-DrugBank.d347.s7.e4"
            e2="DDI-DrugBank.d347.s7.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d347.s7.d4" e1="DDI-DrugBank.d347.s7.e5"
            e2="DDI-DrugBank.d347.s7.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d347.s7.d5" e1="DDI-DrugBank.d347.s7.e6"
            e2="DDI-DrugBank.d347.s7.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d347.s7.d6" e1="DDI-DrugBank.d347.s7.e7"
            e2="DDI-DrugBank.d347.s7.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d347.s7.d7" e1="DDI-DrugBank.d347.s7.e8"
            e2="DDI-DrugBank.d347.s7.e9" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d347.s8" text="Sucralfate should not be taken within 2 hours of FACTIVE.">
        <entity id="DDI-DrugBank.d347.s8.e0" charOffset="0-9"
            type="drug" text="Sucralfate"/>
        <entity id="DDI-DrugBank.d347.s8.e1" charOffset="49-55"
            type="brand" text="FACTIVE"/>
        <ddi id="DDI-DrugBank.d347.s8.d0" e1="DDI-DrugBank.d347.s8.e0"
            e2="DDI-DrugBank.d347.s8.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d403.s0" text="There have been no formal drug-interaction studies performed with Mylotarg.">
        <entity id="DDI-DrugBank.d403.s0.e0" charOffset="66-73"
            type="brand" text="Mylotarg"/>
    </sentence>
    <sentence id="DDI-DrugBank.d403.s1" text="The potential for drug-drug interaction with drugs affected by cytochrome P450 enzymes may not be ruled out."/>
    <sentence id="DDI-DrugBank.d403.s2" text="Laboratory Test Interactions"/>
    <sentence id="DDI-DrugBank.d403.s3" text="Mylotarg is not known to interfere with any routine diagnostic tests.">
        <entity id="DDI-DrugBank.d403.s3.e0" charOffset="0-7"
            type="brand" text="Mylotarg"/>
    </sentence>
    <sentence id="DDI-DrugBank.d28.s0" text="Interactions between COPAXONE  and other drugs have not been fully evaluated.">
        <entity id="DDI-DrugBank.d28.s0.e0" charOffset="21-28"
            type="brand" text="COPAXONE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d28.s1" text="Results from existing clinical trials suggest no significant interactions between COPAXONE  and other therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days.">
        <entity id="DDI-DrugBank.d28.s1.e0" charOffset="82-89"
            type="brand" text="COPAXONE"/>
        <entity id="DDI-DrugBank.d28.s1.e1" charOffset="174-188"
            type="group" text="corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d28.s2" text="COPAXONE  has not been formally evaluated in combination with Interferon beta.">
        <entity id="DDI-DrugBank.d28.s2.e0" charOffset="0-7"
            type="brand" text="COPAXONE"/>
        <entity id="DDI-DrugBank.d28.s2.e1" charOffset="62-76"
            type="drug" text="Interferon beta"/>
    </sentence>
    <sentence id="DDI-DrugBank.d28.s3" text="However, 10 patients who switched from therapy with Interferon beta to COPAXONE  did not report any serious and unexpected adverse reactions thought to be related to treatment.">
        <entity id="DDI-DrugBank.d28.s3.e0" charOffset="52-66"
            type="drug" text="Interferon beta"/>
        <entity id="DDI-DrugBank.d28.s3.e1" charOffset="71-78"
            type="brand" text="COPAXONE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s0" text="The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.">
        <entity id="DDI-DrugBank.d178.s0.e0" charOffset="27-39"
            type="group" text="sulfonylureas"/>
        <entity id="DDI-DrugBank.d178.s0.e1" charOffset="87-123"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d178.s0.e2" charOffset="172-182"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d178.s0.e3" charOffset="185-196"
            type="group" text="sulfonamides"/>
        <entity id="DDI-DrugBank.d178.s0.e4" charOffset="199-213"
            type="drug" text="chloramphenicol"/>
        <entity id="DDI-DrugBank.d178.s0.e5" charOffset="216-225"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d178.s0.e6" charOffset="228-236"
            type="group" text="coumarins"/>
        <entity id="DDI-DrugBank.d178.s0.e7" charOffset="239-266"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d178.s0.e8" charOffset="273-303"
            type="group" text="beta adrenergic blocking agents"/>
        <ddi id="DDI-DrugBank.d178.s0.d0" e1="DDI-DrugBank.d178.s0.e0"
            e2="DDI-DrugBank.d178.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d178.s0.d1" e1="DDI-DrugBank.d178.s0.e0"
            e2="DDI-DrugBank.d178.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d178.s0.d2" e1="DDI-DrugBank.d178.s0.e0"
            e2="DDI-DrugBank.d178.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d178.s0.d3" e1="DDI-DrugBank.d178.s0.e0"
            e2="DDI-DrugBank.d178.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d178.s0.d4" e1="DDI-DrugBank.d178.s0.e0"
            e2="DDI-DrugBank.d178.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d178.s0.d5" e1="DDI-DrugBank.d178.s0.e0"
            e2="DDI-DrugBank.d178.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d178.s0.d6" e1="DDI-DrugBank.d178.s0.e0"
            e2="DDI-DrugBank.d178.s0.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d178.s0.d7" e1="DDI-DrugBank.d178.s0.e0"
            e2="DDI-DrugBank.d178.s0.e8" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s1" text="When such drugs are administered to a patient receiving MICRONASE, the patient should be observed closely for hypoglycemia.">
        <entity id="DDI-DrugBank.d178.s1.e0" charOffset="56-64"
            type="brand" text="MICRONASE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s2" text="When such drugs are withdrawn from a patient receiving MICRONASE, the patient should be observed closely for loss of control.">
        <entity id="DDI-DrugBank.d178.s2.e0" charOffset="55-63"
            type="brand" text="MICRONASE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s3" text="Certain drugs tend to produce hyperglycemia and may lead to loss of control."/>
    <sentence id="DDI-DrugBank.d178.s4" text="These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.">
        <entity id="DDI-DrugBank.d178.s4.e0" charOffset="24-32"
            type="group" text="thiazides"/>
        <entity id="DDI-DrugBank.d178.s4.e1" charOffset="44-52"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d178.s4.e2" charOffset="55-69"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d178.s4.e3" charOffset="89-104"
            type="group" text="thyroid products"/>
        <entity id="DDI-DrugBank.d178.s4.e4" charOffset="107-115"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d178.s4.e5" charOffset="123-136"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d178.s4.e6" charOffset="139-147"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d178.s4.e7" charOffset="150-163"
            type="drug" text="nicotinic acid"/>
        <entity id="DDI-DrugBank.d178.s4.e8" charOffset="185-214"
            type="group" text="calcium channel blocking drugs"/>
        <entity id="DDI-DrugBank.d178.s4.e9" charOffset="221-229"
            type="drug" text="isoniazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s5" text="When such drugs are administered to a patient receiving MICRONASE, the patient should be closely observed for loss of control.">
        <entity id="DDI-DrugBank.d178.s5.e0" charOffset="56-64"
            type="brand" text="MICRONASE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s6" text="When such drugs are withdrawn from a patient receiving MICRONASE, the patient should be observed closely for hypoglycemia.">
        <entity id="DDI-DrugBank.d178.s6.e0" charOffset="55-63"
            type="brand" text="MICRONASE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s7" text="A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.">
        <entity id="DDI-DrugBank.d178.s7.e0" charOffset="31-39"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d178.s7.e1" charOffset="45-57"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d178.s7.e2" charOffset="62-87"
            type="group" text="fluoroquinolone antibiotic"/>
        <entity id="DDI-DrugBank.d178.s7.e3" charOffset="167-175"
            type="drug" text="glyburide"/>
        <ddi id="DDI-DrugBank.d178.s7.d0" e1="DDI-DrugBank.d178.s7.e0"
            e2="DDI-DrugBank.d178.s7.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s8" text="The mechanism for this interaction is not known."/>
    <sentence id="DDI-DrugBank.d178.s9" text="A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.">
        <entity id="DDI-DrugBank.d178.s9.e0" charOffset="37-46"
            type="drug" text="miconazole"/>
        <entity id="DDI-DrugBank.d178.s9.e1" charOffset="57-75"
            type="group" text="hypoglycemic agents"/>
        <ddi id="DDI-DrugBank.d178.s9.d0" e1="DDI-DrugBank.d178.s9.e0"
            e2="DDI-DrugBank.d178.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s10" text="Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known.">
        <entity id="DDI-DrugBank.d178.s10.e0" charOffset="94-103"
            type="drug" text="miconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s11" text="Metformin: In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable.">
        <entity id="DDI-DrugBank.d178.s11.e0" charOffset="0-8"
            type="drug" text="Metformin"/>
        <entity id="DDI-DrugBank.d178.s11.e1" charOffset="78-86"
            type="drug" text="glyburide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s12" text="The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmaco-dynamic effects, makes the clinical significance of this interaction uncertain.">
        <entity id="DDI-DrugBank.d178.s12.e0" charOffset="73-81"
            type="drug" text="glyburide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d178.s13" text="Coadministration of gly-buride and metformin did not result in any changes in either metformin pharmacokinetics or pharmaco-dynamics.">
        <entity id="DDI-DrugBank.d178.s13.e0" charOffset="35-43"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d178.s13.e1" charOffset="85-93"
            type="drug" text="metformin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s0" text="Many other medicines may increase or decrease the effects of glimepiride or affect your condition.">
        <entity id="DDI-DrugBank.d521.s0.e0" charOffset="61-71"
            type="drug" text="glimepiride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s1" text="Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);">
        <entity id="DDI-DrugBank.d521.s1.e0" charOffset="14-24"
            type="drug" text="glimepiride"/>
        <entity id="DDI-DrugBank.d521.s1.e1" charOffset="96-102"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d521.s1.e2" charOffset="115-124"
            type="group" text="salicylate"/>
        <entity id="DDI-DrugBank.d521.s1.e3" charOffset="134-161"
            type="drug" text="magnesium/choline salicylate"/>
        <entity id="DDI-DrugBank.d521.s1.e4" charOffset="164-172"
            type="brand" text="Trilisate"/>
        <entity id="DDI-DrugBank.d521.s1.e5" charOffset="176-184"
            type="drug" text="salsalate"/>
        <entity id="DDI-DrugBank.d521.s1.e6" charOffset="187-194"
            type="brand" text="Disalcid"/>
        <entity id="DDI-DrugBank.d521.s1.e7" charOffset="206-223"
            type="drug" text="choline salicylate"/>
        <entity id="DDI-DrugBank.d521.s1.e8" charOffset="226-234"
            type="drug" text="Arthropan"/>
        <entity id="DDI-DrugBank.d521.s1.e9" charOffset="238-257"
            type="drug" text="magnesium salicylate"/>
        <entity id="DDI-DrugBank.d521.s1.e10" charOffset="260-264"
            type="brand" text="Magan"/>
        <entity id="DDI-DrugBank.d521.s1.e11" charOffset="271-291"
            type="drug" text="bismuth subsalicylate"/>
        <entity id="DDI-DrugBank.d521.s1.e12" charOffset="294-305"
            type="brand" text="Pepto-Bismol"/>
        <ddi id="DDI-DrugBank.d521.s1.d0" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d521.s1.d1" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d521.s1.d2" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d521.s1.d3" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d521.s1.d4" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d521.s1.d5" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d521.s1.d6" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d521.s1.d7" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d521.s1.d8" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d521.s1.d9" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e10" type="advise"/>
        <ddi id="DDI-DrugBank.d521.s1.d10" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d521.s1.d11" e1="DDI-DrugBank.d521.s1.e0"
            e2="DDI-DrugBank.d521.s1.e12" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s2" text="- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);">
        <entity id="DDI-DrugBank.d521.s2.e0" charOffset="4-38"
            type="group" text="nonsteroidal anti-inflammatory drug"/>
        <entity id="DDI-DrugBank.d521.s2.e1" charOffset="41-45"
            type="group" text="NSAID"/>
        <entity id="DDI-DrugBank.d521.s2.e2" charOffset="56-64"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d521.s2.e3" charOffset="67-72"
            type="brand" text="Motrin"/>
        <entity id="DDI-DrugBank.d521.s2.e4" charOffset="75-79"
            type="brand" text="Advil"/>
        <entity id="DDI-DrugBank.d521.s2.e5" charOffset="82-87"
            type="brand" text="Nuprin"/>
        <entity id="DDI-DrugBank.d521.s2.e6" charOffset="99-108"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d521.s2.e7" charOffset="111-116"
            type="brand" text="Orudis"/>
        <entity id="DDI-DrugBank.d521.s2.e8" charOffset="119-127"
            type="brand" text="Orudis KT"/>
        <entity id="DDI-DrugBank.d521.s2.e9" charOffset="130-136"
            type="brand" text="Oruvail"/>
        <entity id="DDI-DrugBank.d521.s2.e10" charOffset="140-149"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d521.s2.e11" charOffset="152-159"
            type="brand" text="Voltaren"/>
        <entity id="DDI-DrugBank.d521.s2.e12" charOffset="162-169"
            type="brand" text="Cataflam"/>
        <entity id="DDI-DrugBank.d521.s2.e13" charOffset="173-180"
            type="drug" text="etodolac"/>
        <entity id="DDI-DrugBank.d521.s2.e14" charOffset="183-188"
            type="brand" text="Lodine"/>
        <entity id="DDI-DrugBank.d521.s2.e15" charOffset="192-203"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d521.s2.e16" charOffset="206-212"
            type="brand" text="Indocin"/>
        <entity id="DDI-DrugBank.d521.s2.e17" charOffset="216-225"
            type="drug" text="nabumetone"/>
        <entity id="DDI-DrugBank.d521.s2.e18" charOffset="228-234"
            type="brand" text="Relafen"/>
        <entity id="DDI-DrugBank.d521.s2.e19" charOffset="238-246"
            type="drug" text="oxaprozin"/>
        <entity id="DDI-DrugBank.d521.s2.e20" charOffset="249-254"
            type="brand" text="Daypro"/>
        <entity id="DDI-DrugBank.d521.s2.e21" charOffset="262-269"
            type="drug" text="naproxen"/>
        <entity id="DDI-DrugBank.d521.s2.e22" charOffset="272-278"
            type="brand" text="Anaprox"/>
        <entity id="DDI-DrugBank.d521.s2.e23" charOffset="281-288"
            type="brand" text="Naprosyn"/>
        <entity id="DDI-DrugBank.d521.s2.e24" charOffset="291-295"
            type="brand" text="Aleve"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s3" text="- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);">
        <entity id="DDI-DrugBank.d521.s3.e0" charOffset="29-44"
            type="drug" text="sulfamethoxazole"/>
        <entity id="DDI-DrugBank.d521.s3.e1" charOffset="46-57"
            type="drug" text="trimethoprim"/>
        <entity id="DDI-DrugBank.d521.s3.e2" charOffset="60-66"
            type="brand" text="Bactrim"/>
        <entity id="DDI-DrugBank.d521.s3.e3" charOffset="69-74"
            type="brand" text="Septra"/>
        <entity id="DDI-DrugBank.d521.s3.e4" charOffset="78-90"
            type="drug" text="sulfisoxazole"/>
        <entity id="DDI-DrugBank.d521.s3.e5" charOffset="93-101"
            type="brand" text="Gantrisin"/>
        <entity id="DDI-DrugBank.d521.s3.e6" charOffset="108-120"
            type="drug" text="sulfasalazine"/>
        <entity id="DDI-DrugBank.d521.s3.e7" charOffset="123-132"
            type="brand" text="Azulfidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s4" text="- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);">
        <entity id="DDI-DrugBank.d521.s4.e0" charOffset="4-30"
            type="group" text="monoamine oxidase inhibitor"/>
        <entity id="DDI-DrugBank.d521.s4.e1" charOffset="33-36"
            type="group" text="MAOI"/>
        <entity id="DDI-DrugBank.d521.s4.e2" charOffset="47-59"
            type="drug" text="isocarboxazid"/>
        <entity id="DDI-DrugBank.d521.s4.e3" charOffset="62-68"
            type="brand" text="Marplan"/>
        <entity id="DDI-DrugBank.d521.s4.e4" charOffset="72-86"
            type="drug" text="tranylcypromine"/>
        <entity id="DDI-DrugBank.d521.s4.e5" charOffset="89-95"
            type="brand" text="Parnate"/>
        <entity id="DDI-DrugBank.d521.s4.e6" charOffset="102-111"
            type="drug" text="phenelzine"/>
        <entity id="DDI-DrugBank.d521.s4.e7" charOffset="114-119"
            type="brand" text="Nardil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s5" text="- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;">
        <entity id="DDI-DrugBank.d521.s5.e0" charOffset="4-15"
            type="group" text="beta-blocker"/>
        <entity id="DDI-DrugBank.d521.s5.e1" charOffset="25-35"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d521.s5.e2" charOffset="38-44"
            type="brand" text="Inderal"/>
        <entity id="DDI-DrugBank.d521.s5.e3" charOffset="48-55"
            type="drug" text="atenolol"/>
        <entity id="DDI-DrugBank.d521.s5.e4" charOffset="58-65"
            type="brand" text="Tenormin"/>
        <entity id="DDI-DrugBank.d521.s5.e5" charOffset="69-78"
            type="drug" text="acebutolol"/>
        <entity id="DDI-DrugBank.d521.s5.e6" charOffset="81-87"
            type="brand" text="Sectral"/>
        <entity id="DDI-DrugBank.d521.s5.e7" charOffset="91-100"
            type="drug" text="metoprolol"/>
        <entity id="DDI-DrugBank.d521.s5.e8" charOffset="103-111"
            type="brand" text="Lopressor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s6" text="- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;">
        <entity id="DDI-DrugBank.d521.s6.e0" charOffset="4-11"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d521.s6.e1" charOffset="34-52"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d521.s6.e2" charOffset="55-58"
            type="drug" text="HCTZ"/>
        <entity id="DDI-DrugBank.d521.s6.e3" charOffset="61-71"
            type="brand" text="Hydrodiuril"/>
        <entity id="DDI-DrugBank.d521.s6.e4" charOffset="75-88"
            type="drug" text="chlorothiazide"/>
        <entity id="DDI-DrugBank.d521.s6.e5" charOffset="91-96"
            type="brand" text="Diuril"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s7" text="- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;">
        <entity id="DDI-DrugBank.d521.s7.e0" charOffset="4-19"
            type="group" text="steroid medicine"/>
        <entity id="DDI-DrugBank.d521.s7.e1" charOffset="29-38"
            type="drug" text="prednisone"/>
        <entity id="DDI-DrugBank.d521.s7.e2" charOffset="41-49"
            type="brand" text="Deltasone"/>
        <entity id="DDI-DrugBank.d521.s7.e3" charOffset="52-58"
            type="brand" text="Orasone"/>
        <entity id="DDI-DrugBank.d521.s7.e4" charOffset="70-87"
            type="drug" text="methylprednisolone"/>
        <entity id="DDI-DrugBank.d521.s7.e5" charOffset="90-95"
            type="brand" text="Medrol"/>
        <entity id="DDI-DrugBank.d521.s7.e6" charOffset="107-118"
            type="drug" text="prednisolone"/>
        <entity id="DDI-DrugBank.d521.s7.e7" charOffset="121-127"
            type="brand" text="Prelone"/>
        <entity id="DDI-DrugBank.d521.s7.e8" charOffset="130-138"
            type="brand" text="Pediapred"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s8" text="- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;">
        <entity id="DDI-DrugBank.d521.s8.e0" charOffset="4-16"
            type="group" text="phenothiazine"/>
        <entity id="DDI-DrugBank.d521.s8.e1" charOffset="26-39"
            type="drug" text="chlorpromazine"/>
        <entity id="DDI-DrugBank.d521.s8.e2" charOffset="42-50"
            type="brand" text="Thorazine"/>
        <entity id="DDI-DrugBank.d521.s8.e3" charOffset="54-65"
            type="drug" text="fluphenazine"/>
        <entity id="DDI-DrugBank.d521.s8.e4" charOffset="68-75"
            type="brand" text="Prolixin"/>
        <entity id="DDI-DrugBank.d521.s8.e5" charOffset="78-85"
            type="brand" text="Permitil"/>
        <entity id="DDI-DrugBank.d521.s8.e6" charOffset="89-104"
            type="drug" text="prochlorperazine"/>
        <entity id="DDI-DrugBank.d521.s8.e7" charOffset="107-115"
            type="brand" text="Compazine"/>
        <entity id="DDI-DrugBank.d521.s8.e8" charOffset="119-130"
            type="drug" text="promethazine"/>
        <entity id="DDI-DrugBank.d521.s8.e9" charOffset="133-141"
            type="brand" text="Phenergan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s9" text="- phenytoin (Dilantin);">
        <entity id="DDI-DrugBank.d521.s9.e0" charOffset="2-10"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d521.s9.e1" charOffset="13-20"
            type="brand" text="Dilantin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s10" text="- isoniazid (Nydrazid);">
        <entity id="DDI-DrugBank.d521.s10.e0" charOffset="2-10"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d521.s10.e1" charOffset="13-20"
            type="brand" text="Nydrazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s11" text="- rifampin (Rifadin, Rifamate);">
        <entity id="DDI-DrugBank.d521.s11.e0" charOffset="2-9"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d521.s11.e1" charOffset="12-18"
            type="brand" text="Rifadin"/>
        <entity id="DDI-DrugBank.d521.s11.e2" charOffset="21-28"
            type="brand" text="Rifamate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s12" text="or - over-the-counter cough, cold, allergy, or weight loss medications."/>
    <sentence id="DDI-DrugBank.d521.s13" text="You may require a dosage adjustment or special monitoring if you are taking any of the medicines listed above."/>
    <sentence id="DDI-DrugBank.d521.s14" text="Drugs other than those listed here may also interact with glimepiride or affect your condition.">
        <entity id="DDI-DrugBank.d521.s14.e0" charOffset="58-68"
            type="drug" text="glimepiride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d521.s15" text="Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products."/>
    <sentence id="DDI-DrugBank.d225.s0" text="Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.">
        <entity id="DDI-DrugBank.d225.s0.e0" charOffset="66-78"
            type="group" text="sulfonylureas"/>
        <entity id="DDI-DrugBank.d225.s0.e1" charOffset="126-162"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d225.s0.e2" charOffset="170-175"
            type="group" text="azoles"/>
        <entity id="DDI-DrugBank.d225.s0.e3" charOffset="224-234"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d225.s0.e4" charOffset="237-248"
            type="group" text="sulfonamides"/>
        <entity id="DDI-DrugBank.d225.s0.e5" charOffset="251-265"
            type="drug" text="chloramphenicol"/>
        <entity id="DDI-DrugBank.d225.s0.e6" charOffset="268-277"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d225.s0.e7" charOffset="280-288"
            type="group" text="coumarins"/>
        <entity id="DDI-DrugBank.d225.s0.e8" charOffset="291-318"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d225.s0.e9" charOffset="325-355"
            type="group" text="beta adrenergic blocking agents"/>
        <ddi id="DDI-DrugBank.d225.s0.d0" e1="DDI-DrugBank.d225.s0.e0"
            e2="DDI-DrugBank.d225.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d225.s0.d1" e1="DDI-DrugBank.d225.s0.e0"
            e2="DDI-DrugBank.d225.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d225.s0.d2" e1="DDI-DrugBank.d225.s0.e0"
            e2="DDI-DrugBank.d225.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d225.s0.d3" e1="DDI-DrugBank.d225.s0.e0"
            e2="DDI-DrugBank.d225.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d225.s0.d4" e1="DDI-DrugBank.d225.s0.e0"
            e2="DDI-DrugBank.d225.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d225.s0.d5" e1="DDI-DrugBank.d225.s0.e0"
            e2="DDI-DrugBank.d225.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d225.s0.d6" e1="DDI-DrugBank.d225.s0.e0"
            e2="DDI-DrugBank.d225.s0.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d225.s0.d7" e1="DDI-DrugBank.d225.s0.e0"
            e2="DDI-DrugBank.d225.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d225.s0.d8" e1="DDI-DrugBank.d225.s0.e0"
            e2="DDI-DrugBank.d225.s0.e9" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s1" text="When such drugs are administered to a patient receiving glipizide, the patient should be observed closely for hypoglycemia.">
        <entity id="DDI-DrugBank.d225.s1.e0" charOffset="56-64"
            type="drug" text="glipizide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s2" text="When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for loss of control.">
        <entity id="DDI-DrugBank.d225.s2.e0" charOffset="55-63"
            type="drug" text="glipizide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s3" text="In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol.">
        <entity id="DDI-DrugBank.d225.s3.e0" charOffset="65-73"
            type="drug" text="glipizide"/>
        <entity id="DDI-DrugBank.d225.s3.e1" charOffset="98-108"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d225.s3.e2" charOffset="137-146"
            type="group" text="salicylate"/>
        <entity id="DDI-DrugBank.d225.s3.e3" charOffset="151-159"
            type="drug" text="dicumarol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s4" text="However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of glipizide with these drugs.">
        <entity id="DDI-DrugBank.d225.s4.e0" charOffset="111-119"
            type="drug" text="glipizide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s5" text="Certain drugs tend to produce hyperglycemia and may lead to loss of control."/>
    <sentence id="DDI-DrugBank.d225.s6" text="These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.">
        <entity id="DDI-DrugBank.d225.s6.e0" charOffset="24-32"
            type="group" text="thiazides"/>
        <entity id="DDI-DrugBank.d225.s6.e1" charOffset="44-52"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d225.s6.e2" charOffset="55-69"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d225.s6.e3" charOffset="72-85"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d225.s6.e4" charOffset="88-103"
            type="group" text="thyroid products"/>
        <entity id="DDI-DrugBank.d225.s6.e5" charOffset="106-114"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d225.s6.e6" charOffset="122-135"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d225.s6.e7" charOffset="138-146"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d225.s6.e8" charOffset="149-162"
            type="drug" text="nicotinic acid"/>
        <entity id="DDI-DrugBank.d225.s6.e9" charOffset="165-180"
            type="group" text="sympathomimetics"/>
        <entity id="DDI-DrugBank.d225.s6.e10" charOffset="183-212"
            type="group" text="calcium channel blocking drugs"/>
        <entity id="DDI-DrugBank.d225.s6.e11" charOffset="219-227"
            type="drug" text="isoniazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s7" text="When such drugs are administered to a patient receiving glipizide, the patient should be closely observed for loss of control.">
        <entity id="DDI-DrugBank.d225.s7.e0" charOffset="56-64"
            type="drug" text="glipizide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s8" text="When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for hypoglycemia.">
        <entity id="DDI-DrugBank.d225.s8.e0" charOffset="55-63"
            type="drug" text="glipizide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s9" text="A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.">
        <entity id="DDI-DrugBank.d225.s9.e0" charOffset="37-46"
            type="drug" text="miconazole"/>
        <entity id="DDI-DrugBank.d225.s9.e1" charOffset="57-75"
            type="group" text="hypoglycemic agents"/>
        <ddi id="DDI-DrugBank.d225.s9.d0" e1="DDI-DrugBank.d225.s9.e0"
            e2="DDI-DrugBank.d225.s9.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s10" text="Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.">
        <entity id="DDI-DrugBank.d225.s10.e0" charOffset="95-104"
            type="drug" text="miconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s11" text="The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.">
        <entity id="DDI-DrugBank.d225.s11.e0" charOffset="44-54"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d225.s11.e1" charOffset="60-68"
            type="drug" text="glipizide"/>
        <ddi id="DDI-DrugBank.d225.s11.d0" e1="DDI-DrugBank.d225.s11.e0"
            e2="DDI-DrugBank.d225.s11.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s12" text="All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for seven days.">
        <entity id="DDI-DrugBank.d225.s12.e0" charOffset="22-30"
            type="drug" text="glipizide"/>
        <entity id="DDI-DrugBank.d225.s12.e1" charOffset="77-87"
            type="drug" text="fluconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d225.s13" text="The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).">
        <entity id="DDI-DrugBank.d225.s13.e0" charOffset="36-44"
            type="drug" text="glipizide"/>
        <entity id="DDI-DrugBank.d225.s13.e1" charOffset="56-66"
            type="drug" text="fluconazole"/>
        <ddi id="DDI-DrugBank.d225.s13.d0" e1="DDI-DrugBank.d225.s13.e0"
            e2="DDI-DrugBank.d225.s13.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d510.s0" text="The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.">
        <entity id="DDI-DrugBank.d510.s0.e0" charOffset="22-28"
            type="brand" text="Robinul"/>
        <entity id="DDI-DrugBank.d510.s0.e1" charOffset="51-66"
            type="group" text="anticholinergics"/>
        <entity id="DDI-DrugBank.d510.s0.e2" charOffset="122-135"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d510.s0.e3" charOffset="138-156"
            type="group" text="antiparkinson drugs"/>
        <entity id="DDI-DrugBank.d510.s0.e4" charOffset="162-186"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d510.s0.d0" e1="DDI-DrugBank.d510.s0.e0"
            e2="DDI-DrugBank.d510.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d510.s0.d1" e1="DDI-DrugBank.d510.s0.e0"
            e2="DDI-DrugBank.d510.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d510.s0.d2" e1="DDI-DrugBank.d510.s0.e0"
            e2="DDI-DrugBank.d510.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d510.s0.d3" e1="DDI-DrugBank.d510.s0.e0"
            e2="DDI-DrugBank.d510.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d510.s1" text="Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.">
        <entity id="DDI-DrugBank.d510.s1.e0" charOffset="30-36"
            type="brand" text="Robinul"/>
        <entity id="DDI-DrugBank.d510.s1.e1" charOffset="52-69"
            type="drug" text="potassium chloride"/>
        <ddi id="DDI-DrugBank.d510.s1.d0" e1="DDI-DrugBank.d510.s1.e0"
            e2="DDI-DrugBank.d510.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d369.s0" text="The Factrel test should be conducted in the absence of other drugs which directly affect the pituitary secretion of the gonadotropins.">
        <entity id="DDI-DrugBank.d369.s0.e0" charOffset="4-10"
            type="brand" text="Factrel"/>
    </sentence>
    <sentence id="DDI-DrugBank.d369.s1" text="These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.">
        <entity id="DDI-DrugBank.d369.s1.e0" charOffset="60-68"
            type="group" text="androgens"/>
        <entity id="DDI-DrugBank.d369.s1.e1" charOffset="71-79"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d369.s1.e2" charOffset="82-91"
            type="group" text="progestins"/>
        <entity id="DDI-DrugBank.d369.s1.e3" charOffset="97-111"
            type="group" text="glucocorticoids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d369.s2" text="The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.">
        <entity id="DDI-DrugBank.d369.s2.e0" charOffset="55-68"
            type="drug" text="spironolactone"/>
        <entity id="DDI-DrugBank.d369.s2.e1" charOffset="93-100"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d369.s2.e2" charOffset="126-139"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d369.s2.e3" charOffset="145-151"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d369.s3" text="The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.">
        <entity id="DDI-DrugBank.d369.s3.e0" charOffset="16-22"
            type="brand" text="Factrel"/>
        <entity id="DDI-DrugBank.d369.s3.e1" charOffset="42-55"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d369.s3.e2" charOffset="61-80"
            type="group" text="dopamine antagonists"/>
        <ddi id="DDI-DrugBank.d369.s3.d0" e1="DDI-DrugBank.d369.s3.e0"
            e2="DDI-DrugBank.d369.s3.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d369.s3.d1" e1="DDI-DrugBank.d369.s3.e0"
            e2="DDI-DrugBank.d369.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d50.s0" text="No formal drug-drug interaction studies have been performed."/>
    <sentence id="DDI-DrugBank.d50.s1" text="No confirmed interactions have been reported between ZOLADEX and other drugs">
        <entity id="DDI-DrugBank.d50.s1.e0" charOffset="53-59"
            type="brand" text="ZOLADEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s0" text="Antacids, Sucralfate, Metal Cations, Multivitamins Quinolones form chelates with alkaline earth and transition metal cations.">
        <entity id="DDI-DrugBank.d78.s0.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d78.s0.e1" charOffset="10-19"
            type="drug" text="Sucralfate"/>
        <entity id="DDI-DrugBank.d78.s0.e2" charOffset="37-49"
            type="group" text="Multivitamins"/>
        <entity id="DDI-DrugBank.d78.s0.e3" charOffset="51-60"
            type="group" text="Quinolones"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s1" text="Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.">
        <entity id="DDI-DrugBank.d78.s1.e0" charOffset="18-27"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d78.s1.e1" charOffset="34-41"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d78.s1.e2" charOffset="54-61"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d78.s1.e3" charOffset="64-72"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d78.s1.e4" charOffset="78-84"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d78.s1.e5" charOffset="92-101"
            type="drug" text="sucralfate"/>
        <entity id="DDI-DrugBank.d78.s1.e6" charOffset="131-134"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d78.s1.e7" charOffset="145-157"
            type="group" text="multivitamins"/>
        <entity id="DDI-DrugBank.d78.s1.e8" charOffset="170-173"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d78.s1.e9" charOffset="178-181"
            type="drug" text="zinc"/>
        <entity id="DDI-DrugBank.d78.s1.e10" charOffset="255-259"
            type="brand" text="VIDEX"/>
        <entity id="DDI-DrugBank.d78.s1.e11" charOffset="262-271"
            type="drug" text="didanosine"/>
        <entity id="DDI-DrugBank.d78.s1.e12" charOffset="394-403"
            type="group" text="quinolones"/>
        <ddi id="DDI-DrugBank.d78.s1.d0" e1="DDI-DrugBank.d78.s1.e0"
            e2="DDI-DrugBank.d78.s1.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s1.d1" e1="DDI-DrugBank.d78.s1.e0"
            e2="DDI-DrugBank.d78.s1.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s1.d2" e1="DDI-DrugBank.d78.s1.e0"
            e2="DDI-DrugBank.d78.s1.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s1.d3" e1="DDI-DrugBank.d78.s1.e0"
            e2="DDI-DrugBank.d78.s1.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s1.d4" e1="DDI-DrugBank.d78.s1.e0"
            e2="DDI-DrugBank.d78.s1.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s1.d5" e1="DDI-DrugBank.d78.s1.e0"
            e2="DDI-DrugBank.d78.s1.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s1.d6" e1="DDI-DrugBank.d78.s1.e0"
            e2="DDI-DrugBank.d78.s1.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s1.d7" e1="DDI-DrugBank.d78.s1.e0"
            e2="DDI-DrugBank.d78.s1.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s1.d8" e1="DDI-DrugBank.d78.s1.e0"
            e2="DDI-DrugBank.d78.s1.e10" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s1.d9" e1="DDI-DrugBank.d78.s1.e0"
            e2="DDI-DrugBank.d78.s1.e11" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s2" text="These agents should not be taken within 4 hours before or 4 hours after grepafloxacin administration.">
        <entity id="DDI-DrugBank.d78.s2.e0" charOffset="72-84"
            type="drug" text="grepafloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s3" text="Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.">
        <entity id="DDI-DrugBank.d78.s3.e0" charOffset="0-7" type="drug" text="Caffeine"/>
        <entity id="DDI-DrugBank.d78.s3.e1" charOffset="9-19"
            type="drug" text="Theobromine"/>
        <entity id="DDI-DrugBank.d78.s3.e2" charOffset="21-33"
            type="drug" text="Grepafloxacin"/>
        <entity id="DDI-DrugBank.d78.s3.e3" charOffset="47-56"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d78.s3.e4" charOffset="89-96"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d78.s3.e5" charOffset="102-112"
            type="drug" text="theobromine"/>
        <ddi id="DDI-DrugBank.d78.s3.d0" e1="DDI-DrugBank.d78.s3.e2"
            e2="DDI-DrugBank.d78.s3.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s3.d1" e1="DDI-DrugBank.d78.s3.e2"
            e2="DDI-DrugBank.d78.s3.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s3.d2" e1="DDI-DrugBank.d78.s3.e3"
            e2="DDI-DrugBank.d78.s3.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d78.s3.d3" e1="DDI-DrugBank.d78.s3.e3"
            e2="DDI-DrugBank.d78.s3.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s4" text="These stimulants are commonly found in coffee and tea, respectively."/>
    <sentence id="DDI-DrugBank.d78.s5" text="In some patients, this may lead to reduced clearance, prolongation of plasma half-life, and enhanced effects of caffeine and theobromine.">
        <entity id="DDI-DrugBank.d78.s5.e0" charOffset="112-119"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d78.s5.e1" charOffset="125-135"
            type="drug" text="theobromine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s6" text="Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.">
        <entity id="DDI-DrugBank.d78.s6.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d78.s6.e1" charOffset="14-26"
            type="drug" text="Grepafloxacin"/>
        <entity id="DDI-DrugBank.d78.s6.e2" charOffset="76-87"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d78.s6.d0" e1="DDI-DrugBank.d78.s6.e1"
            e2="DDI-DrugBank.d78.s6.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s7" text="Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.">
        <entity id="DDI-DrugBank.d78.s7.e0" charOffset="6-17"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d78.s7.e1" charOffset="48-60"
            type="drug" text="grepafloxacin"/>
        <entity id="DDI-DrugBank.d78.s7.e2" charOffset="102-113"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d78.s7.d0" e1="DDI-DrugBank.d78.s7.e1"
            e2="DDI-DrugBank.d78.s7.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s8" text="When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.">
        <entity id="DDI-DrugBank.d78.s8.e0" charOffset="38-50"
            type="drug" text="grepafloxacin"/>
        <entity id="DDI-DrugBank.d78.s8.e1" charOffset="79-90"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d78.s8.e2" charOffset="97-108"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d78.s8.e3" charOffset="180-192"
            type="drug" text="grepafloxacin"/>
        <entity id="DDI-DrugBank.d78.s8.e4" charOffset="218-229"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d78.s8.d0" e1="DDI-DrugBank.d78.s8.e2"
            e2="DDI-DrugBank.d78.s8.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s9" text="Warfarin: In subjects receiving warfarin, no significant change in clotting time was observed when grepafloxacin was coadministered.">
        <entity id="DDI-DrugBank.d78.s9.e0" charOffset="0-7" type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d78.s9.e1" charOffset="32-39"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d78.s9.e2" charOffset="99-111"
            type="drug" text="grepafloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s10" text="However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.">
        <entity id="DDI-DrugBank.d78.s10.e0" charOffset="22-31"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d78.s10.e1" charOffset="78-85"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d78.s10.e2" charOffset="196-218"
            type="group" text="quinolone antimicrobial"/>
        <entity id="DDI-DrugBank.d78.s10.e3" charOffset="241-248"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d78.s10.d0" e1="DDI-DrugBank.d78.s10.e0"
            e2="DDI-DrugBank.d78.s10.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d78.s10.d1" e1="DDI-DrugBank.d78.s10.e2"
            e2="DDI-DrugBank.d78.s10.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s11" text="Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.">
        <entity id="DDI-DrugBank.d78.s11.e0" charOffset="97-109"
            type="drug" text="grepafloxacin"/>
        <entity id="DDI-DrugBank.d78.s11.e1" charOffset="114-125"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d78.s11.e2" charOffset="142-154"
            type="drug" text="grepafloxacin"/>
        <entity id="DDI-DrugBank.d78.s11.e3" charOffset="165-176"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d78.s11.d0" e1="DDI-DrugBank.d78.s11.e2"
            e2="DDI-DrugBank.d78.s11.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s12" text="While no clinical studies have been conducted to evaluate the effect of grepafloxacin on the metabolism of C.P.A.">
        <entity id="DDI-DrugBank.d78.s12.e0" charOffset="72-84"
            type="drug" text="grepafloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s13" text="substrates, in vitro data suggest similar effects of grepafloxacin in CYP3A4 mediated metabolism and theophylline metabolism.">
        <entity id="DDI-DrugBank.d78.s13.e0" charOffset="53-65"
            type="drug" text="grepafloxacin"/>
        <entity id="DDI-DrugBank.d78.s13.e1" charOffset="101-112"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s14" text="In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.">
        <entity id="DDI-DrugBank.d78.s14.e0" charOffset="19-28"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d78.s14.e1" charOffset="95-106"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d78.s14.d0" e1="DDI-DrugBank.d78.s14.e0"
            e2="DDI-DrugBank.d78.s14.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s15" text="Other drugs metabolized by C.P.A."/>
    <sentence id="DDI-DrugBank.d78.s16" text="include terfenadine, astemizole, cisapride, midazolam, and triazolam.">
        <entity id="DDI-DrugBank.d78.s16.e0" charOffset="8-18"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d78.s16.e1" charOffset="21-30"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d78.s16.e2" charOffset="33-41"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d78.s16.e3" charOffset="44-52"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d78.s16.e4" charOffset="59-67"
            type="drug" text="triazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s17" text="The clinical relevance of the potential effect of grepafloxacin on the metabolism of C.P.A. substrates is not known.">
        <entity id="DDI-DrugBank.d78.s17.e0" charOffset="50-62"
            type="drug" text="grepafloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s18" text="Patients receiving concurrent administration of substrates of C.P.A. were not excluded from clinical trials of grepafloxacin.">
        <entity id="DDI-DrugBank.d78.s18.e0" charOffset="111-123"
            type="drug" text="grepafloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s19" text="Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.">
        <entity id="DDI-DrugBank.d78.s19.e0" charOffset="0-35"
            type="group" text="Nonsteroidal Anti-inflammatory Drugs"/>
        <entity id="DDI-DrugBank.d78.s19.e1" charOffset="38-43"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d78.s19.e2" charOffset="83-117"
            type="group" text="nonsteroidal anti inflammatory drug"/>
        <entity id="DDI-DrugBank.d78.s19.e3" charOffset="126-134"
            type="group" text="quinolone"/>
        <ddi id="DDI-DrugBank.d78.s19.d0" e1="DDI-DrugBank.d78.s19.e2"
            e2="DDI-DrugBank.d78.s19.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s20" text="Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.">
        <entity id="DDI-DrugBank.d78.s20.e0" charOffset="0-18"
            type="group" text="Antidiabetic Agents"/>
        <entity id="DDI-DrugBank.d78.s20.e1" charOffset="152-161"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d78.s20.e2" charOffset="170-187"
            type="group" text="antidiabetic agent"/>
        <ddi id="DDI-DrugBank.d78.s20.d0" e1="DDI-DrugBank.d78.s20.e1"
            e2="DDI-DrugBank.d78.s20.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d78.s21" text="Therefore, careful monitoring of blood glucose is recommended when these agents are coadministered."/>
    <sentence id="DDI-DrugBank.d83.s0" text="Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.">
        <entity id="DDI-DrugBank.d83.s0.e0" charOffset="12-38"
            type="group" text="warfarin-type anticoagulant"/>
        <entity id="DDI-DrugBank.d83.s0.e1" charOffset="116-127"
            type="drug" text="griseofulvin"/>
        <ddi id="DDI-DrugBank.d83.s0.d0" e1="DDI-DrugBank.d83.s0.e0"
            e2="DDI-DrugBank.d83.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d83.s1" text="Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.">
        <entity id="DDI-DrugBank.d83.s1.e0" charOffset="19-30"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d83.s1.e1" charOffset="50-61"
            type="drug" text="griseofulvin"/>
        <ddi id="DDI-DrugBank.d83.s1.d0" e1="DDI-DrugBank.d83.s1.e0"
            e2="DDI-DrugBank.d83.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d83.s2" text="The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.">
        <entity id="DDI-DrugBank.d83.s2.e0" charOffset="34-45"
            type="drug" text="griseofulvin"/>
        <entity id="DDI-DrugBank.d83.s2.e1" charOffset="96-109"
            type="group" text="contraceptives"/>
        <ddi id="DDI-DrugBank.d83.s2.d0" e1="DDI-DrugBank.d83.s2.e0"
            e2="DDI-DrugBank.d83.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d398.s0" text="The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.">
        <entity id="DDI-DrugBank.d398.s0.e0" charOffset="11-17"
            type="drug" text="codeine"/>
        <entity id="DDI-DrugBank.d398.s0.e1" charOffset="90-96"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d398.s0.e2" charOffset="99-112"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d398.s0.e3" charOffset="115-127"
            type="group" text="psychotropics"/>
        <ddi id="DDI-DrugBank.d398.s0.d0" e1="DDI-DrugBank.d398.s0.e0"
            e2="DDI-DrugBank.d398.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d398.s0.d1" e1="DDI-DrugBank.d398.s0.e0"
            e2="DDI-DrugBank.d398.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d398.s0.d2" e1="DDI-DrugBank.d398.s0.e0"
            e2="DDI-DrugBank.d398.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d398.s1" text="Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).">
        <entity id="DDI-DrugBank.d398.s1.e0" charOffset="31-46"
            type="drug" text="dextromethorphan"/>
        <entity id="DDI-DrugBank.d398.s1.e1" charOffset="71-98"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d398.s1.e2" charOffset="101-105"
            type="group" text="MAOIs"/>
        <ddi id="DDI-DrugBank.d398.s1.d0" e1="DDI-DrugBank.d398.s1.e0"
            e2="DDI-DrugBank.d398.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d398.s1.d1" e1="DDI-DrugBank.d398.s1.e0"
            e2="DDI-DrugBank.d398.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d398.s2" text="The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.">
        <entity id="DDI-DrugBank.d398.s2.e0" charOffset="11-39"
            type="drug" text="dextromethorphan hydrobromide"/>
        <entity id="DDI-DrugBank.d398.s2.e1" charOffset="112-118"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d398.s2.e2" charOffset="121-134"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d398.s2.e3" charOffset="137-149"
            type="group" text="psychotropics"/>
        <ddi id="DDI-DrugBank.d398.s2.d0" e1="DDI-DrugBank.d398.s2.e0"
            e2="DDI-DrugBank.d398.s2.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d398.s2.d1" e1="DDI-DrugBank.d398.s2.e0"
            e2="DDI-DrugBank.d398.s2.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d398.s2.d2" e1="DDI-DrugBank.d398.s2.e0"
            e2="DDI-DrugBank.d398.s2.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d302.s0" text="http://www.rxlist.com/cgi/generic3/guanethidine_od.htm"/>
    <sentence id="DDI-DrugBank.d507.s0" text="The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.">
        <entity id="DDI-DrugBank.d507.s0.e0" charOffset="42-51"
            type="drug" text="guanfacine"/>
        <entity id="DDI-DrugBank.d507.s0.e1" charOffset="73-91"
            type="group" text="CNS-depressant drug"/>
        <ddi id="DDI-DrugBank.d507.s0.d0" e1="DDI-DrugBank.d507.s0.e0"
            e2="DDI-DrugBank.d507.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s1" text="The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.">
        <entity id="DDI-DrugBank.d507.s1.e0" charOffset="22-31"
            type="drug" text="guanfacine"/>
        <entity id="DDI-DrugBank.d507.s1.e1" charOffset="85-97"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d507.s1.e2" charOffset="102-110"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d507.s1.d0" e1="DDI-DrugBank.d507.s1.e0"
            e2="DDI-DrugBank.d507.s1.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d507.s1.d1" e1="DDI-DrugBank.d507.s1.e0"
            e2="DDI-DrugBank.d507.s1.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s2" text="In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response."/>
    <sentence id="DDI-DrugBank.d507.s3" text="Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena.">
        <entity id="DDI-DrugBank.d507.s3.e0" charOffset="12-21"
            type="drug" text="guanfacine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s4" text="TCAs decrease the hypotensive effect of guanfacine.">
        <entity id="DDI-DrugBank.d507.s4.e0" charOffset="0-3"
            type="group" text="TCAs"/>
        <entity id="DDI-DrugBank.d507.s4.e1" charOffset="40-49"
            type="drug" text="guanfacine"/>
        <ddi id="DDI-DrugBank.d507.s4.d0" e1="DDI-DrugBank.d507.s4.e0"
            e2="DDI-DrugBank.d507.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s5" text="Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.">
        <entity id="DDI-DrugBank.d507.s5.e0" charOffset="0-31"
            type="group" text="Noncardioselective beta-blockers"/>
        <entity id="DDI-DrugBank.d507.s5.e1" charOffset="34-40"
            type="drug" text="nadolol"/>
        <entity id="DDI-DrugBank.d507.s5.e2" charOffset="54-60"
            type="drug" text="timolol"/>
        <entity id="DDI-DrugBank.d507.s5.e3" charOffset="104-113"
            type="drug" text="guanfacine"/>
        <ddi id="DDI-DrugBank.d507.s5.d0" e1="DDI-DrugBank.d507.s5.e0"
            e2="DDI-DrugBank.d507.s5.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d507.s5.d1" e1="DDI-DrugBank.d507.s5.e1"
            e2="DDI-DrugBank.d507.s5.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d507.s5.d2" e1="DDI-DrugBank.d507.s5.e2"
            e2="DDI-DrugBank.d507.s5.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s6" text="The beta-blocker should be withdrawn first.">
        <entity id="DDI-DrugBank.d507.s6.e0" charOffset="4-15"
            type="group" text="beta-blocker"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s7" text="The gradual withdrawal of guafacine or a cardioselective beta-blocker could be substituted.">
        <entity id="DDI-DrugBank.d507.s7.e0" charOffset="26-34"
            type="drug" text="guafacine"/>
        <entity id="DDI-DrugBank.d507.s7.e1" charOffset="41-68"
            type="group" text="cardioselective beta-blocker"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s8" text="Anticoagulants: Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks.">
        <entity id="DDI-DrugBank.d507.s8.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d507.s8.e1" charOffset="57-70"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d507.s8.e2" charOffset="83-92"
            type="drug" text="guanfacine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s9" text="No changes were observed in the degree of anticoagulation."/>
    <sentence id="DDI-DrugBank.d507.s10" text="In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported.">
        <entity id="DDI-DrugBank.d507.s10.e0" charOffset="36-45"
            type="drug" text="guanfacine"/>
        <entity id="DDI-DrugBank.d507.s10.e1" charOffset="78-86"
            type="group" text="diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s11" text="In the long-term safety studies, guanfacine was given concomitantly with many drugs without evidence of any interactions.">
        <entity id="DDI-DrugBank.d507.s11.e0" charOffset="33-42"
            type="drug" text="guanfacine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s12" text="The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).">
        <entity id="DDI-DrugBank.d507.s12.e0" charOffset="68-85"
            type="group" text="cardiac glycosides"/>
        <entity id="DDI-DrugBank.d507.s12.e1" charOffset="94-102"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d507.s12.e2" charOffset="108-116"
            type="group" text="hypnotics"/>
        <entity id="DDI-DrugBank.d507.s12.e3" charOffset="125-145"
            type="group" text="coronary vasodilators"/>
        <entity id="DDI-DrugBank.d507.s12.e4" charOffset="158-170"
            type="group" text="hypoglycemics"/>
        <entity id="DDI-DrugBank.d507.s12.e5" charOffset="212-217"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d507.s12.e6" charOffset="225-243"
            type="group" text="antihyperlipidemics"/>
        <entity id="DDI-DrugBank.d507.s12.e7" charOffset="251-264"
            type="group" text="antigout drugs"/>
        <entity id="DDI-DrugBank.d507.s12.e8" charOffset="277-290"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d507.s12.e9" charOffset="298-312"
            type="group" text="bronchodilators"/>
        <entity id="DDI-DrugBank.d507.s12.e10" charOffset="320-326"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d507.s12.e11" charOffset="338-350"
            type="group" text="beta blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s13" text="Laboratory Test In clinical trials, no clinically relevant laboratory test abnormalities were identified as causally related to drug during short-term treatment with guanfacine.">
        <entity id="DDI-DrugBank.d507.s13.e0" charOffset="166-175"
            type="drug" text="guanfacine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d507.s14" text="Drug/Laboratory Test Interactions No laboratory test abnormalities related to the use of guanfacine have been identified.">
        <entity id="DDI-DrugBank.d507.s14.e0" charOffset="89-98"
            type="drug" text="guanfacine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d186.s0" text="An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.">
        <entity id="DDI-DrugBank.d186.s0.e0" charOffset="261-267"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d186.s0.e1" charOffset="274-279"
            type="brand" text="HALDOL"/>
        <ddi id="DDI-DrugBank.d186.s0.d0" e1="DDI-DrugBank.d186.s0.e0"
            e2="DDI-DrugBank.d186.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d186.s1" text="A causal relationship between these events and the concomitant administration of lithium and HALDOL has not been established;">
        <entity id="DDI-DrugBank.d186.s1.e0" charOffset="81-87"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d186.s1.e1" charOffset="93-98"
            type="brand" text="HALDOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d186.s2" text="however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear."/>
    <sentence id="DDI-DrugBank.d186.s3" text="As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.">
        <entity id="DDI-DrugBank.d186.s3.e0" charOffset="14-33"
            type="group" text="antipsychotic agents"/>
        <entity id="DDI-DrugBank.d186.s3.e1" charOffset="60-65"
            type="brand" text="HALDOL"/>
        <entity id="DDI-DrugBank.d186.s3.e2" charOffset="98-112"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d186.s3.e3" charOffset="122-132"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d186.s3.e4" charOffset="135-141"
            type="group" text="opiates"/>
        <entity id="DDI-DrugBank.d186.s3.e5" charOffset="148-154"
            type="drug" text="alcohol"/>
        <ddi id="DDI-DrugBank.d186.s3.d0" e1="DDI-DrugBank.d186.s3.e0"
            e2="DDI-DrugBank.d186.s3.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d186.s3.d1" e1="DDI-DrugBank.d186.s3.e0"
            e2="DDI-DrugBank.d186.s3.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d186.s3.d2" e1="DDI-DrugBank.d186.s3.e0"
            e2="DDI-DrugBank.d186.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d186.s3.d3" e1="DDI-DrugBank.d186.s3.e0"
            e2="DDI-DrugBank.d186.s3.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d186.s3.d4" e1="DDI-DrugBank.d186.s3.e1"
            e2="DDI-DrugBank.d186.s3.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d186.s3.d5" e1="DDI-DrugBank.d186.s3.e1"
            e2="DDI-DrugBank.d186.s3.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d186.s3.d6" e1="DDI-DrugBank.d186.s3.e1"
            e2="DDI-DrugBank.d186.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d186.s3.d7" e1="DDI-DrugBank.d186.s3.e1"
            e2="DDI-DrugBank.d186.s3.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d186.s4" text="In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.">
        <entity id="DDI-DrugBank.d186.s4.e0" charOffset="60-70"
            type="drug" text="haloperidol"/>
        <entity id="DDI-DrugBank.d186.s4.e1" charOffset="76-83"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d186.s4.e2" charOffset="93-103"
            type="drug" text="haloperidol"/>
        <ddi id="DDI-DrugBank.d186.s4.d0" e1="DDI-DrugBank.d186.s4.e0"
            e2="DDI-DrugBank.d186.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d186.s5" text="In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.">
        <entity id="DDI-DrugBank.d186.s5.e0" charOffset="52-62"
            type="drug" text="haloperidol"/>
        <entity id="DDI-DrugBank.d186.s5.e1" charOffset="68-75"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d186.s5.e2" charOffset="97-104"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d186.s5.e3" charOffset="143-153"
            type="drug" text="haloperidol"/>
        <ddi id="DDI-DrugBank.d186.s5.d0" e1="DDI-DrugBank.d186.s5.e2"
            e2="DDI-DrugBank.d186.s5.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d186.s6" text="Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.">
        <entity id="DDI-DrugBank.d186.s6.e0" charOffset="62-69"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d186.s6.e1" charOffset="106-116"
            type="drug" text="haloperidol"/>
        <ddi id="DDI-DrugBank.d186.s6.d0" e1="DDI-DrugBank.d186.s6.e0"
            e2="DDI-DrugBank.d186.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d74.s0" text="FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.">
        <entity id="DDI-DrugBank.d74.s0.e0" charOffset="0-8"
            type="brand" text="FLUOTHANE"/>
        <entity id="DDI-DrugBank.d74.s0.e1" charOffset="33-64"
            type="group" text="non-depolarising muscle relaxant"/>
        <entity id="DDI-DrugBank.d74.s0.e2" charOffset="102-116"
            type="group" text="aminoglycosides"/>
        <ddi id="DDI-DrugBank.d74.s0.d0" e1="DDI-DrugBank.d74.s0.e0"
            e2="DDI-DrugBank.d74.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d74.s0.d1" e1="DDI-DrugBank.d74.s0.e0"
            e2="DDI-DrugBank.d74.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d74.s1" text="FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.">
        <entity id="DDI-DrugBank.d74.s1.e0" charOffset="0-8"
            type="brand" text="FLUOTHANE"/>
        <entity id="DDI-DrugBank.d74.s1.e1" charOffset="82-93"
            type="drug" text="tubocurarine"/>
        <ddi id="DDI-DrugBank.d74.s1.d0" e1="DDI-DrugBank.d74.s1.e0"
            e2="DDI-DrugBank.d74.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d74.s2" text="Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.">
        <entity id="DDI-DrugBank.d74.s2.e0" charOffset="57-66"
            type="drug" text="adrenaline"/>
        <entity id="DDI-DrugBank.d74.s2.e1" charOffset="99-107"
            type="brand" text="FLUOTHANE"/>
        <ddi id="DDI-DrugBank.d74.s2.d0" e1="DDI-DrugBank.d74.s2.e0"
            e2="DDI-DrugBank.d74.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d74.s3" text="For this reason the dose of adrenaline should be restricted and an antiarrhythmic agent administered as appropriate.">
        <entity id="DDI-DrugBank.d74.s3.e0" charOffset="28-37"
            type="drug" text="adrenaline"/>
        <entity id="DDI-DrugBank.d74.s3.e1" charOffset="67-86"
            type="group" text="antiarrhythmic agent"/>
    </sentence>
    <sentence id="DDI-DrugBank.d74.s4" text="Caution should also be applied for other sympathomimetics, and for aminophylline and theophylline and tricyclic antidepressants, which may also precipitate arrhythmias.">
        <entity id="DDI-DrugBank.d74.s4.e0" charOffset="41-56"
            type="group" text="sympathomimetics"/>
        <entity id="DDI-DrugBank.d74.s4.e1" charOffset="67-79"
            type="drug" text="aminophylline"/>
        <entity id="DDI-DrugBank.d74.s4.e2" charOffset="85-96"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d74.s4.e3" charOffset="102-126"
            type="group" text="tricyclic antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d488.s0" text="Drug Interactions: a. Drugs Enhancing Heparin Effect: Oral anticoagulants: Heparin sodium may prolong the one-stage prothrombin time.">
        <entity id="DDI-DrugBank.d488.s0.e0" charOffset="38-44"
            type="drug" text="Heparin"/>
        <entity id="DDI-DrugBank.d488.s0.e1" charOffset="59-72"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d488.s0.e2" charOffset="75-88"
            type="drug" text="Heparin sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d488.s1" text="Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.">
        <entity id="DDI-DrugBank.d488.s1.e0" charOffset="16-29"
            type="drug" text="heparin sodium"/>
        <entity id="DDI-DrugBank.d488.s1.e1" charOffset="45-53"
            type="drug" text="dicumarol"/>
        <entity id="DDI-DrugBank.d488.s1.e2" charOffset="58-72"
            type="drug" text="warfarin sodium"/>
        <ddi id="DDI-DrugBank.d488.s1.d0" e1="DDI-DrugBank.d488.s1.e0"
            e2="DDI-DrugBank.d488.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d488.s1.d1" e1="DDI-DrugBank.d488.s1.e0"
            e2="DDI-DrugBank.d488.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d488.s2" text="Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.">
        <entity id="DDI-DrugBank.d488.s2.e0" charOffset="0-18"
            type="group" text="Platelet inhibitors"/>
        <entity id="DDI-DrugBank.d488.s2.e1" charOffset="35-54"
            type="drug" text="acetylsalicylic acid"/>
        <entity id="DDI-DrugBank.d488.s2.e2" charOffset="57-63"
            type="drug" text="dextran"/>
        <entity id="DDI-DrugBank.d488.s2.e3" charOffset="66-79"
            type="drug" text="phenylbutazone"/>
        <entity id="DDI-DrugBank.d488.s2.e4" charOffset="82-90"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d488.s2.e5" charOffset="93-104"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d488.s2.e6" charOffset="107-118"
            type="drug" text="dipyridamole"/>
        <entity id="DDI-DrugBank.d488.s2.e7" charOffset="121-138"
            type="drug" text="hydroxychloroquine"/>
        <entity id="DDI-DrugBank.d488.s2.e8" charOffset="330-343"
            type="drug" text="heparin sodium"/>
        <ddi id="DDI-DrugBank.d488.s2.d0" e1="DDI-DrugBank.d488.s2.e1"
            e2="DDI-DrugBank.d488.s2.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d488.s2.d1" e1="DDI-DrugBank.d488.s2.e2"
            e2="DDI-DrugBank.d488.s2.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d488.s2.d2" e1="DDI-DrugBank.d488.s2.e3"
            e2="DDI-DrugBank.d488.s2.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d488.s2.d3" e1="DDI-DrugBank.d488.s2.e4"
            e2="DDI-DrugBank.d488.s2.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d488.s2.d4" e1="DDI-DrugBank.d488.s2.e5"
            e2="DDI-DrugBank.d488.s2.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d488.s2.d5" e1="DDI-DrugBank.d488.s2.e6"
            e2="DDI-DrugBank.d488.s2.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d488.s2.d6" e1="DDI-DrugBank.d488.s2.e7"
            e2="DDI-DrugBank.d488.s2.e8" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d488.s3" text="The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.">
        <entity id="DDI-DrugBank.d488.s3.e0" charOffset="28-34"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d488.s3.e1" charOffset="77-92"
            type="drug" text="antithrombin III"/>
        <ddi id="DDI-DrugBank.d488.s3.d0" e1="DDI-DrugBank.d488.s3.e0"
            e2="DDI-DrugBank.d488.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d488.s4" text="Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).">
        <entity id="DDI-DrugBank.d488.s4.e0" charOffset="51-57"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d488.s4.e1" charOffset="96-111"
            type="drug" text="antithrombin III"/>
        <ddi id="DDI-DrugBank.d488.s4.d0" e1="DDI-DrugBank.d488.s4.e0"
            e2="DDI-DrugBank.d488.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d488.s5" text="b."/>
    <sentence id="DDI-DrugBank.d488.s6" text="Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.">
        <entity id="DDI-DrugBank.d488.s6.e0" charOffset="17-23"
            type="drug" text="Heparin"/>
        <entity id="DDI-DrugBank.d488.s6.e1" charOffset="33-41"
            type="group" text="Digitalis"/>
        <entity id="DDI-DrugBank.d488.s6.e2" charOffset="44-56"
            type="group" text="tetracyclines"/>
        <entity id="DDI-DrugBank.d488.s6.e3" charOffset="59-66"
            type="drug" text="nicotine"/>
        <entity id="DDI-DrugBank.d488.s6.e4" charOffset="72-85"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d488.s6.e5" charOffset="140-153"
            type="drug" text="heparin sodium"/>
        <ddi id="DDI-DrugBank.d488.s6.d0" e1="DDI-DrugBank.d488.s6.e1"
            e2="DDI-DrugBank.d488.s6.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d488.s6.d1" e1="DDI-DrugBank.d488.s6.e2"
            e2="DDI-DrugBank.d488.s6.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d488.s6.d2" e1="DDI-DrugBank.d488.s6.e3"
            e2="DDI-DrugBank.d488.s6.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d488.s6.d3" e1="DDI-DrugBank.d488.s6.e4"
            e2="DDI-DrugBank.d488.s6.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d488.s7" text="Heparin Sodium Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.">
        <entity id="DDI-DrugBank.d488.s7.e0" charOffset="0-13"
            type="drug" text="Heparin Sodium"/>
        <entity id="DDI-DrugBank.d488.s7.e1" charOffset="50-60"
            type="drug" text="doxorubicin"/>
        <entity id="DDI-DrugBank.d488.s7.e2" charOffset="63-72"
            type="drug" text="droperidol"/>
        <entity id="DDI-DrugBank.d488.s7.e3" charOffset="75-87"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d488.s7.e4" charOffset="93-104"
            type="drug" text="mitoxantrone"/>
        <entity id="DDI-DrugBank.d488.s7.e5" charOffset="173-179"
            type="drug" text="heparin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d488.s8" text="Drug/ Laboratory Tests Interactions Hyperaminotransferasemia: Significant elevations of aminotransferase (SGOT [S-AST] and SGPT [S-ALT]) levels have occurred in a high percentage of patients (and healthy subjects) who have received heparin sodium.">
        <entity id="DDI-DrugBank.d488.s8.e0" charOffset="232-245"
            type="drug" text="heparin sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d488.s9" text="Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction, liver disease and pulmonary emboli, rises that might be caused by drugs (heparin sodium) should be interpreted with caution.">
        <entity id="DDI-DrugBank.d488.s9.e0" charOffset="181-194"
            type="drug" text="heparin sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d514.s0" text="Opioids are strong central nervous system depressants, but regular users develop physiological tolerance allowing gradually increased dosages.">
        <entity id="DDI-DrugBank.d514.s0.e0" charOffset="0-6"
            type="group" text="Opioids"/>
        <entity id="DDI-DrugBank.d514.s0.e1" charOffset="19-52"
            type="group" text="central nervous system depressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d514.s1" text="In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.">
        <entity id="DDI-DrugBank.d514.s1.e0" charOffset="26-59"
            type="group" text="central nervous system depressants"/>
        <entity id="DDI-DrugBank.d514.s1.e1" charOffset="62-67"
            type="drug_n" text="heroin"/>
        <ddi id="DDI-DrugBank.d514.s1.d0" e1="DDI-DrugBank.d514.s1.e0"
            e2="DDI-DrugBank.d514.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d514.s2" text="Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.">
        <entity id="DDI-DrugBank.d514.s2.e0" charOffset="22-27"
            type="drug_n" text="heroin"/>
        <entity id="DDI-DrugBank.d514.s2.e1" charOffset="81-114"
            type="group" text="central nervous system depressants"/>
        <entity id="DDI-DrugBank.d514.s2.e2" charOffset="127-133"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d514.s2.e3" charOffset="136-150"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d514.s2.e4" charOffset="160-167"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d514.s2.e5" charOffset="170-175"
            type="brand" text="Valium"/>
        <entity id="DDI-DrugBank.d514.s2.e6" charOffset="204-212"
            type="drug" text="methadone"/>
        <ddi id="DDI-DrugBank.d514.s2.d0" e1="DDI-DrugBank.d514.s2.e0"
            e2="DDI-DrugBank.d514.s2.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d514.s2.d1" e1="DDI-DrugBank.d514.s2.e0"
            e2="DDI-DrugBank.d514.s2.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d514.s2.d2" e1="DDI-DrugBank.d514.s2.e0"
            e2="DDI-DrugBank.d514.s2.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d514.s2.d3" e1="DDI-DrugBank.d514.s2.e0"
            e2="DDI-DrugBank.d514.s2.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d514.s2.d4" e1="DDI-DrugBank.d514.s2.e0"
            e2="DDI-DrugBank.d514.s2.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d514.s2.d5" e1="DDI-DrugBank.d514.s2.e0"
            e2="DDI-DrugBank.d514.s2.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d514.s3" text="Ironically, benzodiazepines are often used in the treatment of heroin addiction while they cause much more severe withdrawal symptoms.">
        <entity id="DDI-DrugBank.d514.s3.e0" charOffset="12-26"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d514.s3.e1" charOffset="63-68"
            type="drug" text="heroin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d514.s4" text="Cocaine sometimes proves to be fatal when used in combination with heroin.">
        <entity id="DDI-DrugBank.d514.s4.e0" charOffset="0-6"
            type="drug" text="Cocaine"/>
        <entity id="DDI-DrugBank.d514.s4.e1" charOffset="67-72"
            type="drug_n" text="heroin"/>
        <ddi id="DDI-DrugBank.d514.s4.d0" e1="DDI-DrugBank.d514.s4.e0"
            e2="DDI-DrugBank.d514.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d421.s0" text="No information available."/>
    <sentence id="DDI-DrugBank.d457.s0" text="Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.">
        <entity id="DDI-DrugBank.d457.s0.e0" charOffset="0-11"
            type="group" text="Barbiturates"/>
        <entity id="DDI-DrugBank.d457.s0.e1" charOffset="52-65"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d457.s0.e2" charOffset="76-86"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d457.s0.e3" charOffset="89-97"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d457.s0.e4" charOffset="100-111"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d457.s0.e5" charOffset="114-128"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d457.s0.e6" charOffset="131-144"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d457.s0.e7" charOffset="151-163"
            type="group" text="beta blockers"/>
        <ddi id="DDI-DrugBank.d457.s0.d0" e1="DDI-DrugBank.d457.s0.e0"
            e2="DDI-DrugBank.d457.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d457.s0.d1" e1="DDI-DrugBank.d457.s0.e0"
            e2="DDI-DrugBank.d457.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d457.s0.d2" e1="DDI-DrugBank.d457.s0.e0"
            e2="DDI-DrugBank.d457.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d457.s0.d3" e1="DDI-DrugBank.d457.s0.e0"
            e2="DDI-DrugBank.d457.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d457.s0.d4" e1="DDI-DrugBank.d457.s0.e0"
            e2="DDI-DrugBank.d457.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d457.s0.d5" e1="DDI-DrugBank.d457.s0.e0"
            e2="DDI-DrugBank.d457.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d457.s0.d6" e1="DDI-DrugBank.d457.s0.e0"
            e2="DDI-DrugBank.d457.s0.e7" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s0" text="MAO inhibitors should be used with caution in patients receiving hydralazine.">
        <entity id="DDI-DrugBank.d31.s0.e0" charOffset="0-13"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d31.s0.e1" charOffset="65-75"
            type="drug" text="hydralazine"/>
        <ddi id="DDI-DrugBank.d31.s0.d0" e1="DDI-DrugBank.d31.s0.e0"
            e2="DDI-DrugBank.d31.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s1" text="When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.">
        <entity id="DDI-DrugBank.d31.s1.e0" charOffset="27-48"
            type="group" text="antihypertensive drugs"/>
        <entity id="DDI-DrugBank.d31.s1.e1" charOffset="59-67"
            type="drug" text="diazoxide"/>
        <entity id="DDI-DrugBank.d31.s1.e2" charOffset="99-109"
            type="drug" text="hydralazine"/>
        <ddi id="DDI-DrugBank.d31.s1.d0" e1="DDI-DrugBank.d31.s1.e0"
            e2="DDI-DrugBank.d31.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d31.s1.d1" e1="DDI-DrugBank.d31.s1.e0"
            e2="DDI-DrugBank.d31.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s2" text="Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.">
        <entity id="DDI-DrugBank.d31.s2.e0" charOffset="45-53"
            type="drug" text="diazoxide"/>
        <entity id="DDI-DrugBank.d31.s2.e1" charOffset="69-79"
            type="drug" text="hydralazine"/>
        <ddi id="DDI-DrugBank.d31.s2.d0" e1="DDI-DrugBank.d31.s2.e0"
            e2="DDI-DrugBank.d31.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s3" text="Beta-blockers (metoprolol, propranolol) serum concentrations and pharmacologic effects may be increased.">
        <entity id="DDI-DrugBank.d31.s3.e0" charOffset="0-12"
            type="group" text="Beta-blockers"/>
        <entity id="DDI-DrugBank.d31.s3.e1" charOffset="15-24"
            type="drug" text="metoprolol"/>
        <entity id="DDI-DrugBank.d31.s3.e2" charOffset="27-37"
            type="drug" text="propranolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s4" text="Monitor cardiovascular status."/>
    <sentence id="DDI-DrugBank.d31.s5" text="Propranolol increases hydralazines serum concentrations.">
        <entity id="DDI-DrugBank.d31.s5.e0" charOffset="0-10"
            type="drug" text="Propranolol"/>
        <entity id="DDI-DrugBank.d31.s5.e1" charOffset="22-32"
            type="drug" text="hydralazine"/>
        <ddi id="DDI-DrugBank.d31.s5.d0" e1="DDI-DrugBank.d31.s5.e0"
            e2="DDI-DrugBank.d31.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s6" text="Acebutolol, atenolol, and nadolol (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.">
        <entity id="DDI-DrugBank.d31.s6.e0" charOffset="0-9" type="drug" text="Acebutolol"/>
        <entity id="DDI-DrugBank.d31.s6.e1" charOffset="12-19"
            type="drug" text="atenolol"/>
        <entity id="DDI-DrugBank.d31.s6.e2" charOffset="26-32"
            type="drug" text="nadolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s7" text="NSAIDs may decrease the hemodynamic effects of hydralazine;">
        <entity id="DDI-DrugBank.d31.s7.e0" charOffset="0-5"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d31.s7.e1" charOffset="47-57"
            type="drug" text="hydralazine"/>
        <ddi id="DDI-DrugBank.d31.s7.d0" e1="DDI-DrugBank.d31.s7.e0"
            e2="DDI-DrugBank.d31.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s8" text="avoid use if possible or closely monitor cardiovascular status at the end of drug interactions"/>
    <sentence id="DDI-DrugBank.d162.s0" text="When given concurrently the following drugs may interact with thiazide diuretics.">
        <entity id="DDI-DrugBank.d162.s0.e0" charOffset="62-79"
            type="group" text="thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s1" text="Alcohol, barbiturates, or narcotics: potentiation of orthostatic hypotension may occur.">
        <entity id="DDI-DrugBank.d162.s1.e0" charOffset="0-6"
            type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d162.s1.e1" charOffset="9-20"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d162.s1.e2" charOffset="26-34"
            type="group" text="narcotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s2" text="Antidiabetic drugs: (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required.">
        <entity id="DDI-DrugBank.d162.s2.e0" charOffset="0-17"
            type="group" text="Antidiabetic drugs"/>
        <entity id="DDI-DrugBank.d162.s2.e1" charOffset="37-43"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d162.s2.e2" charOffset="73-89"
            type="group" text="antidiabetic drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s3" text="Other antihypertensive drugs: additive effect or potentiation.">
        <entity id="DDI-DrugBank.d162.s3.e0" charOffset="6-27"
            type="group" text="antihypertensive drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s4" text="Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.">
        <entity id="DDI-DrugBank.d162.s4.e0" charOffset="0-13"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d162.s4.e1" charOffset="19-28"
            type="drug" text="colestipol"/>
        <entity id="DDI-DrugBank.d162.s4.e2" charOffset="30-35"
            type="group" text="resins"/>
        <entity id="DDI-DrugBank.d162.s4.e3" charOffset="52-70"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d162.s4.e4" charOffset="103-125"
            type="group" text="anionic exchange resins"/>
        <ddi id="DDI-DrugBank.d162.s4.d0" e1="DDI-DrugBank.d162.s4.e3"
            e2="DDI-DrugBank.d162.s4.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s5" text="Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.">
        <entity id="DDI-DrugBank.d162.s5.e0" charOffset="23-36"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d162.s5.e1" charOffset="41-50"
            type="drug" text="colestipol"/>
        <entity id="DDI-DrugBank.d162.s5.e2" charOffset="52-57"
            type="group" text="resins"/>
        <entity id="DDI-DrugBank.d162.s5.e3" charOffset="68-86"
            type="drug" text="hydrochlorothiazide"/>
        <ddi id="DDI-DrugBank.d162.s5.d0" e1="DDI-DrugBank.d162.s5.e0"
            e2="DDI-DrugBank.d162.s5.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d162.s5.d1" e1="DDI-DrugBank.d162.s5.e1"
            e2="DDI-DrugBank.d162.s5.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s6" text="Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia.">
        <entity id="DDI-DrugBank.d162.s6.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d162.s6.e1" charOffset="17-20"
            type="drug" text="ACTH"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s7" text="Pressor amines (e.g., norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use.">
        <entity id="DDI-DrugBank.d162.s7.e0" charOffset="22-35"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s8" text="Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): possible increased responsiveness to the muscle relaxant.">
        <entity id="DDI-DrugBank.d162.s8.e0" charOffset="0-24"
            type="group" text="Skeletal muscle relaxants"/>
        <entity id="DDI-DrugBank.d162.s8.e1" charOffset="50-61"
            type="drug" text="tubocurarine"/>
        <entity id="DDI-DrugBank.d162.s8.e2" charOffset="106-120"
            type="group" text="muscle relaxant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s9" text="Lithium: generally should not be given with diuretics.">
        <entity id="DDI-DrugBank.d162.s9.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d162.s9.e1" charOffset="44-52"
            type="group" text="diuretics"/>
        <ddi id="DDI-DrugBank.d162.s9.d0" e1="DDI-DrugBank.d162.s9.e0"
            e2="DDI-DrugBank.d162.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s10" text="Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.">
        <entity id="DDI-DrugBank.d162.s10.e0" charOffset="0-14"
            type="group" text="Diuretic agents"/>
        <entity id="DDI-DrugBank.d162.s10.e1" charOffset="46-52"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d162.s10.e2" charOffset="77-83"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d162.s10.d0" e1="DDI-DrugBank.d162.s10.e0"
            e2="DDI-DrugBank.d162.s10.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d162.s10.d1" e1="DDI-DrugBank.d162.s10.e0"
            e2="DDI-DrugBank.d162.s10.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s11" text="Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.">
        <entity id="DDI-DrugBank.d162.s11.e0" charOffset="32-38"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d162.s11.e1" charOffset="90-108"
            type="drug" text="Hydrochlorothiazide"/>
        <ddi id="DDI-DrugBank.d162.s11.d0" e1="DDI-DrugBank.d162.s11.e0"
            e2="DDI-DrugBank.d162.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s12" text="Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.">
        <entity id="DDI-DrugBank.d162.s12.e0" charOffset="0-36"
            type="group" text="Non-steroidal Anti-inflammatory Drugs"/>
        <entity id="DDI-DrugBank.d162.s12.e1" charOffset="81-117"
            type="group" text="non-steroidal anti-inflammatory agent"/>
        <entity id="DDI-DrugBank.d162.s12.e2"
            charOffset="189-192;226-234" type="group" text="loop diuretics"/>
        <entity id="DDI-DrugBank.d162.s12.e3"
            charOffset="195-211;226-234" type="group" text="potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d162.s12.e4" charOffset="217-234"
            type="group" text="thiazide diuretics"/>
        <ddi id="DDI-DrugBank.d162.s12.d0" e1="DDI-DrugBank.d162.s12.e1"
            e2="DDI-DrugBank.d162.s12.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d162.s12.d1" e1="DDI-DrugBank.d162.s12.e1"
            e2="DDI-DrugBank.d162.s12.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d162.s12.d2" e1="DDI-DrugBank.d162.s12.e1"
            e2="DDI-DrugBank.d162.s12.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d162.s13" text="Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.">
        <entity id="DDI-DrugBank.d162.s13.e0" charOffset="16-34"
            type="drug" text="Hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d162.s13.e1" charOffset="40-77"
            type="group" text="non-steroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d162.s13.e2" charOffset="184-191"
            type="group" text="diuretic"/>
        <ddi id="DDI-DrugBank.d162.s13.d0" e1="DDI-DrugBank.d162.s13.e0"
            e2="DDI-DrugBank.d162.s13.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d396.s0" text="Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.">
        <entity id="DDI-DrugBank.d396.s0.e0" charOffset="25-43"
            type="group" text="narcotic analgesics"/>
        <entity id="DDI-DrugBank.d396.s0.e1" charOffset="46-59"
            type="group" text="antipsychotics"/>
        <entity id="DDI-DrugBank.d396.s0.e2" charOffset="62-79"
            type="group" text="antianxiety agents"/>
        <entity id="DDI-DrugBank.d396.s0.e3" charOffset="91-105"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d396.s0.e4" charOffset="118-124"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d396.s0.e5" charOffset="146-156"
            type="drug" text="hydrocodone"/>
        <entity id="DDI-DrugBank.d396.s0.e6" charOffset="162-174"
            type="drug" text="acetaminophen"/>
        <ddi id="DDI-DrugBank.d396.s0.d0" e1="DDI-DrugBank.d396.s0.e0"
            e2="DDI-DrugBank.d396.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d396.s0.d1" e1="DDI-DrugBank.d396.s0.e1"
            e2="DDI-DrugBank.d396.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d396.s0.d2" e1="DDI-DrugBank.d396.s0.e2"
            e2="DDI-DrugBank.d396.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d396.s0.d3" e1="DDI-DrugBank.d396.s0.e3"
            e2="DDI-DrugBank.d396.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d396.s0.d4" e1="DDI-DrugBank.d396.s0.e4"
            e2="DDI-DrugBank.d396.s0.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d396.s1" text="When combined therapy is contemplated, the dose of one or both agents should be reduced."/>
    <sentence id="DDI-DrugBank.d396.s2" text="The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.">
        <entity id="DDI-DrugBank.d396.s2.e0" charOffset="11-24"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d396.s2.e1" charOffset="29-53"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d396.s2.e2" charOffset="60-70"
            type="drug" text="hydrocodone"/>
        <entity id="DDI-DrugBank.d396.s2.e3" charOffset="123-136"
            type="group" text="antidepressant"/>
        <entity id="DDI-DrugBank.d396.s2.e4" charOffset="141-151"
            type="drug" text="hydrocodone"/>
        <ddi id="DDI-DrugBank.d396.s2.d0" e1="DDI-DrugBank.d396.s2.e0"
            e2="DDI-DrugBank.d396.s2.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d396.s2.d1" e1="DDI-DrugBank.d396.s2.e1"
            e2="DDI-DrugBank.d396.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d396.s3" text="The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.">
        <entity id="DDI-DrugBank.d396.s3.e0" charOffset="22-37"
            type="group" text="anticholinergics"/>
        <entity id="DDI-DrugBank.d396.s3.e1" charOffset="44-54"
            type="drug" text="hydrocodone"/>
        <ddi id="DDI-DrugBank.d396.s3.d0" e1="DDI-DrugBank.d396.s3.e0"
            e2="DDI-DrugBank.d396.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d155.s0" text="No information available."/>
    <sentence id="DDI-DrugBank.d17.s0" text="Anticoagulants, oral">
        <entity id="DDI-DrugBank.d17.s0.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s1" text="(Effects may be decreased when used concurrently with thiazide diuretics;">
        <entity id="DDI-DrugBank.d17.s1.e0" charOffset="54-71"
            type="group" text="thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s2" text="dosage adjustments may be necessary.)"/>
    <sentence id="DDI-DrugBank.d17.s3" text="Antigout medications">
        <entity id="DDI-DrugBank.d17.s3.e0" charOffset="0-19"
            type="group" text="Antigout medications"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s4" text="(Thiazide diuretics may raise the level of blood uric acid;">
        <entity id="DDI-DrugBank.d17.s4.e0" charOffset="1-18"
            type="group" text="Thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s5" text="dosage adjustment of antigout medications may be necessary to control hyperuricemia and gout.)">
        <entity id="DDI-DrugBank.d17.s5.e0" charOffset="21-40"
            type="group" text="antigout medications"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s6" text="Antihypertensive medications, other, especially diazoxide, or preanesthetic and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery">
        <entity id="DDI-DrugBank.d17.s6.e0" charOffset="0-27"
            type="group" text="Antihypertensive medications"/>
        <entity id="DDI-DrugBank.d17.s6.e1" charOffset="48-56"
            type="drug" text="diazoxide"/>
        <entity id="DDI-DrugBank.d17.s6.e2" charOffset="65-74"
            type="group" text="anesthetic"/>
        <entity id="DDI-DrugBank.d17.s6.e3" charOffset="117-141"
            type="group" text="skeletal-muscle relaxants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s7" text="(Effects may be potentiated when used concurrently with thiazide diuretics;">
        <entity id="DDI-DrugBank.d17.s7.e0" charOffset="56-73"
            type="group" text="thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s8" text="dosage adjustments may be necessary.)"/>
    <sentence id="DDI-DrugBank.d17.s9" text="Amphotericin B or Corticosteroids or Corticotropin (ACTH)">
        <entity id="DDI-DrugBank.d17.s9.e0" charOffset="0-13"
            type="drug" text="Amphotericin B"/>
        <entity id="DDI-DrugBank.d17.s9.e1" charOffset="18-32"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d17.s9.e2" charOffset="37-49"
            type="drug" text="Corticotropin"/>
        <entity id="DDI-DrugBank.d17.s9.e3" charOffset="52-55"
            type="drug" text="ACTH"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s10" text="(Concurrent use with thiazide diuretics may intensify electrolyte imbalance, particularly hypokalemia.)">
        <entity id="DDI-DrugBank.d17.s10.e0" charOffset="21-38"
            type="group" text="thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s11" text="Cardiac glycosides">
        <entity id="DDI-DrugBank.d17.s11.e0" charOffset="0-17"
            type="group" text="Cardiac glycosides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s12" text="(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.)">
        <entity id="DDI-DrugBank.d17.s12.e0" charOffset="21-38"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d17.s12.e1" charOffset="71-79"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d17.s12.d0" e1="DDI-DrugBank.d17.s12.e0"
            e2="DDI-DrugBank.d17.s12.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s13" text="Colestipol">
        <entity id="DDI-DrugBank.d17.s13.e0" charOffset="0-9"
            type="drug" text="Colestipol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s14" text="(May inhibit gastrointestinal absorption of the thiazide diuretics;">
        <entity id="DDI-DrugBank.d17.s14.e0" charOffset="48-65"
            type="group" text="thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s15" text="administration 1 hour before or 4 hours after colestipol is recommended.)">
        <entity id="DDI-DrugBank.d17.s15.e0" charOffset="46-55"
            type="drug" text="colestipol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s16" text="Hypoglycemics">
        <entity id="DDI-DrugBank.d17.s16.e0" charOffset="0-12"
            type="group" text="Hypoglycemics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s17" text="(Thiazide diuretics may raise blood glucose levels;">
        <entity id="DDI-DrugBank.d17.s17.e0" charOffset="1-18"
            type="group" text="Thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s18" text="for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;">
        <entity id="DDI-DrugBank.d17.s18.e0" charOffset="48-71"
            type="group" text="hypoglycemic medications"/>
        <entity id="DDI-DrugBank.d17.s18.e1" charOffset="107-123"
            type="group" text="thiazide diuretic"/>
        <ddi id="DDI-DrugBank.d17.s18.d0" e1="DDI-DrugBank.d17.s18.e0"
            e2="DDI-DrugBank.d17.s18.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s19" text="insulin requirements may be increased, decreased, or unchanged.)">
        <entity id="DDI-DrugBank.d17.s19.e0" charOffset="0-6"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s20" text="Lithium salts">
        <entity id="DDI-DrugBank.d17.s20.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s21" text="(Concurrent use with thiazide diuretics is not recommended, as they may provoke lithium toxicity because of reduced renal clearance.)">
        <entity id="DDI-DrugBank.d17.s21.e0" charOffset="21-38"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d17.s21.e1" charOffset="80-86"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s22" text="Methenamine">
        <entity id="DDI-DrugBank.d17.s22.e0" charOffset="0-10"
            type="drug" text="Methenamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s23" text="(Effectiveness may be decreased when used concurrently with thiazide diuretics because of alkalinization of the urine.)">
        <entity id="DDI-DrugBank.d17.s23.e0" charOffset="60-77"
            type="group" text="thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s24" text="Nonsteroidal anti-inflammatory agents">
        <entity id="DDI-DrugBank.d17.s24.e0" charOffset="0-36"
            type="group" text="Nonsteroidal anti-inflammatory agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s25" text="(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.">
        <entity id="DDI-DrugBank.d17.s25.e0" charOffset="23-55"
            type="group" text="steroidal anti-inflammatory agent"/>
        <entity id="DDI-DrugBank.d17.s25.e1"
            charOffset="127-130;165-173" type="group" text="loop diuretics"/>
        <entity id="DDI-DrugBank.d17.s25.e2"
            charOffset="133-149;165-173" type="group" text="potassium sparing diuretics"/>
        <entity id="DDI-DrugBank.d17.s25.e3" charOffset="156-173"
            type="group" text="thiazide diuretics"/>
        <ddi id="DDI-DrugBank.d17.s25.d0" e1="DDI-DrugBank.d17.s25.e0"
            e2="DDI-DrugBank.d17.s25.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d17.s25.d1" e1="DDI-DrugBank.d17.s25.e0"
            e2="DDI-DrugBank.d17.s25.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d17.s25.d2" e1="DDI-DrugBank.d17.s25.e0"
            e2="DDI-DrugBank.d17.s25.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s26" text="Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)">
        <entity id="DDI-DrugBank.d17.s26.e0" charOffset="16-33"
            type="drug" text="hydroflumethiazide"/>
        <entity id="DDI-DrugBank.d17.s26.e1" charOffset="39-75"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d17.s26.e2" charOffset="182-189"
            type="group" text="diuretic"/>
        <ddi id="DDI-DrugBank.d17.s26.d0" e1="DDI-DrugBank.d17.s26.e0"
            e2="DDI-DrugBank.d17.s26.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s27" text="Norepinephrine">
        <entity id="DDI-DrugBank.d17.s27.e0" charOffset="0-13"
            type="drug" text="Norepinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s28" text="(Thiazides may decrease arterial responsiveness to norepinephrine.">
        <entity id="DDI-DrugBank.d17.s28.e0" charOffset="1-9"
            type="group" text="Thiazides"/>
        <entity id="DDI-DrugBank.d17.s28.e1" charOffset="51-64"
            type="drug" text="norepinephrine"/>
        <ddi id="DDI-DrugBank.d17.s28.d0" e1="DDI-DrugBank.d17.s28.e0"
            e2="DDI-DrugBank.d17.s28.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s29" text="This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.)"/>
    <sentence id="DDI-DrugBank.d17.s30" text="Tubocurarine">
        <entity id="DDI-DrugBank.d17.s30.e0" charOffset="0-11"
            type="drug" text="Tubocurarine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s31" text="(Thiazide drugs may increase the responsiveness to tubocurarine.)">
        <entity id="DDI-DrugBank.d17.s31.e0" charOffset="1-14"
            type="group" text="Thiazide drugs"/>
        <entity id="DDI-DrugBank.d17.s31.e1" charOffset="51-62"
            type="drug" text="tubocurarine"/>
        <ddi id="DDI-DrugBank.d17.s31.d0" e1="DDI-DrugBank.d17.s31.e0"
            e2="DDI-DrugBank.d17.s31.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s32" text="DIAGNOSTIC INTERFERENCE With expected physiologic effects: Blood and urine glucose levels (usually only in patients with a predisposition for glucose intolerance) and Serum bilirubin levels (by displacement from albumin binding) and Serum calcium levels (thiazide diuretics should be discontinued before parathyroid-function tests are carried out) and Serum uric acid levels (may be increased) Serum magnesium, potassium, and sodium levels (may be decreased;">
        <entity id="DDI-DrugBank.d17.s32.e0" charOffset="255-272"
            type="group" text="thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d17.s33" text="serum magnesium levels may increase in uremic patients) Serum protein-bound iodine (PBI) levels (may be decreased) Thiazides should be discontinued before carrying out tests for parathyroid function.">
        <entity id="DDI-DrugBank.d17.s33.e0" charOffset="115-123"
            type="group" text="Thiazides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d26.s0" text="Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.">
        <entity id="DDI-DrugBank.d26.s0.e0" charOffset="25-42"
            type="group" text="narcotic analgesic"/>
        <entity id="DDI-DrugBank.d26.s0.e1" charOffset="54-64"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d26.s0.e2" charOffset="67-80"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d26.s0.e3" charOffset="83-95"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d26.s0.e4" charOffset="98-115"
            type="group" text="sedative-hypnotics"/>
        <entity id="DDI-DrugBank.d26.s0.e5" charOffset="118-142"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d26.s0.e6" charOffset="153-167"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d26.s0.e7" charOffset="180-186"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d26.s0.e8" charOffset="208-215"
            type="brand" text="DILAUDID"/>
        <ddi id="DDI-DrugBank.d26.s0.d0" e1="DDI-DrugBank.d26.s0.e0"
            e2="DDI-DrugBank.d26.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d26.s0.d1" e1="DDI-DrugBank.d26.s0.e1"
            e2="DDI-DrugBank.d26.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d26.s0.d2" e1="DDI-DrugBank.d26.s0.e2"
            e2="DDI-DrugBank.d26.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d26.s0.d3" e1="DDI-DrugBank.d26.s0.e3"
            e2="DDI-DrugBank.d26.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d26.s0.d4" e1="DDI-DrugBank.d26.s0.e4"
            e2="DDI-DrugBank.d26.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d26.s0.d5" e1="DDI-DrugBank.d26.s0.e5"
            e2="DDI-DrugBank.d26.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d26.s0.d6" e1="DDI-DrugBank.d26.s0.e6"
            e2="DDI-DrugBank.d26.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d26.s0.d7" e1="DDI-DrugBank.d26.s0.e7"
            e2="DDI-DrugBank.d26.s0.e8" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d26.s1" text="When such combined therapy is contemplated, the dose of one or both agents should be reduced."/>
    <sentence id="DDI-DrugBank.d418.s0" text="No formal drug interaction studies have been conducted with Cyanokit.">
        <entity id="DDI-DrugBank.d418.s0.e0" charOffset="60-67"
            type="brand" text="Cyanokit"/>
    </sentence>
    <sentence id="DDI-DrugBank.d16.s0" text="Prospective studies on the potential for hydroxyurea to interact with other drugs have not been performed.">
        <entity id="DDI-DrugBank.d16.s0.e0" charOffset="41-51"
            type="drug" text="hydroxyurea"/>
    </sentence>
    <sentence id="DDI-DrugBank.d16.s1" text="Concurrent use of hydroxyurea and other myelosuppressive agents or radiation therapy may increase the likelihood of bone marrow depression or other adverse events.">
        <entity id="DDI-DrugBank.d16.s1.e0" charOffset="18-28"
            type="drug" text="hydroxyurea"/>
    </sentence>
    <sentence id="DDI-DrugBank.d16.s2" text="Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary">
        <entity id="DDI-DrugBank.d16.s2.e0" charOffset="6-16"
            type="drug" text="hydroxyurea"/>
        <entity id="DDI-DrugBank.d16.s2.e1" charOffset="76-96"
            type="group" text="uricosuric medication"/>
        <ddi id="DDI-DrugBank.d16.s2.d0" e1="DDI-DrugBank.d16.s2.e0"
            e2="DDI-DrugBank.d16.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d16.s3" text="."/>
    <sentence id="DDI-DrugBank.d16.s4" text=""/>
    <sentence id="DDI-DrugBank.d308.s0" text="THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.">
        <entity id="DDI-DrugBank.d308.s0.e0" charOffset="27-37"
            type="drug" text="HYDROXYZINE"/>
        <entity id="DDI-DrugBank.d308.s0.e1" charOffset="100-133"
            type="group" text="CENTRAL NERVOUS SYSTEM DEPRESSANTS"/>
        <entity id="DDI-DrugBank.d308.s0.e2" charOffset="143-151"
            type="group" text="NARCOTICS"/>
        <entity id="DDI-DrugBank.d308.s0.e3" charOffset="154-176"
            type="group" text="NON-NARCOTIC ANALGESICS"/>
        <entity id="DDI-DrugBank.d308.s0.e4" charOffset="182-193"
            type="group" text="BARBITURATES"/>
        <ddi id="DDI-DrugBank.d308.s0.d0" e1="DDI-DrugBank.d308.s0.e0"
            e2="DDI-DrugBank.d308.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d308.s0.d1" e1="DDI-DrugBank.d308.s0.e0"
            e2="DDI-DrugBank.d308.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d308.s0.d2" e1="DDI-DrugBank.d308.s0.e0"
            e2="DDI-DrugBank.d308.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d308.s0.d3" e1="DDI-DrugBank.d308.s0.e0"
            e2="DDI-DrugBank.d308.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d308.s1" text="Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.">
        <entity id="DDI-DrugBank.d308.s1.e0" charOffset="15-48"
            type="group" text="central nervous system depressants"/>
        <entity id="DDI-DrugBank.d308.s1.e1" charOffset="86-96"
            type="drug" text="hydroxyzine"/>
        <ddi id="DDI-DrugBank.d308.s1.d0" e1="DDI-DrugBank.d308.s1.e0"
            e2="DDI-DrugBank.d308.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d308.s2" text="Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking Atarax.">
        <entity id="DDI-DrugBank.d308.s2.e0" charOffset="178-183"
            type="brand" text="Atarax"/>
    </sentence>
    <sentence id="DDI-DrugBank.d308.s3" text="Patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effect of alcohol may be increased.">
        <entity id="DDI-DrugBank.d308.s3.e0" charOffset="65-84"
            type="group" text="CNS depressant drugs"/>
        <entity id="DDI-DrugBank.d308.s3.e1" charOffset="120-126"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d142.s0" text="Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.">
        <entity id="DDI-DrugBank.d142.s0.e0" charOffset="76-81"
            type="brand" text="LEVSIN"/>
        <entity id="DDI-DrugBank.d142.s0.e1" charOffset="124-138"
            type="group" text="antimuscarinics"/>
        <entity id="DDI-DrugBank.d142.s0.e2" charOffset="141-150"
            type="drug" text="amantadine"/>
        <entity id="DDI-DrugBank.d142.s0.e3" charOffset="153-163"
            type="drug" text="haloperidol"/>
        <entity id="DDI-DrugBank.d142.s0.e4" charOffset="166-179"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d142.s0.e5" charOffset="182-215"
            type="group" text="monoamine oxidase (MAO) inhibitors"/>
        <entity id="DDI-DrugBank.d142.s0.e6" charOffset="218-242"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d142.s0.e7" charOffset="252-265"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d142.s0.d0" e1="DDI-DrugBank.d142.s0.e0"
            e2="DDI-DrugBank.d142.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d142.s0.d1" e1="DDI-DrugBank.d142.s0.e0"
            e2="DDI-DrugBank.d142.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d142.s0.d2" e1="DDI-DrugBank.d142.s0.e0"
            e2="DDI-DrugBank.d142.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d142.s0.d3" e1="DDI-DrugBank.d142.s0.e0"
            e2="DDI-DrugBank.d142.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d142.s0.d4" e1="DDI-DrugBank.d142.s0.e0"
            e2="DDI-DrugBank.d142.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d142.s0.d5" e1="DDI-DrugBank.d142.s0.e0"
            e2="DDI-DrugBank.d142.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d142.s0.d6" e1="DDI-DrugBank.d142.s0.e0"
            e2="DDI-DrugBank.d142.s0.e7" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d142.s1" text="Antacids may interfere with the absorption of LEVSIN.">
        <entity id="DDI-DrugBank.d142.s1.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d142.s1.e1" charOffset="46-51"
            type="brand" text="LEVSIN"/>
        <ddi id="DDI-DrugBank.d142.s1.d0" e1="DDI-DrugBank.d142.s1.e0"
            e2="DDI-DrugBank.d142.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d142.s2" text="Administer LEVSIN before meals;">
        <entity id="DDI-DrugBank.d142.s2.e0" charOffset="11-16"
            type="brand" text="LEVSIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d142.s3" text="antacids after meals.">
        <entity id="DDI-DrugBank.d142.s3.e0" charOffset="0-7"
            type="group" text="antacids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s0" text="Calcium Supplements/Antacids">
        <entity id="DDI-DrugBank.d440.s0.e0" charOffset="0-6"
            type="drug" text="Calcium"/>
        <entity id="DDI-DrugBank.d440.s0.e1" charOffset="20-27"
            type="group" text="Antacids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s1" text="Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.">
        <entity id="DDI-DrugBank.d440.s1.e0" charOffset="20-26"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d440.s1.e1" charOffset="67-74"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d440.s1.e2" charOffset="77-85"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d440.s1.e3" charOffset="88-91"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d440.s1.e4" charOffset="137-147"
            type="drug" text="Ibandronate"/>
        <ddi id="DDI-DrugBank.d440.s1.d0" e1="DDI-DrugBank.d440.s1.e0"
            e2="DDI-DrugBank.d440.s1.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d440.s1.d1" e1="DDI-DrugBank.d440.s1.e1"
            e2="DDI-DrugBank.d440.s1.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d440.s1.d2" e1="DDI-DrugBank.d440.s1.e2"
            e2="DDI-DrugBank.d440.s1.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d440.s1.d3" e1="DDI-DrugBank.d440.s1.e3"
            e2="DDI-DrugBank.d440.s1.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s2" text="Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).">
        <entity id="DDI-DrugBank.d440.s2.e0" charOffset="0-10"
            type="drug" text="Ibandronate"/>
        <entity id="DDI-DrugBank.d440.s2.e1" charOffset="118-125"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d440.s2.e2" charOffset="143-150"
            type="group" text="vitamins"/>
        <ddi id="DDI-DrugBank.d440.s2.d0" e1="DDI-DrugBank.d440.s2.e0"
            e2="DDI-DrugBank.d440.s2.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d440.s2.d1" e1="DDI-DrugBank.d440.s2.e0"
            e2="DDI-DrugBank.d440.s2.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s3" text="H2 Blockers and Proton Pump Inhibitors (PPIs)">
        <entity id="DDI-DrugBank.d440.s3.e0" charOffset="0-10"
            type="group" text="H2 Blockers"/>
        <entity id="DDI-DrugBank.d440.s3.e1" charOffset="16-37"
            type="group" text="Proton Pump Inhibitors"/>
        <entity id="DDI-DrugBank.d440.s3.e2" charOffset="40-43"
            type="group" text="PPIs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s4" text="Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and PPIs).">
        <entity id="DDI-DrugBank.d440.s4.e0" charOffset="38-48"
            type="drug" text="Ibandronate"/>
        <entity id="DDI-DrugBank.d440.s4.e1" charOffset="136-146"
            type="group" text="H2 blockers"/>
        <entity id="DDI-DrugBank.d440.s4.e2" charOffset="152-155"
            type="group" text="PPIs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s5" text="Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate was similar to that in placebo-treated patients.">
        <entity id="DDI-DrugBank.d440.s5.e0" charOffset="111-121"
            type="drug" text="Ibandronate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s6" text="Similarly, of over 1600 patients enrolled in a study comparing once-monthly with daily dosing regimens of ibandronate, 14% of patients used anti-peptic agents.">
        <entity id="DDI-DrugBank.d440.s6.e0" charOffset="106-116"
            type="drug" text="ibandronate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s7" text="Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate 150 mg once monthly was similar to that in patients treated with Ibandronate 2.5 mg once daily.">
        <entity id="DDI-DrugBank.d440.s7.e0" charOffset="111-121"
            type="drug" text="Ibandronate"/>
        <entity id="DDI-DrugBank.d440.s7.e1" charOffset="188-198"
            type="drug" text="Ibandronate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s8" text="Aspirin/Nonsteroidal Antiinflammatory Drugs (NSAIDs)">
        <entity id="DDI-DrugBank.d440.s8.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d440.s8.e1" charOffset="8-41"
            type="group" text="Nonsteroidal Antiinflammatory Drug"/>
        <entity id="DDI-DrugBank.d440.s8.e2" charOffset="45-50"
            type="group" text="NSAIDs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s9" text="In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 62% of the 2946 patients.">
        <entity id="DDI-DrugBank.d440.s9.e0" charOffset="63-69"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d440.s9.e1" charOffset="75-110"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s10" text="Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).">
        <entity id="DDI-DrugBank.d440.s10.e0" charOffset="6-12"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d440.s10.e1" charOffset="17-21"
            type="group" text="NSAID"/>
        <entity id="DDI-DrugBank.d440.s10.e2" charOffset="110-120"
            type="drug" text="ibandronate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s11" text="Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 39% of the 1602 patients.">
        <entity id="DDI-DrugBank.d440.s11.e0" charOffset="51-57"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d440.s11.e1" charOffset="63-98"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s12" text="The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).">
        <entity id="DDI-DrugBank.d440.s12.e0" charOffset="80-86"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d440.s12.e1" charOffset="91-96"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d440.s12.e2" charOffset="129-139"
            type="drug" text="ibandronate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s13" text="However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.">
        <entity id="DDI-DrugBank.d440.s13.e0" charOffset="15-21"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d440.s13.e1" charOffset="24-29"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d440.s13.e2" charOffset="36-50"
            type="group" text="bisphosphonates"/>
        <entity id="DDI-DrugBank.d440.s13.e3" charOffset="159-165"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d440.s13.e4" charOffset="170-175"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d440.s13.e5" charOffset="182-192"
            type="drug" text="Ibandronate"/>
        <ddi id="DDI-DrugBank.d440.s13.d0" e1="DDI-DrugBank.d440.s13.e3"
            e2="DDI-DrugBank.d440.s13.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d440.s13.d1" e1="DDI-DrugBank.d440.s13.e4"
            e2="DDI-DrugBank.d440.s13.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s14" text="Drug/Laboratory Test Interactions"/>
    <sentence id="DDI-DrugBank.d440.s15" text="Bisphosphonates are known to interfere with the use of bone-imaging agents.">
        <entity id="DDI-DrugBank.d440.s15.e0" charOffset="0-14"
            type="group" text="Bisphosphonates"/>
    </sentence>
    <sentence id="DDI-DrugBank.d440.s16" text="Specific studies with ibandronate have not been performed.">
        <entity id="DDI-DrugBank.d440.s16.e0" charOffset="22-32"
            type="drug" text="ibandronate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d408.s0" text="No formal drug interaction studies have been performed with ZEVALIN.">
        <entity id="DDI-DrugBank.d408.s0.e0" charOffset="60-66"
            type="brand" text="ZEVALIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d408.s1" text="Due to the frequent occurrence of severe and prolonged thrombocytopenia, the potential benefits of medications which interfere with platelet function and/or anticoagulation should be weighed against the potential increased risks of bleeding and hemorrhage."/>
    <sentence id="DDI-DrugBank.d408.s2" text="Patients receiving medications that interfere with platelet function or coagulation should have more frequent laboratory monitoring for thrombocytopenia."/>
    <sentence id="DDI-DrugBank.d408.s3" text="In addition, the transfusion practices for such patients may need to be modified given the increased risk of bleeding."/>
    <sentence id="DDI-DrugBank.d408.s4" text="Patients in clinical studies were prohibited from receiving growth factor treatment for 2 weeks prior to the ZEVALIN therapeutic regimen as well as for 2 weeks following completion of the regimen.">
        <entity id="DDI-DrugBank.d408.s4.e0" charOffset="109-115"
            type="brand" text="ZEVALIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s0" text="Coumarin-Type Anticoagulants: Several short-term controlled studies failed to wshow that ibuprofen significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on coumarin-type anticoagulants.">
        <entity id="DDI-DrugBank.d415.s0.e0" charOffset="0-27"
            type="group" text="Coumarin-Type Anticoagulants"/>
        <entity id="DDI-DrugBank.d415.s0.e1" charOffset="89-97"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d415.s0.e2" charOffset="215-242"
            type="group" text="coumarin-type anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s1" text="However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.">
        <entity id="DDI-DrugBank.d415.s1.e0" charOffset="49-57"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d415.s1.e1" charOffset="69-105"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d415.s1.e2" charOffset="145-172"
            type="group" text="coumarin-type anticoagulants"/>
        <entity id="DDI-DrugBank.d415.s1.e3" charOffset="227-235"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d415.s1.e4" charOffset="252-265"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d415.s1.d0" e1="DDI-DrugBank.d415.s1.e0"
            e2="DDI-DrugBank.d415.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d415.s1.d1" e1="DDI-DrugBank.d415.s1.e1"
            e2="DDI-DrugBank.d415.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d415.s1.d2" e1="DDI-DrugBank.d415.s1.e3"
            e2="DDI-DrugBank.d415.s1.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s2" text="Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.">
        <entity id="DDI-DrugBank.d415.s2.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d415.s2.e1" charOffset="35-41"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d415.s2.e2" charOffset="54-90"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d415.s2.e3" charOffset="103-111"
            type="drug" text="ibuprofen"/>
        <ddi id="DDI-DrugBank.d415.s2.d0" e1="DDI-DrugBank.d415.s2.e1"
            e2="DDI-DrugBank.d415.s2.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d415.s2.d1" e1="DDI-DrugBank.d415.s2.e1"
            e2="DDI-DrugBank.d415.s2.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s3" text="Single dose bioavailability studies in normal volunteers have failed to wshow an effect of aspirin on ibuprofen blood levels.">
        <entity id="DDI-DrugBank.d415.s3.e0" charOffset="91-97"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d415.s3.e1" charOffset="102-110"
            type="drug" text="ibuprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s4" text="Correlative clinical studies have not been performed."/>
    <sentence id="DDI-DrugBank.d415.s5" text="Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.">
        <entity id="DDI-DrugBank.d415.s5.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d415.s5.e1" charOffset="14-22"
            type="drug" text="Ibuprofen"/>
        <entity id="DDI-DrugBank.d415.s5.e2" charOffset="42-77"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d415.s5.e3" charOffset="122-133"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d415.s5.d0" e1="DDI-DrugBank.d415.s5.e1"
            e2="DDI-DrugBank.d415.s5.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d415.s5.d1" e1="DDI-DrugBank.d415.s5.e2"
            e2="DDI-DrugBank.d415.s5.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s6" text="This may indicate that ibuprofen could enhance the toxicity of methotrexate.">
        <entity id="DDI-DrugBank.d415.s6.e0" charOffset="23-31"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d415.s6.e1" charOffset="63-74"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d415.s6.d0" e1="DDI-DrugBank.d415.s6.e0"
            e2="DDI-DrugBank.d415.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s7" text="Caution should be used if ibuprofen is administered concomitantly with methotrexate.">
        <entity id="DDI-DrugBank.d415.s7.e0" charOffset="26-34"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d415.s7.e1" charOffset="71-82"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d415.s7.d0" e1="DDI-DrugBank.d415.s7.e0"
            e2="DDI-DrugBank.d415.s7.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s8" text="H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.">
        <entity id="DDI-DrugBank.d415.s8.e0" charOffset="72-81"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d415.s8.e1" charOffset="86-95"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d415.s8.e2" charOffset="102-110"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d415.s8.e3" charOffset="141-149"
            type="drug" text="ibuprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s9" text="Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.">
        <entity id="DDI-DrugBank.d415.s9.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d415.s9.e1" charOffset="78-86"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d415.s9.e2" charOffset="125-134"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d415.s9.e3" charOffset="140-148"
            type="group" text="thiazides"/>
        <ddi id="DDI-DrugBank.d415.s9.d0" e1="DDI-DrugBank.d415.s9.e1"
            e2="DDI-DrugBank.d415.s9.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d415.s9.d1" e1="DDI-DrugBank.d415.s9.e1"
            e2="DDI-DrugBank.d415.s9.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s10" text="This response has been attributed to inhibition of renal prostaglandin synthesis."/>
    <sentence id="DDI-DrugBank.d415.s11" text="During concomitant therapy with ibuprofen, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.">
        <entity id="DDI-DrugBank.d415.s11.e0" charOffset="32-40"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d415.s11.e1" charOffset="131-138"
            type="group" text="diuretic"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s12" text="Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.">
        <entity id="DDI-DrugBank.d415.s12.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d415.s12.e1" charOffset="9-17"
            type="drug" text="Ibuprofen"/>
        <entity id="DDI-DrugBank.d415.s12.e2" charOffset="51-57"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d415.s12.e3" charOffset="91-97"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d415.s12.d0" e1="DDI-DrugBank.d415.s12.e1"
            e2="DDI-DrugBank.d415.s12.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s13" text="The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration.">
        <entity id="DDI-DrugBank.d415.s13.e0" charOffset="17-23"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d415.s13.e1" charOffset="80-86"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s14" text="This effect has been attributed to inhibition of renal prostaglandin synthesis by ibuprofen.">
        <entity id="DDI-DrugBank.d415.s14.e0" charOffset="82-90"
            type="drug" text="ibuprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s15" text="Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.">
        <entity id="DDI-DrugBank.d415.s15.e0" charOffset="11-19"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d415.s15.e1" charOffset="25-31"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d415.s15.e2" charOffset="115-121"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d415.s15.d0" e1="DDI-DrugBank.d415.s15.e0"
            e2="DDI-DrugBank.d415.s15.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d415.s16" text="(Read circulars for lithium preparation before use of such concurrent therapy).">
        <entity id="DDI-DrugBank.d415.s16.e0" charOffset="20-26"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d68.s0" text="No specific pharmacokinetic or other formal drug interaction studies were conducted."/>
    <sentence id="DDI-DrugBank.d68.s1" text="Digoxin: Supraventricular arrhythmias may mask the cardiotoxicity associated with excessive digoxin levels.">
        <entity id="DDI-DrugBank.d68.s1.e0" charOffset="0-6" type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d68.s1.e1" charOffset="92-98"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d68.s2" text="Therefore, it is advisable to be particularly cautious in patients whose plasma digoxin levels are above or suspected to be above the usual therapeutic range.">
        <entity id="DDI-DrugBank.d68.s2.e0" charOffset="80-86"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d68.s3" text="Coadministration of digoxin did not have effects on either the safety or efficacy of ibutilide in the clinical trials.">
        <entity id="DDI-DrugBank.d68.s3.e0" charOffset="20-26"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d68.s3.e1" charOffset="85-93"
            type="drug" text="ibutilide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d68.s4" text="Calcium channel blocking agents: Coadministration of calcium channel blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.">
        <entity id="DDI-DrugBank.d68.s4.e0" charOffset="0-30"
            type="group" text="Calcium channel blocking agents"/>
        <entity id="DDI-DrugBank.d68.s4.e1" charOffset="53-76"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d68.s4.e2" charOffset="138-146"
            type="drug" text="ibutilide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d68.s5" text="Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.">
        <entity id="DDI-DrugBank.d68.s5.e0" charOffset="0-30"
            type="group" text="Beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d68.s5.e1" charOffset="53-83"
            type="group" text="beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d68.s5.e2" charOffset="145-153"
            type="drug" text="ibutilide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s0" text="General No clinical drug interaction studies were performed."/>
    <sentence id="DDI-DrugBank.d501.s1" text="No evaluation of EXTRANEALs effects on the cytochrome P450 system was conducted.">
        <entity id="DDI-DrugBank.d501.s1.e0" charOffset="17-25"
            type="brand" text="EXTRANEAL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s2" text="As with other dialysis solutions, blood concentrations of dialyzable drugs may be reduced by dialysis.">
        <entity id="DDI-DrugBank.d501.s2.e0" charOffset="14-31"
            type="group" text="dialysis solutions"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s3" text="Dosage adjustment of concomitant medications may be necessary."/>
    <sentence id="DDI-DrugBank.d501.s4" text="In patients using cardiac glycosides (digoxin and others), plasma levels of calcium, potassium and magnesium must be carefully monitored.">
        <entity id="DDI-DrugBank.d501.s4.e0" charOffset="18-35"
            type="group" text="cardiac glycosides"/>
        <entity id="DDI-DrugBank.d501.s4.e1" charOffset="38-44"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s5" text="Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.">
        <entity id="DDI-DrugBank.d501.s5.e0" charOffset="0-6"
            type="drug" text="Insulin"/>
        <entity id="DDI-DrugBank.d501.s5.e1" charOffset="93-101"
            type="brand" text="EXTRANEAL"/>
        <entity id="DDI-DrugBank.d501.s5.e2" charOffset="106-112"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d501.s5.e3" charOffset="158-164"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d501.s5.e4" charOffset="205-211"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d501.s5.e5" charOffset="253-261"
            type="brand" text="EXTRANEAL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s6" text="However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.">
        <entity id="DDI-DrugBank.d501.s6.e0" charOffset="85-93"
            type="brand" text="EXTRANEAL"/>
        <entity id="DDI-DrugBank.d501.s6.e1" charOffset="120-126"
            type="drug" text="insulin"/>
        <ddi id="DDI-DrugBank.d501.s6.d0" e1="DDI-DrugBank.d501.s6.e0"
            e2="DDI-DrugBank.d501.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s7" text="Heparin: No human drug interaction studies with heparin were conducted.">
        <entity id="DDI-DrugBank.d501.s7.e0" charOffset="0-6"
            type="drug" text="Heparin"/>
        <entity id="DDI-DrugBank.d501.s7.e1" charOffset="48-54"
            type="drug" text="heparin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s8" text="In vitro studies demonstrated no evidence of incompatibility of heparin with EXTRANEAL.">
        <entity id="DDI-DrugBank.d501.s8.e0" charOffset="64-70"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d501.s8.e1" charOffset="77-85"
            type="brand" text="EXTRANEAL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s9" text="Antibiotics: No human drug interaction studies with antibiotics were conducted.">
        <entity id="DDI-DrugBank.d501.s9.e0" charOffset="0-10"
            type="group" text="Antibiotics"/>
        <entity id="DDI-DrugBank.d501.s9.e1" charOffset="52-62"
            type="group" text="antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s10" text="In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.">
        <entity id="DDI-DrugBank.d501.s10.e0" charOffset="74-83"
            type="drug" text="vancomycin"/>
        <entity id="DDI-DrugBank.d501.s10.e1" charOffset="86-94"
            type="drug" text="cefazolin"/>
        <entity id="DDI-DrugBank.d501.s10.e2" charOffset="97-106"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d501.s10.e3" charOffset="109-118"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d501.s10.e4" charOffset="135-145"
            type="drug" text="ceftazidime"/>
        <entity id="DDI-DrugBank.d501.s10.e5" charOffset="148-157"
            type="drug" text="gentamicin"/>
        <entity id="DDI-DrugBank.d501.s10.e6" charOffset="164-175"
            type="drug" text="amphotericin"/>
        <entity id="DDI-DrugBank.d501.s10.e7" charOffset="230-240"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d501.s10.e8" charOffset="247-255"
            type="brand" text="EXTRANEAL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s11" text="Drug/Laboratory Test Interactions Blood Glucose Blood glucose measurement must be done with a glucose-specific method to prevent maltose interference with test results."/>
    <sentence id="DDI-DrugBank.d501.s12" text="Since falsely elevated glucose levels have been observed with blood glucose monitoring devices and test strips that use glucose dehydrogenase pyrroloquinolinequinone (GDH PQQ)-based methods, GDH PQQ-based methods should not be used to measure glucose levels in patients administered EXTRANEAL..">
        <entity id="DDI-DrugBank.d501.s12.e0" charOffset="283-291"
            type="brand" text="EXTRANEAL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s13" text="Serum Amylase An apparent decrease in serum amylase activity has been observed in patients administered EXTRANEAL.">
        <entity id="DDI-DrugBank.d501.s13.e0" charOffset="104-112"
            type="brand" text="EXTRANEAL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s14" text="Preliminary investigations indicate that icodextrin and its metabolites interfere with enzymatic-based amylase assays, resulting in inaccurately low values.">
        <entity id="DDI-DrugBank.d501.s14.e0" charOffset="41-50"
            type="drug" text="icodextrin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d501.s15" text="This should be taken into account when evaluating serum amylase levels for diagnosis or monitoring of pancreatitis in patients using EXTRANEAL.">
        <entity id="DDI-DrugBank.d501.s15.e0" charOffset="133-141"
            type="brand" text="EXTRANEAL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d35.s0" text="Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).">
        <entity id="DDI-DrugBank.d35.s0.e0" charOffset="31-33"
            type="drug" text="EPA"/>
        <entity id="DDI-DrugBank.d35.s0.e1" charOffset="51-57"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d35.s0.e2" charOffset="69-105"
            type="group" text="non-steroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d35.s0.e3" charOffset="153-158"
            type="drug" text="ginkgo"/>
        <entity id="DDI-DrugBank.d35.s0.e4" charOffset="161-173"
            type="drug" text="Ginkgo biloba"/>
        <ddi id="DDI-DrugBank.d35.s0.d0" e1="DDI-DrugBank.d35.s0.e0"
            e2="DDI-DrugBank.d35.s0.e1" type="int"/>
        <ddi id="DDI-DrugBank.d35.s0.d1" e1="DDI-DrugBank.d35.s0.e0"
            e2="DDI-DrugBank.d35.s0.e2" type="int"/>
        <ddi id="DDI-DrugBank.d35.s0.d2" e1="DDI-DrugBank.d35.s0.e0"
            e2="DDI-DrugBank.d35.s0.e3" type="int"/>
        <ddi id="DDI-DrugBank.d35.s0.d3" e1="DDI-DrugBank.d35.s0.e0"
            e2="DDI-DrugBank.d35.s0.e4" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d35.s1" text="Such interactions might be manifested by increased susceptibility to bruising, nosebleeds, hemoptysis, hematemesis, hematuria and blood in the stool."/>
    <sentence id="DDI-DrugBank.d35.s2" text="Most who take EPA supplements and the above drugs or herbs do not suffer from these problems and if they occur, they are rare.">
        <entity id="DDI-DrugBank.d35.s2.e0" charOffset="14-16"
            type="drug" text="EPA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d35.s3" text="If they do occur, the EPA dose should be lowered or discontinued.">
        <entity id="DDI-DrugBank.d35.s3.e0" charOffset="22-24"
            type="drug" text="EPA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d35.s4" text="Conflicting results have been reported regarding the effects of EPA supplements on glycemic control in non-diabetics with glucose intolerance, and those with type 2 diabetes.">
        <entity id="DDI-DrugBank.d35.s4.e0" charOffset="64-66"
            type="drug" text="EPA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d35.s5" text="Some early studies indicated that EPA supplements might have detrimental effects in those groups.">
        <entity id="DDI-DrugBank.d35.s5.e0" charOffset="34-36"
            type="drug" text="EPA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d35.s6" text="Recent, better designed studies have not reported these adverse effects."/>
    <sentence id="DDI-DrugBank.d35.s7" text="There is no evidence that EPA supplements have detrimental effects on glucose tolerance, insulin secretion or insulin resistance in non-diabetic subjects.">
        <entity id="DDI-DrugBank.d35.s7.e0" charOffset="26-28"
            type="drug" text="EPA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d35.s8" text="Diabetics should discuss the use of these supplements with their physicians and note if the supplements affect their glycemic control."/>
    <sentence id="DDI-DrugBank.d35.s9" text="Diabetics who take EPA supplements should be monitored by their physicians.">
        <entity id="DDI-DrugBank.d35.s9.e0" charOffset="19-21"
            type="drug" text="EPA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d91.s0" text="Other medicines - Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur."/>
    <sentence id="DDI-DrugBank.d91.s1" text="In these cases, your doctor may want to change the dose, or other precautions may be necessary."/>
    <sentence id="DDI-DrugBank.d91.s2" text="When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.">
        <entity id="DDI-DrugBank.d91.s2.e0" charOffset="19-29"
            type="drug" text="idoxuridine"/>
        <entity id="DDI-DrugBank.d91.s2.e1" charOffset="154-163"
            type="drug" text="boric acid"/>
        <ddi id="DDI-DrugBank.d91.s2.d0" e1="DDI-DrugBank.d91.s2.e0"
            e2="DDI-DrugBank.d91.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d91.s3" text="Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.">
        <entity id="DDI-DrugBank.d91.s3.e0" charOffset="0-9" type="drug" text="Boric acid"/>
        <entity id="DDI-DrugBank.d91.s3.e1" charOffset="33-43"
            type="drug" text="idoxuridine"/>
        <entity id="DDI-DrugBank.d91.s3.e2" charOffset="137-147"
            type="drug" text="idoxuridine"/>
        <ddi id="DDI-DrugBank.d91.s3.d0" e1="DDI-DrugBank.d91.s3.e0"
            e2="DDI-DrugBank.d91.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d515.s0" text="The physician should be alert for possible combined drug actions, desirable or undesirable, involving ifosfamide even though ifosfamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.">
        <entity id="DDI-DrugBank.d515.s0.e0" charOffset="102-111"
            type="drug" text="ifosfamide"/>
        <entity id="DDI-DrugBank.d515.s0.e1" charOffset="125-134"
            type="drug" text="ifosfamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d549.s0" text="In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous iloprost and either nifedipine, diltiazem, or captopril.">
        <entity id="DDI-DrugBank.d549.s0.e0" charOffset="94-101"
            type="drug" text="iloprost"/>
        <entity id="DDI-DrugBank.d549.s0.e1" charOffset="114-123"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d549.s0.e2" charOffset="126-134"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d549.s0.e3" charOffset="140-148"
            type="drug" text="captopril"/>
    </sentence>
    <sentence id="DDI-DrugBank.d549.s1" text="However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.">
        <entity id="DDI-DrugBank.d549.s1.e0" charOffset="9-16"
            type="drug" text="iloprost"/>
        <entity id="DDI-DrugBank.d549.s1.e1" charOffset="74-85"
            type="group" text="vasodilators"/>
        <entity id="DDI-DrugBank.d549.s1.e2" charOffset="91-113"
            type="group" text="antihypertensive agents"/>
        <ddi id="DDI-DrugBank.d549.s1.d0" e1="DDI-DrugBank.d549.s1.e0"
            e2="DDI-DrugBank.d549.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d549.s1.d1" e1="DDI-DrugBank.d549.s1.e0"
            e2="DDI-DrugBank.d549.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d549.s2" text="Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.">
        <entity id="DDI-DrugBank.d549.s2.e0" charOffset="6-13"
            type="drug" text="iloprost"/>
        <entity id="DDI-DrugBank.d549.s2.e1" charOffset="135-148"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d549.s2.d0" e1="DDI-DrugBank.d549.s2.e0"
            e2="DDI-DrugBank.d549.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d549.s3" text="During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.">
        <entity id="DDI-DrugBank.d549.s3.e0" charOffset="24-31"
            type="drug" text="iloprost"/>
        <entity id="DDI-DrugBank.d549.s3.e1" charOffset="60-73"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d549.s3.e2" charOffset="76-84"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d549.s3.e3" charOffset="87-104"
            type="group" text="cardiac glycosides"/>
        <entity id="DDI-DrugBank.d549.s3.e4" charOffset="107-130"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d549.s3.e5" charOffset="133-142"
            type="group" text="analgesics"/>
        <entity id="DDI-DrugBank.d549.s3.e6" charOffset="145-156"
            type="group" text="antipyretics"/>
        <entity id="DDI-DrugBank.d549.s3.e7" charOffset="159-189"
            type="group" text="nonsteroidal antiinflammatories"/>
        <entity id="DDI-DrugBank.d549.s3.e8" charOffset="192-206"
            type="group" text="corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d549.s4" text="Intravenous infusion of iloprost had no effect on the pharmacokinetics of digoxin.">
        <entity id="DDI-DrugBank.d549.s4.e0" charOffset="24-31"
            type="drug" text="iloprost"/>
        <entity id="DDI-DrugBank.d549.s4.e1" charOffset="74-80"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d549.s5" text="Acetylsalicylic acid did not alter the clearance (pharmacokinetics) of iloprost.">
        <entity id="DDI-DrugBank.d549.s5.e0" charOffset="0-19"
            type="drug" text="Acetylsalicylic acid"/>
        <entity id="DDI-DrugBank.d549.s5.e1" charOffset="71-78"
            type="drug" text="iloprost"/>
    </sentence>
    <sentence id="DDI-DrugBank.d549.s6" text="Although clinical studies have not been conducted, in vitro studies of iloprost indicate that no relevant inhibition of cytochrome P450 drug metabolism would be expected.">
        <entity id="DDI-DrugBank.d549.s6.e0" charOffset="71-78"
            type="drug" text="iloprost"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s0" text="Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).">
        <entity id="DDI-DrugBank.d115.s0.e0" charOffset="21-28"
            type="drug" text="imatinib"/>
        <entity id="DDI-DrugBank.d115.s0.e1" charOffset="76-83"
            type="drug" text="imatinib"/>
        <entity id="DDI-DrugBank.d115.s0.e2" charOffset="150-156"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s0.e3" charOffset="202-213"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d115.s0.e4" charOffset="216-227"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d115.s0.e5" charOffset="230-241"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d115.s0.e6" charOffset="244-257"
            type="drug" text="clarithromycin"/>
        <ddi id="DDI-DrugBank.d115.s0.d0" e1="DDI-DrugBank.d115.s0.e2"
            e2="DDI-DrugBank.d115.s0.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d115.s0.d1" e1="DDI-DrugBank.d115.s0.e2"
            e2="DDI-DrugBank.d115.s0.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d115.s0.d2" e1="DDI-DrugBank.d115.s0.e2"
            e2="DDI-DrugBank.d115.s0.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d115.s0.d3" e1="DDI-DrugBank.d115.s0.e2"
            e2="DDI-DrugBank.d115.s0.e6" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s1" text="Substances that inhibit the cytochrome P450 isoenzyme (CYP3A4) activity may decrease metabolism and increase imatinib concentrations.">
        <entity id="DDI-DrugBank.d115.s1.e0" charOffset="109-116"
            type="drug" text="imatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s2" text="There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).">
        <entity id="DDI-DrugBank.d115.s2.e0" charOffset="47-54"
            type="drug" text="imatinib"/>
        <entity id="DDI-DrugBank.d115.s2.e1" charOffset="61-67"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s2.e2" charOffset="92-103"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d115.s2.d0" e1="DDI-DrugBank.d115.s2.e1"
            e2="DDI-DrugBank.d115.s2.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s3" text="Drugs that may decrease imatinib plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease imatinib plasma concentrations.">
        <entity id="DDI-DrugBank.d115.s3.e0" charOffset="24-31"
            type="drug" text="imatinib"/>
        <entity id="DDI-DrugBank.d115.s3.e1" charOffset="141-148"
            type="drug" text="imatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s4" text="Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital or St.">
        <entity id="DDI-DrugBank.d115.s4.e0" charOffset="41-53"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d115.s4.e1" charOffset="56-64"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d115.s4.e2" charOffset="67-79"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d115.s4.e3" charOffset="82-89"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d115.s4.e4" charOffset="92-104"
            type="drug" text="phenobarbital"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s5" text="Johns Wort) may significantly reduce exposure to Gleevec.">
        <entity id="DDI-DrugBank.d115.s5.e0" charOffset="49-55"
            type="brand" text="Gleevec"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s6" text="Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).">
        <entity id="DDI-DrugBank.d115.s6.e0" charOffset="58-65"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d115.s6.e1" charOffset="96-102"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s6.e2" charOffset="115-121"
            type="brand" text="Gleevec"/>
        <ddi id="DDI-DrugBank.d115.s6.d0" e1="DDI-DrugBank.d115.s6.e0"
            e2="DDI-DrugBank.d115.s6.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s7" text="In patients where rifampin or other CYP3A4 inducers are indicated, alternative therapeutic agents with less enzyme induction potential should be considered.">
        <entity id="DDI-DrugBank.d115.s7.e0" charOffset="18-25"
            type="drug" text="rifampin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s8" text="Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.">
        <entity id="DDI-DrugBank.d115.s8.e0" charOffset="58-64"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s8.e1" charOffset="66-72"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s8.e2" charOffset="109-119"
            type="drug" text="simvastatin"/>
        <entity id="DDI-DrugBank.d115.s8.e3" charOffset="213-219"
            type="brand" text="Gleevec"/>
        <ddi id="DDI-DrugBank.d115.s8.d0" e1="DDI-DrugBank.d115.s8.e1"
            e2="DDI-DrugBank.d115.s8.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s9" text="Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).">
        <entity id="DDI-DrugBank.d115.s9.e0" charOffset="53-59"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s9.e1" charOffset="129-140"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d115.s9.e2" charOffset="145-152"
            type="drug" text="pimozide"/>
        <ddi id="DDI-DrugBank.d115.s9.d0" e1="DDI-DrugBank.d115.s9.e0"
            e2="DDI-DrugBank.d115.s9.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d115.s9.d1" e1="DDI-DrugBank.d115.s9.e0"
            e2="DDI-DrugBank.d115.s9.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s10" text="Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).">
        <entity id="DDI-DrugBank.d115.s10.e0" charOffset="0-6"
            type="brand" text="Gleevec"/>
        <entity id="DDI-DrugBank.d115.s10.e1" charOffset="92-106"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d115.s10.e2" charOffset="109-148"
            type="group" text="dihydropyridine calcium channel blockers"/>
        <entity id="DDI-DrugBank.d115.s10.e3" charOffset="159-186"
            type="group" text="HMG-CoA reductase inhibitors"/>
        <ddi id="DDI-DrugBank.d115.s10.d0" e1="DDI-DrugBank.d115.s10.e0"
            e2="DDI-DrugBank.d115.s10.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d115.s10.d1" e1="DDI-DrugBank.d115.s10.e0"
            e2="DDI-DrugBank.d115.s10.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d115.s10.d2" e1="DDI-DrugBank.d115.s10.e0"
            e2="DDI-DrugBank.d115.s10.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s11" text="Because warfarin is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard heparin.">
        <entity id="DDI-DrugBank.d115.s11.e0" charOffset="8-15"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d115.s11.e1" charOffset="139-145"
            type="drug" text="heparin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s12" text="in vitro, Gleevec inhibits the cytochrome P450 isoenzyme CYP2D6 activity at similar concentrations that affect CYP3A4 activity.">
        <entity id="DDI-DrugBank.d115.s12.e0" charOffset="10-16"
            type="brand" text="Gleevec"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s13" text="Systemic exposure to substrates of CYP2D6 is expected to be increased when coadministered with Gleevec."/>
    <sentence id="DDI-DrugBank.d115.s14" text="No specific studies have been performed and caution is recommended."/>
    <sentence id="DDI-DrugBank.d115.s15" text="in vitro, Gleevec inhibits acetaminophen O-glucuronidation (Ki value of 58.5  M) at therapeutic levels.">
        <entity id="DDI-DrugBank.d115.s15.e0" charOffset="10-16"
            type="brand" text="Gleevec"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s16" text="Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.">
        <entity id="DDI-DrugBank.d115.s16.e0" charOffset="21-33"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d115.s16.e1" charOffset="88-94"
            type="brand" text="Gleevec"/>
        <ddi id="DDI-DrugBank.d115.s16.d0" e1="DDI-DrugBank.d115.s16.e0"
            e2="DDI-DrugBank.d115.s16.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d115.s17" text="No specific studies in humans have been performed and caution is recommended."/>
    <sentence id="DDI-DrugBank.d115.s18" text=""/>
    <sentence id="DDI-DrugBank.d77.s0" text="In occasional susceptible patients or in those receiving anticholinergic drugs (including antiparkinsonism agents) in addition, the atropine-like effects may become more pronounced (e.g., paralytic ileus).">
        <entity id="DDI-DrugBank.d77.s0.e0" charOffset="57-77"
            type="group" text="anticholinergic drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s1" text="Close supervision and careful adjustment of dosage is required when this drug is administered concomitantly with anticholinergic drugs.">
        <entity id="DDI-DrugBank.d77.s1.e0" charOffset="113-133"
            type="group" text="anticholinergic drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s2" text="Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.">
        <entity id="DDI-DrugBank.d77.s2.e0" charOffset="38-50"
            type="group" text="decongestants"/>
        <entity id="DDI-DrugBank.d77.s2.e1" charOffset="62-72"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d77.s2.e2" charOffset="92-112"
            type="group" text="sympathomimetic amine"/>
        <entity id="DDI-DrugBank.d77.s2.e3" charOffset="121-131"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d77.s2.e4" charOffset="134-147"
            type="drug" text="norepinephrine"/>
        <entity id="DDI-DrugBank.d77.s2.e5" charOffset="183-207"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d77.s2.d0" e1="DDI-DrugBank.d77.s2.e0"
            e2="DDI-DrugBank.d77.s2.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d77.s2.d1" e1="DDI-DrugBank.d77.s2.e1"
            e2="DDI-DrugBank.d77.s2.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d77.s2.d2" e1="DDI-DrugBank.d77.s2.e2"
            e2="DDI-DrugBank.d77.s2.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d77.s2.d3" e1="DDI-DrugBank.d77.s2.e3"
            e2="DDI-DrugBank.d77.s2.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d77.s2.d4" e1="DDI-DrugBank.d77.s2.e4"
            e2="DDI-DrugBank.d77.s2.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s3" text="Caution should be exercised when imipramine hydrochloride is used with agents that lower blood pressure.">
        <entity id="DDI-DrugBank.d77.s3.e0" charOffset="33-56"
            type="drug" text="imipramine hydrochloride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s4" text="Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.">
        <entity id="DDI-DrugBank.d77.s4.e0" charOffset="0-23"
            type="drug" text="Imipramine hydrochloride"/>
        <entity id="DDI-DrugBank.d77.s4.e1" charOffset="55-74"
            type="group" text="CNS depressant drugs"/>
        <ddi id="DDI-DrugBank.d77.s4.d0" e1="DDI-DrugBank.d77.s4.e0"
            e2="DDI-DrugBank.d77.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s5" text="The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.">
        <entity id="DDI-DrugBank.d77.s5.e0" charOffset="28-37"
            type="drug" text="imipramine"/>
        <entity id="DDI-DrugBank.d77.s5.e1" charOffset="127-136"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d77.s5.e2" charOffset="139-148"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d77.s5.e3" charOffset="228-239"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d77.s5.e4" charOffset="242-250"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d77.s5.e5" charOffset="286-295"
            type="drug" text="imipramine"/>
        <ddi id="DDI-DrugBank.d77.s5.d0" e1="DDI-DrugBank.d77.s5.e0"
            e2="DDI-DrugBank.d77.s5.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d77.s5.d1" e1="DDI-DrugBank.d77.s5.e0"
            e2="DDI-DrugBank.d77.s5.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d77.s5.d2" e1="DDI-DrugBank.d77.s5.e0"
            e2="DDI-DrugBank.d77.s5.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d77.s5.d3" e1="DDI-DrugBank.d77.s5.e0"
            e2="DDI-DrugBank.d77.s5.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s6" text="Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers);"/>
    <sentence id="DDI-DrugBank.d77.s7" text="reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available."/>
    <sentence id="DDI-DrugBank.d77.s8" text="Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.">
        <entity id="DDI-DrugBank.d77.s8.e0" charOffset="69-93"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d77.s8.e1" charOffset="96-99"
            type="group" text="TCAs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s9" text="Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).">
        <entity id="DDI-DrugBank.d77.s9.e0" charOffset="163-165"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s10" text="In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o."/>
    <sentence id="DDI-DrugBank.d77.s11" text="metabolizers."/>
    <sentence id="DDI-DrugBank.d77.s12" text="An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.">
        <entity id="DDI-DrugBank.d77.s12.e0" charOffset="47-49"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s13" text="The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;">
        <entity id="DDI-DrugBank.d77.s13.e0" charOffset="96-104"
            type="drug" text="quinidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s14" text="cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).">
        <entity id="DDI-DrugBank.d77.s14.e0" charOffset="0-9"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d77.s14.e1" charOffset="66-80"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d77.s14.e2" charOffset="83-96"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d77.s14.e3" charOffset="107-129"
            type="group" text="Type 1C antiarrhythmics"/>
        <entity id="DDI-DrugBank.d77.s14.e4" charOffset="131-141"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d77.s14.e5" charOffset="147-156"
            type="drug" text="flecainide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s15" text="While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.">
        <entity id="DDI-DrugBank.d77.s15.e0" charOffset="14-52"
            type="group" text="selective serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d77.s15.e1" charOffset="55-59"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d77.s15.e2" charOffset="70-79"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d77.s15.e3" charOffset="82-91"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d77.s15.e4" charOffset="98-107"
            type="drug" text="paroxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s16" text="The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.">
        <entity id="DDI-DrugBank.d77.s16.e0" charOffset="20-23"
            type="group" text="SSRI"/>
        <entity id="DDI-DrugBank.d77.s16.e1" charOffset="25-27"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d77.s16.e2" charOffset="142-145"
            type="group" text="SSRI"/>
        <ddi id="DDI-DrugBank.d77.s16.d0" e1="DDI-DrugBank.d77.s16.e0"
            e2="DDI-DrugBank.d77.s16.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s17" text="Nevertheless, caution is indicated in the co-administration of TCA5 with any of the SSRIs and also in switching from one class to the other.">
        <entity id="DDI-DrugBank.d77.s17.e0" charOffset="84-88"
            type="group" text="SSRIs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s18" text="Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).">
        <entity id="DDI-DrugBank.d77.s18.e0" charOffset="120-129"
            type="drug" text="fluoxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s19" text="Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.">
        <entity id="DDI-DrugBank.d77.s19.e0" charOffset="19-43"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d77.s19.e1" charOffset="156-179"
            type="group" text="tricyclic antidepressant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s20" text="Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of tricyclic antidepressant may be required.">
        <entity id="DDI-DrugBank.d77.s20.e0" charOffset="97-120"
            type="group" text="tricyclic antidepressant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d77.s21" text="It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.">
        <entity id="DDI-DrugBank.d77.s21.e0" charOffset="27-29"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d77.s21.e1" charOffset="56-58"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d555.s0" text="No information available"/>
    <sentence id="DDI-DrugBank.d555.s1" text="."/>
    <sentence id="DDI-DrugBank.d555.s2" text=""/>
    <sentence id="DDI-DrugBank.d97.s0" text="Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4.">
        <entity id="DDI-DrugBank.d97.s0.e0" charOffset="0-8" type="drug" text="Indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s1" text="Coadministration of CRIXIVAN and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects.">
        <entity id="DDI-DrugBank.d97.s1.e0" charOffset="20-27"
            type="brand" text="CRIXIVAN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s2" text="Indinavir is metabolized by CYP3A4.">
        <entity id="DDI-DrugBank.d97.s2.e0" charOffset="0-8" type="drug" text="Indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s3" text="Drugs that induce CYP3A4 activity would be expected to increase the clearance of indinavir, resulting in lowered plasma concentrations of indinavir.">
        <entity id="DDI-DrugBank.d97.s3.e0" charOffset="81-89"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d97.s3.e1" charOffset="138-146"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s4" text="Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.">
        <entity id="DDI-DrugBank.d97.s4.e0" charOffset="20-27"
            type="brand" text="CRIXIVAN"/>
        <entity id="DDI-DrugBank.d97.s4.e1" charOffset="95-103"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d97.s4.e2" charOffset="158-166"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s5" text="Table 8"/>
    <sentence id="DDI-DrugBank.d97.s6" text="Drugs That Should Not Be Coadministered with CRIXIVAN">
        <entity id="DDI-DrugBank.d97.s6.e0" charOffset="45-52"
            type="brand" text="CRIXIVAN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s7" text="Drug Class: Drug Name Clinical Comment"/>
    <sentence id="DDI-DrugBank.d97.s8" text="Antiarrhythmics: amiodarone">
        <entity id="DDI-DrugBank.d97.s8.e0" charOffset="0-14"
            type="group" text="Antiarrhythmics"/>
        <entity id="DDI-DrugBank.d97.s8.e1" charOffset="17-26"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s9" text="CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias."/>
    <sentence id="DDI-DrugBank.d97.s10" text="Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine">
        <entity id="DDI-DrugBank.d97.s10.e0" charOffset="19-35"
            type="drug" text="dihydroergotamine"/>
        <entity id="DDI-DrugBank.d97.s10.e1" charOffset="38-47"
            type="drug" text="ergonovine"/>
        <entity id="DDI-DrugBank.d97.s10.e2" charOffset="50-59"
            type="drug" text="ergotamine"/>
        <entity id="DDI-DrugBank.d97.s10.e3" charOffset="62-77"
            type="drug" text="methylergonovine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s11" text="CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."/>
    <sentence id="DDI-DrugBank.d97.s12" text="Sedative/hypnotics: midazolam, triazolam">
        <entity id="DDI-DrugBank.d97.s12.e0" charOffset="0-7"
            type="group" text="Sedative"/>
        <entity id="DDI-DrugBank.d97.s12.e1" charOffset="9-17"
            type="group" text="hypnotics"/>
        <entity id="DDI-DrugBank.d97.s12.e2" charOffset="20-28"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d97.s12.e3" charOffset="31-39"
            type="drug" text="triazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s13" text="CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."/>
    <sentence id="DDI-DrugBank.d97.s14" text="GI motility agents: cisapride">
        <entity id="DDI-DrugBank.d97.s14.e0" charOffset="20-28"
            type="drug" text="cisapride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s15" text="CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias."/>
    <sentence id="DDI-DrugBank.d97.s16" text="Neuroleptic: pimozide">
        <entity id="DDI-DrugBank.d97.s16.e0" charOffset="0-10"
            type="group" text="Neuroleptic"/>
        <entity id="DDI-DrugBank.d97.s16.e1" charOffset="13-20"
            type="drug" text="pimozide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s17" text="CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias."/>
    <sentence id="DDI-DrugBank.d97.s18" text="Herbal products: St. John s wort (Hypericum perforatum)"/>
    <sentence id="DDI-DrugBank.d97.s19" text="May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors.">
        <entity id="DDI-DrugBank.d97.s19.e0" charOffset="66-73"
            type="brand" text="CRIXIVAN"/>
        <entity id="DDI-DrugBank.d97.s19.e1" charOffset="94-112"
            type="group" text="protease inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s20" text="Antimycobacterial: rifampin">
        <entity id="DDI-DrugBank.d97.s20.e0" charOffset="0-16"
            type="group" text="Antimycobacterial"/>
        <entity id="DDI-DrugBank.d97.s20.e1" charOffset="19-26"
            type="drug" text="rifampin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s21" text="May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors or other coadministered antiretroviral agents.">
        <entity id="DDI-DrugBank.d97.s21.e0" charOffset="66-73"
            type="brand" text="CRIXIVAN"/>
        <entity id="DDI-DrugBank.d97.s21.e1" charOffset="94-112"
            type="group" text="protease inhibitors"/>
        <entity id="DDI-DrugBank.d97.s21.e2" charOffset="138-158"
            type="group" text="antiretroviral agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s22" text="HMG-CoA Reductase inhibitors: lovastatin, simvastatin">
        <entity id="DDI-DrugBank.d97.s22.e0" charOffset="0-27"
            type="group" text="HMG-CoA Reductase inhibitors"/>
        <entity id="DDI-DrugBank.d97.s22.e1" charOffset="30-39"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d97.s22.e2" charOffset="42-52"
            type="drug" text="simvastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s23" text="Potential for serious reactions such as risk of myopathy including rhabdomyolysis."/>
    <sentence id="DDI-DrugBank.d97.s24" text="Protease inhibitor: atazanavir">
        <entity id="DDI-DrugBank.d97.s24.e0" charOffset="0-17"
            type="group" text="Protease inhibitor"/>
        <entity id="DDI-DrugBank.d97.s24.e1" charOffset="20-29"
            type="drug" text="atazanavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s25" text="Both CRIXIVAN and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia.">
        <entity id="DDI-DrugBank.d97.s25.e0" charOffset="5-12"
            type="brand" text="CRIXIVAN"/>
        <entity id="DDI-DrugBank.d97.s25.e1" charOffset="18-27"
            type="drug" text="atazanavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s26" text="Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.">
        <entity id="DDI-DrugBank.d97.s26.e0" charOffset="74-81"
            type="brand" text="CRIXIVAN"/>
        <entity id="DDI-DrugBank.d97.s26.e1" charOffset="87-96"
            type="drug" text="atazanavir"/>
        <ddi id="DDI-DrugBank.d97.s26.d0" e1="DDI-DrugBank.d97.s26.e0"
            e2="DDI-DrugBank.d97.s26.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s27" text="Table 9"/>
    <sentence id="DDI-DrugBank.d97.s28" text="Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction"/>
    <sentence id="DDI-DrugBank.d97.s29" text="Drug Name"/>
    <sentence id="DDI-DrugBank.d97.s30" text="Effect"/>
    <sentence id="DDI-DrugBank.d97.s31" text="Clinical Comment"/>
    <sentence id="DDI-DrugBank.d97.s32" text="HIV Antiviral Agents">
        <entity id="DDI-DrugBank.d97.s32.e0" charOffset="0-19"
            type="group" text="HIV Antiviral Agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s33" text="Delavirdine">
        <entity id="DDI-DrugBank.d97.s33.e0" charOffset="0-10"
            type="drug" text="Delavirdine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s34" text="indinavir concentration">
        <entity id="DDI-DrugBank.d97.s34.e0" charOffset="0-8"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s35" text="Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.">
        <entity id="DDI-DrugBank.d97.s35.e0" charOffset="18-25"
            type="brand" text="CRIXIVAN"/>
        <entity id="DDI-DrugBank.d97.s35.e1" charOffset="84-94"
            type="drug" text="delavirdine"/>
        <ddi id="DDI-DrugBank.d97.s35.d0" e1="DDI-DrugBank.d97.s35.e0"
            e2="DDI-DrugBank.d97.s35.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s36" text="Didanosine">
        <entity id="DDI-DrugBank.d97.s36.e0" charOffset="0-9"
            type="drug" text="Didanosine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s37" text="Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.">
        <entity id="DDI-DrugBank.d97.s37.e0" charOffset="0-8"
            type="drug" text="Indinavir"/>
        <entity id="DDI-DrugBank.d97.s37.e1" charOffset="14-23"
            type="drug" text="didanosine"/>
        <ddi id="DDI-DrugBank.d97.s37.d0" e1="DDI-DrugBank.d97.s37.e0"
            e2="DDI-DrugBank.d97.s37.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s38" text="Efavirenz">
        <entity id="DDI-DrugBank.d97.s38.e0" charOffset="0-8"
            type="drug" text="Efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s39" text="indinavir concentration">
        <entity id="DDI-DrugBank.d97.s39.e0" charOffset="0-8"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s40" text="The optimal dose of indinavir, when given in combination with efavirenz, is not known.">
        <entity id="DDI-DrugBank.d97.s40.e0" charOffset="20-28"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d97.s40.e1" charOffset="62-70"
            type="drug" text="efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s41" text="Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.">
        <entity id="DDI-DrugBank.d97.s41.e0" charOffset="15-23"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d97.s41.e1" charOffset="93-101"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d97.s41.e2" charOffset="121-129"
            type="drug" text="efavirenz"/>
        <ddi id="DDI-DrugBank.d97.s41.d0" e1="DDI-DrugBank.d97.s41.e1"
            e2="DDI-DrugBank.d97.s41.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s42" text="Nelfinavir">
        <entity id="DDI-DrugBank.d97.s42.e0" charOffset="0-9"
            type="drug" text="Nelfinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s43" text="indinavir concentration">
        <entity id="DDI-DrugBank.d97.s43.e0" charOffset="0-8"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s44" text="The appropriate doses for this combination, with respect to efficacy and safety, have not been established."/>
    <sentence id="DDI-DrugBank.d97.s45" text="Nevirapine">
        <entity id="DDI-DrugBank.d97.s45.e0" charOffset="0-9"
            type="drug" text="Nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s46" text="indinavir concentration">
        <entity id="DDI-DrugBank.d97.s46.e0" charOffset="0-8"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s47" text="Indinavir concentrations may be decreased in the presence of nevirapine.">
        <entity id="DDI-DrugBank.d97.s47.e0" charOffset="0-8"
            type="drug" text="Indinavir"/>
        <entity id="DDI-DrugBank.d97.s47.e1" charOffset="61-70"
            type="drug" text="nevirapine"/>
        <ddi id="DDI-DrugBank.d97.s47.d0" e1="DDI-DrugBank.d97.s47.e0"
            e2="DDI-DrugBank.d97.s47.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s48" text="The appropriate doses for this combination, with respect to efficacy and safety, have not been established."/>
    <sentence id="DDI-DrugBank.d97.s49" text="Ritonavir">
        <entity id="DDI-DrugBank.d97.s49.e0" charOffset="0-8"
            type="drug" text="Ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s50" text="indinavir concentration   ritonavir concentration">
        <entity id="DDI-DrugBank.d97.s50.e0" charOffset="0-8"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d97.s50.e1" charOffset="26-34"
            type="drug" text="ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s51" text="The appropriate doses for this combination, with respect to efficacy and safety, have not been established."/>
    <sentence id="DDI-DrugBank.d97.s52" text="Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.">
        <entity id="DDI-DrugBank.d97.s52.e0" charOffset="104-112"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d97.s52.e1" charOffset="134-142"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d97.s52.e2" charOffset="165-172"
            type="brand" text="CRIXIVAN"/>
        <ddi id="DDI-DrugBank.d97.s52.d0" e1="DDI-DrugBank.d97.s52.e0"
            e2="DDI-DrugBank.d97.s52.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s53" text="Saquinavir">
        <entity id="DDI-DrugBank.d97.s53.e0" charOffset="0-9"
            type="drug" text="Saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s54" text="saquinavir concentration">
        <entity id="DDI-DrugBank.d97.s54.e0" charOffset="0-9"
            type="drug" text="saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s55" text="The appropriate doses for this combination, with respect to efficacy and safety, have not been established."/>
    <sentence id="DDI-DrugBank.d97.s56" text="Other Agents"/>
    <sentence id="DDI-DrugBank.d97.s57" text="Antiarrhythmics: bepridil, lidocaine (systemic) and quinidine">
        <entity id="DDI-DrugBank.d97.s57.e0" charOffset="0-14"
            type="group" text="Antiarrhythmics"/>
        <entity id="DDI-DrugBank.d97.s57.e1" charOffset="17-24"
            type="drug" text="bepridil"/>
        <entity id="DDI-DrugBank.d97.s57.e2" charOffset="27-35"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d97.s57.e3" charOffset="52-60"
            type="drug" text="quinidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s58" text="antiarrhythmic agents concentration">
        <entity id="DDI-DrugBank.d97.s58.e0" charOffset="0-20"
            type="group" text="antiarrhythmic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s59" text="Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.">
        <entity id="DDI-DrugBank.d97.s59.e0" charOffset="81-95"
            type="group" text="antiarrhythmics"/>
        <entity id="DDI-DrugBank.d97.s59.e1" charOffset="122-129"
            type="brand" text="CRIXIVAN"/>
        <ddi id="DDI-DrugBank.d97.s59.d0" e1="DDI-DrugBank.d97.s59.e0"
            e2="DDI-DrugBank.d97.s59.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s60" text="Anticonvulsants: carbamazepine, phenobarbital, phenytoin">
        <entity id="DDI-DrugBank.d97.s60.e0" charOffset="0-14"
            type="group" text="Anticonvulsants"/>
        <entity id="DDI-DrugBank.d97.s60.e1" charOffset="17-29"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d97.s60.e2" charOffset="32-44"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d97.s60.e3" charOffset="47-55"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s61" text="indinavir concentration">
        <entity id="DDI-DrugBank.d97.s61.e0" charOffset="0-8"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s62" text="Use with caution."/>
    <sentence id="DDI-DrugBank.d97.s63" text="CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.">
        <entity id="DDI-DrugBank.d97.s63.e0" charOffset="0-7"
            type="brand" text="CRIXIVAN"/>
        <entity id="DDI-DrugBank.d97.s63.e1" charOffset="47-55"
            type="drug" text="indinavir"/>
        <ddi id="DDI-DrugBank.d97.s63.d0" e1="DDI-DrugBank.d97.s63.e0"
            e2="DDI-DrugBank.d97.s63.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s64" text="Calcium Channel Blockers, Dihydropyridine: e.g., felodipine, nifedipine, nicardipine">
        <entity id="DDI-DrugBank.d97.s64.e0" charOffset="0-23"
            type="group" text="Calcium Channel Blockers"/>
        <entity id="DDI-DrugBank.d97.s64.e1" charOffset="26-40"
            type="group" text="Dihydropyridine"/>
        <entity id="DDI-DrugBank.d97.s64.e2" charOffset="49-58"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d97.s64.e3" charOffset="61-70"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d97.s64.e4" charOffset="73-83"
            type="drug" text="nicardipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s65" text="dihydropyridine calcium channel blockers concentration">
        <entity id="DDI-DrugBank.d97.s65.e0" charOffset="0-39"
            type="group" text="dihydropyridine calcium channel blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s66" text="Caution is warranted and clinical monitoring of patients is recommended."/>
    <sentence id="DDI-DrugBank.d97.s67" text="Clarithromycin">
        <entity id="DDI-DrugBank.d97.s67.e0" charOffset="0-13"
            type="drug" text="Clarithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s68" text="clarithromycin concentration   indinavir concentration">
        <entity id="DDI-DrugBank.d97.s68.e0" charOffset="0-13"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d97.s68.e1" charOffset="31-39"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s69" text="The appropriate doses for this combination, with respect to efficacy and safety, have not been established."/>
    <sentence id="DDI-DrugBank.d97.s70" text="HMG-CoA Reductase Inhibitor: atorvastatin">
        <entity id="DDI-DrugBank.d97.s70.e0" charOffset="0-26"
            type="group" text="HMG-CoA Reductase Inhibitor"/>
        <entity id="DDI-DrugBank.d97.s70.e1" charOffset="29-40"
            type="drug" text="atorvastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s71" text="atorvastatin concentration">
        <entity id="DDI-DrugBank.d97.s71.e0" charOffset="0-11"
            type="drug" text="atorvastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s72" text="Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.">
        <entity id="DDI-DrugBank.d97.s72.e0" charOffset="28-39"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d97.s72.e1" charOffset="78-105"
            type="group" text="HMG-CoA reductase inhibitors"/>
        <entity id="DDI-DrugBank.d97.s72.e2" charOffset="161-171"
            type="drug" text="pravastatin"/>
        <entity id="DDI-DrugBank.d97.s72.e3" charOffset="174-184"
            type="drug" text="fluvastatin"/>
        <entity id="DDI-DrugBank.d97.s72.e4" charOffset="190-201"
            type="drug" text="rosuvastatin"/>
        <entity id="DDI-DrugBank.d97.s72.e5" charOffset="223-230"
            type="brand" text="CRIXIVAN"/>
        <ddi id="DDI-DrugBank.d97.s72.d0" e1="DDI-DrugBank.d97.s72.e0"
            e2="DDI-DrugBank.d97.s72.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d97.s72.d1" e1="DDI-DrugBank.d97.s72.e1"
            e2="DDI-DrugBank.d97.s72.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s73" text="Immunosuppressants: cyclosporine, tacrolimus, sirolimus">
        <entity id="DDI-DrugBank.d97.s73.e0" charOffset="0-17"
            type="group" text="Immunosuppressants"/>
        <entity id="DDI-DrugBank.d97.s73.e1" charOffset="20-31"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d97.s73.e2" charOffset="34-43"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d97.s73.e3" charOffset="46-54"
            type="drug" text="sirolimus"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s74" text="immunosuppressant agents concentration">
        <entity id="DDI-DrugBank.d97.s74.e0" charOffset="0-23"
            type="group" text="immunosuppressant agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s75" text="Plasma concentrations may be increased by CRIXIVAN.">
        <entity id="DDI-DrugBank.d97.s75.e0" charOffset="42-49"
            type="brand" text="CRIXIVAN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s76" text="Itraconazole">
        <entity id="DDI-DrugBank.d97.s76.e0" charOffset="0-11"
            type="drug" text="Itraconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s77" text="indinavir concentration">
        <entity id="DDI-DrugBank.d97.s77.e0" charOffset="0-8"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s78" text="Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.">
        <entity id="DDI-DrugBank.d97.s78.e0" charOffset="18-25"
            type="brand" text="CRIXIVAN"/>
        <entity id="DDI-DrugBank.d97.s78.e1" charOffset="85-96"
            type="drug" text="itraconazole"/>
        <ddi id="DDI-DrugBank.d97.s78.d0" e1="DDI-DrugBank.d97.s78.e0"
            e2="DDI-DrugBank.d97.s78.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s79" text="Ketoconazole">
        <entity id="DDI-DrugBank.d97.s79.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s80" text="indinavir concentration">
        <entity id="DDI-DrugBank.d97.s80.e0" charOffset="0-8"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s81" text="Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered.">
        <entity id="DDI-DrugBank.d97.s81.e0" charOffset="18-25"
            type="brand" text="CRIXIVAN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s82" text="Rifabutin">
        <entity id="DDI-DrugBank.d97.s82.e0" charOffset="0-8"
            type="drug" text="Rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s83" text="indinavir concentration   rifabutin concentration">
        <entity id="DDI-DrugBank.d97.s83.e0" charOffset="0-8"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d97.s83.e1" charOffset="26-34"
            type="drug" text="rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s84" text="Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.">
        <entity id="DDI-DrugBank.d97.s84.e0" charOffset="18-26"
            type="drug" text="rifabutin"/>
        <entity id="DDI-DrugBank.d97.s84.e1" charOffset="77-84"
            type="brand" text="CRIXIVAN"/>
        <entity id="DDI-DrugBank.d97.s84.e2" charOffset="156-164"
            type="drug" text="rifabutin"/>
        <entity id="DDI-DrugBank.d97.s84.e3" charOffset="170-177"
            type="brand" text="CRIXIVAN"/>
        <ddi id="DDI-DrugBank.d97.s84.d0" e1="DDI-DrugBank.d97.s84.e2"
            e2="DDI-DrugBank.d97.s84.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s85" text="Sildenafil">
        <entity id="DDI-DrugBank.d97.s85.e0" charOffset="0-9"
            type="drug" text="Sildenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s86" text="sildenafil concentration">
        <entity id="DDI-DrugBank.d97.s86.e0" charOffset="0-9"
            type="drug" text="sildenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s87" text="Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.">
        <entity id="DDI-DrugBank.d97.s87.e0" charOffset="0-9"
            type="drug" text="Sildenafil"/>
        <entity id="DDI-DrugBank.d97.s87.e1" charOffset="108-116"
            type="drug" text="indinavir"/>
        <ddi id="DDI-DrugBank.d97.s87.d0" e1="DDI-DrugBank.d97.s87.e0"
            e2="DDI-DrugBank.d97.s87.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s88" text="Tadalafil">
        <entity id="DDI-DrugBank.d97.s88.e0" charOffset="0-8"
            type="drug" text="Tadalafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s89" text="tadalafil concentration">
        <entity id="DDI-DrugBank.d97.s89.e0" charOffset="0-8"
            type="drug" text="tadalafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s90" text="Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.">
        <entity id="DDI-DrugBank.d97.s90.e0" charOffset="0-8"
            type="drug" text="Tadalafil"/>
        <entity id="DDI-DrugBank.d97.s90.e1" charOffset="107-115"
            type="drug" text="indinavir"/>
        <ddi id="DDI-DrugBank.d97.s90.d0" e1="DDI-DrugBank.d97.s90.e0"
            e2="DDI-DrugBank.d97.s90.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s91" text="Vardenafil">
        <entity id="DDI-DrugBank.d97.s91.e0" charOffset="0-9"
            type="drug" text="Vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s92" text="vardenafil concentration">
        <entity id="DDI-DrugBank.d97.s92.e0" charOffset="0-9"
            type="drug" text="vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s93" text="Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.">
        <entity id="DDI-DrugBank.d97.s93.e0" charOffset="0-9"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d97.s93.e1" charOffset="108-116"
            type="drug" text="indinavir"/>
        <ddi id="DDI-DrugBank.d97.s93.d0" e1="DDI-DrugBank.d97.s93.e0"
            e2="DDI-DrugBank.d97.s93.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d97.s94" text="Note:"/>
    <sentence id="DDI-DrugBank.d97.s95" text="= increase;"/>
    <sentence id="DDI-DrugBank.d97.s96" text="= decrease"/>
    <sentence id="DDI-DrugBank.d97.s97" text=""/>
    <sentence id="DDI-DrugBank.d82.s0" text="In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.">
        <entity id="DDI-DrugBank.d82.s0.e0" charOffset="31-42"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d82.s0.e1" charOffset="67-76"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d82.s0.e2" charOffset="157-168"
            type="drug" text="indomethacin"/>
        <ddi id="DDI-DrugBank.d82.s0.d0" e1="DDI-DrugBank.d82.s0.e1"
            e2="DDI-DrugBank.d82.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s1" text="In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.">
        <entity id="DDI-DrugBank.d82.s1.e0" charOffset="34-40"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s1.e1" charOffset="46-55"
            type="drug" text="diflunisal"/>
        <ddi id="DDI-DrugBank.d82.s1.d0" e1="DDI-DrugBank.d82.s1.e0"
            e2="DDI-DrugBank.d82.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s2" text="Therefore, diflunisal and INDOCIN should not be used concomitantly.">
        <entity id="DDI-DrugBank.d82.s2.e0" charOffset="11-20"
            type="drug" text="diflunisal"/>
        <entity id="DDI-DrugBank.d82.s2.e1" charOffset="26-32"
            type="brand" text="INDOCIN"/>
        <ddi id="DDI-DrugBank.d82.s2.d0" e1="DDI-DrugBank.d82.s2.e0"
            e2="DDI-DrugBank.d82.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s3" text="In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.">
        <entity id="DDI-DrugBank.d82.s3.e0" charOffset="97-103"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d82.s3.e1" charOffset="123-134"
            type="drug" text="indomethacin"/>
        <ddi id="DDI-DrugBank.d82.s3.d0" e1="DDI-DrugBank.d82.s3.e0"
            e2="DDI-DrugBank.d82.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s4" text="The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.">
        <entity id="DDI-DrugBank.d82.s4.e0" charOffset="23-29"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s4.e1" charOffset="42-47"
            type="group" text="NSAIDs"/>
        <ddi id="DDI-DrugBank.d82.s4.d0" e1="DDI-DrugBank.d82.s4.e0"
            e2="DDI-DrugBank.d82.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s5" text="Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants.">
        <entity id="DDI-DrugBank.d82.s5.e0" charOffset="33-39"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s5.e1" charOffset="96-109"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s6" text="However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.">
        <entity id="DDI-DrugBank.d82.s6.e0" charOffset="45-51"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s6.e1" charOffset="95-107"
            type="group" text="anticoagulant"/>
        <ddi id="DDI-DrugBank.d82.s6.d0" e1="DDI-DrugBank.d82.s6.e0"
            e2="DDI-DrugBank.d82.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s7" text="In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.">
        <entity id="DDI-DrugBank.d82.s7.e0" charOffset="99-112"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d82.s7.e1" charOffset="118-124"
            type="brand" text="INDOCIN"/>
        <ddi id="DDI-DrugBank.d82.s7.d0" e1="DDI-DrugBank.d82.s7.e0"
            e2="DDI-DrugBank.d82.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s8" text="Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.">
        <entity id="DDI-DrugBank.d82.s8.e0" charOffset="33-39"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s8.e1" charOffset="45-58"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d82.s8.d0" e1="DDI-DrugBank.d82.s8.e0"
            e2="DDI-DrugBank.d82.s8.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s9" text="When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.">
        <entity id="DDI-DrugBank.d82.s9.e0" charOffset="5-11"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s9.e1" charOffset="44-53"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d82.s9.e2" charOffset="77-88"
            type="drug" text="indomethacin"/>
        <ddi id="DDI-DrugBank.d82.s9.d0" e1="DDI-DrugBank.d82.s9.e0"
            e2="DDI-DrugBank.d82.s9.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s10" text="Therefore, a lower total daily dosage of INDOCIN may produce a satisfactory therapeutic effect.">
        <entity id="DDI-DrugBank.d82.s10.e0" charOffset="41-47"
            type="brand" text="INDOCIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s11" text="When increases in the dose of INDOCIN are made, they should be made carefully and in small increments.">
        <entity id="DDI-DrugBank.d82.s11.e0" charOffset="30-36"
            type="brand" text="INDOCIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s12" text="Caution should be used if INDOCIN is administered simultaneously with methotrexate.">
        <entity id="DDI-DrugBank.d82.s12.e0" charOffset="26-32"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s12.e1" charOffset="70-81"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d82.s12.d0" e1="DDI-DrugBank.d82.s12.e0"
            e2="DDI-DrugBank.d82.s12.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s13" text="INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.">
        <entity id="DDI-DrugBank.d82.s13.e0" charOffset="0-6"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s13.e1" charOffset="63-74"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d82.s13.d0" e1="DDI-DrugBank.d82.s13.e0"
            e2="DDI-DrugBank.d82.s13.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s14" text="Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.">
        <entity id="DDI-DrugBank.d82.s14.e0" charOffset="18-54"
            type="group" text="non-steroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d82.s14.e1" charOffset="75-86"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d82.s14.e2" charOffset="128-139"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d82.s14.d0" e1="DDI-DrugBank.d82.s14.e0"
            e2="DDI-DrugBank.d82.s14.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s15" text="NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.">
        <entity id="DDI-DrugBank.d82.s15.e0" charOffset="0-5"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d82.s15.e1" charOffset="54-65"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d82.s15.d0" e1="DDI-DrugBank.d82.s15.e0"
            e2="DDI-DrugBank.d82.s15.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s16" text="Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.">
        <entity id="DDI-DrugBank.d82.s16.e0" charOffset="9-15"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s16.e1" charOffset="81-87"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d82.s16.e2" charOffset="112-118"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d82.s16.e3" charOffset="199-205"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d82.s16.d0" e1="DDI-DrugBank.d82.s16.e0"
            e2="DDI-DrugBank.d82.s16.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s17" text="This effect has been attributed to inhibition of prostaglandin synthesis."/>
    <sentence id="DDI-DrugBank.d82.s18" text="As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.">
        <entity id="DDI-DrugBank.d82.s18.e0" charOffset="23-29"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s18.e1" charOffset="35-41"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d82.s18.e2" charOffset="122-128"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d82.s18.d0" e1="DDI-DrugBank.d82.s18.e0"
            e2="DDI-DrugBank.d82.s18.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s19" text="(Read circulars for lithium preparations before use of such concomitant therapy.)">
        <entity id="DDI-DrugBank.d82.s19.e0" charOffset="20-26"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s20" text="In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment.">
        <entity id="DDI-DrugBank.d82.s20.e0" charOffset="47-53"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s21" text="INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.">
        <entity id="DDI-DrugBank.d82.s21.e0" charOffset="0-6"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s21.e1" charOffset="33-39"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d82.s21.e2" charOffset="124-130"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d82.s21.d0" e1="DDI-DrugBank.d82.s21.e0"
            e2="DDI-DrugBank.d82.s21.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s22" text="Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.">
        <entity id="DDI-DrugBank.d82.s22.e0" charOffset="16-22"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s22.e1" charOffset="28-34"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d82.s22.e2" charOffset="66-72"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d82.s22.d0" e1="DDI-DrugBank.d82.s22.e0"
            e2="DDI-DrugBank.d82.s22.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s23" text="In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.">
        <entity id="DDI-DrugBank.d82.s23.e0" charOffset="40-46"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s23.e1"
            charOffset="118-121;156-164" type="group" text="loop diuretics"/>
        <entity id="DDI-DrugBank.d82.s23.e2"
            charOffset="124-140;156-164" type="group" text="potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d82.s23.e3" charOffset="147-164"
            type="group" text="thiazide diuretics"/>
        <ddi id="DDI-DrugBank.d82.s23.d0" e1="DDI-DrugBank.d82.s23.e0"
            e2="DDI-DrugBank.d82.s23.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d82.s23.d1" e1="DDI-DrugBank.d82.s23.e0"
            e2="DDI-DrugBank.d82.s23.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d82.s23.d2" e1="DDI-DrugBank.d82.s23.e0"
            e2="DDI-DrugBank.d82.s23.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s24" text="Therefore, when INDOCIN and INDOCIN.">
        <entity id="DDI-DrugBank.d82.s24.e0" charOffset="16-22"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s24.e1" charOffset="28-34"
            type="brand" text="INDOCIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s25" text="(Indomethacin) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.">
        <entity id="DDI-DrugBank.d82.s25.e0" charOffset="1-12"
            type="drug" text="Indomethacin"/>
        <entity id="DDI-DrugBank.d82.s25.e1" charOffset="15-23"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d82.s25.e2" charOffset="130-137"
            type="group" text="diuretic"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s26" text="INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion.">
        <entity id="DDI-DrugBank.d82.s26.e0" charOffset="0-6"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s26.e1" charOffset="97-106"
            type="drug" text="furosemide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s27" text="These facts should be considered when evaluating plasma renin activity in hypertensive patients."/>
    <sentence id="DDI-DrugBank.d82.s28" text="It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.">
        <entity id="DDI-DrugBank.d82.s28.e0" charOffset="42-52"
            type="drug" text="triamterene"/>
        <entity id="DDI-DrugBank.d82.s28.e1" charOffset="83-89"
            type="brand" text="INDOCIN"/>
        <ddi id="DDI-DrugBank.d82.s28.d0" e1="DDI-DrugBank.d82.s28.e0"
            e2="DDI-DrugBank.d82.s28.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s29" text="INDOCIN and triamterene should not be administered together.">
        <entity id="DDI-DrugBank.d82.s29.e0" charOffset="0-6"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s29.e1" charOffset="12-22"
            type="drug" text="triamterene"/>
        <ddi id="DDI-DrugBank.d82.s29.d0" e1="DDI-DrugBank.d82.s29.e0"
            e2="DDI-DrugBank.d82.s29.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s30" text="INDOCIN and potassium-sparing diuretics each may be associated with increased serum potassium levels.">
        <entity id="DDI-DrugBank.d82.s30.e0" charOffset="0-6"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s30.e1" charOffset="12-38"
            type="group" text="potassium-sparing diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s31" text="The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.">
        <entity id="DDI-DrugBank.d82.s31.e0" charOffset="25-31"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s31.e1" charOffset="37-63"
            type="group" text="potassium-sparing diuretics"/>
        <ddi id="DDI-DrugBank.d82.s31.d0" e1="DDI-DrugBank.d82.s31.e0"
            e2="DDI-DrugBank.d82.s31.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s32" text="Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.">
        <entity id="DDI-DrugBank.d82.s32.e0" charOffset="37-45"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d82.s32.e1" charOffset="152-158"
            type="brand" text="INDOCIN"/>
        <ddi id="DDI-DrugBank.d82.s32.d0" e1="DDI-DrugBank.d82.s32.e0"
            e2="DDI-DrugBank.d82.s32.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s33" text="Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.">
        <entity id="DDI-DrugBank.d82.s33.e0" charOffset="43-75"
            type="group" text="beta-adrenoceptor blocking agents"/>
        <entity id="DDI-DrugBank.d82.s33.e1" charOffset="80-115"
            type="group" text="non-steroidal antiinflammatory drugs"/>
        <entity id="DDI-DrugBank.d82.s33.e2" charOffset="127-133"
            type="brand" text="INDOCIN"/>
        <ddi id="DDI-DrugBank.d82.s33.d0" e1="DDI-DrugBank.d82.s33.e0"
            e2="DDI-DrugBank.d82.s33.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d82.s33.d1" e1="DDI-DrugBank.d82.s33.e0"
            e2="DDI-DrugBank.d82.s33.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s34" text="Therefore, when using these blocking agents to treat hypertension, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained."/>
    <sentence id="DDI-DrugBank.d82.s35" text="INDOCIN can reduce the antihypertensive effects of captopril and losartan.">
        <entity id="DDI-DrugBank.d82.s35.e0" charOffset="0-6"
            type="brand" text="INDOCIN"/>
        <entity id="DDI-DrugBank.d82.s35.e1" charOffset="51-59"
            type="drug" text="captopril"/>
        <entity id="DDI-DrugBank.d82.s35.e2" charOffset="65-72"
            type="drug" text="losartan"/>
        <ddi id="DDI-DrugBank.d82.s35.d0" e1="DDI-DrugBank.d82.s35.e0"
            e2="DDI-DrugBank.d82.s35.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d82.s35.d1" e1="DDI-DrugBank.d82.s35.e0"
            e2="DDI-DrugBank.d82.s35.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s36" text="False-negative results in the dexamethasone suppression test (DST) in patients being treated with INDOCIN have been reported.">
        <entity id="DDI-DrugBank.d82.s36.e0" charOffset="98-104"
            type="brand" text="INDOCIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s37" text="Thus, results of the DST should be interpreted with caution in these patients."/>
    <sentence id="DDI-DrugBank.d45.s0" text="Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.">
        <entity id="DDI-DrugBank.d45.s0.e0" charOffset="29-38"
            type="drug" text="etanercept"/>
        <entity id="DDI-DrugBank.d45.s0.e1" charOffset="74-81"
            type="drug" text="anakinra"/>
        <entity id="DDI-DrugBank.d45.s0.e2" charOffset="87-110"
            type="group" text="interleukin-1 antagonist"/>
        <ddi id="DDI-DrugBank.d45.s0.d0" e1="DDI-DrugBank.d45.s0.e0"
            e2="DDI-DrugBank.d45.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s1" text="Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.">
        <entity id="DDI-DrugBank.d45.s1.e0" charOffset="6-25"
            type="group" text="TNFa-blocking agents"/>
        <entity id="DDI-DrugBank.d45.s1.e1" charOffset="38-45"
            type="brand" text="REMICADE"/>
        <entity id="DDI-DrugBank.d45.s1.e2" charOffset="73-80"
            type="drug" text="anakinra"/>
        <ddi id="DDI-DrugBank.d45.s1.d0" e1="DDI-DrugBank.d45.s1.e0"
            e2="DDI-DrugBank.d45.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d45.s1.d1" e1="DDI-DrugBank.d45.s1.e1"
            e2="DDI-DrugBank.d45.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s2" text="Specific drug interaction studies, including interactions with MTX, have not been conducted.">
        <entity id="DDI-DrugBank.d45.s2.e0" charOffset="63-65"
            type="drug" text="MTX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s3" text="The majority of patients in rheumatoid arthritis or Crohn s disease clinical studies received one or more concomitant medications."/>
    <sentence id="DDI-DrugBank.d45.s4" text="In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics.">
        <entity id="DDI-DrugBank.d45.s4.e0" charOffset="57-59"
            type="drug" text="MTX"/>
        <entity id="DDI-DrugBank.d45.s4.e1" charOffset="66-102"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d45.s4.e2" charOffset="105-114"
            type="drug" text="folic acid"/>
        <entity id="DDI-DrugBank.d45.s4.e3" charOffset="117-131"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d45.s4.e4" charOffset="140-148"
            type="group" text="narcotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s5" text="Concomitant Crohn s disease medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates.">
        <entity id="DDI-DrugBank.d45.s5.e0" charOffset="45-55"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d45.s5.e1" charOffset="58-67"
            type="group" text="antivirals"/>
        <entity id="DDI-DrugBank.d45.s5.e2" charOffset="70-84"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d45.s5.e3" charOffset="87-90"
            type="drug" text="6-MP"/>
        <entity id="DDI-DrugBank.d45.s5.e4" charOffset="92-94"
            type="drug" text="AZA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s6" text="In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal anti-inflammatory agents, folic acid and corticosteroids.">
        <entity id="DDI-DrugBank.d45.s6.e0" charOffset="73-75"
            type="drug" text="MTX"/>
        <entity id="DDI-DrugBank.d45.s6.e1" charOffset="126-162"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d45.s6.e2" charOffset="165-174"
            type="drug" text="folic acid"/>
        <entity id="DDI-DrugBank.d45.s6.e3" charOffset="180-194"
            type="group" text="corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s7" text="Patients with Crohn s disease who received immunosuppressants tended to experience fewer infusion reactions compared to patients on no immunosuppressants.">
        <entity id="DDI-DrugBank.d45.s7.e0" charOffset="43-60"
            type="group" text="immunosuppressants"/>
        <entity id="DDI-DrugBank.d45.s7.e1" charOffset="135-152"
            type="group" text="immunosuppressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s8" text="Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.">
        <entity id="DDI-DrugBank.d45.s8.e0" charOffset="6-15"
            type="drug" text="infliximab"/>
        <entity id="DDI-DrugBank.d45.s8.e1" charOffset="136-150"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d45.s8.e2" charOffset="153-163"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d45.s8.e3" charOffset="166-178"
            type="drug" text="metronidazole"/>
        <entity id="DDI-DrugBank.d45.s8.e4" charOffset="183-195"
            type="drug" text="ciprofloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d527.s0" text="A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.">
        <entity id="DDI-DrugBank.d527.s0.e0" charOffset="65-71"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d527.s1" text="The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.">
        <entity id="DDI-DrugBank.d527.s1.e0" charOffset="157-170"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d527.s1.e1" charOffset="173-184"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d527.s1.e2" charOffset="187-194"
            type="group" text="fibrates"/>
        <entity id="DDI-DrugBank.d527.s1.e3" charOffset="197-206"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d527.s1.e4" charOffset="209-222"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d527.s1.e5" charOffset="225-236"
            type="drug" text="propoxyphene"/>
        <entity id="DDI-DrugBank.d527.s1.e6" charOffset="239-249"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d527.s1.e7" charOffset="252-270"
            type="group" text="somatostatin analog"/>
        <entity id="DDI-DrugBank.d527.s1.e8" charOffset="279-288"
            type="drug" text="octreotide"/>
        <entity id="DDI-DrugBank.d527.s1.e9" charOffset="292-314"
            type="group" text="sulfonamide antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d527.s2" text="The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).">
        <entity id="DDI-DrugBank.d527.s2.e0" charOffset="94-100"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d527.s2.e1" charOffset="103-117"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d527.s2.e2" charOffset="120-126"
            type="drug" text="danazol"/>
        <entity id="DDI-DrugBank.d527.s2.e3" charOffset="129-137"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d527.s2.e4" charOffset="140-161"
            type="group" text="sympathomimetic agents"/>
        <entity id="DDI-DrugBank.d527.s2.e5" charOffset="170-180"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d527.s2.e6" charOffset="183-191"
            type="drug" text="albuterol"/>
        <entity id="DDI-DrugBank.d527.s2.e7" charOffset="194-204"
            type="drug" text="terbutaline"/>
        <entity id="DDI-DrugBank.d527.s2.e8" charOffset="208-216"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d527.s2.e9" charOffset="219-243"
            type="group" text="phenothiazine derivatives"/>
        <entity id="DDI-DrugBank.d527.s2.e10" charOffset="246-255"
            type="drug" text="somatropin"/>
        <entity id="DDI-DrugBank.d527.s2.e11" charOffset="258-273"
            type="group" text="thyroid hormones"/>
        <entity id="DDI-DrugBank.d527.s2.e12" charOffset="276-284"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d527.s2.e13" charOffset="287-298"
            type="group" text="progestogens"/>
        <entity id="DDI-DrugBank.d527.s2.e14" charOffset="315-328"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d527.s3" text="Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.">
        <entity id="DDI-DrugBank.d527.s3.e0" charOffset="0-12"
            type="group" text="Beta-blockers"/>
        <entity id="DDI-DrugBank.d527.s3.e1" charOffset="15-23"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d527.s3.e2" charOffset="26-32"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d527.s3.e3" charOffset="45-51"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d527.s3.e4" charOffset="122-128"
            type="drug" text="insulin"/>
        <ddi id="DDI-DrugBank.d527.s3.d0" e1="DDI-DrugBank.d527.s3.e0"
            e2="DDI-DrugBank.d527.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d527.s3.d1" e1="DDI-DrugBank.d527.s3.e1"
            e2="DDI-DrugBank.d527.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d527.s3.d2" e1="DDI-DrugBank.d527.s3.e2"
            e2="DDI-DrugBank.d527.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d527.s3.d3" e1="DDI-DrugBank.d527.s3.e3"
            e2="DDI-DrugBank.d527.s3.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d527.s4" text="Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.">
        <entity id="DDI-DrugBank.d527.s4.e0" charOffset="0-10"
            type="drug" text="Pentamidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d527.s5" text="In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.">
        <entity id="DDI-DrugBank.d527.s5.e0" charOffset="77-89"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d527.s5.e1" charOffset="92-100"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d527.s5.e2" charOffset="103-114"
            type="drug" text="guanethidine"/>
        <entity id="DDI-DrugBank.d527.s5.e3" charOffset="121-129"
            type="drug" text="reserpine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s0" text="A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.">
        <entity id="DDI-DrugBank.d313.s0.e0" charOffset="65-71"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s1" text="The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.">
        <entity id="DDI-DrugBank.d313.s1.e0" charOffset="134-154"
            type="group" text="antidiabetic products"/>
        <entity id="DDI-DrugBank.d313.s1.e1" charOffset="157-170"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d313.s1.e2" charOffset="173-184"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d313.s1.e3" charOffset="187-194"
            type="group" text="fibrates"/>
        <entity id="DDI-DrugBank.d313.s1.e4" charOffset="197-206"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d313.s1.e5" charOffset="209-242"
            type="group" text="monoamine oxidase (MAO) inhibitors"/>
        <entity id="DDI-DrugBank.d313.s1.e6" charOffset="245-256"
            type="drug" text="propoxyphene"/>
        <entity id="DDI-DrugBank.d313.s1.e7" charOffset="259-269"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d313.s1.e8" charOffset="272-290"
            type="group" text="somatostatin analog"/>
        <entity id="DDI-DrugBank.d313.s1.e9" charOffset="299-308"
            type="drug" text="octreotide"/>
        <entity id="DDI-DrugBank.d313.s1.e10" charOffset="312-334"
            type="group" text="sulfonamide antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s2" text="The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).">
        <entity id="DDI-DrugBank.d313.s2.e0" charOffset="92-106"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d313.s2.e1" charOffset="109-114"
            type="drug" text="niacin"/>
        <entity id="DDI-DrugBank.d313.s2.e2" charOffset="117-123"
            type="drug" text="danazol"/>
        <entity id="DDI-DrugBank.d313.s2.e3" charOffset="126-134"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d313.s2.e4" charOffset="137-158"
            type="group" text="sympathomimetic agents"/>
        <entity id="DDI-DrugBank.d313.s2.e5" charOffset="167-177"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d313.s2.e6" charOffset="180-189"
            type="drug" text="salbutamol"/>
        <entity id="DDI-DrugBank.d313.s2.e7" charOffset="192-202"
            type="drug" text="terbutaline"/>
        <entity id="DDI-DrugBank.d313.s2.e8" charOffset="206-214"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d313.s2.e9" charOffset="217-241"
            type="group" text="phenothiazine derivatives"/>
        <entity id="DDI-DrugBank.d313.s2.e10" charOffset="244-253"
            type="drug" text="somatropin"/>
        <entity id="DDI-DrugBank.d313.s2.e11" charOffset="256-271"
            type="group" text="thyroid hormones"/>
        <entity id="DDI-DrugBank.d313.s2.e12" charOffset="274-282"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d313.s2.e13" charOffset="285-296"
            type="group" text="progestogens"/>
        <entity id="DDI-DrugBank.d313.s2.e14" charOffset="313-326"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s3" text="Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.">
        <entity id="DDI-DrugBank.d313.s3.e0" charOffset="0-12"
            type="group" text="Beta-blockers"/>
        <entity id="DDI-DrugBank.d313.s3.e1" charOffset="15-23"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d313.s3.e2" charOffset="26-32"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d313.s3.e3" charOffset="45-51"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d313.s3.e4" charOffset="122-128"
            type="drug" text="insulin"/>
        <ddi id="DDI-DrugBank.d313.s3.d0" e1="DDI-DrugBank.d313.s3.e0"
            e2="DDI-DrugBank.d313.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d313.s3.d1" e1="DDI-DrugBank.d313.s3.e1"
            e2="DDI-DrugBank.d313.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d313.s3.d2" e1="DDI-DrugBank.d313.s3.e2"
            e2="DDI-DrugBank.d313.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d313.s3.d3" e1="DDI-DrugBank.d313.s3.e3"
            e2="DDI-DrugBank.d313.s3.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s4" text="Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.">
        <entity id="DDI-DrugBank.d313.s4.e0" charOffset="0-10"
            type="drug" text="Pentamidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s5" text="In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.">
        <entity id="DDI-DrugBank.d313.s5.e0" charOffset="77-89"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d313.s5.e1" charOffset="92-100"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d313.s5.e2" charOffset="103-114"
            type="drug" text="guanethidine"/>
        <entity id="DDI-DrugBank.d313.s5.e3" charOffset="121-129"
            type="drug" text="reserpine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s6" text="Mixing of Insulins">
        <entity id="DDI-DrugBank.d313.s6.e0" charOffset="10-17"
            type="group" text="Insulins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s7" text="A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.">
        <entity id="DDI-DrugBank.d313.s7.e0" charOffset="76-82"
            type="brand" text="NovoLog"/>
        <entity id="DDI-DrugBank.d313.s7.e1" charOffset="89-105"
            type="drug" text="NPH human insulin"/>
        <entity id="DDI-DrugBank.d313.s7.e2" charOffset="191-197"
            type="brand" text="NovoLog"/>
        <entity id="DDI-DrugBank.d313.s7.e3" charOffset="259-265"
            type="brand" text="NovoLog"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s8" text="If NovoLog is mixed with NPH human insulin, NovoLog should be drawn into the syringe first.">
        <entity id="DDI-DrugBank.d313.s8.e0" charOffset="3-9"
            type="brand" text="NovoLog"/>
        <entity id="DDI-DrugBank.d313.s8.e1" charOffset="25-41"
            type="drug" text="NPH human insulin"/>
        <entity id="DDI-DrugBank.d313.s8.e2" charOffset="44-50"
            type="brand" text="NovoLog"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s9" text="The injection should be made immediately after mixing."/>
    <sentence id="DDI-DrugBank.d313.s10" text="Because there are no data on the compatibility of NovoLog and crystalline zinc insulin preparations, NovoLog should not be mixed with these preparations.">
        <entity id="DDI-DrugBank.d313.s10.e0" charOffset="50-56"
            type="brand" text="NovoLog"/>
        <entity id="DDI-DrugBank.d313.s10.e1" charOffset="74-85"
            type="drug" text="zinc insulin"/>
        <entity id="DDI-DrugBank.d313.s10.e2" charOffset="101-107"
            type="brand" text="NovoLog"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s11" text="The effects of mixing NovoLog with insulins of animal source or insulin preparations produced by other manufacturers have not been studied .">
        <entity id="DDI-DrugBank.d313.s11.e0" charOffset="22-28"
            type="brand" text="NovoLog"/>
        <entity id="DDI-DrugBank.d313.s11.e1" charOffset="35-42"
            type="group" text="insulins"/>
        <entity id="DDI-DrugBank.d313.s11.e2" charOffset="64-70"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d313.s12" text="Mixtures should not be administered intravenously."/>
    <sentence id="DDI-DrugBank.d313.s13" text="When used in external subcutaneous infusion pumps for insulin, NovoLog should not be mixed with any other insulins or diluent.">
        <entity id="DDI-DrugBank.d313.s13.e0" charOffset="54-60"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d313.s13.e1" charOffset="63-69"
            type="brand" text="NovoLog"/>
        <entity id="DDI-DrugBank.d313.s13.e2" charOffset="106-113"
            type="group" text="insulins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d433.s0" text="No formal drug interaction studies have been conducted with Rebif .">
        <entity id="DDI-DrugBank.d433.s0.e0" charOffset="60-64"
            type="brand" text="Rebif"/>
    </sentence>
    <sentence id="DDI-DrugBank.d433.s1" text="Due to its potential to cause neutropenia and lymphopenia, proper monitoring of patients is required if Rebif  is given in combination with myelosuppressive agents.">
        <entity id="DDI-DrugBank.d433.s1.e0" charOffset="104-108"
            type="brand" text="Rebif"/>
    </sentence>
    <sentence id="DDI-DrugBank.d433.s2" text="Also, the potential for hepatic injury should be considered when Rebif  is used in combination with other products associated with hepatic injury, or when new agents are added to the regimen of patients already on Rebif .">
        <entity id="DDI-DrugBank.d433.s2.e0" charOffset="65-69"
            type="brand" text="Rebif"/>
        <entity id="DDI-DrugBank.d433.s2.e1" charOffset="214-218"
            type="brand" text="Rebif"/>
    </sentence>
    <sentence id="DDI-DrugBank.d10.s0" text="Interactions between Betaseron and other drugs have not been fully evaluated.">
        <entity id="DDI-DrugBank.d10.s0.e0" charOffset="21-29"
            type="brand" text="Betaseron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d10.s1" text="Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.">
        <entity id="DDI-DrugBank.d10.s1.e0" charOffset="93-106"
            type="group" text="corticosteroid"/>
        <entity id="DDI-DrugBank.d10.s1.e1" charOffset="111-114"
            type="drug" text="ACTH"/>
        <entity id="DDI-DrugBank.d10.s1.e2" charOffset="219-227"
            type="brand" text="Betaseron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d10.s2" text="Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.">
        <entity id="DDI-DrugBank.d10.s2.e0" charOffset="0-8"
            type="brand" text="Betaseron"/>
        <entity id="DDI-DrugBank.d10.s2.e1" charOffset="128-137"
            type="drug" text="antipyrine"/>
        <entity id="DDI-DrugBank.d10.s2.e2" charOffset="211-219"
            type="brand" text="Betaseron"/>
        <ddi id="DDI-DrugBank.d10.s2.d0" e1="DDI-DrugBank.d10.s2.e0"
            e2="DDI-DrugBank.d10.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d51.s0" text="ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, and steroids, commonly used in the treatment of chronic obstructive pulmonary disease.">
        <entity id="DDI-DrugBank.d51.s0.e0" charOffset="0-7"
            type="brand" text="ATROVENT"/>
        <entity id="DDI-DrugBank.d51.s0.e1" charOffset="84-114"
            type="group" text="sympathomimetic bronchodilators"/>
        <entity id="DDI-DrugBank.d51.s0.e2" charOffset="117-131"
            type="group" text="methylxanthines"/>
        <entity id="DDI-DrugBank.d51.s0.e3" charOffset="138-145"
            type="group" text="steroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d51.s1" text="With the exception of albuterol, there are no formal studies fully evaluating the interaction effects of ATROVENT Inhalation Aerosol and these drugs with respect to effectiveness.">
        <entity id="DDI-DrugBank.d51.s1.e0" charOffset="22-30"
            type="drug" text="albuterol"/>
        <entity id="DDI-DrugBank.d51.s1.e1" charOffset="105-112"
            type="brand" text="ATROVENT"/>
    </sentence>
    <sentence id="DDI-DrugBank.d51.s2" text="Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.">
        <entity id="DDI-DrugBank.d51.s2.e0" charOffset="0-21"
            type="group" text="Anticholinergic agents"/>
        <entity id="DDI-DrugBank.d51.s2.e1" charOffset="33-51"
            type="drug" text="ipratropium bromide"/>
        <entity id="DDI-DrugBank.d51.s2.e2" charOffset="182-208"
            type="group" text="anticholinergic medications"/>
        <ddi id="DDI-DrugBank.d51.s2.d0" e1="DDI-DrugBank.d51.s2.e1"
            e2="DDI-DrugBank.d51.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d51.s3" text="Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.">
        <entity id="DDI-DrugBank.d51.s3.e0" charOffset="56-63"
            type="brand" text="ATROVENT"/>
        <entity id="DDI-DrugBank.d51.s3.e1" charOffset="95-109"
            type="group" text="anticholinergic"/>
        <ddi id="DDI-DrugBank.d51.s3.d0" e1="DDI-DrugBank.d51.s3.e0"
            e2="DDI-DrugBank.d51.s3.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d27.s0" text="No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.">
        <entity id="DDI-DrugBank.d27.s0.e0" charOffset="119-137"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d27.s0.e1" charOffset="140-146"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d27.s0.e2" charOffset="149-156"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d27.s0.e3" charOffset="163-172"
            type="drug" text="nifedipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d27.s1" text="In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.">
        <entity id="DDI-DrugBank.d27.s1.e0" charOffset="153-164"
            type="drug" text="sulphenazole"/>
        <entity id="DDI-DrugBank.d27.s1.e1" charOffset="167-177"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d27.s1.e2" charOffset="183-192"
            type="drug" text="nifedipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d27.s2" text="However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.">
        <entity id="DDI-DrugBank.d27.s2.e0" charOffset="61-70"
            type="drug" text="irbesartan"/>
        <entity id="DDI-DrugBank.d27.s2.e1" charOffset="99-106"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d27.s3" text="Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isozymes 1A1, 1A2,2A6,2B6,2D6,2E1,or 3A4."/>
    <sentence id="DDI-DrugBank.d27.s4" text="In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.">
        <entity id="DDI-DrugBank.d27.s4.e0" charOffset="63-70"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d27.s4.e1" charOffset="73-91"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d27.s4.e2" charOffset="97-103"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d27.s4.e3" charOffset="106-115"
            type="drug" text="irbesartan"/>
        <entity id="DDI-DrugBank.d27.s4.e4" charOffset="184-191"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d27.s4.e5" charOffset="235-241"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d27.s5" text="The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide">
        <entity id="DDI-DrugBank.d27.s5.e0" charOffset="24-33"
            type="drug" text="irbesartan"/>
        <entity id="DDI-DrugBank.d27.s5.e1" charOffset="76-85"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d27.s5.e2" charOffset="90-108"
            type="drug" text="hydrochlorothiazide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d27.s6" text="."/>
    <sentence id="DDI-DrugBank.d27.s7" text=""/>
    <sentence id="DDI-DrugBank.d279.s0" text="The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.">
        <entity id="DDI-DrugBank.d279.s0.e0" charOffset="23-31"
            type="brand" text="CAMPTOSAR"/>
        <entity id="DDI-DrugBank.d279.s0.e1" charOffset="118-138"
            type="group" text="antineoplastic agents"/>
        <ddi id="DDI-DrugBank.d279.s0.d0" e1="DDI-DrugBank.d279.s0.e0"
            e2="DDI-DrugBank.d279.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d279.s1" text="Patients who have previously received pelvic/ abdominal irradiation are at increased risk of severe myelosuppression following the administration of CAMPTOSAR.">
        <entity id="DDI-DrugBank.d279.s1.e0" charOffset="149-157"
            type="brand" text="CAMPTOSAR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d279.s2" text="The concurrent administration of CAMPTOSAR with irradiation has not been adequately studied and is not recommended.">
        <entity id="DDI-DrugBank.d279.s2.e0" charOffset="33-41"
            type="brand" text="CAMPTOSAR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d279.s3" text="Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.">
        <entity id="DDI-DrugBank.d279.s3.e0" charOffset="56-64"
            type="brand" text="CAMPTOSAR"/>
        <entity id="DDI-DrugBank.d279.s3.e1" charOffset="113-125"
            type="drug" text="dexamethasone"/>
        <ddi id="DDI-DrugBank.d279.s3.d0" e1="DDI-DrugBank.d279.s3.e0"
            e2="DDI-DrugBank.d279.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d279.s4" text="However, serious opportunistic infections have not been observed, and no complications have specifically been attributed to lymphocytopenia."/>
    <sentence id="DDI-DrugBank.d279.s5" text="Hyperglycemia has also been reported in patients receiving CAMPTOSAR.">
        <entity id="DDI-DrugBank.d279.s5.e0" charOffset="59-67"
            type="brand" text="CAMPTOSAR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d279.s6" text="Usually, this has been observed in patients with a history of diabetes mellitus or evidence of glucose intolerance prior to administration of CAMPTOSAR.">
        <entity id="DDI-DrugBank.d279.s6.e0" charOffset="142-150"
            type="brand" text="CAMPTOSAR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d279.s7" text="It is probable that dexamethasone, given as antiemetic prophylaxis, contributed to hyperglycemia in some patients.">
        <entity id="DDI-DrugBank.d279.s7.e0" charOffset="20-32"
            type="drug" text="dexamethasone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d279.s8" text="The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).">
        <entity id="DDI-DrugBank.d279.s8.e0" charOffset="115-130"
            type="drug" text="prochlorperazine"/>
        <entity id="DDI-DrugBank.d279.s8.e1" charOffset="168-176"
            type="brand" text="CAMPTOSAR"/>
        <ddi id="DDI-DrugBank.d279.s8.d0" e1="DDI-DrugBank.d279.s8.e0"
            e2="DDI-DrugBank.d279.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d279.s9" text="The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.">
        <entity id="DDI-DrugBank.d279.s9.e0" charOffset="82-97"
            type="drug" text="prochlorperazine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d279.s10" text="It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.">
        <entity id="DDI-DrugBank.d279.s10.e0" charOffset="26-33"
            type="group" text="laxative"/>
        <entity id="DDI-DrugBank.d279.s10.e1" charOffset="59-67"
            type="brand" text="CAMPTOSAR"/>
        <ddi id="DDI-DrugBank.d279.s10.d0" e1="DDI-DrugBank.d279.s10.e0"
            e2="DDI-DrugBank.d279.s10.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d279.s11" text="In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.">
        <entity id="DDI-DrugBank.d279.s11.e0" charOffset="94-102"
            type="brand" text="CAMPTOSAR"/>
        <entity id="DDI-DrugBank.d279.s11.e1" charOffset="140-148"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d279.s11.e2" charOffset="169-177"
            type="brand" text="CAMPTOSAR"/>
        <ddi id="DDI-DrugBank.d279.s11.d0" e1="DDI-DrugBank.d279.s11.e1"
            e2="DDI-DrugBank.d279.s11.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d279.s12" text="Drug-Laboratory Test Interactions There are no known interactions between CAMPTOSAR and laboratory tests.">
        <entity id="DDI-DrugBank.d279.s12.e0" charOffset="74-82"
            type="brand" text="CAMPTOSAR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d108.s0" text="Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).">
        <entity id="DDI-DrugBank.d108.s0.e0" charOffset="0-12"
            type="drug" text="Isocarboxazid"/>
        <entity id="DDI-DrugBank.d108.s0.e1" charOffset="72-79"
            type="brand" text="Antabuse"/>
        <entity id="DDI-DrugBank.d108.s0.e2" charOffset="82-91"
            type="drug" text="disulfiram"/>
        <ddi id="DDI-DrugBank.d108.s0.d0" e1="DDI-DrugBank.d108.s0.e0"
            e2="DDI-DrugBank.d108.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d108.s0.d1" e1="DDI-DrugBank.d108.s0.e0"
            e2="DDI-DrugBank.d108.s0.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d108.s1" text="In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.">
        <entity id="DDI-DrugBank.d108.s1.e0" charOffset="63-75"
            type="group" text="MAO inhibitor"/>
        <entity id="DDI-DrugBank.d108.s1.e1" charOffset="82-91"
            type="drug" text="disulfiram"/>
        <ddi id="DDI-DrugBank.d108.s1.d0" e1="DDI-DrugBank.d108.s1.e0"
            e2="DDI-DrugBank.d108.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d108.s2" text="Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.">
        <entity id="DDI-DrugBank.d108.s2.e0" charOffset="19-31"
            type="drug" text="Isocarboxazid"/>
        <entity id="DDI-DrugBank.d108.s2.e1" charOffset="43-61"
            type="group" text="psychotropic agents"/>
        <ddi id="DDI-DrugBank.d108.s2.d0" e1="DDI-DrugBank.d108.s2.e0"
            e2="DDI-DrugBank.d108.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d108.s3" text="This is especially true in patients who may subject themselves to an overdosage of drugs."/>
    <sentence id="DDI-DrugBank.d108.s4" text="If combination therapy is needed, careful consideration should be given to the pharmacology of all agents to be used."/>
    <sentence id="DDI-DrugBank.d108.s5" text="The monoamine oxidase inhibitory effects of Isocarboxazid may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following Isocarboxazid.">
        <entity id="DDI-DrugBank.d108.s5.e0" charOffset="44-56"
            type="drug" text="Isocarboxazid"/>
        <entity id="DDI-DrugBank.d108.s5.e1" charOffset="205-217"
            type="drug" text="Isocarboxazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d108.s6" text="To avoid potentiation, the physician wishing to terminate treatment with Isocarboxazid and begin therapy with another agent should allow for an interval of 10 days.">
        <entity id="DDI-DrugBank.d108.s6.e0" charOffset="73-85"
            type="drug" text="Isocarboxazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d541.s0" text="May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).">
        <entity id="DDI-DrugBank.d541.s0.e0" charOffset="33-63"
            type="group" text="beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d541.s0.e1" charOffset="128-153"
            type="group" text="adrenergic bronchodilators"/>
        <entity id="DDI-DrugBank.d541.s0.e2" charOffset="182-193"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d541.s0.e3" charOffset="196-204"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d541.s0.e4" charOffset="207-220"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d541.s0.e5" charOffset="227-238"
            type="drug" text="procainamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d227.s0" text="Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.">
        <entity id="DDI-DrugBank.d227.s0.e0" charOffset="0-9"
            type="drug" text="Isoflurane"/>
        <entity id="DDI-DrugBank.d227.s0.e1" charOffset="57-72"
            type="group" text="muscle relaxants"/>
        <entity id="DDI-DrugBank.d227.s0.e2" charOffset="88-119"
            type="group" text="nondepolarizing muscle relaxants"/>
        <ddi id="DDI-DrugBank.d227.s0.d0" e1="DDI-DrugBank.d227.s0.e0"
            e2="DDI-DrugBank.d227.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d227.s0.d1" e1="DDI-DrugBank.d227.s0.e0"
            e2="DDI-DrugBank.d227.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d227.s1" text="See CLINICAL PHARMACOLOGY."/>
    <sentence id="DDI-DrugBank.d187.s0" text="Food: Isoniazid should not be administered with food.">
        <entity id="DDI-DrugBank.d187.s0.e0" charOffset="6-14"
            type="drug" text="Isoniazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s1" text="Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food.">
        <entity id="DDI-DrugBank.d187.s1.e0" charOffset="47-55"
            type="drug" text="isoniazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s2" text="Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.">
        <entity id="DDI-DrugBank.d187.s2.e0" charOffset="0-12"
            type="drug" text="Acetaminophen"/>
        <entity id="DDI-DrugBank.d187.s2.e1" charOffset="34-46"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d187.s2.e2" charOffset="93-101"
            type="drug" text="Isoniazid"/>
        <ddi id="DDI-DrugBank.d187.s2.d0" e1="DDI-DrugBank.d187.s2.e1"
            e2="DDI-DrugBank.d187.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s3" text="It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.">
        <entity id="DDI-DrugBank.d187.s3.e0" charOffset="102-110"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d187.s3.e1" charOffset="116-128"
            type="drug" text="acetaminophen"/>
        <ddi id="DDI-DrugBank.d187.s3.d0" e1="DDI-DrugBank.d187.s3.e0"
            e2="DDI-DrugBank.d187.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s4" text="However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver.">
        <entity id="DDI-DrugBank.d187.s4.e0" charOffset="40-48"
            type="drug" text="isoniazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s5" text="Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.">
        <entity id="DDI-DrugBank.d187.s5.e0" charOffset="38-46"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d187.s5.e1" charOffset="170-182"
            type="drug" text="acetaminophen"/>
        <ddi id="DDI-DrugBank.d187.s5.d0" e1="DDI-DrugBank.d187.s5.e0"
            e2="DDI-DrugBank.d187.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s6" text="Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats.">
        <entity id="DDI-DrugBank.d187.s6.e0" charOffset="49-57"
            type="drug" text="isoniazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s7" text="Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.">
        <entity id="DDI-DrugBank.d187.s7.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d187.s7.e1" charOffset="15-23"
            type="drug" text="Isoniazid"/>
        <entity id="DDI-DrugBank.d187.s7.e2" charOffset="60-72"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d187.s7.e3" charOffset="104-116"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d187.s7.e4" charOffset="186-194"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d187.s7.e5" charOffset="219-231"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d187.s7.e6" charOffset="312-325"
            type="group" text="anticonvulsant"/>
        <ddi id="DDI-DrugBank.d187.s7.d0" e1="DDI-DrugBank.d187.s7.e1"
            e2="DDI-DrugBank.d187.s7.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d187.s7.d1" e1="DDI-DrugBank.d187.s7.e3"
            e2="DDI-DrugBank.d187.s7.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s8" text="Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.">
        <entity id="DDI-DrugBank.d187.s8.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d187.s8.e1" charOffset="39-50"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d187.s8.e2" charOffset="56-64"
            type="drug" text="Isoniazid"/>
        <ddi id="DDI-DrugBank.d187.s8.d0" e1="DDI-DrugBank.d187.s8.e1"
            e2="DDI-DrugBank.d187.s8.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s9" text="Phenytoin: Isoniazid may increase serum levels of phenytoin.">
        <entity id="DDI-DrugBank.d187.s9.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d187.s9.e1" charOffset="11-19"
            type="drug" text="Isoniazid"/>
        <entity id="DDI-DrugBank.d187.s9.e2" charOffset="50-58"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d187.s9.d0" e1="DDI-DrugBank.d187.s9.e1"
            e2="DDI-DrugBank.d187.s9.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s10" text="To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made.">
        <entity id="DDI-DrugBank.d187.s10.e0" charOffset="9-17"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d187.s10.e1" charOffset="63-76"
            type="group" text="anticonvulsant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s11" text="Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.">
        <entity id="DDI-DrugBank.d187.s11.e0" charOffset="74-82"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d187.s11.e1" charOffset="88-99"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d187.s11.e2" charOffset="137-148"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d187.s11.e3" charOffset="213-221"
            type="drug" text="isoniazid"/>
        <ddi id="DDI-DrugBank.d187.s11.d0" e1="DDI-DrugBank.d187.s11.e0"
            e2="DDI-DrugBank.d187.s11.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s12" text="Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.">
        <entity id="DDI-DrugBank.d187.s12.e0" charOffset="31-42"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d187.s12.e1" charOffset="54-65"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d187.s12.e2" charOffset="147-158"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s13" text="Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.">
        <entity id="DDI-DrugBank.d187.s13.e0" charOffset="0-8"
            type="drug" text="Valproate"/>
        <entity id="DDI-DrugBank.d187.s13.e1" charOffset="84-92"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d187.s13.e2" charOffset="120-128"
            type="drug" text="isoniazid"/>
        <ddi id="DDI-DrugBank.d187.s13.d0" e1="DDI-DrugBank.d187.s13.e1"
            e2="DDI-DrugBank.d187.s13.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d187.s14" text="Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.">
        <entity id="DDI-DrugBank.d187.s14.e0" charOffset="7-15"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d187.s14.e1" charOffset="56-64"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d187.s14.e2" charOffset="70-78"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d187.s14.e3" charOffset="139-147"
            type="drug" text="valproate"/>
        <ddi id="DDI-DrugBank.d187.s14.d0" e1="DDI-DrugBank.d187.s14.e1"
            e2="DDI-DrugBank.d187.s14.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d55.s0" text="Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.">
        <entity id="DDI-DrugBank.d55.s0.e0" charOffset="0-26"
            type="drug" text="Isoproterenol hydrochloride"/>
        <entity id="DDI-DrugBank.d55.s0.e1" charOffset="42-52"
            type="drug" text="epinephrine"/>
        <ddi id="DDI-DrugBank.d55.s0.d0" e1="DDI-DrugBank.d55.s0.e0"
            e2="DDI-DrugBank.d55.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d55.s1" text="The drugs may, however, be administered alternately provided a proper interval has elapsed between doses."/>
    <sentence id="DDI-DrugBank.d55.s2" text="ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.">
        <entity id="DDI-DrugBank.d55.s2.e0" charOffset="0-6"
            type="brand" text="ISUPREL"/>
        <entity id="DDI-DrugBank.d55.s2.e1" charOffset="73-83"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d55.s2.e2" charOffset="93-101"
            type="drug" text="halothane"/>
        <entity id="DDI-DrugBank.d55.s2.e3" charOffset="179-200"
            type="group" text="sympathomimetic amines"/>
        <ddi id="DDI-DrugBank.d55.s2.d0" e1="DDI-DrugBank.d55.s2.e0"
            e2="DDI-DrugBank.d55.s2.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d55.s2.d1" e1="DDI-DrugBank.d55.s2.e0"
            e2="DDI-DrugBank.d55.s2.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d465.s0" text="The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators.">
        <entity id="DDI-DrugBank.d465.s0.e0" charOffset="28-47"
            type="drug" text="isosorbide dinitrate"/>
        <entity id="DDI-DrugBank.d465.s0.e1" charOffset="85-96"
            type="group" text="vasodilators"/>
        <ddi id="DDI-DrugBank.d465.s0.d0" e1="DDI-DrugBank.d465.s0.e0"
            e2="DDI-DrugBank.d465.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d465.s1" text="Alcohol, in particular, has been found to exhibit additive effects of this variety.">
        <entity id="DDI-DrugBank.d465.s1.e0" charOffset="0-6"
            type="drug" text="Alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d479.s0" text="The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators.">
        <entity id="DDI-DrugBank.d479.s0.e0" charOffset="28-49"
            type="drug" text="isosorbide mononitrate"/>
        <entity id="DDI-DrugBank.d479.s0.e1" charOffset="87-98"
            type="group" text="vasodilators"/>
        <ddi id="DDI-DrugBank.d479.s0.d0" e1="DDI-DrugBank.d479.s0.e0"
            e2="DDI-DrugBank.d479.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d479.s1" text="Alcohol, in particular, has been found to exhibit additive effects of this variety.">
        <entity id="DDI-DrugBank.d479.s1.e0" charOffset="0-6"
            type="drug" text="Alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d479.s2" text="Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.">
        <entity id="DDI-DrugBank.d479.s2.e0" charOffset="66-89"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d479.s2.e1" charOffset="95-110"
            type="group" text="organic nitrates"/>
        <ddi id="DDI-DrugBank.d479.s2.d0" e1="DDI-DrugBank.d479.s2.e0"
            e2="DDI-DrugBank.d479.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d479.s3" text="Dose adjustments of either class of agents may be necessary."/>
    <sentence id="DDI-DrugBank.d163.s0" text="Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects">
        <entity id="DDI-DrugBank.d163.s0.e0" charOffset="0-8"
            type="group" text="Vitamin A"/>
        <entity id="DDI-DrugBank.d163.s0.e1" charOffset="42-49"
            type="brand" text="Accutane"/>
        <entity id="DDI-DrugBank.d163.s0.e2" charOffset="54-62"
            type="group" text="vitamin A"/>
        <entity id="DDI-DrugBank.d163.s0.e3" charOffset="107-125"
            type="group" text="vitamin supplements"/>
        <entity id="DDI-DrugBank.d163.s0.e4" charOffset="138-146"
            type="group" text="vitamin A"/>
        <ddi id="DDI-DrugBank.d163.s0.d0" e1="DDI-DrugBank.d163.s0.e1"
            e2="DDI-DrugBank.d163.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s1" text="."/>
    <sentence id="DDI-DrugBank.d163.s2" text="Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines">
        <entity id="DDI-DrugBank.d163.s2.e0" charOffset="0-12"
            type="group" text="Tetracyclines"/>
        <entity id="DDI-DrugBank.d163.s2.e1" charOffset="42-49"
            type="brand" text="Accutane"/>
        <entity id="DDI-DrugBank.d163.s2.e2" charOffset="55-67"
            type="group" text="tetracyclines"/>
        <entity id="DDI-DrugBank.d163.s2.e3" charOffset="95-102"
            type="brand" text="Accutane"/>
        <entity id="DDI-DrugBank.d163.s2.e4" charOffset="252-264"
            type="group" text="tetracyclines"/>
        <ddi id="DDI-DrugBank.d163.s2.d0" e1="DDI-DrugBank.d163.s2.e1"
            e2="DDI-DrugBank.d163.s2.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d163.s2.d1" e1="DDI-DrugBank.d163.s2.e3"
            e2="DDI-DrugBank.d163.s2.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s3" text="."/>
    <sentence id="DDI-DrugBank.d163.s4" text="Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.">
        <entity id="DDI-DrugBank.d163.s4.e0" charOffset="12-23"
            type="drug" text="Progesterone"/>
        <entity id="DDI-DrugBank.d163.s4.e1" charOffset="51-62"
            type="drug" text="progesterone"/>
        <entity id="DDI-DrugBank.d163.s4.e2" charOffset="111-118"
            type="group" text="estrogen"/>
        <entity id="DDI-DrugBank.d163.s4.e3" charOffset="173-180"
            type="brand" text="Accutane"/>
        <ddi id="DDI-DrugBank.d163.s4.d0" e1="DDI-DrugBank.d163.s4.e1"
            e2="DDI-DrugBank.d163.s4.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s5" text="Although other hormonal contraceptives are highly effective, there have been reports of pregnancy from women who have used combined oral contraceptives, as well as topical/injectable/implantable/insertable hormonal birth control products.">
        <entity id="DDI-DrugBank.d163.s5.e0" charOffset="15-37"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d163.s5.e1" charOffset="123-150"
            type="group" text="combined oral contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s6" text="These reports are more frequent for women who use only a single method of contraception."/>
    <sentence id="DDI-DrugBank.d163.s7" text="It is not known if hormonal contraceptives differ in their effectiveness when used with Accutane.">
        <entity id="DDI-DrugBank.d163.s7.e0" charOffset="19-41"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d163.s7.e1" charOffset="88-95"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s8" text="Therefore, it is critically important for women of childbearing potential to select and commit to use 2 forms of effective contraception simultaneously, at least 1 of which must be a primary form, unless absolute abstinence is the chosen method, or the patient has undergone a hysterectomy"/>
    <sentence id="DDI-DrugBank.d163.s9" text="."/>
    <sentence id="DDI-DrugBank.d163.s10" text="Phenytoin: Accutane has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.">
        <entity id="DDI-DrugBank.d163.s10.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d163.s10.e1" charOffset="11-18"
            type="brand" text="Accutane"/>
        <entity id="DDI-DrugBank.d163.s10.e2" charOffset="72-80"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s11" text="These results are consistent with the in vitro finding that neither isotretinoin nor its metabolites induce or inhibit the activity of the CYP 2C9 human hepatic P450 enzyme.">
        <entity id="DDI-DrugBank.d163.s11.e0" charOffset="68-79"
            type="drug" text="isotretinoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s12" text="Phenytoin is known to cause osteomalacia.">
        <entity id="DDI-DrugBank.d163.s12.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s13" text="No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between phenytoin and Accutane.">
        <entity id="DDI-DrugBank.d163.s13.e0" charOffset="112-120"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d163.s13.e1" charOffset="126-133"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s14" text="Therefore, caution should be exercised when using these drugs together"/>
    <sentence id="DDI-DrugBank.d163.s15" text="."/>
    <sentence id="DDI-DrugBank.d163.s16" text="Systemic Corticosteroids: Systemic corticosteroids are known to cause osteoporosis.">
        <entity id="DDI-DrugBank.d163.s16.e0" charOffset="0-23"
            type="group" text="Systemic Corticosteroids"/>
        <entity id="DDI-DrugBank.d163.s16.e1" charOffset="26-49"
            type="group" text="Systemic corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s17" text="No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between systemic corticosteroids and Accutane.">
        <entity id="DDI-DrugBank.d163.s17.e0" charOffset="112-135"
            type="group" text="systemic corticosteroids"/>
        <entity id="DDI-DrugBank.d163.s17.e1" charOffset="141-148"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s18" text="Therefore, caution should be exercised when using these drugs together."/>
    <sentence id="DDI-DrugBank.d163.s19" text="Prescribers are advised to consult the package insert of medication administered concomitantly with hormonal contraceptives, since some medications may decrease the effectiveness of these birth control products.">
        <entity id="DDI-DrugBank.d163.s19.e0" charOffset="100-122"
            type="group" text="hormonal contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s20" text="Accutane use is associated with depression in some patients.">
        <entity id="DDI-DrugBank.d163.s20.e0" charOffset="0-7"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s21" text="Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. Johns Wort.">
        <entity id="DDI-DrugBank.d163.s21.e0" charOffset="43-74"
            type="group" text="combined hormonal contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s22" text="Laboratory Tests Pregnancy Test Female patients of childbearing potential must have negative results from 2 urine or serum pregnancy tests with a sensitivity of at least 25 mIU/mL before receiving the initial Accutane prescription.">
        <entity id="DDI-DrugBank.d163.s22.e0" charOffset="209-216"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s23" text="The first test is obtained by the prescriber when the decision is made to pursue qualification of the patient for Accutane (a screening test).">
        <entity id="DDI-DrugBank.d163.s23.e0" charOffset="114-121"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s24" text="The second pregnancy test (a confirmation test) should be done during the first 5 days of the menstrual period immediately preceding the beginning of Accutane therapy.">
        <entity id="DDI-DrugBank.d163.s24.e0" charOffset="150-157"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s25" text="For patients with amenorrhea, the second test should be done at least 11 days after the last act of unprotected sexual intercourse (without using 2 effective forms of contraception)."/>
    <sentence id="DDI-DrugBank.d163.s26" text="Each month of therapy, the patient must have a negative result from a urine or serum pregnancy test."/>
    <sentence id="DDI-DrugBank.d163.s27" text="A pregnancy test must be repeated each month prior to the female patient receiving each prescription"/>
    <sentence id="DDI-DrugBank.d163.s28" text="."/>
    <sentence id="DDI-DrugBank.d163.s29" text="Lipids: Pretreatment and follow-up blood lipids should be obtained under fasting conditions."/>
    <sentence id="DDI-DrugBank.d163.s30" text="After consumption of alcohol, at least 36 hours should elapse before these determinations are made.">
        <entity id="DDI-DrugBank.d163.s30.e0" charOffset="21-27"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s31" text="It is recommended that these tests be performed at weekly or biweekly intervals until the lipid response to Accutane is established.">
        <entity id="DDI-DrugBank.d163.s31.e0" charOffset="108-115"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s32" text="The incidence of hypertriglyceridemia is 1 patient in 4 on Accutane therapy">
        <entity id="DDI-DrugBank.d163.s32.e0" charOffset="59-66"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s33" text="."/>
    <sentence id="DDI-DrugBank.d163.s34" text="Liver Function Tests: Since elevations of liver enzymes have been observed during clinical trials, and hepatitis has been reported, pretreatment and follow-up liver function tests should be performed at weekly or biweekly intervals until the response to Accutane has been established">
        <entity id="DDI-DrugBank.d163.s34.e0" charOffset="254-261"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s35" text="."/>
    <sentence id="DDI-DrugBank.d163.s36" text="Glucose: Some patients receiving Accutane have experienced problems in the control of their blood sugar.">
        <entity id="DDI-DrugBank.d163.s36.e0" charOffset="33-40"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s37" text="In addition, new cases of diabetes have been diagnosed during Accutane therapy, although no causal relationship has been established">
        <entity id="DDI-DrugBank.d163.s37.e0" charOffset="62-69"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s38" text="."/>
    <sentence id="DDI-DrugBank.d163.s39" text="CPK: Some patients undergoing vigorous physical activity while on Accutane therapy have experienced elevated CPK levels;">
        <entity id="DDI-DrugBank.d163.s39.e0" charOffset="66-73"
            type="brand" text="Accutane"/>
    </sentence>
    <sentence id="DDI-DrugBank.d163.s40" text="however, the clinical significance is unknown."/>
    <sentence id="DDI-DrugBank.d163.s41" text="There have been rare postmarketing reports of rhabdomyolysis, some associated with strenuous physical activity."/>
    <sentence id="DDI-DrugBank.d163.s42" text="In a clinical trial of 217 pediatric patients (12 to 17 years) with severe recalcitrant nodular acne, transient elevations in CPK were observed in 12% of patients, including those undergoing strenuous physical activity in association with reported musculoskeletal adverse events such as back pain, arthralgia, limb injury, or muscle sprain."/>
    <sentence id="DDI-DrugBank.d163.s43" text="In these patients, approximately half of the CPK elevations returned to normal within 2 weeks and half returned to normal within 4 weeks."/>
    <sentence id="DDI-DrugBank.d163.s44" text="No cases of rhabdomyolysis were reported in this trial."/>
    <sentence id="DDI-DrugBank.d81.s0" text="Nitroglycerin: DynaCirc  (isradipine) has been safely coadministered with nitroglycerin.">
        <entity id="DDI-DrugBank.d81.s0.e0" charOffset="0-12"
            type="drug" text="Nitroglycerin"/>
        <entity id="DDI-DrugBank.d81.s0.e1" charOffset="15-22"
            type="brand" text="DynaCirc"/>
        <entity id="DDI-DrugBank.d81.s0.e2" charOffset="26-35"
            type="drug" text="isradipine"/>
        <entity id="DDI-DrugBank.d81.s0.e3" charOffset="74-86"
            type="drug" text="nitroglycerin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s1" text="Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.">
        <entity id="DDI-DrugBank.d81.s1.e0" charOffset="0-18"
            type="drug" text="Hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d81.s1.e1" charOffset="103-110"
            type="brand" text="DynaCirc"/>
        <entity id="DDI-DrugBank.d81.s1.e2" charOffset="114-123"
            type="drug" text="isradipine"/>
        <entity id="DDI-DrugBank.d81.s1.e3" charOffset="130-148"
            type="drug" text="hydrochlorothiazide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s2" text="In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.">
        <entity id="DDI-DrugBank.d81.s2.e0" charOffset="49-58"
            type="drug" text="isradipine"/>
        <entity id="DDI-DrugBank.d81.s2.e1" charOffset="72-90"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d81.s2.e2" charOffset="154-163"
            type="drug" text="isradipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s3" text="Propranolol: In a single dose study in normal volunteers, coadministration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability.">
        <entity id="DDI-DrugBank.d81.s3.e0" charOffset="0-10"
            type="drug" text="Propranolol"/>
        <entity id="DDI-DrugBank.d81.s3.e1" charOffset="78-88"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d81.s3.e2" charOffset="152-161"
            type="drug" text="isradipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s4" text="Significant increases In AUC (27%) and Cmax (58%) and decreases in tmax (23%) of propranolol were noted in this study.">
        <entity id="DDI-DrugBank.d81.s4.e0" charOffset="81-91"
            type="drug" text="propranolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s5" text="However, concomitant administration of 5 mg b.i.d. isradipine and 40 mg b.i.d.">
        <entity id="DDI-DrugBank.d81.s5.e0" charOffset="51-60"
            type="drug" text="isradipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s6" text="propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.">
        <entity id="DDI-DrugBank.d81.s6.e0" charOffset="0-10"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d81.s6.e1" charOffset="165-174"
            type="drug" text="isradipine"/>
        <entity id="DDI-DrugBank.d81.s6.e2" charOffset="213-223"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d81.s6.e3" charOffset="238-248"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d81.s6.e4" charOffset="287-296"
            type="drug" text="isradipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s7" text="Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).">
        <entity id="DDI-DrugBank.d81.s7.e0" charOffset="0-9" type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d81.s7.e1" charOffset="67-76"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d81.s7.e2" charOffset="122-131"
            type="drug" text="isradipine"/>
        <entity id="DDI-DrugBank.d81.s7.e3" charOffset="172-181"
            type="drug" text="isradipine"/>
        <ddi id="DDI-DrugBank.d81.s7.d0" e1="DDI-DrugBank.d81.s7.e1"
            e2="DDI-DrugBank.d81.s7.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s8" text="If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.">
        <entity id="DDI-DrugBank.d81.s8.e0" charOffset="3-12"
            type="drug" text="isradipine"/>
        <entity id="DDI-DrugBank.d81.s8.e1" charOffset="68-77"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d81.s8.d0" e1="DDI-DrugBank.d81.s8.e0"
            e2="DDI-DrugBank.d81.s8.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s9" text="Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.">
        <entity id="DDI-DrugBank.d81.s9.e0" charOffset="0-9" type="drug" text="Rifampicin"/>
        <entity id="DDI-DrugBank.d81.s9.e1" charOffset="66-75"
            type="drug" text="rifampicin"/>
        <entity id="DDI-DrugBank.d81.s9.e2" charOffset="125-134"
            type="drug" text="isradipine"/>
        <entity id="DDI-DrugBank.d81.s9.e3" charOffset="163-172"
            type="drug" text="isradipine"/>
        <ddi id="DDI-DrugBank.d81.s9.d0" e1="DDI-DrugBank.d81.s9.e1"
            e2="DDI-DrugBank.d81.s9.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s10" text="If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.">
        <entity id="DDI-DrugBank.d81.s10.e0" charOffset="3-12"
            type="drug" text="rifampicin"/>
        <entity id="DDI-DrugBank.d81.s10.e1" charOffset="35-44"
            type="drug" text="isradipine"/>
        <entity id="DDI-DrugBank.d81.s10.e2" charOffset="197-206"
            type="drug" text="isradipine"/>
        <ddi id="DDI-DrugBank.d81.s10.d0" e1="DDI-DrugBank.d81.s10.e0"
            e2="DDI-DrugBank.d81.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s11" text="Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.">
        <entity id="DDI-DrugBank.d81.s11.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d81.s11.e1" charOffset="122-131"
            type="drug" text="isradipine"/>
        <entity id="DDI-DrugBank.d81.s11.e2" charOffset="145-152"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d81.s11.e3" charOffset="193-200"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d81.s11.e4" charOffset="302-311"
            type="drug" text="isradipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s12" text="Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug.">
        <entity id="DDI-DrugBank.d81.s12.e0" charOffset="16-23"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d81.s12.e1" charOffset="29-38"
            type="drug" text="isradipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s13" text="Digoxin: The concomitant administration of DynaCirc  (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin.">
        <entity id="DDI-DrugBank.d81.s13.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d81.s13.e1" charOffset="43-50"
            type="brand" text="DynaCirc"/>
        <entity id="DDI-DrugBank.d81.s13.e2" charOffset="54-63"
            type="drug" text="isradipine"/>
        <entity id="DDI-DrugBank.d81.s13.e3" charOffset="70-76"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d81.s13.e4" charOffset="176-182"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s14" text="Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.">
        <entity id="DDI-DrugBank.d81.s14.e0" charOffset="0-7"
            type="drug" text="Fentanyl"/>
        <entity id="DDI-DrugBank.d81.s14.e1" charOffset="65-72"
            type="drug" text="fentanyl"/>
        <entity id="DDI-DrugBank.d81.s14.e2" charOffset="111-122"
            type="group" text="beta blocker"/>
        <entity id="DDI-DrugBank.d81.s14.e3" charOffset="130-152"
            type="group" text="calcium channel blocker"/>
        <ddi id="DDI-DrugBank.d81.s14.d0" e1="DDI-DrugBank.d81.s14.e1"
            e2="DDI-DrugBank.d81.s14.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d81.s14.d1" e1="DDI-DrugBank.d81.s14.e1"
            e2="DDI-DrugBank.d81.s14.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d81.s15" text="Even though such interactions have not been seen in clinical studies with DynaCirc  (isradipine), an increased volume of circulating fluids might be required if such an interaction were to occur.">
        <entity id="DDI-DrugBank.d81.s15.e0" charOffset="74-81"
            type="brand" text="DynaCirc"/>
        <entity id="DDI-DrugBank.d81.s15.e1" charOffset="85-94"
            type="drug" text="isradipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s0" text="Both itraconazole and its major metabolite, hydroxyitraconazole, are inhibitors of the cytochrome P450 3A4 enzyme system.">
        <entity id="DDI-DrugBank.d165.s0.e0" charOffset="5-16"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d165.s0.e1" charOffset="44-62"
            type="drug_n" text="hydroxyitraconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s1" text="Coadministration of Itraconazole and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects.">
        <entity id="DDI-DrugBank.d165.s1.e0" charOffset="20-31"
            type="drug" text="Itraconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s2" text="Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary."/>
    <sentence id="DDI-DrugBank.d165.s3" text="Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.">
        <entity id="DDI-DrugBank.d165.s3.e0" charOffset="20-30"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d165.s3.e1" charOffset="37-48"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s3.e2" charOffset="95-105"
            type="drug" text="terfenadine"/>
        <ddi id="DDI-DrugBank.d165.s3.d0" e1="DDI-DrugBank.d165.s3.e0"
            e2="DDI-DrugBank.d165.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s4" text="Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.">
        <entity id="DDI-DrugBank.d165.s4.e0" charOffset="13-28"
            type="group" text="azole antifungal"/>
        <entity id="DDI-DrugBank.d165.s4.e1" charOffset="31-42"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d165.s4.e2" charOffset="72-81"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d165.s4.e3" charOffset="131-140"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d165.s4.e4" charOffset="168-187"
            type="drug_n" text="desmethylastermizole"/>
        <ddi id="DDI-DrugBank.d165.s4.d0" e1="DDI-DrugBank.d165.s4.e1"
            e2="DDI-DrugBank.d165.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s5" text="In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.">
        <entity id="DDI-DrugBank.d165.s5.e0" charOffset="27-38"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d165.s5.e1" charOffset="58-69"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d165.s5.e2" charOffset="167-176"
            type="drug" text="astemizole"/>
        <ddi id="DDI-DrugBank.d165.s5.d0" e1="DDI-DrugBank.d165.s5.e0"
            e2="DDI-DrugBank.d165.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s6" text="Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.">
        <entity id="DDI-DrugBank.d165.s6.e0" charOffset="37-48"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d165.s6.e1" charOffset="54-65"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d165.s6.e2" charOffset="88-97"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d165.s6.e3" charOffset="104-115"
            type="drug" text="itraconazole"/>
        <ddi id="DDI-DrugBank.d165.s6.d0" e1="DDI-DrugBank.d165.s6.e2"
            e2="DDI-DrugBank.d165.s6.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s7" text="Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.">
        <entity id="DDI-DrugBank.d165.s7.e0" charOffset="47-58"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d165.s7.e1" charOffset="96-104"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d165.s7.e2" charOffset="161-169"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d165.s7.d0" e1="DDI-DrugBank.d165.s7.e0"
            e2="DDI-DrugBank.d165.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s8" text="Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.">
        <entity id="DDI-DrugBank.d165.s8.e0" charOffset="43-54"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d165.s8.e1" charOffset="60-68"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d165.s8.d0" e1="DDI-DrugBank.d165.s8.e0"
            e2="DDI-DrugBank.d165.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s9" text="In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;">
        <entity id="DDI-DrugBank.d165.s9.e0" charOffset="27-38"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d165.s9.e1" charOffset="133-141"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d165.s9.d0" e1="DDI-DrugBank.d165.s9.e0"
            e2="DDI-DrugBank.d165.s9.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s10" text="therefore concomitant administration of Itraconazole with cisapride is contraindicated.">
        <entity id="DDI-DrugBank.d165.s10.e0" charOffset="40-51"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s10.e1" charOffset="58-66"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d165.s10.d0" e1="DDI-DrugBank.d165.s10.e0"
            e2="DDI-DrugBank.d165.s10.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s11" text="Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.">
        <entity id="DDI-DrugBank.d165.s11.e0" charOffset="20-31"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s11.e1" charOffset="43-51"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d165.s11.e2" charOffset="56-64"
            type="drug" text="triazolam"/>
        <ddi id="DDI-DrugBank.d165.s11.d0" e1="DDI-DrugBank.d165.s11.e0"
            e2="DDI-DrugBank.d165.s11.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d165.s11.d1" e1="DDI-DrugBank.d165.s11.e0"
            e2="DDI-DrugBank.d165.s11.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s12" text="This may potentiate and prolong hypnotic and sedative effects."/>
    <sentence id="DDI-DrugBank.d165.s13" text="These agents should not be used in patients treated with Itraconazole.">
        <entity id="DDI-DrugBank.d165.s13.e0" charOffset="57-68"
            type="drug" text="Itraconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s14" text="If midazolam is administered parenterally, special precaution is required since the sedative effect may be prolonged.">
        <entity id="DDI-DrugBank.d165.s14.e0" charOffset="3-11"
            type="drug" text="midazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s15" text="Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.">
        <entity id="DDI-DrugBank.d165.s15.e0" charOffset="20-31"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s15.e1" charOffset="37-48"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d165.s15.e2" charOffset="51-60"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d165.s15.e3" charOffset="65-71"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d165.s15.d0" e1="DDI-DrugBank.d165.s15.e0"
            e2="DDI-DrugBank.d165.s15.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d165.s15.d1" e1="DDI-DrugBank.d165.s15.e0"
            e2="DDI-DrugBank.d165.s15.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d165.s15.d2" e1="DDI-DrugBank.d165.s15.e0"
            e2="DDI-DrugBank.d165.s15.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s16" text="Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.">
        <entity id="DDI-DrugBank.d165.s16.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d165.s16.e1" charOffset="14-23"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d165.s16.e2" charOffset="29-35"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d165.s16.e3" charOffset="93-104"
            type="drug" text="Itraconazole"/>
        <ddi id="DDI-DrugBank.d165.s16.d0" e1="DDI-DrugBank.d165.s16.e0"
            e2="DDI-DrugBank.d165.s16.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d165.s16.d1" e1="DDI-DrugBank.d165.s16.e1"
            e2="DDI-DrugBank.d165.s16.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d165.s16.d2" e1="DDI-DrugBank.d165.s16.e2"
            e2="DDI-DrugBank.d165.s16.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s17" text="Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.">
        <entity id="DDI-DrugBank.d165.s17.e0" charOffset="55-82"
            type="group" text="HMG-CoA reductase inhibitors"/>
        <entity id="DDI-DrugBank.d165.s17.e1" charOffset="150-172"
            type="group" text="immunosuppressive drugs"/>
        <entity id="DDI-DrugBank.d165.s17.e2" charOffset="184-195"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d165.s17.d0" e1="DDI-DrugBank.d165.s17.e0"
            e2="DDI-DrugBank.d165.s17.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d165.s17.d1" e1="DDI-DrugBank.d165.s17.e0"
            e2="DDI-DrugBank.d165.s17.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s18" text="When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.">
        <entity id="DDI-DrugBank.d165.s18.e0" charOffset="5-16"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s18.e1" charOffset="42-50"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d165.s18.e2" charOffset="53-60"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d165.s18.e3" charOffset="114-125"
            type="drug" text="itraconazole"/>
        <ddi id="DDI-DrugBank.d165.s18.d0" e1="DDI-DrugBank.d165.s18.e0"
            e2="DDI-DrugBank.d165.s18.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d165.s18.d1" e1="DDI-DrugBank.d165.s18.e0"
            e2="DDI-DrugBank.d165.s18.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s19" text="The physician is advised to monitor the plasma concentrations of itraconazole when any of these drugs is taken concurrently, and to increase the dose of Itraconazole if necessary.">
        <entity id="DDI-DrugBank.d165.s19.e0" charOffset="65-76"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d165.s19.e1" charOffset="153-164"
            type="drug" text="Itraconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s20" text="Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;">
        <entity id="DDI-DrugBank.d165.s20.e0" charOffset="71-82"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s20.e1" charOffset="88-96"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d165.s20.e2" charOffset="126-134"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d165.s20.d0" e1="DDI-DrugBank.d165.s20.e0"
            e2="DDI-DrugBank.d165.s20.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s21" text="therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.">
        <entity id="DDI-DrugBank.d165.s21.e0" charOffset="36-44"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d165.s21.e1" charOffset="106-117"
            type="drug" text="Itraconazole"/>
        <ddi id="DDI-DrugBank.d165.s21.d0" e1="DDI-DrugBank.d165.s21.e0"
            e2="DDI-DrugBank.d165.s21.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s22" text="It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.">
        <entity id="DDI-DrugBank.d165.s22.e0" charOffset="26-37"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s22.e1" charOffset="76-83"
            type="group" text="coumarin"/>
        <ddi id="DDI-DrugBank.d165.s22.d0" e1="DDI-DrugBank.d165.s22.e0"
            e2="DDI-DrugBank.d165.s22.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s23" text="Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.">
        <entity id="DDI-DrugBank.d165.s23.e0" charOffset="80-91"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s23.e1" charOffset="97-104"
            type="group" text="coumarin"/>
        <ddi id="DDI-DrugBank.d165.s23.d0" e1="DDI-DrugBank.d165.s23.e0"
            e2="DDI-DrugBank.d165.s23.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s24" text="Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.">
        <entity id="DDI-DrugBank.d165.s24.e0" charOffset="25-47"
            type="group" text="azole antifungal agents"/>
        <entity id="DDI-DrugBank.d165.s24.e1" charOffset="90-98"
            type="drug" text="isoniazid"/>
        <ddi id="DDI-DrugBank.d165.s24.d0" e1="DDI-DrugBank.d165.s24.e0"
            e2="DDI-DrugBank.d165.s24.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s25" text="Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.">
        <entity id="DDI-DrugBank.d165.s25.e0" charOffset="0-11"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s25.e1" charOffset="60-71"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s25.e2" charOffset="77-85"
            type="drug" text="isoniazid"/>
        <ddi id="DDI-DrugBank.d165.s25.d0" e1="DDI-DrugBank.d165.s25.e1"
            e2="DDI-DrugBank.d165.s25.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s26" text="Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.">
        <entity id="DDI-DrugBank.d165.s26.e0" charOffset="74-96"
            type="group" text="azole antifungal agents"/>
        <entity id="DDI-DrugBank.d165.s26.e1" charOffset="107-125"
            type="group" text="hypoglycemic agents"/>
        <ddi id="DDI-DrugBank.d165.s26.d0" e1="DDI-DrugBank.d165.s26.e0"
            e2="DDI-DrugBank.d165.s26.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s27" text="Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.">
        <entity id="DDI-DrugBank.d165.s27.e0" charOffset="64-75"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s27.e1" charOffset="86-104"
            type="group" text="hypoglycemic agents"/>
        <ddi id="DDI-DrugBank.d165.s27.d0" e1="DDI-DrugBank.d165.s27.e0"
            e2="DDI-DrugBank.d165.s27.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s28" text="Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.">
        <entity id="DDI-DrugBank.d165.s28.e0" charOffset="86-97"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s28.e1" charOffset="103-111"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d165.s28.d0" e1="DDI-DrugBank.d165.s28.e0"
            e2="DDI-DrugBank.d165.s28.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s29" text="Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.">
        <entity id="DDI-DrugBank.d165.s29.e0" charOffset="60-71"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d165.s29.e1" charOffset="77-116"
            type="group" text="dihydropyridine calcium channel blockers"/>
        <ddi id="DDI-DrugBank.d165.s29.d0" e1="DDI-DrugBank.d165.s29.e0"
            e2="DDI-DrugBank.d165.s29.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d165.s30" text="Appropriate dosage adjustments may be necessary."/>
    <sentence id="DDI-DrugBank.d165.s31" text="The results from a study in which eight HIV-infected individuals were treated with zidovudine, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of Itraconazole, 100 mg b.i.d.">
        <entity id="DDI-DrugBank.d165.s31.e0" charOffset="83-92"
            type="drug" text="zidovudine"/>
        <entity id="DDI-DrugBank.d165.s31.e1" charOffset="152-161"
            type="drug" text="zidovudine"/>
        <entity id="DDI-DrugBank.d165.s31.e2" charOffset="218-229"
            type="drug" text="Itraconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d57.s0" text="In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.">
        <entity id="DDI-DrugBank.d57.s0.e0" charOffset="22-35"
            type="group" text="aminoglycoside"/>
        <entity id="DDI-DrugBank.d57.s0.e1" charOffset="58-68"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d57.s0.e2" charOffset="71-81"
            type="group" text="penicillins"/>
        <entity id="DDI-DrugBank.d57.s0.e3" charOffset="86-99"
            type="group" text="cephalosporins"/>
        <ddi id="DDI-DrugBank.d57.s0.d0" e1="DDI-DrugBank.d57.s0.e0"
            e2="DDI-DrugBank.d57.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d57.s0.d1" e1="DDI-DrugBank.d57.s0.e0"
            e2="DDI-DrugBank.d57.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d57.s0.d2" e1="DDI-DrugBank.d57.s0.e0"
            e2="DDI-DrugBank.d57.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d57.s1" text="Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.">
        <entity id="DDI-DrugBank.d57.s1.e0" charOffset="13-26"
            type="group" text="aminoglycoside"/>
        <entity id="DDI-DrugBank.d57.s1.e1" charOffset="34-43"
            type="group" text="penicillin"/>
        <entity id="DDI-DrugBank.d57.s1.e2" charOffset="119-132"
            type="group" text="aminoglycoside"/>
        <ddi id="DDI-DrugBank.d57.s1.d0" e1="DDI-DrugBank.d57.s1.e0"
            e2="DDI-DrugBank.d57.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d57.s2" text="Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function..">
        <entity id="DDI-DrugBank.d57.s2.e0" charOffset="34-47"
            type="group" text="aminoglycoside"/>
    </sentence>
    <sentence id="DDI-DrugBank.d57.s3" text="See"/>
    <sentence id="DDI-DrugBank.d518.s0" text="Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.">
        <entity id="DDI-DrugBank.d518.s0.e0" charOffset="37-48"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d518.s0.e1" charOffset="57-65"
            type="group" text="narcotics"/>
        <entity id="DDI-DrugBank.d518.s0.e2" charOffset="94-101"
            type="drug" text="ketamine"/>
        <ddi id="DDI-DrugBank.d518.s0.d0" e1="DDI-DrugBank.d518.s0.e0"
            e2="DDI-DrugBank.d518.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d518.s0.d1" e1="DDI-DrugBank.d518.s0.e1"
            e2="DDI-DrugBank.d518.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d518.s1" text="Ketamine is clinically compatible with the commonly used general and local anesthetic agents when an adequate respiratory exchange is maintained.">
        <entity id="DDI-DrugBank.d518.s1.e0" charOffset="0-7"
            type="drug" text="Ketamine"/>
        <entity id="DDI-DrugBank.d518.s1.e1" charOffset="75-91"
            type="group" text="anesthetic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s0" text="Ketoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system.">
        <entity id="DDI-DrugBank.d458.s0.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s1" text="Coadministration of NIZORAL  Tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects.">
        <entity id="DDI-DrugBank.d458.s1.e0" charOffset="20-26"
            type="brand" text="NIZORAL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s2" text="Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary."/>
    <sentence id="DDI-DrugBank.d458.s3" text="The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.">
        <entity id="DDI-DrugBank.d458.s3.e0" charOffset="63-69"
            type="brand" text="NIZORAL"/>
        <entity id="DDI-DrugBank.d458.s3.e1" charOffset="149-160"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d458.s3.e2" charOffset="196-206"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d458.s3.e3" charOffset="259-269"
            type="drug" text="terfenadine"/>
        <ddi id="DDI-DrugBank.d458.s3.d0" e1="DDI-DrugBank.d458.s3.e1"
            e2="DDI-DrugBank.d458.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s4" text="The increased plasma concentration of terfenadine or its metabolite may result in prolonged QT intervals.">
        <entity id="DDI-DrugBank.d458.s4.e0" charOffset="38-48"
            type="drug" text="terfenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s5" text="Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.">
        <entity id="DDI-DrugBank.d458.s5.e0" charOffset="40-51"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d458.s5.e1" charOffset="80-89"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d458.s5.e2" charOffset="131-140"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d458.s5.e3" charOffset="168-186"
            type="drug_n" text="desmethylastemizole"/>
        <ddi id="DDI-DrugBank.d458.s5.d0" e1="DDI-DrugBank.d458.s5.e0"
            e2="DDI-DrugBank.d458.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s6" text="Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.">
        <entity id="DDI-DrugBank.d458.s6.e0" charOffset="20-29"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d458.s6.e1" charOffset="36-47"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d458.s6.d0" e1="DDI-DrugBank.d458.s6.e0"
            e2="DDI-DrugBank.d458.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s7" text="Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.">
        <entity id="DDI-DrugBank.d458.s7.e0" charOffset="47-58"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d458.s7.e1" charOffset="96-104"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d458.s7.e2" charOffset="156-164"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d458.s7.d0" e1="DDI-DrugBank.d458.s7.e0"
            e2="DDI-DrugBank.d458.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s8" text="Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.">
        <entity id="DDI-DrugBank.d458.s8.e0" charOffset="43-54"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d458.s8.e1" charOffset="60-68"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d458.s8.d0" e1="DDI-DrugBank.d458.s8.e0"
            e2="DDI-DrugBank.d458.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s9" text="Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.">
        <entity id="DDI-DrugBank.d458.s9.e0" charOffset="40-51"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d458.s9.e1" charOffset="66-74"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d458.s9.d0" e1="DDI-DrugBank.d458.s9.e0"
            e2="DDI-DrugBank.d458.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s10" text="Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.">
        <entity id="DDI-DrugBank.d458.s10.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d458.s10.e1" charOffset="49-60"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d458.s10.e2" charOffset="63-72"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d458.s10.e3" charOffset="79-96"
            type="drug" text="methylprednisolone"/>
        <ddi id="DDI-DrugBank.d458.s10.d0" e1="DDI-DrugBank.d458.s10.e0"
            e2="DDI-DrugBank.d458.s10.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d458.s10.d1" e1="DDI-DrugBank.d458.s10.e0"
            e2="DDI-DrugBank.d458.s10.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d458.s10.d2" e1="DDI-DrugBank.d458.s10.e0"
            e2="DDI-DrugBank.d458.s10.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s11" text="Dosage adjustment may be required if cyclosporine, tacrolimus, or methylprednisolone are given concomitantly with NIZORAL  Tablets.">
        <entity id="DDI-DrugBank.d458.s11.e0" charOffset="37-48"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d458.s11.e1" charOffset="51-60"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d458.s11.e2" charOffset="66-83"
            type="drug" text="methylprednisolone"/>
        <entity id="DDI-DrugBank.d458.s11.e3" charOffset="114-120"
            type="brand" text="NIZORAL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s12" text="Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.">
        <entity id="DDI-DrugBank.d458.s12.e0" charOffset="20-26"
            type="brand" text="NIZORAL"/>
        <entity id="DDI-DrugBank.d458.s12.e1" charOffset="42-50"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d458.s12.e2" charOffset="55-63"
            type="drug" text="triazolam"/>
        <ddi id="DDI-DrugBank.d458.s12.d0" e1="DDI-DrugBank.d458.s12.e0"
            e2="DDI-DrugBank.d458.s12.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d458.s12.d1" e1="DDI-DrugBank.d458.s12.e0"
            e2="DDI-DrugBank.d458.s12.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s13" text="This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents."/>
    <sentence id="DDI-DrugBank.d458.s14" text="These agents should not be used in patients treated with NIZORAL  Tablets.">
        <entity id="DDI-DrugBank.d458.s14.e0" charOffset="57-63"
            type="brand" text="NIZORAL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s15" text="If midazolam is administered parenterally, special precaution is required since the sedative effect may be prolonged.">
        <entity id="DDI-DrugBank.d458.s15.e0" charOffset="3-11"
            type="drug" text="midazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s16" text="Rare cases of elevated plasma concentrations of digoxin have been reported.">
        <entity id="DDI-DrugBank.d458.s16.e0" charOffset="48-54"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s17" text="It is not clear whether this was due to the combination of therapy."/>
    <sentence id="DDI-DrugBank.d458.s18" text="It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.">
        <entity id="DDI-DrugBank.d458.s18.e0" charOffset="39-45"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d458.s18.e1" charOffset="84-95"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d458.s18.d0" e1="DDI-DrugBank.d458.s18.e0"
            e2="DDI-DrugBank.d458.s18.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s19" text="When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.">
        <entity id="DDI-DrugBank.d458.s19.e0" charOffset="20-38"
            type="group" text="imidazole compounds"/>
        <entity id="DDI-DrugBank.d458.s19.e1" charOffset="45-56"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d458.s19.e2" charOffset="98-105"
            type="group" text="coumarin"/>
        <ddi id="DDI-DrugBank.d458.s19.d0" e1="DDI-DrugBank.d458.s19.e0"
            e2="DDI-DrugBank.d458.s19.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d458.s19.d1" e1="DDI-DrugBank.d458.s19.e1"
            e2="DDI-DrugBank.d458.s19.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s20" text="In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.">
        <entity id="DDI-DrugBank.d458.s20.e0" charOffset="31-45"
            type="group" text="imidazole drugs"/>
        <entity id="DDI-DrugBank.d458.s20.e1" charOffset="51-64"
            type="group" text="coumarin drugs"/>
        <ddi id="DDI-DrugBank.d458.s20.d0" e1="DDI-DrugBank.d458.s20.e0"
            e2="DDI-DrugBank.d458.s20.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s21" text="Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.">
        <entity id="DDI-DrugBank.d458.s21.e0" charOffset="87-96"
            type="drug" text="miconazole"/>
        <entity id="DDI-DrugBank.d458.s21.e1" charOffset="102-110"
            type="group" text="imidazole"/>
        <entity id="DDI-DrugBank.d458.s21.e2" charOffset="122-140"
            type="group" text="hypoglycemic agents"/>
        <entity id="DDI-DrugBank.d458.s21.e3" charOffset="229-240"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d458.s21.e4" charOffset="254-262"
            type="group" text="imidazole"/>
        <ddi id="DDI-DrugBank.d458.s21.d0" e1="DDI-DrugBank.d458.s21.e0"
            e2="DDI-DrugBank.d458.s21.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s22" text="Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.">
        <entity id="DDI-DrugBank.d458.s22.e0" charOffset="30-41"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d458.s22.e1" charOffset="56-64"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d458.s22.d0" e1="DDI-DrugBank.d458.s22.e0"
            e2="DDI-DrugBank.d458.s22.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s23" text="It is suggested to monitor both ketoconazole and phenytoin.">
        <entity id="DDI-DrugBank.d458.s23.e0" charOffset="32-43"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d458.s23.e1" charOffset="49-57"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d458.s23.d0" e1="DDI-DrugBank.d458.s23.e0"
            e2="DDI-DrugBank.d458.s23.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s24" text="Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.">
        <entity id="DDI-DrugBank.d458.s24.e0" charOffset="30-37"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d458.s24.e1" charOffset="44-55"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d458.s24.d0" e1="DDI-DrugBank.d458.s24.e0"
            e2="DDI-DrugBank.d458.s24.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s25" text="INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.">
        <entity id="DDI-DrugBank.d458.s25.e0" charOffset="0-2"
            type="drug" text="INH"/>
        <entity id="DDI-DrugBank.d458.s25.e1" charOffset="5-13"
            type="drug" text="Isoniazid"/>
        <entity id="DDI-DrugBank.d458.s25.e2" charOffset="43-54"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d458.s25.d0" e1="DDI-DrugBank.d458.s25.e0"
            e2="DDI-DrugBank.d458.s25.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d458.s25.d1" e1="DDI-DrugBank.d458.s25.e1"
            e2="DDI-DrugBank.d458.s25.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s26" text="These drugs should not be given concomitantly."/>
    <sentence id="DDI-DrugBank.d458.s27" text="After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.">
        <entity id="DDI-DrugBank.d458.s27.e0" charOffset="42-53"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d458.s27.e1" charOffset="89-98"
            type="drug" text="loratadine"/>
        <entity id="DDI-DrugBank.d458.s27.e2" charOffset="136-145"
            type="drug" text="loratadine"/>
        <ddi id="DDI-DrugBank.d458.s27.d0" e1="DDI-DrugBank.d458.s27.e0"
            e2="DDI-DrugBank.d458.s27.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s28" text="The AUC and Cmax of descarboethoxyloratadine, an active metabolite, averaged 155% (  27 S.D.) and 141% (  35 S.D.), respectively.">
        <entity id="DDI-DrugBank.d458.s28.e0" charOffset="20-43"
            type="drug_n" text="descarboethoxyloratadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s29" text="However, no related changes were noted in the QT0 on ECG taken at 2, 6, and 24 hours after the coadministration."/>
    <sentence id="DDI-DrugBank.d458.s30" text="Also, there were no clinically significant differences in adverse events when loratadine was administered with or without ketoconazole.">
        <entity id="DDI-DrugBank.d458.s30.e0" charOffset="78-87"
            type="drug" text="loratadine"/>
        <entity id="DDI-DrugBank.d458.s30.e1" charOffset="122-133"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s31" text="Rare cases of a disulfiram-like reaction to alcohol have been reported.">
        <entity id="DDI-DrugBank.d458.s31.e0" charOffset="44-50"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d458.s32" text="These experiences have been characterized by flushing, rash, peripheral edema, nausea, and headache."/>
    <sentence id="DDI-DrugBank.d458.s33" text="Symptoms resolved within a few hours."/>
    <sentence id="DDI-DrugBank.d499.s0" text="The following drug interactions were studied with ketoprofen doses of 200 mg/day.">
        <entity id="DDI-DrugBank.d499.s0.e0" charOffset="50-59"
            type="drug" text="ketoprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s1" text="The possibility of increased interaction should be kept in mind when Orudis doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs.">
        <entity id="DDI-DrugBank.d499.s1.e0" charOffset="69-74"
            type="brand" text="Orudis"/>
        <entity id="DDI-DrugBank.d499.s1.e1" charOffset="131-140"
            type="drug" text="ketoprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s2" text="1."/>
    <sentence id="DDI-DrugBank.d499.s3" text="Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.">
        <entity id="DDI-DrugBank.d499.s3.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d499.s3.e1" charOffset="40-58"
            type="drug" text="magnesium hydroxide"/>
        <entity id="DDI-DrugBank.d499.s3.e2" charOffset="64-81"
            type="drug" text="aluminum hydroxide"/>
        <entity id="DDI-DrugBank.d499.s3.e3" charOffset="147-156"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s3.e4" charOffset="174-179"
            type="brand" text="Orudis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s4" text="2."/>
    <sentence id="DDI-DrugBank.d499.s5" text="Aspirin: Ketoprofen does not alter aspirin absorption;">
        <entity id="DDI-DrugBank.d499.s5.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d499.s5.e1" charOffset="9-18"
            type="drug" text="Ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s5.e2" charOffset="35-41"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s6" text="however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.">
        <entity id="DDI-DrugBank.d499.s6.e0" charOffset="72-78"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d499.s6.e1" charOffset="90-99"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s6.e2" charOffset="131-140"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s6.e3" charOffset="184-190"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d499.s6.e4" charOffset="212-218"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d499.s6.d0" e1="DDI-DrugBank.d499.s6.e0"
            e2="DDI-DrugBank.d499.s6.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d499.s6.d1" e1="DDI-DrugBank.d499.s6.e0"
            e2="DDI-DrugBank.d499.s6.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s7" text="The clinical significance of these changes has not been adequately studied."/>
    <sentence id="DDI-DrugBank.d499.s8" text="Therefore, concurrent use of aspirin and ketoprofen is not recommended.">
        <entity id="DDI-DrugBank.d499.s8.e0" charOffset="29-35"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d499.s8.e1" charOffset="41-50"
            type="drug" text="ketoprofen"/>
        <ddi id="DDI-DrugBank.d499.s8.d0" e1="DDI-DrugBank.d499.s8.e0"
            e2="DDI-DrugBank.d499.s8.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s9" text="3."/>
    <sentence id="DDI-DrugBank.d499.s10" text="Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.">
        <entity id="DDI-DrugBank.d499.s10.e0" charOffset="0-7"
            type="group" text="Diuretic"/>
        <entity id="DDI-DrugBank.d499.s10.e1" charOffset="10-28"
            type="drug" text="Hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d499.s10.e2" charOffset="56-65"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s10.e3" charOffset="145-163"
            type="drug" text="hydrochlorothiazide"/>
        <ddi id="DDI-DrugBank.d499.s10.d0" e1="DDI-DrugBank.d499.s10.e1"
            e2="DDI-DrugBank.d499.s10.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s11" text="Patients taking diuretics are at a greater risk of developing renal failure secondary to a decrease in renal blood flow caused by prostaglandin inhibition.">
        <entity id="DDI-DrugBank.d499.s11.e0" charOffset="16-24"
            type="group" text="diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s12" text="4."/>
    <sentence id="DDI-DrugBank.d499.s13" text="Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.">
        <entity id="DDI-DrugBank.d499.s13.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d499.s13.e1" charOffset="71-80"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s13.e2" charOffset="86-92"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d499.s13.e3" charOffset="127-136"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s13.e4" charOffset="172-178"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s14" text="5."/>
    <sentence id="DDI-DrugBank.d499.s15" text="Warfarin: In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time.">
        <entity id="DDI-DrugBank.d499.s15.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d499.s15.e1" charOffset="68-77"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s15.e2" charOffset="130-137"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s16" text="Bleeding from a number of sites may be a complication of warfarin treatment and GI bleeding a complication of ketoprofen treatment.">
        <entity id="DDI-DrugBank.d499.s16.e0" charOffset="57-64"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d499.s16.e1" charOffset="110-119"
            type="drug" text="ketoprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s17" text="Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.">
        <entity id="DDI-DrugBank.d499.s17.e0" charOffset="64-73"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s17.e1" charOffset="142-151"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s17.e2" charOffset="157-164"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d499.s17.d0" e1="DDI-DrugBank.d499.s17.e1"
            e2="DDI-DrugBank.d499.s17.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s18" text="6."/>
    <sentence id="DDI-DrugBank.d499.s19" text="Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.">
        <entity id="DDI-DrugBank.d499.s19.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d499.s19.e1" charOffset="12-21"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d499.s19.e2" charOffset="53-62"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s19.e3" charOffset="100-109"
            type="drug" text="ketoprofen"/>
        <ddi id="DDI-DrugBank.d499.s19.d0" e1="DDI-DrugBank.d499.s19.e1"
            e2="DDI-DrugBank.d499.s19.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s20" text="Therefore, the combination of ketoprofen and probenecid is not recommended.">
        <entity id="DDI-DrugBank.d499.s20.e0" charOffset="30-39"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s20.e1" charOffset="45-54"
            type="drug" text="probenecid"/>
        <ddi id="DDI-DrugBank.d499.s20.d0" e1="DDI-DrugBank.d499.s20.e0"
            e2="DDI-DrugBank.d499.s20.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s21" text="7."/>
    <sentence id="DDI-DrugBank.d499.s22" text="Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.">
        <entity id="DDI-DrugBank.d499.s22.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d499.s22.e1" charOffset="14-23"
            type="drug" text="Ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s22.e2" charOffset="37-42"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d499.s22.e3" charOffset="85-96"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d499.s22.d0" e1="DDI-DrugBank.d499.s22.e1"
            e2="DDI-DrugBank.d499.s22.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d499.s22.d1" e1="DDI-DrugBank.d499.s22.e2"
            e2="DDI-DrugBank.d499.s22.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s23" text="8."/>
    <sentence id="DDI-DrugBank.d499.s24" text="Lithium: Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.">
        <entity id="DDI-DrugBank.d499.s24.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d499.s24.e1" charOffset="9-45"
            type="group" text="Nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d499.s24.e2" charOffset="97-103"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d499.s24.d0" e1="DDI-DrugBank.d499.s24.e1"
            e2="DDI-DrugBank.d499.s24.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s25" text="It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.">
        <entity id="DDI-DrugBank.d499.s25.e0" charOffset="30-36"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d499.s25.e1" charOffset="63-72"
            type="drug" text="ketoprofen"/>
        <entity id="DDI-DrugBank.d499.s25.e2" charOffset="97-103"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d499.s25.d0" e1="DDI-DrugBank.d499.s25.e1"
            e2="DDI-DrugBank.d499.s25.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s26" text="DRUG/LABORATORY TEST INTERACTIONS: EFFECT ON BLOOD COAGULATION Ketoprofen decreases platelet adhesion and aggregation.">
        <entity id="DDI-DrugBank.d499.s26.e0" charOffset="63-72"
            type="drug" text="Ketoprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d499.s27" text="Therefore, it can prolong bleeding time by approximately 3 to 4 minutes from baseline values."/>
    <sentence id="DDI-DrugBank.d499.s28" text="There is no significant change in platelet count, prothrombin time, partial thromboplastin time, or thrombin time."/>
    <sentence id="DDI-DrugBank.d3.s0" text="Ketorolac is highly bound to human plasma protein (mean 99.2%).">
        <entity id="DDI-DrugBank.d3.s0.e0" charOffset="0-8" type="drug" text="Ketorolac"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s1" text="Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.">
        <entity id="DDI-DrugBank.d3.s1.e0" charOffset="0-7" type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d3.s1.e1" charOffset="10-16"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d3.s1.e2" charOffset="19-28"
            type="group" text="Salicylate"/>
        <entity id="DDI-DrugBank.d3.s1.e3" charOffset="35-41"
            type="drug" text="Heparin"/>
        <entity id="DDI-DrugBank.d3.s1.e4" charOffset="67-74"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d3.s1.e5" charOffset="123-144"
            type="drug" text="ketorolac tromethamine"/>
        <entity id="DDI-DrugBank.d3.s1.e6" charOffset="176-184"
            type="drug" text="ketorolac"/>
        <ddi id="DDI-DrugBank.d3.s1.d0" e1="DDI-DrugBank.d3.s1.e4"
            e2="DDI-DrugBank.d3.s1.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s2" text="Ketorolac does not alter digoxin protein binding.">
        <entity id="DDI-DrugBank.d3.s2.e0" charOffset="0-8" type="drug" text="Ketorolac"/>
        <entity id="DDI-DrugBank.d3.s2.e1" charOffset="25-31"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s3" text="In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.">
        <entity id="DDI-DrugBank.d3.s3.e0" charOffset="65-74"
            type="group" text="salicylate"/>
        <entity id="DDI-DrugBank.d3.s3.e1" charOffset="105-113"
            type="drug" text="ketorolac"/>
        <entity id="DDI-DrugBank.d3.s3.e2" charOffset="215-223"
            type="drug" text="ketorolac"/>
        <ddi id="DDI-DrugBank.d3.s3.d0" e1="DDI-DrugBank.d3.s3.e0"
            e2="DDI-DrugBank.d3.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s4" text="Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.">
        <entity id="DDI-DrugBank.d3.s4.e0" charOffset="30-36"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d3.s4.e1" charOffset="39-46"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d3.s4.e2" charOffset="49-57"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d3.s4.e3" charOffset="60-67"
            type="drug" text="naproxen"/>
        <entity id="DDI-DrugBank.d3.s4.e4" charOffset="70-78"
            type="drug" text="piroxicam"/>
        <entity id="DDI-DrugBank.d3.s4.e5" charOffset="81-93"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d3.s4.e6" charOffset="96-104"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d3.s4.e7" charOffset="135-156"
            type="drug" text="ketorolac tromethamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s5" text="In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg warfarin, causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin.">
        <entity id="DDI-DrugBank.d3.s5.e0" charOffset="101-108"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d3.s5.e1" charOffset="185-192"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s6" text="In another study, TORADOLIV/IM was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo.">
        <entity id="DDI-DrugBank.d3.s6.e0" charOffset="69-75"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d3.s6.e1" charOffset="234-240"
            type="drug" text="heparin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s7" text="Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.">
        <entity id="DDI-DrugBank.d3.s7.e0" charOffset="73-79"
            type="brand" text="TORADOL"/>
        <entity id="DDI-DrugBank.d3.s7.e1" charOffset="85-92"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d3.s7.e2" charOffset="97-103"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d3.s7.e3" charOffset="128-134"
            type="brand" text="TORADOL"/>
        <entity id="DDI-DrugBank.d3.s7.e4" charOffset="155-168"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d3.s7.d0" e1="DDI-DrugBank.d3.s7.e3"
            e2="DDI-DrugBank.d3.s7.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s8" text="Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).">
        <entity id="DDI-DrugBank.d3.s8.e0" charOffset="0-9" type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d3.s8.e1" charOffset="12-18"
            type="brand" text="TORADOL"/>
        <entity id="DDI-DrugBank.d3.s8.e2" charOffset="38-45"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d3.s8.e3" charOffset="59-68"
            type="drug" text="furosemide"/>
        <ddi id="DDI-DrugBank.d3.s8.d0" e1="DDI-DrugBank.d3.s8.e1"
            e2="DDI-DrugBank.d3.s8.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s9" text="Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.">
        <entity id="DDI-DrugBank.d3.s9.e0" charOffset="0-9" type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d3.s9.e1" charOffset="42-48"
            type="brand" text="TORADOL"/>
        <entity id="DDI-DrugBank.d3.s9.e2" charOffset="59-68"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d3.s9.e3" charOffset="105-113"
            type="drug" text="ketorolac"/>
        <entity id="DDI-DrugBank.d3.s9.e4" charOffset="144-152"
            type="drug" text="ketorolac"/>
        <ddi id="DDI-DrugBank.d3.s9.d0" e1="DDI-DrugBank.d3.s9.e1"
            e2="DDI-DrugBank.d3.s9.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s10" text="Therefore, concomitant use of TORADOL and probenecid is contraindicated.">
        <entity id="DDI-DrugBank.d3.s10.e0" charOffset="30-36"
            type="brand" text="TORADOL"/>
        <entity id="DDI-DrugBank.d3.s10.e1" charOffset="42-51"
            type="drug" text="probenecid"/>
        <ddi id="DDI-DrugBank.d3.s10.d0" e1="DDI-DrugBank.d3.s10.e0"
            e2="DDI-DrugBank.d3.s10.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s11" text="Lithium: Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.">
        <entity id="DDI-DrugBank.d3.s11.e0" charOffset="0-6" type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d3.s11.e1" charOffset="29-35"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d3.s11.e2" charOffset="81-87"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s12" text="The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.">
        <entity id="DDI-DrugBank.d3.s12.e0" charOffset="14-20"
            type="brand" text="TORADOL"/>
        <entity id="DDI-DrugBank.d3.s12.e1" charOffset="32-38"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d3.s12.e2" charOffset="85-91"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d3.s12.e3" charOffset="114-120"
            type="brand" text="TORADOL"/>
        <ddi id="DDI-DrugBank.d3.s12.d0" e1="DDI-DrugBank.d3.s12.e2"
            e2="DDI-DrugBank.d3.s12.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s13" text="Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.">
        <entity id="DDI-DrugBank.d3.s13.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d3.s13.e1" charOffset="44-55"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d3.s13.e2" charOffset="66-71"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d3.s13.e3" charOffset="118-129"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d3.s13.e4" charOffset="158-169"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d3.s13.d0" e1="DDI-DrugBank.d3.s13.e1"
            e2="DDI-DrugBank.d3.s13.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s14" text="The effect of TORADOL on methotrexate clearance has not been studied.">
        <entity id="DDI-DrugBank.d3.s14.e0" charOffset="14-20"
            type="brand" text="TORADOL"/>
        <entity id="DDI-DrugBank.d3.s14.e1" charOffset="25-36"
            type="drug" text="methotrexate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s15" text="Nondepolarizing Muscle Relaxants: In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and nondepolarizing muscle relaxants that resulted in apnea.">
        <entity id="DDI-DrugBank.d3.s15.e0" charOffset="0-31"
            type="group" text="Nondepolarizing Muscle Relaxants"/>
        <entity id="DDI-DrugBank.d3.s15.e1" charOffset="137-168"
            type="group" text="nondepolarizing muscle relaxants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s16" text="The concurrent use of TORADOL with muscle relaxants has not been formally studied.">
        <entity id="DDI-DrugBank.d3.s16.e0" charOffset="22-28"
            type="brand" text="TORADOL"/>
        <entity id="DDI-DrugBank.d3.s16.e1" charOffset="35-50"
            type="group" text="muscle relaxants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s17" text="ACE Inhibitors: Concomitant use of ACE inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients.">
        <entity id="DDI-DrugBank.d3.s17.e0" charOffset="0-13"
            type="group" text="ACE Inhibitors"/>
        <entity id="DDI-DrugBank.d3.s17.e1" charOffset="35-48"
            type="group" text="ACE inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s18" text="Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).">
        <entity id="DDI-DrugBank.d3.s18.e0" charOffset="0-18"
            type="group" text="Antiepileptic Drugs"/>
        <entity id="DDI-DrugBank.d3.s18.e1" charOffset="93-99"
            type="brand" text="TORADOL"/>
        <entity id="DDI-DrugBank.d3.s18.e2" charOffset="105-123"
            type="group" text="antiepileptic drugs"/>
        <entity id="DDI-DrugBank.d3.s18.e3" charOffset="126-134"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d3.s18.e4" charOffset="137-149"
            type="drug" text="carbamazepine"/>
        <ddi id="DDI-DrugBank.d3.s18.d0" e1="DDI-DrugBank.d3.s18.e1"
            e2="DDI-DrugBank.d3.s18.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d3.s18.d1" e1="DDI-DrugBank.d3.s18.e1"
            e2="DDI-DrugBank.d3.s18.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d3.s18.d2" e1="DDI-DrugBank.d3.s18.e1"
            e2="DDI-DrugBank.d3.s18.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s19" text="Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).">
        <entity id="DDI-DrugBank.d3.s19.e0" charOffset="0-17"
            type="group" text="Psychoactive Drugs"/>
        <entity id="DDI-DrugBank.d3.s19.e1" charOffset="59-65"
            type="brand" text="TORADOL"/>
        <entity id="DDI-DrugBank.d3.s19.e2" charOffset="95-112"
            type="group" text="psychoactive drugs"/>
        <entity id="DDI-DrugBank.d3.s19.e3" charOffset="115-124"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d3.s19.e4" charOffset="127-137"
            type="drug" text="thiothixene"/>
        <entity id="DDI-DrugBank.d3.s19.e5" charOffset="140-149"
            type="drug" text="alprazolam"/>
        <ddi id="DDI-DrugBank.d3.s19.d0" e1="DDI-DrugBank.d3.s19.e1"
            e2="DDI-DrugBank.d3.s19.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d3.s19.d1" e1="DDI-DrugBank.d3.s19.e1"
            e2="DDI-DrugBank.d3.s19.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d3.s19.d2" e1="DDI-DrugBank.d3.s19.e1"
            e2="DDI-DrugBank.d3.s19.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d3.s19.d3" e1="DDI-DrugBank.d3.s19.e1"
            e2="DDI-DrugBank.d3.s19.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s20" text="Morphine: TORADOLIV/IM has been administered concurrently with morphine in several clinical trials of postoperative pain without evidence of adverse interactions.">
        <entity id="DDI-DrugBank.d3.s20.e0" charOffset="0-7" type="drug" text="Morphine"/>
        <entity id="DDI-DrugBank.d3.s20.e1" charOffset="63-70"
            type="drug" text="morphine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s21" text="Do not mix TORADOL and morphine in the same syringe.">
        <entity id="DDI-DrugBank.d3.s21.e0" charOffset="11-17"
            type="brand" text="TORADOL"/>
        <entity id="DDI-DrugBank.d3.s21.e1" charOffset="23-30"
            type="drug" text="morphine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s22" text="There is no evidence in animal or human studies that TORADOL induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs">
        <entity id="DDI-DrugBank.d3.s22.e0" charOffset="53-59"
            type="brand" text="TORADOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d3.s23" text="."/>
    <sentence id="DDI-DrugBank.d3.s24" text=""/>
    <sentence id="DDI-DrugBank.d95.s0" text="Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.">
        <entity id="DDI-DrugBank.d95.s0.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d95.s0.e1" charOffset="15-24"
            type="drug" text="L-arginine"/>
        <entity id="DDI-DrugBank.d95.s0.e2" charOffset="69-79"
            type="drug" text="cyclosporin"/>
        <ddi id="DDI-DrugBank.d95.s0.d0" e1="DDI-DrugBank.d95.s0.e1"
            e2="DDI-DrugBank.d95.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d95.s1" text="Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.">
        <entity id="DDI-DrugBank.d95.s1.e0" charOffset="0-8" type="drug" text="Ibuprofen"/>
        <entity id="DDI-DrugBank.d95.s1.e1" charOffset="12-21"
            type="drug" text="L-arginine"/>
        <entity id="DDI-DrugBank.d95.s1.e2" charOffset="54-62"
            type="drug" text="ibuprofen"/>
        <ddi id="DDI-DrugBank.d95.s1.d0" e1="DDI-DrugBank.d95.s1.e1"
            e2="DDI-DrugBank.d95.s1.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d95.s2" text="Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.">
        <entity id="DDI-DrugBank.d95.s2.e0" charOffset="8-15"
            type="group" text="nitrates"/>
        <entity id="DDI-DrugBank.d95.s2.e1" charOffset="19-28"
            type="drug" text="L-arginine"/>
        <entity id="DDI-DrugBank.d95.s2.e2" charOffset="94-101"
            type="drug" text="nitrates"/>
        <ddi id="DDI-DrugBank.d95.s2.d0" e1="DDI-DrugBank.d95.s2.e1"
            e2="DDI-DrugBank.d95.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d95.s3" text="Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.">
        <entity id="DDI-DrugBank.d95.s3.e0" charOffset="0-17"
            type="drug" text="Sildenafil citrate"/>
        <entity id="DDI-DrugBank.d95.s3.e1" charOffset="36-45"
            type="drug" text="L-arginine"/>
        <entity id="DDI-DrugBank.d95.s3.e2" charOffset="84-101"
            type="drug" text="sildenafil citrate"/>
        <ddi id="DDI-DrugBank.d95.s3.d0" e1="DDI-DrugBank.d95.s3.e1"
            e2="DDI-DrugBank.d95.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d243.s0" text="No drug, nutritional supplement, food or herb interactions are known."/>
    <sentence id="DDI-DrugBank.d539.s0" text="Interacts with valproic acid">
        <entity id="DDI-DrugBank.d539.s0.e0" charOffset="15-27"
            type="drug" text="valproic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d92.s0" text="No well-known drug interactions with glutamic acid">
        <entity id="DDI-DrugBank.d92.s0.e0" charOffset="37-49"
            type="drug" text="glutamic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d66.s0" text="Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.">
        <entity id="DDI-DrugBank.d66.s0.e0" charOffset="0-19"
            type="drug" text="Human growth hormone"/>
        <entity id="DDI-DrugBank.d66.s0.e1" charOffset="42-52"
            type="drug" text="L-glutamine"/>
        <entity id="DDI-DrugBank.d66.s0.e2" charOffset="58-77"
            type="drug" text="human growth hormone"/>
        <ddi id="DDI-DrugBank.d66.s0.d0" e1="DDI-DrugBank.d66.s0.e1"
            e2="DDI-DrugBank.d66.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d66.s1" text="L-glutamine has orphan drug status for this indication.">
        <entity id="DDI-DrugBank.d66.s1.e0" charOffset="0-10"
            type="drug" text="L-glutamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d66.s2" text="Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.">
        <entity id="DDI-DrugBank.d66.s2.e0" charOffset="0-11"
            type="drug" text="Indomethacin"/>
        <entity id="DDI-DrugBank.d66.s2.e1" charOffset="34-44"
            type="drug" text="L-glutamine"/>
        <entity id="DDI-DrugBank.d66.s2.e2" charOffset="50-61"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d66.s2.e3" charOffset="122-133"
            type="drug" text="indomethacin"/>
        <ddi id="DDI-DrugBank.d66.s2.d0" e1="DDI-DrugBank.d66.s2.e1"
            e2="DDI-DrugBank.d66.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d66.s3" text="The reported dose used for L-glutamine was 21 grams daily taken in divided doses three times a day.">
        <entity id="DDI-DrugBank.d66.s3.e0" charOffset="27-37"
            type="drug" text="L-glutamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d66.s4" text="Further, misoprostol is reported to have a synergistic effect with this combination in ameliorating intestinal permeability.">
        <entity id="DDI-DrugBank.d66.s4.e0" charOffset="9-19"
            type="drug" text="misoprostol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d66.s5" text="Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.">
        <entity id="DDI-DrugBank.d66.s5.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d66.s5.e1" charOffset="40-51"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d66.s5.e2" charOffset="109-119"
            type="drug" text="L-glutamine"/>
        <ddi id="DDI-DrugBank.d66.s5.d0" e1="DDI-DrugBank.d66.s5.e1"
            e2="DDI-DrugBank.d66.s5.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d66.s6" text="In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.">
        <entity id="DDI-DrugBank.d66.s6.e0" charOffset="96-107"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d66.s6.e1" charOffset="150-160"
            type="drug" text="L-glutamine"/>
        <ddi id="DDI-DrugBank.d66.s6.d0" e1="DDI-DrugBank.d66.s6.e0"
            e2="DDI-DrugBank.d66.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d66.s7" text="Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.">
        <entity id="DDI-DrugBank.d66.s7.e0" charOffset="0-9" type="drug" text="Paclitaxel"/>
        <entity id="DDI-DrugBank.d66.s7.e1" charOffset="28-38"
            type="drug" text="L-glutamine"/>
        <entity id="DDI-DrugBank.d66.s7.e2" charOffset="112-121"
            type="drug" text="paclitaxel"/>
        <entity id="DDI-DrugBank.d66.s7.e3" charOffset="208-217"
            type="drug" text="paclitaxel"/>
        <ddi id="DDI-DrugBank.d66.s7.d0" e1="DDI-DrugBank.d66.s7.e1"
            e2="DDI-DrugBank.d66.s7.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d365.s0" text="Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.">
        <entity id="DDI-DrugBank.d365.s0.e0" charOffset="0-26"
            type="drug" text="Medroxyprogesterone Acetate"/>
        <entity id="DDI-DrugBank.d365.s0.e1" charOffset="30-40"
            type="drug" text="L-histidine"/>
        <entity id="DDI-DrugBank.d365.s0.e2" charOffset="100-126"
            type="drug" text="medroxyprogesterone acetate"/>
        <ddi id="DDI-DrugBank.d365.s0.d0" e1="DDI-DrugBank.d365.s0.e1"
            e2="DDI-DrugBank.d365.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d365.s1" text="H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.">
        <entity id="DDI-DrugBank.d365.s1.e0" charOffset="0-1;10-17"
            type="group" text="H1 Blockers"/>
        <entity id="DDI-DrugBank.d365.s1.e1" charOffset="7-17"
            type="group" text="H2 Blockers"/>
        <entity id="DDI-DrugBank.d365.s1.e2" charOffset="44-54"
            type="drug" text="L-histidine"/>
        <entity id="DDI-DrugBank.d365.s1.e3"
            charOffset="121-122;131-138" type="group" text="H1 blockers"/>
        <entity id="DDI-DrugBank.d365.s1.e4" charOffset="128-138"
            type="group" text="H2 blockers"/>
        <ddi id="DDI-DrugBank.d365.s1.d0" e1="DDI-DrugBank.d365.s1.e2"
            e2="DDI-DrugBank.d365.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d365.s1.d1" e1="DDI-DrugBank.d365.s1.e2"
            e2="DDI-DrugBank.d365.s1.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d344.s0" text="Concomitant use of calcium supplements and L-lysine may increase calcium absorption">
        <entity id="DDI-DrugBank.d344.s0.e0" charOffset="19-25"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d344.s0.e1" charOffset="43-50"
            type="drug" text="L-lysine"/>
        <entity id="DDI-DrugBank.d344.s0.e2" charOffset="65-71"
            type="drug" text="calcium"/>
        <ddi id="DDI-DrugBank.d344.s0.d0" e1="DDI-DrugBank.d344.s0.e0"
            e2="DDI-DrugBank.d344.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d528.s0" text="Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.">
        <entity id="DDI-DrugBank.d528.s0.e0" charOffset="0-12"
            type="drug" text="Acetaminophen"/>
        <entity id="DDI-DrugBank.d528.s0.e1" charOffset="18-29"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d528.s0.e2" charOffset="33-44"
            type="drug" text="L-methionine"/>
        <entity id="DDI-DrugBank.d528.s0.e3" charOffset="90-102"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d528.s0.e4" charOffset="134-145"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d528.s0.d0" e1="DDI-DrugBank.d528.s0.e2"
            e2="DDI-DrugBank.d528.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d528.s0.d1" e1="DDI-DrugBank.d528.s0.e2"
            e2="DDI-DrugBank.d528.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d528.s1" text="Theoretically, it may decrease hepatic toxicity in the case of other potential hepatotoxic drugs, as well."/>
    <sentence id="DDI-DrugBank.d528.s2" text="Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.">
        <entity id="DDI-DrugBank.d528.s2.e0" charOffset="0-9"
            type="drug" text="Gentamicin"/>
        <entity id="DDI-DrugBank.d528.s2.e1" charOffset="13-22"
            type="drug" text="Methionine"/>
        <entity id="DDI-DrugBank.d528.s2.e2" charOffset="68-77"
            type="drug" text="gentamicin"/>
        <ddi id="DDI-DrugBank.d528.s2.d0" e1="DDI-DrugBank.d528.s2.e1"
            e2="DDI-DrugBank.d528.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d530.s0" text="Non-selective monoamine oxidase (MAO) inhibitors - including phenelzine sulfate, tranylcypromine sulfate and pargyline HC1.">
        <entity id="DDI-DrugBank.d530.s0.e0" charOffset="0-47"
            type="group" text="Non-selective monoamine oxidase (MAO) inhibitors"/>
        <entity id="DDI-DrugBank.d530.s0.e1" charOffset="61-78"
            type="drug" text="phenelzine sulfate"/>
        <entity id="DDI-DrugBank.d530.s0.e2" charOffset="81-103"
            type="drug" text="tranylcypromine sulfate"/>
        <entity id="DDI-DrugBank.d530.s0.e3" charOffset="109-117"
            type="drug" text="pargyline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d530.s1" text="Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.">
        <entity id="DDI-DrugBank.d530.s1.e0" charOffset="19-33"
            type="drug" text="L-phenylalanine"/>
        <entity id="DDI-DrugBank.d530.s1.e1" charOffset="39-66"
            type="group" text="non-selective MAO inhibitors"/>
        <ddi id="DDI-DrugBank.d530.s1.d0" e1="DDI-DrugBank.d530.s1.e0"
            e2="DDI-DrugBank.d530.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d530.s2" text="Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.">
        <entity id="DDI-DrugBank.d530.s2.e0" charOffset="0-9"
            type="drug" text="Selegiline"/>
        <entity id="DDI-DrugBank.d530.s2.e1" charOffset="13-27"
            type="drug" text="L-phenylalanine"/>
        <entity id="DDI-DrugBank.d530.s2.e2" charOffset="37-59"
            type="group" text="selective MAO inhibitor"/>
        <entity id="DDI-DrugBank.d530.s2.e3" charOffset="61-70"
            type="drug" text="selegiline"/>
        <ddi id="DDI-DrugBank.d530.s2.d0" e1="DDI-DrugBank.d530.s2.e1"
            e2="DDI-DrugBank.d530.s2.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d530.s3" text="Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.">
        <entity id="DDI-DrugBank.d530.s3.e0" charOffset="0-16"
            type="group" text="Neuroleptic Drugs"/>
        <entity id="DDI-DrugBank.d530.s3.e1" charOffset="20-34"
            type="drug" text="L-phenylalanine"/>
        <entity id="DDI-DrugBank.d530.s3.e2" charOffset="92-108"
            type="group" text="neuroleptic drugs"/>
        <ddi id="DDI-DrugBank.d530.s3.d0" e1="DDI-DrugBank.d530.s3.e0"
            e2="DDI-DrugBank.d530.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d63.s0" text="Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.">
        <entity id="DDI-DrugBank.d63.s0.e0" charOffset="0-33"
            type="group" text="Monoamine oxidase (MAO) inhibitors"/>
        <entity id="DDI-DrugBank.d63.s0.e1" charOffset="43-55"
            type="drug" text="isocarboxazid"/>
        <entity id="DDI-DrugBank.d63.s0.e2" charOffset="64-70"
            type="brand" text="Marplan"/>
        <entity id="DDI-DrugBank.d63.s0.e3" charOffset="74-83"
            type="drug" text="phenelzine"/>
        <entity id="DDI-DrugBank.d63.s0.e4" charOffset="92-97"
            type="brand" text="Nardil"/>
        <entity id="DDI-DrugBank.d63.s0.e5" charOffset="101-112"
            type="drug" text="procarbazine"/>
        <entity id="DDI-DrugBank.d63.s0.e6" charOffset="121-128"
            type="brand" text="Matulane"/>
        <entity id="DDI-DrugBank.d63.s0.e7" charOffset="132-141"
            type="drug" text="selegiline"/>
        <entity id="DDI-DrugBank.d63.s0.e8" charOffset="150-157"
            type="brand" text="Eldepryl"/>
        <entity id="DDI-DrugBank.d63.s0.e9" charOffset="165-179"
            type="drug" text="tranylcypromine"/>
        <entity id="DDI-DrugBank.d63.s0.e10" charOffset="188-194"
            type="brand" text="Parnate"/>
        <entity id="DDI-DrugBank.d63.s0.e11" charOffset="225-236"
            type="drug" text="L-tryptophan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d111.s0" text="Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.">
        <entity id="DDI-DrugBank.d111.s0.e0" charOffset="0-27"
            type="group" text="Non-selective MAO inhibitors"/>
        <entity id="DDI-DrugBank.d111.s0.e1" charOffset="39-61"
            type="drug" text="tranylcypromine sulfate"/>
        <entity id="DDI-DrugBank.d111.s0.e2" charOffset="64-81"
            type="drug" text="phenelzine sulfate"/>
        <entity id="DDI-DrugBank.d111.s0.e3" charOffset="88-96"
            type="drug" text="pargyline"/>
        <entity id="DDI-DrugBank.d111.s0.e4" charOffset="122-131"
            type="drug" text="L-tyrosine"/>
        <entity id="DDI-DrugBank.d111.s0.e5" charOffset="151-164"
            type="group" text="MAO inhibitors"/>
        <ddi id="DDI-DrugBank.d111.s0.d0" e1="DDI-DrugBank.d111.s0.e4"
            e2="DDI-DrugBank.d111.s0.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s0" text="In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.">
        <entity id="DDI-DrugBank.d412.s0.e0" charOffset="39-51"
            type="drug" text="labetalol HCl"/>
        <entity id="DDI-DrugBank.d412.s0.e1" charOffset="73-97"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d412.s0.e2" charOffset="162-174"
            type="drug" text="labetalol HCl"/>
        <ddi id="DDI-DrugBank.d412.s0.d0" e1="DDI-DrugBank.d412.s0.e0"
            e2="DDI-DrugBank.d412.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s1" text="The contribution of each of the treatments to this adverse reaction is unknown but the possibility of a drug interaction cannot be excluded."/>
    <sentence id="DDI-DrugBank.d412.s2" text="Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm;">
        <entity id="DDI-DrugBank.d412.s2.e0" charOffset="81-107"
            type="group" text="beta-receptor agonist drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s3" text="therefore, doses greater than the normal antiasthmatic dose of beta-agonist bronchodilator drugs may be required.">
        <entity id="DDI-DrugBank.d412.s3.e0" charOffset="63-95"
            type="group" text="beta-agonist bronchodilator drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s4" text="Cimetidine has been shown to increase the bioavailability of labetalol HCl.">
        <entity id="DDI-DrugBank.d412.s4.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d412.s4.e1" charOffset="61-73"
            type="drug" text="labetalol HCl"/>
        <ddi id="DDI-DrugBank.d412.s4.d0" e1="DDI-DrugBank.d412.s4.e0"
            e2="DDI-DrugBank.d412.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s5" text="Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients.">
        <entity id="DDI-DrugBank.d412.s5.e0" charOffset="105-117"
            type="drug" text="labetalol HCl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s6" text="Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.">
        <entity id="DDI-DrugBank.d412.s6.e0" charOffset="33-41"
            type="drug" text="halothane"/>
        <entity id="DDI-DrugBank.d412.s6.e1" charOffset="85-97"
            type="drug" text="labetalol HCl"/>
        <ddi id="DDI-DrugBank.d412.s6.d0" e1="DDI-DrugBank.d412.s6.e0"
            e2="DDI-DrugBank.d412.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s7" text="During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.">
        <entity id="DDI-DrugBank.d412.s7.e0" charOffset="47-59"
            type="drug" text="labetalol HCl"/>
        <entity id="DDI-DrugBank.d412.s7.e1" charOffset="81-89"
            type="drug" text="halothane"/>
        <entity id="DDI-DrugBank.d412.s7.e2" charOffset="129-137"
            type="drug" text="halothane"/>
        <ddi id="DDI-DrugBank.d412.s7.d0" e1="DDI-DrugBank.d412.s7.e0"
            e2="DDI-DrugBank.d412.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s8" text="The anesthesiologist should be informed when a patient is receiving labetalol HCl.">
        <entity id="DDI-DrugBank.d412.s8.e0" charOffset="68-80"
            type="drug" text="labetalol HCl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s9" text="Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.">
        <entity id="DDI-DrugBank.d412.s9.e0" charOffset="0-12"
            type="drug" text="Labetalol HCl"/>
        <entity id="DDI-DrugBank.d412.s9.e1" charOffset="56-68"
            type="drug" text="nitroglycerin"/>
        <ddi id="DDI-DrugBank.d412.s9.d0" e1="DDI-DrugBank.d412.s9.e0"
            e2="DDI-DrugBank.d412.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s10" text="If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.">
        <entity id="DDI-DrugBank.d412.s10.e0" charOffset="3-15"
            type="drug" text="labetalol HCl"/>
        <entity id="DDI-DrugBank.d412.s10.e1" charOffset="30-42"
            type="drug" text="nitroglycerin"/>
        <ddi id="DDI-DrugBank.d412.s10.d0" e1="DDI-DrugBank.d412.s10.e0"
            e2="DDI-DrugBank.d412.s10.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s11" text="Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.">
        <entity id="DDI-DrugBank.d412.s11.e0" charOffset="24-32"
            type="drug" text="labetalol"/>
        <entity id="DDI-DrugBank.d412.s11.e1" charOffset="61-78"
            type="group" text="calcium antagonist"/>
        <entity id="DDI-DrugBank.d412.s11.e2" charOffset="88-96"
            type="drug" text="verapamil"/>
        <ddi id="DDI-DrugBank.d412.s11.d0" e1="DDI-DrugBank.d412.s11.e0"
            e2="DDI-DrugBank.d412.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s12" text="Risk of Anaphylactic Reaction While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.">
        <entity id="DDI-DrugBank.d412.s12.e0" charOffset="43-55"
            type="group" text="beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s13" text="Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.">
        <entity id="DDI-DrugBank.d412.s13.e0" charOffset="56-66"
            type="drug" text="epinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s14" text="Drug/Laboratory Test Interactions The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine and vanillylmandelic acid when measured by fluorimetric or photometric methods."/>
    <sentence id="DDI-DrugBank.d412.s15" text="In screening patients suspected of having a pheochromocytoma and being treated with labetalol HCl, a specific method, such as a high performance liquid chromatographic assay with solid phase extraction (e.g., J Chromatogr 385:241,1987) should be employed in determining levels of catecholamines.">
        <entity id="DDI-DrugBank.d412.s15.e0" charOffset="84-96"
            type="drug" text="labetalol HCl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s16" text="Labetalol HCl has also been reported to produce a false positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A  (thin-layer chromatographic assay) and Emit-d.a.u.  (radioenzymatic assay).">
        <entity id="DDI-DrugBank.d412.s16.e0" charOffset="0-12"
            type="drug" text="Labetalol HCl"/>
        <entity id="DDI-DrugBank.d412.s16.e1" charOffset="74-84"
            type="drug" text="amphetamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d412.s17" text="When patients being treated with labetalol have a positive urine test for amphetamine using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique.">
        <entity id="DDI-DrugBank.d412.s17.e0" charOffset="33-41"
            type="drug" text="labetalol"/>
        <entity id="DDI-DrugBank.d412.s17.e1" charOffset="74-84"
            type="drug" text="amphetamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d206.s0" text="Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.">
        <entity id="DDI-DrugBank.d206.s0.e0" charOffset="77-84"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d206.s0.e1" charOffset="110-118"
            type="drug" text="lactulose"/>
        <entity id="DDI-DrugBank.d206.s0.e2" charOffset="144-152"
            type="drug" text="lactulose"/>
        <ddi id="DDI-DrugBank.d206.s0.d0" e1="DDI-DrugBank.d206.s0.e0"
            e2="DDI-DrugBank.d206.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d206.s1" text="Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose.">
        <entity id="DDI-DrugBank.d206.s1.e0" charOffset="140-148"
            type="drug" text="lactulose"/>
    </sentence>
    <sentence id="DDI-DrugBank.d71.s0" text="Lamivudine is predominantly eliminated in the urine by active organic cationic secretion.">
        <entity id="DDI-DrugBank.d71.s0.e0" charOffset="0-9" type="drug" text="Lamivudine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d71.s1" text="The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim).">
        <entity id="DDI-DrugBank.d71.s1.e0" charOffset="222-233"
            type="drug" text="trimethoprim"/>
    </sentence>
    <sentence id="DDI-DrugBank.d71.s2" text="No change in dose of either drug is recommended."/>
    <sentence id="DDI-DrugBank.d71.s3" text="There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.">
        <entity id="DDI-DrugBank.d71.s3.e0" charOffset="48-57"
            type="drug" text="lamivudine"/>
        <entity id="DDI-DrugBank.d71.s3.e1" charOffset="95-97"
            type="drug" text="TMP"/>
        <entity id="DDI-DrugBank.d71.s3.e2" charOffset="99-101"
            type="drug" text="SMX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d71.s4" text="No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.">
        <entity id="DDI-DrugBank.d71.s4.e0" charOffset="118-127"
            type="drug" text="lamivudine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d71.s5" text="Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.">
        <entity id="DDI-DrugBank.d71.s5.e0" charOffset="0-9" type="drug" text="Lamivudine"/>
        <entity id="DDI-DrugBank.d71.s5.e1" charOffset="15-25"
            type="drug" text="zalcitabine"/>
        <ddi id="DDI-DrugBank.d71.s5.d0" e1="DDI-DrugBank.d71.s5.e0"
            e2="DDI-DrugBank.d71.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d71.s6" text="Therefore, use of lamivudine in combination with zalcitabine is not recommended">
        <entity id="DDI-DrugBank.d71.s6.e0" charOffset="18-27"
            type="drug" text="lamivudine"/>
        <entity id="DDI-DrugBank.d71.s6.e1" charOffset="49-59"
            type="drug" text="zalcitabine"/>
        <ddi id="DDI-DrugBank.d71.s6.d0" e1="DDI-DrugBank.d71.s6.e0"
            e2="DDI-DrugBank.d71.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d71.s7" text="."/>
    <sentence id="DDI-DrugBank.d71.s8" text=""/>
    <sentence id="DDI-DrugBank.d431.s0" text="Lansoprazole is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes.">
        <entity id="DDI-DrugBank.d431.s0.e0" charOffset="0-11"
            type="drug" text="Lansoprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d431.s1" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.">
        <entity id="DDI-DrugBank.d431.s1.e0" charOffset="24-35"
            type="drug" text="lansoprazole"/>
        <entity id="DDI-DrugBank.d431.s1.e1" charOffset="155-162"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d431.s1.e2" charOffset="165-174"
            type="drug" text="antipyrine"/>
        <entity id="DDI-DrugBank.d431.s1.e3" charOffset="177-188"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d431.s1.e4" charOffset="191-199"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d431.s1.e5" charOffset="202-210"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d431.s1.e6" charOffset="213-223"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d431.s1.e7" charOffset="226-235"
            type="drug" text="prednisone"/>
        <entity id="DDI-DrugBank.d431.s1.e8" charOffset="238-245"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d431.s1.e9" charOffset="248-261"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d431.s1.e10" charOffset="267-277"
            type="drug" text="terfenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d431.s2" text="These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A."/>
    <sentence id="DDI-DrugBank.d431.s3" text="When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.">
        <entity id="DDI-DrugBank.d431.s3.e0" charOffset="5-16"
            type="drug" text="lansoprazole"/>
        <entity id="DDI-DrugBank.d431.s3.e1" charOffset="54-65"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d431.s3.e2" charOffset="127-138"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d431.s3.d0" e1="DDI-DrugBank.d431.s3.e0"
            e2="DDI-DrugBank.d431.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d431.s4" text="Because the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be clinical concern.">
        <entity id="DDI-DrugBank.d431.s4.e0" charOffset="63-74"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d431.s5" text="Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.">
        <entity id="DDI-DrugBank.d431.s5.e0" charOffset="75-86"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d431.s5.e1" charOffset="100-111"
            type="drug" text="lansoprazole"/>
        <ddi id="DDI-DrugBank.d431.s5.d0" e1="DDI-DrugBank.d431.s5.e0"
            e2="DDI-DrugBank.d431.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d431.s6" text="Lansoprazole has also been shown to have no clinically significant interaction with amoxicillin.">
        <entity id="DDI-DrugBank.d431.s6.e0" charOffset="0-11"
            type="drug" text="Lansoprazole"/>
        <entity id="DDI-DrugBank.d431.s6.e1" charOffset="84-94"
            type="drug" text="amoxicillin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d431.s7" text="In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.">
        <entity id="DDI-DrugBank.d431.s7.e0" charOffset="43-54"
            type="drug" text="lansoprazole"/>
        <entity id="DDI-DrugBank.d431.s7.e1" charOffset="66-75"
            type="drug" text="omeprazole"/>
        <entity id="DDI-DrugBank.d431.s7.e2" charOffset="130-139"
            type="drug" text="sucralfate"/>
        <entity id="DDI-DrugBank.d431.s7.e3" charOffset="167-188"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-DrugBank.d431.s7.e4" charOffset="307-316"
            type="drug" text="sucralfate"/>
        <ddi id="DDI-DrugBank.d431.s7.d0" e1="DDI-DrugBank.d431.s7.e3"
            e2="DDI-DrugBank.d431.s7.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d431.s8" text="Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.">
        <entity id="DDI-DrugBank.d431.s8.e0" charOffset="11-32"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-DrugBank.d431.s8.e1" charOffset="79-88"
            type="drug" text="sucralfate"/>
        <ddi id="DDI-DrugBank.d431.s8.d0" e1="DDI-DrugBank.d431.s8.e0"
            e2="DDI-DrugBank.d431.s8.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d431.s9" text="In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules;">
        <entity id="DDI-DrugBank.d431.s9.e0" charOffset="20-27"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d431.s9.e1" charOffset="66-77"
            type="drug" text="lansoprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d431.s10" text="this did not interfere with its effect."/>
    <sentence id="DDI-DrugBank.d431.s11" text="Lansoprazole causes a profound and long lasting inhibition of gastric acid secretion;">
        <entity id="DDI-DrugBank.d431.s11.e0" charOffset="0-11"
            type="drug" text="Lansoprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d431.s12" text="therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).">
        <entity id="DDI-DrugBank.d431.s12.e0" charOffset="45-56"
            type="drug" text="lansoprazole"/>
        <entity id="DDI-DrugBank.d431.s12.e1" charOffset="171-182"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d431.s12.e2" charOffset="185-194"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d431.s12.e3" charOffset="204-207"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d431.s12.e4" charOffset="216-222"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d431.s12.d0" e1="DDI-DrugBank.d431.s12.e0"
            e2="DDI-DrugBank.d431.s12.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d431.s12.d1" e1="DDI-DrugBank.d431.s12.e0"
            e2="DDI-DrugBank.d431.s12.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d431.s12.d2" e1="DDI-DrugBank.d431.s12.e0"
            e2="DDI-DrugBank.d431.s12.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d431.s12.d3" e1="DDI-DrugBank.d431.s12.e0"
            e2="DDI-DrugBank.d431.s12.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s0" text="Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.">
        <entity id="DDI-DrugBank.d135.s0.e0" charOffset="11-19"
            type="drug" text="Lapatinib"/>
        <entity id="DDI-DrugBank.d135.s0.e1" charOffset="77-85"
            type="drug" text="Lapatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s1" text="Caution should be exercised and dose reduction of the concomitant substrate drug should be considered when dosing lapatinib concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4 or CYP2C8.">
        <entity id="DDI-DrugBank.d135.s1.e0" charOffset="114-122"
            type="drug" text="lapatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s2" text="Lapatinib did not significantly inhibit the following enzymes in human liver microsomes: CYP1A2, CYP2C9, CYP2C19, and CYP2D6 or UGT enzymes in vitro, however, the clinical significance is unknown.">
        <entity id="DDI-DrugBank.d135.s2.e0" charOffset="0-8"
            type="drug" text="Lapatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s3" text="Lapatinib inhibits human P-glycoprotein.">
        <entity id="DDI-DrugBank.d135.s3.e0" charOffset="0-8"
            type="drug" text="Lapatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s4" text="If TYKERB is administered with drugs that are substrates of Pgp, increased concentrations of the substrate drug are likely, and caution should be exercised.">
        <entity id="DDI-DrugBank.d135.s4.e0" charOffset="3-8"
            type="brand" text="TYKERB"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s5" text="Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.">
        <entity id="DDI-DrugBank.d135.s5.e0" charOffset="57-65"
            type="drug" text="Lapatinib"/>
        <entity id="DDI-DrugBank.d135.s5.e1" charOffset="189-197"
            type="drug" text="lapatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s6" text="Dose adjustment of lapatinib should be considered for patients who must receive concomitant strong inhibitors or concomitant strong inducers of CYP3A4 enzymes.">
        <entity id="DDI-DrugBank.d135.s6.e0" charOffset="19-27"
            type="drug" text="lapatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s7" text="Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.">
        <entity id="DDI-DrugBank.d135.s7.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d135.s7.e1" charOffset="44-55"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d135.s7.e2" charOffset="139-147"
            type="drug" text="lapatinib"/>
        <ddi id="DDI-DrugBank.d135.s7.d0" e1="DDI-DrugBank.d135.s7.e1"
            e2="DDI-DrugBank.d135.s7.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s8" text="Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.">
        <entity id="DDI-DrugBank.d135.s8.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d135.s8.e1" charOffset="65-77"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d135.s8.e2" charOffset="176-184"
            type="drug" text="lapatinib"/>
        <ddi id="DDI-DrugBank.d135.s8.d0" e1="DDI-DrugBank.d135.s8.e1"
            e2="DDI-DrugBank.d135.s8.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s9" text="Drugs that Inhibit Drug Transport Systems Lapatinib is a substrate of the efflux transporter P-glycoprotein (Pgp, ABCB1).">
        <entity id="DDI-DrugBank.d135.s9.e0" charOffset="42-50"
            type="drug" text="Lapatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s10" text="If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.">
        <entity id="DDI-DrugBank.d135.s10.e0" charOffset="3-8"
            type="brand" text="TYKERB"/>
        <entity id="DDI-DrugBank.d135.s10.e1" charOffset="83-91"
            type="drug" text="lapatinib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d135.s11" text="Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).">
        <entity id="DDI-DrugBank.d135.s11.e0" charOffset="77-85"
            type="drug" text="lapatinib"/>
        <entity id="DDI-DrugBank.d135.s11.e1" charOffset="92-103"
            type="drug" text="capecitabine"/>
        <entity id="DDI-DrugBank.d135.s11.e2" charOffset="192-203"
            type="drug" text="capecitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d300.s0" text="No formal drug interaction studies have been conducted."/>
    <sentence id="DDI-DrugBank.d118.s0" text="In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost.">
        <entity id="DDI-DrugBank.d118.s0.e0" charOffset="80-89"
            type="drug_n" text="thimerosal"/>
        <entity id="DDI-DrugBank.d118.s0.e1" charOffset="106-116"
            type="drug" text="latanoprost"/>
    </sentence>
    <sentence id="DDI-DrugBank.d118.s1" text="If such drugs are used they should be administered with an interval of at least 5 minutes between applications."/>
    <sentence id="DDI-DrugBank.d41.s0" text="Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .">
        <entity id="DDI-DrugBank.d41.s0.e0" charOffset="0-13"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d41.s0.e1" charOffset="19-26"
            type="drug" text="Charcoal"/>
        <entity id="DDI-DrugBank.d41.s0.e2" charOffset="46-59"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d41.s0.e3" charOffset="64-81"
            type="drug" text="activated charcoal"/>
        <entity id="DDI-DrugBank.d41.s0.e4" charOffset="208-218"
            type="drug" text="leflunomide"/>
        <ddi id="DDI-DrugBank.d41.s0.d0" e1="DDI-DrugBank.d41.s0.e2"
            e2="DDI-DrugBank.d41.s0.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d41.s0.d1" e1="DDI-DrugBank.d41.s0.e3"
            e2="DDI-DrugBank.d41.s0.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d41.s1" text="Hepatotoxic Drugs Increased side effects may occur when leflunomide is given concomitantly with hepatotoxic substances.">
        <entity id="DDI-DrugBank.d41.s1.e0" charOffset="56-66"
            type="drug" text="leflunomide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d41.s2" text="This is also to be considered when leflunomide treatment is followed by such drugs without a drug elimination procedure.">
        <entity id="DDI-DrugBank.d41.s2.e0" charOffset="35-45"
            type="drug" text="leflunomide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d41.s3" text="In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.">
        <entity id="DDI-DrugBank.d41.s3.e0" charOffset="39-43"
            type="brand" text="ARAVA"/>
        <entity id="DDI-DrugBank.d41.s3.e1" charOffset="50-61"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d41.s3.d0" e1="DDI-DrugBank.d41.s3.e0"
            e2="DDI-DrugBank.d41.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d41.s4" text="All elevations resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide.">
        <entity id="DDI-DrugBank.d41.s4.e0" charOffset="90-100"
            type="drug" text="leflunomide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d41.s5" text="A  3-fold increase was seen in another 5 patients."/>
    <sentence id="DDI-DrugBank.d41.s6" text="All of these also resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide.">
        <entity id="DDI-DrugBank.d41.s6.e0" charOffset="93-103"
            type="drug" text="leflunomide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d41.s7" text="Three patients met ACR criteria for liver biopsy (1: Roegnik Grade I, 2: Roegnik Grade IIIa)."/>
    <sentence id="DDI-DrugBank.d41.s8" text="No pharmacokinetic interaction was identified."/>
    <sentence id="DDI-DrugBank.d41.s9" text="NSAIDs: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.">
        <entity id="DDI-DrugBank.d41.s9.e0" charOffset="0-5"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d41.s9.e1" charOffset="107-116"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d41.s9.e2" charOffset="122-130"
            type="drug" text="ibuprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d41.s10" text="The clinical significance of this finding is unknown;"/>
    <sentence id="DDI-DrugBank.d41.s11" text="however, there was extensive concomitant use of NSAIDs in clinical studies and no differential effect was observed.">
        <entity id="DDI-DrugBank.d41.s11.e0" charOffset="48-53"
            type="group" text="NSAIDs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d41.s12" text="Tolbutamide: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range.">
        <entity id="DDI-DrugBank.d41.s12.e0" charOffset="0-10"
            type="drug" text="Tolbutamide"/>
        <entity id="DDI-DrugBank.d41.s12.e1" charOffset="112-122"
            type="drug" text="tolbutamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d41.s13" text="The clinical significance of this finding is unknown."/>
    <sentence id="DDI-DrugBank.d41.s14" text="Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.">
        <entity id="DDI-DrugBank.d41.s14.e0" charOffset="0-7"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d41.s14.e1" charOffset="67-71"
            type="brand" text="ARAVA"/>
        <entity id="DDI-DrugBank.d41.s14.e2" charOffset="113-120"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d41.s14.e3" charOffset="181-185"
            type="brand" text="ARAVA"/>
        <ddi id="DDI-DrugBank.d41.s14.d0" e1="DDI-DrugBank.d41.s14.e1"
            e2="DDI-DrugBank.d41.s14.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d41.s15" text="Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.">
        <entity id="DDI-DrugBank.d41.s15.e0" charOffset="29-33"
            type="brand" text="ARAVA"/>
        <entity id="DDI-DrugBank.d41.s15.e1" charOffset="148-152"
            type="brand" text="ARAVA"/>
        <entity id="DDI-DrugBank.d41.s15.e2" charOffset="158-165"
            type="drug" text="rifampin"/>
        <ddi id="DDI-DrugBank.d41.s15.d0" e1="DDI-DrugBank.d41.s15.e1"
            e2="DDI-DrugBank.d41.s15.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d41.s16" text="Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.">
        <entity id="DDI-DrugBank.d41.s16.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d41.s16.e1" charOffset="62-66"
            type="brand" text="ARAVA"/>
        <entity id="DDI-DrugBank.d41.s16.e2" charOffset="72-79"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d41.s16.d0" e1="DDI-DrugBank.d41.s16.e1"
            e2="DDI-DrugBank.d41.s16.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d169.s0" text="Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID  (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.">
        <entity id="DDI-DrugBank.d169.s0.e0" charOffset="81-88"
            type="brand" text="REVLIMID"/>
        <entity id="DDI-DrugBank.d169.s0.e1" charOffset="92-103"
            type="drug" text="lenalidomide"/>
        <entity id="DDI-DrugBank.d169.s0.e2" charOffset="200-211"
            type="drug" text="lenalidomide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d169.s1" text="Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin.">
        <entity id="DDI-DrugBank.d169.s1.e0" charOffset="48-59"
            type="drug" text="lenalidomide"/>
        <entity id="DDI-DrugBank.d169.s1.e1"
            charOffset="114-115;124-131" type="drug" text="R- warfarin"/>
        <entity id="DDI-DrugBank.d169.s1.e2" charOffset="121-131"
            type="drug" text="S- warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d169.s2" text="Co-administration of single 25-mg dose warfarin had no effect on the pharmacokinetics of total lenalidomide.">
        <entity id="DDI-DrugBank.d169.s2.e0" charOffset="39-46"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d169.s2.e1" charOffset="95-106"
            type="drug" text="lenalidomide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d169.s3" text="Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration.">
        <entity id="DDI-DrugBank.d169.s3.e0" charOffset="77-84"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d169.s3.e1" charOffset="153-164"
            type="drug" text="lenalidomide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d52.s0" text="Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation">
        <entity id="DDI-DrugBank.d52.s0.e0" charOffset="27-39"
            type="group" text="thrombolytics"/>
        <entity id="DDI-DrugBank.d52.s0.e1" charOffset="55-67"
            type="drug" text="streptokinase"/>
        <entity id="DDI-DrugBank.d52.s0.e2" charOffset="158-165"
            type="brand" text="REFLUDAN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d52.s1" text="Concomitant treatment with coumarin derivatives (vitamin K antagonists) and drugs that affect platelet function may also increase the risk of bleeding.">
        <entity id="DDI-DrugBank.d52.s1.e0" charOffset="27-46"
            type="group" text="coumarin derivatives"/>
        <entity id="DDI-DrugBank.d52.s1.e1" charOffset="49-69"
            type="group" text="vitamin K antagonists"/>
    </sentence>
    <sentence id="DDI-DrugBank.d157.s0" text="Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.">
        <entity id="DDI-DrugBank.d157.s0.e0" charOffset="34-43"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d157.s0.e1" charOffset="49-56"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d157.s0.e2" charOffset="97-102"
            type="brand" text="Femara"/>
    </sentence>
    <sentence id="DDI-DrugBank.d157.s1" text="(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.">
        <entity id="DDI-DrugBank.d157.s1.e0" charOffset="48-53"
            type="brand" text="Femara"/>
        <entity id="DDI-DrugBank.d157.s1.e1" charOffset="59-67"
            type="drug" text="tamoxifen"/>
        <entity id="DDI-DrugBank.d157.s1.e2" charOffset="108-116"
            type="drug" text="letrozole"/>
        <ddi id="DDI-DrugBank.d157.s1.d0" e1="DDI-DrugBank.d157.s1.e0"
            e2="DDI-DrugBank.d157.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d157.s2" text="There is no clinical experience to date on the use of Femara in combination with other anticancer agents.">
        <entity id="DDI-DrugBank.d157.s2.e0" charOffset="54-59"
            type="brand" text="Femara"/>
    </sentence>
    <sentence id="DDI-DrugBank.d157.s3" text="Drug/Laboratory Test-Interactions None observed."/>
    <sentence id="DDI-DrugBank.d151.s0" text="Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.">
        <entity id="DDI-DrugBank.d151.s0.e0" charOffset="0-9"
            type="drug" text="Folic acid"/>
        <entity id="DDI-DrugBank.d151.s0.e1" charOffset="71-83"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d151.s0.e2" charOffset="86-94"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d151.s0.e3" charOffset="100-108"
            type="drug" text="primidone"/>
        <ddi id="DDI-DrugBank.d151.s0.d0" e1="DDI-DrugBank.d151.s0.e0"
            e2="DDI-DrugBank.d151.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d151.s0.d1" e1="DDI-DrugBank.d151.s0.e0"
            e2="DDI-DrugBank.d151.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d151.s0.d2" e1="DDI-DrugBank.d151.s0.e0"
            e2="DDI-DrugBank.d151.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d151.s1" text="Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.">
        <entity id="DDI-DrugBank.d151.s1.e0" charOffset="99-108"
            type="drug" text="leucovorin"/>
        <entity id="DDI-DrugBank.d151.s1.e1" charOffset="234-245"
            type="drug" text="methotrexate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d151.s2" text="However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.">
        <entity id="DDI-DrugBank.d151.s2.e0" charOffset="23-32"
            type="drug" text="leucovorin"/>
        <entity id="DDI-DrugBank.d151.s2.e1" charOffset="88-99"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d151.s2.d0" e1="DDI-DrugBank.d151.s2.e0"
            e2="DDI-DrugBank.d151.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d151.s3" text="Leucovorin may enhance the toxicity of 5-fluorouracil.">
        <entity id="DDI-DrugBank.d151.s3.e0" charOffset="0-9"
            type="drug" text="Leucovorin"/>
        <entity id="DDI-DrugBank.d151.s3.e1" charOffset="39-52"
            type="drug" text="5-fluorouracil"/>
        <ddi id="DDI-DrugBank.d151.s3.d0" e1="DDI-DrugBank.d151.s3.e0"
            e2="DDI-DrugBank.d151.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d381.s0" text="ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.">
        <entity id="DDI-DrugBank.d381.s0.e0" charOffset="0-8"
            type="brand" text="ERGAMISOL"/>
        <entity id="DDI-DrugBank.d381.s0.e1" charOffset="12-35"
            type="drug" text="levamisole hydrochloride"/>
        <entity id="DDI-DrugBank.d381.s0.e2" charOffset="124-130"
            type="drug" text="alcohol"/>
        <ddi id="DDI-DrugBank.d381.s0.d0" e1="DDI-DrugBank.d381.s0.e0"
            e2="DDI-DrugBank.d381.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d381.s0.d1" e1="DDI-DrugBank.d381.s0.e1"
            e2="DDI-DrugBank.d381.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d381.s1" text="The physician is advised to monitor plasma levels of phenytoin and to decrease the dose if necessary.">
        <entity id="DDI-DrugBank.d381.s1.e0" charOffset="53-61"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d381.s2" text="Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.">
        <entity id="DDI-DrugBank.d381.s2.e0" charOffset="118-127"
            type="drug" text="levamisole"/>
        <entity id="DDI-DrugBank.d381.s2.e1" charOffset="133-147"
            type="drug" text="warfarin sodium"/>
        <entity id="DDI-DrugBank.d381.s2.e2" charOffset="232-246"
            type="drug" text="warfarin sodium"/>
        <entity id="DDI-DrugBank.d381.s2.e3" charOffset="257-264"
            type="group" text="coumarin"/>
        <ddi id="DDI-DrugBank.d381.s2.d0" e1="DDI-DrugBank.d381.s2.e0"
            e2="DDI-DrugBank.d381.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s0" text="in vitro data on metabolic interactions indicate that Keppra  is unlikely to produce, or be subject to, pharmacokinetic interactions.">
        <entity id="DDI-DrugBank.d212.s0.e0" charOffset="54-59"
            type="brand" text="Keppra"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s1" text="Levetiracetam and its major metabolite, at concentrations well above cmax levels achieved within the therapeutic dose range, are neither inhibitors of nor high affinity substrates for human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes.">
        <entity id="DDI-DrugBank.d212.s1.e0" charOffset="0-12"
            type="drug" text="Levetiracetam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s2" text="In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.">
        <entity id="DDI-DrugBank.d212.s2.e0" charOffset="13-25"
            type="drug" text="levetiracetam"/>
        <entity id="DDI-DrugBank.d212.s2.e1" charOffset="75-87"
            type="drug" text="valproic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s3" text="Levetiracetam circulates largely unbound ( 10% bound) to plasma proteins;">
        <entity id="DDI-DrugBank.d212.s3.e0" charOffset="0-12"
            type="drug" text="Levetiracetam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s4" text="clinically significant interactions with other drugs through competition for protein binding sites are therefore unlikely."/>
    <sentence id="DDI-DrugBank.d212.s5" text="Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.">
        <entity id="DDI-DrugBank.d212.s5.e0" charOffset="90-98"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d212.s5.e1" charOffset="101-109"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d212.s5.e2" charOffset="117-129"
            type="group" text="contraceptive"/>
        <entity id="DDI-DrugBank.d212.s5.e3" charOffset="132-138"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d212.s5.e4" charOffset="141-148"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d212.s5.e5" charOffset="151-160"
            type="drug" text="probenecid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s6" text="Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.">
        <entity id="DDI-DrugBank.d212.s6.e0" charOffset="31-36"
            type="brand" text="Keppra"/>
        <entity id="DDI-DrugBank.d212.s6.e1" charOffset="49-67"
            type="group" text="Antiepileptic Drugs"/>
        <entity id="DDI-DrugBank.d212.s6.e2" charOffset="70-73"
            type="group" text="AEDs"/>
        <entity id="DDI-DrugBank.d212.s6.e3" charOffset="76-84"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d212.s6.e4" charOffset="86-91"
            type="brand" text="Keppra"/>
        <entity id="DDI-DrugBank.d212.s6.e5" charOffset="162-170"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s7" text="Pharmacokinetics of levetiracetam were also not affected by phenytoin.">
        <entity id="DDI-DrugBank.d212.s7.e0" charOffset="20-32"
            type="drug" text="levetiracetam"/>
        <entity id="DDI-DrugBank.d212.s7.e1" charOffset="60-68"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s8" text="Valproate Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.">
        <entity id="DDI-DrugBank.d212.s8.e0" charOffset="0-8"
            type="drug" text="Valproate"/>
        <entity id="DDI-DrugBank.d212.s8.e1" charOffset="10-15"
            type="brand" text="Keppra"/>
        <entity id="DDI-DrugBank.d212.s8.e2" charOffset="78-86"
            type="drug" text="valproate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s9" text="Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion.">
        <entity id="DDI-DrugBank.d212.s9.e0" charOffset="0-8"
            type="drug" text="Valproate"/>
        <entity id="DDI-DrugBank.d212.s9.e1" charOffset="66-78"
            type="drug" text="levetiracetam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s10" text="There also was no effect on exposure to and the excretion of the primary metabolite, ucb L057."/>
    <sentence id="DDI-DrugBank.d212.s11" text="Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.">
        <entity id="DDI-DrugBank.d212.s11.e0" charOffset="36-41"
            type="brand" text="Keppra"/>
        <entity id="DDI-DrugBank.d212.s11.e1" charOffset="54-57"
            type="group" text="AEDs"/>
        <entity id="DDI-DrugBank.d212.s11.e2" charOffset="60-72"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d212.s11.e3" charOffset="75-84"
            type="drug" text="gabapentin"/>
        <entity id="DDI-DrugBank.d212.s11.e4" charOffset="87-97"
            type="drug" text="lamotrigine"/>
        <entity id="DDI-DrugBank.d212.s11.e5" charOffset="100-112"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d212.s11.e6" charOffset="115-123"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d212.s11.e7" charOffset="126-134"
            type="drug" text="primidone"/>
        <entity id="DDI-DrugBank.d212.s11.e8" charOffset="140-148"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d212.s11.e9" charOffset="212-224"
            type="drug" text="levetiracetam"/>
        <entity id="DDI-DrugBank.d212.s11.e10" charOffset="236-239"
            type="group" text="AEDs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s12" text="These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.">
        <entity id="DDI-DrugBank.d212.s12.e0" charOffset="25-37"
            type="drug" text="levetiracetam"/>
        <entity id="DDI-DrugBank.d212.s12.e1" charOffset="92-95"
            type="group" text="AEDs"/>
        <entity id="DDI-DrugBank.d212.s12.e2" charOffset="112-115"
            type="group" text="AEDs"/>
        <entity id="DDI-DrugBank.d212.s12.e3" charOffset="158-170"
            type="drug" text="levetiracetam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s13" text="Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.">
        <entity id="DDI-DrugBank.d212.s13.e0" charOffset="10-13"
            type="group" text="AEDs"/>
        <entity id="DDI-DrugBank.d212.s13.e1" charOffset="104-116"
            type="drug" text="levetiracetam"/>
        <entity id="DDI-DrugBank.d212.s13.e2" charOffset="167-170"
            type="group" text="AEDs"/>
        <ddi id="DDI-DrugBank.d212.s13.d0" e1="DDI-DrugBank.d212.s13.e1"
            e2="DDI-DrugBank.d212.s13.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s14" text="Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.">
        <entity id="DDI-DrugBank.d212.s14.e0" charOffset="35-47"
            type="drug" text="Levetiracetam"/>
        <entity id="DDI-DrugBank.d212.s14.e1" charOffset="91-103"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d212.s14.e2" charOffset="106-114"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d212.s14.e3" charOffset="117-126"
            type="drug" text="topiramate"/>
        <entity id="DDI-DrugBank.d212.s14.e4" charOffset="132-142"
            type="drug" text="lamotrigine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s15" text="Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.">
        <entity id="DDI-DrugBank.d212.s15.e0" charOffset="29-42"
            type="group" text="Contraceptives"/>
        <entity id="DDI-DrugBank.d212.s15.e1" charOffset="44-49"
            type="brand" text="Keppra"/>
        <entity id="DDI-DrugBank.d212.s15.e2" charOffset="123-135"
            type="group" text="contraceptive"/>
        <entity id="DDI-DrugBank.d212.s15.e3" charOffset="156-172"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d212.s15.e4" charOffset="186-199"
            type="drug" text="levonorgestrel"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s16" text="Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam.">
        <entity id="DDI-DrugBank.d212.s16.e0" charOffset="30-42"
            type="group" text="contraceptive"/>
        <entity id="DDI-DrugBank.d212.s16.e1" charOffset="86-98"
            type="drug" text="levetiracetam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s17" text="Digoxin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day.">
        <entity id="DDI-DrugBank.d212.s17.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d212.s17.e1" charOffset="8-13"
            type="brand" text="Keppra"/>
        <entity id="DDI-DrugBank.d212.s17.e2" charOffset="107-113"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s18" text="Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam.">
        <entity id="DDI-DrugBank.d212.s18.e0" charOffset="20-26"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d212.s18.e1" charOffset="70-82"
            type="drug" text="levetiracetam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s19" text="Warfarin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.">
        <entity id="DDI-DrugBank.d212.s19.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d212.s19.e1" charOffset="9-14"
            type="brand" text="Keppra"/>
        <entity id="DDI-DrugBank.d212.s19.e2" charOffset="81-81;89-96"
            type="drug" text="R warfarin"/>
        <entity id="DDI-DrugBank.d212.s19.e3" charOffset="87-96"
            type="drug" text="S warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s20" text="Prothrombin time was not affected by levetiracetam.">
        <entity id="DDI-DrugBank.d212.s20.e0" charOffset="37-49"
            type="drug" text="levetiracetam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s21" text="Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam.">
        <entity id="DDI-DrugBank.d212.s21.e0" charOffset="20-27"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d212.s21.e1" charOffset="68-80"
            type="drug" text="levetiracetam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s22" text="Probenecid: Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily.">
        <entity id="DDI-DrugBank.d212.s22.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d212.s22.e1" charOffset="12-21"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d212.s22.e2" charOffset="156-168"
            type="drug" text="levetiracetam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s23" text="Cssmax of the metabolite, ucb L057, was approximately doubled in the presence of probenecid while the fraction of drug excreted unchanged in the urine remained the same.">
        <entity id="DDI-DrugBank.d212.s23.e0" charOffset="81-90"
            type="drug" text="probenecid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s24" text="Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057.">
        <entity id="DDI-DrugBank.d212.s24.e0" charOffset="47-56"
            type="drug" text="probenecid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d212.s25" text="The effect of Keppra  on probenecid was not studied.">
        <entity id="DDI-DrugBank.d212.s25.e0" charOffset="14-19"
            type="brand" text="Keppra"/>
        <entity id="DDI-DrugBank.d212.s25.e1" charOffset="25-34"
            type="drug" text="probenecid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d252.s0" text="Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.">
        <entity id="DDI-DrugBank.d252.s0.e0" charOffset="9-15"
            type="brand" text="BETAGAN"/>
        <entity id="DDI-DrugBank.d252.s0.e1" charOffset="117-123"
            type="brand" text="BETAGAN"/>
        <entity id="DDI-DrugBank.d252.s0.e2" charOffset="129-139"
            type="drug" text="epinephrine"/>
        <ddi id="DDI-DrugBank.d252.s0.d0" e1="DDI-DrugBank.d252.s0.e1"
            e2="DDI-DrugBank.d252.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d252.s1" text="Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.">
        <entity id="DDI-DrugBank.d252.s1.e0" charOffset="55-66"
            type="group" text="beta-blocker"/>
        <entity id="DDI-DrugBank.d252.s1.e1" charOffset="144-152"
            type="drug" text="reserpine"/>
        <ddi id="DDI-DrugBank.d252.s1.d0" e1="DDI-DrugBank.d252.s1.e0"
            e2="DDI-DrugBank.d252.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d252.s2" text="Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.">
        <entity id="DDI-DrugBank.d252.s2.e0" charOffset="19-49"
            type="group" text="beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d252.s2.e1" charOffset="89-107"
            type="group" text="calcium antagonists"/>
        <ddi id="DDI-DrugBank.d252.s2.d0" e1="DDI-DrugBank.d252.s2.e0"
            e2="DDI-DrugBank.d252.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d252.s3" text="In patients with impaired cardiac function, simultaneous use should be avoided altogether."/>
    <sentence id="DDI-DrugBank.d252.s4" text="The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.">
        <entity id="DDI-DrugBank.d252.s4.e0" charOffset="23-53"
            type="group" text="beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d252.s4.e1" charOffset="60-68"
            type="group" text="digitalis"/>
        <entity id="DDI-DrugBank.d252.s4.e2" charOffset="74-91"
            type="group" text="calcium antagonist"/>
        <ddi id="DDI-DrugBank.d252.s4.d0" e1="DDI-DrugBank.d252.s4.e0"
            e2="DDI-DrugBank.d252.s4.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d252.s4.d1" e1="DDI-DrugBank.d252.s4.e0"
            e2="DDI-DrugBank.d252.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d252.s5" text="Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.">
        <entity id="DDI-DrugBank.d252.s5.e0" charOffset="0-30"
            type="group" text="Phenothiazine-related compounds"/>
        <entity id="DDI-DrugBank.d252.s5.e1" charOffset="36-66"
            type="group" text="beta-adrenergic blocking agents"/>
        <ddi id="DDI-DrugBank.d252.s5.d0" e1="DDI-DrugBank.d252.s5.e0"
            e2="DDI-DrugBank.d252.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d320.s0" text="Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.">
        <entity id="DDI-DrugBank.d320.s0.e0" charOffset="0-9"
            type="brand" text="Chirocaine"/>
        <entity id="DDI-DrugBank.d320.s0.e1" charOffset="75-85"
            type="group" text="anesthetics"/>
        <ddi id="DDI-DrugBank.d320.s0.d0" e1="DDI-DrugBank.d320.s0.e0"
            e2="DDI-DrugBank.d320.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d320.s1" text="In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively.">
        <entity id="DDI-DrugBank.d320.s1.e0" charOffset="86-100"
            type="drug" text="levobupivacaine"/>
        <entity id="DDI-DrugBank.d320.s1.e1" charOffset="105-128"
            type="drug_n" text="desbutyl levobupivacaine"/>
        <entity id="DDI-DrugBank.d320.s1.e2" charOffset="134-158"
            type="drug_n" text="3-hydroxy levobupivacaine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d320.s2" text="Thus agents likely to be concomitantly administered with Chirocaine that are metabolized by this isoenzyme family may potentially interact with Chirocaine.">
        <entity id="DDI-DrugBank.d320.s2.e0" charOffset="57-66"
            type="brand" text="Chirocaine"/>
        <entity id="DDI-DrugBank.d320.s2.e1" charOffset="144-153"
            type="brand" text="Chirocaine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d320.s3" text="Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;">
        <entity id="DDI-DrugBank.d320.s3.e0" charOffset="86-100"
            type="drug" text="levobupivacaine"/>
        <entity id="DDI-DrugBank.d320.s3.e1" charOffset="156-164"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d320.s3.e2" charOffset="167-179"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d320.s3.e3" charOffset="182-189"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d320.s3.e4" charOffset="237-248"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d320.s3.d0" e1="DDI-DrugBank.d320.s3.e0"
            e2="DDI-DrugBank.d320.s3.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d320.s3.d1" e1="DDI-DrugBank.d320.s3.e0"
            e2="DDI-DrugBank.d320.s3.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d320.s3.d2" e1="DDI-DrugBank.d320.s3.e0"
            e2="DDI-DrugBank.d320.s3.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d320.s3.d3" e1="DDI-DrugBank.d320.s3.e0"
            e2="DDI-DrugBank.d320.s3.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d320.s4" text="certain protease inhibitors e.g., ritanovir;">
        <entity id="DDI-DrugBank.d320.s4.e0" charOffset="8-26"
            type="group" text="protease inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d320.s5" text="macrolide antibiotics e.g., erythromycin;">
        <entity id="DDI-DrugBank.d320.s5.e0" charOffset="0-20"
            type="group" text="macrolide antibiotics"/>
        <entity id="DDI-DrugBank.d320.s5.e1" charOffset="28-39"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d320.s6" text="and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).">
        <entity id="DDI-DrugBank.d320.s6.e0" charOffset="4-30"
            type="group" text="calcium channel antagonists"/>
        <entity id="DDI-DrugBank.d320.s6.e1" charOffset="38-46"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d320.s6.e2" charOffset="67-76"
            type="drug" text="omeprazole"/>
        <entity id="DDI-DrugBank.d320.s6.e3" charOffset="102-112"
            type="drug" text="furafylline"/>
        <entity id="DDI-DrugBank.d320.s6.e4" charOffset="118-131"
            type="drug" text="clarithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d320.s7" text="Dosage adjustment may be warranted when levobupivacaine is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic levobupivacaine levels may rise resulting in toxicity.">
        <entity id="DDI-DrugBank.d320.s7.e0" charOffset="40-54"
            type="drug" text="levobupivacaine"/>
        <entity id="DDI-DrugBank.d320.s7.e1" charOffset="142-156"
            type="drug" text="levobupivacaine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d242.s0" text="Specific drug interaction studies have not been conducted with Levofloxacin.">
        <entity id="DDI-DrugBank.d242.s0.e0" charOffset="63-74"
            type="drug" text="Levofloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d242.s1" text="However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.">
        <entity id="DDI-DrugBank.d242.s1.e0" charOffset="45-54"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d242.s1.e1" charOffset="107-118"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d242.s1.e2" charOffset="154-161"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d242.s1.e3" charOffset="200-212"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d242.s1.e4" charOffset="214-221"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d242.s1.e5" charOffset="345-356"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d242.s1.d0" e1="DDI-DrugBank.d242.s1.e0"
            e2="DDI-DrugBank.d242.s1.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d242.s1.d1" e1="DDI-DrugBank.d242.s1.e0"
            e2="DDI-DrugBank.d242.s1.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d242.s1.d2" e1="DDI-DrugBank.d242.s1.e0"
            e2="DDI-DrugBank.d242.s1.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d242.s1.d3" e1="DDI-DrugBank.d242.s1.e0"
            e2="DDI-DrugBank.d242.s1.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d257.s0" text="Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.">
        <entity id="DDI-DrugBank.d257.s0.e0" charOffset="54-66"
            type="brand" text="Levo-Dromoran"/>
        <entity id="DDI-DrugBank.d257.s0.e1" charOffset="77-110"
            type="group" text="central nervous system depressants"/>
        <entity id="DDI-DrugBank.d257.s0.e2" charOffset="117-123"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d257.s0.e3" charOffset="126-134"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d257.s0.e4" charOffset="137-145"
            type="group" text="hypnotics"/>
        <entity id="DDI-DrugBank.d257.s0.e5" charOffset="154-160"
            type="group" text="opioids"/>
        <entity id="DDI-DrugBank.d257.s0.e6" charOffset="171-181"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d257.s0.e7" charOffset="184-195"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d257.s0.e8" charOffset="198-222"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d257.s0.e9" charOffset="225-238"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d257.s0.e10" charOffset="241-253"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d257.s0.e11" charOffset="256-280"
            type="group" text="skeletal muscle relaxants"/>
        <entity id="DDI-DrugBank.d257.s0.e12" charOffset="286-299"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d257.s0.d0" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d257.s0.d1" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d257.s0.d2" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d257.s0.d3" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d257.s0.d4" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d257.s0.d5" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d257.s0.d6" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d257.s0.d7" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d257.s0.d8" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d257.s0.d9" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e10" type="effect"/>
        <ddi id="DDI-DrugBank.d257.s0.d10" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e11" type="effect"/>
        <ddi id="DDI-DrugBank.d257.s0.d11" e1="DDI-DrugBank.d257.s0.e0"
            e2="DDI-DrugBank.d257.s0.e12" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d257.s1" text="Respiratory depression, hypotension, and profound sedation or coma may occur."/>
    <sentence id="DDI-DrugBank.d257.s2" text="When such combined therapy is contemplated, the dose of one or both agents should be reduced."/>
    <sentence id="DDI-DrugBank.d257.s3" text="Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.">
        <entity id="DDI-DrugBank.d257.s3.e0" charOffset="32-45"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d257.s3.e1" charOffset="51-63"
            type="brand" text="Levo-Dromoran"/>
        <entity id="DDI-DrugBank.d257.s3.e2" charOffset="119-132"
            type="group" text="MAO inhibitors"/>
        <ddi id="DDI-DrugBank.d257.s3.d0" e1="DDI-DrugBank.d257.s3.e1"
            e2="DDI-DrugBank.d257.s3.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d257.s4" text="Most cases of serious or fatal adverse events involving Levo-Dromoran reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of levorphanol with other drugs affecting respiration.">
        <entity id="DDI-DrugBank.d257.s4.e0" charOffset="56-68"
            type="brand" text="Levo-Dromoran"/>
        <entity id="DDI-DrugBank.d257.s4.e1" charOffset="277-287"
            type="drug" text="levorphanol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d257.s5" text="The initial dose of levorphanol should be reduced by approximately 50% or more when it is given to patients along with another drug affecting respiration.">
        <entity id="DDI-DrugBank.d257.s5.e0" charOffset="20-30"
            type="drug" text="levorphanol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d257.s6" text="Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.">
        <entity id="DDI-DrugBank.d257.s6.e0" charOffset="18-59"
            type="group" text="Mixed Agonist/Antagonist Opioid Analgesics"/>
        <entity id="DDI-DrugBank.d257.s6.e1" charOffset="62-90"
            type="group" text="Agonist/antagonist analgesics"/>
        <entity id="DDI-DrugBank.d257.s6.e2" charOffset="97-107"
            type="drug" text="pentazocine"/>
        <entity id="DDI-DrugBank.d257.s6.e3" charOffset="110-119"
            type="drug" text="nalbuphine"/>
        <entity id="DDI-DrugBank.d257.s6.e4" charOffset="122-132"
            type="drug" text="butorphanol"/>
        <entity id="DDI-DrugBank.d257.s6.e5" charOffset="135-142"
            type="drug" text="dezocine"/>
        <entity id="DDI-DrugBank.d257.s6.e6" charOffset="148-160"
            type="drug" text="buprenorphine"/>
        <entity id="DDI-DrugBank.d257.s6.e7" charOffset="263-291"
            type="group" text="pure agonist opioid analgesic"/>
        <entity id="DDI-DrugBank.d257.s6.e8" charOffset="301-313"
            type="brand" text="Levo-Dromoran"/>
        <ddi id="DDI-DrugBank.d257.s6.d0" e1="DDI-DrugBank.d257.s6.e1"
            e2="DDI-DrugBank.d257.s6.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d257.s6.d1" e1="DDI-DrugBank.d257.s6.e2"
            e2="DDI-DrugBank.d257.s6.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d257.s6.d2" e1="DDI-DrugBank.d257.s6.e3"
            e2="DDI-DrugBank.d257.s6.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d257.s6.d3" e1="DDI-DrugBank.d257.s6.e4"
            e2="DDI-DrugBank.d257.s6.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d257.s6.d4" e1="DDI-DrugBank.d257.s6.e5"
            e2="DDI-DrugBank.d257.s6.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d257.s6.d5" e1="DDI-DrugBank.d257.s6.e6"
            e2="DDI-DrugBank.d257.s6.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d257.s6.d6" e1="DDI-DrugBank.d257.s6.e7"
            e2="DDI-DrugBank.d257.s6.e8" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d257.s7" text="In opioid-dependent patients, mixed agonist/antagonist analgesics may precipitate withdrawal symptoms.">
        <entity id="DDI-DrugBank.d257.s7.e0" charOffset="3-8"
            type="group" text="opioid"/>
        <entity id="DDI-DrugBank.d257.s7.e1" charOffset="30-64"
            type="group" text="mixed agonist/antagonist analgesics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d189.s0" text="No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.">
        <entity id="DDI-DrugBank.d189.s0.e0" charOffset="34-45"
            type="drug" text="Levosimendan"/>
        <entity id="DDI-DrugBank.d189.s0.e1" charOffset="116-124"
            type="drug" text="captopril"/>
        <entity id="DDI-DrugBank.d189.s0.e2" charOffset="127-139"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d189.s0.e3" charOffset="142-151"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d189.s0.e4" charOffset="154-160"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d189.s0.e5" charOffset="163-170"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d189.s0.e6" charOffset="173-194"
            type="drug" text="isosorbide mononitrate"/>
        <entity id="DDI-DrugBank.d189.s0.e7" charOffset="197-206"
            type="drug" text="carvedilol"/>
        <entity id="DDI-DrugBank.d189.s0.e8" charOffset="209-215"
            type="drug" text="ethanol"/>
        <entity id="DDI-DrugBank.d189.s0.e9" charOffset="220-231"
            type="drug" text="itraconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s0" text="The magnitude and relative importance of the effects noted below are likely to be patient specific and may vary by such factors as age, gender, race, intercurrent illnesses, dose of either agent, additional concomitant medications, and timing of drug administration."/>
    <sentence id="DDI-DrugBank.d411.s1" text="Any agent that alters thyroid hormone synthesis, secretion, distribution, effect on target tissues, metabolism, or elimination may alter the optimal therapeutic dose of levothyroxine sodium.">
        <entity id="DDI-DrugBank.d411.s1.e0" charOffset="169-181"
            type="drug" text="levothyroxine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s2" text="Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.">
        <entity id="DDI-DrugBank.d411.s2.e0" charOffset="0-19"
            type="drug" text="Levothyroxine Sodium"/>
        <entity id="DDI-DrugBank.d411.s2.e1" charOffset="90-109"
            type="drug" text="levothyroxine sodium"/>
        <entity id="DDI-DrugBank.d411.s2.e2" charOffset="144-160"
            type="drug" text="aluminum hydoxide"/>
        <entity id="DDI-DrugBank.d411.s2.e3" charOffset="163-176"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d411.s2.e4" charOffset="185-208"
            type="drug" text="colestipol hydrochloride"/>
        <entity id="DDI-DrugBank.d411.s2.e5" charOffset="211-225"
            type="drug" text="ferrous sulfate"/>
        <entity id="DDI-DrugBank.d411.s2.e6" charOffset="228-255"
            type="drug" text="sodium polystyrene sulfonate"/>
        <entity id="DDI-DrugBank.d411.s2.e7" charOffset="296-305"
            type="drug" text="sucralfate"/>
        <ddi id="DDI-DrugBank.d411.s2.d0" e1="DDI-DrugBank.d411.s2.e1"
            e2="DDI-DrugBank.d411.s2.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s2.d1" e1="DDI-DrugBank.d411.s2.e1"
            e2="DDI-DrugBank.d411.s2.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s2.d2" e1="DDI-DrugBank.d411.s2.e1"
            e2="DDI-DrugBank.d411.s2.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s2.d3" e1="DDI-DrugBank.d411.s2.e1"
            e2="DDI-DrugBank.d411.s2.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s2.d4" e1="DDI-DrugBank.d411.s2.e1"
            e2="DDI-DrugBank.d411.s2.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s2.d5" e1="DDI-DrugBank.d411.s2.e1"
            e2="DDI-DrugBank.d411.s2.e7" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s3" text="Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.">
        <entity id="DDI-DrugBank.d411.s3.e0" charOffset="67-86"
            type="drug" text="levothyroxine sodium"/>
        <entity id="DDI-DrugBank.d411.s3.e1" charOffset="169-177"
            type="group" text="androgens"/>
        <entity id="DDI-DrugBank.d411.s3.e2" charOffset="191-207"
            type="group" text="anabolic hormones"/>
        <entity id="DDI-DrugBank.d411.s3.e3" charOffset="210-221"
            type="drug" text="asparaginase"/>
        <entity id="DDI-DrugBank.d411.s3.e4" charOffset="224-233"
            type="drug" text="clofibrate"/>
        <entity id="DDI-DrugBank.d411.s3.e5" charOffset="236-244"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d411.s3.e6" charOffset="250-278"
            type="group" text="estrogen-containing compounds"/>
        <entity id="DDI-DrugBank.d411.s3.e7" charOffset="281-294"
            type="drug" text="5-fluorouracil"/>
        <entity id="DDI-DrugBank.d411.s3.e8" charOffset="297-306"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d411.s3.e9" charOffset="309-323"
            type="group" text="glucocorticoids"/>
        <entity id="DDI-DrugBank.d411.s3.e10" charOffset="326-342"
            type="drug" text="meclofenamic acid"/>
        <entity id="DDI-DrugBank.d411.s3.e11" charOffset="345-358"
            type="drug" text="mefenamic acid"/>
        <entity id="DDI-DrugBank.d411.s3.e12" charOffset="361-369"
            type="drug" text="methadone"/>
        <entity id="DDI-DrugBank.d411.s3.e13" charOffset="372-383"
            type="drug" text="perphenazine"/>
        <entity id="DDI-DrugBank.d411.s3.e14" charOffset="386-399"
            type="drug" text="phenylbutazone"/>
        <entity id="DDI-DrugBank.d411.s3.e15" charOffset="402-410"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d411.s3.e16" charOffset="413-423"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d411.s3.e17" charOffset="426-434"
            type="drug" text="tamoxifen"/>
        <ddi id="DDI-DrugBank.d411.s3.d0" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d1" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d2" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d3" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d4" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d5" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d6" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d7" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d8" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d9" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e10" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d10" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e11" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d11" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e12" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d12" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e13" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d13" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e14" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d14" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e15" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d15" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d411.s3.d16" e1="DDI-DrugBank.d411.s3.e0"
            e2="DDI-DrugBank.d411.s3.e17" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s4" text="Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.">
        <entity id="DDI-DrugBank.d411.s4.e0" charOffset="228-244"
            type="drug" text="aminoglutethimide"/>
        <entity id="DDI-DrugBank.d411.s4.e1" charOffset="247-267"
            type="drug" text="p-aminosalicylic acid"/>
        <entity id="DDI-DrugBank.d411.s4.e2" charOffset="270-279"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d411.s4.e3" charOffset="282-290"
            type="group" text="androgens"/>
        <entity id="DDI-DrugBank.d411.s4.e4" charOffset="339-349"
            type="drug" text="thiocyanate"/>
        <entity id="DDI-DrugBank.d411.s4.e5" charOffset="352-362"
            type="drug" text="perchlorate"/>
        <entity id="DDI-DrugBank.d411.s4.e6" charOffset="365-377"
            type="drug" text="pertechnetate"/>
        <entity id="DDI-DrugBank.d411.s4.e7" charOffset="381-397"
            type="group" text="antithyroid drugs"/>
        <entity id="DDI-DrugBank.d411.s4.e8" charOffset="400-427"
            type="group" text="b-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d411.s4.e9" charOffset="430-442"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d411.s4.e10" charOffset="445-459"
            type="drug" text="chloral hydrate"/>
        <entity id="DDI-DrugBank.d411.s4.e11" charOffset="462-469"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d411.s4.e12" charOffset="472-479"
            type="drug" text="dopamine"/>
        <entity id="DDI-DrugBank.d411.s4.e13" charOffset="485-501"
            type="group" text="dopamine agonists"/>
        <entity id="DDI-DrugBank.d411.s4.e14" charOffset="504-514"
            type="drug" text="ethionamide"/>
        <entity id="DDI-DrugBank.d411.s4.e15" charOffset="517-531"
            type="group" text="glucocorticoids"/>
        <entity id="DDI-DrugBank.d411.s4.e16" charOffset="534-540"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d411.s4.e17" charOffset="568-574"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d411.s4.e18" charOffset="611-637"
            type="group" text="iodine-containing compounds"/>
        <entity id="DDI-DrugBank.d411.s4.e19" charOffset="640-647"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d411.s4.e20" charOffset="650-659"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d411.s4.e21" charOffset="662-668"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d411.s4.e22" charOffset="671-686"
            type="drug" text="6-mercaptopurine"/>
        <entity id="DDI-DrugBank.d411.s4.e23" charOffset="689-702"
            type="drug" text="metoclopramide"/>
        <entity id="DDI-DrugBank.d411.s4.e24" charOffset="705-712"
            type="drug" text="mitotane"/>
        <entity id="DDI-DrugBank.d411.s4.e25" charOffset="715-727"
            type="drug" text="nitroprusside"/>
        <entity id="DDI-DrugBank.d411.s4.e26" charOffset="730-742"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d411.s4.e27" charOffset="745-753"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d411.s4.e28" charOffset="756-765"
            type="drug" text="resorcinol"/>
        <entity id="DDI-DrugBank.d411.s4.e29" charOffset="768-775"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d411.s4.e30" charOffset="778-797"
            type="group" text="somatostatin analogs"/>
        <entity id="DDI-DrugBank.d411.s4.e31" charOffset="800-811"
            type="group" text="sulfonamides"/>
        <entity id="DDI-DrugBank.d411.s4.e32" charOffset="814-826"
            type="group" text="sulfonylureas"/>
        <entity id="DDI-DrugBank.d411.s4.e33" charOffset="829-846"
            type="group" text="thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s5" text="Adrenocorticoids: Metabolic clearance of adrenocorticoids is decreased in hypothyroid patients and increased in hyperthyroid patients, and may therefore change with changing thyroid status."/>
    <sentence id="DDI-DrugBank.d411.s6" text="Amiodarone: Amiodarone therapy alone can cause hypothyroidism or hyperthyroidism.">
        <entity id="DDI-DrugBank.d411.s6.e0" charOffset="0-9"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d411.s6.e1" charOffset="12-21"
            type="drug" text="Amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s7" text="Anticoagulants (Oral): The hypoprothrombinemic effect of anticoagulants may be potentiated, apparently by increased catabloism of vitamin K-dependent clotting factors.">
        <entity id="DDI-DrugBank.d411.s7.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d411.s7.e1" charOffset="57-70"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s8" text="Antidiabetic Agents (Insulin, Sulfonylureas): Requirements for insulin or oral antidiabetic agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.">
        <entity id="DDI-DrugBank.d411.s8.e0" charOffset="0-18"
            type="group" text="Antidiabetic Agents"/>
        <entity id="DDI-DrugBank.d411.s8.e1" charOffset="21-27"
            type="drug" text="Insulin"/>
        <entity id="DDI-DrugBank.d411.s8.e2" charOffset="30-42"
            type="group" text="Sulfonylureas"/>
        <entity id="DDI-DrugBank.d411.s8.e3" charOffset="63-69"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d411.s8.e4" charOffset="79-97"
            type="group" text="antidiabetic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s9" text="b-Adrenergic Blocking Agents: Actions of some of beta-blocking agents may be impaired when hypothyroid patients become euthyroid.">
        <entity id="DDI-DrugBank.d411.s9.e0" charOffset="0-27"
            type="group" text="b-Adrenergic Blocking Agents"/>
        <entity id="DDI-DrugBank.d411.s9.e1" charOffset="49-68"
            type="group" text="beta-blocking agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s10" text="Cytokines (interferon, interleukin): Cytokines have been reported to induce both hyperthyroidism and hypothyroidism.">
        <entity id="DDI-DrugBank.d411.s10.e0" charOffset="0-8"
            type="group" text="Cytokines"/>
        <entity id="DDI-DrugBank.d411.s10.e1" charOffset="11-20"
            type="group" text="interferon"/>
        <entity id="DDI-DrugBank.d411.s10.e2" charOffset="23-33"
            type="group" text="interleukin"/>
        <entity id="DDI-DrugBank.d411.s10.e3" charOffset="37-45"
            type="group" text="Cytokines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s11" text="Digitalis Glycosides: Therapeutic effects of digitalis glycosides may be reduced.">
        <entity id="DDI-DrugBank.d411.s11.e0" charOffset="0-19"
            type="group" text="Digitalis Glycosides"/>
        <entity id="DDI-DrugBank.d411.s11.e1" charOffset="45-64"
            type="group" text="digitalis glycosides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s12" text="Serum digitalis levels may be decreased in hyperthyroidism or when a hypothyroid patient becomes euthyroid.">
        <entity id="DDI-DrugBank.d411.s12.e0" charOffset="6-14"
            type="group" text="digitalis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s13" text="Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.">
        <entity id="DDI-DrugBank.d411.s13.e0" charOffset="0-7"
            type="drug" text="Ketamine"/>
        <entity id="DDI-DrugBank.d411.s13.e1" charOffset="115-134"
            type="drug" text="levothyroxine sodium"/>
        <entity id="DDI-DrugBank.d411.s13.e2" charOffset="140-147"
            type="drug" text="ketamine"/>
        <ddi id="DDI-DrugBank.d411.s13.d0" e1="DDI-DrugBank.d411.s13.e1"
            e2="DDI-DrugBank.d411.s13.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s14" text="Maprotiline: Risk of cardiac arrhythmias may increase.">
        <entity id="DDI-DrugBank.d411.s14.e0" charOffset="0-10"
            type="drug" text="Maprotiline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s15" text="Sodium Iodide (123I and 131I), Sodium Pertechnetate Tc99m: Uptake of radiolabeled ions may be decreased.">
        <entity id="DDI-DrugBank.d411.s15.e0" charOffset="0-12"
            type="drug" text="Sodium Iodide"/>
        <entity id="DDI-DrugBank.d411.s15.e1" charOffset="31-56"
            type="drug" text="Sodium Pertechnetate Tc99m"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s16" text="Somatrem/Somatropin: Excessive concurrent use of thyroid hormone may accelerate epiphyseal closure.">
        <entity id="DDI-DrugBank.d411.s16.e0" charOffset="0-7"
            type="drug" text="Somatrem"/>
        <entity id="DDI-DrugBank.d411.s16.e1" charOffset="9-18"
            type="drug" text="Somatropin"/>
        <entity id="DDI-DrugBank.d411.s16.e2" charOffset="49-63"
            type="group" text="thyroid hormone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s17" text="Untreated hypothyroidism may interfere with the growth response to somatrem or somatropin.">
        <entity id="DDI-DrugBank.d411.s17.e0" charOffset="67-74"
            type="drug" text="somatrem"/>
        <entity id="DDI-DrugBank.d411.s17.e1" charOffset="79-88"
            type="drug" text="somatropin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s18" text="Theophylline: Theophylline clearance may decrease in hypothyroid patients and return toward normal when a euthyroid state is achieved.">
        <entity id="DDI-DrugBank.d411.s18.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d411.s18.e1" charOffset="14-25"
            type="drug" text="Theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s19" text="Tricyclic Antidepressants: Concurrent use may increase the therapeutic and toxic effects of both drugs, possibly due to increased catecholamine sensitivity.">
        <entity id="DDI-DrugBank.d411.s19.e0" charOffset="0-24"
            type="group" text="Tricyclic Antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s20" text="Onset of action of tricyclics may be accelerated.">
        <entity id="DDI-DrugBank.d411.s20.e0" charOffset="19-28"
            type="group" text="tricyclics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d411.s21" text="Sympathomimetic Agents: Possible increased risk of coronary insufficiency in patients with coronary artery disease.">
        <entity id="DDI-DrugBank.d411.s21.e0" charOffset="0-21"
            type="group" text="Sympathomimetic Agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d564.s0" text="The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.">
        <entity id="DDI-DrugBank.d564.s0.e0" charOffset="28-47"
            type="group" text="anesthetic solutions"/>
        <entity id="DDI-DrugBank.d564.s0.e1" charOffset="60-70"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d564.s0.e2" charOffset="75-88"
            type="drug" text="norepinephrine"/>
        <entity id="DDI-DrugBank.d564.s0.e3" charOffset="112-139"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d564.s0.e4" charOffset="144-168"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d564.s0.d0" e1="DDI-DrugBank.d564.s0.e1"
            e2="DDI-DrugBank.d564.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d564.s0.d1" e1="DDI-DrugBank.d564.s0.e1"
            e2="DDI-DrugBank.d564.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d564.s0.d2" e1="DDI-DrugBank.d564.s0.e2"
            e2="DDI-DrugBank.d564.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d564.s0.d3" e1="DDI-DrugBank.d564.s0.e2"
            e2="DDI-DrugBank.d564.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d564.s1" text="Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.">
        <entity id="DDI-DrugBank.d564.s1.e0" charOffset="0-13"
            type="group" text="Phenothiazines"/>
        <entity id="DDI-DrugBank.d564.s1.e1" charOffset="19-32"
            type="group" text="butyrophenones"/>
        <entity id="DDI-DrugBank.d564.s1.e2" charOffset="78-88"
            type="drug" text="epinephrine"/>
        <ddi id="DDI-DrugBank.d564.s1.d0" e1="DDI-DrugBank.d564.s1.e0"
            e2="DDI-DrugBank.d564.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d564.s1.d1" e1="DDI-DrugBank.d564.s1.e1"
            e2="DDI-DrugBank.d564.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d564.s2" text="Concurrent use of these agents should generally be avoided."/>
    <sentence id="DDI-DrugBank.d564.s3" text="In situations when concurrent therapy is necessary, careful patient monitoring is essential."/>
    <sentence id="DDI-DrugBank.d564.s4" text="Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.">
        <entity id="DDI-DrugBank.d564.s4.e0" charOffset="29-45"
            type="group" text="vasopressor drugs"/>
        <entity id="DDI-DrugBank.d564.s4.e1" charOffset="114-138"
            type="group" text="ergot-type oxytocic drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d130.s0" text="Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.">
        <entity id="DDI-DrugBank.d130.s0.e0" charOffset="0-9"
            type="drug" text="Lincomycin"/>
        <entity id="DDI-DrugBank.d130.s0.e1" charOffset="105-133"
            type="group" text="neuromuscular blocking agents"/>
        <ddi id="DDI-DrugBank.d130.s0.d0" e1="DDI-DrugBank.d130.s0.e0"
            e2="DDI-DrugBank.d130.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d130.s1" text="Therefore, it should be used in caution in patients receiving such agents."/>
    <sentence id="DDI-DrugBank.d130.s2" text="Antagonism between lincomycin and erythromycin in vitro has been demonstrated.">
        <entity id="DDI-DrugBank.d130.s2.e0" charOffset="19-28"
            type="drug" text="lincomycin"/>
        <entity id="DDI-DrugBank.d130.s2.e1" charOffset="34-45"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d130.s2.d0" e1="DDI-DrugBank.d130.s2.e0"
            e2="DDI-DrugBank.d130.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d130.s3" text="Because of possible clinical significance, the two drugs should not be administered concurrently."/>
    <sentence id="DDI-DrugBank.d268.s0" text="Oils may enhance absorption."/>
    <sentence id="DDI-DrugBank.d268.s1" text="Therefore, simultaneous use of creams, ointments or oils should be avoided."/>
    <sentence id="DDI-DrugBank.d441.s0" text="Monoamine Oxidase Inhibition: Linezolid is a reversible, nonselective inhibitor of monoamine oxidase.">
        <entity id="DDI-DrugBank.d441.s0.e0" charOffset="30-38"
            type="drug" text="Linezolid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s1" text="Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.">
        <entity id="DDI-DrugBank.d441.s1.e0" charOffset="11-19"
            type="drug" text="linezolid"/>
        <entity id="DDI-DrugBank.d441.s1.e1" charOffset="60-69"
            type="group" text="adrenergic"/>
        <entity id="DDI-DrugBank.d441.s1.e2" charOffset="75-93"
            type="group" text="serotonergic agents"/>
        <ddi id="DDI-DrugBank.d441.s1.d0" e1="DDI-DrugBank.d441.s1.e0"
            e2="DDI-DrugBank.d441.s1.e1" type="int"/>
        <ddi id="DDI-DrugBank.d441.s1.d1" e1="DDI-DrugBank.d441.s1.e0"
            e2="DDI-DrugBank.d441.s1.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s2" text="Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.">
        <entity id="DDI-DrugBank.d441.s2.e0" charOffset="0-16"
            type="group" text="Adrenergic Agents"/>
        <entity id="DDI-DrugBank.d441.s2.e1" charOffset="45-49"
            type="brand" text="ZYVOX"/>
        <entity id="DDI-DrugBank.d441.s2.e2" charOffset="134-155"
            type="group" text="sympathomimetic agents"/>
        <entity id="DDI-DrugBank.d441.s2.e3" charOffset="158-168"
            type="group" text="vasopressor"/>
        <entity id="DDI-DrugBank.d441.s2.e4" charOffset="173-191"
            type="group" text="dopaminergic agents"/>
        <ddi id="DDI-DrugBank.d441.s2.d0" e1="DDI-DrugBank.d441.s2.e1"
            e2="DDI-DrugBank.d441.s2.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d441.s2.d1" e1="DDI-DrugBank.d441.s2.e1"
            e2="DDI-DrugBank.d441.s2.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d441.s2.d2" e1="DDI-DrugBank.d441.s2.e1"
            e2="DDI-DrugBank.d441.s2.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s3" text="Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied.">
        <entity id="DDI-DrugBank.d441.s3.e0" charOffset="28-46"
            type="drug" text="phenylpropanolamine"/>
        <entity id="DDI-DrugBank.d441.s3.e1" charOffset="52-66"
            type="drug" text="pseudoephedrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s4" text="Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response.">
        <entity id="DDI-DrugBank.d441.s4.e0" charOffset="17-33"
            type="group" text="adrenergic agents"/>
        <entity id="DDI-DrugBank.d441.s4.e1" charOffset="44-51"
            type="drug" text="dopamine"/>
        <entity id="DDI-DrugBank.d441.s4.e2" charOffset="56-66"
            type="drug" text="epinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s5" text="Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.">
        <entity id="DDI-DrugBank.d441.s5.e0" charOffset="0-18"
            type="group" text="Serotonergic Agents"/>
        <entity id="DDI-DrugBank.d441.s5.e1" charOffset="42-50"
            type="drug" text="linezolid"/>
        <entity id="DDI-DrugBank.d441.s5.e2" charOffset="56-74"
            type="group" text="serotonergic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s6" text="Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.">
        <entity id="DDI-DrugBank.d441.s6.e0" charOffset="79-83"
            type="brand" text="ZYVOX"/>
        <entity id="DDI-DrugBank.d441.s6.e1" charOffset="89-107"
            type="group" text="serotonergic agents"/>
        <entity id="DDI-DrugBank.d441.s6.e2" charOffset="120-134"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d441.s6.e3" charOffset="144-182"
            type="group" text="selective serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d441.s6.e4" charOffset="185-189"
            type="group" text="SSRIs"/>
        <ddi id="DDI-DrugBank.d441.s6.d0" e1="DDI-DrugBank.d441.s6.e0"
            e2="DDI-DrugBank.d441.s6.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d441.s6.d1" e1="DDI-DrugBank.d441.s6.e0"
            e2="DDI-DrugBank.d441.s6.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d441.s6.d2" e1="DDI-DrugBank.d441.s6.e0"
            e2="DDI-DrugBank.d441.s6.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d441.s6.d3" e1="DDI-DrugBank.d441.s6.e0"
            e2="DDI-DrugBank.d441.s6.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s7" text="Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).">
        <entity id="DDI-DrugBank.d441.s7.e0" charOffset="30-34"
            type="brand" text="ZYVOX"/>
        <entity id="DDI-DrugBank.d441.s7.e1" charOffset="52-70"
            type="group" text="serotonergic agents"/>
        <ddi id="DDI-DrugBank.d441.s7.d0" e1="DDI-DrugBank.d441.s7.e0"
            e2="DDI-DrugBank.d441.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s8" text="If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (ZYVOX or concomitant serotonergic agents).">
        <entity id="DDI-DrugBank.d441.s8.e0" charOffset="104-108"
            type="brand" text="ZYVOX"/>
        <entity id="DDI-DrugBank.d441.s8.e1" charOffset="125-143"
            type="group" text="serotonergic agents"/>
        <ddi id="DDI-DrugBank.d441.s8.d0" e1="DDI-DrugBank.d441.s8.e0"
            e2="DDI-DrugBank.d441.s8.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s9" text="Drug-Laboratory Test Interactions There are no reported drug-laboratory test interactions."/>
    <sentence id="DDI-DrugBank.d54.s0" text="Oral Anticoagulants: Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors.">
        <entity id="DDI-DrugBank.d54.s0.e0" charOffset="5-18"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d54.s0.e1" charOffset="21-36"
            type="group" text="Thyroid hormones"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s1" text="If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired.">
        <entity id="DDI-DrugBank.d54.s1.e0" charOffset="8-21"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s2" text="Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.">
        <entity id="DDI-DrugBank.d54.s2.e0" charOffset="28-41"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d54.s2.e1" charOffset="68-74"
            type="group" text="thyroid"/>
        <ddi id="DDI-DrugBank.d54.s2.d0" e1="DDI-DrugBank.d54.s2.e0"
            e2="DDI-DrugBank.d54.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s3" text="If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required.">
        <entity id="DDI-DrugBank.d54.s3.e0" charOffset="68-80"
            type="group" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s4" text="No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy."/>
    <sentence id="DDI-DrugBank.d54.s5" text="Insulin or Oral Hypoglycemics: Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.">
        <entity id="DDI-DrugBank.d54.s5.e0" charOffset="0-6" type="drug" text="Insulin"/>
        <entity id="DDI-DrugBank.d54.s5.e1" charOffset="16-28"
            type="group" text="Hypoglycemics"/>
        <entity id="DDI-DrugBank.d54.s5.e2" charOffset="93-99"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d54.s5.e3" charOffset="109-120"
            type="group" text="hypoglycemic"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s6" text="The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient.">
        <entity id="DDI-DrugBank.d54.s6.e0" charOffset="101-120"
            type="group" text="thyroid preparations"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s7" text="Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy.">
        <entity id="DDI-DrugBank.d54.s7.e0" charOffset="19-25"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d54.s7.e1" charOffset="35-47"
            type="group" text="hypoglycemics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s8" text="Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.">
        <entity id="DDI-DrugBank.d54.s8.e0" charOffset="0-13"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d54.s8.e1" charOffset="16-29"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d54.s8.e2" charOffset="42-43"
            type="drug" text="T4"/>
        <entity id="DDI-DrugBank.d54.s8.e3" charOffset="49-50"
            type="drug" text="T3"/>
        <entity id="DDI-DrugBank.d54.s8.e4" charOffset="105-120"
            type="group" text="thyroid hormones"/>
        <ddi id="DDI-DrugBank.d54.s8.d0" e1="DDI-DrugBank.d54.s8.e1"
            e2="DDI-DrugBank.d54.s8.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d54.s8.d1" e1="DDI-DrugBank.d54.s8.e1"
            e2="DDI-DrugBank.d54.s8.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s9" text="In vitro studies indicate that the binding is not easily removed."/>
    <sentence id="DDI-DrugBank.d54.s10" text="Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.">
        <entity id="DDI-DrugBank.d54.s10.e0" charOffset="64-77"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d54.s10.e1" charOffset="83-98"
            type="group" text="thyroid hormones"/>
        <ddi id="DDI-DrugBank.d54.s10.d0" e1="DDI-DrugBank.d54.s10.e0"
            e2="DDI-DrugBank.d54.s10.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s11" text="Estrogen, Oral Contraceptives: Estrogens tend to increase serum thyroxine-binding globulin (TBg).">
        <entity id="DDI-DrugBank.d54.s11.e0" charOffset="0-7"
            type="group" text="Estrogen"/>
        <entity id="DDI-DrugBank.d54.s11.e1" charOffset="15-28"
            type="group" text="Contraceptives"/>
        <entity id="DDI-DrugBank.d54.s11.e2" charOffset="31-39"
            type="group" text="Estrogens"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s12" text="In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.">
        <entity id="DDI-DrugBank.d54.s12.e0" charOffset="100-112"
            type="drug" text="levothyroxine"/>
        <entity id="DDI-DrugBank.d54.s12.e1" charOffset="136-144"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d54.s12.e2" charOffset="174-180"
            type="group" text="thyroid"/>
        <ddi id="DDI-DrugBank.d54.s12.d0" e1="DDI-DrugBank.d54.s12.e0"
            e2="DDI-DrugBank.d54.s12.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s13" text="However, if the patients thyroid gland has sufficient function, the decreased free thyroxine will result in a compensatory increase in thyroxine output by the thyroid.">
        <entity id="DDI-DrugBank.d54.s13.e0" charOffset="83-90"
            type="drug" text="thyroxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s14" text="Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.">
        <entity id="DDI-DrugBank.d54.s14.e0" charOffset="42-48"
            type="group" text="thyroid"/>
        <entity id="DDI-DrugBank.d54.s14.e1" charOffset="138-146"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d54.s14.e2" charOffset="151-158"
            type="group" text="estrogen"/>
        <entity id="DDI-DrugBank.d54.s14.e3" charOffset="176-189"
            type="group" text="contraceptives"/>
        <ddi id="DDI-DrugBank.d54.s14.d0" e1="DDI-DrugBank.d54.s14.e0"
            e2="DDI-DrugBank.d54.s14.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d54.s14.d1" e1="DDI-DrugBank.d54.s14.e0"
            e2="DDI-DrugBank.d54.s14.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s15" text="Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.">
        <entity id="DDI-DrugBank.d54.s15.e0" charOffset="0-24"
            type="group" text="Tricyclic Antidepressants"/>
        <entity id="DDI-DrugBank.d54.s15.e1" charOffset="34-49"
            type="group" text="thyroid products"/>
        <entity id="DDI-DrugBank.d54.s15.e2" charOffset="56-65"
            type="drug" text="imipramine"/>
        <entity id="DDI-DrugBank.d54.s15.e3" charOffset="77-101"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d54.s15.d0" e1="DDI-DrugBank.d54.s15.e1"
            e2="DDI-DrugBank.d54.s15.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d54.s15.d1" e1="DDI-DrugBank.d54.s15.e1"
            e2="DDI-DrugBank.d54.s15.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s16" text="Thyroid hormone activity may also be enhanced.">
        <entity id="DDI-DrugBank.d54.s16.e0" charOffset="0-14"
            type="group" text="Thyroid hormone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s17" text="Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.">
        <entity id="DDI-DrugBank.d54.s17.e0" charOffset="0-8"
            type="group" text="Digitalis"/>
        <entity id="DDI-DrugBank.d54.s17.e1" charOffset="11-30"
            type="group" text="Thyroid preparations"/>
        <entity id="DDI-DrugBank.d54.s17.e2" charOffset="68-76"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d54.s17.d0" e1="DDI-DrugBank.d54.s17.e1"
            e2="DDI-DrugBank.d54.s17.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s18" text="Thyroid hormonal replacement increases metabolic rate, which requires an increase in digitalis dosage.">
        <entity id="DDI-DrugBank.d54.s18.e0" charOffset="85-93"
            type="group" text="digitalis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s19" text="Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.">
        <entity id="DDI-DrugBank.d54.s19.e0" charOffset="0-7"
            type="drug" text="Ketamine"/>
        <entity id="DDI-DrugBank.d54.s19.e1" charOffset="45-63"
            type="group" text="thyroid preparation"/>
        <entity id="DDI-DrugBank.d54.s19.e2" charOffset="82-91"
            type="group" text="anesthetic"/>
        <ddi id="DDI-DrugBank.d54.s19.d0" e1="DDI-DrugBank.d54.s19.e1"
            e2="DDI-DrugBank.d54.s19.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s20" text="Use with caution and be prepared to treat hypertension, if necessary."/>
    <sentence id="DDI-DrugBank.d54.s21" text="Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.">
        <entity id="DDI-DrugBank.d54.s21.e0" charOffset="0-10"
            type="group" text="Vasopressor"/>
        <entity id="DDI-DrugBank.d54.s21.e1" charOffset="14-22"
            type="drug" text="Thyroxine"/>
        <entity id="DDI-DrugBank.d54.s21.e2" charOffset="82-92"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d54.s21.e3" charOffset="98-111"
            type="drug" text="norepinephrine"/>
        <ddi id="DDI-DrugBank.d54.s21.d0" e1="DDI-DrugBank.d54.s21.e1"
            e2="DDI-DrugBank.d54.s21.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d54.s21.d1" e1="DDI-DrugBank.d54.s21.e1"
            e2="DDI-DrugBank.d54.s21.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s22" text="Therefore, injection of these agents into patients receiving thyroid preparations increases the risk of precipitating coronary insufficiency especially in patients with coronary artery disease.">
        <entity id="DDI-DrugBank.d54.s22.e0" charOffset="61-80"
            type="group" text="thyroid preparations"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s23" text="Careful observation is required."/>
    <sentence id="DDI-DrugBank.d54.s24" text="Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.">
        <entity id="DDI-DrugBank.d54.s24.e0" charOffset="136-150"
            type="group" text="thyroid hormone"/>
        <entity id="DDI-DrugBank.d54.s24.e1" charOffset="161-169"
            type="group" text="androgens"/>
        <entity id="DDI-DrugBank.d54.s24.e2" charOffset="172-186"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d54.s24.e3" charOffset="189-197"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d54.s24.e4" charOffset="205-218"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d54.s24.e5" charOffset="231-239"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d54.s24.e6" charOffset="242-247"
            type="group" text="iodine"/>
        <entity id="DDI-DrugBank.d54.s24.e7" charOffset="314-324"
            type="group" text="salicylates"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s25" text="- Changes in TBg concentration should be taken into consideration in the interpretation of T4 and T3 values."/>
    <sentence id="DDI-DrugBank.d54.s26" text="In such cases, the unbound (free) hormone should be measured."/>
    <sentence id="DDI-DrugBank.d54.s27" text="Pregnancy estrogens and estrogen-containing oral contraceptives increase TBg concentrations.">
        <entity id="DDI-DrugBank.d54.s27.e0" charOffset="10-18"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d54.s27.e1" charOffset="24-31"
            type="group" text="estrogen"/>
        <entity id="DDI-DrugBank.d54.s27.e2" charOffset="49-62"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s28" text="TBg may also be increased during infectious hepatitis."/>
    <sentence id="DDI-DrugBank.d54.s29" text="Decreases in TBg concentrations are observed in nephrosis, acromegaly and after androgen or corticosteroid therapy.">
        <entity id="DDI-DrugBank.d54.s29.e0" charOffset="80-87"
            type="group" text="androgen"/>
        <entity id="DDI-DrugBank.d54.s29.e1" charOffset="92-105"
            type="group" text="corticosteroid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s30" text="Familial hyper- or hypo-thyroxine-binding-globulinemias have been described."/>
    <sentence id="DDI-DrugBank.d54.s31" text="The incidence of TBg deficiency approximates 1 in 9000."/>
    <sentence id="DDI-DrugBank.d54.s32" text="The binding of thyroxine by thyroxine-binding prealbumin (TBPA) is inhibited by salicylates">
        <entity id="DDI-DrugBank.d54.s32.e0" charOffset="80-90"
            type="group" text="salicylates"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s33" text="."/>
    <sentence id="DDI-DrugBank.d54.s34" text="- Medicinal or dietary iodine interferes with all in vivo tests of radio-iodine uptake producing low uptakes which may not be reflective of a true decrease in hormone synthesis">
        <entity id="DDI-DrugBank.d54.s34.e0" charOffset="23-28"
            type="group" text="iodine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d54.s35" text="."/>
    <sentence id="DDI-DrugBank.d54.s36" text="- The persistence of clinical and laboratory evidence of hypothyroidism in spite of adequate dosage replacement indicates either poor patient compliance, poor absorption, excessive fecal loss, or inactivity of the preparation."/>
    <sentence id="DDI-DrugBank.d54.s37" text="Intracellular resistance to thyroid hormone is quite rare.">
        <entity id="DDI-DrugBank.d54.s37.e0" charOffset="28-42"
            type="group" text="thyroid hormone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s0" text="Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.">
        <entity id="DDI-DrugBank.d158.s0.e0" charOffset="40-56"
            type="drug" text="ammonium chloride"/>
        <entity id="DDI-DrugBank.d158.s0.e1" charOffset="59-79"
            type="drug" text="sodium acid phosphate"/>
        <entity id="DDI-DrugBank.d158.s0.e2" charOffset="145-155"
            type="drug" text="amphetamine"/>
        <ddi id="DDI-DrugBank.d158.s0.d0" e1="DDI-DrugBank.d158.s0.e0"
            e2="DDI-DrugBank.d158.s0.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d158.s0.d1" e1="DDI-DrugBank.d158.s0.e1"
            e2="DDI-DrugBank.d158.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s1" text="Both groups of agents lower blood levels and efficacy of amphetamines.">
        <entity id="DDI-DrugBank.d158.s1.e0" charOffset="57-68"
            type="group" text="amphetamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s2" text="Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.">
        <entity id="DDI-DrugBank.d158.s2.e0" charOffset="0-18"
            type="group" text="Adrenergic blockers"/>
        <entity id="DDI-DrugBank.d158.s2.e1" charOffset="20-38"
            type="group" text="Adrenergic blockers"/>
        <entity id="DDI-DrugBank.d158.s2.e2" charOffset="57-68"
            type="group" text="amphetamines"/>
        <ddi id="DDI-DrugBank.d158.s2.d0" e1="DDI-DrugBank.d158.s2.e1"
            e2="DDI-DrugBank.d158.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s3" text="Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;">
        <entity id="DDI-DrugBank.d158.s3.e0" charOffset="0-14"
            type="group" text="Antidepressants"/>
        <entity id="DDI-DrugBank.d158.s3.e1" charOffset="17-25"
            type="group" text="tricyclic"/>
        <entity id="DDI-DrugBank.d158.s3.e2" charOffset="27-38"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d158.s3.e3" charOffset="68-92"
            type="drug" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d158.s3.e4" charOffset="97-118"
            type="group" text="sympathomimetic agents"/>
        <ddi id="DDI-DrugBank.d158.s3.d0" e1="DDI-DrugBank.d158.s3.e2"
            e2="DDI-DrugBank.d158.s3.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d158.s3.d1" e1="DDI-DrugBank.d158.s3.e2"
            e2="DDI-DrugBank.d158.s3.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s4" text="d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;">
        <entity id="DDI-DrugBank.d158.s4.e0" charOffset="0-12"
            type="drug" text="d-amphetamine"/>
        <entity id="DDI-DrugBank.d158.s4.e1" charOffset="19-29"
            type="drug" text="desipramine"/>
        <entity id="DDI-DrugBank.d158.s4.e2" charOffset="34-46"
            type="drug" text="protriptyline"/>
        <entity id="DDI-DrugBank.d158.s4.e3" charOffset="67-76"
            type="group" text="tricyclics"/>
        <entity id="DDI-DrugBank.d158.s4.e4" charOffset="141-153"
            type="drug" text="d-amphetamine"/>
        <ddi id="DDI-DrugBank.d158.s4.d0" e1="DDI-DrugBank.d158.s4.e0"
            e2="DDI-DrugBank.d158.s4.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d158.s4.d1" e1="DDI-DrugBank.d158.s4.e0"
            e2="DDI-DrugBank.d158.s4.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d158.s4.d2" e1="DDI-DrugBank.d158.s4.e0"
            e2="DDI-DrugBank.d158.s4.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s5" text="cardiovascular effects can be potentiated."/>
    <sentence id="DDI-DrugBank.d158.s6" text="MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.">
        <entity id="DDI-DrugBank.d158.s6.e0" charOffset="0-13"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d158.s6.e1" charOffset="15-34"
            type="group" text="MAOI antidepressants"/>
        <entity id="DDI-DrugBank.d158.s6.e2" charOffset="64-75"
            type="drug" text="furazolidone"/>
        <entity id="DDI-DrugBank.d158.s6.e3" charOffset="83-93"
            type="drug" text="amphetamine"/>
        <ddi id="DDI-DrugBank.d158.s6.d0" e1="DDI-DrugBank.d158.s6.e1"
            e2="DDI-DrugBank.d158.s6.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d158.s6.d1" e1="DDI-DrugBank.d158.s6.e2"
            e2="DDI-DrugBank.d158.s6.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s7" text="This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings;">
        <entity id="DDI-DrugBank.d158.s7.e0" charOffset="25-36"
            type="group" text="amphetamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s8" text="this can cause headaches and other signs of hypertensive crisis."/>
    <sentence id="DDI-DrugBank.d158.s9" text="A variety of toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results."/>
    <sentence id="DDI-DrugBank.d158.s10" text="Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.">
        <entity id="DDI-DrugBank.d158.s10.e0" charOffset="0-13"
            type="group" text="Antihistamines"/>
        <entity id="DDI-DrugBank.d158.s10.e1" charOffset="16-27"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d158.s10.e2" charOffset="67-80"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d158.s10.d0" e1="DDI-DrugBank.d158.s10.e1"
            e2="DDI-DrugBank.d158.s10.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s11" text="Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.">
        <entity id="DDI-DrugBank.d158.s11.e0" charOffset="0-16"
            type="group" text="Antihypertensives"/>
        <entity id="DDI-DrugBank.d158.s11.e1" charOffset="19-30"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d158.s11.e2" charOffset="74-90"
            type="drug" text="antihypertensives"/>
        <ddi id="DDI-DrugBank.d158.s11.d0" e1="DDI-DrugBank.d158.s11.e1"
            e2="DDI-DrugBank.d158.s11.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s12" text="Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.">
        <entity id="DDI-DrugBank.d158.s12.e0" charOffset="0-13"
            type="drug" text="Chlorpromazine"/>
        <entity id="DDI-DrugBank.d158.s12.e1" charOffset="16-29"
            type="drug" text="Chlorpromazine"/>
        <entity id="DDI-DrugBank.d158.s12.e2" charOffset="126-137"
            type="group" text="amphetamines"/>
        <entity id="DDI-DrugBank.d158.s12.e3" charOffset="164-174"
            type="group" text="amphetamine"/>
        <ddi id="DDI-DrugBank.d158.s12.d0" e1="DDI-DrugBank.d158.s12.e1"
            e2="DDI-DrugBank.d158.s12.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s13" text="Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.">
        <entity id="DDI-DrugBank.d158.s13.e0" charOffset="0-11"
            type="drug" text="Ethosuximide"/>
        <entity id="DDI-DrugBank.d158.s13.e1" charOffset="14-25"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d158.s13.e2" charOffset="62-73"
            type="drug" text="ethosuximide"/>
        <ddi id="DDI-DrugBank.d158.s13.d0" e1="DDI-DrugBank.d158.s13.e1"
            e2="DDI-DrugBank.d158.s13.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s14" text="Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.">
        <entity id="DDI-DrugBank.d158.s14.e0" charOffset="0-10"
            type="drug" text="Haloperidol"/>
        <entity id="DDI-DrugBank.d158.s14.e1" charOffset="13-23"
            type="drug" text="Haloperidol"/>
        <entity id="DDI-DrugBank.d158.s14.e2" charOffset="101-112"
            type="group" text="amphetamines"/>
        <ddi id="DDI-DrugBank.d158.s14.d0" e1="DDI-DrugBank.d158.s14.e1"
            e2="DDI-DrugBank.d158.s14.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s15" text="Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.">
        <entity id="DDI-DrugBank.d158.s15.e0" charOffset="0-16"
            type="drug" text="Lithium carbonate"/>
        <entity id="DDI-DrugBank.d158.s15.e1" charOffset="60-71"
            type="group" text="amphetamines"/>
        <entity id="DDI-DrugBank.d158.s15.e2" charOffset="93-109"
            type="drug" text="lithium carbonate"/>
        <ddi id="DDI-DrugBank.d158.s15.d0" e1="DDI-DrugBank.d158.s15.e1"
            e2="DDI-DrugBank.d158.s15.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s16" text="Meperidine: Amphetamines potentiate the analgesic effect of meperidine.">
        <entity id="DDI-DrugBank.d158.s16.e0" charOffset="0-9"
            type="drug" text="Meperidine"/>
        <entity id="DDI-DrugBank.d158.s16.e1" charOffset="12-23"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d158.s16.e2" charOffset="60-69"
            type="drug" text="meperidine"/>
        <ddi id="DDI-DrugBank.d158.s16.d0" e1="DDI-DrugBank.d158.s16.e1"
            e2="DDI-DrugBank.d158.s16.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s17" text="Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.">
        <entity id="DDI-DrugBank.d158.s17.e0" charOffset="0-10"
            type="drug" text="Methenamine"/>
        <entity id="DDI-DrugBank.d158.s17.e1" charOffset="41-52"
            type="group" text="amphetamines"/>
        <entity id="DDI-DrugBank.d158.s17.e2" charOffset="121-131"
            type="drug" text="methenamine"/>
        <ddi id="DDI-DrugBank.d158.s17.d0" e1="DDI-DrugBank.d158.s17.e1"
            e2="DDI-DrugBank.d158.s17.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s18" text="Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.">
        <entity id="DDI-DrugBank.d158.s18.e0" charOffset="0-13"
            type="drug" text="Norepinephrine"/>
        <entity id="DDI-DrugBank.d158.s18.e1" charOffset="16-27"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d158.s18.e2" charOffset="62-75"
            type="drug" text="norepinephrine"/>
        <ddi id="DDI-DrugBank.d158.s18.d0" e1="DDI-DrugBank.d158.s18.e1"
            e2="DDI-DrugBank.d158.s18.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s19" text="Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;">
        <entity id="DDI-DrugBank.d158.s19.e0" charOffset="0-12"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d158.s19.e1" charOffset="15-26"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d158.s19.e2" charOffset="63-75"
            type="drug" text="phenobarbital"/>
        <ddi id="DDI-DrugBank.d158.s19.d0" e1="DDI-DrugBank.d158.s19.e1"
            e2="DDI-DrugBank.d158.s19.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s20" text="co-administration of phenobarbital may produce a synergistic anticonvulsant action.">
        <entity id="DDI-DrugBank.d158.s20.e0" charOffset="21-33"
            type="drug" text="phenobarbital"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s21" text="Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;">
        <entity id="DDI-DrugBank.d158.s21.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d158.s21.e1" charOffset="11-22"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d158.s21.e2" charOffset="59-67"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d158.s21.d0" e1="DDI-DrugBank.d158.s21.e1"
            e2="DDI-DrugBank.d158.s21.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s22" text="co-administration of phenytoin may produce a synergistic anticonvulsant action.">
        <entity id="DDI-DrugBank.d158.s22.e0" charOffset="21-29"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s23" text="Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.">
        <entity id="DDI-DrugBank.d158.s23.e0" charOffset="0-11"
            type="drug" text="Propoxyphene"/>
        <entity id="DDI-DrugBank.d158.s23.e1" charOffset="26-37"
            type="drug" text="propoxyphene"/>
        <entity id="DDI-DrugBank.d158.s23.e2" charOffset="51-61"
            type="drug" text="amphetamine"/>
        <ddi id="DDI-DrugBank.d158.s23.d0" e1="DDI-DrugBank.d158.s23.e1"
            e2="DDI-DrugBank.d158.s23.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s24" text="Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.">
        <entity id="DDI-DrugBank.d158.s24.e0" charOffset="0-17"
            type="group" text="Veratrum alkaloids"/>
        <entity id="DDI-DrugBank.d158.s24.e1" charOffset="20-31"
            type="group" text="Amphetamines"/>
        <entity id="DDI-DrugBank.d158.s24.e2" charOffset="67-84"
            type="group" text="veratrum alkaloids"/>
        <ddi id="DDI-DrugBank.d158.s24.d0" e1="DDI-DrugBank.d158.s24.e1"
            e2="DDI-DrugBank.d158.s24.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s25" text="Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.">
        <entity id="DDI-DrugBank.d158.s25.e0" charOffset="35-46"
            type="group" text="Amphetamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d158.s26" text="This increase is greatest in the evening."/>
    <sentence id="DDI-DrugBank.d158.s27" text="Amphetamines may interfere with urinary steroid determinations.">
        <entity id="DDI-DrugBank.d158.s27.e0" charOffset="0-11"
            type="group" text="Amphetamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s0" text="Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.">
        <entity id="DDI-DrugBank.d334.s0.e0" charOffset="56-64"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d334.s0.e1" charOffset="240-247"
            type="brand" text="PRINIVIL"/>
        <ddi id="DDI-DrugBank.d334.s0.d0" e1="DDI-DrugBank.d334.s0.e0"
            e2="DDI-DrugBank.d334.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s1" text="The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.">
        <entity id="DDI-DrugBank.d334.s1.e0" charOffset="44-51"
            type="brand" text="PRINIVIL"/>
        <entity id="DDI-DrugBank.d334.s1.e1" charOffset="98-105"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d334.s1.e2" charOffset="175-182"
            type="brand" text="PRINIVIL"/>
        <ddi id="DDI-DrugBank.d334.s1.d0" e1="DDI-DrugBank.d334.s1.e1"
            e2="DDI-DrugBank.d334.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s2" text="If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.">
        <entity id="DDI-DrugBank.d334.s2.e0" charOffset="35-42"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d334.s2.e1" charOffset="67-74"
            type="brand" text="PRINIVIL"/>
        <ddi id="DDI-DrugBank.d334.s2.d0" e1="DDI-DrugBank.d334.s2.e0"
            e2="DDI-DrugBank.d334.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s3" text="When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.">
        <entity id="DDI-DrugBank.d334.s3.e0" charOffset="7-14"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d334.s3.e1" charOffset="63-70"
            type="brand" text="PRINIVIL"/>
        <ddi id="DDI-DrugBank.d334.s3.d0" e1="DDI-DrugBank.d334.s3.e0"
            e2="DDI-DrugBank.d334.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s4" text="Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.">
        <entity id="DDI-DrugBank.d334.s4.e0" charOffset="13-26"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d334.s4.e1" charOffset="48-56"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d334.s4.e2" charOffset="88-100"
            type="group" text="ACE inhibitor"/>
        <entity id="DDI-DrugBank.d334.s4.e3" charOffset="141-148"
            type="group" text="diuretic"/>
        <ddi id="DDI-DrugBank.d334.s4.d0" e1="DDI-DrugBank.d334.s4.e2"
            e2="DDI-DrugBank.d334.s4.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s5" text="Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.">
        <entity id="DDI-DrugBank.d334.s5.e0" charOffset="0-37"
            type="group" text="Non-steroidal Anti-inflammatory Agents"/>
        <entity id="DDI-DrugBank.d334.s5.e1" charOffset="116-152"
            type="group" text="non-steroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d334.s5.e2" charOffset="180-189"
            type="drug" text="lisinopril"/>
        <ddi id="DDI-DrugBank.d334.s5.d0" e1="DDI-DrugBank.d334.s5.e1"
            e2="DDI-DrugBank.d334.s5.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s6" text="These effects are usually reversible."/>
    <sentence id="DDI-DrugBank.d334.s7" text="Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.">
        <entity id="DDI-DrugBank.d334.s7.e0" charOffset="21-26"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d334.s7.e1" charOffset="72-85"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d334.s7.e2" charOffset="98-107"
            type="drug" text="lisinopril"/>
        <ddi id="DDI-DrugBank.d334.s7.d0" e1="DDI-DrugBank.d334.s7.e0"
            e2="DDI-DrugBank.d334.s7.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d334.s7.d1" e1="DDI-DrugBank.d334.s7.e0"
            e2="DDI-DrugBank.d334.s7.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s8" text="This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.">
        <entity id="DDI-DrugBank.d334.s8.e0" charOffset="66-71"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d334.s8.e1" charOffset="92-105"
            type="group" text="ACE inhibitors"/>
        <ddi id="DDI-DrugBank.d334.s8.d0" e1="DDI-DrugBank.d334.s8.e0"
            e2="DDI-DrugBank.d334.s8.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s9" text="In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.">
        <entity id="DDI-DrugBank.d334.s9.e0" charOffset="99-106"
            type="brand" text="PRINIVIL"/>
        <entity id="DDI-DrugBank.d334.s9.e1" charOffset="131-138"
            type="brand" text="PRINIVIL"/>
        <entity id="DDI-DrugBank.d334.s9.e2" charOffset="165-176"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d334.s9.e3" charOffset="190-201"
            type="drug" text="indomethacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s10" text="Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.">
        <entity id="DDI-DrugBank.d334.s10.e0" charOffset="14-21"
            type="brand" text="PRINIVIL"/>
        <entity id="DDI-DrugBank.d334.s10.e1" charOffset="56-63"
            type="group" text="nitrates"/>
        <entity id="DDI-DrugBank.d334.s10.e2" charOffset="72-78"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s11" text="This included post myocardial infarction patients who were receiving intravenous or transdermal nitroglycerin.">
        <entity id="DDI-DrugBank.d334.s11.e0" charOffset="96-108"
            type="drug" text="nitroglycerin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s12" text="No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with propranolol or hydrochlorothiazide.">
        <entity id="DDI-DrugBank.d334.s12.e0" charOffset="67-74"
            type="brand" text="PRINIVIL"/>
        <entity id="DDI-DrugBank.d334.s12.e1" charOffset="104-114"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d334.s12.e2" charOffset="119-137"
            type="drug" text="hydrochlorothiazide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s13" text="The presence of food in the stomach does not alter the bioavailability of PRINIVIL.">
        <entity id="DDI-DrugBank.d334.s13.e0" charOffset="74-81"
            type="brand" text="PRINIVIL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s14" text="Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.">
        <entity id="DDI-DrugBank.d334.s14.e0" charOffset="35-42"
            type="brand" text="PRINIVIL"/>
        <entity id="DDI-DrugBank.d334.s14.e1" charOffset="80-102"
            type="group" text="thiazide-type diuretics"/>
        <ddi id="DDI-DrugBank.d334.s14.d0" e1="DDI-DrugBank.d334.s14.e0"
            e2="DDI-DrugBank.d334.s14.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s15" text="Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.">
        <entity id="DDI-DrugBank.d334.s15.e0" charOffset="7-14"
            type="brand" text="PRINIVIL"/>
        <entity id="DDI-DrugBank.d334.s15.e1" charOffset="21-47"
            type="group" text="potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d334.s15.e2" charOffset="56-69"
            type="drug" text="spironolactone"/>
        <entity id="DDI-DrugBank.d334.s15.e3" charOffset="72-82"
            type="drug" text="triamterene"/>
        <entity id="DDI-DrugBank.d334.s15.e4" charOffset="88-96"
            type="drug" text="amiloride"/>
        <entity id="DDI-DrugBank.d334.s15.e5" charOffset="100-108"
            type="drug" text="potassium"/>
        <ddi id="DDI-DrugBank.d334.s15.d0" e1="DDI-DrugBank.d334.s15.e0"
            e2="DDI-DrugBank.d334.s15.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d334.s15.d1" e1="DDI-DrugBank.d334.s15.e0"
            e2="DDI-DrugBank.d334.s15.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d334.s15.d2" e1="DDI-DrugBank.d334.s15.e0"
            e2="DDI-DrugBank.d334.s15.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d334.s15.d3" e1="DDI-DrugBank.d334.s15.e0"
            e2="DDI-DrugBank.d334.s15.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d334.s15.d4" e1="DDI-DrugBank.d334.s15.e0"
            e2="DDI-DrugBank.d334.s15.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s16" text="Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium."/>
    <sentence id="DDI-DrugBank.d334.s17" text="Potassium sparing agents should generally not be used in patients with heart failure who are receiving PRINIVIL.">
        <entity id="DDI-DrugBank.d334.s17.e0" charOffset="103-110"
            type="brand" text="PRINIVIL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s18" text="Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.">
        <entity id="DDI-DrugBank.d334.s18.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d334.s18.e1" charOffset="9-15"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d334.s18.e2" charOffset="66-72"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d334.s18.e3" charOffset="144-157"
            type="group" text="ACE inhibitors"/>
        <ddi id="DDI-DrugBank.d334.s18.d0" e1="DDI-DrugBank.d334.s18.e2"
            e2="DDI-DrugBank.d334.s18.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s19" text="Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.">
        <entity id="DDI-DrugBank.d334.s19.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d334.s19.e1" charOffset="64-70"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d334.s19.e2" charOffset="80-92"
            type="group" text="ACE inhibitor"/>
        <ddi id="DDI-DrugBank.d334.s19.d0" e1="DDI-DrugBank.d334.s19.e1"
            e2="DDI-DrugBank.d334.s19.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d334.s20" text="It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.">
        <entity id="DDI-DrugBank.d334.s20.e0" charOffset="29-35"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d334.s20.e1" charOffset="71-78"
            type="brand" text="PRINIVIL"/>
        <entity id="DDI-DrugBank.d334.s20.e2" charOffset="115-121"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d334.s20.d0" e1="DDI-DrugBank.d334.s20.e1"
            e2="DDI-DrugBank.d334.s20.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d454.s0" text="- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives">
        <entity id="DDI-DrugBank.d454.s0.e0" charOffset="2-11"
            type="drug" text="Lofexidine"/>
        <entity id="DDI-DrugBank.d454.s0.e1" charOffset="55-61"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d454.s0.e2" charOffset="64-75"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d454.s0.e3" charOffset="87-95"
            type="group" text="sedatives"/>
        <ddi id="DDI-DrugBank.d454.s0.d0" e1="DDI-DrugBank.d454.s0.e0"
            e2="DDI-DrugBank.d454.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d454.s0.d1" e1="DDI-DrugBank.d454.s0.e0"
            e2="DDI-DrugBank.d454.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d454.s0.d2" e1="DDI-DrugBank.d454.s0.e0"
            e2="DDI-DrugBank.d454.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d454.s1" text="."/>
    <sentence id="DDI-DrugBank.d454.s2" text="- Lofexidine may enhance the effects of anti-hypertensive drug therapy">
        <entity id="DDI-DrugBank.d454.s2.e0" charOffset="2-11"
            type="drug" text="Lofexidine"/>
        <entity id="DDI-DrugBank.d454.s2.e1" charOffset="40-61"
            type="group" text="anti-hypertensive drug"/>
        <ddi id="DDI-DrugBank.d454.s2.d0" e1="DDI-DrugBank.d454.s2.e0"
            e2="DDI-DrugBank.d454.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d454.s3" text="."/>
    <sentence id="DDI-DrugBank.d454.s4" text="- Concomitant use of tricyclic antidepressants may reduce the efficacy of lofexidine.">
        <entity id="DDI-DrugBank.d454.s4.e0" charOffset="21-45"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d454.s4.e1" charOffset="74-83"
            type="drug" text="lofexidine"/>
        <ddi id="DDI-DrugBank.d454.s4.d0" e1="DDI-DrugBank.d454.s4.e0"
            e2="DDI-DrugBank.d454.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s0" text="Theophylline: In three pharmacokinetic studies including 46 normal, healthy subjects, theophylline clearance and concentration were not significantly altered by the addition of lomefloxacin.">
        <entity id="DDI-DrugBank.d516.s0.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d516.s0.e1" charOffset="86-97"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d516.s0.e2" charOffset="177-188"
            type="drug" text="lomefloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s1" text="In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.">
        <entity id="DDI-DrugBank.d516.s1.e0" charOffset="51-62"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d516.s1.e1" charOffset="73-84"
            type="drug" text="lomefloxacin"/>
        <entity id="DDI-DrugBank.d516.s1.e2" charOffset="139-150"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d516.s1.e3" charOffset="192-203"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s2" text="Though individual theophylline levels fluctuated, there were no clinically significant symptoms of drug inter-action.">
        <entity id="DDI-DrugBank.d516.s2.e0" charOffset="18-29"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s3" text="Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.">
        <entity id="DDI-DrugBank.d516.s3.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d516.s3.e1" charOffset="13-22"
            type="drug" text="sucralfate"/>
        <entity id="DDI-DrugBank.d516.s3.e2" charOffset="25-34"
            type="drug" text="Sucralfate"/>
        <entity id="DDI-DrugBank.d516.s3.e3" charOffset="40-47"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d516.s3.e4" charOffset="60-68"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d516.s3.e5" charOffset="73-80"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d516.s3.e6" charOffset="157-161"
            type="brand" text="Videx"/>
        <entity id="DDI-DrugBank.d516.s3.e7" charOffset="165-174"
            type="drug" text="didanosine"/>
        <entity id="DDI-DrugBank.d516.s3.e8" charOffset="280-291"
            type="drug" text="lomefloxacin"/>
        <ddi id="DDI-DrugBank.d516.s3.d0" e1="DDI-DrugBank.d516.s3.e2"
            e2="DDI-DrugBank.d516.s3.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d516.s3.d1" e1="DDI-DrugBank.d516.s3.e4"
            e2="DDI-DrugBank.d516.s3.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d516.s3.d2" e1="DDI-DrugBank.d516.s3.e5"
            e2="DDI-DrugBank.d516.s3.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d516.s3.d3" e1="DDI-DrugBank.d516.s3.e6"
            e2="DDI-DrugBank.d516.s3.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d516.s3.d4" e1="DDI-DrugBank.d516.s3.e7"
            e2="DDI-DrugBank.d516.s3.e8" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s4" text="Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).">
        <entity id="DDI-DrugBank.d516.s4.e0" charOffset="0-9"
            type="drug" text="Sucralfate"/>
        <entity id="DDI-DrugBank.d516.s4.e1" charOffset="39-50"
            type="drug" text="lomefloxacin"/>
        <ddi id="DDI-DrugBank.d516.s4.d0" e1="DDI-DrugBank.d516.s4.e0"
            e2="DDI-DrugBank.d516.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s5" text="Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.">
        <entity id="DDI-DrugBank.d516.s5.e0" charOffset="0-8"
            type="drug" text="Magnesium"/>
        <entity id="DDI-DrugBank.d516.s5.e1" charOffset="15-22"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d516.s5.e2" charOffset="35-42"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d516.s5.e3" charOffset="77-88"
            type="drug" text="lomefloxacin"/>
        <entity id="DDI-DrugBank.d516.s5.e4" charOffset="144-155"
            type="drug" text="lomefloxacin"/>
        <ddi id="DDI-DrugBank.d516.s5.d0" e1="DDI-DrugBank.d516.s5.e0"
            e2="DDI-DrugBank.d516.s5.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d516.s5.d1" e1="DDI-DrugBank.d516.s5.e1"
            e2="DDI-DrugBank.d516.s5.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d516.s5.d2" e1="DDI-DrugBank.d516.s5.e2"
            e2="DDI-DrugBank.d516.s5.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s6" text="Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;">
        <entity id="DDI-DrugBank.d516.s6.e0" charOffset="24-30"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d516.s6.e1" charOffset="36-47"
            type="drug" text="lomefloxacin"/>
        <ddi id="DDI-DrugBank.d516.s6.d0" e1="DDI-DrugBank.d516.s6.e0"
            e2="DDI-DrugBank.d516.s6.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s7" text="therefore, administration of these agents should precede lomefloxacin dosing by 4 hours or follow lomefloxacin dosing by at least 2 hours.">
        <entity id="DDI-DrugBank.d516.s7.e0" charOffset="57-68"
            type="drug" text="lomefloxacin"/>
        <entity id="DDI-DrugBank.d516.s7.e1" charOffset="98-109"
            type="drug" text="lomefloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s8" text="Caffeine: Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of lomefloxacin after being dosed at 400 mg qd.">
        <entity id="DDI-DrugBank.d516.s8.e0" charOffset="0-7"
            type="drug" text="Caffeine"/>
        <entity id="DDI-DrugBank.d516.s8.e1" charOffset="28-35"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d516.s8.e2" charOffset="188-199"
            type="drug" text="lomefloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s9" text="This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either caffeine or its major metabolite, paraxanthine.">
        <entity id="DDI-DrugBank.d516.s9.e0" charOffset="116-123"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d516.s9.e1" charOffset="150-161"
            type="drug_n" text="paraxanthine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s10" text="No data are available on potential interactions in individuals who consume greater than 200 mg of caffeine per day or in those, such as the geriatric population, who are generally believed to be more susceptible to the development of drug-induced CNS-related adverse effects.">
        <entity id="DDI-DrugBank.d516.s10.e0" charOffset="98-105"
            type="drug" text="caffeine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s11" text="Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.">
        <entity id="DDI-DrugBank.d516.s11.e0" charOffset="6-15"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d516.s11.e1" charOffset="90-97"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d516.s11.e2" charOffset="228-235"
            type="drug" text="caffeine"/>
        <ddi id="DDI-DrugBank.d516.s11.d0" e1="DDI-DrugBank.d516.s11.e0"
            e2="DDI-DrugBank.d516.s11.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s12" text="Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.">
        <entity id="DDI-DrugBank.d516.s12.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d516.s12.e1" charOffset="12-21"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d516.s12.e2" charOffset="88-97"
            type="group" text="quinolones"/>
        <ddi id="DDI-DrugBank.d516.s12.d0" e1="DDI-DrugBank.d516.s12.e1"
            e2="DDI-DrugBank.d516.s12.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s13" text="This interference has resulted in significant increases in half-life and AUC."/>
    <sentence id="DDI-DrugBank.d516.s14" text="The interaction between lomefloxacin and cimetidine has not been studied.">
        <entity id="DDI-DrugBank.d516.s14.e0" charOffset="24-35"
            type="drug" text="lomefloxacin"/>
        <entity id="DDI-DrugBank.d516.s14.e1" charOffset="41-50"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s15" text="Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.">
        <entity id="DDI-DrugBank.d516.s15.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d516.s15.e1" charOffset="39-50"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d516.s15.e2" charOffset="95-106"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d516.s15.e3" charOffset="134-148"
            type="group" text="quinolone class"/>
        <ddi id="DDI-DrugBank.d516.s15.d0" e1="DDI-DrugBank.d516.s15.e2"
            e2="DDI-DrugBank.d516.s15.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s16" text="Interaction between lomefloxacin and cyclosporine has not been studied.">
        <entity id="DDI-DrugBank.d516.s16.e0" charOffset="20-31"
            type="drug" text="lomefloxacin"/>
        <entity id="DDI-DrugBank.d516.s16.e1" charOffset="37-48"
            type="drug" text="cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s17" text="Omeprazole: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.">
        <entity id="DDI-DrugBank.d516.s17.e0" charOffset="0-9"
            type="drug" text="Omeprazole"/>
        <entity id="DDI-DrugBank.d516.s17.e1" charOffset="49-60"
            type="drug" text="lomefloxacin"/>
        <entity id="DDI-DrugBank.d516.s17.e2" charOffset="140-151"
            type="drug" text="lomefloxacin"/>
        <entity id="DDI-DrugBank.d516.s17.e3" charOffset="194-203"
            type="drug" text="omeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s18" text="Changes in omeprazole pharmacokinetics were not studied.">
        <entity id="DDI-DrugBank.d516.s18.e0" charOffset="11-20"
            type="drug" text="omeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s19" text="Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.">
        <entity id="DDI-DrugBank.d516.s19.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d516.s19.e1" charOffset="60-68"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d516.s19.e2" charOffset="146-161"
            type="drug" text="phenytoin sodium"/>
        <entity id="DDI-DrugBank.d516.s19.e3" charOffset="210-221"
            type="drug" text="lomefloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s20" text="Lomefloxacin is unlikely to have a significant effect on phenytoin metabolism.">
        <entity id="DDI-DrugBank.d516.s20.e0" charOffset="0-11"
            type="drug" text="Lomefloxacin"/>
        <entity id="DDI-DrugBank.d516.s20.e1" charOffset="57-65"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s21" text="Probenecid: Probenecid slows the renal elimination of lome-floxacin.">
        <entity id="DDI-DrugBank.d516.s21.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d516.s21.e1" charOffset="12-21"
            type="drug" text="Probenecid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s22" text="An increase of 63% in the mean AUC and increases of 50% and 4%, respectively, in the mean T max and mean C max were noted in 1 study of 6 individuals."/>
    <sentence id="DDI-DrugBank.d516.s23" text="Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.">
        <entity id="DDI-DrugBank.d516.s23.e0" charOffset="0-10"
            type="drug" text="Terfenadine"/>
        <entity id="DDI-DrugBank.d516.s23.e1" charOffset="103-113"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d516.s23.e2" charOffset="129-140"
            type="drug" text="lomefloxacin"/>
        <entity id="DDI-DrugBank.d516.s23.e3" charOffset="196-207"
            type="drug" text="lomefloxacin"/>
        <entity id="DDI-DrugBank.d516.s23.e4" charOffset="213-223"
            type="drug" text="terfenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s24" text="Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.">
        <entity id="DDI-DrugBank.d516.s24.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d516.s24.e1" charOffset="10-19"
            type="group" text="Quinolones"/>
        <entity id="DDI-DrugBank.d516.s24.e2" charOffset="57-69"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d516.s24.e3" charOffset="72-79"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d516.s24.d0" e1="DDI-DrugBank.d516.s24.e1"
            e2="DDI-DrugBank.d516.s24.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d516.s24.d1" e1="DDI-DrugBank.d516.s24.e1"
            e2="DDI-DrugBank.d516.s24.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d516.s25" text="When these products are administered concomitantly, prothrombin or other suitable coagulation tests should be monitored closely."/>
    <sentence id="DDI-DrugBank.d516.s26" text="However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and lomefloxacin under steady-state conditions.">
        <entity id="DDI-DrugBank.d516.s26.e0" charOffset="93-100"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d516.s26.e1" charOffset="198-205"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d516.s26.e2" charOffset="211-222"
            type="drug" text="lomefloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d125.s0" text="There was no evidence in clinical trials of drug interactions with concurrent medications."/>
    <sentence id="DDI-DrugBank.d351.s0" text="Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.">
        <entity id="DDI-DrugBank.d351.s0.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d351.s0.e1" charOffset="26-45"
            type="group" text="b-lactam antibiotics"/>
        <entity id="DDI-DrugBank.d351.s0.e2" charOffset="67-76"
            type="drug" text="loracarbef"/>
        <entity id="DDI-DrugBank.d351.s0.e3" charOffset="94-103"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d351.s0.e4" charOffset="164-173"
            type="drug" text="loracarbef"/>
        <ddi id="DDI-DrugBank.d351.s0.d0" e1="DDI-DrugBank.d351.s0.e1"
            e2="DDI-DrugBank.d351.s0.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d351.s0.d1" e1="DDI-DrugBank.d351.s0.e2"
            e2="DDI-DrugBank.d351.s0.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d258.s0" text="Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.">
        <entity id="DDI-DrugBank.d258.s0.e0" charOffset="0-9"
            type="drug" text="Loratadine"/>
        <entity id="DDI-DrugBank.d258.s0.e1" charOffset="80-91"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d258.s0.e2" charOffset="94-103"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d258.s0.e3" charOffset="110-121"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d258.s1" text="Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.">
        <entity id="DDI-DrugBank.d258.s1.e0" charOffset="59-68"
            type="drug" text="loratadine"/>
        <entity id="DDI-DrugBank.d258.s1.e1" charOffset="77-100"
            type="drug" text="descarboethoxyloratadine"/>
        <entity id="DDI-DrugBank.d258.s1.e2" charOffset="146-155"
            type="drug" text="loratadine"/>
        <entity id="DDI-DrugBank.d258.s1.e3" charOffset="294-303"
            type="drug" text="loratadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d258.s2" text="There were no significant effects on QTc intervals, and no reports of sedation or syncope."/>
    <sentence id="DDI-DrugBank.d258.s3" text="No effects on plasma concentrations of cimetidine or ketoconazole were observed.">
        <entity id="DDI-DrugBank.d258.s3.e0" charOffset="39-48"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d258.s3.e1" charOffset="53-64"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d258.s4" text="Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.">
        <entity id="DDI-DrugBank.d258.s4.e0" charOffset="40-51"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d258.s4.e1" charOffset="92-101"
            type="drug" text="loratadine"/>
        <entity id="DDI-DrugBank.d258.s4.e2" charOffset="134-145"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d258.s4.d0" e1="DDI-DrugBank.d258.s4.e0"
            e2="DDI-DrugBank.d258.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d258.s5" text="The clinical relevance of this difference is unknown."/>
    <sentence id="DDI-DrugBank.d258.s6" text="These above findings are summarized in TABLE 1."/>
    <sentence id="DDI-DrugBank.d258.s7" text="TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of Loratadine and Descarboethoxyloratadine After 10 Days of Coadministration (Loratadine 10 mg) in Normal Volunteers">
        <entity id="DDI-DrugBank.d258.s7.e0" charOffset="59-68"
            type="drug" text="Loratadine"/>
        <entity id="DDI-DrugBank.d258.s7.e1" charOffset="74-97"
            type="drug" text="Descarboethoxyloratadine"/>
        <entity id="DDI-DrugBank.d258.s7.e2" charOffset="134-143"
            type="drug" text="Loratadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d258.s8" text="Loratadine Descarboethoxyloratadine">
        <entity id="DDI-DrugBank.d258.s8.e0" charOffset="0-9"
            type="drug" text="Loratadine"/>
        <entity id="DDI-DrugBank.d258.s8.e1" charOffset="11-34"
            type="drug" text="Descarboethoxyloratadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d258.s9" text="Erythromycin (500 mg q8h) + 40% +46%">
        <entity id="DDI-DrugBank.d258.s9.e0" charOffset="0-11"
            type="drug" text="Erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d258.s10" text="Cimetidine (300 mg qid) +103% + 6%">
        <entity id="DDI-DrugBank.d258.s10.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d258.s11" text="Ketoconazole (200 mg q12h) +307% +73%">
        <entity id="DDI-DrugBank.d258.s11.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d258.s12" text="There does not appear to be an increase in adverse events in subjects who received oral contraceptives and loratadine.">
        <entity id="DDI-DrugBank.d258.s12.e0" charOffset="88-101"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d258.s12.e1" charOffset="107-116"
            type="drug" text="loratadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d18.s0" text="Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.">
        <entity id="DDI-DrugBank.d18.s0.e0" charOffset="13-27"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d18.s0.e1" charOffset="40-48"
            type="drug" text="lorazepam"/>
        <entity id="DDI-DrugBank.d18.s0.e2" charOffset="125-136"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d18.s0.e3" charOffset="141-147"
            type="drug" text="alcohol"/>
        <ddi id="DDI-DrugBank.d18.s0.d0" e1="DDI-DrugBank.d18.s0.e0"
            e2="DDI-DrugBank.d18.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s0.d1" e1="DDI-DrugBank.d18.s0.e0"
            e2="DDI-DrugBank.d18.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s0.d2" e1="DDI-DrugBank.d18.s0.e1"
            e2="DDI-DrugBank.d18.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s0.d3" e1="DDI-DrugBank.d18.s0.e1"
            e2="DDI-DrugBank.d18.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d18.s1" text="Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.">
        <entity id="DDI-DrugBank.d18.s1.e0" charOffset="11-19"
            type="drug" text="Lorazepam"/>
        <entity id="DDI-DrugBank.d18.s1.e1" charOffset="54-68"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d18.s1.e2" charOffset="144-156"
            type="drug" text="ethyl alcohol"/>
        <entity id="DDI-DrugBank.d18.s1.e3" charOffset="159-172"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d18.s1.e4" charOffset="175-186"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d18.s1.e5" charOffset="189-202"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d18.s1.e6" charOffset="215-229"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d18.s1.e7" charOffset="236-246"
            type="drug" text="scopolamine"/>
        <entity id="DDI-DrugBank.d18.s1.e8" charOffset="286-294"
            type="drug" text="lorazepam"/>
        <ddi id="DDI-DrugBank.d18.s1.d0" e1="DDI-DrugBank.d18.s1.e0"
            e2="DDI-DrugBank.d18.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s1.d1" e1="DDI-DrugBank.d18.s1.e0"
            e2="DDI-DrugBank.d18.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s1.d2" e1="DDI-DrugBank.d18.s1.e0"
            e2="DDI-DrugBank.d18.s1.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s1.d3" e1="DDI-DrugBank.d18.s1.e0"
            e2="DDI-DrugBank.d18.s1.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s1.d4" e1="DDI-DrugBank.d18.s1.e0"
            e2="DDI-DrugBank.d18.s1.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s1.d5" e1="DDI-DrugBank.d18.s1.e1"
            e2="DDI-DrugBank.d18.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s1.d6" e1="DDI-DrugBank.d18.s1.e1"
            e2="DDI-DrugBank.d18.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s1.d7" e1="DDI-DrugBank.d18.s1.e1"
            e2="DDI-DrugBank.d18.s1.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s1.d8" e1="DDI-DrugBank.d18.s1.e1"
            e2="DDI-DrugBank.d18.s1.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s1.d9" e1="DDI-DrugBank.d18.s1.e1"
            e2="DDI-DrugBank.d18.s1.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d18.s1.d10" e1="DDI-DrugBank.d18.s1.e7"
            e2="DDI-DrugBank.d18.s1.e8" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d30.s0" text="No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.">
        <entity id="DDI-DrugBank.d30.s0.e0" charOffset="98-116"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d30.s0.e1" charOffset="119-125"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d30.s0.e2" charOffset="128-135"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d30.s0.e3" charOffset="138-147"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d30.s0.e4" charOffset="153-165"
            type="drug" text="phenobarbital"/>
    </sentence>
    <sentence id="DDI-DrugBank.d30.s1" text="Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.">
        <entity id="DDI-DrugBank.d30.s1.e0" charOffset="0-7" type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d30.s1.e1" charOffset="73-80"
            type="drug" text="losartan"/>
        <ddi id="DDI-DrugBank.d30.s1.d0" e1="DDI-DrugBank.d30.s1.e0"
            e2="DDI-DrugBank.d30.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d30.s2" text="In humans, two inhibitors of P450 3A4 have been studied."/>
    <sentence id="DDI-DrugBank.d30.s3" text="Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.">
        <entity id="DDI-DrugBank.d30.s3.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d30.s3.e1" charOffset="46-53"
            type="drug" text="losartan"/>
        <entity id="DDI-DrugBank.d30.s3.e2" charOffset="116-123"
            type="drug" text="losartan"/>
        <entity id="DDI-DrugBank.d30.s3.e3" charOffset="130-141"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d30.s4" text="Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.">
        <entity id="DDI-DrugBank.d30.s4.e0" charOffset="0-10"
            type="drug" text="Fluconazole"/>
        <entity id="DDI-DrugBank.d30.s4.e1" charOffset="95-102"
            type="drug" text="losartan"/>
        <ddi id="DDI-DrugBank.d30.s4.d0" e1="DDI-DrugBank.d30.s4.e0"
            e2="DDI-DrugBank.d30.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d30.s5" text="The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined.">
        <entity id="DDI-DrugBank.d30.s5.e0" charOffset="55-62"
            type="drug" text="losartan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d30.s6" text="Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9.">
        <entity id="DDI-DrugBank.d30.s6.e0" charOffset="31-38"
            type="drug" text="losartan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d30.s7" text="These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.">
        <entity id="DDI-DrugBank.d30.s7.e0" charOffset="42-49"
            type="drug" text="losartan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d30.s8" text="As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.">
        <entity id="DDI-DrugBank.d30.s8.e0" charOffset="81-107"
            type="group" text="potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d30.s8.e1" charOffset="116-129"
            type="drug" text="spironolactone"/>
        <entity id="DDI-DrugBank.d30.s8.e2" charOffset="132-142"
            type="drug" text="triamterene"/>
        <entity id="DDI-DrugBank.d30.s8.e3" charOffset="145-153"
            type="drug" text="amiloride"/>
        <entity id="DDI-DrugBank.d30.s8.e4" charOffset="157-165"
            type="drug" text="potassium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d30.s9" text="As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin">
        <entity id="DDI-DrugBank.d30.s9.e0" charOffset="14-36"
            type="group" text="antihypertensive agents"/>
        <entity id="DDI-DrugBank.d30.s9.e1" charOffset="70-77"
            type="drug" text="losartan"/>
        <entity id="DDI-DrugBank.d30.s9.e2" charOffset="101-136"
            type="group" text="non-steroidal anti-inflammatory drug"/>
        <entity id="DDI-DrugBank.d30.s9.e3" charOffset="138-149"
            type="drug" text="indomethacin"/>
        <ddi id="DDI-DrugBank.d30.s9.d0" e1="DDI-DrugBank.d30.s9.e1"
            e2="DDI-DrugBank.d30.s9.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d30.s10" text="."/>
    <sentence id="DDI-DrugBank.d30.s11" text=""/>
    <sentence id="DDI-DrugBank.d567.s0" text="CYP3A4 Interactions"/>
    <sentence id="DDI-DrugBank.d567.s1" text="Lovastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity;">
        <entity id="DDI-DrugBank.d567.s1.e0" charOffset="0-9"
            type="drug" text="Lovastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s2" text="therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4."/>
    <sentence id="DDI-DrugBank.d567.s3" text="Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of lovastatin.">
        <entity id="DDI-DrugBank.d567.s3.e0" charOffset="97-106"
            type="drug" text="lovastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s4" text="Pharmacokinetics."/>
    <sentence id="DDI-DrugBank.d567.s5" text="Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)">
        <entity id="DDI-DrugBank.d567.s5.e0" charOffset="0-11"
            type="drug" text="Itraconazole"/>
        <entity id="DDI-DrugBank.d567.s5.e1" charOffset="13-24"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d567.s5.e2" charOffset="26-37"
            type="drug" text="Erythromycin"/>
        <entity id="DDI-DrugBank.d567.s5.e3" charOffset="39-52"
            type="drug" text="Clarithromycin"/>
        <entity id="DDI-DrugBank.d567.s5.e4" charOffset="54-66"
            type="drug" text="Telithromycin"/>
        <entity id="DDI-DrugBank.d567.s5.e5" charOffset="68-90"
            type="group" text="HIV protease inhibitors"/>
        <entity id="DDI-DrugBank.d567.s5.e6" charOffset="92-101"
            type="drug" text="Nefazodone"/>
        <entity id="DDI-DrugBank.d567.s5.e7" charOffset="103-114"
            type="drug" text="Cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s6" text="Interactions with lipid-lowering drugs that can cause myopathy when given alone."/>
    <sentence id="DDI-DrugBank.d567.s7" text="The risk of myopathy is also increased by the following lipid-lowering drugs that are not potent CYP3A4 inhibitors, but which can cause myopathy when given alone."/>
    <sentence id="DDI-DrugBank.d567.s8" text="See WARNINGS, Myopathy/Rhabdomyolysis."/>
    <sentence id="DDI-DrugBank.d567.s9" text="Gemfibrozil Other fibrates Niacin (nicotinic acid) (=1 g/day)">
        <entity id="DDI-DrugBank.d567.s9.e0" charOffset="0-10"
            type="drug" text="Gemfibrozil"/>
        <entity id="DDI-DrugBank.d567.s9.e1" charOffset="18-25"
            type="group" text="fibrates"/>
        <entity id="DDI-DrugBank.d567.s9.e2" charOffset="27-32"
            type="drug" text="Niacin"/>
        <entity id="DDI-DrugBank.d567.s9.e3" charOffset="35-48"
            type="drug" text="nicotinic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s10" text="Other drug interactions"/>
    <sentence id="DDI-DrugBank.d567.s11" text="Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).">
        <entity id="DDI-DrugBank.d567.s11.e0" charOffset="0-6"
            type="drug" text="Danazol"/>
        <entity id="DDI-DrugBank.d567.s11.e1" charOffset="91-97"
            type="drug" text="danazol"/>
        <entity id="DDI-DrugBank.d567.s11.e2" charOffset="133-142"
            type="drug" text="lovastatin"/>
        <ddi id="DDI-DrugBank.d567.s11.d0" e1="DDI-DrugBank.d567.s11.e1"
            e2="DDI-DrugBank.d567.s11.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s12" text="Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).">
        <entity id="DDI-DrugBank.d567.s12.e0" charOffset="0-9"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d567.s12.e1" charOffset="14-22"
            type="drug" text="Verapamil"/>
        <entity id="DDI-DrugBank.d567.s12.e2" charOffset="86-95"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d567.s12.e3" charOffset="100-108"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d567.s12.e4" charOffset="169-201"
            type="group" text="HMG-CoA reductase inhibitor class"/>
        <ddi id="DDI-DrugBank.d567.s12.d0" e1="DDI-DrugBank.d567.s12.e2"
            e2="DDI-DrugBank.d567.s12.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d567.s12.d1" e1="DDI-DrugBank.d567.s12.e3"
            e2="DDI-DrugBank.d567.s12.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s13" text="Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected.">
        <entity id="DDI-DrugBank.d567.s13.e0" charOffset="0-21"
            type="group" text="Coumarin Anticoagulant"/>
        <entity id="DDI-DrugBank.d567.s13.e1" charOffset="60-69"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d567.s13.e2" charOffset="91-98"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s14" text="However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.">
        <entity id="DDI-DrugBank.d567.s14.e0" charOffset="17-43"
            type="group" text="HMG-CoA reductase inhibitor"/>
        <entity id="DDI-DrugBank.d567.s14.e1" charOffset="168-175"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d567.s14.d0" e1="DDI-DrugBank.d567.s14.e0"
            e2="DDI-DrugBank.d567.s14.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s15" text="Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.">
        <entity id="DDI-DrugBank.d567.s15.e0" charOffset="93-114"
            type="group" text="coumarin anticoagulant"/>
        <entity id="DDI-DrugBank.d567.s15.e1" charOffset="136-145"
            type="drug" text="lovastatin"/>
        <ddi id="DDI-DrugBank.d567.s15.d0" e1="DDI-DrugBank.d567.s15.e0"
            e2="DDI-DrugBank.d567.s15.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s16" text="It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.">
        <entity id="DDI-DrugBank.d567.s16.e0" charOffset="42-55"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d567.s16.e1" charOffset="105-114"
            type="drug" text="lovastatin"/>
        <ddi id="DDI-DrugBank.d567.s16.d0" e1="DDI-DrugBank.d567.s16.e0"
            e2="DDI-DrugBank.d567.s16.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s17" text="Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.">
        <entity id="DDI-DrugBank.d567.s17.e0" charOffset="140-162"
            type="group" text="coumarin anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s18" text="If the dose of lovastatin is changed, the same procedure should be repeated.">
        <entity id="DDI-DrugBank.d567.s18.e0" charOffset="15-24"
            type="drug" text="lovastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s19" text="Lovastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.">
        <entity id="DDI-DrugBank.d567.s19.e0" charOffset="0-9"
            type="drug" text="Lovastatin"/>
        <entity id="DDI-DrugBank.d567.s19.e1" charOffset="116-129"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s20" text="Propranolol: In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol.">
        <entity id="DDI-DrugBank.d567.s20.e0" charOffset="0-10"
            type="drug" text="Propranolol"/>
        <entity id="DDI-DrugBank.d567.s20.e1" charOffset="169-178"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d567.s20.e2" charOffset="184-194"
            type="drug" text="propranolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s21" text="Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.">
        <entity id="DDI-DrugBank.d567.s21.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d567.s21.e1" charOffset="78-87"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d567.s21.e2" charOffset="93-99"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d567.s21.e3" charOffset="126-132"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d567.s22" text="Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide">
        <entity id="DDI-DrugBank.d567.s22.e0" charOffset="5-23"
            type="group" text="Hypoglycemic Agents"/>
        <entity id="DDI-DrugBank.d567.s22.e1" charOffset="56-62"
            type="brand" text="MEVACOR"/>
        <entity id="DDI-DrugBank.d567.s22.e2" charOffset="163-171"
            type="drug" text="glipizide"/>
        <entity id="DDI-DrugBank.d567.s22.e3" charOffset="181-194"
            type="drug" text="chlorpropamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d504.s0" text="There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.">
        <entity id="DDI-DrugBank.d504.s0.e0" charOffset="122-129"
            type="drug" text="loxapine"/>
        <entity id="DDI-DrugBank.d504.s0.e1" charOffset="135-143"
            type="drug" text="lorazepam"/>
        <ddi id="DDI-DrugBank.d504.s0.d0" e1="DDI-DrugBank.d504.s0.e0"
            e2="DDI-DrugBank.d504.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d504.s1" text="The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated.">
        <entity id="DDI-DrugBank.d504.s1.e0" charOffset="18-25"
            type="drug" text="loxapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d504.s2" text="Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.">
        <entity id="DDI-DrugBank.d504.s2.e0" charOffset="67-74"
            type="drug" text="loxapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d79.s0" text="The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.">
        <entity id="DDI-DrugBank.d79.s0.e0" charOffset="18-28"
            type="drug" text="lymecycline"/>
        <entity id="DDI-DrugBank.d79.s0.e1" charOffset="106-109"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d79.s0.e2" charOffset="114-117"
            type="drug" text="zinc"/>
        <ddi id="DDI-DrugBank.d79.s0.d0" e1="DDI-DrugBank.d79.s0.e0"
            e2="DDI-DrugBank.d79.s0.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d79.s0.d1" e1="DDI-DrugBank.d79.s0.e0"
            e2="DDI-DrugBank.d79.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d79.s1" text="Oral contraceptives may be less effective while you are taking lymecycline.">
        <entity id="DDI-DrugBank.d79.s1.e0" charOffset="5-18"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d79.s1.e1" charOffset="63-73"
            type="drug" text="lymecycline"/>
        <ddi id="DDI-DrugBank.d79.s1.d0" e1="DDI-DrugBank.d79.s1.e0"
            e2="DDI-DrugBank.d79.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d113.s0" text="Warfarin: Meclofenamate sodium enhances the effect of warfarin.">
        <entity id="DDI-DrugBank.d113.s0.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d113.s0.e1" charOffset="10-29"
            type="drug" text="Meclofenamate sodium"/>
        <entity id="DDI-DrugBank.d113.s0.e2" charOffset="54-61"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d113.s0.d0" e1="DDI-DrugBank.d113.s0.e0"
            e2="DDI-DrugBank.d113.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d113.s1" text="Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.">
        <entity id="DDI-DrugBank.d113.s1.e0" charOffset="16-35"
            type="drug" text="meclofenamate sodium"/>
        <entity id="DDI-DrugBank.d113.s1.e1" charOffset="69-76"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d113.s1.e2" charOffset="93-100"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d113.s1.d0" e1="DDI-DrugBank.d113.s1.e0"
            e2="DDI-DrugBank.d113.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d113.s2" text="Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.">
        <entity id="DDI-DrugBank.d113.s2.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d113.s2.e1" charOffset="38-44"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d113.s2.e2" charOffset="56-75"
            type="drug" text="meclofenamate sodium"/>
        <ddi id="DDI-DrugBank.d113.s2.d0" e1="DDI-DrugBank.d113.s2.e1"
            e2="DDI-DrugBank.d113.s2.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d113.s3" text="The urinary excretion of meclofenamate sodium is unaffected by aspirin, indicating no change in meclofenamate sodium absorption.">
        <entity id="DDI-DrugBank.d113.s3.e0" charOffset="25-44"
            type="drug" text="meclofenamate sodium"/>
        <entity id="DDI-DrugBank.d113.s3.e1" charOffset="63-69"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d113.s3.e2" charOffset="96-115"
            type="drug" text="meclofenamate sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d113.s4" text="Meclofenamate sodium does not affect serum salicylate levels.">
        <entity id="DDI-DrugBank.d113.s4.e0" charOffset="0-19"
            type="drug" text="Meclofenamate sodium"/>
        <entity id="DDI-DrugBank.d113.s4.e1" charOffset="43-52"
            type="group" text="salicylate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d113.s5" text="Greater fecal blood loss results from concomitant administration of both drugs than from either drug alone."/>
    <sentence id="DDI-DrugBank.d113.s6" text="Propoxyphene: The concurrent administration of propoxyphene hydrochloride does not affect the bioavailability of meclofenamate sodium.">
        <entity id="DDI-DrugBank.d113.s6.e0" charOffset="0-11"
            type="drug" text="Propoxyphene"/>
        <entity id="DDI-DrugBank.d113.s6.e1" charOffset="47-72"
            type="drug" text="propoxyphene hydrochloride"/>
        <entity id="DDI-DrugBank.d113.s6.e2" charOffset="113-132"
            type="drug" text="meclofenamate sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d113.s7" text="Antacids: Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of meclofenamate sodium.">
        <entity id="DDI-DrugBank.d113.s7.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d113.s7.e1" charOffset="40-47;63-71"
            type="drug" text="aluminum hydroxide"/>
        <entity id="DDI-DrugBank.d113.s7.e2" charOffset="53-71"
            type="drug" text="magnesium hydroxide"/>
        <entity id="DDI-DrugBank.d113.s7.e3" charOffset="112-131"
            type="drug" text="meclofenamate sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s0" text="Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.">
        <entity id="DDI-DrugBank.d400.s0.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d400.s0.e1" charOffset="23-28"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d400.s0.e2" charOffset="61-67"
            type="brand" text="Ponstel"/>
        <entity id="DDI-DrugBank.d400.s0.e3" charOffset="73-79"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d400.s0.d0" e1="DDI-DrugBank.d400.s0.e1"
            e2="DDI-DrugBank.d400.s0.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d400.s0.d1" e1="DDI-DrugBank.d400.s0.e2"
            e2="DDI-DrugBank.d400.s0.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s1" text="Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.">
        <entity id="DDI-DrugBank.d400.s1.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d400.s1.e1" charOffset="14-19"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d400.s1.e2" charOffset="65-76"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d400.s1.d0" e1="DDI-DrugBank.d400.s1.e1"
            e2="DDI-DrugBank.d400.s1.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s2" text="This may indicate that they could enhance the toxicity of methotrexate.">
        <entity id="DDI-DrugBank.d400.s2.e0" charOffset="58-69"
            type="drug" text="methotrexate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s3" text="Caution should be used when NSAIDs are administered concomitantly with methotrexate.">
        <entity id="DDI-DrugBank.d400.s3.e0" charOffset="28-33"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d400.s3.e1" charOffset="71-82"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d400.s3.d0" e1="DDI-DrugBank.d400.s3.e0"
            e2="DDI-DrugBank.d400.s3.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s4" text="ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.">
        <entity id="DDI-DrugBank.d400.s4.e0" charOffset="0-13"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d400.s4.e1" charOffset="37-42"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d400.s4.e2" charOffset="88-101"
            type="group" text="ACE inhibitors"/>
        <ddi id="DDI-DrugBank.d400.s4.d0" e1="DDI-DrugBank.d400.s4.e1"
            e2="DDI-DrugBank.d400.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s5" text="This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.">
        <entity id="DDI-DrugBank.d400.s5.e0" charOffset="66-71"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d400.s5.e1" charOffset="92-105"
            type="group" text="ACE inhibitors"/>
        <ddi id="DDI-DrugBank.d400.s5.d0" e1="DDI-DrugBank.d400.s5.e0"
            e2="DDI-DrugBank.d400.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s6" text="Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.">
        <entity id="DDI-DrugBank.d400.s6.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d400.s6.e1" charOffset="86-91"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d400.s6.e2" charOffset="130-139"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d400.s6.e3" charOffset="145-153"
            type="group" text="thiazides"/>
        <ddi id="DDI-DrugBank.d400.s6.d0" e1="DDI-DrugBank.d400.s6.e1"
            e2="DDI-DrugBank.d400.s6.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d400.s6.d1" e1="DDI-DrugBank.d400.s6.e1"
            e2="DDI-DrugBank.d400.s6.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s7" text="This response has been attributed to inhibition of renal prostaglandin synthesis."/>
    <sentence id="DDI-DrugBank.d400.s8" text="During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.">
        <entity id="DDI-DrugBank.d400.s8.e0" charOffset="30-36"
            type="brand" text="Ponstel"/>
        <entity id="DDI-DrugBank.d400.s8.e1" charOffset="43-52"
            type="drug" text="furosemide"/>
        <ddi id="DDI-DrugBank.d400.s8.d0" e1="DDI-DrugBank.d400.s8.e0"
            e2="DDI-DrugBank.d400.s8.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s9" text="Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.">
        <entity id="DDI-DrugBank.d400.s9.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d400.s9.e1" charOffset="9-14"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d400.s9.e2" charOffset="53-59"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d400.s9.e3" charOffset="93-99"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d400.s9.d0" e1="DDI-DrugBank.d400.s9.e1"
            e2="DDI-DrugBank.d400.s9.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d400.s9.d1" e1="DDI-DrugBank.d400.s9.e1"
            e2="DDI-DrugBank.d400.s9.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s10" text="The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%.">
        <entity id="DDI-DrugBank.d400.s10.e0" charOffset="17-23"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s11" text="These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID.">
        <entity id="DDI-DrugBank.d400.s11.e0" charOffset="89-93"
            type="group" text="NSAID"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s12" text="Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.">
        <entity id="DDI-DrugBank.d400.s12.e0" charOffset="11-16"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d400.s12.e1" charOffset="22-28"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d400.s12.e2" charOffset="112-118"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d400.s12.d0" e1="DDI-DrugBank.d400.s12.e0"
            e2="DDI-DrugBank.d400.s12.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s13" text="Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.">
        <entity id="DDI-DrugBank.d400.s13.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d400.s13.e1" charOffset="25-32"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d400.s13.e2" charOffset="38-43"
            type="group" text="NSAIDs"/>
        <ddi id="DDI-DrugBank.d400.s13.d0" e1="DDI-DrugBank.d400.s13.e1"
            e2="DDI-DrugBank.d400.s13.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s14" text="Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.">
        <entity id="DDI-DrugBank.d400.s14.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d400.s14.e1" charOffset="56-62"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d400.s14.e2" charOffset="87-105"
            type="drug" text="magnesium hydroxide"/>
        <entity id="DDI-DrugBank.d400.s14.e3" charOffset="122-135"
            type="drug" text="mefenamic acid"/>
        <entity id="DDI-DrugBank.d400.s14.e4" charOffset="167-180"
            type="drug" text="mefenamic acid"/>
        <entity id="DDI-DrugBank.d400.s14.e5" charOffset="271-281"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d400.s14.e6" charOffset="284-293"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d400.s14.e7" charOffset="299-310"
            type="drug" text="trimethoprim"/>
        <ddi id="DDI-DrugBank.d400.s14.d0" e1="DDI-DrugBank.d400.s14.e2"
            e2="DDI-DrugBank.d400.s14.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s15" text="Drug interaction studies of mefenamic acid and these compounds have not been conducted.">
        <entity id="DDI-DrugBank.d400.s15.e0" charOffset="28-41"
            type="drug" text="mefenamic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d400.s16" text="The possibility of altered safety and efficacy should be considered when Ponstel is used concomitantly with these drugs.">
        <entity id="DDI-DrugBank.d400.s16.e0" charOffset="73-79"
            type="brand" text="Ponstel"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s0" text="Drug-drug interactions with Mefloquine have not been explored in detail.">
        <entity id="DDI-DrugBank.d220.s0.e0" charOffset="28-37"
            type="drug" text="Mefloquine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s1" text="There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol).">
        <entity id="DDI-DrugBank.d220.s1.e0" charOffset="97-108"
            type="group" text="beta blocker"/>
        <entity id="DDI-DrugBank.d220.s1.e1" charOffset="111-121"
            type="drug" text="propranolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s2" text="The effects of Mefloquineuine on the compromised cardiovascular system have not been evaluated."/>
    <sentence id="DDI-DrugBank.d220.s3" text="The benefits of Mefloquine therapy should be weighed against the possibility of adverse effects in patients with cardiac disease.">
        <entity id="DDI-DrugBank.d220.s3.e0" charOffset="16-25"
            type="drug" text="Mefloquine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s4" text="Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.">
        <entity id="DDI-DrugBank.d220.s4.e0" charOffset="79-90"
            type="drug" text="halofantrine"/>
        <entity id="DDI-DrugBank.d220.s4.e1" charOffset="147-156"
            type="drug" text="Mefloquine"/>
        <ddi id="DDI-DrugBank.d220.s4.d0" e1="DDI-DrugBank.d220.s4.e0"
            e2="DDI-DrugBank.d220.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s5" text="Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.">
        <entity id="DDI-DrugBank.d220.s5.e0" charOffset="30-39"
            type="drug" text="Mefloquine"/>
        <entity id="DDI-DrugBank.d220.s5.e1" charOffset="74-80"
            type="drug" text="quinine"/>
        <entity id="DDI-DrugBank.d220.s5.e2" charOffset="83-91"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d220.s5.e3" charOffset="97-107"
            type="drug" text="chloroquine"/>
        <ddi id="DDI-DrugBank.d220.s5.d0" e1="DDI-DrugBank.d220.s5.e0"
            e2="DDI-DrugBank.d220.s5.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s5.d1" e1="DDI-DrugBank.d220.s5.e0"
            e2="DDI-DrugBank.d220.s5.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s5.d2" e1="DDI-DrugBank.d220.s5.e0"
            e2="DDI-DrugBank.d220.s5.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s6" text="If these drugs are to be used in the initial treatment of severe malaria, Mefloquine administration should be delayed at least 12 hours after the last dose.">
        <entity id="DDI-DrugBank.d220.s6.e0" charOffset="74-83"
            type="drug" text="Mefloquine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s7" text="There is evidence that the use of halofantrine after Mefloquineuine causes a significant lengthening of the QTc interval.">
        <entity id="DDI-DrugBank.d220.s7.e0" charOffset="34-45"
            type="drug" text="halofantrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s8" text="Clinically significant QTc prolongation has not been found with Mefloquineuine alone."/>
    <sentence id="DDI-DrugBank.d220.s9" text="This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.">
        <entity id="DDI-DrugBank.d220.s9.e0" charOffset="78-87"
            type="drug" text="Mefloquine"/>
        <entity id="DDI-DrugBank.d220.s9.e1" charOffset="185-199"
            type="drug" text="anti-arrhythmic"/>
        <entity id="DDI-DrugBank.d220.s9.e2" charOffset="204-234"
            type="group" text="beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d220.s9.e3" charOffset="237-260"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d220.s9.e4" charOffset="263-276"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d220.s9.e5" charOffset="281-298"
            type="group" text="H1-blocking agents"/>
        <entity id="DDI-DrugBank.d220.s9.e6" charOffset="301-325"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d220.s9.e7" charOffset="331-344"
            type="group" text="phenothiazines"/>
        <ddi id="DDI-DrugBank.d220.s9.d0" e1="DDI-DrugBank.d220.s9.e0"
            e2="DDI-DrugBank.d220.s9.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s9.d1" e1="DDI-DrugBank.d220.s9.e0"
            e2="DDI-DrugBank.d220.s9.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s9.d2" e1="DDI-DrugBank.d220.s9.e0"
            e2="DDI-DrugBank.d220.s9.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s9.d3" e1="DDI-DrugBank.d220.s9.e0"
            e2="DDI-DrugBank.d220.s9.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s9.d4" e1="DDI-DrugBank.d220.s9.e0"
            e2="DDI-DrugBank.d220.s9.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s9.d5" e1="DDI-DrugBank.d220.s9.e0"
            e2="DDI-DrugBank.d220.s9.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s9.d6" e1="DDI-DrugBank.d220.s9.e0"
            e2="DDI-DrugBank.d220.s9.e7" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s10" text="There are no data that conclusively establish whether the concomitant administration of Mefloquineuine and the above listed agents has an effect on cardiac function."/>
    <sentence id="DDI-DrugBank.d220.s11" text="In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.">
        <entity id="DDI-DrugBank.d220.s11.e0" charOffset="22-35"
            type="group" text="anticonvulsant"/>
        <entity id="DDI-DrugBank.d220.s11.e1" charOffset="42-54"
            type="drug" text="valproic acid"/>
        <entity id="DDI-DrugBank.d220.s11.e2" charOffset="57-69"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d220.s11.e3" charOffset="72-84"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d220.s11.e4" charOffset="89-97"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d220.s11.e5" charOffset="124-133"
            type="drug" text="Mefloquine"/>
        <entity id="DDI-DrugBank.d220.s11.e6" charOffset="199-212"
            type="group" text="anticonvulsant"/>
        <ddi id="DDI-DrugBank.d220.s11.d0" e1="DDI-DrugBank.d220.s11.e0"
            e2="DDI-DrugBank.d220.s11.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s11.d1" e1="DDI-DrugBank.d220.s11.e1"
            e2="DDI-DrugBank.d220.s11.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s11.d2" e1="DDI-DrugBank.d220.s11.e2"
            e2="DDI-DrugBank.d220.s11.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s11.d3" e1="DDI-DrugBank.d220.s11.e3"
            e2="DDI-DrugBank.d220.s11.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d220.s11.d4" e1="DDI-DrugBank.d220.s11.e4"
            e2="DDI-DrugBank.d220.s11.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s12" text="Therefore, patients concurrently taking antiseizure medication and Mefloquine should have the blood level of their antiseizure medication monitored and the dosage adjusted appropriately.">
        <entity id="DDI-DrugBank.d220.s12.e0" charOffset="67-76"
            type="drug" text="Mefloquine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s13" text="When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.">
        <entity id="DDI-DrugBank.d220.s13.e0" charOffset="5-14"
            type="drug" text="Mefloquine"/>
        <entity id="DDI-DrugBank.d220.s13.e1" charOffset="48-68"
            type="group" text="live typhoid vaccines"/>
        <ddi id="DDI-DrugBank.d220.s13.d0" e1="DDI-DrugBank.d220.s13.e0"
            e2="DDI-DrugBank.d220.s13.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s14" text="Vaccinations with attenuated live bacteria should therefore be completed at least 3 days before the first dose of Mefloquine.">
        <entity id="DDI-DrugBank.d220.s14.e0" charOffset="114-123"
            type="drug" text="Mefloquine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s15" text="No other drug interactions are known."/>
    <sentence id="DDI-DrugBank.d220.s16" text="Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.">
        <entity id="DDI-DrugBank.d220.s16.e0" charOffset="29-38"
            type="drug" text="Mefloquine"/>
        <entity id="DDI-DrugBank.d220.s16.e1" charOffset="118-131"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d220.s16.d0" e1="DDI-DrugBank.d220.s16.e0"
            e2="DDI-DrugBank.d220.s16.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d220.s17" text="In clinical trials, the concomitant administration of sulfadoxine and pyrimethamine did not alter the adverse reaction profile.">
        <entity id="DDI-DrugBank.d220.s17.e0" charOffset="54-64"
            type="drug" text="sulfadoxine"/>
        <entity id="DDI-DrugBank.d220.s17.e1" charOffset="70-82"
            type="drug" text="pyrimethamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d139.s0" text="Broad-Spectrum Antibiotics-Broad-spectrum antibiotics may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.">
        <entity id="DDI-DrugBank.d139.s0.e0" charOffset="0-25"
            type="group" text="Broad-Spectrum Antibiotics"/>
        <entity id="DDI-DrugBank.d139.s0.e1" charOffset="27-52"
            type="group" text="Broad-spectrum antibiotics"/>
        <entity id="DDI-DrugBank.d139.s0.e2" charOffset="95-103"
            type="group" text="vitamin K"/>
    </sentence>
    <sentence id="DDI-DrugBank.d139.s1" text="Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.">
        <entity id="DDI-DrugBank.d139.s1.e0" charOffset="0-13"
            type="group" text="Cephalosporins"/>
        <entity id="DDI-DrugBank.d139.s1.e1" charOffset="15-28"
            type="group" text="Cephalosporins"/>
        <entity id="DDI-DrugBank.d139.s1.e2" charOffset="79-89"
            type="drug" text="cefmenoxime"/>
        <entity id="DDI-DrugBank.d139.s1.e3" charOffset="92-103"
            type="drug" text="cefoperazone"/>
        <entity id="DDI-DrugBank.d139.s1.e4" charOffset="106-114"
            type="drug" text="cefotetan"/>
        <entity id="DDI-DrugBank.d139.s1.e5" charOffset="117-127"
            type="drug" text="cefamandole"/>
        <entity id="DDI-DrugBank.d139.s1.e6" charOffset="130-138"
            type="drug" text="latamoxef"/>
        <entity id="DDI-DrugBank.d139.s1.e7" charOffset="163-171"
            type="drug" text="cefazolin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d139.s2" text="These cephalosporins are inhibitors of hepatic vitamin K epoxide reductase.">
        <entity id="DDI-DrugBank.d139.s2.e0" charOffset="6-19"
            type="group" text="cephalosporins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d139.s3" text="Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.">
        <entity id="DDI-DrugBank.d139.s3.e0" charOffset="0-13"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d139.s3.e1" charOffset="37-50"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d139.s3.e2" charOffset="56-64"
            type="group" text="vitamin K"/>
        <entity id="DDI-DrugBank.d139.s3.e3" charOffset="95-103"
            type="group" text="vitamin K"/>
        <ddi id="DDI-DrugBank.d139.s3.d0" e1="DDI-DrugBank.d139.s3.e1"
            e2="DDI-DrugBank.d139.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d139.s4" text="Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.">
        <entity id="DDI-DrugBank.d139.s4.e0" charOffset="0-9"
            type="drug" text="Colestipol"/>
        <entity id="DDI-DrugBank.d139.s4.e1" charOffset="33-42"
            type="drug" text="colestipol"/>
        <entity id="DDI-DrugBank.d139.s4.e2" charOffset="48-56"
            type="group" text="vitamin K"/>
        <entity id="DDI-DrugBank.d139.s4.e3" charOffset="87-95"
            type="group" text="vitamin K"/>
        <ddi id="DDI-DrugBank.d139.s4.d0" e1="DDI-DrugBank.d139.s4.e1"
            e2="DDI-DrugBank.d139.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d139.s5" text="Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.">
        <entity id="DDI-DrugBank.d139.s5.e0" charOffset="0-10"
            type="drug_n" text="Mineral Oil"/>
        <entity id="DDI-DrugBank.d139.s5.e1" charOffset="34-44"
            type="drug_n" text="mineral oil"/>
        <entity id="DDI-DrugBank.d139.s5.e2" charOffset="50-58"
            type="group" text="vitamin K"/>
        <entity id="DDI-DrugBank.d139.s5.e3" charOffset="89-97"
            type="group" text="vitamin K"/>
        <ddi id="DDI-DrugBank.d139.s5.d0" e1="DDI-DrugBank.d139.s5.e1"
            e2="DDI-DrugBank.d139.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d139.s6" text="Orlistat-Orlistat may decrease the absorption of vitamin K.">
        <entity id="DDI-DrugBank.d139.s6.e0" charOffset="0-7"
            type="drug" text="Orlistat"/>
        <entity id="DDI-DrugBank.d139.s6.e1" charOffset="9-16"
            type="drug" text="Orlistat"/>
        <entity id="DDI-DrugBank.d139.s6.e2" charOffset="49-57"
            type="group" text="vitamin K"/>
        <ddi id="DDI-DrugBank.d139.s6.d0" e1="DDI-DrugBank.d139.s6.e1"
            e2="DDI-DrugBank.d139.s6.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d139.s7" text="Salicylates-Salicylates in large doses may inhibit vitamin K epoxide reductase resulting in vitamin K deficiency.">
        <entity id="DDI-DrugBank.d139.s7.e0" charOffset="0-10"
            type="group" text="Salicylates"/>
        <entity id="DDI-DrugBank.d139.s7.e1" charOffset="12-22"
            type="group" text="Salicylates"/>
    </sentence>
    <sentence id="DDI-DrugBank.d139.s8" text="Warfarin-Vitamin K can antagonize the effect of warfarin">
        <entity id="DDI-DrugBank.d139.s8.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d139.s8.e1" charOffset="9-17"
            type="group" text="Vitamin K"/>
        <entity id="DDI-DrugBank.d139.s8.e2" charOffset="48-55"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d139.s8.d0" e1="DDI-DrugBank.d139.s8.e1"
            e2="DDI-DrugBank.d139.s8.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d552.s0" text="Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).">
        <entity id="DDI-DrugBank.d552.s0.e0" charOffset="0-7"
            type="drug" text="Nabilone"/>
        <entity id="DDI-DrugBank.d552.s0.e1" charOffset="78-95"
            type="group" text="psychoactive drugs"/>
        <entity id="DDI-DrugBank.d552.s0.e2" charOffset="100-114"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d552.s0.e3" charOffset="127-133"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d552.s0.e4" charOffset="136-147"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d552.s0.e5" charOffset="153-171"
            type="group" text="narcotic analgesics"/>
        <ddi id="DDI-DrugBank.d552.s0.d0" e1="DDI-DrugBank.d552.s0.e0"
            e2="DDI-DrugBank.d552.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d552.s0.d1" e1="DDI-DrugBank.d552.s0.e0"
            e2="DDI-DrugBank.d552.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d552.s0.d2" e1="DDI-DrugBank.d552.s0.e0"
            e2="DDI-DrugBank.d552.s0.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d552.s0.d3" e1="DDI-DrugBank.d552.s0.e0"
            e2="DDI-DrugBank.d552.s0.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d552.s0.d4" e1="DDI-DrugBank.d552.s0.e0"
            e2="DDI-DrugBank.d552.s0.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d552.s1" text="Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.">
        <entity id="DDI-DrugBank.d552.s1.e0" charOffset="0-7"
            type="drug" text="Nabilone"/>
        <entity id="DDI-DrugBank.d552.s1.e1" charOffset="89-96"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d552.s1.e2" charOffset="99-118"
            type="brand" text="secobarbitone sodium"/>
        <entity id="DDI-DrugBank.d552.s1.e3" charOffset="121-127"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d552.s1.e4" charOffset="132-138"
            type="drug" text="codeine"/>
        <ddi id="DDI-DrugBank.d552.s1.d0" e1="DDI-DrugBank.d552.s1.e0"
            e2="DDI-DrugBank.d552.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d552.s1.d1" e1="DDI-DrugBank.d552.s1.e0"
            e2="DDI-DrugBank.d552.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d552.s1.d2" e1="DDI-DrugBank.d552.s1.e0"
            e2="DDI-DrugBank.d552.s1.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d552.s1.d3" e1="DDI-DrugBank.d552.s1.e0"
            e2="DDI-DrugBank.d552.s1.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d174.s0" text="In vitro studies have shown that, because of its affinity for protein, 6MNA may displace other protein-bound drugs from their binding site.">
        <entity id="DDI-DrugBank.d174.s0.e0" charOffset="71-74"
            type="drug_n" text="6MNA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d174.s1" text="Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.">
        <entity id="DDI-DrugBank.d174.s1.e0" charOffset="47-56"
            type="drug" text="nabumetone"/>
        <entity id="DDI-DrugBank.d174.s1.e1" charOffset="63-70"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d174.s1.e2" charOffset="117-122"
            type="group" text="NSAIDs"/>
        <ddi id="DDI-DrugBank.d174.s1.d0" e1="DDI-DrugBank.d174.s1.e0"
            e2="DDI-DrugBank.d174.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d174.s1.d1" e1="DDI-DrugBank.d174.s1.e1"
            e2="DDI-DrugBank.d174.s1.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d174.s2" text="Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA.">
        <entity id="DDI-DrugBank.d174.s2.e0" charOffset="33-40"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d174.s2.e1" charOffset="53-59"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d174.s2.e2" charOffset="113-116"
            type="drug_n" text="6MNA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d174.s3" text="When administered with food or milk, there is more rapid absorption;"/>
    <sentence id="DDI-DrugBank.d174.s4" text="however, the total amount of 6MNA in the plasma is unchanged .">
        <entity id="DDI-DrugBank.d174.s4.e0" charOffset="29-32"
            type="drug_n" text="6MNA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d204.s0" text="When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.">
        <entity id="DDI-DrugBank.d204.s0.e0" charOffset="70-109"
            type="group" text="beta-adrenergic receptor blocking agents"/>
        <entity id="DDI-DrugBank.d204.s0.e1" charOffset="112-122"
            type="group" text="Anesthetics"/>
        <entity id="DDI-DrugBank.d204.s0.e2" charOffset="185-195"
            type="group" text="anesthetics"/>
        <ddi id="DDI-DrugBank.d204.s0.d0" e1="DDI-DrugBank.d204.s0.e0"
            e2="DDI-DrugBank.d204.s0.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d204.s1" text="Antidiabetic drugs (oral agents and insulin): hypoglycemia or hyperglycemia;">
        <entity id="DDI-DrugBank.d204.s1.e0" charOffset="0-17"
            type="group" text="Antidiabetic drugs"/>
        <entity id="DDI-DrugBank.d204.s1.e1" charOffset="36-42"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d204.s2" text="adjust dosage of antidiabetic drug accordingly.">
        <entity id="DDI-DrugBank.d204.s2.e0" charOffset="17-33"
            type="group" text="antidiabetic drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d204.s3" text="Catecholamine-depleting drugs (e.g., reserpine): additive effect;">
        <entity id="DDI-DrugBank.d204.s3.e0" charOffset="37-45"
            type="drug" text="reserpine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d204.s4" text="monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension)."/>
    <sentence id="DDI-DrugBank.d204.s5" text="Response to Treatment for Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.">
        <entity id="DDI-DrugBank.d204.s5.e0" charOffset="62-74"
            type="group" text="beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d204.s6" text="Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.">
        <entity id="DDI-DrugBank.d204.s6.e0" charOffset="56-66"
            type="drug" text="epinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d218.s0" text="No pharmacokinetic-based drug-drug interaction studies have been conducted with SYNAREL.">
        <entity id="DDI-DrugBank.d218.s0.e0" charOffset="80-86"
            type="brand" text="SYNAREL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d218.s1" text="However, because nafarelin acetate is a peptide that is primarily degraded by peptidase and not by cytochrome P-450 enzymes, and the drug is only about 80% bound to plasma proteins at 4 C, drug interactions would not be expected to occur.">
        <entity id="DDI-DrugBank.d218.s1.e0" charOffset="17-33"
            type="drug" text="nafarelin acetate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d261.s0" text="Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.">
        <entity id="DDI-DrugBank.d261.s0.e0" charOffset="0-11"
            type="drug" text="Tetracycline"/>
        <entity id="DDI-DrugBank.d261.s0.e1" charOffset="16-40"
            type="group" text="bacteriostatic antibiotic"/>
        <entity id="DDI-DrugBank.d261.s0.e2" charOffset="85-94"
            type="drug" text="penicillin"/>
        <ddi id="DDI-DrugBank.d261.s0.d0" e1="DDI-DrugBank.d261.s0.e0"
            e2="DDI-DrugBank.d261.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d37.s0" text="No specific information available"/>
    <sentence id="DDI-DrugBank.d37.s1" text="."/>
    <sentence id="DDI-DrugBank.d37.s2" text=""/>
    <sentence id="DDI-DrugBank.d427.s0" text="Elevated plasma levels of theophylline have been reported with concomitant quinolone use.">
        <entity id="DDI-DrugBank.d427.s0.e0" charOffset="26-37"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d427.s0.e1" charOffset="75-83"
            type="group" text="quinolone"/>
        <ddi id="DDI-DrugBank.d427.s0.d0" e1="DDI-DrugBank.d427.s0.e0"
            e2="DDI-DrugBank.d427.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s1" text="There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.">
        <entity id="DDI-DrugBank.d427.s1.e0" charOffset="27-38"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d427.s1.e1" charOffset="101-110"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d427.s1.e2" charOffset="116-127"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d427.s1.d0" e1="DDI-DrugBank.d427.s1.e1"
            e2="DDI-DrugBank.d427.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s2" text="Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted, as required.">
        <entity id="DDI-DrugBank.d427.s2.e0" charOffset="25-36"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d427.s2.e1" charOffset="87-98"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s3" text="Quinolones have been shown to interfere with the metabolism of caffeine.">
        <entity id="DDI-DrugBank.d427.s3.e0" charOffset="0-9"
            type="group" text="Quinolones"/>
        <entity id="DDI-DrugBank.d427.s3.e1" charOffset="63-70"
            type="drug" text="caffeine"/>
        <ddi id="DDI-DrugBank.d427.s3.d0" e1="DDI-DrugBank.d427.s3.e0"
            e2="DDI-DrugBank.d427.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s4" text="This may lead to reduced clearance of caffeine and the prolongation of its plasma half-life.">
        <entity id="DDI-DrugBank.d427.s4.e0" charOffset="38-45"
            type="drug" text="caffeine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s5" text="Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.">
        <entity id="DDI-DrugBank.d427.s5.e0" charOffset="0-9"
            type="group" text="Quinolones"/>
        <entity id="DDI-DrugBank.d427.s5.e1" charOffset="22-35"
            type="drug" text="nalidixic acid"/>
        <entity id="DDI-DrugBank.d427.s5.e2" charOffset="74-86"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d427.s5.e3" charOffset="88-95"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d427.s5.d0" e1="DDI-DrugBank.d427.s5.e0"
            e2="DDI-DrugBank.d427.s5.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d427.s5.d1" e1="DDI-DrugBank.d427.s5.e1"
            e2="DDI-DrugBank.d427.s5.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s6" text="When these products are administered concomitantly, prothrombin time or other suitable coagulation test should be closely monitored."/>
    <sentence id="DDI-DrugBank.d427.s7" text="Nitrofurantoin interferes with the therapeutic action of nalidixic acid.">
        <entity id="DDI-DrugBank.d427.s7.e0" charOffset="0-13"
            type="drug" text="Nitrofurantoin"/>
        <entity id="DDI-DrugBank.d427.s7.e1" charOffset="57-70"
            type="drug" text="nalidixic acid"/>
        <ddi id="DDI-DrugBank.d427.s7.d0" e1="DDI-DrugBank.d427.s7.e0"
            e2="DDI-DrugBank.d427.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s8" text="Antacids containing magnesium, aluminum, or calcium;">
        <entity id="DDI-DrugBank.d427.s8.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d427.s8.e1" charOffset="20-28"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d427.s8.e2" charOffset="31-38"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d427.s8.e3" charOffset="44-50"
            type="drug" text="calcium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s9" text="sucralfate or divalent or trivalent cations such as iron;">
        <entity id="DDI-DrugBank.d427.s9.e0" charOffset="0-9"
            type="drug" text="sucralfate"/>
        <entity id="DDI-DrugBank.d427.s9.e1" charOffset="52-55"
            type="drug" text="iron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s10" text="multivitamins containing zinc;">
        <entity id="DDI-DrugBank.d427.s10.e0" charOffset="0-12"
            type="group" text="multivitamins"/>
        <entity id="DDI-DrugBank.d427.s10.e1" charOffset="25-28"
            type="drug" text="zinc"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s11" text="and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.">
        <entity id="DDI-DrugBank.d427.s11.e0" charOffset="4-8"
            type="brand" text="Videx"/>
        <entity id="DDI-DrugBank.d427.s11.e1" charOffset="13-22"
            type="drug" text="Didanosine"/>
        <entity id="DDI-DrugBank.d427.s11.e2" charOffset="145-154"
            type="group" text="quinolones"/>
        <ddi id="DDI-DrugBank.d427.s11.d0" e1="DDI-DrugBank.d427.s11.e0"
            e2="DDI-DrugBank.d427.s11.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d427.s11.d1" e1="DDI-DrugBank.d427.s11.e1"
            e2="DDI-DrugBank.d427.s11.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s12" text="These agents should not be taken within the two hour period before or within the two-hour period after nalidixic acid administration.">
        <entity id="DDI-DrugBank.d427.s12.e0" charOffset="103-116"
            type="drug" text="nalidixic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s13" text="Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.">
        <entity id="DDI-DrugBank.d427.s13.e0" charOffset="25-36"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d427.s13.e1" charOffset="90-99"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d427.s13.e2" charOffset="105-116"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d427.s13.d0" e1="DDI-DrugBank.d427.s13.e1"
            e2="DDI-DrugBank.d427.s13.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d427.s14" text="Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.">
        <entity id="DDI-DrugBank.d427.s14.e0" charOffset="11-22"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d427.s14.e1" charOffset="73-84"
            type="drug" text="cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d346.s0" text="Studies to evaluate possible interactions between REVIA and drugs other than opiates have not been performed.">
        <entity id="DDI-DrugBank.d346.s0.e0" charOffset="50-54"
            type="brand" text="REVIA"/>
        <entity id="DDI-DrugBank.d346.s0.e1" charOffset="77-83"
            type="group" text="opiates"/>
    </sentence>
    <sentence id="DDI-DrugBank.d346.s1" text="Consequently, caution is advised if the concomitant administration of REVIA and other drugs is required.">
        <entity id="DDI-DrugBank.d346.s1.e0" charOffset="70-74"
            type="brand" text="REVIA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d346.s2" text="The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.">
        <entity id="DDI-DrugBank.d346.s2.e0" charOffset="46-50"
            type="brand" text="REVIA"/>
        <entity id="DDI-DrugBank.d346.s2.e1" charOffset="56-65"
            type="drug" text="disulfiram"/>
        <ddi id="DDI-DrugBank.d346.s2.d0" e1="DDI-DrugBank.d346.s2.e0"
            e2="DDI-DrugBank.d346.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d346.s3" text="Lethargy and somnolence have been reported following doses of REVIA and thioridazine.">
        <entity id="DDI-DrugBank.d346.s3.e0" charOffset="62-66"
            type="brand" text="REVIA"/>
        <entity id="DDI-DrugBank.d346.s3.e1" charOffset="72-83"
            type="drug" text="thioridazine"/>
        <ddi id="DDI-DrugBank.d346.s3.d0" e1="DDI-DrugBank.d346.s3.e0"
            e2="DDI-DrugBank.d346.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d346.s4" text="Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.">
        <entity id="DDI-DrugBank.d346.s4.e0" charOffset="16-20"
            type="brand" text="REVIA"/>
        <entity id="DDI-DrugBank.d346.s4.e1" charOffset="43-48"
            type="group" text="opioid"/>
        <entity id="DDI-DrugBank.d346.s4.e2" charOffset="141-157"
            type="group" text="opioid analgesics"/>
        <ddi id="DDI-DrugBank.d346.s4.d0" e1="DDI-DrugBank.d346.s4.e0"
            e2="DDI-DrugBank.d346.s4.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d346.s4.d1" e1="DDI-DrugBank.d346.s4.e0"
            e2="DDI-DrugBank.d346.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d346.s5" text="In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.">
        <entity id="DDI-DrugBank.d346.s5.e0" charOffset="92-96"
            type="brand" text="REVIA"/>
        <entity id="DDI-DrugBank.d346.s5.e1" charOffset="113-118"
            type="group" text="opioid"/>
        <ddi id="DDI-DrugBank.d346.s5.d0" e1="DDI-DrugBank.d346.s5.e0"
            e2="DDI-DrugBank.d346.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s0" text="The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.">
        <entity id="DDI-DrugBank.d85.s0.e0" charOffset="11-16"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d85.s0.e1" charOffset="48-61"
            type="group" text="ACE inhibitors"/>
        <ddi id="DDI-DrugBank.d85.s0.d0" e1="DDI-DrugBank.d85.s0.e0"
            e2="DDI-DrugBank.d85.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s1" text="In vitro studies have shown that naproxen anion, because of its affinity for protein, may displace from their binding sites other drugs which are also albumin-bound .">
        <entity id="DDI-DrugBank.d85.s1.e0" charOffset="33-40"
            type="drug" text="naproxen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s2" text="Theoretically, the naproxen anion itself could likewise be displaced.">
        <entity id="DDI-DrugBank.d85.s2.e0" charOffset="19-26"
            type="drug" text="naproxen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s3" text="Short-term controlled studies failed to show that taking the drug significantly affects prothrombin times when administered to individuals on coumarin-type anticoagulants.">
        <entity id="DDI-DrugBank.d85.s3.e0" charOffset="142-169"
            type="group" text="coumarin-type anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s4" text="Caution is advised nonetheless, since interactions have been seen with other nonsteroidal agents of this class."/>
    <sentence id="DDI-DrugBank.d85.s5" text="Similarly, patients receiving the drug and a hydantoin, sulfonamide or sulfonylurea should be observed for signs of toxicity to these drugs.">
        <entity id="DDI-DrugBank.d85.s5.e0" charOffset="45-53"
            type="group" text="hydantoin"/>
        <entity id="DDI-DrugBank.d85.s5.e1" charOffset="56-66"
            type="group" text="sulfonamide"/>
        <entity id="DDI-DrugBank.d85.s5.e2" charOffset="71-82"
            type="group" text="sulfonylurea"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s6" text="Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.">
        <entity id="DDI-DrugBank.d85.s6.e0" charOffset="30-37"
            type="drug" text="naproxen"/>
        <entity id="DDI-DrugBank.d85.s6.e1" charOffset="43-49"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d85.s6.e2" charOffset="78-85"
            type="drug" text="naproxen"/>
        <entity id="DDI-DrugBank.d85.s6.e3" charOffset="164-170"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d85.s6.d0" e1="DDI-DrugBank.d85.s6.e0"
            e2="DDI-DrugBank.d85.s6.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d85.s6.d1" e1="DDI-DrugBank.d85.s6.e2"
            e2="DDI-DrugBank.d85.s6.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s7" text="The natriuretic effect of furosemide has been reported to be inhibited by some drugs of this class.">
        <entity id="DDI-DrugBank.d85.s7.e0" charOffset="26-35"
            type="drug" text="furosemide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s8" text="Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.">
        <entity id="DDI-DrugBank.d85.s8.e0" charOffset="20-26"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d85.s8.e1" charOffset="69-75"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s9" text="Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.">
        <entity id="DDI-DrugBank.d85.s9.e0" charOffset="0-7" type="drug" text="Naproxen"/>
        <entity id="DDI-DrugBank.d85.s9.e1" charOffset="19-24"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d85.s9.e2" charOffset="68-78"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d85.s9.e3" charOffset="90-102"
            type="group" text="beta-blockers"/>
        <ddi id="DDI-DrugBank.d85.s9.d0" e1="DDI-DrugBank.d85.s9.e0"
            e2="DDI-DrugBank.d85.s9.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d85.s9.d1" e1="DDI-DrugBank.d85.s9.e0"
            e2="DDI-DrugBank.d85.s9.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d85.s9.d2" e1="DDI-DrugBank.d85.s9.e1"
            e2="DDI-DrugBank.d85.s9.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d85.s9.d3" e1="DDI-DrugBank.d85.s9.e1"
            e2="DDI-DrugBank.d85.s9.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s10" text="Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.">
        <entity id="DDI-DrugBank.d85.s10.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d85.s10.e1" charOffset="40-47"
            type="drug" text="naproxen"/>
        <ddi id="DDI-DrugBank.d85.s10.d0" e1="DDI-DrugBank.d85.s10.e0"
            e2="DDI-DrugBank.d85.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s11" text="Caution should be used if naproxen is administered concomitantly with methotrexate.">
        <entity id="DDI-DrugBank.d85.s11.e0" charOffset="26-33"
            type="drug" text="naproxen"/>
        <entity id="DDI-DrugBank.d85.s11.e1" charOffset="70-81"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d85.s11.d0" e1="DDI-DrugBank.d85.s11.e0"
            e2="DDI-DrugBank.d85.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s12" text="Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.">
        <entity id="DDI-DrugBank.d85.s12.e0" charOffset="0-7"
            type="drug" text="Naproxen"/>
        <entity id="DDI-DrugBank.d85.s12.e1" charOffset="10-24"
            type="drug" text="naproxen sodium"/>
        <entity id="DDI-DrugBank.d85.s12.e2" charOffset="36-41"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d85.s12.e3" charOffset="97-108"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d85.s12.e4" charOffset="166-177"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d85.s12.d0" e1="DDI-DrugBank.d85.s12.e0"
            e2="DDI-DrugBank.d85.s12.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d85.s12.d1" e1="DDI-DrugBank.d85.s12.e1"
            e2="DDI-DrugBank.d85.s12.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d85.s12.d2" e1="DDI-DrugBank.d85.s12.e2"
            e2="DDI-DrugBank.d85.s12.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s13" text="Drug/Laboratory Test Interactions Naproxen may decrease platelet aggregation and prolong bleeding time.">
        <entity id="DDI-DrugBank.d85.s13.e0" charOffset="34-41"
            type="drug" text="Naproxen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s14" text="This effect should be kept in mind when bleeding times are determined."/>
    <sentence id="DDI-DrugBank.d85.s15" text="The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-dinitrobenzene used in this assay.">
        <entity id="DDI-DrugBank.d85.s15.e0" charOffset="22-29"
            type="drug" text="naproxen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s16" text="Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used.">
        <entity id="DDI-DrugBank.d85.s16.e0" charOffset="146-153"
            type="drug" text="naproxen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d85.s17" text="Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA).">
        <entity id="DDI-DrugBank.d85.s17.e0" charOffset="0-7"
            type="drug" text="Naproxen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s0" text="Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.">
        <entity id="DDI-DrugBank.d478.s0.e0" charOffset="0-4"
            type="group" text="Ergot"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s1" text="Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.">
        <entity id="DDI-DrugBank.d478.s1.e0" charOffset="80-89"
            type="drug" text="ergotamine"/>
        <entity id="DDI-DrugBank.d478.s1.e1" charOffset="105-126"
            type="group" text="ergot-type medications"/>
        <entity id="DDI-DrugBank.d478.s1.e2" charOffset="134-150"
            type="drug" text="dihydroergotamine"/>
        <entity id="DDI-DrugBank.d478.s1.e3" charOffset="155-166"
            type="drug" text="methysergide"/>
        <entity id="DDI-DrugBank.d478.s1.e4" charOffset="173-183"
            type="drug" text="naratriptan"/>
        <ddi id="DDI-DrugBank.d478.s1.d0" e1="DDI-DrugBank.d478.s1.e0"
            e2="DDI-DrugBank.d478.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d478.s1.d1" e1="DDI-DrugBank.d478.s1.e1"
            e2="DDI-DrugBank.d478.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d478.s1.d2" e1="DDI-DrugBank.d478.s1.e2"
            e2="DDI-DrugBank.d478.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d478.s1.d3" e1="DDI-DrugBank.d478.s1.e3"
            e2="DDI-DrugBank.d478.s1.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s2" text="The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients.">
        <entity id="DDI-DrugBank.d478.s2.e0" charOffset="22-32"
            type="drug" text="naratriptan"/>
        <entity id="DDI-DrugBank.d478.s2.e1" charOffset="45-58"
            type="group" text="5-HT1 agonists"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s3" text="Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.">
        <entity id="DDI-DrugBank.d478.s3.e0" charOffset="71-81"
            type="drug" text="naratriptan"/>
        <entity id="DDI-DrugBank.d478.s3.e1" charOffset="93-106"
            type="group" text="5-HT1 agonists"/>
        <ddi id="DDI-DrugBank.d478.s3.d0" e1="DDI-DrugBank.d478.s3.e0"
            e2="DDI-DrugBank.d478.s3.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s4" text="Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.">
        <entity id="DDI-DrugBank.d478.s4.e0" charOffset="0-38"
            type="group" text="Selective serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d478.s4.e1" charOffset="41-45"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d478.s4.e2" charOffset="55-64"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d478.s4.e3" charOffset="67-77"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d478.s4.e4" charOffset="80-89"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d478.s4.e5" charOffset="92-101"
            type="drug" text="sertraline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s5" text="If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.">
        <entity id="DDI-DrugBank.d478.s5.e0" charOffset="30-40"
            type="drug" text="naratriptan"/>
        <entity id="DDI-DrugBank.d478.s5.e1" charOffset="49-52"
            type="group" text="SSRI"/>
        <ddi id="DDI-DrugBank.d478.s5.d0" e1="DDI-DrugBank.d478.s5.e0"
            e2="DDI-DrugBank.d478.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s6" text="Drug/ Laboratory Test Interactions AMERGE Tablets are not known to interfere with commonly employed clinical laboratory tests.">
        <entity id="DDI-DrugBank.d478.s6.e0" charOffset="35-40"
            type="brand" text="AMERGE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d232.s0" text="After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.">
        <entity id="DDI-DrugBank.d232.s0.e0" charOffset="23-40"
            type="drug" text="interferon beta-1a"/>
        <entity id="DDI-DrugBank.d232.s0.e1" charOffset="43-48"
            type="brand" text="AVONEX"/>
        <entity id="DDI-DrugBank.d232.s0.e2" charOffset="82-88"
            type="brand" text="TYSABRI"/>
        <ddi id="DDI-DrugBank.d232.s0.d0" e1="DDI-DrugBank.d232.s0.e0"
            e2="DDI-DrugBank.d232.s0.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d232.s0.d1" e1="DDI-DrugBank.d232.s0.e1"
            e2="DDI-DrugBank.d232.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d232.s1" text="The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).">
        <entity id="DDI-DrugBank.d232.s1.e0" charOffset="22-28"
            type="brand" text="TYSABRI"/>
        <entity id="DDI-DrugBank.d232.s1.e1" charOffset="105-110"
            type="brand" text="AVONEX"/>
        <entity id="DDI-DrugBank.d232.s1.e2" charOffset="148-153"
            type="brand" text="AVONEX"/>
        <entity id="DDI-DrugBank.d232.s1.e3" charOffset="239-245"
            type="brand" text="TYSABRI"/>
    </sentence>
    <sentence id="DDI-DrugBank.d232.s2" text="Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.">
        <entity id="DDI-DrugBank.d232.s2.e0" charOffset="57-63"
            type="brand" text="TYSABRI"/>
        <entity id="DDI-DrugBank.d232.s2.e1" charOffset="82-99"
            type="drug" text="interferon beta-1a"/>
        <entity id="DDI-DrugBank.d232.s2.e2" charOffset="102-107"
            type="brand" text="AVONEX"/>
        <entity id="DDI-DrugBank.d232.s2.e3" charOffset="136-153"
            type="drug" text="glatiramer acetate"/>
        <entity id="DDI-DrugBank.d232.s2.e4" charOffset="224-238"
            type="drug" text="beta-interferon"/>
        <entity id="DDI-DrugBank.d232.s2.e5" charOffset="243-260"
            type="drug" text="glatiramer acetate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s0" text="In vitro drug metabolism studies indicate that Starlix is predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%).">
        <entity id="DDI-DrugBank.d460.s0.e0" charOffset="47-53"
            type="brand" text="Starlix"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s1" text="Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.">
        <entity id="DDI-DrugBank.d460.s1.e0" charOffset="0-6"
            type="brand" text="Starlix"/>
        <entity id="DDI-DrugBank.d460.s1.e1" charOffset="131-141"
            type="drug" text="tolbutamide"/>
        <ddi id="DDI-DrugBank.d460.s1.d0" e1="DDI-DrugBank.d460.s1.e0"
            e2="DDI-DrugBank.d460.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s2" text="Inhibition of CYP3A4 metabolic reactions was not detected in in vitro experiments."/>
    <sentence id="DDI-DrugBank.d460.s3" text="Glyburide: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily.">
        <entity id="DDI-DrugBank.d460.s3.e0" charOffset="0-8"
            type="drug" text="Glyburide"/>
        <entity id="DDI-DrugBank.d460.s3.e1" charOffset="114-120"
            type="brand" text="Starlix"/>
        <entity id="DDI-DrugBank.d460.s3.e2" charOffset="183-191"
            type="drug" text="glyburide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s4" text="There were no clinically relevant alterations in the pharmacokinetics of either agent."/>
    <sentence id="DDI-DrugBank.d460.s5" text="Metformin: When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.">
        <entity id="DDI-DrugBank.d460.s5.e0" charOffset="0-8"
            type="drug" text="Metformin"/>
        <entity id="DDI-DrugBank.d460.s5.e1" charOffset="16-22"
            type="brand" text="Starlix"/>
        <entity id="DDI-DrugBank.d460.s5.e2" charOffset="99-107"
            type="drug" text="metformin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s6" text="Digoxin: When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.">
        <entity id="DDI-DrugBank.d460.s6.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d460.s6.e1" charOffset="14-20"
            type="brand" text="Starlix"/>
        <entity id="DDI-DrugBank.d460.s6.e2" charOffset="101-107"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s7" text="Warfarin: When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.">
        <entity id="DDI-DrugBank.d460.s7.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d460.s7.e1" charOffset="50-56"
            type="brand" text="Starlix"/>
        <entity id="DDI-DrugBank.d460.s7.e2" charOffset="147-154"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s8" text="Prothrombin time was not affected."/>
    <sentence id="DDI-DrugBank.d460.s9" text="Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.">
        <entity id="DDI-DrugBank.d460.s9.e0" charOffset="0-9"
            type="drug" text="Diclofenac"/>
        <entity id="DDI-DrugBank.d460.s9.e1" charOffset="57-63"
            type="brand" text="Starlix"/>
        <entity id="DDI-DrugBank.d460.s9.e2" charOffset="115-124"
            type="drug" text="diclofenac"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s10" text="Nateglinide is highly bound to plasma proteins (98%), mainly albumin.">
        <entity id="DDI-DrugBank.d460.s10.e0" charOffset="0-10"
            type="drug" text="Nateglinide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s11" text="In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.">
        <entity id="DDI-DrugBank.d460.s11.e0" charOffset="70-79"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d460.s11.e1" charOffset="82-92"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d460.s11.e2" charOffset="95-103"
            type="drug" text="captopril"/>
        <entity id="DDI-DrugBank.d460.s11.e3" charOffset="106-116"
            type="drug" text="nicardipine"/>
        <entity id="DDI-DrugBank.d460.s11.e4" charOffset="119-129"
            type="drug" text="pravastatin"/>
        <entity id="DDI-DrugBank.d460.s11.e5" charOffset="132-140"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d460.s11.e6" charOffset="143-150"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d460.s11.e7" charOffset="153-161"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d460.s11.e8" charOffset="164-183"
            type="drug" text="acetylsalicylic acid"/>
        <entity id="DDI-DrugBank.d460.s11.e9" charOffset="186-196"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d460.s11.e10" charOffset="203-211"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d460.s11.e11" charOffset="250-260"
            type="drug" text="nateglinide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s12" text="Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .">
        <entity id="DDI-DrugBank.d460.s12.e0" charOffset="11-21"
            type="drug" text="nateglinide"/>
        <entity id="DDI-DrugBank.d460.s12.e1" charOffset="72-82"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d460.s12.e2" charOffset="85-93"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d460.s12.e3" charOffset="96-106"
            type="drug" text="nicardipine"/>
        <entity id="DDI-DrugBank.d460.s12.e4" charOffset="109-116"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d460.s12.e5" charOffset="119-127"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d460.s12.e6" charOffset="130-149"
            type="drug" text="acetylsalicylic acid"/>
        <entity id="DDI-DrugBank.d460.s12.e7" charOffset="156-166"
            type="drug" text="tolbutamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s13" text="However, prudent evaluation of individual cases is warranted in the clinical setting."/>
    <sentence id="DDI-DrugBank.d460.s14" text="Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.">
        <entity id="DDI-DrugBank.d460.s14.e0" charOffset="25-61"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d460.s14.e1" charOffset="64-69"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d460.s14.e2" charOffset="73-83"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d460.s14.e3" charOffset="86-113"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d460.s14.e4" charOffset="120-164"
            type="group" text="non-selective beta-adrenergic-blocking agents"/>
        <entity id="DDI-DrugBank.d460.s14.e5" charOffset="208-214"
            type="brand" text="Starlix"/>
        <entity id="DDI-DrugBank.d460.s14.e6" charOffset="231-248"
            type="group" text="antidiabetic drugs"/>
        <ddi id="DDI-DrugBank.d460.s14.d0" e1="DDI-DrugBank.d460.s14.e0"
            e2="DDI-DrugBank.d460.s14.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s14.d1" e1="DDI-DrugBank.d460.s14.e1"
            e2="DDI-DrugBank.d460.s14.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s14.d2" e1="DDI-DrugBank.d460.s14.e2"
            e2="DDI-DrugBank.d460.s14.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s14.d3" e1="DDI-DrugBank.d460.s14.e3"
            e2="DDI-DrugBank.d460.s14.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s14.d4" e1="DDI-DrugBank.d460.s14.e4"
            e2="DDI-DrugBank.d460.s14.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s14.d5" e1="DDI-DrugBank.d460.s14.e0"
            e2="DDI-DrugBank.d460.s14.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s14.d6" e1="DDI-DrugBank.d460.s14.e1"
            e2="DDI-DrugBank.d460.s14.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s14.d7" e1="DDI-DrugBank.d460.s14.e2"
            e2="DDI-DrugBank.d460.s14.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s14.d8" e1="DDI-DrugBank.d460.s14.e3"
            e2="DDI-DrugBank.d460.s14.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s14.d9" e1="DDI-DrugBank.d460.s14.e4"
            e2="DDI-DrugBank.d460.s14.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s15" text="Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.">
        <entity id="DDI-DrugBank.d460.s15.e0" charOffset="24-32"
            type="group" text="thiazides"/>
        <entity id="DDI-DrugBank.d460.s15.e1" charOffset="35-49"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d460.s15.e2" charOffset="52-67"
            type="group" text="thyroid products"/>
        <entity id="DDI-DrugBank.d460.s15.e3" charOffset="74-89"
            type="group" text="sympathomimetics"/>
        <entity id="DDI-DrugBank.d460.s15.e4" charOffset="129-135"
            type="brand" text="Starlix"/>
        <entity id="DDI-DrugBank.d460.s15.e5" charOffset="152-169"
            type="group" text="antidiabetic drugs"/>
        <ddi id="DDI-DrugBank.d460.s15.d0" e1="DDI-DrugBank.d460.s15.e0"
            e2="DDI-DrugBank.d460.s15.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s15.d1" e1="DDI-DrugBank.d460.s15.e1"
            e2="DDI-DrugBank.d460.s15.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s15.d2" e1="DDI-DrugBank.d460.s15.e2"
            e2="DDI-DrugBank.d460.s15.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s15.d3" e1="DDI-DrugBank.d460.s15.e3"
            e2="DDI-DrugBank.d460.s15.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s15.d4" e1="DDI-DrugBank.d460.s15.e0"
            e2="DDI-DrugBank.d460.s15.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s15.d5" e1="DDI-DrugBank.d460.s15.e1"
            e2="DDI-DrugBank.d460.s15.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s15.d6" e1="DDI-DrugBank.d460.s15.e2"
            e2="DDI-DrugBank.d460.s15.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d460.s15.d7" e1="DDI-DrugBank.d460.s15.e3"
            e2="DDI-DrugBank.d460.s15.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d460.s16" text="When these drugs are administered to or withdrawn from patients receiving Starlix, the patient should be observed closely for changes in glycemic control.">
        <entity id="DDI-DrugBank.d460.s16.e0" charOffset="74-80"
            type="brand" text="Starlix"/>
    </sentence>
    <sentence id="DDI-DrugBank.d61.s0" text="In clinical studies, Tilade has been co-administered with other anti-asthma medications, including inhaled and oral bronchodilators, and inhaled corticosteroids, with no evidence of increased frequency of adverse events or laboratory abnormalities.">
        <entity id="DDI-DrugBank.d61.s0.e0" charOffset="21-26"
            type="brand" text="Tilade"/>
        <entity id="DDI-DrugBank.d61.s0.e1" charOffset="116-130"
            type="group" text="bronchodilators"/>
        <entity id="DDI-DrugBank.d61.s0.e2" charOffset="145-159"
            type="group" text="corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d61.s1" text="No formal drug-drug interaction studies, however, have been conducted."/>
    <sentence id="DDI-DrugBank.d340.s0" text="Nelfinavir is an inhibitor of CYP3A (cytochrome P450 3A).">
        <entity id="DDI-DrugBank.d340.s0.e0" charOffset="0-9"
            type="drug" text="Nelfinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s1" text="Coadministration of VIRACEPT and drugs primarily metabolized by CYP3A (e.g., dihydropyridine calcium channel blockers) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects.">
        <entity id="DDI-DrugBank.d340.s1.e0" charOffset="20-27"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s1.e1" charOffset="77-116"
            type="group" text="dihydropyridine calcium channel blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s2" text="Nelfinavir is metabolized in proof by C.P.A.">
        <entity id="DDI-DrugBank.d340.s2.e0" charOffset="0-9"
            type="drug" text="Nelfinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s3" text="Coadministration of VIRACEPT and drugs that induce CYP3A may decrease nelfinavir plasma concentrations and reduce its therapeutic effect.">
        <entity id="DDI-DrugBank.d340.s3.e0" charOffset="20-27"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s3.e1" charOffset="70-79"
            type="drug" text="nelfinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s4" text="Coadministration of VIRACEPT and drugs that inhibit CYP3A may increase nelfinavir plasma concentrations.">
        <entity id="DDI-DrugBank.d340.s4.e0" charOffset="20-27"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s4.e1" charOffset="71-80"
            type="drug" text="nelfinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s5" text="Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.">
        <entity id="DDI-DrugBank.d340.s5.e0" charOffset="101-108"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s5.e1" charOffset="114-120"
            type="drug" text="dapsone"/>
        <entity id="DDI-DrugBank.d340.s5.e2" charOffset="123-134"
            type="drug" text="trimethoprim"/>
        <entity id="DDI-DrugBank.d340.s5.e3" charOffset="136-151"
            type="drug" text="sulfamethoxazole"/>
        <entity id="DDI-DrugBank.d340.s5.e4" charOffset="154-167"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d340.s5.e5" charOffset="170-181"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d340.s5.e6" charOffset="184-195"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d340.s5.e7" charOffset="200-210"
            type="drug" text="fluconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s6" text="Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride">
        <entity id="DDI-DrugBank.d340.s6.e0" charOffset="45-52"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s6.e1" charOffset="54-68"
            type="group" text="Antiarrhythmics"/>
        <entity id="DDI-DrugBank.d340.s6.e2" charOffset="71-80"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d340.s6.e3" charOffset="83-91"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d340.s6.e4" charOffset="93-106"
            type="group" text="Antihistamines"/>
        <entity id="DDI-DrugBank.d340.s6.e5" charOffset="109-118"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d340.s6.e6" charOffset="121-131"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d340.s6.e7" charOffset="147-163"
            type="group" text="ergot derivatives"/>
        <entity id="DDI-DrugBank.d340.s6.e8" charOffset="165-188"
            type="group" text="Antimycobacterial agents"/>
        <entity id="DDI-DrugBank.d340.s6.e9" charOffset="191-198"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d340.s6.e10" charOffset="200-214"
            type="group" text="Benzodiazepines"/>
        <entity id="DDI-DrugBank.d340.s6.e11" charOffset="216-224"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d340.s6.e12" charOffset="227-235"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d340.s6.e13" charOffset="257-265"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d340.s6.d0" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d1" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d2" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d3" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d4" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d5" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d6" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d7" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d8" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d9" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e10" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d10" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d11" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e12" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s6.d12" e1="DDI-DrugBank.d340.s6.e0"
            e2="DDI-DrugBank.d340.s6.e13" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s7" text="Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin">
        <entity id="DDI-DrugBank.d340.s7.e0" charOffset="61-68"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s7.e1" charOffset="70-93"
            type="group" text="Antimycobacterial agents"/>
        <entity id="DDI-DrugBank.d340.s7.e2" charOffset="96-104"
            type="drug" text="rifabutin"/>
        <ddi id="DDI-DrugBank.d340.s7.d0" e1="DDI-DrugBank.d340.s7.e0"
            e2="DDI-DrugBank.d340.s7.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d340.s7.d1" e1="DDI-DrugBank.d340.s7.e0"
            e2="DDI-DrugBank.d340.s7.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s8" text="* This table is not all inclusive ** VIRACEPT may not be effective due to decreased nelfinavir plasma concentrations in patients taking these agents concomitantly">
        <entity id="DDI-DrugBank.d340.s8.e0" charOffset="37-44"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s8.e1" charOffset="84-93"
            type="drug" text="nelfinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s9" text="Antihistamines">
        <entity id="DDI-DrugBank.d340.s9.e0" charOffset="0-13"
            type="group" text="Antihistamines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s10" text="Terfenadine: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;">
        <entity id="DDI-DrugBank.d340.s10.e0" charOffset="0-10"
            type="drug" text="Terfenadine"/>
        <entity id="DDI-DrugBank.d340.s10.e1" charOffset="31-41"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d340.s10.e2" charOffset="48-55"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s10.e3" charOffset="97-107"
            type="drug" text="terfenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s11" text="therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.">
        <entity id="DDI-DrugBank.d340.s11.e0" charOffset="11-18"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s11.e1" charOffset="65-75"
            type="drug" text="terfenadine"/>
        <ddi id="DDI-DrugBank.d340.s11.d0" e1="DDI-DrugBank.d340.s11.e0"
            e2="DDI-DrugBank.d340.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s12" text="Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.">
        <entity id="DDI-DrugBank.d340.s12.e0" charOffset="41-48"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s12.e1" charOffset="100-109"
            type="drug" text="astemizole"/>
        <ddi id="DDI-DrugBank.d340.s12.d0" e1="DDI-DrugBank.d340.s12.e0"
            e2="DDI-DrugBank.d340.s12.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s13" text="Anti-HIV Protease Inhibitors">
        <entity id="DDI-DrugBank.d340.s13.e0" charOffset="0-27"
            type="group" text="Anti-HIV Protease Inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s14" text="Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.">
        <entity id="DDI-DrugBank.d340.s14.e0" charOffset="0-8"
            type="drug" text="Indinavir"/>
        <entity id="DDI-DrugBank.d340.s14.e1" charOffset="31-39"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d340.s14.e2" charOffset="46-53"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s14.e3" charOffset="86-95"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d340.s14.e4" charOffset="130-138"
            type="drug" text="indinavir"/>
        <ddi id="DDI-DrugBank.d340.s14.d0" e1="DDI-DrugBank.d340.s14.e1"
            e2="DDI-DrugBank.d340.s14.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s15" text="Currently, there are no safety and efficacy data available from the use of this combination."/>
    <sentence id="DDI-DrugBank.d340.s16" text="Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.">
        <entity id="DDI-DrugBank.d340.s16.e0" charOffset="0-8"
            type="drug" text="Ritonavir"/>
        <entity id="DDI-DrugBank.d340.s16.e1" charOffset="31-39"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d340.s16.e2" charOffset="46-53"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s16.e3" charOffset="86-95"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d340.s16.e4" charOffset="134-142"
            type="drug" text="ritonavir"/>
        <ddi id="DDI-DrugBank.d340.s16.d0" e1="DDI-DrugBank.d340.s16.e1"
            e2="DDI-DrugBank.d340.s16.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s17" text="Currently, there are no safety and efficacy data available from the use of this combination."/>
    <sentence id="DDI-DrugBank.d340.s18" text="Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.">
        <entity id="DDI-DrugBank.d340.s18.e0" charOffset="0-9"
            type="drug" text="Saquinavir"/>
        <entity id="DDI-DrugBank.d340.s18.e1" charOffset="32-41"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d340.s18.e2" charOffset="102-111"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d340.s18.e3" charOffset="126-133"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s18.e4" charOffset="166-175"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d340.s18.e5" charOffset="213-222"
            type="drug" text="saquinavir"/>
        <ddi id="DDI-DrugBank.d340.s18.d0" e1="DDI-DrugBank.d340.s18.e1"
            e2="DDI-DrugBank.d340.s18.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s19" text="If used in combination with saquinavir hard gelatin capsules at the recommended dose of 600 mg tid, no dose adjustments are needed.">
        <entity id="DDI-DrugBank.d340.s19.e0" charOffset="28-37"
            type="drug" text="saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s20" text="Currently, there are no safety and efficacy data available from the use of this combination."/>
    <sentence id="DDI-DrugBank.d340.s21" text="Antifungal Agents">
        <entity id="DDI-DrugBank.d340.s21.e0" charOffset="0-16"
            type="group" text="Antifungal Agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s22" text="Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.">
        <entity id="DDI-DrugBank.d340.s22.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d340.s22.e1" charOffset="34-45"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d340.s22.e2" charOffset="52-59"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s22.e3" charOffset="91-100"
            type="drug" text="nelfinavir"/>
        <ddi id="DDI-DrugBank.d340.s22.d0" e1="DDI-DrugBank.d340.s22.e1"
            e2="DDI-DrugBank.d340.s22.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s23" text="This change was not considered clinically significant and no dose adjustment is needed when ketoconazole and VIRACEPT are coadministered.">
        <entity id="DDI-DrugBank.d340.s23.e0" charOffset="92-103"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d340.s23.e1" charOffset="109-116"
            type="brand" text="VIRACEPT"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s24" text="Anti-HIV Reverse Transcriptase Inhibitors">
        <entity id="DDI-DrugBank.d340.s24.e0" charOffset="0-40"
            type="group" text="Anti-HIV Reverse Transcriptase Inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s25" text="Didanosine: It is recommended that didanosine be administered on an empty stomach;">
        <entity id="DDI-DrugBank.d340.s25.e0" charOffset="0-9"
            type="drug" text="Didanosine"/>
        <entity id="DDI-DrugBank.d340.s25.e1" charOffset="35-44"
            type="drug" text="didanosine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s26" text="therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.">
        <entity id="DDI-DrugBank.d340.s26.e0" charOffset="11-20"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d340.s26.e1" charOffset="102-111"
            type="drug" text="didanosine"/>
        <ddi id="DDI-DrugBank.d340.s26.d0" e1="DDI-DrugBank.d340.s26.e0"
            e2="DDI-DrugBank.d340.s26.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s27" text="A dose adjustment is not needed when zidovudine is administered with VIRACEPT.">
        <entity id="DDI-DrugBank.d340.s27.e0" charOffset="37-46"
            type="drug" text="zidovudine"/>
        <entity id="DDI-DrugBank.d340.s27.e1" charOffset="69-76"
            type="brand" text="VIRACEPT"/>
        <ddi id="DDI-DrugBank.d340.s27.d0" e1="DDI-DrugBank.d340.s27.e0"
            e2="DDI-DrugBank.d340.s27.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s28" text="Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with lamivudine or stavudine.">
        <entity id="DDI-DrugBank.d340.s28.e0" charOffset="77-84"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s28.e1" charOffset="110-119"
            type="drug" text="lamivudine"/>
        <entity id="DDI-DrugBank.d340.s28.e2" charOffset="124-132"
            type="drug" text="stavudine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s29" text="Antimycobacterial Agents">
        <entity id="DDI-DrugBank.d340.s29.e0" charOffset="0-23"
            type="group" text="Antimycobacterial Agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s30" text="Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.">
        <entity id="DDI-DrugBank.d340.s30.e0" charOffset="0-8"
            type="drug" text="Rifabutin"/>
        <entity id="DDI-DrugBank.d340.s30.e1" charOffset="31-39"
            type="drug" text="rifabutin"/>
        <entity id="DDI-DrugBank.d340.s30.e2" charOffset="45-52"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s30.e3" charOffset="84-93"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d340.s30.e4" charOffset="129-137"
            type="drug" text="rifabutin"/>
        <ddi id="DDI-DrugBank.d340.s30.d0" e1="DDI-DrugBank.d340.s30.e1"
            e2="DDI-DrugBank.d340.s30.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s31" text="It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.">
        <entity id="DDI-DrugBank.d340.s31.e0" charOffset="35-43"
            type="drug" text="rifabutin"/>
        <entity id="DDI-DrugBank.d340.s31.e1" charOffset="106-113"
            type="brand" text="VIRACEPT"/>
        <ddi id="DDI-DrugBank.d340.s31.d0" e1="DDI-DrugBank.d340.s31.e0"
            e2="DDI-DrugBank.d340.s31.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s32" text="Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.">
        <entity id="DDI-DrugBank.d340.s32.e0" charOffset="0-7"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d340.s32.e1" charOffset="30-37"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d340.s32.e2" charOffset="43-50"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s32.e3" charOffset="83-92"
            type="drug" text="nelfinavir"/>
        <ddi id="DDI-DrugBank.d340.s32.d0" e1="DDI-DrugBank.d340.s32.e1"
            e2="DDI-DrugBank.d340.s32.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s33" text="VIRACEPT and rifampin should not be coadministered.">
        <entity id="DDI-DrugBank.d340.s33.e0" charOffset="0-7"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s33.e1" charOffset="13-20"
            type="drug" text="rifampin"/>
        <ddi id="DDI-DrugBank.d340.s33.d0" e1="DDI-DrugBank.d340.s33.e0"
            e2="DDI-DrugBank.d340.s33.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s34" text="Oral Contraceptives">
        <entity id="DDI-DrugBank.d340.s34.e0" charOffset="5-18"
            type="group" text="Contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s35" text="Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.">
        <entity id="DDI-DrugBank.d340.s35.e0" charOffset="0-16"
            type="drug" text="Ethinyl Estradiol"/>
        <entity id="DDI-DrugBank.d340.s35.e1" charOffset="22-34"
            type="drug" text="Norethindrone"/>
        <entity id="DDI-DrugBank.d340.s35.e2" charOffset="57-64"
            type="brand" text="VIRACEPT"/>
        <entity id="DDI-DrugBank.d340.s35.e3" charOffset="71-78"
            type="brand" text="OVCON-35"/>
        <entity id="DDI-DrugBank.d340.s35.e4" charOffset="110-126"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d340.s35.e5" charOffset="151-163"
            type="drug" text="norethindrone"/>
        <ddi id="DDI-DrugBank.d340.s35.d0" e1="DDI-DrugBank.d340.s35.e2"
            e2="DDI-DrugBank.d340.s35.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d340.s36" text="Alternate or additional contraceptive measures should be used during therapy with VIRACEPT">
        <entity id="DDI-DrugBank.d340.s36.e0" charOffset="82-89"
            type="brand" text="VIRACEPT"/>
    </sentence>
    <sentence id="DDI-DrugBank.d330.s0" text="Caution should be taken in concurrent or serial use of other neurotoxic and/ or nephrotoxic drugs because of possible enhancement of the nephrotoxicity and/or ototoxicity of neomycin.">
        <entity id="DDI-DrugBank.d330.s0.e0" charOffset="174-181"
            type="drug" text="neomycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d330.s1" text="Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.">
        <entity id="DDI-DrugBank.d330.s1.e0" charOffset="66-80"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d330.s1.e1" charOffset="86-95"
            type="group" text="polymyxins"/>
        <entity id="DDI-DrugBank.d330.s1.e2" charOffset="182-197"
            type="drug" text="neomycin sulfate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d330.s2" text="Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.">
        <entity id="DDI-DrugBank.d330.s2.e0" charOffset="5-12"
            type="drug" text="neomycin"/>
        <entity id="DDI-DrugBank.d330.s2.e1" charOffset="58-69"
            type="drug" text="penicillin V"/>
        <entity id="DDI-DrugBank.d330.s2.e2" charOffset="77-88"
            type="drug" text="vitamin B-12"/>
        <entity id="DDI-DrugBank.d330.s2.e3" charOffset="91-102"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d330.s2.e4" charOffset="108-121"
            type="drug" text="5-fluorouracil"/>
        <ddi id="DDI-DrugBank.d330.s2.d0" e1="DDI-DrugBank.d330.s2.e0"
            e2="DDI-DrugBank.d330.s2.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d330.s2.d1" e1="DDI-DrugBank.d330.s2.e0"
            e2="DDI-DrugBank.d330.s2.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d330.s2.d2" e1="DDI-DrugBank.d330.s2.e0"
            e2="DDI-DrugBank.d330.s2.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d330.s2.d3" e1="DDI-DrugBank.d330.s2.e0"
            e2="DDI-DrugBank.d330.s2.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d330.s3" text="The gastrointestinal absorption of digoxin also appears to be inhibited.">
        <entity id="DDI-DrugBank.d330.s3.e0" charOffset="35-41"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d330.s4" text="Therefore, digoxin serum levels should be monitored.">
        <entity id="DDI-DrugBank.d330.s4.e0" charOffset="11-17"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d330.s5" text="Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.">
        <entity id="DDI-DrugBank.d330.s5.e0" charOffset="5-20"
            type="drug" text="neomycin sulfate"/>
        <entity id="DDI-DrugBank.d330.s5.e1" charOffset="48-55"
            type="group" text="coumarin"/>
        <entity id="DDI-DrugBank.d330.s5.e2" charOffset="60-73"
            type="group" text="anticoagulants"/>
        <ddi id="DDI-DrugBank.d330.s5.d0" e1="DDI-DrugBank.d330.s5.e0"
            e2="DDI-DrugBank.d330.s5.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d330.s5.d1" e1="DDI-DrugBank.d330.s5.e0"
            e2="DDI-DrugBank.d330.s5.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d498.s0" text="Certain antibiotics, especially neomycin, streptomycin and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.">
        <entity id="DDI-DrugBank.d498.s0.e0" charOffset="8-18"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d498.s0.e1" charOffset="32-39"
            type="drug" text="neomycin"/>
        <entity id="DDI-DrugBank.d498.s0.e2" charOffset="42-53"
            type="drug" text="streptomycin"/>
        <entity id="DDI-DrugBank.d498.s0.e3" charOffset="59-67"
            type="drug" text="kanamycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d498.s1" text="These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.">
        <entity id="DDI-DrugBank.d498.s1.e0" charOffset="6-16"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d498.s1.e1" charOffset="149-166"
            type="group" text="anticholinesterase"/>
        <ddi id="DDI-DrugBank.d498.s1.d0" e1="DDI-DrugBank.d498.s1.e0"
            e2="DDI-DrugBank.d498.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d498.s2" text="Local and some general anesthetics, antiarrhythmic agents and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, in patients with myasthenia gravis;">
        <entity id="DDI-DrugBank.d498.s2.e0" charOffset="23-33"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d498.s2.e1" charOffset="36-56"
            type="group" text="antiarrhythmic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d498.s3" text="the dose of Prostigmin may have to be increased accordingly.">
        <entity id="DDI-DrugBank.d498.s3.e0" charOffset="12-21"
            type="brand" text="Prostigmin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d239.s0" text="No trials specifically examining potential drug interactions with Natrecor were conducted, although many concomitant drugs were used in clinical trials.">
        <entity id="DDI-DrugBank.d239.s0.e0" charOffset="66-73"
            type="brand" text="Natrecor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d239.s1" text="No drug interactions were detected except for an increase in symptomatic hypotension in patients receiving oral ACE inhibitors.">
        <entity id="DDI-DrugBank.d239.s1.e0" charOffset="112-125"
            type="group" text="ACE inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d239.s2" text="The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).">
        <entity id="DDI-DrugBank.d239.s2.e0" charOffset="25-32"
            type="brand" text="Natrecor"/>
        <entity id="DDI-DrugBank.d239.s2.e1" charOffset="42-53"
            type="group" text="vasodilators"/>
        <entity id="DDI-DrugBank.d239.s2.e2" charOffset="63-75"
            type="drug" text="nitroglycerin"/>
        <entity id="DDI-DrugBank.d239.s2.e3" charOffset="78-90"
            type="drug" text="nitroprusside"/>
        <entity id="DDI-DrugBank.d239.s2.e4" charOffset="93-101"
            type="drug" text="milrinone"/>
        <entity id="DDI-DrugBank.d239.s2.e5" charOffset="110-123"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d239.s2.e6" charOffset="191-198"
            type="brand" text="Natrecor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d417.s0" text="Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.">
        <entity id="DDI-DrugBank.d417.s0.e0" charOffset="0-9"
            type="drug" text="Netilmicin"/>
        <entity id="DDI-DrugBank.d417.s0.e1" charOffset="64-77"
            type="group" text="loop diuretics"/>
        <entity id="DDI-DrugBank.d417.s0.e2" charOffset="87-96"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d417.s0.e3" charOffset="102-116"
            type="drug" text="ethacrynic acid"/>
        <ddi id="DDI-DrugBank.d417.s0.d0" e1="DDI-DrugBank.d417.s0.e0"
            e2="DDI-DrugBank.d417.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d417.s0.d1" e1="DDI-DrugBank.d417.s0.e0"
            e2="DDI-DrugBank.d417.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d417.s0.d2" e1="DDI-DrugBank.d417.s0.e0"
            e2="DDI-DrugBank.d417.s0.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s0" text="Nevirapine is principally metabolized by the liver via the cytochrome P450 isoenzymes, 3A4 and 2B6.">
        <entity id="DDI-DrugBank.d270.s0.e0" charOffset="0-9"
            type="drug" text="Nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s1" text="Nevirapine is known to be an inducer of these enzymes.">
        <entity id="DDI-DrugBank.d270.s1.e0" charOffset="0-9"
            type="drug" text="Nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s2" text="As a result, drugs that are metabolized by these enzyme systems may have lower than expected plasma levels when coadministered with nevirapine.">
        <entity id="DDI-DrugBank.d270.s2.e0" charOffset="132-141"
            type="drug" text="nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s3" text="The specific pharmacokinetic changes that occur with co-administration of nevirapine and other drugs are listed in CLINICAL PHARMACOLOGY, Table 1.">
        <entity id="DDI-DrugBank.d270.s3.e0" charOffset="74-83"
            type="drug" text="nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s4" text="Clinical comments about possible dosage modifications based on these pharmacokinetic changes are listed in Table 3."/>
    <sentence id="DDI-DrugBank.d270.s5" text="The data inTables 1 and 3 are based on the results of drug interaction studies conducted in HIV-1 seropositive subjects unless otherwise indicated."/>
    <sentence id="DDI-DrugBank.d270.s6" text="In addition to established drug interactions, there may be potential pharmacokinetic interactions between nevirapine and other drug classes that are metabolized by the cytochrome P450 system.">
        <entity id="DDI-DrugBank.d270.s6.e0" charOffset="106-115"
            type="drug" text="nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s7" text="These potential drug interactions are listed in Table 4."/>
    <sentence id="DDI-DrugBank.d270.s8" text="Although specific drug interaction studies in HIV-1 seropositive subjects have not been conducted for the classes of drugs listed in Table 4, additional clinical monitoring may be warranted when co-administering these drugs."/>
    <sentence id="DDI-DrugBank.d270.s9" text="The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.">
        <entity id="DDI-DrugBank.d270.s9.e0" charOffset="33-42"
            type="drug" text="nevirapine"/>
        <entity id="DDI-DrugBank.d270.s9.e1" charOffset="52-71"
            type="group" text="antithrombotic agent"/>
        <entity id="DDI-DrugBank.d270.s9.e2" charOffset="73-80"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d270.s9.d0" e1="DDI-DrugBank.d270.s9.e0"
            e2="DDI-DrugBank.d270.s9.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s10" text="As a result, when giving these drugs concomitantly, plasma warfarin levels may change with the potential for increases in coagulation time.">
        <entity id="DDI-DrugBank.d270.s10.e0" charOffset="59-66"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s11" text="When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.">
        <entity id="DDI-DrugBank.d270.s11.e0" charOffset="5-12"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d270.s11.e1" charOffset="38-47"
            type="drug" text="nevirapine"/>
        <ddi id="DDI-DrugBank.d270.s11.d0" e1="DDI-DrugBank.d270.s11.e0"
            e2="DDI-DrugBank.d270.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s12" text="Table 3 Established Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies"/>
    <sentence id="DDI-DrugBank.d270.s13" text="Drug Name"/>
    <sentence id="DDI-DrugBank.d270.s14" text="Effect on Concentration of Nevirapine or Concomitant Drug">
        <entity id="DDI-DrugBank.d270.s14.e0" charOffset="27-36"
            type="drug" text="Nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s15" text="Clinical Comment"/>
    <sentence id="DDI-DrugBank.d270.s16" text="Clarithromycin">
        <entity id="DDI-DrugBank.d270.s16.e0" charOffset="0-13"
            type="drug" text="Clarithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s17" text="Clarithromycin  14OH- clarithromycin">
        <entity id="DDI-DrugBank.d270.s17.e0" charOffset="0-13"
            type="drug" text="Clarithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s18" text="Clarithromycin exposure was significantly decreased by nevirapine;">
        <entity id="DDI-DrugBank.d270.s18.e0" charOffset="0-13"
            type="drug" text="Clarithromycin"/>
        <entity id="DDI-DrugBank.d270.s18.e1" charOffset="55-64"
            type="drug" text="nevirapine"/>
        <ddi id="DDI-DrugBank.d270.s18.d0" e1="DDI-DrugBank.d270.s18.e0"
            e2="DDI-DrugBank.d270.s18.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s19" text="however, 14-OH metabolite concentrations were increased.Because clarithromycin active metabolite has reduced activity against Mycobacteriumavium-intracellulare complex, overallactivity against this pathogen may bealtered.">
        <entity id="DDI-DrugBank.d270.s19.e0" charOffset="64-77"
            type="drug" text="clarithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s20" text="Alternatives to clarithromycin,such as azithromycin, should be considered.">
        <entity id="DDI-DrugBank.d270.s20.e0" charOffset="16-29"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d270.s20.e1" charOffset="39-50"
            type="drug" text="azithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s21" text="Efavirenz">
        <entity id="DDI-DrugBank.d270.s21.e0" charOffset="0-8"
            type="drug" text="Efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s22" text="Efavirenz">
        <entity id="DDI-DrugBank.d270.s22.e0" charOffset="0-8"
            type="drug" text="Efavirenz"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s23" text="Appropriate doses for this combination are not established."/>
    <sentence id="DDI-DrugBank.d270.s24" text="Ethinyl estradiol and Norethindrone">
        <entity id="DDI-DrugBank.d270.s24.e0" charOffset="0-16"
            type="drug" text="Ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d270.s24.e1" charOffset="22-34"
            type="drug" text="Norethindrone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s25" text="Ethinyl estradiol Norethindrone">
        <entity id="DDI-DrugBank.d270.s25.e0" charOffset="0-16"
            type="drug" text="Ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d270.s25.e1" charOffset="18-30"
            type="drug" text="Norethindrone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s26" text="Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.">
        <entity id="DDI-DrugBank.d270.s26.e0" charOffset="5-18"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d270.s26.e1" charOffset="132-141"
            type="drug" text="nevirapine"/>
        <ddi id="DDI-DrugBank.d270.s26.d0" e1="DDI-DrugBank.d270.s26.e0"
            e2="DDI-DrugBank.d270.s26.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s27" text="An alternative or additional method of contraception is recommended."/>
    <sentence id="DDI-DrugBank.d270.s28" text="Fluconazole">
        <entity id="DDI-DrugBank.d270.s28.e0" charOffset="0-10"
            type="drug" text="Fluconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s29" text="Nevirapine">
        <entity id="DDI-DrugBank.d270.s29.e0" charOffset="0-9"
            type="drug" text="Nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s30" text="Because of the risk of increased exposure tonevirapine, caution should be used inconcomitant administration, and patients should be monitored closely for nevirapine-associated adverse events.">
        <entity id="DDI-DrugBank.d270.s30.e0" charOffset="44-53"
            type="drug" text="nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s31" text="Indinavir">
        <entity id="DDI-DrugBank.d270.s31.e0" charOffset="0-8"
            type="drug" text="Indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s32" text="Indinavir">
        <entity id="DDI-DrugBank.d270.s32.e0" charOffset="0-8"
            type="drug" text="Indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s33" text="Appropriate doses for this combination arenot established, but an increase in thedosage of indinavir may be required.">
        <entity id="DDI-DrugBank.d270.s33.e0" charOffset="91-99"
            type="drug" text="indinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s34" text="Ketoconazole">
        <entity id="DDI-DrugBank.d270.s34.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s35" text="Ketoconazole">
        <entity id="DDI-DrugBank.d270.s35.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s36" text="Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.">
        <entity id="DDI-DrugBank.d270.s36.e0" charOffset="0-9"
            type="drug" text="Nevirapine"/>
        <entity id="DDI-DrugBank.d270.s36.e1" charOffset="15-26"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d270.s36.e2" charOffset="88-99"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d270.s36.d0" e1="DDI-DrugBank.d270.s36.e0"
            e2="DDI-DrugBank.d270.s36.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s37" text="Lopinavir/Ritonavir">
        <entity id="DDI-DrugBank.d270.s37.e0" charOffset="0-8"
            type="drug" text="Lopinavir"/>
        <entity id="DDI-DrugBank.d270.s37.e1" charOffset="10-18"
            type="drug" text="Ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s38" text="Lopinavir">
        <entity id="DDI-DrugBank.d270.s38.e0" charOffset="0-8"
            type="drug" text="Lopinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s39" text="A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.">
        <entity id="DDI-DrugBank.d270.s39.e0" charOffset="19-27"
            type="drug" text="lopinavir"/>
        <entity id="DDI-DrugBank.d270.s39.e1" charOffset="29-37"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d270.s39.e2" charOffset="109-118"
            type="drug" text="nevirapine"/>
        <ddi id="DDI-DrugBank.d270.s39.d0" e1="DDI-DrugBank.d270.s39.e0"
            e2="DDI-DrugBank.d270.s39.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d270.s39.d1" e1="DDI-DrugBank.d270.s39.e1"
            e2="DDI-DrugBank.d270.s39.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s40" text="Methadone">
        <entity id="DDI-DrugBank.d270.s40.e0" charOffset="0-8"
            type="drug" text="Methadone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s41" text="Methadonea"/>
    <sentence id="DDI-DrugBank.d270.s42" text="Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.">
        <entity id="DDI-DrugBank.d270.s42.e0" charOffset="0-8"
            type="drug" text="Methadone"/>
        <entity id="DDI-DrugBank.d270.s42.e1" charOffset="92-97"
            type="group" text="opiate"/>
        <entity id="DDI-DrugBank.d270.s42.e2" charOffset="111-119"
            type="drug" text="Methadone"/>
        <entity id="DDI-DrugBank.d270.s42.e3" charOffset="151-160"
            type="drug" text="nevirapine"/>
        <entity id="DDI-DrugBank.d270.s42.e4" charOffset="220-228"
            type="drug" text="methadone"/>
        <ddi id="DDI-DrugBank.d270.s42.d0" e1="DDI-DrugBank.d270.s42.e2"
            e2="DDI-DrugBank.d270.s42.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s43" text="Nelfinavir">
        <entity id="DDI-DrugBank.d270.s43.e0" charOffset="0-9"
            type="drug" text="Nelfinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s44" text="Nelfinavir M8">
        <entity id="DDI-DrugBank.d270.s44.e0" charOffset="0-9"
            type="drug" text="Nelfinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s45" text="The appropriate dose for nelfinavir incombination with nevirapine, with respectto safety and efficacy, has not been established.">
        <entity id="DDI-DrugBank.d270.s45.e0" charOffset="25-34"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d270.s45.e1" charOffset="55-64"
            type="drug" text="nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s46" text="Rifabutin">
        <entity id="DDI-DrugBank.d270.s46.e0" charOffset="0-8"
            type="drug" text="Rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s47" text="Rifabutin">
        <entity id="DDI-DrugBank.d270.s47.e0" charOffset="0-8"
            type="drug" text="Rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s48" text="Rifabutin and its metabolite concentrationswere moderately increased.">
        <entity id="DDI-DrugBank.d270.s48.e0" charOffset="0-8"
            type="drug" text="Rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s49" text="Due to highintersubject variability, however, somepatients may experience large increases inrifabutin exposure and may be at higher riskfor rifabutin toxicity.">
        <entity id="DDI-DrugBank.d270.s49.e0" charOffset="92-100"
            type="drug" text="rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s50" text="Therefore, caution should be used in concomitant administration."/>
    <sentence id="DDI-DrugBank.d270.s51" text="Rifampin">
        <entity id="DDI-DrugBank.d270.s51.e0" charOffset="0-7"
            type="drug" text="Rifampin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s52" text="Nevirapine">
        <entity id="DDI-DrugBank.d270.s52.e0" charOffset="0-9"
            type="drug" text="Nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s53" text="Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.">
        <entity id="DDI-DrugBank.d270.s53.e0" charOffset="0-9"
            type="drug" text="Nevirapine"/>
        <entity id="DDI-DrugBank.d270.s53.e1" charOffset="15-22"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d270.s53.e2" charOffset="84-93"
            type="drug" text="nevirapine"/>
        <ddi id="DDI-DrugBank.d270.s53.d0" e1="DDI-DrugBank.d270.s53.e0"
            e2="DDI-DrugBank.d270.s53.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s54" text="Physicians needing to treatpatients co-infected with tuberculosis andusing a nevirapine containing regimen mayuse rifabutin instead.">
        <entity id="DDI-DrugBank.d270.s54.e0" charOffset="77-86"
            type="drug" text="nevirapine"/>
        <entity id="DDI-DrugBank.d270.s54.e1" charOffset="114-122"
            type="drug" text="rifabutin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s55" text="Saquinavir">
        <entity id="DDI-DrugBank.d270.s55.e0" charOffset="0-9"
            type="drug" text="Saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s56" text="Saquinavir">
        <entity id="DDI-DrugBank.d270.s56.e0" charOffset="0-9"
            type="drug" text="Saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s57" text="Appropriate doses for this combination arenot established, but an increase in thedosage of saquinavir may be required.">
        <entity id="DDI-DrugBank.d270.s57.e0" charOffset="91-100"
            type="drug" text="saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s58" text="aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.">
        <entity id="DDI-DrugBank.d270.s58.e0" charOffset="75-84"
            type="drug" text="nevirapine"/>
        <entity id="DDI-DrugBank.d270.s58.e1" charOffset="90-98"
            type="drug" text="methadone"/>
        <entity id="DDI-DrugBank.d270.s58.e2" charOffset="165-173"
            type="drug" text="methadone"/>
        <ddi id="DDI-DrugBank.d270.s58.d0" e1="DDI-DrugBank.d270.s58.e0"
            e2="DDI-DrugBank.d270.s58.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s59" text="Table 4        Potential Drug Interactions:Use With Caution, Dose Adjustment of Co-administered Drug May Be Needed due to Possible Decrease in Clinical Effect"/>
    <sentence id="DDI-DrugBank.d270.s60" text="Examples of Drugs in Which Plasma Concentrations May Be Decreased By Co-administration With Nevirapine">
        <entity id="DDI-DrugBank.d270.s60.e0" charOffset="92-101"
            type="drug" text="Nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s61" text="Drug Class Examples of Drugs"/>
    <sentence id="DDI-DrugBank.d270.s62" text="Antiarrhythmics">
        <entity id="DDI-DrugBank.d270.s62.e0" charOffset="0-14"
            type="group" text="Antiarrhythmics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s63" text="Amiodarone, disopyramide, lidocaine">
        <entity id="DDI-DrugBank.d270.s63.e0" charOffset="0-9"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d270.s63.e1" charOffset="12-23"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d270.s63.e2" charOffset="26-34"
            type="drug" text="lidocaine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s64" text="Anticonvulsants">
        <entity id="DDI-DrugBank.d270.s64.e0" charOffset="0-14"
            type="group" text="Anticonvulsants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s65" text="Carbamazepine, clonazepam, ethosuximide">
        <entity id="DDI-DrugBank.d270.s65.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d270.s65.e1" charOffset="15-24"
            type="drug" text="clonazepam"/>
        <entity id="DDI-DrugBank.d270.s65.e2" charOffset="27-38"
            type="drug" text="ethosuximide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s66" text="Antifungals">
        <entity id="DDI-DrugBank.d270.s66.e0" charOffset="0-10"
            type="group" text="Antifungals"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s67" text="Itraconazole">
        <entity id="DDI-DrugBank.d270.s67.e0" charOffset="0-11"
            type="drug" text="Itraconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s68" text="Calcium channel blockers">
        <entity id="DDI-DrugBank.d270.s68.e0" charOffset="0-23"
            type="group" text="Calcium channel blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s69" text="Diltiazem, nifedipine, verapamil">
        <entity id="DDI-DrugBank.d270.s69.e0" charOffset="0-8"
            type="drug" text="Diltiazem"/>
        <entity id="DDI-DrugBank.d270.s69.e1" charOffset="11-20"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d270.s69.e2" charOffset="23-31"
            type="drug" text="verapamil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s70" text="Cancer chemotherapy"/>
    <sentence id="DDI-DrugBank.d270.s71" text="Cyclophosphamide">
        <entity id="DDI-DrugBank.d270.s71.e0" charOffset="0-15"
            type="drug" text="Cyclophosphamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s72" text="Ergot alkaloids">
        <entity id="DDI-DrugBank.d270.s72.e0" charOffset="0-14"
            type="group" text="Ergot alkaloids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s73" text="Ergotamine">
        <entity id="DDI-DrugBank.d270.s73.e0" charOffset="0-9"
            type="drug" text="Ergotamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s74" text="Immunosuppressants">
        <entity id="DDI-DrugBank.d270.s74.e0" charOffset="0-17"
            type="group" text="Immunosuppressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s75" text="Cyclosporin, tacrolimus, sirolimus">
        <entity id="DDI-DrugBank.d270.s75.e0" charOffset="0-10"
            type="drug" text="Cyclosporin"/>
        <entity id="DDI-DrugBank.d270.s75.e1" charOffset="13-22"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d270.s75.e2" charOffset="25-33"
            type="drug" text="sirolimus"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s76" text="Motility agents"/>
    <sentence id="DDI-DrugBank.d270.s77" text="Cisapride">
        <entity id="DDI-DrugBank.d270.s77.e0" charOffset="0-8"
            type="drug" text="Cisapride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s78" text="Opiate agonists">
        <entity id="DDI-DrugBank.d270.s78.e0" charOffset="0-14"
            type="group" text="Opiate agonists"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s79" text="Fentanyl">
        <entity id="DDI-DrugBank.d270.s79.e0" charOffset="0-7"
            type="drug" text="Fentanyl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s80" text="Examples of Drugs in Which Plasma Concentrations May Be Increased By Co-administration With Nevirapine">
        <entity id="DDI-DrugBank.d270.s80.e0" charOffset="92-101"
            type="drug" text="Nevirapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s81" text="Antithrombotics">
        <entity id="DDI-DrugBank.d270.s81.e0" charOffset="0-14"
            type="group" text="Antithrombotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s82" text="Warfarin">
        <entity id="DDI-DrugBank.d270.s82.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s83" text="Potential effect on anticoagulation."/>
    <sentence id="DDI-DrugBank.d270.s84" text="Monitoring of anticoagulation levels is recommended."/>
    <sentence id="DDI-DrugBank.d270.s85" text="Fat redistribution: Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and cushingoid appearance have been observed in patients receiving antiretroviral therapy.">
        <entity id="DDI-DrugBank.d270.s85.e0" charOffset="256-269"
            type="group" text="antiretroviral"/>
    </sentence>
    <sentence id="DDI-DrugBank.d270.s86" text="The mechanism and long-term consequences of these events are currently unknown."/>
    <sentence id="DDI-DrugBank.d270.s87" text="A causal relationship has not been established"/>
    <sentence id="DDI-DrugBank.d270.s88" text="."/>
    <sentence id="DDI-DrugBank.d270.s89" text=""/>
    <sentence id="DDI-DrugBank.d542.s0" text="Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.">
        <entity id="DDI-DrugBank.d542.s0.e0" charOffset="17-26"
            type="drug" text="Vitamin B3"/>
        <entity id="DDI-DrugBank.d542.s0.e1" charOffset="29-34"
            type="drug" text="Niacin"/>
        <entity id="DDI-DrugBank.d542.s0.e2" charOffset="38-53"
            type="group" text="Antihypertensive"/>
        <entity id="DDI-DrugBank.d542.s0.e3" charOffset="64-77"
            type="drug" text="Nicotinic acid"/>
        <entity id="DDI-DrugBank.d542.s0.e4" charOffset="109-134"
            type="group" text="ganglionic blocking agents"/>
        <ddi id="DDI-DrugBank.d542.s0.d0" e1="DDI-DrugBank.d542.s0.e3"
            e2="DDI-DrugBank.d542.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d542.s1" text="Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.">
        <entity id="DDI-DrugBank.d542.s1.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d542.s1.e1" charOffset="21-27"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d542.s1.e2" charOffset="69-82"
            type="drug" text="nicotinic acid"/>
        <ddi id="DDI-DrugBank.d542.s1.d0" e1="DDI-DrugBank.d542.s1.e1"
            e2="DDI-DrugBank.d542.s1.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d542.s2" text="The clinical relevance of this finding is unclear."/>
    <sentence id="DDI-DrugBank.d542.s3" text="Other: Concomitant alcohol or hot drinks may increase the side effects of flushing and pruritus and should be avoided at the time of drug ingestion.">
        <entity id="DDI-DrugBank.d542.s3.e0" charOffset="19-25"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d468.s0" text="Beta-Blockers: In controlled clinical studies, adrenergic beta-receptor blockers have been frequently administered concomitantly with nicardipine HCl.">
        <entity id="DDI-DrugBank.d468.s0.e0" charOffset="0-12"
            type="group" text="Beta-Blockers"/>
        <entity id="DDI-DrugBank.d468.s0.e1" charOffset="47-79"
            type="group" text="adrenergic beta-receptor blockers"/>
        <entity id="DDI-DrugBank.d468.s0.e2" charOffset="134-148"
            type="drug" text="nicardipine HCl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d468.s1" text="The combination is well tolerated."/>
    <sentence id="DDI-DrugBank.d468.s2" text="Cimetidine: Cimetidine increases nicardipine HCl plasma levels.">
        <entity id="DDI-DrugBank.d468.s2.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d468.s2.e1" charOffset="12-21"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d468.s2.e2" charOffset="33-47"
            type="drug" text="nicardipine HCl"/>
        <ddi id="DDI-DrugBank.d468.s2.d0" e1="DDI-DrugBank.d468.s2.e1"
            e2="DDI-DrugBank.d468.s2.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d468.s3" text="Patients receiving the two drugs concomitantly should be carefully monitored."/>
    <sentence id="DDI-DrugBank.d468.s4" text="Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.">
        <entity id="DDI-DrugBank.d468.s4.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d468.s4.e1" charOffset="14-29"
            type="group" text="calcium blockers"/>
        <entity id="DDI-DrugBank.d468.s4.e2" charOffset="65-86"
            type="group" text="digitalis preparations"/>
        <ddi id="DDI-DrugBank.d468.s4.d0" e1="DDI-DrugBank.d468.s4.e1"
            e2="DDI-DrugBank.d468.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d468.s5" text="Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.">
        <entity id="DDI-DrugBank.d468.s5.e0" charOffset="0-14"
            type="drug" text="Nicardipine HCl"/>
        <entity id="DDI-DrugBank.d468.s5.e1" charOffset="60-66"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d468.s5.e2" charOffset="84-90"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d468.s5.e3" charOffset="150-164"
            type="drug" text="nicardipine HCl"/>
        <ddi id="DDI-DrugBank.d468.s5.d0" e1="DDI-DrugBank.d468.s5.e2"
            e2="DDI-DrugBank.d468.s5.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d468.s6" text="Maalox * Coadministration of Maalox TC had no effect on nicardipine HCl absorption.">
        <entity id="DDI-DrugBank.d468.s6.e0" charOffset="0-5"
            type="brand" text="Maalox"/>
        <entity id="DDI-DrugBank.d468.s6.e1" charOffset="29-37"
            type="brand" text="Maalox TC"/>
        <entity id="DDI-DrugBank.d468.s6.e2" charOffset="56-70"
            type="drug" text="nicardipine HCl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d468.s7" text="Even though such interactions were not seen during clinical studies with nicardipine HCl, an increased volume of circulating fluids might be required if such an interaction were to occur.">
        <entity id="DDI-DrugBank.d468.s7.e0" charOffset="73-87"
            type="drug" text="nicardipine HCl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d468.s8" text="Cyclosporine: Concomitant administration of nicardipine and cyclosporine levels.">
        <entity id="DDI-DrugBank.d468.s8.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d468.s8.e1" charOffset="44-54"
            type="drug" text="nicardipine"/>
        <entity id="DDI-DrugBank.d468.s8.e2" charOffset="60-71"
            type="drug" text="cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d468.s9" text="Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.">
        <entity id="DDI-DrugBank.d468.s9.e0" charOffset="25-36"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d468.s9.e1" charOffset="138-148"
            type="drug" text="nicardipine"/>
        <ddi id="DDI-DrugBank.d468.s9.d0" e1="DDI-DrugBank.d468.s9.e0"
            e2="DDI-DrugBank.d468.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d468.s10" text="When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.">
        <entity id="DDI-DrugBank.d468.s10.e0" charOffset="35-44"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d468.s10.e1" charOffset="47-57"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d468.s10.e2" charOffset="60-71"
            type="drug" text="dipyridamole"/>
        <entity id="DDI-DrugBank.d468.s10.e3" charOffset="74-81"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d468.s10.e4" charOffset="84-92"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d468.s10.e5" charOffset="98-105"
            type="drug" text="naproxen"/>
        <entity id="DDI-DrugBank.d468.s10.e6" charOffset="176-190"
            type="drug" text="nicardipine HCl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d271.s0" text="Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic antidepressants and theophylline.">
        <entity id="DDI-DrugBank.d271.s0.e0" charOffset="72-79"
            type="drug" text="nicotine"/>
        <entity id="DDI-DrugBank.d271.s0.e1" charOffset="169-193"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d271.s0.e2" charOffset="199-210"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d271.s1" text="Doses of these and perhaps other medications may need to be adjusted in patients who successfully quit smoking."/>
    <sentence id="DDI-DrugBank.d373.s0" text="Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.">
        <entity id="DDI-DrugBank.d373.s0.e0" charOffset="0-30"
            type="group" text="Beta-adrenergic Blocking Agents"/>
        <entity id="DDI-DrugBank.d373.s0.e1" charOffset="147-156"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d373.s0.e2" charOffset="162-181"
            type="group" text="beta-blocking agents"/>
        <ddi id="DDI-DrugBank.d373.s0.d0" e1="DDI-DrugBank.d373.s0.e1"
            e2="DDI-DrugBank.d373.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s1" text="Long Acting Nitrates: Nifedipine may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.">
        <entity id="DDI-DrugBank.d373.s1.e0" charOffset="12-19"
            type="group" text="Nitrates"/>
        <entity id="DDI-DrugBank.d373.s1.e1" charOffset="22-31"
            type="drug" text="Nifedipine"/>
        <entity id="DDI-DrugBank.d373.s1.e2" charOffset="68-75"
            type="group" text="nitrates"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s2" text="Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.">
        <entity id="DDI-DrugBank.d373.s2.e0" charOffset="0-8"
            type="group" text="Digitalis"/>
        <entity id="DDI-DrugBank.d373.s2.e1" charOffset="104-110"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d373.s2.e2" charOffset="164-170"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d373.s2.e3" charOffset="176-185"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d373.s2.e4" charOffset="211-217"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d373.s2.e5" charOffset="285-294"
            type="drug" text="nifedipine"/>
        <ddi id="DDI-DrugBank.d373.s2.d0" e1="DDI-DrugBank.d373.s2.e2"
            e2="DDI-DrugBank.d373.s2.e3" type="int"/>
        <ddi id="DDI-DrugBank.d373.s2.d1" e1="DDI-DrugBank.d373.s2.e4"
            e2="DDI-DrugBank.d373.s2.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s3" text="Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.">
        <entity id="DDI-DrugBank.d373.s3.e0" charOffset="44-53"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d373.s3.e1" charOffset="60-66"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d373.s3.e2" charOffset="78-84"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d373.s3.d0" e1="DDI-DrugBank.d373.s3.e1"
            e2="DDI-DrugBank.d373.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s4" text="The average increase was 45%."/>
    <sentence id="DDI-DrugBank.d373.s5" text="Another investigator found no increase in digoxin levels in 13 patients with coronary artery disease.">
        <entity id="DDI-DrugBank.d373.s5.e0" charOffset="42-48"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s6" text="In an uncontrolled study of over 200 patients with congestive heart failure during which digoxin blood levels were not measured, digitalis toxicity was not observed.">
        <entity id="DDI-DrugBank.d373.s6.e0" charOffset="89-95"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s7" text="Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.">
        <entity id="DDI-DrugBank.d373.s7.e0" charOffset="65-71"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d373.s7.e1" charOffset="104-110"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d373.s7.e2" charOffset="178-187"
            type="drug" text="nifedipine"/>
        <ddi id="DDI-DrugBank.d373.s7.d0" e1="DDI-DrugBank.d373.s7.e1"
            e2="DDI-DrugBank.d373.s7.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s8" text="Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).">
        <entity id="DDI-DrugBank.d373.s8.e0" charOffset="0-8"
            type="drug" text="Quinidine"/>
        <entity id="DDI-DrugBank.d373.s8.e1" charOffset="94-102"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d373.s8.e2" charOffset="108-117"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d373.s8.e3" charOffset="153-161"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d373.s8.d0" e1="DDI-DrugBank.d373.s8.e1"
            e2="DDI-DrugBank.d373.s8.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s9" text="Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.">
        <entity id="DDI-DrugBank.d373.s9.e0" charOffset="0-22"
            type="group" text="Coumarin Anticoagulants"/>
        <entity id="DDI-DrugBank.d373.s9.e1" charOffset="103-125"
            type="group" text="coumarin anticoagulants"/>
        <entity id="DDI-DrugBank.d373.s9.e2" charOffset="135-144"
            type="drug" text="nifedipine"/>
        <ddi id="DDI-DrugBank.d373.s9.d0" e1="DDI-DrugBank.d373.s9.e1"
            e2="DDI-DrugBank.d373.s9.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s10" text="However, the relationship to nifedipine therapy is uncertain.">
        <entity id="DDI-DrugBank.d373.s10.e0" charOffset="29-38"
            type="drug" text="nifedipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s11" text="Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.">
        <entity id="DDI-DrugBank.d373.s11.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d373.s11.e1" charOffset="85-94"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d373.s11.e2" charOffset="172-181"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d373.s11.e3" charOffset="206-215"
            type="drug" text="nifedipine"/>
        <ddi id="DDI-DrugBank.d373.s11.d0" e1="DDI-DrugBank.d373.s11.e2"
            e2="DDI-DrugBank.d373.s11.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s12" text="Ranitidine produced smaller, non-significant increases.">
        <entity id="DDI-DrugBank.d373.s12.e0" charOffset="0-9"
            type="drug" text="Ranitidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s13" text="The effect may be mediated by the known inhibition of cimetidine on hepatic cytochrome P-450, the enzyme system probably responsible for the first-pass metabolism of nifedipine.">
        <entity id="DDI-DrugBank.d373.s13.e0" charOffset="54-63"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d373.s13.e1" charOffset="166-175"
            type="drug" text="nifedipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d373.s14" text="If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.">
        <entity id="DDI-DrugBank.d373.s14.e0" charOffset="3-12"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d373.s14.e1" charOffset="68-77"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d373.s14.d0" e1="DDI-DrugBank.d373.s14.e0"
            e2="DDI-DrugBank.d373.s14.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d177.s0" text="In vitro, nilutamide has been shown to inhibit the activity of liver cytochrome P-450 isoenzymes and therefore, may reduce the metabolism of compounds requiring these systems.">
        <entity id="DDI-DrugBank.d177.s0.e0" charOffset="10-19"
            type="drug" text="nilutamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d177.s1" text="Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, phenytoin, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level.">
        <entity id="DDI-DrugBank.d177.s1.e0" charOffset="59-79"
            type="group" text="vitamin K antagonists"/>
        <entity id="DDI-DrugBank.d177.s1.e1" charOffset="82-90"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d177.s1.e2" charOffset="97-108"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d177.s2" text="The dosage of these drugs or others with a similar metabolism may need to be modified if they are administered concomitantly with nilutamide.">
        <entity id="DDI-DrugBank.d177.s2.e0" charOffset="130-139"
            type="drug" text="nilutamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d177.s3" text="For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.">
        <entity id="DDI-DrugBank.d177.s3.e0" charOffset="18-38"
            type="group" text="vitamin K antagonists"/>
        <entity id="DDI-DrugBank.d177.s3.e1" charOffset="76-85"
            type="drug" text="nilutamide"/>
        <entity id="DDI-DrugBank.d177.s3.e2" charOffset="167-187"
            type="group" text="vitamin K antagonists"/>
        <ddi id="DDI-DrugBank.d177.s3.d0" e1="DDI-DrugBank.d177.s3.e0"
            e2="DDI-DrugBank.d177.s3.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d310.s0" text="It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop .">
        <entity id="DDI-DrugBank.d310.s0.e0" charOffset="55-78"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d310.s0.e1" charOffset="117-123"
            type="brand" text="Nimotop"/>
        <ddi id="DDI-DrugBank.d310.s0.d0" e1="DDI-DrugBank.d310.s0.e0"
            e2="DDI-DrugBank.d310.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d310.s1" text="In Europe, Nimotop  was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension;">
        <entity id="DDI-DrugBank.d310.s1.e0" charOffset="11-17"
            type="brand" text="Nimotop"/>
        <entity id="DDI-DrugBank.d310.s1.e1" charOffset="73-98"
            type="group" text="antihypertensive compounds"/>
        <ddi id="DDI-DrugBank.d310.s1.d0" e1="DDI-DrugBank.d310.s1.e0"
            e2="DDI-DrugBank.d310.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d310.s2" text="this phenomenon was not observed in North American clinical trials."/>
    <sentence id="DDI-DrugBank.d310.s3" text="A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.">
        <entity id="DDI-DrugBank.d310.s3.e0" charOffset="74-83"
            type="drug" text="nimodipine"/>
        <entity id="DDI-DrugBank.d310.s3.e1" charOffset="183-192"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d310.s3.e2" charOffset="214-223"
            type="drug" text="nimodipine"/>
        <ddi id="DDI-DrugBank.d310.s3.d0" e1="DDI-DrugBank.d310.s3.e1"
            e2="DDI-DrugBank.d310.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d310.s4" text="This effect may be mediated by the known inhibition of hepatic cytochrome P- 450 by cimetidine, which could decrease first pass metabolism of nimodipine.">
        <entity id="DDI-DrugBank.d310.s4.e0" charOffset="84-93"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d310.s4.e1" charOffset="142-151"
            type="drug" text="nimodipine"/>
        <ddi id="DDI-DrugBank.d310.s4.d0" e1="DDI-DrugBank.d310.s4.e1"
            e2="DDI-DrugBank.d310.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d106.s0" text="A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.">
        <entity id="DDI-DrugBank.d106.s0.e0" charOffset="40-50"
            type="drug" text="nisoldipine"/>
        <entity id="DDI-DrugBank.d106.s0.e1" charOffset="100-116"
            type="drug" text="cimetidine 400 mg"/>
        <ddi id="DDI-DrugBank.d106.s0.d0" e1="DDI-DrugBank.d106.s0.e0"
            e2="DDI-DrugBank.d106.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d106.s1" text="Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %).">
        <entity id="DDI-DrugBank.d106.s1.e0" charOffset="0-9"
            type="drug" text="Ranitidine"/>
        <entity id="DDI-DrugBank.d106.s1.e1" charOffset="66-76"
            type="drug" text="nisoldipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d106.s2" text="No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.">
        <entity id="DDI-DrugBank.d106.s2.e0" charOffset="37-68"
            type="group" text="histamine H2 receptor antagonist"/>
    </sentence>
    <sentence id="DDI-DrugBank.d106.s3" text="Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.">
        <entity id="DDI-DrugBank.d106.s3.e0" charOffset="20-28"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d106.s3.e1" charOffset="41-45"
            type="brand" text="SULAR"/>
        <entity id="DDI-DrugBank.d106.s3.e2" charOffset="89-99"
            type="drug" text="nisoldipine"/>
        <ddi id="DDI-DrugBank.d106.s3.d0" e1="DDI-DrugBank.d106.s3.e0"
            e2="DDI-DrugBank.d106.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d106.s4" text="Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.">
        <entity id="DDI-DrugBank.d106.s4.e0" charOffset="20-24"
            type="brand" text="SULAR"/>
        <entity id="DDI-DrugBank.d106.s4.e1" charOffset="31-39"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d106.s4.e2" charOffset="103-118"
            type="group" text="antihypertensive"/>
        <ddi id="DDI-DrugBank.d106.s4.d0" e1="DDI-DrugBank.d106.s4.e0"
            e2="DDI-DrugBank.d106.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d106.s5" text="Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.">
        <entity id="DDI-DrugBank.d106.s5.e0" charOffset="37-47"
            type="drug" text="nisoldipine"/>
        <entity id="DDI-DrugBank.d106.s5.e1" charOffset="53-65"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d106.s5.e2" charOffset="68-75"
            type="drug" text="atenolol"/>
        <entity id="DDI-DrugBank.d106.s5.e3" charOffset="78-88"
            type="drug" text="propranolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d106.s6" text="Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.">
        <entity id="DDI-DrugBank.d106.s6.e0" charOffset="0-10"
            type="drug" text="Propranolol"/>
        <entity id="DDI-DrugBank.d106.s6.e1" charOffset="93-103"
            type="drug" text="nisoldipine"/>
        <ddi id="DDI-DrugBank.d106.s6.d0" e1="DDI-DrugBank.d106.s6.e0"
            e2="DDI-DrugBank.d106.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d106.s7" text="The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.">
        <entity id="DDI-DrugBank.d106.s7.e0" charOffset="29-33"
            type="brand" text="SULAR"/>
        <entity id="DDI-DrugBank.d106.s7.e1" charOffset="71-78"
            type="drug" text="atenolol"/>
        <entity id="DDI-DrugBank.d106.s7.e2" charOffset="109-124"
            type="group" text="antihypertensive"/>
        <ddi id="DDI-DrugBank.d106.s7.d0" e1="DDI-DrugBank.d106.s7.e0"
            e2="DDI-DrugBank.d106.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d106.s8" text="Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.">
        <entity id="DDI-DrugBank.d106.s8.e0" charOffset="0-8"
            type="drug" text="Quinidine"/>
        <entity id="DDI-DrugBank.d106.s8.e1" charOffset="63-73"
            type="drug" text="nisoldipine"/>
        <ddi id="DDI-DrugBank.d106.s8.d0" e1="DDI-DrugBank.d106.s8.e0"
            e2="DDI-DrugBank.d106.s8.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d106.s9" text="The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.">
        <entity id="DDI-DrugBank.d106.s9.e0" charOffset="60-70"
            type="drug" text="nisoldipine"/>
        <entity id="DDI-DrugBank.d106.s9.e1" charOffset="89-97"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d106.s9.d0" e1="DDI-DrugBank.d106.s9.e0"
            e2="DDI-DrugBank.d106.s9.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d106.s10" text="This interaction was not accompanied by ECG changes and its clinical significance is not known."/>
    <sentence id="DDI-DrugBank.d106.s11" text="No significant interactions were found between nisoldipine and warfarin or digoxin.">
        <entity id="DDI-DrugBank.d106.s11.e0" charOffset="47-57"
            type="drug" text="nisoldipine"/>
        <entity id="DDI-DrugBank.d106.s11.e1" charOffset="63-70"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d106.s11.e2" charOffset="75-81"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d354.s0" text="Tizoxanide is highly bound to plasma protein ( 99.9%).">
        <entity id="DDI-DrugBank.d354.s0.e0" charOffset="0-9"
            type="drug" text="Tizoxanide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d354.s1" text="Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).">
        <entity id="DDI-DrugBank.d354.s1.e0" charOffset="53-64"
            type="drug" text="nitazoxanide"/>
        <entity id="DDI-DrugBank.d354.s1.e1" charOffset="207-214"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d354.s1.d0" e1="DDI-DrugBank.d354.s1.e0"
            e2="DDI-DrugBank.d354.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d354.s2" text="In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes.">
        <entity id="DDI-DrugBank.d354.s2.e0" charOffset="51-60"
            type="drug" text="tizoxanide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d354.s3" text="Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.">
        <entity id="DDI-DrugBank.d354.s3.e0" charOffset="135-146"
            type="drug" text="nitazoxanide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d183.s0" text="No formal drug-interaction studies have been performed, and a clinically significant interaction with other medications used in the treatment of hypoxic respiratory failure cannot be excluded based on the available data."/>
    <sentence id="DDI-DrugBank.d183.s1" text="INOmax has been administered with tolazoline, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.">
        <entity id="DDI-DrugBank.d183.s1.e0" charOffset="0-5"
            type="brand" text="INOmax"/>
        <entity id="DDI-DrugBank.d183.s1.e1" charOffset="34-43"
            type="drug" text="tolazoline"/>
        <entity id="DDI-DrugBank.d183.s1.e2" charOffset="46-53"
            type="drug" text="dopamine"/>
        <entity id="DDI-DrugBank.d183.s1.e3" charOffset="56-65"
            type="drug" text="dobutamine"/>
        <entity id="DDI-DrugBank.d183.s1.e4" charOffset="68-75"
            type="group" text="steroids"/>
        <entity id="DDI-DrugBank.d183.s1.e5" charOffset="78-87"
            type="drug" text="surfactant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d183.s2" text="Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.">
        <entity id="DDI-DrugBank.d183.s2.e0" charOffset="62-89"
            type="group" text="nitric oxide donor compounds"/>
        <entity id="DDI-DrugBank.d183.s2.e1" charOffset="102-121"
            type="drug" text="sodium nitroprusside"/>
        <entity id="DDI-DrugBank.d183.s2.e2" charOffset="127-139"
            type="drug" text="nitroglycerin"/>
        <entity id="DDI-DrugBank.d183.s2.e3" charOffset="175-180"
            type="brand" text="INOmax"/>
        <ddi id="DDI-DrugBank.d183.s2.d0" e1="DDI-DrugBank.d183.s2.e0"
            e2="DDI-DrugBank.d183.s2.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d183.s2.d1" e1="DDI-DrugBank.d183.s2.e1"
            e2="DDI-DrugBank.d183.s2.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d183.s2.d2" e1="DDI-DrugBank.d183.s2.e2"
            e2="DDI-DrugBank.d183.s2.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d183.s3" text="An association between prilocaine and an increased risk of methaemoglobinaemia, particularly in infants, has specifically been described in a literature case report.">
        <entity id="DDI-DrugBank.d183.s3.e0" charOffset="23-32"
            type="drug" text="prilocaine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d183.s4" text="This risk is present whether the drugs are administered as oral, parenteral, or topical formulations."/>
    <sentence id="DDI-DrugBank.d276.s0" text="Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.">
        <entity id="DDI-DrugBank.d276.s0.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d276.s0.e1" charOffset="20-40"
            type="drug" text="magnesium trisilicate"/>
        <entity id="DDI-DrugBank.d276.s0.e2" charOffset="80-93"
            type="drug" text="nitrofurantoin"/>
        <ddi id="DDI-DrugBank.d276.s0.d0" e1="DDI-DrugBank.d276.s0.e1"
            e2="DDI-DrugBank.d276.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d276.s1" text="The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.">
        <entity id="DDI-DrugBank.d276.s1.e0" charOffset="61-74"
            type="drug" text="nitrofurantoin"/>
        <entity id="DDI-DrugBank.d276.s1.e1" charOffset="96-116"
            type="drug" text="magnesium trisilicate"/>
        <ddi id="DDI-DrugBank.d276.s1.d0" e1="DDI-DrugBank.d276.s1.e0"
            e2="DDI-DrugBank.d276.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d276.s2" text="Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.">
        <entity id="DDI-DrugBank.d276.s2.e0" charOffset="0-15"
            type="group" text="Uricosuric drugs"/>
        <entity id="DDI-DrugBank.d276.s2.e1" charOffset="26-35"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d276.s2.e2" charOffset="41-54"
            type="drug" text="sulfinpyrazone"/>
        <entity id="DDI-DrugBank.d276.s2.e3" charOffset="96-109"
            type="drug" text="nitrofurantoin"/>
        <ddi id="DDI-DrugBank.d276.s2.d0" e1="DDI-DrugBank.d276.s2.e0"
            e2="DDI-DrugBank.d276.s2.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d276.s2.d1" e1="DDI-DrugBank.d276.s2.e1"
            e2="DDI-DrugBank.d276.s2.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d276.s2.d2" e1="DDI-DrugBank.d276.s2.e2"
            e2="DDI-DrugBank.d276.s2.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d276.s3" text="The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.">
        <entity id="DDI-DrugBank.d276.s3.e0" charOffset="26-39"
            type="drug" text="nitrofurantoin"/>
        <entity id="DDI-DrugBank.d276.s3.e1" charOffset="155-167"
            type="group" text="antibacterial"/>
    </sentence>
    <sentence id="DDI-DrugBank.d276.s4" text="Drug/Laboratory Test Interactions As a result of the presence of nitrofurantoin, a false-positive reaction for glucose in the urine may occur.">
        <entity id="DDI-DrugBank.d276.s4.e0" charOffset="65-78"
            type="drug" text="nitrofurantoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d276.s5" text="This has been observed with Benedict s and Fehling s solutions but not with the glucose enzymatic test."/>
    <sentence id="DDI-DrugBank.d14.s0" text="The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.">
        <entity id="DDI-DrugBank.d14.s0.e0" charOffset="28-40"
            type="drug" text="nitroglycerin"/>
        <entity id="DDI-DrugBank.d14.s0.e1" charOffset="78-89"
            type="group" text="vasodilators"/>
        <ddi id="DDI-DrugBank.d14.s0.d0" e1="DDI-DrugBank.d14.s0.e0"
            e2="DDI-DrugBank.d14.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d14.s1" text="Alcohol, in particular, has been found to exhibit additive effects of this variety.">
        <entity id="DDI-DrugBank.d14.s1.e0" charOffset="0-6" type="drug" text="Alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d14.s2" text="Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.">
        <entity id="DDI-DrugBank.d14.s2.e0" charOffset="66-89"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d14.s2.e1" charOffset="103-110"
            type="group" text="nitrates"/>
        <ddi id="DDI-DrugBank.d14.s2.d0" e1="DDI-DrugBank.d14.s2.e0"
            e2="DDI-DrugBank.d14.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d14.s3" text="Dose adjustments of either class of agents may be necessary."/>
    <sentence id="DDI-DrugBank.d394.s0" text="The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.">
        <entity id="DDI-DrugBank.d394.s0.e0" charOffset="26-45"
            type="drug" text="sodium nitroprusside"/>
        <entity id="DDI-DrugBank.d394.s0.e1" charOffset="82-98"
            type="group" text="hypotensive drugs"/>
        <entity id="DDI-DrugBank.d394.s0.e2" charOffset="111-136"
            type="group" text="ganglionic blocking agents"/>
        <entity id="DDI-DrugBank.d394.s0.e3" charOffset="178-188"
            type="group" text="anesthetics"/>
        <ddi id="DDI-DrugBank.d394.s0.d0" e1="DDI-DrugBank.d394.s0.e0"
            e2="DDI-DrugBank.d394.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d394.s0.d1" e1="DDI-DrugBank.d394.s0.e0"
            e2="DDI-DrugBank.d394.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d394.s0.d2" e1="DDI-DrugBank.d394.s0.e0"
            e2="DDI-DrugBank.d394.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d475.s0" text="No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.">
        <entity id="DDI-DrugBank.d475.s0.e0" charOffset="43-52"
            type="drug" text="nizatidine"/>
        <entity id="DDI-DrugBank.d475.s0.e1" charOffset="58-69"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d475.s0.e2" charOffset="72-87"
            type="drug" text="chlordiazepoxide"/>
        <entity id="DDI-DrugBank.d475.s0.e3" charOffset="90-98"
            type="drug" text="lorazepam"/>
        <entity id="DDI-DrugBank.d475.s0.e4" charOffset="101-109"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d475.s0.e5" charOffset="112-120"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d475.s0.e6" charOffset="127-134"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d475.s1" text="Nizatidine does not inhibit the cytochrome P-450-linked drug-metabolizing enzyme system;">
        <entity id="DDI-DrugBank.d475.s1.e0" charOffset="0-9"
            type="drug" text="Nizatidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d475.s2" text="therefore, drug interactions mediated by inhibition of hepatic metabolism are not expected to occur."/>
    <sentence id="DDI-DrugBank.d475.s3" text="In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.">
        <entity id="DDI-DrugBank.d475.s3.e0" charOffset="47-53"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d475.s3.e1" charOffset="81-90"
            type="group" text="salicylate"/>
        <entity id="DDI-DrugBank.d475.s3.e2" charOffset="114-123"
            type="drug" text="nizatidine"/>
        <ddi id="DDI-DrugBank.d475.s3.d0" e1="DDI-DrugBank.d475.s3.e0"
            e2="DDI-DrugBank.d475.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d306.s0" text="The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.">
        <entity id="DDI-DrugBank.d306.s0.e0" charOffset="21-29"
            type="group" text="progestin"/>
        <entity id="DDI-DrugBank.d306.s0.e1" charOffset="98-112"
            type="group" text="anticonvulsants"/>
        <entity id="DDI-DrugBank.d306.s0.e2" charOffset="114-122"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d306.s0.e3" charOffset="125-137"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d306.s0.e4" charOffset="144-155"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d306.s0.e5" charOffset="166-186"
            type="group" text="antituberculosis drug"/>
        <entity id="DDI-DrugBank.d306.s0.e6" charOffset="188-195"
            type="drug" text="rifampin"/>
        <ddi id="DDI-DrugBank.d306.s0.d0" e1="DDI-DrugBank.d306.s0.e0"
            e2="DDI-DrugBank.d306.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d306.s0.d1" e1="DDI-DrugBank.d306.s0.e0"
            e2="DDI-DrugBank.d306.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d306.s0.d2" e1="DDI-DrugBank.d306.s0.e0"
            e2="DDI-DrugBank.d306.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d306.s0.d3" e1="DDI-DrugBank.d306.s0.e0"
            e2="DDI-DrugBank.d306.s0.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d306.s1" text="No significant interaction has been found with broad-spectrum antibiotics.">
        <entity id="DDI-DrugBank.d306.s1.e0" charOffset="62-72"
            type="group" text="antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s0" text="Elevated plasma levels of theophylline have been reported with concomitant quinolone use.">
        <entity id="DDI-DrugBank.d217.s0.e0" charOffset="26-37"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d217.s0.e1" charOffset="75-83"
            type="group" text="quinolone"/>
        <ddi id="DDI-DrugBank.d217.s0.d0" e1="DDI-DrugBank.d217.s0.e0"
            e2="DDI-DrugBank.d217.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s1" text="There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.">
        <entity id="DDI-DrugBank.d217.s1.e0" charOffset="27-38"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d217.s1.e1" charOffset="101-111"
            type="drug" text="norfloxacin"/>
        <entity id="DDI-DrugBank.d217.s1.e2" charOffset="117-128"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d217.s1.d0" e1="DDI-DrugBank.d217.s1.e1"
            e2="DDI-DrugBank.d217.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s2" text="Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.">
        <entity id="DDI-DrugBank.d217.s2.e0" charOffset="25-36"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d217.s2.e1" charOffset="87-98"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s3" text="Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.">
        <entity id="DDI-DrugBank.d217.s3.e0" charOffset="25-36"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d217.s3.e1" charOffset="81-92"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d217.s3.e2" charOffset="99-109"
            type="drug" text="norfloxacin"/>
        <ddi id="DDI-DrugBank.d217.s3.d0" e1="DDI-DrugBank.d217.s3.e1"
            e2="DDI-DrugBank.d217.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s4" text="Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.">
        <entity id="DDI-DrugBank.d217.s4.e0" charOffset="11-22"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d217.s4.e1" charOffset="73-84"
            type="drug" text="cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s5" text="Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.">
        <entity id="DDI-DrugBank.d217.s5.e0" charOffset="0-9"
            type="group" text="Quinolones"/>
        <entity id="DDI-DrugBank.d217.s5.e1" charOffset="22-32"
            type="drug" text="norfloxacin"/>
        <entity id="DDI-DrugBank.d217.s5.e2" charOffset="67-80"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d217.s5.e3" charOffset="93-100"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d217.s5.d0" e1="DDI-DrugBank.d217.s5.e0"
            e2="DDI-DrugBank.d217.s5.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d217.s5.d1" e1="DDI-DrugBank.d217.s5.e0"
            e2="DDI-DrugBank.d217.s5.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d217.s5.d2" e1="DDI-DrugBank.d217.s5.e1"
            e2="DDI-DrugBank.d217.s5.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d217.s5.d3" e1="DDI-DrugBank.d217.s5.e1"
            e2="DDI-DrugBank.d217.s5.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s6" text="When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored."/>
    <sentence id="DDI-DrugBank.d217.s7" text="The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.">
        <entity id="DDI-DrugBank.d217.s7.e0" charOffset="34-43"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d217.s7.e1" charOffset="55-65"
            type="drug" text="norfloxacin"/>
        <entity id="DDI-DrugBank.d217.s7.e2" charOffset="72-80"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d217.s7.e3" charOffset="85-102"
            type="group" text="sulfonylurea agent"/>
        <ddi id="DDI-DrugBank.d217.s7.d0" e1="DDI-DrugBank.d217.s7.e0"
            e2="DDI-DrugBank.d217.s7.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d217.s7.d1" e1="DDI-DrugBank.d217.s7.e1"
            e2="DDI-DrugBank.d217.s7.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s8" text="Therefore, monitoring of blood glucose is recommended when these agents are co-administered."/>
    <sentence id="DDI-DrugBank.d217.s9" text="Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.">
        <entity id="DDI-DrugBank.d217.s9.e0" charOffset="32-42"
            type="drug" text="norfloxacin"/>
        <entity id="DDI-DrugBank.d217.s9.e1" charOffset="103-112"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d217.s9.e2" charOffset="118-128"
            type="drug" text="norfloxacin"/>
        <ddi id="DDI-DrugBank.d217.s9.d0" e1="DDI-DrugBank.d217.s9.e1"
            e2="DDI-DrugBank.d217.s9.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s10" text="The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.">
        <entity id="DDI-DrugBank.d217.s10.e0" charOffset="23-36"
            type="drug" text="nitrofurantoin"/>
        <entity id="DDI-DrugBank.d217.s10.e1" charOffset="63-76"
            type="drug" text="nitrofurantoin"/>
        <entity id="DDI-DrugBank.d217.s10.e2" charOffset="121-131"
            type="drug" text="Norfloxacin"/>
        <ddi id="DDI-DrugBank.d217.s10.d0" e1="DDI-DrugBank.d217.s10.e1"
            e2="DDI-DrugBank.d217.s10.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s11" text="Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.">
        <entity id="DDI-DrugBank.d217.s11.e0" charOffset="0-12"
            type="group" text="Multivitamins"/>
        <entity id="DDI-DrugBank.d217.s11.e1" charOffset="44-47"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d217.s11.e2" charOffset="52-55"
            type="drug" text="zinc"/>
        <entity id="DDI-DrugBank.d217.s11.e3" charOffset="58-65"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d217.s11.e4" charOffset="70-79"
            type="drug" text="sucralfate"/>
        <entity id="DDI-DrugBank.d217.s11.e5" charOffset="172-182"
            type="drug" text="norfloxacin"/>
        <entity id="DDI-DrugBank.d217.s11.e6" charOffset="273-283"
            type="drug" text="norfloxacin"/>
        <ddi id="DDI-DrugBank.d217.s11.d0" e1="DDI-DrugBank.d217.s11.e0"
            e2="DDI-DrugBank.d217.s11.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d217.s11.d1" e1="DDI-DrugBank.d217.s11.e1"
            e2="DDI-DrugBank.d217.s11.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d217.s11.d2" e1="DDI-DrugBank.d217.s11.e2"
            e2="DDI-DrugBank.d217.s11.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d217.s11.d3" e1="DDI-DrugBank.d217.s11.e3"
            e2="DDI-DrugBank.d217.s11.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d217.s11.d4" e1="DDI-DrugBank.d217.s11.e4"
            e2="DDI-DrugBank.d217.s11.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s12" text="Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.">
        <entity id="DDI-DrugBank.d217.s12.e0" charOffset="0-4"
            type="brand" text="Videx"/>
        <entity id="DDI-DrugBank.d217.s12.e1" charOffset="7-16"
            type="drug" text="Didanosine"/>
        <entity id="DDI-DrugBank.d217.s12.e2" charOffset="178-188"
            type="drug" text="norfloxacin"/>
        <entity id="DDI-DrugBank.d217.s12.e3" charOffset="289-299"
            type="drug" text="norfloxacin"/>
        <ddi id="DDI-DrugBank.d217.s12.d0" e1="DDI-DrugBank.d217.s12.e0"
            e2="DDI-DrugBank.d217.s12.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d217.s12.d1" e1="DDI-DrugBank.d217.s12.e1"
            e2="DDI-DrugBank.d217.s12.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s13" text="Some quinolones have also been shown to interfere with the metabolism of caffeine.">
        <entity id="DDI-DrugBank.d217.s13.e0" charOffset="5-14"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d217.s13.e1" charOffset="73-80"
            type="drug" text="caffeine"/>
        <ddi id="DDI-DrugBank.d217.s13.d0" e1="DDI-DrugBank.d217.s13.e0"
            e2="DDI-DrugBank.d217.s13.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d217.s14" text="This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life.">
        <entity id="DDI-DrugBank.d217.s14.e0" charOffset="38-45"
            type="drug" text="caffeine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d360.s0" text="Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin.">
        <entity id="DDI-DrugBank.d360.s0.e0" charOffset="140-147"
            type="drug" text="rifampin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d360.s1" text="A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.">
        <entity id="DDI-DrugBank.d360.s1.e0" charOffset="67-78"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d360.s1.e1" charOffset="81-94"
            type="drug" text="phenylbutazone"/>
        <entity id="DDI-DrugBank.d360.s1.e2" charOffset="97-112"
            type="drug" text="phenytoin sodium"/>
        <entity id="DDI-DrugBank.d360.s1.e3" charOffset="115-127"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d360.s1.e4" charOffset="130-141"
            type="drug" text="griseofulvin"/>
        <entity id="DDI-DrugBank.d360.s1.e5" charOffset="144-153"
            type="drug" text="topiramate"/>
        <entity id="DDI-DrugBank.d360.s1.e6" charOffset="174-183"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d360.s1.e7" charOffset="189-201"
            type="group" text="tetracyclines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d360.s2" text="A possible interaction has been suggested with hormonal contraceptives and the herbal supplement St. Johns Wort based on some reports of oral contraceptive users experiencing breakthrough bleeding shortly after starting St. Johns Wort.">
        <entity id="DDI-DrugBank.d360.s2.e0" charOffset="47-69"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d360.s2.e1" charOffset="142-154"
            type="group" text="contraceptive"/>
    </sentence>
    <sentence id="DDI-DrugBank.d360.s3" text="Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. Johns Wort.">
        <entity id="DDI-DrugBank.d360.s3.e0" charOffset="43-74"
            type="group" text="combined hormonal contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d360.s4" text="Healthcare prescribers are advised to consult the package inserts of medication administered concomitantly with oral contraceptives.">
        <entity id="DDI-DrugBank.d360.s4.e0" charOffset="117-130"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s0" text="Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.">
        <entity id="DDI-DrugBank.d202.s0.e0" charOffset="37-61"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d202.s0.e1" charOffset="108-117"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d202.s0.d0" e1="DDI-DrugBank.d202.s0.e0"
            e2="DDI-DrugBank.d202.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s1" text="Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.">
        <entity id="DDI-DrugBank.d202.s1.e0" charOffset="147-171"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d202.s1.e1" charOffset="178-187"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d202.s1.d0" e1="DDI-DrugBank.d202.s1.e0"
            e2="DDI-DrugBank.d202.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s2" text="In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.">
        <entity id="DDI-DrugBank.d202.s2.e0" charOffset="71-95"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d202.s2.e1" charOffset="169-178"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d202.s2.d0" e1="DDI-DrugBank.d202.s2.e0"
            e2="DDI-DrugBank.d202.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s3" text="In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.">
        <entity id="DDI-DrugBank.d202.s3.e0" charOffset="63-72"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d202.s3.e1" charOffset="130-154"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d202.s3.d0" e1="DDI-DrugBank.d202.s3.e0"
            e2="DDI-DrugBank.d202.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s4" text="The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.">
        <entity id="DDI-DrugBank.d202.s4.e0" charOffset="28-52"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d202.s4.e1" charOffset="96-105"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d202.s4.d0" e1="DDI-DrugBank.d202.s4.e0"
            e2="DDI-DrugBank.d202.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s5" text="Several of the tricyclic antidepressants have been cited in these reports.">
        <entity id="DDI-DrugBank.d202.s5.e0" charOffset="15-39"
            type="group" text="tricyclic antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s6" text="There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.">
        <entity id="DDI-DrugBank.d202.s6.e0" charOffset="90-104"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d202.s6.e1" charOffset="117-129"
            type="drug" text="nortriptyline"/>
        <entity id="DDI-DrugBank.d202.s6.e2" charOffset="137-160"
            type="drug" text="fluoxetine hydrochloride"/>
        <ddi id="DDI-DrugBank.d202.s6.d0" e1="DDI-DrugBank.d202.s6.e0"
            e2="DDI-DrugBank.d202.s6.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d202.s6.d1" e1="DDI-DrugBank.d202.s6.e1"
            e2="DDI-DrugBank.d202.s6.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s7" text="Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other.">
        <entity id="DDI-DrugBank.d202.s7.e0" charOffset="0-9"
            type="drug" text="Fluoxetine"/>
        <entity id="DDI-DrugBank.d202.s7.e1" charOffset="93-105"
            type="drug_n" text="norfluoxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s8" text="Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.">
        <entity id="DDI-DrugBank.d202.s8.e0" charOffset="18-26"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d202.s8.e1" charOffset="50-73"
            type="group" text="tricyclic antidepressant"/>
        <ddi id="DDI-DrugBank.d202.s8.d0" e1="DDI-DrugBank.d202.s8.e0"
            e2="DDI-DrugBank.d202.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s9" text="Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.">
        <entity id="DDI-DrugBank.d202.s9.e0" charOffset="73-99"
            type="drug" text="nortriptyline hydrochloride"/>
        <entity id="DDI-DrugBank.d202.s9.e1" charOffset="120-140"
            type="group" text="anticholinergic drugs"/>
        <entity id="DDI-DrugBank.d202.s9.e2" charOffset="145-165"
            type="group" text="sympathomimetic drugs"/>
        <ddi id="DDI-DrugBank.d202.s9.d0" e1="DDI-DrugBank.d202.s9.e0"
            e2="DDI-DrugBank.d202.s9.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d202.s9.d1" e1="DDI-DrugBank.d202.s9.e0"
            e2="DDI-DrugBank.d202.s9.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s10" text="The patient should be informed that the response to alcohol may be exaggerated.">
        <entity id="DDI-DrugBank.d202.s10.e0" charOffset="52-58"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s11" text="Drugs Metabolized by P450IID6  A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6."/>
    <sentence id="DDI-DrugBank.d202.s12" text="Such individuals are referred to as  poor metabolizers  of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants.">
        <entity id="DDI-DrugBank.d202.s12.e0" charOffset="73-83"
            type="drug" text="debrisoquin"/>
        <entity id="DDI-DrugBank.d202.s12.e1" charOffset="86-101"
            type="drug" text="dextromethorphan"/>
        <entity id="DDI-DrugBank.d202.s12.e2" charOffset="112-136"
            type="group" text="tricyclic antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s13" text="These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses.">
        <entity id="DDI-DrugBank.d202.s13.e0" charOffset="73-97"
            type="group" text="tricyclic antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s14" text="In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.">
        <entity id="DDI-DrugBank.d202.s14.e0" charOffset="82-96"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d202.s14.e1" charOffset="99-123"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d202.s14.e2" charOffset="126-164"
            type="group" text="selective serotonin reuptake inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s15" text="Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.">
        <entity id="DDI-DrugBank.d202.s15.e0" charOffset="19-43"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d202.s15.e1" charOffset="160-183"
            type="group" text="tricyclic antidepressant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d202.s16" text="Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.">
        <entity id="DDI-DrugBank.d202.s16.e0" charOffset="32-56"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d202.s16.e1" charOffset="131-145"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d202.s16.e2" charOffset="148-161"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d202.s16.e3" charOffset="164-176"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d202.s16.e4" charOffset="183-205"
            type="group" text="Type 1C antiarrhythmics"/>
        <entity id="DDI-DrugBank.d202.s16.e5" charOffset="212-222"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d202.s16.e6" charOffset="225-234"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d202.s16.e7" charOffset="241-249"
            type="drug" text="encainide"/>
        <entity id="DDI-DrugBank.d202.s16.e8" charOffset="286-294"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d202.s16.d0" e1="DDI-DrugBank.d202.s16.e0"
            e2="DDI-DrugBank.d202.s16.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d202.s16.d1" e1="DDI-DrugBank.d202.s16.e0"
            e2="DDI-DrugBank.d202.s16.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d202.s16.d2" e1="DDI-DrugBank.d202.s16.e0"
            e2="DDI-DrugBank.d202.s16.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d202.s16.d3" e1="DDI-DrugBank.d202.s16.e0"
            e2="DDI-DrugBank.d202.s16.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d202.s16.d4" e1="DDI-DrugBank.d202.s16.e0"
            e2="DDI-DrugBank.d202.s16.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d202.s16.d5" e1="DDI-DrugBank.d202.s16.e0"
            e2="DDI-DrugBank.d202.s16.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d202.s16.d6" e1="DDI-DrugBank.d202.s16.e0"
            e2="DDI-DrugBank.d202.s16.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d202.s16.d7" e1="DDI-DrugBank.d202.s16.e0"
            e2="DDI-DrugBank.d202.s16.e8" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s0" text="Oxcarbazepine can inhibit CYP2C19 and induce CYP3A4/5 with potentially important effects on plasma concentrations of other drugs.">
        <entity id="DDI-DrugBank.d307.s0.e0" charOffset="0-12"
            type="drug" text="Oxcarbazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s1" text="In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.">
        <entity id="DDI-DrugBank.d307.s1.e0" charOffset="21-23"
            type="group" text="AED"/>
        <entity id="DDI-DrugBank.d307.s1.e1" charOffset="99-111"
            type="drug" text="oxcarbazepine"/>
        <entity id="DDI-DrugBank.d307.s1.e2" charOffset="117-119"
            type="drug_n" text="MHD"/>
        <ddi id="DDI-DrugBank.d307.s1.d0" e1="DDI-DrugBank.d307.s1.e0"
            e2="DDI-DrugBank.d307.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s2" text="Oxcarbazepine was evaluated in human liver microsomes to determine its capacity to inhibit the major cytochrome P450 enzymes responsible for the metabolism of other drugs.">
        <entity id="DDI-DrugBank.d307.s2.e0" charOffset="0-12"
            type="drug" text="Oxcarbazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s3" text="Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite (MHD) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated (CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9 and CYP4A11) with the exception of CYP2C19 and CYP3A4/5.">
        <entity id="DDI-DrugBank.d307.s3.e0" charOffset="25-37"
            type="drug" text="oxcarbazepine"/>
        <entity id="DDI-DrugBank.d307.s3.e1" charOffset="99-101"
            type="drug_n" text="MHD"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s4" text="Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance.">
        <entity id="DDI-DrugBank.d307.s4.e0" charOffset="36-38"
            type="drug" text="OXC"/>
        <entity id="DDI-DrugBank.d307.s4.e1" charOffset="44-46"
            type="drug_n" text="MHD"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s5" text="The inhibition of CYP-2C19 by OXC and MHD, however, is clinically relevant.">
        <entity id="DDI-DrugBank.d307.s5.e0" charOffset="30-32"
            type="drug" text="OXC"/>
        <entity id="DDI-DrugBank.d307.s5.e1" charOffset="38-40"
            type="drug_n" text="MHD"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s6" text="In vitro, the UDP-glucuronyl transferase level was increased, indicating induction of this enzyme."/>
    <sentence id="DDI-DrugBank.d307.s7" text="Increases of 22% with MHD and 47% with oxcarbazepine were observed.">
        <entity id="DDI-DrugBank.d307.s7.e0" charOffset="22-24"
            type="drug_n" text="MHD"/>
        <entity id="DDI-DrugBank.d307.s7.e1" charOffset="39-51"
            type="drug" text="oxcarbazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s8" text="As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid, lamotrigine).">
        <entity id="DDI-DrugBank.d307.s8.e0" charOffset="3-5"
            type="drug_n" text="MHD"/>
        <entity id="DDI-DrugBank.d307.s8.e1" charOffset="222-234"
            type="drug" text="valproic acid"/>
        <entity id="DDI-DrugBank.d307.s8.e2" charOffset="237-247"
            type="drug" text="lamotrigine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s9" text="In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.">
        <entity id="DDI-DrugBank.d307.s9.e0" charOffset="13-25"
            type="drug" text="oxcarbazepine"/>
        <entity id="DDI-DrugBank.d307.s9.e1" charOffset="31-33"
            type="drug_n" text="MHD"/>
        <entity id="DDI-DrugBank.d307.s9.e2" charOffset="140-174"
            type="group" text="dihydropyridine calcium antagonists"/>
        <entity id="DDI-DrugBank.d307.s9.e3" charOffset="185-198"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s10" text="As binding of MHD to plasma proteins is low (40%), clinically significant interactions with other drugs through competition for protein binding sites are unlikely.">
        <entity id="DDI-DrugBank.d307.s10.e0" charOffset="14-16"
            type="drug_n" text="MHD"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s11" text="Antiepileptic drugs: Potential interactions between Trileptal and other AEDs were assessed in clinical studies.">
        <entity id="DDI-DrugBank.d307.s11.e0" charOffset="0-18"
            type="group" text="Antiepileptic drugs"/>
        <entity id="DDI-DrugBank.d307.s11.e1" charOffset="52-60"
            type="brand" text="Trileptal"/>
        <entity id="DDI-DrugBank.d307.s11.e2" charOffset="72-75"
            type="group" text="AEDs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s12" text="The effect of these interactions on mean AUCs and Cmin are summarized in Table 2: Table 2: Summary of AED interactions with Trileptal">
        <entity id="DDI-DrugBank.d307.s12.e0" charOffset="124-132"
            type="brand" text="Trileptal"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s13" text="AED Co-administered">
        <entity id="DDI-DrugBank.d307.s13.e0" charOffset="0-2"
            type="group" text="AED"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s14" text="Dose of AED (mg/day)">
        <entity id="DDI-DrugBank.d307.s14.e0" charOffset="8-10"
            type="group" text="AED"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s15" text="Trileptal dose (mg/day)">
        <entity id="DDI-DrugBank.d307.s15.e0" charOffset="0-8"
            type="brand" text="Trileptal"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s16" text="Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval)">
        <entity id="DDI-DrugBank.d307.s16.e0" charOffset="13-21"
            type="brand" text="Trileptal"/>
        <entity id="DDI-DrugBank.d307.s16.e1" charOffset="26-28"
            type="group" text="AED"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s17" text="Influence of AED On MHD Concentration (Mean change, 90% Confidence Interval)">
        <entity id="DDI-DrugBank.d307.s17.e0" charOffset="13-15"
            type="group" text="AED"/>
        <entity id="DDI-DrugBank.d307.s17.e1" charOffset="20-22"
            type="drug_n" text="MHD"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s18" text="Carbamazepine">
        <entity id="DDI-DrugBank.d307.s18.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s19" text="400-2000"/>
    <sentence id="DDI-DrugBank.d307.s20" text="900"/>
    <sentence id="DDI-DrugBank.d307.s21" text="nc1 40% decrease [CI: 17% decrease, 57% decrease]"/>
    <sentence id="DDI-DrugBank.d307.s22" text="Phenobarbital">
        <entity id="DDI-DrugBank.d307.s22.e0" charOffset="0-12"
            type="drug" text="Phenobarbital"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s23" text="100-150"/>
    <sentence id="DDI-DrugBank.d307.s24" text="600-1800"/>
    <sentence id="DDI-DrugBank.d307.s25" text="14% increase [CI: 2% increase, 24% increase] 25% decrease [CI: 12% decrease, 51% decrease]"/>
    <sentence id="DDI-DrugBank.d307.s26" text="Phenytoin">
        <entity id="DDI-DrugBank.d307.s26.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s27" text="250-500"/>
    <sentence id="DDI-DrugBank.d307.s28" text="600-1800"/>
    <sentence id="DDI-DrugBank.d307.s29" text="nc1,2 30% decrease [CI: 3% decrease, 48 % decrease]"/>
    <sentence id="DDI-DrugBank.d307.s30" text="1200-2400 up to 40% increase3 [CI: 12% increase, 60 % increase]"/>
    <sentence id="DDI-DrugBank.d307.s31" text="Valproic acid">
        <entity id="DDI-DrugBank.d307.s31.e0" charOffset="0-12"
            type="drug" text="Valproic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s32" text="400-2800"/>
    <sentence id="DDI-DrugBank.d307.s33" text="600-1800"/>
    <sentence id="DDI-DrugBank.d307.s34" text="nc1 18% decrease [CI: 13% decrease, 40 % decrease]"/>
    <sentence id="DDI-DrugBank.d307.s35" text="1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.">
        <entity id="DDI-DrugBank.d307.s35.e0" charOffset="94-102"
            type="brand" text="Trileptal"/>
        <entity id="DDI-DrugBank.d307.s35.e1" charOffset="140-148"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d307.s35.e2" charOffset="179-187"
            type="brand" text="Trileptal"/>
        <ddi id="DDI-DrugBank.d307.s35.d0" e1="DDI-DrugBank.d307.s35.e1"
            e2="DDI-DrugBank.d307.s35.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s36" text="Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.">
        <entity id="DDI-DrugBank.d307.s36.e0" charOffset="31-39"
            type="brand" text="Trileptal"/>
        <entity id="DDI-DrugBank.d307.s36.e1" charOffset="119-127"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d307.s36.d0" e1="DDI-DrugBank.d307.s36.e0"
            e2="DDI-DrugBank.d307.s36.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s37" text="The increase of phenobarbital level, however, is small (15%) when given with Trileptal.">
        <entity id="DDI-DrugBank.d307.s37.e0" charOffset="16-28"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d307.s37.e1" charOffset="77-85"
            type="brand" text="Trileptal"/>
        <ddi id="DDI-DrugBank.d307.s37.d0" e1="DDI-DrugBank.d307.s37.e0"
            e2="DDI-DrugBank.d307.s37.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s38" text="Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma levels of MHD (29-40%).">
        <entity id="DDI-DrugBank.d307.s38.e0" charOffset="49-61"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d307.s38.e1" charOffset="64-72"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d307.s38.e2" charOffset="78-90"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d307.s38.e3" charOffset="142-144"
            type="drug_n" text="MHD"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s39" text="No autoinduction has been observed with Trileptal.">
        <entity id="DDI-DrugBank.d307.s39.e0" charOffset="40-48"
            type="brand" text="Trileptal"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s40" text="Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).">
        <entity id="DDI-DrugBank.d307.s40.e0" charOffset="9-22"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d307.s40.e1" charOffset="45-53"
            type="brand" text="Trileptal"/>
        <entity id="DDI-DrugBank.d307.s40.e2" charOffset="68-80"
            type="group" text="contraceptive"/>
        <entity id="DDI-DrugBank.d307.s40.e3" charOffset="168-183"
            type="drug" text="ethinylestradiol"/>
        <entity id="DDI-DrugBank.d307.s40.e4" charOffset="194-207"
            type="drug" text="levonorgestrel"/>
        <ddi id="DDI-DrugBank.d307.s40.d0" e1="DDI-DrugBank.d307.s40.e1"
            e2="DDI-DrugBank.d307.s40.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s41" text="The mean AUC values of EE were decreased by 48% [90% CI: 22-65] in one study and 52% [90% CI: 38-52] in another study [1,2]."/>
    <sentence id="DDI-DrugBank.d307.s42" text="The mean AUC values of LNG were decreased by 32% [90% CI: 20-45] in one study and 52% [90% CI: 42-52] in another study."/>
    <sentence id="DDI-DrugBank.d307.s43" text="Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.">
        <entity id="DDI-DrugBank.d307.s43.e0" charOffset="29-37"
            type="brand" text="Trileptal"/>
        <entity id="DDI-DrugBank.d307.s43.e1" charOffset="44-66"
            type="group" text="hormonal contraceptives"/>
        <entity id="DDI-DrugBank.d307.s43.e2" charOffset="85-98"
            type="group" text="contraceptives"/>
        <ddi id="DDI-DrugBank.d307.s43.d0" e1="DDI-DrugBank.d307.s43.e0"
            e2="DDI-DrugBank.d307.s43.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s44" text="Studies with other oral or implant contraceptives have not been conducted.">
        <entity id="DDI-DrugBank.d307.s44.e0" charOffset="35-48"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s45" text="Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].">
        <entity id="DDI-DrugBank.d307.s45.e0" charOffset="0-17"
            type="group" text="Calcium Antagonist"/>
        <entity id="DDI-DrugBank.d307.s45.e1" charOffset="57-65"
            type="brand" text="Trileptal"/>
        <entity id="DDI-DrugBank.d307.s45.e2" charOffset="79-88"
            type="drug" text="felodipine"/>
        <ddi id="DDI-DrugBank.d307.s45.d0" e1="DDI-DrugBank.d307.s45.e1"
            e2="DDI-DrugBank.d307.s45.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s46" text="Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD.">
        <entity id="DDI-DrugBank.d307.s46.e0" charOffset="0-8"
            type="drug" text="Verapamil"/>
        <entity id="DDI-DrugBank.d307.s46.e1" charOffset="77-79"
            type="drug_n" text="MHD"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s47" text="Other drug interactions Cimetidine, erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.">
        <entity id="DDI-DrugBank.d307.s47.e0" charOffset="24-33"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d307.s47.e1" charOffset="36-47"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d307.s47.e2" charOffset="53-70"
            type="drug" text="dextropropoxyphene"/>
        <entity id="DDI-DrugBank.d307.s47.e3" charOffset="113-115"
            type="drug_n" text="MHD"/>
    </sentence>
    <sentence id="DDI-DrugBank.d307.s48" text="Results with warfarin wshow no evidence of interaction with either single or repeated doses of Trileptal.">
        <entity id="DDI-DrugBank.d307.s48.e0" charOffset="13-20"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d307.s48.e1" charOffset="95-103"
            type="brand" text="Trileptal"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s0" text="In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).">
        <entity id="DDI-DrugBank.d288.s0.e0" charOffset="45-49"
            type="brand" text="TAXOL"/>
        <entity id="DDI-DrugBank.d288.s0.e1" charOffset="71-79"
            type="drug" text="cisplatin"/>
        <entity id="DDI-DrugBank.d288.s0.e2" charOffset="169-173"
            type="brand" text="TAXOL"/>
        <entity id="DDI-DrugBank.d288.s0.e3" charOffset="191-199"
            type="drug" text="cisplatin"/>
        <entity id="DDI-DrugBank.d288.s0.e4" charOffset="239-243"
            type="brand" text="TAXOL"/>
        <entity id="DDI-DrugBank.d288.s0.e5" charOffset="252-260"
            type="drug" text="cisplatin"/>
        <ddi id="DDI-DrugBank.d288.s0.d0" e1="DDI-DrugBank.d288.s0.e2"
            e2="DDI-DrugBank.d288.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s1" text="Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.">
        <entity id="DDI-DrugBank.d288.s1.e0" charOffset="68-77"
            type="drug" text="paclitaxel"/>
        <entity id="DDI-DrugBank.d288.s1.e1" charOffset="115-119"
            type="brand" text="TAXOL"/>
        <entity id="DDI-DrugBank.d288.s1.e2" charOffset="148-156"
            type="drug" text="cisplatin"/>
        <ddi id="DDI-DrugBank.d288.s1.d0" e1="DDI-DrugBank.d288.s1.e1"
            e2="DDI-DrugBank.d288.s1.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s2" text="The metabolism of TAXOL is catalyzed by cytochrome P450 isoen-zymes CYP2C8 and CYP3A4.">
        <entity id="DDI-DrugBank.d288.s2.e0" charOffset="18-22"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s3" text="In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4.">
        <entity id="DDI-DrugBank.d288.s3.e0" charOffset="107-111"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s4" text="Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.">
        <entity id="DDI-DrugBank.d288.s4.e0" charOffset="31-35"
            type="brand" text="TAXOL"/>
        <entity id="DDI-DrugBank.d288.s4.e1" charOffset="65-83"
            type="group" text="protease inhibitors"/>
        <entity id="DDI-DrugBank.d288.s4.e2" charOffset="86-94"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d288.s4.e3" charOffset="97-106"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d288.s4.e4" charOffset="109-117"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d288.s4.e5" charOffset="124-133"
            type="drug" text="nelfinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s5" text="Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.">
        <entity id="DDI-DrugBank.d288.s5.e0" charOffset="56-66"
            type="drug" text="doxorubicin"/>
        <entity id="DDI-DrugBank.d288.s5.e1" charOffset="95-107"
            type="drug_n" text="doxorubicinol"/>
        <entity id="DDI-DrugBank.d288.s5.e2" charOffset="132-141"
            type="drug" text="paclitaxel"/>
        <entity id="DDI-DrugBank.d288.s5.e3" charOffset="147-157"
            type="drug" text="doxorubicin"/>
        <ddi id="DDI-DrugBank.d288.s5.d0" e1="DDI-DrugBank.d288.s5.e2"
            e2="DDI-DrugBank.d288.s5.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s6" text="Hematology: TAXOL therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3.">
        <entity id="DDI-DrugBank.d288.s6.e0" charOffset="12-16"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s7" text="In order to monitor the occurrence of myelotoxicity, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL.">
        <entity id="DDI-DrugBank.d288.s7.e0" charOffset="153-157"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s8" text="Patients should not be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level  1500 cells/mm3 and platelets recover to a level  100,000 cells/mm3.">
        <entity id="DDI-DrugBank.d288.s8.e0" charOffset="60-64"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s9" text="In the case of severe neutropenia ( 500 cells/mm3 for seven days or more) during a course of TAXOL therapy, a 20% reduction in dose for subsequent courses of therapy is recommended.">
        <entity id="DDI-DrugBank.d288.s9.e0" charOffset="93-97"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s10" text="For patients with advanced HIV disease and poor-risk AIDS-related Kaposi s sarcoma, TAXOL, at the recommended dose for this disease, can be initiated and repeated if the neutrophil count is at least 1000 cells/mm3.">
        <entity id="DDI-DrugBank.d288.s10.e0" charOffset="84-88"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s11" text="Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.">
        <entity id="DDI-DrugBank.d288.s11.e0" charOffset="131-141"
            type="drug" text="cyclosporin"/>
        <entity id="DDI-DrugBank.d288.s11.e1" charOffset="173-182"
            type="drug" text="teniposide"/>
        <entity id="DDI-DrugBank.d288.s11.e2" charOffset="238-242"
            type="brand" text="TAXOL"/>
        <ddi id="DDI-DrugBank.d288.s11.d0" e1="DDI-DrugBank.d288.s11.e0"
            e2="DDI-DrugBank.d288.s11.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d288.s11.d1" e1="DDI-DrugBank.d288.s11.e1"
            e2="DDI-DrugBank.d288.s11.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s12" text="In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).">
        <entity id="DDI-DrugBank.d288.s12.e0" charOffset="97-101"
            type="brand" text="TAXOL"/>
        <entity id="DDI-DrugBank.d288.s12.e1" charOffset="131-145"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d288.s12.e2" charOffset="156-168"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d288.s12.e3" charOffset="193-206"
            type="group" text="H2 antagonists"/>
        <entity id="DDI-DrugBank.d288.s12.e4" charOffset="217-226"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d288.s12.e5" charOffset="231-240"
            type="drug" text="ranitidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s13" text="Minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia do not require interruption of therapy."/>
    <sentence id="DDI-DrugBank.d288.s14" text="However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy.">
        <entity id="DDI-DrugBank.d288.s14.e0" charOffset="86-100"
            type="group" text="bronchodilators"/>
        <entity id="DDI-DrugBank.d288.s14.e1" charOffset="177-181"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s15" text="Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOL.">
        <entity id="DDI-DrugBank.d288.s15.e0" charOffset="94-98"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s16" text="Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL, but generally do not require treatment.">
        <entity id="DDI-DrugBank.d288.s16.e0" charOffset="103-107"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s17" text="Occasionally TAXOL infusions must be interrupted or discontinued because of initial or recurrent hypertension.">
        <entity id="DDI-DrugBank.d288.s17.e0" charOffset="13-17"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s18" text="Frequent vital sign monitoring, particularly during the first hour of TAXOL infusion, is recommended.">
        <entity id="DDI-DrugBank.d288.s18.e0" charOffset="70-74"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s19" text="Continuous cardiac monitoring is not required except for patients with serious conduction abnormalities."/>
    <sentence id="DDI-DrugBank.d288.s20" text="Nervous System: Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and requires a dose reduction of 20% for all subsequentcourses of TAXOL.">
        <entity id="DDI-DrugBank.d288.s20.e0" charOffset="196-200"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s21" text="TAXOL contains dehydrated alcohol USP, 396 mg/mL;">
        <entity id="DDI-DrugBank.d288.s21.e0" charOffset="0-4"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s22" text="consideration should be given to possible CNS and other effects of alcohol.">
        <entity id="DDI-DrugBank.d288.s22.e0" charOffset="67-73"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s23" text="Hepatic: There is limited evidence that the myelotoxicity of TAXOL may be exacerbated in patients with serum total bilirubin  2 times ULN.">
        <entity id="DDI-DrugBank.d288.s23.e0" charOffset="61-65"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s24" text="Extreme caution should be exercised when administering TAXOL to such patients, with dose reduction as recommended in DOSAGE AND ADMINISTRATION, Table 17.">
        <entity id="DDI-DrugBank.d288.s24.e0" charOffset="55-59"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s25" text="InjectionSite Reaction: Injection site reactions, including reactions secondary to extravasation, were usually mild and consisted of erythema, tenderness, skin discoloration, or swelling at the injection site."/>
    <sentence id="DDI-DrugBank.d288.s26" text="These reactions have been observed more frequently with the 24-hour infusion than with the 3-hour infusion."/>
    <sentence id="DDI-DrugBank.d288.s27" text="Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, ie, recall, has been reported rarely.">
        <entity id="DDI-DrugBank.d288.s27.e0" charOffset="93-97"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s28" text="Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of TAXOL safety.">
        <entity id="DDI-DrugBank.d288.s28.e0" charOffset="180-184"
            type="brand" text="TAXOL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d288.s29" text="In some cases the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to ten days."/>
    <sentence id="DDI-DrugBank.d288.s30" text="A specific treatment for extravasation reactions is unknown at this time."/>
    <sentence id="DDI-DrugBank.d288.s31" text="Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration."/>
    <sentence id="DDI-DrugBank.d196.s0" text="Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.">
        <entity id="DDI-DrugBank.d196.s0.e0" charOffset="15-21"
            type="brand" text="PEGASYS"/>
        <entity id="DDI-DrugBank.d196.s0.e1" charOffset="135-146"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d196.s0.d0" e1="DDI-DrugBank.d196.s0.e0"
            e2="DDI-DrugBank.d196.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s1" text="Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.">
        <entity id="DDI-DrugBank.d196.s1.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d196.s1.e1" charOffset="114-125"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d196.s1.e2" charOffset="131-137"
            type="brand" text="PEGASYS"/>
        <ddi id="DDI-DrugBank.d196.s1.d0" e1="DDI-DrugBank.d196.s1.e1"
            e2="DDI-DrugBank.d196.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s2" text="There was no effect on the pharmacokinetics of representative drugs metabolized by CYP 2C9, CYP 2C19, CYP 2D6 or CYP 3A4."/>
    <sentence id="DDI-DrugBank.d196.s3" text="In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS, PEGASYS treatment did not affect ribavirin distribution or clearance.">
        <entity id="DDI-DrugBank.d196.s3.e0" charOffset="50-56"
            type="brand" text="PEGASYS"/>
        <entity id="DDI-DrugBank.d196.s3.e1" charOffset="78-84"
            type="brand" text="COPEGUS"/>
        <entity id="DDI-DrugBank.d196.s3.e2" charOffset="87-93"
            type="brand" text="PEGASYS"/>
        <entity id="DDI-DrugBank.d196.s3.e3" charOffset="120-128"
            type="drug" text="ribavirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s4" text="Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.">
        <entity id="DDI-DrugBank.d196.s4.e0" charOffset="21-30"
            type="drug" text="Didanosine"/>
        <entity id="DDI-DrugBank.d196.s4.e1" charOffset="53-59"
            type="brand" text="COPEGUS"/>
        <entity id="DDI-DrugBank.d196.s4.e2" charOffset="65-74"
            type="drug" text="didanosine"/>
        <ddi id="DDI-DrugBank.d196.s4.d0" e1="DDI-DrugBank.d196.s4.e1"
            e2="DDI-DrugBank.d196.s4.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s5" text="Reports of fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials."/>
    <sentence id="DDI-DrugBank.d196.s6" text="Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.">
        <entity id="DDI-DrugBank.d196.s6.e0" charOffset="0-8"
            type="drug" text="Stavudine"/>
        <entity id="DDI-DrugBank.d196.s6.e1" charOffset="14-23"
            type="drug" text="Zidovudine"/>
        <entity id="DDI-DrugBank.d196.s6.e2" charOffset="25-33"
            type="drug" text="Ribavirin"/>
        <entity id="DDI-DrugBank.d196.s6.e3" charOffset="85-93"
            type="drug" text="stavudine"/>
        <entity id="DDI-DrugBank.d196.s6.e4" charOffset="99-108"
            type="drug" text="zidovudine"/>
        <ddi id="DDI-DrugBank.d196.s6.d0" e1="DDI-DrugBank.d196.s6.e2"
            e2="DDI-DrugBank.d196.s6.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d196.s6.d1" e1="DDI-DrugBank.d196.s6.e2"
            e2="DDI-DrugBank.d196.s6.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s7" text="Therefore, concomitant use of ribavirin with either of these drugs should be avoided.">
        <entity id="DDI-DrugBank.d196.s7.e0" charOffset="30-38"
            type="drug" text="ribavirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s8" text="Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis PEGASYS has not been tested for its carcinogenic potential.">
        <entity id="DDI-DrugBank.d196.s8.e0" charOffset="68-74"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s9" text="Mutagenesis PEGASYS did not cause DNA damage when tested in the Ames bacterial mutagenicity assay and in the in vitro chromosomal aberration assay in human lymphocytes, either in the presence or absence of metabolic activation.">
        <entity id="DDI-DrugBank.d196.s9.e0" charOffset="12-18"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s10" text="Use With Ribavirin Ribavirin is genotoxic and mutagenic.">
        <entity id="DDI-DrugBank.d196.s10.e0" charOffset="9-17"
            type="drug" text="Ribavirin"/>
        <entity id="DDI-DrugBank.d196.s10.e1" charOffset="19-27"
            type="drug" text="Ribavirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s11" text="The carcinogenic potential of ribavirin has not been fully determined.">
        <entity id="DDI-DrugBank.d196.s11.e0" charOffset="30-38"
            type="drug" text="ribavirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s12" text="In a p53 (+/-) mouse carcinogenicity study at doses up to the maximum tolerated dose of 100 mg/kg/day ribavirin was not oncogenic.">
        <entity id="DDI-DrugBank.d196.s12.e0" charOffset="102-110"
            type="drug" text="ribavirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s13" text="However, on a body surface area basis, this dose was 0.5 times maximum recommended human 24-hour dose of ribavirin.">
        <entity id="DDI-DrugBank.d196.s13.e0" charOffset="105-113"
            type="drug" text="ribavirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s14" text="A study in rats to assess the carcinogenic potential of ribavirin is ongoing.">
        <entity id="DDI-DrugBank.d196.s14.e0" charOffset="56-64"
            type="drug" text="ribavirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s15" text="Mutagenesis Impairment of Fertility PEGASYS may impair fertility in women.">
        <entity id="DDI-DrugBank.d196.s15.e0" charOffset="36-42"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s16" text="Prolonged menstrual cycles and/or amenorrhea were observed in female cynomolgus monkeys given sc injections of 600 m g/kg/dose (7200 m g/m2/dose) of PEGASYS every other day for one month, at approximately 180 times the recommended weekly human dose for a 60 kg person (based on body surface area).">
        <entity id="DDI-DrugBank.d196.s16.e0" charOffset="149-155"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s17" text="Menstrual cycle irregularities were accompanied by both a decrease and delay in the peak 17b -estradiol and progesterone levels following administration of PEGASYS to female monkeys.">
        <entity id="DDI-DrugBank.d196.s17.e0" charOffset="156-162"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s18" text="A return to normal menstrual rhythm followed cessation of treatment."/>
    <sentence id="DDI-DrugBank.d196.s19" text="Every other day dosing with 100m g/kg (1200m g/m2) PEGASYS (equivalent to approximately 30 times the recommended human dose) had no effects on cycle duration or reproductive hormone status.">
        <entity id="DDI-DrugBank.d196.s19.e0" charOffset="51-57"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s20" text="The effects of PEGASYS on male fertility have not been studied.">
        <entity id="DDI-DrugBank.d196.s20.e0" charOffset="15-21"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s21" text="However, no adverse effects on fertility were observed in male Rhesus monkeys treated with non-pegylated interferon alfa-2a for 5 months at doses up to 25 x 106 IU/kg/day.">
        <entity id="DDI-DrugBank.d196.s21.e0" charOffset="95-122"
            type="drug" text="pegylated interferon alfa-2a"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s22" text="Pregnancy Pregnancy: Category C PEGASYS has not been studied for its teratogenic effect.">
        <entity id="DDI-DrugBank.d196.s22.e0" charOffset="32-38"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s23" text="Non-pegylated interferon alfa-2a treatment of pregnant Rhesus monkeys at approximately 20 to 500 times the human weekly dose resulted in a statistically significant increase in abortions.">
        <entity id="DDI-DrugBank.d196.s23.e0" charOffset="0-31"
            type="drug" text="Non-pegylated interferon alfa-2a"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s24" text="No teratogenic effects were seen in the offspring delivered at term."/>
    <sentence id="DDI-DrugBank.d196.s25" text="PEGASYS should be assumed to have abortifacient potential.">
        <entity id="DDI-DrugBank.d196.s25.e0" charOffset="0-6"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s26" text="There are no adequate and well-controlled studies of PEGASYS in pregnant women.">
        <entity id="DDI-DrugBank.d196.s26.e0" charOffset="53-59"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s27" text="PEGASYS is to be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.">
        <entity id="DDI-DrugBank.d196.s27.e0" charOffset="0-6"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s28" text="PEGASYS is recommended for use in women of childbearing potential only when they are using effective contraception during therapy.">
        <entity id="DDI-DrugBank.d196.s28.e0" charOffset="0-6"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s29" text="Pregnancy: Category X: Use With Ribavirin (see CONTRAINDICATIONS) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin.">
        <entity id="DDI-DrugBank.d196.s29.e0" charOffset="32-40"
            type="drug" text="Ribavirin"/>
        <entity id="DDI-DrugBank.d196.s29.e1" charOffset="173-181"
            type="drug" text="ribavirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s30" text="COPEGUS therapy is contraindicated in women who are pregnant and in the male partners of women who are pregnant .">
        <entity id="DDI-DrugBank.d196.s30.e0" charOffset="0-6"
            type="brand" text="COPEGUS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s31" text="If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment cessation, such cases should be reported to the COPEGUS Pregnancy Registry at 1-800-526-6367.">
        <entity id="DDI-DrugBank.d196.s31.e0" charOffset="161-167"
            type="brand" text="COPEGUS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s32" text="Nursing Mothers It is not known whether peginterferon or ribavirin or its components are excreted in human milk.">
        <entity id="DDI-DrugBank.d196.s32.e0" charOffset="40-52"
            type="drug" text="peginterferon"/>
        <entity id="DDI-DrugBank.d196.s32.e1" charOffset="57-65"
            type="drug" text="ribavirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s33" text="The effect of orally ingested peginterferon or ribavirin from breast milk on the nursing infant has not been evaluated.">
        <entity id="DDI-DrugBank.d196.s33.e0" charOffset="30-42"
            type="drug" text="peginterferon"/>
        <entity id="DDI-DrugBank.d196.s33.e1" charOffset="47-55"
            type="drug" text="ribavirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s34" text="Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue PEGASYS and COPEGUS treatment.">
        <entity id="DDI-DrugBank.d196.s34.e0" charOffset="152-158"
            type="brand" text="PEGASYS"/>
        <entity id="DDI-DrugBank.d196.s34.e1" charOffset="164-170"
            type="brand" text="COPEGUS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s35" text="Pediatric Use The safety and effectiveness of PEGASYS, alone or in combination with COPEGUS in patients below the age of 18 years have not been established.">
        <entity id="DDI-DrugBank.d196.s35.e0" charOffset="46-52"
            type="brand" text="PEGASYS"/>
        <entity id="DDI-DrugBank.d196.s35.e1" charOffset="84-90"
            type="brand" text="COPEGUS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s36" text="PEGASYS contains benzyl alcohol.">
        <entity id="DDI-DrugBank.d196.s36.e0" charOffset="0-6"
            type="brand" text="PEGASYS"/>
        <entity id="DDI-DrugBank.d196.s36.e1" charOffset="17-30"
            type="drug_n" text="benzyl alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s37" text="Benzyl alcohol has been reported to be associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal.">
        <entity id="DDI-DrugBank.d196.s37.e0" charOffset="0-13"
            type="drug_n" text="Benzyl alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s38" text="Geriatric Use Younger patients have higher virologic response rates than older patients."/>
    <sentence id="DDI-DrugBank.d196.s39" text="Clinical studies of PEGASYS alone or in combination with COPEGUS did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects.">
        <entity id="DDI-DrugBank.d196.s39.e0" charOffset="20-26"
            type="brand" text="PEGASYS"/>
        <entity id="DDI-DrugBank.d196.s39.e1" charOffset="57-63"
            type="brand" text="COPEGUS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s40" text="Adverse reactions related to alpha interferons, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of PEGASYS in this population.">
        <entity id="DDI-DrugBank.d196.s40.e0" charOffset="29-44"
            type="drug" text="alpha interferon"/>
        <entity id="DDI-DrugBank.d196.s40.e1" charOffset="186-192"
            type="brand" text="PEGASYS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s41" text="PEGASYS and COPEGUS are excreted by the kidney, and the risk of toxic reactions to this therapy may be greater in patients with impaired renal function.">
        <entity id="DDI-DrugBank.d196.s41.e0" charOffset="0-6"
            type="brand" text="PEGASYS"/>
        <entity id="DDI-DrugBank.d196.s41.e1" charOffset="12-18"
            type="brand" text="COPEGUS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s42" text="Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function."/>
    <sentence id="DDI-DrugBank.d196.s43" text="PEGASYS should be used with caution in patients with creatinine clearance  50 mL/min and COPEGUS should not be administered to patients with creatinine clearance  50 mL/min">
        <entity id="DDI-DrugBank.d196.s43.e0" charOffset="0-6"
            type="brand" text="PEGASYS"/>
        <entity id="DDI-DrugBank.d196.s43.e1" charOffset="89-95"
            type="brand" text="COPEGUS"/>
    </sentence>
    <sentence id="DDI-DrugBank.d196.s44" text="."/>
    <sentence id="DDI-DrugBank.d196.s45" text=""/>
    <sentence id="DDI-DrugBank.d462.s0" text="Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.">
        <entity id="DDI-DrugBank.d462.s0.e0" charOffset="0-14"
            type="group" text="Aminoglycosides"/>
        <entity id="DDI-DrugBank.d462.s0.e1" charOffset="31-42"
            type="drug" text="piperacillin"/>
        <entity id="DDI-DrugBank.d462.s0.e2" charOffset="52-65"
            type="group" text="aminoglycoside"/>
        <entity id="DDI-DrugBank.d462.s0.e3" charOffset="122-135"
            type="group" text="aminoglycoside"/>
        <ddi id="DDI-DrugBank.d462.s0.d0" e1="DDI-DrugBank.d462.s0.e1"
            e2="DDI-DrugBank.d462.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d462.s1" text="Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.">
        <entity id="DDI-DrugBank.d462.s1.e0" charOffset="0-9"
            type="drug" text="Vecuronium"/>
        <entity id="DDI-DrugBank.d462.s1.e1" charOffset="51-62"
            type="drug" text="piperacillin"/>
        <entity id="DDI-DrugBank.d462.s1.e2" charOffset="137-146"
            type="drug" text="vecuronium"/>
        <ddi id="DDI-DrugBank.d462.s1.d0" e1="DDI-DrugBank.d462.s1.e1"
            e2="DDI-DrugBank.d462.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d462.s2" text="Caution is indicated when piperacillin is used perioperatively.">
        <entity id="DDI-DrugBank.d462.s2.e0" charOffset="26-37"
            type="drug" text="piperacillin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d462.s3" text="In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.">
        <entity id="DDI-DrugBank.d462.s3.e0" charOffset="67-78"
            type="drug" text="piperacillin"/>
        <entity id="DDI-DrugBank.d462.s3.e1" charOffset="120-129"
            type="drug" text="vecuronium"/>
        <ddi id="DDI-DrugBank.d462.s3.d0" e1="DDI-DrugBank.d462.s3.e0"
            e2="DDI-DrugBank.d462.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d462.s4" text="Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.">
        <entity id="DDI-DrugBank.d462.s4.e0" charOffset="112-144"
            type="group" text="non-depolarizing muscle relaxants"/>
        <entity id="DDI-DrugBank.d462.s4.e1" charOffset="184-195"
            type="drug" text="piperacillin"/>
        <ddi id="DDI-DrugBank.d462.s4.d0" e1="DDI-DrugBank.d462.s4.e0"
            e2="DDI-DrugBank.d462.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d462.s5" text="Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.">
        <entity id="DDI-DrugBank.d462.s5.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d462.s5.e1" charOffset="36-45"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d462.s5.e2" charOffset="81-88"
            type="brand" text="PIPRACIL"/>
        <entity id="DDI-DrugBank.d462.s5.e3" charOffset="114-125"
            type="drug" text="piperacillin"/>
        <ddi id="DDI-DrugBank.d462.s5.d0" e1="DDI-DrugBank.d462.s5.e1"
            e2="DDI-DrugBank.d462.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d462.s6" text="Anticoagulants: Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function.">
        <entity id="DDI-DrugBank.d462.s6.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d462.s6.e1" charOffset="148-154"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d462.s6.e2" charOffset="162-175"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d462.s7" text="Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.">
        <entity id="DDI-DrugBank.d462.s7.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d462.s7.e1" charOffset="14-32"
            type="drug" text="Piperacillin sodium"/>
        <entity id="DDI-DrugBank.d462.s7.e2" charOffset="62-73"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d462.s7.d0" e1="DDI-DrugBank.d462.s7.e1"
            e2="DDI-DrugBank.d462.s7.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d462.s8" text="Therefore, serum levels of methotrexate should be monitored in patients to avoid drug toxicity.">
        <entity id="DDI-DrugBank.d462.s8.e0" charOffset="27-38"
            type="drug" text="methotrexate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d462.s9" text="Drug/Laboratory Test Interactions As with other penicillins, the administration of PIPRACIL may result in a false-positive reaction for glucose in the urine using a copper-reduction method.">
        <entity id="DDI-DrugBank.d462.s9.e0" charOffset="48-58"
            type="drug" text="penicillins"/>
        <entity id="DDI-DrugBank.d462.s9.e1" charOffset="83-90"
            type="brand" text="PIPRACIL"/>
    </sentence>
    <sentence id="DDI-DrugBank.d462.s10" text="It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used."/>
    <sentence id="DDI-DrugBank.d462.s11" text="There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of Aspergillus infection.">
        <entity id="DDI-DrugBank.d462.s11.e0" charOffset="132-143"
            type="drug" text="piperacillin"/>
        <entity id="DDI-DrugBank.d462.s11.e1" charOffset="145-154"
            type="drug" text="tazobactam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d462.s12" text="Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported."/>
    <sentence id="DDI-DrugBank.d462.s13" text="Therefore, positive test results in patients receiving piperacillin should be interpreted cautiously and confirmed by other diagnostic methods.">
        <entity id="DDI-DrugBank.d462.s13.e0" charOffset="55-66"
            type="drug" text="piperacillin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d326.s0" text="Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).">
        <entity id="DDI-DrugBank.d326.s0.e0" charOffset="0-13"
            type="group" text="Phenothiazines"/>
        <entity id="DDI-DrugBank.d326.s0.e1" charOffset="24-33"
            type="drug" text="piperazine"/>
        <entity id="DDI-DrugBank.d326.s0.e2" charOffset="41-53"
            type="group" text="phenothiazine"/>
        <ddi id="DDI-DrugBank.d326.s0.d0" e1="DDI-DrugBank.d326.s0.e1"
            e2="DDI-DrugBank.d326.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d326.s1" text="Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.">
        <entity id="DDI-DrugBank.d326.s1.e0" charOffset="0-7"
            type="drug" text="Pyrantel"/>
        <entity id="DDI-DrugBank.d326.s1.e1" charOffset="16-24"
            type="drug" text="Antiminth"/>
        <entity id="DDI-DrugBank.d326.s1.e2" charOffset="36-45"
            type="drug" text="piperazine"/>
        <entity id="DDI-DrugBank.d326.s1.e3" charOffset="51-58"
            type="drug" text="pyrantel"/>
        <entity id="DDI-DrugBank.d326.s1.e4" charOffset="97-106"
            type="drug" text="piperazine"/>
        <ddi id="DDI-DrugBank.d326.s1.d0" e1="DDI-DrugBank.d326.s1.e2"
            e2="DDI-DrugBank.d326.s1.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s0" text="ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.">
        <entity id="DDI-DrugBank.d210.s0.e0" charOffset="0-13"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d210.s0.e1" charOffset="37-42"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d210.s0.e2" charOffset="88-133"
            type="group" text="Angiotensin Converting Enzyme (ACE) inhibitors"/>
        <ddi id="DDI-DrugBank.d210.s0.d0" e1="DDI-DrugBank.d210.s0.e1"
            e2="DDI-DrugBank.d210.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s1" text="In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.">
        <entity id="DDI-DrugBank.d210.s1.e0" charOffset="81-85"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s1.e1" charOffset="96-108"
            type="group" text="ACE inhibitor"/>
        <entity id="DDI-DrugBank.d210.s1.e2" charOffset="110-119"
            type="drug" text="benazepril"/>
        <entity id="DDI-DrugBank.d210.s1.e3" charOffset="242-254"
            type="group" text="ACE inhibitor"/>
        <ddi id="DDI-DrugBank.d210.s1.d0" e1="DDI-DrugBank.d210.s1.e0"
            e2="DDI-DrugBank.d210.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s2" text="This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.">
        <entity id="DDI-DrugBank.d210.s2.e0" charOffset="66-70"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s2.e1" charOffset="91-104"
            type="group" text="ACE inhibitors"/>
        <ddi id="DDI-DrugBank.d210.s2.d0" e1="DDI-DrugBank.d210.s2.e0"
            e2="DDI-DrugBank.d210.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s3" text="Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.">
        <entity id="DDI-DrugBank.d210.s3.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d210.s3.e1" charOffset="48-54"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d210.s3.e2" charOffset="61-65"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s3.e3" charOffset="159-163"
            type="brand" text="VIOXX"/>
        <ddi id="DDI-DrugBank.d210.s3.d0" e1="DDI-DrugBank.d210.s3.e1"
            e2="DDI-DrugBank.d210.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s4" text="In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.">
        <entity id="DDI-DrugBank.d210.s4.e0" charOffset="193-199"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d210.s4.e1" charOffset="206-210"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s4.e2" charOffset="253-261"
            type="drug" text="ibuprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s5" text="Patients taking low-dose aspirin plus ibuprofen were not studied.">
        <entity id="DDI-DrugBank.d210.s5.e0" charOffset="25-31"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d210.s5.e1" charOffset="38-46"
            type="drug" text="ibuprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s6" text="At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.">
        <entity id="DDI-DrugBank.d210.s6.e0" charOffset="17-21"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s6.e1" charOffset="115-121"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s7" text="Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis.">
        <entity id="DDI-DrugBank.d210.s7.e0" charOffset="41-45"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s7.e1" charOffset="71-77"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s8" text="Therefore, in patients taking VIOXX, antiplatelet therapies should not be discontinued and should be considered in patients with an indication for cardiovascular prophylaxis.">
        <entity id="DDI-DrugBank.d210.s8.e0" charOffset="30-34"
            type="brand" text="VIOXX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s9" text="Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted.">
        <entity id="DDI-DrugBank.d210.s9.e0" charOffset="64-68"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s9.e1" charOffset="74-80"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s10" text="Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.">
        <entity id="DDI-DrugBank.d210.s10.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d210.s10.e1" charOffset="49-58"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d210.s10.e2" charOffset="103-111"
            type="drug" text="rofecoxib"/>
        <ddi id="DDI-DrugBank.d210.s10.d0" e1="DDI-DrugBank.d210.s10.e1"
            e2="DDI-DrugBank.d210.s10.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s11" text="These small changes are not clinically significant and no dose adjustment is necessary."/>
    <sentence id="DDI-DrugBank.d210.s12" text="Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose.">
        <entity id="DDI-DrugBank.d210.s12.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d210.s12.e1" charOffset="9-17"
            type="drug" text="Rofecoxib"/>
        <entity id="DDI-DrugBank.d210.s12.e2" charOffset="120-126"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s13" text="Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.">
        <entity id="DDI-DrugBank.d210.s13.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d210.s13.e1" charOffset="86-91"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d210.s13.e2" charOffset="130-139"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d210.s13.e3" charOffset="145-153"
            type="group" text="thiazides"/>
        <ddi id="DDI-DrugBank.d210.s13.d0" e1="DDI-DrugBank.d210.s13.e1"
            e2="DDI-DrugBank.d210.s13.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d210.s13.d1" e1="DDI-DrugBank.d210.s13.e1"
            e2="DDI-DrugBank.d210.s13.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s14" text="This response has been attributed to inhibition of renal prostaglandin synthesis."/>
    <sentence id="DDI-DrugBank.d210.s15" text="Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib.">
        <entity id="DDI-DrugBank.d210.s15.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d210.s15.e1" charOffset="14-25"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d210.s15.e2" charOffset="112-120"
            type="drug" text="rofecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s16" text="Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.">
        <entity id="DDI-DrugBank.d210.s16.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d210.s16.e1" charOffset="9-14"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d210.s16.e2" charOffset="53-59"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d210.s16.e3" charOffset="93-99"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d210.s16.d0" e1="DDI-DrugBank.d210.s16.e1"
            e2="DDI-DrugBank.d210.s16.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s17" text="In post-marketing experience there have been reports of increases in plasma lithium levels.">
        <entity id="DDI-DrugBank.d210.s17.e0" charOffset="76-82"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s18" text="Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.">
        <entity id="DDI-DrugBank.d210.s18.e0" charOffset="11-15"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s18.e1" charOffset="21-27"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d210.s18.e2" charOffset="111-117"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d210.s18.d0" e1="DDI-DrugBank.d210.s18.e0"
            e2="DDI-DrugBank.d210.s18.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s19" text="Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.">
        <entity id="DDI-DrugBank.d210.s19.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d210.s19.e1" charOffset="13-17"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s19.e2" charOffset="131-142"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d210.s19.e3" charOffset="205-216"
            type="drug" text="methotrexate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s20" text="At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.">
        <entity id="DDI-DrugBank.d210.s20.e0" charOffset="34-38"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s20.e1" charOffset="168-179"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d210.s20.d0" e1="DDI-DrugBank.d210.s20.e0"
            e2="DDI-DrugBank.d210.s20.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s21" text="At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).">
        <entity id="DDI-DrugBank.d210.s21.e0" charOffset="68-79"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d210.s21.e1" charOffset="123-134"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d210.s21.e2" charOffset="166-174"
            type="drug" text="rofecoxib"/>
        <entity id="DDI-DrugBank.d210.s21.e3" charOffset="186-197"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d210.s21.d0" e1="DDI-DrugBank.d210.s21.e1"
            e2="DDI-DrugBank.d210.s21.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s22" text="Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.">
        <entity id="DDI-DrugBank.d210.s22.e0" charOffset="23-34"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d210.s22.e1" charOffset="76-80"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s22.e2" charOffset="86-97"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d210.s22.d0" e1="DDI-DrugBank.d210.s22.e1"
            e2="DDI-DrugBank.d210.s22.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s23" text="Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone.">
        <entity id="DDI-DrugBank.d210.s23.e0" charOffset="5-18"
            type="group" text="Contraceptives"/>
        <entity id="DDI-DrugBank.d210.s23.e1" charOffset="20-28"
            type="drug" text="Rofecoxib"/>
        <entity id="DDI-DrugBank.d210.s23.e2" charOffset="102-118"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d210.s23.e3" charOffset="124-136"
            type="drug" text="norethindrone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s24" text="Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.">
        <entity id="DDI-DrugBank.d210.s24.e0" charOffset="0-9"
            type="drug" text="Prednisone"/>
        <entity id="DDI-DrugBank.d210.s24.e1" charOffset="11-22"
            type="drug" text="prednisolone"/>
        <entity id="DDI-DrugBank.d210.s24.e2" charOffset="25-33"
            type="drug" text="Rofecoxib"/>
        <entity id="DDI-DrugBank.d210.s24.e3" charOffset="107-118"
            type="drug" text="prednisolone"/>
        <entity id="DDI-DrugBank.d210.s24.e4" charOffset="123-132"
            type="drug" text="prednisone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s25" text="Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.">
        <entity id="DDI-DrugBank.d210.s25.e0" charOffset="0-7"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d210.s25.e1" charOffset="31-35"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s25.e2" charOffset="42-49"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d210.s25.e3" charOffset="145-153"
            type="drug" text="rofecoxib"/>
        <ddi id="DDI-DrugBank.d210.s25.d0" e1="DDI-DrugBank.d210.s25.e1"
            e2="DDI-DrugBank.d210.s25.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s26" text="Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism.">
        <entity id="DDI-DrugBank.d210.s26.e0" charOffset="45-49"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s26.e1" charOffset="113-117"
            type="brand" text="VIOXX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s27" text="Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.">
        <entity id="DDI-DrugBank.d210.s27.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d210.s27.e1" charOffset="13-17"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s27.e2" charOffset="91-102"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d210.s27.e3" charOffset="200-211"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d210.s27.d0" e1="DDI-DrugBank.d210.s27.e1"
            e2="DDI-DrugBank.d210.s27.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s28" text="Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.">
        <entity id="DDI-DrugBank.d210.s28.e0" charOffset="23-34"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d210.s28.e1" charOffset="97-101"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s28.e2" charOffset="149-160"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d210.s28.d0" e1="DDI-DrugBank.d210.s28.e1"
            e2="DDI-DrugBank.d210.s28.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s29" text="These data suggest that rofecoxib may produce a modest inhibition of cytochrome P450 (CYP) 1A2.">
        <entity id="DDI-DrugBank.d210.s29.e0" charOffset="24-32"
            type="drug" text="rofecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s30" text="Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton).">
        <entity id="DDI-DrugBank.d210.s30.e0" charOffset="107-119"
            type="drug" text="amitriptyline"/>
        <entity id="DDI-DrugBank.d210.s30.e1" charOffset="122-128"
            type="drug" text="tacrine"/>
        <entity id="DDI-DrugBank.d210.s30.e2" charOffset="135-142"
            type="drug" text="zileuton"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s31" text="Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.">
        <entity id="DDI-DrugBank.d210.s31.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d210.s31.e1" charOffset="118-122"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s31.e2" charOffset="154-161"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d210.s31.d0" e1="DDI-DrugBank.d210.s31.e1"
            e2="DDI-DrugBank.d210.s31.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s32" text="In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.">
        <entity id="DDI-DrugBank.d210.s32.e0" charOffset="71-78"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d210.s32.e1" charOffset="84-92"
            type="drug" text="rofecoxib"/>
        <ddi id="DDI-DrugBank.d210.s32.d0" e1="DDI-DrugBank.d210.s32.e0"
            e2="DDI-DrugBank.d210.s32.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d210.s33" text="In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.">
        <entity id="DDI-DrugBank.d210.s33.e0" charOffset="168-172"
            type="brand" text="VIOXX"/>
        <entity id="DDI-DrugBank.d210.s33.e1" charOffset="192-199"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d210.s33.d0" e1="DDI-DrugBank.d210.s33.e0"
            e2="DDI-DrugBank.d210.s33.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s0" text="DRUG INTERACTIONS"/>
    <sentence id="DDI-DrugBank.d124.s1" text="Several drug interaction studies have been completed with both INVIRASE and FORTOVASE.">
        <entity id="DDI-DrugBank.d124.s1.e0" charOffset="63-70"
            type="brand" text="INVIRASE"/>
        <entity id="DDI-DrugBank.d124.s1.e1" charOffset="76-84"
            type="brand" text="FORTOVASE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s2" text="Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE.">
        <entity id="DDI-DrugBank.d124.s2.e0" charOffset="48-56"
            type="brand" text="FORTOVASE"/>
        <entity id="DDI-DrugBank.d124.s2.e1" charOffset="84-91"
            type="brand" text="INVIRASE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s3" text="Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent.">
        <entity id="DDI-DrugBank.d124.s3.e0" charOffset="8-16"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d124.s3.e1" charOffset="102-110"
            type="drug" text="ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s4" text="The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism.">
        <entity id="DDI-DrugBank.d124.s4.e0" charOffset="18-27"
            type="drug" text="saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s5" text="Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp).">
        <entity id="DDI-DrugBank.d124.s5.e0" charOffset="14-23"
            type="drug" text="saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s6" text="Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir.">
        <entity id="DDI-DrugBank.d124.s6.e0" charOffset="83-92"
            type="drug" text="saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s7" text="Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp.">
        <entity id="DDI-DrugBank.d124.s7.e0" charOffset="11-20"
            type="drug" text="saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s8" text="Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS."/>
    <sentence id="DDI-DrugBank.d124.s9" text="Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below.">
        <entity id="DDI-DrugBank.d124.s9.e0" charOffset="68-75"
            type="brand" text="INVIRASE"/>
        <entity id="DDI-DrugBank.d124.s9.e1" charOffset="81-89"
            type="drug" text="ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s10" text="These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy."/>
    <sentence id="DDI-DrugBank.d124.s11" text="With some agents, the metabolism may be induced, resulting in decreased concentrations."/>
    <sentence id="DDI-DrugBank.d124.s12" text="Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir">
        <entity id="DDI-DrugBank.d124.s12.e0" charOffset="45-52"
            type="brand" text="INVIRASE"/>
        <entity id="DDI-DrugBank.d124.s12.e1" charOffset="54-62"
            type="drug" text="Ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s13" text="Drug Class: Drug Name Clinical Comment"/>
    <sentence id="DDI-DrugBank.d124.s14" text="Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.">
        <entity id="DDI-DrugBank.d124.s14.e0" charOffset="0-14"
            type="group" text="Antiarrhythmics"/>
        <entity id="DDI-DrugBank.d124.s14.e1" charOffset="17-26"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d124.s14.e2" charOffset="29-36"
            type="drug" text="bepridil"/>
        <entity id="DDI-DrugBank.d124.s14.e3" charOffset="39-48"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d124.s14.e4" charOffset="51-61"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d124.s14.e5" charOffset="64-72"
            type="drug" text="quinidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s15" text="Antihistamines: astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.">
        <entity id="DDI-DrugBank.d124.s15.e0" charOffset="0-13"
            type="drug" text="Antihistamines"/>
        <entity id="DDI-DrugBank.d124.s15.e1" charOffset="16-25"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d124.s15.e2" charOffset="29-39"
            type="drug" text="terfenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s16" text="Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.">
        <entity id="DDI-DrugBank.d124.s16.e0" charOffset="0-16"
            type="group" text="Ergot Derivatives"/>
        <entity id="DDI-DrugBank.d124.s16.e1" charOffset="19-35"
            type="drug" text="Dihydroergotamine"/>
        <entity id="DDI-DrugBank.d124.s16.e2" charOffset="38-47"
            type="drug" text="ergonovine"/>
        <entity id="DDI-DrugBank.d124.s16.e3" charOffset="50-59"
            type="drug" text="ergotamine"/>
        <entity id="DDI-DrugBank.d124.s16.e4" charOffset="62-77"
            type="drug" text="methylergonovine"/>
        <entity id="DDI-DrugBank.d124.s16.e5" charOffset="169-173"
            type="group" text="ergot"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s17" text="Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.">
        <entity id="DDI-DrugBank.d124.s17.e0" charOffset="0-23"
            type="group" text="Antimycobacterial Agents"/>
        <entity id="DDI-DrugBank.d124.s17.e1" charOffset="26-33"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d124.s17.e2" charOffset="99-108"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d124.s17.e3" charOffset="116-129"
            type="group" text="antiretroviral"/>
        <entity id="DDI-DrugBank.d124.s17.e4" charOffset="176-185"
            type="drug" text="saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s18" text="Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.">
        <entity id="DDI-DrugBank.d124.s18.e0" charOffset="64-73"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d124.s18.e1" charOffset="76-84"
            type="brand" text="FORTOVASE"/>
        <entity id="DDI-DrugBank.d124.s18.e2" charOffset="99-116"
            type="group" text="protease inhibitor"/>
        <entity id="DDI-DrugBank.d124.s18.e3" charOffset="147-156"
            type="drug" text="saquinavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s19" text="No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules.">
        <entity id="DDI-DrugBank.d124.s19.e0" charOffset="50-57"
            type="brand" text="INVIRASE"/>
        <entity id="DDI-DrugBank.d124.s19.e1" charOffset="59-67"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d124.s19.e2" charOffset="72-80"
            type="brand" text="FORTOVASE"/>
        <entity id="DDI-DrugBank.d124.s19.e3" charOffset="82-90"
            type="drug" text="ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s20" text="GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.">
        <entity id="DDI-DrugBank.d124.s20.e0" charOffset="19-27"
            type="drug" text="cisapride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s21" text="Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors.">
        <entity id="DDI-DrugBank.d124.s21.e0" charOffset="147-154"
            type="brand" text="INVIRASE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s22" text="HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.">
        <entity id="DDI-DrugBank.d124.s22.e0" charOffset="0-27"
            type="group" text="HMG-CoA Reductase Inhibitors"/>
        <entity id="DDI-DrugBank.d124.s22.e1" charOffset="30-39"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d124.s22.e2" charOffset="42-52"
            type="drug" text="simvastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s23" text="Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.">
        <entity id="DDI-DrugBank.d124.s23.e0" charOffset="0-8"
            type="group" text="Sedatives"/>
        <entity id="DDI-DrugBank.d124.s23.e1" charOffset="10-18"
            type="group" text="Hypnotics"/>
        <entity id="DDI-DrugBank.d124.s23.e2" charOffset="21-29"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d124.s23.e3" charOffset="32-40"
            type="drug" text="midazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s24" text="* No longer marketed in the US."/>
    <sentence id="DDI-DrugBank.d124.s25" text="Drugs That Are Mainly Metabolized by CYP3A4"/>
    <sentence id="DDI-DrugBank.d124.s26" text="Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;">
        <entity id="DDI-DrugBank.d124.s26.e0" charOffset="122-145"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d124.s26.e1" charOffset="148-154"
            type="drug" text="dapsone"/>
        <entity id="DDI-DrugBank.d124.s26.e2" charOffset="157-168"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d124.s26.e3" charOffset="171-177"
            type="drug" text="quinine"/>
        <entity id="DDI-DrugBank.d124.s26.e4" charOffset="180-189"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d124.s26.e5" charOffset="192-200"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d124.s26.e6" charOffset="203-210"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d124.s26.e7" charOffset="213-222"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d124.s26.e8" charOffset="225-236"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d124.s26.e9" charOffset="239-255"
            type="group" text="ergot derivatives"/>
        <entity id="DDI-DrugBank.d124.s26.e10" charOffset="258-265"
            type="drug" text="pimozide"/>
        <entity id="DDI-DrugBank.d124.s26.e11" charOffset="268-280"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d124.s26.e12" charOffset="283-290"
            type="drug" text="fentanyl"/>
        <entity id="DDI-DrugBank.d124.s26.e13" charOffset="293-302"
            type="drug" text="alfentanyl"/>
        <entity id="DDI-DrugBank.d124.s26.e14" charOffset="305-314"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d124.s26.e15" charOffset="321-329"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d124.s26.e16" charOffset="397-406"
            type="drug" text="saquinavir"/>
        <ddi id="DDI-DrugBank.d124.s26.d0" e1="DDI-DrugBank.d124.s26.e0"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d1" e1="DDI-DrugBank.d124.s26.e1"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d2" e1="DDI-DrugBank.d124.s26.e2"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d3" e1="DDI-DrugBank.d124.s26.e3"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d4" e1="DDI-DrugBank.d124.s26.e4"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d5" e1="DDI-DrugBank.d124.s26.e5"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d6" e1="DDI-DrugBank.d124.s26.e6"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d7" e1="DDI-DrugBank.d124.s26.e7"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d8" e1="DDI-DrugBank.d124.s26.e8"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d9" e1="DDI-DrugBank.d124.s26.e9"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d10"
            e1="DDI-DrugBank.d124.s26.e10"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d11"
            e1="DDI-DrugBank.d124.s26.e11"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d12"
            e1="DDI-DrugBank.d124.s26.e12"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d13"
            e1="DDI-DrugBank.d124.s26.e13"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d14"
            e1="DDI-DrugBank.d124.s26.e14"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s26.d15"
            e1="DDI-DrugBank.d124.s26.e15"
            e2="DDI-DrugBank.d124.s26.e16" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s27" text="therefore, these combinations should be used with caution."/>
    <sentence id="DDI-DrugBank.d124.s28" text="Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.">
        <entity id="DDI-DrugBank.d124.s28.e0" charOffset="6-13"
            type="brand" text="INVIRASE"/>
        <entity id="DDI-DrugBank.d124.s28.e1" charOffset="38-46"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d124.s28.e2" charOffset="53-61"
            type="drug" text="ritonavir"/>
        <ddi id="DDI-DrugBank.d124.s28.d0" e1="DDI-DrugBank.d124.s28.e0"
            e2="DDI-DrugBank.d124.s28.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d124.s29" text="Inducers of CYP3A4"/>
    <sentence id="DDI-DrugBank.d124.s30" text="Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.">
        <entity id="DDI-DrugBank.d124.s30.e0" charOffset="72-84"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d124.s30.e1" charOffset="87-95"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d124.s30.e2" charOffset="98-110"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d124.s30.e3" charOffset="113-125"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d124.s30.e4" charOffset="169-178"
            type="drug" text="saquinavir"/>
        <ddi id="DDI-DrugBank.d124.s30.d0" e1="DDI-DrugBank.d124.s30.e0"
            e2="DDI-DrugBank.d124.s30.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s30.d1" e1="DDI-DrugBank.d124.s30.e1"
            e2="DDI-DrugBank.d124.s30.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s30.d2" e1="DDI-DrugBank.d124.s30.e2"
            e2="DDI-DrugBank.d124.s30.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d124.s30.d3" e1="DDI-DrugBank.d124.s30.e3"
            e2="DDI-DrugBank.d124.s30.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d65.s0" text="Sulfacetamide preparations are incompatible with silver preparations.">
        <entity id="DDI-DrugBank.d65.s0.e0" charOffset="0-12"
            type="drug" text="Sulfacetamide"/>
        <entity id="DDI-DrugBank.d65.s0.e1" charOffset="49-54"
            type="drug" text="silver"/>
        <ddi id="DDI-DrugBank.d65.s0.d0" e1="DDI-DrugBank.d65.s0.e0"
            e2="DDI-DrugBank.d65.s0.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s0" text="Interations"/>
    <sentence id="DDI-DrugBank.d179.s1" text="Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or">
        <entity id="DDI-DrugBank.d179.s1.e0" charOffset="0-12"
            type="drug" text="Sulfapyridine"/>
        <entity id="DDI-DrugBank.d179.s1.e1" charOffset="56-68"
            type="drug" text="Acetaminophen"/>
        <entity id="DDI-DrugBank.d179.s1.e2" charOffset="77-83"
            type="brand" text="Tylenol"/>
        <ddi id="DDI-DrugBank.d179.s1.d0" e1="DDI-DrugBank.d179.s1.e0"
            e2="DDI-DrugBank.d179.s1.e1" type="int"/>
        <ddi id="DDI-DrugBank.d179.s1.d1" e1="DDI-DrugBank.d179.s1.e0"
            e2="DDI-DrugBank.d179.s1.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s2" text="- Amiodarone (e.g., Cordarone) or">
        <entity id="DDI-DrugBank.d179.s2.e0" charOffset="2-11"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d179.s2.e1" charOffset="20-28"
            type="brand" text="Cordarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s3" text="- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or">
        <entity id="DDI-DrugBank.d179.s3.e0" charOffset="2-18"
            type="group" text="Anabolic steroids"/>
        <entity id="DDI-DrugBank.d179.s3.e1" charOffset="21-30"
            type="drug" text="nandrolone"/>
        <entity id="DDI-DrugBank.d179.s3.e2" charOffset="39-46"
            type="brand" text="Anabolin"/>
        <entity id="DDI-DrugBank.d179.s3.e3" charOffset="50-60"
            type="drug" text="oxandrolone"/>
        <entity id="DDI-DrugBank.d179.s3.e4" charOffset="69-74"
            type="brand" text="Anavar"/>
        <entity id="DDI-DrugBank.d179.s3.e5" charOffset="78-89"
            type="drug" text="oxymetholone"/>
        <entity id="DDI-DrugBank.d179.s3.e6" charOffset="98-104"
            type="brand" text="Anadrol"/>
        <entity id="DDI-DrugBank.d179.s3.e7" charOffset="108-117"
            type="drug" text="stanozolol"/>
        <entity id="DDI-DrugBank.d179.s3.e8" charOffset="126-133"
            type="brand" text="Winstrol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s4" text="- Androgens (male hormones) or">
        <entity id="DDI-DrugBank.d179.s4.e0" charOffset="2-10"
            type="group" text="Androgens"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s5" text="- Antithyroid agents (medicine for overactive thyroid) or">
        <entity id="DDI-DrugBank.d179.s5.e0" charOffset="2-19"
            type="group" text="Antithyroid agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s6" text="- Carbamazepine (e.g., Tegretol) or">
        <entity id="DDI-DrugBank.d179.s6.e0" charOffset="2-14"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d179.s6.e1" charOffset="23-30"
            type="brand" text="Tegretol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s7" text="- Carmustine (e.g., BiCNU) or">
        <entity id="DDI-DrugBank.d179.s7.e0" charOffset="2-11"
            type="drug" text="Carmustine"/>
        <entity id="DDI-DrugBank.d179.s7.e1" charOffset="20-24"
            type="brand" text="BiCNU"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s8" text="- Chloroquine (e.g., Aralen) or">
        <entity id="DDI-DrugBank.d179.s8.e0" charOffset="2-12"
            type="drug" text="Chloroquine"/>
        <entity id="DDI-DrugBank.d179.s8.e1" charOffset="21-26"
            type="brand" text="Aralen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s9" text="- Dantrolene (e.g., Dantrium) or">
        <entity id="DDI-DrugBank.d179.s9.e0" charOffset="2-11"
            type="drug" text="Dantrolene"/>
        <entity id="DDI-DrugBank.d179.s9.e1" charOffset="20-27"
            type="brand" text="Dantrium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s10" text="- Daunorubicin (e.g., Cerubidine) or">
        <entity id="DDI-DrugBank.d179.s10.e0" charOffset="2-13"
            type="drug" text="Daunorubicin"/>
        <entity id="DDI-DrugBank.d179.s10.e1" charOffset="22-31"
            type="brand" text="Cerubidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s11" text="- Disulfiram (e.g., Antabuse) or">
        <entity id="DDI-DrugBank.d179.s11.e0" charOffset="2-11"
            type="drug" text="Disulfiram"/>
        <entity id="DDI-DrugBank.d179.s11.e1" charOffset="20-27"
            type="brand" text="Antabuse"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s12" text="- Divalproex (e.g., Depakote) or">
        <entity id="DDI-DrugBank.d179.s12.e0" charOffset="2-11"
            type="drug" text="Divalproex"/>
        <entity id="DDI-DrugBank.d179.s12.e1" charOffset="20-27"
            type="brand" text="Depakote"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s13" text="- Estrogens (female hormones) or">
        <entity id="DDI-DrugBank.d179.s13.e0" charOffset="2-10"
            type="group" text="Estrogens"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s14" text="- Etretinate (e.g., Tegison) or">
        <entity id="DDI-DrugBank.d179.s14.e0" charOffset="2-11"
            type="drug" text="Etretinate"/>
        <entity id="DDI-DrugBank.d179.s14.e1" charOffset="20-26"
            type="brand" text="Tegison"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s15" text="- Gold salts (medicine for arthritis) or">
        <entity id="DDI-DrugBank.d179.s15.e0" charOffset="2-5"
            type="drug" text="Gold"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s16" text="- Hydroxychloroquine (e.g., Plaquenil) or">
        <entity id="DDI-DrugBank.d179.s16.e0" charOffset="2-19"
            type="drug" text="Hydroxychloroquine"/>
        <entity id="DDI-DrugBank.d179.s16.e1" charOffset="28-36"
            type="brand" text="Plaquenil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s17" text="- Mercaptopurine (e.g., Purinethol) or">
        <entity id="DDI-DrugBank.d179.s17.e0" charOffset="2-15"
            type="drug" text="Mercaptopurine"/>
        <entity id="DDI-DrugBank.d179.s17.e1" charOffset="24-33"
            type="brand" text="Purinethol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s18" text="- Naltrexone (e.g., Trexan) (with long-term, high-dose use) or">
        <entity id="DDI-DrugBank.d179.s18.e0" charOffset="2-11"
            type="drug" text="Naltrexone"/>
        <entity id="DDI-DrugBank.d179.s18.e1" charOffset="20-25"
            type="brand" text="Trexan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s19" text="- Oral contraceptives (birth control pills) containing estrogen or">
        <entity id="DDI-DrugBank.d179.s19.e0" charOffset="7-20"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d179.s19.e1" charOffset="55-62"
            type="group" text="estrogen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s20" text="- Other anti-infectives by mouth or by injection (medicine for infection) or">
        <entity id="DDI-DrugBank.d179.s20.e0" charOffset="8-22"
            type="group" text="anti-infectives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s21" text="- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or">
        <entity id="DDI-DrugBank.d179.s21.e0" charOffset="2-15"
            type="group" text="Phenothiazines"/>
        <entity id="DDI-DrugBank.d179.s21.e1" charOffset="18-31"
            type="drug" text="acetophenazine"/>
        <entity id="DDI-DrugBank.d179.s21.e2" charOffset="40-45"
            type="brand" text="Tindal"/>
        <entity id="DDI-DrugBank.d179.s21.e3" charOffset="49-62"
            type="drug" text="chlorpromazine"/>
        <entity id="DDI-DrugBank.d179.s21.e4" charOffset="71-79"
            type="brand" text="Thorazine"/>
        <entity id="DDI-DrugBank.d179.s21.e5" charOffset="83-94"
            type="drug" text="fluphenazine"/>
        <entity id="DDI-DrugBank.d179.s21.e6" charOffset="103-110"
            type="brand" text="Prolixin"/>
        <entity id="DDI-DrugBank.d179.s21.e7" charOffset="114-125"
            type="brand" text="mesoridazine"/>
        <entity id="DDI-DrugBank.d179.s21.e8" charOffset="134-141"
            type="brand" text="Serentil"/>
        <entity id="DDI-DrugBank.d179.s21.e9" charOffset="145-156"
            type="drug" text="perphenazine"/>
        <entity id="DDI-DrugBank.d179.s21.e10" charOffset="165-172"
            type="brand" text="Trilafon"/>
        <entity id="DDI-DrugBank.d179.s21.e11" charOffset="176-191"
            type="drug" text="prochlorperazine"/>
        <entity id="DDI-DrugBank.d179.s21.e12" charOffset="200-208"
            type="brand" text="Compazine"/>
        <entity id="DDI-DrugBank.d179.s21.e13" charOffset="212-220"
            type="drug" text="promazine"/>
        <entity id="DDI-DrugBank.d179.s21.e14" charOffset="229-235"
            type="brand" text="Sparine"/>
        <entity id="DDI-DrugBank.d179.s21.e15" charOffset="239-250"
            type="drug" text="promethazine"/>
        <entity id="DDI-DrugBank.d179.s21.e16" charOffset="259-267"
            type="brand" text="Phenergan"/>
        <entity id="DDI-DrugBank.d179.s21.e17" charOffset="271-282"
            type="drug" text="thioridazine"/>
        <entity id="DDI-DrugBank.d179.s21.e18" charOffset="291-298"
            type="brand" text="Mellaril"/>
        <entity id="DDI-DrugBank.d179.s21.e19" charOffset="302-316"
            type="drug" text="trifluoperazine"/>
        <entity id="DDI-DrugBank.d179.s21.e20" charOffset="325-333"
            type="brand" text="Stelazine"/>
        <entity id="DDI-DrugBank.d179.s21.e21" charOffset="337-351"
            type="drug" text="triflupromazine"/>
        <entity id="DDI-DrugBank.d179.s21.e22" charOffset="360-366"
            type="brand" text="Vesprin"/>
        <entity id="DDI-DrugBank.d179.s21.e23" charOffset="370-381"
            type="drug" text="trimeprazine"/>
        <entity id="DDI-DrugBank.d179.s21.e24" charOffset="390-396"
            type="brand" text="Temaril"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s22" text="- Plicamycin (e.g., Mithracin) or">
        <entity id="DDI-DrugBank.d179.s22.e0" charOffset="2-11"
            type="drug" text="Plicamycin"/>
        <entity id="DDI-DrugBank.d179.s22.e1" charOffset="20-28"
            type="brand" text="Mithracin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s23" text="- Valproic acid (e.g., Depakene) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the liver">
        <entity id="DDI-DrugBank.d179.s23.e0" charOffset="2-14"
            type="drug" text="Valproic acid"/>
        <entity id="DDI-DrugBank.d179.s23.e1" charOffset="23-30"
            type="brand" text="Depakene"/>
        <entity id="DDI-DrugBank.d179.s23.e2" charOffset="40-52"
            type="drug" text="sulfapyridine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s24" text="- Acetohydroxamic acid (e.g., Lithostat) or">
        <entity id="DDI-DrugBank.d179.s24.e0" charOffset="2-21"
            type="drug" text="Acetohydroxamic acid"/>
        <entity id="DDI-DrugBank.d179.s24.e1" charOffset="30-38"
            type="brand" text="Lithostat"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s25" text="- Dapsone or">
        <entity id="DDI-DrugBank.d179.s25.e0" charOffset="2-8"
            type="drug" text="Dapsone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s26" text="- Furazolidone (e.g., Furoxone) or">
        <entity id="DDI-DrugBank.d179.s26.e0" charOffset="2-13"
            type="drug" text="Furazolidone"/>
        <entity id="DDI-DrugBank.d179.s26.e1" charOffset="22-29"
            type="brand" text="Furoxone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s27" text="- Nitrofurantoin (e.g., Furadantin) or">
        <entity id="DDI-DrugBank.d179.s27.e0" charOffset="2-15"
            type="drug" text="Nitrofurantoin"/>
        <entity id="DDI-DrugBank.d179.s27.e1" charOffset="24-33"
            type="brand" text="Furadantin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s28" text="- Primaquine or">
        <entity id="DDI-DrugBank.d179.s28.e0" charOffset="2-11"
            type="drug" text="Primaquine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s29" text="- Procainamide (e.g., Pronestyl) or">
        <entity id="DDI-DrugBank.d179.s29.e0" charOffset="2-13"
            type="drug" text="Procainamide"/>
        <entity id="DDI-DrugBank.d179.s29.e1" charOffset="22-30"
            type="brand" text="Pronestyl"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s30" text="- Quinidine (e.g., Quinidex) or">
        <entity id="DDI-DrugBank.d179.s30.e0" charOffset="2-10"
            type="drug" text="Quinidine"/>
        <entity id="DDI-DrugBank.d179.s30.e1" charOffset="19-26"
            type="brand" text="Quinidex"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s31" text="- Quinine (e.g., Quinamm) or">
        <entity id="DDI-DrugBank.d179.s31.e0" charOffset="2-8"
            type="drug" text="Quinine"/>
        <entity id="DDI-DrugBank.d179.s31.e1" charOffset="17-23"
            type="brand" text="Quinamm"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s32" text="- Sulfoxone (e.g., Diasone) or">
        <entity id="DDI-DrugBank.d179.s32.e0" charOffset="2-10"
            type="drug" text="Sulfoxone"/>
        <entity id="DDI-DrugBank.d179.s32.e1" charOffset="19-25"
            type="brand" text="Diasone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s33" text="- Vitamin K (e.g., AquaMEPHYTON, Synkayvite) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood">
        <entity id="DDI-DrugBank.d179.s33.e0" charOffset="2-10"
            type="group" text="Vitamin K"/>
        <entity id="DDI-DrugBank.d179.s33.e1" charOffset="19-30"
            type="brand" text="AquaMEPHYTON"/>
        <entity id="DDI-DrugBank.d179.s33.e2" charOffset="33-42"
            type="brand" text="Synkayvite"/>
        <entity id="DDI-DrugBank.d179.s33.e3" charOffset="52-64"
            type="drug" text="sulfapyridine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s34" text="- Anticoagulants (blood thinners) or">
        <entity id="DDI-DrugBank.d179.s34.e0" charOffset="2-15"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d179.s34.e1" charOffset="18-30"
            type="group" text="blood thinner"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s35" text="- Ethotoin (e.g., Peganone) or">
        <entity id="DDI-DrugBank.d179.s35.e0" charOffset="2-9"
            type="drug" text="Ethotoin"/>
        <entity id="DDI-DrugBank.d179.s35.e1" charOffset="18-25"
            type="brand" text="Peganone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s36" text="- Mephenytoin (e.g., Mesantoin) Use of sulfapyridine with these medicines may increase the chance of side effects of these medicines">
        <entity id="DDI-DrugBank.d179.s36.e0" charOffset="2-12"
            type="drug" text="Mephenytoin"/>
        <entity id="DDI-DrugBank.d179.s36.e1" charOffset="21-29"
            type="brand" text="Mesantoin"/>
        <entity id="DDI-DrugBank.d179.s36.e2" charOffset="39-51"
            type="drug" text="sulfapyridine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s37" text="- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics">
        <entity id="DDI-DrugBank.d179.s37.e0" charOffset="2-14"
            type="group" text="Antidiabetics"/>
        <entity id="DDI-DrugBank.d179.s37.e1" charOffset="72-84"
            type="group" text="antidiabetics"/>
        <entity id="DDI-DrugBank.d179.s37.e2" charOffset="91-103"
            type="drug" text="sulfapyridine"/>
        <entity id="DDI-DrugBank.d179.s37.e3" charOffset="197-209"
            type="group" text="antidiabetics"/>
        <ddi id="DDI-DrugBank.d179.s37.d0" e1="DDI-DrugBank.d179.s37.e1"
            e2="DDI-DrugBank.d179.s37.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s38" text="- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate">
        <entity id="DDI-DrugBank.d179.s38.e0" charOffset="2-13"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d179.s38.e1" charOffset="22-27"
            type="brand" text="Mexate"/>
        <entity id="DDI-DrugBank.d179.s38.e2" charOffset="37-48"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d179.s38.e3" charOffset="55-67"
            type="drug" text="sulfapyridine"/>
        <entity id="DDI-DrugBank.d179.s38.e4" charOffset="156-167"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d179.s38.d0" e1="DDI-DrugBank.d179.s38.e2"
            e2="DDI-DrugBank.d179.s38.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s39" text="- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood">
        <entity id="DDI-DrugBank.d179.s39.e0" charOffset="2-11"
            type="drug" text="Methyldopa"/>
        <entity id="DDI-DrugBank.d179.s39.e1" charOffset="20-26"
            type="brand" text="Aldomet"/>
        <entity id="DDI-DrugBank.d179.s39.e2" charOffset="36-45"
            type="drug" text="methyldopa"/>
        <entity id="DDI-DrugBank.d179.s39.e3" charOffset="52-64"
            type="drug" text="sulfapyridine"/>
        <ddi id="DDI-DrugBank.d179.s39.d0" e1="DDI-DrugBank.d179.s39.e2"
            e2="DDI-DrugBank.d179.s39.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d179.s40" text="- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin">
        <entity id="DDI-DrugBank.d179.s40.e0" charOffset="2-10"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d179.s40.e1" charOffset="19-26"
            type="brand" text="Dilantin"/>
        <entity id="DDI-DrugBank.d179.s40.e2" charOffset="36-44"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d179.s40.e3" charOffset="51-63"
            type="drug" text="sulfapyridine"/>
        <entity id="DDI-DrugBank.d179.s40.e4" charOffset="152-160"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d179.s40.d0" e1="DDI-DrugBank.d179.s40.e2"
            e2="DDI-DrugBank.d179.s40.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s0" text="In evaluating the potential for interactions among co-administered antiepilepsy drugs (AEDs), whether or not an AED induces or does not induce metabolic enzymes is an important consideration.">
        <entity id="DDI-DrugBank.d277.s0.e0" charOffset="87-90"
            type="group" text="AEDs"/>
        <entity id="DDI-DrugBank.d277.s0.e1" charOffset="112-114"
            type="group" text="AED"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s1" text="Phenytoin, phenobarbital and carbamazepine are ge nerally classified as enzyme inducers;">
        <entity id="DDI-DrugBank.d277.s1.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d277.s1.e1" charOffset="11-23"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d277.s1.e2" charOffset="29-41"
            type="drug" text="carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s2" text="valproate and gabapentin are not.">
        <entity id="DDI-DrugBank.d277.s2.e0" charOffset="0-8"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d277.s2.e1" charOffset="14-23"
            type="drug" text="gabapentin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s3" text="GABITRIL is considered to be a non-enzyme inducing AED.">
        <entity id="DDI-DrugBank.d277.s3.e0" charOffset="0-7"
            type="brand" text="GABITRIL"/>
        <entity id="DDI-DrugBank.d277.s3.e1" charOffset="51-53"
            type="group" text="AED"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s4" text="The drug interaction data described in this section were obtained from studies involving either healthy subjects or patients with epilepsy."/>
    <sentence id="DDI-DrugBank.d277.s5" text="Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.">
        <entity id="DDI-DrugBank.d277.s5.e0" charOffset="11-18"
            type="brand" text="GABITRIL"/>
        <entity id="DDI-DrugBank.d277.s5.e1" charOffset="49-52"
            type="group" text="AEDs"/>
        <entity id="DDI-DrugBank.d277.s5.e2" charOffset="57-65"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d277.s5.e3" charOffset="68-76"
            type="drug" text="Tiagabine"/>
        <entity id="DDI-DrugBank.d277.s5.e4" charOffset="137-145"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s6" text="Carbamazepine: Tiagabine had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.">
        <entity id="DDI-DrugBank.d277.s6.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d277.s6.e1" charOffset="15-23"
            type="drug" text="Tiagabine"/>
        <entity id="DDI-DrugBank.d277.s6.e2" charOffset="84-96"
            type="drug" text="carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s7" text="Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.">
        <entity id="DDI-DrugBank.d277.s7.e0" charOffset="0-8"
            type="drug" text="Valproate"/>
        <entity id="DDI-DrugBank.d277.s7.e1" charOffset="11-19"
            type="drug" text="Tiagabine"/>
        <entity id="DDI-DrugBank.d277.s7.e2" charOffset="74-82"
            type="drug" text="valproate"/>
        <ddi id="DDI-DrugBank.d277.s7.d0" e1="DDI-DrugBank.d277.s7.e1"
            e2="DDI-DrugBank.d277.s7.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s8" text="Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone.">
        <entity id="DDI-DrugBank.d277.s8.e0" charOffset="0-12"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d277.s8.e1" charOffset="17-25"
            type="drug" text="Primidone"/>
        <entity id="DDI-DrugBank.d277.s8.e2" charOffset="109-117"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s8.e3" charOffset="142-154"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d277.s8.e4" charOffset="159-167"
            type="drug" text="primidone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s9" text="The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.">
        <entity id="DDI-DrugBank.d277.s9.e0" charOffset="16-24"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s9.e1" charOffset="123-135"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d277.s9.e2" charOffset="140-148"
            type="drug" text="primidone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s10" text="Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.">
        <entity id="DDI-DrugBank.d277.s10.e0" charOffset="37-40"
            type="group" text="AEDs"/>
        <entity id="DDI-DrugBank.d277.s10.e1" charOffset="46-53"
            type="brand" text="GABITRIL"/>
        <entity id="DDI-DrugBank.d277.s10.e2" charOffset="57-69"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d277.s10.e3" charOffset="122-130"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s10.e4" charOffset="176-188"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d277.s10.e5" charOffset="229-232"
            type="group" text="AEDs"/>
        <ddi id="DDI-DrugBank.d277.s10.d0" e1="DDI-DrugBank.d277.s10.e3"
            e2="DDI-DrugBank.d277.s10.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s11" text="Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.">
        <entity id="DDI-DrugBank.d277.s11.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d277.s11.e1" charOffset="61-69"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s11.e2" charOffset="115-123"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d277.s11.e3" charOffset="164-167"
            type="group" text="AEDs"/>
        <ddi id="DDI-DrugBank.d277.s11.d0" e1="DDI-DrugBank.d277.s11.e1"
            e2="DDI-DrugBank.d277.s11.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s12" text="Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.">
        <entity id="DDI-DrugBank.d277.s12.e0" charOffset="0-12"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d277.s12.e1" charOffset="15-23"
            type="drug" text="Primidone"/>
        <entity id="DDI-DrugBank.d277.s12.e2" charOffset="77-85"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s12.e3" charOffset="131-143"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d277.s12.e4" charOffset="146-154"
            type="drug" text="primidone"/>
        <entity id="DDI-DrugBank.d277.s12.e5" charOffset="195-198"
            type="group" text="AEDs"/>
        <ddi id="DDI-DrugBank.d277.s12.d0" e1="DDI-DrugBank.d277.s12.e2"
            e2="DDI-DrugBank.d277.s12.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d277.s12.d1" e1="DDI-DrugBank.d277.s12.e2"
            e2="DDI-DrugBank.d277.s12.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s13" text="Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.">
        <entity id="DDI-DrugBank.d277.s13.e0" charOffset="0-8"
            type="drug" text="Valproate"/>
        <entity id="DDI-DrugBank.d277.s13.e1" charOffset="27-35"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s13.e2" charOffset="56-64"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d277.s13.e3" charOffset="95-103"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s13.e4" charOffset="127-135"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d277.s13.e5" charOffset="161-169"
            type="drug" text="tiagabine"/>
        <ddi id="DDI-DrugBank.d277.s13.d0" e1="DDI-DrugBank.d277.s13.e4"
            e2="DDI-DrugBank.d277.s13.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s14" text="The clinical relevance of this in vitro finding is unknown."/>
    <sentence id="DDI-DrugBank.d277.s15" text="Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.">
        <entity id="DDI-DrugBank.d277.s15.e0" charOffset="15-22"
            type="brand" text="GABITRIL"/>
        <entity id="DDI-DrugBank.d277.s15.e1" charOffset="43-52"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d277.s15.e2" charOffset="77-86"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d277.s15.e3" charOffset="120-128"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s15.e4" charOffset="159-167"
            type="drug" text="tiagabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s16" text="Theophylline: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state.">
        <entity id="DDI-DrugBank.d277.s16.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d277.s16.e1" charOffset="37-45"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s16.e2" charOffset="86-97"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s17" text="Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.">
        <entity id="DDI-DrugBank.d277.s17.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d277.s17.e1" charOffset="91-100"
            type="drug" text="R-warfarin"/>
        <entity id="DDI-DrugBank.d277.s17.e2" charOffset="105-114"
            type="drug" text="S-warfarin"/>
        <entity id="DDI-DrugBank.d277.s17.e3" charOffset="137-145"
            type="drug" text="tiagabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s18" text="Prothrombin times were not affected by tiagabine.">
        <entity id="DDI-DrugBank.d277.s18.e0" charOffset="39-47"
            type="drug" text="tiagabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s19" text="Digoxin: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.">
        <entity id="DDI-DrugBank.d277.s19.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d277.s19.e1" charOffset="39-47"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s19.e2" charOffset="101-107"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d277.s19.e3" charOffset="149-155"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s20" text="Ethanol or Triazolam: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.">
        <entity id="DDI-DrugBank.d277.s20.e0" charOffset="0-6"
            type="drug" text="Ethanol"/>
        <entity id="DDI-DrugBank.d277.s20.e1" charOffset="11-19"
            type="drug" text="Triazolam"/>
        <entity id="DDI-DrugBank.d277.s20.e2" charOffset="90-98"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d277.s20.e3" charOffset="115-123"
            type="drug" text="tiagabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s21" text="The pharmacokinetics of ethanol were not affected by multiple-dose administration of tiagabine.">
        <entity id="DDI-DrugBank.d277.s21.e0" charOffset="24-30"
            type="drug" text="ethanol"/>
        <entity id="DDI-DrugBank.d277.s21.e1" charOffset="85-93"
            type="drug" text="tiagabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s22" text="Tiagabine has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or alcohol.">
        <entity id="DDI-DrugBank.d277.s22.e0" charOffset="0-8"
            type="drug" text="Tiagabine"/>
        <entity id="DDI-DrugBank.d277.s22.e1" charOffset="105-111"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s23" text="Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.">
        <entity id="DDI-DrugBank.d277.s23.e0" charOffset="87-93"
            type="drug" text="ethanol"/>
        <entity id="DDI-DrugBank.d277.s23.e1" charOffset="98-106"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d277.s23.e2" charOffset="154-162"
            type="drug" text="tiagabine"/>
        <ddi id="DDI-DrugBank.d277.s23.d0" e1="DDI-DrugBank.d277.s23.e0"
            e2="DDI-DrugBank.d277.s23.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d277.s23.d1" e1="DDI-DrugBank.d277.s23.e1"
            e2="DDI-DrugBank.d277.s23.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s24" text="Oral Contraceptives: Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.">
        <entity id="DDI-DrugBank.d277.s24.e0" charOffset="5-18"
            type="group" text="Contraceptives"/>
        <entity id="DDI-DrugBank.d277.s24.e1" charOffset="53-61"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s24.e2" charOffset="129-142"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s25" text="Antipyrine : Antipyrine pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.">
        <entity id="DDI-DrugBank.d277.s25.e0" charOffset="0-9"
            type="drug" text="Antipyrine"/>
        <entity id="DDI-DrugBank.d277.s25.e1" charOffset="13-22"
            type="drug" text="Antipyrine"/>
        <entity id="DDI-DrugBank.d277.s25.e2" charOffset="91-99"
            type="drug" text="tiagabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s26" text="This indicates that tiagabine does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of antipyrine.">
        <entity id="DDI-DrugBank.d277.s26.e0" charOffset="20-28"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d277.s26.e1" charOffset="144-153"
            type="drug" text="antipyrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s27" text="Interaction of GABITRIL with Highly Protein Bound Drugs: In vitro data showed that tiagabine is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.">
        <entity id="DDI-DrugBank.d277.s27.e0" charOffset="15-22"
            type="brand" text="GABITRIL"/>
        <entity id="DDI-DrugBank.d277.s27.e1" charOffset="83-91"
            type="drug" text="tiagabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d277.s28" text="Such an interaction can potentially lead to higher free fractions of either tiagabine or the competing drug.">
        <entity id="DDI-DrugBank.d277.s28.e0" charOffset="76-84"
            type="drug" text="tiagabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s0" text="The drug interaction studies with valdecoxib were performed both with valdecoxib and a rapidly hydrolyzed intravenous prodrug form.">
        <entity id="DDI-DrugBank.d328.s0.e0" charOffset="34-43"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s0.e1" charOffset="70-79"
            type="drug" text="valdecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s1" text="The results from trials using the intravenous prodrug are reported in this section as they relate to the role of valdecoxib in drug interactions.">
        <entity id="DDI-DrugBank.d328.s1.e0" charOffset="113-122"
            type="drug" text="valdecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s2" text="General: In humans, valdecoxib metabolism is predominantly mediated via CYP 3A4 and 2C9 with glucuronidation being a further (20%) route of metabolism.">
        <entity id="DDI-DrugBank.d328.s2.e0" charOffset="20-29"
            type="drug" text="valdecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s3" text="In vitro studies indicate that valdecoxib is a moderate inhibitor of CYP 2C19 (IC50 = 6  g/mL or 19  M) and 2C9 (IC50 = 13  g/mL or 41  M), and a weak inhibitor of CYP 2D6 (IC50 = 31  g/mL or 100  M) and 3A4 (IC50 = 44  g/mL or 141  M )..">
        <entity id="DDI-DrugBank.d328.s3.e0" charOffset="31-40"
            type="drug" text="valdecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s4" text="Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.">
        <entity id="DDI-DrugBank.d328.s4.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d328.s4.e1" charOffset="39-45"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d328.s4.e2" charOffset="52-61"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s4.e3" charOffset="142-151"
            type="drug" text="valdecoxib"/>
        <ddi id="DDI-DrugBank.d328.s4.d0" e1="DDI-DrugBank.d328.s4.e1"
            e2="DDI-DrugBank.d328.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s5" text="Because of its lack of anti-platelet effect valdecoxib is not a substitute for aspirin for cardiovascular prophylaxis.">
        <entity id="DDI-DrugBank.d328.s5.e0" charOffset="44-53"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s5.e1" charOffset="79-85"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s6" text="In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro aspirin-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.">
        <entity id="DDI-DrugBank.d328.s6.e0" charOffset="85-94"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s6.e1" charOffset="134-143"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s6.e2" charOffset="171-177"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s7" text="Methotrexate: Valdecoxib 10 mg BID did not show a significant effect on the plasma exposure or renal clearance of methotrexate.">
        <entity id="DDI-DrugBank.d328.s7.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d328.s7.e1" charOffset="14-29"
            type="drug" text="Valdecoxib 10 mg"/>
        <entity id="DDI-DrugBank.d328.s7.e2" charOffset="114-125"
            type="drug" text="methotrexate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s8" text="ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.">
        <entity id="DDI-DrugBank.d328.s8.e0" charOffset="0-13"
            type="group" text="ACE-inhibitors"/>
        <entity id="DDI-DrugBank.d328.s8.e1" charOffset="36-41"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d328.s8.e2" charOffset="87-100"
            type="group" text="ACE-inhibitors"/>
        <ddi id="DDI-DrugBank.d328.s8.d0" e1="DDI-DrugBank.d328.s8.e1"
            e2="DDI-DrugBank.d328.s8.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s9" text="This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.">
        <entity id="DDI-DrugBank.d328.s9.e0" charOffset="66-71"
            type="brand" text="BEXTRA"/>
        <entity id="DDI-DrugBank.d328.s9.e1" charOffset="92-105"
            type="group" text="ACE-inhibitors"/>
        <ddi id="DDI-DrugBank.d328.s9.d0" e1="DDI-DrugBank.d328.s9.e0"
            e2="DDI-DrugBank.d328.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s10" text="Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.">
        <entity id="DDI-DrugBank.d328.s10.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d328.s10.e1" charOffset="86-91"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d328.s10.e2" charOffset="130-139"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d328.s10.e3" charOffset="145-153"
            type="group" text="thiazides"/>
        <ddi id="DDI-DrugBank.d328.s10.d0" e1="DDI-DrugBank.d328.s10.e1"
            e2="DDI-DrugBank.d328.s10.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d328.s10.d1" e1="DDI-DrugBank.d328.s10.e1"
            e2="DDI-DrugBank.d328.s10.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s11" text="This response has been attributed to inhibition of renal prostaglandin synthesis."/>
    <sentence id="DDI-DrugBank.d328.s12" text="Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).">
        <entity id="DDI-DrugBank.d328.s12.e0" charOffset="0-14"
            type="group" text="Anticonvulsants"/>
        <entity id="DDI-DrugBank.d328.s12.e1" charOffset="17-25"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d328.s12.e2" charOffset="67-76"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s12.e3" charOffset="191-199"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d328.s12.d0" e1="DDI-DrugBank.d328.s12.e2"
            e2="DDI-DrugBank.d328.s12.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s13" text="Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.">
        <entity id="DDI-DrugBank.d328.s13.e0" charOffset="31-40"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s13.e1" charOffset="103-111"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d328.s13.d0" e1="DDI-DrugBank.d328.s13.e0"
            e2="DDI-DrugBank.d328.s13.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s14" text="Valdecoxib did not have a statistically significant effect on the pharmacokinetics of phenytoin (a CYP 2C9 and CYP 2C19 substrate).">
        <entity id="DDI-DrugBank.d328.s14.e0" charOffset="0-9"
            type="drug" text="Valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s14.e1" charOffset="86-94"
            type="drug" text="phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s15" text="Drug interaction studies with other anticonvulsants have not been conducted.">
        <entity id="DDI-DrugBank.d328.s15.e0" charOffset="36-50"
            type="group" text="anticonvulsants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s16" text="Routine monitoring should be performed when therapy with BEXTRA is either initiated or discontinued in patients on anticonvulsant therapy.">
        <entity id="DDI-DrugBank.d328.s16.e0" charOffset="57-62"
            type="brand" text="BEXTRA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s17" text="Dextromethorphan: Dextromethorphan is primarily metabolized by CYP 2D6 and to a lesser extent by 3A4.">
        <entity id="DDI-DrugBank.d328.s17.e0" charOffset="0-15"
            type="drug" text="Dextromethorphan"/>
        <entity id="DDI-DrugBank.d328.s17.e1" charOffset="18-33"
            type="drug" text="Dextromethorphan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s18" text="Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.">
        <entity id="DDI-DrugBank.d328.s18.e0" charOffset="22-31"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s18.e1" charOffset="94-109"
            type="drug" text="dextromethorphan"/>
        <entity id="DDI-DrugBank.d328.s18.e2" charOffset="158-167"
            type="drug" text="valdecoxib"/>
        <ddi id="DDI-DrugBank.d328.s18.d0" e1="DDI-DrugBank.d328.s18.e0"
            e2="DDI-DrugBank.d328.s18.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s19" text="Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.">
        <entity id="DDI-DrugBank.d328.s19.e0" charOffset="8-23"
            type="drug" text="dextromethorphan"/>
        <entity id="DDI-DrugBank.d328.s19.e1" charOffset="80-89"
            type="drug" text="valdecoxib"/>
        <ddi id="DDI-DrugBank.d328.s19.d0" e1="DDI-DrugBank.d328.s19.e0"
            e2="DDI-DrugBank.d328.s19.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s20" text="Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.">
        <entity id="DDI-DrugBank.d328.s20.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d328.s20.e1" charOffset="9-18"
            type="drug" text="Valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s20.e2" charOffset="75-81"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d328.s20.e3" charOffset="176-182"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d328.s20.d0" e1="DDI-DrugBank.d328.s20.e1"
            e2="DDI-DrugBank.d328.s20.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s21" text="Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.">
        <entity id="DDI-DrugBank.d328.s21.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d328.s21.e1" charOffset="98-103"
            type="brand" text="BEXTRA"/>
        <entity id="DDI-DrugBank.d328.s21.e2" charOffset="127-133"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d328.s21.d0" e1="DDI-DrugBank.d328.s21.e1"
            e2="DDI-DrugBank.d328.s21.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s22" text="Lithium carbonate (450 mg BID for 7 days) had no effect on valdecoxib pharmacokinetics.">
        <entity id="DDI-DrugBank.d328.s22.e0" charOffset="0-16"
            type="drug" text="Lithium carbonate"/>
        <entity id="DDI-DrugBank.d328.s22.e1" charOffset="59-68"
            type="drug" text="valdecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s23" text="Warfarin: The effect of valdecoxib on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.">
        <entity id="DDI-DrugBank.d328.s23.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d328.s23.e1" charOffset="24-33"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s23.e2" charOffset="66-73"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d328.s23.e3" charOffset="145-150"
            type="brand" text="BEXTRA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s24" text="Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.">
        <entity id="DDI-DrugBank.d328.s24.e0" charOffset="0-9"
            type="drug" text="Valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s24.e1" charOffset="78-87"
            type="drug" text="R-warfarin"/>
        <entity id="DDI-DrugBank.d328.s24.e2" charOffset="93-102"
            type="drug" text="S-warfarin"/>
        <entity id="DDI-DrugBank.d328.s24.e3" charOffset="207-214"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d328.s24.d0" e1="DDI-DrugBank.d328.s24.e0"
            e2="DDI-DrugBank.d328.s24.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d328.s24.d1" e1="DDI-DrugBank.d328.s24.e0"
            e2="DDI-DrugBank.d328.s24.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d328.s24.d2" e1="DDI-DrugBank.d328.s24.e0"
            e2="DDI-DrugBank.d328.s24.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s25" text="While mean INR values were only slightly increased with coadministration of valdecoxib, the day-to-day variability in individual INR values was increased.">
        <entity id="DDI-DrugBank.d328.s25.e0" charOffset="76-85"
            type="drug" text="valdecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s26" text="Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.">
        <entity id="DDI-DrugBank.d328.s26.e0" charOffset="0-12"
            type="brand" text="Anticoagulant"/>
        <entity id="DDI-DrugBank.d328.s26.e1" charOffset="114-119"
            type="brand" text="BEXTRA"/>
        <entity id="DDI-DrugBank.d328.s26.e2" charOffset="143-150"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d328.s26.d0" e1="DDI-DrugBank.d328.s26.e1"
            e2="DDI-DrugBank.d328.s26.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s27" text="Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.">
        <entity id="DDI-DrugBank.d328.s27.e0" charOffset="0-10"
            type="drug" text="Fluconazole"/>
        <entity id="DDI-DrugBank.d328.s27.e1" charOffset="16-27"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d328.s27.e2" charOffset="30-41"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d328.s27.e3" charOffset="47-57"
            type="drug" text="fluconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s28" text="Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.">
        <entity id="DDI-DrugBank.d328.s28.e0" charOffset="42-51"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s28.e1" charOffset="82-93"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d328.s28.e2" charOffset="99-109"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d328.s28.e3" charOffset="158-167"
            type="drug" text="valdecoxib"/>
        <ddi id="DDI-DrugBank.d328.s28.d0" e1="DDI-DrugBank.d328.s28.e0"
            e2="DDI-DrugBank.d328.s28.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d328.s28.d1" e1="DDI-DrugBank.d328.s28.e0"
            e2="DDI-DrugBank.d328.s28.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s29" text="Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.">
        <entity id="DDI-DrugBank.d328.s29.e0" charOffset="25-34"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s29.e1" charOffset="79-89"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d328.s29.e2" charOffset="124-135"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d328.s29.d0" e1="DDI-DrugBank.d328.s29.e0"
            e2="DDI-DrugBank.d328.s29.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d328.s29.d1" e1="DDI-DrugBank.d328.s29.e0"
            e2="DDI-DrugBank.d328.s29.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s30" text="Glyburide: Glyburide is a CYP 2C9 substrate.">
        <entity id="DDI-DrugBank.d328.s30.e0" charOffset="0-8"
            type="drug" text="Glyburide"/>
        <entity id="DDI-DrugBank.d328.s30.e1" charOffset="11-19"
            type="drug" text="Glyburide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s31" text="Coadministration of valdecoxib (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide.">
        <entity id="DDI-DrugBank.d328.s31.e0" charOffset="20-29"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s31.e1" charOffset="59-67"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d328.s31.e2" charOffset="142-150"
            type="drug" text="glyburide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s32" text="Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.">
        <entity id="DDI-DrugBank.d328.s32.e0" charOffset="20-29"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s32.e1" charOffset="80-88"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d328.s32.e2" charOffset="216-224"
            type="drug" text="glyburide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s33" text="Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.">
        <entity id="DDI-DrugBank.d328.s33.e0" charOffset="20-29"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s33.e1" charOffset="80-88"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d328.s33.e2" charOffset="97-105"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d328.s33.e3" charOffset="140-148"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d328.s33.e4" charOffset="180-188"
            type="drug" text="glyburide"/>
        <ddi id="DDI-DrugBank.d328.s33.d0" e1="DDI-DrugBank.d328.s33.e0"
            e2="DDI-DrugBank.d328.s33.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s34" text="Insulin parameters were not affected."/>
    <sentence id="DDI-DrugBank.d328.s35" text="Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.">
        <entity id="DDI-DrugBank.d328.s35.e0" charOffset="47-56"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s35.e1" charOffset="197-205"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d328.s35.e2" charOffset="236-245"
            type="drug" text="valdecoxib"/>
        <ddi id="DDI-DrugBank.d328.s35.d0" e1="DDI-DrugBank.d328.s35.e1"
            e2="DDI-DrugBank.d328.s35.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s36" text="Coadministration of glyburide with doses higher than 40 mg valdecoxib (e.g., 40 mg BID) have not been studied.">
        <entity id="DDI-DrugBank.d328.s36.e0" charOffset="20-28"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d328.s36.e1" charOffset="59-68"
            type="drug" text="valdecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s37" text="Omeprazole: Omeprazole is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor.">
        <entity id="DDI-DrugBank.d328.s37.e0" charOffset="0-9"
            type="drug" text="Omeprazole"/>
        <entity id="DDI-DrugBank.d328.s37.e1" charOffset="12-21"
            type="drug" text="Omeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s38" text="Valdecoxib steady state plasma concentrations (40 mg BID) were not affected significantly with multiple doses of omeprazole (40 mg QD).">
        <entity id="DDI-DrugBank.d328.s38.e0" charOffset="0-9"
            type="drug" text="Valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s38.e1" charOffset="113-122"
            type="drug" text="omeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s39" text="Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.">
        <entity id="DDI-DrugBank.d328.s39.e0" charOffset="22-31"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s39.e1" charOffset="55-64"
            type="drug" text="omeprazole"/>
        <ddi id="DDI-DrugBank.d328.s39.d0" e1="DDI-DrugBank.d328.s39.e0"
            e2="DDI-DrugBank.d328.s39.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s40" text="Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of omeprazole and valdecoxib.">
        <entity id="DDI-DrugBank.d328.s40.e0" charOffset="102-111"
            type="drug" text="omeprazole"/>
        <entity id="DDI-DrugBank.d328.s40.e1" charOffset="117-126"
            type="drug" text="valdecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s41" text="However, because higher doses (up to 360 mg QD) of omeprazole are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for omeprazole is recommended at current doses.">
        <entity id="DDI-DrugBank.d328.s41.e0" charOffset="51-60"
            type="drug" text="omeprazole"/>
        <entity id="DDI-DrugBank.d328.s41.e1" charOffset="135-144"
            type="drug" text="omeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s42" text="Coadministration of valdecoxib with doses higher than 40 mg QD omeprazole has not been studied.">
        <entity id="DDI-DrugBank.d328.s42.e0" charOffset="20-29"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s42.e1" charOffset="63-72"
            type="drug" text="omeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s43" text="Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).">
        <entity id="DDI-DrugBank.d328.s43.e0" charOffset="5-18"
            type="group" text="Contraceptives"/>
        <entity id="DDI-DrugBank.d328.s43.e1" charOffset="21-30"
            type="drug" text="Valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s43.e2" charOffset="98-110"
            type="group" text="contraceptive"/>
        <entity id="DDI-DrugBank.d328.s43.e3" charOffset="112-124"
            type="drug" text="norethindrone"/>
        <entity id="DDI-DrugBank.d328.s43.e4" charOffset="126-142"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d328.s43.e5" charOffset="171-181"
            type="brand" text="Ortho-Novum"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s44" text="Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.">
        <entity id="DDI-DrugBank.d328.s44.e0" charOffset="20-29"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s44.e1" charOffset="35-45"
            type="brand" text="Ortho-Novum"/>
        <entity id="DDI-DrugBank.d328.s44.e2" charOffset="79-91"
            type="drug" text="norethindrone"/>
        <entity id="DDI-DrugBank.d328.s44.e3" charOffset="97-113"
            type="drug" text="ethinyl estradiol"/>
        <ddi id="DDI-DrugBank.d328.s44.d0" e1="DDI-DrugBank.d328.s44.e0"
            e2="DDI-DrugBank.d328.s44.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s45" text="Although there is little risk for loss of contraceptive efficacy, the clinical significance of these increased exposures in terms of safety is not known."/>
    <sentence id="DDI-DrugBank.d328.s46" text="These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.">
        <entity id="DDI-DrugBank.d328.s46.e0" charOffset="29-41"
            type="drug" text="norethindrone"/>
        <entity id="DDI-DrugBank.d328.s46.e1" charOffset="47-63"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d328.s46.e2" charOffset="123-135"
            type="group" text="contraceptive"/>
        <entity id="DDI-DrugBank.d328.s46.e3" charOffset="154-163"
            type="drug" text="valdecoxib"/>
        <ddi id="DDI-DrugBank.d328.s46.d0" e1="DDI-DrugBank.d328.s46.e2"
            e2="DDI-DrugBank.d328.s46.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s47" text="Diazepam: Diazepam (Valium) is a CYP 3A4 and CYP 2C19 substrate.">
        <entity id="DDI-DrugBank.d328.s47.e0" charOffset="0-7"
            type="drug" text="Diazepam"/>
        <entity id="DDI-DrugBank.d328.s47.e1" charOffset="10-17"
            type="drug" text="Diazepam"/>
        <entity id="DDI-DrugBank.d328.s47.e2" charOffset="20-25"
            type="brand" text="Valium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s48" text="Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.">
        <entity id="DDI-DrugBank.d328.s48.e0" charOffset="19-26"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d328.s48.e1" charOffset="89-98"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s48.e2" charOffset="150-159"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s48.e3" charOffset="233-240"
            type="drug" text="diazepam"/>
        <ddi id="DDI-DrugBank.d328.s48.d0" e1="DDI-DrugBank.d328.s48.e0"
            e2="DDI-DrugBank.d328.s48.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s49" text="Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.">
        <entity id="DDI-DrugBank.d328.s49.e0" charOffset="37-44"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d328.s49.e1" charOffset="87-96"
            type="drug" text="valdecoxib"/>
        <entity id="DDI-DrugBank.d328.s49.e2" charOffset="236-243"
            type="drug" text="diazepam"/>
        <ddi id="DDI-DrugBank.d328.s49.d0" e1="DDI-DrugBank.d328.s49.e1"
            e2="DDI-DrugBank.d328.s49.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d328.s50" text="Patients should be cautioned against engaging in hazardous activities requiring complete mental alertness such as operating machinery or driving a motor vehicle."/>
    <sentence id="DDI-DrugBank.d198.s0" text="Effect of other drugs on Vardenafil">
        <entity id="DDI-DrugBank.d198.s0.e0" charOffset="25-34"
            type="drug" text="Vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s1" text="In vitro studies: Studies in human liver microsomes showed that vardenafil is metabolized primarily by cytochrome P450 (CYP) isoforms 3A4/5, and to a lesser degree by CYP2C9.">
        <entity id="DDI-DrugBank.d198.s1.e0" charOffset="64-73"
            type="drug" text="vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s2" text="Therefore, inhibitors of these enzymes are expected to reduce vardenafil clearance.">
        <entity id="DDI-DrugBank.d198.s2.e0" charOffset="62-71"
            type="drug" text="vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s3" text="In vivo studies: Cytochrome P450 Inhibitors"/>
    <sentence id="DDI-DrugBank.d198.s4" text="Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.">
        <entity id="DDI-DrugBank.d198.s4.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d198.s4.e1" charOffset="44-53"
            type="drug" text="vardenafil"/>
        <entity id="DDI-DrugBank.d198.s4.e2" charOffset="113-122"
            type="drug" text="vardenafil"/>
        <entity id="DDI-DrugBank.d198.s4.e3" charOffset="156-165"
            type="drug" text="Vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s5" text="Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.">
        <entity id="DDI-DrugBank.d198.s5.e0" charOffset="0-11"
            type="drug" text="Erythromycin"/>
        <entity id="DDI-DrugBank.d198.s5.e1" charOffset="58-67"
            type="drug" text="vardenafil"/>
        <entity id="DDI-DrugBank.d198.s5.e2" charOffset="129-138"
            type="drug" text="Vardenafil"/>
        <ddi id="DDI-DrugBank.d198.s5.d0" e1="DDI-DrugBank.d198.s5.e0"
            e2="DDI-DrugBank.d198.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s6" text="It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.">
        <entity id="DDI-DrugBank.d198.s6.e0" charOffset="54-63"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s6.e1" charOffset="115-126"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d198.s6.d0" e1="DDI-DrugBank.d198.s6.e0"
            e2="DDI-DrugBank.d198.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s7" text="Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.">
        <entity id="DDI-DrugBank.d198.s7.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d198.s7.e1" charOffset="64-73"
            type="drug" text="vardenafil"/>
        <entity id="DDI-DrugBank.d198.s7.e2" charOffset="135-144"
            type="drug" text="Vardenafil"/>
        <ddi id="DDI-DrugBank.d198.s7.d0" e1="DDI-DrugBank.d198.s7.e0"
            e2="DDI-DrugBank.d198.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s8" text="A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.">
        <entity id="DDI-DrugBank.d198.s8.e0" charOffset="7-16"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s8.e1" charOffset="94-105"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d198.s8.d0" e1="DDI-DrugBank.d198.s8.e0"
            e2="DDI-DrugBank.d198.s8.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s9" text="Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.">
        <entity id="DDI-DrugBank.d198.s9.e0" charOffset="22-33"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d198.s9.e1" charOffset="122-131"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s9.e2" charOffset="206-217"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d198.s9.d0" e1="DDI-DrugBank.d198.s9.e1"
            e2="DDI-DrugBank.d198.s9.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s10" text="HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.">
        <entity id="DDI-DrugBank.d198.s10.e0" charOffset="0-22"
            type="group" text="HIV Protease Inhibitors"/>
        <entity id="DDI-DrugBank.d198.s10.e1" charOffset="25-33"
            type="drug" text="Indinavir"/>
        <entity id="DDI-DrugBank.d198.s10.e2" charOffset="72-81"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s10.e3" charOffset="123-132"
            type="drug" text="vardenafil"/>
        <entity id="DDI-DrugBank.d198.s10.e4" charOffset="160-169"
            type="drug" text="vardenafil"/>
        <entity id="DDI-DrugBank.d198.s10.e5" charOffset="201-210"
            type="drug" text="vardenafil"/>
        <ddi id="DDI-DrugBank.d198.s10.d0" e1="DDI-DrugBank.d198.s10.e1"
            e2="DDI-DrugBank.d198.s10.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s11" text="It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.">
        <entity id="DDI-DrugBank.d198.s11.e0" charOffset="48-57"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s11.e1" charOffset="114-122"
            type="drug" text="indinavir"/>
        <ddi id="DDI-DrugBank.d198.s11.d0" e1="DDI-DrugBank.d198.s11.e0"
            e2="DDI-DrugBank.d198.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s12" text="Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.">
        <entity id="DDI-DrugBank.d198.s12.e0" charOffset="0-8"
            type="drug" text="Ritonavir"/>
        <entity id="DDI-DrugBank.d198.s12.e1" charOffset="47-56"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s12.e2" charOffset="97-106"
            type="drug" text="vardenafil"/>
        <entity id="DDI-DrugBank.d198.s12.e3" charOffset="138-147"
            type="drug" text="vardenafil"/>
        <ddi id="DDI-DrugBank.d198.s12.d0" e1="DDI-DrugBank.d198.s12.e0"
            e2="DDI-DrugBank.d198.s12.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s13" text="The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.">
        <entity id="DDI-DrugBank.d198.s13.e0" charOffset="67-76"
            type="drug" text="vardenafil"/>
        <entity id="DDI-DrugBank.d198.s13.e1" charOffset="81-89"
            type="drug" text="ritonavir"/>
        <ddi id="DDI-DrugBank.d198.s13.d0" e1="DDI-DrugBank.d198.s13.e0"
            e2="DDI-DrugBank.d198.s13.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s14" text="Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.">
        <entity id="DDI-DrugBank.d198.s14.e0" charOffset="0-8"
            type="drug" text="Ritonavir"/>
        <entity id="DDI-DrugBank.d198.s14.e1" charOffset="51-60"
            type="drug" text="vardenafil"/>
        <ddi id="DDI-DrugBank.d198.s14.d0" e1="DDI-DrugBank.d198.s14.e0"
            e2="DDI-DrugBank.d198.s14.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s15" text="Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.">
        <entity id="DDI-DrugBank.d198.s15.e0" charOffset="62-71"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s15.e1" charOffset="128-136"
            type="drug" text="ritonavir"/>
        <ddi id="DDI-DrugBank.d198.s15.d0" e1="DDI-DrugBank.d198.s15.e0"
            e2="DDI-DrugBank.d198.s15.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s16" text="Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, Maalox, and ranitidine.">
        <entity id="DDI-DrugBank.d198.s16.e0" charOffset="79-88"
            type="drug" text="vardenafil"/>
        <entity id="DDI-DrugBank.d198.s16.e1" charOffset="115-123"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d198.s16.e2" charOffset="126-133"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d198.s16.e3" charOffset="136-142"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d198.s16.e4" charOffset="145-150"
            type="brand" text="Maalox"/>
        <entity id="DDI-DrugBank.d198.s16.e5" charOffset="157-166"
            type="drug" text="ranitidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s17" text="In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.">
        <entity id="DDI-DrugBank.d198.s17.e0" charOffset="7-14"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d198.s17.e1" charOffset="23-32"
            type="drug" text="vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s18" text="Effects of Vardenafil on other drugs">
        <entity id="DDI-DrugBank.d198.s18.e0" charOffset="11-20"
            type="drug" text="Vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s19" text="In vitro studies: Vardenafil and its metabolites had no effect on CYP1A2, 2A6, and 2E1 (Ki   100uM).">
        <entity id="DDI-DrugBank.d198.s19.e0" charOffset="18-27"
            type="drug" text="Vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s20" text="Weak inhibitory effects toward other isoforms (CYP2C8, 2C9, 2C19, 2D6, 3A4) were found, but Ki values were in excess of plasma concentrations achieved following dosing."/>
    <sentence id="DDI-DrugBank.d198.s21" text="The most potent inhibitory activity was observed for vardenafil metabolite M1, which had a Ki of 1.4 uM toward CYP3A4, which is about 20 times higher than the M1 Cmax values after an 80 mg Vardenafil dose.">
        <entity id="DDI-DrugBank.d198.s21.e0" charOffset="189-198"
            type="drug" text="Vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s22" text="In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.">
        <entity id="DDI-DrugBank.d198.s22.e0" charOffset="17-24"
            type="group" text="Nitrates"/>
        <entity id="DDI-DrugBank.d198.s22.e1" charOffset="77-84"
            type="group" text="nitrates"/>
        <entity id="DDI-DrugBank.d198.s22.e2" charOffset="121-130"
            type="drug" text="vardenafil"/>
        <entity id="DDI-DrugBank.d198.s22.e3" charOffset="227-236"
            type="drug" text="Vardenafil"/>
        <ddi id="DDI-DrugBank.d198.s22.d0" e1="DDI-DrugBank.d198.s22.e1"
            e2="DDI-DrugBank.d198.s22.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s23" text="These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.">
        <entity id="DDI-DrugBank.d198.s23.e0" charOffset="37-46"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s23.e1" charOffset="84-86"
            type="drug" text="NTG"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s24" text="Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.">
        <entity id="DDI-DrugBank.d198.s24.e0" charOffset="43-50"
            type="group" text="nitrates"/>
        <entity id="DDI-DrugBank.d198.s24.e1" charOffset="140-149"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s24.e2" charOffset="155-162"
            type="group" text="nitrates"/>
        <ddi id="DDI-DrugBank.d198.s24.d0" e1="DDI-DrugBank.d198.s24.e1"
            e2="DDI-DrugBank.d198.s24.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s25" text="Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.">
        <entity id="DDI-DrugBank.d198.s25.e0" charOffset="0-9"
            type="drug" text="Nifedipine"/>
        <entity id="DDI-DrugBank.d198.s25.e1" charOffset="12-21"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s25.e2" charOffset="69-78"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d198.s25.e3" charOffset="192-201"
            type="drug" text="nifedipine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s26" text="Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.">
        <entity id="DDI-DrugBank.d198.s26.e0" charOffset="0-9"
            type="drug" text="Nifedipine"/>
        <entity id="DDI-DrugBank.d198.s26.e1" charOffset="46-55"
            type="drug" text="Vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s27" text="In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.">
        <entity id="DDI-DrugBank.d198.s27.e0" charOffset="57-66"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d198.s27.e1" charOffset="69-78"
            type="drug" text="Vardenafil"/>
        <ddi id="DDI-DrugBank.d198.s27.d0" e1="DDI-DrugBank.d198.s27.e0"
            e2="DDI-DrugBank.d198.s27.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s28" text="Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.">
        <entity id="DDI-DrugBank.d198.s28.e0" charOffset="0-13"
            type="group" text="Alpha-blockers"/>
        <entity id="DDI-DrugBank.d198.s28.e1" charOffset="21-30"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s28.e2" charOffset="131-139"
            type="drug" text="terazosin"/>
        <ddi id="DDI-DrugBank.d198.s28.d0" e1="DDI-DrugBank.d198.s28.e1"
            e2="DDI-DrugBank.d198.s28.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s29" text="With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.">
        <entity id="DDI-DrugBank.d198.s29.e0" charOffset="28-37"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s29.e1" charOffset="49-57"
            type="drug" text="terazosin"/>
        <ddi id="DDI-DrugBank.d198.s29.d0" e1="DDI-DrugBank.d198.s29.e0"
            e2="DDI-DrugBank.d198.s29.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s30" text="With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.">
        <entity id="DDI-DrugBank.d198.s30.e0" charOffset="28-37"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s30.e1" charOffset="49-57"
            type="drug" text="terazosin"/>
        <ddi id="DDI-DrugBank.d198.s30.d0" e1="DDI-DrugBank.d198.s30.e0"
            e2="DDI-DrugBank.d198.s30.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s31" text="When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.">
        <entity id="DDI-DrugBank.d198.s31.e0" charOffset="5-14"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s31.e1" charOffset="42-50"
            type="drug" text="terazosin"/>
        <entity id="DDI-DrugBank.d198.s31.e2" charOffset="109-118"
            type="drug" text="Vardenafil"/>
        <ddi id="DDI-DrugBank.d198.s31.d0" e1="DDI-DrugBank.d198.s31.e0"
            e2="DDI-DrugBank.d198.s31.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s32" text="In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.">
        <entity id="DDI-DrugBank.d198.s32.e0" charOffset="24-33"
            type="drug" text="tamsulosin"/>
        <entity id="DDI-DrugBank.d198.s32.e1" charOffset="86-95"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s32.e2" charOffset="107-116"
            type="drug" text="tamsulosin"/>
        <ddi id="DDI-DrugBank.d198.s32.d0" e1="DDI-DrugBank.d198.s32.e1"
            e2="DDI-DrugBank.d198.s32.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s33" text="Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.">
        <entity id="DDI-DrugBank.d198.s33.e0" charOffset="45-54"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s33.e1" charOffset="66-75"
            type="drug" text="tamsulosin"/>
        <ddi id="DDI-DrugBank.d198.s33.d0" e1="DDI-DrugBank.d198.s33.e0"
            e2="DDI-DrugBank.d198.s33.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s34" text="The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.">
        <entity id="DDI-DrugBank.d198.s34.e0" charOffset="37-46"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s34.e1" charOffset="53-66"
            type="group" text="alpha-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s35" text="Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.">
        <entity id="DDI-DrugBank.d198.s35.e0" charOffset="21-30"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s35.e1" charOffset="66-78"
            type="group" text="alpha-blocker"/>
        <ddi id="DDI-DrugBank.d198.s35.d0" e1="DDI-DrugBank.d198.s35.e0"
            e2="DDI-DrugBank.d198.s35.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s36" text="Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.">
        <entity id="DDI-DrugBank.d198.s36.e0" charOffset="0-8"
            type="drug" text="Ritonavir"/>
        <entity id="DDI-DrugBank.d198.s36.e1" charOffset="14-22"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d198.s36.e2" charOffset="68-77"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s36.e3" charOffset="95-103"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d198.s36.e4" charOffset="126-134"
            type="drug" text="ritonavir"/>
        <ddi id="DDI-DrugBank.d198.s36.d0" e1="DDI-DrugBank.d198.s36.e2"
            e2="DDI-DrugBank.d198.s36.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s37" text="Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.">
        <entity id="DDI-DrugBank.d198.s37.e0" charOffset="32-41"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s37.e1" charOffset="59-67"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d198.s37.e2" charOffset="90-98"
            type="drug" text="indinavir"/>
        <ddi id="DDI-DrugBank.d198.s37.d0" e1="DDI-DrugBank.d198.s37.e0"
            e2="DDI-DrugBank.d198.s37.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s38" text="Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.">
        <entity id="DDI-DrugBank.d198.s38.e0" charOffset="0-6"
            type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d198.s38.e1" charOffset="9-15"
            type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d198.s38.e2" charOffset="103-112"
            type="drug" text="vardenafil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s39" text="Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).">
        <entity id="DDI-DrugBank.d198.s39.e0" charOffset="0-9"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s39.e1" charOffset="65-71"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d198.s39.e2" charOffset="155-161"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s40" text="Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).">
        <entity id="DDI-DrugBank.d198.s40.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d198.s40.e1" charOffset="9-18"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s40.e2" charOffset="97-103"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d198.s41" text="Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).">
        <entity id="DDI-DrugBank.d198.s41.e0" charOffset="20-29"
            type="drug" text="Vardenafil"/>
        <entity id="DDI-DrugBank.d198.s41.e1" charOffset="72-80"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d198.s41.e2" charOffset="123-130"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s0" text="Zidovudine: There is no significant pharmacokinetic interaction between ZDV and zalcitabine which has been confirmed clinically.">
        <entity id="DDI-DrugBank.d263.s0.e0" charOffset="0-9"
            type="drug" text="Zidovudine"/>
        <entity id="DDI-DrugBank.d263.s0.e1" charOffset="72-74"
            type="drug" text="ZDV"/>
        <entity id="DDI-DrugBank.d263.s0.e2" charOffset="80-90"
            type="drug" text="zalcitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s1" text="Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).">
        <entity id="DDI-DrugBank.d263.s1.e0" charOffset="0-10"
            type="drug" text="Zalcitabine"/>
        <entity id="DDI-DrugBank.d263.s1.e1" charOffset="83-85"
            type="drug" text="ZDV"/>
        <ddi id="DDI-DrugBank.d263.s1.d0" e1="DDI-DrugBank.d263.s1.e0"
            e2="DDI-DrugBank.d263.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s2" text="In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.">
        <entity id="DDI-DrugBank.d263.s2.e0" charOffset="36-45"
            type="drug" text="didanosine"/>
        <entity id="DDI-DrugBank.d263.s2.e1" charOffset="51-59"
            type="drug" text="stavudine"/>
        <entity id="DDI-DrugBank.d263.s2.e2" charOffset="127-137"
            type="drug" text="zalcitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s3" text="Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.">
        <entity id="DDI-DrugBank.d263.s3.e0" charOffset="0-9"
            type="drug" text="Lamivudine"/>
        <entity id="DDI-DrugBank.d263.s3.e1" charOffset="104-113"
            type="drug" text="lamivudine"/>
        <entity id="DDI-DrugBank.d263.s3.e2" charOffset="139-149"
            type="drug" text="zalcitabine"/>
        <ddi id="DDI-DrugBank.d263.s3.d0" e1="DDI-DrugBank.d263.s3.e1"
            e2="DDI-DrugBank.d263.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s4" text="Effects were already seen with doses corresponding to relevant plasma levels in humans, and the intracellular phosphorylation of zalcitabine to its three metabolites (including the active zalcitabine triphosphate metabolite) was significantly inhibited.">
        <entity id="DDI-DrugBank.d263.s4.e0" charOffset="129-139"
            type="drug" text="zalcitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s5" text="Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);">
        <entity id="DDI-DrugBank.d263.s5.e0" charOffset="0-10"
            type="drug" text="Zalcitabine"/>
        <entity id="DDI-DrugBank.d263.s5.e1" charOffset="22-31"
            type="drug" text="lamivudine"/>
        <ddi id="DDI-DrugBank.d263.s5.d0" e1="DDI-DrugBank.d263.s5.e0"
            e2="DDI-DrugBank.d263.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s6" text="however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine.">
        <entity id="DDI-DrugBank.d263.s6.e0" charOffset="78-87"
            type="drug" text="lamivudine"/>
        <entity id="DDI-DrugBank.d263.s6.e1" charOffset="135-144"
            type="drug" text="lamivudine"/>
        <entity id="DDI-DrugBank.d263.s6.e2" charOffset="206-216"
            type="drug" text="zalcitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s7" text="These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.">
        <entity id="DDI-DrugBank.d263.s7.e0" charOffset="66-76"
            type="drug" text="zalcitabine"/>
        <entity id="DDI-DrugBank.d263.s7.e1" charOffset="82-91"
            type="drug" text="lamivudine"/>
        <entity id="DDI-DrugBank.d263.s7.e2" charOffset="173-183"
            type="drug" text="zalcitabine"/>
        <entity id="DDI-DrugBank.d263.s7.e3" charOffset="216-229"
            type="group" text="antiretroviral"/>
        <entity id="DDI-DrugBank.d263.s7.e4" charOffset="241-251"
            type="drug" text="zalcitabine"/>
        <ddi id="DDI-DrugBank.d263.s7.d0" e1="DDI-DrugBank.d263.s7.e0"
            e2="DDI-DrugBank.d263.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s8" text="It is unknown how the effect seen in these in vitro studies translates into clinical consequences."/>
    <sentence id="DDI-DrugBank.d263.s9" text="Concomitant use of zalcitabine and lamivudine is not recommended.">
        <entity id="DDI-DrugBank.d263.s9.e0" charOffset="19-29"
            type="drug" text="zalcitabine"/>
        <entity id="DDI-DrugBank.d263.s9.e1" charOffset="35-44"
            type="drug" text="lamivudine"/>
        <ddi id="DDI-DrugBank.d263.s9.d0" e1="DDI-DrugBank.d263.s9.e0"
            e2="DDI-DrugBank.d263.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s10" text="Saquinavir: The combination of HIVID, saquinavir, and ZDV has been studied (as triple combination) in adults.">
        <entity id="DDI-DrugBank.d263.s10.e0" charOffset="0-9"
            type="drug" text="Saquinavir"/>
        <entity id="DDI-DrugBank.d263.s10.e1" charOffset="31-35"
            type="drug" text="HIVID"/>
        <entity id="DDI-DrugBank.d263.s10.e2" charOffset="38-47"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d263.s10.e3" charOffset="54-56"
            type="drug" text="ZDV"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s11" text="Pharmacokinetic data suggest that absorption, metabolism, and elimination of each of these drugs are unchanged when they are used together."/>
    <sentence id="DDI-DrugBank.d263.s12" text="Drugs Associated With Peripheral Neuropathy: The concomitant use of HIVID with drugs that have the potential to cause peripheral neuropathy should be avoided where possible.">
        <entity id="DDI-DrugBank.d263.s12.e0" charOffset="68-72"
            type="drug" text="HIVID"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s13" text="Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.">
        <entity id="DDI-DrugBank.d263.s13.e0" charOffset="67-101"
            type="drug" text="antiretroviral nucleoside analogues"/>
        <entity id="DDI-DrugBank.d263.s13.e1" charOffset="104-118"
            type="drug" text="chloramphenicol"/>
        <entity id="DDI-DrugBank.d263.s13.e2" charOffset="121-129"
            type="drug" text="cisplatin"/>
        <entity id="DDI-DrugBank.d263.s13.e3" charOffset="132-138"
            type="drug" text="dapsone"/>
        <entity id="DDI-DrugBank.d263.s13.e4" charOffset="141-150"
            type="drug" text="disulfiram"/>
        <entity id="DDI-DrugBank.d263.s13.e5" charOffset="153-163"
            type="drug" text="ethionamide"/>
        <entity id="DDI-DrugBank.d263.s13.e6" charOffset="166-177"
            type="drug" text="glutethimide"/>
        <entity id="DDI-DrugBank.d263.s13.e7" charOffset="180-183"
            type="drug" text="gold"/>
        <entity id="DDI-DrugBank.d263.s13.e8" charOffset="186-196"
            type="drug" text="hydralazine"/>
        <entity id="DDI-DrugBank.d263.s13.e9" charOffset="199-208"
            type="drug" text="iodoquinol"/>
        <entity id="DDI-DrugBank.d263.s13.e10" charOffset="211-219"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d263.s13.e11" charOffset="222-234"
            type="drug" text="metronidazole"/>
        <entity id="DDI-DrugBank.d263.s13.e12" charOffset="237-250"
            type="drug" text="nitrofurantoin"/>
        <entity id="DDI-DrugBank.d263.s13.e13" charOffset="253-261"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d263.s13.e14" charOffset="264-272"
            type="drug" text="ribavirin"/>
        <entity id="DDI-DrugBank.d263.s13.e15" charOffset="279-289"
            type="drug" text="vincristine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s14" text="Concomitant use of HIVID with didanosine is not recommended.">
        <entity id="DDI-DrugBank.d263.s14.e0" charOffset="19-23"
            type="drug" text="HIVID"/>
        <entity id="DDI-DrugBank.d263.s14.e1" charOffset="30-39"
            type="drug" text="didanosine"/>
        <ddi id="DDI-DrugBank.d263.s14.d0" e1="DDI-DrugBank.d263.s14.e0"
            e2="DDI-DrugBank.d263.s14.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s15" text="Intravenous Pentamidine: Treatment with HIVID should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.">
        <entity id="DDI-DrugBank.d263.s15.e0" charOffset="12-22"
            type="drug" text="Pentamidine"/>
        <entity id="DDI-DrugBank.d263.s15.e1" charOffset="40-44"
            type="drug" text="HIVID"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s16" text="Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.">
        <entity id="DDI-DrugBank.d263.s16.e0" charOffset="68-78"
            type="drug" text="pentamidine"/>
        <entity id="DDI-DrugBank.d263.s16.e1" charOffset="84-88"
            type="drug" text="HIVID"/>
        <ddi id="DDI-DrugBank.d263.s16.d0" e1="DDI-DrugBank.d263.s16.e0"
            e2="DDI-DrugBank.d263.s16.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s17" text="If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.">
        <entity id="DDI-DrugBank.d263.s17.e0" charOffset="15-25"
            type="drug" text="pentamidine"/>
        <entity id="DDI-DrugBank.d263.s17.e1" charOffset="95-99"
            type="drug" text="HIVID"/>
        <ddi id="DDI-DrugBank.d263.s17.d0" e1="DDI-DrugBank.d263.s17.e0"
            e2="DDI-DrugBank.d263.s17.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s18" text="Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).">
        <entity id="DDI-DrugBank.d263.s18.e0" charOffset="0-11"
            type="drug" text="Amphotericin"/>
        <entity id="DDI-DrugBank.d263.s18.e1" charOffset="14-22"
            type="drug" text="Foscarnet"/>
        <entity id="DDI-DrugBank.d263.s18.e2" charOffset="29-43"
            type="group" text="Aminoglycosides"/>
        <entity id="DDI-DrugBank.d263.s18.e3" charOffset="60-71"
            type="drug" text="amphotericin"/>
        <entity id="DDI-DrugBank.d263.s18.e4" charOffset="74-82"
            type="drug" text="foscarnet"/>
        <entity id="DDI-DrugBank.d263.s18.e5" charOffset="89-103"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d263.s18.e6" charOffset="172-176"
            type="drug" text="HIVID"/>
        <entity id="DDI-DrugBank.d263.s18.e7" charOffset="247-257"
            type="drug" text="zalcitabine"/>
        <ddi id="DDI-DrugBank.d263.s18.d0" e1="DDI-DrugBank.d263.s18.e3"
            e2="DDI-DrugBank.d263.s18.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d263.s18.d1" e1="DDI-DrugBank.d263.s18.e4"
            e2="DDI-DrugBank.d263.s18.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d263.s18.d2" e1="DDI-DrugBank.d263.s18.e5"
            e2="DDI-DrugBank.d263.s18.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d263.s18.d3" e1="DDI-DrugBank.d263.s18.e3"
            e2="DDI-DrugBank.d263.s18.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d263.s18.d4" e1="DDI-DrugBank.d263.s18.e4"
            e2="DDI-DrugBank.d263.s18.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d263.s18.d5" e1="DDI-DrugBank.d263.s18.e5"
            e2="DDI-DrugBank.d263.s18.e7" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s19" text="Patients who require the use of one of these drugs with HIVID should have frequent clinical and laboratory monitoring with dosage adjustment for any significant change in renal function.">
        <entity id="DDI-DrugBank.d263.s19.e0" charOffset="56-60"
            type="drug" text="HIVID"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s20" text="Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.">
        <entity id="DDI-DrugBank.d263.s20.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d263.s20.e1" charOffset="14-23"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d263.s20.e2" charOffset="56-65"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d263.s20.e3" charOffset="70-79"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d263.s20.e4" charOffset="110-120"
            type="drug" text="zalcitabine"/>
        <entity id="DDI-DrugBank.d263.s20.e5" charOffset="179-189"
            type="drug" text="zalcitabine"/>
        <ddi id="DDI-DrugBank.d263.s20.d0" e1="DDI-DrugBank.d263.s20.e2"
            e2="DDI-DrugBank.d263.s20.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d263.s20.d1" e1="DDI-DrugBank.d263.s20.e3"
            e2="DDI-DrugBank.d263.s20.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s21" text="Patients receiving these drugs in combination with zalcitabine should be monitored for signs of toxicity and the dose of zalcitabine reduced if warranted.">
        <entity id="DDI-DrugBank.d263.s21.e0" charOffset="51-61"
            type="drug" text="zalcitabine"/>
        <entity id="DDI-DrugBank.d263.s21.e1" charOffset="121-131"
            type="drug" text="zalcitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s22" text="Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.">
        <entity id="DDI-DrugBank.d263.s22.e0" charOffset="0-8"
            type="drug" text="Magnesium"/>
        <entity id="DDI-DrugBank.d263.s22.e1" charOffset="10-17"
            type="drug" text="Aluminum"/>
        <entity id="DDI-DrugBank.d263.s22.e2" charOffset="30-45"
            type="group" text="Antacid Products"/>
        <entity id="DDI-DrugBank.d263.s22.e3" charOffset="62-72"
            type="drug" text="zalcitabine"/>
        <entity id="DDI-DrugBank.d263.s22.e4" charOffset="141-149"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d263.s22.e5" charOffset="151-158"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d263.s22.e6" charOffset="171-186"
            type="group" text="antacid products"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s23" text="The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.">
        <entity id="DDI-DrugBank.d263.s23.e0" charOffset="64-74"
            type="drug" text="zalcitabine"/>
        <entity id="DDI-DrugBank.d263.s23.e1" charOffset="130-138"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d263.s23.e2" charOffset="140-147"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d263.s23.e3" charOffset="160-167"
            type="group" text="antacids"/>
        <ddi id="DDI-DrugBank.d263.s23.d0" e1="DDI-DrugBank.d263.s23.e0"
            e2="DDI-DrugBank.d263.s23.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d263.s23.d1" e1="DDI-DrugBank.d263.s23.e0"
            e2="DDI-DrugBank.d263.s23.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d263.s23.d2" e1="DDI-DrugBank.d263.s23.e0"
            e2="DDI-DrugBank.d263.s23.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s24" text="Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.">
        <entity id="DDI-DrugBank.d263.s24.e0" charOffset="0-13"
            type="drug" text="Metoclopramide"/>
        <entity id="DDI-DrugBank.d263.s24.e1" charOffset="75-85"
            type="drug" text="zalcitabine"/>
        <entity id="DDI-DrugBank.d263.s24.e2" charOffset="91-104"
            type="drug" text="metoclopramide"/>
        <ddi id="DDI-DrugBank.d263.s24.d0" e1="DDI-DrugBank.d263.s24.e1"
            e2="DDI-DrugBank.d263.s24.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s25" text="Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.">
        <entity id="DDI-DrugBank.d263.s25.e0" charOffset="0-10"
            type="drug" text="Doxorubicin"/>
        <entity id="DDI-DrugBank.d263.s25.e1" charOffset="13-23"
            type="drug" text="Doxorubicin"/>
        <entity id="DDI-DrugBank.d263.s25.e2" charOffset="46-56"
            type="drug" text="zalcitabine"/>
        <ddi id="DDI-DrugBank.d263.s25.d0" e1="DDI-DrugBank.d263.s25.e1"
            e2="DDI-DrugBank.d263.s25.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d263.s26" text="Although there may be decreased zalcitabine activity because of lessened active metabolite formation, the clinical relevance of these in vitro results are not known.">
        <entity id="DDI-DrugBank.d263.s26.e0" charOffset="32-42"
            type="drug" text="zalcitabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s0" text="As with all drugs, the potential exists for interaction with other drugs by a variety of mechanisms."/>
    <sentence id="DDI-DrugBank.d324.s1" text="CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.">
        <entity id="DDI-DrugBank.d324.s1.e0" charOffset="17-23"
            type="drug" text="Ethanol"/>
        <entity id="DDI-DrugBank.d324.s1.e1" charOffset="26-31"
            type="brand" text="Sonata"/>
        <entity id="DDI-DrugBank.d324.s1.e2" charOffset="80-86"
            type="drug" text="ethanol"/>
        <entity id="DDI-DrugBank.d324.s1.e3" charOffset="152-158"
            type="drug" text="ethanol"/>
        <entity id="DDI-DrugBank.d324.s1.e4" charOffset="326-332"
            type="drug" text="ethanol"/>
        <ddi id="DDI-DrugBank.d324.s1.d0" e1="DDI-DrugBank.d324.s1.e1"
            e2="DDI-DrugBank.d324.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s2" text="The potentiation resulted from a CNS pharmacodynamic interaction;"/>
    <sentence id="DDI-DrugBank.d324.s3" text="zaleplon did not affect the pharmacokinetics of ethanol.">
        <entity id="DDI-DrugBank.d324.s3.e0" charOffset="0-7"
            type="drug" text="zaleplon"/>
        <entity id="DDI-DrugBank.d324.s3.e1" charOffset="48-54"
            type="drug" text="ethanol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s4" text="Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.">
        <entity id="DDI-DrugBank.d324.s4.e0" charOffset="0-9"
            type="drug" text="Imipramine"/>
        <entity id="DDI-DrugBank.d324.s4.e1" charOffset="48-53"
            type="brand" text="Sonata"/>
        <entity id="DDI-DrugBank.d324.s4.e2" charOffset="65-74"
            type="drug" text="imipramine"/>
        <ddi id="DDI-DrugBank.d324.s4.d0" e1="DDI-DrugBank.d324.s4.e1"
            e2="DDI-DrugBank.d324.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s5" text="The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug."/>
    <sentence id="DDI-DrugBank.d324.s6" text="Paroxetine: Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.">
        <entity id="DDI-DrugBank.d324.s6.e0" charOffset="0-9"
            type="drug" text="Paroxetine"/>
        <entity id="DDI-DrugBank.d324.s6.e1" charOffset="49-54"
            type="brand" text="Sonata"/>
        <entity id="DDI-DrugBank.d324.s6.e2" charOffset="66-75"
            type="drug" text="paroxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s7" text="Additionally, paroxetine did not alter the pharmacokinetics of Sonata, reflecting the absence of a role of CYP2D6 in zaleplon s metabolism.">
        <entity id="DDI-DrugBank.d324.s7.e0" charOffset="14-23"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d324.s7.e1" charOffset="63-68"
            type="brand" text="Sonata"/>
        <entity id="DDI-DrugBank.d324.s7.e2" charOffset="117-124"
            type="drug" text="zaleplon"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s8" text="Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.">
        <entity id="DDI-DrugBank.d324.s8.e0" charOffset="0-11"
            type="drug" text="Thioridazine"/>
        <entity id="DDI-DrugBank.d324.s8.e1" charOffset="50-55"
            type="brand" text="Sonata"/>
        <entity id="DDI-DrugBank.d324.s8.e2" charOffset="67-78"
            type="drug" text="thioridazine"/>
        <ddi id="DDI-DrugBank.d324.s8.d0" e1="DDI-DrugBank.d324.s8.e1"
            e2="DDI-DrugBank.d324.s8.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s9" text="The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug."/>
    <sentence id="DDI-DrugBank.d324.s10" text="Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.">
        <entity id="DDI-DrugBank.d324.s10.e0" charOffset="0-10"
            type="drug" text="Venlafaxine"/>
        <entity id="DDI-DrugBank.d324.s10.e1" charOffset="50-57"
            type="drug" text="zaleplon"/>
        <entity id="DDI-DrugBank.d324.s10.e2" charOffset="87-97"
            type="drug" text="venlafaxine"/>
        <entity id="DDI-DrugBank.d324.s10.e3" charOffset="204-211"
            type="drug" text="zaleplon"/>
        <entity id="DDI-DrugBank.d324.s10.e4" charOffset="216-226"
            type="drug" text="venlafaxine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s11" text="In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER.">
        <entity id="DDI-DrugBank.d324.s11.e0" charOffset="89-96"
            type="drug" text="zaleplon"/>
        <entity id="DDI-DrugBank.d324.s11.e1" charOffset="102-112"
            type="drug" text="venlafaxine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s12" text="Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.">
        <entity id="DDI-DrugBank.d324.s12.e0" charOffset="0-11"
            type="drug" text="Promethazine"/>
        <entity id="DDI-DrugBank.d324.s12.e1" charOffset="51-58"
            type="drug" text="zaleplon"/>
        <entity id="DDI-DrugBank.d324.s12.e2" charOffset="64-75"
            type="drug" text="promethazine"/>
        <entity id="DDI-DrugBank.d324.s12.e3" charOffset="169-176"
            type="drug" text="zaleplon"/>
        <ddi id="DDI-DrugBank.d324.s12.d0" e1="DDI-DrugBank.d324.s12.e1"
            e2="DDI-DrugBank.d324.s12.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s13" text="However, the pharmacodynamics of coadministration of zaleplon and promethazine have not been evaluated.">
        <entity id="DDI-DrugBank.d324.s13.e0" charOffset="53-60"
            type="drug" text="zaleplon"/>
        <entity id="DDI-DrugBank.d324.s13.e1" charOffset="66-77"
            type="drug" text="promethazine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s14" text="Caution should be exercised when these 2 agents are coadministered."/>
    <sentence id="DDI-DrugBank.d324.s15" text="Drugs That Induce CYP3A4 Rifampin: CYP3A4 is ordinarily a minor metabolizing enzyme of zaleplon.">
        <entity id="DDI-DrugBank.d324.s15.e0" charOffset="25-32"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d324.s15.e1" charOffset="87-94"
            type="drug" text="zaleplon"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s16" text="Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.">
        <entity id="DDI-DrugBank.d324.s16.e0" charOffset="58-65"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d324.s16.e1" charOffset="128-135"
            type="drug" text="zaleplon"/>
        <ddi id="DDI-DrugBank.d324.s16.d0" e1="DDI-DrugBank.d324.s16.e0"
            e2="DDI-DrugBank.d324.s16.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s17" text="The coadministration of a potent CYP3A4 enzyme inducer, although not posing a safety concern, thus could lead to ineffectiveness of zaleplon.">
        <entity id="DDI-DrugBank.d324.s17.e0" charOffset="132-139"
            type="drug" text="zaleplon"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s18" text="An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and phenobarbital.">
        <entity id="DDI-DrugBank.d324.s18.e0" charOffset="36-49"
            type="group" text="hypnotic agent"/>
        <entity id="DDI-DrugBank.d324.s18.e1" charOffset="112-119"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d324.s18.e2" charOffset="122-130"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d324.s18.e3" charOffset="133-145"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d324.s18.e4" charOffset="152-164"
            type="drug" text="phenobarbital"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s19" text="Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.">
        <entity id="DDI-DrugBank.d324.s19.e0" charOffset="85-92"
            type="drug" text="zaleplon"/>
        <entity id="DDI-DrugBank.d324.s19.e1" charOffset="180-201"
            type="drug_n" text="5-oxo-desethylzaleplon"/>
        <entity id="DDI-DrugBank.d324.s19.e2" charOffset="207-240"
            type="drug_n" text="5-oxo-desethylzaleplon glucuronide"/>
        <entity id="DDI-DrugBank.d324.s19.e3" charOffset="292-299"
            type="drug" text="zaleplon"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s20" text="Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.">
        <entity id="DDI-DrugBank.d324.s20.e0" charOffset="42-49"
            type="drug" text="zaleplon"/>
        <entity id="DDI-DrugBank.d324.s20.e1" charOffset="56-67"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d324.s20.e2" charOffset="167-174"
            type="drug" text="zaleplon"/>
        <ddi id="DDI-DrugBank.d324.s20.d0" e1="DDI-DrugBank.d324.s20.e0"
            e2="DDI-DrugBank.d324.s20.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s21" text="The magnitude of interaction with multiple doses of erythromycin is unknown.">
        <entity id="DDI-DrugBank.d324.s21.e0" charOffset="52-63"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s22" text="Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.">
        <entity id="DDI-DrugBank.d324.s22.e0" charOffset="49-60"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d324.s22.e1" charOffset="111-118"
            type="drug" text="zaleplon"/>
        <ddi id="DDI-DrugBank.d324.s22.d0" e1="DDI-DrugBank.d324.s22.e0"
            e2="DDI-DrugBank.d324.s22.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s23" text="A routine dosage adjustment of zaleplon is not considered necessary.">
        <entity id="DDI-DrugBank.d324.s23.e0" charOffset="31-38"
            type="drug" text="zaleplon"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s24" text="Drugs That Inhibit Aldehyde Oxidase The aldehyde oxidase enzyme system is less well studied than the cytochrome P450 enzyme system."/>
    <sentence id="DDI-DrugBank.d324.s25" text="Diphenhydramine: Diphenhydramine is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.">
        <entity id="DDI-DrugBank.d324.s25.e0" charOffset="0-14"
            type="drug" text="Diphenhydramine"/>
        <entity id="DDI-DrugBank.d324.s25.e1" charOffset="17-31"
            type="drug" text="Diphenhydramine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s26" text="There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 mg, respectively) of each drug.">
        <entity id="DDI-DrugBank.d324.s26.e0" charOffset="48-55"
            type="drug" text="zaleplon"/>
        <entity id="DDI-DrugBank.d324.s26.e1" charOffset="61-75"
            type="drug" text="diphenhydramine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s27" text="However, because both of these compounds have CNS effects, an additive pharmacodynamic effect is possible."/>
    <sentence id="DDI-DrugBank.d324.s28" text="Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.">
        <entity id="DDI-DrugBank.d324.s28.e0" charOffset="52-61"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d324.s28.e1" charOffset="64-73"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d324.s28.e2" charOffset="217-224"
            type="drug" text="zaleplon"/>
        <ddi id="DDI-DrugBank.d324.s28.d0" e1="DDI-DrugBank.d324.s28.e1"
            e2="DDI-DrugBank.d324.s28.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s29" text="Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.">
        <entity id="DDI-DrugBank.d324.s29.e0" charOffset="30-35"
            type="brand" text="Sonata"/>
        <entity id="DDI-DrugBank.d324.s29.e1" charOffset="49-58"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d324.s29.e2" charOffset="122-129"
            type="drug" text="zaleplon"/>
        <ddi id="DDI-DrugBank.d324.s29.d0" e1="DDI-DrugBank.d324.s29.e0"
            e2="DDI-DrugBank.d324.s29.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s30" text="An initial dose of 5 mg should be given to patients who are concomitantly being treated with cimetidine.">
        <entity id="DDI-DrugBank.d324.s30.e0" charOffset="93-102"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s31" text="Drugs Highly Bound to Plasma Protein Zaleplon is not highly bound to plasma proteins (fraction bound 60% 15%);">
        <entity id="DDI-DrugBank.d324.s31.e0" charOffset="37-44"
            type="drug" text="Zaleplon"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s32" text="therefore, the disposition of zaleplon is not expected to be sensitive to alterations in protein binding.">
        <entity id="DDI-DrugBank.d324.s32.e0" charOffset="30-37"
            type="drug" text="zaleplon"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s33" text="In addition, administration of Sonata to a patient taking another drug that is highly protein bound should not cause transient increase in free concentrations of the other drug.">
        <entity id="DDI-DrugBank.d324.s33.e0" charOffset="31-36"
            type="brand" text="Sonata"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s34" text="Drugs with a Narrow Therapeutic Index Digoxin: Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days).">
        <entity id="DDI-DrugBank.d324.s34.e0" charOffset="38-44"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d324.s34.e1" charOffset="47-52"
            type="brand" text="Sonata"/>
        <entity id="DDI-DrugBank.d324.s34.e2" charOffset="127-133"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s35" text="Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.">
        <entity id="DDI-DrugBank.d324.s35.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d324.s35.e1" charOffset="33-38"
            type="brand" text="Sonata"/>
        <entity id="DDI-DrugBank.d324.s35.e2" charOffset="104-111"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d324.s35.e3" charOffset="220-227"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s36" text="Drugs That Alter Renal Excretion Ibuprofen: Ibuprofen is known to affect renal function and, consequently, alter the renal excretion of other drugs.">
        <entity id="DDI-DrugBank.d324.s36.e0" charOffset="33-41"
            type="drug" text="Ibuprofen"/>
        <entity id="DDI-DrugBank.d324.s36.e1" charOffset="44-52"
            type="drug" text="Ibuprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s37" text="There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug.">
        <entity id="DDI-DrugBank.d324.s37.e0" charOffset="58-65"
            type="drug" text="zaleplon"/>
        <entity id="DDI-DrugBank.d324.s37.e1" charOffset="71-79"
            type="drug" text="ibuprofen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d324.s38" text="This was expected because zaleplon is primarily metabolized and renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.">
        <entity id="DDI-DrugBank.d324.s38.e0" charOffset="26-33"
            type="drug" text="zaleplon"/>
        <entity id="DDI-DrugBank.d324.s38.e1" charOffset="93-100"
            type="drug" text="zaleplon"/>
    </sentence>
</document>
